
<html lang="en"     class="pb-page"  data-request-id="e7b33830-3c15-4a9a-b801-8168e2b1f0b6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.1c00335;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy" /></meta><meta name="dc.Creator" content="Thanigaimalai  Pillaiyar" /></meta><meta name="dc.Creator" content="Stefan  Laufer" /></meta><meta name="dc.Description" content="The global coronavirus disease-19 (COVID-19) has affected more than 140 million and killed more than 3 million people worldwide as of April 20, 2021. The novel human severe acute respiratory syndro..." /></meta><meta name="Description" content="The global coronavirus disease-19 (COVID-19) has affected more than 140 million and killed more than 3 million people worldwide as of April 20, 2021. The novel human severe acute respiratory syndro..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 3, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00335" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2021 The Authors. Published by American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00335" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00335" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00335" /></link>
        
    
    

<title>Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00335" /></meta><meta property="og:title" content="Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0018.jpeg" /></meta><meta property="og:description" content="The global coronavirus disease-19 (COVID-19) has affected more than 140 million and killed more than 3 million people worldwide as of April 20, 2021. The novel human severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been identified as an etiological agent for COVID-19. Several kinases have been proposed as possible mediators of multiple viral infections, including life-threatening coronaviruses like SARS-CoV-1, Middle East syndrome coronavirus (MERS-CoV), and SARS-CoV-2. Viral infections hijack abundant cell signaling pathways, resulting in drastic phosphorylation rewiring in the host and viral proteins. Some kinases play a significant role throughout the viral infection cycle (entry, replication, assembly, and egress), and several of them are involved in the virus-induced hyperinflammatory response that leads to cytokine storm, acute respiratory distress syndrome (ARDS), organ injury, and death. Here, we highlight kinases that are associated with coronavirus infections and their inhibitors with antiviral and potentially anti-inflammatory, cytokine-suppressive, or antifibrotic activity." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00335"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00335">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00335&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00335&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00335&amp;href=/doi/10.1021/acs.jmedchem.1c00335" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00614" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00146" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Thanigaimalai Pillaiyar</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thanigaimalai Pillaiyar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tuebingen Center for Academic Drug Discovery, Eberhard Karls University TÃ¼bingen, Auf der Morgenstelle 8, 72076 TÃ¼bingen, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#cdb9a5aca3a4aaaca4a0aca1aca4e3bda4a1a1aca4b4acbf8db8a3a4e0b9b8a8afa4a3aaa8a3e3a9a8"><span class="__cf_email__" data-cfemail="285c404946414f494145494449410658414444494151495a685d4641055c5d4d4a41464f4d46064c4d">[emailÂ protected]</span></a>. Phone: +49 7071 2977458.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thanigaimalai++Pillaiyar">Thanigaimalai Pillaiyar</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-5575-8896" title="Orcid link">https://orcid.org/0000-0001-5575-8896</a></div></div></span></li><span class="comma-separator">Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Stefan Laufer</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefan Laufer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tuebingen Center for Academic Drug Discovery, Eberhard Karls University TÃ¼bingen, Auf der Morgenstelle 8, 72076 TÃ¼bingen, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#6013140506010e4e0c011506051220150e094d14150502090e07050e4e0405"><span class="__cf_email__" data-cfemail="f98a8d9c9f9897d795988c9f9c8bb98c9790d48d8c9c9b90979e9c97d79d9c">[emailÂ protected]</span></a>. Phone: + 49 7071 2972459.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Laufer">Stefan Laufer</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-6952-1486" title="Orcid link">https://orcid.org/0000-0001-6952-1486</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00335&amp;href=/doi/10.1021%2Facs.jmedchem.1c00335" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 3, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 February 2021</li><li><span class="item_label"><b>Published</b> online</span>3 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00335" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00335</a></div><div class="article_header-article-copyright"><strong>Â© 2021 The Authors. Published by American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D28%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DThanigaimalai%2BPillaiyar%252C%2BStefan%2BLaufer%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.1c00335%26title%3DKinases%2Bas%2BPotential%2BTherapeutic%2BTargets%2Bfor%2BAnti-coronaviral%2BTherapy%26numPages%3D28%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D28%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00335"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2581</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00335" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Thanigaimalai&quot;,&quot;last_name&quot;:&quot;Pillaiyar&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Laufer&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00335&quot;},&quot;abstract&quot;:&quot;The global coronavirus disease-19 (COVID-19) has affected more than 140 million and killed more than 3 million people worldwide as of April 20, 2021. The novel human severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been identified as an etiological agent for COVID-19. Several kinases have been proposed as possible mediators of multiple viral infections, including life-threatening coronaviruses like SARS-CoV-1, Middle East syndrome coronavirus (MERS-CoV), and SARS-CoV-2. Viral infections hijack abundant cell signaling pathways, resulting in drastic phosphorylation rewiring in the host and viral proteins. Some kinases play a significant role throughout the viral infection cycle (entry, replication, assembly, and egress), and several of them are involved in the virus-induced hyperinflammatory response that leads to cytokine storm, acute respiratory distress syndrome (ARDS), organ injury, and death. Here, we highlight kinases that are associated with coronavirus infections and their inhibitors wit&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00335&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00335" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00335&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00335" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00335&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00335" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00335&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00335&amp;href=/doi/10.1021/acs.jmedchem.1c00335" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00335" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00335" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00335%26sid%3Dliteratum%253Aachs%26pmid%3D34081439%26genre%3Darticle%26aulast%3DPillaiyar%26date%3D2021%26atitle%3DKinases%2Bas%2BPotential%2BTherapeutic%2BTargets%2Bfor%2BAnti-coronaviral%2BTherapy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292644" title="SARS-CoV-2">SARS-CoV-2</a>,</li><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292639" title="COVID-19">COVID-19</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The global coronavirus disease-19 (COVID-19) has affected more than 140 million and killed more than 3 million people worldwide as of April 20, 2021. The novel human severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been identified as an etiological agent for COVID-19. Several kinases have been proposed as possible mediators of multiple viral infections, including life-threatening coronaviruses like SARS-CoV-1, Middle East syndrome coronavirus (MERS-CoV), and SARS-CoV-2. Viral infections hijack abundant cell signaling pathways, resulting in drastic phosphorylation rewiring in the host and viral proteins. Some kinases play a significant role throughout the viral infection cycle (entry, replication, assembly, and egress), and several of them are involved in the virus-induced hyperinflammatory response that leads to cytokine storm, acute respiratory distress syndrome (ARDS), organ injury, and death. Here, we highlight kinases that are associated with coronavirus infections and their inhibitors with antiviral and potentially anti-inflammatory, cytokine-suppressive, or antifibrotic activity.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar"><issue-title>New Horizons in Drug Discovery - Understanding and Advancing Kinase Inhibitors</issue-title></a> special issue.</p></div><div class="extra-info-sec articleNote"><h4><span></span>Â  Note</h4><p class="first last">This article is made available via the <a href="/page/vi/chemistry_coronavirus_research" class="ext-link">ACS COVID-19 subset</a> for unrestricted RESEARCH re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The coronavirus disease-19 (COVID-19) pandemic is a potentially fatal respiratory infection caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> SARS-CoV-2 first appeared in previously unexposed human populations in late 2019 in Wuhan, China, from an undisclosed source. Subsequently, the virus rapidly spread worldwide with a high transmission efficacy.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> According to the latest data, as of April 20, 2021, the virus has affected more than 140 million people, and deaths have surpassed more than 3 million.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The unprecedented efforts from health care workers, industry, and academic scientists have resulted in a wide variety of vaccines, several of which have recently been authorized and recommended for use in controlling the SARS-CoV-2 spread around the world. The U.S. Food and Drug Administration (FDA) approved remdesivir in October for use in adult and pediatric patients aged 12 and up with COVID-19 who need hospitalization. However, the World Health Organization (WHO) has not recommended the use of remdesivir irrespective of the seriousness of the disorder, as there is no evidence that it improves survival and other outcomes in hospitalized patients. Moreover, the WHO recommends that seriously ill COVID-19 patients receive systemic corticosteroid medication (e.g., 6 mg dexamethasone daily) for 7â10 days but that nonsevere COVID-19 patients should not receive this treatment. Antibodies like bamlanivimab and etesevimab, which have been approved by the FDA, are only for emergency use in patients with mild to severe COVID-19. However, they were not approved for patients who are hospitalized or need oxygen therapy due to COVID-19.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Monoclonal antibodies can be associated with poorer outcomes in hospitalized COVID-19 patients who require oxygen or mechanical ventilation. As a result, treatment options for human coronavirus (HCoV) diseases are limited, and experts expect that the virus will survive for a longer period.</div><div class="NLM_p">It is essential to comprehend the coronavirusâs basic features and life cycle to develop potential antiviral therapeutics. Coronaviruses are enveloped, positive-sense RNA viruses with the worldâs largest viral RNA genome (â¼26â32 kilobases)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> that comprises about 30â¯000 nucleotides. So far, seven human coronaviruses have been discovered, and they are classified into four main genera (Î±, Î², Î³, and Î´) under the family <i>Coronaviridae</i>:<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Î±-CoVs are (i) HCoV-229E and (ii) HCoV-OC43, and Î²-CoVs are (iii) HCoV-HKU1, (iv) HCoV-NL63, (v) SARS-CoV-1, (vi) MERS-CoV, and (vii) SARS-CoV-2 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Of the three last-mentioned Î²-coronaviruses, SARS-CoV-1 and MERS-CoV are mostly concerned with nosocomial transmission, while SARS-CoV-2 is commonly transmitted in the population. The basic structure of a coronavirus is illustrated in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. SARS-CoV-1, the etiological agent of SARS that first appeared in 2002-2003, caused 8096 infections with a 10% fatality rate.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> MERS-CoV, which emerged from its zoonotic reservoir in 2012, affected a total of 2574 individuals, including 885 associated deaths (fatality rate = 34.4%) as of March 2021.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13â15)</a> The new SARS-CoV-2 continues to spread incredibly rapidly, and it has had an unprecedented effect on individuals and the global economy, as many governments have imposed travel restrictions, social distancing, and quarantine measurements.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Taxonomy of human coronaviruses depicted schematically. (A) Seven human CoVs assigned to four genera of Î±, Î², Î³, and Î´ are highlighted blue. The discovery of each HCoV is indicated in the brackets. The percent of spike protein (S) amino acid identity between classes is indicated green. (B) Structure of a coronavirus with its functional proteins. Abbreviations: HCoV, human coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; SARS-CoV, severe acute respiratory syndrome coronavirus; BuCoV, bubaline coronavirus.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As the name indicates, the genome organization of SARS-CoV-2 shares a high degree of similarity to that of the previously known SARS-CoV-1 (79% genetic similarity),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> SARS-related CoVs that reside in bats (genetic similarity of up to 98%), and to a lesser extent MERS-CoV (genetic similarity of up to 50%).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">Most coronaviruses have a four-step life cycle: entry, replication, assembly, and release (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref7 ref17'); return false;" href="javascript:void(0);" class="ref ref7 ref17">(7,17)</a> At the molecular level, (i) the spike protein-host receptor, which is responsible for the viral entry, (ii) proteases such as the main protease (M<sup>pro</sup>) and the papain-like protease (PL<sup>pro</sup>) required for the proteolytic cleavage of viral proteins, which are required for viral replication and the assembly of the viral particles, and (iii) the RNA-dependent RNA polymerase (RdRp), which is critical for the multiplication of the genome of viral RNA, are considered to be very important biochemical events in the virus life cycle. Targeting any of these processes could become an important therapeutic approach that can directly invade the virus in coronavirus-associated diseases.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) SARS-CoV-2 life cycle as an example: entry, transcription and translation, assembly of virion, and release. (B) Viral infection results in the hyperproduction of proinflammatory cytokines. Kinases involved in both coronavirus viral replication and associated diseases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  The Role of Kinases in SARS-CoV Infection and Their Potential as Therapeutic Targets</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46401" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46401" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">SARS-CoV-2 mainly interacts with the respiratory system and induces dry cough, fever, fatigue, sore throat, and shortness of breath.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> However, in serious circumstances, it can cause acute respiratory distress syndrome (ARDS) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), a virus-driven hyperinflammatory reaction that is one of COVID-19âs leading causes of mortality. The cytokine storm, which is caused by the release of proinflammatory cytokines, is the most prominent feature of ARDS. Some of the cytokines include interleukin (IL)-2, IL-6, IL-7, granulocyte-colony stimulating factor (GM-CSF), TNF-Î±, interferon-Î³ inducible protein 10, macrophage inflammatory protein 1-Î± (MIP-1Î±), and monocyte chemoattractant protein-1 (MCP-1).<a onclick="showRef(event, 'ref9 ref21 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref9 ref21 ref22 ref23 ref24 ref25">(9,21â25)</a> This virulent inflammatory immune response contributes to ARDS, respiratory failure, organ failure affecting the heart, liver, kidney, and central nervous system (CNS),<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and death from severe infection.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Of all the host resources, cellular kinases can play a part in various stages of the virusâs life cycle. Numerous kinases have been suggested as potential mediators of different virus infections. Several kinases have been suggested as possible mediators of multiple viral infections, including life-threatening coronaviruses like SARS-CoV-1, MERS-CoV, and SARS-CoV-2 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> SARS-CoV-1 and MERS-CoV fusion with the endosomal membrane is mediated by Abelson (Abl) kinases.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> For the replication of the murine coronavirus HCoV-229E and other unrelated viruses, activation of p38 MAPK and c-Jun N terminal kinases (JNK1/2) is needed.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30â32)</a> Studies revealed that p38 is implicated in the phosphorylation of the initial translation factor eIF4E, which plays a crucial role in the translation of viral mRNAs and subsequent production of infection of murine CoV (mCoV).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The p38 MAPK/ERK signaling pathway has been employed in the entry and production of the influenza A and Ebola viruses.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33â35)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Kinases as Mediators and Their Roles in Coronavirus Infections</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">coronavirus</th><th class="colsep0 rowsep0" align="center">kinases<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">roles</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SARS-CoV-1, SARS-CoV-2</td><td class="colsep0 rowsep0" align="left">Ca<sub>2</sub>+/calmodulin-dependent,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> protein kinase II,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> ERK1/2/5,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> EGFR,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> GSK-3,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> JAK/STAT,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> p38 MAPK,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> NAK, SFK signaling pathway,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> PI3K/Akt, mTOR,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> AXL,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> CDK,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> CK2,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Abl kinases<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></td><td class="colsep0 rowsep0" align="left">viral life cycle (entry, replication, assembly, release), hyperimmune activation, proinflammatory cytokine production, cell cycle regulation (pneumonia, inflammation, and fibrosis)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MERS-CoV</td><td class="colsep0 rowsep0" align="left">Abl kinases,<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> p38 MAPK, ERK1/2/5, PI3K/Akt/mTOR,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> SFK signaling pathway<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></td><td class="colsep0 rowsep0" align="left">viral life cycle (entry, replication), symptom associated diseases</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCoV-229E</td><td class="colsep0 rowsep0" align="left">p38 MAPK,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> SFK signaling pathway<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCoV-OC43</td><td class="colsep0 rowsep0" align="left">receptor-interacting protein kinase 1,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> mixed lineage kinase domain-like<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></td><td class="colsep0 rowsep0" align="left">Â </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Abl, Abelson tyrosine kinase; CDK, cyclin-dependent kinases; CK2, casein kinase 2; EGFR, epidermal growth factor receptor; GSK-3, glycogen synthase kinase 3; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; NAK, numb-associated kinase; PI3K, phosphatidylinositol 3-kinase; PDGFR, platelet-derived growth factor receptors; STAT, signal transducer and activator of transcription; SRPK, serine/threonine-protein kinase.</p></div></div></div><div class="NLM_p">Many kinases also play a role in the progression of symptoms like pneumonia, inflammation, and fibrosis that are linked to CoV infections.<a onclick="showRef(event, 'ref27 ref39 ref46'); return false;" href="javascript:void(0);" class="ref ref27 ref39 ref46">(27,39,46)</a> Kinases respond to and regulate the synthesis of potentially harmful cytokines (IL-6, IL-10, and TNF) and proteins associated with inflammation and pulmonary fibrosis induction (such as the proinflammatory cytokine TGF-Î²).<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> Therefore, kinase inhibitors can have direct antiviral effects and anti-inflammatory, cytokine-suppressive, and antifibrotic activities, all of which may be useful in the fight against respiratory viral infections (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Indeed, several kinase inhibitors are currently being tested in clinical trials for COVID-19 therapy.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinases as potential targets for the management of coronavirus diseases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several reviews have been published that illustrate the function of cellular kinases in a variety of viral infections. Raghuvanshi and Bharate discussed how kinase inhibitors have recently been developed to treat various viral infections.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> They primarily focused on different stages of kinase inhibitors as FDA approved, clinical candidates and on discovery that targeted various virus infections, but they did not discuss kinase inhibitors that target human coronaviruses to date. Several research groups reviewed the critical function of different host kinases in influenza A virus infection.<a onclick="showRef(event, 'ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52">(50â52)</a> Schor and Einav discussed the possibility of repurposing branded kinase inhibitors to have broad antiviral efficacy.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Weisberg et al. focused solely on repurposing licensed kinase inhibitors against SARS-CoV-2, the new COVID-19 pandemicâs causative agent.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> However, no systematic review of kinase inhibitors as anti-coronaviral agents has been published to date.</div><div class="NLM_p last">In this Perspective, we systematically discuss different kinases associated with coronavirus infections and their inhibitors with antiviral and potential for anti-inflammatory, cytokine-suppressive, or antifibrotic activity.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">3.  Kinase Inhibitors as Potential Antiviral Agents</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83685" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83685" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">3.1.  Inhibitors Targeting Abl and Src Kinases</h3><div class="NLM_p">Abl kinases are ubiquitous signaling kinases that play a role in cell proliferation, adhesion, and stress response. They are housekeeping proteins in all cell types. Several experiments have shown that Abl kinases are involved in various stages of the viral life cycle in viruses, including the Ebola virus,<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> coxsackievirus,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> and vaccinia virus.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Abl kinases, which are involved in viral entry and replication, have recently been identified as possible therapeutic targets for coronavirus diseases.</div><div class="NLM_p">Dyall et al. screened approved or experimental drug libraries to identify potential therapeutics against SARS-CoV-1 and MERS-CoV.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> This led to the development of three kinase signaling pathway inhibitors: imatinib, dasatinib, and nilotinib. Imatinib and dasatinib were active against SARS-CoV-1 and MERS-CoV, while nilotinib was only active against SARS-CoV-1 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Both imatinib (4-[(4-methylpiperazin-1-yl)methyl]-<i>N</i>-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide) and dasatinib (<i>N</i>-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate) inhibit SARS-CoV-1 and MERS-CoV with EC<sub>50</sub> values of 2.1â17.6 Î¼M, though SARS-CoV-1 appeared to be sensitive to these kinase inhibitors as well. Dasatinib, for example, inhibited SARS-CoV-1 with a low micromolar EC<sub>50</sub> of 2.1 Î¼M, while the EC<sub>50</sub> for inhibiting MERS-CoV was 5.4 Î¼M. Imatinib, instead, needed a high concentration (EC<sub>50</sub> 9.23 Î¼M) to inhibit SARS-CoV-1, despite having been confirmed to inhibit the Ebola virus, coxsackievirus B, and vaccinia virus with concentrations in the same range.<a onclick="showRef(event, 'ref4 ref58'); return false;" href="javascript:void(0);" class="ref ref4 ref58">(4,58)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Abl tyrosine kinase and Src kinase inhibitors as antiviral agents (imatinib: SARS-CoV-1, EC<sub>50</sub> 9.823 Î¼M, MERS-CoV, EC<sub>50</sub> 2.100 Î¼M;<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> dasatinib: SARS-CoV-1, EC<sub>50</sub> 17.689 Î¼M, MERS-CoV, EC<sub>50</sub> 5.468 Î¼M).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Imatinib is an orally available Abl kinase inhibitor for chronic myeloid leukemia (CML) treatment.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Dasatinib is an orally available, second generation Abl kinase inhibitor for CML and acute lymphoblastic leukemia (ALL).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p">Nilotinib (4-methyl-<i>N</i>-[3-(4-methyl-1<i>H</i>-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide), a structural analogy to imatinib, has been used to treat CML. It inhibited the SARS-CoV-1 replication in the micromolar range without compromising cell cytotoxicity but not significantly inhibiting the MERS-CoV (only 39% inhibition). In Abl-expressing cells, nilotinib, rather than imatinib, effectively blocked Abl activity and proliferation.<a onclick="showRef(event, 'ref41 ref60 ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref41 ref60 ref61 ref62 ref63">(41,60â63)</a></div><div class="NLM_p">In the subsequent study, imatinib was discovered to be effective in preventing viral infection in its early stages for SARS-CoV-1 and MERS-CoV.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> It blocked viral entry and replication by preventing virions from fusing at the endosomal membrane. Further insights into mechanistic studies revealed the SARS-CoV-1 and MERS-CoV to rely on Abl2 kinase activity for viral entry but not on Abl1 kinase: inhibition of Abl2 kinase by imatinib blocks viral entry. Imatinib was previously found to inhibit the Ebola virus, poxvirus, and coxsackievirus.<a onclick="showRef(event, 'ref40 ref54 ref56'); return false;" href="javascript:void(0);" class="ref ref40 ref54 ref56">(40,54,56)</a></div><div class="NLM_p">SH2 and SH3 domains in Abl2 kinase hold the protein in a dormant state.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Since the substrate binds to either the SH2 or the SH3 domain, Abl2 may turn from its inactive to active state.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Adenosine triphosphate (ATP) binding at the catalytic site and corresponding kinase activity are allowed by Abl2âs open, active conformation. It has been proposed that coronavirus infection increases Abl2 substrate binding, allowing Abl2 into an active state and phosphorylate downstream targets.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Imatinib inhibited the kinases activity of Abl2 by preventing the phosphorylation of proteins in cells.</div><div class="NLM_p">Since SARS-CoV-1 and SARS-CoV-2 have a high degree of genome sequence identity (80%), imatinib is predicted to inhibit SARS-CoV-2 as well. Zhao et al. utilized pseudotyped viruses with SARS-CoV-2 spike protein to study imatinibâs anti-SARS-CoV-2 activity in Caco-2 cells.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> At concentrations up to 10 Î¼M, imatinib, on the other hand, did not affect SARS-CoV-2 entry or infection. This result supports the weak activity of imatinib in inhibiting SARS-CoV-1 replication in Vero cells (EC<sub>50</sub> 9.85 Î¼M).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_p">Severe COVID-19 is characterized by ARDS triggered by enhanced proinflammatory cytokine production. Imatinib has immunomodulatory effects<a onclick="showRef(event, 'ref66 ref68'); return false;" href="javascript:void(0);" class="ref ref66 ref68">(66,68)</a> and inhibits cytokine receptor signaling (PDGFR, c-Kit, and CSF1R), potentially suppressing cytokine storms. As a result of its immunomodulatory effects, imatinib may display clinical benefits for COVID-19.</div><div class="NLM_p">In contrast to Zhao et al., a recent preprint reported imatinib to effectively inhibit SARS-CoV-2 replication with an IC<sub>50</sub> value of 130 nM.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> However, it was toxic in concentrations between 25 and 3.2 Î¼M. For both SARS-CoV-1 and MERS-CoV virus fusion inhibition, imatinibâs antiviral efficacy was the same. Furthermore, imatinib binds to the SARS-CoV-2 spike proteinâs receptor-binding domain (RBD) with a 2.32 Î¼M affinity, meaning that imatinib did not specifically inhibit the SARS-CoV-2 RBD/ACE2 interaction. As a result, imatinib inhibited both cellular tyrosine kinase and viral fusion, preventing virus replication. Indeed, three clinical trials investigating the therapeutic efficacy of imatinib in COVID-19 patients are currently underway: NCT04394416 (USA), EudraCT2020-001236-10 (The Netherlands), and NCT04357613 (France).</div><div class="NLM_p">Galimberti et al. reported tyrosine kinase inhibitors (TKIs) to play a protective role against SARS-CoV-2 in patients with Ph+ ALL and CML.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In Ph+ ALL and CML Italian cohorts, they found just a few cases of COVID-19. According to the evidence, the use of TKIs may be to account for the low infection rate. It was interesting to see that during treatment of patients with TKIs, such as imatinib or nilotinib, several âproimmuneâ genes such as CD28 and IFN Î³ were induced, whereas the expression of anti-immune genes such as ARG-1, CEACAM1, and FUT4 was reduced.</div><div class="NLM_p last">The entry of the virus, which includes receptor binding, S glycoprotein modification, and proteolysis, is the first step in viral replication. Cathepsin L and the transmembrane serine protease 2 (TTSP) TMPRSS2 are playing crucial roles in viral entry. Cathepsin L mediates the proteolysis,<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> while TMPRSS2 helps in the CoV S glycoprotein cleavage to enter the host cells.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> It was discovered that inhibiting cathepsin L prevented SARS-CoV-1 infection and that using a mixture of EST (a cathepsin inhibitor) and camostat (a serine protease inhibitor, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) prevented viral entry and replication completely. The study indicated that imatinib inhibits the functionality or action of TMPRSS2.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> On the other hand, Abl and ARG kinases have been linked to promoting the production of the endosomal protease cathepsin L in cancer cells.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Thus, inhibiting cathepsin L in the context of viral replication by targeting these kinases may be a promising strategy.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.2.  Src Family Kinases</h3><div class="NLM_p">Src family kinases (SFKs), crucial modulators of signal transduction, are nonreceptor tyrosine kinases with nine members in the family: Src, Yes, Fyn, Fgr, Lck, Hck, Blk, Lyn, and Yrk. They control a variety of cellular signaling pathways that stimulate cell survival and motility. SFKs are important in the life cycle of a variety of viruses.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Src kinases were involved in the vaccinia virus replication via activation of Abl kinases linked to virus actin-based motility. Different SFKs like Fyn, Lyn, c-Src, and Csk (dengue virus,<a onclick="showRef(event, 'ref74 ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref74 ref75 ref76">(74â76)</a> hepatitis C virus (HCV)<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a>), and c-Yes (West Nile virus (WNV)<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a>) were implicated in the replication of the <i>Flaviviridae</i> family. De Wispelaere et al. reported that dasatinib and saracatinib (<i>N</i>-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2<i>H</i>-pyran-4-yl)oxy]-4-quinazolinamine) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) inhibited the assembly of the dengue virus.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> The antiviral activity of these agents contributed to inhibiting SFKs, especially c-Src and Fyn. Saracatinib is a Phase III investigational dual kinase inhibitor that inhibits both Src and Bcr-Abl tyrosine kinases.</div><div class="NLM_p">Shin et al. discovered that saracatinib inhibited MERS-CoV in Huh-7 cells at an early stage of its life cycle (EC<sub>50</sub> of 2.9 M, CC<sub>50</sub> of >50 Î¼M).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The authors hypothesized that saracatinib could inhibit MERS-CoV by inhibiting SFK signaling pathways. In a subsequent study, they identified the targets of saracatinib as Lyn and Fyn through a siRNA knock-down study. The study also showed that knocking out Lyn and Fyn resulted in a substantial reduction in viral load, implying that these kinases are needed for effective MERS-CoV replication. In Huh-7 cells, however, knockdown of Yes had little effect on MERS-CoV replication. The coadministration of saracatinib with gemcitabine (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), a chemotherapy medication for different types of cancers, showed a synergistic effect. Saracatinib also demonstrated broad antiviral activity against HCoV-229E and HCoV-OC43, with EC<sub>50</sub> values of 2.4 and 5.1 Î¼M, respectively.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p">Src family kinases have also been shown to be potential molecular targets for HCV77 and dengue virus infection and replication. Kumar et al. discovered that the Src kinase (Csk) is a critical host kinase in dengue virus replication.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Dengue virus RNA levels were suppressed when Csk expression was knocked down by siRNA or inhibitor, and dengue infection was greatly reduced when cells lacked Src kinases (Fyn, Src, and Yes). This data indicates that Src kinases are crucial players in dengue virus replication and assembly. Csk was identified to be hyperphosphorylated during virus infection, and inhibiting protein kinase A (PKA) prevented viral replication, implying that PKA phosphorylation of Csk is involved in the dengue virus life cycle.</div><div class="NLM_p last">Chu and Yang discovered that the inhibition of Csk by dasatinib exhibits a potent inhibitory effect on dengue virus replication.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Mechanistic studies demonstrated that dasatinib prevents the formation of infectious virus particles. Saracatinib and dasatinib were identified as effective agents against the dengue virus, and both of them targeted Fyn for RNA replication.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> The genetic knock-down study of Yes was shown to inhibit the West Nile virus titer through the virus replication cycle.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.3.  Numb-Associated Kinase (NAK) Family and AXL Kinase Inhibitors</h3><div class="NLM_p">The numb-associated family of Ser/Ther kinases plays a crucial role in the replication of many unrelated viruses.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Four human homologues are in the family: (i) AK1 adaptor protein-associated kinase 1 (AAK1), (ii) BMP-2-inducible kinase (BIKE/BMP2K), (iii) cyclin G-associated kinase (GAK), and (iv) myristoylated and palmitoylated serine/threonine kinase 1 (MPSK1). Two of these homologues, AAK1 and GAK, have been linked to the entry, assembly, and release of viruses such as dengue, HCV, Ebola, SARS-CoV-1 and -2, and MERS-CoV.<a onclick="showRef(event, 'ref79 ref80 ref81 ref82 ref83 ref84 ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref79 ref80 ref81 ref82 ref83 ref84 ref85 ref86">(79â86)</a></div><div class="NLM_p">Sunitinib (<i>N</i>-(2-diethylaminoethyl)-5-[(<i>Z</i>)-(5-fluoro-2-oxo-1<i>H</i>-indol-3-ylidene)methyl]-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxamide) and erlotinib (<i>N</i>-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine) (for structures, see <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) potentially suppressed AAK1 and GAK and showed antiviral action against dengue and ebolaviruses in cultured cells.<a onclick="showRef(event, 'ref78 ref87'); return false;" href="javascript:void(0);" class="ref ref78 ref87">(78,87)</a> The gene silencing of AAK1 and GAK demonstrated their crucial role in viral entry and infection.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Sunitinib and erlotinib were found to prevent viral infection through inhibiting AP-mediated intracellular membrane trafficking by AAK1 and GAK at the molecular level.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> In murine models of dengue and ebolaviruses, the drug combination sunitinib/erlotinib has been shown to minimize morbidity and mortality.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> However, the dosage required for inhibiting AAK1 and GAK by sunitinib and erlotinib would be much higher in COVID-19 patients.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. NAK family inhibitors (sunitinib,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> erlotinib,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> and baricitinib<a onclick="showRef(event, 'ref44 ref86'); return false;" href="javascript:void(0);" class="ref ref44 ref86">(44,86)</a>) and AXL kinase inhibitor (gilteritinib: SARS-CoV-2, IC<sub>50</sub> of 0.807 Î¼M)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> for the treatment of coronavirus infection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Sunitinib is an approved multitargeted kinase inhibitor used for renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) treatment. Erlotinib is an EGFR tyrosine kinase inhibitor, which has been licensed by the FDA for the treatment of metastatic non-small cell lung cancer (NSCLC) and pancreatic cancer. Erlotinib is one of the World Health Organizationâs Essential Medicines.</div><div class="NLM_p">Baricitinib (2-[1-ethylsulfonyl-3-[4-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile) has recently been suggested as a promising inhibitor of SARS-CoV-2 activity (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Indeed, baricitinib showed a promising result for ARDS in COVID-19. In November 2020, the FDA approved baricitinib for emergency use authorization (EUA) status for COVID-19 care in hospitalized patients in combination with remdesivir.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Baricitinib is an inhibitor of Janus kinase-1 (JAK-1) and JAK-2, and it has been licensed for treating rheumatoid arthritis and myelofibrosis.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><div class="NLM_p">ACE2 has several regulators, among which AAK1 and G-associated kinase (GAK) are known for clathrin-mediated endocytosis. The mode of action of baricitinib on viral entry and controlling ARDS are indicated in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. Baricitinib not only reduced the ARDS in patients but also interrupted the passage and intracellular assembly of SARS-CoV-2 into the target cells by inhibiting the AAK1 signaling. Furthermore, the clinical dose of baricitinib (2 or 4 mg once daily) rendered it superior as an antiviral agent. In vitro studies demonstrated baricitinibâs antiviral properties, and therapy with baricitinib boosted the clinical results of COVID-19 patients. Baricitinib reduced the SARS-CoV-2 viral load by 30â40% in primary human liver spheroids at 400 and 500 nM concentrations, indicating antiviral activity.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> In human clinical trials with effectiveness in rheumatoid arthritis (RA) patients, baricitinib had a high oral bioavailability (79%) and was well tolerated.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Furthermore, baricitinib is a unique candidate for the treatment of COVID-19 because of its favorable side-effect profile, low plasma protein binding, and negligible involvement with CYP enzymes.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Baricitinib inhibits JAK1 and thereby prevents SARS-CoV-2 entry and ARD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Baricitinibâs possible role in the treatment of COVID-19 patients has recently been highlighted. The study examined the safety and effectiveness of baricitinib in COVID-19 patients and found that it provided substantial clinical improvement with no infections or side effects 2 weeks after treatment. These findings indicated that using baricitinib for a brief period (1â2 weeks) was the best way to mitigate viral replication and an abnormal host inflammatory response when on the therapeutic dosage.</div><div class="NLM_p">Another study demonstrated baricitinib as a potential drug to reduce systematic inflammation caused by SARS-CoV-2 infection in rhesus macaques.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Inflammation was minimized in animals given baricitinib. More specifically, baricitinib-treated animals had a rapid and potent inhibition of inflammation-related cytokines and chemokines. These data indicated the beneficial role of baricitinib as a potential candidate for the management of inflammation induced by SARS-CoV-2 infection.</div><div class="NLM_p">The antiviral effect of baricitinib is being studied in several clinical trials either alone or combined with other antivirals for COVID-19 (<a href="https://clinicaltrials.gov/ct2/results?cond=Baricitinib" class="extLink">https://clinicaltrials.gov/ct2/results?cond=Baricitinib</a>) (see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The anti-SARS-CoV actions of baricitinib in conjunction with remdesivir are being studied in the Adaptive COVID-19 Treatment Trial (ACTT-2; NCT04401579). The FDA approved this combination in November 2020 for emergency use in hospitalized COVID/19 patients who need oxygen.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Baricitinib is being studied as a monotherapy in the COV-BARRIER trial (NCT04421027). Also, baricitinib is proposed to interrupt the passage and intracellular assembly of SARS-CoV-2 into the target cells mediated by the ACE2 receptor.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. List of Baricitinib Clinical Trials for the Treatment of COVID-19</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">clinical trial identifier and use</th><th class="colsep0 rowsep0" align="center">primary end point</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04345289, Phase III: Baricitinib, sarilumab, hydroxychloroquine (HQ), convalescent plasma, intravenous and subcutaneous placebo, or oral placebo were both included in this study</td><td class="colsep0 rowsep0" align="left">mortality due to any cause or the need for intrusive respiratory support</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04390464, Phase IV: baricitinib and ravulizumab</td><td class="colsep0 rowsep0" align="left">composite end pointâs time to occurrence: death, artificial breathing, ECMO, cardiovascular organ support, or renal failure</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04401579, Phase III: baricitinib + remdesivir compared with remdesivir alone</td><td class="colsep0 rowsep0" align="left">time to recovery</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04321993; (i) lopinavir/ritonavir; (ii) HQ; (iii) baricitinib; and (iv) sarilumab are the four arms of the study</td><td class="colsep0 rowsep0" align="left">clinical status of subject at day 15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04362943, Observational: baricitinib or anakinra</td><td class="colsep0 rowsep0" align="left">mortality for all causes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04365764, Observational: specific therapies, such as baricitinib, but not limited to it</td><td class="colsep0 rowsep0" align="left">respiratory support and mortality as a composite</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04320277, Phase III: baricitinib</td><td class="colsep0 rowsep0" align="left">percent of patients who need ICU admission</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04346147, HQ in combination with baricitinib, imatinib, or lopinavir/ritonavir in the early stages</td><td class="colsep0 rowsep0" align="left">time to clinical improvement</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04346147, Phase II: baricitinib + HQ + imatinib, or lopinavir/ritonavir</td><td class="colsep0 rowsep0" align="left">time to clinical improvement</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04366206, Observational: relevant treatments, such as baricitinib, although not limited to it</td><td class="colsep0 rowsep0" align="left">composite of death and mechanical ventilation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04393051, Phase II: baricitinib</td><td class="colsep0 rowsep0" align="left">need of invasive mechanical ventilation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04340232, Phase II/III: baricitinib</td><td class="colsep0 rowsep0" align="left">Baricitinibâs safety (Phase II) and effectiveness (Phase II and III)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04373044, Phase II: baricitinib</td><td class="colsep0 rowsep0" align="left">percentage of patients who need intrusive mechanical ventilation or who die</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04399798, Phase II: baricitinib</td><td class="colsep0 rowsep0" align="left">response to treatment: absence of moderate to severe oxygenation impairment</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04358614, Phase II/III: baricitinib + lopinavir/ritonavir</td><td class="colsep0 rowsep0" align="left">the aim of this study was to determine the efficacy of baricitinib in combination with an antiviral (lopinavir-ritonavir) in terms of the rate of serious and nonserious adverse effects</td></tr></tbody></table></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.4.  AXL Kinase Inhibitors</h3><div class="NLM_p">AXL, a tyrosine kinase on the cell surface, controls cell replication, growth, differentiation, and immunity.<a onclick="showRef(event, 'ref95 ref96 ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref95 ref96 ref97 ref98">(95â98)</a> Upon activation by its ligands such as vitamin-K-dependent protein growth-arrest-specific gene 6 (GAS 6), AXL stimulates various downstream signaling pathways that include RAS/ERK, PI3K-AKT-mTOR, MEK-ERK, NF-ÎºB, JAK/STAT, and p38.<a onclick="showRef(event, 'ref99 ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref99 ref100 ref101">(99â101)</a></div><div class="NLM_p">For the Zika virus<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> and the Ebola virus,<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> AXL has been confirmed to serve as a viral entry factor/immune modulator. AXL a has crucial role in the relationship between the virus and the host. AXL facilitated virus entry and modulated the antiviral state of human Sertoli cells during Zika virus infection.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> AXL inhibition led to decreased suppressor of the cytokine signaling-1 (SOCS1) and SOCS3 proteins, increased expression of IFNÎ³, and reduced replication. In a recently published study, the authors discovered that AXL interacts with the SARS-CoV-2 S glycoprotein on the host cell membrane, allowing the virus to enter the cell.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> SARS-CoV-2 virus entry into pulmonary and bronchial epithelial cells was substantially reduced when AXL was knocked down in H1299 and A549 cells, indicating that AXL is needed for SARS-CoV-2 virus entry.</div><div class="NLM_p last">Recently, gilteritinib (6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) was reported to inhibit the replication of SARS-CoV-2 with an IC<sub>50</sub> value of 0.807 Î¼M in cellular assays.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The inhibition of AXL kinase, which is upstream of p38, led to gilteritinibâs anti-SARS-CoV-2 replication function. The use of bemcentinib, an AXL inhibitor, in the RECOVERY COVID-19 trial in the United Kingdom, backs up this argument. Gilteritinib is a tyrosine kinase inhibitor105 that has been licensed for the treatment of AML.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.5.  EGFR Signaling Pathway Inhibitors</h3><div class="NLM_p">The epidermal growth factor receptor (EGFR) is a prototypical tyrosine kinase (RTK) receptor. Activation of the EGFR signaling pathway influences a range of cell functions, including cell proliferation, survival, growth, and development.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> The EGFR signaling pathway has been identified as one of the crucial players in cancer pathogenesis and has also been linked to various viruses,<a onclick="showRef(event, 'ref107 ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref107 ref108 ref109">(107â109)</a> such as the spread and mortality of the vaccinia virus and the process of entry for influenza A, HCV, and EpsteinâBarr viruses.<a onclick="showRef(event, 'ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref110 ref111">(110,111)</a></div><div class="NLM_p">EGFR is a cofactor for HCV entry into human host cells. Activation of EGFR signaling leads to suppressed interferon signaling in respiratory virus diseases (influenza and rhinovirus).<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> A loss of functional STAT1 has been associated with the upregulation of EGFR, which may indirectly activate STAT3 constitutively. As a result, targeting EGFR as an approach to managing COVID-19 could be a viable option. A synergized antiviral reaction against HCV was observed when a possible EGFR inhibitor, erlotinib, was combined with IFN-1 therapy. The reduction of IFN1-induced STAT3 by enhancing SOCS3 expression was the mode of the action of erlotinib.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><div class="NLM_p">Osimertinib (<i>N</i>-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1<i>H</i>-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide) was reported to be an effective inhibitor of SARS-CoV-2 S protein (EC<sub>50</sub> 3.98 Î¼M) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> It rescued 60% of the SARS-CoV-2 cytopathogenic effect (CPE), though cytotoxicity limited the therapeutic window.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Osimertinib is an EGFR inhibitor that has been approved for the treatment of NSCLC.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibitors of SARS-CoV-2 and MERS-CoV replication that target EGFR and its downstream signaling pathways. Osimertinib, SARS-CoV-2 S: IC<sub>50</sub> 3.98 Î¼M;<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> pictilisib: SARS-CoV-2, IC<sub>50</sub> 2.58 Î¼M;<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> omipalisib: SARS-CoV-2, IC<sub>50</sub> 0.014 Î¼M;<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> sorafenib: SARS-CoV-2, IC<sub>50</sub> 4.85 Î¼M<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> RO5126766: SARS-CoV-2, IC<sub>50</sub> 0.6 Î¼M;<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> lonafarnib: SARS-CoV-2, IC<sub>50</sub> 4.99 Î¼M;<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> everolimus: 56 or 59% MERS-CoV inhibition;<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> miltefosine: 28% MERS-CoV inhibition;<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> wortmannin: 40% MERS-CoV inhibition;<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> rapamycin: 40% MERS-CoV inhibition.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.6.  PI3K/Akt/mTOR Pathway Inhibitors</h3><div class="NLM_p">GFRs integrate and regulate several signaling processes inside the cell. GFR signaling (1) activates the RAF/MEK/ERK MAPK signaling cascade and (2) incorporates (via phosphatidylinositol 3-kinase [PI3K] protein kinase B [AKT]) into mTORC1 signaling to control proliferation.</div><div class="NLM_p">Klann et al. recently confirmed that many EGFR inhibitors inhibited the replication of SARS-CoV-2.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> They used the colon epithelial cell line Caco-2, which is extremely permissive for the virus, to create a SARS-CoV-2-infected in vitro cell culture model.<a onclick="showRef(event, 'ref116 ref117'); return false;" href="javascript:void(0);" class="ref ref116 ref117">(116,117)</a> The cellular phosphoprotein networks revealed extensive cellular signaling pathway rearrangements after infection with SARS-CoV-2, especially GFR signaling. Pictilisib (IC<sub>50</sub> 2.58 Î¼M), a PI3K inhibitor, and omipalisib (IC<sub>50</sub> 0.014 Î¼M), a dual PI3K/mTOR inhibitor, inhibited viral replication in cells<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><div class="NLM_p">Sorafenib (IC<sub>50</sub> 4.85 Î¼M) and RO5126766 (IC<sub>50</sub> 0.6 Î¼M), a dual RAF/MEK inhibitor, both blocked viral replication (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). During infection and viral replication, both compounds blocked cytopathic effects. Lonafarnib, a RAS inhibitor, inhibited the replication of SARS-CoV-2 (IC<sub>50</sub> value of 4.99 Î¼M) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Antiviral activity of these drugs was reported in UKF-RC-2 cells infected with SARS-CoV-2 at clinically achievable concentrations,<a onclick="showRef(event, 'ref118 ref119 ref120 ref121 ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref118 ref119 ref120 ref121 ref122 ref123">(118â123)</a> highlighting the importance of GFR signaling during SARS-CoV-2 infection. Before the MERS-CoV infection, cells treated with sorafenib, a RAF kinase inhibitor approved for primary kidney cancer treatment, demonstrated good inhibition of the early phases of replication.</div><div class="NLM_p">EGFR-mediated STAT3 activation is controlled by the RAS/RAF/MAPK and PI3K pathways, and inhibition of these pathways will potentiate IFN-1 and anti-SARS-CoV-2 activity in a synergistic manner. GFR signaling is also implicated in SARS-CoV-1-induced fibrosis.<a onclick="showRef(event, 'ref107 ref109 ref115 ref116 ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref107 ref109 ref115 ref116 ref124 ref125">(107,109,115,116,124,125)</a> An inhibitor, omipalisib, has been shown to slow fibrosis development in patients with idiopathic pulmonary fibrosis, which may be related to the deregulation of GFR signaling pathways in coronavirus patientsâ lung fibrosis.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a></div><div class="NLM_p">Several unrelated viruses activate the PI3K/Akt/mTOR pathway to enhance their replication.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> For example, HCV<a onclick="showRef(event, 'ref124 ref129'); return false;" href="javascript:void(0);" class="ref ref124 ref129">(124,129)</a> and WNV utilize this pathway in their life cycle and control apoptosis. Everolimus (dihydroxy-12-[(2<i>R</i>)-1-[(1<i>S</i>,3<i>R</i>,4<i>R</i>)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), an approved mTOR inhibitor, showed moderate inhibitory activity (56 or 59% inhibition at 10 Î¼M) against MERS-CoV based on whether it was added pre- or postinfection. Miltefosine (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), an approved Akt inhibitor for leishmanial infection, had minimal (28%) or no activity against MERS-CoV at the highest concentration tested when added preor postinfectionally.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Teriflunomide, an active metabolite of leflunomide, on the other hand, demonstrated good anti-HCV activity in both in vitro and in vivo studies.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Leflunomide, a drug that inhibits Akt phosphorylation, has been approved for rheumatoid arthritis.</div><div class="NLM_p last">AXL is known to control various signaling pathways including PI3K, Ras/ERK, and p38. Therefore, the inhibition of AXL may contribute to the downregulation of p38 signaling. PI3K/Akt/mTOR activation has been demonstrated in the growth and replication of various unrelated viruses such as HCV, WNV, and influenza A virus.<a onclick="showRef(event, 'ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref128 ref129">(128,129)</a> Wortmannin (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), a covalent inhibitor of PI3Ks, had a 40% inhibitory effect on MERS-CoV. At a concentration of 10 Î¼M, the mTOR inhibitor rapamycin (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) inhibited MERS-CoV replication in virus-infected cells by 61%.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Rapamycin is a macrolide compound and has an immunosuppressant function in humans.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">3.7.  Cyclin Dependent Kinases (CDKs) Inhibitors</h3><div class="NLM_p">CDKs are kinases that control the cell cycle and have been targeted for anticancer drugs. CDKs are also used in infectious diseases, where the virus alters the expression and function of host CDKs to influence cell cycle progression.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> For example, several viruses, such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), Zika virus, and herpes simplex virus (HSV) have been linked to CDKs.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> CDK4 and CD6 have been validated as potential targets for the inhibition of HIV-1 infection,<a onclick="showRef(event, 'ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref132 ref133">(132,133)</a> and CDK9 for herpes simplex virus type 1 (HSV-1) infection.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> An adenovirus promotes progression into the late G1/S process by increasing CDK2 phosphorylation.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> HBV infection increases the activity of the G1-phase CDK4.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Several CDK inhibitors such as dinaciclib (an inhibitor of CDK1/2/5/9, Phase III), seliciclib (an inhibitor of CDK2/5, Phase II), alvocidip (an inhibitor of CDK9, Phase II), and PHA-690509 (CDK2 inhibitor, Phase I) displayed a broad spectral antiviral activity against HIV-1,<a onclick="showRef(event, 'ref137 ref138'); return false;" href="javascript:void(0);" class="ref ref137 ref138">(137,138)</a> influenza A virus,<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> and Zika (for structures, see <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. CDK inhibitors as antiviral agents. Dinaciclib: SARS-CoV-2, IC<sub>50</sub> 0.127 Î¼M (Vero E6), IC<sub>50</sub> 0.032 Î¼M (A549-ACE2);<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> apilimod: SARS-CoV-2, IC<sub>50</sub> < 0.08 Î¼M (Vero E6), IC<sub>50</sub>0.007 Î¼M (A549-ACE2);<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> abemaciclib, SARS-CoV-2: EC<sub>50</sub> 2.16 Î¼M.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Alvocidib (2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3<i>S</i>,4<i>R</i>)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), a flavonoid alkaloid CDK9 kinase inhibitor and commonly known as flavopiridol, showed activity against influenza A virus, in which CDK9 mediated the activity of RdRP.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Palbociclib (6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), a licensed inhibitor of CDK4/6, was able to inhibit HSV-1, and HSV-1 replication in vitro, possibly through a blockade of cellular protein phosphorylation.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></div><div class="NLM_p">SARS-CoV-2 significantly reduced CDK1/2 behaviors during infection, resulting in an S/G2 phase arrest, close to infectious bronchitis virus (IBV),<a onclick="showRef(event, 'ref142 ref143'); return false;" href="javascript:void(0);" class="ref ref142 ref143">(142,143)</a> and other RNA viruses,<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144,145)</a> according to a recent report. This indicates that the SARS-CoV-2 virus can control the cell cycle to boost the viral life cycle.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Dinaciclib is being tested in clinical studies for different types of variety of cancer. Recently, dinaciclib has shown strong anti-SARS-CoV-2 activity.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The antiviral activity of dinaciclib in two cell lines (Vero E6 and A549-ACE2 cells) infected with SARS-CoV-2 showed IC<sub>50</sub> 0.127 Î¼M and IC<sub>50</sub> 0.032 Î¼M, respectively.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The phosphatidylinositol enzyme activities of PIK3CQ, PLCB3, and PIKFYVE were also highlighted in the same study showing that the required balance of phosphatidylinositol species may play a role.</div><div class="NLM_p">The pharmacological inhibition of PIKFYVE, an FYVE finger-containing phosphoinositide kinase, by its inhibitor apilimod (<i>N</i>-[(<i>E</i>)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) exhibited strong anti-SARS-CoV-2 activity in two cell lines (Vero E6, IC<sub>50</sub> < 0.08 Î¼M; A549-ACE2, IC<sub>50</sub> 0.007 Î¼M). Apilimod was first discovered as an inhibitor of IL-12 and IL-23, but it was recently repurposed for Ebola and Lassa virus fever.<a onclick="showRef(event, 'ref147 ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref147 ref148 ref149">(147â149)</a></div><div class="NLM_p last">Interestingly, abemaciclib (<i>N</i>-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1<i>H</i>-benzimidazol-6-yl]-2-pyrimidinamine) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) showed specific inhibition of SARS-CoV-2 S (EC<sub>50</sub> in Calu3 cell lines).<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> The SARS-CoV-2 CPE was reduced by 60% using this compound.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Abemaciclib is a selective CDK4/6 inhibitor that has been used for the treatment of metastatic breast cancer.<a onclick="showRef(event, 'ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref150 ref151">(150,151)</a> In general, CDK inhibitors block viral genome replication in host cells as part of their antiviral mechanism of action.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Abemaciclib, on the other hand, inhibits coronavirus CPE by blocking cell entry, meaning that this compound may be optimized as an active SARS-CoV-2 entry inhibitor.</div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">3.8.  Casein Kinase 2 Inhibitors</h3><div class="NLM_p">Casein kinase 2 (CK2/CSNK2) regulates various cellular processes and is essential for the life cycle of several unrelated viruses such as vesicular stomatitis virus (VCV), HIV, HCV, human papillomavirus (HPV), and HSV-1.<a onclick="showRef(event, 'ref152 ref153'); return false;" href="javascript:void(0);" class="ref ref152 ref153">(152,153)</a> Recent shreds of evidence suggest that CK2 is involved in various mechanisms to downregulate the potential of cells to generate IFN-1 in response to viral infection.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Thus, the pharmacological intervention of CK2 has been considered a potential strategy for antiviral treatment. CK2 is involved in the development of actin tails during vaccinia infection, which allows the virus to travel efficiently from cell to cell.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> The inhibition of CK2 by its selective inhibitor TBBz (at 8.0 Î¼M concentration) impaired the vaccinia virus spread and actin tail formation. According to a recent analysis, the SARS-CoV-2 nucleocapsid (N) directly targets CK2, and they both colocalize at the filopodia protrusions, which may be essential for virus egress and rapid cell-to-cell spread.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p">The inhibition of CK2 by silmitasertib (5-[(3-chlorophenyl)amino]benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic acid) displayed robust antiviral activity (IC<sub>50</sub> 1.28 Î¼M) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), suggesting the significant role of CK2 in the life cycle of SARS-CoV-2. Silmitasertib is being tested in clinical and preclinical trials to treat cholangiocarcinoma and other cancers. Recently, Phase II clinical studies of silmitasertib have been initiated for the management of COVID-19 (<a href="https://www.scienceboard.net/index.aspx?sec=sup&amp;sub=can&amp;pag=dis&amp;ItemID=1645" class="extLink">https://www.scienceboard.net/index.aspx?sec=sup&sub=can&pag=dis&ItemID=1645</a>).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. CK2 inhibitors for SARS-CoV-2 (silmitasertib: IC<sub>50</sub>1.28 Î¼M),<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> vaccinia virus (4,5,6,7-tetrabromo-1<i>H</i>-benzimidazole (TBBz)),<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> and quercetin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The recent clinical trial of intravenous CIGB-325 (formerly known as CIGB-300), a peptidic inhibitor of CK2, in patients with COVID-19 (<a href="https://covid-19.cochrane.org/studies/crs-13844822" class="extLink">https://covid-19.cochrane.org/studies/crs-13844822</a>, code: IG/CIGB300I/CV/2001) investigated the function of CK2 in coronavirus infection.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Twenty patients were randomly allocated to receive either CIGB-325 (2.5 mg/kg/day for 5 days) plus standard-of-care (10 patients) or standard-of-care alone (10 patients). In COVID-19 patients with pneumonia on day 7 received a mixture of CIGB-325 and standard-of-care enhanced chest computed tomography (CT). This study proposed that inhibiting CK2 could be a good way to treat COVID-19.</div><div class="NLM_p last">For the treatment of COVID-19, a significant number of CK2 inhibitors must be investigated. For example, quercetin and enzymatically modified isoquercitrin (EMIQ) have been suggested as potential candidates.<a onclick="showRef(event, 'ref154 ref157'); return false;" href="javascript:void(0);" class="ref ref154 ref157">(154,157)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">4.  Kinase Pathway Inhibitors as Anti-inflammatory, Cytokine-Suppressive, or Antifibrotic Agents in COVID-19</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52248" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52248" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">4.1.  Inhibitors of the p38 MAPK Signaling Pathway</h3><div class="NLM_p">The p38 MAPK signaling pathway is activated by various factors, such as environmental stress, pathogenic infection, and proinflammatory cytokines, and is involved in cell differentiation, apoptosis, and autophagy. Several pathogenic viruses, including SARS-CoV-1, DENV, and IBA activate the p38 MAPK, which results in unregulated inflammatory responses linked to serious diseases. Therefore, the p38 MAPK pathway could be used to regulate proinflammatory cytokine production caused by multiple viral infections.<a onclick="showRef(event, 'ref158 ref159 ref160'); return false;" href="javascript:void(0);" class="ref ref158 ref159 ref160">(158â160)</a></div><div class="NLM_p">The reason for death in COVID-19 patients mainly occurs due to the overwhelming inflammatory effect that leads to ARDS and myocarditis.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> The p38 MAPK pathway has previously been linked to the inflammatory response in animal models of acute lung injury and myocarditis.<a onclick="showRef(event, 'ref162 ref163'); return false;" href="javascript:void(0);" class="ref ref162 ref163">(162,163)</a> The p38 MAPK pathway is activated, which enhances the synthesis of cytokines including IL-6, TNF-Î±, and Î².<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Therefore, it has been proposed that the upregulation of the p38 MAPK pathway may be one of the causes of inflammatory injury in SARS-CoV-2 patients.</div><div class="NLM_p">SARS-CoV-2 uses ACE2 to enter host cells, much as SARS-CoV-1 did.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Studies revealed that, following SARS-Co-1 infection, ACE2 expression is reduced in lungs, leading to disruption of the renin-angiotensin system.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> ACE2 transforms angiotensin II (Ang1â8) to angiotensin I (Ang1â7), which activates the Mas receptor and induces the anti-inflammatory, antiproliferogenic, antifibrogenic, and vasodilation effects by downregulation of p38 MAPK activation (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Angiotensin II activation of p38 MAPK, on the other hand, indicates proinflammatory, provasoconstrictive, and prothrombotic action. The p38 MAPK network is complicated, and it interacts with several signaling pathways and proinflammatory cytokines that cause ARDS and organ damage in SARS-CoV-1 and SARS-CoV-2 patients.<a onclick="showRef(event, 'ref168 ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref168 ref169 ref170">(168â170)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Role of p38 MAPK, as well as its interactions with other signaling pathways and inflammatory cytokines.<a onclick="showRef(event, 'ref167 ref168 ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref167 ref168 ref169 ref170">(167â170)</a> GM-CSF, granulocyte macrophage-colony stimulating factor; IL, interleukin; MIP, macrophage inflammatory protein; MCP, monocyte chemoattractant protein; TNF, tumor necrosis factor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It has been proposed that the viral entry suppresses the ACE2 activity to produce Ang1â7, leading to an increased expression of inflammatory responses by activating the p38 MAPK pathway in the lungs and heart. Additionally, p38 MAPK activation upregulates ADAM17, reducing the supply of ACE2 activity even further.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Therefore, ACE2 inhibitors or ACE blockers that balance the renin-angiotensin system may be useful for COVID-19 management.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Indeed, proinflammatory AngII levels were linearly correlated with the degree of lung damage and viral load in a recent study of COVID-19 patients, implying a RAS deficiency in the pathogenesis of COVID-19.<a onclick="showRef(event, 'ref172 ref173'); return false;" href="javascript:void(0);" class="ref ref172 ref173">(172,173)</a></div><div class="NLM_p">Bouhaddou et al. recently investigated whether the p38 MAPK pathway was involved in the formation of cytokines in SARS-CoV-2-infected ACE2-A549 cells that were treated with the p38 inhibitor SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-imidazole, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In a dose-dependent way, the inhibitor reduced the mRNA of cytokines such as IL-6, TNF, and others that were elevated during infection. Interestingly, this p38 inhibition led to reducing SARS-CoV-2 replication without significant cellular cytotoxicity. In an ELISA study of supernatant cells, SB203580 inhibited the expression of IL-6, CXCL8, CCL20, and CCL2. An anti-SARS-CoV-2 N protein antibody-based assay confirmed SB203580s inhibitory activity in viral reduction. They also reported that SARS-CoV-2 infection caused cell cycle arrest between the S and G2 phases, implying that p38 activity and cell cycle arrest are systematically related during infection. At a 10 Î¼M concentration, SB203580 prevented MERS-CoV by 45% through p38/MAPK.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> SB203580 showed antiviral activity against HCoV-229E and, at 4 Î¼M concentration, reduced the viral RNA by â¼60%.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Inhibitors of the p38 MAPK pathway for the treatment of COVID-19 (Gilteritinib: SARS-CoV-2, IC<sub>50</sub> 0.807 Î¼M;<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> ralimetinib: SARS-CoV-2, IC<sub>50</sub> 0.873 Î¼M;<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> MPAK13-IN-1: SARS-CoV-2, IC<sub>50</sub>4.63 Î¼M;<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> ARRY 371797: SARS-CoV-2, IC<sub>50</sub> 0.913 Î¼M).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In ACE2-A549 cells, the MAPK signaling pathway dependency of SARS-CoV-2 infection was investigated during viral infection. Bouhaddou et al. found that SARS-CoV-2 infection promotes different p38 MAPK signals in ACE2-A549 cells.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Effective viral inhibitory activities were identified for gilteritinib (IC<sub>50</sub> 0.807 Î¼M), AXL inhibitor;<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> ralimetinib (IC<sub>50</sub>0.873 Î¼M), MAPK11 (p38Î±) and MAPK14 (p38Î²) inhibitor,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> MAPK13-IN-1 (IC<sub>50</sub> 4.63 Î¼M), MAPK13 (p38-Î´) inhibitor;<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and ARRY-797 (IC<sub>50</sub>0.913 Î¼M),<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> an inhibitor of MAPK14. 20(<i>S</i>)Ginsenoside is a plant-derived glycoside that inhibits MAPK. It has antiviral activity against mCoV in vitro, with an IC<sub>50</sub> of 10 Î¼M. 20(<i>S</i>)Ginsenoside inhibits mCoV by suppressing the p38/JNK/MAPK signaling pathway.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><div class="NLM_p">The presence of another small molecule AXL inhibitor, bemcentinib, in the RECOVERY COVID-19 Phase II clinical trial COVID-19 patients backed up gilteritinibâs antiviral efficacy.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Bemcentinib was previously reported to show potent antiviral activity against Ebola and Zika virus in preclinical studies.<a onclick="showRef(event, 'ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref176 ref177">(176,177)</a> Ralimetinib is being tested in Phase II clinical trials for ovarian cancer,<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> and ARRY-797 is being tested in Phase III clinical trials for cardiomyopathy, a degenerative cardiovascular disease.</div><div class="NLM_p last">Some previous reports revealed that p38 is directly involved in the replication of respiratory viruses like SARS-CoV-1 and H5N1.<a onclick="showRef(event, 'ref179 ref180 ref181'); return false;" href="javascript:void(0);" class="ref ref179 ref180 ref181">(179â181)</a> p38 MAPK signaling induces the receptor-mediated endocytosis for the viral entry,<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> and its activation is also employed in the endocytosis of ACE2.<a onclick="showRef(event, 'ref183 ref184 ref185'); return false;" href="javascript:void(0);" class="ref ref183 ref184 ref185">(183â185)</a> These findings indicated that SARS-CoV-2 may use a related mechanism to activate p38 MAPK directly. Indeed, SARS-CoV-2 triggered p38 MAPK in vitro, according to a recent report.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Treatment of SARS-CoV-1 infected mice with a p38 inhibitor resulted in an 80% survival rate in the treatment community relative to the control group in a preclinical trial (0%).<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">4.2.  JAK-STAT Signaling Pathway Inhibitors</h3><div class="NLM_p">When cells detect a viral attack, they activate numerous downstream interferon regulatory factors, which cause IFN-1, IFN-II, and IFN-III to be generated.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> IFNs attach to receptors on nearby cells, signaling them to be on the lookout for a viral threat. This IFN receptor engagement activates various members of Janus kinases and the signal transducers and activators of transcriptions (JAK-STAT) signaling pathway families.</div><div class="NLM_p">The JAK-STAT signaling pathway is one of the main regulatory cell signaling cascades for many cytokines and growth factors.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> The nonreceptor JAK family includes JAK1, JAK2, JAK3, and tyrosine kinase 2 (Tyk2) proteins. The STAT family comprises STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. The JAK-STAT signaling cascade regulates cell growth and differentiation, oxidative stress, and immune modulation, among other biological functions (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Hyperactivation of the immune response and cytokine storm through the JAK-STAT signaling pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The JAK-STAT signaling pathway has been unraveled in many DNA and RNA viruses. The interaction of HCV protein with JAK1 through its proline-rich motif is necessary for the development of infectious viruses, indicating that JAK1âs function in the HCV life cycle is critical.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> The JAK-STAT signaling pathway is crucial for the HIV replication via the stimulation of IL-2 by T cells activation in T-lymphocytes. Coronavirus utilizes a variety of mechanisms to hamper IFN production and response.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> For example, SARS-CoV-1 NSP1 and ORF6 are the main factors that utilize multiplication to measure IFN production and response. As a result, the antiviral JAK1-STAT1 signaling pathway response is inhibited while STAT3 is activated in a compensating manner.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> STAT3 is a receptor for a harmful IL-6 to stimulate TGF-1Î², which may show a crucial role in pulmonary fibrosis development observed in COVID-19 patients.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a></div><div class="NLM_p">Several studies have shown that, in patients with serious COVID-19 infection, the level of cytokines is elevated.<a onclick="showRef(event, 'ref192 ref193'); return false;" href="javascript:void(0);" class="ref ref192 ref193">(192,193)</a> These include IL-1, IL-2, L-6, IL-7, IL-10, TNF-Î±, granulocyte colony-stimulating hormone, interferon-inducible protein-1Î±, MCP-1, and MIP-1Î±. Cytokines have crucial roles in ARDS development, leading to multiple organ failure and even death in patients with COVID-19. This suggests that blocking the cytokine storm through the JAK-STAT signaling cascade may be a potential approach to enhance COVID-19 clinical management techniques currently in use.<a onclick="showRef(event, 'ref194 ref195 ref196 ref197'); return false;" href="javascript:void(0);" class="ref ref194 ref195 ref196 ref197">(194â197)</a> Indeed, several clinical trials are underway investigating JAK-STAT signaling pathway inhibitors in patients with COVID-19. Inflammation-related disorders such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis are all treated with JAK inhibitors. Selected examples are ruxolitinib,<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> baricitinib,<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> tofacitinib,<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> fedratinib,<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> oclacitinib,<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> and upatacitinib.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a></div><div class="NLM_p">The preservation of JAK1-STAT1 function is one of the first considerations in treating SARS-CoV-2 infection (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). The virus works by delaying an antiviral reaction while hijacking cellular processes for multiplication. If the infection is identified early, however, using IFN-1 to stimulate JAK1 for the antiviral response may be a viable approach.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Cytokines and their interaction with JAK signaling pathways in the development of cytokine storm caused by SARS-CoV-2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the other hand, a delay in IFN-1 treatment would fail to suppress the viral infection and induce cytokines, leading to fatal pneumonia.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Since the upper respiratory tract is the main site for viral replication, mucosal therapies of IFN-1 were suggested as a way of preventing SARS-CoV-2. Meng et al. found that using IFN-1 nasal drops in combination with thymosin 1, an immune stimulator, prevented symptoms in over 500 high-risk healthcare workers who came into contact with SARS-CoV-2 affected patients with COVID-19 pneumonia.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a></div><div class="NLM_p">Some studies have suggested that the H2-mediated antiviral effect could reduce the mortality rate of patients with COVID-19.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> For example, histamine antagonists may promote the STAT1 activation and IFN response. Indeed, the administration of famotidine (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), a histamine H2 receptor blocker, was correlated with a 2-fold decrease in clinical worsening leading to intubation or death in COVID-19 patients. However, it did not show any direct antiviral activity in vitro in Vero E6 cells, although computational studies suggested that famotidine could directly bind to the SARS-CoV-2 NSP5.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structure of H2 antagonist famotidine<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> and the broad spectral antiviral agent ivermectin (SARS-CoV-2; IC<sub>50</sub>2.2â2.8 Î¼M).<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ivermectin is an antiparasitic and antiviral drug with a wide range of action. It showed antiviral activity against distinct positive-sense single-strand RNA viruses, which include SARS-CoV-2. With an IC<sub>50</sub> of 2.2â2.8 Î¼M, ivermectin (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) inhibited SARS-CoV-2 in the cellular study, making it a possible candidate for the COVID-19 drug repurposing approach.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> Authors claimed that ivermectin blocked the nuclear transport of viral proteins mediated by KPNA/KPNB1. On the other hand, ivermectin inhibits STAT3 and IL-6 production by inhibiting p21 activated kinase (PAK1), an oncogenic serine-threonine kinase.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a></div><div class="NLM_p">Aberrantly activated STAT3 can also be controlled by regulation of endogenous inhibitor PIAS3.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> Some inhibitors like curcumin and resveratrol have shown to be promising in suppressing the constitutive activity of STAT3<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> through upregulation of PIAS3. However, they did not show any effect in any randomized, placebo-controlled clinical trials, although both have been widely used for many indications.</div><div class="NLM_p">Tofacitinib (3-[(3<i>R</i>,4<i>R</i>)-4-methyl-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile) (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) is an orally available JAK inhibitor that is approved as an anti-inflammatory agent to treat RA, an autoimmune disease. It inhibits JAK3 and TYK2 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) with an EC<sub>50</sub> of less than 5 nM, suppressing inflammatory cytokines like IL-2, IL-4, IL-6, and IL-7 that are linked to RA.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Inhibitors (tofacitinib,<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> fedratinib,<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> and ruxolitinib<a onclick="showRef(event, 'ref223 ref224'); return false;" href="javascript:void(0);" class="ref ref223 ref224">(223,224)</a>) that target the JAK-STAT pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Tofacitinib has a decent pharmacokinetic profile, with 74% oral bioavailability and a half-life of 2.3â3.1 h.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> In RA patients, tofacitinib showed a consistent safety profile and efficacy. However, there is a risk of herpes zoster, cellulitis infections, and thrombosis with the use of tofacitinib.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> This drug was demonstrated to be effective in COVID-19 patients who had a 13-year history of ulcerative colitis. All symptoms were resolved without the need for hospitalization after 2 weeks, according to the recent report.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a></div><div class="NLM_p">The study suggested that tofacitinib therapy can be continued in patients suffering from SARS-CoV-2, but it was not shown that tofacitinib helped patients recover from COVID-19 in this situation. Several clinical trials have been started to see how it will help with COVID-19 (see, for example, in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Clinical Trials of Tofacitinib for the Management of COVID-19</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">clinical trial identifier and use</th><th class="colsep0 rowsep0" align="center">primary end point</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04412252, Phase II: tofacitinib</td><td class="colsep0 rowsep0" align="left">using an ordinal scale to assess clinical condition</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04390061, Phase II: tofacitinib plus hydroxychloroquine versus hydroxychloroquine</td><td class="colsep0 rowsep0" align="left">mechanical ventilation is needed to prevent serious respiratory failure</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04415151, Phase II: tofacitinib</td><td class="colsep0 rowsep0" align="left">disease severity</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT04332042, Phase II: tofacitinib</td><td class="colsep0 rowsep0" align="left">rates of artificial ventilation, ICU entry, mortality, and adverse events in patients</td></tr></tbody></table></div></div><div class="NLM_p">Another report proposed the selective JAK2 inhibitor fedratinib (<i>N</i>-<i>tert</i>-butyl-3-{5-methyl-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-pyrimidin-4-ylamino}-benzenesulfonamide) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a> and <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>) that has been accepted for myelofibrosis as a possible candidate in COVID-19 management to suppress TH17-associated cytokine activation.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a></div><div class="NLM_p">TH17 type responses are mediated by several cytokines linked to extreme COVID-19 patients, and TH17 cells themselves produce IL-17 and GM-CSF. It was found that murine TH17 cells treated with fedratinib showed decreased expression of IL-17, and therefore, this can be promising to prevent the outcomes of TH17-associated cytokine storm in COVID-19 patients.</div><div class="NLM_p">Ruxolitinib ((3<i>R</i>)-3-cyclopentyl-3-[4-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a> and <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>), is an orally available medication that suppresses the elevated levels of cytokine production associated with myelofibrosis, polycythemia vera, and acute graft-versus-host disease. Ruxolitinib was demonstrated to inhibit HIV-1 virus replication in lymphocytes and macrophages<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> by suppressing a range of cytokines like IL-Î², IL-2, IL-5, IL-6, IL-7, IL-13, IL-15, and IFNG.<a onclick="showRef(event, 'ref215 ref216 ref217'); return false;" href="javascript:void(0);" class="ref ref215 ref216 ref217">(215â217)</a> In peripheral blood mononuclear cells, it inhibits the phosphorylation of STAT3 by IL-6 and the development of monocyte chemoattractant protein-1.<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a> In animal studies, oral administration of ruxolitinib was found to be involved in cytokine suppression. The antiviral potency of ruxolitinib also proved to be effective against EpsteinâBarr (EBV) infection.<a onclick="showRef(event, 'ref219 ref220'); return false;" href="javascript:void(0);" class="ref ref219 ref220">(219,220)</a> Mechanistically, ruxolitinib inhibited the EBV-infected proliferation and reduced cytokines by inhibition of STAT3.<a onclick="showRef(event, 'ref221 ref222'); return false;" href="javascript:void(0);" class="ref ref221 ref222">(221,222)</a> Since ruxolitinib is a powerful candidate for the diseases associated with the hyperimmune syndrome, its efficacy has been employed in COVID-19 patients. As a result, when compared to the control group, patients who obtained ruxolitinib plus standard of care had a quicker clinical development and no major side effects.<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> At least 20 clinical trials evaluating the effectiveness of ruxolitinib in patients with COVID-19 are currently underway. Few studies published results revealing its potential to overcome ARD in patients.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a></div><div class="NLM_p">COVID-19 patients have been reported to be vulnerable to bacterial infections.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> Since the JAK-STAT pathway mediates signal transduction of type 1 IFNs<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> and is also a player in suppressing virus replication and infection at the early stages, JAK inhibitors in treating COVID-19 patients may have an elevated risk of bacterial infections.<a onclick="showRef(event, 'ref227 ref228'); return false;" href="javascript:void(0);" class="ref ref227 ref228">(227,228)</a> Inhibition of the JAK signaling pathway can thus result in suppression of the antiviral responses mediated by type 1 IFNs through the JAK-STAT pathway. Indeed, some experiments demonstrated that patients taking JAK inhibitors have a higher risk of infection.<a onclick="showRef(event, 'ref228 ref229'); return false;" href="javascript:void(0);" class="ref ref228 ref229">(228,229)</a></div><div class="NLM_p">The most frequent side effects identified in patients treated with ruxolitinib<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a> and baricitinib,<a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(231)</a> respectively, were urinary tract infections and upper respiratory tract infections. JAK inhibitors have also been linked to an increased risk of viral infections, such as herpes virus reactivation infection.<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a> A recent study reported the development of hematologic toxicity in the treatment of ruxolitinib in two patients with COVID-19: one developed soft-tissue infection, and the other one developed an infection associated with herpes labialis. These severe drug reactions led to the suspension of the ruxolitinib treatment in both cases.<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> While type 1 IFNs play an important role in the antibacterial and antiviral responses, their role in coronavirus infections has yet to be fully understood.</div><div class="NLM_p">In animal models of MERS-CoV infection, type 1 IFNs were shown to be useful during the early stages of infection in some trials. However, it was not advantageous in the later stages because it raised the risk of death.<a onclick="showRef(event, 'ref234'); return false;" href="javascript:void(0);" class="ref ref234">(234)</a> Another research study found that IFNÎ± and type II IFN (TFN) signaling were elevated in patients with SARS-CoV-1 infection who experienced hypoxemia and died but lower in those who survived after a comparatively mild SARS illness.<a onclick="showRef(event, 'ref235'); return false;" href="javascript:void(0);" class="ref ref235">(235)</a></div><div class="NLM_p">The SARS-CoV-2 infection resulted in low IFN expression but substantially improved chemotactic and inflammatory responses, including CCL2, CCL8, IL-6, IL-1 Î², and IL1RA, according to a recent review. SARS-CoV-2 infection in patients inhibits IFN-mediated immune cell recruitment and promotion of IFN-stimulated genes.<a onclick="showRef(event, 'ref236'); return false;" href="javascript:void(0);" class="ref ref236">(236)</a></div><div class="NLM_p">The SARS-CoV-2 entry receptor ACE is also an  interferon-stimulated gene (ISG) that is primarily expressed in human airway epithelial cells.<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(237)</a> All of these findings led to the suggestion that further research is needed to classify IFNs in response to SARS-CoV-2 infection, implying that the COVID-19 control strategy targeting JAK inhibition can still be used. It is also possible that selective JAK2 inhibition (e.g., fedratinib) or JAK2 and JAK3 inhibition (e.g., tofacitinib) will be advantageous since they would not interfere with JAK-type 1 IFN-mediated antiviral and antibacterial immunity.<a onclick="showRef(event, 'ref238 ref239'); return false;" href="javascript:void(0);" class="ref ref238 ref239">(238,239)</a><named-content content-type="anchor" rid="tbl4" type="simple"></named-content></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Kinase Inhibitors: Targets, Original Use, and Repurposing Benefits in Viral Infections</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug (brand name)</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">kinases as targets</th><th class="colsep0 rowsep0" align="center">original use</th><th class="colsep0 rowsep0" align="center">repurposing</th><th class="colsep0 rowsep0" align="center">benefits</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">imatinibÂ (Gleevec)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">Abl (Abl-1, Abl-2) kinase</td><td class="colsep0 rowsep0" align="left">chronic myeloid leukemia</td><td class="colsep0 rowsep0" align="left">SARS-CoV-1,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> MERS-CoV,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> SARS-CoV-2, ebolavirus,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> poxvirus,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> coxsackievirus<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></td><td class="colsep0 rowsep0" align="left">antiviral, anti-inflammatory, immunomodulatory/cytokine suppression, antifibrotic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dasatinibÂ (Sprycel)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">Abl (Abl-1, Abl-2) kinase, SFKs (FYN, SRC, YES), CSK</td><td class="colsep0 rowsep0" align="left">chronic myeloid leukemia</td><td class="colsep0 rowsep0" align="left">SARS-CoV-1,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> MERS-CoV,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> dengue virus<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></td><td class="colsep0 rowsep0" align="left">antiviral, anti-inflammatory, cytokine suppression, antifibrotic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nilotinib (Tasigna)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">Abl (Abl-1, Abl-2) kinase</td><td class="colsep0 rowsep0" align="left">chronic myeloid leukemia,</td><td class="colsep0 rowsep0" align="left">SARS-CoV-1, MERS-CoV,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></td><td class="colsep0 rowsep0" align="left">antiviral, antifibrotic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">saracatinib</td><td class="colsep0 rowsep0" align="left">experimental (Phase III) drug</td><td class="colsep0 rowsep0" align="left">Abl-1, SFKs (FYN, LYN, SRC, YES)</td><td class="colsep0 rowsep0" align="left">idiopathic pulmonary fibrosis</td><td class="colsep0 rowsep0" align="left">dengue virus,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> MERS-CoV,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> hCoV-229E,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> hCoV-OC43<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></td><td class="colsep0 rowsep0" align="left">antiviral, antifibrotic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sunitinib (Sutent)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">AAK1, AXL, GAK, JAK1, KIT</td><td class="colsep0 rowsep0" align="left">renal cell carcinoma, gastrointestinal stromal tumor (GIST),</td><td class="colsep0 rowsep0" align="left">dengue and ebolaviruses</td><td class="colsep0 rowsep0" align="left">antiviral, anti-inflammatory, cytokine suppression, antifibrotic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">erlotinib (Tarceva)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">EGFR tyrosine kinase, GAK, Abl1</td><td class="colsep0 rowsep0" align="left">non-small cell lung cancer (NSCLC) and pancreatic cancer</td><td class="colsep0 rowsep0" align="left">dengue and ebolaviruses<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></td><td class="colsep0 rowsep0" align="left">antiviral, antifibrotic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">baricitinibÂ (Olumiant)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">JAK1, JAK2, TYK1</td><td class="colsep0 rowsep0" align="left">rheumatoid arthritis</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref44 ref86'); return false;" href="javascript:void(0);" class="ref ref44 ref86">(44,86)</a></td><td class="colsep0 rowsep0" align="left">antiviral, anticytokine, anti-inflammatory</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gilteritinibÂ (Xospata)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">AXL kinase</td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bemcentinib</td><td class="colsep0 rowsep0" align="left">experimental (Phase II) drug</td><td class="colsep0 rowsep0" align="left">AXL kinase</td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2,<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Ebola and Zika viruses<a onclick="showRef(event, 'ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref176 ref177">(176,177)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">osimertinibÂ (Tagrisso)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a></td><td class="colsep0 rowsep0" align="left">antiviral, anticytokine</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pictilisib</td><td class="colsep0 rowsep0" align="left">experimental (Phase I) drug</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">breast cancer, relapsed or refractory chronic lymphocytic leukemia</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">omipalisib</td><td class="colsep0 rowsep0" align="left">experimental (Phase III) drug</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">cancer and idiopathic pulmonary fibrosis</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></td><td class="colsep0 rowsep0" align="left">antiviral, antifibrotic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sorafenib (Nexavar)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">VEGFR, PDGFR, RAF kinases</td><td class="colsep0 rowsep0" align="left">renal cell carcinoma, hepatocellular carcinoma, thyroid cancer</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RO5126766</td><td class="colsep0 rowsep0" align="left">An experimental (Phase I)drug</td><td class="colsep0 rowsep0" align="left">RAF/MEK</td><td class="colsep0 rowsep0" align="left">solid tumors or multiple myeloma</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lonafarnib (Zokinvy)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">RAS, GFR signaling</td><td class="colsep0 rowsep0" align="left">Hutchinson-Gilford progeria syndrome</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">leflunomideÂ (Arava)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">Akt</td><td class="colsep0 rowsep0" align="left">rheumatoid arthritis and psoriatic arthritis.</td><td class="colsep0 rowsep0" align="left">HCV<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dinaciclib</td><td class="colsep0 rowsep0" align="left">experimental (Phase III) drug</td><td class="colsep0 rowsep0" align="left">CDK1/2/5/9</td><td class="colsep0 rowsep0" align="left">different types of cancer</td><td class="colsep0 rowsep0" align="left">influenza A virus,<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> SARS-CoV-2<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">seliciclib</td><td class="colsep0 rowsep0" align="left">experimental (Phase II) drug</td><td class="colsep0 rowsep0" align="left">CDK2/5</td><td class="colsep0 rowsep0" align="left">multiple myeloma</td><td class="colsep0 rowsep0" align="left">HIV-1, herpes simplex virus</td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">alvocidip</td><td class="colsep0 rowsep0" align="left">experimental (Phase II) drug</td><td class="colsep0 rowsep0" align="left">CDK9</td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td><td class="colsep0 rowsep0" align="left">influenza A virus<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a></td><td class="colsep0 rowsep0" align="left">antiviral, anti-inflammatory</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">palbociclibÂ (Ibrance)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">CDK4/6</td><td class="colsep0 rowsep0" align="left">breast cancer</td><td class="colsep0 rowsep0" align="left">HSV-1<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PHA-690509</td><td class="colsep0 rowsep0" align="left">experimental (Phase I) drug</td><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="left">cancer</td><td class="colsep0 rowsep0" align="left">ZIKA<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">apilimod</td><td class="colsep0 rowsep0" align="left">experimental (Phase II) drug</td><td class="colsep0 rowsep0" align="left">PIKfyve</td><td class="colsep0 rowsep0" align="left">B-cell non-Hodgkin lymphoma</td><td class="colsep0 rowsep0" align="left">ebolavirus, Lassa virus,<a onclick="showRef(event, 'ref147 ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref147 ref148 ref149">(147â149)</a> SARS-CoV-2<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></td><td class="colsep0 rowsep0" align="left">antiviral, anti-inflammatory</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">abemaciclibÂ (Verzenio)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">CDK4/6</td><td class="colsep0 rowsep0" align="left">metastatic breast cancer</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TBBz</td><td class="colsep0 rowsep0" align="left">experimental drug</td><td class="colsep0 rowsep0" align="left">CK2</td><td class="colsep0 rowsep0" align="left">cancer</td><td class="colsep0 rowsep0" align="left">vaccinia virus<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">silmitasertib</td><td class="colsep0 rowsep0" align="left">orphan drug status by FDA</td><td class="colsep0 rowsep0" align="left">CK2</td><td class="colsep0 rowsep0" align="left">cholangiocarcinoma (bile duct cancer)</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></td><td class="colsep0 rowsep0" align="left">antiviral, anti-inflammatory</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CIGB-325</td><td class="colsep0 rowsep0" align="left">experimental drug</td><td class="colsep0 rowsep0" align="left">CK2</td><td class="colsep0 rowsep0" align="left">cancer</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></td><td class="colsep0 rowsep0" align="left">antiviral, anti-inflammatory</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SB203580</td><td class="colsep0 rowsep0" align="left">experimental drug</td><td class="colsep0 rowsep0" align="left">p38 MAPK</td><td class="colsep0 rowsep0" align="left">autoimmune inflammatory diseases</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> MERS-CoV<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></td><td class="colsep0 rowsep0" align="left">anti-inflammatory, anticytokine</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ralimetinib</td><td class="colsep0 rowsep0" align="left">experimental (Phase II) drug</td><td class="colsep0 rowsep0" align="left">MAPK11 (p38Î±) and MAPK14 (p38Î²),</td><td class="colsep0 rowsep0" align="left">ovarian cancer</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></td><td class="colsep0 rowsep0" align="left">anti-inflammatory</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAPK13-IN-1</td><td class="colsep0 rowsep0" align="left">experimental drug</td><td class="colsep0 rowsep0" align="left">MAPK13 (p38-Î´)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></td><td class="colsep0 rowsep0" align="left">anti-inflammatory</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ARRY-797</td><td class="colsep0 rowsep0" align="left">experimental drug</td><td class="colsep0 rowsep0" align="left">MAPK14 (p38Î²),</td><td class="colsep0 rowsep0" align="left">dilated cardiomyopathy, multiple myeloma</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></td><td class="colsep0 rowsep0" align="left">anti-inflammatory</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tofacitinib (Xeljanz)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">JAK/TYK</td><td class="colsep0 rowsep0" align="left">rheumatoid arthritis, ulcerative colitis, psoriatic arthritis</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a></td><td class="colsep0 rowsep0" align="left">anti-inflammatory, anticytokine</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fedratinibÂ (INREBIC)</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="left">myelofibrosis</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a></td><td class="colsep0 rowsep0" align="left">anti-inflammatory, anticytokine</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ruxolitinib (JAKAFI)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">JAK1/2</td><td class="colsep0 rowsep0" align="left">myelofibrosis, polycythemeia vera, and acute graft-versus-host diseases</td><td class="colsep0 rowsep0" align="left">Ebola,<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a> HIV-1,<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> SARS-CoV-2<a onclick="showRef(event, 'ref223 ref224'); return false;" href="javascript:void(0);" class="ref ref223 ref224">(223,224)</a></td><td class="colsep0 rowsep0" align="left">anti-inflammatory, anticytokine, antifibrotic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kenpaullone</td><td class="colsep0 rowsep0" align="left">experimental drug</td><td class="colsep0 rowsep0" align="left">GSK-3Î²</td><td class="colsep0 rowsep0" align="left">glioblastoma</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref266'); return false;" href="javascript:void(0);" class="ref ref266">(266)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tideglusib</td><td class="colsep0 rowsep0" align="left">experimental drug</td><td class="colsep0 rowsep0" align="left">GSK-3Î²</td><td class="colsep0 rowsep0" align="left">Alzheimerâs disease and progressive supranuclear palsy, myotonic muscular dystrophy type I</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref269'); return false;" href="javascript:void(0);" class="ref ref269">(269)</a></td><td class="colsep0 rowsep0" align="left">antiviral</td></tr></tbody></table></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">4.3.  The Signaling Pathway of Glycogen Synthase Kinase 3 (GSK-3)</h3><div class="NLM_p">Glycogen synthase kinase 3 exists in GSK-3Î± and GSK-3Î² isoforms. The kinase domains of the isoforms have a high degree of sequence similarity (98%) between them.<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(240)</a> It plays a role in metabolism, inflammatory reaction, and modulation of innate immunity.<a onclick="showRef(event, 'ref241'); return false;" href="javascript:void(0);" class="ref ref241">(241)</a> Therefore, targeting GSK-3 has been linked to treating various diseases like diabetes, neurodegenerative disorders, different types of cancer, and bipolar disorders.<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a></div><div class="NLM_p">GSK-3 can mediate the expression of other genes by transcription factors, including c-Jun, CREB, STAT3, C/EBP, NFAT, NF-B, and p53. IL-1, IL-16,<a onclick="showRef(event, 'ref243'); return false;" href="javascript:void(0);" class="ref ref243">(243)</a> IL-17, IL-18,<a onclick="showRef(event, 'ref244'); return false;" href="javascript:void(0);" class="ref ref244">(244)</a> IL-23,<a onclick="showRef(event, 'ref245'); return false;" href="javascript:void(0);" class="ref ref245">(245)</a> IL-12, and IFN-Î³,<a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a> chemokines IL-8,<a onclick="showRef(event, 'ref244'); return false;" href="javascript:void(0);" class="ref ref244">(244)</a> CâC motif chemokine ligands 2,<a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a> 3, 4 and 12,<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a> and C-X-C motif chemokine ligands 1, 2, 5, and 10<a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a> are all positive regulators of GSK-3.</div><div class="NLM_p">In comparison to the MAPK, PI3K, PKC, and Wnt/-catenin signaling pathways, GSK 3 is a lesser-known signaling pathway in the virology field. Recent research suggests that GSK-3 can play a crucial role in viral replication, replication, and pathogenesis.<a onclick="showRef(event, 'ref249 ref250'); return false;" href="javascript:void(0);" class="ref ref249 ref250">(249,250)</a> Also, GSK-3 activation is linked to a reduction in host immunity and antioxidant response. The GSK-3-associated signals have been employed in the entry, replication, and egress of various unrelated viruses.<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a> GSK-3 has been reported to be involved in the phosphorylation of occludin at Ser341, which enhances the binding and entry of HCV.<a onclick="showRef(event, 'ref252 ref253'); return false;" href="javascript:void(0);" class="ref ref252 ref253">(252,253)</a> GSK-3Î², a substrate for AKT, has been identified as one of the host factors in influenza virus entry.<a onclick="showRef(event, 'ref254 ref255'); return false;" href="javascript:void(0);" class="ref ref254 ref255">(254,255)</a> The overexpression of GSK-3Î² has been associated with HCV entry.<a onclick="showRef(event, 'ref256'); return false;" href="javascript:void(0);" class="ref ref256">(256)</a> In HIV-1 infected T cells and monocytic cell lines, the upregulation of GSK-3Î² has been identified.<a onclick="showRef(event, 'ref257'); return false;" href="javascript:void(0);" class="ref ref257">(257)</a> Coxsackievirus B3 (CVB3) infection induced GSK-3 expression in HeLa cell lines and a mouse model, resulting in virus-driven cytopathic effects and apoptosis.<a onclick="showRef(event, 'ref258'); return false;" href="javascript:void(0);" class="ref ref258">(258)</a></div><div class="NLM_p">GSK-3 has been investigated as a possible mediator of HCV virion assembly and release. As a result, blocking GSK-3 prevented the process.<a onclick="showRef(event, 'ref259'); return false;" href="javascript:void(0);" class="ref ref259">(259)</a> In HIV-1-infected macrophages or cell lines, inhibiting GSK-3 decreased viral replication, according to another study.<a onclick="showRef(event, 'ref260 ref257'); return false;" href="javascript:void(0);" class="ref ref260 ref257">(260,257)</a> In Huh 7.5 cells, inhibition of GSK-3Î² led to a reduction of both replication and viral particle production of HCV but for hepatitis E virus (HEV).<a onclick="showRef(event, 'ref261'); return false;" href="javascript:void(0);" class="ref ref261">(261)</a> The increased GSK-3Î²-Ser9 phosphorylation has been linked to the replication of the HBV,<a onclick="showRef(event, 'ref262 ref263'); return false;" href="javascript:void(0);" class="ref ref262 ref263">(262,263)</a> indicating a beneficial effect of GSK-3Î² inhibition for HBV replication. GSK-3 phosphorylation of assembly protein precursor, a protein involved in the organization and maturation of cytomegalovirus, is required.<a onclick="showRef(event, 'ref264 ref265'); return false;" href="javascript:void(0);" class="ref ref264 ref265">(264,265)</a></div><div class="NLM_p">One of the most important structural proteins in coronaviruses, nucleocapsid-protein N, is strongly conserved across organisms. Protein N has a variety of roles in the viral life cycle, the most important of which is packing the virusâs genomic RNA into the protective coating. The N protein of SARS-CoV-1 hijacks the host immune system for virus progeny and related diseases to spread. GSK-3 has been linked to SARS-CoV-1 N phosphorylation on a serine residue, which is necessary for viral replication. As a result, it acts as a viral life cycle regulator.<a onclick="showRef(event, 'ref266'); return false;" href="javascript:void(0);" class="ref ref266">(266)</a> The host translational machinery is also inhibited by phosphorylation of N protein, which interferes with antiviral response signaling. Inhibition of GSK 3 in cells infected with SARS-CoV-1 resulted in the prevention of SARS-CoV-1 N phosphorylation, and, as a result, the viral replication was impaired.<a onclick="showRef(event, 'ref66 ref67 ref68 ref69 ref70 ref71 ref72 ref73 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84 ref85 ref86 ref87 ref88 ref89 ref90 ref91 ref92 ref93 ref94 ref95 ref96 ref97 ref98 ref99 ref100 ref101 ref102 ref103 ref104 ref105 ref106 ref107 ref108 ref109 ref110 ref111 ref112 ref113 ref114 ref115 ref116 ref117 ref118 ref119 ref120 ref121 ref122 ref123 ref124 ref125 ref126 ref127 ref128 ref129 ref130 ref131 ref132 ref133 ref134 ref135 ref136 ref137 ref138 ref139 ref140 ref141 ref142 ref143 ref144 ref145 ref146 ref147 ref148 ref149 ref150 ref151 ref152 ref153 ref154 ref155 ref156 ref157 ref158 ref159 ref160 ref161 ref162 ref163 ref164 ref165 ref166 ref167 ref168 ref169 ref170 ref171 ref172 ref173 ref174 ref175 ref176 ref177 ref178 ref179 ref180 ref181 ref182 ref183 ref184 ref185 ref186 ref187 ref188 ref189 ref190 ref191 ref192 ref193 ref194 ref195 ref196 ref197 ref198 ref199 ref200 ref201 ref202 ref203 ref204 ref205 ref206 ref207 ref208 ref209 ref210 ref211 ref212 ref213 ref214 ref215 ref216 ref217 ref218 ref219 ref220 ref221 ref222 ref223 ref224 ref225 ref226 ref227 ref228 ref229 ref230 ref231 ref232 ref233 ref234 ref235 ref236 ref237 ref238 ref239 ref240 ref241 ref242 ref243 ref244 ref245 ref246 ref247 ref248 ref249 ref250 ref251 ref252 ref253 ref254 ref255 ref256 ref257 ref258 ref259 ref260 ref261 ref262 ref263 ref264 ref265 ref266 ref267 ref268'); return false;" href="javascript:void(0);" class="ref ref66 ref67 ref68 ref69 ref70 ref71 ref72 ref73 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84 ref85 ref86 ref87 ref88 ref89 ref90 ref91 ref92 ref93 ref94 ref95 ref96 ref97 ref98 ref99 ref100 ref101 ref102 ref103 ref104 ref105 ref106 ref107 ref108 ref109 ref110 ref111 ref112 ref113 ref114 ref115 ref116 ref117 ref118 ref119 ref120 ref121 ref122 ref123 ref124 ref125 ref126 ref127 ref128 ref129 ref130 ref131 ref132 ref133 ref134 ref135 ref136 ref137 ref138 ref139 ref140 ref141 ref142 ref143 ref144 ref145 ref146 ref147 ref148 ref149 ref150 ref151 ref152 ref153 ref154 ref155 ref156 ref157 ref158 ref159 ref160 ref161 ref162 ref163 ref164 ref165 ref166 ref167 ref168 ref169 ref170 ref171 ref172 ref173 ref174 ref175 ref176 ref177 ref178 ref179 ref180 ref181 ref182 ref183 ref184 ref185 ref186 ref187 ref188 ref189 ref190 ref191 ref192 ref193 ref194 ref195 ref196 ref197 ref198 ref199 ref200 ref201 ref202 ref203 ref204 ref205 ref206 ref207 ref208 ref209 ref210 ref211 ref212 ref213 ref214 ref215 ref216 ref217 ref218 ref219 ref220 ref221 ref222 ref223 ref224 ref225 ref226 ref227 ref228 ref229 ref230 ref231 ref232 ref233 ref234 ref235 ref236 ref237 ref238 ref239 ref240 ref241 ref242 ref243 ref244 ref245 ref246 ref247 ref248 ref249 ref250 ref251 ref252 ref253 ref254 ref255 ref256 ref257 ref258 ref259 ref260 ref261 ref262 ref263 ref264 ref265 ref266 ref267 ref268">(66â268)</a></div><div class="NLM_p">The GSK-3 selective inhibitors LiCl and kenpaullone (9-bromo-7,12-dihydro-indolo[3,2-<i>d</i>][1]benzazepin-6 (5<i>H</i>)-one) (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) reduced viral titer and cytopathic effects in Vero E6 cells infected with SARS-CoV-1 without affecting cell viability.<a onclick="showRef(event, 'ref266'); return false;" href="javascript:void(0);" class="ref ref266">(266)</a> According to this study, this kinaseâs phosphorylation is closely linked to viral replication. The nitro analogue alsterpaullone potently inhibits the replication of HIV-1 with an IC<sub>50</sub> value of 150 nM in virus-infected cells.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Lithium, a GSK-3 inhibitor, has been used to treat mood and bipolar conditions in patients. In porcine cells, lithium chloride therapy helped to cure a transmissible gastroenteritis coronavirus infection. In avian cells, lithium chloride treatment protects against the bronchitis virus by blocking the synthesis of genomic and subgenomic RNA while leaving the host translation pathways unaffected. A recent study showed the potential antiviral activity of thiadiazolidinone tideglusib (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) against SARS-CoV-2 M<sup>pro</sup> activity.<a onclick="showRef(event, 'ref269'); return false;" href="javascript:void(0);" class="ref ref269">(269)</a> Tideglusib (NP031112, NP-12) is a non-ATP-competitive, irreversible GSK-3 inhibitor that has recently been shown to have an IC<sub>50</sub> of 1.5 Î¼M in inhibiting SARS-CoV-2 M<sup>pro</sup>.<a onclick="showRef(event, 'ref269'); return false;" href="javascript:void(0);" class="ref ref269">(269)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. GSK-3 inhibitors (kenpaullone,<a onclick="showRef(event, 'ref266'); return false;" href="javascript:void(0);" class="ref ref266">(266)</a> alsterpaullone,<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> and tideglusib: SARS-CoV-2, IC<sub>50</sub> 1.5 Î¼M,<a onclick="showRef(event, 'ref269'); return false;" href="javascript:void(0);" class="ref ref269">(269)</a> SB415286<a onclick="showRef(event, 'ref276 ref277'); return false;" href="javascript:void(0);" class="ref ref276 ref277">(276,277)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The SARS-CoV-1 N protein has a high degree of resemblance to the SARS-CoV-2 N protein, and both proteins have conserved serine residues (Ser189 and Ser207), according to the sequence analysis.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Thus, the serine residues in SARS-CoV-2 are predicted to be phosphorylated by GSK-3 in the same way as they are in SARS-CoV-1. CoVâs key protease, which is necessary for viral replication and transcription, is also inhibited by GSK-3 inhibition.<a onclick="showRef(event, 'ref270 ref271 ref272'); return false;" href="javascript:void(0);" class="ref ref270 ref271 ref272">(270â272)</a></div><div class="NLM_p">T cell proliferation and activity are believed to be negatively regulated by GSK-3.<a onclick="showRef(event, 'ref273 ref274'); return false;" href="javascript:void(0);" class="ref ref273 ref274">(273,274)</a> Indeed, inhibiting GSK-3 with molecules like SB415286 improved the adaptive CD8+ cytolytic cell (CTL) role significantly.<a onclick="showRef(event, 'ref275 ref276'); return false;" href="javascript:void(0);" class="ref ref275 ref276">(275,276)</a> This effect is essential for the production of cytolytic effectors such as granzyme B, perforin, and interferon-Î³ in CD8+ cells.<a onclick="showRef(event, 'ref277 ref278'); return false;" href="javascript:void(0);" class="ref ref277 ref278">(277,278)</a> GSK-3 has an impact on CD4+ T cells, which are essential for the growth of cytokine release syndrome (CRS) in the more extreme COVID-19 cases.</div><div class="NLM_p">Inhibiting GSK-3 with small molecules has been shown to cause CD4+ T cells to produce the suppressive cytokine IL-10, which can help to reduce CRS in severe disease.<a onclick="showRef(event, 'ref279'); return false;" href="javascript:void(0);" class="ref ref279">(279)</a> In infections and autoimmune disorders, IL-10 suppresses the immune response and prevents tissue damage.<a onclick="showRef(event, 'ref280'); return false;" href="javascript:void(0);" class="ref ref280">(280)</a></div><div class="NLM_p">In addition, inhibiting GSK-3 stimulates the development of natural killer cells,<a onclick="showRef(event, 'ref281'); return false;" href="javascript:void(0);" class="ref ref281">(281)</a> which are innate immune system effector cells that help to control infection.<a onclick="showRef(event, 'ref282'); return false;" href="javascript:void(0);" class="ref ref282">(282)</a> Based on the findings, inhibiting GSK-3 may be a promising therapeutic strategy for preventing SARS-CoV-2 infection by reducing viral replication and enhancing the immune response to the virus, as seen in <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. GSK-3 as a possible target for anti-coronaviral treatment, such as anti-SARS-CoV-2 therapy. According to the model, inhibiting GSK-3 will also inhibit SARS-CoV-2 N protein and improve CD8+ T cell resistance to the virus. Left: SARS-CoV-2 N protein and viral replication are assumed to be inhibited by inhibiting GSK-3. Right: Inhibition of GSK 3 improves CD8+ cell responses to viruses. In CD8+ T cells, inhibiting GSK-3 decreases the expression of inhibitory receptors PD-1 and LAG-3 while increasing the expression of GMZB and IFNg1. Inhibition of GSK-3 also escalates natural killer function. PD-1, programmed cell death protein 1; LAG-3, lymphocyte-activation gene 3; GMZB, granzyme B; IFNg1, interferon-gamma.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">5.  Conclusions and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44533" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44533" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The novel human SARS-CoV-2 is a causative agent for COVID-19 that has emerged in the human population. For the treatment of COVID-19, several antiviral agents are being tested in clinical trials as single agents or conjunction with other therapies. Many inhibitors targeting kinases have direct antiviral effects, targeting essential virus-associated proteins and proteins that play a role in the production of COVID-19 symptoms such as pneumonia-like infection, ARDS, cytokine storm, systemic inflammation, and fibrosis.</div><div class="NLM_p">The summary of kinase inhibitors, their original use, and their repurposing for viral diseases, including COVID-19, are outlined in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. Several of these kinase inhibitors are already approved, and some are being clinically investigated in Phase IâIII trials for various diseases. However, adverse effects and pharmacokinetic properties of kinases inhibitors need to be considered, when repurposing them for the treatment of COVID-19. For example, some drugs need long-term dosing to achieve the required pharmacological concentrations and exert their effect, which may not be a suitable option to treat the symptoms associated with COVID-19 as immediate treatment is required for the affected patients. Likewise, treatment of kinase inhibitors associated with a series of side effects or that could decrease immune responses at the beginning of the viral life cycle (e.g., inhibitors that interrupt type 1 IFNs-JAK1, see <a class="ref internalNav" href="#sec4_2" aria-label="section 4.2">section 4.2</a>) would pose a challenge for patients infected with COVID-19.</div><div class="NLM_p">In a murine model of the vaccinia virus, imatinib, an inhibitor of Abl tyrosine kinase, effectively decreased viral load, dissemination, and mortality. However, it did not protect the mice from the infection.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> This raises the issue concerning its efficacy in governing the viral infection in vivo. In animal models of other viral infections, such as SARS-CoV-2, it is crucial to investigate the antiviral efficacy and safety profile of drugs that target Abl and Src.</div><div class="NLM_p">Combination therapy in the context of COVID-19 will have significant therapeutic advantages, as this technique has previously been seen to be effective in the treatment of life-threatening diseases including HIV-related AIDS. As a result, antivirals (ribavirin, ritonavir-lopinavir, remdesivir) combined with kinase inhibitors (sunitinib, erlotinib, sorafenib, imatinib, gilteritinib, gilteritinib, osimertinib) or kinase inhibitors that target both virus-related proteins and proteins associated with pulmonary health would be beneficial.</div><div class="NLM_p last">One of the effective therapeutic techniques in the control of the COVID-19 pandemic may be to target the JAK-STAT signaling pathway. This signaling pathway mediates a hyperimmune activation by proinflammatory cytokines that leads to ARD, organ damage, and ultimately death in COVID-19 patients. Therefore, the approach that allows the repurposing of already FDA-approved and experimental drugs targeting the JAK-STAT signaling pathway would be potentially beneficial. Additionally, drugs that selectively target JAK2, JAK3, or JAK2/3 would be a potential treatment option concerning the suppression of cytokines, and at the same time, they would not interrupt IFN-JAK1-mediated antiviral and antibacterial immunity in patients infected with COVID-19 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). On the other hand, bacterial infections can be a risk factor for using JAK-STAT pathway inhibitors for COVID-19 because JAK inhibitors inhibit IFN type 1 IFNs, which are formed in response to bacterial infections, and thus can prevent viral replication and infection.<a onclick="showRef(event, 'ref227 ref228'); return false;" href="javascript:void(0);" class="ref ref227 ref228">(227,228)</a> However, selective inhibitors that target JAK2/JAK3 can still be repositioned for COVID-19 treatment as they would not interact with JAK-1.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00335" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77737" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77737" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thanigaimalai Pillaiyar</span> - <span class="hlFld-Affiliation affiliation">Institute of Pharmacy, Pharmaceutical/Medicinal
Chemistry and Tuebingen Center for Academic Drug Discovery, Eberhard Karls University TÃ¼bingen, Auf der Morgenstelle 8, 72076 TÃ¼bingen, Germany</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-5575-8896" title="Orcid link">https://orcid.org/0000-0001-5575-8896</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#700418111e191711191d111c11195e00191c1c111909110230051e195d04051512191e17151e5e1415"><span class="__cf_email__" data-cfemail="9beff3faf5f2fcfaf2f6faf7faf2b5ebf2f7f7faf2e2fae9dbeef5f2b6efeefef9f2f5fcfef5b5fffe">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Laufer</span> - <span class="hlFld-Affiliation affiliation">Institute of Pharmacy, Pharmaceutical/Medicinal
Chemistry and Tuebingen Center for Academic Drug Discovery, Eberhard Karls University TÃ¼bingen, Auf der Morgenstelle 8, 72076 TÃ¼bingen, Germany</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-6952-1486" title="Orcid link">https://orcid.org/0000-0001-6952-1486</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2152554447404f0f4d405447445361544f480c55544443484f46444f0f4544"><span class="__cf_email__" data-cfemail="98ebecfdfef9f6b6f4f9edfefdead8edf6f1b5ecedfdfaf1f6fffdf6b6fcfd">[emailÂ protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53758" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53758" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Thanigaimalai Pillaiyar</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=BIO-d7e3235-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Thanigaimalai Pillaiyar</b> obtained his Ph.D. in Medicinal Chemistry (2011) under the supervision of Prof. Sang-Hun Jung, South Korea. As a Japanese Society for the Promotion of Science (JSPS) postdoctoral fellow (2011-2013) with Prof. Yoshio Hayashi, Japan, he focused on the development of SARS-CoV-1 M<sup>pro</sup> inhibitors. He awarded an Alexander von Humboldt postdoctoral fellowship (AvH) (2013-2015) with Prof. Christa E. MÃ¼ller, Germany, where he involved in the development of GPCR modulators. He was a visiting scientist at the Prof. Steven V. Leyâs Laboratory, University of Cambridge. Currently, he is working as an independent junior research group leader and establishing a research group at the Tuebingen Center for Academic Drug Discovery, University of TÃ¼bingen. His research interests include medicinal chemistry of GPCRs, synthetic organic chemistry, and dual SARS-CoV-2 M<sup>pro</sup>-kinase inhibitors.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Stefan Laufer</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=BIO-d7e3246-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Stefan Laufer</b> studied Pharmacy and completed his Ph.D. at Regensburg University. After postdoctoral research in Frankfurt, he took a position in the pharmaceutical industry but maintained lectureships at Frankfurt and later at Mainz University, where he finished his habilitation in 1997. Since 1999, he has been full professor (chair) for pharmaceutical and medicinal chemistry at TÃ¼bingen University. He is cofounder/spokesman of ICEPHA (Interfaculty Center for Pharmacogenomics and Pharma Research), TÃ¼CAD<sub>2</sub> (TÃ¼bingen Center for Academic Drug Discovery), and cofounder of the two startups CAIR Biosciences and Heparegenix. Three compounds from his lab made it first into man. His research interests are protein kinase inhibitors and eicosanoid modulators.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61112" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61112" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">T.P. and S.L. thank Ms. Kristine Schmidt for language proofreading. TÃ¼CAD2 is funded by the Federal Ministry of Education and Research (BMBF) and the Baden-WÃ¼rttemberg Ministry of Science as part of the Excellence Strategy of the German Federal and State Governments.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Abl</td><td class="NLM_def"><p class="first last">Abelson tyrosine kinase</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphoblastic leukemia</p></td></tr><tr><td class="NLM_term">ARDS</td><td class="NLM_def"><p class="first last">acute respiratory distress syndrome</p></td></tr><tr><td class="NLM_term">AAK1</td><td class="NLM_def"><p class="first last">adaptor protein-associated kinase 1</p></td></tr><tr><td class="NLM_term">ACE2</td><td class="NLM_def"><p class="first last">angiotensin-converting enzyme 2</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">BMP2K</td><td class="NLM_def"><p class="first last">BMP-2-inducible kinase</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myeloid leukemia</p></td></tr><tr><td class="NLM_term">CREB</td><td class="NLM_def"><p class="first last">cAMP response element-binding protein</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinases</p></td></tr><tr><td class="NLM_term">CKII</td><td class="NLM_def"><p class="first last">casein kinase 2</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CoV</td><td class="NLM_def"><p class="first last">coronavirus</p></td></tr><tr><td class="NLM_term">COVID-19</td><td class="NLM_def"><p class="first last">coronavirus disease-19</p></td></tr><tr><td class="NLM_term">CVB</td><td class="NLM_def"><p class="first last">coxsackievirus B</p></td></tr><tr><td class="NLM_term">CPE</td><td class="NLM_def"><p class="first last">cytopathic effects</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">GAK</td><td class="NLM_def"><p class="first last">cyclin G-associated kinase</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumor</p></td></tr><tr><td class="NLM_term">GM-CSF</td><td class="NLM_def"><p class="first last">granulocyte-colony stimulating factor</p></td></tr><tr><td class="NLM_term">GAS 6</td><td class="NLM_def"><p class="first last">growth-arrest-specific gene 6</p></td></tr><tr><td class="NLM_term">GSK-3</td><td class="NLM_def"><p class="first last">glycogen synthase kinase; herpes simplex virus</p></td></tr><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">HPV</td><td class="NLM_def"><p class="first last">human papillomavirus</p></td></tr><tr><td class="NLM_term">HCoV</td><td class="NLM_def"><p class="first last">human coronavirus</p></td></tr><tr><td class="NLM_term">HSV</td><td class="NLM_def"><p class="first last">herpes simplex virus</p></td></tr><tr><td class="NLM_term">HKU</td><td class="NLM_def"><p class="first last">Hong Kong University</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">interferon</p></td></tr><tr><td class="NLM_term">IBV</td><td class="NLM_def"><p class="first last">infectious bronchitis virus</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">M<sup>pro</sup></td><td class="NLM_def"><p class="first last">main protease</p></td></tr><tr><td class="NLM_term">mTORC</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin complex</p></td></tr><tr><td class="NLM_term">MERS-COV</td><td class="NLM_def"><p class="first last">Middle East respiratory syndrome</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MPSK1</td><td class="NLM_def"><p class="first last">myristoylated and palmitoylated serine/threonine kinase 1</p></td></tr><tr><td class="NLM_term">NAK</td><td class="NLM_def"><p class="first last">numb-associated kinase</p></td></tr><tr><td class="NLM_term">SARS</td><td class="NLM_def"><p class="first last">severe acute respiratory syndrome</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">NSP</td><td class="NLM_def"><p class="first last">nonstructural protein</p></td></tr><tr><td class="NLM_term">NF-ÎºB</td><td class="NLM_def"><p class="first last">nuclear factor âkappa-light-chain-enhancerâ of activated B-cell</p></td></tr><tr><td class="NLM_term">PL<sup>pro</sup></td><td class="NLM_def"><p class="first last">papain-like protease</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptors</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">protein kinase</p></td></tr><tr><td class="NLM_term">RBD</td><td class="NLM_def"><p class="first last">receptor-binding domain</p></td></tr><tr><td class="NLM_term">RNA</td><td class="NLM_def"><p class="first last">ribonucleic acid</p></td></tr><tr><td class="NLM_term">RCC</td><td class="NLM_def"><p class="first last">renal cell carcinoma</p></td></tr><tr><td class="NLM_term">RdRp</td><td class="NLM_def"><p class="first last">RNA dependent RNA polymerase</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">siRNA</td><td class="NLM_def"><p class="first last">small interfering ribonucleic acid</p></td></tr><tr><td class="NLM_term">SOCS</td><td class="NLM_def"><p class="first last">suppressor of the cytokine signaling</p></td></tr><tr><td class="NLM_term">SFKs</td><td class="NLM_def"><p class="first last">Src family kinases</p></td></tr><tr><td class="NLM_term">TNF</td><td class="NLM_def"><p class="first last">tumor necrosis factor</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitors</p></td></tr><tr><td class="NLM_term">TTSP</td><td class="NLM_def"><p class="first last">type II transmembrane serine protease</p></td></tr><tr><td class="NLM_term">VCV</td><td class="NLM_def"><p class="first last">vesicular stomatitis virus</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77353" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77353" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 282 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z. L.</span></span> <span> </span><span class="NLM_article-title">A pneumonia outbreak associated with a new coronavirus of probable bat origin</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>579</i></span>,  <span class="NLM_fpage">270</span>â <span class="NLM_lpage">273</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2012-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41586-020-2012-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32015507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFKlsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=579&publication_year=2020&pages=270-273&author=P.+Zhouauthor=X.+L.+Yangauthor=X.+G.+Wangauthor=B.+Huauthor=L.+Zhangauthor=W.+Zhangauthor=H.+R.+Siauthor=Y.+Zhuauthor=B.+Liauthor=C.+L.+Huangauthor=H.+D.+Chenauthor=J.+Chenauthor=Y.+Luoauthor=H.+Guoauthor=R.+D.+Jiangauthor=M.+Q.+Liuauthor=Y.+Chenauthor=X.+R.+Shenauthor=X.+Wangauthor=X.+S.+Zhengauthor=K.+Zhaoauthor=Q.+J.+Chenauthor=F.+Dengauthor=L.+L.+Liuauthor=B.+Yanauthor=F.+X.+Zhanauthor=Y.+Y.+Wangauthor=G.+F.+Xiaoauthor=Z.+L.+Shi&title=A+pneumonia+outbreak+associated+with+a+new+coronavirus+of+probable+bat+origin&doi=10.1038%2Fs41586-020-2012-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A pneumonia outbreak associated with a new coronavirus of probable bat origin</span></div><div class="casAuthors">Zhou, Peng; Yang, Xing-Lou; Wang, Xian-Guang; Hu, Ben; Zhang, Lei; Zhang, Wei; Si, Hao-Rui; Zhu, Yan; Li, Bei; Huang, Chao-Lin; Chen, Hui-Dong; Chen, Jing; Luo, Yun; Guo, Hua; Jiang, Ren-Di; Liu, Mei-Qin; Chen, Ying; Shen, Xu-Rui; Wang, Xi; Zheng, Xiao-Shuang; Zhao, Kai; Chen, Quan-Jiao; Deng, Fei; Liu, Lin-Lin; Yan, Bing; Zhan, Fa-Xian; Wang, Yan-Yi; Xiao, Geng-Fu; Shi, Zheng-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">579</span>
        (<span class="NLM_cas:issue">7798</span>),
    <span class="NLM_cas:pages">270-273</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large no. of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural reservoir host, bats1-4.  Previous studies have shown that some bat SARSr-CoVs have the potential to infect humans5-7.  Here we report the identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China.  The epidemic, which started on 12 Dec. 2019, had caused 2,794 lab.-confirmed infections including 80 deaths by 26 Jan. 2020.  Full-length genome sequences were obtained from five patients at an early stage of the outbreak.  The sequences are almost identical and share 79.6% sequence identity to SARS-CoV.  Furthermore, we show that 2019-nCoV is 96% identical at the whole-genome level to a bat coronavirus.  Pairwise protein sequence anal. of seven conserved non-structural proteins domains show that this virus belongs to the species of SARSr-CoV.  In addn., 2019-nCoV virus isolated from the bronchoalveolar lavage fluid of a critically ill patient could be neutralized by sera from several patients.  Notably, we confirmed that 2019-nCoV uses the same cell entry receptor-angiotensin converting enzyme II (ACE2)-as SARS-CoV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV_Wb_iUsbFrVg90H21EOLACvtfcHk0lhDvArTXSeVFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFKlsLg%253D&md5=236f17d4d3c7978d72513e5e0258f1b3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2012-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2012-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DX.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BG.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSi%26aufirst%3DH.%2BR.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DC.%2BL.%26aulast%3DChen%26aufirst%3DH.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DR.%2BD.%26aulast%3DLiu%26aufirst%3DM.%2BQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DX.%2BR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DX.%2BS.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DQ.%2BJ.%26aulast%3DDeng%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DL.%2BL.%26aulast%3DYan%26aufirst%3DB.%26aulast%3DZhan%26aufirst%3DF.%2BX.%26aulast%3DWang%26aufirst%3DY.%2BY.%26aulast%3DXiao%26aufirst%3DG.%2BF.%26aulast%3DShi%26aufirst%3DZ.%2BL.%26atitle%3DA%2520pneumonia%2520outbreak%2520associated%2520with%2520a%2520new%2520coronavirus%2520of%2520probable%2520bat%2520origin%26jtitle%3DNature%26date%3D2020%26volume%3D579%26spage%3D270%26epage%3D273%26doi%3D10.1038%2Fs41586-020-2012-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Z.</span></span> <span> </span><span class="NLM_article-title">A new coronavirus associated with human respiratory disease in China</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>579</i></span>,  <span class="NLM_fpage">265</span>â <span class="NLM_lpage">269</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2008-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41586-020-2008-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32015508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFKlsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=579&publication_year=2020&pages=265-269&author=F.+Wuauthor=S.+Zhaoauthor=B.+Yuauthor=Y.+M.+Chenauthor=W.+Wangauthor=Z.+G.+Songauthor=Y.+Huauthor=Z.+W.+Taoauthor=J.+H.+Tianauthor=Y.+Y.+Peiauthor=M.+L.+Yuanauthor=Y.+L.+Zhangauthor=F.+H.+Daiauthor=Y.+Liuauthor=Q.+M.+Wangauthor=J.+J.+Zhengauthor=L.+Xuauthor=E.+C.+Holmesauthor=Y.+Z.+Zhang&title=A+new+coronavirus+associated+with+human+respiratory+disease+in+China&doi=10.1038%2Fs41586-020-2008-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A new coronavirus associated with human respiratory disease in China</span></div><div class="casAuthors">Wu, Fan; Zhao, Su; Yu, Bin; Chen, Yan-Mei; Wang, Wen; Song, Zhi-Gang; Hu, Yi; Tao, Zhao-Wu; Tian, Jun-Hua; Pei, Yuan-Yuan; Yuan, Ming-Li; Zhang, Yu-Ling; Dai, Fa-Hui; Liu, Yi; Wang, Qi-Min; Zheng, Jiao-Jiao; Xu, Lin; Holmes, Edward C.; Zhang, Yong-Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">579</span>
        (<span class="NLM_cas:issue">7798</span>),
    <span class="NLM_cas:pages">265-269</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Emerging infectious diseases, such as severe acute respiratory syndrome (SARS) and Zika virus disease, present a major threat to public health.  Despite intense research efforts, how, when and where new diseases appear are still a source of considerable uncertainty.  A severe respiratory disease was recently reported in Wuhan, Hubei province, China.  As of 25 Jan. 2020, at least 1,975 cases had been reported since the first patient was hospitalized on 12 Dec. 2019.  Epidemiol. investigations have suggested that the outbreak was assocd. with a seafood market in Wuhan.  Here we study a single patient who was a worker at the market and who was admitted to the Central Hospital of Wuhan on 26 Dec. 2019 while experiencing a severe respiratory syndrome that included fever, dizziness and a cough.  Metagenomic RNA sequencing of a sample of bronchoalveolar lavage fluid from the patient identified a new RNA virus strain from the family Coronaviridae, which is designated here 'WH-Human 1' coronavirus (and has also been referred to as '2019-nCoV').  Phylogenetic anal. of the complete viral genome (29,903 nucleotides) revealed that the virus was most closely related (89.1% nucleotide similarity) to a group of SARS-like coronaviruses (genus Betacoronavirus, subgenus Sarbecovirus) that had previously been found in bats in China.  This outbreak highlights the ongoing ability of viral spill-over from animals to cause severe disease in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5h_VHfuDuTbVg90H21EOLACvtfcHk0lhu5kzq6X_Z0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFKlsLc%253D&md5=0163a684829e880a0c3347e19f0ce52a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2008-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2008-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DY.%2BM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DZ.%2BG.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTao%26aufirst%3DZ.%2BW.%26aulast%3DTian%26aufirst%3DJ.%2BH.%26aulast%3DPei%26aufirst%3DY.%2BY.%26aulast%3DYuan%26aufirst%3DM.%2BL.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DDai%26aufirst%3DF.%2BH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%2BM.%26aulast%3DZheng%26aufirst%3DJ.%2BJ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DHolmes%26aufirst%3DE.%2BC.%26aulast%3DZhang%26aufirst%3DY.%2BZ.%26atitle%3DA%2520new%2520coronavirus%2520associated%2520with%2520human%2520respiratory%2520disease%2520in%2520China%26jtitle%3DNature%26date%3D2020%26volume%3D579%26spage%3D265%26epage%3D269%26doi%3D10.1038%2Fs41586-020-2008-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span> <span> </span><span class="NLM_article-title">China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">727</span>â <span class="NLM_lpage">733</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa2001017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1056%2FNEJMoa2001017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31978945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslGmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=727-733&author=N.+Zhuauthor=D.+Zhangauthor=W.+Wangauthor=X.+Liauthor=B.+Yangauthor=J.+Songauthor=X.+Zhaoauthor=B.+Huangauthor=W.+Shiauthor=R.+Luauthor=P.+Niuauthor=F.+Zhanauthor=X.+Maauthor=D.+Wangauthor=W.+Xuauthor=G.+Wuauthor=G.+F.+Gaoauthor=W.+Tan&title=China+novel+coronavirus+investigating+and+research+team.+A+novel+coronavirus+from+patients+with+pneumonia+in+China%2C+2019&doi=10.1056%2FNEJMoa2001017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A novel coronavirus from patients with pneumonia in China, 2019</span></div><div class="casAuthors">Zhu, Na; Zhang, Dingyu; Wang, Wenling; Li, Xingwang; Yang, Bo; Song, Jingdong; Zhao, Xiang; Huang, Baoying; Shi, Weifeng; Lu, Roujian; Niu, Peihua; Zhan, Faxian; Ma, Xuejun; Wang, Dayan; Xu, Wenbo; Wu, Guizhen; Gao, George F.; Tan, Wenjie</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">727-733</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In Dec. 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China.  A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia.  Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily.  Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans.  Enhanced surveillance and further investigation are ongoing.  Complete genome sequences of the three novel coronaviruses were submitted to GISAID (BetaCoV/Wuhan/ IVDC-HB-01/2019, accession ID: EPI_ISL_402119; BetaCoV/Wuhan/IVDC-HB-04/2020, accession ID: EPI_ISL_402120; BetaCoV/Wuhan/IVDC-HB-05/2019, accession ID: EPI_ISL_402121).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoibbAn_VqfXbVg90H21EOLACvtfcHk0lhu5kzq6X_Z0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslGmsrc%253D&md5=73cc5c839e1e934da69b39537063b7b3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2001017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2001017%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DR.%26aulast%3DNiu%26aufirst%3DP.%26aulast%3DZhan%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DTan%26aufirst%3DW.%26atitle%3DChina%2520novel%2520coronavirus%2520investigating%2520and%2520research%2520team.%2520A%2520novel%2520coronavirus%2520from%2520patients%2520with%2520pneumonia%2520in%2520China%252C%25202019%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D727%26epage%3D733%26doi%3D10.1056%2FNEJMoa2001017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, P. R.</span></span> <span> </span><span class="NLM_article-title">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">105924</span>, <span class="refDoi">Â DOI: 10.1016/j.ijantimicag.2020.105924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.ijantimicag.2020.105924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32081636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1Ogtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2020&pages=105924&author=C.+C.+Laiauthor=T.+P.+Shihauthor=W.+C.+Koauthor=H.+J.+Tangauthor=P.+R.+Hsueh&title=Severe+acute+respiratory+syndrome+coronavirus+2+%28SARS-CoV-2%29+and+coronavirus+disease-2019+%28COVID-19%29%3A+The+epidemic+and+the+challenges&doi=10.1016%2Fj.ijantimicag.2020.105924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges</span></div><div class="casAuthors">Lai, Chih-Cheng; Shih, Tzu-Ping; Ko, Wen-Chien; Tang, Hung-Jen; Hsueh, Po-Ren</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">105924</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019 has caused a large global outbreak and is a major public health issue.  As of 11 Feb. 2020, data from the World Health Organization (WHO) have shown that more than 43 000 confirmed cases have been identified in 28 countries/regions, with >99% of cases being detected in China.  On 30 Jan. 2020, the WHO declared COVID-19 as the sixth public health emergency of international concern.  SARS-CoV-2 is closely related to two bat-derived severe acute respiratory syndrome-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21.  It is spread by human-to-human transmission via droplets or direct contact, and infection has been estd. to have mean incubation period of 6.4 days and a basic reprodn. no. of 2.24-3.58.  Among patients with pneumonia caused by SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough.  Bilateral lung involvement with ground-glass opacity was the most common finding from computed tomog. images of the chest.  The one case of SARS-CoV-2 pneumonia in the USA is responding well to remdesivir, which is now undergoing a clin. trial in China.  Currently, controlling infection to prevent the spread of SARS-CoV-2 is the primary intervention being used.  However, public health authorities should keep monitoring the situation closely, as the more we can learn about this novel virus and its assocd. outbreak, the better we can respond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6fCWu5X9AILVg90H21EOLACvtfcHk0ljmErnntEwlcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1Ogtr8%253D&md5=2ece25e2290b6a1c78f23a3dda37ad64</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2020.105924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2020.105924%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%2BC.%26aulast%3DShih%26aufirst%3DT.%2BP.%26aulast%3DKo%26aufirst%3DW.%2BC.%26aulast%3DTang%26aufirst%3DH.%2BJ.%26aulast%3DHsueh%26aufirst%3DP.%2BR.%26atitle%3DSevere%2520acute%2520respiratory%2520syndrome%2520coronavirus%25202%2520%2528SARS-CoV-2%2529%2520and%2520coronavirus%2520disease-2019%2520%2528COVID-19%2529%253A%2520The%2520epidemic%2520and%2520the%2520challenges%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2020%26volume%3D55%26spage%3D105924%26doi%3D10.1016%2Fj.ijantimicag.2020.105924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span> <i>WHO Coronavirus (COVID-19) Dashboard</i>; <span class="NLM_publisher-name">World
Health Organization</span>. <a href="https://covid19.who.int/" class="extLink">https://covid19.who.int/</a> (accessed <span class="NLM_year">2020</span>-12-26).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+WHO+Coronavirus+%28COVID-19%29+Dashboard%3B+World%0AHealth+Organization.+https%3A%2F%2Fcovid19.who.int%2F+%28accessed+2020-12-26%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DWHO%2520Coronavirus%2520%2528COVID-19%2529%2520Dashboard%26pub%3DWorld%250AHealth%2520Organization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span> <i>Coronavirus (COVID-19) Update:
FDA Authorizes Monoclonal Antibodies
for Treatment of COVID-19</i>; <span class="NLM_publisher-name">U.S. Food and
Drug Administration</span>. <a href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0" class="extLink">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0</a> (accessed <span class="NLM_year">2021</span>-02-09).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Coronavirus+%28COVID-19%29+Update%3A%0AFDA+Authorizes+Monoclonal+Antibodies%0Afor+Treatment+of+COVID-19%3B+U.S.+Food+and%0ADrug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Fcoronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0+%28accessed+2021-02-09%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCoronavirus%2520%2528COVID-19%2529%2520Update%253A%250AFDA%2520Authorizes%2520Monoclonal%2520Antibodies%250Afor%2520Treatment%2520of%2520COVID-19%26pub%3DU.S.%2520Food%2520and%250ADrug%2520Administration%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillaiyar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manickam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easwaran, M.</span></span> <span> </span><span class="NLM_article-title">The recent outbreaks of human coronaviruses: A medicinal chemistry perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">72</span>â <span class="NLM_lpage">135</span>, <span class="refDoi">Â DOI: 10.1002/med.21724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Fmed.21724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32852058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhsVagt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2021&pages=72-135&author=T.+Pillaiyarauthor=L.+L.+Wendtauthor=M.+Manickamauthor=M.+Easwaran&title=The+recent+outbreaks+of+human+coronaviruses%3A+A+medicinal+chemistry+perspective&doi=10.1002%2Fmed.21724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The recent outbreaks of human coronaviruses: A medicinal chemistry perspective</span></div><div class="casAuthors">Pillaiyar, Thanigaimalai; Wendt, Lukas L.; Manickam, Manoj; Easwaran, Maheswaran</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-135</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Coronaviruses (CoVs) infect both humans and animals.  In humans, CoVs can cause respiratory, kidney, heart, brain, and intestinal infections that can range from mild to lethal.  Since the start of the 21st century, three Î²-coronaviruses have crossed the species barrier to infect humans: severe-acute respiratory syndrome (SARS)-CoV-1, Middle East respiratory syndrome (MERS)-CoV, and SARS-CoV-2 (2019-nCoV).  These viruses are dangerous and can easily be transmitted from human to human.  Therefore, the development of anticoronaviral therapies is urgently needed.  However, to date, no approved vaccines or drugs against CoV infections are available.  In this review, we focus on the medicinal chem. efforts toward the development of antiviral agents against SARS-CoV-1, MERS-CoV, SARS-CoV-2, targeting biochem. events important for viral replication and its life cycle.  These targets include the spike glycoprotein and its host-receptors for viral entry, proteases that are essential for cleaving polyproteins to produce functional proteins, and RNA-dependent RNA polymerase for viral RNA replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowH3Dpqna3Q7Vg90H21EOLACvtfcHk0ljmErnntEwlcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhsVagt7Y%253D&md5=efe56354f1182ce8c16cede75e04842b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fmed.21724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21724%26sid%3Dliteratum%253Aachs%26aulast%3DPillaiyar%26aufirst%3DT.%26aulast%3DWendt%26aufirst%3DL.%2BL.%26aulast%3DManickam%26aufirst%3DM.%26aulast%3DEaswaran%26aufirst%3DM.%26atitle%3DThe%2520recent%2520outbreaks%2520of%2520human%2520coronaviruses%253A%2520A%2520medicinal%2520chemistry%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2021%26volume%3D41%26spage%3D72%26epage%3D135%26doi%3D10.1002%2Fmed.21724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillaiyar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meenakshisundaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manickam, M.</span></span> <span> </span><span class="NLM_article-title">Recent discovery and development of inhibitors targeting coronaviruses</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">668</span>â <span class="NLM_lpage">688</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2020.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.drudis.2020.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32006468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFKgtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=668-688&author=T.+Pillaiyarauthor=S.+Meenakshisundaramauthor=M.+Manickam&title=Recent+discovery+and+development+of+inhibitors+targeting+coronaviruses&doi=10.1016%2Fj.drudis.2020.01.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Recent discovery and development of inhibitors targeting coronaviruses</span></div><div class="casAuthors">Pillaiyar, Thanigaimalai; Meenakshisundaram, Sangeetha; Manickam, Manoj</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">668-688</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Human coronaviruses (CoVs) are enveloped viruses with a pos.-sense single-stranded RNA genome.  Currently, six human CoVs have been reported including human coronavirus 229E (HCoV-229E), OC43 (HCoV-OC43), NL63 (HCoV-NL63), HKU1 (HCoV-HKU1), severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and MiddleEast respiratory syndrome (MERS) coronavirus (MERS-CoV).  They cause moderate to severe respiratory and intestinal infections in humans.  In this review, we focus on recent advances in the research and development of small-mol. anti-human coronavirus therapies targeting different stages of the CoV life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGaJIxrfUjnLVg90H21EOLACvtfcHk0lgjqReVbG3Yyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFKgtro%253D&md5=08faec7e1ec7df3a3f6d4c4e34fe0807</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2020.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2020.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DPillaiyar%26aufirst%3DT.%26aulast%3DMeenakshisundaram%26aufirst%3DS.%26aulast%3DManickam%26aufirst%3DM.%26atitle%3DRecent%2520discovery%2520and%2520development%2520of%2520inhibitors%2520targeting%2520coronaviruses%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D668%26epage%3D688%26doi%3D10.1016%2Fj.drudis.2020.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span> <span> </span><span class="NLM_article-title">The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status</span>. <i>Military Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11</span>, <span class="refDoi">Â DOI: 10.1186/s40779-020-00240-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2Fs40779-020-00240-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32169119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXns1aht78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2020&pages=11&author=Y.+R.+Guoauthor=Q.+D.+Caoauthor=Z.+S.+Hongauthor=Y.+Y.+Tanauthor=S.+D.+Chenauthor=H.+J.+Jinauthor=K.+S.+Tanauthor=D.+Y.+Wangauthor=Y.+Yan&title=The+origin%2C+transmission+and+clinical+therapies+on+coronavirus+disease+2019+%28COVID-19%29+outbreak+-+an+update+on+the+status&doi=10.1186%2Fs40779-020-00240-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status</span></div><div class="casAuthors">Guo, Yan-Rong; Cao, Qing-Dong; Hong, Zhong-Si; Tan, Yuan-Yang; Chen, Shou-Deng; Jin, Hong-Jun; Tan, Kai-Sen; Wang, De-Yun; Yan, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Military Medical Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11</span>CODEN:
                <span class="NLM_cas:coden">MMRICN</span>;
        ISSN:<span class="NLM_cas:issn">2054-9369</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention.  On 30 Jan. 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern.  The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the 3rd introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the 21st century.  As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO.  Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to Î²-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host.  The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract.  Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe.  The clin. symptoms of COVID-19 patients include fever, cough, fatigue, and a small population of patients appeared gastrointestinal infection symptoms.  The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be assocd. with acute respiratory distress syndrome (ARDS) and cytokine storm.  Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation.  We summarized the latest research progress of the epidemiol., pathogenesis, and clin. characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKHUTw0IleQbVg90H21EOLACvtfcHk0lgjqReVbG3Yyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXns1aht78%253D&md5=040aa4a4b4c385793ea2e49c536299f3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1186%2Fs40779-020-00240-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40779-020-00240-0%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%2BR.%26aulast%3DCao%26aufirst%3DQ.%2BD.%26aulast%3DHong%26aufirst%3DZ.%2BS.%26aulast%3DTan%26aufirst%3DY.%2BY.%26aulast%3DChen%26aufirst%3DS.%2BD.%26aulast%3DJin%26aufirst%3DH.%2BJ.%26aulast%3DTan%26aufirst%3DK.%2BS.%26aulast%3DWang%26aufirst%3DD.%2BY.%26aulast%3DYan%26aufirst%3DY.%26atitle%3DThe%2520origin%252C%2520transmission%2520and%2520clinical%2520therapies%2520on%2520coronavirus%2520disease%25202019%2520%2528COVID-19%2529%2520outbreak%2520-%2520an%2520update%2520on%2520the%2520status%26jtitle%3DMilitary%2520Med.%2520Res.%26date%3D2020%26volume%3D7%26spage%3D11%26doi%3D10.1186%2Fs40779-020-00240-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunderink, R. G.</span></span> <span> </span><span class="NLM_article-title">MERS, SARS and other coronaviruses as causes of pneumonia</span>. <i>Respirology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">130</span>â <span class="NLM_lpage">137</span>, <span class="refDoi">Â DOI: 10.1111/resp.13196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1111%2Fresp.13196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29052924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC1M7islyhtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=130-137&author=Y.+Yinauthor=R.+G.+Wunderink&title=MERS%2C+SARS+and+other+coronaviruses+as+causes+of+pneumonia&doi=10.1111%2Fresp.13196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">MERS, SARS and other coronaviruses as causes of pneumonia</span></div><div class="casAuthors">Yin Yudong; Wunderink Richard G</div><div class="citationInfo"><span class="NLM_cas:title">Respirology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human coronaviruses (HCoVs) have been considered to be relatively harmless respiratory pathogens in the past.  However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection.  This review focuses on the epidemiology, pathogenesis and clinical characteristics among SARS-coronaviruses (CoV), MERS-CoV and other HCoV infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOAujGwxBhcwHqQV89nF-2fW6udTcc2ean11CgzQhOf7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7islyhtg%253D%253D&md5=cb5739c9d94f762af1bc4738e0134331</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fresp.13196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fresp.13196%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DY.%26aulast%3DWunderink%26aufirst%3DR.%2BG.%26atitle%3DMERS%252C%2520SARS%2520and%2520other%2520coronaviruses%2520as%2520causes%2520of%2520pneumonia%26jtitle%3DRespirology%26date%3D2018%26volume%3D23%26spage%3D130%26epage%3D137%26doi%3D10.1111%2Fresp.13196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillaiyar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manickam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. H.</span></span> <span> </span><span class="NLM_article-title">An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6595</span>â <span class="NLM_lpage">628</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01461</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01461" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyns7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6595-628&author=T.+Pillaiyarauthor=M.+Manickamauthor=V.+Namasivayamauthor=Y.+Hayashiauthor=S.+H.+Jung&title=An+overview+of+severe+acute+respiratory+syndrome-coronavirus+%28SARS-CoV%29+3CL+protease+inhibitors%3A+Peptidomimetics+and+small+molecule+chemotherapy&doi=10.1021%2Facs.jmedchem.5b01461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy</span></div><div class="casAuthors">Pillaiyar, Thanigaimalai; Manickam, Manoj; Namasivayam, Vigneshwaran; Hayashi, Yoshio; Jung, Sang-Hun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6595-6628</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus that infected more than 8000 individuals and resulted in more than 800 (10-15%) fatalities in 2003.  The causative agent of SARS has been identified as a novel human coronavirus (SARS-CoV), and its viral protease, SARS-CoV 3CLpro, has been shown to be essential for replication and has hence been recognized as a potent drug target for SARS infection.  Currently, there is no effective treatment for this epidemic despite the intensive research that has been undertaken since 2003 (over 3500 publications).  This perspective focuses on the status of various efficacious anti-SARS-CoV 3CLpro chemotherapies discovered during the last 12 years (2003-2015) from all sources, including lab. synthetic methods, natural products, and virtual screening.  We describe here mainly peptidomimetic and small mol. inhibitors of SARS-CoV 3CLpro.  Attempts have been made to provide a complete description of the structural features and binding modes of these inhibitors under many conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB_JCXe-m0RLVg90H21EOLACvtfcHk0lgOgs7IBFYMXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyns7c%253D&md5=6ce37076204280f64a7f362633fcee1a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01461%26sid%3Dliteratum%253Aachs%26aulast%3DPillaiyar%26aufirst%3DT.%26aulast%3DManickam%26aufirst%3DM.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DJung%26aufirst%3DS.%2BH.%26atitle%3DAn%2520overview%2520of%2520severe%2520acute%2520respiratory%2520syndrome-coronavirus%2520%2528SARS-CoV%2529%25203CL%2520protease%2520inhibitors%253A%2520Peptidomimetics%2520and%2520small%2520molecule%2520chemotherapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6595%26epage%3D628%26doi%3D10.1021%2Facs.jmedchem.5b01461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span> <i>Summary of probable SARS cases with onset of illness from
1 November
2002 to 31 July 2003</i>. <a href="https://www.who.int/csr/sars/country/table2004_04_21/en/" class="extLink">https://www.who.int/csr/sars/country/table2004_04_21/en/</a> (as of 31 December <span class="NLM_year">2003</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Summary+of+probable+SARS+cases+with+onset+of+illness+from%0A1+November%0A2002+to+31+July+2003.+https%3A%2F%2Fwww.who.int%2Fcsr%2Fsars%2Fcountry%2Ftable2004_04_21%2Fen%2F+%28as+of+31+December+2003%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DSummary%2520of%2520probable%2520SARS%2520cases%2520with%2520onset%2520of%2520illness%2520from%250A1%2520November%250A2002%2520to%252031%2520July%25202003%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daszak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karesh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipkin, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, S. S.</span></span>; <span class="NLM_contrib-group">PREDICT consortium</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazet, J. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, T.</span></span> <span> </span><span class="NLM_article-title">Global patterns in coronavirus diversity</span>. <i>Virus Evol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">vex012</span> <span class="refDoi">Â DOI: 10.1093/ve/vex012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1093%2Fve%2Fvex012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28630747" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&issue=1&author=S.+J.+Anthonyauthor=C.+K.+Johnsonauthor=D.+J.+Greigauthor=S.+Kramerauthor=X.+Cheauthor=H.+Wellsauthor=A.+L.+Hicksauthor=D.+O.+Jolyauthor=N.+D.+Wolfeauthor=P.+Daszakauthor=W.+Kareshauthor=W.+I.+Lipkinauthor=S.+S.+Morseauthor=PREDICT+consortiumauthor=J.+A.+K.+Mazetauthor=T.+Goldstein&title=Global+patterns+in+coronavirus+diversity&doi=10.1093%2Fve%2Fvex012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Fve%2Fvex012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fve%252Fvex012%26sid%3Dliteratum%253Aachs%26aulast%3DAnthony%26aufirst%3DS.%2BJ.%26aulast%3DJohnson%26aufirst%3DC.%2BK.%26aulast%3DGreig%26aufirst%3DD.%2BJ.%26aulast%3DKramer%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DX.%26aulast%3DWells%26aufirst%3DH.%26aulast%3DHicks%26aufirst%3DA.%2BL.%26aulast%3DJoly%26aufirst%3DD.%2BO.%26aulast%3DWolfe%26aufirst%3DN.%2BD.%26aulast%3DDaszak%26aufirst%3DP.%26aulast%3DKaresh%26aufirst%3DW.%26aulast%3DLipkin%26aufirst%3DW.%2BI.%26aulast%3DMorse%26aufirst%3DS.%2BS.%26aulast%3D%26aulast%3DMazet%26aufirst%3DJ.%2BA.%2BK.%26aulast%3DGoldstein%26aufirst%3DT.%26atitle%3DGlobal%2520patterns%2520in%2520coronavirus%2520diversity%26jtitle%3DVirus%2520Evol.%26date%3D2017%26volume%3D3%26issue%3D1%26doi%3D10.1093%2Fve%2Fvex012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillaiyar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manickam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. H.</span></span> <span> </span><span class="NLM_article-title">Middle East respiratory syndrome-coronavirus (MERS-CoV): An updated overview and pharmacotherapeutics</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">361</span>â <span class="NLM_lpage">372</span>, <span class="refDoi">Â DOI: 10.4172/2161-0444.1000287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.4172%2F2161-0444.1000287" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=361-372&author=T.+Pillaiyarauthor=M.+Manickamauthor=S.+H.+Jung&title=Middle+East+respiratory+syndrome-coronavirus+%28MERS-CoV%29%3A+An+updated+overview+and+pharmacotherapeutics&doi=10.4172%2F2161-0444.1000287"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.4172%2F2161-0444.1000287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2161-0444.1000287%26sid%3Dliteratum%253Aachs%26aulast%3DPillaiyar%26aufirst%3DT.%26aulast%3DManickam%26aufirst%3DM.%26aulast%3DJung%26aufirst%3DS.%2BH.%26atitle%3DMiddle%2520East%2520respiratory%2520syndrome-coronavirus%2520%2528MERS-CoV%2529%253A%2520An%2520updated%2520overview%2520and%2520pharmacotherapeutics%26jtitle%3DMed.%2520Chem.%26date%3D2015%26volume%3D5%26spage%3D361%26epage%3D372%26doi%3D10.4172%2F2161-0444.1000287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><a href="http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html" class="extLink">http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html</a> (as of March <span class="NLM_year">2021</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.emro.who.int%2Fhealth-topics%2Fmers-cov%2Fmers-outbreaks.html+%28as+of+March+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span> <span> </span><span class="NLM_article-title">Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">565</span>â <span class="NLM_lpage">574</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30251-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS0140-6736%2820%2930251-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32007145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFOmsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=565-574&author=R.+Luauthor=X.+Zhaoauthor=J.+Liauthor=P.+Niuauthor=B.+Yangauthor=H.+Wuauthor=W.+Wangauthor=H.+Songauthor=B.+Huangauthor=N.+Zhuauthor=Y.+Biauthor=X.+Maauthor=F.+Zhanauthor=L.+Wangauthor=T.+Huauthor=H.+Zhouauthor=Z.+Huauthor=W.+Zhouauthor=L.+Zhaoauthor=J.+Chenauthor=Y.+Mengauthor=J.+Wangauthor=Y.+Linauthor=J.+Yuanauthor=Z.+Xieauthor=J.+Maauthor=W.+J.+Liuauthor=D.+Wangauthor=W.+Xuauthor=E.+C.+Holmesauthor=G.+F.+Gaoauthor=G.+Wuauthor=W.+Chenauthor=W.+Shiauthor=W.+Tan&title=Genomic+characterisation+and+epidemiology+of+2019+novel+coronavirus%3A+Implications+for+virus&doi=10.1016%2FS0140-6736%2820%2930251-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</span></div><div class="casAuthors">Lu, Roujian; Zhao, Xiang; Li, Juan; Niu, Peihua; Yang, Bo; Wu, Honglong; Wang, Wenling; Song, Hao; Huang, Baoying; Zhu, Na; Bi, Yuhai; Ma, Xuejun; Zhan, Faxian; Wang, Liang; Hu, Tao; Zhou, Hong; Hu, Zhenhong; Zhou, Weimin; Zhao, Li; Chen, Jing; Meng, Yao; Wang, Ji; Lin, Yang; Yuan, Jianying; Xie, Zhihao; Ma, Jinmin; Liu, William J.; Wang, Dayan; Xu, Wenbo; Holmes, Edward C.; Gao, George F.; Wu, Guizhen; Chen, Weijun; Shi, Weifeng; Tan, Wenjie</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10224</span>),
    <span class="NLM_cas:pages">565-574</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In late Dec., 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China.  A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV).  As of Jan 26, 2020, more than 2000 cases of 2019-nCoV infection have been confirmed, most of which involved people living in or visiting Wuhan, and human-to-human transmission has been confirmed.  We did next-generation sequencing of samples from bronchoalveolar lavage fluid and cultured isolates from nine inpatients, eight of whom had visited the Huanan seafood market in Wuhan.  Complete and partial 2019-nCoV genome sequences were obtained from these individuals.  Viral contigs were connected using Sanger sequencing to obtain the full-length genomes, with the terminal regions detd. by rapid amplification of cDNA ends.  Phylogenetic anal. of these 2019-nCoV genomes and those of other coronaviruses was used to det. the evolutionary history of the virus and help infer its likely origin.  Homol. modeling was done to explore the likely receptor-binding properties of the virus.  The ten genome sequences of 2019-nCoV obtained from the nine patients were extremely similar, exhibiting more than 99Â·98% sequence identity.  Notably, 2019-nCoV was closely related (with 88% identity) to two bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21, collected in 2018 in Zhoushan, eastern China, but were more distant from SARS-CoV (about 79%) and MERS-CoV (about 50%).  Phylogenetic anal. revealed that 2019-nCoV fell within the subgenus Sarbecovirus of the genus Betacoronavirus, with a relatively long branch length to its closest relatives bat-SL-CoVZC45 and bat-SL-CoVZXC21, and was genetically distinct from SARS-CoV.  Notably, homol. modeling revealed that 2019-nCoV had a similar receptor-binding domain structure to that of SARS-CoV, despite amino acid variation at some key residues.2019-nCoV is sufficiently divergent from SARS-CoV to be considered a new human-infecting betacoronavirus.  Although our phylogenetic anal. suggests that bats might be the original host of this virus, an animal sold at the seafood market in Wuhan might represent an intermediate host facilitating the emergence of the virus in humans.  Importantly, structural anal. suggests that 2019-nCoV might be able to bind to the angiotensin-converting enzyme 2 receptor in humans.  The future evolution, adaptation, and spread of this virus warrant urgent investigation.  National Key Research and Development Program of China, National Major Project for Control and Prevention of Infectious Disease in China, Chinese Academy of Sciences, Shandong First Medical University.  These data have been deposited in the ChinaNational Microbiol. Data Center (accession no. NMDC10013002 and genome accession nos. NMDC60013002-01 to NMDC60013002-10) and the datafrom BGI have been deposited in the China National GeneBank (accession nos. CNA000733235).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSLcS-1ejQbVg90H21EOLACvtfcHk0lj2VNaJ8QW04g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFOmsLY%253D&md5=3a644f602ea1c68114e23b5f12625265</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930251-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930251-8%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%2BJ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DHolmes%26aufirst%3DE.%2BC.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DTan%26aufirst%3DW.%26atitle%3DGenomic%2520characterisation%2520and%2520epidemiology%2520of%25202019%2520novel%2520coronavirus%253A%2520Implications%2520for%2520virus%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D565%26epage%3D574%26doi%3D10.1016%2FS0140-6736%2820%2930251-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupoli, T. J.</span></span> <span> </span><span class="NLM_article-title">Exploiting existing molecular scaffolds for long-term COVID treatment</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1357</span>â <span class="NLM_lpage">1360</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.0c00254</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00254" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVGhurrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1357-1360&author=K.+Kumarauthor=T.+J.+Lupoli&title=Exploiting+existing+molecular+scaffolds+for+long-term+COVID+treatment&doi=10.1021%2Facsmedchemlett.0c00254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting existing molecular scaffolds for long-term COVID treatment</span></div><div class="casAuthors">Kumar, Krishna; Lupoli, Tania J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1357-1360</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Discovery and development of COVID-19 prophylactics and treatments remains a global imperative.  This perspective provides an overview of important mol. pathways involved in the viral life cycle of SARS-CoV-2, the infectious agent of COVID-19.  The authors highlight past and recent findings in essential coronavirus proteins, including RNA polymerase machinery, proteases, and fusion proteins, that offer opportunities for the design of novel inhibitors of SARS-CoV-2 infection.  By discussing the current inventory of viral inhibitors, the authors identify mol. scaffolds that may be improved by medicinal chem. efforts for effective therapeutics to treat current and future coronavirus-caused diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNdM1L0txxVrVg90H21EOLACvtfcHk0lj2VNaJ8QW04g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVGhurrE&md5=cbaa88ccb52fb147bda055affe317ffa</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00254%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DLupoli%26aufirst%3DT.%2BJ.%26atitle%3DExploiting%2520existing%2520molecular%2520scaffolds%2520for%2520long-term%2520COVID%2520treatment%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1357%26epage%3D1360%26doi%3D10.1021%2Facsmedchemlett.0c00254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKee, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stange, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naujokat, C.</span></span> <span> </span><span class="NLM_article-title">Candidate drugs against SARS-CoV-2 and COVID-19</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">104859</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2020.104859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.phrs.2020.104859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32360480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovFKht7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2020&pages=104859&author=D.+L.+McKeeauthor=A.+Sternbergauthor=U.+Stangeauthor=S.+Lauferauthor=C.+Naujokat&title=Candidate+drugs+against+SARS-CoV-2+and+COVID-19&doi=10.1016%2Fj.phrs.2020.104859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Candidate drugs against SARS-CoV-2 and COVID-19</span></div><div class="casAuthors">McKee, Dwight L.; Sternberg, Ariane; Stange, Ulrike; Laufer, Stefan; Naujokat, Cord</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104859</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future.  Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacol. strategy to combat the virus.  There exists a no. of candidate drugs that may inhibit infection with and replication of SARS-CoV-2.  Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2).  Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2.  Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analog remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochems. available to date may limit spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlH8zxqu9S37Vg90H21EOLACvtfcHk0lgr4yk4Gb9ZIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovFKht7g%253D&md5=9956ee00baf6844137067e6b2c4f626e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2020.104859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2020.104859%26sid%3Dliteratum%253Aachs%26aulast%3DMcKee%26aufirst%3DD.%2BL.%26aulast%3DSternberg%26aufirst%3DA.%26aulast%3DStange%26aufirst%3DU.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DNaujokat%26aufirst%3DC.%26atitle%3DCandidate%2520drugs%2520against%2520SARS-CoV-2%2520and%2520COVID-19%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D157%26spage%3D104859%26doi%3D10.1016%2Fj.phrs.2020.104859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiogi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koutsogiannaki, S.</span></span> <span> </span><span class="NLM_article-title">COVID-19 pathophysiology: A review</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">108427</span>, <span class="refDoi">Â DOI: 10.1016/j.clim.2020.108427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.clim.2020.108427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32325252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosFWitr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2020&pages=108427&author=K.+Yukiauthor=M.+Fujiogiauthor=S.+Koutsogiannaki&title=COVID-19+pathophysiology%3A+A+review&doi=10.1016%2Fj.clim.2020.108427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19 pathophysiology: A review</span></div><div class="casAuthors">Yuki, Koichi; Fujiogi, Miho; Koutsogiannaki, Sophia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">108427</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In Dec. 2019, a novel coronavirus, now named as SARS-CoV-2, caused a series of acute atypical respiratory diseases in Wuhan, Hubei Province, China.  The disease caused by this virus was termed COVID-19.  The virus is transmittable between humans and has caused pandemic worldwide.  The no. of death tolls continues to rise and a large no. of countries have been forced to do social distancing and lockdown.  Lack of targeted therapy continues to be a problem.  Epidemiol. studies showed that elder patients were more susceptible to severe diseases, while children tend to have milder symptoms.  Here we reviewed the current knowledge about this disease and considered the potential explanation of the different symptomatol. between children and adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3DUqtixUaorVg90H21EOLACvtfcHk0lgr4yk4Gb9ZIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosFWitr0%253D&md5=8c97d9785e6bfbf2a1885e12400cc55f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2020.108427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2020.108427%26sid%3Dliteratum%253Aachs%26aulast%3DYuki%26aufirst%3DK.%26aulast%3DFujiogi%26aufirst%3DM.%26aulast%3DKoutsogiannaki%26aufirst%3DS.%26atitle%3DCOVID-19%2520pathophysiology%253A%2520A%2520review%26jtitle%3DClin.%2520Immunol.%26date%3D2020%26volume%3D215%26spage%3D108427%26doi%3D10.1016%2Fj.clim.2020.108427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Attaway, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheraga, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhimraj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biehl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HatipoÄlu, U.</span></span> <span> </span><span class="NLM_article-title">Severe covid-19 pneumonia: Pathogenesis and clinical management</span>. <i>BMJ.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>372</i></span>, <span class="NLM_elocation-id">n436</span> <span class="refDoi">Â DOI: 10.1136/bmj.n436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1136%2Fbmj.n436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33692022" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2021&author=A.+H.+Attawayauthor=R.+G.+Scheragaauthor=A.+Bhimrajauthor=M.+Biehlauthor=U.+Hatipo%C4%9Flu&title=Severe+covid-19+pneumonia%3A+Pathogenesis+and+clinical+management&doi=10.1136%2Fbmj.n436"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1136%2Fbmj.n436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.n436%26sid%3Dliteratum%253Aachs%26aulast%3DAttaway%26aufirst%3DA.%2BH.%26aulast%3DScheraga%26aufirst%3DR.%2BG.%26aulast%3DBhimraj%26aufirst%3DA.%26aulast%3DBiehl%26aufirst%3DM.%26aulast%3DHatipo%25C4%259Flu%26aufirst%3DU.%26atitle%3DSevere%2520covid-19%2520pneumonia%253A%2520Pathogenesis%2520and%2520clinical%2520management%26jtitle%3DBMJ.%26date%3D2021%26volume%3D372%26doi%3D10.1136%2Fbmj.n436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Coronavirus infections and immune responses</span>. <i>J. Med. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">424</span>â <span class="NLM_lpage">432</span>, <span class="refDoi">Â DOI: 10.1002/jmv.25685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Fjmv.25685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31981224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntVKntr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2020&pages=424-432&author=G.+Liauthor=Y.+Fanauthor=Y.+Laiauthor=T.+Hanauthor=Z.+Liauthor=P.+Zhouauthor=P.+Panauthor=W.+Wangauthor=D.+Huauthor=X.+Liuauthor=Q.+Zhangauthor=J.+Wu&title=Coronavirus+infections+and+immune+responses&doi=10.1002%2Fjmv.25685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Coronavirus infections and immune responses</span></div><div class="casAuthors">Li, Geng; Fan, Yaohua; Lai, Yanni; Han, Tiantian; Li, Zonghui; Zhou, Peiwen; Pan, Pan; Wang, Wenbiao; Hu, Dingwen; Liu, Xiaohong; Zhang, Qiwei; Wu, Jianguo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Virology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-432</span>CODEN:
                <span class="NLM_cas:coden">JMVIDB</span>;
        ISSN:<span class="NLM_cas:issn">0146-6615</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Coronaviruses (CoVs) are by far the largest group of known pos.-sense RNA viruses having an extensive range of natural hosts.  In the past few decades, newly evolved Coronaviruses have posed a global threat to public health.  The immune response is essential to control and eliminate CoV infections, however, maladjusted immune responses may result in immunopathol. and impaired pulmonary gas exchange.  Gaining a deeper understanding of the interaction between Coronaviruses and the innate immune systems of the hosts may shed light on the development and persistence of inflammation in the lungs and hopefully can reduce the risk of lung inflammation caused by CoVs.  In this review, we provide an update on CoV infections and relevant diseases, particularly the host defense against CoV-induced inflammation of lung tissue, as well as the role of the innate immune system in the pathogenesis and clin. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV2qgbg4xqk7Vg90H21EOLACvtfcHk0lgr4yk4Gb9ZIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntVKntr4%253D&md5=f2de904af37ab888695f51c9b9222ac0</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fjmv.25685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmv.25685%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DG.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DCoronavirus%2520infections%2520and%2520immune%2520responses%26jtitle%3DJ.%2520Med.%2520Virol.%26date%3D2020%26volume%3D92%26spage%3D424%26epage%3D432%26doi%3D10.1002%2Fjmv.25685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span> <span> </span><span class="NLM_article-title">Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">497</span>â <span class="NLM_lpage">506</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30183-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS0140-6736%2820%2930183-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31986264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Kqu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=497-506&author=C.+Huangauthor=Y.+Wangauthor=X.+Liauthor=L.+Renauthor=J.+Zhaoauthor=Y.+Huauthor=L.+Zhangauthor=G.+Fanauthor=J.+Xuauthor=X.+Guauthor=Z.+Chengauthor=T.+Yuauthor=J.+Xiaauthor=Y.+Weiauthor=W.+Wuauthor=X.+Xieauthor=W.+Yinauthor=H.+Liauthor=M.+Liuauthor=Y.+Xiaoauthor=H.+Gaoauthor=L.+Guoauthor=J.+Xieauthor=G.+Wangauthor=R.+Jiangauthor=H.+Gaoauthor=Q.+Jinauthor=J.+Wangauthor=B.+Cao&title=Clinical+features+of+patients+infected+with+2019+novel+coronavirus+in+Wuhan%2C+China&doi=10.1016%2FS0140-6736%2820%2930183-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</span></div><div class="casAuthors">Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10223</span>),
    <span class="NLM_cas:pages">497-506</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV).  We report the epidemiol., clin., lab., and radiol. characteristics and treatment and clin. outcomes of these patients.  All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan.  We prospectively collected and analyzed data on patients with lab.-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing.  Data were obtained with standardised data collection forms shared by the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records.  Researchers also directly communicated with patients or their families to ascertain epidemiol. and symptom data.  Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not.  By Jan 2, 2020, 41 admitted hospital patients had been identified as having lab.-confirmed 2019-nCoV infection.  Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]).  Median age was 49Â·0 years (IQR 41Â·0-58Â·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market.  One family cluster was found.  Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum prodn. (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38).  Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8Â·0 days [IQR 5Â·0-13Â·0]).  26 (63%) Of 41 patients had lymphopenia.  All 41 patients had pneumonia with abnormal findings on chest CT.  Complications included acute respiratory distress syndrome (12 [29%]), RNAemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died.  Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.  The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was assocd. with ICU admission and high mortality.  Major gaps in our knowledge of the origin, epidemiol., duration of human transmission, and clin. spectrum of disease need fulfilment by future studies.  Ministry of Science and Technol., Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technol. Commission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1VbprmL3SvLVg90H21EOLACvtfcHk0lhSHyjWAJAYzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Kqu7c%253D&md5=b279b965c1054d99e60f673859c03b49</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930183-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930183-5%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DYin%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DB.%26atitle%3DClinical%2520features%2520of%2520patients%2520infected%2520with%25202019%2520novel%2520coronavirus%2520in%2520Wuhan%252C%2520China%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D497%26epage%3D506%26doi%3D10.1016%2FS0140-6736%2820%2930183-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. Q.</span></span> <span> </span><span class="NLM_article-title">The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">105954</span>, <span class="refDoi">Â DOI: 10.1016/j.ijantimicag.2020.105954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.ijantimicag.2020.105954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32234467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFOjtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2020&pages=105954&author=C.+Zhangauthor=Z.+Wuauthor=J.+W.+Liauthor=H.+Zhaoauthor=G.+Q.+Wang&title=The+cytokine+release+syndrome+%28CRS%29+of+severe+COVID-19+and+Interleukin-6+receptor+%28IL-6R%29+antagonist+Tocilizumab+may+be+the+key+to+reduce+the+mortality&doi=10.1016%2Fj.ijantimicag.2020.105954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality</span></div><div class="casAuthors">Zhang, Chi; Wu, Zhao; Li, Jia-Wen; Zhao, Hong; Wang, Gui-Qiang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">105954</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since Dec. 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world.  Although the case fatality rate is not high, the no. of people infected is large, and there are still a large no. of patients dying.  With the collation and publication of more and more clin. data, a large no. of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death.  Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients.  Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS).  If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients.  Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway.  So, tocilizumab is likely to become an effective drug for patients with severe COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfTK01cYVuX7Vg90H21EOLACvtfcHk0lhSHyjWAJAYzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFOjtbc%253D&md5=d25c0da775acd071c4e93b372e8e032c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2020.105954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2020.105954%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%2BW.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DG.%2BQ.%26atitle%3DThe%2520cytokine%2520release%2520syndrome%2520%2528CRS%2529%2520of%2520severe%2520COVID-19%2520and%2520Interleukin-6%2520receptor%2520%2528IL-6R%2529%2520antagonist%2520Tocilizumab%2520may%2520be%2520the%2520key%2520to%2520reduce%2520the%2520mortality%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2020%26volume%3D55%26spage%3D105954%26doi%3D10.1016%2Fj.ijantimicag.2020.105954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bermejo-Martin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danesh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelvin, D. J.</span></span> <span> </span><span class="NLM_article-title">Human immunopathogenesis of severe acute respiratory syndrome (SARS)</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">13</span>â <span class="NLM_lpage">19</span>, <span class="refDoi">Â DOI: 10.1016/j.virusres.2007.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.virusres.2007.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17374415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtlWksLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2008&pages=13-19&author=M.+J.+Cameronauthor=J.+F.+Bermejo-Martinauthor=A.+Daneshauthor=M.+P.+Mullerauthor=D.+J.+Kelvin&title=Human+immunopathogenesis+of+severe+acute+respiratory+syndrome+%28SARS%29&doi=10.1016%2Fj.virusres.2007.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Human immunopathogenesis of severe acute respiratory syndrome (SARS)</span></div><div class="casAuthors">Cameron, Mark J.; Bermejo-Martin, Jesus F.; Danesh, Ali; Muller, Matthew P.; Kelvin, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-19</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Progressive immune-assocd. injury is a hallmark of severe acute respiratory syndrome (SARS).  Viral evasion of innate immunity, hypercytokinemia and systemic immunopathol. in the SARS coronavirus (SARS CoV) infected host have been suggested as possible mechanisms for the cause of severe pathol. and morbidity in SARS patients.  The mol. and cellular basis for how SARS CoV impacts the host immune system resulting in severe SARS, however, has not been elucidated.  The variable clin. course of SARS may be the result of complex programs of host responses against the infectious agent.  Therefore, the systematic anal. of innate and adaptive immune responses to SARS CoV is imperative in building as complete an immunol. model as possible of host immunity and inflammatory responses during illness.  Here the authors review recent advances in SARS immunopathogenesis research and present a summary of their findings regarding host responses in SARS patients.  The authors contend that dysregulated type I and II interferon (IFN) responses during SARS may culminate in a failure of the switch from hyper-innate immunity to protective adaptive immune responses in the human host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFpRmeePaFHLVg90H21EOLACvtfcHk0ljHlk8ghvm11Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtlWksLg%253D&md5=7500dd72d353eba5fe3c683d08a72eb6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2007.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2007.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DBermejo-Martin%26aufirst%3DJ.%2BF.%26aulast%3DDanesh%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%2BP.%26aulast%3DKelvin%26aufirst%3DD.%2BJ.%26atitle%3DHuman%2520immunopathogenesis%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520%2528SARS%2529%26jtitle%3DVirus%2520Res.%26date%3D2008%26volume%3D133%26spage%3D13%26epage%3D19%26doi%3D10.1016%2Fj.virusres.2007.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, R. C.</span></span> <span> </span><span class="NLM_article-title">The mercurial nature of neutrophils: Still an enigma in ARDS?</span>. <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">L217</span>â <span class="NLM_lpage">230</span>, <span class="refDoi">Â DOI: 10.1152/ajplung.00311.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1152%2Fajplung.00311.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24318116" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2014&pages=L217-230&author=A.+E.+Williamsauthor=R.+C.+Chambers&title=The+mercurial+nature+of+neutrophils%3A+Still+an+enigma+in+ARDS%3F&doi=10.1152%2Fajplung.00311.2013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00311.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00311.2013%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DA.%2BE.%26aulast%3DChambers%26aufirst%3DR.%2BC.%26atitle%3DThe%2520mercurial%2520nature%2520of%2520neutrophils%253A%2520Still%2520an%2520enigma%2520in%2520ARDS%253F%26jtitle%3DAm.%2520J.%2520Physiol.%2520Lung%2520Cell%2520Mol.%2520Physiol.%26date%3D2014%26volume%3D306%26spage%3DL217%26epage%3D230%26doi%3D10.1152%2Fajplung.00311.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F. S.</span></span> <span> </span><span class="NLM_article-title">Pathological findings of COVID-19 associated with acute respiratory distress syndrome</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">420</span>â <span class="NLM_lpage">422</span>, <span class="refDoi">Â DOI: 10.1016/S2213-2600(20)30076-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS2213-2600%2820%2930076-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32085846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsValtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=420-422&author=Z.+Xuauthor=L.+Shiauthor=Y.+Wangauthor=J.+Zhangauthor=L.+Huangauthor=C.+Zhangauthor=S.+Liuauthor=P.+Zhaoauthor=H.+Liuauthor=L.+Zhuauthor=Y.+Taiauthor=C.+Baiauthor=T.+Gaoauthor=J.+Songauthor=P.+Xiaauthor=J.+Dongauthor=J.+Zhaoauthor=F.+S.+Wang&title=Pathological+findings+of+COVID-19+associated+with+acute+respiratory+distress+syndrome&doi=10.1016%2FS2213-2600%2820%2930076-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Pathological findings of COVID-19 associated with acute respiratory distress syndrome</span></div><div class="casAuthors">Xu, Zhe; Shi, Lei; Wang, Yijin; Zhang, Jiyuan; Huang, Lei; Zhang, Chao; Liu, Shuhong; Zhao, Peng; Liu, Hongxia; Zhu, Li; Tai, Yanhong; Bai, Changqing; Gao, Tingting; Song, Jinwen; Xia, Peng; Dong, Jinghui; Zhao, Jingmin; Wang, Fu-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">420-422</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In late Dec., 2019, an outbreak of a novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was reported in Wuhan, China; it subsequently spread worldwide.  In general, COVID-19 is an acute resolved disease but it can also be deadly, with a 2% case fatality rate.  Severe disease onset might result in death due to massive alveolar damage and progressive respiratory failure.  Here, we investigated the pathol. characteristics of a patient who died from severe infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by obtaining biopsy samples at autopsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSW8W-Tknn3bVg90H21EOLACvtfcHk0ljHlk8ghvm11Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsValtbk%253D&md5=9eece7ef49ab45d13ff000ae1a43dfc2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2820%2930076-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252820%252930076-X%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DTai%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DXia%26aufirst%3DP.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%2BS.%26atitle%3DPathological%2520findings%2520of%2520COVID-19%2520associated%2520with%2520acute%2520respiratory%2520distress%2520syndrome%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2020%26volume%3D8%26spage%3D420%26epage%3D422%26doi%3D10.1016%2FS2213-2600%2820%2930076-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Repurposing of kinase inhibitors for treatment of COVID-19</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">167</span>, <span class="refDoi">Â DOI: 10.1007/s11095-020-02851-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs11095-020-02851-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32778962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKksrfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=167&author=E.+Weisbergauthor=A.+Parentauthor=P.+L.+Yangauthor=M.+Sattlerauthor=Q.+Liuauthor=Q.+Liuauthor=J.+Wangauthor=C.+Mengauthor=S.+J.+Buhrlageauthor=N.+Grayauthor=J.+D.+Griffin&title=Repurposing+of+kinase+inhibitors+for+treatment+of+COVID-19&doi=10.1007%2Fs11095-020-02851-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of Kinase Inhibitors for Treatment of COVID-19</span></div><div class="casAuthors">Weisberg, Ellen; Parent, Alexander; Yang, Priscilla L.; Sattler, Martin; Liu, Qingsong; Liu, Qingwang; Wang, Jinhua; Meng, Chengcheng; Buhrlage, Sara J.; Gray, Nathanael; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">167</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the scientific community.  In the absence of a vaccine, the goal is to target the viral life cycle and alleviate the lung-damaging symptoms of infection, which can be life-threatening.  There are numerous protein kinases assocd. with these processes that can be inhibited by FDA-approved drugs, the repurposing of which presents an alluring option as they have been thoroughly vetted for safety and are more readily available for treatment of patients and testing in clin. trials.  Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metab., or reprodn.  We also highlight inhibitors with potential to reverse pulmonary insufficiency because of their anti-inflammatory activity, cytokine suppression, or antifibrotic activity.  Certain agents are projected to be dual-purpose drugs in terms of antiviral activity and alleviation of disease symptoms, however drug combination is also an option for inhibitors with optimal pharmacokinetic properties that allow safe and efficacious co-administration with other drugs, such as antiviral agents, IL-6 blocking agents, or other kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotAd3_eFezr7Vg90H21EOLACvtfcHk0ljHlk8ghvm11Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKksrfN&md5=5edc7624fa51b69ec9d487262584a051</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs11095-020-02851-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-020-02851-7%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DParent%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DC.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DRepurposing%2520of%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520COVID-19%26jtitle%3DPharm.%2520Res.%26date%3D2020%26volume%3D37%26spage%3D167%26doi%3D10.1007%2Fs11095-020-02851-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mingo, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span> <span> </span><span class="NLM_article-title">Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">8924</span>â <span class="NLM_lpage">8933</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01429-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01429-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27466418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2lu7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=8924-8933&author=C.+M.+Colemanauthor=J.+M.+Siskauthor=R.+M.+Mingoauthor=E.+A.+Nelsonauthor=J.+M.+Whiteauthor=M.+B.+Frieman&title=Abelson+kinase+inhibitors+are+potent+inhibitors+of+severe+acute+respiratory+syndrome+coronavirus+and+middle+east+respiratory+syndrome+coronavirus+fusion&doi=10.1128%2FJVI.01429-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion</span></div><div class="casAuthors">Coleman, Christopher M.; Sisk, Jeanne M.; Mingo, Rebecca M.; Nelson, Elizabeth A.; White, Judith M.; Frieman, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8924-8933</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The highly pathogenic severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) cause significant morbidity and morality.  There is currently no approved therapeutic for highly pathogenic coronaviruses, even as MERS-CoV is spreading throughout the Middle East.  We previously screened a library of FDA-approved drugs for inhibitors of coronavirus replication in which we identified Abelson (Abl) kinase inhibitors, including the anticancer drug imatinib, as inhibitors of both SARS-CoV and MERS-CoV in vitro.  Here we show that the anti-CoV activity of imatinib occurs at the early stages of infection, after internalization and endosomal trafficking, by inhibiting fusion of the virions at the endosomal membrane.  We specifically identified the imatinib target, Abelson tyrosine-protein kinase 2 (Abl2), as required for efficient SARS-CoV and MERS-CoV replication in vitro.  These data demonstrate that specific approved drugs can be characterized in vitro for their anticoronavirus activity and used to identify host proteins required for coronavirus replication.  This type of study is an important step in the repurposing of approved drugs for treatment of emerging coronaviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJU1Zz7G1ED7Vg90H21EOLACvtfcHk0lj73eiIfCVPcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2lu7fE&md5=090a5b4bb7680982944fc665dfbdc5e5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1128%2FJVI.01429-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01429-16%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DC.%2BM.%26aulast%3DSisk%26aufirst%3DJ.%2BM.%26aulast%3DMingo%26aufirst%3DR.%2BM.%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26atitle%3DAbelson%2520kinase%2520inhibitors%2520are%2520potent%2520inhibitors%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%2520and%2520middle%2520east%2520respiratory%2520syndrome%2520coronavirus%2520fusion%26jtitle%3DJ.%2520Virol.%26date%3D2016%26volume%3D90%26spage%3D8924%26epage%3D8933%26doi%3D10.1128%2FJVI.01429-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sisk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machamer, C. E.</span></span> <span> </span><span class="NLM_article-title">Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">619</span>â <span class="NLM_lpage">630</span>, <span class="refDoi">Â DOI: 10.1099/jgv.0.001047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1099%2Fjgv.0.001047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29557770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVahtLjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2018&pages=619-630&author=J.+M.+Siskauthor=M.+B.+Friemanauthor=C.+E.+Machamer&title=Coronavirus+S+protein-induced+fusion+is+blocked+prior+to+hemifusion+by+Abl+kinase+inhibitors&doi=10.1099%2Fjgv.0.001047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors</span></div><div class="casAuthors">Sisk, Jeanne M.; Frieman, Matthew B.; Machamer, Carolyn E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">619-630</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">1465-2099</span>.
    
            (<span class="NLM_cas:orgname">Microbiology Society</span>)
        </div><div class="casAbstract">Enveloped viruses gain entry into host cells by fusing with cellular membranes, a step that is required for virus replication.  The virus spike (S) protein mediates fusion with the host cell membrane.  We have shown previously that an Abelson (Abl) kinase inhibitor, imatinib, significantly reduces SARS-CoV and MERS-CoV viral titers and prevents endosomal entry by HIV SARS S and MERS S pseudotyped virions.  SARS-CoV and MERS-CoV are classified as BSL-3 viruses, which makes experimentation into the cellular mechanisms involved in infection more challenging.  Here, we use IBV, a BSL-2 virus, as a model for studying the role of Abl kinase activity during coronavirus infection.  We found that imatinib and two specific Abl kinase inhibitors, GNF2 and GNF5, reduce IBV titers by blocking the first round of virus infection.  Addnl., all three drugs prevented IBV S-induced syncytia formation prior to the hemifusion step.  Our results indicate that membrane fusion (both virus-cell and cell-cell) is blocked in the presence of Abl kinase inhibitors.  Studying the effects of Abl kinase inhibitors on IBV will be useful in identifying the host cell pathways required for coronavirus infection.  This will provide an insight into possible therapeutic targets to treat infections by current as well as newly emerging coronaviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp3OXSytq77rVg90H21EOLACvtfcHk0lj73eiIfCVPcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVahtLjF&md5=af00456c0177a52a04764bcaeb717cdb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1099%2Fjgv.0.001047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fjgv.0.001047%26sid%3Dliteratum%253Aachs%26aulast%3DSisk%26aufirst%3DJ.%2BM.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26aulast%3DMachamer%26aufirst%3DC.%2BE.%26atitle%3DCoronavirus%2520S%2520protein-induced%2520fusion%2520is%2520blocked%2520prior%2520to%2520hemifusion%2520by%2520Abl%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2018%26volume%3D99%26spage%3D619%26epage%3D630%26doi%3D10.1099%2Fjgv.0.001047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, J. H.</span></span> <span> </span><span class="NLM_article-title">JNK and p38 mitogen-activated protein kinase pathways contribute to porcine epidemic diarrhea virus infection</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>222</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">12</span>, <span class="refDoi">Â DOI: 10.1016/j.virusres.2016.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.virusres.2016.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27215486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Shtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=2016&pages=1-12&author=C.+Leeauthor=Y.+Kimauthor=J.+H.+Jeon&title=JNK+and+p38+mitogen-activated+protein+kinase+pathways+contribute+to+porcine+epidemic+diarrhea+virus+infection&doi=10.1016%2Fj.virusres.2016.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">JNK and p38 mitogen-activated protein kinase pathways contribute to porcine epidemic diarrhea virus infection</span></div><div class="casAuthors">Lee, Changhee; Kim, Youngnam; Jeon, Ji Hyun</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) pathways, which are central building blocks in the intracellular signaling network, are often manipulated by viruses of diverse families to favor their replication.  Among the MAPK family, the extracellular signal-regulated kinase (ERK) pathway is known to be modulated during the infection with porcine epidemic diarrhea virus (PEDV); however, involvement of stress-activated protein kinases (SAPKs) comprising p38 MAPK and c-Jun NH2-terminal kinase (JNK) remains to be detd.  Therefore, in the present study, we investigated whether activation of p38 MAPK and JNK cascades is required for PEDV replication.  Our results showed that PEDV activates p38 MAPK and JNK1/2 up to 24 h post-infection, whereas, thereafter their phosphorylation levels recede to baseline levels or even fall below them.  Notably, UV-irradiated inactivated PEDV, which can enter cells but cannot replicate inside them, failed to induce phosphorylation of p38 MAPK and JNK1/2 suggesting that viral biosynthesis is essential for activation of these kinases.  Treatment of cells with selective p38 or JNK inhibitors markedly impaired PEDV replication in a dose-dependent manner and these antiviral effects were found to be maximal during the early times of the infection.  Furthermore, direct pharmacol. inhibition of p38 MAPK or JNK1/2 activation resulted in a significant redn. of viral RNA synthesis, viral protein expression, and progeny release.  However, independent treatments with either SAPK inhibitor did not inhibit PEDV-induced apoptotic cell death mediated by activation of mitochondrial apoptosis-inducing factor (AIF) suggesting that SAPKs are irrelevant to the apoptosis pathway during PEDV infection.  In summary, our data demonstrated crit. roles of the p38 and JNK1/2 signaling pathways in facilitating successful viral infection during the post-entry steps of the PEDV life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFU6UbPFBvXLVg90H21EOLACvtfcHk0lj73eiIfCVPcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Shtr4%253D&md5=c0bffb5299069d3fad2a3c1123040b14</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2016.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2016.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DJeon%26aufirst%3DJ.%2BH.%26atitle%3DJNK%2520and%2520p38%2520mitogen-activated%2520protein%2520kinase%2520pathways%2520contribute%2520to%2520porcine%2520epidemic%2520diarrhea%2520virus%2520infection%26jtitle%3DVirus%2520Res.%26date%3D2016%26volume%3D222%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.virusres.2016.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makino, S.</span></span> <span> </span><span class="NLM_article-title">Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">5937</span>â <span class="NLM_lpage">5948</span>, <span class="refDoi">Â DOI: 10.1128/JVI.76.12.5937-5948.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.76.12.5937-5948.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=12021326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlSru7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2002&pages=5937-5948&author=S.+Banerjeeauthor=K.+Narayananauthor=T.+Mizutaniauthor=S.+Makino&title=Murine+coronavirus+replication-induced+p38+mitogen-activated+protein+kinase+activation+promotes+interleukin-6+production+and+virus+replication+in+cultured+cells&doi=10.1128%2FJVI.76.12.5937-5948.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells</span></div><div class="casAuthors">Banerjee, Sangeeta; Narayanan, Krishna; Mizutani, Tetsuya; Makino, Shinji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5937-5948</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Analyses of mitogen-activated protein kinases (MAPKs) in a mouse hepatitis virus (MHV)-infected macrophage-derived J774.1 cell line showed activation of two MAPKs, p38 MAPK and c-Jun N-terminal kinase (JNK), but not of extracellular signal-regulated kinase (ERK).  Activation of MAPKs was evident by 6 h post-infection.  However, UV-irradiated MHV failed to activate MAPKs, which demonstrated that MHV replication was necessary for their activation.  Several other MHV-permissive cell lines also showed activation of both p38 MAPK and JNK, which indicated that the MHV-induced stress-kinase activation was not restricted to any particular cell type.  The upstream kinase responsible for activating MHV-induced p38 MAPK was the MAPK kinase 3.  Expts. with a specific inhibitor of p38 MAPK, SB 203580, demonstrated that MHV-induced p38 MAPK activation resulted in the accumulation of interleukin-6 (IL-6) mRNAs and an increase in the prodn. of IL-6, regardless of MHV-induced general host protein synthesis inhibition.  Furthermore, MHV prodn. was suppressed in SB 203580-treated cells, demonstrating that activated p38 MAPK played a role in MHV replication.  The reduced MHV prodn. in SB 203580-treated cells was, at least in part, due to a decrease in virus-specific protein synthesis and virus-specific mRNA accumulation.  Interestingly, there was a transient increase in the amt. of phosphorylation of the translation initiation factor 4E (eIF4E) in infected cells, and this eIF4E phosphorylation was p38 MAPK dependent; it is known that phosphorylated eIF4E enhances translation rates of cap-contg. mRNAs.  Furthermore, the upstream kinase responsible for eIF4E phosphorylation, MAPK-interacting kinase 1, was also phosphorylated and activated in response to MHV infection.  Our data suggested that host cells, in response to MHV replication, activated p38 MAPK, which subsequently phosphorylated eIF4E to efficiently translate certain host proteins, including IL-6, during virus-induced severe host protein synthesis inhibition.  MHV utilized this p38 MAPK-dependent increase in eIF4E phosphorylation to promote virus-specific protein synthesis and subsequent progeny virus prodn.  Enhancement of virus-specific protein synthesis through virus-induced eIF4E activation has not been reported in any other viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0BvjYf6qJwrVg90H21EOLACvtfcHk0lix6aDv0V9VjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlSru7g%253D&md5=a6bbc508aba8194d38d090363792355c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1128%2FJVI.76.12.5937-5948.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.76.12.5937-5948.2002%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DNarayanan%26aufirst%3DK.%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DMakino%26aufirst%3DS.%26atitle%3DMurine%2520coronavirus%2520replication-induced%2520p38%2520mitogen-activated%2520protein%2520kinase%2520activation%2520promotes%2520interleukin-6%2520production%2520and%2520virus%2520replication%2520in%2520cultured%2520cells%26jtitle%3DJ.%2520Virol.%26date%3D2002%26volume%3D76%26spage%3D5937%26epage%3D5948%26doi%3D10.1128%2FJVI.76.12.5937-5948.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirasawa, H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">150</span>â <span class="NLM_lpage">152</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2007.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2007.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18055026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlOlug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=150-152&author=M.+Konoauthor=K.+Tatsumiauthor=A.+M.+Imaiauthor=K.+Saitoauthor=T.+Kuriyamaauthor=H.+Shirasawa&title=Inhibition+of+human+coronavirus+229E+infection+in+human+epithelial+lung+cells+%28L132%29+by+chloroquine%3A+involvement+of+p38+MAPK+and+ERK&doi=10.1016%2Fj.antiviral.2007.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK</span></div><div class="casAuthors">Kono, Masakazu; Tatsumi, Koichiro; Imai, Alberto M.; Saito, Kengo; Kuriyama, Takayuki; Shirasawa, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">150-152</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The antiviral effects of chloroquine (CQ) on human coronavirus 229E (HCoV-229E) infection of human fetal lung cell line, L132 are reported.  CQ significantly decreased the viral replication at concns. lower than in clin. usage.  We demonstrated that CQ affects the activation of p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK).  Furthermore, p38 MAPK inhibitor, SB203580, inhibits CPE induced by HCoV-229E infection and viral replication.  Our findings suggest that CQ affects the activation of MAPKs, involved in the replication of HCoV-229E.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtCBeEC2erNLVg90H21EOLACvtfcHk0lix6aDv0V9VjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlOlug%253D%253D&md5=33d4220cb47dd09c191e35275adff654</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DKono%26aufirst%3DM.%26aulast%3DTatsumi%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DA.%2BM.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DKuriyama%26aufirst%3DT.%26aulast%3DShirasawa%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520human%2520coronavirus%2520229E%2520infection%2520in%2520human%2520epithelial%2520lung%2520cells%2520%2528L132%2529%2520by%2520chloroquine%253A%2520involvement%2520of%2520p38%2520MAPK%2520and%2520ERK%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26spage%3D150%26epage%3D152%26doi%3D10.1016%2Fj.antiviral.2007.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">301</span>â <span class="NLM_lpage">305</span>, <span class="refDoi">Â DOI: 10.1038/35060098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2F35060098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11231581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=301-305&author=S.+Pleschkaauthor=T.+Wolffauthor=C.+Ehrhardtauthor=G.+Hobomauthor=O.+Planzauthor=U.+R.+Rappauthor=S.+Ludwig&title=Influenza+virus+propagation+is+impaired+by+inhibition+of+the+Raf%2FMEK%2FERK+signalling+cascade&doi=10.1038%2F35060098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span></div><div class="casAuthors">Pleschka, Stephan; Wolff, Thorsten; Ehrhard, Christina; Hobom, Gerd; Planz, Oliver; Rapp, Ulf R.; Ludwig, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-305</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Influenza A viruses are important worldwide pathogens in humans and different animal species.  The functions of most of the ten different viral proteins of this neg.-strand RNA virus have been well elucidated.  However, little is known about the virus-induced intracellular signalling events that support viral replication.  The Raf/MEK/ERK cascade is the prototype of mitogen-activated protein (MAP) kinase cascades and has an important role in cell growth, differentiation and survival.  Investigation of the function of this pathway has been facilitated by the identification of specific inhibitors, such as U0126, which blocks the cascade at the level of MAPK/ERK kinase (MEK).  Here, the authors show that infection of cells with influenza A virus leads to biphasic activation of the Raf/MEK/ERK cascade.  Inhibition of Raf signalling results in nuclear retention of viral ribonucleoprotein complexes (RNPs), impaired function of the nuclear-export protein (NEP/NS2) and concomitant inhibition of virus prodn.  Thus, signalling through the mitogenic cascade seems to be essential for virus prodn. and RNP export from the nucleus during the viral life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx1KgfMDKJPLVg90H21EOLACvtfcHk0lix6aDv0V9VjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D&md5=b5283932b9d29e474583d8dfa0ec5658</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2F35060098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35060098%26sid%3Dliteratum%253Aachs%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DHobom%26aufirst%3DG.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DInfluenza%2520virus%2520propagation%2520is%2520impaired%2520by%2520inhibition%2520of%2520the%2520Raf%252FMEK%252FERK%2520signalling%2520cascade%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D301%26epage%3D305%26doi%3D10.1038%2F35060098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabel, G. J.</span></span> <span> </span><span class="NLM_article-title">The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">1230</span>â <span class="NLM_lpage">1240</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01586-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01586-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17108034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFCgurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2007&pages=1230-1240&author=C.+A.+Zampieriauthor=J.+F.+Fortinauthor=G.+P.+Nolanauthor=G.+J.+Nabel&title=The+ERK+mitogen-activated+protein+kinase+pathway+contributes+to+Ebola+virus+glycoprotein-induced+cytotoxicity&doi=10.1128%2FJVI.01586-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity</span></div><div class="casAuthors">Zampieri, Carisa A.; Fortin, Jean-Francois; Nolan, Garry P.; Nabel, Gary J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1230-1240</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Ebola virus is a highly lethal pathogen that causes hemorrhagic fever in humans and nonhuman primates.  Among the seven known viral gene products, the envelope glycoprotein (GP) alone induces cell rounding and detachment that ultimately leads to cell death.  Cellular cytotoxicity is not seen with comparable levels of expression of a mutant form of GP lacking a mucin-like domain (GPÎmuc).  GP-induced cell death is non-apoptotic and is preceded by down-modulation of cell surface mols. involved in signaling pathways, including certain integrins and epidermal growth factor receptor.  To investigate the mechanism of GP-induced cellular toxicity, we analyzed the activation of several signal transduction pathways involved in cell growth and survival.  The active form of extracellular signal-regulated kinases type 1 and 2 (ERK1/2), phospho-ERK1/2, was reduced in cells expressing GP compared to those expressing GPÎmuc as detd. by flow cytometry, in contrast to the case for several other signaling proteins.  Subsequent anal. of the activation states and kinase activities of related kinases revealed a more pronounced effect on the ERK2 kinase isoform.  Disruption of ERK2 activity by a dominant neg. ERK or by small interfering RNA-mediated ERK2 knockdown potentiated the decrease in Î±V integrin expression assocd. with toxicity.  Conversely, activation of the pathway through the expression of a constitutively active form of ERK2 significantly protected against this effect.  These results indicate that the ERK signaling cascade mediates GP-mediated cytotoxicity and plays a role in pathogenicity induced by this gene product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb9VqOOhotUrVg90H21EOLACvtfcHk0lgieJUJP47IfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFCgurs%253D&md5=a5bd3c4731380c3ad2cda2673f9300cb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1128%2FJVI.01586-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01586-06%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DC.%2BA.%26aulast%3DFortin%26aufirst%3DJ.%2BF.%26aulast%3DNolan%26aufirst%3DG.%2BP.%26aulast%3DNabel%26aufirst%3DG.%2BJ.%26atitle%3DThe%2520ERK%2520mitogen-activated%2520protein%2520kinase%2520pathway%2520contributes%2520to%2520Ebola%2520virus%2520glycoprotein-induced%2520cytotoxicity%26jtitle%3DJ.%2520Virol.%26date%3D2007%26volume%3D81%26spage%3D1230%26epage%3D1240%26doi%3D10.1128%2FJVI.01586-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honko, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, C. F.</span></span> <span> </span><span class="NLM_article-title">Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">102</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2014.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2014.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24815087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC2cjhsFWhuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2014&pages=102-109&author=J.+C.+Johnsonauthor=O.+Martinezauthor=A.+N.+Honkoauthor=L.+E.+Hensleyauthor=G.+G.+Olingerauthor=C.+F.+Basler&title=Pyridinyl+imidazole+inhibitors+of+p38+MAP+kinase+impair+viral+entry+and+reduce+cytokine+induction+by+Zaire+ebolavirus+in+human+dendritic+cells&doi=10.1016%2Fj.antiviral.2014.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells</span></div><div class="casAuthors">Johnson Joshua C; Honko Anna N; Hensley Lisa E; Olinger Gene G; Martinez Osvaldo; Basler Christopher F</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">102-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antigen presenting cells (APCs), including macrophages and dendritic cells, are early and sustained targets of Ebola virus (EBOV) infection in vivo.  Because EBOV activates mitogen-activated protein kinase (MAPK) signaling upon infection of APCs, we evaluated the effect of pyridinyl imidazole inhibitors of p38 MAPK on EBOV infection of human APCs and EBOV mediated cytokine production from human DCs.  The p38 MAPK inhibitors reduced viral replication in PMA-differentiated macrophage-like human THP-1 cells with an IC50 of 4.73Î¼M (SB202190), 8.26Î¼M (p38kinhIII) and 8.21Î¼M (SB203580) and primary human monocyte-derived dendritic cells (MDDCs) with an IC50 of 2.67Î¼M (SB202190).  Furthermore, cytokine production from EBOV-treated MDDCs was inhibited in a dose-dependent manner.  A control pyridinyl imidazole compound failed to inhibit either EBOV infection or cytokine induction.  Using an established EBOV virus-like particle (VLP) entry assay, we demonstrate that inhibitor pretreatment blocked VLP entry suggesting that the inhibitors blocked infection and replication at least in part by blocking EBOV entry.  Taken together, our results indicate that pyridinyl imidazole p38 MAPK inhibitors may serve as leads for the development of therapeutics to treat EBOV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSzVh8HZxaG5yXXDYhVZBdlfW6udTcc2eYO6dzoYf29Wrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjhsFWhuw%253D%253D&md5=fa401790144b2321b79f27ceb0d4c26d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DJ.%2BC.%26aulast%3DMartinez%26aufirst%3DO.%26aulast%3DHonko%26aufirst%3DA.%2BN.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DBasler%26aufirst%3DC.%2BF.%26atitle%3DPyridinyl%2520imidazole%2520inhibitors%2520of%2520p38%2520MAP%2520kinase%2520impair%2520viral%2520entry%2520and%2520reduce%2520cytokine%2520induction%2520by%2520Zaire%2520ebolavirus%2520in%2520human%2520dendritic%2520cells%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D107%26spage%3D102%26epage%3D109%26doi%3D10.1016%2Fj.antiviral.2014.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ordyan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartol, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangamani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sejnowski, T.</span></span> <span> </span><span class="NLM_article-title">Interactions between calmodulin and neurogranin govern the dynamics of CaMKII as a leaky integrator</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>, <span class="NLM_elocation-id">e1008015</span> <span class="refDoi">Â DOI: 10.1371/journal.pcbi.1008015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.pcbi.1008015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32678848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFeqtLrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&author=M.+Ordyanauthor=T.+Bartolauthor=M.+Kennedyauthor=P.+Rangamaniauthor=T.+Sejnowski&title=Interactions+between+calmodulin+and+neurogranin+govern+the+dynamics+of+CaMKII+as+a+leaky+integrator&doi=10.1371%2Fjournal.pcbi.1008015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions between calmodulin and neurogranin govern the dynamics of CaMKII as a leaky integrator</span></div><div class="casAuthors">Ordyan, Mariam; Bartol, Tom; Kennedy, Mary; Rangamani, Padmini; Sejnowski, Terrence</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e1008015</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Calmodulin-dependent kinase II (CaMKII) has long been known to play an important role in learning and memory as well as long term potentiation (LTP).  More recently it has been suggested that it might be involved in the time averaging of synaptic signals, which can then lead to the high precision of information stored at a single synapse.  However, the role of the scaffolding mol., neurogranin (Ng), in governing the dynamics of CaMKII is not yet fully understood.  In this work, we adopt a rule-based modeling approach through the Monte Carlo method to study the effect of Ca2+ signals on the dynamics of CaMKII phosphorylation in the postsynaptic d. (PSD).  Calcium surges are obsd. in synaptic spines during an EPSP and back-propagating action potential due to the opening of NMDA receptors and voltage dependent calcium channels.  Using agent-based models, we computationally investigate the dynamics of phosphorylation of CaMKII monomers and dodecameric holoenzymes.  The scaffolding mol., Ng, when present in significant concn., limits the availability of free calmodulin (CaM), the protein which activates CaMKII in the presence of calcium.  We show that Ng plays an important modulatory role in CaMKII phosphorylation following a surge of high calcium concn.  We find a non-intuitive dependence of this effect on CaM concn. that results from the different affinities of CaM for CaMKII depending on the no. of calcium ions bound to the former.  It has been shown previously that in the absence of phosphatase, CaMKII monomers integrate over Ca2+ signals of certain frequencies through autophosphorylation (Pepke et al, Plos Comp Bio., 2010)..  We also study the effect of multiple calcium spikes on CaMKII holoenzyme autophosphorylation, and show that in the presence of phosphatase, CaMKII behaves as a leaky integrator of calcium signals, a result that has been recently obsd. in vivo.  Our models predict that the parameters of this leaky integrator are finely tuned through the interactions of Ng, CaM, CaMKII, and PP1, providing a mechanism to precisely control the sensitivity of synapses to calcium signals.  Author Summary not valid for PLOS ONE submissions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfJpaxKlXakLVg90H21EOLACvtfcHk0lgieJUJP47IfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFeqtLrI&md5=95b81e8803678d44243c1d74136cece5</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1008015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1008015%26sid%3Dliteratum%253Aachs%26aulast%3DOrdyan%26aufirst%3DM.%26aulast%3DBartol%26aufirst%3DT.%26aulast%3DKennedy%26aufirst%3DM.%26aulast%3DRangamani%26aufirst%3DP.%26aulast%3DSejnowski%26aufirst%3DT.%26atitle%3DInteractions%2520between%2520calmodulin%2520and%2520neurogranin%2520govern%2520the%2520dynamics%2520of%2520CaMKII%2520as%2520a%2520leaky%2520integrator%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2020%26volume%3D16%26doi%3D10.1371%2Fjournal.pcbi.1008015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hemmat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asadzadeh, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahangar, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemohammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najafzadeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derakhshani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baghbanzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baghi, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javadrashid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najafi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ar Gouilh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran, B.</span></span> <span> </span><span class="NLM_article-title">The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV</span>. <i>Arch. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">675</span>â <span class="NLM_lpage">696</span>, <span class="refDoi">Â DOI: 10.1007/s00705-021-04958-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs00705-021-04958-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33462671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhsFOhu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2021&pages=675-696&author=N.+Hemmatauthor=Z.+Asadzadehauthor=N.+K.+Ahangarauthor=H.+Alemohammadauthor=B.+Najafzadehauthor=A.+Derakhshaniauthor=A.+Baghbanzadehauthor=H.+B.+Baghiauthor=D.+Javadrashidauthor=S.+Najafiauthor=M.+Ar+Gouilhauthor=B.+Baradaran&title=The+roles+of+signaling+pathways+in+SARS-CoV-2+infection%3B+lessons+learned+from+SARS-CoV+and+MERS-CoV&doi=10.1007%2Fs00705-021-04958-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV</span></div><div class="casAuthors">Hemmat, Nima; Asadzadeh, Zahra; Ahangar, Noora Karim; Alemohammad, Hajar; Najafzadeh, Basira; Derakhshani, Afshin; Baghbanzadeh, Amir; Baghi, Hossein Bannazadeh; Javadrashid, Darya; Najafi, Souzan; Ar Gouilh, Meriadeg; Baradaran, Behzad</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Virology</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">675-696</span>CODEN:
                <span class="NLM_cas:coden">ARVIDF</span>;
        ISSN:<span class="NLM_cas:issn">0304-8608</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">A review.  Abstr.: The no. of descriptions of emerging viruses has grown at an unprecedented rate since the beginning of the 21st century.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is the third highly pathogenic coronavirus that has introduced itself into the human population in the current era, after SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV).  Mol. and cellular studies of the pathogenesis of this novel coronavirus are still in the early stages of research; however, based on similarities of SARS-CoV-2 to other coronaviruses, it can be hypothesized that the NF-ÎºB, cytokine regulation, ERK, and TNF-Î± signaling pathways are the likely causes of inflammation at the onset of COVID-19.  Several drugs have been prescribed and used to alleviate the adverse effects of these inflammatory cellular signaling pathways, and these might be beneficial for developing novel therapeutic modalities against COVID-19.  In this review, we briefly summarize alterations of cellular signaling pathways that are assocd. with coronavirus infection, particularly SARS-CoV and MERS-CoV, and tabulate the therapeutic agents that are currently approved for treating other human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYxiUAcPzocrVg90H21EOLACvtfcHk0lja_67tYIk7ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhsFOhu7g%253D&md5=55a7ecde7e0f3c1b4d74da458951e50e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs00705-021-04958-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00705-021-04958-7%26sid%3Dliteratum%253Aachs%26aulast%3DHemmat%26aufirst%3DN.%26aulast%3DAsadzadeh%26aufirst%3DZ.%26aulast%3DAhangar%26aufirst%3DN.%2BK.%26aulast%3DAlemohammad%26aufirst%3DH.%26aulast%3DNajafzadeh%26aufirst%3DB.%26aulast%3DDerakhshani%26aufirst%3DA.%26aulast%3DBaghbanzadeh%26aufirst%3DA.%26aulast%3DBaghi%26aufirst%3DH.%2BB.%26aulast%3DJavadrashid%26aufirst%3DD.%26aulast%3DNajafi%26aufirst%3DS.%26aulast%3DAr%2BGouilh%26aufirst%3DM.%26aulast%3DBaradaran%26aufirst%3DB.%26atitle%3DThe%2520roles%2520of%2520signaling%2520pathways%2520in%2520SARS-CoV-2%2520infection%253B%2520lessons%2520learned%2520from%2520SARS-CoV%2520and%2520MERS-CoV%26jtitle%3DArch.%2520Virol.%26date%3D2021%26volume%3D166%26spage%3D675%26epage%3D696%26doi%3D10.1007%2Fs00705-021-04958-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span> <span> </span><span class="NLM_article-title">GSK-3 inhibition as a therapeutic approach against SARs CoV2: Dual benefit of inhibiting viral replication while potentiating the immune response</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">1638</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2020.01638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffimmu.2020.01638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32695123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVWns7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1638&author=C.+E.+Rudd&title=GSK-3+inhibition+as+a+therapeutic+approach+against+SARs+CoV2%3A+Dual+benefit+of+inhibiting+viral+replication+while+potentiating+the+immune+response&doi=10.3389%2Ffimmu.2020.01638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 inhibition as a therapeutic approach against SARs CoV2: dual benefit of inhibiting viral replication while potentiating the immune response</span></div><div class="casAuthors">Rudd, Christopher E.; Flynn, JoAnne L.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1638</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The SARS-CoV2 (COVID-19) pandemic and uncertainties in developing a vaccine have created an urgent need for new therapeutic approaches.  A key question is whether it is possible to make rational predictions of new therapies based on the presently available scientific and medical information.  In this regard, I have noticed an omission in the present anal. in the literature related to the exploitation of glycogen synthase kinase 3 (GSK-3) as a therapeutic approach.  This is based on two key observations, that GSK-3 inhibitors can simultaneously block SARs viral replication, while boosting CD8+ adaptive T-cell and innate natural killer (NK) responses.  Firstly, it is already clear that GSK-3 phosphorylation of SARs CoV1 N protein on key serine residues is needed for viral replication such that small mol. inhibitors (SMIs) of GSK-3 can inhibit viral replication.  In comparing protein sequences, I show here that the key sites in the N protein of SARs CoV1 N for replication are conserved in SARs CoV2.  This strongly suggests that GSK-3 SMIs will also inhibit SARs Cov2 replication.  Secondly, we and others have previously documented that GSK-3 SMIs markedly enhance CD8+ cytolytic T-cell (CTL) and NK cell anti-viral effector functions leading to a redn. in both acute and chronic viral infections in mice.  My hypothesis is that the repurposing of low-cost inhibitors of GSK-3 such as lithium will limit SARS-CoV2 infections by both reducing viral replication and potentiating the immune response against the virus.  To date, there has been no mention of this dual connection between GSK-3 and SARs CoV2 in the literature.  To my knowledge, no other drugs exist with the potential to simultaneously target both viral replication and immune response against SARs CoV2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojYb1HqsdaL7Vg90H21EOLACvtfcHk0lja_67tYIk7ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVWns7jN&md5=4b1cea5d7c4acdb84654995521fc3780</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.01638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.01638%26sid%3Dliteratum%253Aachs%26aulast%3DRudd%26aufirst%3DC.%2BE.%26atitle%3DGSK-3%2520inhibition%2520as%2520a%2520therapeutic%2520approach%2520against%2520SARs%2520CoV2%253A%2520Dual%2520benefit%2520of%2520inhibiting%2520viral%2520replication%2520while%2520potentiating%2520the%2520immune%2520response%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26spage%3D1638%26doi%3D10.3389%2Ffimmu.2020.01638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezelj, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa Marrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polacco, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulferts, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obernier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabius, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucheray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miorin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson-Payant, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Armenta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knerr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugourd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdeolivas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HÃ¼ttenhain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cakir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muralidharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutuncuoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathy, C. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manners, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FÃ©lix, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeal, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klippsten, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wit, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortemme, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez-Rodriguez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Oever, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a-Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignuzzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogan, N. J.</span></span> <span> </span><span class="NLM_article-title">The global phosphorylation landscape of SARS-CoV-2 infection</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">685</span>â <span class="NLM_lpage">712</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.06.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cell.2020.06.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32645325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKkt7zF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2020&pages=685-712&author=M.+Bouhaddouauthor=D.+Memonauthor=B.+Meyerauthor=K.+M.+Whiteauthor=V.+V.+Rezeljauthor=M.+Correa+Marreroauthor=B.+J.+Polaccoauthor=J.+E.+Melnykauthor=S.+Ulfertsauthor=R.+M.+Kaakeauthor=J.+Batraauthor=A.+L.+Richardsauthor=E.+Stevensonauthor=D.+E.+Gordonauthor=A.+Rojcauthor=K.+Obernierauthor=J.+M.+Fabiusauthor=M.+Soucherayauthor=L.+Miorinauthor=E.+Morenoauthor=C.+Kohauthor=Q.+D.+Tranauthor=A.+Hardyauthor=R.+Robinotauthor=T.+Valletauthor=B.+E.+Nilsson-Payantauthor=C.+Hernandez-Armentaauthor=A.+Dunhamauthor=S.+Weigangauthor=J.+Knerrauthor=M.+Modakauthor=D.+Quinteroauthor=Y.+Zhouauthor=A.+Dugourdauthor=A.+Valdeolivasauthor=T.+Patilauthor=Q.+Liauthor=R.+H%C3%BCttenhainauthor=M.+Cakirauthor=M.+Muralidharanauthor=M.+Kimauthor=G.+Jangauthor=B.+Tutuncuogluauthor=J.+Hiattauthor=J.+Z.+Guoauthor=J.+Xuauthor=S.+Bouhaddouauthor=C.+J.+P.+Mathyauthor=A.+Gaultonauthor=E.+J.+Mannersauthor=E.+F%C3%A9lixauthor=Y.+Shiauthor=M.+Goffauthor=J.+K.+Limauthor=T.+McBrideauthor=M.+C.+O%E2%80%99Nealauthor=Y.+Caiauthor=J.+C.+J.+Changauthor=D.+J.+Broadhurstauthor=S.+Klippstenauthor=E.+De+Witauthor=A.+R.+Leachauthor=T.+Kortemmeauthor=B.+Shoichetauthor=M.+Ottauthor=J.+Saez-Rodriguezauthor=B.+R.+ten+Oeverauthor=R.+D.+Mullinsauthor=E.+R.+Fischerauthor=G.+Kochsauthor=R.+Grosseauthor=A.+Garc%C3%ADa-Sastreauthor=M.+Vignuzziauthor=J.+R.+Johnsonauthor=K.+M.+Shokatauthor=D.+L.+Swaneyauthor=P.+Beltraoauthor=N.+J.+Krogan&title=The+global+phosphorylation+landscape+of+SARS-CoV-2+infection&doi=10.1016%2Fj.cell.2020.06.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Global Phosphorylation Landscape of SARS-CoV-2 Infection</span></div><div class="casAuthors">Bouhaddou, Mehdi; Memon, Danish; Meyer, Bjoern; White, Kris M.; Rezelj, Veronica V.; Correa Marrero, Miguel; Polacco, Benjamin J.; Melnyk, James E.; Ulferts, Svenja; Kaake, Robyn M.; Batra, Jyoti; Richards, Alicia L.; Stevenson, Erica; Gordon, David E.; Rojc, Ajda; Obernier, Kirsten; Fabius, Jacqueline M.; Soucheray, Margaret; Miorin, Lisa; Moreno, Elena; Koh, Cassandra; Tran, Quang Dinh; Hardy, Alexandra; Robinot, Remy; Vallet, Thomas; Nilsson-Payant, Benjamin E.; Hernandez-Armenta, Claudia; Dunham, Alistair; Weigang, Sebastian; Knerr, Julian; Modak, Maya; Quintero, Diego; Zhou, Yuan; Dugourd, Aurelien; Valdeolivas, Alberto; Patil, Trupti; Li, Qiongyu; Huttenhain, Ruth; Cakir, Merve; Muralidharan, Monita; Kim, Minkyu; Jang, Gwendolyn; Tutuncuoglu, Beril; Hiatt, Joseph; Guo, Jeffrey Z.; Xu, Jiewei; Bouhaddou, Sophia; Mathy, Christopher J. P.; Gaulton, Anna; Manners, Emma J.; Felix, Eloy; Shi, Ying; Goff, Marisa; Lim, Jean K.; McBride, Timothy; O'Neal, Michael C.; Cai, Yiming; Chang, Jason C. J.; Broadhurst, David J.; Klippsten, Saker; De wit, Emmie; Leach, Andrew R.; Kortemme, Tanja; Shoichet, Brian; Ott, Melanie; Saez-Rodriguez, Julio; tenOever, Benjamin R.; Mullins, R. Dyche; Fischer, Elizabeth R.; Kochs, Georg; Grosse, Robert; Garcia-Sastre, Adolfo; Vignuzzi, Marco; Johnson, Jeffery R.; Shokat, Kevan M.; Swaney, Danielle L.; Beltrao, Pedro; Krogan, Nevan J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">685-712.e19</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The causative agent of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected millions and killed hundreds of thousands of people worldwide, highlighting an urgent need to develop antiviral therapies.  Here, we present a quant. mass spectrometry-based phosphoproteomics survey of SARS-CoV-2 infection in Vero E6 cells, revealing dramatic rewiring of phosphorylation on host and viral proteins.  SARS-CoV-2 infection promoted casein kinase II (CK2) and p38 MAPK activation, prodn. of diverse cytokines, and shutdown of mitotic kinases, resulting in cell cycle arrest.  Infection also stimulated a marked induction of CK2-contg. filopodial protrusions possessing budding viral particles.  Eighty-seven drugs and compds. were identified by mapping global phosphorylation profiles to dysregulated kinases and pathways.  We found pharmacol. inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaeZZGqGpEn7Vg90H21EOLACvtfcHk0liZV2DorWjq6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKkt7zF&md5=cb6e1da08aaaf061b76004416ce27355</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.06.034%26sid%3Dliteratum%253Aachs%26aulast%3DBouhaddou%26aufirst%3DM.%26aulast%3DMemon%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DB.%26aulast%3DWhite%26aufirst%3DK.%2BM.%26aulast%3DRezelj%26aufirst%3DV.%2BV.%26aulast%3DCorrea%2BMarrero%26aufirst%3DM.%26aulast%3DPolacco%26aufirst%3DB.%2BJ.%26aulast%3DMelnyk%26aufirst%3DJ.%2BE.%26aulast%3DUlferts%26aufirst%3DS.%26aulast%3DKaake%26aufirst%3DR.%2BM.%26aulast%3DBatra%26aufirst%3DJ.%26aulast%3DRichards%26aufirst%3DA.%2BL.%26aulast%3DStevenson%26aufirst%3DE.%26aulast%3DGordon%26aufirst%3DD.%2BE.%26aulast%3DRojc%26aufirst%3DA.%26aulast%3DObernier%26aufirst%3DK.%26aulast%3DFabius%26aufirst%3DJ.%2BM.%26aulast%3DSoucheray%26aufirst%3DM.%26aulast%3DMiorin%26aufirst%3DL.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DKoh%26aufirst%3DC.%26aulast%3DTran%26aufirst%3DQ.%2BD.%26aulast%3DHardy%26aufirst%3DA.%26aulast%3DRobinot%26aufirst%3DR.%26aulast%3DVallet%26aufirst%3DT.%26aulast%3DNilsson-Payant%26aufirst%3DB.%2BE.%26aulast%3DHernandez-Armenta%26aufirst%3DC.%26aulast%3DDunham%26aufirst%3DA.%26aulast%3DWeigang%26aufirst%3DS.%26aulast%3DKnerr%26aufirst%3DJ.%26aulast%3DModak%26aufirst%3DM.%26aulast%3DQuintero%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DDugourd%26aufirst%3DA.%26aulast%3DValdeolivas%26aufirst%3DA.%26aulast%3DPatil%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DH%25C3%25BCttenhain%26aufirst%3DR.%26aulast%3DCakir%26aufirst%3DM.%26aulast%3DMuralidharan%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DJang%26aufirst%3DG.%26aulast%3DTutuncuoglu%26aufirst%3DB.%26aulast%3DHiatt%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DJ.%2BZ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DBouhaddou%26aufirst%3DS.%26aulast%3DMathy%26aufirst%3DC.%2BJ.%2BP.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DManners%26aufirst%3DE.%2BJ.%26aulast%3DF%25C3%25A9lix%26aufirst%3DE.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DGoff%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DMcBride%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Neal%26aufirst%3DM.%2BC.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DBroadhurst%26aufirst%3DD.%2BJ.%26aulast%3DKlippsten%26aufirst%3DS.%26aulast%3DDe%2BWit%26aufirst%3DE.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DKortemme%26aufirst%3DT.%26aulast%3DShoichet%26aufirst%3DB.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DSaez-Rodriguez%26aufirst%3DJ.%26aulast%3Dten%2BOever%26aufirst%3DB.%2BR.%26aulast%3DMullins%26aufirst%3DR.%2BD.%26aulast%3DFischer%26aufirst%3DE.%2BR.%26aulast%3DKochs%26aufirst%3DG.%26aulast%3DGrosse%26aufirst%3DR.%26aulast%3DGarc%25C3%25ADa-Sastre%26aufirst%3DA.%26aulast%3DVignuzzi%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DSwaney%26aufirst%3DD.%2BL.%26aulast%3DBeltrao%26aufirst%3DP.%26aulast%3DKrogan%26aufirst%3DN.%2BJ.%26atitle%3DThe%2520global%2520phosphorylation%2520landscape%2520of%2520SARS-CoV-2%2520infection%26jtitle%3DCell%26date%3D2020%26volume%3D182%26spage%3D685%26epage%3D712%26doi%3D10.1016%2Fj.cell.2020.06.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorne, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, D.</span></span> <span> </span><span class="NLM_article-title">Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">21</span>â <span class="NLM_lpage">31</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01814-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01814-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20962097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlCjtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=21-31&author=P.+M.+Reevesauthor=S.+K.+Smithauthor=V.+A.+Olsonauthor=S.+H.+Thorneauthor=W.+Bornmannauthor=I.+K.+Damonauthor=D.+Kalman&title=Variola+and+monkeypox+viruses+utilize+conserved+mechanisms+of+virion+motility+and+release+that+depend+on+abl+and+SRC+family+tyrosine+kinases&doi=10.1128%2FJVI.01814-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on Abl and Src family tyrosine kinases</span></div><div class="casAuthors">Reeves, Patrick M.; Smith, Scott K.; Olson, Victoria A.; Thorne, Steve H.; Bornmann, William; Damon, Inger K.; Kalman, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-31</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Vaccinia virus (VacV) enters mammalian cells, replicates extranuclearly, and produces virions that move to the cell surface along microtubules, fuse with the plasma membrane, and move from infected cells toward apposing cells on actin-filled membranous protrusions or actin tails.  To form actin tails, cell-assocd. enveloped virions (CEV) required Abl and Src family tyrosine kinases.  Furthermore, release of CEV from the cell requires Abl but not Src family tyrosine kinases and is blocked by imatinib mesylate (STI-571; Gleevec), an Abl family kinase inhibitor used to treat chronic myelogenous leukemia in humans.  Here we demonstrate that the Poxviridae family members monkeypox virus (MPX) and variola virus (VarV) use conserved mechanisms for actin motility and extracellular enveloped virion (EEV) release.  Furthermore, we show that imatinib mesylate is effective in a mouse model of infection with VacV, whether delivered prophylactically or postinfection, and restricts spread of virions from the site of inoculation.  While inhibitors of both Src and Abl family kinases, such as dasatinib (BMS-354825; Sprycel), are effective in limiting dissemination of VacV, VarV, and MPX in vitro, members of this class of drugs appear to have immunosuppressive effects in vivo that preclude their use as anti-infectives.  Together, these data suggest a possible utility for imatinib mesylate in treating smallpox or MPX infections or complications assocd. with vaccination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp110ZF6U0WXbVg90H21EOLACvtfcHk0liZV2DorWjq6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlCjtrc%253D&md5=587e7600337ba2d6169ea9c9c0ab2f5d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1128%2FJVI.01814-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01814-10%26sid%3Dliteratum%253Aachs%26aulast%3DReeves%26aufirst%3DP.%2BM.%26aulast%3DSmith%26aufirst%3DS.%2BK.%26aulast%3DOlson%26aufirst%3DV.%2BA.%26aulast%3DThorne%26aufirst%3DS.%2BH.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DDamon%26aufirst%3DI.%2BK.%26aulast%3DKalman%26aufirst%3DD.%26atitle%3DVariola%2520and%2520monkeypox%2520viruses%2520utilize%2520conserved%2520mechanisms%2520of%2520virion%2520motility%2520and%2520release%2520that%2520depend%2520on%2520abl%2520and%2520SRC%2520family%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D21%26epage%3D31%26doi%3D10.1128%2FJVI.01814-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzione, L.</span></span> <span> </span><span class="NLM_article-title">Dasatinib: A new step in molecular target therapy</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">Suppl 6</span>), <span class="NLM_elocation-id">vi42</span> <span class="refDoi">Â DOI: 10.1093/annonc/mdm223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1093%2Fannonc%2Fmdm223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17591830" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&issue=Suppl+6&author=A.+Olivieriauthor=L.+Manzione&title=Dasatinib%3A+A+new+step+in+molecular+target+therapy&doi=10.1093%2Fannonc%2Fmdm223"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdm223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdm223%26sid%3Dliteratum%253Aachs%26aulast%3DOlivieri%26aufirst%3DA.%26aulast%3DManzione%26aufirst%3DL.%26atitle%3DDasatinib%253A%2520A%2520new%2520step%2520in%2520molecular%2520target%2520therapy%26jtitle%3DAnn.%2520Oncol.%26date%3D2007%26volume%3D18%26issue%3DSuppl%25206%26doi%3D10.1093%2Fannonc%2Fmdm223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koleske, A. J.</span></span> <span> </span><span class="NLM_article-title">Regulation of cell migration and morphogenesis by Abl-family kinases: Emerging mechanisms and physiological contexts</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3441</span>â <span class="NLM_lpage">3454</span>, <span class="refDoi">Â DOI: 10.1242/jcs.039859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1242%2Fjcs.039859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=19759284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSkurnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2009&pages=3441-3454&author=W.+D.+Bradleyauthor=A.+J.+Koleske&title=Regulation+of+cell+migration+and+morphogenesis+by+Abl-family+kinases%3A+Emerging+mechanisms+and+physiological+contexts&doi=10.1242%2Fjcs.039859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts</span></div><div class="casAuthors">Bradley, William D.; Koleske, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3441-3454</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The Abl-family non-receptor tyrosine kinases are essential regulators of the cytoskeleton.  They transduce diverse extracellular cues into cytoskeletal rearrangements that have dramatic effects on cell motility and morphogenesis.  Recent biochem. and genetic studies have revealed several mechanisms that Abl-family kinases use to mediate these effects.  Abl-family kinases stimulate actin polymn. through the activation of cortactin, hematopoietic lineage cell-specific protein (HS1), WASp- and WAVE-family proteins, and Rac1.  They also attenuate cell contractility by inhibiting RhoA and altering adhesion dynamics.  These pathways impinge on several physiol. processes, including development and maintenance of the nervous and immune systems, and epithelial morphogenesis.  Elucidating how Abl-family kinases are regulated, and where and when they coordinate cytoskeletal changes, is essential for garnering a better understanding of these complex processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKfpvJfbX0xrVg90H21EOLACvtfcHk0liyGl1PLasqYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSkurnM&md5=d796f40c4b2340d842be588dfa73c98c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1242%2Fjcs.039859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.039859%26sid%3Dliteratum%253Aachs%26aulast%3DBradley%26aufirst%3DW.%2BD.%26aulast%3DKoleske%26aufirst%3DA.%2BJ.%26atitle%3DRegulation%2520of%2520cell%2520migration%2520and%2520morphogenesis%2520by%2520Abl-family%2520kinases%253A%2520Emerging%2520mechanisms%2520and%2520physiological%2520contexts%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2009%26volume%3D122%26spage%3D3441%26epage%3D3454%26doi%3D10.1242%2Fjcs.039859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindrachuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ork, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span> <span> </span><span class="NLM_article-title">Antiviral potential of ERK/MAPK and PI3K/AKT/ mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1088</span>â <span class="NLM_lpage">1099</span>, <span class="refDoi">Â DOI: 10.1128/AAC.03659-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FAAC.03659-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25487801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVagsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1088-1099&author=J.+Kindrachukauthor=B.+Orkauthor=B.+J.+Hartauthor=S.+Mazurauthor=M.+R.+Holbrookauthor=M.+B.+Friemanauthor=D.+Traynorauthor=R.+F.+Johnsonauthor=J.+Dyallauthor=J.+H.+Kuhnauthor=G.+G.+Olingerauthor=L.+E.+Hensleyauthor=P.+B.+Jahrling&title=Antiviral+potential+of+ERK%2FMAPK+and+PI3K%2FAKT%2F+mTOR+signaling+modulation+for+middle+east+respiratory+syndrome+coronavirus+infection+as+identified+by+temporal+kinome+analysis&doi=10.1128%2FAAC.03659-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</span></div><div class="casAuthors">Kindrachuk, Jason; Ork, Britini; Hart, Brit J.; Mazur, Steven; Holbrook, Michael R.; Frieman, Matthew B.; Traynor, Dawn; Johnson, Reed F.; Dyall, Julie; Kuhn, Jens H.; Olinger, Gene G.; Hensley, Lisa E.; Jahrling, Peter B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1088-1099/1-1088-1099/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus, and infections with this virus can result in acute respiratory syndrome with renal failure.  Globally, MERS-CoV has been responsible for 877 lab.-confirmed infections, including 317 deaths, since Sept. 2012.  As there is a paucity of information regarding the mol. pathogenesis assocd. with this virus or the identities of novel antiviral drug targets, we performed temporal kinome anal. on human hepatocytes infected with the Erasmus isolate of MERS-CoV with peptide kinome arrays. bioinformatics anal. of our kinome data, including pathway overrepresentation anal. (ORA) and functional network anal., suggested that extracellular signalregulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphoinositol 3-kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling responses were specifically modulated in response to MERS-CoV infection in vitro throughout the course of infection.  The overrepresentation of specific intermediates within these pathways detd. by pathway and functional network anal. of our kinome data correlated with similar patterns of phosphorylation detd. through Western blot array anal.  In addn., anal. of the effects of specific kinase inhibitors on MERS-CoV infection in tissue culture models confirmed these cellular response observations.  Further, we have demonstrated that a subset of licensed kinase inhibitors targeting the ERK/MAPK and PI3K/AKT/mTOR pathways significantly inhibited MERS-CoV replication in vitro whether they were added before or after viral infection.  Taken together, our data suggest that ERK/MAPK and PI3K/AKT/mTOR signaling responses play important roles in MERS-CoV infection and may represent novel drug targets for therapeutic intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwo9H9W_zXg7Vg90H21EOLACvtfcHk0liyGl1PLasqYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVagsbw%253D&md5=1fef3dd7bccc643cec0762fdfbee27bb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1128%2FAAC.03659-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03659-14%26sid%3Dliteratum%253Aachs%26aulast%3DKindrachuk%26aufirst%3DJ.%26aulast%3DOrk%26aufirst%3DB.%26aulast%3DHart%26aufirst%3DB.%2BJ.%26aulast%3DMazur%26aufirst%3DS.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26aulast%3DTraynor%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DR.%2BF.%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DKuhn%26aufirst%3DJ.%2BH.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26atitle%3DAntiviral%2520potential%2520of%2520ERK%252FMAPK%2520and%2520PI3K%252FAKT%252F%2520mTOR%2520signaling%2520modulation%2520for%2520middle%2520east%2520respiratory%2520syndrome%2520coronavirus%2520infection%2520as%2520identified%2520by%2520temporal%2520kinome%2520analysis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1088%26epage%3D1099%26doi%3D10.1128%2FAAC.03659-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Saracatinib inhibits Middle East respiratory syndrome-coronavirus replication in vitro</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">283</span>, <span class="refDoi">Â DOI: 10.3390/v10060283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3390%2Fv10060283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVanurzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=283&author=J.+S.+Shinauthor=E.+Jungauthor=M.+Kimauthor=R.+S.+Baricauthor=Y.+Y.+Go&title=Saracatinib+inhibits+Middle+East+respiratory+syndrome-coronavirus+replication+in+vitro&doi=10.3390%2Fv10060283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro</span></div><div class="casAuthors">Shin, Jin Soo; Jung, Eunhye; Kim, Meehyein; Baric, Ralph S.; Go, Yun Young</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">283/1-283/19</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The Middle East respiratory syndrome-coronavirus (MERS-CoV), first identified in Saudi Arabia, is an emerging zoonotic pathogen that causes severe acute respiratory illness in humans with a high fatality rate.  Since its emergence, MERS-CoV continues to spread to countries outside of the Arabian Peninsula and gives rise to sporadic human infections following the entry of infected individuals to other countries, which can ppt. outbreaks similar to the one that occurred in South Korea in 2015.  Current therapeutics against MERS-CoV infection have primarily been adapted from previous drugs used for the treatment of severe acute respiratory syndrome.  In search of new potential drug candidates, we screened a library composed of 2334 clin. approved drugs and pharmacol. active compds.  The drug saracatinib, a potent inhibitor of Src-family of tyrosine kinases (SFK), was identified as an inhibitor of MERS-CoV replication in vitro.  Our results suggest that saracatinib potently inhibits MERS-CoV at the early stages of the viral life cycle in Huh-7 cells, possibly through the suppression of SFK signaling pathways.  Furthermore, saracatinib exhibited a synergistic effect with gemcitabine, an anticancer drug with antiviral activity against several RNA viruses.  These data indicate that saracatinib alone or in combination with gemcitabine can provide a new therapeutic option for the treatment of MERS-CoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZ_gxf2E7R7Vg90H21EOLACvtfcHk0lgl_O74KZYBZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVanurzF&md5=46083e949f27772ec4ed534ea8933f27</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3390%2Fv10060283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv10060283%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DJ.%2BS.%26aulast%3DJung%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DGo%26aufirst%3DY.%2BY.%26atitle%3DSaracatinib%2520inhibits%2520Middle%2520East%2520respiratory%2520syndrome-coronavirus%2520replication%2520in%2520vitro%26jtitle%3DViruses%26date%3D2018%26volume%3D10%26spage%3D283%26doi%3D10.3390%2Fv10060283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meessen-Pinard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Coupanec, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desforges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, P. J.</span></span> <span> </span><span class="NLM_article-title">Pivotal role of receptor-interacting protein kinase 1 and mixed lineage kinase domain-like in neuronal cell death induced by the human neuroinvasive coronavirus OC43</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>, <span class="NLM_elocation-id">e01513-16</span> <span class="refDoi">Â DOI: 10.1128/JVI.01513-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01513-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27795420" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&author=M.+Meessen-Pinardauthor=A.+Le+Coupanecauthor=M.+Desforgesauthor=P.+J.+Talbot&title=Pivotal+role+of+receptor-interacting+protein+kinase+1+and+mixed+lineage+kinase+domain-like+in+neuronal+cell+death+induced+by+the+human+neuroinvasive+coronavirus+OC43&doi=10.1128%2FJVI.01513-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1128%2FJVI.01513-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01513-16%26sid%3Dliteratum%253Aachs%26aulast%3DMeessen-Pinard%26aufirst%3DM.%26aulast%3DLe%2BCoupanec%26aufirst%3DA.%26aulast%3DDesforges%26aufirst%3DM.%26aulast%3DTalbot%26aufirst%3DP.%2BJ.%26atitle%3DPivotal%2520role%2520of%2520receptor-interacting%2520protein%2520kinase%25201%2520and%2520mixed%2520lineage%2520kinase%2520domain-like%2520in%2520neuronal%2520cell%2520death%2520induced%2520by%2520the%2520human%2520neuroinvasive%2520coronavirus%2520OC43%26jtitle%3DJ.%2520Virol.%26date%3D2017%26volume%3D91%26doi%3D10.1128%2FJVI.01513-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galimberti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BaratÃ¨, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balducci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciabatti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baglietto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spezia, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggi, F.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: A possible model supporting their use in the fight against SARS-CoV-2</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1428</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2020.01428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffonc.2020.01428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33014780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FntlWmsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=1428&author=S.+Galimbertiauthor=M.+Petriniauthor=C.+Barat%C3%A8author=F.+Ricciauthor=S.+Balducciauthor=S.+Grassiauthor=F.+Guerriniauthor=E.+Ciabattiauthor=S.+Mechelliauthor=A.+Di+Paoloauthor=C.+Baldiniauthor=L.+Bagliettoauthor=L.+Maceraauthor=P.+G.+Speziaauthor=F.+Maggi&title=Tyrosine+kinase+inhibitors+play+an+antiviral+action+in+patients+affected+by+chronic+myeloid+leukemia%3A+A+possible+model+supporting+their+use+in+the+fight+against+SARS-CoV-2&doi=10.3389%2Ffonc.2020.01428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2</span></div><div class="casAuthors">Galimberti Sara; Petrini Mario; Ricci Federica; Balducci Serena; Grassi Susanna; Guerrini Francesca; Ciabatti Elena; Di Paolo Antonello; Baldini Chiara; Baglietto Laura; Barate Claudia; Mechelli Sandra; Macera Lisa; Spezia Pietro Giorgio; Maggi Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1428</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">SARS-CoV-2 is the viral agent responsible for the pandemic that in the first months of 2020 caused about 400,000 deaths.  Among compounds proposed to fight the SARS-CoV-2-related disease (COVID-19), tyrosine kinase inhibitors (TKIs), already effective in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML), have been proposed on the basis of their antiviral action already demonstrated against SARS-CoV-1.  Very few cases of COVID-19 have been reported in Ph+ ALL and in CML Italian cohorts; authors suggested that this low rate of infections might depend on the use of TKIs, but the biological causes of this phenomenon remain unknown.  In this study, the CML model was used to test if TKIs would sustain or not the viral replication and if they could damage patient immunity.  Firstly, the infection and replication rate of torquetenovirus (TTV), whose load is inversely proportional to the host immunological control, have been measured in CML patients receiving nilotinib.  A very low percentage of subjects were infected at baseline, and TTV did not replicate or at least showed a low replication rate during the follow-up, with a mean load comparable to the measured one in healthy subjects.  Then, after gene expression profiling experiments, we found that several "antiviral" genes, such as CD28 and IFN gamma, were upregulated, while genes with "proviral" action, such as ARG-1, CEACAM1, and FUT4, were less expressed during treatment with imatinib, thus demonstrating that TKIs are not detrimental from the immunological point of view.  To sum up, our data could offer some biological explanations to the low COVID-19 occurrence in Ph+ ALL and CML patients and sustain the use of TKIs in COVID-19, as already proposed by several international ongoing studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQU0RJ53r8NbgaK-_ZudimnfW6udTcc2eb26V38K8xZ4rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FntlWmsQ%253D%253D&md5=979be41f8e43fa2089311b8f453e5f29</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2020.01428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2020.01428%26sid%3Dliteratum%253Aachs%26aulast%3DGalimberti%26aufirst%3DS.%26aulast%3DPetrini%26aufirst%3DM.%26aulast%3DBarat%25C3%25A8%26aufirst%3DC.%26aulast%3DRicci%26aufirst%3DF.%26aulast%3DBalducci%26aufirst%3DS.%26aulast%3DGrassi%26aufirst%3DS.%26aulast%3DGuerrini%26aufirst%3DF.%26aulast%3DCiabatti%26aufirst%3DE.%26aulast%3DMechelli%26aufirst%3DS.%26aulast%3DDi%2BPaolo%26aufirst%3DA.%26aulast%3DBaldini%26aufirst%3DC.%26aulast%3DBaglietto%26aufirst%3DL.%26aulast%3DMacera%26aufirst%3DL.%26aulast%3DSpezia%26aufirst%3DP.%2BG.%26aulast%3DMaggi%26aufirst%3DF.%26atitle%3DTyrosine%2520kinase%2520inhibitors%2520play%2520an%2520antiviral%2520action%2520in%2520patients%2520affected%2520by%2520chronic%2520myeloid%2520leukemia%253A%2520A%2520possible%2520model%2520supporting%2520their%2520use%2520in%2520the%2520fight%2520against%2520SARS-CoV-2%26jtitle%3DFront.%2520Oncol.%26date%3D2020%26volume%3D10%26spage%3D1428%26doi%3D10.3389%2Ffonc.2020.01428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">The p38 MAP kinase family as regulators of proinflammatory cytokine production in degenerative diseases of the CNS</span>. <i>Aging Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">199</span>â <span class="NLM_lpage">211</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=199-211&author=A.+D.+Bachstetterauthor=L.+J.+Van+Eldik&title=The+p38+MAP+kinase+family+as+regulators+of+proinflammatory+cytokine+production+in+degenerative+diseases+of+the+CNS"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DThe%2520p38%2520MAP%2520kinase%2520family%2520as%2520regulators%2520of%2520proinflammatory%2520cytokine%2520production%2520in%2520degenerative%2520diseases%2520of%2520the%2520CNS%26jtitle%3DAging%2520Dis.%26date%3D2010%26volume%3D3%26spage%3D199%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monahan, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. G.</span></span> <span> </span><span class="NLM_article-title">p38 Pathway kinases as anti-inflammatory drug targets</span>. <i>J. Dent. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">800</span>â <span class="NLM_lpage">811</span>, <span class="refDoi">Â DOI: 10.1177/154405910708600902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1177%2F154405910708600902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17720847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVOqurfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2007&pages=800-811&author=J.+F.+Schindlerauthor=J.+B.+Monahanauthor=W.+G.+Smith&title=p38+Pathway+kinases+as+anti-inflammatory+drug+targets&doi=10.1177%2F154405910708600902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">p38 pathway kinases as anti-inflammatory drug targets</span></div><div class="casAuthors">Schindler, J. F.; Monahan, J. B.; Smith, W. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dental Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">800-811</span>CODEN:
                <span class="NLM_cas:coden">JDREAF</span>;
        ISSN:<span class="NLM_cas:issn">0022-0345</span>.
    
            (<span class="NLM_cas:orgname">International Association for Dental Research</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinases (MAPK) are intracellular signaling mols. involved in cytokine synthesis.  Several classes of mammalian MAPK have been identified, including extracellular signal-regulated kinase, c-jun N-terminal kinase, and p38 MAP kinase.  P38Î± is a key MAPK involved in tumor necrosis factor Î± and other cytokine prodn., as well as enzyme induction (cyclooxygenase-2, inducible nitric oxide synthase, and matrix metalloproteinases) and adhesion mol. expression.  An understanding of the broad biol. and pathophysiol. roles of p38 MAPK family members has grown significantly over the past decade, as has the complexity of the signaling network leading to their activation.  Downstream substrates of MAPK include other kinases (e.g., mitogen-activated protein-kinase-activated protein kinase 2) and factors that regulate transcription, nuclear export, and mRNA stability and translation.  The high-resoln. crystal structure of p38Î± has led to the design of selective inhibitors that have good pharmacol. activity.  Despite the strong rationale for MAPK inhibitors in human disease, direct proof of concept in the clinic has yet to be demonstrated, with most compds. demonstrating dose-limiting adverse effects.  The role of MAPK in inflammation makes them attractive targets for new therapies, and efforts are continuing to identify newer, more selective inhibitors for inflammatory diseases.  Abbreviations used: MAPK, mitogen-activated protein kinase; ERK, extracellular signaling kinase; JNK, c-jun N-terminal kinase; COX2, cyclo-oxygenase-2; iNOS, inducible nitric oxide synthase; MMP, matrix metalloproteinase; MAPKK, mitogen-activated protein kinase kinase; MK-2, mitogen-activated protein-kinase-activated protein kinase-2; MAPKAP, mitogen-activated protein kinase-activated protein; MAPKKK, mitogen-activated protein kinase kinase kinase; RANKL, receptor activator of NF-ÎºB ligand; MNK, MAP kinase signal-integrating kinase; MSK, mitogen and stress-activated protein kinase; RSK, ribosomal S6 kinase; AP-1, activator protein-1; Tp1, tumor progression locus 2; IL, interleukin; ASK1, apoptosis signal-regulating kinase 1; TAO, thousand-and-one amino acids; MLK3, mixed-lineage kinase 3; TBK, transforming growth factor Î² activated protein kinase; TGFÎ², transforming growth factor Î²; LPS, lipopolysaccharide; TRAF6, TNF receptor-assocd. factor 6; MKK, mitogen-activated protein kinase kinase; TAK-1, TGF-beta activated protein kinase; GRK2, G-protein coupled receptor kinase-2 MKPs, MAP kinase phosphatases; PRAK, p38 regulated/ activated protein kinase; IFNÎ³, interferon gamma; AREs, AU-rich elements; AUBPs, AU-rich binding proteins; TTP, tristetraprolin; hnRNP A0, heterogeneous nuclear ribonuclear protein A0; HUR, human R antigen; PGE2, prostaglandin E2; Hsp27, small heat-shock protein-27; TNF-Î±, tumor necrosis factor alpha.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp29bqrL8B2KrVg90H21EOLACvtfcHk0ljscM4QGvPwZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVOqurfN&md5=38486f3ec8603a4bf793b111441617b4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1177%2F154405910708600902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F154405910708600902%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DJ.%2BF.%26aulast%3DMonahan%26aufirst%3DJ.%2BB.%26aulast%3DSmith%26aufirst%3DW.%2BG.%26atitle%3Dp38%2520Pathway%2520kinases%2520as%2520anti-inflammatory%2520drug%2520targets%26jtitle%3DJ.%2520Dent.%2520Res.%26date%3D2007%26volume%3D86%26spage%3D800%26epage%3D811%26doi%3D10.1177%2F154405910708600902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghuvanshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, S. B.</span></span> <span> </span><span class="NLM_article-title">Recent developments in the use of kinase inhibitors for management of viral Infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c01467</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01467" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=R.+Raghuvanshiauthor=S.+B.+Bharate&title=Recent+developments+in+the+use+of+kinase+inhibitors+for+management+of+viral+Infections&doi=10.1021%2Facs.jmedchem.0c01467"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01467%26sid%3Dliteratum%253Aachs%26aulast%3DRaghuvanshi%26aufirst%3DR.%26aulast%3DBharate%26aufirst%3DS.%2BB.%26atitle%3DRecent%2520developments%2520in%2520the%2520use%2520of%2520kinase%2520inhibitors%2520for%2520management%2520of%2520viral%2520Infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26doi%3D10.1021%2Facs.jmedchem.0c01467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span> <span> </span><span class="NLM_article-title">Influenza-virusinduced signaling cascades: Targets for antiviral therapy?</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">46</span>â <span class="NLM_lpage">52</span>, <span class="refDoi">Â DOI: 10.1016/S1471-4914(02)00010-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS1471-4914%2802%2900010-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=12615037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsVWqsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=46-52&author=S.+Ludwigauthor=O.+Planzauthor=S.+Pleschkaauthor=T.+Wolff&title=Influenza-virusinduced+signaling+cascades%3A+Targets+for+antiviral+therapy%3F&doi=10.1016%2FS1471-4914%2802%2900010-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza-virus-induced signaling cascades: targets for antiviral therapy?</span></div><div class="casAuthors">Ludwig, Stephan; Planz, Oliver; Pleschka, Stephan; Wolff, Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">46-52</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Influenza viruses continue to pose a severe threat worldwide, causing thousands of deaths and an enormous economic loss every year.  The major problem in fighting influenza is the high genetic variability of the virus, resulting in the rapid formation of variants that escape the acquired immunity against previous virus strains, or have resistance to antiviral agents.  Every virus depends on its host cell and, hence, cellular functions that are essential for viral replication might be suitable targets for antiviral therapy.  As a result, intracellular signaling cascades induced by the virus, in particular mitogen-activated protein kinase pathways, have recently come into focus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqTupjREwwibVg90H21EOLACvtfcHk0lhfz1ZcEQAAnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsVWqsrg%253D&md5=0824b4a81b06874f3a8e4964e4737eb8</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2FS1471-4914%2802%2900010-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4914%252802%252900010-2%26sid%3Dliteratum%253Aachs%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26atitle%3DInfluenza-virusinduced%2520signaling%2520cascades%253A%2520Targets%2520for%2520antiviral%2520therapy%253F%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D46%26epage%3D52%26doi%3D10.1016%2FS1471-4914%2802%2900010-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Development of cellular signaling pathway inhibitors as new antivirals against influenza</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">457</span>â <span class="NLM_lpage">468</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2013.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2013.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=23603495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotlGntbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=457-468&author=O.+Planz&title=Development+of+cellular+signaling+pathway+inhibitors+as+new+antivirals+against+influenza&doi=10.1016%2Fj.antiviral.2013.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Development of cellular signaling pathway inhibitors as new antivirals against influenza</span></div><div class="casAuthors">Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">457-468</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Influenza virus exploits a no. of cellular signaling pathways during the course of its replication, rendering them potential targets for new therapeutic interventions.  Several preclin. approaches are now focusing on cellular factors or pathways as a means of treating influenza.  By targeting host factors, rather than viral mechanisms, these novel therapies may be effective against multiple virus strains and subtypes, and are less likely to elicit viral drug resistance.  The most promising candidates are inhibitors of intracellular signaling cascades that are essential for virus replication.  This article reviews novel approaches and compds. that target the Raf/MEK/ERK signaling pathway, NF-ÎºB signaling, the PI3K/Akt pathway and the PKC signaling cascade.  Although these new antiviral strategies are still in an early phase of preclin. development, results to date suggest they offer a new approach to the treatment of influenza, supplementing direct-acting antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk82XeTtb077Vg90H21EOLACvtfcHk0lhfz1ZcEQAAnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotlGntbk%253D&md5=51b9a73e0faa5a894c7cef307cda92cd</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2013.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2013.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DDevelopment%2520of%2520cellular%2520signaling%2520pathway%2520inhibitors%2520as%2520new%2520antivirals%2520against%2520influenza%26jtitle%3DAntiviral%2520Res.%26date%3D2013%26volume%3D98%26spage%3D457%26epage%3D468%26doi%3D10.1016%2Fj.antiviral.2013.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meineke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimmelzwaan, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elbahesh, H.</span></span> <span> </span><span class="NLM_article-title">Influenza virus infections and cellular kinases</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">171</span>, <span class="refDoi">Â DOI: 10.3390/v11020171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3390%2Fv11020171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslymtbjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=171&author=R.+Meinekeauthor=G.+F.+Rimmelzwaanauthor=H.+Elbahesh&title=Influenza+virus+infections+and+cellular+kinases&doi=10.3390%2Fv11020171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus infections and cellular kinases</span></div><div class="casAuthors">Meineke, Robert; Rimmelzwaan, Guus F.; Elbahesh, Husni</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Influenza A viruses (IAVs) are a major cause of respiratory illness and are responsible for yearly epidemics assocd. with more than 500,000 annual deaths globally.  Novel IAVs may cause pandemic outbreaks and zoonotic infections with, for example, highly pathogenic avian influenza virus (HPAIV) of the H5N1 and H7N9 subtypes, which pose a threat to public health.  Treatment options are limited and emergence of strains resistant to antiviral drugs jeopardize this even further.  Like all viruses, IAVs depend on host factors for every step of the virus replication cycle.  Host kinases link multiple signaling pathways in respond to a myriad of stimuli, including viral infections.  Their regulation of multiple response networks has justified actively targeting cellular kinases for anti-cancer therapies and immune modulators for decades.  There is a growing vol. of research highlighting the significant role of cellular kinases in regulating IAV infections.  Their functional role is illustrated by the required phosphorylation of several IAV proteins necessary for replication and/or evasion/suppression of the innate immune response.  Identified in the majority of host factor screens, functional studies further support the important role of kinases and their potential as host restriction factors.  PKC, ERK, PI3K and FAK, to name a few, are kinases that regulate viral entry and replication.  Addnl., kinases such as IKK, JNK and p38 MAPK are essential in mediating viral sensor signaling cascades that regulate expression of antiviral chemokines and cytokines.  The feasibility of targeting kinases is steadily moving from bench to clinic and already-approved cancer drugs could potentially be repurposed for treatments of severe IAV infections.  In this review, we will focus on the contribution of cellular kinases to IAV infections and their value as potential therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSc-PzlVOvnrVg90H21EOLACvtfcHk0lgR0KVuXA-AGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslymtbjI&md5=7f0bed27a7c1bf8ea5c8870c7533f087</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.3390%2Fv11020171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv11020171%26sid%3Dliteratum%253Aachs%26aulast%3DMeineke%26aufirst%3DR.%26aulast%3DRimmelzwaan%26aufirst%3DG.%2BF.%26aulast%3DElbahesh%26aufirst%3DH.%26atitle%3DInfluenza%2520virus%2520infections%2520and%2520cellular%2520kinases%26jtitle%3DViruses%26date%3D2019%26volume%3D11%26spage%3D171%26doi%3D10.3390%2Fv11020171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Repurposing of kinase inhibitors as broadspectrum antiviral drugs</span>. <i>DNA Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">63</span>â <span class="NLM_lpage">69</span>, <span class="refDoi">Â DOI: 10.1089/dna.2017.4033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1089%2Fdna.2017.4033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29148875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ylsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=63-69&author=S.+Schorauthor=S.+Einav&title=Repurposing+of+kinase+inhibitors+as+broadspectrum+antiviral+drugs&doi=10.1089%2Fdna.2017.4033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs</span></div><div class="casAuthors">Schor, Stanford; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">DNA and Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">63-69</span>CODEN:
                <span class="NLM_cas:coden">DCEBE8</span>;
        ISSN:<span class="NLM_cas:issn">1044-5498</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">The high cost of drug development and the narrow spectrum of coverage typically provided by direct-acting antivirals limit the scalability of this antiviral approach.  This review summarizes progress and challenges in the repurposing of approved kinase inhibitors as host-targeted broad-spectrum antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNoqjCQHksU7Vg90H21EOLACvtfcHk0lgR0KVuXA-AGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ylsLg%253D&md5=4c6cad02eaecd11bf25b3d3de88f3cfe</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1089%2Fdna.2017.4033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fdna.2017.4033%26sid%3Dliteratum%253Aachs%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DRepurposing%2520of%2520kinase%2520inhibitors%2520as%2520broadspectrum%2520antiviral%2520drugs%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2018%26volume%3D37%26spage%3D63%26epage%3D69%26doi%3D10.1089%2Fdna.2017.4033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrion, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabel, G. J.</span></span> <span> </span><span class="NLM_article-title">Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">123ra24</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3003500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1126%2Fscitranslmed.3003500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22378924" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=123ra24&author=M.+Garciaauthor=A.+Cooperauthor=W.+Shiauthor=W.+Bornmannauthor=R.+Carrionauthor=D.+Kalmanauthor=G.+J.+Nabel&title=Productive+replication+of+Ebola+virus+is+regulated+by+the+c-Abl1+tyrosine+kinase&doi=10.1126%2Fscitranslmed.3003500"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003500%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DM.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DCarrion%26aufirst%3DR.%26aulast%3DKalman%26aufirst%3DD.%26aulast%3DNabel%26aufirst%3DG.%2BJ.%26atitle%3DProductive%2520replication%2520of%2520Ebola%2520virus%2520is%2520regulated%2520by%2520the%2520c-Abl1%2520tyrosine%2520kinase%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26spage%3D123ra24%26doi%3D10.1126%2Fscitranslmed.3003500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kouznetsova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Romero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKew, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Sastre, A.</span></span> <span> </span><span class="NLM_article-title">Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs</span>. <i>Emerging Microbes Infect.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">7</span>, <span class="refDoi">Â DOI: 10.1038/emi.2014.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Femi.2014.88" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=1-7&author=J.+Kouznetsovaauthor=W.+Sunauthor=C.+Martinez-Romeroauthor=G.+Tawaauthor=P.+Shinnauthor=C.+Z.+Chenauthor=A.+Schimmerauthor=P.+Sandersonauthor=J.+C.+McKewauthor=W.+Zhengauthor=A.+Garcia-Sastre&title=Identification+of+53+compounds+that+block+Ebola+virus-like+particle+entry+via+a+repurposing+screen+of+approved+drugs&doi=10.1038%2Femi.2014.88"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Femi.2014.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femi.2014.88%26sid%3Dliteratum%253Aachs%26aulast%3DKouznetsova%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DMartinez-Romero%26aufirst%3DC.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DShinn%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DC.%2BZ.%26aulast%3DSchimmer%26aufirst%3DA.%26aulast%3DSanderson%26aufirst%3DP.%26aulast%3DMcKew%26aufirst%3DJ.%2BC.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DGarcia-Sastre%26aufirst%3DA.%26atitle%3DIdentification%2520of%252053%2520compounds%2520that%2520block%2520Ebola%2520virus-like%2520particle%2520entry%2520via%2520a%2520repurposing%2520screen%2520of%2520approved%2520drugs%26jtitle%3DEmerging%2520Microbes%2520Infect.%26date%3D2014%26volume%3D3%26spage%3D1%26epage%3D7%26doi%3D10.1038%2Femi.2014.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergelson, J. M.</span></span> <span> </span><span class="NLM_article-title">Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">119</span>â <span class="NLM_lpage">131</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2005.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cell.2005.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16413486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XntVGktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2006&pages=119-131&author=C.+B.+Coyneauthor=J.+M.+Bergelson&title=Virus-induced+Abl+and+Fyn+kinase+signals+permit+coxsackievirus+entry+through+epithelial+tight+junctions&doi=10.1016%2Fj.cell.2005.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Virus-induced abl and fyn kinase signals permit coxsackievirus entry through epithelial tight junctions</span></div><div class="casAuthors">Coyne, Carolyn B.; Bergelson, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-131</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Group B coxsackieviruses (CVBs) must cross the epithelium as they initiate infection, but the mechanism by which this occurs remains uncertain.  The coxsackievirus and adenovirus receptor (CAR) is a component of the tight junction and is inaccessible to virus approaching from the apical surface.  Many CVBs also interact with the GPI-anchored protein decay-accelerating factor (DAF).  Here, we report that virus attachment to DAF on the apical cell surface activates Abl kinase, triggering Rac-dependent actin rearrangements that permit virus movement to the tight junction.  Within the junction, interaction with CAR promotes conformational changes in the virus capsid that are essential for virus entry and release of viral RNA.  Interaction with DAF also activates Fyn kinase, an event that is required for the phosphorylation of caveolin and transport of virus into the cell within caveolar vesicles.  CVBs thus exploit DAF-mediated signaling pathways to surmount the epithelial barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMExrkWO5tVLVg90H21EOLACvtfcHk0lhksaeAuw1ePA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntVGktg%253D%253D&md5=50cd83bdbcc0356e32b163ef4dcd9f43</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DCoyne%26aufirst%3DC.%2BB.%26aulast%3DBergelson%26aufirst%3DJ.%2BM.%26atitle%3DVirus-induced%2520Abl%2520and%2520Fyn%2520kinase%2520signals%2520permit%2520coxsackievirus%2520entry%2520through%2520epithelial%2520tight%2520junctions%26jtitle%3DCell%26date%3D2006%26volume%3D124%26spage%3D119%26epage%3D131%26doi%3D10.1016%2Fj.cell.2005.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newsome, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisswange, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frischknecht, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Way, M.</span></span> <span> </span><span class="NLM_article-title">Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus</span>. <i>Cell. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">233</span>â <span class="NLM_lpage">241</span>, <span class="refDoi">Â DOI: 10.1111/j.1462-5822.2005.00613.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1111%2Fj.1462-5822.2005.00613.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16441434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFant7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=233-241&author=T.+P.+Newsomeauthor=I.+Weisswangeauthor=F.+Frischknechtauthor=M.+Way&title=Abl+collaborates+with+Src+family+kinases+to+stimulate+actin-based+motility+of+vaccinia+virus&doi=10.1111%2Fj.1462-5822.2005.00613.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus</span></div><div class="casAuthors">Newsome, Timothy P.; Weisswange, Ina; Frischknecht, Friedrich; Way, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Microbiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-241</span>CODEN:
                <span class="NLM_cas:coden">CEMIF5</span>;
        ISSN:<span class="NLM_cas:issn">1462-5814</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Local activation of Src at the plasma membrane by extracellular vaccinia virus results in a signaling cascade that acts to stimulate actin polymn. beneath the virus to enhance its cell-to-cell spread.  Initiation of this signaling cascade involves Src-mediated phosphorylation of tyrosine 112 and 132 of the viral membrane protein A36R.  Here we show that recruitment of Src is dependent on its myristoylation and an interaction with A36R upstream of tyrosine 112 and 132.  We further show that Src, Fyn and Yes have unique specificities toward these tyrosine residues.  Using cell lines deficient in Src, Fyn and Yes, we demonstrate that multiple Src family members can stimulate vaccinia-induced actin polymn. and also uncover a role for Abl family kinases.  Addnl., Abl and Arg are able to phosphorylate A36R in vitro and are recruited to vaccinia-induced actin tails.  The ability of multiple families of tyrosine kinases to directly phosphorylate A36R ensures robust cell-to-cell spread of vaccinia virus will occur under a variety of cellular conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvWPtkZkCiHLVg90H21EOLACvtfcHk0lhksaeAuw1ePA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFant7s%253D&md5=94c5c1339d85280d6f80cb7064a7f2bc</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1111%2Fj.1462-5822.2005.00613.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1462-5822.2005.00613.x%26sid%3Dliteratum%253Aachs%26aulast%3DNewsome%26aufirst%3DT.%2BP.%26aulast%3DWeisswange%26aufirst%3DI.%26aulast%3DFrischknecht%26aufirst%3DF.%26aulast%3DWay%26aufirst%3DM.%26atitle%3DAbl%2520collaborates%2520with%2520Src%2520family%2520kinases%2520to%2520stimulate%2520actin-based%2520motility%2520of%2520vaccinia%2520virus%26jtitle%3DCell.%2520Microbiol.%26date%3D2006%26volume%3D8%26spage%3D233%26epage%3D241%26doi%3D10.1111%2Fj.1462-5822.2005.00613.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindrachuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidlaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lear-Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span> <span> </span><span class="NLM_article-title">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4885</span>â <span class="NLM_lpage">4893</span>, <span class="refDoi">Â DOI: 10.1128/AAC.03036-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FAAC.03036-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24841273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1art73L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=4885-4893&author=J.+Dyallauthor=C.+M.+Colemanauthor=B.+J.+Hartauthor=T.+Venkataramanauthor=M.+R.+Holbrookauthor=J.+Kindrachukauthor=R.+F.+Johnsonauthor=G.+G.+Olingerauthor=P.+B.+Jahrlingauthor=M.+Laidlawauthor=L.+M.+Johansenauthor=C.+M.+Lear-Rooneyauthor=P.+J.+Glassauthor=L.+E.+Hensleyauthor=M.+B.+Frieman&title=Repurposing+of+clinically+developed+drugs+for+treatment+of+Middle+East+respiratory+syndrome+coronavirus+infection&doi=10.1128%2FAAC.03036-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</span></div><div class="casAuthors">Dyall, Julie; Coleman, Christopher M.; Hart, Brit J.; Venkataraman, Thiagarajan; Holbrook, Michael R.; Kindrachuk, Jason; Johnson, Reed F.; Olinger, Gene G.; Jahrling, Peter B.; Laidlaw, Monique; Johansen, Lisa M.; Lear-Rooney, Calli M.; Glass, Pamela J.; Hensley, Lisa E.; Frieman, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4885-4893, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacol. treatments in the clinic with little time available for drug testing and development.  Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options.  Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers and funding agencies.  Given the development times and manufg. requirements for new products, repurposing of existing drugs is likely the only soln. for outbreaks due to emerging viruses.  In the studies described here, a library of 290 compds. was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).  Selection of compds. for inclusion in the library was dependent on current or previous FDA approval or advanced clin. development.  Some drugs that had a well-defined cellular pathway as target were included.  In total, 27 compds. with activity against both MERS-CoV and SARS-CoV were identified.  The compds. belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics.  The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE_PH7j54pPrVg90H21EOLACvtfcHk0liRG3Fyh-AzMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1art73L&md5=4cd7f71c09de4c1965b7c6f42f3ae2ce</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1128%2FAAC.03036-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03036-14%26sid%3Dliteratum%253Aachs%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DC.%2BM.%26aulast%3DHart%26aufirst%3DB.%2BJ.%26aulast%3DVenkataraman%26aufirst%3DT.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DKindrachuk%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DR.%2BF.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26aulast%3DLaidlaw%26aufirst%3DM.%26aulast%3DJohansen%26aufirst%3DL.%2BM.%26aulast%3DLear-Rooney%26aufirst%3DC.%2BM.%26aulast%3DGlass%26aufirst%3DP.%2BJ.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26atitle%3DRepurposing%2520of%2520clinically%2520developed%2520drugs%2520for%2520treatment%2520of%2520Middle%2520East%2520respiratory%2520syndrome%2520coronavirus%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D4885%26epage%3D4893%26doi%3D10.1128%2FAAC.03036-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalmanti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saussele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauseker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietz, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanfstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proetel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabarius, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppliger-Leibundgut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegelmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfreundschuh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfirrmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hehlmann, R.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of imatinib in CML over a period of 10 years: Data from the randomized CML-study IV</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1123</span>â <span class="NLM_lpage">1132</span>, <span class="refDoi">Â DOI: 10.1038/leu.2015.36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fleu.2015.36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25676422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXks1aitbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=1123-1132&author=L.+Kalmantiauthor=S.+Sausseleauthor=M.+Lausekerauthor=M.+C.+Mullerauthor=C.+T.+Dietzauthor=L.+Heinrichauthor=B.+Hanfsteinauthor=U.+Proetelauthor=A.+Fabariusauthor=S.+W.+Krauseauthor=S.+Rinaldettiauthor=J.+Denglerauthor=C.+Falgeauthor=E.+Oppliger-Leibundgutauthor=A.+Burchertauthor=A.+Neubauerauthor=L.+Kanzauthor=F.+Stegelmannauthor=M.+Pfreundschuhauthor=K.+Spiekermannauthor=C.+Scheidauthor=M.+Pfirrmannauthor=A.+Hochhausauthor=J.+Hasfordauthor=R.+Hehlmann&title=Safety+and+efficacy+of+imatinib+in+CML+over+a+period+of+10+years%3A+Data+from+the+randomized+CML-study+IV&doi=10.1038%2Fleu.2015.36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV</span></div><div class="casAuthors">Kalmanti, L.; Saussele, S.; Lauseker, M.; Mueller, M. C.; Dietz, C. T.; Heinrich, L.; Hanfstein, B.; Proetel, U.; Fabarius, A.; Krause, S. W.; Rinaldetti, S.; Dengler, J.; Falge, C.; Oppliger-Leibundgut, E.; Burchert, A.; Neubauer, A.; Kanz, L.; Stegelmann, F.; Pfreundschuh, M.; Spiekermann, K.; Scheid, C.; Pfirrmann, M.; Hochhaus, A.; Hasford, J.; Hehlmann, R.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1123-1132</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors (TKI) have changed the natural course of chronic myeloid leukemia (CML).  With the advent of second-generation TKI safety and efficacy issues have gained interest.  The randomized CML - Study IV was used for a long-term evaluation of imatinib (IM). 1503 patients have received IM, 1379 IM monotherapy.  After a median observation of 7.1 years, 965 patients (64%) still received IM.  At 10 years, progression-free survival was 82%, overall survival 84%, 59% achieved MR5, 72% MR4.5, 81% MR4, 89% major mol. remission and 92% MR2 (mol. equiv. to complete cytogenetic remission).  All response levels were reached faster with IM800 mg except MR5.  Eight-year probabilities of adverse drug reactions (ADR) were 76%, of grades 3-4 22%, of non-hematol. 73%, and of hematol. 28%.  More ADR were obsd. with IM800 mg and IM400 mg plus interferon Î± (IFN).  Most patients had their first ADR early with decreasing frequency later on.  No new late toxicity was obsd.  ADR to IM are frequent, but mostly mild and manageable, also with IM 800 mg and IM 400 mg+IFN.  The deep mol. response rates indicate that most patients are candidates for IM discontinuation.  After 10 years, IM continues to be an excellent initial choice for most patients with CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdYjW13OccG7Vg90H21EOLACvtfcHk0liRG3Fyh-AzMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXks1aitbw%253D&md5=83e83b1e30df4420f4944aa7d3479b02</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.36%26sid%3Dliteratum%253Aachs%26aulast%3DKalmanti%26aufirst%3DL.%26aulast%3DSaussele%26aufirst%3DS.%26aulast%3DLauseker%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DM.%2BC.%26aulast%3DDietz%26aufirst%3DC.%2BT.%26aulast%3DHeinrich%26aufirst%3DL.%26aulast%3DHanfstein%26aufirst%3DB.%26aulast%3DProetel%26aufirst%3DU.%26aulast%3DFabarius%26aufirst%3DA.%26aulast%3DKrause%26aufirst%3DS.%2BW.%26aulast%3DRinaldetti%26aufirst%3DS.%26aulast%3DDengler%26aufirst%3DJ.%26aulast%3DFalge%26aufirst%3DC.%26aulast%3DOppliger-Leibundgut%26aufirst%3DE.%26aulast%3DBurchert%26aufirst%3DA.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DKanz%26aufirst%3DL.%26aulast%3DStegelmann%26aufirst%3DF.%26aulast%3DPfreundschuh%26aufirst%3DM.%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DScheid%26aufirst%3DC.%26aulast%3DPfirrmann%26aufirst%3DM.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DHasford%26aufirst%3DJ.%26aulast%3DHehlmann%26aufirst%3DR.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520imatinib%2520in%2520CML%2520over%2520a%2520period%2520of%252010%2520years%253A%2520Data%2520from%2520the%2520randomized%2520CML-study%2520IV%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D1123%26epage%3D1132%26doi%3D10.1038%2Fleu.2015.36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâHare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffregen, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherbenou, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span> <span> </span><span class="NLM_article-title">Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">6987</span>â <span class="NLM_lpage">6993</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-05-0622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F1078-0432.CCR-05-0622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16203792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKiurvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=6987-6993&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=E.+P.+Stoffregenauthor=D.+W.+Sherbenouauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=Combined+Abl+inhibitor+therapy+for+minimizing+drug+resistance+in+chronic+myeloid+leukemia%3A+Src%2FAbl+inhibitors+are+compatible+with+imatinib&doi=10.1158%2F1078-0432.CCR-05-0622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib</span></div><div class="casAuthors">O'Hare, Thomas; Walters, Denise K.; Stoffregen, Eric P.; Sherbenou, Daniel W.; Heinrich, Michael C.; Deininger, Michael W. N.; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">19, Pt. 1</span>),
    <span class="NLM_cas:pages">6987-6993</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Chronic myeloid leukemia (CML) is effectively treated with imatinib.  However, reactivation of Bcr-Abl via kinase domain mutations that reduce sensitivity to imatinib can cause relapse.  As combination therapy is frequently used to prevent emergence of resistance, the combination of imatinib with an inhibitor of imatinib-resistant Bcr-Abl mutants (e.g., Src/Abl inhibitors AP23848 and BMS-354825) was investigated.  Exptl. Design: To test this approach, cellular proliferation and Bcr-Abl tyrosine phosphorylation assays were done on Ba/F3 cells expressing wild-type (WT) Bcr-Abl and four common imatinib-resistant mutants (Y253F, E255K, T315I, and M351T).  Colony-forming assays with primary CML cells were also done.  Results: Both Src/Abl inhibitors retained full inhibitory capacity when coadministered with imatinib at concns. above typical clin. levels.  For cells expressing WT Bcr-Abl or the marginally imatinib-resistant mutant M351T, inclusion of imatinib at therapeutic levels enhanced the effects of the Src/Abl inhibitors.  By comparison, for the highly imatinib-resistant mutants Y253F and E255K, inclusion of imatinib at clin. levels resulted in only a slight enhancement beyond the effects of the Src/Abl inhibitors.  None of the inhibitors affected Bcr-Abl T315I cells.  Colony-forming assays with primary CML cells yielded analogous results.  Conclusions: Our results indicate that Src/Abl inhibitors are compatible with imatinib and suggest that combined Abl inhibitor therapy is a feasible treatment strategy for patients with CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXeesK3Ez7wrVg90H21EOLACvtfcHk0li5_GvP4PJ9xQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKiurvF&md5=b4f21bf482289d05a9b79da55acd72f4</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0622%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DSherbenou%26aufirst%3DD.%2BW.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DCombined%2520Abl%2520inhibitor%2520therapy%2520for%2520minimizing%2520drug%2520resistance%2520in%2520chronic%2520myeloid%2520leukemia%253A%2520Src%252FAbl%2520inhibitors%2520are%2520compatible%2520with%2520imatinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D6987%26epage%3D6993%26doi%3D10.1158%2F1078-0432.CCR-05-0622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span> <span> </span><span class="NLM_article-title">Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1754</i></span>,  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">13</span>, <span class="refDoi">Â DOI: 10.1016/j.bbapap.2005.07.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.bbapap.2005.07.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16172030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlags7fI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=3-13&author=P.+Manleyauthor=S.+Cowan-Jacobauthor=J.+Mestan&title=Advances+in+the+structural+biology%2C+design+and+clinical+development+of+Bcr-Abl+kinase+inhibitors+for+the+treatment+of+chronic+myeloid+leukaemia&doi=10.1016%2Fj.bbapap.2005.07.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia</span></div><div class="casAuthors">Manley, Paul William; Cowan-Jacob, Sandra W.; Mestan, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1754</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">3-13</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The constitutively activated Abl tyrosine kinase domain of the chimeric Bcr-Abl oncoprotein is responsible for the transformation of hematopoietic stem cells and the symptoms of chronic myeloid leukemia (CML).  Imatinib targets the tyrosine kinase activity of Bcr-Abl and is a first-line therapy for this malignancy.  Although highly effective in chronic phase CML, patients who have progressed to the advanced phase of the disease frequently fail to respond to imatinib or develop resistance to therapy and relapse.  This is often due to the emergence of clones expressing mutant forms of Bcr-Abl, which exhibit a decreased sensitivity towards inhibition by imatinib.  Considerable progress has recently been made in understanding the structural biol. of Abl and the mol. basis for resistance, facilitating the discovery and development of second generation drugs designed to combat mutant forms of Bcr-Abl.  The first of these compds. to enter clin. development were BMS-354825 (BristolMyersSquibb) and AMN107 (Novartis Pharma) and, from Phase I results, both of these promise a breakthrough in the treatment of imatinib-resistant CML.  Recent advances with these and other promising classes of new CML drugs are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0fkeC4vxU_bVg90H21EOLACvtfcHk0li5_GvP4PJ9xQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlags7fI&md5=b9d67d465f61804d2acd78605a4e9a75</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2005.07.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2005.07.040%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%26aulast%3DCowan-Jacob%26aufirst%3DS.%26aulast%3DMestan%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520the%2520structural%2520biology%252C%2520design%2520and%2520clinical%2520development%2520of%2520Bcr-Abl%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520myeloid%2520leukaemia%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2005%26volume%3D1754%26spage%3D3%26epage%3D13%26doi%3D10.1016%2Fj.bbapap.2005.07.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span> <span> </span><span class="NLM_article-title">Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review</span>. <i>Core Evidence</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">207</span>â <span class="NLM_lpage">213</span>, <span class="refDoi">Â DOI: 10.2147/ce.s6003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.2147%2Fce.s6003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20694077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC3cjjt1Oktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=207-213&author=E.+Jabbourauthor=J.+Cortesauthor=H.+Kantarjian&title=Nilotinib+for+the+treatment+of+chronic+myeloid+leukemia%3A+An+evidence-based+review&doi=10.2147%2Fce.s6003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review</span></div><div class="casAuthors">Jabbour Elias; Cortes Jorge; Kantarjian Hagop</div><div class="citationInfo"><span class="NLM_cas:title">Core evidence</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207-13</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm.  The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% of patients obtaining complete hematologic response, and 70%-80% of patients achieving a complete cytogenetic response.  Despite the high efficacy of imatinib, a minority of patients in chronic phase CML and more patients in advanced phases are resistant to imatinib, or develop resistance during treatment.  This is attributed, in 40% to 50% of cases, to the development of mutations in the Bcr-Abl tyrosine kinase domain that impair imatinib binding.  Attempts to circumvent resistance led to the discovery of nilotinib (Tasigna), a novel, potent and selective oral Bcr-Abl kinase inhibitor.  AIMS:  To review the evidence for the use of nilotinib in the management of CML.  EVIDENCE REVIEW:  Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has further improved the treatment of CML.  PLACE IN THERAPY:  Nilotinib is currently indicated for patients with CML in chronic and accelerated phases following imatinib failure.  Randomized studies are ongoing to assess the efficacy of nilotinib in patients with newly diagnosed CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTo9R1fEvmZGlMGsG_HTXYFfW6udTcc2earP7t4XbG6ILntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjjt1Oktg%253D%253D&md5=f4de61f0b53dc07418faae35aa8c51b4</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.2147%2Fce.s6003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fce.s6003%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DNilotinib%2520for%2520the%2520treatment%2520of%2520chronic%2520myeloid%2520leukemia%253A%2520An%2520evidence-based%2520review%26jtitle%3DCore%2520Evidence%26date%3D2010%26volume%3D4%26spage%3D207%26epage%3D213%26doi%3D10.2147%2Fce.s6003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breccia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimena, G.</span></span> <span> </span><span class="NLM_article-title">Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">129</span>â <span class="NLM_lpage">134</span>, <span class="refDoi">Â DOI: 10.1016/j.leukres.2009.08.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.leukres.2009.08.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=19783301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=129-134&author=M.+Brecciaauthor=G.+Alimena&title=Nilotinib%3A+A+second-generation+tyrosine+kinase+inhibitor+for+chronic+myeloid+leukemia&doi=10.1016%2Fj.leukres.2009.08.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia</span></div><div class="casAuthors">Breccia, Massimo; Alimena, Giuliana</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-134</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Imatinib mesylate is currently the std. of care for chronic myeloid leukemia (CML) patients in early chronic phase.  However, the emergence of resistance and intolerance has dampened the enthusiasm for this drug.  To overcome this phenomenon, different strategies have been developed, including novel targeted agents.  Nilotinib, formerly known as AMN107, is a second-generation tyrosine kinase inhibitor 30-fold more potent than imatinib, with high affinity and selectivity on BCR/ABL, and also active against a wide range of mutant clones, except T315I mutation.  Phase II trials of nilotinib showed high activity in imatinib-resistant or intolerant CML patients, whereas front-line treatment of the disease in chronic phase demonstrated rapid and stable cytogenetic responses and increasing mol. responses.  We here review the development of nilotinib and the efficacy data in phase II and front-line trials.  The aim of this review is to evaluate the pharmacol., pharmacokinetic and pharmacodynamic properties of the drug and the recent results of clin. trials performed in patients with CML and Ph+ acute lymphoblastic leukemia (ALL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHbB1d-7Xyn7Vg90H21EOLACvtfcHk0lhP_KNdU3a2Vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtrc%253D&md5=182529932452e885fa2f90de7cd2b44d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2009.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2009.08.031%26sid%3Dliteratum%253Aachs%26aulast%3DBreccia%26aufirst%3DM.%26aulast%3DAlimena%26aufirst%3DG.%26atitle%3DNilotinib%253A%2520A%2520second-generation%2520tyrosine%2520kinase%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2010%26volume%3D34%26spage%3D129%26epage%3D134%26doi%3D10.1016%2Fj.leukres.2009.08.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colicelli, J.</span></span> <span> </span><span class="NLM_article-title">ABL tyrosine kinases: Evolution of function, regulation, and specificity</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">re6</span> <span class="refDoi">Â DOI: 10.1126/scisignal.3139re6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1126%2Fscisignal.3139re6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20841568" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&author=J.+Colicelli&title=ABL+tyrosine+kinases%3A+Evolution+of+function%2C+regulation%2C+and+specificity&doi=10.1126%2Fscisignal.3139re6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.3139re6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.3139re6%26sid%3Dliteratum%253Aachs%26aulast%3DColicelli%26aufirst%3DJ.%26atitle%3DABL%2520tyrosine%2520kinases%253A%2520Evolution%2520of%2520function%252C%2520regulation%252C%2520and%2520specificity%26jtitle%3DSci.%2520Signaling%26date%3D2010%26volume%3D3%26doi%3D10.1126%2Fscisignal.3139re6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newitt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittekind, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzillerri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klei, H. E.</span></span> <span> </span><span class="NLM_article-title">The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">5790</span>â <span class="NLM_lpage">5797</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-05-4187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F0008-5472.CAN-05-4187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16740718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XltFyjtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=5790-5797&author=J.+S.+Tokarskiauthor=J.+A.+Newittauthor=C.+Y.+Changauthor=J.+D.+Chengauthor=M.+Wittekindauthor=S.+E.+Kieferauthor=K.+Kishauthor=F.+Y.+Leeauthor=R.+Borzillerriauthor=L.+J.+Lombardoauthor=D.+Xieauthor=Y.+Zhangauthor=H.+E.+Klei&title=The+structure+of+Dasatinib+%28BMS-354825%29+bound+to+activated+ABL+kinase+domain+elucidates+its+inhibitory+activity+against+imatinib-resistant+ABL+mutants&doi=10.1158%2F0008-5472.CAN-05-4187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants</span></div><div class="casAuthors">Tokarski, John S.; Newitt, John A.; Chang, Chieh Ying J.; Cheng, Janet D.; Wittekind, Michael; Kiefer, Susan E.; Kish, Kevin; Lee, Francis Y. F.; Borzillerri, Robert; Lombardo, Louis J.; Xie, Dianlin; Zhang, Yaqun; Klei, Herbert E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5790-5797</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase breakpoint cluster (BCR)-ABL.  Current frontline therapy for CML is imatinib, an inhibitor of BCR-ABL.  Although imatinib has a high rate of clin. success in early phase CML, treatment resistance is problematic, particularly in later stages of the disease, and is frequently mediated by mutations in BCR-ABL.  Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets oncogenic pathways and is a more potent inhibitor than imatinib against wild-type BCR-ABL.  It has also shown preclin. activity against all but one of the imatinib-resistant BCR-ABL mutants tested to date.  Anal. of the crystal structure of dasatinib-bound ABL kinase suggests that the increased binding affinity of dasatinib over imatinib is at least partially due to its ability to recognize multiple states of BCR-ABL.  The structure also provides an explanation for the activity of dasatinib against imatinib-resistant BCR-ABL mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLZE4le_VTErVg90H21EOLACvtfcHk0ljoMIXVhcTyzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltFyjtbw%253D&md5=f48b46b8c7c38a9888a6de41f84c94fa</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-4187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-4187%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DWittekind%26aufirst%3DM.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DBorzillerri%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26atitle%3DThe%2520structure%2520of%2520Dasatinib%2520%2528BMS-354825%2529%2520bound%2520to%2520activated%2520ABL%2520kinase%2520domain%2520elucidates%2520its%2520inhibitory%2520activity%2520against%2520imatinib-resistant%2520ABL%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D5790%26epage%3D5797%26doi%3D10.1158%2F0008-5472.CAN-05-4187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendenhall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span> <span> </span><span class="NLM_article-title">Imatinib is not a potent anti-SARS-CoV-2 drug</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3085</span>â <span class="NLM_lpage">3087</span>, <span class="refDoi">Â DOI: 10.1038/s41375-020-01045-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41375-020-01045-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32999432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVSqurvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=3085-3087&author=H.+Zhaoauthor=M.+Mendenhallauthor=M.+W.+Deininger&title=Imatinib+is+not+a+potent+anti-SARS-CoV-2+drug&doi=10.1038%2Fs41375-020-01045-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib is not a potent anti-SARS-CoV-2 drug</span></div><div class="casAuthors">Zhao, Helong; Mendenhall, Michelle; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3085-3087</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Imatinib is not a potent anti-SARS-CoV-2 drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC_1Nzxr3RxrVg90H21EOLACvtfcHk0lj1bx4_-ATjxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVSqurvJ&md5=44846fa32deeaf672ba1b8bf2d066b7b</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-01045-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-01045-9%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMendenhall%26aufirst%3DM.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DImatinib%2520is%2520not%2520a%2520potent%2520anti-SARS-CoV-2%2520drug%26jtitle%3DLeukemia%26date%3D2020%26volume%3D34%26spage%3D3085%26epage%3D3087%26doi%3D10.1038%2Fs41375-020-01045-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span> <span> </span><span class="NLM_article-title">Targeting nonmalignant disorders with tyrosine kinase inhibitors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">956</span>â <span class="NLM_lpage">970</span>, <span class="refDoi">Â DOI: 10.1038/nrd3297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnrd3297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=21119733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=956-970&author=F.+Grimmingerauthor=R.+T.+Schermulyauthor=H.+A.+Ghofrani&title=Targeting+nonmalignant+disorders+with+tyrosine+kinase+inhibitors&doi=10.1038%2Fnrd3297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting non-malignant disorders with tyrosine kinase inhibitors</span></div><div class="casAuthors">Grimminger, Friedrich; Schermuly, Ralph T.; Ghofrani, Hossein A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">956-970</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor and non-receptor tyrosine kinases are involved in multiple proliferative signalling pathways.  Imatinib, one of the first tyrosine kinase inhibitors (TKIs) to be approved, revolutionized the treatment of chronic myelogenous leukemia, and other TKIs with different spectra of kinase inhibition are used to treat renal cell carcinoma, non-small-cell lung cancer and colon cancer.  Studies also support the potential use of TKIs as anti-proliferative agents in non-malignant disorders such as cardiac hypertrophy, and in benign-proliferative disorders including pulmonary hypertension, lung fibrosis, rheumatoid disorders, atherosclerosis, in-stent restenosis and glomerulonephritis.  In this Review, we provide an overview of the most recent developments - both exptl. as well as clin. - regarding the therapeutic potential of TKIs in non-malignant disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKrUsuU0d1-LVg90H21EOLACvtfcHk0lj1bx4_-ATjxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfJ&md5=81869f75918ff2130e4f05d46ef7cc9c</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnrd3297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3297%26sid%3Dliteratum%253Aachs%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26atitle%3DTargeting%2520nonmalignant%2520disorders%2520with%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D956%26epage%3D970%26doi%3D10.1038%2Fnrd3297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaise, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaugler, B.</span></span> <span> </span><span class="NLM_article-title">Imatinib: The narrow line between immune tolerance and activation</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">397</span>â <span class="NLM_lpage">402</span>, <span class="refDoi">Â DOI: 10.1016/j.molmed.2005.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.molmed.2005.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16087402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvV2ltbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=397-402&author=M.+Mohtyauthor=D.+Blaiseauthor=D.+Oliveauthor=B.+Gaugler&title=Imatinib%3A+The+narrow+line+between+immune+tolerance+and+activation&doi=10.1016%2Fj.molmed.2005.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib: the narrow line between immune tolerance and activation</span></div><div class="casAuthors">Mohty, Mohamad; Blaise, Didier; Olive, Daniel; Gaugler, Beatrice</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">397-402</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite the rapid success of imatinib as a targeted cancer therapy, there seems to be some controversy about its influence on immune function.  Research relating to the immunol. effects of imatinib has aimed to gain insight into this paradoxical picture, whereby imatinib appears to be on the edge between immune tolerance and immune defense.  In addn. to the flexibility of several immune effectors, subtle but important exptl. variations might explain the seemingly conflicting data, pointing to the possible use of imatinib to modulate immune responses against tumors.  The clin. use of imatinib, and its putative immunomodulatory properties, represent challenging issues still to be resolved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSXCjWAeN4FrVg90H21EOLACvtfcHk0lj1bx4_-ATjxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvV2ltbo%253D&md5=78cea06fb3c828d87fa03c4c70ccf146</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2005.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2005.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DMohty%26aufirst%3DM.%26aulast%3DBlaise%26aufirst%3DD.%26aulast%3DOlive%26aufirst%3DD.%26aulast%3DGaugler%26aufirst%3DB.%26atitle%3DImatinib%253A%2520The%2520narrow%2520line%2520between%2520immune%2520tolerance%2520and%2520activation%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D397%26epage%3D402%26doi%3D10.1016%2Fj.molmed.2005.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulgaonkar, N.</span>; <span class="NLM_string-name">Wang, H.</span>; <span class="NLM_string-name">Mallawarachchi, S.</span>; <span class="NLM_string-name">Fernando, S.</span>; <span class="NLM_string-name">Martina, B.</span>; <span class="NLM_string-name">Ruzek, D.</span></span> <span> </span><span class="NLM_article-title">Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19</span>.  <i>bioRxiv</i>, August 18, <span class="NLM_year" style="font-weight: bold;">2020</span>, ver. 1.<span class="refDoi">Â DOI: 10.1101/2020.06.18.158196</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1101%2F2020.06.18.158196" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=N.+Mulgaonkar&author=H.+Wang&author=S.+Mallawarachchi&author=S.+Fernando&author=B.+Martina&author=D.+Ruzek&title=Bcr-Abl+tyrosine+kinase+inhibitor+imatinib+as+a+potential+drug+for+COVID-19&doi=10.1101%2F2020.06.18.158196"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1101%2F2020.06.18.158196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.06.18.158196%26sid%3Dliteratum%253Aachs%26aulast%3DMulgaonkar%26aufirst%3DN.%26atitle%3DBcr-Abl%2520tyrosine%2520kinase%2520inhibitor%2520imatinib%2520as%2520a%2520potential%2520drug%2520for%2520COVID-19%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.06.18.158196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosalia, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rennekamp, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, P.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">11876</span>â <span class="NLM_lpage">11881</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0505577102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1073%2Fpnas.0505577102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16081529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFGgurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11876-11881&author=G.+Simmonsauthor=D.+N.+Gosaliaauthor=A.+J.+Rennekampauthor=J.+D.+Reevesauthor=S.+L.+Diamondauthor=P.+Bates&title=Inhibitors+of+cathepsin+L+prevent+severe+acute+respiratory+syndrome+coronavirus+entry&doi=10.1073%2Fpnas.0505577102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry</span></div><div class="casAuthors">Simmons, Graham; Gosalia, Dhaval N.; Rennekamp, Andrew J.; Reeves, Jacqueline D.; Diamond, Scott L.; Bates, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">11876-11881</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome (SARS) is caused by an emergent coronavirus (SARS-CoV), for which there is currently no effective treatment.  SARS-CoV mediates receptor binding and entry by its spike (S) glycoprotein, and infection is sensitive to lysosomotropic agents that perturb endosomal pH.  We demonstrate here that the lysosomotropic-agent-mediated block to SARS-CoV infection is overcome by protease treatment of target-cell-assocd. virus.  In addn., SARS-CoV infection was blocked by specific inhibitors of the pH-sensitive endosomal protease cathepsin L.  A cell-free membrane-fusion system demonstrates that engagement of receptor followed by proteolysis is required for SARS-CoV membrane fusion and indicates that cathepsin L is sufficient to activate membrane fusion by SARS-CoV S.  These results suggest that SARS-CoV infection results from a unique, three-step process: receptor binding and induced conformational changes in S glycoprotein followed by cathepsin L proteolysis within endosomes.  The requirement for cathepsin L proteolysis identifies a previously uncharacterized class of inhibitor for SARS-CoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol5n5BQpBDX7Vg90H21EOLACvtfcHk0lgGVNJUiCQiWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFGgurw%253D&md5=99f26bc819463a5377187542db9bdfe5</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0505577102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0505577102%26sid%3Dliteratum%253Aachs%26aulast%3DSimmons%26aufirst%3DG.%26aulast%3DGosalia%26aufirst%3DD.%2BN.%26aulast%3DRennekamp%26aufirst%3DA.%2BJ.%26aulast%3DReeves%26aufirst%3DJ.%2BD.%26aulast%3DDiamond%26aufirst%3DS.%2BL.%26aulast%3DBates%26aufirst%3DP.%26atitle%3DInhibitors%2520of%2520cathepsin%2520L%2520prevent%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%2520entry%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D11876%26epage%3D11881%26doi%3D10.1073%2Fpnas.0505577102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuyama, S.</span></span> <span> </span><span class="NLM_article-title">Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">12552</span>â <span class="NLM_lpage">12561</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01890-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01890-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24027332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVygsrjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=12552-12561&author=K.+Shiratoauthor=M.+Kawaseauthor=S.+Matsuyama&title=Middle+East+respiratory+syndrome+coronavirus+infection+mediated+by+the+transmembrane+serine+protease+TMPRSS2&doi=10.1128%2FJVI.01890-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Middle east respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2</span></div><div class="casAuthors">Shirato, Kazuya; Kawase, Miyuki; Matsuyama, Shutoku</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">12552-12561</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Middle East respiratory syndrome coronavirus (MERS-CoV) utilizes host proteases for virus entry into lung cells.  In the current study, Vero cells constitutively expressing type II transmembrane serine protease (Vero-TMPRSS2 cells) showed larger syncytia at 18 h after infection with MERS-CoV than after infection with other coronaviruses.  Furthermore, the susceptibility of Vero-TMPRSS2 cells to MERS-CoV was 100-fold higher than that of non-TMPRSS2-expressing parental Vero cells.  The serine protease inhibitor camostat, which inhibits TMPRSS2 activity, completely blocked syncytium formation but only partially blocked virus entry into Vero-TMPRSS2 cells.  Importantly, the coronavirus is thought to enter cells via two distinct pathways, one mediated by TMPRSS2 at the cell surface and the other mediated by cathepsin L in the endosome.  Simultaneous treatment with inhibitors of cathepsin L and TMPRSS2 completely blocked virus entry into Vero-TMPRSS2 cells, indicating that MERS-CoV employs both the cell surface and the endosomal pathway to infect Vero-TMPRSS2 cells.  In contrast, a single camostat treatment suppressed MERS-CoV entry into human bronchial submucosal gland-derived Calu-3 cells by 10-fold and virus growth by 270-fold, although treatment with both camostat and (23,25)-trans-epoxysuccinyl-L-leucylamindo-3-methylbutane Et ester, a cathepsin inhibitor, or treatment with leupeptin, an inhibitor of cysteine, serine, and threonine peptidases, was no more efficacious than treatment with camostat alone.  Further, these inhibitors were not efficacious against MERS-CoV infection of MRC-5 and WI-38 cells, which were derived from lung, but these characters differed from those of mature pneumocytes.  These results suggest that a single treatment with camostat is sufficient to block MERS-CoV entry into a well-differentiated lung-derived cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUQYSrh_mBe7Vg90H21EOLACvtfcHk0lgGVNJUiCQiWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVygsrjM&md5=808a19ec6bbba3b9f0829f82b37bfd89</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1128%2FJVI.01890-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01890-13%26sid%3Dliteratum%253Aachs%26aulast%3DShirato%26aufirst%3DK.%26aulast%3DKawase%26aufirst%3DM.%26aulast%3DMatsuyama%26aufirst%3DS.%26atitle%3DMiddle%2520East%2520respiratory%2520syndrome%2520coronavirus%2520infection%2520mediated%2520by%2520the%2520transmembrane%2520serine%2520protease%2520TMPRSS2%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D12552%26epage%3D12561%26doi%3D10.1128%2FJVI.01890-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiore, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, R.</span></span> <span> </span><span class="NLM_article-title">Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasis</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">518</span>),  <span class="NLM_fpage">eaao0422</span>, <span class="refDoi">Â DOI: 10.1126/scisignal.aao0422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1126%2Fscisignal.aao0422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29463776" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=eaao0422&issue=518&author=R.+Tripathiauthor=L.+S.+Fioreauthor=D.+L.+Richardsauthor=Y.+Yangauthor=J.+Liuauthor=C.+Wangauthor=R.+Plattner&title=Abl+and+Arg+mediate+cysteine+cathepsin+secretion+to+facilitate+melanoma+invasion+and+metastasis&doi=10.1126%2Fscisignal.aao0422"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aao0422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aao0422%26sid%3Dliteratum%253Aachs%26aulast%3DTripathi%26aufirst%3DR.%26aulast%3DFiore%26aufirst%3DL.%2BS.%26aulast%3DRichards%26aufirst%3DD.%2BL.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DPlattner%26aufirst%3DR.%26atitle%3DAbl%2520and%2520Arg%2520mediate%2520cysteine%2520cathepsin%2520secretion%2520to%2520facilitate%2520melanoma%2520invasion%2520and%2520metastasis%26jtitle%3DSci.%2520Signaling%26date%3D2018%26volume%3D11%26issue%3D518%26spage%3Deaao0422%26doi%3D10.1126%2Fscisignal.aao0422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibaldi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunati, A. M.</span></span> <span> </span><span class="NLM_article-title">Viral proteins and Src family kinases: Mechanisms of pathogenicity from a âliaison dangereuse</span>. <i>World J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">71</span>â <span class="NLM_lpage">78</span>, <span class="refDoi">Â DOI: 10.5501/wjv.v2.i2.71</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.5501%2Fwjv.v2.i2.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24175231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC2cfltlOjsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=71-78&author=M.+A.+Paganoauthor=E.+Tibaldiauthor=G.+Paluauthor=A.+M.+Brunati&title=Viral+proteins+and+Src+family+kinases%3A+Mechanisms+of+pathogenicity+from+a+%E2%80%98liaison+dangereuse&doi=10.5501%2Fwjv.v2.i2.71"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Viral proteins and Src family kinases: Mechanisms of pathogenicity from a "liaison dangereuse"</span></div><div class="casAuthors">Pagano Mario Angelo; Tibaldi Elena; Palu Giorgio; Brunati Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">World journal of virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">71-8</span>
        ISSN:<span class="NLM_cas:issn">2220-3249</span>.
    </div><div class="casAbstract">To complete their life cycle and spread, viruses interfere with and gain control of diverse cellular processes, this most often occurring through interaction between viral proteins (VPs) and resident protein partners.  Among the latter, Src family kinases (SFKs), a class of non-receptor tyrosine kinases that contributes to the conversion of extracellular signals into intracellular signaling cascades and is involved in virtually all cellular processes, have recently emerged as critical mediators between the cell's infrastructure and the viral demands.  In this scenario, structural or ex novo synthesized VPs are able to bind to the different domains of these enzymes through specific short linear motifs present along their sequences.  Proline-rich motifs displaying the conserved minimal consensus PxxP and recognizing the SFK Src homology (SH)3 domain constitute a cardinal signature for the formation of multiprotein complexes and this interaction may promote phosphorylation of VPs by SFKs, thus creating phosphotyrosine motifs that become a docking site for the SH2 domains of SFKs or other SH2 domain-bearing signaling molecules.  Importantly, the formation of these assemblies also results in a change in the activity and/or location of SFKs, and these events are critical in perturbing key signaling pathways so that viruses can utilize the cell's machinery to their own benefit.  In the light of these observations, although VPs as such, especially those with enzyme activity, are still regarded as valuable targets for therapeutic strategies, multiprotein complexes composed of viral and host cell proteins are increasingly becoming objects of investigation with a view to deeply characterize the structural aspects that favor their formation and to develop new compounds able to contrast viral diseases in an alternative manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQl36EPxdkdnhKDYG3bNImrfW6udTcc2eYYcFvYHfmX2rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfltlOjsQ%253D%253D&md5=ae1a4c763cc1e225701f74d446d39598</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.5501%2Fwjv.v2.i2.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5501%252Fwjv.v2.i2.71%26sid%3Dliteratum%253Aachs%26aulast%3DPagano%26aufirst%3DM.%2BA.%26aulast%3DTibaldi%26aufirst%3DE.%26aulast%3DPalu%26aufirst%3DG.%26aulast%3DBrunati%26aufirst%3DA.%2BM.%26atitle%3DViral%2520proteins%2520and%2520Src%2520family%2520kinases%253A%2520Mechanisms%2520of%2520pathogenicity%2520from%2520a%2520%25E2%2580%2598liaison%2520dangereuse%26jtitle%3DWorld%2520J.%2520Virol.%26date%3D2013%26volume%3D2%26spage%3D71%26epage%3D78%26doi%3D10.5501%2Fwjv.v2.i2.71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">c-Src protein kinase inhibitors block assembly and maturation of dengue virus</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">3520</span>â <span class="NLM_lpage">3525</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0611681104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1073%2Fpnas.0611681104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17360676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtVWltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=3520-3525&author=J.+J.+Chuauthor=P.+L.+Yang&title=c-Src+protein+kinase+inhibitors+block+assembly+and+maturation+of+dengue+virus&doi=10.1073%2Fpnas.0611681104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src protein kinase inhibitor block assembly and maturation of dengue virus</span></div><div class="casAuthors">Chu, J. J. H.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3520-3525</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Dengue virus is a mosquito-borne flavivirus that represents an important emerging infectious disease and is an international health concern.  Currently, there is no vaccine or effective antiviral therapy to prevent or to treat dengue virus infection.  The slow progress in developing antiviral agents might be alleviated by the availability of efficient high-throughput anti-dengue virus screening assays.  In this study, we report an immunofluorescence image-based assay suitable for identification of small mol. inhibitors of dengue virus infection and replication.  Using this assay, we have discovered that inhibitors of the c-Src protein kinase exhibit a potent inhibitory effect on dengue virus (serotypes 1-4) and murine flavivirus Modoc.  Mechanism of action studies demonstrated that the c-Src protein kinase inhibitor dasatinib prevents the assembly of dengue virions within the virus-induced membranous replication complex.  These results demonstrate that this cell-based screen may provide a powerful means to identify new potential targets for anti-dengue drug development while simultaneously providing pharmacol. probes to investigate dengue virus-host cell interactions at the biochem. level.  Given the simplicity and excellent reproducibility of the assay, it should be useful in high-throughput screens of both small mol. and RNAi libraries when implemented on a robotic image-based high- throughput screen (HTS) platform.  Given the reasonable clin. safety of inhibitors such as dasatinib and AZD0530, inhibitors of c-Src protein kinase may have the potential to become a new class of anti-dengue viral therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT5wnglMCrULVg90H21EOLACvtfcHk0lgqszKt-WObXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtVWltbc%253D&md5=7b8dd352cb73b762b349ee386a39f649</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0611681104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0611681104%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%2BJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3Dc-Src%2520protein%2520kinase%2520inhibitors%2520block%2520assembly%2520and%2520maturation%2520of%2520dengue%2520virus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D3520%26epage%3D3525%26doi%3D10.1073%2Fpnas.0611681104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medigeshi, G. R.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of the role of c-terminal Src kinase in dengue virus replication</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">30490</span>, <span class="refDoi">Â DOI: 10.1038/srep30490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fsrep30490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27457684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12gu7%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=30490&author=R.+Kumarauthor=T.+Agrawalauthor=N.+A.+Khanauthor=Y.+Nakayamaauthor=G.+R.+Medigeshi&title=Identification+and+characterization+of+the+role+of+c-terminal+Src+kinase+in+dengue+virus+replication&doi=10.1038%2Fsrep30490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of the role of c-terminal Src kinase in dengue virus replication</span></div><div class="casAuthors">Kumar, Rinki; Agrawal, Tanvi; Khan, Naseem Ahmed; Nakayama, Yuji; Medigeshi, Guruprasad R.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30490</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We screened a siRNA library targeting human tyrosine kinases in Huh-7 cells and identified c-terminal Src kinase (Csk) as one of the kinases involved in dengue virus replication.  Knock-down of Csk expression by siRNAs or inhibition of Csk by an inhibitor reduced dengue virus RNA levels but did not affect viral entry.  Csk partially colocalized with viral replication compartments.  Dengue infection was drastically reduced in cells lacking the three ubiquitous src family kinases, Src, Fyn and Yes.  Csk knock-down in these cells failed to block dengue virus replication suggesting that the effect of Csk is via regulation of Src family kinases.  Csk was found to be hyper-phosphorylated during dengue infection and inhibition of protein kinase A led to a block in Csk phosphorylation and dengue virus replication.  Overexpression studies suggest an important role for the kinase and SH3 domains in this process.  Our results identified a novel role for Csk as a host tyrosine kinase involved in dengue virus replication and provide further insights into the role of host factors in dengue replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVlEp-nx5hb7Vg90H21EOLACvtfcHk0lgqszKt-WObXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12gu7%252FJ&md5=91a61fd24e54e8517cd5bd07bf27bb74</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fsrep30490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep30490%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DAgrawal%26aufirst%3DT.%26aulast%3DKhan%26aufirst%3DN.%2BA.%26aulast%3DNakayama%26aufirst%3DY.%26aulast%3DMedigeshi%26aufirst%3DG.%2BR.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520the%2520role%2520of%2520c-terminal%2520Src%2520kinase%2520in%2520dengue%2520virus%2520replication%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D30490%26doi%3D10.1038%2Fsrep30490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Wispelaere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCroix, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">7367</span>â <span class="NLM_lpage">7381</span>, <span class="refDoi">Â DOI: 10.1128/JVI.00632-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.00632-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=23616652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFCqsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=7367-7381&author=M.+de%0AWispelaereauthor=A.+J.+LaCroixauthor=P.+L.+Yang&title=The+small+molecules+AZD0530+and+dasatinib+inhibit+dengue+virus+RNA+replication+via+Fyn+kinase&doi=10.1128%2FJVI.00632-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase</span></div><div class="casAuthors">de Wispelaere, Melissanne; LaCroix, Amy J.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7367-7381</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In this study, we characterized the antiviral mechanism of action of AZD0530 and dasatinib, two pharmacol. inhibitors of host kinases, that also inhibit dengue virus (DV) infection.  Using Northern blot and reporter replicon assays, we demonstrated that both small mols. inhibit the DV2 infectious cycle at the step of steady-state RNA replication.  In order to identify the cellular target of AZD0530 and dasatinib mediating this anti-DV2 activity, we examd. the effects of RNA interference (RNAi)-mediated depletion of the major kinases known to be inhibited by these small mols.  We detd. that Fyn kinase, a target of both AZD0530 and dasatinib, is involved in DV2 RNA replication and is probably a major mediator of the anti-DV activity of these compds.  Furthermore, serial passaging of DV2 in the presence of dasatinib led to the identification of a mutation in the transmembrane domain 3 of the NS4B protein that overcomes the inhibition of RNA replication by AZD0530, dasatinib, and Fyn RNAi.  Although we obsd. that dasatinib also inhibits DV2 particle assembly and/or secretion, this activity does not appear to be mediated by Src-family kinases.  Together, our results suggest that AZD0530 and dasatinib inhibit DV at the step of viral RNA replication and demonstrate a crit. role for Fyn kinase in this viral process.  The antiviral activity of these compds. in vitro makes them useful pharmacol. tools to validate Fyn or other host kinases as anti-DV targets in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDobBEv8oAxrVg90H21EOLACvtfcHk0lgqszKt-WObXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFCqsbs%253D&md5=3030a3de1e36bdf7563f97d6e97b5f29</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1128%2FJVI.00632-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00632-13%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWispelaere%26aufirst%3DM.%26aulast%3DLaCroix%26aufirst%3DA.%2BJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3DThe%2520small%2520molecules%2520AZD0530%2520and%2520dasatinib%2520inhibit%2520dengue%2520virus%2520RNA%2520replication%2520via%2520Fyn%2520kinase%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D7367%26epage%3D7381%26doi%3D10.1128%2FJVI.00632-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Supekova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezacki, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlapbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span> <span> </span><span class="NLM_article-title">Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">29</span>â <span class="NLM_lpage">36</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M703988200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.M703988200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17951261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=29-36&author=L.+Supekovaauthor=F.+Supekauthor=J.+Leeauthor=S.+Chenauthor=N.+Grayauthor=J.+P.+Pezackiauthor=A.+Schlapbachauthor=P.+G.+Schultz&title=Identification+of+human+kinases+involved+in+hepatitis+C+virus+replication+by+small+interference+RNA+library+screening&doi=10.1074%2Fjbc.M703988200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human kinases involved in Hepatitis C virus replication by small interference RNA library screening</span></div><div class="casAuthors">Supekova, Lubica; Supek, Frantisek; Lee, Jongkook; Chen, Shawn; Gray, Nathanael; Pezacki, John P.; Schlapbach, Achim; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-36</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The propagation of the hepatitis C virus (HCV) is a complex process that requires both host and viral proteins.  To facilitate identification of host cell factors that are required for HCV replication, we screened a panel of small interference RNAs that preferentially target human protein kinases using an HCV replicon expressing the firefly luciferase gene as a genetic reporter.  Small interference RNAs specific for three human kinases, Csk, Jak1, and Vrk1, were identified that reproducibly reduce viral RNA and viral protein levels in HCV replicon-bearing cells.  Treatment of replicon cells with a small mol. inhibitor of Csk also resulted in a significant redn. in HCV RNA and proteins, further supporting a role for Csk in HCV replication.  The effects of siRNAs targeting eight kinases known to be neg. regulated by Csk were then examd.; knock down of one of these kinases, Fyn, resulted in up-regulation of the HCV replicon, suggesting that Csk mediates its effect on HCV replication through Fyn.  This conclusion was further corroborated by demonstration that replicon cells treated with Csk inhibitor contained lower levels of the phosphorylated form of Fyn than control cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2twHkVKI2sLVg90H21EOLACvtfcHk0ljsXv6ndKIErg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOksA%253D%253D&md5=a78cc4bfc82aeb94e0f3a7cdf7641200</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M703988200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M703988200%26sid%3Dliteratum%253Aachs%26aulast%3DSupekova%26aufirst%3DL.%26aulast%3DSupek%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DPezacki%26aufirst%3DJ.%2BP.%26aulast%3DSchlapbach%26aufirst%3DA.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DIdentification%2520of%2520human%2520kinases%2520involved%2520in%2520hepatitis%2520C%2520virus%2520replication%2520by%2520small%2520interference%2520RNA%2520library%2520screening%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D29%26epage%3D36%26doi%3D10.1074%2Fjbc.M703988200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medigeshi, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeFilippis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FrÃ¼h, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briese, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipkin, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. A.</span></span> <span> </span><span class="NLM_article-title">The Src family kinase c-yes is required for maturation of West Nile virus particles</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">11943</span>â <span class="NLM_lpage">11951</span>, <span class="refDoi">Â DOI: 10.1128/JVI.79.18.11943-11951.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.79.18.11943-11951.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16140770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWktL%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=11943-11951&author=A.+J.+Hirschauthor=G.+R.+Medigeshiauthor=H.+L.+Meyersauthor=V.+DeFilippisauthor=K.+Fr%C3%BChauthor=T.+Brieseauthor=W.+I.+Lipkinauthor=J.+A.+Nelson&title=The+Src+family+kinase+c-yes+is+required+for+maturation+of+West+Nile+virus+particles&doi=10.1128%2FJVI.79.18.11943-11951.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">The Src family kinase c-yes is required for maturation of West Nile virus particles</span></div><div class="casAuthors">Hirsch, Alec J.; Medigeshi, Guruprasad R.; Meyers, Heather L.; DeFilippis, Victor; Fruh, Klaus; Briese, Thomas; Lipkin, W. Ian; Nelson, Jay A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">11943-11951</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The role of cellular genes in West Nile virus (WNY) replication is not well understood.  Examn. of cellular transcripts upregulated during WNV infection revealed an increase in the expression of the src family kinase (SFK) c-Yes.  WNV-infected cell lines treated with the SFK inhibitor PP2 demonstrated a 2- to 4-log decrease in viral titers, suggesting that SFK activity is required for completion of the viral replication cycle.  RNA interference mediated knock-down of c-Yes, but not c-Src, and similarly reduced virus yield, specifically implicating c-Yes in WNV prodn.  Interestingly, PP2 treatment did not reduce intracellular levels of either viral RNA or protein, suggesting that the drug does not act on the early stages of replication.  However, endoglycosidase H (endoH) digestion of the viral envelope (E) glycoprotein revealed that the acquisition of endoH-resistant glycans by E, but not endogenous major histocompatibility complex class I, was reduced in PP2-treated cells, demonstrating that E specifically does not traffic beyond the endoplasmic reticulum in the absence of SFK activity.  Electron microscopy further revealed that PP2-treated WNV-infected cells accumulated an increased no. of virions in the ER compared to untreated cells.  Therefore, we conclude that inhibition of SFK activity did not interfere with virus assembly but prevented transit of virions through the secretory pathway.  These results identify c-Yes as a cellular protein that is involved in WNV assembly and egress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMuU3rVQ-9qLVg90H21EOLACvtfcHk0ljsXv6ndKIErg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWktL%252FK&md5=5826259686f57aed83606f1f44c33f38</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.18.11943-11951.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.18.11943-11951.2005%26sid%3Dliteratum%253Aachs%26aulast%3DHirsch%26aufirst%3DA.%2BJ.%26aulast%3DMedigeshi%26aufirst%3DG.%2BR.%26aulast%3DMeyers%26aufirst%3DH.%2BL.%26aulast%3DDeFilippis%26aufirst%3DV.%26aulast%3DFr%25C3%25BCh%26aufirst%3DK.%26aulast%3DBriese%26aufirst%3DT.%26aulast%3DLipkin%26aufirst%3DW.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Src%2520family%2520kinase%2520c-yes%2520is%2520required%2520for%2520maturation%2520of%2520West%2520Nile%2520virus%2520particles%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D11943%26epage%3D11951%26doi%3D10.1128%2FJVI.79.18.11943-11951.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conner, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, S. L.</span></span> <span> </span><span class="NLM_article-title">Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">921</span>â <span class="NLM_lpage">929</span>, <span class="refDoi">Â DOI: 10.1083/jcb.200108123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1083%2Fjcb.200108123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11877461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVGmtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2002&pages=921-929&author=S.+D.+Connerauthor=S.+L.+Schmid&title=Identification+of+an+adaptor-associated+kinase%2C+AAK1%2C+as+a+regulator+of+clathrin-mediated+endocytosis&doi=10.1083%2Fjcb.200108123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis</span></div><div class="casAuthors">Conner, Sean D.; Schmid, Sandra L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">921-929</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The Î¼2 subunit of the AP2 complex is known to be phosphorylated in vitro by a copurifying kinase, and it has been demonstrated recently that Î¼2 phosphorylation is required for transferrin endocytosis.  However, the identity of the endogenous kinase responsible for this phosphorylation is unknown.  Here we identify and characterize a novel member of the Prk/Ark family of serine/threonine kinases, adaptor-assocd. kinase (AAK)1.  We find that AAK1 copurifies with adaptor protein (AP)2 and that it directly binds the ear domain of Î±-adaptin in vivo and in vitro.  In neuronal cells, AAK1 is enriched at presynaptic terminals, whereas in nonneuronal cells it colocalizes with clathrin and AP2 in clathrin-coated pits and at the leading edge of migrating cells.  AAK1 specifically phosphorylates the Î¼ subunit in vitro, and stage-specific assays for endocytosis show that Î¼ phosphorylation by AAK1 results in a decrease in AP2-stimulated transferrin internalization.  Together, these results provide strong evidence that AAK1 is the endogenous Î¼2 kinase and plays a regulatory role in clathrin-mediated endocytosis.  These results also lend support to the idea that clathrin-mediated endocytosis is controlled by cycles of phosphorylation/desphosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp62q8kuSqokbVg90H21EOLACvtfcHk0ljsXv6ndKIErg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVGmtrg%253D&md5=0f9061fb428373240da331f7d25bb9bf</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200108123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200108123%26sid%3Dliteratum%253Aachs%26aulast%3DConner%26aufirst%3DS.%2BD.%26aulast%3DSchmid%26aufirst%3DS.%2BL.%26atitle%3DIdentification%2520of%2520an%2520adaptor-associated%2520kinase%252C%2520AAK1%252C%2520as%2520a%2520regulator%2520of%2520clathrin-mediated%2520endocytosis%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2002%26volume%3D156%26spage%3D921%26epage%3D929%26doi%3D10.1083%2Fjcb.200108123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Q. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S. X.</span></span> <span> </span><span class="NLM_article-title">Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence</span>. <i>Travel Med. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">101647</span>, <span class="refDoi">Â DOI: 10.1016/j.tmaid.2020.101647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.tmaid.2020.101647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32247927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB38zgvF2ktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2020&pages=101647&author=Y.+C.+Caoauthor=Q.+X.+Dengauthor=S.+X.+Dai&title=Remdesivir+for+severe+acute+respiratory+syndrome+coronavirus+2+causing+COVID-19%3A+An+evaluation+of+the+evidence&doi=10.1016%2Fj.tmaid.2020.101647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence</span></div><div class="casAuthors">Cao Yu-Chen; Deng Qi-Xin; Dai Shi-Xue</div><div class="citationInfo"><span class="NLM_cas:title">Travel medicine and infectious disease</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">101647</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The novel coronavirus infection that initially found at the end of 2019 has attracted great attention.  So far, the number of infectious cases has increased globally to more than 100 thousand and the outbreak has been defined as a pandemic situation, but there are still no "specific drug" available.  Relevant reports have pointed out the novel coronavirus has 80% homology with SARS.  In the difficulty where new synthesized drug cannot be applied immediately to patients, "conventional drug in new use" becomes a feasible solution.  The first medication experience of the recovered patients in the US has led remdesivir to be the "specific drug".  China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19).  We started from the structure, immunogenicity, and pathogenesis of coronavirus infections of the novel coronavirus.  Further, we analyzed the pharmacological actions and previous trials of remdesivir to identify the feasibility of conducting experiments on COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDTwWNXaoCBa_dlEzl_fBafW6udTcc2eZ_2Ud3DKPIxrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zgvF2ktg%253D%253D&md5=cdc4d26f35c81a1b931d755bc801f7be</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.tmaid.2020.101647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tmaid.2020.101647%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%2BC.%26aulast%3DDeng%26aufirst%3DQ.%2BX.%26aulast%3DDai%26aufirst%3DS.%2BX.%26atitle%3DRemdesivir%2520for%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%25202%2520causing%2520COVID-19%253A%2520An%2520evaluation%2520of%2520the%2520evidence%26jtitle%3DTravel%2520Med.%2520Infect.%2520Dis.%26date%3D2020%26volume%3D35%26spage%3D101647%26doi%3D10.1016%2Fj.tmaid.2020.101647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. E.</span></span> <span> </span><span class="NLM_article-title">Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">4311</span>â <span class="NLM_lpage">4321</span>, <span class="refDoi">Â DOI: 10.1242/jcs.02548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1242%2Fjcs.02548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16155256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCgt7fK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2005&pages=4311-4321&author=D.+W.+Leeauthor=X.+Zhaoauthor=F.+Zhangauthor=E.+Eisenbergauthor=L.+E.+Greene&title=Depletion+of+GAK%2Fauxilin+2+inhibits+receptor-mediated+endocytosis+and+recruitment+of+both+clathrin+and+clathrin+adaptors&doi=10.1242%2Fjcs.02548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors</span></div><div class="casAuthors">Lee, Dong-won; Zhao, Xiaohong; Zhang, Fang; Eisenberg, Evan; Greene, Lois E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4311-4321</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Cyclin G-assocd. kinase (GAK/auxilin 2), the ubiquitous form of the neuronal-specific protein auxilin 1, is an essential cofactor for the Hsc70-dependent uncoating of clathrin-coated vesicles.  We have now investigated the effect of knocking down GAK in HeLa cells by vector-based small hairpin RNA.  Functionally, depletion of GAK caused a marked decrease in internalization of both transferrin and epidermal growth factor and altered mannose 6-phosphate receptor trafficking, but had little effect on the recycling of transferrin receptor back to the plasma membrane.  Structurally, depletion of GAK caused a marked redn. in perinuclear clathrin assocd. with the trans-Golgi network and in the no. of clathrin-coated pits on the plasma membrane, and reduced clathrin exchange on the few clathrin-coated pits that remained.  Surprisingly, while clathrin depletion does not prevent adaptors from assembling on the membrane, depletion of GAK caused a dramatic redn. in AP2 and epsin on the plasma membrane and AP1 and GGA at the trans-Golgi network.  A similar effect was caused by expression of a dominant neg. Hsp70 mutant.  These results suggest that GAK, in conjunction with Hsc70, not only uncoats clathrin-coated vesicles and induces clathrin exchange on clathrin-coated pits, but also mediates binding of clathrin and adaptors to the plasma membrane and the trans-Golgi network.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8IvRfVSaZT7Vg90H21EOLACvtfcHk0liDcUTynpkkFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCgt7fK&md5=0172190491cf9b908e705e434b763d60</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1242%2Fjcs.02548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.02548%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DEisenberg%26aufirst%3DE.%26aulast%3DGreene%26aufirst%3DL.%2BE.%26atitle%3DDepletion%2520of%2520GAK%252Fauxilin%25202%2520inhibits%2520receptor-mediated%2520endocytosis%2520and%2520recruitment%2520of%2520both%2520clathrin%2520and%2520clathrin%2520adaptors%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2005%26volume%3D118%26spage%3D4311%26epage%3D4321%26doi%3D10.1242%2Fjcs.02548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e1002845</span> <span class="refDoi">Â DOI: 10.1371/journal.ppat.1002845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.ppat.1002845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22916011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&author=G.+Neveuauthor=R.+Barouch-Bentovauthor=A.+Ziv-Avauthor=D.+Gerberauthor=Y.+Jacobauthor=S.+Einav&title=Identification+and+targeting+of+an+interaction+between+a+tyrosine+motif+within+hepatitis+C+virus+core+protein+and+AP2M1+essential+for+viral+assembly&doi=10.1371%2Fjournal.ppat.1002845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span></div><div class="casAuthors">Neveu, Gregory; Barouch-Bentov, Rina; Ziv-Av, Amotz; Gerber, Doron; Jacob, Yves; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1002845</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Novel therapies are urgently needed against hepatitis C virus infection (HCV), a major global health problem.  The current model of infectious virus prodn. suggests that HCV virions are assembled on or near the surface of lipid droplets, acquire their envelope at the ER, and egress through the secretory pathway.  The mechanisms of HCV assembly and particularly the role of viral-host protein-protein interactions in mediating this process are, however, poorly understood.  We identified a conserved heretofore unrecognized YXXÎ¦ motif (Î¦ is a bulky hydrophobic residue) within the core protein.  This motif is homologous to sorting signals within host cargo proteins known to mediate binding of AP2M1, the Î¼ subunit of clathrin adaptor protein complex 2 (AP-2), and intracellular trafficking.  Using microfluidics affinity anal., protein-fragment complementation assays, and co-immunopptns. in infected cells, we show that this motif mediates core binding to AP2M1.  YXXÎ¦ mutations, silencing AP2M1 expression or overexpressing a dominant neg. AP2M1 mutant had no effect on HCV RNA replication, however, they dramatically inhibited intra- and extra-cellular infectivity, consistent with a defect in viral assembly.  Quant. confocal immunofluorescence anal. revealed that core's YXXÎ¦ motif mediates recruitment of AP2M1 to lipid droplets and that the obsd. defect in HCV assembly following disruption of core-AP2M1 binding correlates with accumulation of core on lipid droplets, reduced core colocalization with E2 and reduced core localization to trans-Golgi network (TGN), the presumed site of viral particles maturation.  Furthermore, AAK1 and GAK, serine/threonine kinases known to stimulate binding of AP2M1 to host cargo proteins, regulate core-AP2M1 binding and are essential for HCV assembly.  Last, approved anti-cancer drugs that inhibit AAK1 or GAK not only disrupt core-AP2M1 binding, but also significantly inhibit HCV assembly and infectious virus prodn.  These results validate viral-host interactions essential for HCV assembly and yield compds. for pharmaceutical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjKaGJVLP2vLVg90H21EOLACvtfcHk0liDcUTynpkkFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF&md5=811c0818d4b2500b1b788076ac4abc5d</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002845%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DGerber%26aufirst%3DD.%26aulast%3DJacob%26aufirst%3DY.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DIdentification%2520and%2520targeting%2520of%2520an%2520interaction%2520between%2520a%2520tyrosine%2520motif%2520within%2520hepatitis%2520C%2520virus%2520core%2520protein%2520and%2520AP2M1%2520essential%2520for%2520viral%2520assembly%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26doi%3D10.1371%2Fjournal.ppat.1002845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">4387</span>â <span class="NLM_lpage">4404</span>, <span class="refDoi">Â DOI: 10.1128/JVI.02705-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.02705-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25653444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVWlurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=4387-4404&author=G.+Neveuauthor=A.+Ziv-Avauthor=R.+Barouch-Bentovauthor=E.+Berkermanauthor=J.+Mulhollandauthor=S.+Einav&title=AP-2-associated+protein+kinase+1+and+cyclin+G-associated+kinase+regulate+hepatitis+C+virus+entry+and+are+potential+drug+targets&doi=10.1128%2FJVI.02705-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets</span></div><div class="casAuthors">Neveu, Gregory; Ziv-Av, Amotz; Barouch-Bentov, Rina; Berkerman, Elena; Mulholland, Jon; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4387-4404</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) enters its target cell via clathrin-mediated endocytosis.  AP-2-assocd. protein kinase 1 (AAK1) and cyclin G-assocd. kinase (GAK) are host kinases that regulate clathrin adaptor protein (AP)-mediated trafficking in the endocytic and secretory pathways.  We previously reported that AAK1 and GAK regulate HCV assembly by stimulating binding of the Î¼ subunit of AP-2, AP2M1, to HCV core protein.  We also discovered that AAK1 and GAK inhibitors, including the approved anticancer drugs sunitinib and erlotinib, could block HCV assembly.  Here, we hypothesized that AAK1 and GAK regulate HCV entry independently of their effect on HCV assembly.  Indeed, silencing AAK1 and GAK expression inhibited entry of pseudoparticles and cell culture grown-HCV and internalization of Dil-labeled HCV particles with no effect on HCV attachment or RNA replication.  AAK1 or GAK depletion impaired epidermal growth factor (EGF)-mediated enhanced HCV entry and endocytosis of EGF receptor (EGFR), an HCV entry cofactor and erlotinib's cancer target.  Moreover, either RNA interference-mediated depletion of AP2M1 or NUMB, each a substrate of AAK1 and/or GAK, or overexpression of either an AP2M1 or NUMB phosphorylation site mutant inhibited HCV entry.  Last, in addn. to affecting assembly, sunitinib and erlotinib inhibited HCV entry at a postbinding step, their combination was synergistic, and their antiviral effect was reversed by either AAK1 or GAK overexpression.  Together, these results validate AAK1 and GAK as crit. regulators of HCV entry that function in part by activating EGFR, AP2M1, and NUMB and as the mol. targets underlying the antiviral effect of sunitinib and erlotinib (in addn. to EGFR), resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB1x5sJzyhrLVg90H21EOLACvtfcHk0lgxRSdoeiKfZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVWlurg%253D&md5=cbdd3e12d29f383c73dc53c0e9954300</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1128%2FJVI.02705-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02705-14%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DBerkerman%26aufirst%3DE.%26aulast%3DMulholland%26aufirst%3DJ.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DAP-2-associated%2520protein%2520kinase%25201%2520and%2520cyclin%2520G-associated%2520kinase%2520regulate%2520hepatitis%2520C%2520virus%2520entry%2520and%2520are%2520potential%2520drug%2520targets%26jtitle%3DJ.%2520Virol.%26date%3D2015%26volume%3D89%26spage%3D4387%26epage%3D4404%26doi%3D10.1128%2FJVI.02705-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yau, S. S.</span></span> <span> </span><span class="NLM_article-title">Ebolavirus classification based on natural vectors</span>. <i>DNA Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">418</span>â <span class="NLM_lpage">428</span>, <span class="refDoi">Â DOI: 10.1089/dna.2014.2678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1089%2Fdna.2014.2678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25803489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFKqs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=418-428&author=H.+Zhengauthor=C.+Yinauthor=T.+Hoangauthor=R.+L.+Heauthor=J.+Yangauthor=S.+S.+Yau&title=Ebolavirus+classification+based+on+natural+vectors&doi=10.1089%2Fdna.2014.2678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ebolavirus Classification Based on Natural Vectors</span></div><div class="casAuthors">Zheng, Hui; Yin, Changchuan; Hoang, Tung; He, Rong Lucy; Yang, Jie; Yau, Stephen S.-T.</div><div class="citationInfo"><span class="NLM_cas:title">DNA and Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">418-428</span>CODEN:
                <span class="NLM_cas:coden">DCEBE8</span>;
        ISSN:<span class="NLM_cas:issn">1044-5498</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">According to the WHO, ebolaviruses have resulted in 8818 human deaths in West Africa as of Jan. 2015.  To better understand the evolutionary relationship of the ebolaviruses and infer virulence from the relationship, we applied the alignment-free natural vector method to classify the newest ebolaviruses.  The dataset includes three new Guinea viruses as well as 99 viruses from Sierra Leone.  For the viruses of the family of Filoviridae, both genus label classification and species label classification achieve an accuracy rate of 100%.  We represented the relationships among Filoviridae viruses by Unweighted Pair Group Method with Arithmetic Mean (UPGMA) phylogenetic trees and found that the filoviruses can be sepd. well by three genera.  We performed the phylogenetic anal. on the relationship among different species of Ebolavirus by their coding-complete genomes and seven viral protein genes (glycoprotein [GP], nucleoprotein [NP], VP24, VP30, VP35, VP40, and RNA polymerase [L]).  The topol. of the phylogenetic tree by the viral protein VP24 shows consistency with the variations of virulence of ebolaviruses.  The result suggests that VP24 be a pharmaceutical target for treating or preventing ebolaviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVq4s7RU1qiLVg90H21EOLACvtfcHk0lgxRSdoeiKfZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFKqs7g%253D&md5=5c9d87e44ede9c977841ddac7b89e8c1</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1089%2Fdna.2014.2678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fdna.2014.2678%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DC.%26aulast%3DHoang%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DR.%2BL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYau%26aufirst%3DS.%2BS.%26atitle%3DEbolavirus%2520classification%2520based%2520on%2520natural%2520vectors%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2015%26volume%3D34%26spage%3D418%26epage%3D428%26doi%3D10.1089%2Fdna.2014.2678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">67</span>â <span class="NLM_lpage">75</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2018.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2018.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29753658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslaqtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=67-75&author=S.+Y.+Puauthor=F.+Xiaoauthor=S.+Schorauthor=E.+Bekermanauthor=F.+Zaniniauthor=R.+Barouch-Bentovauthor=C.+M.+Nagamineauthor=S.+Einav&title=Feasibility+and+biological+rationale+of+repurposing+sunitinib+and+erlotinib+for+dengue+treatment&doi=10.1016%2Fj.antiviral.2018.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment</span></div><div class="casAuthors">Pu, Szu-Yuan; Xiao, Fei; Schor, Stanford; Bekerman, Elena; Zanini, Fabio; Barouch-Bentov, Rina; Nagamine, Claude M.; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">67-75</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There is an urgent need for strategies to combat dengue virus (DENV) infection; a major global threat.  We reported that the cellular kinases AAK1 and GAK regulate intracellular trafficking of multiple viruses and that sunitinib and erlotinib, approved anticancer drugs with potent activity against these kinases, protect DENV-infected mice from mortality.  Nevertheless, further characterization of the therapeutic potential and underlying mechanism of this approach is required prior to clin. evaluation.  Here, we demonstrate that sunitinib/erlotinib combination achieves sustained suppression of systemic infection at approved dose in DENV-infected IFN-Î±/Î² and IFN-Î³ receptor-deficient mice.  Nevertheless, treatment with these blood-brain barrier impermeable drugs delays, yet does not prevent, late-onset paralysis; a common manifestation in this immunodeficient mouse model but not in humans.  Sunitinib and erlotinib treatment also demonstrates efficacy in human primary monocyte-derived dendritic cells.  Addnl., DENV infection induces expression of AAK1 transcripts, but not GAK, via single-cell transcriptomics, and these kinases are important mol. targets underlying the anti-DENV effect of sunitinib and erlotinib.  Lastly, sunitinib/erlotinib combination alters inflammatory cytokine responses in DENV-infected mice.  These findings support feasibility of repurposing sunitinib/erlotinib combination as a host-targeted antiviral approach and contribute to understanding its mechanism of antiviral action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2cs8UpuoykLVg90H21EOLACvtfcHk0lgxRSdoeiKfZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslaqtbk%253D&md5=acde697b6e3c6d9f42a2011be6091e83</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DZanini%26aufirst%3DF.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DNagamine%26aufirst%3DC.%2BM.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DFeasibility%2520and%2520biological%2520rationale%2520of%2520repurposing%2520sunitinib%2520and%2520erlotinib%2520for%2520dengue%2520treatment%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D155%26spage%3D67%26epage%3D75%26doi%3D10.1016%2Fj.antiviral.2018.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oechsle, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savory, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span> <span> </span><span class="NLM_article-title">Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>, <span class="NLM_elocation-id">e30</span> <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30304-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS0140-6736%2820%2930304-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32032529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1Chtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&author=P.+Richardsonauthor=I.+Griffinauthor=C.+Tuckerauthor=D.+Smithauthor=O.+Oechsleauthor=A.+Phelanauthor=M.+Rawlingauthor=E.+Savoryauthor=J.+Stebbing&title=Baricitinib+as+potential+treatment+for+2019-nCoV+acute+respiratory+disease&doi=10.1016%2FS0140-6736%2820%2930304-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</span></div><div class="casAuthors">Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Stebbing, Justin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10223</span>),
    <span class="NLM_cas:pages">e30-e31</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced.  Results of rapid sequencing of 2019-nCoV, coupled with mol. modeling based on the genomes of related virus proteins, have suggested a few compds. that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination.  Most viruses enter cells through receptor-mediated endocytosis.  One of the known regulators of endocytosis is the AP2-assocd. protein kinase 1 (AAK1).  Disruption of AAK1 might, in turn, interrupt the passage of the virus into cells and also the intracellular assembly of virus particles.  One of six high affinity AAK1-binding drugs was the janus kinase inhibitor baricitinib, which also binds the cyclin G-assocd. kinase, another regulator of endocytosis.  Because the plasma concn. of baricitinib on therapeutic dosing (either as 2 mg or 4 mg once daily) is sufficient to inhibit AAK1, we suggest it could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT8bDm3HM7aLVg90H21EOLACvtfcHk0lhbEVGl5R7vfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1Chtr4%253D&md5=9e884d046780c8aa5f3a0934bf4a59ed</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930304-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930304-4%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DGriffin%26aufirst%3DI.%26aulast%3DTucker%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DOechsle%26aufirst%3DO.%26aulast%3DPhelan%26aufirst%3DA.%26aulast%3DRawling%26aufirst%3DM.%26aulast%3DSavory%26aufirst%3DE.%26aulast%3DStebbing%26aufirst%3DJ.%26atitle%3DBaricitinib%2520as%2520potential%2520treatment%2520for%25202019-nCoV%2520acute%2520respiratory%2520disease%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26doi%3D10.1016%2FS0140-6736%2820%2930304-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakken, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1338</span>â <span class="NLM_lpage">1352</span>, <span class="refDoi">Â DOI: 10.1172/JCI89857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1172%2FJCI89857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28240606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC1czgvFajtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=1338-1352&author=E.+Bekermanauthor=G.+Neveuauthor=A.+Shullaauthor=J.+Brannanauthor=S.+Y.+Puauthor=S.+Wangauthor=F.+Xiaoauthor=R.+Barouch-Bentovauthor=R.+R.+Bakkenauthor=R.+Mateoauthor=J.+Goveroauthor=C.+M.+Nagamineauthor=M.+S.+Diamondauthor=S.+De+Jongheauthor=P.+Herdewijnauthor=J.+M.+Dyeauthor=G.+Randallauthor=S.+Einav&title=Anticancer+kinase+inhibitors+impair+intracellular+viral+trafficking+and+exert+broad-spectrum+antiviral+effects&doi=10.1172%2FJCI89857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</span></div><div class="casAuthors">Bekerman Elena; Neveu Gregory; Shulla Ana; Brannan Jennifer; Pu Szu-Yuan; Wang Stanley; Xiao Fei; Barouch-Bentov Rina; Bakken Russell R; Mateo Roberto; Govero Jennifer; Nagamine Claude M; Diamond Michael S; De Jonghe Steven; Herdewijn Piet; Dye John M; Randall Glenn; Einav Shirit</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1338-1352</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Global health is threatened by emerging viral infections, which largely lack effective vaccines or therapies.  Targeting host pathways that are exploited by multiple viruses could offer broad-spectrum solutions.  We previously reported that AAK1 and GAK, kinase regulators of the host adaptor proteins AP1 and AP2, are essential for hepatitis C virus (HCV) infection, but the underlying mechanism and relevance to other viruses or in vivo infections remained unknown.  Here, we have discovered that AP1 and AP2 cotraffic with HCV particles in live cells.  Moreover, we found that multiple viruses, including dengue and Ebola, exploit AAK1 and GAK during entry and infectious virus production.  In cultured cells, treatment with sunitinib and erlotinib, approved anticancer drugs that inhibit AAK1 or GAK activity, or with more selective compounds inhibited intracellular trafficking of HCV and multiple unrelated RNA viruses with a high barrier to resistance.  In murine models of dengue and Ebola infection, sunitinib/erlotinib combination protected against morbidity and mortality.  We validated sunitinib- and erlotinib-mediated inhibition of AAK1 and GAK activity as an important mechanism of antiviral action.  Additionally, we revealed potential roles for additional kinase targets.  These findings advance our understanding of virus-host interactions and establish a proof of principle for a repurposed, host-targeted approach to combat emerging viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeR1dYk1i_czQLBVDQn4bCfW6udTcc2eZyPU16hzm-Krntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czgvFajtg%253D%253D&md5=2de0a5d7668651f92be3c2e79823ced4</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1172%2FJCI89857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI89857%26sid%3Dliteratum%253Aachs%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DShulla%26aufirst%3DA.%26aulast%3DBrannan%26aufirst%3DJ.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DBakken%26aufirst%3DR.%2BR.%26aulast%3DMateo%26aufirst%3DR.%26aulast%3DGovero%26aufirst%3DJ.%26aulast%3DNagamine%26aufirst%3DC.%2BM.%26aulast%3DDiamond%26aufirst%3DM.%2BS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DRandall%26aufirst%3DG.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DAnticancer%2520kinase%2520inhibitors%2520impair%2520intracellular%2520viral%2520trafficking%2520and%2520exert%2520broad-spectrum%2520antiviral%2520effects%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D1338%26epage%3D1352%26doi%3D10.1172%2FJCI89857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span> </span><span class="NLM_article-title">Coronavirus (COVID-19)
Update: FDA authorizes drug combination for treatment of COVID-19</span>; U.S. Food and Drug Administration (Press release), November 19, <span class="NLM_year">2020</span> (retrieved 2020-11-19).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Coronavirus+%28COVID-19%29%0AUpdate%3A+FDA+authorizes+drug+combination+for+treatment+of+COVID-19%3B+U.S.+Food+and+Drug+Administration+%28Press+release%29%2C+November+19%2C+2020+%28retrieved+2020-11-19%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DCoronavirus%2520%2528COVID-19%2529%250AUpdate%253A%2520FDA%2520authorizes%2520drug%2520combination%2520for%2520treatment%2520of%2520COVID-19%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casalini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirazimi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youhanna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldanti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarasini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terres, J. A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickoloff, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirula, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbellino, M.</span></span> <span> </span><span class="NLM_article-title">Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e12697</span> <span class="refDoi">Â DOI: 10.15252/emmm.202012697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.15252%2Femmm.202012697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32473600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CmurbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&author=J.+Stebbingauthor=V.+Krishnanauthor=S.+Bonoauthor=S.+Ottavianiauthor=G.+Casaliniauthor=P.+J.+Richardsonauthor=V.+Monteilauthor=V.+M.+Lauschkeauthor=A.+Mirazimiauthor=S.+Youhannaauthor=Y.-J.+Tanauthor=F.+Baldantiauthor=A.+Sarasiniauthor=J.+A.+R.+Terresauthor=B.+J.+Nickoloffauthor=R.+E.+Higgsauthor=G.+Rochaauthor=N.+L.+Byersauthor=D.+E.+Schlichtingauthor=A.+Nirulaauthor=A.+Cardosoauthor=M.+Corbellino&title=Mechanism+of+baricitinib+supports+artificial+intelligence-predicted+testing+in+COVID-19+patients&doi=10.15252%2Femmm.202012697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</span></div><div class="casAuthors">Stebbing, Justin; Krishnan, Venkatesh; de Bono, Stephanie; Ottaviani, Silvia; Casalini, Giacomo; Richardson, Peter J.; Monteil, Vanessa; Lauschke, Volker M.; Mirazimi, Ali; Youhanna, Sonia; Tan, Yee-Joo; Baldanti, Fausto; Sarasini, Antonella; Terres, Jorge A. Ross; Nickoloff, Brian J.; Higgs, Richard E.; Rocha, Guilherme; Byers, Nicole L.; Schlichting, Douglas E.; Nirula, Ajay; Cardoso, Anabela; Corbellino, Mario; the Sacco Baricitinib Study Group</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e12697</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID-19 infection via proposed anti-cytokine effects and as an inhibitor of host cell viral propagation.  We evaluated the in vitro pharmacol. of baricitinib across relevant leukocyte subpopulations coupled to its in vivo pharmacokinetics and showed it inhibited signaling of cytokines implicated in COVID-19 infection.  We validated the AI-predicted biochem. inhibitory effects of baricitinib on human numb-assocd. kinase (hNAK) members measuring nanomolar affinities for AAK1, BIKE, and GAK.  Inhibition of NAKs led to reduced viral infectivity with baricitinib using human primary liver spheroids.  These effects occurred at exposure levels seen clin.  In a case series of patients with bilateral COVID-19 pneumonia, baricitinib treatment was assocd. with clin. and radiol. recovery, a rapid decline in SARS-CoV-2 viral load, inflammatory markers, and IL-6 levels.  Collectively, these data support further evaluation of the anti-cytokine and anti-viral activity of baricitinib and support its assessment in randomized trials in hospitalized COVID-19 patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiGmXcP_Gbz7Vg90H21EOLACvtfcHk0liTMjutcZmdjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CmurbJ&md5=86d41fe8f3b03133c08acb5552266ef7</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.15252%2Femmm.202012697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.202012697%26sid%3Dliteratum%253Aachs%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DKrishnan%26aufirst%3DV.%26aulast%3DBono%26aufirst%3DS.%26aulast%3DOttaviani%26aufirst%3DS.%26aulast%3DCasalini%26aufirst%3DG.%26aulast%3DRichardson%26aufirst%3DP.%2BJ.%26aulast%3DMonteil%26aufirst%3DV.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DMirazimi%26aufirst%3DA.%26aulast%3DYouhanna%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DY.-J.%26aulast%3DBaldanti%26aufirst%3DF.%26aulast%3DSarasini%26aufirst%3DA.%26aulast%3DTerres%26aufirst%3DJ.%2BA.%2BR.%26aulast%3DNickoloff%26aufirst%3DB.%2BJ.%26aulast%3DHiggs%26aufirst%3DR.%2BE.%26aulast%3DRocha%26aufirst%3DG.%26aulast%3DByers%26aufirst%3DN.%2BL.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DNirula%26aufirst%3DA.%26aulast%3DCardoso%26aufirst%3DA.%26aulast%3DCorbellino%26aufirst%3DM.%26atitle%3DMechanism%2520of%2520baricitinib%2520supports%2520artificial%2520intelligence-predicted%2520testing%2520in%2520COVID-19%2520patients%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2020%26volume%3D12%26doi%3D10.15252%2Femmm.202012697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyslop, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddle
Camp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winthrop, K. L.</span></span> <span> </span><span class="NLM_article-title">Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">7</span>â <span class="NLM_lpage">18</span>, <span class="refDoi">Â DOI: 10.3899/jrheum.171361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3899%2Fjrheum.171361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30219772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2rtLjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2019&pages=7-18&author=J.+S.+Smolenauthor=M.+C.+Genoveseauthor=T.+Takeuchiauthor=D.+L.+Hyslopauthor=W.+L.+Maciasauthor=T.+Rooneyauthor=L.+Chenauthor=C.+L.+Dicksonauthor=J.+Riddle%0ACampauthor=T.+E.+Cardilloauthor=T.+Ishiiauthor=K.+L.+Winthrop&title=Safety+profile+of+baricitinib+in+patients+with+active+rheumatoid+arthritis+with+over+2+years+median+time+in+treatment&doi=10.3899%2Fjrheum.171361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment</span></div><div class="casAuthors">Smolen, Josef S.; Genovese, Mark C.; Takeuchi, Tsutomu; Hyslop, David L.; Macias, William L.; Rooney, Terence; Chen, Lei; Dickson, Christina L.; Camp, Jennifer Riddle; Cardillo, Tracy E.; Ishii, Taeko; Winthrop, Kevin L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-18</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">1499-2752</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA).  We evaluated baricitinib's safety profile through 288 wk (up to Sept. 1, 2016) with an integrated database [8 phase III/II/Ib trials, 1 longterm extension (LTE)].  The "all-bari-RA" group included patients who received any baricitinib dose.  Placebo comparison was based on the 6 studies with 4 mg and placebo up to Week 24 ("placebo-4 mg" dataset).  Dose response assessment was based on 4 studies with 2 mg and 4 mg including LTE data ("2 mg-4 mg - extended").  The uncommon events description used the non-controlled all-bari-RA.  There were 3492 patients who received baricitinib for 6637 total patient-years (PY) of exposure (median 2.1 yrs, max. 5.5 yrs).  No differences in rates of death, adverse events leading to drug discontinuation, malignancies, major adverse cardiovascular event (MACE), or serious infections were seen for 4 mg vs. placebo or for 4 mg vs. 2 mg.  Infections including herpes zoster were significantly more frequent for 4 mg vs. placebo.  Deep vein thrombosis/pulmonary embolism were reported with 4 mg but not placebo [all-bari-RA incidence rate (IR) 0.5/100 PY]; the IR did not differ between doses (0.5 vs 0.6/100 PY, 2 mg vs 4 mg, resp.) or compared to published RA rates.  All-bari-RA had 6 cases of lymphoma (IR 0.09/100 PY), 3 gastrointestinal perforations (0.05/100 PY), 10 cases of tuberculosis (all in endemic areas; 0.15/100 PY), and 22 all-cause deaths (0.33/100 PY).  IR for malignancies (0.8/100 PY) and MACE (0.5/100 PY) were low and did not increase with prolonged exposure.  In this integrated anal. of patients with moderate to severe active RA with exposure up to 5.5 years, baricitinib has an acceptable safety profile in the context of demonstrated efficacy.  Trial registration nos.: NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT01721044, NCT01721057, NCT01711359, and NCT01885078 at clinicaltrials.gov.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGtLt3TTbQXrVg90H21EOLACvtfcHk0liTMjutcZmdjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2rtLjL&md5=65e80ff8290c092f167e04f6505ca261</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.171361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.171361%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DHyslop%26aufirst%3DD.%2BL.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3DRooney%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDickson%26aufirst%3DC.%2BL.%26aulast%3DRiddle%2BCamp%26aufirst%3DJ.%26aulast%3DCardillo%26aufirst%3DT.%2BE.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DWinthrop%26aufirst%3DK.%2BL.%26atitle%3DSafety%2520profile%2520of%2520baricitinib%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520over%25202%2520years%2520median%2520time%2520in%2520treatment%26jtitle%3DJ.%2520Rheumatol.%26date%3D2019%26volume%3D46%26spage%3D7%26epage%3D18%26doi%3D10.3899%2Fjrheum.171361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddapati, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viox, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starke, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busman-Sahay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strongin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tharp, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirejczyk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zandi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beagle, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahar, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor-Stroud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmas, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooney, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayegh, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiskopf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filev, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waggoner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piantadosi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasturi, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakhshir, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekaly, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderford, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosinger, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paiardini, M.</span></span> <span> </span><span class="NLM_article-title">Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">460</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cell.2020.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33278358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisV2nur7F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2021&pages=460&author=T.+N.+Hoangauthor=M.+Pinoauthor=A.+K.+Boddapatiauthor=E.+G.+Vioxauthor=C.+E.+Starkeauthor=A.+A.+Upadhyayauthor=S.+Gumberauthor=K.+Busman-Sahayauthor=Z.+Stronginauthor=J.+L.+Harperauthor=G.+K.+Tharpauthor=K.+L.+Pellegriniauthor=S.+Kirejczykauthor=K.+Zandiauthor=S.+Taoauthor=T.+R.+Hortonauthor=E.+N.+Beagleauthor=E.+A.+Maharauthor=M.+Y.+Leeauthor=J.+Cohenauthor=S.+M.+Jeanauthor=J.+S.+Woodauthor=F.+Connor-Stroudauthor=R.+L.+Stammenauthor=O.+M.+Delmasauthor=S.+Wangauthor=K.+A.+Cooneyauthor=M.+N.+Sayeghauthor=L.+Wangauthor=D.+Weiskopfauthor=P.+D.+Filevauthor=J.+Waggonerauthor=A.+Piantadosiauthor=S.+P.+Kasturiauthor=H.+A.+Shakhshirauthor=S.+P.+Ribeiroauthor=R.+P.+Sekalyauthor=R.+D.+Levitauthor=J.+D.+Estesauthor=T.+H.+Vanderfordauthor=R.+F.+Schinaziauthor=S.+E.+Bosingerauthor=M.+Paiardini&title=Baricitinib+treatment+resolves+lower+airway+inflammation+and+neutrophil+recruitment+in+SARS-CoV-2-infected+rhesus+macaques&doi=10.1016%2Fj.cell.2020.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques</span></div><div class="casAuthors">Hoang, Timothy N.; Pino, Maria; Boddapati, Arun K.; Viox, Elise G.; Starke, Carly E.; Upadhyay, Amit A.; Gumber, Sanjeev; Nekorchuk, Michael; Busman-Sahay, Kathleen; Strongin, Zachary; Harper, Justin L.; Tharp, Gregory K.; Pellegrini, Kathryn L.; Kirejczyk, Shannon; Zandi, Keivan; Tao, Sijia; Horton, Tristan R.; Beagle, Elizabeth N.; Mahar, Ernestine A.; Lee, Michelle Y. H.; Cohen, Joyce; Jean, Sherrie M.; Wood, Jennifer S.; Connor-Stroud, Fawn; Stammen, Rachelle L.; Delmas, Olivia M.; Wang, Shelly; Cooney, Kimberly A.; Sayegh, Michael N.; Wang, Lanfang; Filev, Peter D.; Weiskopf, Daniela; Silvestri, Guido; Waggoner, Jesse; Piantadosi, Anne; Kasturi, Sudhir P.; Al-Shakhshir, Hilmi; Ribeiro, Susan P.; Sekaly, Rafick P.; Levit, Rebecca D.; Estes, Jacob D.; Vanderford, Thomas H.; Schinazi, Raymond F.; Bosinger, Steven E.; Paiardini, Mirko</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">460-475.e21</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">SARS-CoV-2-induced hypercytokinemia and inflammation are critically assocd. with COVID-19 severity.  Baricitinib, a clin. approved JAK1/JAK2 inhibitor, is currently being investigated in COVID-19 clin. trials.  Here, we investigated the immunol. and virol. efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection.  Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages, and tissues was not reduced with baricitinib.  Type I interferon (IFN) antiviral responses and SARS-CoV-2-specific T cell responses remained similar between the two groups.  Animals treated with baricitinib showed reduced inflammation, decreased lung infiltration of inflammatory cells, reduced NETosis activity, and more limited lung pathol.  Importantly, baricitinib-treated animals had a rapid and remarkably potent suppression of lung macrophage prodn. of cytokines and chemokines responsible for inflammation and neutrophil recruitment.  These data support a beneficial role for, and elucidate the immunol. mechanisms underlying, the use of baricitinib as a frontline treatment for inflammation induced by SARS-CoV-2 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA9Aj5Z0fOVLVg90H21EOLACvtfcHk0liTMjutcZmdjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisV2nur7F&md5=3634bae4c47e11d43c0dac8637e7d6e9</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DHoang%26aufirst%3DT.%2BN.%26aulast%3DPino%26aufirst%3DM.%26aulast%3DBoddapati%26aufirst%3DA.%2BK.%26aulast%3DViox%26aufirst%3DE.%2BG.%26aulast%3DStarke%26aufirst%3DC.%2BE.%26aulast%3DUpadhyay%26aufirst%3DA.%2BA.%26aulast%3DGumber%26aufirst%3DS.%26aulast%3DBusman-Sahay%26aufirst%3DK.%26aulast%3DStrongin%26aufirst%3DZ.%26aulast%3DHarper%26aufirst%3DJ.%2BL.%26aulast%3DTharp%26aufirst%3DG.%2BK.%26aulast%3DPellegrini%26aufirst%3DK.%2BL.%26aulast%3DKirejczyk%26aufirst%3DS.%26aulast%3DZandi%26aufirst%3DK.%26aulast%3DTao%26aufirst%3DS.%26aulast%3DHorton%26aufirst%3DT.%2BR.%26aulast%3DBeagle%26aufirst%3DE.%2BN.%26aulast%3DMahar%26aufirst%3DE.%2BA.%26aulast%3DLee%26aufirst%3DM.%2BY.%26aulast%3DCohen%26aufirst%3DJ.%26aulast%3DJean%26aufirst%3DS.%2BM.%26aulast%3DWood%26aufirst%3DJ.%2BS.%26aulast%3DConnor-Stroud%26aufirst%3DF.%26aulast%3DStammen%26aufirst%3DR.%2BL.%26aulast%3DDelmas%26aufirst%3DO.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCooney%26aufirst%3DK.%2BA.%26aulast%3DSayegh%26aufirst%3DM.%2BN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWeiskopf%26aufirst%3DD.%26aulast%3DFilev%26aufirst%3DP.%2BD.%26aulast%3DWaggoner%26aufirst%3DJ.%26aulast%3DPiantadosi%26aufirst%3DA.%26aulast%3DKasturi%26aufirst%3DS.%2BP.%26aulast%3DShakhshir%26aufirst%3DH.%2BA.%26aulast%3DRibeiro%26aufirst%3DS.%2BP.%26aulast%3DSekaly%26aufirst%3DR.%2BP.%26aulast%3DLevit%26aufirst%3DR.%2BD.%26aulast%3DEstes%26aufirst%3DJ.%2BD.%26aulast%3DVanderford%26aufirst%3DT.%2BH.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DBosinger%26aufirst%3DS.%2BE.%26aulast%3DPaiardini%26aufirst%3DM.%26atitle%3DBaricitinib%2520treatment%2520resolves%2520lower%2520airway%2520inflammation%2520and%2520neutrophil%2520recruitment%2520in%2520SARS-CoV-2-infected%2520rhesus%2520macaques%26jtitle%3DCell%26date%3D2021%26volume%3D184%26spage%3D460%26doi%3D10.1016%2Fj.cell.2020.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span>FDA news
release, Coronavirus (COVID-19) update: <span> </span><span class="NLM_article-title">FDA authorizes
drug combination for treatment of COVID-19</span>, November
19, <span class="NLM_year">2020</span>. <a href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19" class="extLink">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19</a> (accessed <span class="NLM_year">2020</span>-11-26).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+news%0Arelease%2C+Coronavirus+%28COVID-19%29+update%3A+FDA+authorizes%0Adrug+combination+for+treatment+of+COVID-19%2C+November%0A19%2C+2020.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Fcoronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19+%28accessed+2020-11-26%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520authorizes%250Adrug%2520combination%2520for%2520treatment%2520of%2520COVID-19%26date%3D2020%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span> <span> </span><span class="NLM_article-title">Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19</span>. <i>Int. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">106749</span>, <span class="refDoi">Â DOI: 10.1016/j.intimp.2020.106749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.intimp.2020.106749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32645632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlent7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2020&pages=106749&author=X.+Zhangauthor=Y.+Zhangauthor=W.+Qiaoauthor=J.+Zhangauthor=Z.+Qi&title=Baricitinib%2C+a+drug+with+potential+effect+to+prevent+SARS-COV-2+from+entering+target+cells+and+control+cytokine+storm+induced+by+COVID-19&doi=10.1016%2Fj.intimp.2020.106749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19</span></div><div class="casAuthors">Zhang, Xiuhong; Zhang, Yan; Qiao, Weizhen; Zhang, Ji; Qi, Zhigang</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">106749</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In Dec. 2019, a novel coronavirus pneumonia (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly broke out in China and rapidly spread all over the world.  Recently, a cell surface protein, known as angiotensin-converting enzyme II (ACE2), has been identified to be involved in receptor-mediated endocytosis for SARS-CoV-2 entry to the cells.  Many studies have reported the clin. characteristics of COVID-19: sudden deterioration of disease around 1-2 wk after onset; much lower level of lymphocytes, esp. natural killer (NK) cells in peripheral blood; extremely high pro-inflammatory cytokines and C reactive protein (CRP).  About 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression.  Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes.  Baricitinib intracellularly inhibits the proinflammatory signal of several cytokines by suppressing Janus kinase (JAK) JAK1/JAK2.  It has been demonstrated clin. benefits for the patients with rheumatoid arthritis (RA), activew and atopic dermatitis with good efficacy and safety records.  Baricitinib is expected to interrupt the passage and intracellular assembly of SARS-CoV-2 into the target cells mediated by ACE2 receptor, and treat cytokine storm caused by COVID-19.  Several clin. trials are currently investigating the drug, and one of which has been completed with encouraging results.  In this paper, we will elaborate the role of cytokine storm mediated by JAK-STAT pathway in severe COVID-19, the possible mechanisms of baricitinib on reducing the viral entry into the target cells and cytokine storm, the key points of pharmaceutical care based on the latest research reports, clin. trials progress and drug instruction from the US FDA, so as to provide ref. for the treatment of severe COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowoPzzX14kBLVg90H21EOLACvtfcHk0lgiietT_tLymg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlent7vE&md5=c14838b0bae4a8b60e7eb33377245b03</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2020.106749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2020.106749%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DQiao%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DZ.%26atitle%3DBaricitinib%252C%2520a%2520drug%2520with%2520potential%2520effect%2520to%2520prevent%2520SARS-COV-2%2520from%2520entering%2520target%2520cells%2520and%2520control%2520cytokine%2520storm%2520induced%2520by%2520COVID-19%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2020%26volume%3D86%26spage%3D106749%26doi%3D10.1016%2Fj.intimp.2020.106749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâBryan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogswell, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokop, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinosa, R.,  3rd.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le
Beau, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. T.</span></span> <span> </span><span class="NLM_article-title">A transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">5016</span>â <span class="NLM_lpage">5031</span>, <span class="refDoi">Â DOI: 10.1128/MCB.11.10.5016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FMCB.11.10.5016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1656220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=5016-5031&author=J.+P.+O%E2%80%99Bryanauthor=R.+A.+Fryeauthor=P.+C.+Cogswellauthor=A.+Neubauerauthor=B.+Kitchauthor=C.+Prokopauthor=R.+Espinosaauthor=M.+M.+Le%0ABeauauthor=H.+S.+Earpauthor=E.+T.+Liu&title=A+transforming+gene+isolated+from+primary+human+myeloid+leukemia+cells%2C+encodes+a+novel+receptor+tyrosine+kinase&doi=10.1128%2FMCB.11.10.5016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">axl, A transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span></div><div class="casAuthors">O'Bryan, John P.; Frye, Roy A.; Cogswell, Patricia C.; Neubauer, Andreas; Kitch, Barry; Prokop, Carol; Espinosa, Rafael, III; Le Beau, Michelle M.; Earp, H. Shelton; Liu, Edison T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5016-31</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">A sensitive transfection-tumorigenicity assay was used to isolate a novel transforming gene from the DNA of 2 patients with chronic myelogenous leukemia.  Sequence anal. indicates that the product of this gene, axl, is a receptor tyrosine kinase.  Overexpression of axl cDNA in NIH 3T3 cells induces neoplastic transformation with the concomitant appearance of a 140-kDa axl tyrosine-phosphorylated protein.  Expression of axl cDNA in the baculovirus system results in the expression of the appropriate recombinant protein that is tyrosine kinase.  The juxtaposition of fibronectin type III and immunoglobulinlike repeats in the extracellular domain, as well as distinct amino acid sequences in the kinase domain, indicate that the axl protein represents a novel subclass of receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIaouGK3RfrVg90H21EOLACvtfcHk0lgiietT_tLymg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D&md5=f244ff83822fdb98c22a35f918723d3a</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1128%2FMCB.11.10.5016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.11.10.5016%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Bryan%26aufirst%3DJ.%2BP.%26aulast%3DFrye%26aufirst%3DR.%2BA.%26aulast%3DCogswell%26aufirst%3DP.%2BC.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DKitch%26aufirst%3DB.%26aulast%3DProkop%26aufirst%3DC.%26aulast%3DEspinosa%26aufirst%3DR.%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26atitle%3DA%2520transforming%2520gene%2520isolated%2520from%2520primary%2520human%2520myeloid%2520leukemia%2520cells%252C%2520encodes%2520a%2520novel%2520receptor%2520tyrosine%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1991%26volume%3D11%26spage%3D5016%26epage%3D5031%26doi%3D10.1128%2FMCB.11.10.5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goruppi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruaro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C.</span></span> <span> </span><span class="NLM_article-title">Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 broblasts</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">471</span>â <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=8637702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK28XhtFCms74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1996&pages=471-480&author=S.+Goruppiauthor=E.+Ruaroauthor=C.+Schneider&title=Gas6%2C+the+ligand+of+Axl+tyrosine+kinase+receptor%2C+has+mitogenic+and+survival+activities+for+serum+starved+NIH3T3+broblasts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts</span></div><div class="casAuthors">Goruppi, Sandro; Ruaro, Elisabetta; Schneider, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">471-80</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Reversible growth arrest has been characterized for enhanced expression of a set of genes called gas (growth arrest specific).  Gas6 product (Gas6) is a secreted protein that was identified as the ligand for the tyrosine kinase receptor Axl.  Here the authors report that Gas6 is able to induce cell cycle division entry in serum starved NIH3T3 cells.  This mitogenic activity of Gas6 strictly correlates with its ability to interact with NIH3T3 endogenous Axl receptor since it can be abolished by sol. Axl extracellular domain and activates both Axl intrinsic kinase activity and the downstream MAPK pathway.  Moreover when ectopic Axl overexpression is performed by microinjection in serum starved NIH3T3 cells, addn. of a nonmitogenic level of Gas6 induces selective entry into S phase in Axl overexpressing cells.  Interestingly, Axl overexpression per se is not able to induce S phase entry.  Finally the authors present evidences indicating that Gas6 is able to protect serum starved NIH3T3 cells from cell death by apoptosis as induced by complete growth factor depletion.  The reported survival activity seems to be independent of Gas6 mitogenic activity, thus implicating a double and separable activity for Gas6 during growth arrest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmV75pwx0DQbVg90H21EOLACvtfcHk0lilwwkZXTf6og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhtFCms74%253D&md5=c9836350bb97a0f21e9e30e58da89b57</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoruppi%26aufirst%3DS.%26aulast%3DRuaro%26aufirst%3DE.%26aulast%3DSchneider%26aufirst%3DC.%26atitle%3DGas6%252C%2520the%2520ligand%2520of%2520Axl%2520tyrosine%2520kinase%2520receptor%252C%2520has%2520mitogenic%2520and%2520survival%2520activities%2520for%2520serum%2520starved%2520NIH3T3%2520broblasts%26jtitle%3DOncogene%26date%3D1996%26volume%3D12%26spage%3D471%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stitt, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radziejewski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terence, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nancy, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiStefano, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basilico, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfarb, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span> <span> </span><span class="NLM_article-title">The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">661</span>â <span class="NLM_lpage">670</span>, <span class="refDoi">Â DOI: 10.1016/0092-8674(95)90520-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2F0092-8674%2895%2990520-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=7867073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK2MXktV2it74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1995&pages=661-670&author=T.+N.+Stittauthor=G.+Connauthor=M.+Goreauthor=C.+Laiauthor=J.+Brunoauthor=C.+Radziejewskiauthor=K.+Mattssonauthor=J.+Fisherauthor=D.+R.+Giesauthor=P.+F.+Jonesauthor=M.+Piotrauthor=E.+R.+Terenceauthor=J.+T.+Nancyauthor=D.+H.+Chenauthor=P.+S.+DiStefanoauthor=G.+L.+Longauthor=C.+Basilicoauthor=M.+P.+Goldfarbauthor=G.+Lemkeauthor=D.+J.+Glassauthor=G.+D.+Yancopoulos&title=The+anticoagulation+factor+protein+S+and+its+relative%2C+Gas6%2C+are+ligands+for+the+Tyro+3%2FAxl+family+of+receptor+tyrosine+kinases&doi=10.1016%2F0092-8674%2895%2990520-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases</span></div><div class="casAuthors">Stitt, Trevor N.; Conn, Greg; Gore, Martin; Lai, Cary; Bruno, Joanne; Radziejewski, Czeslaw; Mattsson, Karen; Fisher, John; Gies, David R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">661-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The authors report the identification of ligands for Tyro 3 (alternatively called Sky, rse, brt, or tif) and Axl (alternatively, Ark or UFO), members of a previously orphan family of receptor-like tyrosine kinases.  These ligands correspond to protein S, a protease regulator that is a potent anticoagulant, and Gas6, a protein related to protein S but lacking any known function.  The results are reminiscent of recent findings that the procoagulant thrombin, a protease that drives clot formation by cleaving fibrinogen to form fibrin, also binds and activates intracellular signaling via a G protein-coupled cell surface receptor.  Proteases and protease regulators that also activate specific cell surface receptors may serve to integrate coagulation with assocd. cellular responses required for tissue repair and growth, as well as to coordinate protease cascades and assocd. cellular responses in other systems, such as those involved in growth and remodeling of the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Kc6zOMgNobVg90H21EOLACvtfcHk0lilwwkZXTf6og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktV2it74%253D&md5=a12eece9ec055c4ee7927d97a9789fdb</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2895%2990520-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252895%252990520-0%26sid%3Dliteratum%253Aachs%26aulast%3DStitt%26aufirst%3DT.%2BN.%26aulast%3DConn%26aufirst%3DG.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DBruno%26aufirst%3DJ.%26aulast%3DRadziejewski%26aufirst%3DC.%26aulast%3DMattsson%26aufirst%3DK.%26aulast%3DFisher%26aufirst%3DJ.%26aulast%3DGies%26aufirst%3DD.%2BR.%26aulast%3DJones%26aufirst%3DP.%2BF.%26aulast%3DPiotr%26aufirst%3DM.%26aulast%3DTerence%26aufirst%3DE.%2BR.%26aulast%3DNancy%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DD.%2BH.%26aulast%3DDiStefano%26aufirst%3DP.%2BS.%26aulast%3DLong%26aufirst%3DG.%2BL.%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DGoldfarb%26aufirst%3DM.%2BP.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DGlass%26aufirst%3DD.%2BJ.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26atitle%3DThe%2520anticoagulation%2520factor%2520protein%2520S%2520and%2520its%2520relative%252C%2520Gas6%252C%2520are%2520ligands%2520for%2520the%2520Tyro%25203%252FAxl%2520family%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D1995%26volume%3D80%26spage%3D661%26epage%3D670%26doi%3D10.1016%2F0092-8674%2895%2990520-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toshima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, K.</span></span> <span> </span><span class="NLM_article-title">Stimulation of sky receptor tyrosine kinase by the product of growth arrestspecic gene 6</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">22681</span>â <span class="NLM_lpage">22684</span>, <span class="refDoi">Â DOI: 10.1074/jbc.270.39.22681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.270.39.22681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=7559388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK2MXosFOqtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=22681-22684&author=K.+Ohashiauthor=K.+Nagataauthor=J.+Toshimaauthor=T.+Nakanoauthor=H.+Aritaauthor=H.+Tsudaauthor=K.+Suzukiauthor=K.+Mizuno&title=Stimulation+of+sky+receptor+tyrosine+kinase+by+the+product+of+growth+arrestspecic+gene+6&doi=10.1074%2Fjbc.270.39.22681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of Sky receptor tyrosine kinase by the product of growth arrest-specific gene 6</span></div><div class="casAuthors">Ohashi, Kazumasa; Nagata, Kyoko; Toshima, Jiro; Nakano, Toru; Arita, Hitoshi; Tsuda, Hiroko; Suzuki, Koji; Mizuno, Kensaku</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">22681-4</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Sky (also called Rse, Brt, and Tyro3) is a member of a subfamily of related receptor tyrosine kinases, including Axl/Ufo/Ark and c-Eyk/Mer.  We obtained evidence that Gas6 (the product of growth arrest-specific gene 6) is a ligand of the Sky receptor tyrosine kinase.  Gas6, but not protein S (an anticoagulant protein structurally similar to Gas6), specifically bound to the sol. form of Sky (Sky-Fc), composed of the extracellular domain of Sky fused to the Fc domain of human IgG1.  The native and recombinant Gas6, but not protein S, stimulated tyrosine phosphorylation of Sky ectopically expressed in Chinese hamster ovary cells.  Stimulation of Sky in response to Gas6 was inhibited by Sky-Fc.  The half-maximal concn. of Gas6 that stimulated Sky was about 1 nM.  Thus, Gas6 as a ligand for Sky specifically binds to and stimulates Sky receptor tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGO5YQrZPEP7Vg90H21EOLACvtfcHk0lilwwkZXTf6og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXosFOqtLc%253D&md5=435b45c259f3b264b78401a8d8f2e592</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.39.22681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.39.22681%26sid%3Dliteratum%253Aachs%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DNagata%26aufirst%3DK.%26aulast%3DToshima%26aufirst%3DJ.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DArita%26aufirst%3DH.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DMizuno%26aufirst%3DK.%26atitle%3DStimulation%2520of%2520sky%2520receptor%2520tyrosine%2520kinase%2520by%2520the%2520product%2520of%2520growth%2520arrestspecic%2520gene%25206%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D22681%26epage%3D22684%26doi%3D10.1074%2Fjbc.270.39.22681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, G.</span></span> <span> </span><span class="NLM_article-title">Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">306</span>â <span class="NLM_lpage">311</span>, <span class="refDoi">Â DOI: 10.1126/science.1061663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1126%2Fscience.1061663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11452127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1ymsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=306-311&author=Q.+Luauthor=G.+Lemke&title=Homeostatic+regulation+of+the+immune+system+by+receptor+tyrosine+kinases+of+the+Tyro+3+family&doi=10.1126%2Fscience.1061663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family</span></div><div class="casAuthors">Lu, Qingxian; Lemke, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">5528</span>),
    <span class="NLM_cas:pages">306-311</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases and their ligands mediate cell-cell communication and interaction in many organ systems, but have not been known to act in this capacity in the mature immune system.  The authors now provide genetic evidence that three closely related receptor tyrosine kinases, Tyro 3, Axl, and Mer, play an essential immunoregulatory role.  Mutant mice that lack these receptors develop a severe lymphoproliferative disorder accompanied by broad-spectrum autoimmunity.  These phenotypes are cell non-autonomous with respect to lymphocytes and result from the hyperactivation of antigen-presenting cells in which the three receptors are normally expressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp8p8YELw6TLVg90H21EOLACvtfcHk0lgHGM4JiCOpPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1ymsbY%253D&md5=7b6a3d91485e82fdb47f715331b1f310</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1126%2Fscience.1061663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1061663%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DLemke%26aufirst%3DG.%26atitle%3DHomeostatic%2520regulation%2520of%2520the%2520immune%2520system%2520by%2520receptor%2520tyrosine%2520kinases%2520of%2520the%2520Tyro%25203%2520family%26jtitle%3DScience%26date%3D2001%26volume%3D293%26spage%3D306%26epage%3D311%26doi%3D10.1126%2Fscience.1061663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linseman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaack, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnum, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandel, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidenreich, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierman, M. E.</span></span> <span> </span><span class="NLM_article-title">Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">599</span>â <span class="NLM_lpage">613</span>, <span class="refDoi">Â DOI: 10.1128/MCB.22.2.599-613.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FMCB.22.2.599-613.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11756555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvVeqtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=599-613&author=M.+P.+Allenauthor=D.+A.+Linsemanauthor=H.+Udoauthor=M.+Xuauthor=J.+B.+Schaackauthor=B.+Varnumauthor=E.+R.+Kandelauthor=K.+A.+Heidenreichauthor=M.+E.+Wierman&title=Novel+mechanism+for+gonadotropin-releasing+hormone+neuronal+migration+involving+Gas6%2FArk+signaling+to+p38+mitogen-activated+protein+kinase&doi=10.1128%2FMCB.22.2.599-613.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase</span></div><div class="casAuthors">Allen, Melissa P.; Linseman, Daniel A.; Udo, Hiroshi; Xu, Mei; Schaack, Jerome B.; Varnum, Brian; Kandel, Eric R.; Heidenreich, Kim A.; Wierman, Margaret E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">599-613</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Gonadotropin-releasing hormone (GnRH) is the central regulator of the reproductive axis.  Normal sexual maturation depends on the migration of GnRH neurons from the olfactory placode to the hypothalamus during development.  Previously, we showed restricted expression of the membrane receptor adhesion-related kinase (Ark) in immortalized cell lines derived from migratory but not postmigratory GnRH neurons.  In addn., Ark and GnRH transcripts were detected along the GnRH neuron migratory route in the E13 mouse cribriform plate.  In the present study, we examd. the role of Ark and its ligand, Gas6 (encoded by growth arrest-specific gene 6), in GnRH neuron migration.  Gas6 stimulated lamellipodial extension, membrane ruffling, and chemotaxis of immortalized NLT GnRH neuronal cells via the Ark receptor.  Gas6/Ark signaling promoted activation of the Rho family GTPase Rac, and adenoviral-mediated expression of dominant neg. N17Rac abolished Gas6/Ark-induced actin cytoskeletal reorganization and migration of GnRH neuronal cells.  In addn., p38 MAPK was activated downstream of Ark and Rac, and inhibition of p38 MAPK with either SB203580 or adenoviral dominant neg. p38Î± also blocked Gas6/Ark-mediated migration.  Finally, downstream of Rac and p38 mitogen-activated protein kinase (MAPK), Gas6/Ark signaling promoted activation of MAPK-activated protein kinase 2 and induced phosphorylation of HSP25, a known regulator of cortical actin remodeling.  The data are the first to demonstrate a migratory signaling pathway downstream of Ark/Axl family receptors and suggest a previously unidentified role for p38 MAPK in neuronal migration.  Furthermore, these studies support a potential role for Ark in the regulation of GnRH neuronal migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEtuRyVS8QebVg90H21EOLACvtfcHk0lgHGM4JiCOpPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvVeqtg%253D%253D&md5=fe1dd91600eb4efb8512719c62a9aee3</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1128%2FMCB.22.2.599-613.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.22.2.599-613.2002%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DM.%2BP.%26aulast%3DLinseman%26aufirst%3DD.%2BA.%26aulast%3DUdo%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DSchaack%26aufirst%3DJ.%2BB.%26aulast%3DVarnum%26aufirst%3DB.%26aulast%3DKandel%26aufirst%3DE.%2BR.%26aulast%3DHeidenreich%26aufirst%3DK.%2BA.%26aulast%3DWierman%26aufirst%3DM.%2BE.%26atitle%3DNovel%2520mechanism%2520for%2520gonadotropin-releasing%2520hormone%2520neuronal%2520migration%2520involving%2520Gas6%252FArk%2520signaling%2520to%2520p38%2520mitogen-activated%2520protein%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2002%26volume%3D22%26spage%3D599%26epage%3D613%26doi%3D10.1128%2FMCB.22.2.599-613.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hafizi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DahlbÃ¤ck, B.</span></span> <span> </span><span class="NLM_article-title">Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinase</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">295</span>â <span class="NLM_lpage">304</span>, <span class="refDoi">Â DOI: 10.1016/j.cytogfr.2006.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cytogfr.2006.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16737840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFSgsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=295-304&author=S.+Hafiziauthor=B.+Dahlb%C3%A4ck&title=Signalling+and+functional+diversity+within+the+Axl+subfamily+of+receptor+tyrosine+kinase&doi=10.1016%2Fj.cytogfr.2006.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases</span></div><div class="casAuthors">Hafizi, Sassan; Dahlbaeck, Bjoern</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">295-304</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The related Axl, Sky, and Mer receptor tyrosine kinases (RTKs) are increasingly being implicated in a host of discrete cellular responses including cell survival, proliferation, migration, and phagocytosis.  Furthermore, their ligands Gas6 and protein S are characteristically dependent on vitamin K for expression of their functions.  The Gas6/Axl system is implicated in several types of human cancer as well as inflammatory, autoimmune, vascular, and kidney diseases.  Each member of the Axl RTK subfamily possesses distinct expression profiles as well as discrete functions.  In this article, we review the knowledge so far on the intracellular signaling interactions and pathways concerning each of the Axl RTKs.  In this way, we hope to gain a greater understanding of the mechanisms that set each of them apart, and that relay their assocd. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdTpEe1fJt7bVg90H21EOLACvtfcHk0lgHGM4JiCOpPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFSgsbg%253D&md5=497007a195b1c20e9f4b27b7315f8f92</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2006.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2006.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DHafizi%26aufirst%3DS.%26aulast%3DDahlb%25C3%25A4ck%26aufirst%3DB.%26atitle%3DSignalling%2520and%2520functional%2520diversity%2520within%2520the%2520Axl%2520subfamily%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2006%26volume%3D17%26spage%3D295%26epage%3D304%26doi%3D10.1016%2Fj.cytogfr.2006.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span> <span> </span><span class="NLM_article-title">Giving AXL the axe: Targeting AXL in human malignancy</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">415</span>â <span class="NLM_lpage">423</span>, <span class="refDoi">Â DOI: 10.1038/bjc.2016.428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fbjc.2016.428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28072762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVSruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2017&pages=415-423&author=C.+M.+Gayauthor=K.+Balajiauthor=L.+A.+Byers&title=Giving+AXL+the+axe%3A+Targeting+AXL+in+human+malignancy&doi=10.1038%2Fbjc.2016.428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Giving AXL the axe: targeting AXL in human malignancy</span></div><div class="casAuthors">Gay, Carl M.; Balaji, Kavitha; Byers, Lauren Averett</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">415-423</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase AXL, activated by a complex interaction between its ligand growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular processes, including proliferation, survival, motility, and immunol. response.  Although not implicated as an oncogenic driver itself, AXL, a member of the TYRO3, AXL, and MERTK family of receptor tyrosine kinases, is overexpressed in several haematol. and solid malignancies, including acute myeloid leukemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers.  In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumor angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response.  As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies.  Several AXL inhibitors are currently in preclin. and clin. development.  This article reviews the structure, regulation, and function of AXL; the role of AXL in the tumor microenvironment; the development of AXL as a therapeutic target; and areas of ongoing and future investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHXM9RJ8TVsLVg90H21EOLACvtfcHk0lgyGrqIp-jv9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVSruw%253D%253D&md5=c24668744fe4b017def75b08bac2a863</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.428%26sid%3Dliteratum%253Aachs%26aulast%3DGay%26aufirst%3DC.%2BM.%26aulast%3DBalaji%26aufirst%3DK.%26aulast%3DByers%26aufirst%3DL.%2BA.%26atitle%3DGiving%2520AXL%2520the%2520axe%253A%2520Targeting%2520AXL%2520in%2520human%2520malignancy%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2017%26volume%3D116%26spage%3D415%26epage%3D423%26doi%3D10.1038%2Fbjc.2016.428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strange, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiyarom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourhabibi, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadri-Ardekani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S.</span></span> <span> </span><span class="NLM_article-title">Axl promotes zika virus entry and modulates the antiviral state of human sertoli cells</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e01372-19</span> <span class="refDoi">Â DOI: 10.1128/mBio.01372-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FmBio.01372-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31311882" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&author=D.+P.+Strangeauthor=B.+Jiyaromauthor=Z.+N.+Pourhabibiauthor=X.+Xieauthor=C.+Bakerauthor=H.+Sadri-Ardekaniauthor=P.+Y.+Shiauthor=S.+Verma&title=Axl+promotes+zika+virus+entry+and+modulates+the+antiviral+state+of+human+sertoli+cells&doi=10.1128%2FmBio.01372-19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1128%2FmBio.01372-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.01372-19%26sid%3Dliteratum%253Aachs%26aulast%3DStrange%26aufirst%3DD.%2BP.%26aulast%3DJiyarom%26aufirst%3DB.%26aulast%3DPourhabibi%26aufirst%3DZ.%2BN.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DSadri-Ardekani%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DP.%2BY.%26aulast%3DVerma%26aufirst%3DS.%26atitle%3DAxl%2520promotes%2520zika%2520virus%2520entry%2520and%2520modulates%2520the%2520antiviral%2520state%2520of%2520human%2520sertoli%2520cells%26jtitle%3DmBio%26date%3D2019%26volume%3D10%26doi%3D10.1128%2FmBio.01372-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimojima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaoka, Y.</span></span> <span> </span><span class="NLM_article-title">Tyro3 family-mediated cell entry of Ebola and Marburg viruses</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">10109</span>â <span class="NLM_lpage">10116</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01157-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01157-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17005688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVyls7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=10109-10116&author=M.+Shimojimaauthor=A.+Takadaauthor=H.+Ebiharaauthor=G.+Neumannauthor=K.+Fujiokaauthor=T.+Irimuraauthor=S.+Jonesauthor=H.+Feldmannauthor=Y.+Kawaoka&title=Tyro3+family-mediated+cell+entry+of+Ebola+and+Marburg+viruses&doi=10.1128%2FJVI.01157-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Tyro3 family-mediated cell entry of Ebola and Marburg viruses</span></div><div class="casAuthors">Shimojima, Masayuki; Takada, Ayato; Ebihara, Hideki; Neumann, Gabriele; Fujioka, Kouki; Irimura, Tatsuro; Jones, Steven; Feldmann, Heinz; Kawaoka, Yoshihiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">10109-10116</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Filoviruses, represented by the genera Ebolavirus and Marburgvirus, cause a lethal hemorrhagic fever in humans and in nonhuman primates.  Although filovirus can replicate in various tissues or cell types in these animals, the mol. mechanisms of its broad tropism remain poorly understood.  Here we show the involvement of members of the Tyro3 receptor tyrosine kinase family, Axl, Dtk, and Mer, in cell entry of filoviruses.  Ectopic expression of these family members in lymphoid cells, which otherwise are highly resistant to filovirus infection, enhanced infection by pseudotype viruses carrying filovirus glycoproteins on their envelopes.  This enhancement was reduced by antibodies to Tyro3 family members, Gas6 ligand, or sol. ectodomains of the members.  Live Ebola viruses infected both Axl- and Dtk-expressing cells more efficiently than control cells.  Antibody to Axl inhibited infection of pseudotype viruses in a no. of Axl-pos. cell lines.  These results implicate each Tyro3 family member as a cell entry factor in filovirus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqCQuIltWeVrVg90H21EOLACvtfcHk0lhCjcNrGbgHYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVyls7rP&md5=f2678cc7b5ab0c69111b960bf618876b</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1128%2FJVI.01157-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01157-06%26sid%3Dliteratum%253Aachs%26aulast%3DShimojima%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DA.%26aulast%3DEbihara%26aufirst%3DH.%26aulast%3DNeumann%26aufirst%3DG.%26aulast%3DFujioka%26aufirst%3DK.%26aulast%3DIrimura%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DFeldmann%26aufirst%3DH.%26aulast%3DKawaoka%26aufirst%3DY.%26atitle%3DTyro3%2520family-mediated%2520cell%2520entry%2520of%2520Ebola%2520and%2520Marburg%2520viruses%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D10109%26epage%3D10116%26doi%3D10.1128%2FJVI.01157-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">126</span>â <span class="NLM_lpage">140</span>, <span class="refDoi">Â DOI: 10.1038/s41422-020-00460-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41422-020-00460-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33420426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhs1Sjs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2021&pages=126-140&author=S.+Wangauthor=Z.+Qiuauthor=Y.+Houauthor=X.+Dengauthor=T.+Zhengauthor=R.+Yanauthor=P.+Wuauthor=S.+Xieauthor=Q.+Zhouauthor=J.+Huangauthor=X.+Li&title=AXL+is+a+candidate+receptor+for+SARS-CoV-2+that+promotes+infection+of+pulmonary+and+bronchial+epithelial+cells&doi=10.1038%2Fs41422-020-00460-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells</span></div><div class="casAuthors">Wang, Shuai; Qiu, Zongyang; Hou, Yingnan; Deng, Xiya; Xu, Wei; Zheng, Tingting; Wu, Peihan; Xie, Shaofang; Bian, Weixiang; Zhang, Chong; Sun, Zewei; Liu, Kunpeng; Shan, Chao; Lin, Aifu; Jiang, Shibo; Xie, Youhua; Zhou, Qiang; Lu, Lu; Huang, Jing; Li, Xu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-140</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The current coronavirus disease 2019 (COVID-19) pandemic presents a global public health challenge.  The viral pathogen responsible, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), binds to the host receptor ACE2 through its spike (S) glycoprotein, which mediates membrane fusion and viral entry.  Although the role of ACE2 as a receptor for SARS-CoV-2 is clear, studies have shown that ACE2 expression is extremely low in various human tissues, esp. in the respiratory tract.  Thus, other host receptors and/or co-receptors that promote the entry of SARS-CoV-2 into cells of the respiratory system may exist.  In this study, we found that the tyrosine-protein kinase receptor UFO (AXL) specifically interacts with the N-terminal domain of SARS-CoV-2 S.  Using both a SARS-CoV-2 virus pseudotype and authentic SARS-CoV-2, we found that overexpression of AXL in HEK293T cells promotes SARS-CoV-2 entry as efficiently as overexpression of ACE2, while knocking out AXL significantly reduces SARS-CoV-2 infection in H1299 pulmonary cells and in human primary lung epithelial cells.  Sol. human recombinant AXL blocks SARS-CoV-2 infection in cells expressing high levels of AXL.  The AXL expression level is well correlated with SARS-CoV-2 S level in bronchoalveolar lavage fluid cells from COVID-19 patients.  Taken together, our findings suggest that AXL is a novel candidate receptor for SARS-CoV-2 which may play an important role in promoting viral infection of the human respiratory system and indicate that it is a potential target for future clin. intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI1wmry9H6UrVg90H21EOLACvtfcHk0lhCjcNrGbgHYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhs1Sjs7s%253D&md5=d708204bc6dd130cdb30f0bf5fc2742b</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fs41422-020-00460-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-020-00460-y%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DT.%26aulast%3DYan%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DAXL%2520is%2520a%2520candidate%2520receptor%2520for%2520SARS-CoV-2%2520that%2520promotes%2520infection%2520of%2520pulmonary%2520and%2520bronchial%2520epithelial%2520cells%26jtitle%3DCell%2520Res.%26date%3D2021%26volume%3D31%26spage%3D126%26epage%3D140%26doi%3D10.1038%2Fs41422-020-00460-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkhowa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Preclinical studies of gilteritinib, a nextgeneration FLT3 inhibitor</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">257</span>â <span class="NLM_lpage">260</span>, <span class="refDoi">Â DOI: 10.1182/blood-2016-10-745133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1182%2Fblood-2016-10-745133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27908881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVKitL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=257-260&author=L.+Y.+Leeauthor=D.+Hernandezauthor=T.+Rajkhowaauthor=S.+C.+Smithauthor=J.+R.+Ramanauthor=B.+Nguyenauthor=D.+Smallauthor=M.+Levis&title=Preclinical+studies+of+gilteritinib%2C+a+nextgeneration+FLT3+inhibitor&doi=10.1182%2Fblood-2016-10-745133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor</span></div><div class="casAuthors">Lee, Lauren Y.; Hernandez, Daniela; Rajkhowa, Trivikram; Smith, Samuel C.; Raman, Jayant Ranganathan; Nguyen, Bao; Small, Donald; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-260</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">This article describes about the activity of gilteritinib and compared it with 4 other FLT3 TKIs in clin. development: midostaurin, sorafenib, quizartinib, and crenolanib.  In this article, inhibitory activity of gilteritinib against different forms of FLT3 in leukemia cells are studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKpTUQzYy5lrVg90H21EOLACvtfcHk0lhCjcNrGbgHYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVKitL0%253D&md5=75429ea03b906ea92d24033613f0315b</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-10-745133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-10-745133%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DL.%2BY.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DRaman%26aufirst%3DJ.%2BR.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DPreclinical%2520studies%2520of%2520gilteritinib%252C%2520a%2520nextgeneration%2520FLT3%2520inhibitor%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D257%26epage%3D260%26doi%3D10.1182%2Fblood-2016-10-745133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span> <span> </span><span class="NLM_article-title">The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">Suppl 4</span>),  <span class="NLM_fpage">S3</span>â <span class="NLM_lpage">S8</span>, <span class="refDoi">Â DOI: 10.1016/S0959-8049(01)00230-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS0959-8049%2801%2900230-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11597398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntlOku78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=S3-S8&issue=Suppl+4&author=Y.+Yarden&title=The+EGFR+family+and+its+ligands+in+human+cancer.+Signalling+mechanisms+and+therapeutic+opportunities&doi=10.1016%2FS0959-8049%2801%2900230-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities</span></div><div class="casAuthors">Yarden, Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">Suppl. 4</span>),
    <span class="NLM_cas:pages">S3-S8</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Growth factors and their transmembrane receptor tyrosine kinases play important roles in cell proliferation, survival, migration and differentiation.  One group of growth factors, comprising epidermal growth factor (EGF)-like proteins and neuregulins, stimulates cells to divide by activating members of the EGF receptor (EGFR) family, which consists of the EGFR itself and the receptors known as HER2-4.  This highly conserved signaling module plays a fundamental role in the morphogenesis of a diverse spectrum of organisms, ranging from humans to nematodes, and has also been implicated in the development and growth of many types of human tumor cells.  In humans, more than 30 ligands and the EGFR family of four receptors lie at the head of a complex, multi-layered signal-transduction network.  Different activated receptor-ligand complexes vary in both the strength and type of cellular responses that they induce.  Anal. of the multiple processes that modulate EGFR signal transduction, such as receptor heterodimerization and endocytosis, has revealed new therapeutic opportunities and elucidated mechanisms contributing to the efficacy of existing anticancer treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruCkMkD5i497Vg90H21EOLACvtfcHk0li_4jpTpPwVDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntlOku78%253D&md5=b512e9006ed63e9f01f2cdd525dc4d96</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2801%2900230-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252801%252900230-1%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DThe%2520EGFR%2520family%2520and%2520its%2520ligands%2520in%2520human%2520cancer.%2520Signalling%2520mechanisms%2520and%2520therapeutic%2520opportunities%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2001%26volume%3D37%26issue%3DSuppl%25204%26spage%3DS3%26epage%3DS8%26doi%3D10.1016%2FS0959-8049%2801%2900230-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beerli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakimovich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynoso, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaschner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, J.</span></span> <span> </span><span class="NLM_article-title">Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility</span>. <i>Nat. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">216</span>â <span class="NLM_lpage">225</span>, <span class="refDoi">Â DOI: 10.1038/s41564-018-0288-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41564-018-0288-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30420785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Sgur%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=216-225&author=C.+Beerliauthor=A.+Yakimovichauthor=S.+Kilcherauthor=G.+V.+Reynosoauthor=G.+Flaschnerauthor=D.+J.+M%C3%BCllerauthor=H.+D.+Hickmanauthor=J.+Mercer&title=Vaccinia+virus+hijacks+EGFR+signalling+to+enhance+virus+spread+through+rapid+and+directed+infected+cell+motility&doi=10.1038%2Fs41564-018-0288-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility</span></div><div class="casAuthors">Beerli, Corina; Yakimovich, Artur; Kilcher, Samuel; Reynoso, Glennys V.; Flaschner, Gotthold; Muller, Daniel J.; Hickman, Heather D.; Mercer, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Nature Microbiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">216-225</span>CODEN:
                <span class="NLM_cas:coden">NMAICH</span>;
        ISSN:<span class="NLM_cas:issn">2058-5276</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cell motility is essential for viral dissemination1.  Vaccinia virus (VACV), a close relative of smallpox virus, is thought to exploit cell motility as a means to enhance the spread of infection1.  A single viral protein, F11L, contributes to this by blocking RhoA signalling to facilitate cell retraction2.  However, F11L alone is not sufficient for VACV-induced cell motility, indicating that addnl. viral factors must be involved.  Here, we show that the VACV epidermal growth factor homolog, VGF, promotes infected cell motility and the spread of viral infection.  We found that VGF secreted from early infected cells is cleaved by ADAM10, after which it acts largely in a paracrine manner to direct cell motility at the leading edge of infection.  Real-time tracking of cells infected in the presence of EGFR, MAPK, FAK and ADAM10 inhibitors or with VGF-deleted and F11-deleted viruses revealed defects in radial velocity and directional migration efficiency, leading to impaired cell-to-cell spread of infection.  Furthermore, intravital imaging showed that virus spread and lesion formation are attenuated in the absence of VGF.  Our results demonstrate how poxviruses hijack epidermal growth factor receptor-induced cell motility to promote rapid and efficient spread of infection in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn_oMFPOjS1rVg90H21EOLACvtfcHk0li_4jpTpPwVDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Sgur%252FL&md5=6cf75250c3685c6c51097b55a33f921a</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fs41564-018-0288-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41564-018-0288-2%26sid%3Dliteratum%253Aachs%26aulast%3DBeerli%26aufirst%3DC.%26aulast%3DYakimovich%26aufirst%3DA.%26aulast%3DKilcher%26aufirst%3DS.%26aulast%3DReynoso%26aufirst%3DG.%2BV.%26aulast%3DFlaschner%26aufirst%3DG.%26aulast%3DM%25C3%25BCller%26aufirst%3DD.%2BJ.%26aulast%3DHickman%26aufirst%3DH.%2BD.%26aulast%3DMercer%26aufirst%3DJ.%26atitle%3DVaccinia%2520virus%2520hijacks%2520EGFR%2520signalling%2520to%2520enhance%2520virus%2520spread%2520through%2520rapid%2520and%2520directed%2520infected%2520cell%2520motility%26jtitle%3DNat.%2520Microbiol.%26date%3D2019%26volume%3D4%26spage%3D216%26epage%3D225%26doi%3D10.1038%2Fs41564-018-0288-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, C.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meckes, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab-Traub, N.</span></span> <span> </span><span class="NLM_article-title">Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCÎ´</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">4399</span>â <span class="NLM_lpage">4408</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01703-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01703-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=21307189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSmsLbO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=4399-4408&author=C.-P.+Kungauthor=D.+G.+Meckesauthor=N.+Raab-Traub&title=Epstein-Barr+virus+LMP1+activates+EGFR%2C+STAT3%2C+and+ERK+through+effects+on+PKC%CE%B4&doi=10.1128%2FJVI.01703-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCÎ´</span></div><div class="casAuthors">Kung, Che-Pei; Meckes, David G., Jr.; Raab-Traub, Nancy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4399-4408</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that infects more than 90% of the world's adult population and is linked to multiple malignancies, including Burkitt lymphoma, Hodgkin disease, and nasopharyngeal carcinoma (NPC).  The EBV oncoprotein LMP1 induces transcription of the epidermal growth factor receptor (EGFR), which is expressed at high levels in NPC.  EGFR transcription is induced by LMP1 through a p50 NFÎºB1-Bcl-3 complex, and Bcl-3 is induced by LMP1-mediated activation of STAT3.  This study reveals that LMP1, through its carboxyl-terminal activation domain 1 (LMP1-CTAR1), activates both STAT3 and EGFR in a serum-independent manner with constitutive serine phosphorylation of STAT3.  Upon treatment with EGF, the LMP1-CTAR1-induced EGFR was addnl. phosphorylated and STAT3 became phosphorylated on tyrosine, concomitant with upregulation of a subset of STAT3 target genes.  The kinase responsible for LMP1-CTAR1-mediated serine phosphorylation of STAT3 was identified to be PKCÎ´ using specific RNAi, a dominant neg. PKCÎ´, and the PKCÎ´ inhibitor rottlerin.  Interestingly, inhibition of PKCÎ´ also inhibited constitutive phosphorylation of EGFR and LMP1-CTAR1-induced phosphorylation of ERK.  Inhibition of PKCÎ´ blocked LMP1-CTAR1-mediated transformation of Rat-1 cells, likely through the inhibition of ERK activation.  These findings indicate that LMP1 activates multiple distinct signaling pathways and suggest that PKCÎ´ functions as a master regulator of EGFR, STAT3, and ERK activation by LMP1-CTAR1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTHHkR2eUL_rVg90H21EOLACvtfcHk0ljmnhfG7tnRaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSmsLbO&md5=ab4059ceb1322fc9e283bb978502b7d7</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1128%2FJVI.01703-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01703-10%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DC.-P.%26aulast%3DMeckes%26aufirst%3DD.%2BG.%26aulast%3DRaab-Traub%26aufirst%3DN.%26atitle%3DEpstein-Barr%2520virus%2520LMP1%2520activates%2520EGFR%252C%2520STAT3%252C%2520and%2520ERK%2520through%2520effects%2520on%2520PKC%25CE%25B4%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D4399%26epage%3D4408%26doi%3D10.1128%2FJVI.01703-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Rhinovirusinduced major airway mucin production involves a novel TLR3-EGFR-dependent pathway</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">610</span>â <span class="NLM_lpage">619</span>, <span class="refDoi">Â DOI: 10.1165/rcmb.2008-0223OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1165%2Frcmb.2008-0223OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18978302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsF2itro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2009&pages=610-619&author=L.+Zhuauthor=P.+K.+Leeauthor=W.+M.+Leeauthor=Y.+Zhaoauthor=D.+Yuauthor=Y.+Chen&title=Rhinovirusinduced+major+airway+mucin+production+involves+a+novel+TLR3-EGFR-dependent+pathway&doi=10.1165%2Frcmb.2008-0223OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Rhinovirus-induced major airway mucin production involves a novel TLR3-EGFR-dependent pathway</span></div><div class="casAuthors">Zhu, Lingxiang; Lee, Pak-kei; Lee, Wai-ming; Zhao, Yuhua; Yu, Dongfang; Chen, Yin</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">610-619</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Mucociliary clearance is a crit. innate defense system responsible for clearing up invading pathogens including bacteria and virus.  Although the right amt. of mucus is good, excessive mucus causes airway obstruction and tends to ppt. disease symptoms.  Rhinovirus (RV) is a common cold virus that causes asthma and chronic obstructive pulmonary disease exacerbation.  Mucus overprodn. has been linked to the pathogenesis of RV-induced diseases and disease exacerbations.  However, the mol. mechanism is not clear.  Here, using one of the major airway mucin-MUC5AC as marker, the authors found that both major and minor groups of RV induced mucin prodn. in primary human epithelial cells and cell line.  RV1A (a minor group of RV) could induce mucous cell metaplasia in vivo.  Viral replication was needed for RV-induced mucin expression, and this induction was also dependent on TLR3, suggesting the involvement of double-stranded (ds) RNA signaling.  Indeed, dsRNA alone could also induce mucin expression.  TLR3-mediated mucin induction was neg. regulated by MyD88, and only partially dependent on TRIF, which suggests a departure from well-documented TLR3 signaling paradigm that mediates inflammatory and other innate defense gene inductions.  In addn., TLR3 signaling activated epidermal growth factor receptor (EGFR) via induction of the expression of EGFR ligands (transforming growth factor-Î± and amphiregulin), which in turn activated EGFR-ERK signaling and mucin expression through an autocrine/paracrine loop.  This novel coupling of antiviral defense machinery (i.e., TLR3) and major epithelial proliferation/repair pathway (i.e., EGFR) might play an important role in viral-induced airway remodeling and airway disease exacerbation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodfRh50tVjWLVg90H21EOLACvtfcHk0ljmnhfG7tnRaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsF2itro%253D&md5=0795eb98e37d4ad9bc7def02b77b232d</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2008-0223OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2008-0223OC%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DP.%2BK.%26aulast%3DLee%26aufirst%3DW.%2BM.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DRhinovirusinduced%2520major%2520airway%2520mucin%2520production%2520involves%2520a%2520novel%2520TLR3-EGFR-dependent%2520pathway%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2009%26volume%3D40%26spage%3D610%26epage%3D619%26doi%3D10.1165%2Frcmb.2008-0223OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eierhoff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrincius, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span> <span> </span><span class="NLM_article-title">The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e1001099</span> <span class="refDoi">Â DOI: 10.1371/journal.ppat.1001099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.ppat.1001099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20844577" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&author=T.+Eierhoffauthor=E.+R.+Hrinciusauthor=U.+Rescherauthor=S.+Ludwigauthor=C.+Ehrhardt&title=The+epidermal+growth+factor+receptor+%28EGFR%29+promotes+uptake+of+influenza+A+viruses+%28IAV%29+into+host+cells&doi=10.1371%2Fjournal.ppat.1001099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1001099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1001099%26sid%3Dliteratum%253Aachs%26aulast%3DEierhoff%26aufirst%3DT.%26aulast%3DHrincius%26aufirst%3DE.%2BR.%26aulast%3DRescher%26aufirst%3DU.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DEhrhardt%26aufirst%3DC.%26atitle%3DThe%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520promotes%2520uptake%2520of%2520influenza%2520A%2520viruses%2520%2528IAV%2529%2520into%2520host%2520cells%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26doi%3D10.1371%2Fjournal.ppat.1001099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lupberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeisel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thumann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fofana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zona, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mee, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavillette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fresquet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosset, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietschmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DoffoÃ«l, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffelsberger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeating, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, T. F.</span></span> <span> </span><span class="NLM_article-title">EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">589</span>â <span class="NLM_lpage">595</span>, <span class="refDoi">Â DOI: 10.1038/nm.2341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnm.2341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=21516087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFyqtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=589-595&author=J.+Lupbergerauthor=M.+B.+Zeiselauthor=F.+Xiaoauthor=C.+Thumannauthor=I.+Fofanaauthor=L.+Zonaauthor=C.+Davisauthor=C.+J.+Meeauthor=M.+Turekauthor=S.+Gorkeauthor=C.+Royerauthor=B.+Fischerauthor=M.+N.+Zahidauthor=D.+Lavilletteauthor=J.+Fresquetauthor=F.+L.+Cossetauthor=S.+M.+Rothenbergauthor=T.+Pietschmannauthor=A.+H.+Patelauthor=P.+Pessauxauthor=M.+Doffo%C3%ABlauthor=W.+Raffelsbergerauthor=O.+Pochauthor=J.+A.+McKeatingauthor=L.+Brinoauthor=T.+F.+Baumert&title=EGFR+and+EphA2+are+host+factors+for+hepatitis+C+virus+entry+and+possible+targets+for+antiviral+therapy&doi=10.1038%2Fnm.2341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy</span></div><div class="casAuthors">Lupberger, Joachim; Zeisel, Mirjam B.; Xiao, Fei; Thumann, Christine; Fofana, Isabel; Zona, Laetitia; Davis, Christopher; Mee, Christopher J.; Turek, Marine; Gorke, Sebastian; Royer, Cathy; Fischer, Benoit; Zahid, Muhammad N.; Lavillette, Dimitri; Fresquet, Judith; Cosset, Francois-Loic; Rothenberg, S. Michael; Pietschmann, Thomas; Patel, Arvind H.; Pessaux, Patrick; Doffoel, Michel; Raffelsberger, Wolfgang; Poch, Olivier; McKeating, Jane A.; Brino, Laurent; Baumert, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">589-595</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a major cause of liver disease, but therapeutic options are limited and there are no prevention strategies.  Viral entry is the first step of infection and requires the cooperative interaction of several host cell factors.  Using a functional RNAi kinase screen, we identified epidermal growth factor receptor and ephrin receptor A2 as host cofactors for HCV entry.  Blocking receptor kinase activity by approved inhibitors broadly impaired infection by all major HCV genotypes and viral escape variants in cell culture and in a human liver chimeric mouse model in vivo.  The identified receptor tyrosine kinases (RTKs) mediate HCV entry by regulating CD81-claudin-1 co-receptor assocns. and viral glycoprotein-dependent membrane fusion.  These results identify RTKs as previously unknown HCV entry cofactors and show that tyrosine kinase inhibitors have substantial antiviral activity.  Inhibition of RTK function may constitute a new approach for prevention and treatment of HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPNZcMOXBl57Vg90H21EOLACvtfcHk0ljwCrZLyisgUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFyqtL4%253D&md5=9a772f9cb03077335c7e7f5918a6e1ef</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1038%2Fnm.2341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2341%26sid%3Dliteratum%253Aachs%26aulast%3DLupberger%26aufirst%3DJ.%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DThumann%26aufirst%3DC.%26aulast%3DFofana%26aufirst%3DI.%26aulast%3DZona%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DC.%26aulast%3DMee%26aufirst%3DC.%2BJ.%26aulast%3DTurek%26aufirst%3DM.%26aulast%3DGorke%26aufirst%3DS.%26aulast%3DRoyer%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DZahid%26aufirst%3DM.%2BN.%26aulast%3DLavillette%26aufirst%3DD.%26aulast%3DFresquet%26aufirst%3DJ.%26aulast%3DCosset%26aufirst%3DF.%2BL.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DA.%2BH.%26aulast%3DPessaux%26aufirst%3DP.%26aulast%3DDoffo%25C3%25ABl%26aufirst%3DM.%26aulast%3DRaffelsberger%26aufirst%3DW.%26aulast%3DPoch%26aufirst%3DO.%26aulast%3DMcKeating%26aufirst%3DJ.%2BA.%26aulast%3DBrino%26aufirst%3DL.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26atitle%3DEGFR%2520and%2520EphA2%2520are%2520host%2520factors%2520for%2520hepatitis%2520C%2520virus%2520entry%2520and%2520possible%2520targets%2520for%2520antiviral%2520therapy%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D589%26epage%3D595%26doi%3D10.1038%2Fnm.2341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueki, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min-Oo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballon-Landa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanier, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koff, J. L.</span></span> <span> </span><span class="NLM_article-title">Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon l and antiviral defense in airway epithelium</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">1929</span>â <span class="NLM_lpage">1936</span>, <span class="refDoi">Â DOI: 10.1084/jem.20121401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1084%2Fjem.20121401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=23999497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFelsLvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2013&pages=1929-1936&author=I.+F.+Uekiauthor=G.+Min-Ooauthor=A.+Kalinowskiauthor=E.+Ballon-Landaauthor=L.+L.+Lanierauthor=J.+A.+Nadelauthor=J.+L.+Koff&title=Respiratory+virus-induced+EGFR+activation+suppresses+IRF1-dependent+interferon+l+and+antiviral+defense+in+airway+epithelium&doi=10.1084%2Fjem.20121401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon Î» and antiviral defense in airway epithelium</span></div><div class="casAuthors">Ueki, Iris F.; Min-Oo, Gundula; Kalinowski, April; Ballon-Landa, Eric; Lanier, Lewis L.; Nadel, Jay A.; Koff, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1929-1936</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Viruses suppress host responses to increase infection, and understanding these mechanisms has provided insights into cellular signaling and led to novel therapies.  Many viruses (e.g., influenza virus, Rhinovirus [RV], Cytomegalovirus, Epstein-Barr virus, and Hepatitis C virus) activate epithelial epidermal growth factor receptor (EGFR), a tyrosine kinase receptor, but the role of EGFR in viral pathogenesis is not clear.  Interferon (IFN) signaling is a crit. innate antiviral host response and recent expts. have implicated IFN-Î», a type III IFN, as the most significant IFN for mucosal antiviral immune responses.  Despite the importance of IFN-Î» in epithelial antiviral responses, the role and mechanisms of epithelial IFN-Î» signaling have not been fully elucidated.  We report that respiratory virus-induced EGFR activation suppresses endogenous airway epithelial antiviral signaling.  We found that Influenza virus- and RV-induced EGFR activation suppressed IFN regulatory factor (IRF) 1-induced IFN-Î» prodn. and increased viral infection.  In addn., inhibition of EGFR during viral infection augmented IRF1 and IFN-Î», which resulted in decreased viral titers in vitro and in vivo.  These findings describe a novel mechanism that viruses use to suppress endogenous antiviral defenses, and provide potential targets for future therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2xVzMrOcUv7Vg90H21EOLACvtfcHk0ljwCrZLyisgUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFelsLvM&md5=121a4a1514a53f104045e6516447e860</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1084%2Fjem.20121401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20121401%26sid%3Dliteratum%253Aachs%26aulast%3DUeki%26aufirst%3DI.%2BF.%26aulast%3DMin-Oo%26aufirst%3DG.%26aulast%3DKalinowski%26aufirst%3DA.%26aulast%3DBallon-Landa%26aufirst%3DE.%26aulast%3DLanier%26aufirst%3DL.%2BL.%26aulast%3DNadel%26aufirst%3DJ.%2BA.%26aulast%3DKoff%26aufirst%3DJ.%2BL.%26atitle%3DRespiratory%2520virus-induced%2520EGFR%2520activation%2520suppresses%2520IRF1-dependent%2520interferon%2520l%2520and%2520antiviral%2520defense%2520in%2520airway%2520epithelium%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2013%26volume%3D210%26spage%3D1929%26epage%3D1936%26doi%3D10.1084%2Fjem.20121401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorshkov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straus, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp-Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, G. R.</span></span> <span> </span><span class="NLM_article-title">Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1165</span>â <span class="NLM_lpage">1175</span>, <span class="refDoi">Â DOI: 10.1021/acsptsci.0c00112</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.0c00112" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVyku7jP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2020&pages=1165-1175&author=C.+Z.+Chenauthor=M.+Xuauthor=M.+Pradhanauthor=K.+Gorshkovauthor=J.+Petersenauthor=M.+R.+Strausauthor=W.+Zhuauthor=P.+Shinnauthor=H.+Guoauthor=M.+Shenauthor=C.+Klumpp-Thomasauthor=S.+G.+Michaelauthor=J.+Zimmerbergauthor=W.+Zhengauthor=G.+R.+Whittaker&title=Identifying+SARS-CoV-2+entry+inhibitors+through+drug+repurposing+screens+of+SARS-S+and+MERS-S+pseudotyped+particles&doi=10.1021%2Facsptsci.0c00112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles</span></div><div class="casAuthors">Chen, Catherine Z.; Xu, Miao; Pradhan, Manisha; Gorshkov, Kirill; Petersen, Jennifer D.; Straus, Marco R.; Zhu, Wei; Shinn, Paul; Guo, Hui; Shen, Min; Klumpp-Thomas, Carleen; Michael, Samuel G.; Zimmerberg, Joshua; Zheng, Wei; Whittaker, Gary R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1165-1175</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  While vaccine development will hopefully quell the global pandemic of COVID-19 caused by SARS-CoV-2, small mol. drugs that can effectively control SARS-CoV-2 infection are urgently needed.  Here, inhibitors of spike (S) mediated cell entry were identified in a high throughput screen of an approved drugs library with SARS-S and MERS-S pseudotyped particle entry assays.  We discovered six compds. (cepharanthine, abemaciclib, osimertinib, trimipramine, colforsin, and ingenol) to be broad spectrum inhibitors for spike-mediated entry.  This work could contribute to the development of effective treatments against the initial stage of viral infection, and provide mechanistic information that might aid the design of new drug combinations for clin. trials for COVID-19 patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5vCnAKlZLlLVg90H21EOLACvtfcHk0ljMrjfXZZgoww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVyku7jP&md5=86127d0e425488f7621ba547f2606c56</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.0c00112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.0c00112%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BZ.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DPradhan%26aufirst%3DM.%26aulast%3DGorshkov%26aufirst%3DK.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DStraus%26aufirst%3DM.%2BR.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DShinn%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DKlumpp-Thomas%26aufirst%3DC.%26aulast%3DMichael%26aufirst%3DS.%2BG.%26aulast%3DZimmerberg%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DWhittaker%26aufirst%3DG.%2BR.%26atitle%3DIdentifying%2520SARS-CoV-2%2520entry%2520inhibitors%2520through%2520drug%2520repurposing%2520screens%2520of%2520SARS-S%2520and%2520MERS-S%2520pseudotyped%2520particles%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2020%26volume%3D3%26spage%3D1165%26epage%3D1175%26doi%3D10.1021%2Facsptsci.0c00112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheema, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saggese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span> <span> </span><span class="NLM_article-title">Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">41</span>â <span class="NLM_lpage">50</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1913662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1056%2FNEJMoa1913662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31751012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFGgtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=41-50&author=S.+S.+Ramalingamauthor=J.+Vansteenkisteauthor=D.+Planchardauthor=B.+C.+Choauthor=J.+E.+Grayauthor=Y.+Oheauthor=C.+Zhouauthor=T.+Reungwetwattanaauthor=Y.+Chengauthor=B.+Chewaskulyongauthor=R.+Shahauthor=M.+Coboauthor=K.+H.+Leeauthor=P.+Cheemaauthor=M.+Tiseoauthor=T.+Johnauthor=M.-C.+Linauthor=F.+Imamuraauthor=T.+Kurataauthor=A.+Toddauthor=R.+Hodgeauthor=M.+Saggeseauthor=Y.+Rukazenkovauthor=J.-C.+Soria&title=Overall+survival+with+osimertinib+in+untreated%2C+EGFR-mutated+advanced+NSCLC&doi=10.1056%2FNEJMoa1913662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC</span></div><div class="casAuthors">Ramalingam, S. S.; Vansteenkiste, J.; Planchard, D.; Cho, B. C.; Gray, J. E.; Ohe, Y.; Zhou, C.; Reungwetwattana, T.; Cheng, Y.; Chewaskulyong, B.; Shah, R.; Cobo, M.; Lee, K. H.; Cheema, P.; Tiseo, M.; John, T.; Lin, M.-C.; Imamura, F.; Kurata, T.; Todd, A.; Hodge, R.; Saggese, M.; Rukazenkov, Y.; Soria, J.-C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI- sensitizing and EGFR T790M resistance mutations.  A phase 3 trial compared firstline osimertinib with other EGFR-TKIs in patients with EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  The trial showed longer progressionfree survival with osimertinib than with the comparator EGFR-TKIs (hazard ratio for disease progression or death, 0.46).  Data from the final anal. of overall survival have not been reported. methods In this trial, we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation (exon 19 deletion or L858R allele) in a 1:1 ratio to receive either osimertinib (80 mg once daily) or one of two other EGFR-TKIs (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily, with patients receiving these drugs combined in a single comparator group).  Overall survival was a secondary end point. results The median overall survival was 38.6 mo (95% confidence interval [CI], 34.5 to 41.8) in the osimertinib group and 31.8 mo (95% CI, 26.6 to 36.0) in the comparator group (hazard ratio for death, 0.80; 95.05% CI, 0.64 to 1.00; P = 0.046).  At 3 years, 79 of 279 patients (28%) in the osimertinib group and 26 of 277 (9%) in the comparator group were continuing to receive a trial regimen; the median exposure was 20.7 mo and 11.5 mo, resp.  Adverse events of grade 3 or higher were reported in 42% of the patients in the osimertinib group and in 47% of those in the comparator group. conclusions Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI.  The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq081UIt-O5nrVg90H21EOLACvtfcHk0ljMrjfXZZgoww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFGgtL4%253D&md5=2f78a87d4578be09e07e91f303b71acf</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1913662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1913662%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DCobo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DCheema%26aufirst%3DP.%26aulast%3DTiseo%26aufirst%3DM.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DM.-C.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DTodd%26aufirst%3DA.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DSaggese%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DSoria%26aufirst%3DJ.-C.%26atitle%3DOverall%2520survival%2520with%2520osimertinib%2520in%2520untreated%252C%2520EGFR-mutated%2520advanced%2520NSCLC%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D41%26epage%3D50%26doi%3D10.1056%2FNEJMoa1913662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojkova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tascher, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼nch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinatl, J.</span></span> <span> </span><span class="NLM_article-title">Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">164</span>â <span class="NLM_lpage">174</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2020.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.molcel.2020.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32877642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslCksLzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=164-174&author=K.+Klannauthor=D.+Bojkovaauthor=G.+Tascherauthor=S.+Ciesekauthor=C.+M%C3%BCnchauthor=J.+Cinatl&title=Growth+factor+receptor+signaling+inhibition+prevents+SARS-CoV-2+replication&doi=10.1016%2Fj.molcel.2020.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication</span></div><div class="casAuthors">Klann, Kevin; Bojkova, Denisa; Tascher, Georg; Ciesek, Sandra; Muench, Christian; Cinatl, Jindrich</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">164-174.e4</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">SARS-CoV-2 infections are rapidly spreading around the globe.  The rapid development of therapies is of major importance.  However, our lack of understanding of the mol. processes and host cell signaling events underlying SARS-CoV-2 infection hinders therapy development.  We use a SARS-CoV-2 infection system in permissible human cells to study signaling changes by phosphoproteomics.  We identify viral protein phosphorylation and define phosphorylation-driven host cell signaling changes upon infection.  Growth factor receptor (GFR) signaling and downstream pathways are activated.  Drug-protein network analyses revealed GFR signaling as key pathways targetable by approved drugs.  The inhibition of GFR downstream signaling by five compds. prevents SARS-CoV-2 replication in cells, assessed by cytopathic effect, viral dsRNA prodn., and viral RNA release into the supernatant.  This study describes host cell signaling events upon SARS-CoV-2 infection and reveals GFR signaling as a central pathway essential for SARS-CoV-2 replication.  It provides novel strategies for COVID-19 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2wJyMwGpdVLVg90H21EOLACvtfcHk0ljMrjfXZZgoww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslCksLzL&md5=feace92d14e24a5a7d59d3ac3ff94764</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2020.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2020.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DKlann%26aufirst%3DK.%26aulast%3DBojkova%26aufirst%3DD.%26aulast%3DTascher%26aufirst%3DG.%26aulast%3DCiesek%26aufirst%3DS.%26aulast%3DM%25C3%25BCnch%26aufirst%3DC.%26aulast%3DCinatl%26aufirst%3DJ.%26atitle%3DGrowth%2520factor%2520receptor%2520signaling%2520inhibition%2520prevents%2520SARS-CoV-2%2520replication%26jtitle%3DMol.%2520Cell%26date%3D2020%26volume%3D80%26spage%3D164%26epage%3D174%26doi%3D10.1016%2Fj.molcel.2020.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drosten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. A.</span></span> <span> </span><span class="NLM_article-title">Plaque assay for human coronavirus NL63 using human colon carcinoma cells</span>. <i>Virol. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">138</span>, <span class="refDoi">Â DOI: 10.1186/1743-422X-5-138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2F1743-422X-5-138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=19014487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FitFKjsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=138&author=P.+Herzogauthor=C.+Drostenauthor=M.+A.+Muller&title=Plaque+assay+for+human+coronavirus+NL63+using+human+colon+carcinoma+cells&doi=10.1186%2F1743-422X-5-138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Plaque assay for human coronavirus NL63 using human colon carcinoma cells</span></div><div class="casAuthors">Herzog Petra; Drosten Christian; Muller Marcel A</div><div class="citationInfo"><span class="NLM_cas:title">Virology journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Coronaviruses cause a broad range of diseases in animals and humans.  Human coronavirus (hCoV) NL63 is associated with up to 10% of common colds.  Viral plaque assays enable the characterization of virus infectivity and allow for purifying virus stock solutions.  They are essential for drug screening.  Hitherto used cell cultures for hCoV-NL63 show low levels of virus replication and weak and diffuse cytopathogenic effects.  It has not yet been possible to establish practicable plaque assays for this important human pathogen.  RESULTS:  12 different cell cultures were tested for susceptibility to hCoV-NL63 infection.  Human colon carcinoma cells (CaCo-2) replicated virus more than 100 fold more efficiently than commonly used African green monkey kidney cells (LLC-MK2).  CaCo-2 cells showed cytopathogenic effects 4 days post infection.  Avicel, agarose and carboxymethyl-cellulose overlays proved suitable for plaque assays.  Best results were achieved with Avicel, which produced large and clear plaques from the 4th day of infection.  The utility of plaque assays with agrose overlay was demonstrated for purifying virus, thereby increasing viral infectivity by 1 log 10 PFU/mL.  CONCLUSION:  CaCo-2 cells support hCoV-NL63 better than LLC-MK2 cells and enable cytopathogenic plaque assays.  Avicel overlay is favourable for plaque quantification, and agarose overlay is preferred for plaque purification.  HCoV-NL63 virus stock of increased infectivity will be beneficial in antiviral screening, animal modelling of disease, and other experimental tasks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtLhsJjctkv4NpW7w2tapOfW6udTcc2eYAN0SYQtmzbbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FitFKjsg%253D%253D&md5=bdcda2504293381228c18c2fd9deb6f2</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1186%2F1743-422X-5-138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1743-422X-5-138%26sid%3Dliteratum%253Aachs%26aulast%3DHerzog%26aufirst%3DP.%26aulast%3DDrosten%26aufirst%3DC.%26aulast%3DMuller%26aufirst%3DM.%2BA.%26atitle%3DPlaque%2520assay%2520for%2520human%2520coronavirus%2520NL63%2520using%2520human%2520colon%2520carcinoma%2520cells%26jtitle%3DVirol.%2520J.%26date%3D2008%26volume%3D5%26spage%3D138%26doi%3D10.1186%2F1743-422X-5-138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glende, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Falah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwegmann-Wessels, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschernig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naim, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrler, G.</span></span> <span> </span><span class="NLM_article-title">Analysis of ACE2 in polarized epithelial cells: Surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1691</span>â <span class="NLM_lpage">1695</span>, <span class="refDoi">Â DOI: 10.1099/vir.0.81749-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1099%2Fvir.0.81749-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16690935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFCis78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2006&pages=1691-1695&author=X.+Renauthor=J.+Glendeauthor=M.+Al-Falahauthor=V.+de+Vriesauthor=C.+Schwegmann-Wesselsauthor=X.+Quauthor=L.+Tanauthor=T.+Tschernigauthor=H.+Dengauthor=H.+Y.+Naimauthor=G.+Herrler&title=Analysis+of+ACE2+in+polarized+epithelial+cells%3A+Surface+expression+and+function+as+receptor+for+severe+acute+respiratory+syndrome-associated+coronavirus&doi=10.1099%2Fvir.0.81749-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus</span></div><div class="casAuthors">Ren, Xiaofeng; Glende, Joerg; Al-Falah, Marwan; de Vries, Victor; Schwegmann-Wessels, Christel; Qu, Xiuxia; Tan, Lei; Tschernig, Thomas; Deng, Hongkui; Naim, Hassan Y.; Herrler, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1691-1695</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">The primary target of severe acute respiratory syndrome-assocd. coronavirus (SARS-CoV) is epithelial cells in the respiratory and intestinal tract.  The cellular receptor for SARS-CoV, angiotensin-converting enzyme 2 (ACE2), has been shown to be localized on the apical plasma membrane of polarized respiratory epithelial cells and to mediate infection from the apical side of these cells.  Here, these results were confirmed and extended by including a colon carcinoma cell line (Caco-2), a lung carcinoma cell line (Calu-3) and Vero E6 cells in our anal.  All three cell types expressed human ACE2 on the apical membrane domain and were infected via this route, as detd. with vesicular stomatitis virus pseudotypes contg. the S protein of SARS-CoV.  In a histol. anal. of the respiratory tract, ACE2 was detected in the trachea, main bronchus and alveoli, and occasionally also in the small bronchi.  These data will help us to understand the pathogenesis of SARS-CoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeflvctPoBUbVg90H21EOLACvtfcHk0ljUqrv5Ha1akQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFCis78%253D&md5=38d7e70be96971a22d5ee2ae430d05fa</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.81749-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.81749-0%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGlende%26aufirst%3DJ.%26aulast%3DAl-Falah%26aufirst%3DM.%26aulast%3Dde%2BVries%26aufirst%3DV.%26aulast%3DSchwegmann-Wessels%26aufirst%3DC.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DTschernig%26aufirst%3DT.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DNaim%26aufirst%3DH.%2BY.%26aulast%3DHerrler%26aufirst%3DG.%26atitle%3DAnalysis%2520of%2520ACE2%2520in%2520polarized%2520epithelial%2520cells%253A%2520Surface%2520expression%2520and%2520function%2520as%2520receptor%2520for%2520severe%2520acute%2520respiratory%2520syndrome-associated%2520coronavirus%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2006%26volume%3D87%26spage%3D1691%26epage%3D1695%26doi%3D10.1099%2Fvir.0.81749-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eskens, F. A. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, M. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luyten, G. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faber, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statkevich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparreboom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanauske, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart, M.</span></span> <span> </span><span class="NLM_article-title">European organization for research and treatment of cancer early clinical studies group Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1167</span>â <span class="NLM_lpage">1175</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2001.19.4.1167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1200%2FJCO.2001.19.4.1167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11181683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhvFertrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=1167-1175&author=F.+A.+L.+M.+Eskensauthor=A.+Awadaauthor=D.+L.+Cutlerauthor=M.+J.+A.+de+Jongeauthor=G.+P.+M.+Luytenauthor=M.+N.+Faberauthor=P.+Statkevichauthor=A.+Sparreboomauthor=J.+Verweijauthor=A.+R.+Hanauskeauthor=M.+Piccart&title=European+organization+for+research+and+treatment+of+cancer+early+clinical+studies+group+Phase+I+and+pharmacokinetic+study+of+the+oral+farnesyl+transferase+inhibitor+SCH+66336+given+twice+daily+to+patients+with+advanced+solid+tumors&doi=10.1200%2FJCO.2001.19.4.1167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors</span></div><div class="casAuthors">Eskens, Ferry A. L. M.; Awada, Ahmad; Cutler, David L.; de Jonge, Maja J. A.; Luyten, Gre P. M.; Faber, Marije N.; Statkevich, Paul; Sparreboom, Alex; Verweij, Jaap; Hanauske, Axel-R.; Piccart, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1167-1175</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A single-agent dose-escalating phase I and pharmacokinetic study on the farnesyl transferase inhibitor SCH 66336 was performed to det. the safety profile, max.-tolerated dose, and recommended dose for phase II studies.  Plasma and urine pharmacokinetics were detd.  SCH 66336 was given orally bid without interruption to patients with histol. or cytol. confirmed solid tumors.  Routine antiemetics were not prescribed.  Twenty-four patients were enrolled onto the study.  Dose levels studied were 25, 50, 100, 200, 400, and 300 mg bid.  Pharmacokinetic sampling was performed on days 1 and 15.  At 400 mg bid, the dose-limiting toxicity (DLT) consisted of grade 4 vomiting, grade 4 neutropenia and thrombocytopenia, and the combination of grade 3 anorexia and diarrhea with reversible grade 3 plasma creatinine elevation.  After dose redn., at 300 mg bid, the DLTs consisted of grade 4 neutropenia, grade 3 neurocortical toxicity, and the combination of grade 3 fatigue with grade 2 nausea and diarrhea.  The recommended dose for phase II studies is 200 mg bid, which was found feasible for prolonged periods of time.  Pharmacokinetic anal. showed a greater than dose-proportional increase in drug exposure and peak plasma concns., with increased parameters at day 15 compared with day 1, indicating some accumulation on multiple dosing.  Plasma half-life ranged from 4 to 11 h and seemed to increase with increasing doses.  Steady-state plasma concns. were attained at days 7 through 14.  A large vol. of distribution at steady-state indicated extensive distribution outside the plasma compartment.  SCH 66336 can be administered safely using a continuous oral bid dosing regimen.  The recommended dose for phase II studies using this regimen is 200 mg bid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojqQZvEp_iBLVg90H21EOLACvtfcHk0ljUqrv5Ha1akQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhvFertrg%253D&md5=3e0ff6d44b83485cac58467afe0687de</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1200%2FJCO.2001.19.4.1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2001.19.4.1167%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26aulast%3DAwada%26aufirst%3DA.%26aulast%3DCutler%26aufirst%3DD.%2BL.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BJ.%2BA.%26aulast%3DLuyten%26aufirst%3DG.%2BP.%2BM.%26aulast%3DFaber%26aufirst%3DM.%2BN.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DSparreboom%26aufirst%3DA.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DHanauske%26aufirst%3DA.%2BR.%26aulast%3DPiccart%26aufirst%3DM.%26atitle%3DEuropean%2520organization%2520for%2520research%2520and%2520treatment%2520of%2520cancer%2520early%2520clinical%2520studies%2520group%2520Phase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520the%2520oral%2520farnesyl%2520transferase%2520inhibitor%2520SCH%252066336%2520given%2520twice%2520daily%2520to%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2001%26volume%3D19%26spage%3D1167%26epage%3D1175%26doi%3D10.1200%2FJCO.2001.19.4.1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fucile, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marenco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazzica, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccoli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbiano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Gion, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stura, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savarino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattioli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picciotto, A.</span></span> <span> </span><span class="NLM_article-title">Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: Is it useful the application in clinical practice? A pilot study</span>. <i>Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">335</span>, <span class="refDoi">Â DOI: 10.1007/s12032-014-0335-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs12032-014-0335-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25429830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC2MzhtlyntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=335&author=C.+Fucileauthor=S.+Marencoauthor=M.+Bazzicaauthor=M.+L.+Zuccoliauthor=F.+Lantieriauthor=L.+Robbianoauthor=V.+Mariniauthor=P.+Di+Gionauthor=G.+Pieriauthor=P.+Sturaauthor=A.+Martelliauthor=V.+Savarinoauthor=F.+Mattioliauthor=A.+Picciotto&title=Measurement+of+sorafenib+plasma+concentration+by+high-performance+liquid+chromatography+in+patients+with+advanced+hepatocellular+carcinoma%3A+Is+it+useful+the+application+in+clinical+practice%3F+A+pilot+study&doi=10.1007%2Fs12032-014-0335-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study</span></div><div class="casAuthors">Fucile Carmen; Marenco Simona; Bazzica Marco; Zuccoli Maria Laura; Lantieri Francesca; Robbiano Luigi; Marini Valeria; Di Gion Paola; Pieri Giulia; Stura Paola; Martelli Antonietta; Savarino Vincenzo; Mattioli Francesca; Picciotto Antonino</div><div class="citationInfo"><span class="NLM_cas:title">Medical oncology (Northwood, London, England)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">335</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pharmacokinetics and dose-finding studies on sorafenib were conducted on heterogeneous groups of patients with solid tumors.  Portal hypertension, gut motility impairment and altered bile enterohepatic circulation may explain different sorafenib toxicological profile in cirrhotic patients.  This study evaluated sorafenib plasma concentration in a homogeneous group of cirrhotic patients with hepatocellular carcinoma (HCC).  Sorafenib concentrations were determined by liquid chromatography in 12 consecutive patients.  Data have been evaluated by the generalized estimating equations method (p value statistical level was set at Î± = 0.05). (1) There were not significant differences between sorafenib concentrations in patients who tolerate the full dose versus patients with reduced dose due to toxicity; (2) the average sorafenib concentrations measured 3 h after the morning dosing were lower than those measured 12 h after the evening dosing (p = 0.005); (3) sorafenib concentrations decrease overtime (p < 10(-4)); (4) it has been found an association between the development of severe adverse reactions and sorafenib concentrations (p < 10(-5)).  The relationship between dose and concentration of sorafenib in HCC patients is poor and not clinically predictable, confirming the variability both in the maximum tolerated dose and in plasma concentrations.  Several factors may influence the pharmacokinetics in patients with liver disease.  This may explain the inter-patient variability of concentrations and the lack of differences in concentration at different dosages.  It could be interesting to extend the series of HCC patients to enhance information on the kinetics of the drug; furthermore, to establish a threshold of plasma sorafenib concentrations to predict severe adverse reactions would be clinically useful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTduceYDnsZa2yYR5VtavbzfW6udTcc2eaIKnH_hk4KI7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzhtlyntA%253D%253D&md5=f7460e44778e69d7ba0ead39d70f8f30</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1007%2Fs12032-014-0335-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-014-0335-7%26sid%3Dliteratum%253Aachs%26aulast%3DFucile%26aufirst%3DC.%26aulast%3DMarenco%26aufirst%3DS.%26aulast%3DBazzica%26aufirst%3DM.%26aulast%3DZuccoli%26aufirst%3DM.%2BL.%26aulast%3DLantieri%26aufirst%3DF.%26aulast%3DRobbiano%26aufirst%3DL.%26aulast%3DMarini%26aufirst%3DV.%26aulast%3DDi%2BGion%26aufirst%3DP.%26aulast%3DPieri%26aufirst%3DG.%26aulast%3DStura%26aufirst%3DP.%26aulast%3DMartelli%26aufirst%3DA.%26aulast%3DSavarino%26aufirst%3DV.%26aulast%3DMattioli%26aufirst%3DF.%26aulast%3DPicciotto%26aufirst%3DA.%26atitle%3DMeasurement%2520of%2520sorafenib%2520plasma%2520concentration%2520by%2520high-performance%2520liquid%2520chromatography%2520in%2520patients%2520with%2520advanced%2520hepatocellular%2520carcinoma%253A%2520Is%2520it%2520useful%2520the%2520application%2520in%2520clinical%2520practice%253F%2520A%2520pilot%2520study%26jtitle%3DMed.%2520Oncol.%26date%3D2015%26volume%3D32%26spage%3D335%26doi%3D10.1007%2Fs12032-014-0335-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albanell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahleda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraeber-BodÃ©rÃ©, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guarin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessier, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shochat, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blotner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naegelen, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">First-in human, Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4806</span>â <span class="NLM_lpage">4819</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-12-0742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F1078-0432.CCR-12-0742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22761467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygsbzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4806-4819&author=M.+Martinez-Garciaauthor=U.+Banerjiauthor=J.+Albanellauthor=R.+Bahledaauthor=S.+Dollyauthor=F.+Kraeber-Bod%C3%A9r%C3%A9author=F.+Rojoauthor=E.+Routierauthor=E.+Guarinauthor=Z.+X.+Xuauthor=R.+Ruegerauthor=J.+J.+Tessierauthor=E.+Shochatauthor=S.+Blotnerauthor=V.+M.+Naegelenauthor=J.+C.+Soria&title=First-in+human%2C+Phase+I+dose-escalation+study+of+the+safety%2C+pharmacokinetics%2C+and+pharmacodynamics+of+RO5126766%2C+a+first-in-class+dual+MEK%2FRAF+inhibitor+in+patients+with+solid+tumors&doi=10.1158%2F1078-0432.CCR-12-0742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors</span></div><div class="casAuthors">Martinez-Garcia, Maria; Banerji, Udai; Albanell, Joan; Bahleda, Rastilav; Dolly, Saoirse; Kraeber-Bodere, Francoise; Rojo, Federico; Routier, Emilie; Guarin, Ernesto; Xu, Zhi-Xin; Rueger, Ruediger; Tessier, Jean J. L.; Shochat, Eliezer; Blotner, Steve; Naegelen, Valerie Meresse; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4806-4819</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This phase I study assessed the max. tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetics, pharmacodynamics, and clin. activity of the first-in-class dual MEK/RAF inhibitor, RO5126766.  Exptl. Design: Initial dose-escalation was conducted using once daily dosing over 28 consecutive days in 4-wk cycles.  Further escalation was completed using 2 intermittent dosing schedules [7 days on treatment followed by 7 days off (7on/7off); 4 days on treatment followed by 3 days off (4on/3off)].  Results: Fifty-two patients received RO5126766 at doses of 0.1 to 2.7 mg once daily, 2.7 to 4.0 mg (4 on/3 off), or 2.7 to 5.0 mg (7 on/7 off).  The most common DLTs were elevated creatine phosphokinase (CPK) and blurred vision.  The MTD for each dosing schedule was 2.25 mg once daily, 4.0 mg (4 on/3 off), and 2.7 mg (7 on/7 off).  The dose/schedule recommended for phase II (RP2D) investigation was 2.7 mg (4 on/3 off).  Frequent adverse events included rash-related disorders (94.2%), elevated CPK (55.8%), and diarrhea (51.9%).  Cmax occurred 1 to 2 h after dosing and mean terminal half-life was approx. 60 h.  Pharmacodynamic changes included reduced ERK phosphorylation, an increase in apoptosis in tumor tissue, and a redn. in fluorodeoxyglucose (FDG) uptake after 15 days of dosing.  Three partial responses were seen: two in BRAF-mutant melanoma tumors and one in an NRAS-mutant melanoma.  Conclusion: This first-in-human study shows that oral RO5126766 has manageable toxicity, a favorable pharmacokinetic/pharmacodynamic profile, and encouraging preliminary antitumor activity in this population of heavily pretreated patients, achieving tumor shrinkage in around 40% of patients across all dose levels and all tumor types.  Clin Cancer Res; 18(17); 4806-19. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0WJz0TYB2kbVg90H21EOLACvtfcHk0lg5y3oaD4e4qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygsbzN&md5=8652ed9c0dba880907ef4125da44eb24</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0742%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Garcia%26aufirst%3DM.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DAlbanell%26aufirst%3DJ.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DDolly%26aufirst%3DS.%26aulast%3DKraeber-Bod%25C3%25A9r%25C3%25A9%26aufirst%3DF.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DRoutier%26aufirst%3DE.%26aulast%3DGuarin%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DZ.%2BX.%26aulast%3DRueger%26aufirst%3DR.%26aulast%3DTessier%26aufirst%3DJ.%2BJ.%26aulast%3DShochat%26aufirst%3DE.%26aulast%3DBlotner%26aufirst%3DS.%26aulast%3DNaegelen%26aufirst%3DV.%2BM.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DFirst-in%2520human%252C%2520Phase%2520I%2520dose-escalation%2520study%2520of%2520the%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520RO5126766%252C%2520a%2520first-in-class%2520dual%2520MEK%252FRAF%2520inhibitor%2520in%2520patients%2520with%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4806%26epage%3D4819%26doi%3D10.1158%2F1078-0432.CCR-12-0742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Noll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Specht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witteveen, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dees, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleha, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampkin, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span> <span> </span><span class="NLM_article-title">First-in-human Phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1932</span>â <span class="NLM_lpage">1939</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-15-1665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F1078-0432.CCR-15-1665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26603258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsFeqsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1932-1939&author=P.+Munsterauthor=R.+Aggarwalauthor=D.+Hongauthor=J.+H.+Schellensauthor=R.+van+der+Nollauthor=J.+Spechtauthor=P.+O.+Witteveenauthor=T.+L.+Wernerauthor=E.+C.+Deesauthor=E.+Bergslandauthor=N.+Agarwalauthor=J.+F.+Klehaauthor=M.+Duranteauthor=L.+Adamsauthor=D.+A.+Smithauthor=T.+A.+Lampkinauthor=S.+R.+Morrisauthor=R.+Kurzrock&title=First-in-human+Phase+I+study+of+GSK2126458%2C+an+oral+pan-class+I+phosphatidylinositol-3-kinase+inhibitor%2C+in+patients+with+advanced+solid+tumor+malignancies&doi=10.1158%2F1078-0432.CCR-15-1665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies</span></div><div class="casAuthors">Munster, Pamela; Aggarwal, Rahul; Hong, David; Schellens, Jan H. M.; van der Noll, Ruud; Specht, Jennifer; Witteveen, Petronella O.; Werner, Theresa L.; Dees, E. Claire; Bergsland, Emily; Agarwal, Neeraj; Kleha, Joseph F.; Durante, Michael; Adams, Laurel; Smith, Deborah A.; Lampkin, Thomas A.; Morris, Shannon R.; Kurzrock, Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1932-1939</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GSK2126458 (GSK458) is a potent inhibitor of PI3K (Î±, Î², Î³, and Î´), with preclin. studies demonstrating broad antitumor activity.  We performed a first-in-human phase I study in patients with advanced solid tumors.  Patients received oral GSK458 once or twice daily in a dose-escalation design to define the max. tolerated dose (MTD).  Expansion cohorts evaluated pharmacodynamics, pharmacokinetics, and clin. activity in histol. and molecularly defined cohorts.  One hundred and seventy patients received doses ranging from 0.1 to 3 mg once or twice daily.  Dose-limiting toxicities (grade 3 diarrhea, n = 4; fatigue and rash, n = 1) occurred in 5 patients (n = 3 at 3 mg/day).  The MTD was 2.5 mg/day (MTD with twice daily dosing undefined).  The most common grade â¥3 treatment-related adverse events included diarrhea (8%) and skin rash (5%).  Pharmacokinetic analyses demonstrated increased duration of drug exposure above target level with twice daily dosing.  Fasting insulin and glucose levels increased with dose and exposure of GSK458.  Durable objective responses (ORs) were obsd. across multiple tumor types (sarcoma, kidney, breast, endometrial, oropharyngeal, and bladder cancer).  Responses were not assocd. with PIK3CA mutations (OR rate: 5% wild-type vs. 6% mutant).  Although the MTD of GSK458 was 2.5 mg once daily, twice-daily dosing may increase duration of target inhibition.  Fasting insulin and glucose levels served as pharmacodynamic markers of drug exposure.  Select patients achieved durable responses; however, PIK3CA mutations were neither necessary nor predictive of response.  Combination treatment strategies and novel biomarkers may be needed to optimally target PI3K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5IMnYsnpPVLVg90H21EOLACvtfcHk0lg5y3oaD4e4qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsFeqsLs%253D&md5=3306a5e6586e8865bea5ef70aadf68d6</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1665%26sid%3Dliteratum%253Aachs%26aulast%3DMunster%26aufirst%3DP.%26aulast%3DAggarwal%26aufirst%3DR.%26aulast%3DHong%26aufirst%3DD.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3Dvan%2Bder%2BNoll%26aufirst%3DR.%26aulast%3DSpecht%26aufirst%3DJ.%26aulast%3DWitteveen%26aufirst%3DP.%2BO.%26aulast%3DWerner%26aufirst%3DT.%2BL.%26aulast%3DDees%26aufirst%3DE.%2BC.%26aulast%3DBergsland%26aufirst%3DE.%26aulast%3DAgarwal%26aufirst%3DN.%26aulast%3DKleha%26aufirst%3DJ.%2BF.%26aulast%3DDurante%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DLampkin%26aufirst%3DT.%2BA.%26aulast%3DMorris%26aufirst%3DS.%2BR.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DFirst-in-human%2520Phase%2520I%2520study%2520of%2520GSK2126458%252C%2520an%2520oral%2520pan-class%2520I%2520phosphatidylinositol-3-kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumor%2520malignancies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D1932%26epage%3D1939%26doi%3D10.1158%2F1078-0432.CCR-15-1665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Riverol, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csordas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal-Llinares, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewapathirana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inuganti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenacher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uszkoreit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeuffer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yilmaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarnuczak, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ternent, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brazma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VizcaÃ­no, J. A.</span></span> <span> </span><span class="NLM_article-title">The PRIDE database and related tools and resources in 2019: Improving support for quantification data</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">D442</span>â <span class="NLM_lpage">D450</span>, <span class="refDoi">Â DOI: 10.1093/nar/gky1106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1093%2Fnar%2Fgky1106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30395289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1GqtrzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=D442-D450&author=Y.+Perez-Riverolauthor=A.+Csordasauthor=J.+Baiauthor=M.+Bernal-Llinaresauthor=S.+Hewapathiranaauthor=D.+J.+Kunduauthor=A.+Inugantiauthor=J.+Grissauthor=G.+Mayerauthor=M.+Eisenacherauthor=E.+P%C3%A9rezauthor=J.+Uszkoreitauthor=J.+Pfeufferauthor=T.+Sachsenbergauthor=S.+Yilmazauthor=S.+Tiwaryauthor=J.+Coxauthor=E.+Audainauthor=M.+Walzerauthor=A.+F.+Jarnuczakauthor=T.+Ternentauthor=A.+Brazmaauthor=J.+A.+Vizca%C3%ADno&title=The+PRIDE+database+and+related+tools+and+resources+in+2019%3A+Improving+support+for+quantification+data&doi=10.1093%2Fnar%2Fgky1106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">The PRIDE database and related tools and resources in 2019: improving support for quantification data</span></div><div class="casAuthors">Perez-Riverol, Yasset; Csordas, Attila; Bai, Jingwen; Bernal-Llinare, Manuel; Hewapathirana, Suresh; Kundu, Deepti J.; Iuganti, Avinash; Griss, Johannes; Mayer, Gerhard; Eisenacher, Martin; Perez, Enrique; Uszkoreit, Julian; Pfeuffer, Julianus; Sachsenberg, Timo; Yilmaz, Sule; Tiwary, Shivani; Cox, Jurgen; Audain, Enrique; Walzer, Mathias; Jarnuczak, Andrew F.; Ternent, Tobias; Brazma, Alvis; Vizcaino, Juan Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D442-D450</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The PRoteomics IDEntifications (PRIDE) database is the world's largest data repository of mass spectrometry-based proteomics data, and is one of the founding members of the global ProteomeXchange (PX) consortium.  In this manuscript, we summarize the developments in PRIDE resources and related tools since the previous update manuscript was published in Nucleic Acids Research in 2016.  In the last 3 years, public data sharing through PRIDE (as part of PX) has definitely become the norm in the field.  In parallel, data re-use of public proteomics data has increased enormously, with multiple applications.  We first describe the new architecture of PRIDE Archive, the archival component of PRIDE.  PRIDE Archive and the related data submission framework have been further developed to support the increase in submitted data vols. and addnl. data types.  A new scalable and fault tolerant storage backed, Application Programming Interface and web interface have been implemented, as a part of an ongoing process.  Addnl., we emphasize the improved support for quant. proteomics data through the mzTab format.  At last, we outline key statistics on the current data contents and vol. of downloads, and how PRIDE data are starting to be disseminated to added-value resources including Ensembl, UniProt and Expression Atlas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0A73vO-W9E7Vg90H21EOLACvtfcHk0lgK2po-RXvzoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1GqtrzK&md5=4cd0f929c2df840a5cc0631d0d708d6c</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgky1106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgky1106%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Riverol%26aufirst%3DY.%26aulast%3DCsordas%26aufirst%3DA.%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DBernal-Llinares%26aufirst%3DM.%26aulast%3DHewapathirana%26aufirst%3DS.%26aulast%3DKundu%26aufirst%3DD.%2BJ.%26aulast%3DInuganti%26aufirst%3DA.%26aulast%3DGriss%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DG.%26aulast%3DEisenacher%26aufirst%3DM.%26aulast%3DP%25C3%25A9rez%26aufirst%3DE.%26aulast%3DUszkoreit%26aufirst%3DJ.%26aulast%3DPfeuffer%26aufirst%3DJ.%26aulast%3DSachsenberg%26aufirst%3DT.%26aulast%3DYilmaz%26aufirst%3DS.%26aulast%3DTiwary%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DJ.%26aulast%3DAudain%26aufirst%3DE.%26aulast%3DWalzer%26aufirst%3DM.%26aulast%3DJarnuczak%26aufirst%3DA.%2BF.%26aulast%3DTernent%26aufirst%3DT.%26aulast%3DBrazma%26aufirst%3DA.%26aulast%3DVizca%25C3%25ADno%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520PRIDE%2520database%2520and%2520related%2520tools%2520and%2520resources%2520in%25202019%253A%2520Improving%2520support%2520for%2520quantification%2520data%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2019%26volume%3D47%26spage%3DD442%26epage%3DD450%26doi%3D10.1093%2Fnar%2Fgky1106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredrickson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derynck, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span> <span> </span><span class="NLM_article-title">First-in-human Phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">77</span>â <span class="NLM_lpage">86</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-0947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F1078-0432.CCR-14-0947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25370471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis12ltw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=77-86&author=D.+Sarkerauthor=J.+E.+Angauthor=R.+Bairdauthor=R.+Kristeleitauthor=K.+Shahauthor=V.+Morenoauthor=P.+A.+Clarkeauthor=F.+I.+Raynaudauthor=G.+Levyauthor=J.+A.+Wareauthor=K.+Mazinaauthor=R.+Linauthor=J.+Wuauthor=J.+Fredricksonauthor=J.+M.+Spoerkeauthor=M.+R.+Lacknerauthor=Y.+Yanauthor=L.+S.+Friedmanauthor=S.+B.+Kayeauthor=M.+K.+Derynckauthor=P.+Workmanauthor=J.+S.+de+Bono&title=First-in-human+Phase+I+study+of+pictilisib+%28GDC-0941%29%2C+a+potent+pan-class+I+phosphatidylinositol-3-kinase+%28PI3K%29+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-14-0947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Sarker, Debashis; Ang, Joo Ern; Baird, Richard; Kristeleit, Rebecca; Shah, Krunal; Moreno, Victor; Clarke, Paul A.; Raynaud, Florence I.; Levy, Gallia; Ware, Joseph A.; Mazina, Kathryn; Lin, Ray; Wu, Jenny; Fredrickson, Jill; Spoerke, Jill M.; Lackner, Mark R.; Yan, Yibing; Friedman, Lori S.; Kaye, Stan B.; Derynck, Mika K.; Workman, Paul; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-86</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clin. activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K).  Patients and Methods: Sixty patients with solid tumors received pictilisib at 14 dose levels from 15 to 450 mg once-daily, initially on days 1 to 21 every 28 days and later, using continuous dosing for selected dose levels.  Pharmacodynamic studies incorporated 18F-FDG-PET, and assessment of phosphorylated AKT and S6 ribosomal protein in platelet-rich plasma (PRP) and tumor tissue.  Results: Pictilisib was well tolerated.  The most common toxicities were grade 1-2 nausea, rash, and fatigue, whereas the DLT was grade 3 maculopapular rash (450 mg, 2 of 3 patients; 330 mg, 1 of 7 patients).  The pharmacokinetic profile was dose-proportional and supported once-daily dosing.  Levels of phosphorylated serine-473 AKT were suppressed >90% in PRP at 3 h after dose at the MTD and in tumor at pictilisib doses assocd. with AUC >20 hÂ·Î¼mol/L.  Significant increase in plasma insulin and glucose levels, and >25% decrease in 18F-FDG uptake by PET in 7 of 32 evaluable patients confirmed target modulation.  A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, resp.  Conclusion: Pictilisib was safely administered with a dose-proportional pharmacokinetic profile, on-target pharmacodynamic activity at dose levels â¥100 mg and signs of antitumor activity.  The recommended phase II dose was continuous dosing at 330 mg once-daily.  Clin Cancer Res; 21(1); 77-86. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw-xdpJi9RV7Vg90H21EOLACvtfcHk0lgK2po-RXvzoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis12ltw%253D%253D&md5=35d52a025e34f4f13844b2721014aca3</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0947%26sid%3Dliteratum%253Aachs%26aulast%3DSarker%26aufirst%3DD.%26aulast%3DAng%26aufirst%3DJ.%2BE.%26aulast%3DBaird%26aufirst%3DR.%26aulast%3DKristeleit%26aufirst%3DR.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DLevy%26aufirst%3DG.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DMazina%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DFredrickson%26aufirst%3DJ.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DDerynck%26aufirst%3DM.%2BK.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DFirst-in-human%2520Phase%2520I%2520study%2520of%2520pictilisib%2520%2528GDC-0941%2529%252C%2520a%2520potent%2520pan-class%2520I%2520phosphatidylinositol-3-kinase%2520%2528PI3K%2529%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D77%26epage%3D86%26doi%3D10.1158%2F1078-0432.CCR-14-0947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">301</span>â <span class="NLM_lpage">305</span>, <span class="refDoi">Â DOI: 10.1038/35060098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2F35060098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11231581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=301-305&author=S.+Pleschkaauthor=T.+Wolffauthor=C.+Ehrhardtauthor=G.+Hobomauthor=O.+Planzauthor=U.+R.+Rappauthor=S.+Ludwig&title=Influenza+virus+propagation+is+impaired+by+inhibition+of+the+Raf%2FMEK%2FERK+signalling+cascade&doi=10.1038%2F35060098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span></div><div class="casAuthors">Pleschka, Stephan; Wolff, Thorsten; Ehrhard, Christina; Hobom, Gerd; Planz, Oliver; Rapp, Ulf R.; Ludwig, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-305</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Influenza A viruses are important worldwide pathogens in humans and different animal species.  The functions of most of the ten different viral proteins of this neg.-strand RNA virus have been well elucidated.  However, little is known about the virus-induced intracellular signalling events that support viral replication.  The Raf/MEK/ERK cascade is the prototype of mitogen-activated protein (MAP) kinase cascades and has an important role in cell growth, differentiation and survival.  Investigation of the function of this pathway has been facilitated by the identification of specific inhibitors, such as U0126, which blocks the cascade at the level of MAPK/ERK kinase (MEK).  Here, the authors show that infection of cells with influenza A virus leads to biphasic activation of the Raf/MEK/ERK cascade.  Inhibition of Raf signalling results in nuclear retention of viral ribonucleoprotein complexes (RNPs), impaired function of the nuclear-export protein (NEP/NS2) and concomitant inhibition of virus prodn.  Thus, signalling through the mitogenic cascade seems to be essential for virus prodn. and RNP export from the nucleus during the viral life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx1KgfMDKJPLVg90H21EOLACvtfcHk0lhIOBgjS2Bc9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D&md5=b5283932b9d29e474583d8dfa0ec5658</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2F35060098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35060098%26sid%3Dliteratum%253Aachs%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DHobom%26aufirst%3DG.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DInfluenza%2520virus%2520propagation%2520is%2520impaired%2520by%2520inhibition%2520of%2520the%2520Raf%252FMEK%252FERK%2520signalling%2520cascade%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D301%26epage%3D305%26doi%3D10.1038%2F35060098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span> <span> </span><span class="NLM_article-title">The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">142</span>â <span class="NLM_lpage">150</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2017.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2017.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28390872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXms1CgtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2017&pages=142-150&author=T.+Venkataramanauthor=M.+B.+Frieman&title=The+role+of+epidermal+growth+factor+receptor+%28EGFR%29+signaling+in+SARS+coronavirus-induced+pulmonary+fibrosis&doi=10.1016%2Fj.antiviral.2017.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis</span></div><div class="casAuthors">Venkataraman, Thiagarajan; Frieman, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">142-150</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Many survivors of the 2003 outbreak of severe acute respiratory syndrome (SARS) developed residual pulmonary fibrosis with increased severity seen in older patients.  Autopsies of patients that died from SARS also showed fibrosis to varying extents.  Pulmonary fibrosis can be occasionally seen as a consequence to several respiratory viral infections but is much more common after a SARS coronavirus (SARS-CoV) infection.  Given the threat of future outbreaks of severe coronavirus disease, including Middle East respiratory syndrome (MERS), it is important to understand the mechanisms responsible for pulmonary fibrosis, so as to support the development of therapeutic countermeasures and mitigate sequelae of infection.  In this article, we summarize pulmonary fibrotic changes obsd. after a SARS-CoV infection, discuss the extent to which other respiratory viruses induce fibrosis, describe available animal models to study the development of SARS-CoV induced fibrosis and review evidence that pulmonary fibrosis is caused by a hyperactive host response to lung injury mediated by epidermal growth factor receptor (EGFR) signaling.  We summarize work from our group and others indicating that inhibiting EGFR signaling may prevent an excessive fibrotic response to SARS-CoV and other respiratory viral infections and propose directions for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk0X-F-YtUyLVg90H21EOLACvtfcHk0lhIOBgjS2Bc9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXms1CgtLs%253D&md5=35c10a0d15c558719b6a5389621984cc</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2017.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2017.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DVenkataraman%26aufirst%3DT.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26atitle%3DThe%2520role%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520signaling%2520in%2520SARS%2520coronavirus-induced%2520pulmonary%2520fibrosis%26jtitle%3DAntiviral%2520Res.%26date%3D2017%26volume%3D143%26spage%3D142%26epage%3D150%26doi%3D10.1016%2Fj.antiviral.2017.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M.</span></span> <span> </span><span class="NLM_article-title">Overactive EGFR signaling leads to increased fibrosis after SARS-CoV infection</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>, <span class="NLM_elocation-id">e00182-17</span> <span class="refDoi">Â DOI: 10.1128/JVI.00182-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.00182-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28404843" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&author=T.+Venkataramanauthor=C.+Colemanauthor=M.+Frieman&title=Overactive+EGFR+signaling+leads+to+increased+fibrosis+after+SARS-CoV+infection&doi=10.1128%2FJVI.00182-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1128%2FJVI.00182-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00182-17%26sid%3Dliteratum%253Aachs%26aulast%3DVenkataraman%26aufirst%3DT.%26aulast%3DColeman%26aufirst%3DC.%26aulast%3DFrieman%26aufirst%3DM.%26atitle%3DOveractive%2520EGFR%2520signaling%2520leads%2520to%2520increased%2520fibrosis%2520after%2520SARS-CoV%2520infection%26jtitle%3DJ.%2520Virol.%26date%3D2017%26volume%3D91%26doi%3D10.1128%2FJVI.00182-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchkovich, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alwine, J. C.</span></span> <span> </span><span class="NLM_article-title">The TORrid affairs of viruses: Effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">266</span>â <span class="NLM_lpage">275</span>, <span class="refDoi">Â DOI: 10.1038/nrmicro1855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnrmicro1855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18311165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BD1c7otVSnug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=266-275&author=N.+J.+Buchkovichauthor=Y.+Yuauthor=C.+A.+Zampieriauthor=J.+C.+Alwine&title=The+TORrid+affairs+of+viruses%3A+Effects+of+mammalian+DNA+viruses+on+the+PI3K-Akt-mTOR+signalling+pathway&doi=10.1038%2Fnrmicro1855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway</span></div><div class="casAuthors">Buchkovich Nicholas J; Yu Yongjun; Zampieri Carisa A; Alwine James C</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Microbiology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">266-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The successful replication of mammalian DNA viruses requires that they gain control of key cellular signalling pathways that affect broad aspects of cellular macromolecular synthesis, metabolism, growth and survival.  The phosphatidylinositol 3'-kinase-Akt-mammalian target of rapamycin (PI3K-Akt-mTOR) pathway is one such pathway.  Mammalian DNA viruses have evolved various mechanisms to activate this pathway to obtain the benefits of Akt activation, including the maintenance of translation through the activation of mTOR.  In addition, viruses must overcome the inhibition of this pathway that results from the activation of cellular stress responses during viral infection.  This Review will discuss the range of mechanisms that mammalian DNA viruses use to activate this pathway, as well as the multiple mechanisms these viruses have evolved to circumvent inhibitory stress signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAa934cv2xBL5oR8RchjrrfW6udTcc2ebVru5l1WLIRrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c7otVSnug%253D%253D&md5=475493e501e37ca759dfeb95290db1fb</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro1855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro1855%26sid%3Dliteratum%253Aachs%26aulast%3DBuchkovich%26aufirst%3DN.%2BJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZampieri%26aufirst%3DC.%2BA.%26aulast%3DAlwine%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520TORrid%2520affairs%2520of%2520viruses%253A%2520Effects%2520of%2520mammalian%2520DNA%2520viruses%2520on%2520the%2520PI3K-Akt-mTOR%2520signalling%2520pathway%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2008%26volume%3D6%26spage%3D266%26epage%3D275%26doi%3D10.1038%2Fnrmicro1855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MannovÃ¡, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beretta, L.</span></span> <span> </span><span class="NLM_article-title">Activation of the N-Ras- PI3K-Akt-mTOR pathway by hepatitis C virus: Control of cell survival and viral replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">8742</span>â <span class="NLM_lpage">8749</span>, <span class="refDoi">Â DOI: 10.1128/JVI.79.14.8742-8749.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.79.14.8742-8749.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=15994768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFOjsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=8742-8749&author=P.+Mannov%C3%A1author=L.+Beretta&title=Activation+of+the+N-Ras-+PI3K-Akt-mTOR+pathway+by+hepatitis+C+virus%3A+Control+of+cell+survival+and+viral+replication&doi=10.1128%2FJVI.79.14.8742-8749.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: Control of cell survival and viral replication</span></div><div class="casAuthors">Mannova, Petra; Beretta, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">8742-8749</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) replication complex is localized within detergent-resistant membranes or lipid rafts.  We analyzed the protein contents of detergent-resistant fractions isolated from Huh7 cells expressing a self-replicating full-length HCV-1b genome.  Using two-dimensional gel electrophoresis followed by mass spectrometry, we identified N-Ras as one of the proteins in which expression was increased in the detergent-resistant fractions from HCV genomic replicon clones compared to control cells.  N-Ras is an activator of the phosphatidylinositol-3-kinase (PI3K)-Akt pathway.  We found that the activities of PI3K and Akt, as well as the activity of their downstream target, mTOR, in the HCV-replicating cells were increased.  Both PI3K-Akt- and mTOR-dependent pathways have been shown to promote cell survival.  In agreement with this, HCV replicon cells were resistant to serum starvation-induced apoptosis.  We also characterized the role of this pathway in HCV replication.  Redn. of N-Ras expression by transfection of N-Ras small interfering RNA (siRNA) resulted in increased replication of HCV.  We obsd. a similar increase in HCV replication in cells treated with the PI3K inhibitor LY294002 and in cells transfected with mTOR siRNA.  Taken together, these data suggest that increased N-Ras levels in subcellular sites of HCV replication and stimulation of the prosurvival PI3K-Akt pathway and mTOR by HCV not only protect cells against apoptosis but also contribute to the maintenance of steady-state levels of HCV replication.  These effects may contribute to the establishment of persistent infection by HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqga8XFsHx6mrVg90H21EOLACvtfcHk0lg_DnBBIs6hMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFOjsrs%253D&md5=123bb247229b7f4c984fbf59fb446183</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.14.8742-8749.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.14.8742-8749.2005%26sid%3Dliteratum%253Aachs%26aulast%3DMannov%25C3%25A1%26aufirst%3DP.%26aulast%3DBeretta%26aufirst%3DL.%26atitle%3DActivation%2520of%2520the%2520N-Ras-%2520PI3K-Akt-mTOR%2520pathway%2520by%2520hepatitis%2520C%2520virus%253A%2520Control%2520of%2520cell%2520survival%2520and%2520viral%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D8742%26epage%3D8749%26doi%3D10.1128%2FJVI.79.14.8742-8749.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shives, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beatman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobson-Peters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckham, J. D.</span></span> <span> </span><span class="NLM_article-title">West Nile virus induced activation of mammalian target of rapamycin complex 1 supports viral growth and viral protein expression</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">9458</span>â <span class="NLM_lpage">9471</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01323-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01323-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24920798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1arurnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=9458-9471&author=K.+D.+Shivesauthor=E.+L.+Beatmanauthor=M.+Chamanianauthor=C.+O%E2%80%99Brienauthor=J.+Hobson-Petersauthor=J.+D.+Beckham&title=West+Nile+virus+induced+activation+of+mammalian+target+of+rapamycin+complex+1+supports+viral+growth+and+viral+protein+expression&doi=10.1128%2FJVI.01323-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">West Nile virus-induced activation of mammalian target of rapamycin complex 1 supports viral growth and viral protein expression</span></div><div class="casAuthors">Shives, Katherine D.; Beatman, Erica L.; Chamanian, Mastooreh; O'Brien, Caitlin; Hobson-Peters, Jody; Beckham, J. David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">9458-9471, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Since its introduction in New York City, NY, in 1999, West Nile virus (WNV) has spread to all 48 contiguous states of the United States and is now the leading cause of epidemic encephalitis in North America.  As a member of the family Flaviviridae, WNV is part of a group of clin. important human pathogens, including dengue virus and Japanese encephalitis virus.  The members of this family of pos.-sense, single-stranded RNA viruses have limited coding capacity and are therefore obligated to co-opt a significant amt. of cellular factors to translate their genomes effectively.  Our previous work has shown that WNV growth was independent of macroautophagy activation, but the role of the evolutionarily conserved mammalian target of rapamycin (mTOR) pathway during WNV infection was not well understood.  MTOR is a serine/threonine kinase that acts as a central cellular censor of nutrient status and exercises control of vital anabolic and catabolic cellular responses such as protein synthesis and autophagy, resp.  We now show that WNV activates mTOR and cognate downstream activators of cap-dependent protein synthesis at early time points postinfection and that pharmacol. inhibition of mTOR (KU0063794) significantly reduced WNV growth.  We used an inducible Raptor and Rictor knockout mouse embryonic fibroblast (MEF) system to further define the role of mTOR complexes 1 and 2 in WNV growth and viral protein synthesis.  Following inducible genetic knockout of the major mTOR cofactors raptor (TOR complex 1 [TORC1]) and rictor (TORC2), we now show that TORC1 supports flavivirus protein synthesis via cap-dependent protein synthesis pathways and supports subsequent WNV growth.  Importance: Since its introduction in New York City, NY, in 1999, West Nile virus (WNV) has spread to all 48 contiguous states in the United States and is now the leading cause of epidemic encephalitis in North America.  Currently, the mechanism by which flaviviruses such as WNV translate their genomes in host cells is incompletely understood.  Elucidation of the host mechanisms required to support WNV genome translation will provide broad understanding for the basic mechanisms required to translate capped viral RNAs.  We now show that WNV activates mTOR and cognate downstream activators of cap-dependent protein synthesis at early time points postinfection.  Following inducible genetic knockout of the major mTOR complex cofactors raptor (TORC1) and rictor (TORC2), we now show that TORC1 supports WNV growth and protein synthesis.  This study demonstrates the requirement for TORC1 function in support of WNV RNA translation and provides insight into the mechanisms underlying flaviviral RNA translation in mammalian cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOdvHUWOxCc7Vg90H21EOLACvtfcHk0lg_DnBBIs6hMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1arurnK&md5=48f1230ec6ba03689774e53f475c6062</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1128%2FJVI.01323-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01323-14%26sid%3Dliteratum%253Aachs%26aulast%3DShives%26aufirst%3DK.%2BD.%26aulast%3DBeatman%26aufirst%3DE.%2BL.%26aulast%3DChamanian%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DHobson-Peters%26aufirst%3DJ.%26aulast%3DBeckham%26aufirst%3DJ.%2BD.%26atitle%3DWest%2520Nile%2520virus%2520induced%2520activation%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520complex%25201%2520supports%2520viral%2520growth%2520and%2520viral%2520protein%2520expression%26jtitle%3DJ.%2520Virol.%26date%3D2014%26volume%3D88%26spage%3D9458%26epage%3D9471%26doi%3D10.1128%2FJVI.01323-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lurain, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedmak, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, A. S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide</span>. <i>Intervirology</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">412</span>â <span class="NLM_lpage">418</span>, <span class="refDoi">Â DOI: 10.1159/000053979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1159%2F000053979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVKisLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2000&pages=412-418&author=W.+J.+Waldmanauthor=D.+A.+Knightauthor=L.+Blinderauthor=J.+Shenauthor=N.+S.+Lurainauthor=D.+M.+Millerauthor=D.+D.+Sedmakauthor=J.+W.+Williamsauthor=A.+S.+Chong&title=Inhibition+of+cytomegalovirus+in+vitro+and+in+vivo+by+the+experimental+immunosuppressive+agent+leflunomide&doi=10.1159%2F000053979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide</span></div><div class="casAuthors">Waldman, W. James; Knight, Deborah A.; Blinder, Leonard; Shen, JiKun; Lurain, Nell S.; Miller, Daniel M.; Sedmak, Daniel D.; Williams, James W.; Chong, Anita S.-F.</div><div class="citationInfo"><span class="NLM_cas:title">Intervirology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">412-418</span>CODEN:
                <span class="NLM_cas:coden">IVRYAK</span>;
        ISSN:<span class="NLM_cas:issn">0300-5526</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Despite progress in antiviral chemotherapy, cytomegalovirus (CMV) remains a major cause of morbidity and mortality among pharmacol. immunosuppressed transplant recipients, frequently engaging the clinician in a struggle to balance graft preservation with control of CMV disease.  Leflunomide, an inhibitor of protein kinase activity and pyrimidine synthesis, is an exptl. immunosuppressive agent effective against acute and chronic rejection in animal models.  Herein we summarize our recent studies demonstrating that leflunomide inhibits the prodn. of multiple clin. CMV isolates (including multi-drug-resistant virus) in both human fibroblasts and endothelial cells.  In contrast to all other anti-CMV drugs currently in use, leflunomide does not inhibit viral DNA synthesis, but rather appears to interfere with virion assembly.  Finally, preliminary studies in a rat model suggest that this agent reduces viral load in vivo.  These findings imply that leflunomide, an effective immunosuppressive agent, shows potential to concurrently attenuate a major complication of immunosuppression, CMV disease, by a novel mechanism of antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolSzgyco_QqrVg90H21EOLACvtfcHk0lhtFxwbXcUUcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVKisLk%253D&md5=e2fa6f422349ef0f74d13194a944c239</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1159%2F000053979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000053979%26sid%3Dliteratum%253Aachs%26aulast%3DWaldman%26aufirst%3DW.%2BJ.%26aulast%3DKnight%26aufirst%3DD.%2BA.%26aulast%3DBlinder%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLurain%26aufirst%3DN.%2BS.%26aulast%3DMiller%26aufirst%3DD.%2BM.%26aulast%3DSedmak%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DJ.%2BW.%26aulast%3DChong%26aufirst%3DA.%2BS.%26atitle%3DInhibition%2520of%2520cytomegalovirus%2520in%2520vitro%2520and%2520in%2520vivo%2520by%2520the%2520experimental%2520immunosuppressive%2520agent%2520leflunomide%26jtitle%3DIntervirology%26date%3D2000%26volume%3D42%26spage%3D412%26epage%3D418%26doi%3D10.1159%2F000053979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Vincent, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacasse, J. J.</span></span> <span> </span><span class="NLM_article-title">Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs</span>. <i>Antivir. Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">293</span>â <span class="NLM_lpage">320</span>, <span class="refDoi">Â DOI: 10.1177/095632020601700601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1177%2F095632020601700601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17249245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1CktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=293-320&author=L.+M.+Schangauthor=M.+R.+St.+Vincentauthor=J.+J.+Lacasse&title=Five+years+of+progress+on+cyclin-dependent+kinases+and+other+cellular+proteins+as+potential+targets+for+antiviral+drugs&doi=10.1177%2F095632020601700601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs</span></div><div class="casAuthors">Schang, Luis M.; St. Vincent, Mireille R.; Lacasse, Jonathan J.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">293-320</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press, Ltd.</span>)
        </div><div class="casAbstract">A review.  In 1997-1998, the pharmacol. cyclin-dependent kinase (CDK) inhibitors (PCIs) were independently discovered to inhibit replication of human cytomegalovirus, herpes simplex virus type 1 and HIV-1.  The results from small clin. trials against cancer were then suggesting that PCIs could be safe enough to be used clin.  It was thus hypothesized that PCIs could have the potential to be developed as novel antivirals targeting cellular proteins.  Consequently, Antiviral Chem. & Chemotherapy published in 2001 the first review on the potential of CDKs, and cellular proteins in general, as potential targets for antivirals.  The viral functions inhibited by PCIs, or their cellular targets, were then just starting to be characterized.  The antiviral spectrum of PCIs and their effects on viral disease were still mostly untested.  Even their actual specificity was not yet completely characterized.  In addn., cellular proteins were not accepted as valid targets for antivirals.  Significant progress has been made in the last 5 years in understanding the antiviral activities of PCIs and the potential roles of cellular proteins in general as targets for antivirals.  The first clin. trials of the antiviral activities of PCIs and other inhibitors of cellular protein kinases have now been scheduled.  Herein, we review the progress made since the publication of the first review on PCIs as potential antiviral drugs and on CDKs, and cellular proteins in general, as potential targets for antiviral drugs.  We also highlight the major issues that still need to be addressed before PCIs or other drugs targeting cellular proteins can be developed as clin. antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrVdUG1WNgiLVg90H21EOLACvtfcHk0lhtFxwbXcUUcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1CktA%253D%253D&md5=df2f56161599faf496637f3259c7f605</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1177%2F095632020601700601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020601700601%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26aulast%3DSt.%2BVincent%26aufirst%3DM.%2BR.%26aulast%3DLacasse%26aufirst%3DJ.%2BJ.%26atitle%3DFive%2520years%2520of%2520progress%2520on%2520cyclin-dependent%2520kinases%2520and%2520other%2520cellular%2520proteins%2520as%2520potential%2520targets%2520for%2520antiviral%2520drugs%26jtitle%3DAntivir.%2520Chem.%2520Chemother.%26date%3D2006%26volume%3D17%26spage%3D293%26epage%3D320%26doi%3D10.1177%2F095632020601700601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">NÃ©meth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greff, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bencze, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SzÃ¡ntai-Kis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baska, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyuris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelemenics, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SzathmÃ¡ry, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MinÃ¡rovits, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KÃ©ri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfi, L.</span></span> <span> </span><span class="NLM_article-title">Novel, selective CDK9 inhibitors for the treatment of HIV infection</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">342</span>â <span class="NLM_lpage">358</span>, <span class="refDoi">Â DOI: 10.2174/092986711794839188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.2174%2F092986711794839188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=21143121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslahtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=342-358&author=G.+N%C3%A9methauthor=Z.+Vargaauthor=Z.+Greffauthor=G.+Benczeauthor=A.+Siposauthor=C.+Sz%C3%A1ntai-Kisauthor=F.+Baskaauthor=A.+Gyurisauthor=K.+Kelemenicsauthor=Z.+Szathm%C3%A1ryauthor=J.+Min%C3%A1rovitsauthor=G.+K%C3%A9riauthor=L.+Orfi&title=Novel%2C+selective+CDK9+inhibitors+for+the+treatment+of+HIV+infection&doi=10.2174%2F092986711794839188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, selective CDK9 inhibitors for the treatment of HIV infection</span></div><div class="casAuthors">Nemeth, G.; Varga, Z.; Greff, Z.; Bencze, G.; Sipos, A.; Szantai-Kis, C.; Baska, F.; Gyuris, A.; Kelemenics, K.; Szathmary, Z.; Minarovits, J.; Keri, G.; Orfi, L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">342-358</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclin Dependent Kinases (CDKs) are important regulators of cell cycle and gene expression.  Since an up-to-date review about the pharmacol. inhibitors of CDK family (CDK1-10) is not available; therefore in the present paper we briefly summarize the most relevant inhibitors and point out the low no. of selective inhibitors.  Among CDKs, CDK9 is a validated pathol. target in HIV infection, inflammation and cardiac hypertrophy; however selective CDK9 inhibitors are still not available.  We present a selective inhibitor family of CDK9 based on the 4-phenylamino-6-phenylpyrimidine nucleus.  We show a convenient synthetic method to prep. a useful intermediate and its derivatisation resulting in novel compds.  The CDK9 inhibitory activity of the derivs. was measured in specific kinase assay and the CDK inhibitory profile of the best ones (IC50 < 100nM) was detd.  The most selective compds. had high selectivity over CDK1, 2, 3, 5, 6, 7 and showed at least one order of magnitude higher inhibitory activity over CDK4 inhibition.  The most selective mols. were examd. in cytotoxicity assays and their ability to inhibit HIV-1 replication was detd. in cellular assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-AaopHRq0S7Vg90H21EOLACvtfcHk0ljiLxPQM7Vgjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslahtr4%253D&md5=2777a90d212ded68b2399beb97d48531</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.2174%2F092986711794839188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794839188%26sid%3Dliteratum%253Aachs%26aulast%3DN%25C3%25A9meth%26aufirst%3DG.%26aulast%3DVarga%26aufirst%3DZ.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DBencze%26aufirst%3DG.%26aulast%3DSipos%26aufirst%3DA.%26aulast%3DSz%25C3%25A1ntai-Kis%26aufirst%3DC.%26aulast%3DBaska%26aufirst%3DF.%26aulast%3DGyuris%26aufirst%3DA.%26aulast%3DKelemenics%26aufirst%3DK.%26aulast%3DSzathm%25C3%25A1ry%26aufirst%3DZ.%26aulast%3DMin%25C3%25A1rovits%26aufirst%3DJ.%26aulast%3DK%25C3%25A9ri%26aufirst%3DG.%26aulast%3DOrfi%26aufirst%3DL.%26atitle%3DNovel%252C%2520selective%2520CDK9%2520inhibitors%2520for%2520the%2520treatment%2520of%2520HIV%2520infection%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D342%26epage%3D358%26doi%3D10.2174%2F092986711794839188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Permanyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gubern, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-MuÃ±oz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mothe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MenÃ©ndez-Arias, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">EstÃ©, J. A.</span></span> <span> </span><span class="NLM_article-title">Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">1988</span>â <span class="NLM_lpage">1997</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1400873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.4049%2Fjimmunol.1400873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25015816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Kju7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2014&pages=1988-1997&author=E.+Paulsauthor=A.+Ruizauthor=R.+Badiaauthor=M.+Permanyerauthor=A.+Gubernauthor=E.+Riveira-Mu%C3%B1ozauthor=J.+Torres-Torronterasauthor=M.+Alvarezauthor=B.+Motheauthor=C.+Branderauthor=M.+Crespoauthor=L.+Men%C3%A9ndez-Ariasauthor=B.+Clotetauthor=O.+T.+Kepplerauthor=R.+Mart%C3%ADauthor=F.+Posasauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Cell+cycle+control+and+HIV-1+susceptibility+are+linked+by+CDK6-dependent+CDK2+phosphorylation+of+SAMHD1+in+myeloid+and+lymphoid+cells&doi=10.4049%2Fjimmunol.1400873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Cell Cycle Control and HIV-1 Susceptibility Are Linked by CDK6-Dependent CDK2 Phosphorylation of SAMHD1 in Myeloid and Lymphoid Cells</span></div><div class="casAuthors">Pauls, Eduardo; Ruiz, Alba; Badia, Roger; Permanyer, Marc; Gubern, Albert; Riveira-Munoz, Eva; Torres-Torronteras, Javier; Alvarez, Mar; Mothe, Beatriz; Brander, Christian; Crespo, Manel; Menendez-Arias, Luis; Clotet, Bonaventura; Keppler, Oliver T.; Marti, Ramon; Posas, Francesc; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1988-1997</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Proliferating cells are preferentially susceptible to infection by retroviruses.  Sterile Î± motif and HD domain-contg. protein-1 (SAMHD1) is a recently described deoxynucleotide phosphohydrolase controlling the size of the intracellular deoxynucleotide triphosphate (dNTP) pool, a limiting factor for retroviral reverse transcription in noncycling cells.  Proliferating (Ki67+) primary CD4+ T cells or macrophages express a phosphorylated form of SAMHD1 that corresponds with susceptibility to infection in cell culture.  We identified cyclin-dependent kinase (CDK) 6 as an upstream regulator of CDK2 controlling SAMHD1 phosphorylation in primary T cells and macrophages susceptible to infection by HIV-1.  In turn, CDK2 was strongly linked to cell cycle progression and coordinated SAMHD1 phosphorylation and inactivation.  CDK inhibitors specifically blocked HIV-1 infection at the reverse transcription step in a SAMHD1-dependent manner, reducing the intracellular dNTP pool.  Our findings identify a direct relationship between control of the cell cycle by CDK6 and SAMHD1 activity, which is important for replication of lentiviruses, as well as other viruses whose replication may be regulated by intracellular dNTP availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-LI-z2ggFCbVg90H21EOLACvtfcHk0ljiLxPQM7Vgjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Kju7%252FM&md5=5c1c895a20f64ad71e0578ea2fca74bf</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1400873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1400873%26sid%3Dliteratum%253Aachs%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DPermanyer%26aufirst%3DM.%26aulast%3DGubern%26aufirst%3DA.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3DAlvarez%26aufirst%3DM.%26aulast%3DMothe%26aufirst%3DB.%26aulast%3DBrander%26aufirst%3DC.%26aulast%3DCrespo%26aufirst%3DM.%26aulast%3DMen%25C3%25A9ndez-Arias%26aufirst%3DL.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DKeppler%26aufirst%3DO.%2BT.%26aulast%3DMart%25C3%25AD%26aufirst%3DR.%26aulast%3DPosas%26aufirst%3DF.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DCell%2520cycle%2520control%2520and%2520HIV-1%2520susceptibility%2520are%2520linked%2520by%2520CDK6-dependent%2520CDK2%2520phosphorylation%2520of%2520SAMHD1%2520in%2520myeloid%2520and%2520lymphoid%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D193%26spage%3D1988%26epage%3D1997%26doi%3D10.4049%2Fjimmunol.1400873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durand, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roizman, B.</span></span> <span> </span><span class="NLM_article-title">Role of CDK9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">10591</span>â <span class="NLM_lpage">10599</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01242-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01242-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18753202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWitbbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=10591-10599&author=L.+O.+Durandauthor=B.+Roizman&title=Role+of+CDK9+in+the+optimization+of+expression+of+the+genes+regulated+by+ICP22+of+herpes+simplex+virus+1&doi=10.1128%2FJVI.01242-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1</span></div><div class="casAuthors">Durand, Lizette Olga; Roizman, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">10591-10599</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">ICP22 is a multi-functional herpes simplex virus 1 (HSV-1) regulatory protein that regulates the accumulation of a subset of late (Î³2) proteins exemplified by UL38, UL41, and US11.  ICP22 binds the cyclin-dependent kinase 9 (cdk9) but not cdk7, and this complex in conjunction with viral protein kinases phosphorylates the carboxyl terminus of RNA polymerase II (Pol II) in vitro.  The primary function of cdk9 and its partners, the cyclin T variants, is in the elongation of RNA transcripts, although functions related to the initiation and processing of transcripts have also been reported.  We report two series of expts. designed to probe the role of cdk9 in infected cells.  In the first, infected cells were treated with 5,6-dichloro-1-Î²-D-ribofuranosylbenzimidazole (DRB), a specific inhibitor of cdk9.  In cells treated with DRB, the major effect was in the accumulation of viral RNAs and proteins regulated by ICP22.  The accumulation of Î±, Î², or Î³ proteins not regulated by ICP22 was not affected by the drug.  The results obtained with DRB were duplicated in cells transfected with small interfering RNA (siRNA) targeting cdk9 mRNAs.  Interestingly, DRB and siRNA reduced the levels of ICP22 but not those of other Î± gene products.  In addn., cdk9 and ICP22 appeared to colocalize with RNA Pol II in wild-type-virus-infected cells but not in ÎUL13-infected cells.  We conclude that cdk9 plays a crit. role in the optimization of expression of genes regulated by ICP22 and that one function of cdk9 in HSV-1-infected cells may be to bring ICP22 into the RNA Pol II transcriptional complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeXb1W_R979rVg90H21EOLACvtfcHk0ljiLxPQM7Vgjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWitbbF&md5=7a494e43fe778e3ad849facc21b13143</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1128%2FJVI.01242-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01242-08%26sid%3Dliteratum%253Aachs%26aulast%3DDurand%26aufirst%3DL.%2BO.%26aulast%3DRoizman%26aufirst%3DB.%26atitle%3DRole%2520of%2520CDK9%2520in%2520the%2520optimization%2520of%2520expression%2520of%2520the%2520genes%2520regulated%2520by%2520ICP22%2520of%2520herpes%2520simplex%2520virus%25201%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D10591%26epage%3D10599%26doi%3D10.1128%2FJVI.01242-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, P.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMasters, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. S.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for viral selective replication in cancer cells: Activation of CDK2 by adenovirus-induced cyclin E</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e57340</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0057340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.pone.0057340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=23437375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs12iuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=P.-H.+Chengauthor=X.-M.+Raoauthor=K.+M.+McMastersauthor=H.+S.+Zhou&title=Molecular+basis+for+viral+selective+replication+in+cancer+cells%3A+Activation+of+CDK2+by+adenovirus-induced+cyclin+E&doi=10.1371%2Fjournal.pone.0057340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for viral selective replication in cancer cells: activation of CDK2 by adenovirus-induced cyclin E</span></div><div class="casAuthors">Cheng, Pei-Hsin; Rao, Xiao-Mei; McMasters, Kelly M.; Zhou, Heshan Sam</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e57340</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Adenoviruses (Ads) with deletion of E1b55K preferentially replicate in cancer cells and have been used in cancer therapies.  We have previously shown that Ad E1B55K protein is involved in induction of cyclin E for Ad replication, but this E1B55K function is not required in cancer cells in which deregulation of cyclin E is frequently obsd.  In this study, we investigated the interaction of cyclin E and CDK2 in Ad-infected cells.  Ad infection significantly increased the large form of cyclin E (cyclin EL), promoted cyclin E/CDK2 complex formation and increased CDK2 phosphorylation at the T160 site.  Activated CDK2 caused pRb phosphorylation at the S612 site.  Repression of CDK2 activity with the chem. inhibitor roscovitine or with specific small interfering RNAs significantly decreased pRb phosphorylation, with concomitant repression of viral replication.  Our results suggest that Ad-induced cyclin E activates CDK2 that targets the transcriptional repressor pRb to generate a cellular environment for viral productive replication.  This study reveals a new mol. basis for oncolytic replication of E1b -deleted Ads and will aid in the development of new strategies for Ad oncolytic virotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL5pnNdzAc_rVg90H21EOLACvtfcHk0lhuewfdv4ybvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjs12iuro%253D&md5=0ec9e41cac8556097e62a1b2d48a144c</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0057340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0057340%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DP.-H.%26aulast%3DRao%26aufirst%3DX.-M.%26aulast%3DMcMasters%26aufirst%3DK.%2BM.%26aulast%3DZhou%26aufirst%3DH.%2BS.%26atitle%3DMolecular%2520basis%2520for%2520viral%2520selective%2520replication%2520in%2520cancer%2520cells%253A%2520Activation%2520of%2520CDK2%2520by%2520adenovirus-induced%2520cyclin%2520E%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0057340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gearhart, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchard, M. J.</span></span> <span> </span><span class="NLM_article-title">The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">2675</span>â <span class="NLM_lpage">2686</span>, <span class="refDoi">Â DOI: 10.1128/JVI.02196-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.02196-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20053744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC3c7itVOkuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=2675-2686&author=T.+L.+Gearhartauthor=M.+J.+Bouchard&title=The+hepatitis+B+virus+X+protein+modulates+hepatocyte+proliferation+pathways+to+stimulate+viral+replication&doi=10.1128%2FJVI.02196-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication</span></div><div class="casAuthors">Gearhart Tricia L; Bouchard Michael J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2675-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Worldwide, there are over 350 million people who are chronically infected with the human hepatitis B virus (HBV); chronic HBV infections are associated with the development of hepatocellular carcinoma (HCC).  The results of various studies suggest that the HBV X protein (HBx) has a role in the development of HBV-associated HCC.  HBx can regulate numerous cellular signal transduction pathways, including those that modulate cell proliferation.  Many previous studies that analyzed the impact of HBx on cell proliferation pathways were conducted using established or immortalized cell lines, and when HBx was expressed in the absence of HBV replication, and the precise effect of HBx on these pathways has often differed depending on experimental conditions.  We have studied the effect of HBx on cell proliferation in cultured primary rat hepatocytes, a biologically relevant system.  We demonstrate that HBx, both by itself and in the context of HBV replication, affected the levels and activities of various cell cycle-regulatory proteins to induce normally quiescent hepatocytes to enter the G(1) phase of the cell cycle but not to proceed to S phase.  We linked HBx regulation of cell proliferation to cytosolic calcium signaling and HBx stimulation of HBV replication.  Cumulatively, our studies suggest that HBx induces normally quiescent hepatocytes to enter the G(1) phase of the cell cycle and that this calcium-dependent HBx activity is required for HBV replication.  These studies identify an essential function of HBx during HBV replication and a mechanism that may connect HBV infections to the development of HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxzi0KmxFNAXwOGIfWJ7-GfW6udTcc2eZKyV7Fy5rCG7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7itVOkuw%253D%253D&md5=bd49db174e98c4111dc1cc4ef072bbdf</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1128%2FJVI.02196-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02196-09%26sid%3Dliteratum%253Aachs%26aulast%3DGearhart%26aufirst%3DT.%2BL.%26aulast%3DBouchard%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520hepatitis%2520B%2520virus%2520X%2520protein%2520modulates%2520hepatocyte%2520proliferation%2520pathways%2520to%2520stimulate%2520viral%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D2675%26epage%3D2686%26doi%3D10.1128%2FJVI.02196-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guendel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbottah, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human immunodeficiency virus type-1 by cdk inhibitors</span>. <i>AIDS Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7</span>, <span class="refDoi">Â DOI: 10.1186/1742-6405-7-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2F1742-6405-7-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20334651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC3c3ltFyntg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=7&author=I.+Guendelauthor=E.+T.+Agbottahauthor=K.+Kehn-Hallauthor=F.+Kashanchi&title=Inhibition+of+human+immunodeficiency+virus+type-1+by+cdk+inhibitors&doi=10.1186%2F1742-6405-7-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human immunodeficiency virus type-1 by cdk inhibitors</span></div><div class="casAuthors">Guendel Irene; Kashanchi Fatah; Guendel Irene; Kehn-Hall Kylene; Kashanchi Fatah; Agbottah Emmanuel T; Kashanchi Fatah</div><div class="citationInfo"><span class="NLM_cas:title">AIDS research and therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current therapy for human immunodeficiency virus (HIV-1) infection relies primarily on the administration of anti-retroviral nucleoside analogues, either alone or in combination with HIV-protease inhibitors.  Although these drugs have a clinical benefit, continuous therapy with the drugs leads to drug-resistant strains of the virus.  Recently, significant progress has been made towards the development of natural and synthetic agents that can directly inhibit HIV-1 replication or its essential enzymes.  We previously reported on the pharmacological cyclin-dependent kinase inhibitor (PCI) r-roscovitine as a potential inhibitor of HIV-1 replication.  PCIs are among the most promising novel antiviral agents to emerge over the past few years.  Potent activity on viral replication combined with proliferation inhibition without the emergence of resistant viruses, which are normally observed in HAART patients; make PCIs ideal candidates for HIV-1 inhibition.  To this end we evaluated twenty four cdk inhibitors for their effect on HIV-1 replication in vitro.  Screening of these compounds identified alsterpaullone as the most potent inhibitor of HIV-1 with activity at 150 nM.  We found that alsterpaullone effectively inhibits cdk2 activity in HIV-1 infected cells with a low IC50 compared to control uninfected cells.  The effects of alsterpaullone were associated with suppression of cdk2 and cyclin expression.  Combining both alsterpaullone and r-roscovitine (cyc202) in treatment exhibited even stronger inhibitory activities in HIV-1 infected PBMCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgNOPCu4WBGeb6AVA-44PTfW6udTcc2eZKyV7Fy5rCG7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3ltFyntg%253D%253D&md5=1abe0f1c81cf604ffd3ac7354e5b7d95</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1186%2F1742-6405-7-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-6405-7-7%26sid%3Dliteratum%253Aachs%26aulast%3DGuendel%26aufirst%3DI.%26aulast%3DAgbottah%26aufirst%3DE.%2BT.%26aulast%3DKehn-Hall%26aufirst%3DK.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520human%2520immunodeficiency%2520virus%2520type-1%2520by%2520cdk%2520inhibitors%26jtitle%3DAIDS%2520Res.%2520Ther.%26date%3D2010%26volume%3D7%26spage%3D7%26doi%3D10.1186%2F1742-6405-7-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marion, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterlin, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. H.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol inhibits P-TEFb and blocks HIV-1 replication</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">28345</span>â <span class="NLM_lpage">28348</span>, <span class="refDoi">Â DOI: 10.1074/jbc.C000446200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.C000446200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10906320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1Crtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=28345-28348&author=S.+H.+Chaoauthor=K.+Fujinagaauthor=J.+E.+Marionauthor=R.+Taubeauthor=E.+A.+Sausvilleauthor=A.+M.+Senderowiczauthor=B.+M.+Peterlinauthor=D.+H.+Price&title=Flavopiridol+inhibits+P-TEFb+and+blocks+HIV-1+replication&doi=10.1074%2Fjbc.C000446200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol inhibits P-TEFb and blocks HIV-1 replication</span></div><div class="casAuthors">Chao, Sheng-Hao; Fujinaga, Koh; Marion, Jon E.; Taube, Ran; Sausville, Edward A.; Senderowicz, Adrian M.; Peterlin, B. Matija; Price, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">28345-28348</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor that is in clin. trials as a cancer treatment because of its antiproliferative properties.  We found that the flavonoid potently inhibited transcription by RNA polymerase II in vitro by blocking the transition into productive elongation, a step controlled by P-TEFb.  The ability of P-TEFb to phosphorylate the carboxyl-terminal domain of the large subunit of RNA polymerase II was inhibited by flavopiridol with a Ki of 3 nM.  Interestingly, the drug was not competitive with ATP.  P-TEFb composed of Cdk9 and cyclin T1 is a required cellular cofactor for the human immunodeficiency virus (HIV-1) transactivator, Tat.  Consistent with its ability to inhibit P-TEFb, flavopiridol blocked Tat transactivation of the viral promoter in vitro.  Furthermore, flavopiridol blocked HIV-1 replication in both single-round and viral spread assays with an IC50 of less than 10 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmLtfeSo62BrVg90H21EOLACvtfcHk0lhuewfdv4ybvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1Crtbs%253D&md5=3458cf5e661acf6e5de7dd99bc8e8502</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C000446200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C000446200%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DS.%2BH.%26aulast%3DFujinaga%26aufirst%3DK.%26aulast%3DMarion%26aufirst%3DJ.%2BE.%26aulast%3DTaube%26aufirst%3DR.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DPeterlin%26aufirst%3DB.%2BM.%26aulast%3DPrice%26aufirst%3DD.%2BH.%26atitle%3DFlavopiridol%2520inhibits%2520P-TEFb%2520and%2520blocks%2520HIV-1%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D28345%26epage%3D28348%26doi%3D10.1074%2Fjbc.C000446200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perwitasari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, R. A.</span></span> <span> </span><span class="NLM_article-title">Repurposing kinase inhibitors as antiviral agents to control influenza A</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">638</span>â <span class="NLM_lpage">649</span>, <span class="refDoi">Â DOI: 10.1089/adt.2015.0003.drrr</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1089%2Fadt.2015.0003.drrr" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26192013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGiu7rF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=638-649&author=O.+Perwitasariauthor=X.+Yanauthor=J.+O%E2%80%99Donnellauthor=S.+Johnsonauthor=R.+A.+Tripp&title=Repurposing+kinase+inhibitors+as+antiviral+agents+to+control+influenza+A&doi=10.1089%2Fadt.2015.0003.drrr"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication</span></div><div class="casAuthors">Perwitasari, Olivia; Yan, Xiuzhen; O'Donnell, Jason; Johnson, Scott; Tripp, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">638-649</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Influenza A virus (IAV) infection causes seasonal epidemics of contagious respiratory illness that causes substantial morbidity and some mortality.  Regular vaccination is the principal strategy for controlling influenza virus, although vaccine efficacy is variable.  IAV antiviral drugs are available; however, substantial drug resistance has developed to two of the four currently FDA-approved antiviral drugs.  Thus, new therapeutic approaches are being sought to reduce the burden of influenza-related disease.  A high-throughput screen using a human kinase inhibitor library was performed targeting an emerging IAV strain (H7N9) in A549 cells.  The inhibitor library contained 273 structurally diverse, active cell permeable kinase inhibitors with known bioactivity and safety profiles, many of which are at advanced stages of clin. development.  The current study shows that treatment of human A549 cells with kinase inhibitors dinaciclib, flavopiridol, or PIK-75 exhibits potent antiviral activity against H7N9 IAV as well as other IAV strains.  Thus, targeting host kinases can provide a broad-spectrum therapeutic approach against IAV.  These findings provide a path forward for repurposing existing kinase inhibitors safely as potential antivirals, particularly those that can be tested in vivo and ultimately for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI0vSkwPosrrVg90H21EOLACvtfcHk0lg21Ws2hF2yRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGiu7rF&md5=cf1f193bc2e8b0278caa3e43158180d7</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1089%2Fadt.2015.0003.drrr&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2015.0003.drrr%26sid%3Dliteratum%253Aachs%26aulast%3DPerwitasari%26aufirst%3DO.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DTripp%26aufirst%3DR.%2BA.%26atitle%3DRepurposing%2520kinase%2520inhibitors%2520as%2520antiviral%2520agents%2520to%2520control%2520influenza%2520A%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2015%26volume%3D13%26spage%3D638%26epage%3D649%26doi%3D10.1089%2Fadt.2015.0003.drrr" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tcw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouznetsova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itkin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennand, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span> <span> </span><span class="NLM_article-title">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1101</span>â <span class="NLM_lpage">1107</span>, <span class="refDoi">Â DOI: 10.1038/nm.4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnm.4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27571349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWks7%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1101-1107&author=M.+Xuauthor=E.+M.+Leeauthor=Z.+Wenauthor=Y.+Chengauthor=W.+K.+Huangauthor=X.+Qianauthor=J.+Tcwauthor=J.+Kouznetsovaauthor=S.+C.+Ogdenauthor=C.+Hammackauthor=F.+Jacobauthor=H.+N.+Nguyenauthor=M.+Itkinauthor=C.+Hannaauthor=P.+Shinnauthor=C.+Allenauthor=S.+G.+Michaelauthor=A.+Simeonovauthor=W.+Huangauthor=K.+M.+Christianauthor=A.+Goateauthor=K.+J.+Brennandauthor=R.+Huangauthor=M.+Xiaauthor=G.+L.+Mingauthor=W.+Zhengauthor=H.+Songauthor=H.+Tang&title=Identification+of+small-molecule+inhibitors+of+Zika+virus+infection+and+induced+neural+cell+death+via+a+drug+repurposing+screen&doi=10.1038%2Fnm.4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</span></div><div class="casAuthors">Xu, Miao; Lee, Emily M.; Wen, Zhexing; Cheng, Yichen; Huang, Wei-Kai; Qian, Xuyu; Tcw, Julia; Kouznetsova, Jennifer; Ogden, Sarah C.; Hammack, Christy; Jacob, Fadi; Nguyen, Ha Nam; Itkin, Misha; Hanna, Catherine; Shinn, Paul; Allen, Chase; Michael, Samuel G.; Simeonov, Anton; Huang, Wenwei; Christian, Kimberly M.; Goate, Alison; Brennand, Kristen J.; Huang, Ruili; Xia, Menghang; Ming, Guo-li; Zheng, Wei; Song, Hongjun; Tang, Hengli</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1101-1107</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In response to the current global health emergency posed by the Zika virus (ZIKV) outbreak and its link to microcephaly and other neurol. conditions, we performed a drug repurposing screen of â¼6,000 compds. that included approved drugs, clin. trial drug candidates and pharmacol. active compds.; we identified compds. that either inhibit ZIKV infection or suppress infection-induced caspase-3 activity in different neural cells.  A pan-caspase inhibitor, emricasan, inhibited ZIKV-induced increases in caspase-3 activity and protected human cortical neural progenitors in both monolayer and three-dimensional organoid cultures.  Ten structurally unrelated inhibitors of cyclin-dependent kinases inhibited ZIKV replication.  Niclosamide, a category B anthelmintic drug approved by the US Food and Drug Administration, also inhibited ZIKV replication.  Finally, combination treatments using one compd. from each category (neuroprotective and antiviral) further increased protection of human neural progenitors and astrocytes from ZIKV-induced cell death.  Our results demonstrate the efficacy of this screening strategy and identify lead compds. for anti-ZIKV drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3-p_dTqQnbVg90H21EOLACvtfcHk0lg21Ws2hF2yRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWks7%252FF&md5=dd03539176ee2712f45391eca46d996f</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1038%2Fnm.4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4184%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DE.%2BM.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.%2BK.%26aulast%3DQian%26aufirst%3DX.%26aulast%3DTcw%26aufirst%3DJ.%26aulast%3DKouznetsova%26aufirst%3DJ.%26aulast%3DOgden%26aufirst%3DS.%2BC.%26aulast%3DHammack%26aufirst%3DC.%26aulast%3DJacob%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DH.%2BN.%26aulast%3DItkin%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DC.%26aulast%3DShinn%26aufirst%3DP.%26aulast%3DAllen%26aufirst%3DC.%26aulast%3DMichael%26aufirst%3DS.%2BG.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DChristian%26aufirst%3DK.%2BM.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DBrennand%26aufirst%3DK.%2BJ.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DMing%26aufirst%3DG.%2BL.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520small-molecule%2520inhibitors%2520of%2520Zika%2520virus%2520infection%2520and%2520induced%2520neural%2520cell%2520death%2520via%2520a%2520drug%2520repurposing%2520screen%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D1101%26epage%3D1107%26doi%3D10.1038%2Fnm.4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-MuÃ±oz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujantell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">EstÃ©, J. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">387</span>â <span class="NLM_lpage">394</span>, <span class="refDoi">Â DOI: 10.1093/jac/dkv363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1093%2Fjac%2Fdkv363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26542306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslWjtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2016&pages=387-394&author=R.+Badiaauthor=G.+Anguloauthor=E.+Riveira-Mu%C3%B1ozauthor=M.+Pujantellauthor=T.+Puigauthor=C.+Ramirezauthor=J.+Torres-Torronterasauthor=R.+Mart%C3%ADauthor=E.+Paulsauthor=B.+Clotetauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Inhibition+of+herpes+simplex+virus+type+1+by+the+CDK6+inhibitor+PD-0332991+%28palbociclib%29+through+the+control+of+SAMHD1&doi=10.1093%2Fjac%2Fdkv363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1</span></div><div class="casAuthors">Badia, Roger; Angulo, Guillem; Riveira-Munoz, Eva; Pujantell, Maria; Puig, Teresa; Ramirez, Cristina; Torres-Torronteras, Javier; Marti, Ramon; Pauls, Eduardo; Clotet, Bonaventura; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">387-394</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives Sterile Î± motif and histidine-aspartate domain-contg. protein 1 (SAMHD1) has been shown to restrict retroviruses and DNA viruses by decreasing the pool of intracellular deoxynucleotides.  In turn, SAMHD1 is controlled by cyclin-dependent kinases (CDK) that regulate the cell cycle and cell proliferation.  Here, we explore the effect of CDK6 inhibitors on the replication of herpes simplex virus type 1 (HSV-1) in primary monocyte-derived macrophages (MDM).  Methods MDM were treated with palbociclib, a selective CDK4/6 inhibitor, and then infected with a GFP-expressing HSV-1.  Intracellular deoxynucleotide triphosphate (dNTP) content was detd. using a polymerase-based method.  Results CDK6 inhibitor palbociclib blocked SAMHD1 phosphorylation, intracellular dNTP levels and HSV-1 replication in MDM at subtoxic concns.  Treatment of MDM with palbociclib reduced CDK2 activation, measured as the phosphorylation of the T-loop at Thr160.  The antiviral activity of palbociclib was lost when SAMHD1 was degraded by viral protein X.  Similarly, palbociclib did not block HSV-1 replication in SAMHD1-neg. Vero cells at subtoxic concns., providing further evidence for a role of SAMHD1 in mediating the antiviral effect.  Conclusions SAMHD1-mediated HSV-1 restriction is controlled by CDK and points to a preferential role for CDK6 and CDK2 as mediators of SAMHD1 activation.  Similarly, the restricting activity of SAMHD1 against DNA viruses suggests that control of dNTP availability is the major determinant of its antiviral activity.  This is the first study describing the anti-HSV-1 activity of palbociclib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-y_UxXw_iDbVg90H21EOLACvtfcHk0lgjCLS25zMudw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslWjtr4%253D&md5=b527d13ba9403fd4da637f39dd20ad5b</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv363%26sid%3Dliteratum%253Aachs%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DAngulo%26aufirst%3DG.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DPujantell%26aufirst%3DM.%26aulast%3DPuig%26aufirst%3DT.%26aulast%3DRamirez%26aufirst%3DC.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3DMart%25C3%25AD%26aufirst%3DR.%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DInhibition%2520of%2520herpes%2520simplex%2520virus%2520type%25201%2520by%2520the%2520CDK6%2520inhibitor%2520PD-0332991%2520%2528palbociclib%2529%2520through%2520the%2520control%2520of%2520SAMHD1%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2016%26volume%3D71%26spage%3D387%26epage%3D394%26doi%3D10.1093%2Fjac%2Fdkv363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dove, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicknell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiscox, J. A.</span></span> <span> </span><span class="NLM_article-title">Cell cycle perturbations induced by infection with the coronavirus infectious bronchitis virus and their effect on virus replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">4147</span>â <span class="NLM_lpage">4156</span>, <span class="refDoi">Â DOI: 10.1128/JVI.80.8.4147-4156.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.80.8.4147-4156.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16571830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs1Sqsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=4147-4156&author=B.+Doveauthor=G.+Brooksauthor=K.+Bicknellauthor=T.+Wurmauthor=J.+A.+Hiscox&title=Cell+cycle+perturbations+induced+by+infection+with+the+coronavirus+infectious+bronchitis+virus+and+their+effect+on+virus+replication&doi=10.1128%2FJVI.80.8.4147-4156.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle perturbations induced by infection with the coronavirus Infectious Bronchitis Virus and their effect on virus replication</span></div><div class="casAuthors">Dove, Brian; Brooks, Gavin; Bicknell, Katrina; Wurm, Torsten; Hiscox, Julian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4147-4156</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In eukaryotic cells, cell growth and division occur in a stepwise, orderly fashion described by a process known as the cell cycle.  The relationship between pos.-strand RNA viruses and the cell cycle and the concomitant effects on virus replication are not clearly understood.  We have shown that infection of asynchronously replicating and synchronized replicating cells with the avian coronavirus infectious bronchitis virus (IBV), a pos.-strand RNA virus, resulted in the accumulation of infected cells in the G2/M phase of the cell cycle.  Anal. of various cell cycle-regulatory proteins and cellular morphol. indicated that there was a down-regulation of cyclins D1 and D2 (G1 regulatory cyclins) and that a proportion of virus-infected cells underwent aberrant cytokinesis, in which the cells underwent nuclear, but not cytoplasmic, division.  We assessed the impact of the perturbations on the cell cycle for virus-infected cells and found that IBV-infected G2/M-phase-synchronized cells exhibited increased viral protein prodn. when released from the block when compared to cells synchronized in the G0 phase or asynchronously replicating cells.  Our data suggested that IBV induces a G2/M phase arrest in infected cells to promote favorable conditions for viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRLrM-UqXdo7Vg90H21EOLACvtfcHk0lgjCLS25zMudw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs1Sqsr8%253D&md5=47b9d4edc176e57f677ee10ca68b3369</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1128%2FJVI.80.8.4147-4156.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.80.8.4147-4156.2006%26sid%3Dliteratum%253Aachs%26aulast%3DDove%26aufirst%3DB.%26aulast%3DBrooks%26aufirst%3DG.%26aulast%3DBicknell%26aufirst%3DK.%26aulast%3DWurm%26aufirst%3DT.%26aulast%3DHiscox%26aufirst%3DJ.%2BA.%26atitle%3DCell%2520cycle%2520perturbations%2520induced%2520by%2520infection%2520with%2520the%2520coronavirus%2520infectious%2520bronchitis%2520virus%2520and%2520their%2520effect%2520on%2520virus%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D4147%26epage%3D4156%26doi%3D10.1128%2FJVI.80.8.4147-4156.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Cell cycle arrest and apoptosis induced by the coronavirus infectious bronchitis virus in the absence of p53</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">435</span>â <span class="NLM_lpage">445</span>, <span class="refDoi">Â DOI: 10.1016/j.virol.2007.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.virol.2007.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17493653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFKju7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2007&pages=435-445&author=F.+Q.+Liauthor=J.+P.+Tamauthor=D.+Liu&title=Cell+cycle+arrest+and+apoptosis+induced+by+the+coronavirus+infectious+bronchitis+virus+in+the+absence+of+p53&doi=10.1016%2Fj.virol.2007.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle arrest and apoptosis induced by the coronavirus infectious bronchitis virus in the absence of p53</span></div><div class="casAuthors">Li, Frank Q.; Tam, James P.; Liu, Ding Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">435-445</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Manipulation of the cell cycle and induction of apoptosis are two common strategies used by many viruses to regulate their infection cycles.  In cells infected with coronaviruses, cell cycle perturbation and apoptosis were obsd. in several reports.  However, little is known about how these effects are brought out, and how manipulation of the functions of host cells would influence the replication cycle of coronavirus.  In this study, we demonstrate that infection with coronavirus infectious bronchitis virus (IBV) imposed a growth-inhibitory effect on cultured cells by inducing cell cycle arrest at S and G2/M phases in both p53-null cell line H1299 and Vero cells.  This cell cycle arrest was catalyzed by the modulation of various cell cycle regulatory genes and the accumulation of hypophosphorylated RB, but was independent of p53.  Proteasome inhibitors, such as lactacystin and NLVS, could bypass the IBV-induced S-phase arrest by restoring the expression of corresponding cyclin/Cdk complexes.  Our data also showed that cell cycle arrest at both S- and G2/M-phases was manipulated by IBV for the enhancement of viral replication.  In addn., apoptosis induced by IBV at late stages of the infection cycle in cultured cells was shown to be p53-independent.  This conclusion was drawn based on the observations that apoptosis occurred in both IBV-infected H1299 and Vero cells, and that IBV infection did not affect the expression of p53 in host cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4-f-7FCWAzrVg90H21EOLACvtfcHk0lgjCLS25zMudw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFKju7c%253D&md5=fec3d4ca92d15cfd6b8a5c33beb48995</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2007.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2007.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%2BQ.%26aulast%3DTam%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DCell%2520cycle%2520arrest%2520and%2520apoptosis%2520induced%2520by%2520the%2520coronavirus%2520infectious%2520bronchitis%2520virus%2520in%2520the%2520absence%2520of%2520p53%26jtitle%3DVirology%26date%3D2007%26volume%3D365%26spage%3D435%26epage%3D445%26doi%3D10.1016%2Fj.virol.2007.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lilley, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzman, M. D.</span></span> <span> </span><span class="NLM_article-title">Using or abusing: Viruses and the cellular DNA damage response</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">119</span>â <span class="NLM_lpage">126</span>, <span class="refDoi">Â DOI: 10.1016/j.tim.2007.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.tim.2007.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17275307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisleis7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=119-126&author=C.+E.+Lilleyauthor=R.+A.+Schwartzauthor=M.+D.+Weitzman&title=Using+or+abusing%3A+Viruses+and+the+cellular+DNA+damage+response&doi=10.1016%2Fj.tim.2007.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Using or abusing: Viruses and the cellular DNA damage response</span></div><div class="casAuthors">Lilley, Caroline E.; Schwartz, Rachel A.; Weitzman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">119-126</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  During infection, viruses attempt to hijack the cell while the host responds with various defense systems.  Traditional defenses include the interferon response and apoptosis, but recent work suggests that this antiviral arsenal also includes the cellular DNA damage response machinery.  The observation of interactions between viruses and cellular DNA repair proteins has not only uncovered new complexities of the virus-host interaction but is also reinforcing the view that viruses can reveal key regulators of cellular pathways through the proteins they target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6utSPArUa4rVg90H21EOLACvtfcHk0lg-0rf7R9t6Pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisleis7c%253D&md5=f0656239394aabaf27766e5c6ab93dc2</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2007.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2007.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DLilley%26aufirst%3DC.%2BE.%26aulast%3DSchwartz%26aufirst%3DR.%2BA.%26aulast%3DWeitzman%26aufirst%3DM.%2BD.%26atitle%3DUsing%2520or%2520abusing%253A%2520Viruses%2520and%2520the%2520cellular%2520DNA%2520damage%2520response%26jtitle%3DTrends%2520Microbiol.%26date%3D2007%26volume%3D15%26spage%3D119%26epage%3D126%26doi%3D10.1016%2Fj.tim.2007.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ariumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dansako, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span> <span> </span><span class="NLM_article-title">The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">9639</span>â <span class="NLM_lpage">9646</span>, <span class="refDoi">Â DOI: 10.1128/JVI.00351-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.00351-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18667510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKgsL%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=9639-9646&author=Y.+Ariumiauthor=M.+Kurokiauthor=H.+Dansakoauthor=K.+Abeauthor=M.+Ikedaauthor=T.+Wakitaauthor=N.+Kato&title=The+DNA+damage+sensors+ataxia-telangiectasia+mutated+kinase+and+checkpoint+kinase+2+are+required+for+hepatitis+C+virus+RNA+replication&doi=10.1128%2FJVI.00351-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication</span></div><div class="casAuthors">Ariumi, Yasuo; Kuroki, Misao; Dansako, Hiromichi; Abe, Ken-Ichi; Ikeda, Masanori; Wakita, Takaji; Kato, Nobuyuko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9639-9646</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Cellular responses to DNA damage are crucial for maintaining genome integrity, virus infection, and preventing the development of cancer.  Hepatitis C virus (HCV) infection and the expression of the HCV nonstructural protein NS3 and core protein have been proposed as factors involved in the induction of double-stranded DNA breaks and enhancement of the mutation frequency of cellular genes.  Since DNA damage sensors, such as the ataxia-telangiectasia mutated kinase (ATM), ATM- and Rad3-related kinase (ATR), poly(ADP-ribose) polymerase 1 (PARP-1), and checkpoint kinase 2 (Chk2), play central roles in the response to genotoxic stress, we hypothesized that these sensors might affect HCV replication.  To test this hypothesis, we examd. the level of HCV RNA in HuH-7-derived cells stably expressing short hairpin RNA targeted to ATM, ATR, PARP-1, or Chk2.  Consequently, we found that replication of both genome-length HCV RNA (HCV-O, genotype 1b) and the subgenomic replicon RNA were notably suppressed in ATM- or Chk2-knockdown cells.  In addn., the RNA replicated of HCV-JFH1 (genotype 2a) and the release of core protein into the culture supernatants were suppressed in these knockdown cells after inoculation of the cell culture-generated HCV.  Consistent with these observations, ATM kinase inhibitor could suppress the HCV RNA replication.  Furthermore, we obsd. that HCV NS3-NS4A interacted with ATM and that HCV NS5B interacted with both ATM and Chk2.  Taken together, these results suggest that the ATM signaling pathway is crit. for HCV RNA replication and may represent a novel target for the clin. treatment of patients with chronic hepatitis C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWtA81BaohzLVg90H21EOLACvtfcHk0lg-0rf7R9t6Pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKgsL%252FE&md5=292d41057b357535b2b62b20387765fb</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1128%2FJVI.00351-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00351-08%26sid%3Dliteratum%253Aachs%26aulast%3DAriumi%26aufirst%3DY.%26aulast%3DKuroki%26aufirst%3DM.%26aulast%3DDansako%26aufirst%3DH.%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DM.%26aulast%3DWakita%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DN.%26atitle%3DThe%2520DNA%2520damage%2520sensors%2520ataxia-telangiectasia%2520mutated%2520kinase%2520and%2520checkpoint%2520kinase%25202%2520are%2520required%2520for%2520hepatitis%2520C%2520virus%2520RNA%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D9639%26epage%3D9646%26doi%3D10.1128%2FJVI.00351-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaurushiya, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzman, M. D.</span></span> <span> </span><span class="NLM_article-title">Viral manipulation of DNA repair and cell cycle checkpoints</span>. <i>DNA Repair</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1166</span>â <span class="NLM_lpage">1176</span>, <span class="refDoi">Â DOI: 10.1016/j.dnarep.2009.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.dnarep.2009.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=19473887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1WrsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1166-1176&author=M.+S.+Chaurushiyaauthor=M.+D.+Weitzman&title=Viral+manipulation+of+DNA+repair+and+cell+cycle+checkpoints&doi=10.1016%2Fj.dnarep.2009.04.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Viral manipulation of DNA repair and cell cycle checkpoints</span></div><div class="casAuthors">Chaurushiya, Mira S.; Weitzman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">DNA Repair</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1166-1176</span>CODEN:
                <span class="NLM_cas:coden">DRNEAR</span>;
        ISSN:<span class="NLM_cas:issn">1568-7864</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recognition and repair of DNA damage is crit. for maintaining genomic integrity and suppressing tumorigenesis.  In eukaryotic cells, the sensing and repair of DNA damage are coordinated with cell cycle progression and checkpoints, in order to prevent the propagation of damaged DNA.  The carefully maintained cellular response to DNA damage is challenged by viruses, which produce a large amt. of exogenous DNA during infection.  Viruses also express proteins that perturb cellular DNA repair and cell cycle pathways, promoting tumorigenesis in their quest for cellular domination.  This review presents an overview of strategies employed by viruses to manipulate DNA damage responses and cell cycle checkpoints as they commandeer the cell to maximize their own viral replication.  Studies of viruses have identified key cellular regulators and revealed insights into mol. mechanisms governing DNA repair, cell cycle checkpoints, and transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZN_3vCalZxrVg90H21EOLACvtfcHk0lg-0rf7R9t6Pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1WrsrY%253D&md5=b49f8a14f5679514b2ecfa43f3354086</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.dnarep.2009.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dnarep.2009.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DChaurushiya%26aufirst%3DM.%2BS.%26aulast%3DWeitzman%26aufirst%3DM.%2BD.%26atitle%3DViral%2520manipulation%2520of%2520DNA%2520repair%2520and%2520cell%2520cycle%2520checkpoints%26jtitle%3DDNA%2520Repair%26date%3D2009%26volume%3D8%26spage%3D1166%26epage%3D1176%26doi%3D10.1016%2Fj.dnarep.2009.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoenen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelotti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewey, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWald, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp-Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKnight, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span> <span> </span><span class="NLM_article-title">The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0005540</span> <span class="refDoi">Â DOI: 10.1371/journal.pntd.0005540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.pntd.0005540" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28403145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWrsb3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&author=E.+A.+Nelsonauthor=J.+Dyallauthor=T.+Hoenenauthor=A.+B.+Barnesauthor=H.+Zhouauthor=J.+Y.+Liangauthor=J.+Michelottiauthor=W.+H.+Deweyauthor=L.+E.+DeWaldauthor=R.+S.+Bennettauthor=P.+J.+Morrisauthor=R.+Guhaauthor=C.+Klumpp-Thomasauthor=C.+McKnightauthor=Y.+C.+Chenauthor=X.+Xuauthor=A.+Wangauthor=E.+Hughesauthor=S.+Martinauthor=C.+Thomasauthor=P.+B.+Jahrlingauthor=L.+E.+Hensleyauthor=G.+G.+Olingerauthor=J.+M.+White&title=The+phosphatidylinositol-3-phosphate+5-kinase+inhibitor+apilimod+blocks+filoviral+entry+and+infection&doi=10.1371%2Fjournal.pntd.0005540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection</span></div><div class="casAuthors">Nelson, Elizabeth A.; Dyall, Julie; Hoenen, Thomas; Barnes, Alyson B.; Zhou, Huanying; Liang, Janie Y.; Michelotti, Julia; Dewey, William H.; DeWald, Lisa Evans; Bennett, Richard S.; Morris, Patrick J.; Guha, Rajarshi; Klumpp-Thomas, Carleen; McKnight, Crystal; Chen, Yu-Chi; Xu, Xin; Wang, Amy; Hughes, Emma; Martin, Scott; Thomas, Craig; Jahrling, Peter B.; Hensley, Lisa E.; Olinger, Gene G. Jr.; White, Judith M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0005540/1-e0005540/22</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) is a lipid kinase involved in endosome maturation that emerged from a haploid genetic screen as being required for Ebola virus (EBOV) infection.  Here we analyzed the effects of apilimod, a PIKfyve inhibitor that was reported to be well tolerated in humans in phase 2 clin. trials, for its effects on entry and infection of EBOV and Marburg virus (MARV).  We first found that apilimod blocks infections by EBOV and MARV in Huh 7, Vero E6 and primary human macrophage cells, with notable potency in the macrophages (IC50, 10 nM).  We next obsd. that similar doses of apilimod block EBOV-glycoprotein-virus like particle (VLP) entry and transcription-replication competent VLP infection, suggesting that the primary mode of action of apilimod is as an entry inhibitor, preventing release of the viral genome into the cytoplasm to initiate replication.  After providing evidence that the anti-EBOV action of apilimod is via PIKfyve, we showed that it blocks trafficking of EBOV VLPs to endolysosomes contg. Niemann-Pick C1 (NPC1), the intracellular receptor for EBOV.  Concurrently apilimod caused VLPs to accumulate in early endosome antigen 1-pos. endosomes.  We did not detect any effects of apilimod on bulk endosome acidification, on the activity of cathepsins B and L, or on cholesterol export from endolysosomes.  Hence by antagonizing PIKfyve, apilimod appears to block EBOV trafficking to its site of fusion and entry into the cytoplasm.  Given the drug's obsd. anti-filoviral activity, relatively unexplored mechanism of entry inhibition, and reported tolerability in humans, we propose that apilimod be further explored as part of a therapeutic regimen to treat filoviral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlUaAMvLkQT7Vg90H21EOLACvtfcHk0lg-0rf7R9t6Pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWrsb3O&md5=c2f72fa69b941bcc8c97dcacf0e210bd</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005540%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DHoenen%26aufirst%3DT.%26aulast%3DBarnes%26aufirst%3DA.%2BB.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%2BY.%26aulast%3DMichelotti%26aufirst%3DJ.%26aulast%3DDewey%26aufirst%3DW.%2BH.%26aulast%3DDeWald%26aufirst%3DL.%2BE.%26aulast%3DBennett%26aufirst%3DR.%2BS.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DKlumpp-Thomas%26aufirst%3DC.%26aulast%3DMcKnight%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DC.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520phosphatidylinositol-3-phosphate%25205-kinase%2520inhibitor%2520apilimod%2520blocks%2520filoviral%2520entry%2520and%2520infection%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26doi%3D10.1371%2Fjournal.pntd.0005540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulseberg, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FÃ©nÃ©ant, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SzymaÅska-De
Wijs, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmaljohn, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyak, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span> <span> </span><span class="NLM_article-title">Arbidol and other low-molecular-weight drugs that inhibit lassa and Ebola viruses</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>93</i></span>, <span class="NLM_elocation-id">e02185-18</span> <span class="refDoi">Â DOI: 10.1128/JVI.02185-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.02185-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30700611" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2019&author=C.+E.+Hulsebergauthor=L.+F%C3%A9n%C3%A9antauthor=K.+M.+Szyma%C5%84ska-De%0AWijsauthor=N.+P.+Kesslerauthor=E.+A.+Nelsonauthor=C.+J.+Shoemakerauthor=C.+S.+Schmaljohnauthor=S.+J.+Polyakauthor=J.+M.+White&title=Arbidol+and+other+low-molecular-weight+drugs+that+inhibit+lassa+and+Ebola+viruses&doi=10.1128%2FJVI.02185-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1128%2FJVI.02185-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02185-18%26sid%3Dliteratum%253Aachs%26aulast%3DHulseberg%26aufirst%3DC.%2BE.%26aulast%3DF%25C3%25A9n%25C3%25A9ant%26aufirst%3DL.%26aulast%3DSzyma%25C5%2584ska-De%2BWijs%26aufirst%3DK.%2BM.%26aulast%3DKessler%26aufirst%3DN.%2BP.%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DShoemaker%26aufirst%3DC.%2BJ.%26aulast%3DSchmaljohn%26aufirst%3DC.%2BS.%26aulast%3DPolyak%26aufirst%3DS.%2BJ.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26atitle%3DArbidol%2520and%2520other%2520low-molecular-weight%2520drugs%2520that%2520inhibit%2520lassa%2520and%2520Ebola%2520viruses%26jtitle%3DJ.%2520Virol.%26date%3D2019%26volume%3D93%26doi%3D10.1128%2FJVI.02185-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikonomov, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbrissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shisheva, A.</span></span> <span> </span><span class="NLM_article-title">Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">114771</span>, <span class="refDoi">Â DOI: 10.1016/j.taap.2019.114771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.taap.2019.114771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31628917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKgt7rJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2019&pages=114771&author=O.+C.+Ikonomovauthor=D.+Sbrissaauthor=A.+Shisheva&title=Small+molecule+PIKfyve+inhibitors+as+cancer+therapeutics%3A+Translational+promises+and+limitations&doi=10.1016%2Fj.taap.2019.114771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations</span></div><div class="casAuthors">Ikonomov, Ognian C.; Sbrissa, Diego; Shisheva, Assia</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114771</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Through synthesis of two rare phosphoinositides, PtdIns(3,5)P2 and PtdIns5P, the ubiquitously expressed phosphoinositide kinase PIKfyve is implicated in pleiotropic cellular functions.  Small mols. specifically inhibiting PIKfyve activity cause cytoplasmic vacuolation in all dividing cells in culture yet trigger non-apoptotic death through excessive vacuolation only in cancer cells.  Intriguingly, cancer cell toxicity appears to be inhibitor-specific suggesting that addnl. targets beyond PIKfyve are affected.  One PIKfyve inhibitor - apilimod - is already in clin. trials for treatment of B-cell malignancies.  However, apilimod is inactivated in cultured cells and exhibits unexpectedly low plasma levels in patients treated with max. oral dosage.  Thus, the potential widespread use of PIKfyve inhibitors as cancer therapeutics requires progress on multiple fronts: (i) advances in methods for isolating relevant cancer cells from individual patients; (ii) delineation of the mol. mechanisms potentiating the vacuolation induced by PIKfyve inhibitors in sensitive cancer cells; (iii) design of PIKfyve inhibitors with favorable pharmacokinetics; and (iv) development of effective drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVCqd6_1ZLsrVg90H21EOLACvtfcHk0lhp7prQ88iNGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKgt7rJ&md5=992d773408d82e75fe81132678d6c0df</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2019.114771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2019.114771%26sid%3Dliteratum%253Aachs%26aulast%3DIkonomov%26aufirst%3DO.%2BC.%26aulast%3DSbrissa%26aufirst%3DD.%26aulast%3DShisheva%26aufirst%3DA.%26atitle%3DSmall%2520molecule%2520PIKfyve%2520inhibitors%2520as%2520cancer%2520therapeutics%253A%2520Translational%2520promises%2520and%2520limitations%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2019%26volume%3D383%26spage%3D114771%26doi%3D10.1016%2Fj.taap.2019.114771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eggersmann, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhardt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gluz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuerstlein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span> <span> </span><span class="NLM_article-title">CDK4/6 inhibitors expand the therapeutic options in breast cancer: Palbociclib, Ribociclib and Abemaciclib</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">125</span>â <span class="NLM_lpage">135</span>, <span class="refDoi">Â DOI: 10.1007/s40259-019-00337-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs40259-019-00337-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30847853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyitbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=125-135&author=T.+K.+Eggersmannauthor=T.+Degenhardtauthor=O.+Gluzauthor=R.+Wuerstleinauthor=N.+Harbeck&title=CDK4%2F6+inhibitors+expand+the+therapeutic+options+in+breast+cancer%3A+Palbociclib%2C+Ribociclib+and+Abemaciclib&doi=10.1007%2Fs40259-019-00337-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib</span></div><div class="casAuthors">Eggersmann, Tanja K.; Degenhardt, Tom; Gluz, Oleg; Wuerstlein, Rachel; Harbeck, Nadia</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-135</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The majority of patients with metastatic breast cancer (MBC) have hormone receptor-pos. HER2-neg. disease.  For this subgroup, endocrine therapy is the key therapeutic option.  Recently, therapeutic options have been expanded by introduction of the inhibitors of cyclin-dependent kinases 4/6 (CDK4/6i).  Three compds., palbociclib, ribociclib, and abemaciclib, have already been approved by the FDA for use together with endocrine therapy such as aromatase inhibitors (AIs) or fulvestrant; abemaciclib is also approved as a single agent.  In the first-line setting, all three agents-together with an AI-substantially prolonged progression-free survival with a consistent hazard ratio of around 0.5 in all phase III trials.  The data for second-line settings and beyond is also quite consistent, with again a substantial prolongation of progression-free survival demonstrated for fulvestrant together with palbociclib, ribociclib, or abemaciclib.  Treatment with CDK4/6i is well tolerated and side effects are manageable.  With palbociclib and ribociclib, hematol. toxicities are most frequent.  Abemaciclib has a lower incidence of neutropenia and a much greater incidence of all grades of diarrhea compared with other CDK4/6i, making diarrhea the key toxicity for abemaciclib.  Patient quality of life is maintained under therapy and, particularly in later line settings, deterioration of quality of life is slowed down and symptoms such as pain are better controlled by CDK4/6i.  Their consistent and clin. relevant efficacy makes these drugs an important improvement in our armamentarium against MBC and, potentially, ideal candidates in early breast cancer (EBC).  This review summarizes the available clin. data for CDK4/6i and current research activities, particularly in EBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpioH0AnGSW0LVg90H21EOLACvtfcHk0lgHMloc4j3swg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyitbc%253D&md5=95c5d92b8e8a215dc3199dd4b96775c9</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1007%2Fs40259-019-00337-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-019-00337-6%26sid%3Dliteratum%253Aachs%26aulast%3DEggersmann%26aufirst%3DT.%2BK.%26aulast%3DDegenhardt%26aufirst%3DT.%26aulast%3DGluz%26aufirst%3DO.%26aulast%3DWuerstlein%26aufirst%3DR.%26aulast%3DHarbeck%26aufirst%3DN.%26atitle%3DCDK4%252F6%2520inhibitors%2520expand%2520the%2520therapeutic%2520options%2520in%2520breast%2520cancer%253A%2520Palbociclib%252C%2520Ribociclib%2520and%2520Abemaciclib%26jtitle%3DBioDrugs%26date%3D2019%26volume%3D33%26spage%3D125%26epage%3D135%26doi%3D10.1007%2Fs40259-019-00337-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poratti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzaro, G.</span></span> <span> </span><span class="NLM_article-title">Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">143</span>â <span class="NLM_lpage">153</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.03.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.ejmech.2019.03.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30978559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVSgtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2019&pages=143-153&author=M.+Porattiauthor=G.+Marzaro&title=Third-generation+CDK+inhibitors%3A+A+review+on+the+synthesis+and+binding+modes+of+Palbociclib%2C+Ribociclib+and+Abemaciclib&doi=10.1016%2Fj.ejmech.2019.03.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib</span></div><div class="casAuthors">Poratti, Melania; Marzaro, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">143-153</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The role of cyclin-dependent kinases (CDKs) in regulating the transition of cell cycle steps makes this class of enzymes a suitable target for cancer therapy.  Three different generations of CDKs inhibitors have been developed so far.  Third-generation compds. (i.e. selective CDK4/6 inhibitors) are the most promising ones, due to their limited toxicity and high in vivo activity.  To date, three compds. have entered the therapy, namely Palbociclib, Ribociclib and Abemaciclib.  Herein we review the medicinal chem. aspects of these drugs, with some refs. to very similar analogs that have been published.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXSxnZIYEUgLVg90H21EOLACvtfcHk0lgHMloc4j3swg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVSgtbk%253D&md5=4d22f955150b069a2d0418538323d71f</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.03.064%26sid%3Dliteratum%253Aachs%26aulast%3DPoratti%26aufirst%3DM.%26aulast%3DMarzaro%26aufirst%3DG.%26atitle%3DThird-generation%2520CDK%2520inhibitors%253A%2520A%2520review%2520on%2520the%2520synthesis%2520and%2520binding%2520modes%2520of%2520Palbociclib%252C%2520Ribociclib%2520and%2520Abemaciclib%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D172%26spage%3D143%26epage%3D153%26doi%3D10.1016%2Fj.ejmech.2019.03.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meggio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span> <span> </span><span class="NLM_article-title">One-thousand-and-one substrates of protein kinase CK2?</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">349</span>â <span class="NLM_lpage">368</span>, <span class="refDoi">Â DOI: 10.1096/fj.02-0473rev</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1096%2Ffj.02-0473rev" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=12631575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFeitbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=349-368&author=F.+Meggioauthor=L.+A.+Pinna&title=One-thousand-and-one+substrates+of+protein+kinase+CK2%3F&doi=10.1096%2Ffj.02-0473rev"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">One-thousand-and-one substrates of protein kinase CK2?</span></div><div class="casAuthors">Meggio, Flavio; Pinna, Lorenzo A.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-368</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review.  CK2 (formerly termed "casein kinase 2") is a ubiquitous, highly pleiotropic and constitutively active Ser/Thr protein kinase whose implication in neoplasia, cell survival, and virus infection is supported by an increasing no. of arguments.  Here an updated inventory of 307 CK2 protein substrates is presented.  More than one-third of these are implicated in gene expression and protein synthesis as being either transcriptional factors (60) or effectors of DNA/RNA structure (50) or translational elements.  Also numerous are signaling proteins and proteins of viral origin or essential to virus life cycle.  In comparison, only a minority of CK2 targets (a dozen or so) are classical metabolic enzymes.  An anal. of 308 sites phosphorylated by CK2 highlights the paramount relevance of neg. charged side chains that are (by far) predominant over any other residues at positions n+3 (the most crucial one), n+1, and n+2.  Based on this signature, it is predictable that proteins phosphorylated by CK2 are much more numerous than those identified to date, and it is possible that CK2 alone contributes to the generation of the eukaryotic phosphoproteome more so than any other individual protein kinase.  The possibility that CK2 phosphosites play some global role, e.g., by destabilizing Î± helices, counteracting caspase cleavage, and generating adhesive motifs, will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6sfPYsWeCNrVg90H21EOLACvtfcHk0lgHMloc4j3swg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFeitbk%253D&md5=0b11315ac9652e8866a1ed99a7010b68</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1096%2Ffj.02-0473rev&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.02-0473rev%26sid%3Dliteratum%253Aachs%26aulast%3DMeggio%26aufirst%3DF.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26atitle%3DOne-thousand-and-one%2520substrates%2520of%2520protein%2520kinase%2520CK2%253F%26jtitle%3DFASEB%2520J.%26date%3D2003%26volume%3D17%26spage%3D349%26epage%3D368%26doi%3D10.1096%2Ffj.02-0473rev" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keating, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striker, R.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation events during viral infections provide potential therapeutic targets</span>. <i>Rev. Med. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">166</span>â <span class="NLM_lpage">181</span>, <span class="refDoi">Â DOI: 10.1002/rmv.722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Frmv.722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22113983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVGksb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=166-181&author=J.+A.+Keatingauthor=R.+Striker&title=Phosphorylation+events+during+viral+infections+provide+potential+therapeutic+targets&doi=10.1002%2Frmv.722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation events during viral infections provide potential therapeutic targets</span></div><div class="casAuthors">Keating, Julie A.; Striker, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in Medical Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">166-181</span>CODEN:
                <span class="NLM_cas:coden">RMVIEW</span>;
        ISSN:<span class="NLM_cas:issn">1052-9276</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  SUMMARY : For many medically relevant viruses, there is now considerable evidence that both viral and cellular kinases play important roles in viral infection.  Ultimately, these kinases, and the cellular signaling pathways that they exploit, may serve as therapeutic targets for treating patients.  Currently, small mol. inhibitors of kinases are under investigation as therapy for herpes viral infections.  Addnl., a no. of cellular or host-directed tyrosine kinase inhibitors that have been previously FDA approved for cancer treatment are under study in animal models and clin. trials, as they have shown promise for the treatment of various viral infections as well.  This review will highlight the wide range of viral proteins phosphorylated by viral and cellular kinases, and the potential for variability of kinase recognition sites within viral substrates to impact phosphorylation and kinase prediction.  Research studying kinase-targeting prophylactic and therapeutic treatments for a no. of viral infections will also be discussed.  Copyright Â© 2011 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAakENW1lBobVg90H21EOLACvtfcHk0lgHMloc4j3swg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVGksb4%253D&md5=101ce4dec72322383e78230028d79569</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1002%2Frmv.722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frmv.722%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DJ.%2BA.%26aulast%3DStriker%26aufirst%3DR.%26atitle%3DPhosphorylation%2520events%2520during%2520viral%2520infections%2520provide%2520potential%2520therapeutic%2520targets%26jtitle%3DRev.%2520Med.%2520Virol.%26date%3D2012%26volume%3D22%26spage%3D166%26epage%3D181%26doi%3D10.1002%2Frmv.722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarty, M. F.</span></span> <span> </span><span class="NLM_article-title">Targeting Casein kinase 2 with quercetin or enzymatically modified isoquercitrin as a strategy for boosting the type 1 interferon response to viruses and promoting cardiovascular health</span>. <i>Med. Hypotheses</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">109800</span>, <span class="refDoi">Â DOI: 10.1016/j.mehy.2020.109800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.mehy.2020.109800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32388479" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=109800&author=J.+J.+Di+Nicolantonioauthor=M.+F.+McCarty&title=Targeting+Casein+kinase+2+with+quercetin+or+enzymatically+modified+isoquercitrin+as+a+strategy+for+boosting+the+type+1+interferon+response+to+viruses+and+promoting+cardiovascular+health&doi=10.1016%2Fj.mehy.2020.109800"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.mehy.2020.109800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mehy.2020.109800%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BNicolantonio%26aufirst%3DJ.%2BJ.%26aulast%3DMcCarty%26aufirst%3DM.%2BF.%26atitle%3DTargeting%2520Casein%2520kinase%25202%2520with%2520quercetin%2520or%2520enzymatically%2520modified%2520isoquercitrin%2520as%2520a%2520strategy%2520for%2520boosting%2520the%2520type%25201%2520interferon%2520response%2520to%2520viruses%2520and%2520promoting%2520cardiovascular%2520health%26jtitle%3DMed.%2520Hypotheses%26date%3D2020%26volume%3D142%26spage%3D109800%26doi%3D10.1016%2Fj.mehy.2020.109800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agaisse, H.</span></span> <span> </span><span class="NLM_article-title">Casein kinase 2 regulates vaccinia virus actin tail formation</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">143</span>â <span class="NLM_lpage">151</span>, <span class="refDoi">Â DOI: 10.1016/j.virol.2011.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.virol.2011.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22209233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFGrtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2012&pages=143-151&author=D.+E.+Alvarezauthor=H.+Agaisse&title=Casein+kinase+2+regulates+vaccinia+virus+actin+tail+formation&doi=10.1016%2Fj.virol.2011.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Casein kinase 2 regulates vaccinia virus actin tail formation</span></div><div class="casAuthors">Alvarez, Diego E.; Agaisse, Herve</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-151</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Casein kinase 2 (CK2) is a pleiotropic serine/threonine kinase that regulates numerous cellular processes and is essential to the infectious cycle of several viruses.  Here we investigated the potential role of CK2 in vaccinia virus (VACV) infection.  We used the CK2 inhibitor TBB and found that CK2 inactivation impaired VACV dissemination and actin tail formation.  We used RNAi and confirmed that CK2 depletion impaired VACV actin tail formation.  Furthermore, we designed a recombinant virus that allowed us to specifically detect cell-assocd. enveloped viruses (CEVs) at the plasma membrane and demonstrated that CK2 inactivation does not affect CEV formation.  Finally, we showed that CK2 depletion impaired the recruitment of Src to CEVs.  We discuss the possibility that CK2 may stimulate the A36-dependent recruitment of Src through A36 phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdjQrIl5SRKrVg90H21EOLACvtfcHk0lhoQ-7G9fK9mA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFGrtw%253D%253D&md5=347c33a4c7adcfbb187411725beeef8f</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2011.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2011.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez%26aufirst%3DD.%2BE.%26aulast%3DAgaisse%26aufirst%3DH.%26atitle%3DCasein%2520kinase%25202%2520regulates%2520vaccinia%2520virus%2520actin%2520tail%2520formation%26jtitle%3DVirology%26date%3D2012%26volume%3D423%26spage%3D143%26epage%3D151%26doi%3D10.1016%2Fj.virol.2011.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baladron, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rittoles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DÃ­az, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzuela, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarÄÃ­a, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chacon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GonzÃ¡lez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RodrigueÅº, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Bloomquist, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RamÃ³n, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GuillÃ©n, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perea, S. E.</span></span> <span> </span><span class="NLM_article-title">ATENEA-Co-300 Group. Treatment with an anti-ck2 synthetic peptide improves clinical response in COVID-19 patients with pneumonia. A randomized and controlled clinical trial</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">206</span>, <span class="refDoi">Â DOI: 10.1021/acsptsci.0c00175</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.0c00175" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFeqtr7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2021&pages=206&author=L.+R.+Cruzauthor=I.+Baladronauthor=A.+Rittolesauthor=P.+A.+D%C3%ADazauthor=C.+Valenzuelaauthor=R.+Santanaauthor=M.+M.+Vazquezauthor=A.+Gar%C4%87%C3%ADaauthor=D.+Chaconauthor=D.+Thompsonauthor=G.+Pereraauthor=A.+Gonz%C3%A1lezauthor=R.+Reyesauthor=L.+Torresauthor=J.+Perezauthor=Y.+Validoauthor=R.+Rodrigue%C5%BAauthor=D.+M.+Vazquez-Bloomquistauthor=M.+Rosalesauthor=A.+C.+Ram%C3%B3nauthor=G.+V.+P%C3%A9rezauthor=G.+Guill%C3%A9nauthor=V.+Muzioauthor=Y.+Pereraauthor=S.+E.+Perea&title=ATENEA-Co-300+Group.+Treatment+with+an+anti-ck2+synthetic+peptide+improves+clinical+response+in+COVID-19+patients+with+pneumonia.+A+randomized+and+controlled+clinical+trial&doi=10.1021%2Facsptsci.0c00175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial</span></div><div class="casAuthors">Cruz, Leticia R.; Baladron, Idania; Rittoles, Aliusha; Diaz, Pablo A.; Valenzuela, Carmen; Santana, Raul; Vazquez, Maria M.; Garcia, Ariadna; Chacon, Deyli; Thompson, Delvin; Perera, Gustavo; Gonzalez, Ariel; Reyes, Rafael; Torres, Loida; Perez, Jesus; Valido, Yania; Rodriguez, Ralysmay; Vazquez-Bloomquist, Dania M.; Rosales, Mauro; Ramon, Ailyn C.; Perez, George V.; Guillen, Gerardo; Muzio, Verena; Perera, Yasser; Perea, Silvio E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">206-212</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The instrumental role of CK2 in the SARS-CoV-2 infection has pointed out this protein kinase as promising therapeutic target in COVID-19.  Anti-SARS-CoV-2 activity has been reported by CK2 inhibitors in vitro; however, no anti-CK2 clin. approach has been investigated in COVID-19.  This trial aimed to explore the safety and putative clin. benefit of CIGB-325, an anti-CK2 peptide previously assessed in cancer patients.  A monocentric, controlled, and therapeutic exploratory trial of i.v. CIGB-325 in adults hospitalized with COVID-19 was performed.  Twenty patients were randomly assigned to receive CIGB-325 (2.5 mg/kg/day during 5-consecutive days) plus std.-of-care (10 patients) or std.-of-care alone (10 patients).  Adverse events were classified by the WHO Adverse Reaction Terminol.  Parametric and nonparametric statistical analyses were performed according to the type of variable.  Considering the small sample size, differences between groups were estd. by Bayesian anal.  CIGB-325 induced transient mild and(or) moderate adverse events such as pruritus, flushing, and rash in some patients.  Both therapeutic regimens were similar with respect to SARS-CoV-2 clearance in nasopharynx swabs over time.  However, CIGB-325 significantly reduced the median no. of pulmonary lesions (9.5 to 5.5) at day 7 and the proportion of patients with such an effect was also higher according to Bayesian anal.  Also, CIGB-325 significantly reduced the CPK and LDH plasma levels at day 7.  Our preliminary findings suggest that this anti-CK2 clin. approach could be combined with std.-of-care in COVID-19 in larger studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_htv0WJqtMLVg90H21EOLACvtfcHk0lhoQ-7G9fK9mA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFeqtr7J&md5=3a20ffbee3ad12723ef9e54ebccfb170</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.0c00175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.0c00175%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DL.%2BR.%26aulast%3DBaladron%26aufirst%3DI.%26aulast%3DRittoles%26aufirst%3DA.%26aulast%3DD%25C3%25ADaz%26aufirst%3DP.%2BA.%26aulast%3DValenzuela%26aufirst%3DC.%26aulast%3DSantana%26aufirst%3DR.%26aulast%3DVazquez%26aufirst%3DM.%2BM.%26aulast%3DGar%25C4%2587%25C3%25ADa%26aufirst%3DA.%26aulast%3DChacon%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DD.%26aulast%3DPerera%26aufirst%3DG.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DA.%26aulast%3DReyes%26aufirst%3DR.%26aulast%3DTorres%26aufirst%3DL.%26aulast%3DPerez%26aufirst%3DJ.%26aulast%3DValido%26aufirst%3DY.%26aulast%3DRodrigue%25C5%25BA%26aufirst%3DR.%26aulast%3DVazquez-Bloomquist%26aufirst%3DD.%2BM.%26aulast%3DRosales%26aufirst%3DM.%26aulast%3DRam%25C3%25B3n%26aufirst%3DA.%2BC.%26aulast%3DP%25C3%25A9rez%26aufirst%3DG.%2BV.%26aulast%3DGuill%25C3%25A9n%26aufirst%3DG.%26aulast%3DMuzio%26aufirst%3DV.%26aulast%3DPerera%26aufirst%3DY.%26aulast%3DPerea%26aufirst%3DS.%2BE.%26atitle%3DATENEA-Co-300%2520Group.%2520Treatment%2520with%2520an%2520anti-ck2%2520synthetic%2520peptide%2520improves%2520clinical%2520response%2520in%2520COVID-19%2520patients%2520with%2520pneumonia.%2520A%2520randomized%2520and%2520controlled%2520clinical%2520trial%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2021%26volume%3D4%26spage%3D206%26doi%3D10.1021%2Facsptsci.0c00175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colunga Biancatelli, R. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catravas, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marik, P. E.</span></span> <span> </span><span class="NLM_article-title">Quercetin and vitamin C: An experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related Disease (COVID-19)</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1451</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2020.01451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffimmu.2020.01451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32636851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB38npslWmsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1451&author=R.+M.+L.+Colunga+Biancatelliauthor=M.+Berrillauthor=J.+D.+Catravasauthor=P.+E.+Marik&title=Quercetin+and+vitamin+C%3A+An+experimental%2C+synergistic+therapy+for+the+prevention+and+treatment+of+SARS-CoV-2+related+Disease+%28COVID-19%29&doi=10.3389%2Ffimmu.2020.01451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)</span></div><div class="casAuthors">Colunga Biancatelli Ruben Manuel Luciano; Catravas John D; Marik Paul E; Colunga Biancatelli Ruben Manuel Luciano; Catravas John D; Colunga Biancatelli Ruben Manuel Luciano; Berrill Max; Catravas John D</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1451</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an emergent global threat which is straining worldwide healthcare capacity.  As of May 27th, the disease caused by SARS-CoV-2 (COVID-19) has resulted in more than 340,000 deaths worldwide, with 100,000 deaths in the US alone.  It is imperative to study and develop pharmacological treatments suitable for the prevention and treatment of COVID-19.  Ascorbic acid is a crucial vitamin necessary for the correct functioning of the immune system.  It plays a role in stress response and has shown promising results when administered to the critically ill.  Quercetin is a well-known flavonoid whose antiviral properties have been investigated in numerous studies.  There is evidence that vitamin C and quercetin co-administration exerts a synergistic antiviral action due to overlapping antiviral and immunomodulatory properties and the capacity of ascorbate to recycle quercetin, increasing its efficacy.  Safe, cheap interventions which have a sound biological rationale should be prioritized for experimental use in the current context of a global health pandemic.  We present the current evidence for the use of vitamin C and quercetin both for prophylaxis in high-risk populations and for the treatment of COVID-19 patients as an adjunct to promising pharmacological agents such as Remdesivir or convalescent plasma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_Gndv-Y5NPZdYoSR9eyvsfW6udTcc2ea9tnghU9BLNbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38npslWmsQ%253D%253D&md5=16499ce93f500885e09d016e8a4bf3c5</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.01451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.01451%26sid%3Dliteratum%253Aachs%26aulast%3DColunga%2BBiancatelli%26aufirst%3DR.%2BM.%2BL.%26aulast%3DBerrill%26aufirst%3DM.%26aulast%3DCatravas%26aufirst%3DJ.%2BD.%26aulast%3DMarik%26aufirst%3DP.%2BE.%26atitle%3DQuercetin%2520and%2520vitamin%2520C%253A%2520An%2520experimental%252C%2520synergistic%2520therapy%2520for%2520the%2520prevention%2520and%2520treatment%2520of%2520SARS-CoV-2%2520related%2520Disease%2520%2528COVID-19%2529%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26volume%3D11%26spage%3D1451%26doi%3D10.3389%2Ffimmu.2020.01451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seah, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HervÃ©, M.</span></span> <span> </span><span class="NLM_article-title">Modulation of inflammation and pathology during dengue virus infection by p38 MAPK inhibitor SB203580</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">151</span>â <span class="NLM_lpage">157</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2014.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2014.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25131378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSmsbbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2014&pages=151-157&author=Y.+Fuauthor=A.+Yipauthor=P.+G.+Seahauthor=F.+Blascoauthor=P.-Y.+Shiauthor=M.+Herv%C3%A9&title=Modulation+of+inflammation+and+pathology+during+dengue+virus+infection+by+p38+MAPK+inhibitor+SB203580&doi=10.1016%2Fj.antiviral.2014.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of inflammation and pathology during dengue virus infection by p38 MAPK inhibitor SB203580</span></div><div class="casAuthors">Fu, Yilong; Yip, Andy; Seah, Peck Gee; Blasco, Francesca; Shi, Pei-Yong; Herve, Maxime</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-157</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dengue virus (DENV) infection could lead to dengue fever (DF), dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).  The disease outcome is controlled by both viral and host factors.  Inflammation mediators from DENV-infected cells could contribute to increased vascular permeability, leading to severe DHF/DSS.  Therefore, suppression of inflammation could be a potential therapeutic approach for treatment of dengue patients.  In this context, p38 MAPK (mitogen-activated protein kinase) is a key enzyme that modulates the initiation of stress and inflammatory responses.  Here we show that SB203580, a p38 MAPK inhibitor, suppressed the over prodn. of DENV-induced pro-inflammatory mediators such as TNF-Î±, IL-8, and RANTES from human PBMCs, monocytic THP-1, and granulocyte KU812 cell lines.  Oral administration of SB203580 in DENV-infected AG129 mice prevented hematocrit rise and lymphopenia, limited the development of inflammation and pathol. (including intestine leakage), and significantly improved survival.  These results, for the first time, have provided exptl. evidence to imply that a short term inhibition of p38 MAPK may be beneficial to reduce disease symptoms in dengue patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnQAZQRmn0h7Vg90H21EOLACvtfcHk0ljo3KH9vQlrnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSmsbbF&md5=05737028353b73175d6a64146732bdd5</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DY.%26aulast%3DYip%26aufirst%3DA.%26aulast%3DSeah%26aufirst%3DP.%2BG.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DP.-Y.%26aulast%3DHerv%25C3%25A9%26aufirst%3DM.%26atitle%3DModulation%2520of%2520inflammation%2520and%2520pathology%2520during%2520dengue%2520virus%2520infection%2520by%2520p38%2520MAPK%2520inhibitor%2520SB203580%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D110%26spage%3D151%26epage%3D157%26doi%3D10.1016%2Fj.antiviral.2014.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Growcott, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galarneau, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, V. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schul, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. S.</span></span> <span> </span><span class="NLM_article-title">The effect of P38 MAP kinase inhibition in a mouse model of influenza</span>. <i>J. Med. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">452</span>â <span class="NLM_lpage">462</span>, <span class="refDoi">Â DOI: 10.1099/jmm.0.000684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1099%2Fjmm.0.000684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29458547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSmsbzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2018&pages=452-462&author=E.+J.+Growcottauthor=D.+Bambaauthor=J.+R.+Galarneauauthor=V.+H.+J.+Leonardauthor=W.+Schulauthor=D.+Steinauthor=C.+S.+Osborne&title=The+effect+of+P38+MAP+kinase+inhibition+in+a+mouse+model+of+influenza&doi=10.1099%2Fjmm.0.000684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of P38 MAP kinase inhibition in a mouse model of influenza</span></div><div class="casAuthors">Growcott, E. J.; Bamba, D.; Galarneau, J-.R.; Leonard, V. H. J.; Schul, W.; Stein, D.; Osborne, C. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">452-462</span>CODEN:
                <span class="NLM_cas:coden">JMMIAV</span>;
        ISSN:<span class="NLM_cas:issn">1473-5644</span>.
    
            (<span class="NLM_cas:orgname">Microbiology Society</span>)
        </div><div class="casAbstract">Influenza viruses are a common cause of human respiratory infections, resulting in epidemics of high morbidity and mortality.  We investigated the effect of a novel mitogen-activated protein kinase (MAPK) inhibitor in vitro and in a murine influenza model to further explore whether p38 MAPK inhibition could reduce viral replication.  Methods.In vitro, the antiviral effect of p38 MAPK inhibitor BCT194 was evaluated in differentiated human bronchial epithelial cells (HBECs); in vivo, female BALB/c mice were infected intranasally with 150 pfu of influenza H1N1 A/Puerto Rico/8/34 and treated with BCT197 (a closely related p38 MAPK inhibitor with an IC50 value of <1 Î¼M, currently in clin. testing), dexamethasone or oseltamivir (Tamiflu) starting 24 h post infection.  Body wt., bronchoalveolar lavage cells, cytokines, total protein and lactate dehydrogenase as well as serum cytokines were measured; a subset of animals was evaluated histopathol.  Results/Key findings. p38MAP kinase inhibition with BCT194 had no impact on influenza replication in HBECs.  When examg. BCT197 in vivo, and comparing to vehicle-treated animals, reduced wt. loss, improvement in survival and lack of impaired viral control was obsd. at BCT197 concns. relevant to those being used in clin. trials of acute exacerbations of chronic obstructive pulmonary disease; at higher concns. of BCT197 these effects were reduced.  Conclusions.  Compared to vehicle treatment, BCT197 (administered at a clin. relevant concn.) improved outcomes in a mouse model of influenza.  This is encouraging given that the use of innate inflammatory pathway inhibitors may raise concerns of neg. effects on infection regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp54HUMz77tu7Vg90H21EOLACvtfcHk0lh3spvSdqh8VQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSmsbzF&md5=b74cb96c7f237f3d277d67a57e0d7393</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1099%2Fjmm.0.000684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fjmm.0.000684%26sid%3Dliteratum%253Aachs%26aulast%3DGrowcott%26aufirst%3DE.%2BJ.%26aulast%3DBamba%26aufirst%3DD.%26aulast%3DGalarneau%26aufirst%3DJ.%2BR.%26aulast%3DLeonard%26aufirst%3DV.%2BH.%2BJ.%26aulast%3DSchul%26aufirst%3DW.%26aulast%3DStein%26aufirst%3DD.%26aulast%3DOsborne%26aufirst%3DC.%2BS.%26atitle%3DThe%2520effect%2520of%2520P38%2520MAP%2520kinase%2520inhibition%2520in%2520a%2520mouse%2520model%2520of%2520influenza%26jtitle%3DJ.%2520Med.%2520Microbiol.%26date%3D2018%26volume%3D67%26spage%3D452%26epage%3D462%26doi%3D10.1099%2Fjmm.0.000684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-GuardeÃ±o, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto-Torres, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeDiego, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regla-Nava, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Delgado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">CastaÃ±o-Rodriguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjuanes, L.</span></span> <span> </span><span class="NLM_article-title">The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e1004320</span> <span class="refDoi">Â DOI: 10.1371/journal.ppat.1004320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.ppat.1004320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25122212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12isrrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&author=J.+M.+Jimenez-Guarde%C3%B1oauthor=J.+L.+Nieto-Torresauthor=M.+L.+DeDiegoauthor=J.+A.+Regla-Navaauthor=R.+Fernandez-Delgadoauthor=C.+Casta%C3%B1o-Rodriguezauthor=L.+Enjuanes&title=The+PDZ-binding+motif+of+severe+acute+respiratory+syndrome+coronavirus+envelope+protein+is+a+determinant+of+viral+pathogenesis&doi=10.1371%2Fjournal.ppat.1004320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis</span></div><div class="casAuthors">Jimenez-Guardeno, Jose M.; Nieto-Torres, Jose L.; DeDiego, Marta L.; Regla-Nava, Jose A.; Fernandez-Delgado, Raul; Castano-Rodriguez, Carlos; Enjuanes, Luis</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1004320/1-e1004320/20, 20 pp.</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">A recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) lacking the envelope (E) protein is attenuated in vivo.  Here we report that E protein PDZ-binding motif (PBM), a domain involved in protein-protein interactions, is a major determinant of virulence.  Elimination of SARS-CoV E protein PBM by using reverse genetics caused a redn. in the deleterious exacerbation of the immune response triggered during infection with the parental virus and virus attenuation.  Cellular protein syntenin was identified to bind the E protein PBM during SARS-CoV infection by using three complementary strategies, yeast two-hybrid, reciprocal coimmunopptn. and confocal microscopy assays.  Syntenin redistributed from the nucleus to the cell cytoplasm during infection with viruses contg. the E protein PBM, activating p38 MAPK and leading to the overexpression of inflammatory cytokines.  Silencing of syntenin using siRNAs led to a decrease in p38 MAPK activation in SARS-CoV infected cells, further reinforcing their functional relationship.  Active p38 MAPK was reduced in lungs of mice infected with SARS-CoVs lacking E protein PBM as compared with the parental virus, leading to a decreased expression of inflammatory cytokines and to virus attenuation.  Interestingly, administration of a p38 MAPK inhibitor led to an increase in mice survival after infection with SARS-CoV, confirming the relevance of this pathway in SARS-CoV virulence.  Therefore, the E protein PBM is a virulence domain that activates immunopathol. most likely by using syntenin as a mediator of p38 MAPK induced inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoputsl14GlW7Vg90H21EOLACvtfcHk0lh3spvSdqh8VQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12isrrN&md5=21aeb7c1782666ec2312cd7145130bef</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004320%26sid%3Dliteratum%253Aachs%26aulast%3DJimenez-Guarde%25C3%25B1o%26aufirst%3DJ.%2BM.%26aulast%3DNieto-Torres%26aufirst%3DJ.%2BL.%26aulast%3DDeDiego%26aufirst%3DM.%2BL.%26aulast%3DRegla-Nava%26aufirst%3DJ.%2BA.%26aulast%3DFernandez-Delgado%26aufirst%3DR.%26aulast%3DCasta%25C3%25B1o-Rodriguez%26aufirst%3DC.%26aulast%3DEnjuanes%26aufirst%3DL.%26atitle%3DThe%2520PDZ-binding%2520motif%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%2520envelope%2520protein%2520is%2520a%2520determinant%2520of%2520viral%2520pathogenesis%26jtitle%3DPLoS%2520Pathog.%26date%3D2014%26volume%3D10%26doi%3D10.1371%2Fjournal.ppat.1004320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span> <span> </span><span class="NLM_article-title">Clinical predictors of mortality due to COID-19 based on an analysis of data of 150 patients from Wuhan, China</span>. <i>Intensive Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1294</span>â <span class="NLM_lpage">1297</span>, <span class="refDoi">Â DOI: 10.1007/s00134-020-06028-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs00134-020-06028-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32253449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB38zhsFCqsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2020&pages=1294-1297&author=Q.+Ruanauthor=K.+Yangauthor=W.+Wangauthor=L.+Jiangauthor=J.+Song&title=Clinical+predictors+of+mortality+due+to+COID-19+based+on+an+analysis+of+data+of+150+patients+from+Wuhan%2C+China&doi=10.1007%2Fs00134-020-06028-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China</span></div><div class="casAuthors">Ruan Qiurong; Ruan Qiurong; Yang Kun; Wang Wenxia; Song Jianxin; Jiang Lingyu</div><div class="citationInfo"><span class="NLM_cas:title">Intensive care medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1294-1297</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfSvk7SjQ0DbGbPKh4T9eAfW6udTcc2eZtb5sohRLYPLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zhsFCqsA%253D%253D&md5=ce3379b1871b7e841cf16e0b82a11164</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1007%2Fs00134-020-06028-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00134-020-06028-z%26sid%3Dliteratum%253Aachs%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DJ.%26atitle%3DClinical%2520predictors%2520of%2520mortality%2520due%2520to%2520COID-19%2520based%2520on%2520an%2520analysis%2520of%2520data%2520of%2520150%2520patients%2520from%2520Wuhan%252C%2520China%26jtitle%3DIntensive%2520Care%2520Med.%26date%3D2020%26volume%3D46%26spage%3D1294%26epage%3D1297%26doi%3D10.1007%2Fs00134-020-06028-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span> <span> </span><span class="NLM_article-title">Modulation of mitogen-activated protein kinase attenuates sepsis-induced acute lung injury in acute respiratory distress syndrome rats</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">9652</span>â <span class="NLM_lpage">9658</span>, <span class="refDoi">Â DOI: 10.3892/mmr.2017.7811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3892%2Fmmr.2017.7811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29039541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC1M7hsVCktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=9652-9658&author=W.+Fangauthor=S.+X.+Caiauthor=C.+L.+Wangauthor=X.+X.+Sunauthor=K.+Liauthor=X.+W.+Yanauthor=Y.+B.+Sunauthor=X.+Z.+Sunauthor=C.+K.+Guauthor=M.+Y.+Daiauthor=H.+M.+Wangauthor=Z.+Zhou&title=Modulation+of+mitogen-activated+protein+kinase+attenuates+sepsis-induced+acute+lung+injury+in+acute+respiratory+distress+syndrome+rats&doi=10.3892%2Fmmr.2017.7811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of mitogen-activated protein kinase attenuates sepsis-induced acute lung injury in acute respiratory distress syndrome rats</span></div><div class="casAuthors">Fang Wei; Cai Shi-Xia; Wang Chuan-Lei; Sun Xiao-Xia; Li Kun; Yan Xiao-Wen; Sun Yun-Bo; Sun Xiao-Zhe; Gu Chuan-Kai; Dai Ming-Ying; Wang Hui-Ming; Zhou Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular medicine reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">9652-9658</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sepsis is the most important predisposing cause inducing acute respiratory distress syndrome (ARDS); however, the mechanism of sepsis leading to the development of ARDS remains to be elucidated.  Suppression of the mitogen-activated protein kinase (MAPK) signal by blocking the phosphorylation of Jun N-terminal kinase (JNK) and p38 in lung tissues could alleviate acute lung injury induced by sepsis.  MAPK signaling may have a crucial role in development of the sepsis-induced acute lung injury.  The specific inhibitors of JNK and p38 MAPK, SP600125 and SB203580, were administrated by intragastric injection 4 h before induction of ARDS after cecal ligation and puncture (CLP).  Rats were sacrificed at 1, 6 or 24 h after CLP challenge.  The histological evaluation, lung water content, and biochemical analysis were performed.  The results revealed that the JNK and p38 MAPK inhibitor improved lung permeability, attenuated system inflammation, further alleviated the lung injury induced by sepsis.  In conclusion, JNK and p38 MAPK signaling are essential for the development of ARDS following sepsis.  Further studies are needed to illuminate the detailed mechanisms of JNK and p38 MAPK signaling in sepsis-induced ARDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkFw-oTWL33XELvajU9pjPfW6udTcc2eZtb5sohRLYPLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7hsVCktg%253D%253D&md5=a04cf910044bbb79c927defb5d0a6846</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2017.7811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2017.7811%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DS.%2BX.%26aulast%3DWang%26aufirst%3DC.%2BL.%26aulast%3DSun%26aufirst%3DX.%2BX.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DX.%2BW.%26aulast%3DSun%26aufirst%3DY.%2BB.%26aulast%3DSun%26aufirst%3DX.%2BZ.%26aulast%3DGu%26aufirst%3DC.%2BK.%26aulast%3DDai%26aufirst%3DM.%2BY.%26aulast%3DWang%26aufirst%3DH.%2BM.%26aulast%3DZhou%26aufirst%3DZ.%26atitle%3DModulation%2520of%2520mitogen-activated%2520protein%2520kinase%2520attenuates%2520sepsis-induced%2520acute%2520lung%2520injury%2520in%2520acute%2520respiratory%2520distress%2520syndrome%2520rats%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2017%26volume%3D16%26spage%3D9652%26epage%3D9658%26doi%3D10.3892%2Fmmr.2017.7811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louden, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuerstein, G. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, T. L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1685</span>â <span class="NLM_lpage">1691</span>, <span class="refDoi">Â DOI: 10.1161/01.CIR.99.13.1685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1161%2F01.CIR.99.13.1685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10190877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK1MXisFalsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1999&pages=1685-1691&author=X.+L.+Maauthor=S.+Kumarauthor=F.+Gaoauthor=C.+S.+Loudenauthor=B.+L.+Lopezauthor=T.+A.+Christopherauthor=C.+Wangauthor=J.+C.+Leeauthor=G.+Z.+Feuersteinauthor=T.+L.+Yue&title=Inhibition+of+p38+mitogen-activated+protein+kinase+decreases+cardiomyocyte+apoptosis+and+improves+cardiac+function+after+myocardial+ischemia+and+reperfusion&doi=10.1161%2F01.CIR.99.13.1685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion</span></div><div class="casAuthors">Ma, Xin L.; Kumar, Sanjay; Gao, Feng; Louden, Calvert S.; Lopez, Bernard L.; Christopher, Theodore A.; Wang, Chuanlin; Lee, John C.; Feuerstein, Giora Z.; Yue, Tian-Li</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1685-1691</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Activation of p38 mitogen-activated protein kinase (MAPK) plays an important role in apoptotic cell death.  The role of p38 MAPK in myocardial injury caused by ischemia/reperfusion, an extreme stress to the heart, is unknown.  Studies were performed with isolated, Langendorff-perfused rabbit hearts.  Ischemia alone caused a moderate but transient increase in p38 MAPK activity (3.5-fold increase).  Ischemia followed by reperfusion further activated p38 MAPK, and the maximal level of activation (6.3-fold) was reached 10 min after reperfusion.  Administration of SB 203580, a p38 MAPK inhibitor, decreased myocardial apoptosis (14.7Â±3.2% vs. 30.6Â±3.5% in vehicle) and improved postischemic cardiac function.  The cardioprotective effects of SB 203580 were closely related to its inhibition of p38 MAPK.  Administering SB 203580 before ischemia and during reperfusion completely inhibited p38 MAPK activation and exerted the most cardioprotective effects.  In contrast, administering SB 203580 10 min after reperfusion (a time point when maximal MAPK activation had already been achieved) failed to convey significant cardioprotection.  Moreover, inhibition of p38 MAPK attenuated myocardial necrosis after a prolonged reperfusion.  These results demonstrate that p38 MAPK plays a pivotal role in the signal transduction pathway mediating postischemic myocardial apoptosis and that inhibiting p38 MAPK may attenuate reperfusion injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNE1gKscK23rVg90H21EOLACvtfcHk0lhLlLOMgBt88Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXisFalsbo%253D&md5=ca83707742a145eeeffd0c3cb18568b0</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.99.13.1685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.99.13.1685%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%2BL.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DLouden%26aufirst%3DC.%2BS.%26aulast%3DLopez%26aufirst%3DB.%2BL.%26aulast%3DChristopher%26aufirst%3DT.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DFeuerstein%26aufirst%3DG.%2BZ.%26aulast%3DYue%26aufirst%3DT.%2BL.%26atitle%3DInhibition%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520decreases%2520cardiomyocyte%2520apoptosis%2520and%2520improves%2520cardiac%2520function%2520after%2520myocardial%2520ischemia%2520and%2520reperfusion%26jtitle%3DCirculation%26date%3D1999%26volume%3D99%26spage%3D1685%26epage%3D1691%26doi%3D10.1161%2F01.CIR.99.13.1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarubin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span> <span> </span><span class="NLM_article-title">Activation and signaling of the p38 MAP kinase pathway</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">11</span>â <span class="NLM_lpage">18</span>, <span class="refDoi">Â DOI: 10.1038/sj.cr.7290257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fsj.cr.7290257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=15686620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslGisb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=11-18&author=T.+Zarubinauthor=J.+Han&title=Activation+and+signaling+of+the+p38+MAP+kinase+pathway&doi=10.1038%2Fsj.cr.7290257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Activation and signaling of the p38 MAP kinase pathway</span></div><div class="casAuthors">Zarubin, Tyler; Han, Jiahuai</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-18</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Editorial Office of Cell Research</span>)
        </div><div class="casAbstract">A review.  The family members of the MAP kinases mediate a wide variety of cellular behaviors in response to extracellular stimuli.  One of the 4 main sub-groups, the p38 group of MAP kinases, serve as a nexus for signal transduction and play a vital role in numerous biol. processes.  Here, the authors highlight the known characteristics and components of the p38 pathway along with the mechanism and consequences of p38 activation.  The authors focus on the role of p38 as a signal transduction mediator and examine the evidence linking p38 to inflammation, cell cycle, cell death, development, cell differentiation, senescence, and tumorigenesis in specific cell types.  Upstream and downstream components of p38 are described and questions remaining to be answered are posed.  Finally, the authors propose several directions for future research on p38.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIDzDSa5vqULVg90H21EOLACvtfcHk0lhLlLOMgBt88Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslGisb4%253D&md5=c0f98c8f6db6e10b0a20357c401273d5</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1038%2Fsj.cr.7290257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cr.7290257%26sid%3Dliteratum%253Aachs%26aulast%3DZarubin%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DJ.%26atitle%3DActivation%2520and%2520signaling%2520of%2520the%2520p38%2520MAP%2520kinase%2520pathway%26jtitle%3DCell%2520Res.%26date%3D2005%26volume%3D15%26spage%3D11%26epage%3D18%26doi%3D10.1038%2Fsj.cr.7290257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gheblawi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viveiros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raizada, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudit, G. Y.</span></span> <span> </span><span class="NLM_article-title">Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1456</span>, <span class="refDoi">Â DOI: 10.1161/CIRCRESAHA.120.317015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1161%2FCIRCRESAHA.120.317015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32264791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVaksrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2020&pages=1456&author=M.+Gheblawiauthor=K.+Wangauthor=A.+Viveirosauthor=Q.+Nguyenauthor=J.+C.+Zhongauthor=A.+J.+Turnerauthor=M.+K.+Raizadaauthor=M.+B.+Grantauthor=G.+Y.+Oudit&title=Angiotensin+converting+enzyme+2%3A+SARS-CoV-2+receptor+and+regulator+of+the+renin-angiotensin+system&doi=10.1161%2FCIRCRESAHA.120.317015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2</span></div><div class="casAuthors">Gheblawi, Mahmoud; Wang, Kaiming; Viveiros, Anissa; Nguyen, Quynh; Zhong, Jiu-Chang; Turner, Anthony J.; Raizada, Mohan K.; Grant, Maria B.; Oudit, Gavin Y.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1456-1474</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  ACE2 (angiotensin-converting enzyme 2) has a multiplicity of physiol. roles that revolve around its trivalent function: a neg. regulator of the renin-angiotensin system, facilitator of amino acid transport, and the severe acute respiratory syndrome-coronavirus (SARS-CoV) and SARS-CoV-2 receptor.  ACE2 is widely expressed, including, in the lungs, cardiovascular system, gut, kidneys, central nervous system, and adipose tissue.  ACE2 has recently been identified as the SARS-CoV-2 receptor, the infective agent responsible for coronavirus disease 2019, providing a crit. link between immunity, inflammation, ACE2, and cardiovascular disease.  Although sharing a close evolutionary relationship with SARS-CoV, the receptor-binding domain of SARS-CoV-2 differs in several key amino acid residues, allowing for stronger binding affinity with the human ACE2 receptor, which may account for the greater pathogenicity of SARS-CoV-2.  The loss of ACE2 function following binding by SARS-CoV-2 is driven by endocytosis and activation of proteolytic cleavage and processing.  The ACE2 system is a crit. protective pathway against heart failure with reduced and preserved ejection fraction including, myocardial infarction and hypertension, and against lung disease and diabetes mellitus.  The control of gut dysbiosis and vascular permeability by ACE2 has emerged as an essential mechanism of pulmonary hypertension and diabetic cardiovascular complications.  Recombinant ACE2, gene-delivery of Ace2, Ang 1-7 analogs, and Mas receptor agonists enhance ACE2 action and serve as potential therapies for disease conditions assocd. with an activated renin-angiotensin system.  RhACE2 (recombinant human ACE2) has completed clin. trials and efficiently lowered or increased plasma angiotensin II and angiotensin 1-7 levels, resp.  Our review summarizes the progress over the past 20 years, highlighting the crit. role of ACE2 as the novel SARS-CoV-2 receptor and as the neg. regulator of the renin-angiotensin system, together with implications for the coronavirus disease 2019 pandemic and assocd. cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo98H70prhSX7Vg90H21EOLACvtfcHk0ljaCGgc2nfnRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVaksrY%253D&md5=f240902dd9bf0f970ad227a1c5d4f037</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.120.317015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.120.317015%26sid%3Dliteratum%253Aachs%26aulast%3DGheblawi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DViveiros%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DQ.%26aulast%3DZhong%26aufirst%3DJ.%2BC.%26aulast%3DTurner%26aufirst%3DA.%2BJ.%26aulast%3DRaizada%26aufirst%3DM.%2BK.%26aulast%3DGrant%26aufirst%3DM.%2BB.%26aulast%3DOudit%26aufirst%3DG.%2BY.%26atitle%3DAngiotensin%2520converting%2520enzyme%25202%253A%2520SARS-CoV-2%2520receptor%2520and%2520regulator%2520of%2520the%2520renin-angiotensin%2520system%26jtitle%3DCirc.%2520Res.%26date%3D2020%26volume%3D126%26spage%3D1456%26doi%3D10.1161%2FCIRCRESAHA.120.317015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neely, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaghubian-Malhami, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Loo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermolaeva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veldhuizen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasparakis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mech, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peiris, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slutsky, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akira, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hultqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmdahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">235</span>â <span class="NLM_lpage">249</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2008.02.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cell.2008.02.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18423196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWnu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2008&pages=235-249&author=Y.+Imaiauthor=K.+Kubaauthor=G.+G.+Neelyauthor=R.+Yaghubian-Malhamiauthor=T.+Perkmannauthor=G.+van+Looauthor=M.+Ermolaevaauthor=R.+Veldhuizenauthor=Y.+H.+Leungauthor=H.+Wangauthor=H.+Liuauthor=Y.+Sunauthor=M.+Pasparakisauthor=M.+Kopfauthor=C.+Mechauthor=S.+Bavariauthor=J.+S.+Peirisauthor=A.+S.+Slutskyauthor=S.+Akiraauthor=M.+Hultqvistauthor=R.+Holmdahlauthor=J.+Nichollsauthor=C.+Jiangauthor=C.+J.+Binderauthor=J.+M.+Penninger&title=Identification+of+oxidative+stress+and+Toll-like+receptor+4+signaling+as+a+key+pathway+of+acute+lung+injury&doi=10.1016%2Fj.cell.2008.02.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury</span></div><div class="casAuthors">Imai, Yumiko; Kuba, Keiji; Neely, G. Greg; Yaghubian-Malhami, Rubina; Perkmann, Thomas; van Loo, Geert; Ermolaeva, Maria; Veldhuizen, Ruud; Leung, Y. H. Connie; Wang, Hongliang; Liu, Haolin; Sun, Yang; Pasparakis, Manolis; Kopf, Manfred; Mech, Christin; Bavari, Sina; Peiris, J. S. Malik; Slutsky, Arthur S.; Akira, Shizuo; Hultqvist, Malin; Holmdahl, Rikard; Nicholls, John; Jiang, Chengyu; Binder, Christoph J.; Penninger, Josef M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-249</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Multiple lung pathogens such as chem. agents, H5N1 avian flu, or SARS cause high lethality due to acute respiratory distress syndrome.  Here the authors report that Toll-like receptor 4 (TLR4) mutant mice display natural resistance to acid-induced acute lung injury (ALI).  They show that TLR4-TRIF-TRAF6 signaling is a key disease pathway that controls the severity of ALI.  The oxidized phospholipid (OxPL) OxPAPC was identified to induce lung injury and cytokine prodn. by lung macrophages via TLR4-TRIF.  The authors obsd. OxPL prodn. in the lungs of humans and animals infected with SARS, Anthrax, or H5N1.  Pulmonary challenge with an inactivated H5N1 avian influenza virus rapidly induces ALI and OxPL formation in mice.  Loss of TLR4 or TRIF expression protects mice from H5N1-induced ALI.  Moreover, deletion of ncf1, which controls ROS prodn., improves the severity of H5N1-mediated ALI.  The authors' data identify oxidative stress and innate immunity as key lung injury pathways that control the severity of ALI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5xpZqE-O04rVg90H21EOLACvtfcHk0ljaCGgc2nfnRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWnu74%253D&md5=88eb341410b86cb3569841d3707a457f</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.02.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.02.043%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DY.%26aulast%3DKuba%26aufirst%3DK.%26aulast%3DNeely%26aufirst%3DG.%2BG.%26aulast%3DYaghubian-Malhami%26aufirst%3DR.%26aulast%3DPerkmann%26aufirst%3DT.%26aulast%3Dvan%2BLoo%26aufirst%3DG.%26aulast%3DErmolaeva%26aufirst%3DM.%26aulast%3DVeldhuizen%26aufirst%3DR.%26aulast%3DLeung%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DPasparakis%26aufirst%3DM.%26aulast%3DKopf%26aufirst%3DM.%26aulast%3DMech%26aufirst%3DC.%26aulast%3DBavari%26aufirst%3DS.%26aulast%3DPeiris%26aufirst%3DJ.%2BS.%26aulast%3DSlutsky%26aufirst%3DA.%2BS.%26aulast%3DAkira%26aufirst%3DS.%26aulast%3DHultqvist%26aufirst%3DM.%26aulast%3DHolmdahl%26aufirst%3DR.%26aulast%3DNicholls%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DBinder%26aufirst%3DC.%2BJ.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520oxidative%2520stress%2520and%2520Toll-like%2520receptor%25204%2520signaling%2520as%2520a%2520key%2520pathway%2520of%2520acute%2520lung%2520injury%26jtitle%3DCell%26date%3D2008%26volume%3D133%26spage%3D235%26epage%3D249%26doi%3D10.1016%2Fj.cell.2008.02.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechend, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shagdarsuren, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gapeljuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiners, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratze, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Saadi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebeler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madwed, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirdewan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luft, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, D. N.</span></span> <span> </span><span class="NLM_article-title">p38 Mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">481</span>â <span class="NLM_lpage">489</span>, <span class="refDoi">Â DOI: 10.1161/01.HYP.0000256831.33459.ea</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1161%2F01.HYP.0000256831.33459.ea" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17224470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSiu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2007&pages=481-489&author=J.+K.+Parkauthor=R.+Fischerauthor=R.+Dechendauthor=E.+Shagdarsurenauthor=A.+Gapeljukauthor=M.+Wellnerauthor=S.+Meinersauthor=P.+Gratzeauthor=N.+Al-Saadiauthor=S.+Feldtauthor=A.+Fiebelerauthor=J.+B.+Madwedauthor=A.+Schirdewanauthor=H.+Hallerauthor=F.+C.+Luftauthor=D.+N.+Muller&title=p38+Mitogen-activated+protein+kinase+inhibition+ameliorates+angiotensin+II-induced+target+organ+damage&doi=10.1161%2F01.HYP.0000256831.33459.ea"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">p38 Mitogen-Activated Protein Kinase Inhibition Ameliorates Angiotensin II-Induced Target Organ Damage</span></div><div class="casAuthors">Park, Joon-Keun; Fischer, Robert; Dechend, Ralf; Shagdarsuren, Erdenechimeg; Gapeljuk, Andrej; Wellner, Maren; Meiners, Silke; Gratze, Petra; Al-Saadi, Nidal; Feldt, Sandra; Fiebeler, Anette; Madwed, Jeffrey B.; Schirdewan, Alexander; Haller, Hermann; Luft, Friedrich C.; Muller, Dominik N.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">481-489</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We investigated whether or not p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage.  We used double transgenic rats harboring both human renin and angiotensinogen genes (dTGRs).  DTGR, with or without p38 inhibitor (BIRB796; 30 mg/kg per day in the diet), and nontransgenic Sprague-Dawley rats were studied in 2 protocols.  In protocol 1 (week 7), systolic blood pressure of untreated dTGRs was 204Â±4 mm Hg, but partially reduced after BIRB796 treatment (166Â±7 mm Hg), whereas Sprague-Dawley rats were normotensive.  The cardiac hypertrophy index was unchanged in untreated and BIRB796-treated dTGRs.  The Î²-myosin heavy chain expression of BIRB796-treated hearts was significantly lower in BIRB796 compared with dTGRs, indicating a delayed switch to the fetal isoform.  BIRB796 treatment significantly reduced cardiac fibrosis, connective tissue growth factor, tumor necrosis factor-Î±, interleukin-6, and macrophage infiltration.  Albuminuria was not reduced in BIRB796-treated dTGRs.  Tubular and glomerular damage with tumor necrosis factor-Î± expression was unaltered, although serum creatinine and cystatin C were normalized.  Renal macrophage infiltration, fibrosis, and vessel damage were reduced.  In protocol 2 (week 8), we focused on mortality and arrhythmogenic elec. remodeling.  Mortality of untreated dTGRs was 100% but was reduced to 10% in the BIRB796 group.  Cardiac magnetic field mapping showed prolongation of depolarization and repolarization in untreated dTGRs compared with Sprague-Dawley rats with a partial redn. by BIRB796.  Programmed elec. stimulation elicited ventricular tachycardias in 81% of untreated dTGRs but only in 48% of BIRB796-treated dTGRs.  In conclusion, BIRB796 improved survival, target organ damage, and arrhythmogenic potential in angiotensin II-induced target organ damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_nLfWR8l12rVg90H21EOLACvtfcHk0lgE9XiwPF-V_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSiu74%253D&md5=c8f285f1ee55b79fb6d1e39821d68199</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000256831.33459.ea&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000256831.33459.ea%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DFischer%26aufirst%3DR.%26aulast%3DDechend%26aufirst%3DR.%26aulast%3DShagdarsuren%26aufirst%3DE.%26aulast%3DGapeljuk%26aufirst%3DA.%26aulast%3DWellner%26aufirst%3DM.%26aulast%3DMeiners%26aufirst%3DS.%26aulast%3DGratze%26aufirst%3DP.%26aulast%3DAl-Saadi%26aufirst%3DN.%26aulast%3DFeldt%26aufirst%3DS.%26aulast%3DFiebeler%26aufirst%3DA.%26aulast%3DMadwed%26aufirst%3DJ.%2BB.%26aulast%3DSchirdewan%26aufirst%3DA.%26aulast%3DHaller%26aufirst%3DH.%26aulast%3DLuft%26aufirst%3DF.%2BC.%26aulast%3DMuller%26aufirst%3DD.%2BN.%26atitle%3Dp38%2520Mitogen-activated%2520protein%2520kinase%2520inhibition%2520ameliorates%2520angiotensin%2520II-induced%2520target%2520organ%2520damage%26jtitle%3DHypertension%26date%3D2007%26volume%3D49%26spage%3D481%26epage%3D489%26doi%3D10.1161%2F01.HYP.0000256831.33459.ea" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">7027</span>, <span class="refDoi">Â DOI: 10.1038/srep07027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fsrep07027" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=7027&author=P.+Yangauthor=H.+Guauthor=Z.+Zhaoauthor=W.+Wangauthor=B.+Caoauthor=C.+Laiauthor=X.+Yangauthor=L.+Zhangauthor=Y.+Duanauthor=S.+Zhangauthor=W.+Chenauthor=W.+Zhenauthor=M.+Caiauthor=J.+M.+Penningerauthor=C.+Jiangauthor=X.+Wang&title=Angiotensin-converting+enzyme+2+%28ACE2%29+mediates+influenza+H7N9+virus-induced+acute+lung+injury&doi=10.1038%2Fsrep07027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fsrep07027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep07027%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DCao%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhen%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DM.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DAngiotensin-converting%2520enzyme%25202%2520%2528ACE2%2529%2520mediates%2520influenza%2520H7N9%2520virus-induced%2520acute%2520lung%2520injury%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D4%26spage%3D7027%26doi%3D10.1038%2Fsrep07027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudemiller, N. P.</span></span> <span> </span><span class="NLM_article-title">Immunologic effects of the renin-angiotensin system</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1350</span>â <span class="NLM_lpage">1361</span>, <span class="refDoi">Â DOI: 10.1681/ASN.2016101066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1681%2FASN.2016101066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28151411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFOluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=1350-1361&author=S.+D.+Crowleyauthor=N.+P.+Rudemiller&title=Immunologic+effects+of+the+renin-angiotensin+system&doi=10.1681%2FASN.2016101066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Immunologic effects of the renin-angiotensin system</span></div><div class="casAuthors">Crowley, Steven D.; Rudemiller, Nathan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1350-1361</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">A review.  Inappropriate activation of the renin-angiotensin system (RAS) exacerbates renal and vascular injury.  Accordingly, treatment with global RAS antagonists attenuates cardiovascular risk and slows the progression of proteinuric kidney disease.  By reducing BP, RAS inhibitors limit secondary immune activation responding to hemodynamic injury in the target organ.  However, RAS activation in hematopoietic cells has immunol. effects that diverge from those of RAS stimulation in the kidney and vasculature.  In preclin. studies, activating type 1 angiotensin (AT1) receptors in T lymphocytes and myeloid cells blunts the polarization of these cells toward proinflammatory phenotypes, protecting the kidney from hypertensive injury and fibrosis.  These endogenous functions of immune AT1 receptors temper the pathogenic actions of renal and vascular AT1 receptors during hypertension.  By counteracting the effects of AT1 receptor stimulation in the target organ, exogenous administration of AT2 receptor agonists or angiotensin 1-7 analogs may similarly limit inflammatory injury to the heart and kidney.  Moreover, although angiotensin II is the classic effector mol. of the RAS, several RAS enzymes affect immune homeostasis independently of canonic angiotensin II generation.  Thus, as reviewed here, multiple components of the RAS signaling cascade influence inflammatory cell phenotype and function with unpredictable and context-specific effects on innate and adaptive immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocF-a5Lp5_QrVg90H21EOLACvtfcHk0lgE9XiwPF-V_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFOluw%253D%253D&md5=c373098083fb11ff6531e39bf3106b83</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1681%2FASN.2016101066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2016101066%26sid%3Dliteratum%253Aachs%26aulast%3DCrowley%26aufirst%3DS.%2BD.%26aulast%3DRudemiller%26aufirst%3DN.%2BP.%26atitle%3DImmunologic%2520effects%2520of%2520the%2520renin-angiotensin%2520system%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2017%26volume%3D28%26spage%3D1350%26epage%3D1361%26doi%3D10.1681%2FASN.2016101066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">SimÃµese Silva, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silveira, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, M. M.</span></span> <span> </span><span class="NLM_article-title">ACE2, angiotensin-(1â7) and Mas receptor axis in inflammation and fibrosis</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">477</span>â <span class="NLM_lpage">492</span>, <span class="refDoi">Â DOI: 10.1111/bph.12159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1111%2Fbph.12159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=23488800" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=477-492&author=A.+C.+Sim%C3%B5ese+Silvaauthor=K.+D.+Silveiraauthor=A.+J.+Ferreiraauthor=M.+M.+Teixeira&title=ACE2%2C+angiotensin-%281%E2%80%937%29+and+Mas+receptor+axis+in+inflammation+and+fibrosis&doi=10.1111%2Fbph.12159"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1111%2Fbph.12159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12159%26sid%3Dliteratum%253Aachs%26aulast%3DSim%25C3%25B5ese%2BSilva%26aufirst%3DA.%2BC.%26aulast%3DSilveira%26aufirst%3DK.%2BD.%26aulast%3DFerreira%26aufirst%3DA.%2BJ.%26aulast%3DTeixeira%26aufirst%3DM.%2BM.%26atitle%3DACE2%252C%2520angiotensin-%25281%25E2%2580%25937%2529%2520and%2520Mas%2520receptor%2520axis%2520in%2520inflammation%2520and%2520fibrosis%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D169%26spage%3D477%26epage%3D492%26doi%3D10.1111%2Fbph.12159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDea, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâCallaghan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokpesi, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handy, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takata, M.</span></span> <span> </span><span class="NLM_article-title">Reactive oxygen species and p38 mitogen-activated protein kinase mediate tumor necrosis factor Î±-converting enzyme (TACE/ADAM-17) activation in primary human monocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">35466</span>â <span class="NLM_lpage">35476</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M111.277434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.M111.277434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=21865167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yhtr3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=35466-35476&author=A.+J.+Scottauthor=K.+P.+O%E2%80%99Deaauthor=D.+O%E2%80%99Callaghanauthor=L.+Williamsauthor=J.+O.+Dokpesiauthor=L.+Tattonauthor=J.+M.+Handyauthor=P.+J.+Hoggauthor=M.+Takata&title=Reactive+oxygen+species+and+p38+mitogen-activated+protein+kinase+mediate+tumor+necrosis+factor+%CE%B1-converting+enzyme+%28TACE%2FADAM-17%29+activation+in+primary+human+monocytes&doi=10.1074%2Fjbc.M111.277434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive Oxygen Species and p38 Mitogen-activated Protein Kinase Mediate Tumor Necrosis Factor Î±-Converting Enzyme (TACE/ADAM-17) Activation in Primary Human Monocytes</span></div><div class="casAuthors">Scott, Alasdair J.; O'Dea, Kieran P.; O'Callaghan, David; Williams, Lynn; Dokpesi, Justina O.; Tatton, Louise; Handy, Jonathan M.; Hogg, Philip J.; Takata, Masao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">35466-35476</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Tumor necrosis factor Î±-converting enzyme (TACE) is responsible for the shedding of cell surface TNF.  Studies suggest that reactive oxygen species (ROS) mediate up-regulation of TACE activity by direct oxidization or modification of the protein.  However, these investigations have been largely based upon nonphysiol. stimulation of promonocytic cell lines which may respond and process TACE differently from primary cells.  Furthermore, investigators have relied upon TACE substrate shedding as a surrogate for activity quantification.  The authors addressed these concerns, employing a direct, cell-based fluorometric assay to investigate the regulation of TACE catalytic activity on freshly isolated primary human monocytes during LPS stimulation.  The authors hypothesized that ROS mediate up-regulation of TACE activity indirectly, by activation of intracellular signaling pathways.  LPS up-regulated TACE activity rapidly (within 30 min) without changing cell surface TACE expression.  Scavenging of ROS or inhibiting their prodn. by flavoprotein oxidoreductases significantly attenuated LPS-induced TACE activity up-regulation.  Exogenous ROS (H2O2) also up-regulated TACE activity with similar kinetics and magnitude as LPS.  H2O2- and LPS-induced TACE activity up-regulation were effectively abolished by a variety of selective p38 MAPK inhibitors.  Activation of p38 was redox-sensitive as H2O2 caused p38 phosphorylation, and ROS scavenging significantly reduced LPS-induced phospho-p38 expression.  Inhibition of the p38 substrate, MAPK-activated protein kinase 2, completely attenuated TACE activity up-regulation, whereas inhibition of ERK had little effect.  Lastly, inhibition of cell surface oxidoreductases prevented TACE activity up-regulation distal to p38 activation.  In conclusion, the data indicate that in primary human monocytes, ROS mediate LPS-induced up-regulation of TACE activity indirectly through activation of the p38 signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj8oHM3UMrIrVg90H21EOLACvtfcHk0li99LjQDFdcSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yhtr3F&md5=ea5da30cf2688386f84e9e631a352d1b</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.277434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.277434%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DA.%2BJ.%26aulast%3DO%25E2%2580%2599Dea%26aufirst%3DK.%2BP.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DDokpesi%26aufirst%3DJ.%2BO.%26aulast%3DTatton%26aufirst%3DL.%26aulast%3DHandy%26aufirst%3DJ.%2BM.%26aulast%3DHogg%26aufirst%3DP.%2BJ.%26aulast%3DTakata%26aufirst%3DM.%26atitle%3DReactive%2520oxygen%2520species%2520and%2520p38%2520mitogen-activated%2520protein%2520kinase%2520mediate%2520tumor%2520necrosis%2520factor%2520%25CE%25B1-converting%2520enzyme%2520%2528TACE%252FADAM-17%2529%2520activation%2520in%2520primary%2520human%2520monocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D35466%26epage%3D35476%26doi%3D10.1074%2Fjbc.M111.277434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touyz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loomba, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1671</span>â <span class="NLM_lpage">1681</span>, <span class="refDoi">Â DOI: 10.1161/CIRCRESAHA.120.317134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1161%2FCIRCRESAHA.120.317134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32302265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVylurvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2020&pages=1671-1681&author=P.+Zhangauthor=L.+Zhuauthor=J.+Caiauthor=F.+Leiauthor=J.+J.+Qinauthor=J.+Xieauthor=Y.+M.+Liuauthor=Y.+C.+Zhaoauthor=X.+Huangauthor=L.+Linauthor=M.+Xiaauthor=M.+M.+Chenauthor=X.+Chengauthor=X.+Zhangauthor=D.+Guoauthor=Y.+Pengauthor=Y.+X.+Jiauthor=J.+Chenauthor=Z.+G.+Sheauthor=Y.+Wangauthor=Q.+Xuauthor=R.+Tanauthor=H.+Wangauthor=J.+Linauthor=P.+Luoauthor=S.+Fuauthor=H.+Caiauthor=P.+Yeauthor=B.+Xiaoauthor=W.+Maoauthor=L.+Liuauthor=Y.+Yanauthor=M.+Liuauthor=M.+Chenauthor=X.+J.+Zhangauthor=X.+Wangauthor=R.+M.+Touyzauthor=J.+Xiaauthor=B.+H.+Zhangauthor=X.+Huangauthor=Y.+Yuanauthor=R.+Loombaauthor=P.+P.+Liuauthor=H.+Li&title=Association+of+inpatient+use+of+angiotensin+converting+enzyme+inhibitors+and+angiotensin+II+receptor+blockers+with+mortality+among+patients+with+hypertension+hospitalized+with+COVID-19&doi=10.1161%2FCIRCRESAHA.120.317134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19</span></div><div class="casAuthors">Zhang, Peng; Zhu, Lihua; Cai, Jingjing; Lei, Fang; Qin, Juan-Juan; Xie, Jing; Liu, Ye-Mao; Zhao, Yan-Ci; Huang, Xuewei; Lin, Lijin; Xia, Meng; Chen, Ming-Ming; Cheng, Xu; Zhang, Xiao; Guo, Deliang; Peng, Yuanyuan; Ji, Yan-Xiao; Chen, Jing; She, Zhi-Gang; Wang, Yibin; Xu, Qingbo; Tan, Renfu; Wang, Haitao; Lin, Jun; Luo, Pengcheng; Fu, Shouzhi; Cai, Hongbin; Ye, Ping; Xiao, Bing; Mao, Weiming; Liu, Liming; Yan, Youqin; Liu, Mingyu; Chen, Manhua; Zhang, Xiao-Jing; Wang, Xinghuan; Touyz, Rhian M.; Xia, Jiahong; Zhang, Bing-Hong; Huang, Xiaodong; Yuan, Yufeng; Rohit, Loomba; Liu, Peter P.; Li, Hongliang</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1671-1681</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with hypertension.  Objective: To det. the assocn. between in-hospital use of ACEI/ARB and all-cause mortality in patients with hypertension and hospitalized due to COVID-19.  Methods and results: This retrospective, multi-center study included 1128 adult patients with hypertension diagnosed with COVID-19, including 188 taking ACEI/ARB (ACEI/ARB group; median age 64 [interquartile range, 55-68] years; 53.2% men) and 940 without using ACEI/ARB (non-ACEI/ARB group; median age 64 [interquartile range 57-69]; 53.5% men), who were admitted to 9 hospitals in Hubei Province, China from Dec. 31, 2019 to Feb. 20, 2020.  In mixed-effect Cox model treating site as a random effect, after adjusting for age, gender, comorbidities, and in-hospital medications, the detected risk for all-cause mortality was lower in the ACEI/ARB group vs. the non-ACEI/ARB group (adjusted hazard ratio, 0.42 [95% CI, 0.19-0.92]; P=0.03).  In a propensity score-matched anal. followed by adjusting imbalanced variables in mixed-effect Cox model, the results consistently demonstrated lower risk of COVID-19 mortality in patients who received ACEI/ARB vs. those who did not receive ACEI/ARB (adjusted hazard ratio, 0.37 [95% CI, 0.15-0.89]; P=0.03).  Further subgroup propensity score-matched anal. indicated that, compared with use of other antihypertensive drugs, ACEI/ARB was also assocd. with decreased mortality (adjusted hazard ratio, 0.30 [95% CI, 0.12-0.70]; P=0.01) in patients with COVID-19 and coexisting hypertension.  Conclusions: Among hospitalized patients with COVID-19 and coexisting hypertension, inpatient use of ACEI/ARB was assocd. with lower risk of all-cause mortality compared with ACEI/ARB nonusers.  While study interpretation needs to consider the potential for residual confounders, it is unlikely that in-hospital use of ACEI/ARB was assocd. with an increased mortality risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1sXffk6sGnLVg90H21EOLACvtfcHk0li8zKMztdt4xg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVylurvO&md5=bb6be19a3383e6f32f192a4aa1919482</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.120.317134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.120.317134%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DF.%26aulast%3DQin%26aufirst%3DJ.%2BJ.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%2BM.%26aulast%3DZhao%26aufirst%3DY.%2BC.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DM.%2BM.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DY.%2BX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DShe%26aufirst%3DZ.%2BG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DTan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DP.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DP.%26aulast%3DXiao%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%2BJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTouyz%26aufirst%3DR.%2BM.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%2BH.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DLoomba%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DP.%2BP.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DAssociation%2520of%2520inpatient%2520use%2520of%2520angiotensin%2520converting%2520enzyme%2520inhibitors%2520and%2520angiotensin%2520II%2520receptor%2520blockers%2520with%2520mortality%2520among%2520patients%2520with%2520hypertension%2520hospitalized%2520with%2520COVID-19%26jtitle%3DCirc.%2520Res.%26date%3D2020%26volume%3D126%26spage%3D1671%26epage%3D1681%26doi%3D10.1161%2FCIRCRESAHA.120.317134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span> <span> </span><span class="NLM_article-title">Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury</span>. <i>Sci. China: Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">364</span>â <span class="NLM_lpage">374</span>, <span class="refDoi">Â DOI: 10.1007/s11427-020-1643-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs11427-020-1643-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32048163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1Wgsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=364-374&author=Y.+Liuauthor=Y.+Yangauthor=C.+Zhangauthor=F.+Huangauthor=F.+Wangauthor=J.+Yuanauthor=Z.+Wangauthor=J.+Liauthor=J.+Liauthor=C.+Fengauthor=Z.+Zhangauthor=L.+Wangauthor=L.+Pengauthor=L.+Chenauthor=Y.+Qinauthor=D.+Zhaoauthor=S.+Tanauthor=L.+Yinauthor=J.+Xuauthor=C.+Zhouauthor=C.+Jiangauthor=L.+Liu&title=Clinical+and+biochemical+indexes+from+2019-nCoV+infected+patients+linked+to+viral+loads+and+lung+injury&doi=10.1007%2Fs11427-020-1643-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury</span></div><div class="casAuthors">Liu, Yingxia; Yang, Yang; Zhang, Cong; Huang, Fengming; Wang, Fuxiang; Yuan, Jing; Wang, Zhaoqin; Li, Jinxiu; Li, Jianming; Feng, Cheng; Zhang, Zheng; Wang, Lifei; Peng, Ling; Chen, Li; Qin, Yuhao; Zhao, Dandan; Tan, Shuguang; Yin, Lu; Xu, Jun; Zhou, Congzhao; Jiang, Chengyu; Liu, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Science China: Life Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">364-374</span>CODEN:
                <span class="NLM_cas:coden">SCLSCJ</span>;
        ISSN:<span class="NLM_cas:issn">1674-7305</span>.
    
            (<span class="NLM_cas:orgname">Science China Press</span>)
        </div><div class="casAbstract">The outbreak of the 2019-nCoV infection began in Dec. 2019 in Wuhan, Hubei province, and rapidly spread to many provinces in China as well as other countries.  Here we report the epidemiol., clin., lab., and radiol. characteristics, as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen, China.  All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).  The most common lab. abnormalities were hypoalbuminemia, lymphopenia, decreased percentage of lymphocytes (LYM) and neutrophils (NEU), elevated C-reactive protein (CRP), and lactate dehydrogenase (LDH), and decreased CD8 count.  The viral load of 2019-nCoV detected from patient respiratory tracts was pos. linked to lung disease severity.  ALB, LYM, LYM(%), LDH, NEU(%), and CRP were highly correlated to the acute lung injury.  Age, viral load, lung injury score, and blood biochem. indexes, albumin (ALB), CRP, LDH, LY(%), LYM, and NEU(%), may be predictors of disease severity.  Moreover, the angiotensin II level in the plasma sample from 2019-nCoV infected patients was markedly elevated and linearly assocd. to viral load and lung injury.  Our results suggest a no. of potential diagnosis biomarkers and angiotensin receptor blocker (ARB) drugs for potential repurposing treatment of 2019-nCoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF-rDj_1t-5rVg90H21EOLACvtfcHk0li8zKMztdt4xg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1Wgsbw%253D&md5=57bf44a5f3d2b4ca7efb19ea218edc48</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1007%2Fs11427-020-1643-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11427-020-1643-8%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DL.%26atitle%3DClinical%2520and%2520biochemical%2520indexes%2520from%25202019-nCoV%2520infected%2520patients%2520linked%2520to%2520viral%2520loads%2520and%2520lung%2520injury%26jtitle%3DSci.%2520China%253A%2520Life%2520Sci.%26date%3D2020%26volume%3D63%26spage%3D364%26epage%3D374%26doi%3D10.1007%2Fs11427-020-1643-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, H.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of ginsenoside Rg3 isomers against gamma herpes virus through inhibition of p38- and JNK-associated pathways</span>. <i>J. Funct. Foods</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">219</span>â <span class="NLM_lpage">228</span>, <span class="refDoi">Â DOI: 10.1016/j.jff.2017.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jff.2017.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVeitrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2018&pages=219-228&author=S.+Kangauthor=M.+J.+Songauthor=H.+Min&title=Antiviral+activity+of+ginsenoside+Rg3+isomers+against+gamma+herpes+virus+through+inhibition+of+p38-+and+JNK-associated+pathways&doi=10.1016%2Fj.jff.2017.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of ginsenoside Rg3 isomers against gammaherpesvirus through inhibition of p38- and JNK-associated pathways</span></div><div class="casAuthors">Kang, Soowon; Song, Moon Jung; Min, Hyeyoung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Functional Foods</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JFFOAX</span>;
        ISSN:<span class="NLM_cas:issn">1756-4646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Natural compds. from functional foods targeting viruses are considered to have important role for regulating virus-related diseases.  Ginsenoside Rg3 is one of the active pharmaceutical components found in Panax ginseng C.  A. Meyer which is widely used as a functional food in East Asia.  In our present study, we have characterized the antiviral activities of the ginsenoside Rg3 isomers, 20(R)- and 20(S)-ginsenoside Rg3, against murine gammaherpesvirus 68 (MHV-68), a mouse model of human gammaherpesvirus which can cause various malignancies including cancer.  We found that both 20(R)- and 20(S)-ginsenoside Rg3 inhibited lytic replication and viral proliferation of MHV-68, although 20(S)-ginsenoside Rg3 was more effective than 20(R)-ginsenoside Rg3.  Furthermore, ginsenoside Rg3 isomers efficiently repressed chem.-induced lytic replication of human gammaherpesviruses in EBV-pos. BC-3 and KSHV-pos. Raji cell lines.  Finally, our data showed that ginsenoside Rg3 isomers suppressed the p38 and/or the JNK-assocd. MAPK signaling pathways, thereby inhibiting viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_oaZOyBy4jLVg90H21EOLACvtfcHk0li_ULK0IwzpeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVeitrrM&md5=10a34e872f4bf9805190044b8f8eec71</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.jff.2017.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jff.2017.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DM.%2BJ.%26aulast%3DMin%26aufirst%3DH.%26atitle%3DAntiviral%2520activity%2520of%2520ginsenoside%2520Rg3%2520isomers%2520against%2520gamma%2520herpes%2520virus%2520through%2520inhibition%2520of%2520p38-%2520and%2520JNK-associated%2520pathways%26jtitle%3DJ.%2520Funct.%2520Foods%26date%3D2018%26volume%3D40%26spage%3D219%26epage%3D228%26doi%3D10.1016%2Fj.jff.2017.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span> </span><span class="NLM_article-title">BerGenBioâs
bemcentinib selected to be fast-tracked as potential
treatment for covid-19 through new national UK government clinical
trial initiative</span>; Cision, <a href="https://www.prnewswire.co.uk/news-releases/bergenbio-s-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative-849232914.html" class="extLink">https://www.prnewswire.co.uk/news-releases/bergenbio-s-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative-849232914.html</a> (retrieved <span class="NLM_year">2020</span>-04-29).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BerGenBio%E2%80%99s%0Abemcentinib+selected+to+be+fast-tracked+as+potential%0Atreatment+for+covid-19+through+new+national+UK+government+clinical%0Atrial+initiative%3B+Cision%2C+https%3A%2F%2Fwww.prnewswire.co.uk%2Fnews-releases%2Fbergenbio-s-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative-849232914.html+%28retrieved+2020-04-29%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DBerGenBio%25E2%2580%2599s%250Abemcentinib%2520selected%2520to%2520be%2520fast-tracked%2520as%2520potential%250Atreatment%2520for%2520covid-19%2520through%2520new%2520national%2520UK%2520government%2520clinical%250Atrial%2520initiative%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bewley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gausdal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barclay, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Dorival, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiscox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easterbrook, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan-Pensley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funnell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vipond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haldar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span> <span> </span><span class="NLM_article-title">Antiviral screening of multiple compounds against Ebola virus</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">277</span>, <span class="refDoi">Â DOI: 10.3390/v8110277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3390%2Fv8110277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptlWmtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=277&author=S.+Dowallauthor=K.+Bewleyauthor=R.+Watsonauthor=S.+Vasanauthor=C.+Ghoshauthor=M.+Konaiauthor=G.+Gausdalauthor=J.+Lorensauthor=J.+Longauthor=W.+Barclayauthor=I.+Garcia-Dorivalauthor=J.+Hiscoxauthor=A.+Bosworthauthor=I.+Taylorauthor=L.+Easterbrookauthor=J.+Pitmanauthor=S.+Summersauthor=J.+Chan-Pensleyauthor=S.+Funnellauthor=J.+Vipondauthor=S.+Charltonauthor=J.+Haldarauthor=R.+Hewsonauthor=M.+Carroll&title=Antiviral+screening+of+multiple+compounds+against+Ebola+virus&doi=10.3390%2Fv8110277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral screening of multiple compounds against Ebola virus</span></div><div class="casAuthors">Dowall, Stuart D.; Bewley, Kevin; Watson, Robert J.; Vasan, Seshadri S.; Ghosh, Chandradhish; Konai, Mohini M.; Gausdal, Gro; Lorens, James B.; Long, Jason; Barclay, Wendy; Garcia-Dorival, Isabel; Hiscox, Julian; Bosworth, Andrew; Taylor, Irene; Easterbrook, Linda; Pitman, James; Summers, Sian; Chan-Pensley, Jenny; Funnell, Simon; Vipond, Julia; Charlton, Sue; Haldar, Jayanta; Hewson, Roger; Carroll, Miles W.</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">277/1-277/17</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In light of the recent outbreak of Ebola virus (EBOV) disease in West Africa, there have been renewed efforts to search for effective antiviral countermeasures.  A range of compds. currently available with broad antimicrobial activity have been tested for activity against EBOV.  Using live EBOV, eighteen candidate compds. were screened for antiviral activity in vitro.  The compds. were selected on a rational basis because their mechanisms of action suggested that they had the potential to disrupt EBOV entry, replication or exit from cells or because they had displayed some antiviral activity against EBOV in previous tests.  Nine compds. caused no redn. in viral replication despite cells remaining healthy, so they were excluded from further anal. (zidovudine; didanosine; stavudine; abacavir sulfate; entecavir; JB1a; Aimspro; celgosivir; and castanospermine).  A second screen of the remaining compds. and the feasibility of appropriateness for in vivo testing removed six further compds. (ouabain; omeprazole; esomeprazole; Gleevec; D-LANA-14; and Tasigna).  The three most promising compds. (17-DMAG; BGB324; and NCK-8) were further screened for in vivo activity in the guinea pig model of EBOV disease.  Two of the compds., BGB324 and NCK-8, showed some effect against lethal infection in vivo at the concns. tested, which warrants further investigation.  Further, these data add to the body of knowledge on the antiviral activities of multiple compds. against EBOV and indicate that the scientific community should invest more effort into the development of novel and specific antiviral compds. to treat Ebola virus disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWc6MB91Dl07Vg90H21EOLACvtfcHk0li_ULK0IwzpeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptlWmtg%253D%253D&md5=ed4479ad55973faa989247930cf105d8</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.3390%2Fv8110277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv8110277%26sid%3Dliteratum%253Aachs%26aulast%3DDowall%26aufirst%3DS.%26aulast%3DBewley%26aufirst%3DK.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DVasan%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DC.%26aulast%3DKonai%26aufirst%3DM.%26aulast%3DGausdal%26aufirst%3DG.%26aulast%3DLorens%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DBarclay%26aufirst%3DW.%26aulast%3DGarcia-Dorival%26aufirst%3DI.%26aulast%3DHiscox%26aufirst%3DJ.%26aulast%3DBosworth%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DEasterbrook%26aufirst%3DL.%26aulast%3DPitman%26aufirst%3DJ.%26aulast%3DSummers%26aufirst%3DS.%26aulast%3DChan-Pensley%26aufirst%3DJ.%26aulast%3DFunnell%26aufirst%3DS.%26aulast%3DVipond%26aufirst%3DJ.%26aulast%3DCharlton%26aufirst%3DS.%26aulast%3DHaldar%26aufirst%3DJ.%26aulast%3DHewson%26aufirst%3DR.%26aulast%3DCarroll%26aufirst%3DM.%26atitle%3DAntiviral%2520screening%2520of%2520multiple%2520compounds%2520against%2520Ebola%2520virus%26jtitle%3DViruses%26date%3D2016%26volume%3D8%26spage%3D277%26doi%3D10.3390%2Fv8110277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meertens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejarnac, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinigaglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet-Madin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Charpentier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafirassou, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamborlini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao-Lormeau, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulpier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MissÃ©, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouvenet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabibiazar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gressens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, A.</span></span> <span> </span><span class="NLM_article-title">Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">324</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2016.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.celrep.2016.12.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28076778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCjuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=324&author=L.+Meertensauthor=A.+Labeauauthor=O.+Dejarnacauthor=S.+Ciprianiauthor=L.+Sinigagliaauthor=L.+Bonnet-Madinauthor=T.+Le+Charpentierauthor=M.+L.+Hafirassouauthor=A.+Zamborliniauthor=V.+M.+Cao-Lormeauauthor=M.+Coulpierauthor=D.+Miss%C3%A9author=N.+Jouvenetauthor=R.+Tabibiazarauthor=P.+Gressensauthor=O.+Schwartzauthor=A.+Amara&title=Axl+mediates+ZIKA+virus+entry+in+human+glial+cells+and+modulates+innate+immune+responses&doi=10.1016%2Fj.celrep.2016.12.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses</span></div><div class="casAuthors">Meertens, Laurent; Labeau, Athena; Dejarnac, Ophelie; Cipriani, Sara; Sinigaglia, Laura; Bonnet-Madin, Lucie; Le Charpentier, Tifenn; Hafirassou, Mohamed Lamine; Zamborlini, Alessia; Cao-Lormeau, Van-Mai; Coulpier, Muriel; Misse, Dorothee; Jouvenet, Nolwenn; Tabibiazar, Ray; Gressens, Pierre; Schwartz, Olivier; Amara, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-333</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ZIKA virus (ZIKV) is an emerging pathogen responsible for neurol. disorders and congenital microcephaly.  However, the mol. basis for ZIKV neurotropism remains poorly understood.  Here, we show that Axl is expressed in human microglia and astrocytes in the developing brain and that it mediates ZIKV infection of glial cells.  Axl-mediated ZIKV entry requires the Axl ligand Gas6, which bridges ZIKV particles to glial cells.  Following binding, ZIKV is internalized through clathrin-mediated endocytosis and traffics to Rab5+ endosomes to establish productive infection.  During entry, the ZIKV/Gas6 complex activates Axl kinase activity, which downmodulates interferon signaling and facilitates infection.  ZIKV infection of human glial cells is inhibited by MYD1, an engineered Axl decoy receptor, and by the Axl kinase inhibitor R428.  Our results highlight the dual role of Axl during ZIKV infection of glial cells: promoting viral entry and modulating innate immune responses.  Therefore, inhibiting Axl function may represent a potential target for future antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDbk6ixuAbyLVg90H21EOLACvtfcHk0lg573Nywgu6mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCjuro%253D&md5=fbc8799266529e2fef7f03e6bee1b6c6</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DMeertens%26aufirst%3DL.%26aulast%3DLabeau%26aufirst%3DA.%26aulast%3DDejarnac%26aufirst%3DO.%26aulast%3DCipriani%26aufirst%3DS.%26aulast%3DSinigaglia%26aufirst%3DL.%26aulast%3DBonnet-Madin%26aufirst%3DL.%26aulast%3DLe%2BCharpentier%26aufirst%3DT.%26aulast%3DHafirassou%26aufirst%3DM.%2BL.%26aulast%3DZamborlini%26aufirst%3DA.%26aulast%3DCao-Lormeau%26aufirst%3DV.%2BM.%26aulast%3DCoulpier%26aufirst%3DM.%26aulast%3DMiss%25C3%25A9%26aufirst%3DD.%26aulast%3DJouvenet%26aufirst%3DN.%26aulast%3DTabibiazar%26aufirst%3DR.%26aulast%3DGressens%26aufirst%3DP.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3DAmara%26aufirst%3DA.%26atitle%3DAxl%2520mediates%2520ZIKA%2520virus%2520entry%2520in%2520human%2520glial%2520cells%2520and%2520modulates%2520innate%2520immune%2520responses%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D18%26spage%3D324%26doi%3D10.1016%2Fj.celrep.2016.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlichman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lensing, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasco, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcos, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijayawardana, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stancato, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulanthaivel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulle, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrington, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, M. P.</span></span> <span> </span><span class="NLM_article-title">A first-in-human Phase I study of the oral p38 MAPK inhibitor, Ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1095</span>â <span class="NLM_lpage">1102</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-15-1718</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F1078-0432.CCR-15-1718" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26581242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVyktb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1095-1102&author=A.+Patnaikauthor=P.+Haluskaauthor=A.+W.+Tolcherauthor=C.+Erlichmanauthor=K.+P.+Papadopoulosauthor=J.+L.+Lensingauthor=M.+Beeramauthor=J.+R.+Molinaauthor=D.+W.+Rascoauthor=R.+R.+Arcosauthor=C.+S.+Kellyauthor=S.+R.+Wijayawardanaauthor=X.+Zhangauthor=L.+F.+Stancatoauthor=R.+Bellauthor=P.+Shiauthor=P.+Kulanthaivelauthor=C.+Pitouauthor=L.+B.+Mulleauthor=D.+L.+Farringtonauthor=E.+M.+Chanauthor=M.+P.+Goetz&title=A+first-in-human+Phase+I+study+of+the+oral+p38+MAPK+inhibitor%2C+Ralimetinib+%28LY2228820+Dimesylate%29%2C+in+patients+with+advanced+cancer&doi=10.1158%2F1078-0432.CCR-15-1718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer</span></div><div class="casAuthors">Patnaik, Amita; Haluska, Paul; Tolcher, Anthony W.; Erlichman, Charles; Papadopoulos, Kyriakos P.; Lensing, Janet L.; Beeram, Muralidhar; Molina, Julian R.; Rasco, Drew W.; Arcos, Rebecca R.; Kelly, Claudia S.; Wijayawardana, Sameera R.; Zhang, Xuekui; Stancato, Louis F.; Bell, Robert; Shi, Peipei; Kulanthaivel, Palaniappan; Pitou, Celine; Mulle, Lynette B.; Farrington, Daphne L.; Chan, Edward M.; Goetz, Matthew P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1095-1102</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: p38 MAPK regulates the prodn. of cytokines in the tumor microenvironment and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, and targeted therapies.  Ralimetinib (LY2228820 dimesylate) is a selective small-mol. inhibitor of p38 MAPK.  This phase I study aimed to evaluate the safety and tolerability of ralimetinib, as a single agent and in combination with tamoxifen, when administered orally to patients with advanced cancer.  Exptl. Design: The study design consisted of a dose-escalation phase performed in a 3+3 design (Part A; n = 54), two dose-confirmation phases [Part B at 420 mg (n = 18) and Part C at 300 mg (n = 8)], and a tumor-specific expansion phase in combination with tamoxifen for women with hormone receptor-pos. metastatic breast cancer refractory to aromatase inhibitors (Part D; n = 9).  Ralimetinib was administered orally every 12 h on days 1 to 14 of a 28-day cycle.  Results: Eighty-nine patients received ralimetinib at 11 dose levels (10, 20, 40, 65, 90, 120, 160, 200, 300, 420, and 560 mg).  Plasma exposure of ralimetinib (Cmax and AUC) increased in a dose-dependent manner.  After a single dose, ralimetinib inhibited p38 MAPK-induced phosphorylation of MAPKAP-K2 in peripheral blood mononuclear cells.  The most common adverse events, possibly drug-related, included rash, fatigue, nausea, constipation, pruritus, and vomiting.  The recommended phase II dose was 300 mg every 12 h as monotherapy or in combination with tamoxifen.  Although no patients achieved a complete response or partial response,19 patients (21.3%) achieved stable disease with a median duration of 3.7 mo, with 9 of these patients on study for â¥6 cycles.  Conclusions: Ralimetinib demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer.  Clin Cancer Res; 22(5); 1095-102. Â©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB5A7aYBLcy7Vg90H21EOLACvtfcHk0lg573Nywgu6mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVyktb0%253D&md5=c24403616cc10022866e1bca8b29b5bc</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1718%26sid%3Dliteratum%253Aachs%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DHaluska%26aufirst%3DP.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DLensing%26aufirst%3DJ.%2BL.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DArcos%26aufirst%3DR.%2BR.%26aulast%3DKelly%26aufirst%3DC.%2BS.%26aulast%3DWijayawardana%26aufirst%3DS.%2BR.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DStancato%26aufirst%3DL.%2BF.%26aulast%3DBell%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DP.%26aulast%3DKulanthaivel%26aufirst%3DP.%26aulast%3DPitou%26aufirst%3DC.%26aulast%3DMulle%26aufirst%3DL.%2BB.%26aulast%3DFarrington%26aufirst%3DD.%2BL.%26aulast%3DChan%26aufirst%3DE.%2BM.%26aulast%3DGoetz%26aufirst%3DM.%2BP.%26atitle%3DA%2520first-in-human%2520Phase%2520I%2520study%2520of%2520the%2520oral%2520p38%2520MAPK%2520inhibitor%252C%2520Ralimetinib%2520%2528LY2228820%2520Dimesylate%2529%252C%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D1095%26epage%3D1102%26doi%3D10.1158%2F1078-0432.CCR-15-1718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hale, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, R. E.</span></span> <span> </span><span class="NLM_article-title">Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">14194</span>â <span class="NLM_lpage">14199</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0606109103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1073%2Fpnas.0606109103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16963558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVClsr3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=14194-14199&author=B.+G.+Haleauthor=D.+Jacksonauthor=Y.+H.+Chenauthor=R.+A.+Lambauthor=R.+E.+Randall&title=Influenza+A+virus+NS1+protein+binds+p85beta+and+activates+phosphatidylinositol-3-kinase+signaling&doi=10.1073%2Fpnas.0606109103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza A virus NS1 protein binds p85Î² and activates phosphatidylinositol-3-kinase signaling</span></div><div class="casAuthors">Hale, Benjamin G.; Jackson, David; Chen, Yun-Hsiang; Lamb, Robert A.; Randall, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">14194-14199</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Influenza A virus NS1 is a multifunctional protein, and in virus-infected cells NS1 modulates a no. of host-cell processes by interacting with cellular factors.  Here, we report that NS1 binds directly to p85Î², a regulatory subunit of phosphatidylinositol-3-kinase (PI3K), but not to the related p85Î± subunit.  Activation of P13K in influenza virus-infected cells depended on genome replication, and showed kinetics that correlated with NS1 expression.  Addnl., it was found that expression of NS1 alone was sufficient to constitutively activate P13K, causing the phosphorylation of a downstream mediator of P13K signal transduction, Akt.  Mutational anal. of a potential SH2-binding motif within NS1 indicated that the highly conserved tyrosine at residue 89 is important for both the interaction with p85Î², and the activation of P13K.  A mutant influenza virus (A/Udorn/72) expressing NS1 with the Y89F amino acid substitution exhibited a small-plaque phenotype, and grew more slowly in tissue culture than WT virus.  These data suggest that activation of P13K signaling in influenza A virus-infected cells is important for efficient virus replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdYH7ONb8077Vg90H21EOLACvtfcHk0liziO5ELZEmzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVClsr3L&md5=e506aedaba2ed384b6afbddf63cfe433</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0606109103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0606109103%26sid%3Dliteratum%253Aachs%26aulast%3DHale%26aufirst%3DB.%2BG.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DLamb%26aufirst%3DR.%2BA.%26aulast%3DRandall%26aufirst%3DR.%2BE.%26atitle%3DInfluenza%2520A%2520virus%2520NS1%2520protein%2520binds%2520p85beta%2520and%2520activates%2520phosphatidylinositol-3-kinase%2520signaling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D14194%26epage%3D14199%26doi%3D10.1073%2Fpnas.0606109103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky-Bromberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Sobrido, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palese, P.</span></span> <span> </span><span class="NLM_article-title">7a Protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">785</span>â <span class="NLM_lpage">793</span>, <span class="refDoi">Â DOI: 10.1128/JVI.80.2.785-793.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.80.2.785-793.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16378980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOrsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=785-793&author=S.+A.+Kopecky-Brombergauthor=L.+Martinez-Sobridoauthor=P.+Palese&title=7a+Protein+of+severe+acute+respiratory+syndrome+coronavirus+inhibits+cellular+protein+synthesis+and+activates+p38+mitogen-activated+protein+kinase&doi=10.1128%2FJVI.80.2.785-793.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase</span></div><div class="casAuthors">Kopecky-Bromberg, Sarah A.; Martinez-Sobrido, Luis; Palese, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">785-793</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">It was recently shown that the 7a protein of severe acute respiratory syndrome coronavirus induces biochem. changes assocd. with apoptosis.  In this study, the mechanism by which the 7a protein induces apoptosis was examd.  The 7a protein was tested for the ability to inhibit cellular gene expression because several proapoptotic viral proteins with this function have previously been identified.  7A protein inhibited expression of luciferase from an mRNA construct that specifically measures translation, whereas inhibitors of transcription and nucleocytoplasmic transport did not.  The inhibition of translation and other cellular processes of gene expression have been assocd. with the induction of a stress response in cells.  Western blot anal. using phosphospecific antibodies indicated that 7a protein activated p38 mitogen-activated protein kinase (MAPK), but not c-Jun N-terminal protein kinase/stress-activated protein kinase.  Taken together, these data indicate that the induction of apoptosis by the 7a protein may be related to its ability to inhibit cellular translation and activate p38 MAPK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyL8_h7kZSFrVg90H21EOLACvtfcHk0liziO5ELZEmzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOrsA%253D%253D&md5=91a561555a8cc07ffe0b3ab08574520b</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1128%2FJVI.80.2.785-793.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.80.2.785-793.2006%26sid%3Dliteratum%253Aachs%26aulast%3DKopecky-Bromberg%26aufirst%3DS.%2BA.%26aulast%3DMartinez-Sobrido%26aufirst%3DL.%26aulast%3DPalese%26aufirst%3DP.%26atitle%3D7a%2520Protein%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%2520inhibits%2520cellular%2520protein%2520synthesis%2520and%2520activates%2520p38%2520mitogen-activated%2520protein%2520kinase%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D785%26epage%3D793%26doi%3D10.1128%2FJVI.80.2.785-793.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¶rgeling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmolke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viemann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordhoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of p38 mitogen-activated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">13</span>â <span class="NLM_lpage">27</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M113.469239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.M113.469239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24189062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC2c7is1yntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=13-27&author=Y.+B%C3%B6rgelingauthor=M.+Schmolkeauthor=D.+Viemannauthor=C.+Nordhoffauthor=J.+Rothauthor=S.+Ludwig&title=Inhibition+of+p38+mitogen-activated+protein+kinase+impairs+influenza+virus-induced+primary+and+secondary+host+gene+responses+and+protects+mice+from+lethal+H5N1+infection&doi=10.1074%2Fjbc.M113.469239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 mitogen-activated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection</span></div><div class="casAuthors">Borgeling Yvonne; Schmolke Mirco; Viemann Dorothee; Nordhoff Carolin; Roth Johannes; Ludwig Stephan</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of biological chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Highly pathogenic avian influenza viruses (HPAIV) induce severe inflammation in poultry and men.  One characteristic of HPAIV infections is the induction of a cytokine burst that strongly contributes to viral pathogenicity.  This cell-intrinsic hypercytokinemia seems to involve hyperinduction of p38 mitogen-activated protein kinase.  Here we investigate the role of p38 MAPK signaling in the antiviral response against HPAIV in mice as well as in human endothelial cells, the latter being a primary source of cytokines during systemic infections.  Global gene expression profiling of HPAIV-infected endothelial cells in the presence of the p38-specific inhibitor SB 202190 revealed that inhibition of p38 MAPK leads to reduced expression of IFNÎ² and other cytokines after H5N1 and H7N7 infection.  More than 90% of all virus-induced genes were either partially or fully dependent on p38 signaling.  Moreover, promoter analysis confirmed a direct impact of p38 on the IFNÎ² promoter activity.  Furthermore, upon treatment with IFN or conditioned media from HPAIV-infected cells, p38 controls interferon-stimulated gene expression by coregulating STAT1 by phosphorylation at serine 727.  In vivo inhibition of p38 MAPK greatly diminishes virus-induced cytokine expression concomitant with reduced viral titers, thereby protecting mice from lethal infection.  These observations show that p38 MAPK acts on two levels of the antiviral IFN response.  Initially the kinase regulates IFN induction and, at a later stage, p38 controls IFN signaling and thereby expression of IFN-stimulated genes.  Thus, inhibition of MAP kinase p38 may be an antiviral strategy that protects mice from lethal influenza by suppressing excessive cytokine expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfTb2VzrvhIT0SWnHPWbmmfW6udTcc2eYvqmDepi4Ugrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7is1yntw%253D%253D&md5=0051eb9c971078ae13ee7ff93d1d7322</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.469239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.469239%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6rgeling%26aufirst%3DY.%26aulast%3DSchmolke%26aufirst%3DM.%26aulast%3DViemann%26aufirst%3DD.%26aulast%3DNordhoff%26aufirst%3DC.%26aulast%3DRoth%26aufirst%3DJ.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520impairs%2520influenza%2520virus-induced%2520primary%2520and%2520secondary%2520host%2520gene%2520responses%2520and%2520protects%2520mice%2520from%2520lethal%2520H5N1%2520infection%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D13%26epage%3D27%26doi%3D10.1074%2Fjbc.M113.469239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhera, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utokaparch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackett, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorscheid, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegele, R. G.</span></span> <span> </span><span class="NLM_article-title">Toll-like receptor 4-mediated activation of p38 mitogen-activated protein kinase is a determinant of respiratory virus entry and tropism</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">11359</span>â <span class="NLM_lpage">11373</span>, <span class="refDoi">Â DOI: 10.1128/JVI.00804-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.00804-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20702616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeisb%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=11359-11373&author=D.+Marchantauthor=G.+K.+Singheraauthor=S.+Utokaparchauthor=T.+L.+Hackettauthor=J.+H.+Boydauthor=Z.+Luoauthor=X.+Siauthor=D.+R.+Dorscheidauthor=B.+M.+McManusauthor=R.+G.+Hegele&title=Toll-like+receptor+4-mediated+activation+of+p38+mitogen-activated+protein+kinase+is+a+determinant+of+respiratory+virus+entry+and+tropism&doi=10.1128%2FJVI.00804-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptor 4-mediated activation of p38 mitogen-activated protein kinase is a determinant of respiratory virus entry and tropism</span></div><div class="casAuthors">Marchant, David; Singhera, Gurpreet K.; Utokaparch, Soraya; Hackett, Tillie L.; Boyd, John H.; Luo, Zongshu; Si, Xiaoning; Dorscheid, Delbert R.; McManus, Bruce M.; Hegele, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">11359-11373</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Respiratory viruses exert a heavy toll of morbidity and mortality worldwide.  Despite this burden there are few specific treatments available for respiratory virus infections.  Since many viruses utilize host cell enzymic machinery such as protein kinases for replication, we detd. whether pharmacol. inhibition of kinases could, in principle, be used as a broad antiviral strategy for common human respiratory virus infections.  A panel of green fluorescent protein (GFP)-expressing recombinant respiratory viruses, including an isolate of H1N1 influenza virus (H1N1/Weiss/43), was used to represent a broad range of virus families responsible for common respiratory infections (Adenoviridae, Paramyxoviridae, Picornaviridae, and Orthomyxoviridae).  Kinase inhibitors were screened in a high-throughput assay that detected virus infection in human airway epithelial cells (1HAEo-) using a fluorescent plate reader.  Inhibition of p38 mitogen-activated protein kinase (MAPK) signaling was able to significantly inhibit replication by all viruses tested.  Therefore, the pathways involved in virus-mediated p38 and extracellular signal-regulated kinase (ERK) MAPK activation were investigated using bronchial epithelial cells and primary fibroblasts derived from MyD88 knockout mouse lungs.  Influenza virus, which activated p38 MAPK to approx. 10-fold-greater levels than did respiratory syncytial virus (RSV) in 1HAEo- cells, was internalized about 8-fold faster and more completely than RSV.  We show for the first time that p38 MAPK is a determinant of virus infection that is dependent upon MyD88 expression and Toll-like receptor 4 (TLR4) ligation.  Imaging of virus-TLR4 interactions showed significant clustering of TLR4 at the site of virus-cell interaction, triggering phosphorylation of downstream targets of p38 MAPK, suggesting the need for a signaling receptor to activate virus internalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNBCrJg_sD_LVg90H21EOLACvtfcHk0ljSYmHw0M9VLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeisb%252FF&md5=4bd7d36f4fc2e8d779d1d63136a81f1b</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1128%2FJVI.00804-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00804-10%26sid%3Dliteratum%253Aachs%26aulast%3DMarchant%26aufirst%3DD.%26aulast%3DSinghera%26aufirst%3DG.%2BK.%26aulast%3DUtokaparch%26aufirst%3DS.%26aulast%3DHackett%26aufirst%3DT.%2BL.%26aulast%3DBoyd%26aufirst%3DJ.%2BH.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DSi%26aufirst%3DX.%26aulast%3DDorscheid%26aufirst%3DD.%2BR.%26aulast%3DMcManus%26aufirst%3DB.%2BM.%26aulast%3DHegele%26aufirst%3DR.%2BG.%26atitle%3DToll-like%2520receptor%25204-mediated%2520activation%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520is%2520a%2520determinant%2520of%2520respiratory%2520virus%2520entry%2520and%2520tropism%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D11359%26epage%3D11373%26doi%3D10.1128%2FJVI.00804-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucker, I. H.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen-activated protein kinase and extracellular signal regulated kinase 1/2 signaling</span>. <i>Am. J. Physiol. Cell Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">C1073</span>â <span class="NLM_lpage">1079</span>, <span class="refDoi">Â DOI: 10.1152/ajpcell.00364.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1152%2Fajpcell.00364.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=23535237" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2013&pages=C1073-1079&author=L.+Xiaoauthor=K.+K.+Haackauthor=I.+H.+Zucker&title=Angiotensin+II+regulates+ACE+and+ACE2+in+neurons+through+p38+mitogen-activated+protein+kinase+and+extracellular+signal+regulated+kinase+1%2F2+signaling&doi=10.1152%2Fajpcell.00364.2012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.00364.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.00364.2012%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DHaack%26aufirst%3DK.%2BK.%26aulast%3DZucker%26aufirst%3DI.%2BH.%26atitle%3DAngiotensin%2520II%2520regulates%2520ACE%2520and%2520ACE2%2520in%2520neurons%2520through%2520p38%2520mitogen-activated%2520protein%2520kinase%2520and%2520extracellular%2520signal%2520regulated%2520kinase%25201%252F2%2520signaling%26jtitle%3DAm.%2520J.%2520Physiol.%2520Cell%2520Physiol.%26date%3D2013%26volume%3D304%26spage%3DC1073%26epage%3D1079%26doi%3D10.1152%2Fajpcell.00364.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshotels, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriramula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazartigues, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipeanu, C. M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-II mediates ACE2 internalization and degradation through an angiotensin-II type I receptor-dependent mechanism</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1368</span>â <span class="NLM_lpage">1375</span>, <span class="refDoi">Â DOI: 10.1161/HYPERTENSIONAHA.114.03743</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1161%2FHYPERTENSIONAHA.114.03743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25225202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2014&pages=1368-1375&author=M.+R.+Deshotelsauthor=H.+Xiaauthor=S.+Sriramulaauthor=E.+Lazartiguesauthor=C.+M.+Filipeanu&title=Angiotensin-II+mediates+ACE2+internalization+and+degradation+through+an+angiotensin-II+type+I+receptor-dependent+mechanism&doi=10.1161%2FHYPERTENSIONAHA.114.03743"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor-Dependent Mechanism</span></div><div class="casAuthors">Deshotels, Matthew R.; Xia, Huijing; Sriramula, Srinivas; Lazartigues, Eric; Filipeanu, Catalin M.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1368-1375</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Angiotensin-converting enzyme type 2 (ACE2) is a pivotal component of the renin-angiotensin system, promoting the conversion of angiotensin II (Ang-II) to Ang-(1-7).  We previously reported that decreased ACE2 expression and activity contributes to the development of Ang-II-mediated hypertension in mice.  The present study aimed to investigate the mechanisms involved in ACE2 downregulation during neurogenic hypertension.  In ACE2-transfected Neuro-2A cells, Ang-II treatment resulted in a significant attenuation of ACE2 enzymic activity.  Examn. of the subcellular localization of ACE2 revealed that Ang-II treatment leads to ACE2 internalization and degrdn. into lysosomes.  These effects were prevented by both the Ang-II type 1 receptor (AT1R) blocker losartan and the lysosomal inhibitor leupeptin.  In contrast, in HEK293T cells, which lack endogenous AT1R, Ang-II failed to promote ACE2 internalization.  Moreover, this effect could be induced after AT1R transfection.  Furthermore, coimmunopptn. expts. demonstrated that AT1R and ACE2 form complexes, and these interactions were decreased by Ang-II treatment, which also enhanced ACE2 ubiquitination.  In contrast, ACE2 activity was not changed by transfection of AT2 or Mas receptors.  In vivo, Ang-II-mediated hypertension was blunted by chronic infusion of leupeptin in wildtype C57Bl/6, but not in ACE2 knockout mice.  Overall, this is the first demonstration that elevated Ang-II levels reduce ACE2 expression and activity by stimulation of lysosomal degrdn. through an AT1R-dependent mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7T_hBPhLt1bVg90H21EOLACvtfcHk0ljSYmHw0M9VLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLjI&md5=299d44058d875d0cdbcd10ef6295d0d8</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.114.03743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.114.03743%26sid%3Dliteratum%253Aachs%26aulast%3DDeshotels%26aufirst%3DM.%2BR.%26aulast%3DXia%26aufirst%3DH.%26aulast%3DSriramula%26aufirst%3DS.%26aulast%3DLazartigues%26aufirst%3DE.%26aulast%3DFilipeanu%26aufirst%3DC.%2BM.%26atitle%3DAngiotensin-II%2520mediates%2520ACE2%2520internalization%2520and%2520degradation%2520through%2520an%2520angiotensin-II%2520type%2520I%2520receptor-dependent%2520mechanism%26jtitle%3DHypertension%26date%3D2014%26volume%3D64%26spage%3D1368%26epage%3D1375%26doi%3D10.1161%2FHYPERTENSIONAHA.114.03743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, A. C.K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, H. Y.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/ p38 MAP kinase pathway</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">1174</span>â <span class="NLM_lpage">1183</span>, <span class="refDoi">Â DOI: 10.2353/ajpath.2008.070762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.2353%2Fajpath.2008.070762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18403595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtFOntLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2008&pages=1174-1183&author=V.+Kokaauthor=X.+R.+Huangauthor=A.+C.K.+Chungauthor=W.+Wangauthor=L.+D.+Truongauthor=H.+Y.+Lan&title=Angiotensin+II+up-regulates+angiotensin+I-converting+enzyme+%28ACE%29%2C+but+down-regulates+ACE2+via+the+AT1-ERK%2F+p38+MAP+kinase+pathway&doi=10.2353%2Fajpath.2008.070762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway</span></div><div class="casAuthors">Koka, Vijay; Huang, Xiao Ru; Chung, Arthur C. K.; Wang, Wansheng; Truong, Luan D.; Lan, Hui Yao</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1174-1183</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">The recent discovery of the angiotensin II (Ang II)-breakdown enzyme, angiotensin I converting enzyme (ACE) 2, suggests the importance of Ang II degrdn. in hypertension.  The present study explored the signaling mechanism by which ACE2 is regulated under hypertensive conditions.  Real-time PCR and immunohistochem. showed that ACE2 mRNA and protein expression levels were high, whereas ACE expression levels were moderate in both normal kidney and heart.  In contrast, patients with hypertension showed marked ACE up-regulation and ACE2 down-regulation in both hypertensive cardiopathy and, particularly, hypertensive nephropathy.  The inhibition of ACE2 expression was shown to be assocd. with ACE up-regulation and activation of extracellular regulated (ERK)1/2 and p38 mitogen-activated protein (MAP) kinases.  In vitro, Ang II was able to up-regulate ACE and down-regulate ACE2 in human kidney tubular cells, which were blocked by an angiotensin II (AT)1 receptor antagonist (losartan), but not by an AT2 receptor blocker (PD123319).  Furthermore, blockade of ERK1/2 or p38 MAP kinases by either specific inhibitors or a dominant-neg. adenovirus was able to abolish Ang II-induced ACE2 down-regulation in human kidney tubular cells.  In conclusion, Ang II is able to up-regulate ACE and down-regulate ACE2 expression levels under hypertensive conditions both in vivo and in vitro.  The AT1 receptor-mediated ERK/p38 MAP kinase signaling pathway may be a key mechanism by which Ang II down-regulates ACE2 expression, implicating an ACE/ACE2 imbalance in hypertensive cardiovascular and renal damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdXJax5318hrVg90H21EOLACvtfcHk0ljSYmHw0M9VLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtFOntLw%253D&md5=d176bedc3af5962d01bfa2f8e1497f47</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2008.070762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2008.070762%26sid%3Dliteratum%253Aachs%26aulast%3DKoka%26aufirst%3DV.%26aulast%3DHuang%26aufirst%3DX.%2BR.%26aulast%3DChung%26aufirst%3DA.%2BC.K.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTruong%26aufirst%3DL.%2BD.%26aulast%3DLan%26aufirst%3DH.%2BY.%26atitle%3DAngiotensin%2520II%2520up-regulates%2520angiotensin%2520I-converting%2520enzyme%2520%2528ACE%2529%252C%2520but%2520down-regulates%2520ACE2%2520via%2520the%2520AT1-ERK%252F%2520p38%2520MAP%2520kinase%2520pathway%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2008%26volume%3D172%26spage%3D1174%26epage%3D1183%26doi%3D10.2353%2Fajpath.2008.070762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span> <span> </span><span class="NLM_article-title">capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-ÎºB signaling pathway</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">104850</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2020.104850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.phrs.2020.104850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32360580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVeltLrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2020&pages=104850&author=Q.+Maauthor=W.+Panauthor=R.+Liauthor=B.+Liuauthor=C.+Liauthor=Y.+Xieauthor=Z.+Wangauthor=J.+Zhaoauthor=H.+Jiangauthor=J.+Huangauthor=Y.+Shiauthor=J.+Daiauthor=K.+Zhengauthor=X.+Liauthor=Z.+Yang&title=capsule+shows+antiviral+and+anti-inflammatory+abilities+against+novel+coronavirus+SARS-CoV-2+via+suppression+of+NF-%CE%BAB+signaling+pathway&doi=10.1016%2Fj.phrs.2020.104850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-ÎºB signaling pathway</span></div><div class="casAuthors">Ma, Qinhai; Pan, Weiqi; Li, Runfeng; Liu, Bin; Li, Chufang; Xie, Yuqi; Wang, Zhoulang; Zhao, Jin; Jiang, Haiming; Huang, Jicheng; Shi, Yongxia; Dai, Jun; Zheng, Kui; Li, Xiaobo; Yang, Zifeng</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104850</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern.  At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection.  Liu Shen capsule (LS), a traditional Chinese medicine, has been proven to have a wide spectrum of pharmacol. properties, such as anti-inflammatory, antiviral and immunomodulatory activities.  However, little is known about the antiviral effect of LS against SARS-CoV-2.  Herein, the study was designed to investigate the antiviral activity of SARS-CoV-2 and its potential effect in regulating the host's immune response.  The inhibitory effect of LS against SARS-CoV-2 replication in Vero E6 cells was evaluated by using the cytopathic effect (CPE) and plaque redn. assay.  The no. of virions of SARS-CoV-2 was obsd. under transmission electron microscope after treatment with LS.  Proinflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quant. PCR assays.  The results showed that LS could significantly inhibit SARS-CoV-2 replication in Vero E6 cells, and reduce the no. of virus particles and it could markedly reduce pro-inflammatory cytokines (TNF-Î±, IL-6, IL-1Î², IL-8, CCL-2/MCP-1 and CXCL-10/IP-10) prodn. at the mRNA levels.  Moreover, the expression of the key proteins in the NF-ÎºB/MAPK signaling pathway was detected by western blot and it was found that LS could inhibit the expression of p-NF-ÎºB p65, p-IÎºBÎ± and p-p38 MAPK, while increasing the expression of IÎºBÎ±.  These findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-ÎºB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxVNqGqzKTn7Vg90H21EOLACvtfcHk0lhQE4se7kcrYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVeltLrK&md5=2e2e69e180ef1f29b4880d5157afec5e</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2020.104850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2020.104850%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DZ.%26atitle%3Dcapsule%2520shows%2520antiviral%2520and%2520anti-inflammatory%2520abilities%2520against%2520novel%2520coronavirus%2520SARS-CoV-2%2520via%2520suppression%2520of%2520NF-%25CE%25BAB%2520signaling%2520pathway%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D158%26spage%3D104850%26doi%3D10.1016%2Fj.phrs.2020.104850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, A.</span></span> <span> </span><span class="NLM_article-title">Type I and type III interferons-induction, signaling, evasion, and application to combat COVID-19</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">870</span>â <span class="NLM_lpage">878</span>, <span class="refDoi">Â DOI: 10.1016/j.chom.2020.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.chom.2020.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32464097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVejtrvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=870-878&author=A.+Parkauthor=A.+Iwasaki&title=Type+I+and+type+III+interferons-induction%2C+signaling%2C+evasion%2C+and+application+to+combat+COVID-19&doi=10.1016%2Fj.chom.2020.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19</span></div><div class="casAuthors">Park, Annsea; Iwasaki, Akiko</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">870-878</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy.  Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host.  In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogq6K7Mhd6JbVg90H21EOLACvtfcHk0lhQE4se7kcrYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVejtrvN&md5=ab75ff6d4eea2aed7aacf15dc647471c</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2020.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2020.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DA.%26aulast%3DIwasaki%26aufirst%3DA.%26atitle%3DType%2520I%2520and%2520type%2520III%2520interferons-induction%252C%2520signaling%252C%2520evasion%252C%2520and%2520application%2520to%2520combat%2520COVID-19%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2020%26volume%3D27%26spage%3D870%26epage%3D878%26doi%3D10.1016%2Fj.chom.2020.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferdinand, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Jak/STAT signaling in immunity and disease</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">21</span>â <span class="NLM_lpage">27</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1401867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.4049%2Fjimmunol.1401867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25527793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWls7rF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2015&pages=21-27&author=A.+V.+Villarinoauthor=Y.+Kannoauthor=J.+R.+Ferdinandauthor=J.+J.+O%E2%80%99Shea&title=Mechanisms+of+Jak%2FSTAT+signaling+in+immunity+and+disease&doi=10.4049%2Fjimmunol.1401867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Jak/STAT Signaling in Immunity and Disease</span></div><div class="casAuthors">Villarino, Alejandro V.; Kanno, Yuka; Ferdinand, John R.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-27</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  More than two decades ago, expts. on the antiviral mechanisms of IFNs led to the discovery of JAKs and their downstream effectors, the STAT proteins.  This pathway has since become a paradigm for membrane-to-nucleus signaling and explains how a broad range of sol. factors, including cytokines and hormones, mediate their diverse functions.  Jak/STAT research has not only impacted basic science, particularly in the context of intercellular communication and cell-extrinsic control of gene expression, it also has become a prototype for transition from bench to bedside, culminating in the development and clin. implementation of pathway-specific therapeutics.  This brief review synthesizes our current understanding of Jak/STAT biol. while taking stock of the lessons learned and the challenges that lie ahead.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotOsFFpF-ChLVg90H21EOLACvtfcHk0lhQE4se7kcrYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWls7rF&md5=777f0f64db038ca8a7f17554931e0655</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1401867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1401867%26sid%3Dliteratum%253Aachs%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DFerdinand%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DMechanisms%2520of%2520Jak%252FSTAT%2520signaling%2520in%2520immunity%2520and%2520disease%26jtitle%3DJ.%2520Immunol.%26date%3D2015%26volume%3D194%26spage%3D21%26epage%3D27%26doi%3D10.4049%2Fjimmunol.1401867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span> <span> </span><span class="NLM_article-title">Interaction of hepatitis C virus core protein with janus kinase is required for efficient production of infectious viruses</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">97</span>â <span class="NLM_lpage">106</span>, <span class="refDoi">Â DOI: 10.4062/biomolther.2013.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.4062%2Fbiomolther.2013.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt12ks7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=97-106&author=C.+Lee&title=Interaction+of+hepatitis+C+virus+core+protein+with+janus+kinase+is+required+for+efficient+production+of+infectious+viruses&doi=10.4062%2Fbiomolther.2013.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of hepatits C virus core protein with Janus kinase is required for efficient production of infectious viruses</span></div><div class="casAuthors">Lee, Choongho</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-106</span>CODEN:
                <span class="NLM_cas:coden">BTIHA3</span>;
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Applied Pharmacology</span>)
        </div><div class="casAbstract">Chronic hepatitis C virus (HCV) infection is responsible for the development of liver cirrhosis and hepatocellular carcinoma.  HCV core protein plays not only a structural role in the virion morphogenesis by encapsidating a virus RNA genome but also a nonstructural role in HCV-induced pathogenesis by blocking innate immunity.  Esp., it has been shown to regulate JAK-STAT signaling pathway through its direct interaction with Janus kinase (JAK) via its proline-rich JAK-binding motif (79PGYPWP84).  However, little is known about the physiol. significance of this HCV core-JAK assocn. in the context of the virus life cycle.  In order to gain an insight, a mutant HCV genome (J6/JFH1-79A82A) was constructed to express the mutant core with a defective JAK-binding motif (79AGYAWP84) using an HCV genotype 2a infectious clone (J6/JFH1).  When this mutant HCV genome was introduced into hepatocarcinoma cells, it was found to be severely impaired in its ability to produce infectious viruses in spite of its robust RNA genome replication.  Taken together, all these results suggest an essential requirement of HCV core-JAK protein interaction for efficient prodn. of infectious viruses and the potential of using core-JAK blockers as a new anti-HCV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB6PBOORRDBbVg90H21EOLACvtfcHk0liI3rmRbx54oA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt12ks7c%253D&md5=01b53d8d5f7d333ae663f7b21e29f509</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2013.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2013.007%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26atitle%3DInteraction%2520of%2520hepatitis%2520C%2520virus%2520core%2520protein%2520with%2520janus%2520kinase%2520is%2520required%2520for%2520efficient%2520production%2520of%2520infectious%2520viruses%26jtitle%3DBiomol.%2520Ther.%26date%3D2013%26volume%3D21%26spage%3D97%26epage%3D106%26doi%3D10.4062%2Fbiomolther.2013.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubli, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinaga, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">An aberrant STAT pathway is central to COVID-19</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3209</span>â <span class="NLM_lpage">3225</span>, <span class="refDoi">Â DOI: 10.1038/s41418-020-00633-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41418-020-00633-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33037393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FpsFOisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=3209-3225&author=T.+Matsuyamaauthor=S.+P.+Kubliauthor=S.+K.+Yoshinagaauthor=K.+Pfefferauthor=T.+W.+Mak&title=An+aberrant+STAT+pathway+is+central+to+COVID-19&doi=10.1038%2Fs41418-020-00633-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">An aberrant STAT pathway is central to COVID-19</span></div><div class="casAuthors">Matsuyama Toshifumi; Kubli Shawn P; Mak Tak W; Yoshinaga Steven K; Pfeffer Klaus; Mak Tak W; Mak Tak W</div><div class="citationInfo"><span class="NLM_cas:title">Cell death and differentiation</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3209-3225</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">COVID-19 is caused by SARS-CoV-2 infection and characterized by diverse clinical symptoms.  Type I interferon (IFN-I) production is impaired and severe cases lead to ARDS and widespread coagulopathy.  We propose that COVID-19 pathophysiology is initiated by SARS-CoV-2 gene products, the NSP1 and ORF6 proteins, leading to a catastrophic cascade of failures.  These viral components induce signal transducer and activator of transcription 1 (STAT1) dysfunction and compensatory hyperactivation of STAT3.  In SARS-CoV-2-infected cells, a positive feedback loop established between STAT3 and plasminogen activator inhibitor-1 (PAI-1) may lead to an escalating cycle of activation in common with the interdependent signaling networks affected in COVID-19.  Specifically, PAI-1 upregulation leads to coagulopathy characterized by intravascular thrombi.  Overproduced PAI-1 binds to TLR4 on macrophages, inducing the secretion of proinflammatory cytokines and chemokines.  The recruitment and subsequent activation of innate immune cells within an infected lung drives the destruction of lung architecture, which leads to the infection of regional endothelial cells and produces a hypoxic environment that further stimulates PAI-1 production.  Acute lung injury also activates EGFR and leads to the phosphorylation of STAT3.  COVID-19 patients' autopsies frequently exhibit diffuse alveolar damage (DAD) and increased hyaluronan (HA) production which also leads to higher levels of PAI-1.  COVID-19 risk factors are consistent with this scenario, as PAI-1 levels are increased in hypertension, obesity, diabetes, cardiovascular diseases, and old age.  We discuss the possibility of using various approved drugs, or drugs currently in clinical development, to treat COVID-19.  This perspective suggests to enhance STAT1 activity and/or inhibit STAT3 functions for COVID-19 treatment.  This might derail the escalating STAT3/PAI-1 cycle central to COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYXP-j8pb6Qntlzo9xastyfW6udTcc2eYsoNm_ADc7Xbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FpsFOisg%253D%253D&md5=9c0bd0214b99bd33df55bf68d9585474</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1038%2Fs41418-020-00633-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41418-020-00633-7%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuyama%26aufirst%3DT.%26aulast%3DKubli%26aufirst%3DS.%2BP.%26aulast%3DYoshinaga%26aufirst%3DS.%2BK.%26aulast%3DPfeffer%26aufirst%3DK.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DAn%2520aberrant%2520STAT%2520pathway%2520is%2520central%2520to%2520COVID-19%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2020%26volume%3D27%26spage%3D3209%26epage%3D3225%26doi%3D10.1038%2Fs41418-020-00633-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients</span>. <i>Emerging Microbes Infect.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">761</span>â <span class="NLM_lpage">770</span>, <span class="refDoi">Â DOI: 10.1080/22221751.2020.1747363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1080%2F22221751.2020.1747363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32228226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovVWmur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=761-770&author=Y.+Xiongauthor=Y.+Liuauthor=L.+Caoauthor=D.+Wangauthor=M.+Guoauthor=A.+Jiangauthor=D.+Guoauthor=W.+Huauthor=J.+Yangauthor=Z.+Tangauthor=H.+Wuauthor=Y.+Linauthor=M.+Zhangauthor=Q.+Zhangauthor=M.+Shiauthor=Y.+Liuauthor=Y.+Zhouauthor=K.+Lanauthor=Y.+Chen&title=Transcriptomic+characteristics+of+bronchoalveolar+lavage+fluid+and+peripheral+blood+mononuclear+cells+in+COVID-19+patients&doi=10.1080%2F22221751.2020.1747363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients</span></div><div class="casAuthors">Xiong, Yong; Liu, Yuan; Cao, Liu; Wang, Dehe; Guo, Ming; Jiang, Ao; Guo, Dong; Hu, Wenjia; Yang, Jiayi; Tang, Zhidong; Wu, Honglong; Lin, Yongquan; Zhang, Meiyuan; Zhang, Qi; Shi, Mang; Liu, Yingle; Zhou, Yu; Lan, Ke; Chen, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Emerging Microbes & Infections</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">761-770</span>CODEN:
                <span class="NLM_cas:coden">EMIMC4</span>;
        ISSN:<span class="NLM_cas:issn">2222-1751</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Circulating in China and 158 other countries and areas, the ongoing COVID-19 outbreak has caused devastating mortality and posed a great threat to public health.  However, efforts to identify effectively supportive therapeutic drugs and treatments has been hampered by our limited understanding of host immune response for this fatal disease.  To characterize the transcriptional signatures of host inflammatory response to SARS-CoV-2 (HCoV-19) infection, we carried out transcriptome sequencing of the RNAs isolated from the bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cells (PBMC) specimens of COVID-19 patients.  Our results reveal distinct host inflammatory cytokine profiles to SARS-CoV-2 infection in patients, and highlight the assocn. between COVID-19 pathogenesis and excessive cytokine release such as CCL2/MCP-1, CXCL10/IP-10, CCL3/MIP-1A, and CCL4/MIP1B.  Furthermore, SARS-CoV-2 induced activation of apoptosis and P53 signalling pathway in lymphocytes may be the cause of patients' lymphopenia.  The transcriptome dataset of COVID-19 patients would be a valuable resource for clin. guidance on anti-inflammatory medication and understanding the mol. mechanisms of host response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiqUnbWEGdS7Vg90H21EOLACvtfcHk0ljgGMWRLPp5wQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovVWmur8%253D&md5=f67d028b3589eeb64fb71d8b953c1901</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1080%2F22221751.2020.1747363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F22221751.2020.1747363%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DA.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DTranscriptomic%2520characteristics%2520of%2520bronchoalveolar%2520lavage%2520fluid%2520and%2520peripheral%2520blood%2520mononuclear%2520cells%2520in%2520COVID-19%2520patients%26jtitle%3DEmerging%2520Microbes%2520Infect.%26date%3D2020%26volume%3D9%26spage%3D761%26epage%3D770%26doi%3D10.1080%2F22221751.2020.1747363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Channappanavar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, S.</span></span> <span> </span><span class="NLM_article-title">Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">529</span>â <span class="NLM_lpage">539</span>, <span class="refDoi">Â DOI: 10.1007/s00281-017-0629-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs00281-017-0629-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28466096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVGquro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2017&pages=529-539&author=R.+Channappanavarauthor=S.+Perlman&title=Pathogenic+human+coronavirus+infections%3A+Causes+and+consequences+of+cytokine+storm+and+immunopathology&doi=10.1007%2Fs00281-017-0629-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology</span></div><div class="casAuthors">Channappanavar, Rudragouda; Perlman, Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">529-539</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Human coronaviruses (hCoVs) can be divided into low pathogenic and highly pathogenic coronaviruses.  The low pathogenic CoVs infect the upper respiratory tract and cause mild, cold-like respiratory illness.  In contrast, highly pathogenic hCoVs such as severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) predominantly infect lower airways and cause fatal pneumonia.  Severe pneumonia caused by pathogenic hCoVs is often assocd. with rapid virus replication, massive inflammatory cell infiltration and elevated pro-inflammatory cytokine/chemokine responses resulting in acute lung injury (ALI), and acute respiratory distress syndrome (ARDS).  Recent studies in exptl. infected animal strongly suggest a crucial role for virus-induced immunopathol. events in causing fatal pneumonia after hCoV infections.  Here we review the current understanding of how a dysregulated immune response may cause lung immunopathol. leading to deleterious clin. manifestations after pathogenic hCoV infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrirTei_9NOcbVg90H21EOLACvtfcHk0ljgGMWRLPp5wQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVGquro%253D&md5=0a03e70c30c8d2f39db0a359f9e2e362</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1007%2Fs00281-017-0629-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-017-0629-x%26sid%3Dliteratum%253Aachs%26aulast%3DChannappanavar%26aufirst%3DR.%26aulast%3DPerlman%26aufirst%3DS.%26atitle%3DPathogenic%2520human%2520coronavirus%2520infections%253A%2520Causes%2520and%2520consequences%2520of%2520cytokine%2520storm%2520and%2520immunopathology%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2017%26volume%3D39%26spage%3D529%26epage%3D539%26doi%3D10.1007%2Fs00281-017-0629-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maini, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woody, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holgate, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussell, T.</span></span> <span> </span><span class="NLM_article-title">Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1407</span>â <span class="NLM_lpage">1409</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30858-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS0140-6736%2820%2930858-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32278362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFSlsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1407-1409&author=M.+Feldmannauthor=R.+N.+Mainiauthor=J.+N.+Woodyauthor=S.+T.+Holgateauthor=G.+Winterauthor=M.+Rowlandauthor=D.+Richardsauthor=T.+Hussell&title=Trials+of+anti-tumour+necrosis+factor+therapy+for+COVID-19+are+urgently+needed&doi=10.1016%2FS0140-6736%2820%2930858-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed</span></div><div class="casAuthors">Feldmann, Marc; Maini, Ravinder N.; Woody, James N.; Holgate, Stephen T.; Winter, Gregory; Rowland, Matthew; Richards, Duncan; Hussell, Tracy</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10234</span>),
    <span class="NLM_cas:pages">1407-1409</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A commentary on the need for more trials of anti-TNF therapy to treat COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrttyhP8InXhrVg90H21EOLACvtfcHk0ljgGMWRLPp5wQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFSlsL0%253D&md5=92f0739592011cdb3f1bcbe219cc1760</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930858-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930858-8%26sid%3Dliteratum%253Aachs%26aulast%3DFeldmann%26aufirst%3DM.%26aulast%3DMaini%26aufirst%3DR.%2BN.%26aulast%3DWoody%26aufirst%3DJ.%2BN.%26aulast%3DHolgate%26aufirst%3DS.%2BT.%26aulast%3DWinter%26aufirst%3DG.%26aulast%3DRowland%26aufirst%3DM.%26aulast%3DRichards%26aufirst%3DD.%26aulast%3DHussell%26aufirst%3DT.%26atitle%3DTrials%2520of%2520anti-tumour%2520necrosis%2520factor%2520therapy%2520for%2520COVID-19%2520are%2520urgently%2520needed%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1407%26epage%3D1409%26doi%3D10.1016%2FS0140-6736%2820%2930858-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D. W.</span></span> <span> </span><span class="NLM_article-title">Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">531</span>â <span class="NLM_lpage">543</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2020.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.tips.2020.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32580895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtF2lsLbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=531-543&author=W.+Luoauthor=Y.+X.+Liauthor=L.+J.+Jiangauthor=Q.+Chenauthor=T.+Wangauthor=D.+W.+Ye&title=Targeting+JAK-STAT+signaling+to+control+cytokine+release+syndrome+in+COVID-19&doi=10.1016%2Fj.tips.2020.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19</span></div><div class="casAuthors">Luo, Wei; Li, Yi-Xin; Jiang, Li-Jun; Chen, Qian; Wang, Tao; Ye, Da-Wei</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">531-543</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent advances in the pathophysiol. understanding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe coronavirus disease 2019 (COVID-19) might experience cytokine release syndrome (CRS), characterized by increased interleukin (IL)-6, IL-2, IL-7, IL-10, etc.  Therefore, the treatment of cytokine storm has been proposed as a crit. part of rescuing severe COVID-19.  Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs).  JAK inhibition, therefore, presents an attractive therapeutic strategy for CRS, which is a common cause of adverse clin. outcomes in COVID-19.  Below, we review the possibilities and challenges of targeting the pathway in COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8D2HH09CZ3LVg90H21EOLACvtfcHk0lgVT8hbNzcryw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtF2lsLbF&md5=4812456ab95bfb61bef7bb78f13b8229</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2020.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2020.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%2BX.%26aulast%3DJiang%26aufirst%3DL.%2BJ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DD.%2BW.%26atitle%3DTargeting%2520JAK-STAT%2520signaling%2520to%2520control%2520cytokine%2520release%2520syndrome%2520in%2520COVID-19%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2020%26volume%3D41%26spage%3D531%26epage%3D543%26doi%3D10.1016%2Fj.tips.2020.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ingraham, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotfi-Emran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thielen, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Techar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtan, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tignanelli, C. J.</span></span> <span> </span><span class="NLM_article-title">Immunomodulation in COVID-19</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">544</span>â <span class="NLM_lpage">546</span>, <span class="refDoi">Â DOI: 10.1016/S2213-2600(20)30226-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS2213-2600%2820%2930226-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32380023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXos1Wgt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=544-546&author=N.+E.+Ingrahamauthor=S.+Lotfi-Emranauthor=B.+K.+Thielenauthor=K.+Techarauthor=R.+S.+Morrisauthor=S.+G.+Holtanauthor=R.+A.+Dudleyauthor=C.+J.+Tignanelli&title=Immunomodulation+in+COVID-19&doi=10.1016%2FS2213-2600%2820%2930226-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulation in COVID-19</span></div><div class="casAuthors">Ingraham, Nicholas E.; Lotfi-Emran, Sahar; Thielen, Beth K.; Techar, Kristina; Morris, Rachel S.; Holtan, Shernan G.; Dudley, R. Adams; Tignanelli, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">544-546</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), continues to spread globally despite unprecedented social isolation and restrictions resulting in widespread economic decline.  More than 3.2 million people have been infected and more than 230,000 of them have died.  To date, no treatments have been definitively shown to be effective; however, a multipronged approach to mitigate transmission, morbidity, and mortality is ongoing.  While upstream prevention strategies such as vaccination are ideal, these strategies are unlikely to be available in time to address current clin. need.  Instead, fast-tracking of drug development and repurposing of approved drugs has facilitated and expedited clin. trials that might hasten effective therapeutics.  Many of these drugs act, at least in part, to directly limit viral replication.  By contrast, the use of interleukin-6 (IL-6) inhibition might have benefits by controlling the pathol. immune response to the virus.  Here, we expand on the theor. basis of IL-6 inhibition and propose potential benefits from other immunomodulators that could, in theory, prove more efficacious.  While IL-6 inhibition attenuates key aspects of the cytokine cascade, we posit other immune targets of inhibition to be considered and their potential to be more efficacious in the setting of COVID-19, specifically IL-1 inhibitors and Janus kinase (JAK) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5vsPO8PNStLVg90H21EOLACvtfcHk0lgVT8hbNzcryw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXos1Wgt7o%253D&md5=f46765c8f803136d15684c23ab0c73bb</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2820%2930226-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252820%252930226-5%26sid%3Dliteratum%253Aachs%26aulast%3DIngraham%26aufirst%3DN.%2BE.%26aulast%3DLotfi-Emran%26aufirst%3DS.%26aulast%3DThielen%26aufirst%3DB.%2BK.%26aulast%3DTechar%26aufirst%3DK.%26aulast%3DMorris%26aufirst%3DR.%2BS.%26aulast%3DHoltan%26aufirst%3DS.%2BG.%26aulast%3DDudley%26aufirst%3DR.%2BA.%26aulast%3DTignanelli%26aufirst%3DC.%2BJ.%26atitle%3DImmunomodulation%2520in%2520COVID-19%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2020%26volume%3D8%26spage%3D544%26epage%3D546%26doi%3D10.1016%2FS2213-2600%2820%2930226-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seif, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aazami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoshmirsafa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohsenzadegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pornour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, D.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a new treatment strategy for patients with COVID-19</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">467</span>â <span class="NLM_lpage">475</span>, <span class="refDoi">Â DOI: 10.1159/000508247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1159%2F000508247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32392562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1WjsrfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=467-475&author=F.+Seifauthor=H.+Aazamiauthor=M.+Khoshmirsafaauthor=M.+Kamaliauthor=M.+Mohsenzadeganauthor=M.+Pornourauthor=D.+Mansouri&title=JAK+inhibition+as+a+new+treatment+strategy+for+patients+with+COVID-19&doi=10.1159%2F000508247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">JAK Inhibition as a New Treatment Strategy for Patients with COVID-19</span></div><div class="casAuthors">Seif, Farhad; Aazami, Hossein; Khoshmirsafa, Majid; Kamali, Monireh; Mohsenzadegan, Monireh; Pornour, Majid; Mansouri, Davood</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">467-475</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world.  Understanding the Immunopathogenesis of COVID-19 is essential for interrupting viral infectivity and preventing aberrant immune responses before a vaccine can be developed.  In this review, we provide the latest insights into the roles of angiotensin-converting enzyme II (ACE2) and Ang II receptor-1 (AT1-R) in this disease.  Novel therapeutic strategies, including recombinant ACE2, ACE inhibitors, AT1-R blockers, and Ang 1-7 peptides, may prevent or reduce viruses-induced pulmonary, cardiac, and renal injuries.  However, more studies are needed to clarify the efficacy of these therapeutics.  Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals.  In addn. to antiviral therapy, potential ACE2- and AT1-R-inhibiting strategies, and other supportive care, we suggest other potential JAKinibs and novel anti-inflammatory combination therapies that affect the JAK-STAT pathway in patients with COVID-19.  Since the combination of MTX and baricitinib leads to outstanding clin. outcomes, the addn. of baricitinib to MTX might be a potential strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpeDIB1cKJRLVg90H21EOLACvtfcHk0lifnGifrDQjxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1WjsrfL&md5=dc9d52d82a5d090166752a684d100942</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1159%2F000508247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000508247%26sid%3Dliteratum%253Aachs%26aulast%3DSeif%26aufirst%3DF.%26aulast%3DAazami%26aufirst%3DH.%26aulast%3DKhoshmirsafa%26aufirst%3DM.%26aulast%3DKamali%26aufirst%3DM.%26aulast%3DMohsenzadegan%26aufirst%3DM.%26aulast%3DPornour%26aufirst%3DM.%26aulast%3DMansouri%26aufirst%3DD.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520new%2520treatment%2520strategy%2520for%2520patients%2520with%2520COVID-19%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2020%26volume%3D181%26spage%3D467%26epage%3D475%26doi%3D10.1159%2F000508247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Convertino, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdiserra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focosi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span> <span> </span><span class="NLM_article-title">Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients</span>. <i>Crit. Care</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">331</span>, <span class="refDoi">Â DOI: 10.1186/s13054-020-03020-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2Fs13054-020-03020-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32527304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB38roslykuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=331&author=I.+Convertinoauthor=M.+Tuccoriauthor=S.+Ferraroauthor=G.+Valdiserraauthor=E.+Cappelloauthor=D.+Focosiauthor=C.+Blandizzi&title=Exploring+pharmacological+approaches+for+managing+cytokine+storm+associated+with+pneumonia+and+acute+respiratory+distress+syndrome+in+COVID-19+patients&doi=10.1186%2Fs13054-020-03020-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients</span></div><div class="casAuthors">Convertino Irma; Tuccori Marco; Ferraro Sara; Valdiserra Giulia; Cappello Emiliano; Blandizzi Corrado; Tuccori Marco; Blandizzi Corrado; Focosi Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Critical care (London, England)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">331</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission.  These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality.  Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure.  Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising.  Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied.  In this article, we discuss the potential advantages of the most promising pharmacological approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrt2z806QLEuxsqfvU0ziafW6udTcc2eb6DFJLLnaWyrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38roslykuw%253D%253D&md5=338f561d1c6796524ffedbcd9b6f8df3</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1186%2Fs13054-020-03020-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13054-020-03020-3%26sid%3Dliteratum%253Aachs%26aulast%3DConvertino%26aufirst%3DI.%26aulast%3DTuccori%26aufirst%3DM.%26aulast%3DFerraro%26aufirst%3DS.%26aulast%3DValdiserra%26aufirst%3DG.%26aulast%3DCappello%26aufirst%3DE.%26aulast%3DFocosi%26aufirst%3DD.%26aulast%3DBlandizzi%26aufirst%3DC.%26atitle%3DExploring%2520pharmacological%2520approaches%2520for%2520managing%2520cytokine%2520storm%2520associated%2520with%2520pneumonia%2520and%2520acute%2520respiratory%2520distress%2520syndrome%2520in%2520COVID-19%2520patients%26jtitle%3DCrit.%2520Care%26date%3D2020%26volume%3D24%26spage%3D331%26doi%3D10.1186%2Fs13054-020-03020-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib: The first FDA approved therapy for the treatment of myelofibrosis</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3008</span>â <span class="NLM_lpage">3014</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-11-3145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F1078-0432.CCR-11-3145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22474318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVOgt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3008-3014&author=J.+Mascarenhasauthor=R.+Hoffman&title=Ruxolitinib%3A+The+first+FDA+approved+therapy+for+the+treatment+of+myelofibrosis&doi=10.1158%2F1078-0432.CCR-11-3145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis</span></div><div class="casAuthors">Mascarenhas, John; Hoffman, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3008-3014</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The BCR-ABL1-neg. myeloproliferative neoplasms (e.g., essential thrombocythemia, polycythemia vera, and primary myelofibrosis) are a group of heterogeneous hematol. malignancies that involve a clonal proliferation of hematopoietic stem cells.  Thrombosis, bleeding, and transformation to acute leukemia reduce the overall survival of patients with myelofibrosis, a disease typified by progressive splenomegaly and disease-related symptoms such as fatigue, pruritus, and bony pains.  Hematopoietic stem cell transplant offers the only potential for cure in a minority of eligible patients, leaving a serious unmet need for improved therapies.  Recent advances in our understanding of the pathogenetic mechanisms underlying these diseases have led to an explosion of clin. trials evaluating novel therapies.  The discovery of an activating mutation in the Janus-activated kinase 2 (JAK2) gene provided a therapeutic target to downregulate this activated signaling pathway, which influences the phenotype of these diseases.  Ruxolitinib (Jakafi; Incyte) is a small-mol. inhibitor of JAK1/2 that has proved to be effective at reducing splenomegaly and ameliorating symptoms in myeloproliferative neoplasms.  Based on the results of 2 pivotal randomized phase III clin. trials, ruxolitinib has become the first therapeutic to be approved by the U.S.  Food and Drug Administration for treatment of patients with myelofibrosis.  Ruxolitinib offers a well-tolerated oral therapeutic option for patients with myelofibrosis with symptomatic splenomegaly and debilitating disease-related symptoms, but it does not seem to be effective at eliminating the underlying hematol. malignancy.  Clin Cancer Res; 18(11); 3008-14. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaXacNKxoFHbVg90H21EOLACvtfcHk0liinGd_9r1acw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVOgt7g%253D&md5=ae859cee63a9ca2768164eb7d840febb</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3145%26sid%3Dliteratum%253Aachs%26aulast%3DMascarenhas%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%26atitle%3DRuxolitinib%253A%2520The%2520first%2520FDA%2520approved%2520therapy%2520for%2520the%2520treatment%2520of%2520myelofibrosis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3008%26epage%3D3014%26doi%3D10.1158%2F1078-0432.CCR-11-3145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">FDA approves Eli Lillyâs Baricitinib</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">460</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2018.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnrd.2018.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Sqtr3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=460&author=A.+Mullard&title=FDA+approves+Eli+Lilly%E2%80%99s+Baricitinib&doi=10.1038%2Fnrd.2018.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">mRNA vaccines get another booster</span></div><div class="casAuthors">Mullard, Asher</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">460</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1pR5FbMQvVLVg90H21EOLACvtfcHk0liinGd_9r1acw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Sqtr3E&md5=025f07fb9a24835c5f349436f0372c10</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.112%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DFDA%2520approves%2520Eli%2520Lilly%25E2%2580%2599s%2520Baricitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D460%26doi%3D10.1038%2Fnrd.2018.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, K.</span></span> <span> </span><span class="NLM_article-title">FDA approves Tofacitinib for rheumatoid arthritis</span>. <i>Am. J. Health-Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2120</span>, <span class="refDoi">Â DOI: 10.2146/news120088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.2146%2Fnews120088" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=2120&author=K.+Traynor&title=FDA+approves+Tofacitinib+for+rheumatoid+arthritis&doi=10.2146%2Fnews120088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.2146%2Fnews120088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fnews120088%26sid%3Dliteratum%253Aachs%26aulast%3DTraynor%26aufirst%3DK.%26atitle%3DFDA%2520approves%2520Tofacitinib%2520for%2520rheumatoid%2520arthritis%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2012%26volume%3D69%26spage%3D2120%26doi%3D10.2146%2Fnews120088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group">American
Association for Cancer Research</span> <span> </span><span class="NLM_article-title">Fedratinib becomes new option in myelofibrosis</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1332.1</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-NB2019-102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F2159-8290.CD-NB2019-102" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1332.1&author=American%0AAssociation+for+Cancer+Research&title=Fedratinib+becomes+new+option+in+myelofibrosis&doi=10.1158%2F2159-8290.CD-NB2019-102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-NB2019-102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-NB2019-102%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFedratinib%2520becomes%2520new%2520option%2520in%2520myelofibrosis%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D1332.1%26doi%3D10.1158%2F2159-8290.CD-NB2019-102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B. A.</span></span> <span> </span><span class="NLM_article-title">JAK inhibitors in dermatology: The promise of a new drug class</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">736</span>â <span class="NLM_lpage">744</span>, <span class="refDoi">Â DOI: 10.1016/j.jaad.2016.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jaad.2016.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28139263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSmu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=736-744&author=W.+Damskyauthor=B.+A.+King&title=JAK+inhibitors+in+dermatology%3A+The+promise+of+a+new+drug+class&doi=10.1016%2Fj.jaad.2016.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibitors in dermatology: The promise of a new drug class</span></div><div class="casAuthors">Damsky, William; King, Brett A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">736-744</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">New molecularly targeted therapeutics are changing dermatol. therapy.  Janus kinase-signal transducer and activator of transcription (JAK-STAT) is an intracellular signaling pathway upon which many different proinflammatory signaling pathways converge.  Numerous inflammatory dermatoses are driven by sol. inflammatory mediators, which rely on JAK-STAT signaling, and inhibition of this pathway using JAK inhibitors might be a useful therapeutic strategy for these diseases.  Growing evidence suggests that JAK inhibitors are efficacious in atopic dermatitis, alopecia areata, psoriasis, and vitiligo.  Addnl. evidence suggests that JAK inhibition might be broadly useful in dermatol., with early reports of efficacy in several other conditions.  JAK inhibitors can be administered orally or used topically and represent a promising new class of medications.  The use of JAK inhibitors in dermatol. is reviewed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUcLA-JaUAFbVg90H21EOLACvtfcHk0ljxnocyHRffOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSmu7g%253D&md5=6b4c7d26b0659a1d89b7f0ef8e043c0e</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2016.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2016.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DDamsky%26aufirst%3DW.%26aulast%3DKing%26aufirst%3DB.%2BA.%26atitle%3DJAK%2520inhibitors%2520in%2520dermatology%253A%2520The%2520promise%2520of%2520a%2520new%2520drug%2520class%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2017%26volume%3D76%26spage%3D736%26epage%3D744%26doi%3D10.1016%2Fj.jaad.2016.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S.</span></span> <span> </span><span class="NLM_article-title">Upadacitinib: First approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1819</span>, <span class="refDoi">Â DOI: 10.1007/s40265-019-01211-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs40265-019-01211-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31642025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3MjgvVSrtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1819&author=S.+Dugganauthor=S.+Keam&title=Upadacitinib%3A+First+approval&doi=10.1007%2Fs40265-019-01211-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Upadacitinib: First Approval</span></div><div class="casAuthors">Duggan Sean; Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1819-1828</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Upadacitinib (RinvoqÂ®), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis.  In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate.  This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfxtr5CsQWZxWfpMXQLRstfW6udTcc2ebGItAvAG8yu7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjgvVSrtg%253D%253D&md5=3ef93907bbec16e744d0fb2b6dae65e0</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01211-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01211-z%26sid%3Dliteratum%253Aachs%26aulast%3DDuggan%26aufirst%3DS.%26aulast%3DKeam%26aufirst%3DS.%26atitle%3DUpadacitinib%253A%2520First%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1819%26doi%3D10.1007%2Fs40265-019-01211-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Z.</span>; <span class="NLM_string-name">Wang, T.</span>; <span class="NLM_string-name">Li, C.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Qin, X.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Luo, J.</span></span> <span> </span><span class="NLM_article-title">An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area</span>.  <i>MedRxiv</i>, May 7, 2020, ver. 1.<span class="refDoi">Â DOI: 10.1101/2020.04.11.20061473</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1101%2F2020.04.11.20061473" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Meng%2C+Z.%3B+Wang%2C+T.%3B+Li%2C+C.%3B+Chen%2C+X.%3B+Li%2C+L.%3B+Qin%2C+X.%3B+Li%2C+H.%3B+Luo%2C+J.+An+experimental+trial+of+recombinant+human+interferon+alpha+nasal+drops+to+prevent+coronavirus+disease+2019+in+medical+staff+in+an+epidemic+area.+MedRxiv%2C+May+7%2C+2020%2C+ver.+1.+10.1101%2F2020.04.11.20061473."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1101%2F2020.04.11.20061473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.04.11.20061473%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DZ.%26atitle%3DAn%2520experimental%2520trial%2520of%2520recombinant%2520human%2520interferon%2520alpha%2520nasal%2520drops%2520to%2520prevent%2520coronavirus%2520disease%25202019%2520in%2520medical%2520staff%2520in%2520an%2520epidemic%2520area%26jtitle%3DMedRxiv%26doi%3D10.1101%2F2020.04.11.20061473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ennis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiligada, K.</span></span> <span> </span><span class="NLM_article-title">Histamine receptors and COVID-19</span>. <i>Inflammation Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">67</span>â <span class="NLM_lpage">75</span>, <span class="refDoi">Â DOI: 10.1007/s00011-020-01422-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs00011-020-01422-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33206207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlOgsrnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2021&pages=67-75&author=M.+Ennisauthor=K.+Tiligada&title=Histamine+receptors+and+COVID-19&doi=10.1007%2Fs00011-020-01422-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine receptors and COVID-19</span></div><div class="casAuthors">Ennis, Madeleine; Tiligada, Katerina</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-75</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  Reports that the over-the-counter histamine H2 receptor antagonist famotidine could help treat the novel coronavirus disease (COVID-19) appeared from Apr. 2020.  We, therefore, examd. reports on interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and histamine receptor antagonists.  A systematic literature search was performed by 19 Sept. 2020, and updated on 28 Oct. 2020, in PubMed, Scopus, Cochrane Library and Google Scholar using (COVID-19 OR coronavirus OR SARS-CoV-2) AND (histamine antagonist OR famotidine OR cimetidine).  ClinicalTrials.gov was searched for COVID-19 and (famotidine or histamine).  Famotidine may be a useful addn. in COVID-19 treatment, but the results from prospective randomized trials are as yet awaited.  Bioinformatics/drug repurposing studies indicated that, among several medicines, H1 and H2 receptor antagonists may interact with key viral enzymes.  However, in vitro studies have to date failed to show a direct inhibition of famotidine on SARS-CoV-2 replication.  Clin. research into the potential benefits of H2 receptor antagonists in managing COVID-19 inflammation began from a simple observation and now is being tested in multi-center clin. trials.  The pos. effects of famotidine may be due to H2 receptor-mediated immunomodulatory actions on mast cell histamine-cytokine cross-talk, rather than a direct action on SARS-CoV-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY_r4jV_yKFbVg90H21EOLACvtfcHk0lgMpq_xxFjKwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlOgsrnF&md5=98ce2ef04e2487d30fd2e6a34e8dd6e5</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1007%2Fs00011-020-01422-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00011-020-01422-1%26sid%3Dliteratum%253Aachs%26aulast%3DEnnis%26aufirst%3DM.%26aulast%3DTiligada%26aufirst%3DK.%26atitle%3DHistamine%2520receptors%2520and%2520COVID-19%26jtitle%3DInflammation%2520Res.%26date%3D2021%26volume%3D70%26spage%3D67%26epage%3D75%26doi%3D10.1007%2Fs00011-020-01422-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druce, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catton, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jans, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagstaff, K. M.</span></span> <span> </span><span class="NLM_article-title">The FDA-approved drug ivermectin inhibits the replication of SARSCoV-2 in vitro</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">104787</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2020.104787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2020.104787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32251768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFalsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=104787&author=L.+Calyauthor=J.+D.+Druceauthor=M.+G.+Cattonauthor=D.+A.+Jansauthor=K.+M.+Wagstaff&title=The+FDA-approved+drug+ivermectin+inhibits+the+replication+of+SARSCoV-2+in+vitro&doi=10.1016%2Fj.antiviral.2020.104787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</span></div><div class="casAuthors">Caly, Leon; Druce, Julian D.; Catton, Mike G.; Jans, David A.; Wagstaff, Kylie M.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104787</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Although several clin. trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment.  We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addn. to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect â¼5000-fold redn. in viral RNA at 48 h.  Ivermectin therefore warrants further investigation for possible benefits in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHJsrOxupqz7Vg90H21EOLACvtfcHk0lgMpq_xxFjKwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFalsL8%253D&md5=d5bac8cb28292f4dc5a2feac22ce6824</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104787%26sid%3Dliteratum%253Aachs%26aulast%3DCaly%26aufirst%3DL.%26aulast%3DDruce%26aufirst%3DJ.%2BD.%26aulast%3DCatton%26aufirst%3DM.%2BG.%26aulast%3DJans%26aufirst%3DD.%2BA.%26aulast%3DWagstaff%26aufirst%3DK.%2BM.%26atitle%3DThe%2520FDA-approved%2520drug%2520ivermectin%2520inhibits%2520the%2520replication%2520of%2520SARSCoV-2%2520in%2520vitro%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D178%26spage%3D104787%26doi%3D10.1016%2Fj.antiviral.2020.104787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nice, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span> <span> </span><span class="NLM_article-title">Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">4457</span>â <span class="NLM_lpage">4469</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-15-2887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F0008-5472.CAN-15-2887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27302166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gmt7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=4457-4469&author=Q.+Douauthor=H.+N.+Chenauthor=K.+Wangauthor=K.+Yuanauthor=Y.+Leiauthor=K.+Liauthor=J.+Lanauthor=Y.+Chenauthor=Z.+Huangauthor=N.+Xieauthor=L.+Zhangauthor=R.+Xiangauthor=E.+C.+Niceauthor=Y.+Weiauthor=C.+Huang&title=Ivermectin+induces+cytostatic+autophagy+by+blocking+the+PAK1%2FAkt+axis+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-15-2887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer</span></div><div class="casAuthors">Dou, Qianhui; Chen, Hai-Ning; Wang, Kui; Yuan, Kefei; Lei, Yunlong; Li, Kai; Lan, Jiang; Chen, Yan; Huang, Zhao; Xie, Na; Zhang, Lu; Xiang, Rong; Nice, Edouard C.; Wei, Yuquan; Huang, Canhua</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4457-4469</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Breast cancer is the most common cancer among women worldwide, yet successful treatment remains a clin. challenge.  Ivermectin, a broad-spectrum antiparasitic drug, has recently been characterized as a potential anticancer agent due to obsd. antitumor effects.  However, the mol. mechanisms involved remain poorly understood.  Here, we report a role for ivermectin in breast cancer suppression by activating cytostatic autophagy both in vitro and in vivo.  Mechanistically, ivermectin-induced autophagy in breast cancer cells is assocd. with decreased P21-activated kinase 1 (PAK1) expression via the ubiquitination-mediated degrdn. pathway.  The inhibition of PAK1 decreases the phosphorylation level of Akt, resulting in the blockade of the Akt/mTOR signaling pathway.  In breast cancer xenografts, the ivermectin-induced cytostatic autophagy leads to suppression of tumor growth.  Together, our results provide a mol. basis for the use of ivermectin to inhibit the proliferation of breast cancer cells and indicate that ivermectin is a potential option for the treatment of breast cancer.  Cancer Res; 76(15); 4457-69.2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZKWcGfsuUE7Vg90H21EOLACvtfcHk0ljnf21XLlknGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gmt7nK&md5=b1475e60805d04efee9040e91d6aaf4f</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2887%26sid%3Dliteratum%253Aachs%26aulast%3DDou%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DH.%2BN.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DK.%26aulast%3DLei%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DNice%26aufirst%3DE.%2BC.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DC.%26atitle%3DIvermectin%2520induces%2520cytostatic%2520autophagy%2520by%2520blocking%2520the%2520PAK1%252FAkt%2520axis%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D4457%26epage%3D4469%26doi%3D10.1158%2F0008-5472.CAN-15-2887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span> <span> </span><span class="NLM_article-title">Specific inhibition of STAT3 signal transduction by PIAS3</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">1803</span>â <span class="NLM_lpage">1805</span>, <span class="refDoi">Â DOI: 10.1126/science.278.5344.1803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1126%2Fscience.278.5344.1803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=9388184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK2sXnvFClt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=1997&pages=1803-1805&author=C.+D.+Chungauthor=J.+Liaoauthor=B.+Liuauthor=X.+Raoauthor=P.+Jayauthor=P.+Bertaauthor=K.+Shuai&title=Specific+inhibition+of+STAT3+signal+transduction+by+PIAS3&doi=10.1126%2Fscience.278.5344.1803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibition of Stat3 signal transduction by PIAS3</span></div><div class="casAuthors">Chung, Chan D.; Liao, Jiayu; Liu, Bin; Rao, Xiaoping; Jay, Philippe; Berta, Philippe; Shuai, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">5344</span>),
    <span class="NLM_cas:pages">1803-1805</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The signal transducer and activator of transcription-3 (Stat3) protein is activated by the interleukin 6(IL-6) family of cytokines, epidermal growth factor, and leptin.  A protein named PIAS3 (protein inhibitor of activated STAT) that binds to Stat3 was isolated and characterized.  The assocn. of PIAS3 with Stat3 in vivo was only obsd. in cells stimulated with ligands that cause the activation of Stat3.  PIAS3 blocked the DNA-binding activity of Stat3 and inhibited Stat3-mediated gene activation.  Although Stat1 is also phosphorylated in response to IL-6, PIAS3 did not interact with Stat1 or affect its DNA-binding or transcriptional activity.  The results indicate that PIAS3 is a specific inhibitor of Stat3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjxR6Y9y0qULVg90H21EOLACvtfcHk0ljnf21XLlknGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvFClt7Y%253D&md5=781da0d380d1024071e1126bb07f6b4b</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1126%2Fscience.278.5344.1803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.278.5344.1803%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DC.%2BD.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DRao%26aufirst%3DX.%26aulast%3DJay%26aufirst%3DP.%26aulast%3DBerta%26aufirst%3DP.%26aulast%3DShuai%26aufirst%3DK.%26atitle%3DSpecific%2520inhibition%2520of%2520STAT3%2520signal%2520transduction%2520by%2520PIAS3%26jtitle%3DScience%26date%3D1997%26volume%3D278%26spage%3D1803%26epage%3D1805%26doi%3D10.1126%2Fscience.278.5344.1803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saydmohammed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, V.</span></span> <span> </span><span class="NLM_article-title">Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">447</span>â <span class="NLM_lpage">456</span>, <span class="refDoi">Â DOI: 10.1002/jcb.22558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Fjcb.22558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20235152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVSktLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2010&pages=447-456&author=M.+Saydmohammedauthor=D.+Josephauthor=V.+Syed&title=Curcumin+suppresses+constitutive+activation+of+STAT-3+by+up-regulating+protein+inhibitor+of+activated+STAT-3+%28PIAS-3%29+in+ovarian+and+endometrial+cancer+cells&doi=10.1002%2Fjcb.22558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells</span></div><div class="casAuthors">Saydmohammed, Manush; Joseph, Doina; Syed, Viqar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">447-456</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription-3 (STAT-3) is constitutively activated in ovarian and endometrial cancers and is implicated in uncontrolled cell growth.  Thus, its disruption could be an effective approach to control tumorigenesis.  Curcumin is a dihydroxyphenolic compd., with proven anti-cancer efficacy in various cancer models.  We examd. the anti-tumor mechanism of curcumin on STAT-3 and on the neg. regulators of STAT-3, including suppressors of cytokine signaling proteins (SOCS-1 and SOCS-3), protein inhibitors of activated STAT (PIAS-1 and PIAS-3), and SH2 domain-contg. phosphatases (SHP-1 and SHP-2) in ovarian and endometrial cancer cell lines.  Treatment of cancer cells with curcumin induced a dose- and time-dependent decrease of constitutive IL-6 expression and of constitutive and IL-6-induced STAT-3 phosphorylation, which is assocd. with decreased cell viability and increased cleavage of caspase-3.  The inhibition of STAT-3 activation by curcumin was reversible, and phosphorylated STAT-3 levels returned to control levels 24 h after curcumin removal.  Compared to normal cells baseline expression of SOCS-3 was high in cancer cells and a marked decrease in SOCS-3 expression was seen following curcumin treatment.  Overexpression of SOCS-3 in curcumin-treated cells increased expression of phosphorylated STAT-3 and resulted in increased cell viability.  Normal ovarian and endometrial cells exhibited high expression of PIAS-3 protein, whereas in cancer cells the expression was greatly reduced.  Curcumin increased PIAS-3 expression in cancer cells.  Of significance, siRNA-mediated knockdown of PIAS-3 overcomes the inhibitory effect of curcumin on STAT-3 phosphorylation and cell viability.  In conclusion, curcumin suppresses JAK-STAT signaling via activation of PIAS-3, thus attenuating STAT-3 phosphorylation and tumor cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH0bEhKquCdrVg90H21EOLACvtfcHk0lgkCOIzLlLF8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVSktLY%253D&md5=2ec30ed38147ff6743532817f768af17</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1002%2Fjcb.22558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.22558%26sid%3Dliteratum%253Aachs%26aulast%3DSaydmohammed%26aufirst%3DM.%26aulast%3DJoseph%26aufirst%3DD.%26aulast%3DSyed%26aufirst%3DV.%26atitle%3DCurcumin%2520suppresses%2520constitutive%2520activation%2520of%2520STAT-3%2520by%2520up-regulating%2520protein%2520inhibitor%2520of%2520activated%2520STAT-3%2520%2528PIAS-3%2529%2520in%2520ovarian%2520and%2520endometrial%2520cancer%2520cells%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2010%26volume%3D110%26spage%3D447%26epage%3D456%26doi%3D10.1002%2Fjcb.22558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollenhaupt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mojcik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strengholt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazariciu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">89</span>, <span class="refDoi">Â DOI: 10.1186/s13075-019-1866-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2Fs13075-019-1866-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30953540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FitlWquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=89&author=J.+Wollenhauptauthor=E.-B.+Leeauthor=J.+R.+Curtisauthor=J.+Silverfieldauthor=K.+Terryauthor=K.+Somaauthor=C.+Mojcikauthor=R.+DeMasiauthor=S.+Strengholtauthor=K.+Kwokauthor=I.+Lazariciuauthor=L.+Wangauthor=S.+Cohen&title=Safety+and+efficacy+of+tofacitinib+for+up+to+9.5+years+in+the+treatment+of+rheumatoid+arthritis%3A+final+results+of+a+global%2C+open-label%2C+long-term+extension+study&doi=10.1186%2Fs13075-019-1866-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study</span></div><div class="casAuthors">Wollenhaupt Jurgen; Lee Eun-Bong; Curtis Jeffrey R; Silverfield Joel; Terry Ketti; Wang Lisy; Soma Koshika; Mojcik Chris; Kwok Kenneth; DeMasi Ryan; Strengholt Sander; Lazariciu Irina; Cohen Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis research & therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA).  METHODS:  Eligible patients had previously completed a phase 1, 2, or 3 qualifying index study of tofacitinib and received open-label tofacitinib 5 mg or 10 mg BID.  Stable background therapy, including csDMARDs, was continued; adjustments to tofacitinib or background therapy were permitted at investigators' discretion.  Assignment to dose groups (5 mg or 10 mg BID) was based on patients' average total daily dose.  The primary objective was to determine the long-term safety and tolerability of tofacitinib 5 mg and 10 mg BID; the key secondary objective was to evaluate the long-term persistence of efficacy.  RESULTS:  Between February 5, 2007, and November 30, 2016, 4481 patients were enrolled.  Total tofacitinib exposure was 16,291 patient-years.  Safety data are reported up to month 114 for all tofacitinib; efficacy data are reported up to month 96 for tofacitinib 5 mg BID and month 72 for 10 mg BID (with low patient numbers limiting interpretation beyond these time points).  Overall, 52% of patients discontinued (24% due to adverse events [AEs] and 4% due to insufficient clinical response); the safety profile remained consistent with that observed in prior phase 1, 2, 3, or LTE studies.  The incidence rate (IR; number of patients with events per 100 patient-years) for AEs leading to discontinuation was 6.8.  For all-cause AEs of special interest, IRs were 3.4 for herpes zoster, 2.4 for serious infections, 0.8 for malignancies excluding non-melanoma skin cancer, 0.4 for major adverse cardiovascular events, and 0.3 for all-cause mortality.  Clinically meaningful improvements in the signs and symptoms of RA and physical functioning, which were observed in the index studies, were maintained.  CONCLUSIONS:  Tofacitinib 5 mg and 10 mg BID demonstrated a consistent safety profile (as monotherapy or combination therapy) and sustained efficacy in this open-label LTE study of patients with RA.  Safety data are reported up to 9.5 years, and efficacy data up to 8 years, based on adequate patient numbers to support conclusions.  TRIAL REGISTRATION:  NCT00413699 , funded by Pfizer Inc (date of trial registration: December 20, 2006).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQry7CBP_Rh3thwrmtH4OBfW6udTcc2eZ-ICmURTBLbLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FitlWquw%253D%253D&md5=15c33765e0ca5ffa5772fe872ede2a8a</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1186%2Fs13075-019-1866-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-019-1866-2%26sid%3Dliteratum%253Aachs%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.-B.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DSilverfield%26aufirst%3DJ.%26aulast%3DTerry%26aufirst%3DK.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DMojcik%26aufirst%3DC.%26aulast%3DDeMasi%26aufirst%3DR.%26aulast%3DStrengholt%26aufirst%3DS.%26aulast%3DKwok%26aufirst%3DK.%26aulast%3DLazariciu%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DS.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520tofacitinib%2520for%2520up%2520to%25209.5%2520years%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%253A%2520final%2520results%2520of%2520a%2520global%252C%2520open-label%252C%2520long-term%2520extension%2520study%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2019%26volume%3D21%26spage%3D89%26doi%3D10.1186%2Fs13075-019-1866-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mease, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charles-Schoeman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolcott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onofrei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanik, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauben, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span> <span> </span><span class="NLM_article-title">Incidence of venous and arterial thromboembolic events reported in the Tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1400</span>â <span class="NLM_lpage">1413</span>, <span class="refDoi">Â DOI: 10.1136/annrheumdis-2019-216761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1136%2Fannrheumdis-2019-216761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32759265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisF2nu7vN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2020&pages=1400-1413&author=P.+Measeauthor=C.+Charles-Schoemanauthor=S.+Cohenauthor=L.+Fallonauthor=J.+Woolcottauthor=H.+Yunauthor=J.+Kremerauthor=J.+Greenbergauthor=W.+Malleyauthor=A.+Onofreiauthor=K.+S.+Kanikauthor=D.+Grahamauthor=C.+Wangauthor=C.+Connellauthor=H.+Valdezauthor=M.+Haubenauthor=E.+Hungauthor=A.+Madsenauthor=T.+V.+Jonesauthor=J.+R.+Curtis&title=Incidence+of+venous+and+arterial+thromboembolic+events+reported+in+the+Tofacitinib+rheumatoid+arthritis%2C+psoriasis+and+psoriatic+arthritis+development+programmes+and+from+real-world+data&doi=10.1136%2Fannrheumdis-2019-216761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data</span></div><div class="casAuthors">Mease, Philip; Charles-Schoeman, Christina; Cohen, Stanley; Fallon, Lara; Woolcott, John; Yun, Huifeng; Kremer, Joel; Greenberg, Jeffrey; Malley, Wendi; Onofrei, Alina; Kanik, Keith S.; Graham, Daniela; Wang, Cunshan; Connell, Carol; Valdez, Hernan; Hauben, Manfred; Hung, Eric; Madsen, Ann; Jones, Thomas V.; Curtis, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1400-1413</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ</span>)
        </div><div class="casAbstract">Objectives Tofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis (PsO).  Routine pharmacovigilance of an ongoing, open-label, blinded-endpoint, tofacitinib RA trial (Study A3921133; NCT02092467) in patients aged â¥50 years and with â¥1 cardiovascular risk factor identified a higher frequency of pulmonary embolism (PE) and all-cause mortality for patients receiving tofacitinib 10 mg twice daily vs. those receiving tumor necrosis factor inhibitors and resulted in identification of a safety signal for tofacitinib.  Here, we report the incidence of deep vein thrombosis (DVT), PE, venous thromboembolism (VTE; DVT or PE) and arterial thromboembolism (ATE) from the tofacitinib RA (excluding Study A3921133), PsA and PsO development programs and observational studies.  Data from an ad hoc safety anal. of Study A3921133 are reported sep within.  Methods This post-hoc anal. used data from sep tofacitinib RA, PsO and PsA programs.  Incidence rates (IRs; patients with events per 100 patient-years exposure) were calcd. for DVT, PE, VTE and ATE, including for populations stratified by defined baseline cardiovascular or VTE risk factors.  Observational data from the US Corrona registries (including cardiovascular risk factor stratification), IBM MarketScan research database and the US FDA Adverse Event Reporting System (FAERS) database were analyzed.  Results 12 410 tofacitinib-treated patients from the development programs (RA: n = 7964; PsO: n = 3663; PsA: n = 783) were included.  IRs (95% CI) of thromboembolic events among the all tofacitinib cohorts av. tofacitinib 5 mg and 10 mg twice daily treated patients for RA, respectivley, were: DVT (0.17 (0.09-0.27) and 0.15 (0.09-0.22)); PE (0.12 (0.06-0.22) and 0.13 (0.08-0.21)); ATE (0.32 (0.22-0.46) and 0.38 (0.28-0.49)).  IRs were similar between tofacitinib doses and generally higher in patients with baseline cardiovascular or VTE risk factors.  IRs from the overall Corrona populations and in Corrona RA patients (including tofacitinib-naive/biol. disease-modifying antirheumatic drug-treated and tofacitinib-treated) with baseline cardiovascular risk factors were similar to IRs obsd. among the corresponding patients in the tofacitinib development program.  No signals of disproportionate reporting of DVT, PE or ATE with tofacitinib were identified in the FAERS database.  Conclusions DVT, PE and ATE IRs in the tofacitinib RA, PsO and PsA programs were similar across tofacitinib doses, and generally consistent with observational data and published IRs of other treatments.  As expected, IRs of thromboembolic events were elevated in patients with vs without baseline cardiovascular or VTE risk factors, and were broadly consistent with those obsd. in the Study A3921133 ad hoc safety anal. data, although the IR (95% CI) for PE was greater in patients treated with tofacitinib 10 mg twice daily in Study A3921133 (0.54 (0.32-0.87)), vs patients with baseline cardiovascular risk factors treated with tofacitinib 10 mg twice daily in the RA program (0.24 (0.13-0.41)).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXpWehht-WfbVg90H21EOLACvtfcHk0ljcnmTzy21IQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisF2nu7vN&md5=dc3bb7d3c470a51e397502b1f5a31d28</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-216761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-216761%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DP.%26aulast%3DCharles-Schoeman%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DFallon%26aufirst%3DL.%26aulast%3DWoolcott%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DH.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DGreenberg%26aufirst%3DJ.%26aulast%3DMalley%26aufirst%3DW.%26aulast%3DOnofrei%26aufirst%3DA.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DGraham%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DConnell%26aufirst%3DC.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DHauben%26aufirst%3DM.%26aulast%3DHung%26aufirst%3DE.%26aulast%3DMadsen%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DT.%2BV.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26atitle%3DIncidence%2520of%2520venous%2520and%2520arterial%2520thromboembolic%2520events%2520reported%2520in%2520the%2520Tofacitinib%2520rheumatoid%2520arthritis%252C%2520psoriasis%2520and%2520psoriatic%2520arthritis%2520development%2520programmes%2520and%2520from%2520real-world%2520data%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2020%26volume%3D79%26spage%3D1400%26epage%3D1413%26doi%3D10.1136%2Fannrheumdis-2019-216761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark-Snustad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span> <span> </span><span class="NLM_article-title">Case report of a SARS-CoV-2 infection in a patient with ulcerative colitis on Tofacitinib</span>. <i>Inflamm. Bowel Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>, <span class="NLM_elocation-id">e64</span> <span class="refDoi">Â DOI: 10.1093/ibd/izaa093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1093%2Fibd%2Fizaa093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32342098" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&author=J.+Jacobsauthor=K.+Clark-Snustadauthor=S.+Lee&title=Case+report+of+a+SARS-CoV-2+infection+in+a+patient+with+ulcerative+colitis+on+Tofacitinib&doi=10.1093%2Fibd%2Fizaa093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1093%2Fibd%2Fizaa093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fibd%252Fizaa093%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DJ.%26aulast%3DClark-Snustad%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DS.%26atitle%3DCase%2520report%2520of%2520a%2520SARS-CoV-2%2520infection%2520in%2520a%2520patient%2520with%2520ulcerative%2520colitis%2520on%2520Tofacitinib%26jtitle%3DInflamm.%2520Bowel%2520Dis.%26date%3D2020%26volume%3D26%26doi%3D10.1093%2Fibd%2Fizaa093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. O.</span></span> <span> </span><span class="NLM_article-title">TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib</span>. <i>J. Microbiol. Immunol. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">368</span>â <span class="NLM_lpage">370</span>, <span class="refDoi">Â DOI: 10.1016/j.jmii.2020.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jmii.2020.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32205092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFalurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2020&pages=368-370&author=D.+Wuauthor=X.+O.+Yang&title=TH17+responses+in+cytokine+storm+of+COVID-19%3A+An+emerging+target+of+JAK2+inhibitor+Fedratinib&doi=10.1016%2Fj.jmii.2020.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib</span></div><div class="casAuthors">Wu, Dandan; Yang, Xuexian O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Microbiology, Immunology and Infection</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">368-370</span>CODEN:
                <span class="NLM_cas:coden">JMIIFG</span>;
        ISSN:<span class="NLM_cas:issn">1995-9133</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Taiwan LLC</span>)
        </div><div class="casAbstract">COVID-19 emerges as a pandemic disease with high mortality.  Development of effective prevention and treatment is an urgent need.  We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxQUfWxGcfQbVg90H21EOLACvtfcHk0ljUGxW8vQ-42A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFalurc%253D&md5=bab4a2496a1381dd062fbaf5349baf57</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.jmii.2020.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmii.2020.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DX.%2BO.%26atitle%3DTH17%2520responses%2520in%2520cytokine%2520storm%2520of%2520COVID-19%253A%2520An%2520emerging%2520target%2520of%2520JAK2%2520inhibitor%2520Fedratinib%26jtitle%3DJ.%2520Microbiol.%2520Immunol.%2520Infect.%26date%3D2020%26volume%3D53%26spage%3D368%26epage%3D370%26doi%3D10.1016%2Fj.jmii.2020.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavegnano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detorio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planelles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1977</span>â <span class="NLM_lpage">1986</span>, <span class="refDoi">Â DOI: 10.1128/AAC.02496-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FAAC.02496-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24419350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVSltr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=1977-1986&author=C.+Gavegnanoauthor=M.+Detorioauthor=C.+Monteroauthor=A.+Bosqueauthor=V.+Planellesauthor=R.+F.+Schinazi&title=Ruxolitinib+and+tofacitinib+are+potent+and+selective+inhibitors+of+HIV-1+replication+and+virus+reactivation+in+vitro&doi=10.1128%2FAAC.02496-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro</span></div><div class="casAuthors">Gavegnano, Christina; Detorio, Mervi; Montero, Catherine; Bosque, Alberto; Planelles, Vicente; Schinazi, Raymond F.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1977-1986, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The JAK-STAT pathway is activated in both macrophages and lymphocytes upon human immunodeficiency virus type 1 (HIV-1) infection and thus represents an attractive cellular target to achieve HIV suppression and reduced inflammation, which may impact virus sanctuaries.  Ruxolitinib and tofacitinib are JAK1/2 inhibitors that are FDA approved for rheumatoid arthritis and myelofibrosis, resp., but their therapeutic application for treatment of HIV infection was unexplored.  Both drugs demonstrated submicromolar inhibition of infection with HIV-1, HIV-2, and a simian-human immunodeficiency virus, RT-SHIV, across primary human or rhesus macaque lymphocytes and macrophages, with no apparent significant cytotoxicity at 2 to 3 logs above the median effective antiviral concn.  Combination of tofacitinib and ruxolitinib increased the efficacy by 53- to 161-fold vs. that obsd. for monotherapy, resp., and each drug applied alone to primary human lymphocytes displayed similar efficacy against HIV-1 contg. various polymerase substitutions.  Both drugs inhibited virus replication in lymphocytes stimulated with phytohemagglutinin (PHA) plus interleukin-2 (IL-2), but not PHA alone, and inhibited reactivation of latent HIV-1 at low-micromolar concns. across the J-Lat T cell latency model and in primary human central memory lymphocytes.  Thus, targeted inhibition of JAK provided a selective, potent, and novel mechanism to inhibit HIV-1 replication in lymphocytes and macrophages, replication of drug-resistant HIV-1, and reactivation of latent HIV-1 and has the potential to reset the immunol. milieu in HIV-infected individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt3eFMp64h4bVg90H21EOLACvtfcHk0ljUGxW8vQ-42A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVSltr8%253D&md5=85566414304fc2f381e99bca472b8691</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1128%2FAAC.02496-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02496-13%26sid%3Dliteratum%253Aachs%26aulast%3DGavegnano%26aufirst%3DC.%26aulast%3DDetorio%26aufirst%3DM.%26aulast%3DMontero%26aufirst%3DC.%26aulast%3DBosque%26aufirst%3DA.%26aulast%3DPlanelles%26aufirst%3DV.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26atitle%3DRuxolitinib%2520and%2520tofacitinib%2520are%2520potent%2520and%2520selective%2520inhibitors%2520of%2520HIV-1%2520replication%2520and%2520virus%2520reactivation%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D1977%26epage%3D1986%26doi%3D10.1128%2FAAC.02496-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavegnano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehm, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuy, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulpa, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marconi, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbagh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ©kaly, R. P.</span></span> <span> </span><span class="NLM_article-title">Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e1006740</span> <span class="refDoi">Â DOI: 10.1371/journal.ppat.1006740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.ppat.1006740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29267399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFalsr7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&author=C.+Gavegnanoauthor=J.+H.+Brehmauthor=F.+P.+Dupuyauthor=A.+Tallaauthor=S.+P.+Ribeiroauthor=D.+A.+Kulpaauthor=C.+Cameronauthor=S.+Santosauthor=S.+J.+Hurwitzauthor=V.+C.+Marconiauthor=J.+P.+Routyauthor=L.+Sabbaghauthor=R.+F.+Schinaziauthor=R.+P.+S%C3%A9kaly&title=Novel+mechanisms+to+inhibit+HIV+reservoir+seeding+using+Jak+inhibitors&doi=10.1371%2Fjournal.ppat.1006740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors</span></div><div class="casAuthors">Gavegnano, Christina; Brehm, Jessica H.; Dupuy, Franck P.; Talla, Aarthi; Ribeiro, Susan Pereira; Kulpa, Deanna A.; Cameron, Cheryl; Santos, Stephanie; Hurwitz, Selwyn J.; Marconi, Vincent C.; Routy, Jean-Pierre; Sabbagh, Laurent; Schinazi, Raymond F.; Sekaly, Rafick Pierre</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e1006740/1-e1006740/30</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Despite advances in the treatment of HIV infection with ART, elucidating strategies to overcome HIV persistence, including blockade of viral reservoir establishment, maintenance, and expansion, remains a challenge.  T cell homeostasis is a major driver of HIV persistence.  Cytokines involved in regulating homeostasis of memory T cells, the major hub of the HIV reservoir, trigger the Jak-STAT pathway.  We evaluated the ability of tofacitinib and ruxolitinib, two FDA-approved Jak inhibitors, to block seeding and maintenance of the HIV reservoir in vitro.  We provide direct demonstration for involvement of the Jak-STAT pathway in HIV persistence in vivo, ex vivo, and in vitro; pSTAT5 strongly correlates with increased levels of integrated viral DNA in vivo, and in vitro Jak inhibitors reduce the frequency of CD4+ T cells harboring integrated HIV DNA.  We show that Jak inhibitors block viral prodn. from infected cells, inhibit Î³-C receptor cytokine (IL-15)-induced viral reactivation from latent stores thereby preventing transmission of infectious particles to bystander activated T cells.  These results show that dysregulation of the Jak-STAT pathway is assocd. with viral persistence in vivo, and that Jak inhibitors target key events downstream of Î³-C cytokine (IL-2, IL-7 and IL-15) ligation to their receptors, impacting the magnitude of the HIV reservoir in all memory CD4 T cell subsets in vitro and ex vivo.  Jak inhibitors represent a therapeutic modality to prevent key events of T cell activation that regulate HIV persistence and together, specific, potent blockade of these events may be integrated to future curative strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqUxFHplJKULVg90H21EOLACvtfcHk0ljuH19TPy0H0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFalsr7N&md5=b311dec0f2c603fcf337df2b3b2a1e56</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1006740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1006740%26sid%3Dliteratum%253Aachs%26aulast%3DGavegnano%26aufirst%3DC.%26aulast%3DBrehm%26aufirst%3DJ.%2BH.%26aulast%3DDupuy%26aufirst%3DF.%2BP.%26aulast%3DTalla%26aufirst%3DA.%26aulast%3DRibeiro%26aufirst%3DS.%2BP.%26aulast%3DKulpa%26aufirst%3DD.%2BA.%26aulast%3DCameron%26aufirst%3DC.%26aulast%3DSantos%26aufirst%3DS.%26aulast%3DHurwitz%26aufirst%3DS.%2BJ.%26aulast%3DMarconi%26aufirst%3DV.%2BC.%26aulast%3DRouty%26aufirst%3DJ.%2BP.%26aulast%3DSabbagh%26aufirst%3DL.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DS%25C3%25A9kaly%26aufirst%3DR.%2BP.%26atitle%3DNovel%2520mechanisms%2520to%2520inhibit%2520HIV%2520reservoir%2520seeding%2520using%2520Jak%2520inhibitors%26jtitle%3DPLoS%2520Pathog.%26date%3D2017%26volume%3D13%26doi%3D10.1371%2Fjournal.ppat.1006740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manganaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, L. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potla, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiazGriffero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Sesma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, V.</span></span> <span> </span><span class="NLM_article-title">IL-15 regulates susceptibility of CD4+ T cells to HIV infection</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E9659</span>â <span class="NLM_lpage">E9667</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1806695115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1073%2Fpnas.1806695115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30257946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOntbzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E9659-E9667&author=L.+Manganaroauthor=P.+Hongauthor=M.+M.+Hernandezauthor=D.+Argyleauthor=L.+C.+F.+Mulderauthor=U.+Potlaauthor=F.+DiazGrifferoauthor=B.+Leeauthor=A.+Fernandez-Sesmaauthor=V.+Simon&title=IL-15+regulates+susceptibility+of+CD4%2B+T+cells+to+HIV+infection&doi=10.1073%2Fpnas.1806695115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">IL-15 regulates susceptibility of CD4+ T cells to HIV infection</span></div><div class="casAuthors">Manganaro, Lara; Hong, Patrick; Hernandez, Matthew M.; Argyle, Dionne; Mulder, Lubbertus C. F.; Potla, Uma; Diaz-Griffero, Felipe; Lee, Benhur; Fernandez-Sesma, Ana; Simon, Viviana</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">E9659-E9667</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">HIV integrates into the host genome to create a persistent viral reservoir.  Stimulation of CD4+ memory T lymphocytes with common Î³c-chain cytokines renders these cells more susceptible to HIV infection, making them a key component of the reservoir itself.  IL-15 is up-regulated during primary HIV infection, a time when the HIV reservoir established.  Therefore, we investigated the mol. and cellular impact of IL-15 on CD4+ T-cell infection.  We found that IL-15 stimulation induces SAM domain and HD domain-contg. protein 1 (SAMHD1) phosphorylation due to cell cycle entry, relieving an early block to infection.  Perturbation of the pathways downstream of IL-15 receptor (IL-15R) indicated that SAMHD1 phosphorylation after IL-15 stimulation is JAK dependent.  Treating CD4+ T cells with Ruxolitinib, an inhibitor of JAK1 and JAK2, effectively blocked IL-15-induced SAMHD1 phosphorylation and protected CD4+ T cells from HIV infection.  Using high-resoln. single-cell immune profiling using mass cytometry by TOF (CyTOF), we found that IL-15 stimulation altered the compn. of CD4+ T-cell memory populations by increasing proliferation of memory CD4+ T cells, including CD4+ T memory stem cells (TSCM).  IL-15-stimulated CD4+ TSCM, harboring phosphorylated SAMHD1, were preferentially infected.  We propose that IL-15 plays a pivotal role in creating a self-renewing, persistent HIV reservoir by facilitating infection of CD4+ T cells with stem cell-like properties.  Time-limited interventions with JAK1 inhibitors, such as Ruxolitinib, should prevent the inactivation of the endogenous restriction factor SAMHD1 and protect this long-lived CD4+ T-memory cell population from HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUnhS_Hhscu7Vg90H21EOLACvtfcHk0ljuH19TPy0H0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOntbzI&md5=60940fd03686661edf95d4bae021ccf2</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1806695115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1806695115%26sid%3Dliteratum%253Aachs%26aulast%3DManganaro%26aufirst%3DL.%26aulast%3DHong%26aufirst%3DP.%26aulast%3DHernandez%26aufirst%3DM.%2BM.%26aulast%3DArgyle%26aufirst%3DD.%26aulast%3DMulder%26aufirst%3DL.%2BC.%2BF.%26aulast%3DPotla%26aufirst%3DU.%26aulast%3DDiazGriffero%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DFernandez-Sesma%26aufirst%3DA.%26aulast%3DSimon%26aufirst%3DV.%26atitle%3DIL-15%2520regulates%2520susceptibility%2520of%2520CD4%252B%2520T%2520cells%2520to%2520HIV%2520infection%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE9659%26epage%3DE9667%26doi%3D10.1073%2Fpnas.1806695115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spivak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larragoite, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, M. K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macedo, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planelles, V.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo</span>. <i>Retrovirology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">88</span>, <span class="refDoi">Â DOI: 10.1186/s12977-016-0319-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2Fs12977-016-0319-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27998278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsFGis70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=88&author=A.+M.+Spivakauthor=E.+T.+Larragoiteauthor=M.+K.+L.+Colettiauthor=A.+B.+Macedoauthor=L.+J.+Martinsauthor=A.+Bosqueauthor=V.+Planelles&title=Janus+kinase+inhibition+suppresses+PKC-induced+cytokine+release+without+affecting+HIV-1+latency+reversal+ex+vivo&doi=10.1186%2Fs12977-016-0319-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo</span></div><div class="casAuthors">Spivak, Adam M.; Larragoite, Erin T.; Coletti, McKenna L.; Macedo, Amanda B.; Martins, Laura J.; Bosque, Alberto; Planelles, Vicente</div><div class="citationInfo"><span class="NLM_cas:title">Retrovirology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">88/1-88/9</span>CODEN:
                <span class="NLM_cas:coden">RETRBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-4690</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Despite the durable viral suppression afforded by antiretroviral therapy, HIV-1 eradication will require strategies to target latently infected cells that persist in infected individuals.  Protein kinase C (PKC) activation is a promising strategy to reactivate latent proviruses and allow for subsequent recognition and clearance of infected cells by the immune system.  Ingenol derivs. are PKC agonists that induce latency reversal but also lead to T cell activation and the release of pro-inflammatory cytokines, which would be undesirable in vivo.  In this work, we sought to identify compds. that would suppress pro-inflammatory cytokine prodn. in the context of PKC activation.  Design and methods: We performed an in vitro screen to identify compds. that could dampen pro-inflammatory cytokine release assocd. with T cell activation, using IL-6 as a model cytokine.  We then tested the ability of the most promising screening hit, the FDA-approved Janus Kinase (JAK) inhibitor ruxolitinib, to diminish release of multiple cytokines and its effect on latency reversal using cells from HIV-1-pos., aviremic participants.  Results: We demonstrate that co-administration of ruxolitinib with ingenol-3,20-dibenzoate significantly reduces pro-inflammatory cytokine release without impairing latency reversal ex vivo.  Conclusions: The combination of ingenol compds. and JAK inhibition represents a novel strategy for HIV-1 eradication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV3J4XV70MabVg90H21EOLACvtfcHk0lin1HTR2nHDiA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsFGis70%253D&md5=20544d19ffe8beecb77e3670fc162bec</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1186%2Fs12977-016-0319-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12977-016-0319-0%26sid%3Dliteratum%253Aachs%26aulast%3DSpivak%26aufirst%3DA.%2BM.%26aulast%3DLarragoite%26aufirst%3DE.%2BT.%26aulast%3DColetti%26aufirst%3DM.%2BK.%2BL.%26aulast%3DMacedo%26aufirst%3DA.%2BB.%26aulast%3DMartins%26aufirst%3DL.%2BJ.%26aulast%3DBosque%26aufirst%3DA.%26aulast%3DPlanelles%26aufirst%3DV.%26atitle%3DJanus%2520kinase%2520inhibition%2520suppresses%2520PKC-induced%2520cytokine%2520release%2520without%2520affecting%2520HIV-1%2520latency%2520reversal%2520ex%2520vivo%26jtitle%3DRetrovirology%26date%3D2016%26volume%3D13%26spage%3D88%26doi%3D10.1186%2Fs12977-016-0319-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, K.</span></span> <span> </span><span class="NLM_article-title">Inflammation research association-15th international conference advances in asthma and COPD and other inflammatory diseases</span>. <i>IDrugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">863</span>â <span class="NLM_lpage">865</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=19051144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BD1cjot1Ghug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=863-865&author=K.+Walker&title=Inflammation+research+association-15th+international+conference+advances+in+asthma+and+COPD+and+other+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation Research Association--15th international conference advances in asthma and COPD and other inflammatory diseases</span></div><div class="casAuthors">Walker Karen</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs : the investigational drugs journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">863-5</span>
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgMoQJbY8mfRBrI9DTGjC0fW6udTcc2ebxB7gsPTcH0bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjot1Ghug%253D%253D&md5=45aa68e772177ff24bf3fd91cfd0557b</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DK.%26atitle%3DInflammation%2520research%2520association-15th%2520international%2520conference%2520advances%2520in%2520asthma%2520and%2520COPD%2520and%2520other%2520inflammatory%2520diseases%26jtitle%3DIDrugs%26date%3D2008%26volume%3D11%26spage%3D863%26epage%3D865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussenzveig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">3538</span>, <span class="refDoi">Â DOI: 10.1182/blood.V110.11.3538.3538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1182%2Fblood.V110.11.3538.3538" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=3538&author=J.+Fridmanauthor=R.+Nussenzveigauthor=P.+Liuauthor=J.+Rodgersauthor=T.+Burnauthor=P.+Haleyauthor=P.+Scherleauthor=R.+Newtonauthor=G.+Hollisauthor=S.+Friedmanauthor=S.+Verstovsekauthor=K.+Vaddi&title=Discovery+and+preclinical+characterization+of+INCB018424%2C+a+selective+JAK2+inhibitor+for+the+treatment+of+myeloproliferative+disorders&doi=10.1182%2Fblood.V110.11.3538.3538"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1182%2Fblood.V110.11.3538.3538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V110.11.3538.3538%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%26aulast%3DNussenzveig%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DRodgers%26aufirst%3DJ.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%2520INCB018424%252C%2520a%2520selective%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520disorders%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D3538%26doi%3D10.1182%2Fblood.V110.11.3538.3538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintas-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeltz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3109</span>â <span class="NLM_lpage">3117</span>, <span class="refDoi">Â DOI: 10.1182/blood-2009-04-214957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quintas-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-04-214957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0ljLtnpi6Ghzsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117%26doi%3D10.1182%2Fblood-2009-04-214957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Onozawa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibayama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imadome, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, A.</span></span> <span> </span><span class="NLM_article-title">STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">31077</span>â <span class="NLM_lpage">31089</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.25780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.18632%2Foncotarget.25780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30123428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ps1KrtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=31077-31089&author=E.+Onozawaauthor=H.+Shibayamaauthor=H.+Takadaauthor=K.+I.+Imadomeauthor=S.+Aokiauthor=M.+Yoshimoriauthor=N.+Shimizuauthor=S.+Fujiwaraauthor=T.+Koyamaauthor=O.+Miuraauthor=A.+Arai&title=STAT3+is+constitutively+activated+in+chronic+active+Epstein-Barr+virus+infection+and+can+be+a+therapeutic+target&doi=10.18632%2Foncotarget.25780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target</span></div><div class="casAuthors">Onozawa Erika; Shibayama Haruna; Takada Honami; Yoshimori Mayumi; Miura Osamu; Arai Ayako; Onozawa Erika; Shibayama Haruna; Takada Honami; Aoki Sho; Yoshimori Mayumi; Koyama Takatoshi; Arai Ayako; Imadome Ken-Ichi; Shimizu Norio; Fujiwara Shigeyoshi; Fujiwara Shigeyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">57</span>),
    <span class="NLM_cas:pages">31077-31089</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic active Epstein-Barr virus infection (CAEBV) is a lymphoproliferative disorder characterized by the clonal proliferation of EBV-infected T or NK cells and is related to severe systemic inflammation.  This study aims to investigate STAT3 to elucidate the mechanism underlying the CAEBV development.  We determined that STAT3 was constitutively activated in EBV-positive T- or NK-cell lines.  We also determined that STAT3 was activated in the peripheral blood mononuclear cells (PBMCs) containing EBV-infected clonally proliferating T or NK cells in six of seven patients with CAEBV.  We conducted direct sequencing of the STAT3 Src homology 2 (SH2) domain, which has previously been reported to be mutated in T- or NK-cell neoplasms.  No mutation was detected in the STAT3 SH2 domain in patients with CAEBV.  Next, we investigated the effects of ruxolitinib, an inhibitor of both JAK1 and JAK2, which phosphorylates and activates STAT3.  Ruxolitinib suppressed the phosphorylation of STAT3 in EBV-positive T- or NK-cell lines.  Ruxolitinib also decreased the viable cell number of EBV-positive T- or NK-cell lines and PBMCs from patients with CAEBV.  Furthermore, ruxolitinib suppressed the production of inflammatory cytokines in the cell lines and CAEBV patient-derived cells.  In conclusion, constitutively activated STAT3, which promotes survival and cytokine production, could be a therapeutic target for CAEBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ22Gp4PMDLXXp3bfzSLaX5fW6udTcc2eZNJmajAAntlrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ps1KrtQ%253D%253D&md5=cbd915fa7aadea326a75012a59d88391</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25780%26sid%3Dliteratum%253Aachs%26aulast%3DOnozawa%26aufirst%3DE.%26aulast%3DShibayama%26aufirst%3DH.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DImadome%26aufirst%3DK.%2BI.%26aulast%3DAoki%26aufirst%3DS.%26aulast%3DYoshimori%26aufirst%3DM.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DKoyama%26aufirst%3DT.%26aulast%3DMiura%26aufirst%3DO.%26aulast%3DArai%26aufirst%3DA.%26atitle%3DSTAT3%2520is%2520constitutively%2520activated%2520in%2520chronic%2520active%2520Epstein-Barr%2520virus%2520infection%2520and%2520can%2520be%2520a%2520therapeutic%2520target%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D31077%26epage%3D31089%26doi%3D10.18632%2Foncotarget.25780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">2003</span>â <span class="NLM_lpage">2004</span>, <span class="refDoi">Â DOI: 10.1007/s00277-019-03647-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs00277-019-03647-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30830248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgtVKiuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2019&pages=2003-2004&author=Z.+Jinauthor=Y.+Wangauthor=J.+Wangauthor=J.+Zhangauthor=L.+Wuauthor=Z.+Wang&title=Long-term+survival+benefit+of+ruxolitinib+in+a+patient+with+relapsed+refractory+chronic+active+Epstein-Barr+virus&doi=10.1007%2Fs00277-019-03647-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus</span></div><div class="casAuthors">Jin Zhili; Wang Yini; Wang Jingshi; Zhang Jia; Wu Lin; Wang Zhao</div><div class="citationInfo"><span class="NLM_cas:title">Annals of hematology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2003-2004</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRc-0Sx9gELaPh3YQQtAhNufW6udTcc2eZNJmajAAntlrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgtVKiuw%253D%253D&md5=351964190ec9d8ff73772e55c697e8c0</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1007%2Fs00277-019-03647-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-019-03647-5%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DLong-term%2520survival%2520benefit%2520of%2520ruxolitinib%2520in%2520a%2520patient%2520with%2520relapsed%2520refractory%2520chronic%2520active%2520Epstein-Barr%2520virus%26jtitle%3DAnn.%2520Hematol.%26date%3D2019%26volume%3D98%26spage%3D2003%26epage%3D2004%26doi%3D10.1007%2Fs00277-019-03647-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">137</span>â <span class="NLM_lpage">146</span>, <span class="refDoi">Â DOI: 10.1016/j.jaci.2020.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jaci.2020.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32470486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlaisbnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=137-146&author=Y.+Caoauthor=J.+Weiauthor=L.+Zouauthor=T.+Jiangauthor=G.+Wangauthor=L.+Chenauthor=L.+Huangauthor=F.+Mengauthor=L.+Huangauthor=N.+Wangauthor=X.+Zhouauthor=H.+Luoauthor=Z.+Maoauthor=X.+Chenauthor=J.+Xieauthor=J.+Liuauthor=H.+Chengauthor=J.+Zhaoauthor=G.+Huangauthor=W.+Wangauthor=J.+Zhou&title=Ruxolitinib+in+treatment+of+severe+coronavirus+disease+2019+%28COVID-19%29%3A+A+multicenter%2C+single-blind%2C+randomized+controlled+trial&doi=10.1016%2Fj.jaci.2020.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial</span></div><div class="casAuthors">Cao, Yang; Wei, Jia; Zou, Liang; Jiang, Tiebin; Wang, Gaoxiang; Chen, Liting; Huang, Liang; Meng, Fankai; Huang, Lifang; Wang, Na; Zhou, Xiaoxi; Luo, Hui; Mao, Zekai; Chen, Xing; Xie, Jungang; Liu, Jing; Cheng, Hui; Zhao, Jianping; Huang, Gang; Wang, Wei; Zhou, Jianfeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-146.e3</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Accumulating evidence proposed Janus-assocd. kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation.  This study evaluated the efficacy and safety of ruxolitinib, a JAK1/2 inhibitor, for coronavirus disease 2019.  We conducted a prospective, multicenter, single-blind, randomized controlled phase II trial involving patients with severe coronavirus disease 2019.  Forty-three patients were randomly assigned (1:1) to receive ruxolitinib plus std.-of-care treatment (22 patients) or placebo based on std.-of-care treatment (21 patients).  After exclusion of 2 patients (1 ineligible, 1 consent withdrawn) from the ruxolitinib group, 20 patients in the intervention group and 21 patients in the control group were included in the study.  Treatment with ruxolitinib plus std.-of-care was not assocd. with significantly accelerated clin. improvement in severe patients with coronavirus disease 2019, although ruxolitinib recipients had a numerically faster clin. improvement.  Eighteen (90%) patients from the ruxolitinib group showed computed tomog. improvement at day 14 compared with 13 (61.9%) patients from the control group (P =.0495).  Three patients in the control group died of respiratory failure, with 14.3% overall mortality at day 28; no patients died in the ruxolitinib group.  Ruxolitinib was well tolerated with low toxicities and no new safety signals.  Levels of 7 cytokines were significantly decreased in the ruxolitinib group in comparison to the control group.  Although no statistical difference was obsd., ruxolitinib recipients had a numerically faster clin. improvement.  Significant chest computed tomog. improvement, a faster recovery from lymphopenia, and favorable side-effect profile in the ruxolitinib group were encouraging and informative to future trials to test efficacy of ruxolitinib in a larger population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsWKI4tj6YcLVg90H21EOLACvtfcHk0ljudOmwgs5ctg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlaisbnJ&md5=b758d7ebcb2a43a00d91009ad4787240</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2020.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2020.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DMao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DRuxolitinib%2520in%2520treatment%2520of%2520severe%2520coronavirus%2520disease%25202019%2520%2528COVID-19%2529%253A%2520A%2520multicenter%252C%2520single-blind%252C%2520randomized%2520controlled%2520trial%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2020%26volume%3D146%26spage%3D137%26epage%3D146%26doi%3D10.1016%2Fj.jaci.2020.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La Rosee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehrke, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birndt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellhauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Rosee, P.</span></span> <span> </span><span class="NLM_article-title">The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1805</span>â <span class="NLM_lpage">1815</span>, <span class="refDoi">Â DOI: 10.1038/s41375-020-0891-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41375-020-0891-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32518419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFelsL7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=1805-1815&author=F.+La+Roseeauthor=H.+C.+Bremerauthor=I.+Gehrkeauthor=A.+Kehrauthor=A.+Hochhausauthor=S.+Birndtauthor=M.+Fellhauerauthor=M.+Henkesauthor=B.+Kumleauthor=S.+G.+Russoauthor=P.+La+Rosee&title=The+Janus+kinase+1%2F2+inhibitor+ruxolitinib+in+COVID-19+with+severe+systemic+hyperinflammation&doi=10.1038%2Fs41375-020-0891-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation</span></div><div class="casAuthors">La Rosee, F.; Bremer, H. C.; Gehrke, I.; Kehr, A.; Hochhaus, A.; Birndt, S.; Fellhauer, M.; Henkes, M.; Kumle, B.; Russo, S. G.; La Rosee, P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1805-1815</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure.  These patients present with progressive hyperinflammation governed by proinflammatory cytokines.  An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation.  Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux).  Patients were treated with efficacy/toxicity guided step up dosing up to 14 days.  Retrospective anal. of CIS redn. and clin. outcome was performed.  Out of 105 patients treated between March 30th and Apr. 15th, 2020, 14 patients with a CIS â¥ 10 out of 16 points received Rux over a median of 9 days with a median cumulative dose of 135 mg.  A total of 12/14 patients achieved significant redn. of CIS by â¥25% on day 7 with sustained clin. improvement in 11/14 patients without short term red flag warnings of Rux-induced toxicity.  Rux treatment for COVID-19 in patients with hyperinflammation is shown to be safe with signals of efficacy in this pilot case series for CRS-intervention to prevent or overcome multiorgan failure.  A multicenter phase-II clin. trial has been initiated (NCT04338958).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnLEoRYA18u7Vg90H21EOLACvtfcHk0ljudOmwgs5ctg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFelsL7K&md5=801ce3cc74a405a334ca0d380aa53333</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-0891-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-0891-0%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRosee%26aufirst%3DF.%26aulast%3DBremer%26aufirst%3DH.%2BC.%26aulast%3DGehrke%26aufirst%3DI.%26aulast%3DKehr%26aufirst%3DA.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DBirndt%26aufirst%3DS.%26aulast%3DFellhauer%26aufirst%3DM.%26aulast%3DHenkes%26aufirst%3DM.%26aulast%3DKumle%26aufirst%3DB.%26aulast%3DRusso%26aufirst%3DS.%2BG.%26aulast%3DLa%2BRosee%26aufirst%3DP.%26atitle%3DThe%2520Janus%2520kinase%25201%252F2%2520inhibitor%2520ruxolitinib%2520in%2520COVID-19%2520with%2520severe%2520systemic%2520hyperinflammation%26jtitle%3DLeukemia%26date%3D2020%26volume%3D34%26spage%3D1805%26epage%3D1815%26doi%3D10.1038%2Fs41375-020-0891-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span> <span> </span><span class="NLM_article-title">Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1054</span>â <span class="NLM_lpage">1062</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30566-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS0140-6736%2820%2930566-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32171076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVGktL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1054-1062&author=F.+Zhouauthor=T.+Yuauthor=R.+Duauthor=G.+Fanauthor=Y.+Liuauthor=Z.+Liuauthor=J.+Xiangauthor=Y.+Wangauthor=B.+Songauthor=X.+Guauthor=L.+Guanauthor=Y.+Weiauthor=H.+Liauthor=X.+Wuauthor=J.+Xuauthor=S.+Tuauthor=Y.+Zhangauthor=H.+Chenauthor=B.+Cao&title=Clinical+course+and+risk+factors+for+mortality+of+adult+inpatients+with+COVID-19+in+Wuhan%2C+China%3A+A+retrospective+cohort+study&doi=10.1016%2FS0140-6736%2820%2930566-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</span></div><div class="casAuthors">Zhou, Fei; Yu, Ting; Du, Ronghui; Fan, Guohui; Liu, Ying; Liu, Zhibo; Xiang, Jie; Wang, Yeming; Song, Bin; Gu, Xiaoying; Guan, Lulu; Wei, Yuan; Li, Hui; Wu, Xudong; Xu, Jiuyang; Tu, Shengjin; Zhang, Yi; Chen, Hua; Cao, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10229</span>),
    <span class="NLM_cas:pages">1054-1062</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Since Dec., 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  Epidemiol. and clin. characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clin. course of illness, including viral shedding, have not been well described.  In this retrospective, multicenter cohort study, we included all adult inpatients (â¥18 yr old) with lab.-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020.  Demog., clin., treatment, and lab. data, including serial samples for viral RNA detection, were extd. from electronic medical records and compared between survivors and non-survivors.  We used univariable and multivariable logistic regression methods to explore the risk factors assocd. with in-hospital death.  One hundred ninety-one patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital.  Ninety-one (48%) patients had a comorbidity, with hypertension being the most common (58 patients), followed by diabetes (36 patients) and coronary heart disease (15 patients).  Multivariable regression showed increasing odds of in-hospital death assocd. with older age, higher Sequential Organ Failure Assessment (SOFA) score, and d-dimer >1Î¼g/L on admission.  Median duration of viral shedding was 20Â·0 days (IQR 17Â·0-24Â·0) in survivors, but SARS-CoV-2 was detectable until death in non-survivors.  The longest obsd. duration of viral shedding in survivors was 37 days.  The potential risk factors of older age, high SOFA score, and d-dimer >1Î¼g/L could help clinicians to identify patients with poor prognosis at an early stage.  Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMm2AR09dalbVg90H21EOLACvtfcHk0lihFjH9IvyLYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVGktL8%253D&md5=66ea14f4f585df80553e63820aad3f00</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930566-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930566-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DDu%26aufirst%3DR.%26aulast%3DFan%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DXiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DB.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DGuan%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DB.%26atitle%3DClinical%2520course%2520and%2520risk%2520factors%2520for%2520mortality%2520of%2520adult%2520inpatients%2520with%2520COVID-19%2520in%2520Wuhan%252C%2520China%253A%2520A%2520retrospective%2520cohort%2520study%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1054%26epage%3D1062%26doi%3D10.1016%2FS0140-6736%2820%2930566-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Decker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockinger, S.</span></span> <span> </span><span class="NLM_article-title">The yin and yang of type I interferon activity in bacterial infection</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">675</span>â <span class="NLM_lpage">687</span>, <span class="refDoi">Â DOI: 10.1038/nri1684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnri1684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16110316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslakuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=675-687&author=T.+Deckerauthor=M.+M%C3%BCllerauthor=S.+Stockinger&title=The+yin+and+yang+of+type+I+interferon+activity+in+bacterial+infection&doi=10.1038%2Fnri1684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">The Yin and Yang of type I interferon activity in bacterial infection</span></div><div class="casAuthors">Decker, Thomas; Mueller, Mathias; Stockinger, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">675-687</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Interferons (IFNs) are cytokines that are important for immune responses, particularly to intracellular pathogens.  They are divided into two structurally and functionally distinct types that interact with different cell-surface receptors.  Classically, type I IFNs are potent antiviral immunoregulators, whereas the type II IFN enhances antibacterial immunity.  However, as outlined here, type I IFNs are also produced in response to infection with other pathogens, and an increasing body of work shows that type I IFNs have an important role in the host response to bacterial infection.  Strikingly, their activity can be either favorable or detrimental, and can influence various immune effector mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY100nyqlEYLVg90H21EOLACvtfcHk0lihFjH9IvyLYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslakuro%253D&md5=6752d713459ee20fe6b78341b18546dd</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1038%2Fnri1684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1684%26sid%3Dliteratum%253Aachs%26aulast%3DDecker%26aufirst%3DT.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DStockinger%26aufirst%3DS.%26atitle%3DThe%2520yin%2520and%2520yang%2520of%2520type%2520I%2520interferon%2520activity%2520in%2520bacterial%2520infection%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2005%26volume%3D5%26spage%3D675%26epage%3D687%26doi%3D10.1038%2Fnri1684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesev, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeDesma, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploss, A.</span></span> <span> </span><span class="NLM_article-title">Decoding type I and III interferon signalling during viral infection</span>. <i>Nat. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">914</span>â <span class="NLM_lpage">924</span>, <span class="refDoi">Â DOI: 10.1038/s41564-019-0421-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41564-019-0421-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30936491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosFKjsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=914-924&author=E.+V.+Mesevauthor=R.+A.+LeDesmaauthor=A.+Ploss&title=Decoding+type+I+and+III+interferon+signalling+during+viral+infection&doi=10.1038%2Fs41564-019-0421-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Decoding type I and III interferon signalling during viral infection</span></div><div class="casAuthors">Mesev, Emily V.; LeDesma, Robert A.; Ploss, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Nature Microbiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">914-924</span>CODEN:
                <span class="NLM_cas:coden">NMAICH</span>;
        ISSN:<span class="NLM_cas:issn">2058-5276</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Interferon (IFN)-mediated antiviral responses are central to host defense against viral infection.  Despite the existence of at least 20 IFNs, there are only three known cell surface receptors.  IFN signalling and viral evasion mechanisms form an immensely complex network that differs across species.  In this Review, we begin by highlighting some of the advances that have been made towards understanding the complexity of differential IFN signalling inputs and outputs that contribute to antiviral defences.  Next, we explore some of the ways viruses can interfere with, or circumvent, these defences.  Lastly, we address the largely under-reviewed impact of IFN signalling on host tropism, and we offer perspectives on the future of research into IFN signalling complexity and viral evasion across species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6IUA6MRCEhrVg90H21EOLACvtfcHk0lihFjH9IvyLYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosFKjsrs%253D&md5=d382e535e09dd0c3e86718b29db050ce</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1038%2Fs41564-019-0421-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41564-019-0421-x%26sid%3Dliteratum%253Aachs%26aulast%3DMesev%26aufirst%3DE.%2BV.%26aulast%3DLeDesma%26aufirst%3DR.%2BA.%26aulast%3DPloss%26aufirst%3DA.%26atitle%3DDecoding%2520type%2520I%2520and%2520III%2520interferon%2520signalling%2520during%2520viral%2520infection%26jtitle%3DNat.%2520Microbiol.%26date%3D2019%26volume%3D4%26spage%3D914%26epage%3D924%26doi%3D10.1038%2Fs41564-019-0421-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span> <span> </span><span class="NLM_article-title">The host type I interferon response to viral and bacterial infections</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">407</span>â <span class="NLM_lpage">422</span>, <span class="refDoi">Â DOI: 10.1038/sj.cr.7290309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fsj.cr.7290309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=15987599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWmtrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=407-422&author=A.+K.+Perryauthor=G.+Chenauthor=D.+Zhengauthor=H.+Tangauthor=G.+Cheng&title=The+host+type+I+interferon+response+to+viral+and+bacterial+infections&doi=10.1038%2Fsj.cr.7290309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">The host type I interferon response to viral and bacterial infections</span></div><div class="casAuthors">Perry, Andrea K.; Chen, Gang; Zheng, Dahai; Tang, Hong; Cheng, Genhong</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">407-422</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Editorial Office of Cell Research</span>)
        </div><div class="casAbstract">A review.  Type I interferons (IFN) are well studied cytokines with anti-viral and immune-modulating functions.  Type I IFNs are produced following viral infections, but until recently, the mechanisms of viral recognition leading to IFN prodn. were largely unknown.  Toll like receptors (TLRs) have emerged as key transducers of type I IFN during viral infections by recognizing various viral components.  Furthermore, much progress has been made in defining the signaling pathways downstream of TLRs for type I IFN prodn.  TLR7 and TLR9 have become apparent as universally important in inducing type I IFN during infection with most viruses, particularly by plasmacytoid dendritic cells.  New intracellular viral pattern recognition receptors leading to type I IFN prodn. have been identified.  Many bacteria can also induce the up-regulation of these cytokines.  Interestingly, recent studies have found a detrimental effect on host cells if type I IFN is produced during infection with the intracellular gram-pos. bacterial pathogen, Listeria monocytogenes.  This review will discuss the recent advances made in defining the signaling pathways leading to type I IFN prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTzROOhbG9RbVg90H21EOLACvtfcHk0lihFjH9IvyLYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWmtrfJ&md5=7c23d67960bcde5cde9141e74aa5b515</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1038%2Fsj.cr.7290309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cr.7290309%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DA.%2BK.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DG.%26atitle%3DThe%2520host%2520type%2520I%2520interferon%2520response%2520to%2520viral%2520and%2520bacterial%2520infections%26jtitle%3DCell%2520Res.%26date%3D2005%26volume%3D15%26spage%3D407%26epage%3D422%26doi%3D10.1038%2Fsj.cr.7290309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lussana, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambaldi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squizzato, A.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib-associated infections: A systematic review and meta-analysis</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">339</span>â <span class="NLM_lpage">347</span>, <span class="refDoi">Â DOI: 10.1002/ajh.24976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Fajh.24976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29150886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2kur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2018&pages=339-347&author=F.+Lussanaauthor=M.+Cattaneoauthor=A.+Rambaldiauthor=A.+Squizzato&title=Ruxolitinib-associated+infections%3A+A+systematic+review+and+meta-analysis&doi=10.1002%2Fajh.24976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib-associated infections: A systematic review and meta-analysis</span></div><div class="casAuthors">Lussana, Federico; Cattaneo, Marco; Rambaldi, Alessandro; Squizzato, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-347</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Ruxolitinib exerts immunosuppressive activity that may increase the risk of infectious complications.  We performed a systematic review of the literature with the aim of estg. the risk of infections in patients treated with ruxolitinib.  Studies were identified by electronic search of MEDLINE and EMBASE database.  Differences in the incidence of infectious events between ruxolitinib and comparison groups were expressed as odds ratios (ORs) and 95% confidence intervals (95% CI).  Five phase III randomized clin. trials (RCTs) (3 phase IIIa with their extended phase and 2 phase IIIb), 6 phase IV studies and 28 case reports were included in this systematic review.  Ruxolitinib was assocd. with a statistically significant increased risk of herpes zoster infection compared to control group in 3 RCTs including patients with polycythemia vera (OR 7.39 [1.33, 41.07]) and in a pooled anal. of the extended phase IIIa RCTs (OR 5.20 [95%CI 1.27, 21.18]).  In the larger phase IV post-marketing study, the incidence of the most frequent infections was 8% for herpes zoster, 6.1% for bronchitis and 6% for urinary tract infections.  In the published case reports, the most frequent infections were tuberculosis (N = 10), hepatitis B reactivation (N = 5) and pneumocystis jeroveci infection (N = 2).  Evidence is not solid enough to accurately est. the risk of infection in ruxolitinib-treated patients.  However, published data clearly suggest that the infection risk may be clin. relevant.  Well-designed studies are warranted to evaluate the risk of ruxolitinib-assocd. infection, in order to identify the most appropriate antimicrobial prophylactic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Ugd6ZlP0dLVg90H21EOLACvtfcHk0lgR4qpRK8K7ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2kur4%253D&md5=3f5fd911d19b2c0a4d561818f90fc4d0</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1002%2Fajh.24976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.24976%26sid%3Dliteratum%253Aachs%26aulast%3DLussana%26aufirst%3DF.%26aulast%3DCattaneo%26aufirst%3DM.%26aulast%3DRambaldi%26aufirst%3DA.%26aulast%3DSquizzato%26aufirst%3DA.%26atitle%3DRuxolitinib-associated%2520infections%253A%2520A%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2018%26volume%3D93%26spage%3D339%26epage%3D347%26doi%3D10.1002%2Fajh.24976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strand, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahadieh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Checchio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tensfeldt, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ³mez-Reino, J. J.</span></span> <span> </span><span class="NLM_article-title">Systematic review and meta-analysis of serious infections with Tofacitinib and biologic disease modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">362</span>, <span class="refDoi">Â DOI: 10.1186/s13075-015-0880-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2Fs13075-015-0880-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26669566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1egu7jL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=362&author=V.+Strandauthor=S.+Ahadiehauthor=J.+Frenchauthor=J.+Geierauthor=S.+Krishnaswamiauthor=S.+Menonauthor=T.+Checchioauthor=T.+G.+Tensfeldtauthor=E.+Hoffmanauthor=R.+Rieseauthor=M.+Boyauthor=J.+J.+G%C3%B3mez-Reino&title=Systematic+review+and+meta-analysis+of+serious+infections+with+Tofacitinib+and+biologic+disease+modifying+antirheumatic+drug+treatment+in+rheumatoid+arthritis+clinical+trials&doi=10.1186%2Fs13075-015-0880-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials</span></div><div class="casAuthors">Strand, Vibeke; Ahadieh, Sima; French, Jonathan; Geier, Jamie; Krishnaswami, Sriram; Menon, Sujatha; Checchio, Tina; Tensfeldt, Thomas G.; Hoffman, Elaine; Riese, Richard; Boy, Mary; Gomez-Reino, Juan J.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">362/1-362/9</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).  Tofacitinib modulates the signaling of cytokines that are integral to lymphocyte activation, proliferation, and function.  Thus, tofacitinib therapy may result in suppression of multiple elements of the immune response.  Serious infections have been reported in tofacitinib RA trials.  However, limited head-to-head comparator data were available within the tofacitinib RA development program to directly compare rates of serious infections with tofacitinib relative to biol. agents, and specifically adalimumab (employed as an active control agent in two randomized controlled trials of tofacitinib).  Methods: A systematic literature search of data from interventional randomized controlled trials and long-term extension studies with biologics in RA was carried out.  Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) consensus was followed for reporting results of the review and meta-anal.  Incidence rates (unique patients with events/100 patient-years) for each therapy were estd. based on data from randomized controlled trials and long-term extension studies using a random-effects model.  Relative and abs. risk comparisons vs. placebo used Mantel-Haenszel methods.  Results: The search produced 657 hits.  In total, 66 randomized controlled trials and 22 long-term extension studies met the selection criteria.  Estd. incidence rates (95 % confidence intervals [CIs]) for abatacept, rituximab, tocilizumab, and tumor necrosis factor inhibitors were 3.04 (2.49, 3.72), 3.72 (2.99, 4.62), 5.45 (4.26, 6.96), and 4.90 (4.41, 5.44), resp.  Incidence rates (95 % CIs) for tofacitinib 5 and 10 mg twice daily (BID) in phase 3 trials were 3.02 (2.25, 4.05) and 3.00 (2.24, 4.02), resp.  Corresponding incidence rates in long-term extension studies were 2.50 (2.05, 3.04) and 3.19 (2.74, 3.72).  The risk ratios (95 % CIs) vs. placebo for tofacitinib 5 and 10 mg BID were 2.21 (0.60, 8.14) and 2.02 (0.56, 7.28), resp.  Risk differences (95 % CIs) vs. placebo for tofacitinib 5 and 10 mg BID were 0.38 % (-0.24 %, 0.99 %) and 0.40 % (-0.22 %, 1.02 %), resp.  Conclusions: In interventional studies, the risk of serious infections with tofacitinib is comparable to published rates for biol. disease-modifying antirheumatic drugs in patients with moderate to severely active RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7qaEfvstNe7Vg90H21EOLACvtfcHk0lgR4qpRK8K7ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1egu7jL&md5=8421cf89c9a6b9e61c98a5886d7f37de</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1186%2Fs13075-015-0880-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-015-0880-2%26sid%3Dliteratum%253Aachs%26aulast%3DStrand%26aufirst%3DV.%26aulast%3DAhadieh%26aufirst%3DS.%26aulast%3DFrench%26aufirst%3DJ.%26aulast%3DGeier%26aufirst%3DJ.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DChecchio%26aufirst%3DT.%26aulast%3DTensfeldt%26aufirst%3DT.%2BG.%26aulast%3DHoffman%26aufirst%3DE.%26aulast%3DRiese%26aufirst%3DR.%26aulast%3DBoy%26aufirst%3DM.%26aulast%3DG%25C3%25B3mez-Reino%26aufirst%3DJ.%2BJ.%26atitle%3DSystematic%2520review%2520and%2520meta-analysis%2520of%2520serious%2520infections%2520with%2520Tofacitinib%2520and%2520biologic%2520disease%2520modifying%2520antirheumatic%2520drug%2520treatment%2520in%2520rheumatoid%2520arthritis%2520clinical%2520trials%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2015%26volume%3D17%26spage%3D362%26doi%3D10.1186%2Fs13075-015-0880-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milojkovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chacko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farquharson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span> <span> </span><span class="NLM_article-title">Response to Ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">29</span>â <span class="NLM_lpage">39</span>, <span class="refDoi">Â DOI: 10.1111/bjh.13379</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1111%2Fbjh.13379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25824940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVGmsbfP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2015&pages=29-39&author=A.+J.+Meadauthor=D.+Milojkovicauthor=S.+Knapperauthor=M.+Gargauthor=J.+Chackoauthor=M.+Farquharsonauthor=J.+Yinauthor=S.+Aliauthor=R.+E.+Clarkauthor=C.+Andrewsauthor=M.+K.+Dawsonauthor=C.+Harrison&title=Response+to+Ruxolitinib+in+patients+with+intermediate-1-%2C+intermediate-2-%2C+and+high-risk+myelofibrosis%3A+results+of+the+UK+ROBUST+Trial&doi=10.1111%2Fbjh.13379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial</span></div><div class="casAuthors">Mead, Adam J.; Milojkovic, Dragana; Knapper, Steven; Garg, Mamta; Chacko, Joseph; Farquharson, Mira; Yin, John; Ali, Sahra; Clark, Richard E.; Andrews, Chris; Dawson, Meryem Ktiouet; Harrison, Claire</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Myelofibrosis is characterized by splenomegaly and debilitating constitutional symptoms that neg. impact patients' quality of life.  ROBUST, a UK, open-label, phase II study, evaluated the safety and efficacy of ruxolitinib in patients with myelofibrosis (N = 48), including intermediate-1 risk patients.  The primary composite endpoint was the proportion of patients achieving treatment success [â¥50% redn. in palpable spleen length and/or a â¥50% decrease in Myelofibrosis Symptom Assessment Form Total Symptom Score (MF-SAF TSS)] at 48 wk.  This was the first time that efficacy of ruxolitinib in myelofibrosis has been evaluated based on these criteria and the first time the MF-SAF was used in a population of patients solely from the United Kingdom.  Overall, 50% of patients and 57% of intermediate-1 risk patients, achieved treatment success; redns. in spleen length and symptoms were obsd. in all risk groups.  The majority of patients (66Â·7%) experienced â¥50% redns. from baseline in spleen length at any time.  Improvements in MF-SAF TSS were seen in 80Â·0%, 72Â·7%, and 72Â·2% of intermediate-1, intermediate-2, and high-risk patients, resp.  Consistent with other studies of ruxolitinib, the most common haematol. adverse events were anemia and thrombocytopenia.  Results indicate that most patients with myelofibrosis, including intermediate-1 risk patients, may benefit from ruxolitinib treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUwk_Y4KOAUrVg90H21EOLACvtfcHk0lgR4qpRK8K7ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVGmsbfP&md5=560cf8f9b5fd441f345277a18f8524ab</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1111%2Fbjh.13379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.13379%26sid%3Dliteratum%253Aachs%26aulast%3DMead%26aufirst%3DA.%2BJ.%26aulast%3DMilojkovic%26aufirst%3DD.%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DGarg%26aufirst%3DM.%26aulast%3DChacko%26aufirst%3DJ.%26aulast%3DFarquharson%26aufirst%3DM.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DR.%2BE.%26aulast%3DAndrews%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DM.%2BK.%26aulast%3DHarrison%26aufirst%3DC.%26atitle%3DResponse%2520to%2520Ruxolitinib%2520in%2520patients%2520with%2520intermediate-1-%252C%2520intermediate-2-%252C%2520and%2520high-risk%2520myelofibrosis%253A%2520results%2520of%2520the%2520UK%2520ROBUST%2520Trial%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2015%26volume%3D170%26spage%3D29%26epage%3D39%26doi%3D10.1111%2Fbjh.13379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><a href="http://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf" class="extLink">www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=www.ema.europa.eu%2Fen%2Fdocuments%2Fproduct-information%2Folumiant-epar-product-information_en.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sepriano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerschbaumer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Heijde, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougados, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vollenhoven, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bijlsma, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burmester, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falzon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LandewÃ©, R.</span></span> <span> </span><span class="NLM_article-title">Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">760</span>â <span class="NLM_lpage">770</span>, <span class="refDoi">Â DOI: 10.1136/annrheumdis-2019-216653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1136%2Fannrheumdis-2019-216653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32033941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFemtLvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2020&pages=760-770&author=A.+Seprianoauthor=A.+Kerschbaumerauthor=J.+S.+Smolenauthor=D.+van+der%0AHeijdeauthor=M.+Dougadosauthor=R.+van+Vollenhovenauthor=I.+B.+McInnesauthor=J.+W.+Bijlsmaauthor=G.+R.+Burmesterauthor=M.+de+Witauthor=L.+Falzonauthor=R.+Landew%C3%A9&title=Safety+of+synthetic+and+biological+DMARDs%3A+A+systematic+literature+review+informing+the+2019+update+of+the+EULAR+recommendations+for+the+management+of+rheumatoid+arthritis&doi=10.1136%2Fannrheumdis-2019-216653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis</span></div><div class="casAuthors">Sepriano, Alexandre; Kerschbaumer, Andreas; Smolen, Josef S.; van der Heijde, Desiree; Dougados, Maxime; van Vollenhoven, Ronald; McInnes, Iain B.; Bijlsma, Johannes W.; Burmester, Gerd R.; de Wit, Maarten; Falzon, Louise; Landewe, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">760-770</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ</span>)
        </div><div class="casAbstract">A review.  To perform a systematic literature review (SLR) concerning the safety of synthetic (s) and biol. (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis (RA).  An SLR of observational studies comparing safety outcomes of any DMARD with another intervention for the management of RA.  A comparator group was required for inclusion.  For treatments still without registry data (eg, sarilumab and the Janus kinase (JAK) inhibitors baricitinib, upadacitinib), randomised controlled trials (RCTs) and long-term extensions (LTEs) were used.  Risk of bias (RoB) was assessed according to std. procedures.  Forty-two observational studies fulfilled the inclusion criteria, addressing safety outcomes with bDMARDs and sDMARDs.  Nine studies showed no difference in the risk of serious infections across bDMARDs and two studies (high RoB) showed an increased risk with bDMARDs compared with conventional synthetic (cs) DMARDs (adjusted incidence rate ratio 3.1-3.9).  The risk of Herpes zoster infection was similar across bDMARDs, but one study showed an increased risk with tofacitinib compared with abatacept (adjusted HR (aHR) 2.0).  Five studies showed no increased risk of cancer for bDMARDs compared with csDMARDs.  An increased risk of lower intestinal perforation was found for tocilizumab compared with csDMARDs (aHR 4.5) and tumor necrosis factor inhibitor (TNFi) (aHR 2.6-4.0).  Sixty manuscripts reported safety data from RCTs/LTEs.  Overall, no unexpected safety outcomes were found, except for the possibly increased risk of venous thromboembolism (VTE) with JAK inhibitors.  Data obtained by this SLR confirm the known safety profile of bDMARDs.  The risk of VTE in RA, esp. in patients on JAK inhibitors, needs further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU7VGNx5sLKLVg90H21EOLACvtfcHk0lhEMjfVNxBQ2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFemtLvE&md5=9ccdccfff2f89cf3f2ca286321134bd2</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-216653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-216653%26sid%3Dliteratum%253Aachs%26aulast%3DSepriano%26aufirst%3DA.%26aulast%3DKerschbaumer%26aufirst%3DA.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%26aulast%3DDougados%26aufirst%3DM.%26aulast%3Dvan%2BVollenhoven%26aufirst%3DR.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DBijlsma%26aufirst%3DJ.%2BW.%26aulast%3DBurmester%26aufirst%3DG.%2BR.%26aulast%3Dde%2BWit%26aufirst%3DM.%26aulast%3DFalzon%26aufirst%3DL.%26aulast%3DLandew%25C3%25A9%26aufirst%3DR.%26atitle%3DSafety%2520of%2520synthetic%2520and%2520biological%2520DMARDs%253A%2520A%2520systematic%2520literature%2520review%2520informing%2520the%25202019%2520update%2520of%2520the%2520EULAR%2520recommendations%2520for%2520the%2520management%2520of%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2020%26volume%3D79%26spage%3D760%26epage%3D770%26doi%3D10.1136%2Fannrheumdis-2019-216653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaspari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zengarini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangeli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastroianni, A.</span></span> <span> </span><span class="NLM_article-title">Side effects of Ruxolitinib in patients with SARS-CoV-2 infection: Two case reports</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">106023</span>, <span class="refDoi">Â DOI: 10.1016/j.ijantimicag.2020.106023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.ijantimicag.2020.106023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32450201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVejtr%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=106023&author=V.+Gaspariauthor=C.+Zengariniauthor=S.+Grecoauthor=V.+Vangeliauthor=A.+Mastroianni&title=Side+effects+of+Ruxolitinib+in+patients+with+SARS-CoV-2+infection%3A+Two+case+reports&doi=10.1016%2Fj.ijantimicag.2020.106023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports</span></div><div class="casAuthors">Gaspari, Valeria; Zengarini, Corrado; Greco, Sonia; Vangeli, Valeria; Mastroianni, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">106023</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This letter to the editor looks at side effects of ruxolitinib in patients with SARS-CoV-2 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouVsdhB3krI7Vg90H21EOLACvtfcHk0lhEMjfVNxBQ2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVejtr%252FF&md5=7e067cf2f7ee3281b15a7846c1019f92</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2020.106023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2020.106023%26sid%3Dliteratum%253Aachs%26aulast%3DGaspari%26aufirst%3DV.%26aulast%3DZengarini%26aufirst%3DC.%26aulast%3DGreco%26aufirst%3DS.%26aulast%3DVangeli%26aufirst%3DV.%26aulast%3DMastroianni%26aufirst%3DA.%26atitle%3DSide%2520effects%2520of%2520Ruxolitinib%2520in%2520patients%2520with%2520SARS-CoV-2%2520infection%253A%2520Two%2520case%2520reports%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2020%26volume%3D56%26spage%3D106023%26doi%3D10.1016%2Fj.ijantimicag.2020.106023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Channappanavar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehr, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlford-Lenane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrahante, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sompallae, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCray, P. B.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerholz, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, S.</span></span> <span> </span><span class="NLM_article-title">IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">3625</span>â <span class="NLM_lpage">3639</span>, <span class="refDoi">Â DOI: 10.1172/JCI126363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1172%2FJCI126363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31355779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3MvitlahsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2019&pages=3625-3639&author=R.+Channappanavarauthor=A.+R.+Fehrauthor=J.+Zhengauthor=C.+Wohlford-Lenaneauthor=J.+E.+Abrahanteauthor=M.+Mackauthor=R.+Sompallaeauthor=P.+B.+McCrayauthor=D.+K.+Meyerholzauthor=S.+Perlman&title=IFN-I+response+timing+relative+to+virus+replication+determines+MERS+coronavirus+infection+outcomes&doi=10.1172%2FJCI126363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes</span></div><div class="casAuthors">Channappanavar Rudragouda; Fehr Anthony R; Zheng Jian; McCray Paul B Jr; Perlman Stanley; Channappanavar Rudragouda; Channappanavar Rudragouda; Wohlford-Lenane Christine; McCray Paul B Jr; Perlman Stanley; Abrahante Juan E; Mack Matthias; Sompallae Ramakrishna; Meyerholz David K; Perlman Stanley</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3625-3639</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type 1 IFNs (IFN-I) generally protect mammalian hosts from virus infections, but in some cases, IFN-I is pathogenic.  Because IFN-I is protective, it is commonly used to treat virus infections for which no specific approved drug or vaccine is available.  The Middle East respiratory syndrome-coronavirus (MERS-CoV) is such an infection, yet little is known about the role of IFN-I in this setting.  Here, we show that IFN-I signaling is protective during MERS-CoV infection.  Blocking IFN-I signaling resulted in delayed virus clearance, enhanced neutrophil infiltration, and impaired MERS-CoV-specific T cell responses.  Notably, IFN-I administration within 1 day after infection (before virus titers peak) protected mice from lethal infection, despite a decrease in IFN-stimulated gene (ISG) and inflammatory cytokine gene expression.  In contrast, delayed IFN-Î² treatment failed to effectively inhibit virus replication, increased infiltration and activation of monocytes, macrophages, and neutrophils in the lungs, and enhanced proinflammatory cytokine expression, resulting in fatal pneumonia in an otherwise sublethal infection.  Together, these results suggest that the relative timing of the IFN-I response and maximal virus replication is key in determining outcomes, at least in infected mice.  By extension, IFN-Î±Î² or combination therapy may need to be used cautiously to treat viral infections in clinical settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnAIHuz_P7JOR_TJajKxJDfW6udTcc2eYsHn8NYOZVW7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvitlahsA%253D%253D&md5=843e52b0e3113db723d76e5a81db0e87</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1172%2FJCI126363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI126363%26sid%3Dliteratum%253Aachs%26aulast%3DChannappanavar%26aufirst%3DR.%26aulast%3DFehr%26aufirst%3DA.%2BR.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DWohlford-Lenane%26aufirst%3DC.%26aulast%3DAbrahante%26aufirst%3DJ.%2BE.%26aulast%3DMack%26aufirst%3DM.%26aulast%3DSompallae%26aufirst%3DR.%26aulast%3DMcCray%26aufirst%3DP.%2BB.%26aulast%3DMeyerholz%26aufirst%3DD.%2BK.%26aulast%3DPerlman%26aufirst%3DS.%26atitle%3DIFN-I%2520response%2520timing%2520relative%2520to%2520virus%2520replication%2520determines%2520MERS%2520coronavirus%2520infection%2520outcomes%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2019%26volume%3D129%26spage%3D3625%26epage%3D3639%26doi%3D10.1172%2FJCI126363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danesh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bermejo-Martin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poutanen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willey, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVries, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seneviratne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosinger, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greller, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somogyi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keshavjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeb, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGeer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelvin, D. J.</span></span>; <span class="NLM_contrib-group">Canadian SARS research network</span> <span> </span><span class="NLM_article-title">Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">8692</span>â <span class="NLM_lpage">8706</span>, <span class="refDoi">Â DOI: 10.1128/JVI.00527-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.00527-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17537853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslOitL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2007&pages=8692-8706&author=M.+J.+Cameronauthor=L.+Ranauthor=L.+Xuauthor=A.+Daneshauthor=J.+F.+Bermejo-Martinauthor=C.+M.+Cameronauthor=M.+P.+Mullerauthor=W.+L.+Goldauthor=S.+E.+Richardsonauthor=S.+M.+Poutanenauthor=B.+M.+Willeyauthor=M.+E.+DeVriesauthor=Y.+Fangauthor=C.+Seneviratneauthor=S.+E.+Bosingerauthor=D.+Persadauthor=P.+Wilkinsonauthor=L.+D.+Grellerauthor=R.+Somogyiauthor=A.+Humarauthor=S.+Keshavjeeauthor=M.+Louieauthor=M.+B.+Loebauthor=J.+Bruntonauthor=A.+J.+McGeerauthor=D.+J.+Kelvinauthor=Canadian+SARS+research+network&title=Interferon-mediated+immunopathological+events+are+associated+with+atypical+innate+and+adaptive+immune+responses+in+patients+with+severe+acute+respiratory+syndrome&doi=10.1128%2FJVI.00527-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome</span></div><div class="casAuthors">Cameron, Mark J.; Ran, Longsi; Xu, Luoling; Danesh, Ali; Bermejo-Martin, Jesus F.; Cameron, Cheryl M.; Muller, Matthew P.; Gold, Wayne L.; Richardson, Susan E.; Poutanen, Susan M.; Willey, Barbara M.; DeVries, Mark E.; Fang, Yuan; Seneviratne, Charit; Bosinger, Steven E.; Persad, Desmond; Wilkinson, Peter; Greller, Larry D.; Somogyi, Roland; Humar, Atul; Keshavjee, Shaf; Louie, Marie; Loeb, Mark B.; Brunton, James; McGeer, Allison J.; Kelvin, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8692-8706</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">It is not understood how immune inflammation influences the pathogenesis of severe acute respiratory syndrome (SARS).  One area of strong controversy is the role of interferon (IFN) responses in the natural history of SARS.  The fact that the majority of SARS patients recover after relatively moderate illness suggests that the prevailing notion of deficient type I IFN-mediated immunity, with hypercytokinemia driving a poor clin. course, is oversimplified.  The authors used proteomic and genomic technol. to systematically analyze host innate and adaptive immune responses of 40 clin. well-described patients with SARS during discrete phases of illness from the onset of symptoms to discharge or a fatal outcome.  A novel signature of high IFN-Î±, IFN-Î³, and IFN-stimulated chemokine levels, plus robust antiviral IFN-stimulated gene (ISG) expression, accompanied early SARS sequelae.  As acute illness progressed, SARS patients entered a crisis phase linked to oxygen satn. profiles.  The majority of SARS patients resolved IFN responses at crisis and expressed adaptive immune genes.  In contrast, patients with poor outcomes showed deviated ISG and Ig gene expression levels, persistent chemokine levels, and deficient anti-SARS spike antibody prodn.  The authors contend that unregulated IFN responses during acute-phase SARS may culminate in a malfunction of the switch from innate immunity to adaptive immunity.  The potential for the use of the gene signatures the authors describe in this study to better assess the immunopathol. and clin. management of severe viral infections, such as SARS and avian influenza (H5N1), is therefore worth careful examn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_HvMsyIdbN7Vg90H21EOLACvtfcHk0lgnYhjIalvIvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslOitL4%253D&md5=25c9a316489dccdbcb4ab425f26597ab</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1128%2FJVI.00527-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00527-07%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DRan%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDanesh%26aufirst%3DA.%26aulast%3DBermejo-Martin%26aufirst%3DJ.%2BF.%26aulast%3DCameron%26aufirst%3DC.%2BM.%26aulast%3DMuller%26aufirst%3DM.%2BP.%26aulast%3DGold%26aufirst%3DW.%2BL.%26aulast%3DRichardson%26aufirst%3DS.%2BE.%26aulast%3DPoutanen%26aufirst%3DS.%2BM.%26aulast%3DWilley%26aufirst%3DB.%2BM.%26aulast%3DDeVries%26aufirst%3DM.%2BE.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DSeneviratne%26aufirst%3DC.%26aulast%3DBosinger%26aufirst%3DS.%2BE.%26aulast%3DPersad%26aufirst%3DD.%26aulast%3DWilkinson%26aufirst%3DP.%26aulast%3DGreller%26aufirst%3DL.%2BD.%26aulast%3DSomogyi%26aufirst%3DR.%26aulast%3DHumar%26aufirst%3DA.%26aulast%3DKeshavjee%26aufirst%3DS.%26aulast%3DLouie%26aufirst%3DM.%26aulast%3DLoeb%26aufirst%3DM.%2BB.%26aulast%3DBrunton%26aufirst%3DJ.%26aulast%3DMcGeer%26aufirst%3DA.%2BJ.%26aulast%3DKelvin%26aufirst%3DD.%2BJ.%26aulast%3D%26atitle%3DInterferon-mediated%2520immunopathological%2520events%2520are%2520associated%2520with%2520atypical%2520innate%2520and%2520adaptive%2520immune%2520responses%2520in%2520patients%2520with%2520severe%2520acute%2520respiratory%2520syndrome%26jtitle%3DJ.%2520Virol.%26date%3D2007%26volume%3D81%26spage%3D8692%26epage%3D8706%26doi%3D10.1128%2FJVI.00527-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanco-Melo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson-Payant, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoagland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¸ller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, T. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">tenOever, B. R.</span></span> <span> </span><span class="NLM_article-title">Imbalanced host response to SARS-CoV-2 drives development of COVID-19</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">1036</span>â <span class="NLM_lpage">1045</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.04.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cell.2020.04.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32416070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXps1yjtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=1036-1045&author=D.+Blanco-Meloauthor=B.+E.+Nilsson-Payantauthor=W.+C.+Liuauthor=S.+Uhlauthor=D.+Hoaglandauthor=R.+M%C3%B8llerauthor=T.+X.+Jordanauthor=K.+Oishiauthor=M.+Panisauthor=D.+Sachsauthor=T.+T.+Wangauthor=R.+E.+Schwartzauthor=J.+K.+Limauthor=R.+A.+Albrechtauthor=B.+R.+tenOever&title=Imbalanced+host+response+to+SARS-CoV-2+drives+development+of+COVID-19&doi=10.1016%2Fj.cell.2020.04.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19</span></div><div class="casAuthors">Blanco-Melo, Daniel; Nilsson-Payant, Benjamin E.; Liu, Wen-Chun; Uhl, Skyler; Hoagland, Daisy; Moeller, Rasmus; Jordan, Tristan X.; Oishi, Kohei; Panis, Maryline; Sachs, David; Wang, Taia T.; Schwartz, Robert E.; Lim, Jean K.; Albrecht, Randy A.; tenOever, Benjamin R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1036-1045.e9</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Viral pandemics, such as the one caused by SARS-CoV-2, pose an imminent threat to humanity.  Because of its recent emergence, there is a paucity of information regarding viral behavior and host response following SARS-CoV-2 infection.  Here we offer an in-depth anal. of the transcriptional response to SARS-CoV-2 compared with other respiratory viruses.  Cell and animal models of SARS-CoV-2 infection, in addn. to transcriptional and serum profiling of COVID-19 patients, consistently revealed a unique and inappropriate inflammatory response.  This response is defined by low levels of type I and III interferons juxtaposed to elevated chemokines and high expression of IL-6.  We propose that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine prodn. are the defining and driving features of COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMWwpoPQkdl7Vg90H21EOLACvtfcHk0li4HWyXFFrH6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXps1yjtrk%253D&md5=cd1c1b429265a563ec1625972e3b07f7</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.04.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.04.026%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco-Melo%26aufirst%3DD.%26aulast%3DNilsson-Payant%26aufirst%3DB.%2BE.%26aulast%3DLiu%26aufirst%3DW.%2BC.%26aulast%3DUhl%26aufirst%3DS.%26aulast%3DHoagland%26aufirst%3DD.%26aulast%3DM%25C3%25B8ller%26aufirst%3DR.%26aulast%3DJordan%26aufirst%3DT.%2BX.%26aulast%3DOishi%26aufirst%3DK.%26aulast%3DPanis%26aufirst%3DM.%26aulast%3DSachs%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DT.%2BT.%26aulast%3DSchwartz%26aufirst%3DR.%2BE.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DAlbrecht%26aufirst%3DR.%2BA.%26aulast%3DtenOever%26aufirst%3DB.%2BR.%26atitle%3DImbalanced%2520host%2520response%2520to%2520SARS-CoV-2%2520drives%2520development%2520of%2520COVID-19%26jtitle%3DCell%26date%3D2020%26volume%3D181%26spage%3D1036%26epage%3D1045%26doi%3D10.1016%2Fj.cell.2020.04.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, C. G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyquist, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mbano, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzouanas, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousif, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bals, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, M. H.,  2nd.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatter, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taliaferro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gras, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaisant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelidis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sucre, J. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waghray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsialis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchheit, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyce, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidlaw, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonna, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkachev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gideon, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winchell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingle, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snapper, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theis, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaragosi, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiem, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortune, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finberg, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kean, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingwood, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalek, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordovas-Montanes, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is enriched in specific cell subsets across tissues</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">1016</span>â <span class="NLM_lpage">1035</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.04.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cell.2020.04.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32413319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsVKkuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=1016-1035&author=C.+G.+K.+Zieglerauthor=S.+J.+Allonauthor=S.+K.+Nyquistauthor=I.+M.+Mbanoauthor=V.+N.+Miaoauthor=C.+N.+Tzouanasauthor=Y.+Caoauthor=A.+S.+Yousifauthor=J.+Balsauthor=B.+M.+Hauserauthor=J.+Feldmanauthor=C.+Muusauthor=M.+H.+Wadsworthauthor=S.+W.+Kazerauthor=T.+K.+Hughesauthor=B.+Doranauthor=G.+J.+Gatterauthor=M.+Vukovicauthor=F.+Taliaferroauthor=B.+E.+Meadauthor=Z.+Guoauthor=J.+P.+Wangauthor=D.+Grasauthor=M.+Plaisantauthor=M.+Ansariauthor=I.+Angelidisauthor=H.+Adlerauthor=J.+M.+S.+Sucreauthor=C.+J.+Taylorauthor=B.+Linauthor=A.+Waghrayauthor=V.+Mitsialisauthor=D.+F.+Dwyerauthor=K.+M.+Buchheitauthor=J.+A.+Boyceauthor=N.+A.+Barrettauthor=T.+M.+Laidlawauthor=S.+L.+Carrollauthor=L.+Colonnaauthor=V.+Tkachevauthor=C.+W.+Petersonauthor=A.+Yuauthor=H.+B.+Zhengauthor=H.+P.+Gideonauthor=C.+G.+Winchellauthor=P.+L.+Linauthor=C.+D.+Bingleauthor=S.+B.+Snapperauthor=J.+A.+Kropskiauthor=F.+J.+Theisauthor=H.+B.+Schillerauthor=L.+E.+Zaragosiauthor=P.+Barbryauthor=A.+Leslieauthor=H.+P.+Kiemauthor=J.+L.+Flynnauthor=S.+M.+Fortuneauthor=B.+Bergerauthor=R.+W.+Finbergauthor=L.+S.+Keanauthor=M.+Garberauthor=A.+G.+Schmidtauthor=D.+Lingwoodauthor=A.+K.+Shalekauthor=J.+Ordovas-Montanes&title=SARS-CoV-2+receptor+ACE2+is+an+interferon-stimulated+gene+in+human+airway+epithelial+cells+and+is+enriched+in+specific+cell+subsets+across+tissues&doi=10.1016%2Fj.cell.2020.04.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues</span></div><div class="casAuthors">Ziegler, Carly G. K.; Allon, Samuel J.; Nyquist, Sarah K.; Mbano, Ian M.; Miao, Vincent N.; Tzouanas, Constantine N.; Cao, Yuming; Yousif, Ashraf S.; Bals, Julia; Hauser, Blake M.; Feldman, Jared; Muus, Christoph; Wadsworth, Marc H. II; Kazer, Samuel W.; Hughes, Travis K.; Doran, Benjamin; Gatter, G. James; Vukovic, Marko; Taliaferro, Faith; Mead, Benjamin E.; Guo, Zhiru; Wang, Jennifer P.; Gras, Delphine; Plaisant, Magali; Ansari, Meshal; Angelidis, Ilias; Adler, Heiko; Sucre, Jennifer M. S.; Taylor, Chase J.; Lin, Brian; Waghray, Avinash; Mitsialis, Vanessa; Dwyer, Daniel F.; Buchheit, Kathleen M.; Boyce, Joshua A.; Barrett, Nora A.; Laidlaw, Tanya M.; Carroll, Shaina L.; Colonna, Lucrezia; Tkachev, Victor; Peterson, Christopher W.; Yu, Alison; Zheng, Hengqi Betty; Gideon, Hannah P.; Winchell, Caylin G.; Lin, Philana Ling; Bingle, Colin D.; Snapper, Scott B.; Kropski, Jonathan A.; Theis, Fabian J.; Schiller, Herbert B.; Zaragosi, Laure-Emmanuelle; Barbry, Pascal; Leslie, Alasdair; Kiem, Hans-Peter; Flynn, JoAnne L.; Fortune, Sarah M.; Berger, Bonnie; Finberg, Robert W.; Kean, Leslie S.; Garber, Manuel; Schmidt, Aaron G.; Lingwood, Daniel; Shalek, Alex K.; Ordovas-Montanes, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1016-1035.e19</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">There is pressing urgency to understand the pathogenesis of the severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2), which causes the disease COVID-19.  SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.  The cell subsets targeted by SARS-CoV-2 in host tissues and the factors that regulate ACE2 expression remain unknown.  Here, we leverage human, non-human primate, and mouse single-cell RNA-sequencing (scRNA-seq) datasets across health and disease to uncover putative targets of SARS-CoV-2 among tissue-resident cell subsets.  We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.  Strikingly, we discovered that ACE2 is a human interferon-stimulated gene (ISG) in vitro using airway epithelial cells and extend our findings to in vivo viral infections.  Our data suggest that SARS-CoV-2 could exploit species-specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmetA92lZJ7LVg90H21EOLACvtfcHk0li4HWyXFFrH6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsVKkuro%253D&md5=82dbf0aa69f338ce6d3ff3b796643bb6</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.04.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.04.035%26sid%3Dliteratum%253Aachs%26aulast%3DZiegler%26aufirst%3DC.%2BG.%2BK.%26aulast%3DAllon%26aufirst%3DS.%2BJ.%26aulast%3DNyquist%26aufirst%3DS.%2BK.%26aulast%3DMbano%26aufirst%3DI.%2BM.%26aulast%3DMiao%26aufirst%3DV.%2BN.%26aulast%3DTzouanas%26aufirst%3DC.%2BN.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DYousif%26aufirst%3DA.%2BS.%26aulast%3DBals%26aufirst%3DJ.%26aulast%3DHauser%26aufirst%3DB.%2BM.%26aulast%3DFeldman%26aufirst%3DJ.%26aulast%3DMuus%26aufirst%3DC.%26aulast%3DWadsworth%26aufirst%3DM.%2BH.%26aulast%3DKazer%26aufirst%3DS.%2BW.%26aulast%3DHughes%26aufirst%3DT.%2BK.%26aulast%3DDoran%26aufirst%3DB.%26aulast%3DGatter%26aufirst%3DG.%2BJ.%26aulast%3DVukovic%26aufirst%3DM.%26aulast%3DTaliaferro%26aufirst%3DF.%26aulast%3DMead%26aufirst%3DB.%2BE.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DJ.%2BP.%26aulast%3DGras%26aufirst%3DD.%26aulast%3DPlaisant%26aufirst%3DM.%26aulast%3DAnsari%26aufirst%3DM.%26aulast%3DAngelidis%26aufirst%3DI.%26aulast%3DAdler%26aufirst%3DH.%26aulast%3DSucre%26aufirst%3DJ.%2BM.%2BS.%26aulast%3DTaylor%26aufirst%3DC.%2BJ.%26aulast%3DLin%26aufirst%3DB.%26aulast%3DWaghray%26aufirst%3DA.%26aulast%3DMitsialis%26aufirst%3DV.%26aulast%3DDwyer%26aufirst%3DD.%2BF.%26aulast%3DBuchheit%26aufirst%3DK.%2BM.%26aulast%3DBoyce%26aufirst%3DJ.%2BA.%26aulast%3DBarrett%26aufirst%3DN.%2BA.%26aulast%3DLaidlaw%26aufirst%3DT.%2BM.%26aulast%3DCarroll%26aufirst%3DS.%2BL.%26aulast%3DColonna%26aufirst%3DL.%26aulast%3DTkachev%26aufirst%3DV.%26aulast%3DPeterson%26aufirst%3DC.%2BW.%26aulast%3DYu%26aufirst%3DA.%26aulast%3DZheng%26aufirst%3DH.%2BB.%26aulast%3DGideon%26aufirst%3DH.%2BP.%26aulast%3DWinchell%26aufirst%3DC.%2BG.%26aulast%3DLin%26aufirst%3DP.%2BL.%26aulast%3DBingle%26aufirst%3DC.%2BD.%26aulast%3DSnapper%26aufirst%3DS.%2BB.%26aulast%3DKropski%26aufirst%3DJ.%2BA.%26aulast%3DTheis%26aufirst%3DF.%2BJ.%26aulast%3DSchiller%26aufirst%3DH.%2BB.%26aulast%3DZaragosi%26aufirst%3DL.%2BE.%26aulast%3DBarbry%26aufirst%3DP.%26aulast%3DLeslie%26aufirst%3DA.%26aulast%3DKiem%26aufirst%3DH.%2BP.%26aulast%3DFlynn%26aufirst%3DJ.%2BL.%26aulast%3DFortune%26aufirst%3DS.%2BM.%26aulast%3DBerger%26aufirst%3DB.%26aulast%3DFinberg%26aufirst%3DR.%2BW.%26aulast%3DKean%26aufirst%3DL.%2BS.%26aulast%3DGarber%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DA.%2BG.%26aulast%3DLingwood%26aufirst%3DD.%26aulast%3DShalek%26aufirst%3DA.%2BK.%26aulast%3DOrdovas-Montanes%26aufirst%3DJ.%26atitle%3DSARS-CoV-2%2520receptor%2520ACE2%2520is%2520an%2520interferon-stimulated%2520gene%2520in%2520human%2520airway%2520epithelial%2520cells%2520and%2520is%2520enriched%2520in%2520specific%2520cell%2520subsets%2520across%2520tissues%26jtitle%3DCell%26date%3D2020%26volume%3D181%26spage%3D1016%26epage%3D1035%26doi%3D10.1016%2Fj.cell.2020.04.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">784</span>â <span class="NLM_lpage">803</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2016.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.phrs.2016.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27473820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=784-803&author=R.+Roskoski&title=Janus+kinase+%28JAK%29+inhibitors+in+the+treatment+of+inflammatory+and+neoplastic+diseases&doi=10.1016%2Fj.phrs.2016.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">784-803</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinase (JAK) family of non-receptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (tyrosine kinase-2).  Each of these proteins contains a JAK homol. pseudokinase (JH2) domain that regulates the adjacent protein kinase domain (JH1).  JAK1/2 and TYK2 are ubiquitously expressed whereas JAK3 is found predominantly in hematopoietic cells.  The Janus kinase family is regulated by numerous cytokines including interleukins, interferons, and hormones such as erythropoietin, thrombopoietin, and growth hormone.  Ligand binding to cytokine and hormone receptors leads to the activation of assocd. Janus kinases, which then mediate the phosphorylation of the receptors.  The SH2 domain of STATs (signal transducers and activators of transcription) binds to the receptor phosphotyrosines thereby promoting STAT phosphorylation by the Janus kinases and consequent activation.  STAT dimers are translocated to the nucleus where they participate in the regulation of the expression of thousands of proteins.  JAK-STAT dysregulation results in autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, and Crohn disease.  JAK-STAT dysregulation also plays a role in the pathogenesis of myelofibrosis, polycythemia vera, and other myeloproliferative illnesses.  An activating JAK2 V617F mutation occurs in 95% of people with polycythemia vera and in a lower percentage of people with other neoplasms.  JAK1/3 signaling participates in the pathogenesis of inflammatory afflictions while JAK1/2 signaling participates in the development of several malignancies including leukemias and lymphomas as well as myeloproliferative neoplasms.  Tofacitinib is a pan-JAK inhibitor that is approved by the FDA for the treatment of rheumatoid arthritis and ruxolitinib is a JAK1/2 inhibitor that is approved for the treatment of polycythemia vera and myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov32m4UjOrv7Vg90H21EOLACvtfcHk0ljPhNAozxtSBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ&md5=a45fba1bb110eff4d5c1b31b78c1b3ac</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DJanus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520in%2520the%2520treatment%2520of%2520inflammatory%2520and%2520neoplastic%2520diseases%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D784%26epage%3D803%26doi%3D10.1016%2Fj.phrs.2016.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hermida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinesh Kumar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, N. R.</span></span> <span> </span><span class="NLM_article-title">GSK3 and its interactions with the I3K/AKT/mTOR signalling network</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">5</span>â <span class="NLM_lpage">15</span>, <span class="refDoi">Â DOI: 10.1016/j.jbior.2017.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jbior.2017.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28712664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOisr%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=5-15&author=M.+Hermidaauthor=A.+J.+Dinesh+Kumarauthor=N.+R.+Leslie&title=GSK3+and+its+interactions+with+the+I3K%2FAKT%2FmTOR+signalling+network&doi=10.1016%2Fj.jbior.2017.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 and its interactions with the PI3K/AKT/mTOR signalling network</span></div><div class="casAuthors">Hermida, Miguel A.; Dinesh Kumar, J.; Leslie, Nick R.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5-15</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Glycogen Synthase Kinase-3 (GSK3 or GSK-3) is a promiscuous protein kinase and its phosphorylation of its diverse substrates has major influences on many areas of physiol. and pathol., including cellular metab., lineage commitment and neuroscience.  GSK3 was one of the first identified substrates of the heavily studied oncogenic kinase AKT, phosphorylation by which inhibits GSK3 activity via the formation of an autoinhibitory pseudosubstrate sequence.  This has led to investigation of the role of GSK3 inhibition as a key component of the cellular responses to growth factors and insulin, which stimulate the class I PI 3-Kinases and in turn AKT activity and GSK3 phosphorylation.  GSK3 has been shown to phosphorylate several upstream and downstream components of the PI3K/AKT/mTOR signalling network, including AKT itself, RICTOR, TSC1 and 2, PTEN and IRS1 and 2, with the potential to apply feedback control within the network.  However, it has been clear for some time that functionally distinct, insulated pools of GSK3 exist which are regulated independently, so that for some GSK3 substrates such as Î² -catenin, phosphorylation by GSK3 is not controlled by input from PI3K and AKT.  Instead, as almost all GSK3 substrates require a priming phosphorylated residue to be 4 amino acids C-terminal to the Ser/Thr phosphorylated by GSK3, the predominant form of regulation of the activity of GSK3 often appears to be through control over these priming events, specific to individual substrates.  Therefore, a major role of GSK3 can be viewed as an amplifier of the electrostatic effects on protein function which are caused by these priming phosphorylation events.  Here we discuss these different aspects to GSK3 regulation and function, and the functions of GSK3 as it integrates with signalling through the PI3K-AKT-mTOR signalling axis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA5TFs3NBzFbVg90H21EOLACvtfcHk0ljPhNAozxtSBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOisr%252FE&md5=acf04cff82e167dde3e555c6e3854a16</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2017.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2017.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DHermida%26aufirst%3DM.%26aulast%3DDinesh%2BKumar%26aufirst%3DA.%2BJ.%26aulast%3DLeslie%26aufirst%3DN.%2BR.%26atitle%3DGSK3%2520and%2520its%2520interactions%2520with%2520the%2520I3K%252FAKT%252FmTOR%2520signalling%2520network%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2017%26volume%3D65%26spage%3D5%26epage%3D15%26doi%3D10.1016%2Fj.jbior.2017.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGrado, T. R.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">571</span>â <span class="NLM_lpage">593</span>, <span class="refDoi">Â DOI: 10.7150/thno.14334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.7150%2Fthno.14334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26941849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvVertbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=571-593&author=M.+K.+Pandeyauthor=T.+R.+DeGrado&title=Glycogen+synthase+kinase-3+%28GSK-3%29-targeted+therapy+and+imaging&doi=10.7150%2Fthno.14334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging</span></div><div class="casAuthors">Pandey, Mukesh K.; DeGrado, Timothy R.</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">571-593</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) is assocd. with various key biol. processes, including glucose regulation, apoptosis, protein synthesis, cell signaling, cellular transport, gene transcription, proliferation, and intracellular communication.  Accordingly, GSK-3 has been implicated in a wide variety of diseases and specifically targeted for both therapeutic and imaging applications by a large no. of academic labs. and pharmaceutical companies.  Here, we review the structure, function, expression levels, and ligand-binding properties of GSK-3 and its connection to various diseases.  A selected list of highly potent GSK-3 inhibitors, with IC50 <20 nM for ATP (ATP)-competitive inhibitors and IC50 <5 Î¼M for non-ATP-competitive inhibitors, were analyzed for structure activity relationships.  Furthermore, ubiquitous expression of GSK-3 and its possible impact on therapy and imaging are also highlighted.  Finally, a rational perspective and possible route to selective and effective GSK-3 inhibitors is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg397DfBVXrrVg90H21EOLACvtfcHk0ljPhNAozxtSBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvVertbs%253D&md5=e66feec1b1b2f460000116b722678478</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.7150%2Fthno.14334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.14334%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DM.%2BK.%26aulast%3DDeGrado%26aufirst%3DT.%2BR.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520%2528GSK-3%2529-targeted%2520therapy%2520and%2520imaging%26jtitle%3DTheranostics%26date%3D2016%26volume%3D6%26spage%3D571%26epage%3D593%26doi%3D10.7150%2Fthno.14334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eldar-Finkelman, H.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3: An emerging therapeutic target</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">126</span>â <span class="NLM_lpage">132</span>, <span class="refDoi">Â DOI: 10.1016/S1471-4914(01)02266-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS1471-4914%2801%2902266-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11879773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsFahtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=126-132&author=H.+Eldar-Finkelman&title=Glycogen+synthase+kinase+3%3A+An+emerging+therapeutic+target&doi=10.1016%2FS1471-4914%2801%2902266-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3: an emerging therapeutic target</span></div><div class="casAuthors">Eldar-Finkelman, Hagit</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">126-132</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase 3 (GSK-3) is a serine/threonine protein kinase that has recently emerged as a key target in drug discovery.  It has been implicated in multiple cellular processes and linked with the pathogenesis of several diseases.  GSK-3 inhibitors might prove useful as therapeutic compds. in the treatment of conditions assocd. with elevated levels of enzyme activity, such as type 2 diabetes and Alzheimer's disease.  The pro-apoptotic feature of GSK-3 activity suggests a potential role for its inhibitors in protection against neuronal cell death, and in the treatment of traumatic head injury and stroke.  Finally, selective inhibitors of GSK-3 could mimic the action of mood stabilizers such as lithium and valproic acid and be used in the treatment of bipolar mood disorders.  Glycogen synthase kinase 3 (GSK-3) is a key therapeutic target in conditions assocd. with elevated levels of GSK-3, such as type 2 diabetes and Alzheimer's disease, as well as traumatic head injury, stroke and bipolar disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqReqQx-BihlbVg90H21EOLACvtfcHk0ljPhNAozxtSBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsFahtLw%253D&md5=17c0a5efb4fc12d9f0dbf777f457ad98</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1016%2FS1471-4914%2801%2902266-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4914%252801%252902266-3%26sid%3Dliteratum%253Aachs%26aulast%3DEldar-Finkelman%26aufirst%3DH.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%253A%2520An%2520emerging%2520therapeutic%2520target%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2002%26volume%3D8%26spage%3D126%26epage%3D132%26doi%3D10.1016%2FS1471-4914%2801%2902266-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ­sniewski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ³jtowicz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ³jcicka, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaskiewicz, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drulis-Fajdasz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gizak, A.</span></span> <span> </span><span class="NLM_article-title">Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">833</span>â <span class="NLM_lpage">848</span>, <span class="refDoi">Â DOI: 10.1080/14728222.2018.1526925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1080%2F14728222.2018.1526925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30244615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKisrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=833-848&author=P.+Dudaauthor=J.+W%C3%ADsniewskiauthor=T.+W%C3%B3jtowiczauthor=O.+W%C3%B3jcickaauthor=M.+R.+Jaskiewiczauthor=D.+Drulis-Fajdaszauthor=D.+Rakusauthor=J.+A.+McCubreyauthor=A.+Gizak&title=Targeting+GSK3+signaling+as+a+potential+therapy+of+neurodegenerative+diseases+and+aging&doi=10.1080%2F14728222.2018.1526925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging</span></div><div class="casAuthors">Duda, Przemyslaw; Wisniewski, Janusz; Wojtowicz, Tomasz; Wojcicka, Olga; Jaskiewicz, Michal; Drulis-Fajdasz, Dominika; Rakus, Dariusz; McCubrey, James A.; Gizak, Agnieszka</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">833-848</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase 3 (GSK3) is at the center of cellular signaling and controls various aspects of brain functions, including development of the nervous system, neuronal plasticity and onset of neurodegenerative disorders.: In this review, recent efforts in elucidating the roles of GSK3 in neuronal plasticity and development of brain pathologies; Alzheimer's and Parkinson's disease, schizophrenia, and age-related neurodegeneration are described.  The effect of microglia and astrocytes on development of the pathol. states is also discussed.: GSK3Î² and its signaling pathway partners hold great promise as therapeutic target(s) for a multitude of neurol. disorders.  Activity of the kinase is often elevated in brain disorders.  However, due to the wide range of GSK3 cellular targets, global inhibition of the kinase leads to severe side-effects and GSK3 inhibitors rarely reach Phase-2 clin. trials.  Thus, a selective modulation of a specific cellular pool of GSK3 or specific down- or upstream partners of the kinase might provide more efficient anti-neurodegenerative therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGBAWhlK0LC7Vg90H21EOLACvtfcHk0lgN4LsLYPjfXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKisrfJ&md5=c209e9ce80b19ac6d489519a3a8ae461</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1080%2F14728222.2018.1526925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728222.2018.1526925%26sid%3Dliteratum%253Aachs%26aulast%3DDuda%26aufirst%3DP.%26aulast%3DW%25C3%25ADsniewski%26aufirst%3DJ.%26aulast%3DW%25C3%25B3jtowicz%26aufirst%3DT.%26aulast%3DW%25C3%25B3jcicka%26aufirst%3DO.%26aulast%3DJaskiewicz%26aufirst%3DM.%2BR.%26aulast%3DDrulis-Fajdasz%26aufirst%3DD.%26aulast%3DRakus%26aufirst%3DD.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DGizak%26aufirst%3DA.%26atitle%3DTargeting%2520GSK3%2520signaling%2520as%2520a%2520potential%2520therapy%2520of%2520neurodegenerative%2520diseases%2520and%2520aging%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2018%26volume%3D22%26spage%3D833%26epage%3D848%26doi%3D10.1080%2F14728222.2018.1526925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3Î² inhibitor reduces LPS induced acute lung injury in mice</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">6715</span>â <span class="NLM_lpage">6721</span>, <span class="refDoi">Â DOI: 10.3892/mmr.2017.7469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3892%2Fmmr.2017.7469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28901469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsFSqu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=6715-6721&author=Q.+Dingauthor=G.+Liuauthor=Y.+Zengauthor=J.+Zhuauthor=Z.+Liuauthor=J.+Jiangauthor=J.+Huang&title=Glycogen+synthase+kinase-3%CE%B2+inhibitor+reduces+LPS+induced+acute+lung+injury+in+mice&doi=10.3892%2Fmmr.2017.7469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3Î² inhibitor reduces LPS-induced acute lung injury in mice</span></div><div class="casAuthors">Ding, Qi; Liu, Gaoqin; Zeng, Yuanyuan; Zhu, Jianjie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">6715-6721</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The aim of the present study was to examine the role of Wnt signaling in lipopolysaccharide (LPS)-induced acute respiratory distress syndrome (ARDS).  ARDS was induced by LPS and compared in mice treated with either glycogen synthase kinase-3Î² inhibitor (GSKI) or PBS.  The protein expression levels of interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-Î±, IL-17, IL-18 and IL-1Î² in the bronchoalveolar lavage fluid (BALF) were examd. using murine cytokine-specific enzyme-linked immunosorbent assays.  The accumulation of neutrophils and macrophages in the BALF were detected using flow cytometry.  The extent of pathol. lesions was evaluated using an immunohistochem. assay.  The differentiation of mesenchymal stem cells (MSCs) into type II alveolar (ATII) epithelial cells was analyzed using immunofluorescence staining.  Treatment with GSKI led to maintained body wts. and survival in mice with LPS-induced ARDS.  Treatment with GSKI effectively reduced the levels of total protein, albumin, IgM and keratinocyte growth factor in the BALF.  Smith scores showed that GSKI significantly alleviated LPS-induced lung injury.  GSKI also functioned to reduce inflammatory cell accumulation and pro-inflammatory cytokine secretion.  Finally, it was found that GSKI promoted the differentiation of MSCs into ATII epithelial cells in vivo.  Taken together, the GSKI-treated mice exhibited reduced acute lung injury through inhibited intra-fluid inflammatory cell infiltration and decreased expression of pro-inflammatory cytokines, and GSKI increased the differentiation of MSCs into ATII epithelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4PO-zykxog7Vg90H21EOLACvtfcHk0lgN4LsLYPjfXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsFSqu7g%253D&md5=ed6dcc33ee211b34a1ff1de44c1b51ab</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2017.7469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2017.7469%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%26atitle%3DGlycogen%2520synthase%2520kinase-3%25CE%25B2%2520inhibitor%2520reduces%2520LPS%2520induced%2520acute%2520lung%2520injury%2520in%2520mice%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2017%26volume%3D16%26spage%3D6715%26epage%3D6721%26doi%3D10.3892%2Fmmr.2017.7469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fichtner-Feigl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesselring, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruemmele, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haimerl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geissler, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strober, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlitt, H. J.</span></span> <span> </span><span class="NLM_article-title">IL-13 orchestrates resolution of chronic intestinal inflammation via phosphorylation of glycogen synthase kinase-3Î²</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">3969</span>â <span class="NLM_lpage">3980</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1301072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.4049%2Fjimmunol.1301072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24634488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gmt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2014&pages=3969-3980&author=S.+Fichtner-Feiglauthor=R.+Kesselringauthor=M.+Martinauthor=F.+Obermeierauthor=P.+Ruemmeleauthor=A.+Kitaniauthor=S.+M.+Brunnerauthor=M.+Haimerlauthor=E.+K.+Geisslerauthor=W.+Stroberauthor=H.+J.+Schlitt&title=IL-13+orchestrates+resolution+of+chronic+intestinal+inflammation+via+phosphorylation+of+glycogen+synthase+kinase-3%CE%B2&doi=10.4049%2Fjimmunol.1301072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">IL-13 Orchestrates Resolution of Chronic Intestinal Inflammation via Phosphorylation of Glycogen Synthase Kinase-3Î²</span></div><div class="casAuthors">Fichtner-Feigl, Stefan; Kesselring, Rebecca; Martin, Maria; Obermeier, Florian; Ruemmele, Petra; Kitani, Atsushi; Brunner, Stefan M.; Haimerl, Michael; Geissler, Edward K.; Strober, Warren; Schlitt, Hans J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3969-3980</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Spontaneous amelioration of inflammation (often accompanied by fibrosis) is a well-known, but poorly understood, outcome of many chronic inflammatory processes.  We studied this phenomenon in a chronic trinitrobenzene sulfonic acid-induced colitis model, an exptl. colitis in mice that we showed to ultimately undergo spontaneous resoln., despite continued trinitrobenzene sulfonic acid stimulation.  Anal. of the mechanism of this resoln. revealed that it was critically dependent on IL-13 activation of STAT6, followed by phosphorylation (inactivation) of glycogen synthase kinase-3Î², at least in part via STAT6 induction of p38 MAPK.  Such glycogen synthase kinase-3Î² inactivation causes changes in CREB and p65 DNA-binding activity that favors decreased proinflammatory IL-17 prodn. and increased anti-inflammatory IL-10 prodn.  Thus, in this case, IL-13 acts as a mol. switch that leads to resoln. of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-2BTsj54rgLVg90H21EOLACvtfcHk0lgN4LsLYPjfXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gmt74%253D&md5=ff405b1b6f7896a44b504f162efe72df</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301072%26sid%3Dliteratum%253Aachs%26aulast%3DFichtner-Feigl%26aufirst%3DS.%26aulast%3DKesselring%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DObermeier%26aufirst%3DF.%26aulast%3DRuemmele%26aufirst%3DP.%26aulast%3DKitani%26aufirst%3DA.%26aulast%3DBrunner%26aufirst%3DS.%2BM.%26aulast%3DHaimerl%26aufirst%3DM.%26aulast%3DGeissler%26aufirst%3DE.%2BK.%26aulast%3DStrober%26aufirst%3DW.%26aulast%3DSchlitt%26aufirst%3DH.%2BJ.%26atitle%3DIL-13%2520orchestrates%2520resolution%2520of%2520chronic%2520intestinal%2520inflammation%2520via%2520phosphorylation%2520of%2520glycogen%2520synthase%2520kinase-3%25CE%25B2%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D192%26spage%3D3969%26epage%3D3980%26doi%3D10.4049%2Fjimmunol.1301072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worthen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beurel, E.</span></span> <span> </span><span class="NLM_article-title">Stressed and inflamed, can GSK3 be blamed?</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">180</span>â <span class="NLM_lpage">192</span>, <span class="refDoi">Â DOI: 10.1016/j.tibs.2016.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.tibs.2016.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27876551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVeqsrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=180-192&author=R.+S.+Jopeauthor=Y.+Chengauthor=J.+Lowellauthor=R.+Worthenauthor=Y.+H.+Sitbonauthor=E.+Beurel&title=Stressed+and+inflamed%2C+can+GSK3+be+blamed%3F&doi=10.1016%2Fj.tibs.2016.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Stressed and Inflamed, Can GSK3 Be Blamed?</span></div><div class="casAuthors">Jope, Richard S.; Cheng, Yuyan; Lowell, Jeffrey A.; Worthen, Ryan J.; Sitbon, Yoel H.; Beurel, Eleonore</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">180-192</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Psychol. stress has a pervasive influence on our lives.  In many cases adapting to stress strengthens organisms, but chronic or severe stress is usually harmful.  One surprising outcome of psychol. stress is the activation of an inflammatory response that resembles inflammation caused by infection or trauma.  Excessive psychol. stress and the consequential inflammation in the brain can increase susceptibility to psychiatric diseases, such as depression, and impair learning and memory, including in some patients with cognitive deficits.  An emerging target to control detrimental outcomes of stress and inflammation is glycogen synthase kinase-3 (GSK3).  GSK3 promotes inflammation, partly by regulating key transcription factors in the inflammation signaling pathway, and GSK3 can impair learning by promoting inflammation and by inhibiting long-term potentiation (LTP).  Drugs inhibiting GSK3 may prove beneficial for controlling mood and cognitive impairments caused by excessive stress and the assocd. neuroinflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHqIYxRhEUPrVg90H21EOLACvtfcHk0lhRFOBSACzuXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVeqsrrM&md5=b7cda246c174af17762a8871283e518c</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2016.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2016.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DJope%26aufirst%3DR.%2BS.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DLowell%26aufirst%3DJ.%26aulast%3DWorthen%26aufirst%3DR.%26aulast%3DSitbon%26aufirst%3DY.%2BH.%26aulast%3DBeurel%26aufirst%3DE.%26atitle%3DStressed%2520and%2520inflamed%252C%2520can%2520GSK3%2520be%2520blamed%253F%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2017%26volume%3D42%26spage%3D180%26epage%3D192%26doi%3D10.1016%2Fj.tibs.2016.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganea, D.</span></span> <span> </span><span class="NLM_article-title">A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">55176</span>â <span class="NLM_lpage">55186</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M409816200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.M409816200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=15498767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFeis7zM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=55176-55186&author=H.+Jingauthor=J.+H.+Yenauthor=D.+Ganea&title=A+novel+signaling+pathway+mediates+the+inhibition+of+CCL3%2F4+expression+by+prostaglandin+E2&doi=10.1074%2Fjbc.M409816200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Signaling Pathway Mediates the Inhibition of CCL3/4 Expression by Prostaglandin E2</span></div><div class="casAuthors">Jing, Huie; Yen, Jui-Hung; Ganea, Doina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">53</span>),
    <span class="NLM_cas:pages">55176-55186</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">In response to pathogen-assocd. mol. patterns, dendritic cells initiate an innate immune response characterized by expression and release of proinflammatory cytokines and chemokines.  The extent of the inflammatory response is limited by various endogenous factors, including lipid mediators such as prostaglandin E2 (PGE2).  We described previously the inhibitory effect of PGE2 on the expression and release of the inflammatory chemokines CCL3 and CCL4 from activated dendritic cells.  In this study we describe a novel PGE2 signaling pathway that proceeds through EP-2 â cAMP â EPAC â phosphatidylinositol 3-kinase â protein kinase B â GSK-3 and results in increased DNA binding of the CCAAT displacement protein (CDP), a potent mammalian transcriptional repressor.  The direct link between CDP and CCL3/4 transcription was established in knock-down expts. using CDP small interference RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPItfa6eoQD7Vg90H21EOLACvtfcHk0lhRFOBSACzuXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFeis7zM&md5=dba3cda10c01cf3772ae07982dffe3ea</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M409816200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M409816200%26sid%3Dliteratum%253Aachs%26aulast%3DJing%26aufirst%3DH.%26aulast%3DYen%26aufirst%3DJ.%2BH.%26aulast%3DGanea%26aufirst%3DD.%26atitle%3DA%2520novel%2520signaling%2520pathway%2520mediates%2520the%2520inhibition%2520of%2520CCL3%252F4%2520expression%2520by%2520prostaglandin%2520E2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D55176%26epage%3D55186%26doi%3D10.1074%2Fjbc.M409816200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, I.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span> <span> </span><span class="NLM_article-title">TLR3-mediated signal induces proinflammatory cytokine and chemokine gene expression in astrocytes: Differential signaling mechanisms of TLR3-induced IP-10 and IL-8 gene expression</span>. <i>Glia</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">248</span>â <span class="NLM_lpage">256</span>, <span class="refDoi">Â DOI: 10.1002/glia.20278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Fglia.20278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16265667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BD2MnotVSisQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2006&pages=248-256&author=C.+Parkauthor=S.+Leeauthor=I.-H.+Choauthor=H.+K.+Leeauthor=N.+Kimauthor=S.-Y.+Choiauthor=S.+B.+Ohauthor=K.+Parkauthor=J.+S.+Kimauthor=S.+J.+Lee&title=TLR3-mediated+signal+induces+proinflammatory+cytokine+and+chemokine+gene+expression+in+astrocytes%3A+Differential+signaling+mechanisms+of+TLR3-induced+IP-10+and+IL-8+gene+expression&doi=10.1002%2Fglia.20278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">TLR3-mediated signal induces proinflammatory cytokine and chemokine gene expression in astrocytes: differential signaling mechanisms of TLR3-induced IP-10 and IL-8 gene expression</span></div><div class="casAuthors">Park Chanhee; Lee Soojin; Cho Ik-Hyun; Lee Hyun Kyoung; Kim Donghoon; Choi Se-Young; Oh Seog Bae; Park Kyungpyo; Kim Joong Soo; Lee Sung Joong</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-56</span>
        ISSN:<span class="NLM_cas:issn">0894-1491</span>.
    </div><div class="casAbstract">Viral infection is one of the leading causes of brain encephalitis and meningitis.  Recently, it was reported that Toll-like receptor-3 (TLR3) induces a double-stranded RNA (dsRNA)-mediated inflammatory signal in the cells of the innate immune system, and studies suggested that dsRNA may induce inflammation in the central nervous system (CNS) by activating the CNS-resident glial cells.  To explore further the connection between dsRNA and inflammation in the CNS, we have studied the effects of dsRNA stimulation in astrocytes.  Our results show that the injection of polyinosinic-polycytidylic acid (poly(I:C)), a synthetic dsRNA, into the striatum of the mouse brain induces the activation of astrocytes and the expression of TNF-alpha, IFN-beta, and IP-10.  Stimulation with poly(I:C) also induces the expression of these proinflammatory genes in primary astrocytes and in CRT-MG, a human astrocyte cell line.  Furthermore, our studies on the intracellular signaling pathways reveal that poly(I:C) stimulation activates IkappaB kinase (IKK), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) in CRT-MG.  Pharmacological inhibitors of nuclear factor-kappaB (NF-kappaB), JNK, ERK, glycogen synthase kinase-3beta (GSK-3beta), and dsRNA-activated protein kinase (PKR) inhibit the expression of IL-8 and IP-10 in astrocytes, indicating that the activation of these signaling molecules is required for the TLR3-mediated chemokine gene induction.  Interestingly, the inhibition of PI3 kinase suppressed the expression of IP-10, but upregulated the expression of IL-8, suggesting differential roles for PI3 kinase, depending on the target genes.  These data suggest that the TLR3 expressed on astrocytes may initiate an inflammatory response upon viral infection in the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0VPvAkkJA_oJKJbLTgsvCfW6udTcc2eZU1NyslcRae7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnotVSisQ%253D%253D&md5=dec1899574f969923d0c141ad0887dd2</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1002%2Fglia.20278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.20278%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DI.-H.%26aulast%3DLee%26aufirst%3DH.%2BK.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DChoi%26aufirst%3DS.-Y.%26aulast%3DOh%26aufirst%3DS.%2BB.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26atitle%3DTLR3-mediated%2520signal%2520induces%2520proinflammatory%2520cytokine%2520and%2520chemokine%2520gene%2520expression%2520in%2520astrocytes%253A%2520Differential%2520signaling%2520mechanisms%2520of%2520TLR3-induced%2520IP-10%2520and%2520IL-8%2520gene%2520expression%26jtitle%3DGlia%26date%3D2006%26volume%3D53%26spage%3D248%26epage%3D256%26doi%3D10.1002%2Fglia.20278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busuttil, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupiec-Weglinski, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3Î² promotes liver innate immune activation by restraining AMP-activated protein kinase activation</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">99</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1016/j.jhep.2018.01.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jhep.2018.01.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29452207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslShsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2018&pages=99-109&author=H.+Zhouauthor=H.+Wangauthor=M.+Niauthor=S.+Yueauthor=Y.+Xiaauthor=R.+W.+Busuttilauthor=J.+W.+Kupiec-Weglinskiauthor=L.+Luauthor=X.+Wangauthor=Y.+Zhai&title=Glycogen+synthase+kinase-3%CE%B2+promotes+liver+innate+immune+activation+by+restraining+AMP-activated+protein+kinase+activation&doi=10.1016%2Fj.jhep.2018.01.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3Î² promotes liver innate immune activation by restraining AMP-activated protein kinase activation</span></div><div class="casAuthors">Zhou, Haoming; Wang, Han; Ni, Ming; Yue, Shi; Xia, Yongxiang; Busuttil, Ronald W.; Kupiec-Weglinski, Jerzy W.; Lu, Ling; Wang, Xuehao; Zhai, Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-109</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3Î² (Gsk3Î² [Gsk3b]) is a ubiquitously expressed kinase with distinctive functions in different types of cells.  Although its roles in regulating innate immune activation and ischemia and reperfusion injuries (IRIs) have been well documented, the underlying mechanisms remain ambiguous, in part because of the lack of cell-specific tools in vivo.  We created a myeloid-specific Gsk3b knockout (KO) strain to study the function of Gsk3Î² in macrophages in a murine liver partial warm ischemia model.  Compared with controls, myeloid Gsk3b KO mice were protected from IRI, with diminished proinflammatory but enhanced anti-inflammatory immune responses in livers.  In bone marrow-derived macrophages, Gsk3Î² deficiency resulted in an early redn. of Tnf gene transcription but sustained increase of Il10 gene transcription on Toll-like receptor 4 stimulation in vitro.  These effects were assocd. with enhanced AMP-activated protein kinase (AMPK) activation, which led to an accelerated and higher level of induction of the novel innate immune neg. regulator small heterodimer partner (SHP [Nr0b2]).  The regulatory function of Gsk3Î² on AMPK activation and SHP induction was confirmed in wild-type bone marrow-derived macrophages with a Gsk3 inhibitor.  Furthermore, we found that this immune regulatory mechanism was independent of Gsk3Î² Ser9 phosphorylation and the phosphoinositide 3-kinase-Akt signalling pathway.  In vivo, myeloid Gsk3Î² deficiency facilitated SHP upregulation by ischemia-reperfusion in liver macrophages.  Treatment of Gsk3b KO mice with either AMPK inhibitor or SHP small interfering RNA before the onset of liver ischemia restored liver proinflammatory immune activation and IRI in these otherwise protected hosts.  Addnl., pharmacol. activation of AMPK protected wild-type mice from liver IRI, with reduced proinflammatory immune activation.  Inhibition of the AMPK-SHP pathway by liver ischemia was demonstrated in tumor resection patients.  Gsk3Î² promotes innate proinflammatory immune activation by restraining AMPK activation.  Glycogen synthase kinase 3Î² promotes macrophage inflammatory activation by inhibiting the immune regulatory signalling of AMP-activated protein kinase and the induction of small heterodimer partner.  Therefore, therapeutic targeting of glycogen synthase kinase 3Î² enhances innate immune regulation and protects liver from ischemia and reperfusion injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0qHahwWjSSrVg90H21EOLACvtfcHk0lgZw_TsraIJqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslShsrw%253D&md5=f3366c5cd501a1914be3ed068533a058</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2018.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2018.01.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNi%26aufirst%3DM.%26aulast%3DYue%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DBusuttil%26aufirst%3DR.%2BW.%26aulast%3DKupiec-Weglinski%26aufirst%3DJ.%2BW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DY.%26atitle%3DGlycogen%2520synthase%2520kinase-3%25CE%25B2%2520promotes%2520liver%2520innate%2520immune%2520activation%2520by%2520restraining%2520AMP-activated%2520protein%2520kinase%2520activation%26jtitle%3DJ.%2520Hepatol.%26date%3D2018%26volume%3D69%26spage%3D99%26epage%3D109%26doi%3D10.1016%2Fj.jhep.2018.01.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DÃ´, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ClÃ©ment, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doble, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servant, M. J.</span></span> <span> </span><span class="NLM_article-title">Fine-tuning of the RIG-I-like receptor/interferon regulatory factor 3-dependent antiviral innate immune response by the glycogen synthase kinase 3/ beta-catenin pathway</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3029</span>â <span class="NLM_lpage">3043</span>, <span class="refDoi">Â DOI: 10.1128/MCB.00344-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FMCB.00344-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26100021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWksrjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=3029-3043&author=K.+A.+Khanauthor=F.+D%C3%B4author=A.+Marineauauthor=P.+Doyonauthor=J.+F.+Cl%C3%A9mentauthor=J.+R.+Woodgettauthor=B.+W.+Dobleauthor=M.+J.+Servant&title=Fine-tuning+of+the+RIG-I-like+receptor%2Finterferon+regulatory+factor+3-dependent+antiviral+innate+immune+response+by+the+glycogen+synthase+kinase+3%2F+beta-catenin+pathway&doi=10.1128%2FMCB.00344-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Fine-tuning of the RIG-I-like receptor/interferon regulatory factor 3-dependent antiviral innate immune response by the glycogen synthase kinase 3/Î²-catenin pathway</span></div><div class="casAuthors">Khan, Kashif Aziz; Do, Florence; Marineau, Alexandre; Doyon, Priscilla; Clement, Jean-Francois; Woodgett, James R.; Doble, Bradley W.; Servant, Marc J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3029-3043</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Induction of an antiviral innate immune response relies on pattern recognition receptors, including retinoic acid-inducible gene 1-like receptors (RLR), to detect invading pathogens, resulting in the activation of multiple latent transcription factors, including interferon regulatory factor 3 (IRF3).  Upon sensing of viral RNA and DNA, IRF3 is phosphorylated and recruits coactivators to induce type I interferons (IFNs) and selected sets of IRF3-regulated IFN-stimulated genes (ISGs) such as those for ISG54 (Ifit2), ISG56 (Ifit1), and viperin (Rsad2).  Here, we used wild-type, glycogen synthase kinase 3Î± knockout (GSK-3Î±_/_), GSK- 3Î²_/_, and GSK-3Î±/ Î² double-knockout (DKO) embryonic stem (ES) cells, as well as GSK-3Î²_/_ mouse embryonic fibroblast cells in which GSK-3Î± was knocked down to demonstrate that both isoforms of GSK-3, GSK-3Î± and GSK-3Î², are required for this antiviral immune response.  Moreover, the use of two selective small-mol. GSK-3 inhibitors (CHIR99021 and BIO-acetoxime) or ES cells reconstituted with the catalytically inactive versions of GSK-3 isoforms showed that GSK-3 activity is required for optimal induction of antiviral innate immunity.  Mechanistically, GSK-3 isoform activation following Sendai virus infection results in phosphorylation of Î²-catenin at S33/S37/T41, promoting IRF3 DNA binding and activation of IRF3-regulated ISGs.  This study identifies the role of a GSK-3/Î²-catenin axis in antiviral innate immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZG1M9xjxwTrVg90H21EOLACvtfcHk0lgZw_TsraIJqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWksrjM&md5=f4caf844113a1aaa7d71fddf41cf8512</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1128%2FMCB.00344-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00344-15%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DK.%2BA.%26aulast%3DD%25C3%25B4%26aufirst%3DF.%26aulast%3DMarineau%26aufirst%3DA.%26aulast%3DDoyon%26aufirst%3DP.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DJ.%2BF.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DDoble%26aufirst%3DB.%2BW.%26aulast%3DServant%26aufirst%3DM.%2BJ.%26atitle%3DFine-tuning%2520of%2520the%2520RIG-I-like%2520receptor%252Finterferon%2520regulatory%2520factor%25203-dependent%2520antiviral%2520innate%2520immune%2520response%2520by%2520the%2520glycogen%2520synthase%2520kinase%25203%252F%2520beta-catenin%2520pathway%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D35%26spage%3D3029%26epage%3D3043%26doi%3D10.1128%2FMCB.00344-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alfhili, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsughayyir, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akula, S. M.</span></span> <span> </span><span class="NLM_article-title">GSK-3-associated signaling is crucial to virus infection of cells</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>1867</i></span>,  <span class="NLM_fpage">118767</span>, <span class="refDoi">Â DOI: 10.1016/j.bbamcr.2020.118767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.bbamcr.2020.118767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32522661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1altrjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1867&publication_year=2020&pages=118767&author=M.+A.+Alfhiliauthor=J.+Alsughayyirauthor=J.+A.+McCubreyauthor=S.+M.+Akula&title=GSK-3-associated+signaling+is+crucial+to+virus+infection+of+cells&doi=10.1016%2Fj.bbamcr.2020.118767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3-associated signaling is crucial to virus infection of cells</span></div><div class="casAuthors">Alfhili, Mohammad A.; Alsughayyir, Jawaher; McCubrey, James A.; Akula, Shaw M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">1867</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">118767</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Signal transduction pathways play important roles in virus infection, replication, and assocd. pathogenesis.  Some of the best understood cell signaling networks are crucial to virus infections such the mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), protein kinase C (PKC), and the WNT/Î²-catenin pathways.  Glycogen synthase kinase-3 (GSK-3) is a lesser known signaling mol. in the field of virus research.  Interestingly, GSK-3 forms the crux of multiple cell signaling pathways.  However, recent studies indicate that GSK-3 may perform key roles in the response to viral infection, replication and pathogenesis.  The effects of activated or inactivated forms of GSK-3 on virus infection are still not yet clearly understood phenomenon.  The comprehension of the mol. mechanisms underlying the regulation of GSK-3-assocd. signaling pathways in terms of different stages of virus replication could be important not only to understand the pathogenesis of virus, but also possibly leading to new therapeutic targets.  This review will focus on recent advances in understanding the roles of GSK-3 on viral replication, pathogenesis and the immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfsGRocay5ILVg90H21EOLACvtfcHk0lgZw_TsraIJqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1altrjF&md5=5a06c524fd36161d779d1c7032d6c61a</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2020.118767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2020.118767%26sid%3Dliteratum%253Aachs%26aulast%3DAlfhili%26aufirst%3DM.%2BA.%26aulast%3DAlsughayyir%26aufirst%3DJ.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DAkula%26aufirst%3DS.%2BM.%26atitle%3DGSK-3-associated%2520signaling%2520is%2520crucial%2520to%2520virus%2520infection%2520of%2520cells%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2020%26volume%3D1867%26spage%3D118767%26doi%3D10.1016%2Fj.bbamcr.2020.118767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa-Tomikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuhara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohira, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, H.</span></span> <span> </span><span class="NLM_article-title">A novel occludin-targeting monoclonal antibody prevents hepatitis C virus infection in vitro</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">16588</span>â <span class="NLM_lpage">16598</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.24742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.18632%2Foncotarget.24742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29682171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC1MjltlOmtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=16588-16598&author=K.+Okaiauthor=N.+Ichikawa-Tomikawaauthor=A.+C.+Saitoauthor=T.+Watabeauthor=K.+Sugimotoauthor=D.+Fujitaauthor=C.+Onoauthor=T.+Fukuharaauthor=Y.+Matsuuraauthor=H.+Ohiraauthor=H.+Chiba&title=A+novel+occludin-targeting+monoclonal+antibody+prevents+hepatitis+C+virus+infection+in+vitro&doi=10.18632%2Foncotarget.24742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">A novel occludin-targeting monoclonal antibody prevents hepatitis C virus infection in vitro</span></div><div class="casAuthors">Okai Ken; Ichikawa-Tomikawa Naoki; Saito Akira C; Watabe Tetsuya; Sugimoto Kotaro; Fujita Daiki; Chiba Hideki; Okai Ken; Ohira Hiromasa; Ono Chikako; Fukuhara Takasuke; Matsuura Yoshiharu</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">16588-16598</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since hepatitis C virus (HCV) is thought to enter into host hepatocytes using the same cellular pathways regardless of the genotypes, the host factors are promising targets to prevent and treat HCV infection.  Human occludin (hOCLN) is one representative entry factor, and its second extracellular loop (EC2) contributes to the species selectivity of HCV-susceptibility.  However, the exact function of hOCLN during HCV entry remains unknown, and no hOCLN-targeting antibodies or synthetic drugs that prevent and treat HCV infection have yet been developed.  Here we generated the anti-hOCLN-EC2 monoclonal antibody (mAb) 67-2, and demonstrated that it efficiently inhibited HCV infection in the HCV-permissive human cell line Huh7.5.1.  We also showed, using three different culture systems of Huh7.5.1 cells, that this novel mAb is accessible to OCLN from the basolateral side of hepatocytes but not from the apical side.  In addition, our Western blot analyses indicated that the established 67-2 mAb reacted not only with hOCLN but also with mouse OCLN, strongly suggesting that 67-2 does not recognize the human-specific amino acids in OCLN-EC2.  Moreover, we revealed that the anti-hOCLN-EC2 mAb 67-2 showed no adverse effects on cell viability or the barrier function of tight junctions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1hytK5b3xMRwLZxei1HN8fW6udTcc2eZxkMcGVBsoLbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjltlOmtw%253D%253D&md5=76b5dec2280289deb041d8f3a17b0b40</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.24742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.24742%26sid%3Dliteratum%253Aachs%26aulast%3DOkai%26aufirst%3DK.%26aulast%3DIchikawa-Tomikawa%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DA.%2BC.%26aulast%3DWatabe%26aufirst%3DT.%26aulast%3DSugimoto%26aufirst%3DK.%26aulast%3DFujita%26aufirst%3DD.%26aulast%3DOno%26aufirst%3DC.%26aulast%3DFukuhara%26aufirst%3DT.%26aulast%3DMatsuura%26aufirst%3DY.%26aulast%3DOhira%26aufirst%3DH.%26aulast%3DChiba%26aufirst%3DH.%26atitle%3DA%2520novel%2520occludin-targeting%2520monoclonal%2520antibody%2520prevents%2520hepatitis%2520C%2520virus%2520infection%2520in%2520vitro%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D16588%26epage%3D16598%26doi%3D10.18632%2Foncotarget.24742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butt, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasrullah, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idrees, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span> <span> </span><span class="NLM_article-title">Computational identification of interplay between phosphorylation and O-beta-glycosylation of human occludin as potential mechanism to impair hepatitis C virus entry</span>. <i>Infect., Genet. Evol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1235</span>â <span class="NLM_lpage">1245</span>, <span class="refDoi">Â DOI: 10.1016/j.meegid.2012.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.meegid.2012.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22516225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38XosFWjtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1235-1245&author=A.+M.+Buttauthor=D.+Fengauthor=I.+Nasrullahauthor=S.+Tahirauthor=M.+Idreesauthor=Y.+Tongauthor=J.+Lu&title=Computational+identification+of+interplay+between+phosphorylation+and+O-beta-glycosylation+of+human+occludin+as+potential+mechanism+to+impair+hepatitis+C+virus+entry&doi=10.1016%2Fj.meegid.2012.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Computational identification of interplay between phosphorylation and O-Î²-glycosylation of human occludin as potential mechanism to impair hepatitis C virus entry</span></div><div class="casAuthors">Butt, Azeem Mehmood; Feng, Dandan; Nasrullah, Izza; Tahir, Shifa; Idrees, Muhammad; Tong, Yigang; Lu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Infection, Genetics and Evolution</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1235-1245</span>CODEN:
                <span class="NLM_cas:coden">IGENCN</span>;
        ISSN:<span class="NLM_cas:issn">1567-1348</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is one of the leading causes of liver diseases.  Several host factors that facilitate the attachment and entry of HCV have been discovered, of which human occludin seems to be the most promising.  Studies have shown that activity of occludin is dependent upon its phosphorylation status, and that during HCV infection deregulation of phosphorylated occludin collectively leads to a redn. in tight junction (TJ) integrity of hepatocytes and favors HCV entry.  However, detailed information of the posttranslational modifications (PTMs) of occludin still remains largely unknown.  In addn. to phosphorylation, serine/threonine residues of several proteins are also regulated by a unique type of modification known as O-Î²-glycosylation and this crosstalk serves as a functional switch.  To identify the O-Î²-glycosylation potential and how interplay between phosphorylation and O-Î²-glycosylation can be exploited for the inhibition of HCV entry, here we report a computational anal. of PTMs of human occludin.  Several conserved phosphorylation residues and kinases that can alter the ability of occludin to regulate the integrity of TJs were identified.  In addn. to previously reported Tyr residues, two addnl. Tyr residues (Tyr29 and Tyr287) were identified as target sites of Src kinase.  To our knowledge, this is the first study to report the O-Î²-GlcNAc potential of occludin and target sites of ERK (Ser8, Ser310, and Thr345), GSK-3 (Ser8, Ser341) and Cdk5 (Thr376).  Furthermore, based on findings from this study, a potential novel interplay between phosphorylation and O-Î²-glycosylation at the two Yin Yang sites (Ser408 and Ser490) is also proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog73x49xsVVbVg90H21EOLACvtfcHk0lib66n0EHiCoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosFWjtbw%253D&md5=dbe642ebdb0a1a96f2297e5298bf5c96</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1016%2Fj.meegid.2012.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.meegid.2012.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DButt%26aufirst%3DA.%2BM.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DNasrullah%26aufirst%3DI.%26aulast%3DTahir%26aufirst%3DS.%26aulast%3DIdrees%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DJ.%26atitle%3DComputational%2520identification%2520of%2520interplay%2520between%2520phosphorylation%2520and%2520O-beta-glycosylation%2520of%2520human%2520occludin%2520as%2520potential%2520mechanism%2520to%2520impair%2520hepatitis%2520C%2520virus%2520entry%26jtitle%3DInfect.%252C%2520Genet.%2520Evol.%26date%3D2012%26volume%3D12%26spage%3D1235%26epage%3D1245%26doi%3D10.1016%2Fj.meegid.2012.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakkola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheltsov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kainov, D. E.</span></span> <span> </span><span class="NLM_article-title">Emerging cellular targets for influenza antiviral agents</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2011.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.tips.2011.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22196854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFamu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=89-99&author=K.+H.+M%C3%BCllerauthor=L.+Kakkolaauthor=A.+S.+Nagarajauthor=A.+V.+Cheltsovauthor=M.+Anastasinaauthor=D.+E.+Kainov&title=Emerging+cellular+targets+for+influenza+antiviral+agents&doi=10.1016%2Fj.tips.2011.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging cellular targets for influenza antiviral agents</span></div><div class="casAuthors">Mueller, Konstantin H.; Kakkola, Laura; Nagaraj, Ashwini S.; Cheltsov, Anton V.; Anastasina, Maria; Kainov, Denis E.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-99</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  At the global level, influenza A virus (IAV) is considered a major health threat because it causes significant morbidity.  Different treatment and prevention options were developed; however, these are insufficient in the face of recent IAV outbreaks.  In particular, available antiviral agents have limited effectiveness owing to IAV resistance to these virus-directed drugs.  Recent advances in understanding of IAV replication have revealed a no. of cellular drug targets that counteract viral drug resistance.  This review summarizes current knowledge on IAV replication with a focus on emerging cellular drug targets.  Interestingly, for many of these targets, compds. for which safety testing was carried out in humans are available.  It is possible that some of these compds., such as inhibitors of heat shock protein 90, proteasome, importin Î±5, or protein kinase C, will be used for treatment of IAV infections after careful evaluation in human primary cells and severely ill flu patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSsGGMfMEaD7Vg90H21EOLACvtfcHk0lib66n0EHiCoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFamu7c%253D&md5=635a9ccff67b913aa8130c3d39b6a802</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2011.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2011.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%2BH.%26aulast%3DKakkola%26aufirst%3DL.%26aulast%3DNagaraj%26aufirst%3DA.%2BS.%26aulast%3DCheltsov%26aufirst%3DA.%2BV.%26aulast%3DAnastasina%26aufirst%3DM.%26aulast%3DKainov%26aufirst%3DD.%2BE.%26atitle%3DEmerging%2520cellular%2520targets%2520for%2520influenza%2520antiviral%2520agents%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D89%26epage%3D99%26doi%3D10.1016%2Fj.tips.2011.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suizu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda-Lennikov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Akt kinase activity suppresses entry and replication of influenza virus</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">891</span>â <span class="NLM_lpage">898</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2014.06.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.bbrc.2014.06.077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24971535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFansLbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2014&pages=891-898&author=N.+Hirataauthor=F.+Suizuauthor=M.+Matsuda-Lennikovauthor=T.+Edamuraauthor=J.+Balaauthor=M.+Noguchi&title=Inhibition+of+Akt+kinase+activity+suppresses+entry+and+replication+of+influenza+virus&doi=10.1016%2Fj.bbrc.2014.06.077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Akt kinase activity suppresses entry and replication of influenza virus</span></div><div class="casAuthors">Hirata, Noriyuki; Suizu, Futoshi; Matsuda-Lennikov, Mami; Edamura, Tatsuma; Bala, Jyoti; Noguchi, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">891-898</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The possibility of the pandemic spread of influenza viruses highlights the need for an effective cure for this life-threatening disease.  Influenza A virus, belonging to a family of orthomyxoviruses, is a neg.-strand RNA virus which encodes 11 viral proteins.  A nos. of intracellular signaling pathways in the host cells interact with influenza the viral proteins, which affect various stages of viral infection and replication.In this study, we investigated how inhibition of Akt kinase activity impacts on influenza virus infection by using "Akt-in", a peptide Akt inhibitor.  In PR8 influenza-infected A549 cells, Akt interacted with the NS1 (Non structural protein 1), and hence increased phosphorylation of Akt kinase activity and NS1.  Treatment of cells with either "TCL1- or TCL1b-based Akt-in" efficiently suppressed Akt kinase activity while decreasing the levels of phosphorylated NS1; this, in turn, inhibited viral replication in a dose- and time-dependent manner.  The inhibitory effect on viral replication appears to not be due to inhibition of the prodn. of inflammatory cytokines, including IL-6 and IL-8, in the host cells.  Inhibition of Akt kinase activity in the host cells inhibited the efficiency of viral entry, which is assocd. with decreased levels of phosphorylated glycogen synthase kinase 3, a substrate of Akt.  Thus inhibition of Akt kinase activity in host cells may have therapeutic advantages for influenza virus infection by inhibiting viral entry and replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKmcrgu_8vcLVg90H21EOLACvtfcHk0lg6e5UsFE0vLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFansLbJ&md5=5dbdfd52b7a9b16328ca99c488a16780</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.06.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.06.077%26sid%3Dliteratum%253Aachs%26aulast%3DHirata%26aufirst%3DN.%26aulast%3DSuizu%26aufirst%3DF.%26aulast%3DMatsuda-Lennikov%26aufirst%3DM.%26aulast%3DEdamura%26aufirst%3DT.%26aulast%3DBala%26aufirst%3DJ.%26aulast%3DNoguchi%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520Akt%2520kinase%2520activity%2520suppresses%2520entry%2520and%2520replication%2520of%2520influenza%2520virus%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D450%26spage%3D891%26epage%3D898%26doi%3D10.1016%2Fj.bbrc.2014.06.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RÃ¼schenbaum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moradpour, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouttenoire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C. M.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3Î² enhances hepatitis C virus replication by supporting miR-122</span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2949</span>, <span class="refDoi">Â DOI: 10.3389/fmicb.2018.02949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffmicb.2018.02949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30542341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3cnht1yhtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2949&author=M.+Salehauthor=S.+R%C3%BCschenbaumauthor=C.+Welschauthor=S.+Zeuzemauthor=D.+Moradpourauthor=J.+Gouttenoireauthor=C.+M.+Lange&title=Glycogen+synthase+kinase-3%CE%B2+enhances+hepatitis+C+virus+replication+by+supporting+miR-122&doi=10.3389%2Ffmicb.2018.02949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen Synthase Kinase 3Î² Enhances Hepatitis C Virus Replication by Supporting miR-122</span></div><div class="casAuthors">Saleh Maged; Ruschenbaum Sabrina; Welsch Christoph; Zeuzem Stefan; Lange Christian M; Moradpour Darius; Gouttenoire Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2949</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) infection is associated with alterations in host lipid and insulin signaling cascades, which are partially explained by a dependence of the HCV life cycle on key molecules in these metabolic pathways.  Yet, little is known on the role in the HCV life cycle of glycogen synthase kinase 3 (GSK3), one of the most important kinases in cellular metabolism.  Therefore, the impact of GSK3 on the HCV life cycle was assessed in human hepatoma cell lines harboring subgenomic genotype 1b and 2a replicons or producing cell culture-derived HCV genotype 2a by exposure to synthetic GSK3 inhibitors, GSK3 gene silencing, overexpression of GSK3 constructs and immunofluorescence analyses.  In addition, the role of GSK3 in hepatitis E virus (HEV) replication was investigated to assess virus specificity of the observed findings.  We found that both inhibition of GSK3 function by synthetic inhibitors as well as silencing of GSK3Î² gene expression resulted in a decrease of HCV replication and infectious particle production, whereas silencing of the GSK3Î± isoform had no relevant effect on the HCV life cycle.  Conversely, overexpression of GSK3Î² resulted in enhanced HCV replication.  In contrast, GSK3Î² had no effect on replication of subgenomic HEV replicon.  The pro-viral effect of GSK3Î² on HCV replication was mediated by supporting expression of microRNA-122 (miR-122), a micro-RNA which is mandatory for wild-type HCV replication, as GSK3 inhibitors suppressed miR-122 levels and as inhibitors of GSK3 had no antiviral effect on a miR-122-independent HCV mutant.  In conclusion, we have identified GSK3Î² is a novel host factor supporting HCV replication by maintaining high levels of hepatic miR-122 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT47XF4UWpgq43yKPtYViAGfW6udTcc2eYfz4YF803VU7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnht1yhtw%253D%253D&md5=457c0121fbe2a5b527b2ac3d0daf64af</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2018.02949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2018.02949%26sid%3Dliteratum%253Aachs%26aulast%3DSaleh%26aufirst%3DM.%26aulast%3DR%25C3%25BCschenbaum%26aufirst%3DS.%26aulast%3DWelsch%26aufirst%3DC.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DMoradpour%26aufirst%3DD.%26aulast%3DGouttenoire%26aufirst%3DJ.%26aulast%3DLange%26aufirst%3DC.%2BM.%26atitle%3DGlycogen%2520synthase%2520kinase-3%25CE%25B2%2520enhances%2520hepatitis%2520C%2520virus%2520replication%2520by%2520supporting%2520miR-122%26jtitle%3DFront.%2520Microbiol.%26date%3D2018%26volume%3D9%26spage%3D2949%26doi%3D10.3389%2Ffmicb.2018.02949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guendel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iordanskiy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Duyne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saifuddin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaworski, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampey, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepene, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Novel neuroprotective GSK-3Î² inhibitor restricts tat-mediated HIV-1 replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">1189</span>â <span class="NLM_lpage">1208</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01940-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01940-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24227837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOktLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=1189-1208&author=I.+Guendelauthor=S.+Iordanskiyauthor=R.+Van+Duyneauthor=K.+Kehn-Hallauthor=M.+Saifuddinauthor=R.+Dasauthor=E.+Jaworskiauthor=G.+C.+Sampeyauthor=S.+Seninaauthor=L.+Shultzauthor=A.+Narayananauthor=H.+Chenauthor=B.+Lepeneauthor=C.+Zengauthor=F.+Kashanchi&title=Novel+neuroprotective+GSK-3%CE%B2+inhibitor+restricts+tat-mediated+HIV-1+replication&doi=10.1128%2FJVI.01940-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Novel neuroprotective GSK-3Î² inhibitor restricts Tat-mediated HIV-1 replication</span></div><div class="casAuthors">Guendel, Irene; Iordanskiy, Sergey; Van Duyne, Rachel; Kehn-Hall, Kylene; Saifuddin, Mohammed; Das, Ravi; Jaworski, Elizabeth; Sampey, Gavin C.; Senina, Svetlana; Shultz, Leonard; Narayanan, Aarthi; Chen, Hao; Lepene, Benjamin; Zeng, Chen; Kashanchi, Fatah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1189-1208, 21 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The implementation of new antiretroviral therapies targeting transcription of early viral proteins in postintegrated HIV-1 can aid in overcoming current therapy limitations.  Using high-throughput screening assays, we have previously described a novel Tat-dependent HIV-1 transcriptional inhibitor named 6-bromoindirubin-3'-oxime (6BIO).  The screening of 6BIO derivs. yielded unique compds. that show potent inhibition of HIV-1 transcription.  We have identified a second-generation deriv. called 18BIOder as an inhibitor of HIV-1 Tat-dependent transcription in TZM-bl cells and a potent inhibitor of GSK-3Î² kinase in vitro.  Structurally, 18BIOder is half the mol. wt. and structure of its parental compd., 6BIO.  More importantly, we also have found a different GSK-3Î² complex present only in HIV-1-infected cells. 18BIOder preferentially inhibits this novel kinase complex from infected cells at nanomolar concns.  Finally, we obsd. that neuronal cultures treated with Tat protein are protected from Tat-mediated cytotoxicity when treated with 18BIOder.  Overall, our data suggest that HIV-1 Tat-dependent transcription is sensitive to small-mol. inhibition of GSK-3Î².</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdRWixre6PE7Vg90H21EOLACvtfcHk0lg6e5UsFE0vLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOktLg%253D&md5=5b83a53a2ef46ceea70a994ef88f7cb1</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1128%2FJVI.01940-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01940-13%26sid%3Dliteratum%253Aachs%26aulast%3DGuendel%26aufirst%3DI.%26aulast%3DIordanskiy%26aufirst%3DS.%26aulast%3DVan%2BDuyne%26aufirst%3DR.%26aulast%3DKehn-Hall%26aufirst%3DK.%26aulast%3DSaifuddin%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DR.%26aulast%3DJaworski%26aufirst%3DE.%26aulast%3DSampey%26aufirst%3DG.%2BC.%26aulast%3DSenina%26aufirst%3DS.%26aulast%3DShultz%26aufirst%3DL.%26aulast%3DNarayanan%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLepene%26aufirst%3DB.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DNovel%2520neuroprotective%2520GSK-3%25CE%25B2%2520inhibitor%2520restricts%2520tat-mediated%2520HIV-1%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2014%26volume%3D88%26spage%3D1189%26epage%3D1208%26doi%3D10.1128%2FJVI.01940-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref258"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref258'); return false;" data-citation="" class="refNumLink">258</a></strong><div class="NLM_citation" id="cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of glycogen synthase kinase-3Î² suppresses coxsackievirus-induced cytopathic effect and apoptosis via stabilization of beta-catenin</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1097</span>â <span class="NLM_lpage">1106</span>, <span class="refDoi">Â DOI: 10.1038/sj.cdd.4401652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fsj.cdd.4401652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=15905881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVymu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=1097-1106&author=J.+Yuanauthor=J.+Zhangauthor=B.+W.+Wongauthor=X.+Siauthor=J.+Wongauthor=D.+Yangauthor=H.+Luo&title=Inhibition+of+glycogen+synthase+kinase-3%CE%B2+suppresses+coxsackievirus-induced+cytopathic+effect+and+apoptosis+via+stabilization+of+beta-catenin&doi=10.1038%2Fsj.cdd.4401652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of glycogen synthase kinase 3Î² suppresses coxsackievirus-induced cytopathic effect and apoptosis via stabilization of Î²-catenin</span></div><div class="casAuthors">Yuan, J.; Zhang, J.; Wong, B. W.; Si, X.; Wong, J.; Yang, D.; Luo, H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1097-1106</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Coxsackievirus B3 (CVB3), a common human pathogen for viral myocarditis, induces a direct cytopathic effect (CPE) and apoptosis on infected cells.  To elucidate the mechanisms that contribute to these processes, we studied the role of glycogen synthase kinase 3Î² (GSK3Î²).  GSK3Î² activity was significantly increased after CVB3 infection and addn. of tyrosine kinase inhibitors blocked CVB3-triggered GSK3Î² activation.  Inhibition of caspase activity had no inhibitory effect on CVB3-induced CPE; however, blockage of GSK3Î² activation attenuated both CVB3-induced CPE and apoptosis.  We further showed that CVB3 infection resulted in reduced Î²-catenin protein expression, and GSK3Î² inhibition led to the accumulation and nuclear translocation of Î²-catenin.  Finally, we found that CVB3-induced CPE and apoptosis were significantly reduced in cells stably overexpressing Î²-catenin.  Taken together, our results demonstrate that CVB3 infection stimulates GSK3Î² activity via a tyrosine kinase-dependent mechanism, which contributes to CVB3-induced CPE and apoptosis through dysregulation of Î²-catenin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1yBNC4k41A7Vg90H21EOLACvtfcHk0limsRfezhqSUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVymu7s%253D&md5=7ca362ba0869bab75a82c52e7c335ec3</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4401652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4401652%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DB.%2BW.%26aulast%3DSi%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520glycogen%2520synthase%2520kinase-3%25CE%25B2%2520suppresses%2520coxsackievirus-induced%2520cytopathic%2520effect%2520and%2520apoptosis%2520via%2520stabilization%2520of%2520beta-catenin%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2005%26volume%3D12%26spage%3D1097%26epage%3D1106%26doi%3D10.1038%2Fsj.cdd.4401652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref259"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref259'); return false;" data-citation="" class="refNumLink">259</a></strong><div class="NLM_citation" id="cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarhan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Hakeem, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrrell, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, M.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3Î² inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2495</span>, <span class="refDoi">Â DOI: 10.1038/s41598-017-02648-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41598-017-02648-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28566716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC1cnjsV2rsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=2495&author=M.+A.+Sarhanauthor=M.+S.+Abdel-Hakeemauthor=A.+L.+Masonauthor=D.+L.+Tyrrellauthor=M.+Houghton&title=Glycogen+synthase+kinase-3%CE%B2+inhibitors+prevent+hepatitis+C+virus+release%2Fassembly+through+perturbation+of+lipid+metabolism&doi=10.1038%2Fs41598-017-02648-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit259R"><div class="casContent"><span class="casTitleNuber">259</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3Î² inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism</span></div><div class="casAuthors">Sarhan Mohammed A; Abdel-Hakeem Mohamed S; Mason Andrew L; Tyrrell D Lorne; Houghton Michael; Sarhan Mohammed A; Abdel-Hakeem Mohamed S; Tyrrell D Lorne; Houghton Michael; Sarhan Mohammed A; Sarhan Mohammed A; Mason Andrew L; Abdel-Hakeem Mohamed S</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2495</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Direct acting antivirals against hepatitis C virus (HCV) have markedly improved cure rates in the past few years.  However, they are expensive, with only few targeting host cell factors, and affecting virus assembly and release.  Huh7.5 cells infected with a JFH-1 clone of HCV were treated with two different glycogen synthase kinase (GSK3)-Î² inhibitors; AR-A014418 and lithium chloride.  Intra- and extracellular HCV virions and specific infectivity was determined using real-time RT-PCR and TCID50, and changes in lipid production were identified by enzyme-linked immunoassay and mass spectrometry analyses.  Similarly, effect on two HCV replicon cells were identified by the luciferase activity.  Although there was limited effect on virus replication in Huh7.5 cells and replicons, Huh7.5 cells treated with GSK3Î² inhibitors produced significantly less viral particles in comparison to untreated cells.  In addition, the treated cells synthesized significantly lower amounts of ApoB and trapped the ApoE lipoproteins in the cells.  In conclusion, our study suggests that GSK3Î² plays a pivotal role in HCV virion assembly and release mediated in part through inhibition of apolipoprotein synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRoHMUg6MLso-xsqfvU0ziafW6udTcc2eb0w1vseaCG4bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnjsV2rsQ%253D%253D&md5=516de994e35f8c64dd72d1132c299678</span></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-02648-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-02648-6%26sid%3Dliteratum%253Aachs%26aulast%3DSarhan%26aufirst%3DM.%2BA.%26aulast%3DAbdel-Hakeem%26aufirst%3DM.%2BS.%26aulast%3DMason%26aufirst%3DA.%2BL.%26aulast%3DTyrrell%26aufirst%3DD.%2BL.%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DGlycogen%2520synthase%2520kinase-3%25CE%25B2%2520inhibitors%2520prevent%2520hepatitis%2520C%2520virus%2520release%252Fassembly%2520through%2520perturbation%2520of%2520lipid%2520metabolism%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D2495%26doi%3D10.1038%2Fs41598-017-02648-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref260"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref260'); return false;" data-citation="" class="refNumLink">260</a></strong><div class="NLM_citation" id="cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guendel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaltsounis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Harthi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutsch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK-3Î² inhibitors</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>415</i></span>,  <span class="NLM_fpage">56</span>â <span class="NLM_lpage">68</span>, <span class="refDoi">Â DOI: 10.1016/j.virol.2011.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.virol.2011.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=21514616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsVGhsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2011&pages=56-68&author=K.+Kehn-Hallauthor=I.+Guendelauthor=L.+Carpioauthor=L.+Skaltsounisauthor=L.+Meijerauthor=L.+Al-Harthiauthor=J.+P.+Steinerauthor=A.+Nathauthor=O.+Kutschauthor=F.+Kashanchi&title=Inhibition+of+Tat-mediated+HIV-1+replication+and+neurotoxicity+by+novel+GSK-3%CE%B2+inhibitors&doi=10.1016%2Fj.virol.2011.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors</span></div><div class="casAuthors">Kehn-Hall, Kylene; Guendel, Irene; Carpio, Lawrence; Skaltsounis, Leandros; Meijer, Laurent; Al-Harthi, Lena; Steiner, Joseph P.; Nath, Avindra; Kutsch, Olaf; Kashanchi, Fatah</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">415</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-68</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The HIV-1 protein Tat is a crit. regulator of viral transcription and has also been implicated as a mediator of HIV-1 induced neurotoxicity.  Here using a high throughput screening assay, we identified the GSK-3 inhibitor 6BIO, as a Tat-dependent HIV-1 transcriptional inhibitor.  Its ability to inhibit HIV-1 transcription was confirmed in TZM-bl cells, with an IC50 of 40 nM.  Through screening 6BIO derivs., we identified 6BIOder, which has a lower IC50 of 4 nM in primary macrophages and 0.5 nM in astrocytes infected with HIV-1.  6BIOder displayed an IC50 value of 0.03 nM through in vitro GSK-3Î² kinase inhibition assays.  Finally, we demonstrated 6BIO and 6BIOder have neuroprotective effects on Tat induced cell death in rat mixed hippocampal cultures.  Therefore 6BIO and its derivs. are unique compds. which, due to their complex mechanisms of action, are able to inhibit HIV-1 transcription as well as to protect against Tat induced neurotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxBon7zHN0XbVg90H21EOLACvtfcHk0limsRfezhqSUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsVGhsrc%253D&md5=fc107bb83a413099573dde370407bbf9</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2011.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2011.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DKehn-Hall%26aufirst%3DK.%26aulast%3DGuendel%26aufirst%3DI.%26aulast%3DCarpio%26aufirst%3DL.%26aulast%3DSkaltsounis%26aufirst%3DL.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DAl-Harthi%26aufirst%3DL.%26aulast%3DSteiner%26aufirst%3DJ.%2BP.%26aulast%3DNath%26aufirst%3DA.%26aulast%3DKutsch%26aufirst%3DO.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520Tat-mediated%2520HIV-1%2520replication%2520and%2520neurotoxicity%2520by%2520novel%2520GSK-3%25CE%25B2%2520inhibitors%26jtitle%3DVirology%26date%3D2011%26volume%3D415%26spage%3D56%26epage%3D68%26doi%3D10.1016%2Fj.virol.2011.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref261"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref261'); return false;" data-citation="" class="refNumLink">261</a></strong><div class="NLM_citation" id="cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruschenbaum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moradpour, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouttenoire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C. M.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3Î² enhances hepatitis C virus replication by supporting miR-122</span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2949</span>, <span class="refDoi">Â DOI: 10.3389/fmicb.2018.02949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffmicb.2018.02949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30542341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3cnht1yhtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2949&author=M.+Salehauthor=S.+Ruschenbaumauthor=C.+Welschauthor=S.+Zeuzemauthor=D.+Moradpourauthor=J.+Gouttenoireauthor=C.+M.+Lange&title=Glycogen+synthase+kinase-3%CE%B2+enhances+hepatitis+C+virus+replication+by+supporting+miR-122&doi=10.3389%2Ffmicb.2018.02949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen Synthase Kinase 3Î² Enhances Hepatitis C Virus Replication by Supporting miR-122</span></div><div class="casAuthors">Saleh Maged; Ruschenbaum Sabrina; Welsch Christoph; Zeuzem Stefan; Lange Christian M; Moradpour Darius; Gouttenoire Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2949</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) infection is associated with alterations in host lipid and insulin signaling cascades, which are partially explained by a dependence of the HCV life cycle on key molecules in these metabolic pathways.  Yet, little is known on the role in the HCV life cycle of glycogen synthase kinase 3 (GSK3), one of the most important kinases in cellular metabolism.  Therefore, the impact of GSK3 on the HCV life cycle was assessed in human hepatoma cell lines harboring subgenomic genotype 1b and 2a replicons or producing cell culture-derived HCV genotype 2a by exposure to synthetic GSK3 inhibitors, GSK3 gene silencing, overexpression of GSK3 constructs and immunofluorescence analyses.  In addition, the role of GSK3 in hepatitis E virus (HEV) replication was investigated to assess virus specificity of the observed findings.  We found that both inhibition of GSK3 function by synthetic inhibitors as well as silencing of GSK3Î² gene expression resulted in a decrease of HCV replication and infectious particle production, whereas silencing of the GSK3Î± isoform had no relevant effect on the HCV life cycle.  Conversely, overexpression of GSK3Î² resulted in enhanced HCV replication.  In contrast, GSK3Î² had no effect on replication of subgenomic HEV replicon.  The pro-viral effect of GSK3Î² on HCV replication was mediated by supporting expression of microRNA-122 (miR-122), a micro-RNA which is mandatory for wild-type HCV replication, as GSK3 inhibitors suppressed miR-122 levels and as inhibitors of GSK3 had no antiviral effect on a miR-122-independent HCV mutant.  In conclusion, we have identified GSK3Î² is a novel host factor supporting HCV replication by maintaining high levels of hepatic miR-122 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT47XF4UWpgq43yKPtYViAGfW6udTcc2eZyZI17AyPbmbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnht1yhtw%253D%253D&md5=457c0121fbe2a5b527b2ac3d0daf64af</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2018.02949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2018.02949%26sid%3Dliteratum%253Aachs%26aulast%3DSaleh%26aufirst%3DM.%26aulast%3DRuschenbaum%26aufirst%3DS.%26aulast%3DWelsch%26aufirst%3DC.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DMoradpour%26aufirst%3DD.%26aulast%3DGouttenoire%26aufirst%3DJ.%26aulast%3DLange%26aufirst%3DC.%2BM.%26atitle%3DGlycogen%2520synthase%2520kinase-3%25CE%25B2%2520enhances%2520hepatitis%2520C%2520virus%2520replication%2520by%2520supporting%2520miR-122%26jtitle%3DFront.%2520Microbiol.%26date%3D2018%26volume%3D9%26spage%3D2949%26doi%3D10.3389%2Ffmicb.2018.02949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref262"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref262'); return false;" data-citation="" class="refNumLink">262</a></strong><div class="NLM_citation" id="cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earnest-Silveira, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeberlein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zentgraf, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowans, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torresi, J.</span></span> <span> </span><span class="NLM_article-title">Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: Factors contributing to hepatocarcinogenesis</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">325</span>â <span class="NLM_lpage">337</span>, <span class="refDoi">Â DOI: 10.1016/j.jhep.2007.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jhep.2007.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17512084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosF2kurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=325-337&author=R.+Chinauthor=L.+Earnest-Silveiraauthor=B.+Koeberleinauthor=S.+Franzauthor=H.+Zentgrafauthor=X.+Dongauthor=E.+Gowansauthor=C.-T.+Bockauthor=J.+Torresi&title=Modulation+of+MAPK+pathways+and+cell+cycle+by+replicating+hepatitis+B+virus%3A+Factors+contributing+to+hepatocarcinogenesis&doi=10.1016%2Fj.jhep.2007.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: Factors contributing to hepatocarcinogenesis</span></div><div class="casAuthors">Chin, Ruth; Earnest-Silveira, Linda; Koeberlein, Bernd; Franz, Susanne; Zentgraf, Hanswalter; Dong, Xuebin; Gowans, Eric; Bock, C.-Thomas; Torresi, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-337</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background/Aims: Chronic infection with the hepatitis B virus (HBV) is strongly assocd. with the development of hepatocellular carcinoma but the mechanism by which this occurs is unknown.  Numerous studies have focused on the HBV X protein showing that it activates signal transduction pathways while few have investigated these changes in HBV-replicating hepatocytes.  Methods: We utilized the recombinant adenovirus system to deliver a replication competent HBV genome into Huh7 and primary marmoset hepatocytes (PMH) to examine the effects of active viral replication on the regulation of Ras-ERK signal transduction and related pathways.  Results: Huh7 cells and PMHs replicating HBV demonstrated significant upregulation in phosphorylated ERK, Akt, c-myc together with increased p53, cyclin B1 and p21cip1 expression and cell cycle progression to G2 phase in the absence of increased cell proliferation.  Phosphorylation of the key cell survival kinase, Akt, was significantly increased, resulting in increased serine phosphorylation of the downstream target, GSK3-Î².  Conclusions: These results demonstrated simultaneous activation of the MAP Kinase and Akt pathways in HBV-replicating hepatocytes that resulted in dysregulation in the control of cell cycle progression and which help explain the early pathogenic mechanisms that underlie malignant transformation assocd. with chronic hepatitis B infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJRS5Dy5pj5bVg90H21EOLACvtfcHk0lj2buIjcneOtA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosF2kurs%253D&md5=0c440d213daf103e592814b15401561a</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2007.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2007.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DR.%26aulast%3DEarnest-Silveira%26aufirst%3DL.%26aulast%3DKoeberlein%26aufirst%3DB.%26aulast%3DFranz%26aufirst%3DS.%26aulast%3DZentgraf%26aufirst%3DH.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DGowans%26aufirst%3DE.%26aulast%3DBock%26aufirst%3DC.-T.%26aulast%3DTorresi%26aufirst%3DJ.%26atitle%3DModulation%2520of%2520MAPK%2520pathways%2520and%2520cell%2520cycle%2520by%2520replicating%2520hepatitis%2520B%2520virus%253A%2520Factors%2520contributing%2520to%2520hepatocarcinogenesis%26jtitle%3DJ.%2520Hepatol.%26date%3D2007%26volume%3D47%26spage%3D325%26epage%3D337%26doi%3D10.1016%2Fj.jhep.2007.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref263"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref263'); return false;" data-citation="" class="refNumLink">263</a></strong><div class="NLM_citation" id="cit263"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piracha, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chwae, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span> <span> </span><span class="NLM_article-title">Sirtuin 2 isoform 1 enhances hepatitis B virus RNA transcription and DNA synthesis through the AKT/GSK-3beta/beta-catenin signaling pathway</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>92</i></span>, <span class="NLM_elocation-id">e00955-18</span> <span class="refDoi">Â DOI: 10.1128/JVI.00955-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.00955-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30111572" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2018&author=Z.+Z.+Pirachaauthor=H.+Kwonauthor=U.+Saeedauthor=J.+Kimauthor=J.+Jungauthor=Y.+J.+Chwaeauthor=S.+Parkauthor=H.+J.+Shinauthor=K.+Kim&title=Sirtuin+2+isoform+1+enhances+hepatitis+B+virus+RNA+transcription+and+DNA+synthesis+through+the+AKT%2FGSK-3beta%2Fbeta-catenin+signaling+pathway&doi=10.1128%2FJVI.00955-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1128%2FJVI.00955-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00955-18%26sid%3Dliteratum%253Aachs%26aulast%3DPiracha%26aufirst%3DZ.%2BZ.%26aulast%3DKwon%26aufirst%3DH.%26aulast%3DSaeed%26aufirst%3DU.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DChwae%26aufirst%3DY.%2BJ.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DK.%26atitle%3DSirtuin%25202%2520isoform%25201%2520enhances%2520hepatitis%2520B%2520virus%2520RNA%2520transcription%2520and%2520DNA%2520synthesis%2520through%2520the%2520AKT%252FGSK-3beta%252Fbeta-catenin%2520signaling%2520pathway%26jtitle%3DJ.%2520Virol.%26date%3D2018%26volume%3D92%26doi%3D10.1128%2FJVI.00955-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref264"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref264'); return false;" data-citation="" class="refNumLink">264</a></strong><div class="NLM_citation" id="cit264"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tatman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rixon, F. J.</span></span> <span> </span><span class="NLM_article-title">Assembly of herpes simplex virus type 1 capsids using a panel of recombinant baculoviruses</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">Pt 5</span>),  <span class="NLM_fpage">1101</span>â <span class="NLM_lpage">1113</span>, <span class="refDoi">Â DOI: 10.1099/0022-1317-75-5-1101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1099%2F0022-1317-75-5-1101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=8176371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK2cXivFertLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1994&pages=1101-1113&issue=Pt+5&author=J.+D.+Tatmanauthor=V.+G.+Prestonauthor=P.+Nicholsonauthor=R.+M.+Elliottauthor=F.+J.+Rixon&title=Assembly+of+herpes+simplex+virus+type+1+capsids+using+a+panel+of+recombinant+baculoviruses&doi=10.1099%2F0022-1317-75-5-1101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit264R"><div class="casContent"><span class="casTitleNuber">264</span><div class="casTitle"><span class="NLM_cas:atitle">Assembly of herpes simplex virus type 1 capsids using a panel of recombinant baculoviruses</span></div><div class="casAuthors">Tatman, J. D.; Preston, V. G.; Nicholson, P.; Elliott, R. M.; Rixon, F. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1101-13</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    </div><div class="casAbstract">Immature or B capsids of herpes simplex virus type 1 (HSV-1) are composed of 7 proteins encoded by 6 viral genes.  The proteins encoded by UL18 (VP23), UL19 (VP5), UL35 (VP26), and UL38 (VP19C) are components of the outer capsid shell, whereas those specified by UL26 (VP21 and VP24) and UL26.5 (VP22a) are involved in scaffold formation.  A panel of recombinant baculoviruses, each expressing 1 of the capsid protein genes, was used to examine the requirements for capsid assembly.  Coexpression of the 6 genes in insect cells resulted in the formation of capsids that were indistinguishable in appearance and protein compn. from those made during HSV-1 infection of mammalian cells.  This demonstrates that the proteins encoded by the known capsid genes contain all the structural information necessary for capsid assembly and that other virus-encoded proteins are not required for this process.  Omission of single recombinant baculoviruses from this system allowed the role of individual HSV-1 proteins in capsid assembly to be detd.  Thus, capsid assembly did not take place in the absence of VP23, VP5, or VP19C, whereas lack of VP26 had no discernible effect on capsid formation.  Capsids assembled in the absence of the UL26 gene products had a large-cored phenotype resembling that previously described for the HSV-1 mutant ts1201, which has a lesion in this gene.  Some apparently intact capsid shells were also made in the absence of the major scaffolding protein, VP22a, whereas the omission of both UL26 and UL26.5 resulted in the appearance of large nos. of partial and deformed capsid shells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXsxuK92wk6LVg90H21EOLACvtfcHk0lj2buIjcneOtA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXivFertLY%253D&md5=b2f3e43d015a6ab6c3c82eb6bab3752b</span></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.1099%2F0022-1317-75-5-1101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252F0022-1317-75-5-1101%26sid%3Dliteratum%253Aachs%26aulast%3DTatman%26aufirst%3DJ.%2BD.%26aulast%3DPreston%26aufirst%3DV.%2BG.%26aulast%3DNicholson%26aufirst%3DP.%26aulast%3DElliott%26aufirst%3DR.%2BM.%26aulast%3DRixon%26aufirst%3DF.%2BJ.%26atitle%3DAssembly%2520of%2520herpes%2520simplex%2520virus%2520type%25201%2520capsids%2520using%2520a%2520panel%2520of%2520recombinant%2520baculoviruses%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D1994%26volume%3D75%26issue%3DPt%25205%26spage%3D1101%26epage%3D1113%26doi%3D10.1099%2F0022-1317-75-5-1101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref265"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref265'); return false;" data-citation="" class="refNumLink">265</a></strong><div class="NLM_citation" id="cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casaday, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalb, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brignole, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loveland, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotter, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, W.</span></span> <span> </span><span class="NLM_article-title">Assembly protein precursor (pUL80.5 homolog) of simian cytomegalovirus is phosphorylated at a glycogen synthase kinase 3 site and its downstream âprimingâ site: Phosphorylation affects interactions of protein with itself and with major capsid protein</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">13501</span>â <span class="NLM_lpage">13511</span>, <span class="refDoi">Â DOI: 10.1128/JVI.78.24.13501-13511.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.78.24.13501-13511.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=15564461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFSis7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=13501-13511&author=R.+J.+Casadayauthor=J.+R.+Baileyauthor=S.+R.+Kalbauthor=E.+J.+Brignoleauthor=A.+N.+Lovelandauthor=R.+J.+Cotterauthor=W.+Gibson&title=Assembly+protein+precursor+%28pUL80.5+homolog%29+of+simian+cytomegalovirus+is+phosphorylated+at+a+glycogen+synthase+kinase+3+site+and+its+downstream+%E2%80%9Cpriming%E2%80%9D+site%3A+Phosphorylation+affects+interactions+of+protein+with+itself+and+with+major+capsid+protein&doi=10.1128%2FJVI.78.24.13501-13511.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">Assembly protein precursor (pUL80.5 homolog) of simian cytomegalovirus is phosphorylated at a glycogen synthase kinase 3 site and its downstream "priming" site: Phosphorylation affects interactions of protein with itself and with major capsid protein</span></div><div class="casAuthors">Casaday, Rebecca J.; Bailey, Justin R.; Kalb, Suzanne R.; Brignole, Edward J.; Loveland, Amy N.; Cotter, Robert J.; Gibson, Wade</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">13501-13511</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Capsid assembly among the herpes-group viruses is coordinated by two related scaffolding proteins.  In cytomegalovirus (CMV), the main scaffolding constituent is called the assembly protein precursor (pAP).  Like its homologs in other herpesviruses, pAP is modified by proteolytic cleavage and phosphorylation.  Cleavage is essential for capsid maturation and prodn. of infectious virus, but the role of phosphorylation is undetd.  As a first step in evaluating the significance of this modification, we have identified the specific sites of phosphorylation in the simian CMV pAP.  Two were established previously to be adjacent serines (Ser156 and Ser157) in a casein kinase II consensus sequence.  The remaining two, identified here as Thr231 and Ser235, are within consensus sequences for glycogen synthase kinase 3 (GSK-3) and mitogen-activated protein kinase, resp.  Consistent with Thr231 being a GSK-3 substrate, its phosphorylation required a downstream "priming" phosphate (i.e., Ser235) and was reduced by a GSK-3-specific inhibitor.  Phosphorylation of Ser235 converts pAP to an electrophoretically slower-mobility isoform, pAP*; subsequent phosphorylation of pAP* at Thr231 converts pAP* to a still-slower isoform, pAP**.  The mobility shift to pAP* was mimicked by substituting an acidic amino acid for either Thr231 or Ser235, but the shift to pAP** required that both positions be phosphorylated.  Glu did not substitute for pSer235 in promoting phosphorylation of Thr231.  We suggest that phosphorylation of Thr231 and Ser235 causes charge-driven conformational changes in pAP, and we demonstrate that preventing these modifications alters interactions of pAP with itself and with major capsid protein, suggesting a functional significance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFZMp5bVHghrVg90H21EOLACvtfcHk0ljAn18kM2n6Ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFSis7bE&md5=69192cb01126b92e33d1efee97928dd1</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.24.13501-13511.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.24.13501-13511.2004%26sid%3Dliteratum%253Aachs%26aulast%3DCasaday%26aufirst%3DR.%2BJ.%26aulast%3DBailey%26aufirst%3DJ.%2BR.%26aulast%3DKalb%26aufirst%3DS.%2BR.%26aulast%3DBrignole%26aufirst%3DE.%2BJ.%26aulast%3DLoveland%26aufirst%3DA.%2BN.%26aulast%3DCotter%26aufirst%3DR.%2BJ.%26aulast%3DGibson%26aufirst%3DW.%26atitle%3DAssembly%2520protein%2520precursor%2520%2528pUL80.5%2520homolog%2529%2520of%2520simian%2520cytomegalovirus%2520is%2520phosphorylated%2520at%2520a%2520glycogen%2520synthase%2520kinase%25203%2520site%2520and%2520its%2520downstream%2520%25E2%2580%259Cpriming%25E2%2580%259D%2520site%253A%2520Phosphorylation%2520affects%2520interactions%2520of%2520protein%2520with%2520itself%2520and%2520with%2520major%2520capsid%2520protein%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D13501%26epage%3D13511%26doi%3D10.1128%2FJVI.78.24.13501-13511.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref266"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref266'); return false;" data-citation="" class="refNumLink">266</a></strong><div class="NLM_citation" id="cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsay, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. J.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 regulates the phosphorylation of severe acute respiratory syndrome coronavirus nucleocapsid protein and viral replication</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">5229</span>â <span class="NLM_lpage">5239</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M805747200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.M805747200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=19106108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVSnt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=5229-5239&author=C.+H.+Wuauthor=S.+H.+Yehauthor=Y.+G.+Tsayauthor=Y.+H.+Shiehauthor=C.+L.+Kaoauthor=Y.+S.+Chenauthor=S.+H.+Wangauthor=T.+J.+Kuoauthor=D.+S.+Chenauthor=P.+J.+Chen&title=Glycogen+synthase+kinase-3+regulates+the+phosphorylation+of+severe+acute+respiratory+syndrome+coronavirus+nucleocapsid+protein+and+viral+replication&doi=10.1074%2Fjbc.M805747200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen Synthase Kinase-3 Regulates the Phosphorylation of Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein and Viral Replication</span></div><div class="casAuthors">Wu, Chia-Hsin; Yeh, Shiou-Hwei; Tsay, Yeou-Guang; Shieh, Ya-Hsiung; Kao, Chuan-Liang; Chen, Yen-Shun; Wang, Sheng-Han; Kuo, Ti-Jung; Chen, Ding-Shinn; Chen, Pei-Jer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5229-5239</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Coronavirus (CoV) nucleocapsid (N) protein is a highly phosphorylated protein required for viral replication, but whether its phosphorylation and the related kinases are involved in the viral life cycle is unknown.  We found the severe acute respiratory syndrome CoV N protein to be an appropriate system to address this issue.  Using high resoln. PAGE anal., this protein could be sepd. into phosphorylated and unphosphorylated isoforms.  Mass spectrometric anal. and deletion mapping showed that the major phosphorylation sites were located at the central serine-arginine (SR)-rich motif that contains several glycogen synthase kinase (GSK)-3 substrate consensus sequences.  GSK-3-specific inhibitor treatment dephosphorylated the N protein, and this could be recovered by the constitutively active GSK-3 kinase.  Immunopptn. brought down both N and GSK-3 proteins in the same complex, and the N protein could be phosphorylated directly at its SR-rich motif by GSK-3 using an in vitro kinase assay.  Mutation of the two priming sites crit. for GSK-3 phosphorylation in the SR-rich motif abolished N protein phosphorylation.  Finally, GSK-3 inhibitor was found to reduce N phosphorylation in the severe acute respiratory syndrome CoV-infected VeroE6 cells and decrease the viral titer and cytopathic effects.  The effect of GSK-3 inhibitor was reproduced in another coronavirus, the neurotropic JHM strain of mouse hepatitis virus.  Our results indicate that GSK-3 is crit. for CoV N protein phosphorylation and suggest that it plays a role in regulating the viral life cycle.  This study, thus, provides new avenues to further investigate the specific role of N protein phosphorylation in CoV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtElQtVm_P7bVg90H21EOLACvtfcHk0ljAn18kM2n6Ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVSnt7s%253D&md5=b4997e0d5f5ed44449d30a9b49d8a63b</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M805747200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M805747200%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DYeh%26aufirst%3DS.%2BH.%26aulast%3DTsay%26aufirst%3DY.%2BG.%26aulast%3DShieh%26aufirst%3DY.%2BH.%26aulast%3DKao%26aufirst%3DC.%2BL.%26aulast%3DChen%26aufirst%3DY.%2BS.%26aulast%3DWang%26aufirst%3DS.%2BH.%26aulast%3DKuo%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DD.%2BS.%26aulast%3DChen%26aufirst%3DP.%2BJ.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520regulates%2520the%2520phosphorylation%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%2520nucleocapsid%2520protein%2520and%2520viral%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D5229%26epage%3D5239%26doi%3D10.1074%2Fjbc.M805747200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref267"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref267'); return false;" data-citation="" class="refNumLink">267</a></strong><div class="NLM_citation" id="cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. H.</span></span> <span> </span><span class="NLM_article-title">Nucleocapsid phosphorylation and RNA helicase DDX1 recruitment enables coronavirus transition from discontinuous to continuous transcription</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">462</span>â <span class="NLM_lpage">472</span>, <span class="refDoi">Â DOI: 10.1016/j.chom.2014.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.chom.2014.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25299332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1GmsL%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=462-472&author=C.+H.+Wuauthor=P.+J.+Chenauthor=S.+H.+Yeh&title=Nucleocapsid+phosphorylation+and+RNA+helicase+DDX1+recruitment+enables+coronavirus+transition+from+discontinuous+to+continuous+transcription&doi=10.1016%2Fj.chom.2014.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit267R"><div class="casContent"><span class="casTitleNuber">267</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleocapsid phosphorylation and RNA helicase DDX1 recruitment enables Coronavirus transition from discontinuous to continuous transcription</span></div><div class="casAuthors">Wu, Chia-Hsin; Chen, Pei-Jer; Yeh, Shiou-Hwei</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">462-472</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Coronaviruses contain a pos.-sense single-stranded genomic (g) RNA, which encodes nonstructural proteins.  Several subgenomic mRNAs (sgmRNAs) encoding structural proteins are generated by template switching from the body transcription regulatory sequence (TRS) to the leader TRS.  The process preferentially generates shorter sgmRNA.  Appropriate readthrough of body TRSs is required to produce longer sgmRNAs and full-length gRNA.  We find that phosphorylation of the viral nucleocapsid (N) by host glycogen synthase kinase-3 (GSK-3) is required for template switching.  GSK-3 inhibition selectively reduces the generation of gRNA and longer sgmRNAs, but not shorter sgmRNAs.  N phosphorylation allows recruitment of the RNA helicase DDX1 to the phosphorylated-N-contg. complex, which facilitates template readthrough and enables longer sgmRNA synthesis.  DDX1 knockdown or loss of helicase activity markedly reduces the levels of longer sgmRNAs.  Thus, coronaviruses employ a unique strategy for the transition from discontinuous to continuous transcription to ensure balanced sgmRNAs and full-length gRNA synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvxHHI6TWiRLVg90H21EOLACvtfcHk0lheCeedwHfqZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1GmsL%252FN&md5=deab53b4fde6755e8a8e107861107cf9</span></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2014.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2014.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DP.%2BJ.%26aulast%3DYeh%26aufirst%3DS.%2BH.%26atitle%3DNucleocapsid%2520phosphorylation%2520and%2520RNA%2520helicase%2520DDX1%2520recruitment%2520enables%2520coronavirus%2520transition%2520from%2520discontinuous%2520to%2520continuous%2520transcription%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2014%26volume%3D16%26spage%3D462%26epage%3D472%26doi%3D10.1016%2Fj.chom.2014.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref268"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref268'); return false;" data-citation="" class="refNumLink">268</a></strong><div class="NLM_citation" id="cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inanami, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurane, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cell proliferation by SARS-CoV infection in Vero E6 cells</span>. <i>FEMS Immunol. Med. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">236</span>â <span class="NLM_lpage">243</span>, <span class="refDoi">Â DOI: 10.1111/j.1574-695X.2005.00028.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1111%2Fj.1574-695X.2005.00028.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16487305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFaltrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=236-243&author=T.+Mizutaniauthor=S.+Fukushiauthor=D.+Iizukaauthor=O.+Inanamiauthor=M.+Kuwabaraauthor=H.+Takashimaauthor=H.+Yanagawaauthor=M.+Saijoauthor=I.+Kuraneauthor=S.+Morikawa&title=Inhibition+of+cell+proliferation+by+SARS-CoV+infection+in+Vero+E6+cells&doi=10.1111%2Fj.1574-695X.2005.00028.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit268R"><div class="casContent"><span class="casTitleNuber">268</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cell proliferation by SARS-CoV infection in Vero E6 cells</span></div><div class="casAuthors">Mizutani, Tetsuya; Fukushi, Shuetsu; Iizuka, Daisuke; Inanami, Osamu; Kuwabara, Mikinori; Takashima, Hideaki; Yanagawa, Hiroshi; Saijo, Masayuki; Kurane, Ichiro; Morikawa, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">FEMS Immunology and Medical Microbiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">FIMIEV</span>;
        ISSN:<span class="NLM_cas:issn">0928-8244</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome (SARS) is caused by SARS-coronavirus (SARS-CoV).  Infection of Vero E6 cells with SARS-CoV inhibits cell proliferation.  Our previous study indicated that Akt, which is poorly phosphorylated in confluent cultures of Vero E6 cells, is phosphorylated and then dephosphorylated upon infection by SARS-CoV.  In the present study, we showed that a serine residue of Akt was phosphorylated in Vero E6 cells in subconfluent culture and that Akt was dephosphorylated rapidly after SARS-CoV infection without up-regulation of its phosphorylation.  Phosphorylation of glycogen synthase kinase-3Î², which is one of the downstream targets of Akt, was prevented in SARS-CoV-infected cells.  However, treatment with glycogen synthase kinase-3Î² small interfering RNA indicated that the glycogen synthase kinase-3Î² signaling pathway was not related to inhibition of cell proliferation.  Treatment of Vero E6 cells with the phosphatidylinositol 3'-kinase/Akt inhibitor, LY294002, which induces dephosphorylation of Akt, inhibited cell proliferation.  As shown in our previous studies, apoptosis occurred in virus-infected cells within 18 h postinfection.  Cellular mRNA transcription, which was reported to be up-regulated in SARS-CoV-infected Caco-2 cells, was not up-regulated in virus-infected Vero E6 cells, partially as a result of apoptosis.  These results suggested that inhibition of cell proliferation is regulated by both the phosphatidylinositol 3'-kinase/Akt signaling pathway and by apoptosis in SARS-CoV-infected Vero E6 cells.  This is the first study to analyze SARS-CoV-induced cell growth inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfktEkRYIA5bVg90H21EOLACvtfcHk0lheCeedwHfqZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFaltrk%253D&md5=76c0a218bb86013a3500493c395cdf10</span></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=10.1111%2Fj.1574-695X.2005.00028.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1574-695X.2005.00028.x%26sid%3Dliteratum%253Aachs%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DFukushi%26aufirst%3DS.%26aulast%3DIizuka%26aufirst%3DD.%26aulast%3DInanami%26aufirst%3DO.%26aulast%3DKuwabara%26aufirst%3DM.%26aulast%3DTakashima%26aufirst%3DH.%26aulast%3DYanagawa%26aufirst%3DH.%26aulast%3DSaijo%26aufirst%3DM.%26aulast%3DKurane%26aufirst%3DI.%26aulast%3DMorikawa%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520cell%2520proliferation%2520by%2520SARS-CoV%2520infection%2520in%2520Vero%2520E6%2520cells%26jtitle%3DFEMS%2520Immunol.%2520Med.%2520Microbiol.%26date%3D2006%26volume%3D46%26spage%3D236%26epage%3D243%26doi%3D10.1111%2Fj.1574-695X.2005.00028.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref269"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref269'); return false;" data-citation="" class="refNumLink">269</a></strong><div class="NLM_citation" id="cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guddat, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span> <span> </span><span class="NLM_article-title">Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>582</i></span>,  <span class="NLM_fpage">289</span>â <span class="NLM_lpage">293</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2223-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41586-020-2223-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32272481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVyhsrrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=582&publication_year=2020&pages=289-293&author=Z.+Jinauthor=X.+Duauthor=Y.+Xuauthor=Y.+Dengauthor=M.+Liuauthor=Y.+Zhaoauthor=B.+Zhangauthor=X.+Liauthor=L.+Zhangauthor=C.+Pengauthor=Y.+Duanauthor=J.+Yuauthor=L.+Wangauthor=K.+Yangauthor=F.+Liuauthor=R.+Jiangauthor=X.+Yangauthor=T.+Youauthor=X.+Liuauthor=X.+Yangauthor=F.+Baiauthor=H.+Liuauthor=X.+Liuauthor=L.+W.+Guddatauthor=W.+Xuauthor=G.+Xiaoauthor=C.+Qinauthor=Z.+Shiauthor=H.+Jiangauthor=Z.+Raoauthor=H.+Yang&title=Structure+of+M%28pro%29+from+SARS-CoV-2+and+discovery+of+its+inhibitors&doi=10.1038%2Fs41586-020-2223-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors</span></div><div class="casAuthors">Jin, Zhenming; Du, Xiaoyu; Xu, Yechun; Deng, Yongqiang; Liu, Meiqin; Zhao, Yao; Zhang, Bing; Li, Xiaofeng; Zhang, Leike; Peng, Chao; Duan, Yinkai; Yu, Jing; Wang, Lin; Yang, Kailin; Liu, Fengjiang; Jiang, Rendi; Yang, Xinglou; You, Tian; Liu, Xiaoce; Yang, Xiuna; Bai, Fang; Liu, Hong; Liu, Xiang; Guddat, Luke W.; Xu, Wenqing; Xiao, Gengfu; Qin, Chengfeng; Shi, Zhengli; Jiang, Hualiang; Rao, Zihe; Yang, Haitao</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">582</span>
        (<span class="NLM_cas:issue">7811</span>),
    <span class="NLM_cas:pages">289-293</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the etiol. agent responsible for the 2019-2020 viral pneumonia outbreak of coronavirus disease 2019 (COVID-19).  Currently, there are no targeted therapeutic agents for the treatment of this disease, and effective treatment options remain very limited.  Here, we describe the results of a program that aimed to rapidly discover lead compds. for clin. use, by combining structure-assisted drug design, virtual drug screening and high-throughput screening.  This program focused on identifying drug leads that target main protease (Mpro) of SARS-CoV-2: Mpro is a key enzyme of coronaviruses and has a pivotal role in mediating viral replication and transcription, making it an attractive drug target for SARS-CoV-2.  We identified a mechanism-based inhibitor (N3) by computer-aided drug design, and then detd. the crystal structure of Mpro of SARS-CoV-2 in complex with this compd.  Through a combination of structure-based virtual and high-throughput screening, we assayed more than 10,000 compds.-including approved drugs, drug candidates in clin. trials and other pharmacol. active compds.-as inhibitors of Mpro.  Six of these compds. inhibited Mpro, showing half-maximal inhibitory concn. values that ranged from 0.67 to 21.4Î¼M.  One of these compds. (ebselen) also exhibited promising antiviral activity in cell-based assays.  Our results demonstrate the efficacy of our screening strategy, which can lead to the rapid discovery of drug leads with clin. potential in response to new infectious diseases for which no specific drugs or vaccines are available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFupuh6WIyW7Vg90H21EOLACvtfcHk0lhYQ5VTshlsIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVyhsrrO&md5=b84f350fe9ce1109485df6caf814ba82</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2223-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2223-y%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYou%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DGuddat%26aufirst%3DL.%2BW.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DG.%26aulast%3DQin%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DRao%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DH.%26atitle%3DStructure%2520of%2520M%2528pro%2529%2520from%2520SARS-CoV-2%2520and%2520discovery%2520of%2520its%2520inhibitors%26jtitle%3DNature%26date%3D2020%26volume%3D582%26spage%3D289%26epage%3D293%26doi%3D10.1038%2Fs41586-020-2223-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref270"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref270'); return false;" data-citation="" class="refNumLink">270</a></strong><div class="NLM_citation" id="cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavora, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safran, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Deiry, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carneiro, B. A.</span></span> <span> </span><span class="NLM_article-title">Commentary: GSK-3 Inhibition as a therapeutic approach against SARs CoV-2: Dual benefit of inhibiting viral replication while potentiating the immune response</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">595289</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2020.595289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffimmu.2020.595289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33193448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3MXitVCitL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=595289&author=A.+De+Souzaauthor=F.+A.+Tavoraauthor=D.+Mahalingamauthor=P.+N.+Munsterauthor=H.+P.+Safranauthor=W.+S.+El-Deiryauthor=B.+A.+Carneiro&title=Commentary%3A+GSK-3+Inhibition+as+a+therapeutic+approach+against+SARs+CoV-2%3A+Dual+benefit+of+inhibiting+viral+replication+while+potentiating+the+immune+response&doi=10.3389%2Ffimmu.2020.595289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit270R"><div class="casContent"><span class="casTitleNuber">270</span><div class="casTitle"><span class="NLM_cas:atitle">Commentary: GSK-3 inhibition as a therapeutic approach against SARs CoV2: dual benefit of inhibiting viral replication while potentiating the immune response</span></div><div class="casAuthors">De Souza, Andre; Tavora, Fabio A.; Mahalingam, Devalingam; Munster, Pamela N.; Safran, Howard P.; El-Deiry, Wafik S.; Carneiro, Benedito A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">595289</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  We read with interest the insightful manuscript by Christopher E. Rudd highlighting the potential of Glycogen Synthase Kinase-3 (GSK-3) inhibitors for the treatment of SARS-CoV2 (1).  The manuscript describes the GSK-3-mediated phosphorylation of key serine residues in SARS-CoV2 nucleocapsid proteins essential for viral replication.  These r esults coupled with preclin. evidence demonstrating the role of GSK-3 in the modulation of innate an d adaptive immune responses support the authors hypothesis that GSK-3 inhibitors could be investigated as a potential treatment for COVID-19 infection.  SK-3 small-mol. inhibitors and GSK-3 siRNA reduced PD-1expression, increased CD8+T cell function, and enhanced viral clearance in models of herpes (MHV-68) and lymphocytic choriomeningitis (LCMV-C13) viral infections .  The increased T cell function induced by GSK-3 inhibition resulted in antitumor activity comparable with the effects obsd. with anti-PD-1 monoclonal antibodies in animal models of metastatic melanoma and lymphoma.  The therapeutic relevance of GSK-3 inhibition is also suggested by studies utilizing animal models of hemorrhagic shock showing that GSK-3 Î² inhibition dampens liver and renal dysfunction by upregulation of anti-inflammatory IL-10 and down-regulation of IL-12p40 and IL-6, a cytokine implicated in the cytokine release syndrome obsd. in patients with severe SARS-CoV2 (4).  GSK-3 Î² inhibition also attenuates the systemic inflammatory response (SIR) in models of sepsis and ischemia/reperfusion injury by modulating NF-kB-induced inflammatory response (5-8).  In this review we discuss on findings which have potential implication to SIR and the frequent disseminated intravascular vascular coagulopathy obsd. during the infection with SARS-CoV2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjy3Sj1mtM8LVg90H21EOLACvtfcHk0lhYQ5VTshlsIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXitVCitL0%253D&md5=1983335c9a08a880f555c1f205156d52</span></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.595289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.595289%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSouza%26aufirst%3DA.%26aulast%3DTavora%26aufirst%3DF.%2BA.%26aulast%3DMahalingam%26aufirst%3DD.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DSafran%26aufirst%3DH.%2BP.%26aulast%3DEl-Deiry%26aufirst%3DW.%2BS.%26aulast%3DCarneiro%26aufirst%3DB.%2BA.%26atitle%3DCommentary%253A%2520GSK-3%2520Inhibition%2520as%2520a%2520therapeutic%2520approach%2520against%2520SARs%2520CoV-2%253A%2520Dual%2520benefit%2520of%2520inhibiting%2520viral%2520replication%2520while%2520potentiating%2520the%2520immune%2520response%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26volume%3D11%26spage%3D595289%26doi%3D10.3389%2Ffimmu.2020.595289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref271"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref271'); return false;" data-citation="" class="refNumLink">271</a></strong><div class="NLM_citation" id="cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">13190</span>â <span class="NLM_lpage">13195</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1835675100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1073%2Fpnas.1835675100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=14585926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFOju7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=13190-13195&author=H.+Yangauthor=M.+Yangauthor=Y.+Dingauthor=Y.+Liuauthor=Z.+Louauthor=Z.+Zhouauthor=L.+Sunauthor=L.+Moauthor=S.+Yeauthor=H.+Pangauthor=G.+F.+Gaoauthor=K.+Anandauthor=M.+Bartlamauthor=R.+Hilgenfeldauthor=Z.+Rao&title=The+crystal+structures+of+severe+acute+respiratory+syndrome+virus+main+protease+and+its+complex+with+an+inhibitor&doi=10.1073%2Fpnas.1835675100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor</span></div><div class="casAuthors">Yang, Haitao; Yang, Maojun; Ding, Yi; Liu, Yiwei; Lou, Zhiyong; Zhou, Zhe; Sun, Lei; Mo, Lijuan; Ye, Sheng; Pang, Hai; Gao, George F.; Anand, Kanchan; Bartlam, Mark; Hilgenfeld, Rolf; Rao, Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">13190-13195</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A newly identified severe acute respiratory syndrome coronavirus (SARS-CoV), is the etiol. agent responsible for the outbreak of SARS.  The SARS-CoV main protease, which is a 33.8-kDa protease (also called the 3C-like protease), plays a pivotal role in mediating viral replication and transcription functions through extensive proteolytic processing of two replicase polyproteins, pp1a (486 kDa) and pp1ab (790 kDa).  Here, the authors report the crystal structures of the SARS-CoV main protease at different pH values and in complex with a specific inhibitor.  The protease structure has a fold that can be described as an augmented serine-protease, but with a Cys-His at the active site.  This series of crystal structures, which is the first, to the authors' knowledge, of any protein from the SARS virus, reveal substantial pH-dependent conformational changes, and an unexpected mode of inhibitor binding, providing a structural basis for rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzcMRDCS0gPbVg90H21EOLACvtfcHk0lhYQ5VTshlsIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFOju7s%253D&md5=b9eb74d9a519f31d3eeca5e26bc7d570</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1835675100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1835675100%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DMo%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DAnand%26aufirst%3DK.%26aulast%3DBartlam%26aufirst%3DM.%26aulast%3DHilgenfeld%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DThe%2520crystal%2520structures%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520virus%2520main%2520protease%2520and%2520its%2520complex%2520with%2520an%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D13190%26epage%3D13195%26doi%3D10.1073%2Fpnas.1835675100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref272"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref272'); return false;" data-citation="" class="refNumLink">272</a></strong><div class="NLM_citation" id="cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3: A kinase for all pathways?</span>. <i>Curr. Top. Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">277</span>â <span class="NLM_lpage">302</span>, <span class="refDoi">Â DOI: 10.1016/bs.ctdb.2016.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fbs.ctdb.2016.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28236969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKjs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2017&pages=277-302&author=P.+Patelauthor=J.+R.+Woodgett&title=Glycogen+synthase+kinase+3%3A+A+kinase+for+all+pathways%3F&doi=10.1016%2Fbs.ctdb.2016.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit272R"><div class="casContent"><span class="casTitleNuber">272</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3: a kinase for all pathways?</span></div><div class="casAuthors">Patel, Prital; Woodgett, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Developmental Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">Protein Kinases in Development and Disease</span>),
    <span class="NLM_cas:pages">277-302</span>CODEN:
                <span class="NLM_cas:coden">CTDBA5</span>;
        ISSN:<span class="NLM_cas:issn">0070-2153</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) is an unusual protein-serine kinase in that it is primarily regulated by inhibition and lies downstream of multiple cell signaling pathways.  This raises a variety of questions in terms of its physiol. role(s), how signaling specificity is maintained and why so many eggs have been placed into one basket.  There are actually two baskets, as there are two isoforms, GSK-3Î± and Î², that are highly related and largely redundant.  Their many substrates range from regulators of cellular metab. to mols. that control growth and differentiation.  In this chapter, we review the characteristics of GSK-3, update progress in understanding the kinase, and try to answer some of the questions raised by its unusual properties.  Indeed, the kinase may trigger transformation in our thinking of how cellular signals are organized and controlled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolxBj01kLDaLVg90H21EOLACvtfcHk0ljKn87FYBCfEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKjs70%253D&md5=4c219601701e017e9101b3e7a15b301c</span></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1016%2Fbs.ctdb.2016.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.ctdb.2016.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%253A%2520A%2520kinase%2520for%2520all%2520pathways%253F%26jtitle%3DCurr.%2520Top.%2520Dev.%2520Biol.%26date%3D2017%26volume%3D123%26spage%3D277%26epage%3D302%26doi%3D10.1016%2Fbs.ctdb.2016.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref273"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref273'); return false;" data-citation="" class="refNumLink">273</a></strong><div class="NLM_citation" id="cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanthong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuniga, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">274</span>â <span class="NLM_lpage">286</span>, <span class="refDoi">Â DOI: 10.1016/j.immuni.2016.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.immuni.2016.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26885856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVCmsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=274-286&author=A.+Taylorauthor=J.+A.+Harkerauthor=K.+Chanthongauthor=P.+G.+Stevensonauthor=E.+I.+Zunigaauthor=C.+E.+Rudd&title=Glycogen+synthase+kinase+3+inactivation+drives+T-bet-mediated+downregulation+of+co-receptor+PD-1+to+enhance+CD8%28%2B%29+cytolytic+T+cell+responses&doi=10.1016%2Fj.immuni.2016.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses</span></div><div class="casAuthors">Taylor, Alison; Harker, James A.; Chanthong, Kittiphat; Stevenson, Philip G.; Zuniga, Elina I.; Rudd, Christopher E.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-286</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Despite the importance of the co-receptor PD-1 in T cell immunity, the upstream signaling pathway that regulates PD-1 expression has not been defined.  Glycogen synthase kinase 3 (GSK-3, isoforms Î± and Î²) is a serine-threonine kinase implicated in cellular processes.  Here, we identified GSK-3 as a key upstream kinase that regulated PD-1 expression in CD8+ T cells.  GSK-3 siRNA downregulation, or inhibition by small mols., blocked PD-1 expression, resulting in increased CD8+ cytotoxic T lymphocyte (CTL) function.  Mechanistically, GSK-3 inactivation increased Tbx21 transcription, promoting enhanced T-bet expression and subsequent suppression of Pdcd1 (encodes PD-1) transcription in CD8+ CTLs.  Injection of GSK-3 inhibitors in mice increased in vivo CD8+ OT-I CTL function and the clearance of murine gamma-herpesvirus 68 and lymphocytic choriomeningitis clone 13 and reversed T cell exhaustion.  Our findings identify GSK-3 as a regulator of PD-1 expression and demonstrate the applicability of GSK-3 inhibitors in the modulation of PD-1 in immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRPdu-n1q3BrVg90H21EOLACvtfcHk0ljKn87FYBCfEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVCmsLg%253D&md5=d9ac06a8943d7dec13d8b12ebb123f27</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2016.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2016.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DHarker%26aufirst%3DJ.%2BA.%26aulast%3DChanthong%26aufirst%3DK.%26aulast%3DStevenson%26aufirst%3DP.%2BG.%26aulast%3DZuniga%26aufirst%3DE.%2BI.%26aulast%3DRudd%26aufirst%3DC.%2BE.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520inactivation%2520drives%2520T-bet-mediated%2520downregulation%2520of%2520co-receptor%2520PD-1%2520to%2520enhance%2520CD8%2528%252B%2529%2520cytolytic%2520T%2520cell%2520responses%26jtitle%3DImmunity%26date%3D2016%26volume%3D44%26spage%3D274%26epage%3D286%26doi%3D10.1016%2Fj.immuni.2016.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref274"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref274'); return false;" data-citation="" class="refNumLink">274</a></strong><div class="NLM_citation" id="cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohteki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakarian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, P. S.</span></span> <span> </span><span class="NLM_article-title">Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">99</span>â <span class="NLM_lpage">104</span>, <span class="refDoi">Â DOI: 10.1084/jem.192.1.99</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1084%2Fjem.192.1.99" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10880530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkslaitb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2000&pages=99-104&author=T.+Ohtekiauthor=M.+Parsonsauthor=A.+Zakarianauthor=R.+G.+Jonesauthor=L.+T.+Nguyenauthor=J.+R.+Woodgettauthor=P.+S.+Ohashi&title=Negative+regulation+of+T+cell+proliferation+and+interleukin+2+production+by+the+serine+threonine+kinase+GSK-3&doi=10.1084%2Fjem.192.1.99"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3</span></div><div class="casAuthors">Ohteki, Toshiaki; Parsons, Michael; Zakarian, Arsen; Jones, Russell G.; Nguyen, Linh T.; Woodgett, James R.; Ohashi, Pamela S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-104</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Glycogen synthase kinase (GSK)-3 is a protein serine/threonine kinase that regulates differentiation and cell fate in a variety of organisms.  This study examd. the role of GSK-3 in antigen-specific T cell responses.  Using resting T cells from P14 T cell receptor (TCR)-transgenic mice (specific for the lymphocytic choriomeningitis virus and H-2Db), the authors demonstrated that GSK-3Î² was inactivated by serine phosphorylation after viral peptide-specific stimulation in vitro.  To further investigate the role of GSK-3, the authors have generated a retroviral vector that expresses a constitutively active form of GSK-3Î² that has an alanine substitution at the regulatory amino acid, serine 9 (GSK-3Î²A9).  Retroviral transduction of P14 TCR-transgenic bone marrow stem cells, followed by reconstitution, led to the expression of GSK-3Î²A9 in bone marrow chimeric mice.  T cells from chimeric mice demonstrate a redn. in proliferation and interleukin (IL)-2 prodn.  In contrast, in vitro assays done in the presence of the GSK-3 inhibitor lithium led to dramatically prolonged T cell proliferation and increased IL-2 prodn.  Furthermore, in the presence of lithium, the authors show that nuclear factor of activated T cells (NF-AT)c remains in the nucleus after antigen-specific stimulation of T cells.  Together, these data demonstrate that GSK-3 neg. regulates the duration of T cell responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVcVS1sxU4ubVg90H21EOLACvtfcHk0ljKn87FYBCfEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkslaitb8%253D&md5=6ecff0134faca0fb2c89b4ff42695b2f</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.1084%2Fjem.192.1.99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.192.1.99%26sid%3Dliteratum%253Aachs%26aulast%3DOhteki%26aufirst%3DT.%26aulast%3DParsons%26aufirst%3DM.%26aulast%3DZakarian%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DR.%2BG.%26aulast%3DNguyen%26aufirst%3DL.%2BT.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DOhashi%26aufirst%3DP.%2BS.%26atitle%3DNegative%2520regulation%2520of%2520T%2520cell%2520proliferation%2520and%2520interleukin%25202%2520production%2520by%2520the%2520serine%2520threonine%2520kinase%2520GSK-3%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D192%26spage%3D99%26epage%3D104%26doi%3D10.1084%2Fjem.192.1.99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref275"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref275'); return false;" data-citation="" class="refNumLink">275</a></strong><div class="NLM_citation" id="cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span> <span> </span><span class="NLM_article-title">Two strings in one bow: PD-1 negatively regulates via co-receptor CD28 on T cells</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">529</span>â <span class="NLM_lpage">531</span>, <span class="refDoi">Â DOI: 10.1016/j.immuni.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.immuni.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28423334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlSku7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=529-531&author=J.+Kruegerauthor=C.+E.+Rudd&title=Two+strings+in+one+bow%3A+PD-1+negatively+regulates+via+co-receptor+CD28+on+T+cells&doi=10.1016%2Fj.immuni.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Two Strings in One Bow: PD-1 Negatively Regulates via Co-receptor CD28 on T Cells</span></div><div class="casAuthors">Krueger, Janna; Rudd, Christopher E.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-531</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The identity of PD-1 dependency on other receptors and signaling has been unclear.  In a recent issue of Science, Hui et al. (2017) and Kamphorst et al. (2017) now show that CD28 expression is a target of PD-1-assocd. phosphatases and is needed for T cell expansion in anti-PD-1 immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW47O1ASL4NbVg90H21EOLACvtfcHk0liEr6IC4BTGoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlSku7w%253D&md5=c639774541610ed3efd51256cbe4a8a7</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DJ.%26aulast%3DRudd%26aufirst%3DC.%2BE.%26atitle%3DTwo%2520strings%2520in%2520one%2520bow%253A%2520PD-1%2520negatively%2520regulates%2520via%2520co-receptor%2520CD28%2520on%2520T%2520cells%26jtitle%3DImmunity%26date%3D2017%26volume%3D46%26spage%3D529%26epage%3D531%26doi%3D10.1016%2Fj.immuni.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref276"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref276'); return false;" data-citation="" class="refNumLink">276</a></strong><div class="NLM_citation" id="cit276"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">706</span>â <span class="NLM_lpage">717</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-17-0491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F0008-5472.CAN-17-0491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29055015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWntrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=706-717&author=A.+Taylorauthor=D.+Rothsteinauthor=C.+E.+Rudd&title=Small-molecule+inhibition+of+PD-1+transcription+is+an+effective+alternative+to+antibody+blockade+in+cancer+therapy&doi=10.1158%2F0008-5472.CAN-17-0491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy</span></div><div class="casAuthors">Taylor, Alison; Rothstein, David; Rudd, Christopher E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">706-717</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The impact of PD-1 immune checkpoint therapy prompts exploration of other strategies to downregulate PD-1 for cancer therapy.  We previously showed that the serine/threonine kinase, glycogen synthase kinase, GSK-3Î±/Î², is a central regulator of PD-1 transcription in CD8+ T cells.  Here, we show that the use of small-mol. inhibitors of GSK-3Î±/Î² (GSK-3i) to reduce pcdc1 (PD-1) transcription and expression was as effective as anti-PD-1 and PD-L1-blocking antibodies in the control of B16 melanoma, or EL4 lymphoma, in primary tumor and metastatic settings.  Furthermore, the conditional genetic deletion of GSK-3Î±/Î² reduced PD-1 expression on CD8+ T cells and limited B16 pulmonary metastasis to the same degree as PD-1 gene deficiency.  In each model, GSK-3i inhibited PD-1 expression on tumor-infiltrating lymphocytes, while increasing Tbx21 (T-bet) transcription, and the expression of CD107a+ (LAMP1) and granzyme B (GZMB) on CD8+ T cells.  Finally, the adoptive transfer of T cells treated ex vivo with a GSK-3 inhibitor delayed the onset of EL4 lymphoma growth to a similar extent as anti-PD-1 pretreatment.  Overall, our findings show how GSK-3 inhibitors that downregulate PD-1 expression can enhance CD8+ T-cell function in cancer therapy to a similar degree as PD-1-blocking antibodies.  Significance: These findings show how GSK-3 inhibitors that downregulate PD-1 expression can enhance CD8+ T-cell function in cancer therapy to a similar degree as PD-1 blocking antibodies, offering a next-generation approach in the design of immunotherapeutic approaches for cancer management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxGzAyDzwXtLVg90H21EOLACvtfcHk0liEr6IC4BTGoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWntrs%253D&md5=17e2c2f4dc48d76f0fa9b6c64ff010e3</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-0491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-0491%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DRothstein%26aufirst%3DD.%26aulast%3DRudd%26aufirst%3DC.%2BE.%26atitle%3DSmall-molecule%2520inhibition%2520of%2520PD-1%2520transcription%2520is%2520an%2520effective%2520alternative%2520to%2520antibody%2520blockade%2520in%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D706%26epage%3D717%26doi%3D10.1158%2F0008-5472.CAN-17-0491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref277"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref277'); return false;" data-citation="" class="refNumLink">277</a></strong><div class="NLM_citation" id="cit277"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8(+) cytotoxic T-cells: Implications for anti-PD-1 immunotherapy</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1653</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2017.01653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffimmu.2017.01653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29312284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOgsrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1653&author=A.+Taylorauthor=C.+E.+Rudd&title=Glycogen+synthase+kinase+3+inactivation+compensates+for+the+lack+of+CD28+in+the+priming+of+CD8%28%2B%29+cytotoxic+T-cells%3A+Implications+for+anti-PD-1+immunotherapy&doi=10.3389%2Ffimmu.2017.01653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8+ cytotoxic T-cells: implications for anti-PD-1 immunotherapy</span></div><div class="casAuthors">Taylor, Alison; Rudd, Christopher E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1653/1-1653/9</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The rescue of exhausted CD8+ cytolytic T-cells (CTLs) by anti-Programmed Cell Death-1 (anti-PD-1) blockade has been found to require CD28 expression.  At the same time, we have shown that the inactivation of the serine/threonine kinase glycogen synthase kinase (GSK)-3Î±/Î² with small-interfering RNAs (siRNAs) and small mol. inhibitors (SMIs) specifically down-regulates PD-1 expression for enhanced CD8+ CTL function and clearance of tumors and viral infections.  Despite this, it has been unclear whether the GSK-3Î±/Î² pathway accounts for CD28 costimulation of CD8+ CTL function.  In this article, we show that inactivation of GSK-3Î±/Î² through siRNA or by SMIs during priming can substitute CD28 co-stimulation in the potentiation of cytotoxic CD8+ CTL function against the EL-4 lymphoma cells expressing OVA peptide.  The effect was seen using several structurally distinct GSK-3 SMIs and was accompanied by an increase in Lamp-1 and GZMB expression.  Conversely, CD28 crosslinking obviated the need for GSK-3Î±/Î² inhibition in its enhancement of CTL function.  Our findings support a model where GSK-3 is the central cosignal for CD28 priming of CD8+ CTLs in anti-PD-1 immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL4BaOmVL5gbVg90H21EOLACvtfcHk0liEr6IC4BTGoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOgsrrM&md5=d9f9ec8f4dd3ba2d11f170068d77f09b</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.01653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.01653%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DRudd%26aufirst%3DC.%2BE.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520inactivation%2520compensates%2520for%2520the%2520lack%2520of%2520CD28%2520in%2520the%2520priming%2520of%2520CD8%2528%252B%2529%2520cytotoxic%2520T-cells%253A%2520Implications%2520for%2520anti-PD-1%2520immunotherapy%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D1653%26doi%3D10.3389%2Ffimmu.2017.01653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref278"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref278'); return false;" data-citation="" class="refNumLink">278</a></strong><div class="NLM_citation" id="cit278"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanthong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibition of GSK-3 specifically inhibits the transcription of inhibitory co-receptor LAG-3 for enhanced anti-tumor I immunity</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2075</span>â <span class="NLM_lpage">2082</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2020.01.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.celrep.2020.01.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32075731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsFyntrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=2075-2082&author=C.+E.+Ruddauthor=K.+Chanthongauthor=A.+Taylor&title=Small+molecule+inhibition+of+GSK-3+specifically+inhibits+the+transcription+of+inhibitory+co-receptor+LAG-3+for+enhanced+anti-tumor+I+immunity&doi=10.1016%2Fj.celrep.2020.01.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity</span></div><div class="casAuthors">Rudd, Christopher E.; Chanthong, Kittiphat; Taylor, Alison</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2075-2082.e4</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Immune checkpoint blockade using antibodies against neg. co-receptors such as cytolytic T cell antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) has seen much success treating cancer.  However, most patients are still not cured, underscoring the need for improved treatments and the possible development of small mol. inhibitors (SMIs) for improved immunotherapy.  We previously showed that glycogen synthase kinase (GSK)-3Î±/Î² is a central regulator of PD-1 expression, where GSK-3 inhibition down-regulates PD-1 and enhances CD8+ cytolytic T cell (CTL) function, reducing viral infections and tumor growth.  Here, we demonstrate that GSK-3 also neg. regulates Lymphocyte Activation Gene-3 (LAG-3) expression on CD4+ and CD8+ T cells.  GSK-3 SMIs are more effective than LAG-3 blockade alone in suppressing B16 melanoma growth, while their combination resulted in enhanced tumor clearance.  This was linked to increased expression of the transcription factor, Tbet, which bound the LAG-3 promoter, inhibiting its transcription, and to increased granzyme B and interferon-Î³1 expression.  Overall, we describe a small mol. approach to inhibit LAG-3, resulting in enhanced anti-tumor immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGjPkICZQtZLVg90H21EOLACvtfcHk0liKhOV2uyfiiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsFyntrc%253D&md5=4290f1c9e2f45041e6d3efbdd3f5b865</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2020.01.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2020.01.076%26sid%3Dliteratum%253Aachs%26aulast%3DRudd%26aufirst%3DC.%2BE.%26aulast%3DChanthong%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DA.%26atitle%3DSmall%2520molecule%2520inhibition%2520of%2520GSK-3%2520specifically%2520inhibits%2520the%2520transcription%2520of%2520inhibitory%2520co-receptor%2520LAG-3%2520for%2520enhanced%2520anti-tumor%2520I%2520immunity%26jtitle%3DCell%2520Rep.%26date%3D2020%26volume%3D30%26spage%3D2075%26epage%3D2082%26doi%3D10.1016%2Fj.celrep.2020.01.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref279"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref279'); return false;" data-citation="" class="refNumLink">279</a></strong><div class="NLM_citation" id="cit279"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakley, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wraith, D. C.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 controls IL-10 expression in CD4(+) effector T-cell subsets through epigenetic modification of the IL-10 promoter</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1103</span>â <span class="NLM_lpage">1115</span>, <span class="refDoi">Â DOI: 10.1002/eji.201444661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Feji.201444661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25627813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXks12hu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=1103-1115&author=E.+V.+Hillauthor=T.+H.+Ngauthor=B.+R.+Burtonauthor=C.+M.+Oakleyauthor=K.+Malikauthor=D.+C.+Wraith&title=Glycogen+synthase+kinase-3+controls+IL-10+expression+in+CD4%28%2B%29+effector+T-cell+subsets+through+epigenetic+modification+of+the+IL-10+promoter&doi=10.1002%2Feji.201444661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit279R"><div class="casContent"><span class="casTitleNuber">279</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 controls IL-10 expression in CD4+ effector T-cell subsets through epigenetic modification of the IL-10 promoter</span></div><div class="casAuthors">Hill, Elaine V.; Ng, T. H. Sky; Burton, Bronwen R.; Oakley, Charly M.; Malik, Karim; Wraith, David C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1103-1115</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The serine/threonine kinase glycogen synthase kinase-3 (GSK3) plays an important role in balancing pro- and anti-inflammatory cytokines.  We have examd. the role of GSK3 in prodn. of IL-10 by subsets of CD4+ T helper cells.  Treatment of naive murine CD4+ T cells with GSK3 inhibitors did not affect their prodn. of IL-10.  However, treatment of Th1 and Th2 cells with GSK3 inhibitors dramatically increased prodn. of IL-10.  GSK3 inhibition also led to upregulation of IL-10 among Th1, Th2, and Th17 subsets isolated from human blood.  The encephalitogenic potential of GSK3 inhibitor treated murine Th1 cells was significantly reduced in adoptive transfer expts. by an IL-10-dependent mechanism.  Anal. of the murine IL-10 promoter in response to inhibition of GSK3 in Th1 cells showed modification to a transcriptionally active state indicated by changes in histone H3 acetylation and methylation.  Addnl., GSK3 inhibition increased expression of the transcription factors c-Maf, Nfil3, and GATA3, correlating with the increase in IL-10.  These findings are important in the context of autoimmune disease since they show that it is possible to reprogram disease-causing cells through GSK3 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo68yArhNbkjbVg90H21EOLACvtfcHk0liKhOV2uyfiiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXks12hu78%253D&md5=5bdcb0a86817340885b740f001aff1be</span></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=10.1002%2Feji.201444661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.201444661%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DE.%2BV.%26aulast%3DNg%26aufirst%3DT.%2BH.%26aulast%3DBurton%26aufirst%3DB.%2BR.%26aulast%3DOakley%26aufirst%3DC.%2BM.%26aulast%3DMalik%26aufirst%3DK.%26aulast%3DWraith%26aufirst%3DD.%2BC.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520controls%2520IL-10%2520expression%2520in%2520CD4%2528%252B%2529%2520effector%2520T-cell%2520subsets%2520through%2520epigenetic%2520modification%2520of%2520the%2520IL-10%2520promoter%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2015%26volume%3D45%26spage%3D1103%26epage%3D1115%26doi%3D10.1002%2Feji.201444661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref280"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref280'); return false;" data-citation="" class="refNumLink">280</a></strong><div class="NLM_citation" id="cit280"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saraiva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâGarra, A.</span></span> <span> </span><span class="NLM_article-title">The regulation of IL-10 production by immune cells</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">170</span>â <span class="NLM_lpage">181</span>, <span class="refDoi">Â DOI: 10.1038/nri2711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnri2711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20154735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFGmsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=170-181&author=M.+Saraivaauthor=A.+O%E2%80%99Garra&title=The+regulation+of+IL-10+production+by+immune+cells&doi=10.1038%2Fnri2711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of IL-10 production by immune cells</span></div><div class="casAuthors">Saraiva, Margarida; O'Garra, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">170-181</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Interleukin-10 (IL-10), a cytokine with anti-inflammatory properties, has a central role in infection by limiting the immune response to pathogens and thereby preventing damage to the host.  Recently, an increasing interest in how IL10 expression is regulated in different immune cells has revealed some of the mol. mechanisms involved at the levels of signal transduction, epigenetics, transcription factor binding and gene activation.  Understanding the specific mol. events that regulate the prodn. of IL-10 will help to answer the remaining questions that are important for the design of new strategies of immune intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCxUhXRUMEvLVg90H21EOLACvtfcHk0liBSyz05YTcDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFGmsrY%253D&md5=b3a72e73c6054abd8d7ddc278083937e</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.1038%2Fnri2711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2711%26sid%3Dliteratum%253Aachs%26aulast%3DSaraiva%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Garra%26aufirst%3DA.%26atitle%3DThe%2520regulation%2520of%2520IL-10%2520production%2520by%2520immune%2520cells%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D10%26spage%3D170%26epage%3D181%26doi%3D10.1038%2Fnri2711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref281"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref281'); return false;" data-citation="" class="refNumLink">281</a></strong><div class="NLM_citation" id="cit281"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cichocki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valamehr, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjordahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidarova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuininga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCullar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlums, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryceson, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazar, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. S.</span></span> <span> </span><span class="NLM_article-title">GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">5664</span>â <span class="NLM_lpage">5675</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-17-0799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F0008-5472.CAN-17-0799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28790065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CqtLjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=5664-5675&author=F.+Cichockiauthor=B.+Valamehrauthor=R.+Bjordahlauthor=B.+Zhangauthor=B.+Reznerauthor=P.+Rogersauthor=S.+Gaidarovaauthor=S.+Morenoauthor=K.+Tuiningaauthor=P.+Doughertyauthor=V.+McCullarauthor=P.+Howardauthor=D.+Sarhanauthor=E.+Tarasauthor=H.+Schlumsauthor=S.+Abbotauthor=D.+Shoemakerauthor=Y.+T.+Brycesonauthor=B.+R.+Blazarauthor=S.+Wolchkoauthor=S.+Cooleyauthor=J.+S.+Miller&title=GSK3+inhibition+drives+maturation+of+NK+cells+and+enhances+their+antitumor+activity&doi=10.1158%2F0008-5472.CAN-17-0799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity</span></div><div class="casAuthors">Cichocki, Frank; Valamehr, Bahram; Bjordahl, Ryan; Zhang, Bin; Rezner, Betsy; Rogers, Paul; Gaidarova, Svetlana; Moreno, Stacey; Tuininga, Katie; Dougherty, Phillip; McCullar, Valarie; Howard, Peter; Sarhan, Dhifaf; Taras, Emily; Schlums, Heinrich; Abbot, Stewart; Shoemaker, Daniel; Bryceson, Yenan T.; Blazar, Bruce R.; Wolchko, Scott; Cooley, Sarah; Miller, Jeffrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5664-5675</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Maturation of human natural killer (NK) cells as defined by accumulation of cell-surface expression of CD57 is assocd. with increased cytotoxic character and TNF and IFNÎ³ prodn. upon target-cell recognition.  Notably, multiple studies point to a unique role for CD57+ NK cells in cancer immunosurveillance, yet there is scant information about how they mature.  In this study, we show that pharmacol. inhibition of GSK3 kinase in peripheral blood NK cells expanded ex vivo with IL15 greatly enhances CD57 upregulation and late-stage maturation.  GSK3 inhibition elevated the expression of several transcription factors assocd. with late-stage NK-cell maturation including T-BET, ZEB2, and BLIMP-1 without affecting viability or proliferation.  When exposed to human cancer cells, NK cell expanded ex vivo in the presence of a GSK3 inhibitor exhibited significantly higher prodn. of TNF and IFNÎ³, elevated natural cytotoxicity, and increased antibody-dependent cellular cytotoxicity.  In an established mouse xenograft model of ovarian cancer, adoptive transfer of NK cells conditioned in the same way also displayed more robust and durable tumor control.  Our findings show how GSK3 kinase inhibition can greatly enhance the mature character of NK cells most desired for effective cancer immunotherapy.  Cancer Res; 77(20); 5664-75. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqNbRm7jN8XLVg90H21EOLACvtfcHk0liBSyz05YTcDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CqtLjL&md5=0dfd9702064be29a2cdae6d90591a916</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-0799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-0799%26sid%3Dliteratum%253Aachs%26aulast%3DCichocki%26aufirst%3DF.%26aulast%3DValamehr%26aufirst%3DB.%26aulast%3DBjordahl%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DRezner%26aufirst%3DB.%26aulast%3DRogers%26aufirst%3DP.%26aulast%3DGaidarova%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DS.%26aulast%3DTuininga%26aufirst%3DK.%26aulast%3DDougherty%26aufirst%3DP.%26aulast%3DMcCullar%26aufirst%3DV.%26aulast%3DHoward%26aufirst%3DP.%26aulast%3DSarhan%26aufirst%3DD.%26aulast%3DTaras%26aufirst%3DE.%26aulast%3DSchlums%26aufirst%3DH.%26aulast%3DAbbot%26aufirst%3DS.%26aulast%3DShoemaker%26aufirst%3DD.%26aulast%3DBryceson%26aufirst%3DY.%2BT.%26aulast%3DBlazar%26aufirst%3DB.%2BR.%26aulast%3DWolchko%26aufirst%3DS.%26aulast%3DCooley%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DJ.%2BS.%26atitle%3DGSK3%2520inhibition%2520drives%2520maturation%2520of%2520NK%2520cells%2520and%2520enhances%2520their%2520antitumor%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D5664%26epage%3D5675%26doi%3D10.1158%2F0008-5472.CAN-17-0799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref282"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref282'); return false;" data-citation="" class="refNumLink">282</a></strong><div class="NLM_citation" id="cit282"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lam, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanier, L. L.</span></span> <span> </span><span class="NLM_article-title">NK cells in host responses to viral infections</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">43</span>â <span class="NLM_lpage">51</span>, <span class="refDoi">Â DOI: 10.1016/j.coi.2016.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.coi.2016.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27984782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSmt7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=43-51&author=V.+C.+Lamauthor=L.+L.+Lanier&title=NK+cells+in+host+responses+to+viral+infections&doi=10.1016%2Fj.coi.2016.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit282R"><div class="casContent"><span class="casTitleNuber">282</span><div class="casTitle"><span class="NLM_cas:atitle">NK cells in host responses to viral infections</span></div><div class="casAuthors">Lam, Viola C.; Lanier, Lewis L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-51</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Natural killer (NK) cells are cytotoxic innate lymphocytes that play an important role in viral clearance.  NK cell responses to viral infections were originally believed to be non-specific and lacked immune memory recall responses.  It is now appreciated that NK cell responses to viral infections can be specific and in some cases memory recall responses are established.  Increasing evidence also illuminates the complexity of NK cell interactions with both innate and adaptive immune cells.  Here, we summarize the evidence for NK cell-specific memory responses to viral infections and the intricate reciprocal interactions between NK cells and other immune cells that dictate their activation and effector functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1yNF-jweBV7Vg90H21EOLACvtfcHk0lgDI7f7LTQUYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSmt7jF&md5=9524466071e80c9123f7c1702de60d70</span></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2016.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2016.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DV.%2BC.%26aulast%3DLanier%26aufirst%3DL.%2BL.%26atitle%3DNK%2520cells%2520in%2520host%2520responses%2520to%2520viral%2520infections%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2017%26volume%3D44%26spage%3D43%26epage%3D51%26doi%3D10.1016%2Fj.coi.2016.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257'],'ref258':['cit258'],'ref259':['cit259'],'ref260':['cit260'],'ref261':['cit261'],'ref262':['cit262'],'ref263':['cit263'],'ref264':['cit264'],'ref265':['cit265'],'ref266':['cit266'],'ref267':['cit267'],'ref268':['cit268'],'ref269':['cit269'],'ref270':['cit270'],'ref271':['cit271'],'ref272':['cit272'],'ref273':['cit273'],'ref274':['cit274'],'ref275':['cit275'],'ref276':['cit276'],'ref277':['cit277'],'ref278':['cit278'],'ref279':['cit279'],'ref280':['cit280'],'ref281':['cit281'],'ref282':['cit282']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Taxonomy of human coronaviruses depicted schematically. (A) Seven human CoVs assigned to four genera of Î±, Î², Î³, and Î´ are highlighted blue. The discovery of each HCoV is indicated in the brackets. The percent of spike protein (S) amino acid identity between classes is indicated green. (B) Structure of a coronavirus with its functional proteins. Abbreviations: HCoV, human coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; SARS-CoV, severe acute respiratory syndrome coronavirus; BuCoV, bubaline coronavirus.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) SARS-CoV-2 life cycle as an example: entry, transcription and translation, assembly of virion, and release. (B) Viral infection results in the hyperproduction of proinflammatory cytokines. Kinases involved in both coronavirus viral replication and associated diseases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinases as potential targets for the management of coronavirus diseases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Abl tyrosine kinase and Src kinase inhibitors as antiviral agents (imatinib: SARS-CoV-1, EC<sub>50</sub> 9.823 Î¼M, MERS-CoV, EC<sub>50</sub> 2.100 Î¼M;<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> dasatinib: SARS-CoV-1, EC<sub>50</sub> 17.689 Î¼M, MERS-CoV, EC<sub>50</sub> 5.468 Î¼M).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. NAK family inhibitors (sunitinib,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> erlotinib,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> and baricitinib<a onclick="showRef(event, 'ref44 ref86'); return false;" href="javascript:void(0);" class="ref ref44 ref86">(44,86)</a>) and AXL kinase inhibitor (gilteritinib: SARS-CoV-2, IC<sub>50</sub> of 0.807 Î¼M)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> for the treatment of coronavirus infection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Baricitinib inhibits JAK1 and thereby prevents SARS-CoV-2 entry and ARD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibitors of SARS-CoV-2 and MERS-CoV replication that target EGFR and its downstream signaling pathways. Osimertinib, SARS-CoV-2 S: IC<sub>50</sub> 3.98 Î¼M;<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> pictilisib: SARS-CoV-2, IC<sub>50</sub> 2.58 Î¼M;<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> omipalisib: SARS-CoV-2, IC<sub>50</sub> 0.014 Î¼M;<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> sorafenib: SARS-CoV-2, IC<sub>50</sub> 4.85 Î¼M<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> RO5126766: SARS-CoV-2, IC<sub>50</sub> 0.6 Î¼M;<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> lonafarnib: SARS-CoV-2, IC<sub>50</sub> 4.99 Î¼M;<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> everolimus: 56 or 59% MERS-CoV inhibition;<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> miltefosine: 28% MERS-CoV inhibition;<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> wortmannin: 40% MERS-CoV inhibition;<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> rapamycin: 40% MERS-CoV inhibition.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. CDK inhibitors as antiviral agents. Dinaciclib: SARS-CoV-2, IC<sub>50</sub> 0.127 Î¼M (Vero E6), IC<sub>50</sub> 0.032 Î¼M (A549-ACE2);<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> apilimod: SARS-CoV-2, IC<sub>50</sub> < 0.08 Î¼M (Vero E6), IC<sub>50</sub>0.007 Î¼M (A549-ACE2);<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> abemaciclib, SARS-CoV-2: EC<sub>50</sub> 2.16 Î¼M.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. CK2 inhibitors for SARS-CoV-2 (silmitasertib: IC<sub>50</sub>1.28 Î¼M),<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> vaccinia virus (4,5,6,7-tetrabromo-1<i>H</i>-benzimidazole (TBBz)),<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> and quercetin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Role of p38 MAPK, as well as its interactions with other signaling pathways and inflammatory cytokines.<a onclick="showRef(event, 'ref167 ref168 ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref167 ref168 ref169 ref170">(167â170)</a> GM-CSF, granulocyte macrophage-colony stimulating factor; IL, interleukin; MIP, macrophage inflammatory protein; MCP, monocyte chemoattractant protein; TNF, tumor necrosis factor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Inhibitors of the p38 MAPK pathway for the treatment of COVID-19 (Gilteritinib: SARS-CoV-2, IC<sub>50</sub> 0.807 Î¼M;<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> ralimetinib: SARS-CoV-2, IC<sub>50</sub> 0.873 Î¼M;<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> MPAK13-IN-1: SARS-CoV-2, IC<sub>50</sub>4.63 Î¼M;<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> ARRY 371797: SARS-CoV-2, IC<sub>50</sub> 0.913 Î¼M).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Hyperactivation of the immune response and cytokine storm through the JAK-STAT signaling pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Cytokines and their interaction with JAK signaling pathways in the development of cytokine storm caused by SARS-CoV-2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structure of H2 antagonist famotidine<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> and the broad spectral antiviral agent ivermectin (SARS-CoV-2; IC<sub>50</sub>2.2â2.8 Î¼M).<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Inhibitors (tofacitinib,<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> fedratinib,<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> and ruxolitinib<a onclick="showRef(event, 'ref223 ref224'); return false;" href="javascript:void(0);" class="ref ref223 ref224">(223,224)</a>) that target the JAK-STAT pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. GSK-3 inhibitors (kenpaullone,<a onclick="showRef(event, 'ref266'); return false;" href="javascript:void(0);" class="ref ref266">(266)</a> alsterpaullone,<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> and tideglusib: SARS-CoV-2, IC<sub>50</sub> 1.5 Î¼M,<a onclick="showRef(event, 'ref269'); return false;" href="javascript:void(0);" class="ref ref269">(269)</a> SB415286<a onclick="showRef(event, 'ref276 ref277'); return false;" href="javascript:void(0);" class="ref ref276 ref277">(276,277)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/medium/jm1c00335_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. GSK-3 as a possible target for anti-coronaviral treatment, such as anti-SARS-CoV-2 therapy. According to the model, inhibiting GSK-3 will also inhibit SARS-CoV-2 N protein and improve CD8+ T cell resistance to the virus. Left: SARS-CoV-2 N protein and viral replication are assumed to be inhibited by inhibiting GSK-3. Right: Inhibition of GSK 3 improves CD8+ cell responses to viruses. In CD8+ T cells, inhibiting GSK-3 decreases the expression of inhibitory receptors PD-1 and LAG-3 while increasing the expression of GMZB and IFNg1. Inhibition of GSK-3 also escalates natural killer function. PD-1, programmed cell death protein 1; LAG-3, lymphocyte-activation gene 3; GMZB, granzyme B; IFNg1, interferon-gamma.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00335/20210609/images/large/jm1c00335_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00335&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i26">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42650" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42650" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 282 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z. L.</span></span> <span> </span><span class="NLM_article-title">A pneumonia outbreak associated with a new coronavirus of probable bat origin</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>579</i></span>,  <span class="NLM_fpage">270</span>â <span class="NLM_lpage">273</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2012-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41586-020-2012-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32015507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFKlsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=579&publication_year=2020&pages=270-273&author=P.+Zhouauthor=X.+L.+Yangauthor=X.+G.+Wangauthor=B.+Huauthor=L.+Zhangauthor=W.+Zhangauthor=H.+R.+Siauthor=Y.+Zhuauthor=B.+Liauthor=C.+L.+Huangauthor=H.+D.+Chenauthor=J.+Chenauthor=Y.+Luoauthor=H.+Guoauthor=R.+D.+Jiangauthor=M.+Q.+Liuauthor=Y.+Chenauthor=X.+R.+Shenauthor=X.+Wangauthor=X.+S.+Zhengauthor=K.+Zhaoauthor=Q.+J.+Chenauthor=F.+Dengauthor=L.+L.+Liuauthor=B.+Yanauthor=F.+X.+Zhanauthor=Y.+Y.+Wangauthor=G.+F.+Xiaoauthor=Z.+L.+Shi&title=A+pneumonia+outbreak+associated+with+a+new+coronavirus+of+probable+bat+origin&doi=10.1038%2Fs41586-020-2012-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A pneumonia outbreak associated with a new coronavirus of probable bat origin</span></div><div class="casAuthors">Zhou, Peng; Yang, Xing-Lou; Wang, Xian-Guang; Hu, Ben; Zhang, Lei; Zhang, Wei; Si, Hao-Rui; Zhu, Yan; Li, Bei; Huang, Chao-Lin; Chen, Hui-Dong; Chen, Jing; Luo, Yun; Guo, Hua; Jiang, Ren-Di; Liu, Mei-Qin; Chen, Ying; Shen, Xu-Rui; Wang, Xi; Zheng, Xiao-Shuang; Zhao, Kai; Chen, Quan-Jiao; Deng, Fei; Liu, Lin-Lin; Yan, Bing; Zhan, Fa-Xian; Wang, Yan-Yi; Xiao, Geng-Fu; Shi, Zheng-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">579</span>
        (<span class="NLM_cas:issue">7798</span>),
    <span class="NLM_cas:pages">270-273</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large no. of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural reservoir host, bats1-4.  Previous studies have shown that some bat SARSr-CoVs have the potential to infect humans5-7.  Here we report the identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China.  The epidemic, which started on 12 Dec. 2019, had caused 2,794 lab.-confirmed infections including 80 deaths by 26 Jan. 2020.  Full-length genome sequences were obtained from five patients at an early stage of the outbreak.  The sequences are almost identical and share 79.6% sequence identity to SARS-CoV.  Furthermore, we show that 2019-nCoV is 96% identical at the whole-genome level to a bat coronavirus.  Pairwise protein sequence anal. of seven conserved non-structural proteins domains show that this virus belongs to the species of SARSr-CoV.  In addn., 2019-nCoV virus isolated from the bronchoalveolar lavage fluid of a critically ill patient could be neutralized by sera from several patients.  Notably, we confirmed that 2019-nCoV uses the same cell entry receptor-angiotensin converting enzyme II (ACE2)-as SARS-CoV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV_Wb_iUsbFrVg90H21EOLACvtfcHk0lj184uW8jJOnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFKlsLg%253D&md5=236f17d4d3c7978d72513e5e0258f1b3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2012-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2012-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DX.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BG.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSi%26aufirst%3DH.%2BR.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DC.%2BL.%26aulast%3DChen%26aufirst%3DH.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DR.%2BD.%26aulast%3DLiu%26aufirst%3DM.%2BQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DX.%2BR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DX.%2BS.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DQ.%2BJ.%26aulast%3DDeng%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DL.%2BL.%26aulast%3DYan%26aufirst%3DB.%26aulast%3DZhan%26aufirst%3DF.%2BX.%26aulast%3DWang%26aufirst%3DY.%2BY.%26aulast%3DXiao%26aufirst%3DG.%2BF.%26aulast%3DShi%26aufirst%3DZ.%2BL.%26atitle%3DA%2520pneumonia%2520outbreak%2520associated%2520with%2520a%2520new%2520coronavirus%2520of%2520probable%2520bat%2520origin%26jtitle%3DNature%26date%3D2020%26volume%3D579%26spage%3D270%26epage%3D273%26doi%3D10.1038%2Fs41586-020-2012-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Z.</span></span> <span> </span><span class="NLM_article-title">A new coronavirus associated with human respiratory disease in China</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>579</i></span>,  <span class="NLM_fpage">265</span>â <span class="NLM_lpage">269</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2008-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41586-020-2008-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32015508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFKlsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=579&publication_year=2020&pages=265-269&author=F.+Wuauthor=S.+Zhaoauthor=B.+Yuauthor=Y.+M.+Chenauthor=W.+Wangauthor=Z.+G.+Songauthor=Y.+Huauthor=Z.+W.+Taoauthor=J.+H.+Tianauthor=Y.+Y.+Peiauthor=M.+L.+Yuanauthor=Y.+L.+Zhangauthor=F.+H.+Daiauthor=Y.+Liuauthor=Q.+M.+Wangauthor=J.+J.+Zhengauthor=L.+Xuauthor=E.+C.+Holmesauthor=Y.+Z.+Zhang&title=A+new+coronavirus+associated+with+human+respiratory+disease+in+China&doi=10.1038%2Fs41586-020-2008-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A new coronavirus associated with human respiratory disease in China</span></div><div class="casAuthors">Wu, Fan; Zhao, Su; Yu, Bin; Chen, Yan-Mei; Wang, Wen; Song, Zhi-Gang; Hu, Yi; Tao, Zhao-Wu; Tian, Jun-Hua; Pei, Yuan-Yuan; Yuan, Ming-Li; Zhang, Yu-Ling; Dai, Fa-Hui; Liu, Yi; Wang, Qi-Min; Zheng, Jiao-Jiao; Xu, Lin; Holmes, Edward C.; Zhang, Yong-Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">579</span>
        (<span class="NLM_cas:issue">7798</span>),
    <span class="NLM_cas:pages">265-269</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Emerging infectious diseases, such as severe acute respiratory syndrome (SARS) and Zika virus disease, present a major threat to public health.  Despite intense research efforts, how, when and where new diseases appear are still a source of considerable uncertainty.  A severe respiratory disease was recently reported in Wuhan, Hubei province, China.  As of 25 Jan. 2020, at least 1,975 cases had been reported since the first patient was hospitalized on 12 Dec. 2019.  Epidemiol. investigations have suggested that the outbreak was assocd. with a seafood market in Wuhan.  Here we study a single patient who was a worker at the market and who was admitted to the Central Hospital of Wuhan on 26 Dec. 2019 while experiencing a severe respiratory syndrome that included fever, dizziness and a cough.  Metagenomic RNA sequencing of a sample of bronchoalveolar lavage fluid from the patient identified a new RNA virus strain from the family Coronaviridae, which is designated here 'WH-Human 1' coronavirus (and has also been referred to as '2019-nCoV').  Phylogenetic anal. of the complete viral genome (29,903 nucleotides) revealed that the virus was most closely related (89.1% nucleotide similarity) to a group of SARS-like coronaviruses (genus Betacoronavirus, subgenus Sarbecovirus) that had previously been found in bats in China.  This outbreak highlights the ongoing ability of viral spill-over from animals to cause severe disease in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5h_VHfuDuTbVg90H21EOLACvtfcHk0lgInZy7ySyJLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFKlsLc%253D&md5=0163a684829e880a0c3347e19f0ce52a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2008-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2008-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DY.%2BM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DZ.%2BG.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTao%26aufirst%3DZ.%2BW.%26aulast%3DTian%26aufirst%3DJ.%2BH.%26aulast%3DPei%26aufirst%3DY.%2BY.%26aulast%3DYuan%26aufirst%3DM.%2BL.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DDai%26aufirst%3DF.%2BH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%2BM.%26aulast%3DZheng%26aufirst%3DJ.%2BJ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DHolmes%26aufirst%3DE.%2BC.%26aulast%3DZhang%26aufirst%3DY.%2BZ.%26atitle%3DA%2520new%2520coronavirus%2520associated%2520with%2520human%2520respiratory%2520disease%2520in%2520China%26jtitle%3DNature%26date%3D2020%26volume%3D579%26spage%3D265%26epage%3D269%26doi%3D10.1038%2Fs41586-020-2008-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span> <span> </span><span class="NLM_article-title">China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">727</span>â <span class="NLM_lpage">733</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa2001017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1056%2FNEJMoa2001017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31978945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslGmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=727-733&author=N.+Zhuauthor=D.+Zhangauthor=W.+Wangauthor=X.+Liauthor=B.+Yangauthor=J.+Songauthor=X.+Zhaoauthor=B.+Huangauthor=W.+Shiauthor=R.+Luauthor=P.+Niuauthor=F.+Zhanauthor=X.+Maauthor=D.+Wangauthor=W.+Xuauthor=G.+Wuauthor=G.+F.+Gaoauthor=W.+Tan&title=China+novel+coronavirus+investigating+and+research+team.+A+novel+coronavirus+from+patients+with+pneumonia+in+China%2C+2019&doi=10.1056%2FNEJMoa2001017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A novel coronavirus from patients with pneumonia in China, 2019</span></div><div class="casAuthors">Zhu, Na; Zhang, Dingyu; Wang, Wenling; Li, Xingwang; Yang, Bo; Song, Jingdong; Zhao, Xiang; Huang, Baoying; Shi, Weifeng; Lu, Roujian; Niu, Peihua; Zhan, Faxian; Ma, Xuejun; Wang, Dayan; Xu, Wenbo; Wu, Guizhen; Gao, George F.; Tan, Wenjie</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">727-733</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In Dec. 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China.  A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia.  Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily.  Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans.  Enhanced surveillance and further investigation are ongoing.  Complete genome sequences of the three novel coronaviruses were submitted to GISAID (BetaCoV/Wuhan/ IVDC-HB-01/2019, accession ID: EPI_ISL_402119; BetaCoV/Wuhan/IVDC-HB-04/2020, accession ID: EPI_ISL_402120; BetaCoV/Wuhan/IVDC-HB-05/2019, accession ID: EPI_ISL_402121).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoibbAn_VqfXbVg90H21EOLACvtfcHk0lgInZy7ySyJLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslGmsrc%253D&md5=73cc5c839e1e934da69b39537063b7b3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2001017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2001017%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DR.%26aulast%3DNiu%26aufirst%3DP.%26aulast%3DZhan%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DTan%26aufirst%3DW.%26atitle%3DChina%2520novel%2520coronavirus%2520investigating%2520and%2520research%2520team.%2520A%2520novel%2520coronavirus%2520from%2520patients%2520with%2520pneumonia%2520in%2520China%252C%25202019%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D727%26epage%3D733%26doi%3D10.1056%2FNEJMoa2001017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, P. R.</span></span> <span> </span><span class="NLM_article-title">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">105924</span>, <span class="refDoi">Â DOI: 10.1016/j.ijantimicag.2020.105924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.ijantimicag.2020.105924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32081636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1Ogtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2020&pages=105924&author=C.+C.+Laiauthor=T.+P.+Shihauthor=W.+C.+Koauthor=H.+J.+Tangauthor=P.+R.+Hsueh&title=Severe+acute+respiratory+syndrome+coronavirus+2+%28SARS-CoV-2%29+and+coronavirus+disease-2019+%28COVID-19%29%3A+The+epidemic+and+the+challenges&doi=10.1016%2Fj.ijantimicag.2020.105924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges</span></div><div class="casAuthors">Lai, Chih-Cheng; Shih, Tzu-Ping; Ko, Wen-Chien; Tang, Hung-Jen; Hsueh, Po-Ren</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">105924</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019 has caused a large global outbreak and is a major public health issue.  As of 11 Feb. 2020, data from the World Health Organization (WHO) have shown that more than 43 000 confirmed cases have been identified in 28 countries/regions, with >99% of cases being detected in China.  On 30 Jan. 2020, the WHO declared COVID-19 as the sixth public health emergency of international concern.  SARS-CoV-2 is closely related to two bat-derived severe acute respiratory syndrome-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21.  It is spread by human-to-human transmission via droplets or direct contact, and infection has been estd. to have mean incubation period of 6.4 days and a basic reprodn. no. of 2.24-3.58.  Among patients with pneumonia caused by SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough.  Bilateral lung involvement with ground-glass opacity was the most common finding from computed tomog. images of the chest.  The one case of SARS-CoV-2 pneumonia in the USA is responding well to remdesivir, which is now undergoing a clin. trial in China.  Currently, controlling infection to prevent the spread of SARS-CoV-2 is the primary intervention being used.  However, public health authorities should keep monitoring the situation closely, as the more we can learn about this novel virus and its assocd. outbreak, the better we can respond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6fCWu5X9AILVg90H21EOLACvtfcHk0li_Do6Ea3c5CA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1Ogtr8%253D&md5=2ece25e2290b6a1c78f23a3dda37ad64</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2020.105924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2020.105924%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%2BC.%26aulast%3DShih%26aufirst%3DT.%2BP.%26aulast%3DKo%26aufirst%3DW.%2BC.%26aulast%3DTang%26aufirst%3DH.%2BJ.%26aulast%3DHsueh%26aufirst%3DP.%2BR.%26atitle%3DSevere%2520acute%2520respiratory%2520syndrome%2520coronavirus%25202%2520%2528SARS-CoV-2%2529%2520and%2520coronavirus%2520disease-2019%2520%2528COVID-19%2529%253A%2520The%2520epidemic%2520and%2520the%2520challenges%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2020%26volume%3D55%26spage%3D105924%26doi%3D10.1016%2Fj.ijantimicag.2020.105924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span> <i>WHO Coronavirus (COVID-19) Dashboard</i>; <span class="NLM_publisher-name">World
Health Organization</span>. <a href="https://covid19.who.int/" class="extLink">https://covid19.who.int/</a> (accessed <span class="NLM_year">2020</span>-12-26).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+WHO+Coronavirus+%28COVID-19%29+Dashboard%3B+World%0AHealth+Organization.+https%3A%2F%2Fcovid19.who.int%2F+%28accessed+2020-12-26%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DWHO%2520Coronavirus%2520%2528COVID-19%2529%2520Dashboard%26pub%3DWorld%250AHealth%2520Organization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span> <i>Coronavirus (COVID-19) Update:
FDA Authorizes Monoclonal Antibodies
for Treatment of COVID-19</i>; <span class="NLM_publisher-name">U.S. Food and
Drug Administration</span>. <a href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0" class="extLink">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0</a> (accessed <span class="NLM_year">2021</span>-02-09).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Coronavirus+%28COVID-19%29+Update%3A%0AFDA+Authorizes+Monoclonal+Antibodies%0Afor+Treatment+of+COVID-19%3B+U.S.+Food+and%0ADrug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Fcoronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0+%28accessed+2021-02-09%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCoronavirus%2520%2528COVID-19%2529%2520Update%253A%250AFDA%2520Authorizes%2520Monoclonal%2520Antibodies%250Afor%2520Treatment%2520of%2520COVID-19%26pub%3DU.S.%2520Food%2520and%250ADrug%2520Administration%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillaiyar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manickam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easwaran, M.</span></span> <span> </span><span class="NLM_article-title">The recent outbreaks of human coronaviruses: A medicinal chemistry perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">72</span>â <span class="NLM_lpage">135</span>, <span class="refDoi">Â DOI: 10.1002/med.21724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Fmed.21724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32852058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhsVagt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2021&pages=72-135&author=T.+Pillaiyarauthor=L.+L.+Wendtauthor=M.+Manickamauthor=M.+Easwaran&title=The+recent+outbreaks+of+human+coronaviruses%3A+A+medicinal+chemistry+perspective&doi=10.1002%2Fmed.21724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The recent outbreaks of human coronaviruses: A medicinal chemistry perspective</span></div><div class="casAuthors">Pillaiyar, Thanigaimalai; Wendt, Lukas L.; Manickam, Manoj; Easwaran, Maheswaran</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-135</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Coronaviruses (CoVs) infect both humans and animals.  In humans, CoVs can cause respiratory, kidney, heart, brain, and intestinal infections that can range from mild to lethal.  Since the start of the 21st century, three Î²-coronaviruses have crossed the species barrier to infect humans: severe-acute respiratory syndrome (SARS)-CoV-1, Middle East respiratory syndrome (MERS)-CoV, and SARS-CoV-2 (2019-nCoV).  These viruses are dangerous and can easily be transmitted from human to human.  Therefore, the development of anticoronaviral therapies is urgently needed.  However, to date, no approved vaccines or drugs against CoV infections are available.  In this review, we focus on the medicinal chem. efforts toward the development of antiviral agents against SARS-CoV-1, MERS-CoV, SARS-CoV-2, targeting biochem. events important for viral replication and its life cycle.  These targets include the spike glycoprotein and its host-receptors for viral entry, proteases that are essential for cleaving polyproteins to produce functional proteins, and RNA-dependent RNA polymerase for viral RNA replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowH3Dpqna3Q7Vg90H21EOLACvtfcHk0li_Do6Ea3c5CA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhsVagt7Y%253D&md5=efe56354f1182ce8c16cede75e04842b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fmed.21724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21724%26sid%3Dliteratum%253Aachs%26aulast%3DPillaiyar%26aufirst%3DT.%26aulast%3DWendt%26aufirst%3DL.%2BL.%26aulast%3DManickam%26aufirst%3DM.%26aulast%3DEaswaran%26aufirst%3DM.%26atitle%3DThe%2520recent%2520outbreaks%2520of%2520human%2520coronaviruses%253A%2520A%2520medicinal%2520chemistry%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2021%26volume%3D41%26spage%3D72%26epage%3D135%26doi%3D10.1002%2Fmed.21724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillaiyar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meenakshisundaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manickam, M.</span></span> <span> </span><span class="NLM_article-title">Recent discovery and development of inhibitors targeting coronaviruses</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">668</span>â <span class="NLM_lpage">688</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2020.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.drudis.2020.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32006468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFKgtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=668-688&author=T.+Pillaiyarauthor=S.+Meenakshisundaramauthor=M.+Manickam&title=Recent+discovery+and+development+of+inhibitors+targeting+coronaviruses&doi=10.1016%2Fj.drudis.2020.01.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Recent discovery and development of inhibitors targeting coronaviruses</span></div><div class="casAuthors">Pillaiyar, Thanigaimalai; Meenakshisundaram, Sangeetha; Manickam, Manoj</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">668-688</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Human coronaviruses (CoVs) are enveloped viruses with a pos.-sense single-stranded RNA genome.  Currently, six human CoVs have been reported including human coronavirus 229E (HCoV-229E), OC43 (HCoV-OC43), NL63 (HCoV-NL63), HKU1 (HCoV-HKU1), severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and MiddleEast respiratory syndrome (MERS) coronavirus (MERS-CoV).  They cause moderate to severe respiratory and intestinal infections in humans.  In this review, we focus on recent advances in the research and development of small-mol. anti-human coronavirus therapies targeting different stages of the CoV life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGaJIxrfUjnLVg90H21EOLACvtfcHk0li_Do6Ea3c5CA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFKgtro%253D&md5=08faec7e1ec7df3a3f6d4c4e34fe0807</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2020.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2020.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DPillaiyar%26aufirst%3DT.%26aulast%3DMeenakshisundaram%26aufirst%3DS.%26aulast%3DManickam%26aufirst%3DM.%26atitle%3DRecent%2520discovery%2520and%2520development%2520of%2520inhibitors%2520targeting%2520coronaviruses%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D668%26epage%3D688%26doi%3D10.1016%2Fj.drudis.2020.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span> <span> </span><span class="NLM_article-title">The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status</span>. <i>Military Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11</span>, <span class="refDoi">Â DOI: 10.1186/s40779-020-00240-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2Fs40779-020-00240-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32169119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXns1aht78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2020&pages=11&author=Y.+R.+Guoauthor=Q.+D.+Caoauthor=Z.+S.+Hongauthor=Y.+Y.+Tanauthor=S.+D.+Chenauthor=H.+J.+Jinauthor=K.+S.+Tanauthor=D.+Y.+Wangauthor=Y.+Yan&title=The+origin%2C+transmission+and+clinical+therapies+on+coronavirus+disease+2019+%28COVID-19%29+outbreak+-+an+update+on+the+status&doi=10.1186%2Fs40779-020-00240-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status</span></div><div class="casAuthors">Guo, Yan-Rong; Cao, Qing-Dong; Hong, Zhong-Si; Tan, Yuan-Yang; Chen, Shou-Deng; Jin, Hong-Jun; Tan, Kai-Sen; Wang, De-Yun; Yan, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Military Medical Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11</span>CODEN:
                <span class="NLM_cas:coden">MMRICN</span>;
        ISSN:<span class="NLM_cas:issn">2054-9369</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention.  On 30 Jan. 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern.  The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the 3rd introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the 21st century.  As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO.  Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to Î²-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host.  The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract.  Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe.  The clin. symptoms of COVID-19 patients include fever, cough, fatigue, and a small population of patients appeared gastrointestinal infection symptoms.  The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be assocd. with acute respiratory distress syndrome (ARDS) and cytokine storm.  Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation.  We summarized the latest research progress of the epidemiol., pathogenesis, and clin. characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKHUTw0IleQbVg90H21EOLACvtfcHk0lgKnCiTA7EhHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXns1aht78%253D&md5=040aa4a4b4c385793ea2e49c536299f3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1186%2Fs40779-020-00240-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40779-020-00240-0%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%2BR.%26aulast%3DCao%26aufirst%3DQ.%2BD.%26aulast%3DHong%26aufirst%3DZ.%2BS.%26aulast%3DTan%26aufirst%3DY.%2BY.%26aulast%3DChen%26aufirst%3DS.%2BD.%26aulast%3DJin%26aufirst%3DH.%2BJ.%26aulast%3DTan%26aufirst%3DK.%2BS.%26aulast%3DWang%26aufirst%3DD.%2BY.%26aulast%3DYan%26aufirst%3DY.%26atitle%3DThe%2520origin%252C%2520transmission%2520and%2520clinical%2520therapies%2520on%2520coronavirus%2520disease%25202019%2520%2528COVID-19%2529%2520outbreak%2520-%2520an%2520update%2520on%2520the%2520status%26jtitle%3DMilitary%2520Med.%2520Res.%26date%3D2020%26volume%3D7%26spage%3D11%26doi%3D10.1186%2Fs40779-020-00240-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunderink, R. G.</span></span> <span> </span><span class="NLM_article-title">MERS, SARS and other coronaviruses as causes of pneumonia</span>. <i>Respirology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">130</span>â <span class="NLM_lpage">137</span>, <span class="refDoi">Â DOI: 10.1111/resp.13196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1111%2Fresp.13196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29052924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC1M7islyhtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=130-137&author=Y.+Yinauthor=R.+G.+Wunderink&title=MERS%2C+SARS+and+other+coronaviruses+as+causes+of+pneumonia&doi=10.1111%2Fresp.13196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">MERS, SARS and other coronaviruses as causes of pneumonia</span></div><div class="casAuthors">Yin Yudong; Wunderink Richard G</div><div class="citationInfo"><span class="NLM_cas:title">Respirology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human coronaviruses (HCoVs) have been considered to be relatively harmless respiratory pathogens in the past.  However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection.  This review focuses on the epidemiology, pathogenesis and clinical characteristics among SARS-coronaviruses (CoV), MERS-CoV and other HCoV infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOAujGwxBhcwHqQV89nF-2fW6udTcc2eaqYf3b-7Yhnbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7islyhtg%253D%253D&md5=cb5739c9d94f762af1bc4738e0134331</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fresp.13196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fresp.13196%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DY.%26aulast%3DWunderink%26aufirst%3DR.%2BG.%26atitle%3DMERS%252C%2520SARS%2520and%2520other%2520coronaviruses%2520as%2520causes%2520of%2520pneumonia%26jtitle%3DRespirology%26date%3D2018%26volume%3D23%26spage%3D130%26epage%3D137%26doi%3D10.1111%2Fresp.13196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillaiyar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manickam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. H.</span></span> <span> </span><span class="NLM_article-title">An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6595</span>â <span class="NLM_lpage">628</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01461</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01461" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyns7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6595-628&author=T.+Pillaiyarauthor=M.+Manickamauthor=V.+Namasivayamauthor=Y.+Hayashiauthor=S.+H.+Jung&title=An+overview+of+severe+acute+respiratory+syndrome-coronavirus+%28SARS-CoV%29+3CL+protease+inhibitors%3A+Peptidomimetics+and+small+molecule+chemotherapy&doi=10.1021%2Facs.jmedchem.5b01461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy</span></div><div class="casAuthors">Pillaiyar, Thanigaimalai; Manickam, Manoj; Namasivayam, Vigneshwaran; Hayashi, Yoshio; Jung, Sang-Hun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6595-6628</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus that infected more than 8000 individuals and resulted in more than 800 (10-15%) fatalities in 2003.  The causative agent of SARS has been identified as a novel human coronavirus (SARS-CoV), and its viral protease, SARS-CoV 3CLpro, has been shown to be essential for replication and has hence been recognized as a potent drug target for SARS infection.  Currently, there is no effective treatment for this epidemic despite the intensive research that has been undertaken since 2003 (over 3500 publications).  This perspective focuses on the status of various efficacious anti-SARS-CoV 3CLpro chemotherapies discovered during the last 12 years (2003-2015) from all sources, including lab. synthetic methods, natural products, and virtual screening.  We describe here mainly peptidomimetic and small mol. inhibitors of SARS-CoV 3CLpro.  Attempts have been made to provide a complete description of the structural features and binding modes of these inhibitors under many conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB_JCXe-m0RLVg90H21EOLACvtfcHk0lgKnCiTA7EhHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyns7c%253D&md5=6ce37076204280f64a7f362633fcee1a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01461%26sid%3Dliteratum%253Aachs%26aulast%3DPillaiyar%26aufirst%3DT.%26aulast%3DManickam%26aufirst%3DM.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DJung%26aufirst%3DS.%2BH.%26atitle%3DAn%2520overview%2520of%2520severe%2520acute%2520respiratory%2520syndrome-coronavirus%2520%2528SARS-CoV%2529%25203CL%2520protease%2520inhibitors%253A%2520Peptidomimetics%2520and%2520small%2520molecule%2520chemotherapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6595%26epage%3D628%26doi%3D10.1021%2Facs.jmedchem.5b01461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span> <i>Summary of probable SARS cases with onset of illness from
1 November
2002 to 31 July 2003</i>. <a href="https://www.who.int/csr/sars/country/table2004_04_21/en/" class="extLink">https://www.who.int/csr/sars/country/table2004_04_21/en/</a> (as of 31 December <span class="NLM_year">2003</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Summary+of+probable+SARS+cases+with+onset+of+illness+from%0A1+November%0A2002+to+31+July+2003.+https%3A%2F%2Fwww.who.int%2Fcsr%2Fsars%2Fcountry%2Ftable2004_04_21%2Fen%2F+%28as+of+31+December+2003%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DSummary%2520of%2520probable%2520SARS%2520cases%2520with%2520onset%2520of%2520illness%2520from%250A1%2520November%250A2002%2520to%252031%2520July%25202003%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daszak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karesh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipkin, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, S. S.</span></span>; <span class="NLM_contrib-group">PREDICT consortium</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazet, J. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, T.</span></span> <span> </span><span class="NLM_article-title">Global patterns in coronavirus diversity</span>. <i>Virus Evol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">vex012</span> <span class="refDoi">Â DOI: 10.1093/ve/vex012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1093%2Fve%2Fvex012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28630747" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&issue=1&author=S.+J.+Anthonyauthor=C.+K.+Johnsonauthor=D.+J.+Greigauthor=S.+Kramerauthor=X.+Cheauthor=H.+Wellsauthor=A.+L.+Hicksauthor=D.+O.+Jolyauthor=N.+D.+Wolfeauthor=P.+Daszakauthor=W.+Kareshauthor=W.+I.+Lipkinauthor=S.+S.+Morseauthor=PREDICT+consortiumauthor=J.+A.+K.+Mazetauthor=T.+Goldstein&title=Global+patterns+in+coronavirus+diversity&doi=10.1093%2Fve%2Fvex012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Fve%2Fvex012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fve%252Fvex012%26sid%3Dliteratum%253Aachs%26aulast%3DAnthony%26aufirst%3DS.%2BJ.%26aulast%3DJohnson%26aufirst%3DC.%2BK.%26aulast%3DGreig%26aufirst%3DD.%2BJ.%26aulast%3DKramer%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DX.%26aulast%3DWells%26aufirst%3DH.%26aulast%3DHicks%26aufirst%3DA.%2BL.%26aulast%3DJoly%26aufirst%3DD.%2BO.%26aulast%3DWolfe%26aufirst%3DN.%2BD.%26aulast%3DDaszak%26aufirst%3DP.%26aulast%3DKaresh%26aufirst%3DW.%26aulast%3DLipkin%26aufirst%3DW.%2BI.%26aulast%3DMorse%26aufirst%3DS.%2BS.%26aulast%3D%26aulast%3DMazet%26aufirst%3DJ.%2BA.%2BK.%26aulast%3DGoldstein%26aufirst%3DT.%26atitle%3DGlobal%2520patterns%2520in%2520coronavirus%2520diversity%26jtitle%3DVirus%2520Evol.%26date%3D2017%26volume%3D3%26issue%3D1%26doi%3D10.1093%2Fve%2Fvex012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillaiyar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manickam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. H.</span></span> <span> </span><span class="NLM_article-title">Middle East respiratory syndrome-coronavirus (MERS-CoV): An updated overview and pharmacotherapeutics</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">361</span>â <span class="NLM_lpage">372</span>, <span class="refDoi">Â DOI: 10.4172/2161-0444.1000287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.4172%2F2161-0444.1000287" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=361-372&author=T.+Pillaiyarauthor=M.+Manickamauthor=S.+H.+Jung&title=Middle+East+respiratory+syndrome-coronavirus+%28MERS-CoV%29%3A+An+updated+overview+and+pharmacotherapeutics&doi=10.4172%2F2161-0444.1000287"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.4172%2F2161-0444.1000287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2161-0444.1000287%26sid%3Dliteratum%253Aachs%26aulast%3DPillaiyar%26aufirst%3DT.%26aulast%3DManickam%26aufirst%3DM.%26aulast%3DJung%26aufirst%3DS.%2BH.%26atitle%3DMiddle%2520East%2520respiratory%2520syndrome-coronavirus%2520%2528MERS-CoV%2529%253A%2520An%2520updated%2520overview%2520and%2520pharmacotherapeutics%26jtitle%3DMed.%2520Chem.%26date%3D2015%26volume%3D5%26spage%3D361%26epage%3D372%26doi%3D10.4172%2F2161-0444.1000287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><a href="http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html" class="extLink">http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html</a> (as of March <span class="NLM_year">2021</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.emro.who.int%2Fhealth-topics%2Fmers-cov%2Fmers-outbreaks.html+%28as+of+March+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span> <span> </span><span class="NLM_article-title">Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">565</span>â <span class="NLM_lpage">574</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30251-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS0140-6736%2820%2930251-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32007145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFOmsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=565-574&author=R.+Luauthor=X.+Zhaoauthor=J.+Liauthor=P.+Niuauthor=B.+Yangauthor=H.+Wuauthor=W.+Wangauthor=H.+Songauthor=B.+Huangauthor=N.+Zhuauthor=Y.+Biauthor=X.+Maauthor=F.+Zhanauthor=L.+Wangauthor=T.+Huauthor=H.+Zhouauthor=Z.+Huauthor=W.+Zhouauthor=L.+Zhaoauthor=J.+Chenauthor=Y.+Mengauthor=J.+Wangauthor=Y.+Linauthor=J.+Yuanauthor=Z.+Xieauthor=J.+Maauthor=W.+J.+Liuauthor=D.+Wangauthor=W.+Xuauthor=E.+C.+Holmesauthor=G.+F.+Gaoauthor=G.+Wuauthor=W.+Chenauthor=W.+Shiauthor=W.+Tan&title=Genomic+characterisation+and+epidemiology+of+2019+novel+coronavirus%3A+Implications+for+virus&doi=10.1016%2FS0140-6736%2820%2930251-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</span></div><div class="casAuthors">Lu, Roujian; Zhao, Xiang; Li, Juan; Niu, Peihua; Yang, Bo; Wu, Honglong; Wang, Wenling; Song, Hao; Huang, Baoying; Zhu, Na; Bi, Yuhai; Ma, Xuejun; Zhan, Faxian; Wang, Liang; Hu, Tao; Zhou, Hong; Hu, Zhenhong; Zhou, Weimin; Zhao, Li; Chen, Jing; Meng, Yao; Wang, Ji; Lin, Yang; Yuan, Jianying; Xie, Zhihao; Ma, Jinmin; Liu, William J.; Wang, Dayan; Xu, Wenbo; Holmes, Edward C.; Gao, George F.; Wu, Guizhen; Chen, Weijun; Shi, Weifeng; Tan, Wenjie</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10224</span>),
    <span class="NLM_cas:pages">565-574</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In late Dec., 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China.  A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV).  As of Jan 26, 2020, more than 2000 cases of 2019-nCoV infection have been confirmed, most of which involved people living in or visiting Wuhan, and human-to-human transmission has been confirmed.  We did next-generation sequencing of samples from bronchoalveolar lavage fluid and cultured isolates from nine inpatients, eight of whom had visited the Huanan seafood market in Wuhan.  Complete and partial 2019-nCoV genome sequences were obtained from these individuals.  Viral contigs were connected using Sanger sequencing to obtain the full-length genomes, with the terminal regions detd. by rapid amplification of cDNA ends.  Phylogenetic anal. of these 2019-nCoV genomes and those of other coronaviruses was used to det. the evolutionary history of the virus and help infer its likely origin.  Homol. modeling was done to explore the likely receptor-binding properties of the virus.  The ten genome sequences of 2019-nCoV obtained from the nine patients were extremely similar, exhibiting more than 99Â·98% sequence identity.  Notably, 2019-nCoV was closely related (with 88% identity) to two bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21, collected in 2018 in Zhoushan, eastern China, but were more distant from SARS-CoV (about 79%) and MERS-CoV (about 50%).  Phylogenetic anal. revealed that 2019-nCoV fell within the subgenus Sarbecovirus of the genus Betacoronavirus, with a relatively long branch length to its closest relatives bat-SL-CoVZC45 and bat-SL-CoVZXC21, and was genetically distinct from SARS-CoV.  Notably, homol. modeling revealed that 2019-nCoV had a similar receptor-binding domain structure to that of SARS-CoV, despite amino acid variation at some key residues.2019-nCoV is sufficiently divergent from SARS-CoV to be considered a new human-infecting betacoronavirus.  Although our phylogenetic anal. suggests that bats might be the original host of this virus, an animal sold at the seafood market in Wuhan might represent an intermediate host facilitating the emergence of the virus in humans.  Importantly, structural anal. suggests that 2019-nCoV might be able to bind to the angiotensin-converting enzyme 2 receptor in humans.  The future evolution, adaptation, and spread of this virus warrant urgent investigation.  National Key Research and Development Program of China, National Major Project for Control and Prevention of Infectious Disease in China, Chinese Academy of Sciences, Shandong First Medical University.  These data have been deposited in the ChinaNational Microbiol. Data Center (accession no. NMDC10013002 and genome accession nos. NMDC60013002-01 to NMDC60013002-10) and the datafrom BGI have been deposited in the China National GeneBank (accession nos. CNA000733235).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSLcS-1ejQbVg90H21EOLACvtfcHk0lgIG_YkYeeLwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFOmsLY%253D&md5=3a644f602ea1c68114e23b5f12625265</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930251-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930251-8%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%2BJ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DHolmes%26aufirst%3DE.%2BC.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DTan%26aufirst%3DW.%26atitle%3DGenomic%2520characterisation%2520and%2520epidemiology%2520of%25202019%2520novel%2520coronavirus%253A%2520Implications%2520for%2520virus%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D565%26epage%3D574%26doi%3D10.1016%2FS0140-6736%2820%2930251-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupoli, T. J.</span></span> <span> </span><span class="NLM_article-title">Exploiting existing molecular scaffolds for long-term COVID treatment</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1357</span>â <span class="NLM_lpage">1360</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.0c00254</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00254" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVGhurrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1357-1360&author=K.+Kumarauthor=T.+J.+Lupoli&title=Exploiting+existing+molecular+scaffolds+for+long-term+COVID+treatment&doi=10.1021%2Facsmedchemlett.0c00254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting existing molecular scaffolds for long-term COVID treatment</span></div><div class="casAuthors">Kumar, Krishna; Lupoli, Tania J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1357-1360</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Discovery and development of COVID-19 prophylactics and treatments remains a global imperative.  This perspective provides an overview of important mol. pathways involved in the viral life cycle of SARS-CoV-2, the infectious agent of COVID-19.  The authors highlight past and recent findings in essential coronavirus proteins, including RNA polymerase machinery, proteases, and fusion proteins, that offer opportunities for the design of novel inhibitors of SARS-CoV-2 infection.  By discussing the current inventory of viral inhibitors, the authors identify mol. scaffolds that may be improved by medicinal chem. efforts for effective therapeutics to treat current and future coronavirus-caused diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNdM1L0txxVrVg90H21EOLACvtfcHk0lgIG_YkYeeLwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVGhurrE&md5=cbaa88ccb52fb147bda055affe317ffa</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00254%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DLupoli%26aufirst%3DT.%2BJ.%26atitle%3DExploiting%2520existing%2520molecular%2520scaffolds%2520for%2520long-term%2520COVID%2520treatment%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1357%26epage%3D1360%26doi%3D10.1021%2Facsmedchemlett.0c00254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKee, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stange, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naujokat, C.</span></span> <span> </span><span class="NLM_article-title">Candidate drugs against SARS-CoV-2 and COVID-19</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">104859</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2020.104859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.phrs.2020.104859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32360480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovFKht7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2020&pages=104859&author=D.+L.+McKeeauthor=A.+Sternbergauthor=U.+Stangeauthor=S.+Lauferauthor=C.+Naujokat&title=Candidate+drugs+against+SARS-CoV-2+and+COVID-19&doi=10.1016%2Fj.phrs.2020.104859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Candidate drugs against SARS-CoV-2 and COVID-19</span></div><div class="casAuthors">McKee, Dwight L.; Sternberg, Ariane; Stange, Ulrike; Laufer, Stefan; Naujokat, Cord</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104859</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future.  Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacol. strategy to combat the virus.  There exists a no. of candidate drugs that may inhibit infection with and replication of SARS-CoV-2.  Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2).  Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2.  Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analog remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochems. available to date may limit spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlH8zxqu9S37Vg90H21EOLACvtfcHk0lgIG_YkYeeLwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovFKht7g%253D&md5=9956ee00baf6844137067e6b2c4f626e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2020.104859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2020.104859%26sid%3Dliteratum%253Aachs%26aulast%3DMcKee%26aufirst%3DD.%2BL.%26aulast%3DSternberg%26aufirst%3DA.%26aulast%3DStange%26aufirst%3DU.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DNaujokat%26aufirst%3DC.%26atitle%3DCandidate%2520drugs%2520against%2520SARS-CoV-2%2520and%2520COVID-19%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D157%26spage%3D104859%26doi%3D10.1016%2Fj.phrs.2020.104859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiogi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koutsogiannaki, S.</span></span> <span> </span><span class="NLM_article-title">COVID-19 pathophysiology: A review</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">108427</span>, <span class="refDoi">Â DOI: 10.1016/j.clim.2020.108427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.clim.2020.108427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32325252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosFWitr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2020&pages=108427&author=K.+Yukiauthor=M.+Fujiogiauthor=S.+Koutsogiannaki&title=COVID-19+pathophysiology%3A+A+review&doi=10.1016%2Fj.clim.2020.108427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19 pathophysiology: A review</span></div><div class="casAuthors">Yuki, Koichi; Fujiogi, Miho; Koutsogiannaki, Sophia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">108427</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In Dec. 2019, a novel coronavirus, now named as SARS-CoV-2, caused a series of acute atypical respiratory diseases in Wuhan, Hubei Province, China.  The disease caused by this virus was termed COVID-19.  The virus is transmittable between humans and has caused pandemic worldwide.  The no. of death tolls continues to rise and a large no. of countries have been forced to do social distancing and lockdown.  Lack of targeted therapy continues to be a problem.  Epidemiol. studies showed that elder patients were more susceptible to severe diseases, while children tend to have milder symptoms.  Here we reviewed the current knowledge about this disease and considered the potential explanation of the different symptomatol. between children and adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3DUqtixUaorVg90H21EOLACvtfcHk0lh39mCbDUzCBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosFWitr0%253D&md5=8c97d9785e6bfbf2a1885e12400cc55f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2020.108427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2020.108427%26sid%3Dliteratum%253Aachs%26aulast%3DYuki%26aufirst%3DK.%26aulast%3DFujiogi%26aufirst%3DM.%26aulast%3DKoutsogiannaki%26aufirst%3DS.%26atitle%3DCOVID-19%2520pathophysiology%253A%2520A%2520review%26jtitle%3DClin.%2520Immunol.%26date%3D2020%26volume%3D215%26spage%3D108427%26doi%3D10.1016%2Fj.clim.2020.108427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Attaway, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheraga, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhimraj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biehl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HatipoÄlu, U.</span></span> <span> </span><span class="NLM_article-title">Severe covid-19 pneumonia: Pathogenesis and clinical management</span>. <i>BMJ.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>372</i></span>, <span class="NLM_elocation-id">n436</span> <span class="refDoi">Â DOI: 10.1136/bmj.n436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1136%2Fbmj.n436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33692022" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2021&author=A.+H.+Attawayauthor=R.+G.+Scheragaauthor=A.+Bhimrajauthor=M.+Biehlauthor=U.+Hatipo%C4%9Flu&title=Severe+covid-19+pneumonia%3A+Pathogenesis+and+clinical+management&doi=10.1136%2Fbmj.n436"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1136%2Fbmj.n436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.n436%26sid%3Dliteratum%253Aachs%26aulast%3DAttaway%26aufirst%3DA.%2BH.%26aulast%3DScheraga%26aufirst%3DR.%2BG.%26aulast%3DBhimraj%26aufirst%3DA.%26aulast%3DBiehl%26aufirst%3DM.%26aulast%3DHatipo%25C4%259Flu%26aufirst%3DU.%26atitle%3DSevere%2520covid-19%2520pneumonia%253A%2520Pathogenesis%2520and%2520clinical%2520management%26jtitle%3DBMJ.%26date%3D2021%26volume%3D372%26doi%3D10.1136%2Fbmj.n436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Coronavirus infections and immune responses</span>. <i>J. Med. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">424</span>â <span class="NLM_lpage">432</span>, <span class="refDoi">Â DOI: 10.1002/jmv.25685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Fjmv.25685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31981224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntVKntr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2020&pages=424-432&author=G.+Liauthor=Y.+Fanauthor=Y.+Laiauthor=T.+Hanauthor=Z.+Liauthor=P.+Zhouauthor=P.+Panauthor=W.+Wangauthor=D.+Huauthor=X.+Liuauthor=Q.+Zhangauthor=J.+Wu&title=Coronavirus+infections+and+immune+responses&doi=10.1002%2Fjmv.25685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Coronavirus infections and immune responses</span></div><div class="casAuthors">Li, Geng; Fan, Yaohua; Lai, Yanni; Han, Tiantian; Li, Zonghui; Zhou, Peiwen; Pan, Pan; Wang, Wenbiao; Hu, Dingwen; Liu, Xiaohong; Zhang, Qiwei; Wu, Jianguo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Virology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-432</span>CODEN:
                <span class="NLM_cas:coden">JMVIDB</span>;
        ISSN:<span class="NLM_cas:issn">0146-6615</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Coronaviruses (CoVs) are by far the largest group of known pos.-sense RNA viruses having an extensive range of natural hosts.  In the past few decades, newly evolved Coronaviruses have posed a global threat to public health.  The immune response is essential to control and eliminate CoV infections, however, maladjusted immune responses may result in immunopathol. and impaired pulmonary gas exchange.  Gaining a deeper understanding of the interaction between Coronaviruses and the innate immune systems of the hosts may shed light on the development and persistence of inflammation in the lungs and hopefully can reduce the risk of lung inflammation caused by CoVs.  In this review, we provide an update on CoV infections and relevant diseases, particularly the host defense against CoV-induced inflammation of lung tissue, as well as the role of the innate immune system in the pathogenesis and clin. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV2qgbg4xqk7Vg90H21EOLACvtfcHk0lh39mCbDUzCBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntVKntr4%253D&md5=f2de904af37ab888695f51c9b9222ac0</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fjmv.25685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmv.25685%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DG.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DCoronavirus%2520infections%2520and%2520immune%2520responses%26jtitle%3DJ.%2520Med.%2520Virol.%26date%3D2020%26volume%3D92%26spage%3D424%26epage%3D432%26doi%3D10.1002%2Fjmv.25685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span> <span> </span><span class="NLM_article-title">Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">497</span>â <span class="NLM_lpage">506</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30183-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS0140-6736%2820%2930183-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31986264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Kqu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=497-506&author=C.+Huangauthor=Y.+Wangauthor=X.+Liauthor=L.+Renauthor=J.+Zhaoauthor=Y.+Huauthor=L.+Zhangauthor=G.+Fanauthor=J.+Xuauthor=X.+Guauthor=Z.+Chengauthor=T.+Yuauthor=J.+Xiaauthor=Y.+Weiauthor=W.+Wuauthor=X.+Xieauthor=W.+Yinauthor=H.+Liauthor=M.+Liuauthor=Y.+Xiaoauthor=H.+Gaoauthor=L.+Guoauthor=J.+Xieauthor=G.+Wangauthor=R.+Jiangauthor=H.+Gaoauthor=Q.+Jinauthor=J.+Wangauthor=B.+Cao&title=Clinical+features+of+patients+infected+with+2019+novel+coronavirus+in+Wuhan%2C+China&doi=10.1016%2FS0140-6736%2820%2930183-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</span></div><div class="casAuthors">Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10223</span>),
    <span class="NLM_cas:pages">497-506</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV).  We report the epidemiol., clin., lab., and radiol. characteristics and treatment and clin. outcomes of these patients.  All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan.  We prospectively collected and analyzed data on patients with lab.-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing.  Data were obtained with standardised data collection forms shared by the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records.  Researchers also directly communicated with patients or their families to ascertain epidemiol. and symptom data.  Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not.  By Jan 2, 2020, 41 admitted hospital patients had been identified as having lab.-confirmed 2019-nCoV infection.  Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]).  Median age was 49Â·0 years (IQR 41Â·0-58Â·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market.  One family cluster was found.  Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum prodn. (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38).  Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8Â·0 days [IQR 5Â·0-13Â·0]).  26 (63%) Of 41 patients had lymphopenia.  All 41 patients had pneumonia with abnormal findings on chest CT.  Complications included acute respiratory distress syndrome (12 [29%]), RNAemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died.  Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.  The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was assocd. with ICU admission and high mortality.  Major gaps in our knowledge of the origin, epidemiol., duration of human transmission, and clin. spectrum of disease need fulfilment by future studies.  Ministry of Science and Technol., Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technol. Commission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1VbprmL3SvLVg90H21EOLACvtfcHk0ljtJ-udrXodEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Kqu7c%253D&md5=b279b965c1054d99e60f673859c03b49</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930183-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930183-5%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DYin%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DB.%26atitle%3DClinical%2520features%2520of%2520patients%2520infected%2520with%25202019%2520novel%2520coronavirus%2520in%2520Wuhan%252C%2520China%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D497%26epage%3D506%26doi%3D10.1016%2FS0140-6736%2820%2930183-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. Q.</span></span> <span> </span><span class="NLM_article-title">The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">105954</span>, <span class="refDoi">Â DOI: 10.1016/j.ijantimicag.2020.105954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.ijantimicag.2020.105954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32234467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFOjtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2020&pages=105954&author=C.+Zhangauthor=Z.+Wuauthor=J.+W.+Liauthor=H.+Zhaoauthor=G.+Q.+Wang&title=The+cytokine+release+syndrome+%28CRS%29+of+severe+COVID-19+and+Interleukin-6+receptor+%28IL-6R%29+antagonist+Tocilizumab+may+be+the+key+to+reduce+the+mortality&doi=10.1016%2Fj.ijantimicag.2020.105954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality</span></div><div class="casAuthors">Zhang, Chi; Wu, Zhao; Li, Jia-Wen; Zhao, Hong; Wang, Gui-Qiang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">105954</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since Dec. 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world.  Although the case fatality rate is not high, the no. of people infected is large, and there are still a large no. of patients dying.  With the collation and publication of more and more clin. data, a large no. of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death.  Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients.  Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS).  If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients.  Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway.  So, tocilizumab is likely to become an effective drug for patients with severe COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfTK01cYVuX7Vg90H21EOLACvtfcHk0ljtJ-udrXodEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFOjtbc%253D&md5=d25c0da775acd071c4e93b372e8e032c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2020.105954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2020.105954%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%2BW.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DG.%2BQ.%26atitle%3DThe%2520cytokine%2520release%2520syndrome%2520%2528CRS%2529%2520of%2520severe%2520COVID-19%2520and%2520Interleukin-6%2520receptor%2520%2528IL-6R%2529%2520antagonist%2520Tocilizumab%2520may%2520be%2520the%2520key%2520to%2520reduce%2520the%2520mortality%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2020%26volume%3D55%26spage%3D105954%26doi%3D10.1016%2Fj.ijantimicag.2020.105954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bermejo-Martin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danesh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelvin, D. J.</span></span> <span> </span><span class="NLM_article-title">Human immunopathogenesis of severe acute respiratory syndrome (SARS)</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">13</span>â <span class="NLM_lpage">19</span>, <span class="refDoi">Â DOI: 10.1016/j.virusres.2007.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.virusres.2007.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17374415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtlWksLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2008&pages=13-19&author=M.+J.+Cameronauthor=J.+F.+Bermejo-Martinauthor=A.+Daneshauthor=M.+P.+Mullerauthor=D.+J.+Kelvin&title=Human+immunopathogenesis+of+severe+acute+respiratory+syndrome+%28SARS%29&doi=10.1016%2Fj.virusres.2007.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Human immunopathogenesis of severe acute respiratory syndrome (SARS)</span></div><div class="casAuthors">Cameron, Mark J.; Bermejo-Martin, Jesus F.; Danesh, Ali; Muller, Matthew P.; Kelvin, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-19</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Progressive immune-assocd. injury is a hallmark of severe acute respiratory syndrome (SARS).  Viral evasion of innate immunity, hypercytokinemia and systemic immunopathol. in the SARS coronavirus (SARS CoV) infected host have been suggested as possible mechanisms for the cause of severe pathol. and morbidity in SARS patients.  The mol. and cellular basis for how SARS CoV impacts the host immune system resulting in severe SARS, however, has not been elucidated.  The variable clin. course of SARS may be the result of complex programs of host responses against the infectious agent.  Therefore, the systematic anal. of innate and adaptive immune responses to SARS CoV is imperative in building as complete an immunol. model as possible of host immunity and inflammatory responses during illness.  Here the authors review recent advances in SARS immunopathogenesis research and present a summary of their findings regarding host responses in SARS patients.  The authors contend that dysregulated type I and II interferon (IFN) responses during SARS may culminate in a failure of the switch from hyper-innate immunity to protective adaptive immune responses in the human host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFpRmeePaFHLVg90H21EOLACvtfcHk0ljtJ-udrXodEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtlWksLg%253D&md5=7500dd72d353eba5fe3c683d08a72eb6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2007.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2007.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DBermejo-Martin%26aufirst%3DJ.%2BF.%26aulast%3DDanesh%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%2BP.%26aulast%3DKelvin%26aufirst%3DD.%2BJ.%26atitle%3DHuman%2520immunopathogenesis%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520%2528SARS%2529%26jtitle%3DVirus%2520Res.%26date%3D2008%26volume%3D133%26spage%3D13%26epage%3D19%26doi%3D10.1016%2Fj.virusres.2007.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, R. C.</span></span> <span> </span><span class="NLM_article-title">The mercurial nature of neutrophils: Still an enigma in ARDS?</span>. <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">L217</span>â <span class="NLM_lpage">230</span>, <span class="refDoi">Â DOI: 10.1152/ajplung.00311.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1152%2Fajplung.00311.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24318116" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2014&pages=L217-230&author=A.+E.+Williamsauthor=R.+C.+Chambers&title=The+mercurial+nature+of+neutrophils%3A+Still+an+enigma+in+ARDS%3F&doi=10.1152%2Fajplung.00311.2013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00311.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00311.2013%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DA.%2BE.%26aulast%3DChambers%26aufirst%3DR.%2BC.%26atitle%3DThe%2520mercurial%2520nature%2520of%2520neutrophils%253A%2520Still%2520an%2520enigma%2520in%2520ARDS%253F%26jtitle%3DAm.%2520J.%2520Physiol.%2520Lung%2520Cell%2520Mol.%2520Physiol.%26date%3D2014%26volume%3D306%26spage%3DL217%26epage%3D230%26doi%3D10.1152%2Fajplung.00311.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F. S.</span></span> <span> </span><span class="NLM_article-title">Pathological findings of COVID-19 associated with acute respiratory distress syndrome</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">420</span>â <span class="NLM_lpage">422</span>, <span class="refDoi">Â DOI: 10.1016/S2213-2600(20)30076-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS2213-2600%2820%2930076-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32085846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsValtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=420-422&author=Z.+Xuauthor=L.+Shiauthor=Y.+Wangauthor=J.+Zhangauthor=L.+Huangauthor=C.+Zhangauthor=S.+Liuauthor=P.+Zhaoauthor=H.+Liuauthor=L.+Zhuauthor=Y.+Taiauthor=C.+Baiauthor=T.+Gaoauthor=J.+Songauthor=P.+Xiaauthor=J.+Dongauthor=J.+Zhaoauthor=F.+S.+Wang&title=Pathological+findings+of+COVID-19+associated+with+acute+respiratory+distress+syndrome&doi=10.1016%2FS2213-2600%2820%2930076-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Pathological findings of COVID-19 associated with acute respiratory distress syndrome</span></div><div class="casAuthors">Xu, Zhe; Shi, Lei; Wang, Yijin; Zhang, Jiyuan; Huang, Lei; Zhang, Chao; Liu, Shuhong; Zhao, Peng; Liu, Hongxia; Zhu, Li; Tai, Yanhong; Bai, Changqing; Gao, Tingting; Song, Jinwen; Xia, Peng; Dong, Jinghui; Zhao, Jingmin; Wang, Fu-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">420-422</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In late Dec., 2019, an outbreak of a novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was reported in Wuhan, China; it subsequently spread worldwide.  In general, COVID-19 is an acute resolved disease but it can also be deadly, with a 2% case fatality rate.  Severe disease onset might result in death due to massive alveolar damage and progressive respiratory failure.  Here, we investigated the pathol. characteristics of a patient who died from severe infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by obtaining biopsy samples at autopsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSW8W-Tknn3bVg90H21EOLACvtfcHk0ljUfdlgyMSuDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsValtbk%253D&md5=9eece7ef49ab45d13ff000ae1a43dfc2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2820%2930076-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252820%252930076-X%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DTai%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DXia%26aufirst%3DP.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%2BS.%26atitle%3DPathological%2520findings%2520of%2520COVID-19%2520associated%2520with%2520acute%2520respiratory%2520distress%2520syndrome%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2020%26volume%3D8%26spage%3D420%26epage%3D422%26doi%3D10.1016%2FS2213-2600%2820%2930076-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Repurposing of kinase inhibitors for treatment of COVID-19</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">167</span>, <span class="refDoi">Â DOI: 10.1007/s11095-020-02851-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs11095-020-02851-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32778962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKksrfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=167&author=E.+Weisbergauthor=A.+Parentauthor=P.+L.+Yangauthor=M.+Sattlerauthor=Q.+Liuauthor=Q.+Liuauthor=J.+Wangauthor=C.+Mengauthor=S.+J.+Buhrlageauthor=N.+Grayauthor=J.+D.+Griffin&title=Repurposing+of+kinase+inhibitors+for+treatment+of+COVID-19&doi=10.1007%2Fs11095-020-02851-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of Kinase Inhibitors for Treatment of COVID-19</span></div><div class="casAuthors">Weisberg, Ellen; Parent, Alexander; Yang, Priscilla L.; Sattler, Martin; Liu, Qingsong; Liu, Qingwang; Wang, Jinhua; Meng, Chengcheng; Buhrlage, Sara J.; Gray, Nathanael; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">167</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the scientific community.  In the absence of a vaccine, the goal is to target the viral life cycle and alleviate the lung-damaging symptoms of infection, which can be life-threatening.  There are numerous protein kinases assocd. with these processes that can be inhibited by FDA-approved drugs, the repurposing of which presents an alluring option as they have been thoroughly vetted for safety and are more readily available for treatment of patients and testing in clin. trials.  Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metab., or reprodn.  We also highlight inhibitors with potential to reverse pulmonary insufficiency because of their anti-inflammatory activity, cytokine suppression, or antifibrotic activity.  Certain agents are projected to be dual-purpose drugs in terms of antiviral activity and alleviation of disease symptoms, however drug combination is also an option for inhibitors with optimal pharmacokinetic properties that allow safe and efficacious co-administration with other drugs, such as antiviral agents, IL-6 blocking agents, or other kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotAd3_eFezr7Vg90H21EOLACvtfcHk0ljUfdlgyMSuDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKksrfN&md5=5edc7624fa51b69ec9d487262584a051</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs11095-020-02851-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-020-02851-7%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DParent%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DC.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DRepurposing%2520of%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520COVID-19%26jtitle%3DPharm.%2520Res.%26date%3D2020%26volume%3D37%26spage%3D167%26doi%3D10.1007%2Fs11095-020-02851-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mingo, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span> <span> </span><span class="NLM_article-title">Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">8924</span>â <span class="NLM_lpage">8933</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01429-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01429-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27466418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2lu7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=8924-8933&author=C.+M.+Colemanauthor=J.+M.+Siskauthor=R.+M.+Mingoauthor=E.+A.+Nelsonauthor=J.+M.+Whiteauthor=M.+B.+Frieman&title=Abelson+kinase+inhibitors+are+potent+inhibitors+of+severe+acute+respiratory+syndrome+coronavirus+and+middle+east+respiratory+syndrome+coronavirus+fusion&doi=10.1128%2FJVI.01429-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion</span></div><div class="casAuthors">Coleman, Christopher M.; Sisk, Jeanne M.; Mingo, Rebecca M.; Nelson, Elizabeth A.; White, Judith M.; Frieman, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8924-8933</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The highly pathogenic severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) cause significant morbidity and morality.  There is currently no approved therapeutic for highly pathogenic coronaviruses, even as MERS-CoV is spreading throughout the Middle East.  We previously screened a library of FDA-approved drugs for inhibitors of coronavirus replication in which we identified Abelson (Abl) kinase inhibitors, including the anticancer drug imatinib, as inhibitors of both SARS-CoV and MERS-CoV in vitro.  Here we show that the anti-CoV activity of imatinib occurs at the early stages of infection, after internalization and endosomal trafficking, by inhibiting fusion of the virions at the endosomal membrane.  We specifically identified the imatinib target, Abelson tyrosine-protein kinase 2 (Abl2), as required for efficient SARS-CoV and MERS-CoV replication in vitro.  These data demonstrate that specific approved drugs can be characterized in vitro for their anticoronavirus activity and used to identify host proteins required for coronavirus replication.  This type of study is an important step in the repurposing of approved drugs for treatment of emerging coronaviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJU1Zz7G1ED7Vg90H21EOLACvtfcHk0ljpFK6Qhk9gYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2lu7fE&md5=090a5b4bb7680982944fc665dfbdc5e5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1128%2FJVI.01429-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01429-16%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DC.%2BM.%26aulast%3DSisk%26aufirst%3DJ.%2BM.%26aulast%3DMingo%26aufirst%3DR.%2BM.%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26atitle%3DAbelson%2520kinase%2520inhibitors%2520are%2520potent%2520inhibitors%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%2520and%2520middle%2520east%2520respiratory%2520syndrome%2520coronavirus%2520fusion%26jtitle%3DJ.%2520Virol.%26date%3D2016%26volume%3D90%26spage%3D8924%26epage%3D8933%26doi%3D10.1128%2FJVI.01429-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sisk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machamer, C. E.</span></span> <span> </span><span class="NLM_article-title">Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">619</span>â <span class="NLM_lpage">630</span>, <span class="refDoi">Â DOI: 10.1099/jgv.0.001047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1099%2Fjgv.0.001047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29557770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVahtLjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2018&pages=619-630&author=J.+M.+Siskauthor=M.+B.+Friemanauthor=C.+E.+Machamer&title=Coronavirus+S+protein-induced+fusion+is+blocked+prior+to+hemifusion+by+Abl+kinase+inhibitors&doi=10.1099%2Fjgv.0.001047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors</span></div><div class="casAuthors">Sisk, Jeanne M.; Frieman, Matthew B.; Machamer, Carolyn E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">619-630</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">1465-2099</span>.
    
            (<span class="NLM_cas:orgname">Microbiology Society</span>)
        </div><div class="casAbstract">Enveloped viruses gain entry into host cells by fusing with cellular membranes, a step that is required for virus replication.  The virus spike (S) protein mediates fusion with the host cell membrane.  We have shown previously that an Abelson (Abl) kinase inhibitor, imatinib, significantly reduces SARS-CoV and MERS-CoV viral titers and prevents endosomal entry by HIV SARS S and MERS S pseudotyped virions.  SARS-CoV and MERS-CoV are classified as BSL-3 viruses, which makes experimentation into the cellular mechanisms involved in infection more challenging.  Here, we use IBV, a BSL-2 virus, as a model for studying the role of Abl kinase activity during coronavirus infection.  We found that imatinib and two specific Abl kinase inhibitors, GNF2 and GNF5, reduce IBV titers by blocking the first round of virus infection.  Addnl., all three drugs prevented IBV S-induced syncytia formation prior to the hemifusion step.  Our results indicate that membrane fusion (both virus-cell and cell-cell) is blocked in the presence of Abl kinase inhibitors.  Studying the effects of Abl kinase inhibitors on IBV will be useful in identifying the host cell pathways required for coronavirus infection.  This will provide an insight into possible therapeutic targets to treat infections by current as well as newly emerging coronaviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp3OXSytq77rVg90H21EOLACvtfcHk0ljpFK6Qhk9gYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVahtLjF&md5=af00456c0177a52a04764bcaeb717cdb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1099%2Fjgv.0.001047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fjgv.0.001047%26sid%3Dliteratum%253Aachs%26aulast%3DSisk%26aufirst%3DJ.%2BM.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26aulast%3DMachamer%26aufirst%3DC.%2BE.%26atitle%3DCoronavirus%2520S%2520protein-induced%2520fusion%2520is%2520blocked%2520prior%2520to%2520hemifusion%2520by%2520Abl%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2018%26volume%3D99%26spage%3D619%26epage%3D630%26doi%3D10.1099%2Fjgv.0.001047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, J. H.</span></span> <span> </span><span class="NLM_article-title">JNK and p38 mitogen-activated protein kinase pathways contribute to porcine epidemic diarrhea virus infection</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>222</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">12</span>, <span class="refDoi">Â DOI: 10.1016/j.virusres.2016.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.virusres.2016.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27215486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Shtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=2016&pages=1-12&author=C.+Leeauthor=Y.+Kimauthor=J.+H.+Jeon&title=JNK+and+p38+mitogen-activated+protein+kinase+pathways+contribute+to+porcine+epidemic+diarrhea+virus+infection&doi=10.1016%2Fj.virusres.2016.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">JNK and p38 mitogen-activated protein kinase pathways contribute to porcine epidemic diarrhea virus infection</span></div><div class="casAuthors">Lee, Changhee; Kim, Youngnam; Jeon, Ji Hyun</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) pathways, which are central building blocks in the intracellular signaling network, are often manipulated by viruses of diverse families to favor their replication.  Among the MAPK family, the extracellular signal-regulated kinase (ERK) pathway is known to be modulated during the infection with porcine epidemic diarrhea virus (PEDV); however, involvement of stress-activated protein kinases (SAPKs) comprising p38 MAPK and c-Jun NH2-terminal kinase (JNK) remains to be detd.  Therefore, in the present study, we investigated whether activation of p38 MAPK and JNK cascades is required for PEDV replication.  Our results showed that PEDV activates p38 MAPK and JNK1/2 up to 24 h post-infection, whereas, thereafter their phosphorylation levels recede to baseline levels or even fall below them.  Notably, UV-irradiated inactivated PEDV, which can enter cells but cannot replicate inside them, failed to induce phosphorylation of p38 MAPK and JNK1/2 suggesting that viral biosynthesis is essential for activation of these kinases.  Treatment of cells with selective p38 or JNK inhibitors markedly impaired PEDV replication in a dose-dependent manner and these antiviral effects were found to be maximal during the early times of the infection.  Furthermore, direct pharmacol. inhibition of p38 MAPK or JNK1/2 activation resulted in a significant redn. of viral RNA synthesis, viral protein expression, and progeny release.  However, independent treatments with either SAPK inhibitor did not inhibit PEDV-induced apoptotic cell death mediated by activation of mitochondrial apoptosis-inducing factor (AIF) suggesting that SAPKs are irrelevant to the apoptosis pathway during PEDV infection.  In summary, our data demonstrated crit. roles of the p38 and JNK1/2 signaling pathways in facilitating successful viral infection during the post-entry steps of the PEDV life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFU6UbPFBvXLVg90H21EOLACvtfcHk0ljpFK6Qhk9gYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Shtr4%253D&md5=c0bffb5299069d3fad2a3c1123040b14</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2016.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2016.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DJeon%26aufirst%3DJ.%2BH.%26atitle%3DJNK%2520and%2520p38%2520mitogen-activated%2520protein%2520kinase%2520pathways%2520contribute%2520to%2520porcine%2520epidemic%2520diarrhea%2520virus%2520infection%26jtitle%3DVirus%2520Res.%26date%3D2016%26volume%3D222%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.virusres.2016.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makino, S.</span></span> <span> </span><span class="NLM_article-title">Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">5937</span>â <span class="NLM_lpage">5948</span>, <span class="refDoi">Â DOI: 10.1128/JVI.76.12.5937-5948.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.76.12.5937-5948.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=12021326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlSru7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2002&pages=5937-5948&author=S.+Banerjeeauthor=K.+Narayananauthor=T.+Mizutaniauthor=S.+Makino&title=Murine+coronavirus+replication-induced+p38+mitogen-activated+protein+kinase+activation+promotes+interleukin-6+production+and+virus+replication+in+cultured+cells&doi=10.1128%2FJVI.76.12.5937-5948.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells</span></div><div class="casAuthors">Banerjee, Sangeeta; Narayanan, Krishna; Mizutani, Tetsuya; Makino, Shinji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5937-5948</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Analyses of mitogen-activated protein kinases (MAPKs) in a mouse hepatitis virus (MHV)-infected macrophage-derived J774.1 cell line showed activation of two MAPKs, p38 MAPK and c-Jun N-terminal kinase (JNK), but not of extracellular signal-regulated kinase (ERK).  Activation of MAPKs was evident by 6 h post-infection.  However, UV-irradiated MHV failed to activate MAPKs, which demonstrated that MHV replication was necessary for their activation.  Several other MHV-permissive cell lines also showed activation of both p38 MAPK and JNK, which indicated that the MHV-induced stress-kinase activation was not restricted to any particular cell type.  The upstream kinase responsible for activating MHV-induced p38 MAPK was the MAPK kinase 3.  Expts. with a specific inhibitor of p38 MAPK, SB 203580, demonstrated that MHV-induced p38 MAPK activation resulted in the accumulation of interleukin-6 (IL-6) mRNAs and an increase in the prodn. of IL-6, regardless of MHV-induced general host protein synthesis inhibition.  Furthermore, MHV prodn. was suppressed in SB 203580-treated cells, demonstrating that activated p38 MAPK played a role in MHV replication.  The reduced MHV prodn. in SB 203580-treated cells was, at least in part, due to a decrease in virus-specific protein synthesis and virus-specific mRNA accumulation.  Interestingly, there was a transient increase in the amt. of phosphorylation of the translation initiation factor 4E (eIF4E) in infected cells, and this eIF4E phosphorylation was p38 MAPK dependent; it is known that phosphorylated eIF4E enhances translation rates of cap-contg. mRNAs.  Furthermore, the upstream kinase responsible for eIF4E phosphorylation, MAPK-interacting kinase 1, was also phosphorylated and activated in response to MHV infection.  Our data suggested that host cells, in response to MHV replication, activated p38 MAPK, which subsequently phosphorylated eIF4E to efficiently translate certain host proteins, including IL-6, during virus-induced severe host protein synthesis inhibition.  MHV utilized this p38 MAPK-dependent increase in eIF4E phosphorylation to promote virus-specific protein synthesis and subsequent progeny virus prodn.  Enhancement of virus-specific protein synthesis through virus-induced eIF4E activation has not been reported in any other viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0BvjYf6qJwrVg90H21EOLACvtfcHk0ljpFK6Qhk9gYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlSru7g%253D&md5=a6bbc508aba8194d38d090363792355c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1128%2FJVI.76.12.5937-5948.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.76.12.5937-5948.2002%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DNarayanan%26aufirst%3DK.%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DMakino%26aufirst%3DS.%26atitle%3DMurine%2520coronavirus%2520replication-induced%2520p38%2520mitogen-activated%2520protein%2520kinase%2520activation%2520promotes%2520interleukin-6%2520production%2520and%2520virus%2520replication%2520in%2520cultured%2520cells%26jtitle%3DJ.%2520Virol.%26date%3D2002%26volume%3D76%26spage%3D5937%26epage%3D5948%26doi%3D10.1128%2FJVI.76.12.5937-5948.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirasawa, H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">150</span>â <span class="NLM_lpage">152</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2007.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2007.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18055026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlOlug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=150-152&author=M.+Konoauthor=K.+Tatsumiauthor=A.+M.+Imaiauthor=K.+Saitoauthor=T.+Kuriyamaauthor=H.+Shirasawa&title=Inhibition+of+human+coronavirus+229E+infection+in+human+epithelial+lung+cells+%28L132%29+by+chloroquine%3A+involvement+of+p38+MAPK+and+ERK&doi=10.1016%2Fj.antiviral.2007.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK</span></div><div class="casAuthors">Kono, Masakazu; Tatsumi, Koichiro; Imai, Alberto M.; Saito, Kengo; Kuriyama, Takayuki; Shirasawa, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">150-152</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The antiviral effects of chloroquine (CQ) on human coronavirus 229E (HCoV-229E) infection of human fetal lung cell line, L132 are reported.  CQ significantly decreased the viral replication at concns. lower than in clin. usage.  We demonstrated that CQ affects the activation of p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK).  Furthermore, p38 MAPK inhibitor, SB203580, inhibits CPE induced by HCoV-229E infection and viral replication.  Our findings suggest that CQ affects the activation of MAPKs, involved in the replication of HCoV-229E.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtCBeEC2erNLVg90H21EOLACvtfcHk0lj6XIfysNv7IQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlOlug%253D%253D&md5=33d4220cb47dd09c191e35275adff654</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DKono%26aufirst%3DM.%26aulast%3DTatsumi%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DA.%2BM.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DKuriyama%26aufirst%3DT.%26aulast%3DShirasawa%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520human%2520coronavirus%2520229E%2520infection%2520in%2520human%2520epithelial%2520lung%2520cells%2520%2528L132%2529%2520by%2520chloroquine%253A%2520involvement%2520of%2520p38%2520MAPK%2520and%2520ERK%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26spage%3D150%26epage%3D152%26doi%3D10.1016%2Fj.antiviral.2007.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">301</span>â <span class="NLM_lpage">305</span>, <span class="refDoi">Â DOI: 10.1038/35060098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2F35060098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11231581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=301-305&author=S.+Pleschkaauthor=T.+Wolffauthor=C.+Ehrhardtauthor=G.+Hobomauthor=O.+Planzauthor=U.+R.+Rappauthor=S.+Ludwig&title=Influenza+virus+propagation+is+impaired+by+inhibition+of+the+Raf%2FMEK%2FERK+signalling+cascade&doi=10.1038%2F35060098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span></div><div class="casAuthors">Pleschka, Stephan; Wolff, Thorsten; Ehrhard, Christina; Hobom, Gerd; Planz, Oliver; Rapp, Ulf R.; Ludwig, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-305</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Influenza A viruses are important worldwide pathogens in humans and different animal species.  The functions of most of the ten different viral proteins of this neg.-strand RNA virus have been well elucidated.  However, little is known about the virus-induced intracellular signalling events that support viral replication.  The Raf/MEK/ERK cascade is the prototype of mitogen-activated protein (MAP) kinase cascades and has an important role in cell growth, differentiation and survival.  Investigation of the function of this pathway has been facilitated by the identification of specific inhibitors, such as U0126, which blocks the cascade at the level of MAPK/ERK kinase (MEK).  Here, the authors show that infection of cells with influenza A virus leads to biphasic activation of the Raf/MEK/ERK cascade.  Inhibition of Raf signalling results in nuclear retention of viral ribonucleoprotein complexes (RNPs), impaired function of the nuclear-export protein (NEP/NS2) and concomitant inhibition of virus prodn.  Thus, signalling through the mitogenic cascade seems to be essential for virus prodn. and RNP export from the nucleus during the viral life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx1KgfMDKJPLVg90H21EOLACvtfcHk0lj6XIfysNv7IQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D&md5=b5283932b9d29e474583d8dfa0ec5658</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2F35060098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35060098%26sid%3Dliteratum%253Aachs%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DHobom%26aufirst%3DG.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DInfluenza%2520virus%2520propagation%2520is%2520impaired%2520by%2520inhibition%2520of%2520the%2520Raf%252FMEK%252FERK%2520signalling%2520cascade%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D301%26epage%3D305%26doi%3D10.1038%2F35060098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabel, G. J.</span></span> <span> </span><span class="NLM_article-title">The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">1230</span>â <span class="NLM_lpage">1240</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01586-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01586-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17108034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFCgurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2007&pages=1230-1240&author=C.+A.+Zampieriauthor=J.+F.+Fortinauthor=G.+P.+Nolanauthor=G.+J.+Nabel&title=The+ERK+mitogen-activated+protein+kinase+pathway+contributes+to+Ebola+virus+glycoprotein-induced+cytotoxicity&doi=10.1128%2FJVI.01586-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity</span></div><div class="casAuthors">Zampieri, Carisa A.; Fortin, Jean-Francois; Nolan, Garry P.; Nabel, Gary J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1230-1240</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Ebola virus is a highly lethal pathogen that causes hemorrhagic fever in humans and nonhuman primates.  Among the seven known viral gene products, the envelope glycoprotein (GP) alone induces cell rounding and detachment that ultimately leads to cell death.  Cellular cytotoxicity is not seen with comparable levels of expression of a mutant form of GP lacking a mucin-like domain (GPÎmuc).  GP-induced cell death is non-apoptotic and is preceded by down-modulation of cell surface mols. involved in signaling pathways, including certain integrins and epidermal growth factor receptor.  To investigate the mechanism of GP-induced cellular toxicity, we analyzed the activation of several signal transduction pathways involved in cell growth and survival.  The active form of extracellular signal-regulated kinases type 1 and 2 (ERK1/2), phospho-ERK1/2, was reduced in cells expressing GP compared to those expressing GPÎmuc as detd. by flow cytometry, in contrast to the case for several other signaling proteins.  Subsequent anal. of the activation states and kinase activities of related kinases revealed a more pronounced effect on the ERK2 kinase isoform.  Disruption of ERK2 activity by a dominant neg. ERK or by small interfering RNA-mediated ERK2 knockdown potentiated the decrease in Î±V integrin expression assocd. with toxicity.  Conversely, activation of the pathway through the expression of a constitutively active form of ERK2 significantly protected against this effect.  These results indicate that the ERK signaling cascade mediates GP-mediated cytotoxicity and plays a role in pathogenicity induced by this gene product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb9VqOOhotUrVg90H21EOLACvtfcHk0lj6XIfysNv7IQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFCgurs%253D&md5=a5bd3c4731380c3ad2cda2673f9300cb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1128%2FJVI.01586-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01586-06%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DC.%2BA.%26aulast%3DFortin%26aufirst%3DJ.%2BF.%26aulast%3DNolan%26aufirst%3DG.%2BP.%26aulast%3DNabel%26aufirst%3DG.%2BJ.%26atitle%3DThe%2520ERK%2520mitogen-activated%2520protein%2520kinase%2520pathway%2520contributes%2520to%2520Ebola%2520virus%2520glycoprotein-induced%2520cytotoxicity%26jtitle%3DJ.%2520Virol.%26date%3D2007%26volume%3D81%26spage%3D1230%26epage%3D1240%26doi%3D10.1128%2FJVI.01586-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honko, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, C. F.</span></span> <span> </span><span class="NLM_article-title">Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">102</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2014.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2014.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24815087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC2cjhsFWhuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2014&pages=102-109&author=J.+C.+Johnsonauthor=O.+Martinezauthor=A.+N.+Honkoauthor=L.+E.+Hensleyauthor=G.+G.+Olingerauthor=C.+F.+Basler&title=Pyridinyl+imidazole+inhibitors+of+p38+MAP+kinase+impair+viral+entry+and+reduce+cytokine+induction+by+Zaire+ebolavirus+in+human+dendritic+cells&doi=10.1016%2Fj.antiviral.2014.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells</span></div><div class="casAuthors">Johnson Joshua C; Honko Anna N; Hensley Lisa E; Olinger Gene G; Martinez Osvaldo; Basler Christopher F</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">102-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antigen presenting cells (APCs), including macrophages and dendritic cells, are early and sustained targets of Ebola virus (EBOV) infection in vivo.  Because EBOV activates mitogen-activated protein kinase (MAPK) signaling upon infection of APCs, we evaluated the effect of pyridinyl imidazole inhibitors of p38 MAPK on EBOV infection of human APCs and EBOV mediated cytokine production from human DCs.  The p38 MAPK inhibitors reduced viral replication in PMA-differentiated macrophage-like human THP-1 cells with an IC50 of 4.73Î¼M (SB202190), 8.26Î¼M (p38kinhIII) and 8.21Î¼M (SB203580) and primary human monocyte-derived dendritic cells (MDDCs) with an IC50 of 2.67Î¼M (SB202190).  Furthermore, cytokine production from EBOV-treated MDDCs was inhibited in a dose-dependent manner.  A control pyridinyl imidazole compound failed to inhibit either EBOV infection or cytokine induction.  Using an established EBOV virus-like particle (VLP) entry assay, we demonstrate that inhibitor pretreatment blocked VLP entry suggesting that the inhibitors blocked infection and replication at least in part by blocking EBOV entry.  Taken together, our results indicate that pyridinyl imidazole p38 MAPK inhibitors may serve as leads for the development of therapeutics to treat EBOV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSzVh8HZxaG5yXXDYhVZBdlfW6udTcc2eYJ09Teq3WuX7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjhsFWhuw%253D%253D&md5=fa401790144b2321b79f27ceb0d4c26d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DJ.%2BC.%26aulast%3DMartinez%26aufirst%3DO.%26aulast%3DHonko%26aufirst%3DA.%2BN.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DBasler%26aufirst%3DC.%2BF.%26atitle%3DPyridinyl%2520imidazole%2520inhibitors%2520of%2520p38%2520MAP%2520kinase%2520impair%2520viral%2520entry%2520and%2520reduce%2520cytokine%2520induction%2520by%2520Zaire%2520ebolavirus%2520in%2520human%2520dendritic%2520cells%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D107%26spage%3D102%26epage%3D109%26doi%3D10.1016%2Fj.antiviral.2014.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ordyan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartol, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangamani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sejnowski, T.</span></span> <span> </span><span class="NLM_article-title">Interactions between calmodulin and neurogranin govern the dynamics of CaMKII as a leaky integrator</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>, <span class="NLM_elocation-id">e1008015</span> <span class="refDoi">Â DOI: 10.1371/journal.pcbi.1008015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.pcbi.1008015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32678848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFeqtLrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&author=M.+Ordyanauthor=T.+Bartolauthor=M.+Kennedyauthor=P.+Rangamaniauthor=T.+Sejnowski&title=Interactions+between+calmodulin+and+neurogranin+govern+the+dynamics+of+CaMKII+as+a+leaky+integrator&doi=10.1371%2Fjournal.pcbi.1008015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions between calmodulin and neurogranin govern the dynamics of CaMKII as a leaky integrator</span></div><div class="casAuthors">Ordyan, Mariam; Bartol, Tom; Kennedy, Mary; Rangamani, Padmini; Sejnowski, Terrence</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e1008015</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Calmodulin-dependent kinase II (CaMKII) has long been known to play an important role in learning and memory as well as long term potentiation (LTP).  More recently it has been suggested that it might be involved in the time averaging of synaptic signals, which can then lead to the high precision of information stored at a single synapse.  However, the role of the scaffolding mol., neurogranin (Ng), in governing the dynamics of CaMKII is not yet fully understood.  In this work, we adopt a rule-based modeling approach through the Monte Carlo method to study the effect of Ca2+ signals on the dynamics of CaMKII phosphorylation in the postsynaptic d. (PSD).  Calcium surges are obsd. in synaptic spines during an EPSP and back-propagating action potential due to the opening of NMDA receptors and voltage dependent calcium channels.  Using agent-based models, we computationally investigate the dynamics of phosphorylation of CaMKII monomers and dodecameric holoenzymes.  The scaffolding mol., Ng, when present in significant concn., limits the availability of free calmodulin (CaM), the protein which activates CaMKII in the presence of calcium.  We show that Ng plays an important modulatory role in CaMKII phosphorylation following a surge of high calcium concn.  We find a non-intuitive dependence of this effect on CaM concn. that results from the different affinities of CaM for CaMKII depending on the no. of calcium ions bound to the former.  It has been shown previously that in the absence of phosphatase, CaMKII monomers integrate over Ca2+ signals of certain frequencies through autophosphorylation (Pepke et al, Plos Comp Bio., 2010)..  We also study the effect of multiple calcium spikes on CaMKII holoenzyme autophosphorylation, and show that in the presence of phosphatase, CaMKII behaves as a leaky integrator of calcium signals, a result that has been recently obsd. in vivo.  Our models predict that the parameters of this leaky integrator are finely tuned through the interactions of Ng, CaM, CaMKII, and PP1, providing a mechanism to precisely control the sensitivity of synapses to calcium signals.  Author Summary not valid for PLOS ONE submissions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfJpaxKlXakLVg90H21EOLACvtfcHk0lg2sl3W_J5ZOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFeqtLrI&md5=95b81e8803678d44243c1d74136cece5</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1008015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1008015%26sid%3Dliteratum%253Aachs%26aulast%3DOrdyan%26aufirst%3DM.%26aulast%3DBartol%26aufirst%3DT.%26aulast%3DKennedy%26aufirst%3DM.%26aulast%3DRangamani%26aufirst%3DP.%26aulast%3DSejnowski%26aufirst%3DT.%26atitle%3DInteractions%2520between%2520calmodulin%2520and%2520neurogranin%2520govern%2520the%2520dynamics%2520of%2520CaMKII%2520as%2520a%2520leaky%2520integrator%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2020%26volume%3D16%26doi%3D10.1371%2Fjournal.pcbi.1008015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hemmat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asadzadeh, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahangar, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemohammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najafzadeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derakhshani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baghbanzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baghi, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javadrashid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najafi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ar Gouilh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran, B.</span></span> <span> </span><span class="NLM_article-title">The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV</span>. <i>Arch. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">675</span>â <span class="NLM_lpage">696</span>, <span class="refDoi">Â DOI: 10.1007/s00705-021-04958-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs00705-021-04958-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33462671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhsFOhu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2021&pages=675-696&author=N.+Hemmatauthor=Z.+Asadzadehauthor=N.+K.+Ahangarauthor=H.+Alemohammadauthor=B.+Najafzadehauthor=A.+Derakhshaniauthor=A.+Baghbanzadehauthor=H.+B.+Baghiauthor=D.+Javadrashidauthor=S.+Najafiauthor=M.+Ar+Gouilhauthor=B.+Baradaran&title=The+roles+of+signaling+pathways+in+SARS-CoV-2+infection%3B+lessons+learned+from+SARS-CoV+and+MERS-CoV&doi=10.1007%2Fs00705-021-04958-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV</span></div><div class="casAuthors">Hemmat, Nima; Asadzadeh, Zahra; Ahangar, Noora Karim; Alemohammad, Hajar; Najafzadeh, Basira; Derakhshani, Afshin; Baghbanzadeh, Amir; Baghi, Hossein Bannazadeh; Javadrashid, Darya; Najafi, Souzan; Ar Gouilh, Meriadeg; Baradaran, Behzad</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Virology</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">675-696</span>CODEN:
                <span class="NLM_cas:coden">ARVIDF</span>;
        ISSN:<span class="NLM_cas:issn">0304-8608</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">A review.  Abstr.: The no. of descriptions of emerging viruses has grown at an unprecedented rate since the beginning of the 21st century.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is the third highly pathogenic coronavirus that has introduced itself into the human population in the current era, after SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV).  Mol. and cellular studies of the pathogenesis of this novel coronavirus are still in the early stages of research; however, based on similarities of SARS-CoV-2 to other coronaviruses, it can be hypothesized that the NF-ÎºB, cytokine regulation, ERK, and TNF-Î± signaling pathways are the likely causes of inflammation at the onset of COVID-19.  Several drugs have been prescribed and used to alleviate the adverse effects of these inflammatory cellular signaling pathways, and these might be beneficial for developing novel therapeutic modalities against COVID-19.  In this review, we briefly summarize alterations of cellular signaling pathways that are assocd. with coronavirus infection, particularly SARS-CoV and MERS-CoV, and tabulate the therapeutic agents that are currently approved for treating other human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYxiUAcPzocrVg90H21EOLACvtfcHk0liXNcvfHey56g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhsFOhu7g%253D&md5=55a7ecde7e0f3c1b4d74da458951e50e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs00705-021-04958-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00705-021-04958-7%26sid%3Dliteratum%253Aachs%26aulast%3DHemmat%26aufirst%3DN.%26aulast%3DAsadzadeh%26aufirst%3DZ.%26aulast%3DAhangar%26aufirst%3DN.%2BK.%26aulast%3DAlemohammad%26aufirst%3DH.%26aulast%3DNajafzadeh%26aufirst%3DB.%26aulast%3DDerakhshani%26aufirst%3DA.%26aulast%3DBaghbanzadeh%26aufirst%3DA.%26aulast%3DBaghi%26aufirst%3DH.%2BB.%26aulast%3DJavadrashid%26aufirst%3DD.%26aulast%3DNajafi%26aufirst%3DS.%26aulast%3DAr%2BGouilh%26aufirst%3DM.%26aulast%3DBaradaran%26aufirst%3DB.%26atitle%3DThe%2520roles%2520of%2520signaling%2520pathways%2520in%2520SARS-CoV-2%2520infection%253B%2520lessons%2520learned%2520from%2520SARS-CoV%2520and%2520MERS-CoV%26jtitle%3DArch.%2520Virol.%26date%3D2021%26volume%3D166%26spage%3D675%26epage%3D696%26doi%3D10.1007%2Fs00705-021-04958-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span> <span> </span><span class="NLM_article-title">GSK-3 inhibition as a therapeutic approach against SARs CoV2: Dual benefit of inhibiting viral replication while potentiating the immune response</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">1638</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2020.01638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffimmu.2020.01638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32695123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVWns7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1638&author=C.+E.+Rudd&title=GSK-3+inhibition+as+a+therapeutic+approach+against+SARs+CoV2%3A+Dual+benefit+of+inhibiting+viral+replication+while+potentiating+the+immune+response&doi=10.3389%2Ffimmu.2020.01638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 inhibition as a therapeutic approach against SARs CoV2: dual benefit of inhibiting viral replication while potentiating the immune response</span></div><div class="casAuthors">Rudd, Christopher E.; Flynn, JoAnne L.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1638</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The SARS-CoV2 (COVID-19) pandemic and uncertainties in developing a vaccine have created an urgent need for new therapeutic approaches.  A key question is whether it is possible to make rational predictions of new therapies based on the presently available scientific and medical information.  In this regard, I have noticed an omission in the present anal. in the literature related to the exploitation of glycogen synthase kinase 3 (GSK-3) as a therapeutic approach.  This is based on two key observations, that GSK-3 inhibitors can simultaneously block SARs viral replication, while boosting CD8+ adaptive T-cell and innate natural killer (NK) responses.  Firstly, it is already clear that GSK-3 phosphorylation of SARs CoV1 N protein on key serine residues is needed for viral replication such that small mol. inhibitors (SMIs) of GSK-3 can inhibit viral replication.  In comparing protein sequences, I show here that the key sites in the N protein of SARs CoV1 N for replication are conserved in SARs CoV2.  This strongly suggests that GSK-3 SMIs will also inhibit SARs Cov2 replication.  Secondly, we and others have previously documented that GSK-3 SMIs markedly enhance CD8+ cytolytic T-cell (CTL) and NK cell anti-viral effector functions leading to a redn. in both acute and chronic viral infections in mice.  My hypothesis is that the repurposing of low-cost inhibitors of GSK-3 such as lithium will limit SARS-CoV2 infections by both reducing viral replication and potentiating the immune response against the virus.  To date, there has been no mention of this dual connection between GSK-3 and SARs CoV2 in the literature.  To my knowledge, no other drugs exist with the potential to simultaneously target both viral replication and immune response against SARs CoV2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojYb1HqsdaL7Vg90H21EOLACvtfcHk0liXNcvfHey56g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVWns7jN&md5=4b1cea5d7c4acdb84654995521fc3780</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.01638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.01638%26sid%3Dliteratum%253Aachs%26aulast%3DRudd%26aufirst%3DC.%2BE.%26atitle%3DGSK-3%2520inhibition%2520as%2520a%2520therapeutic%2520approach%2520against%2520SARs%2520CoV2%253A%2520Dual%2520benefit%2520of%2520inhibiting%2520viral%2520replication%2520while%2520potentiating%2520the%2520immune%2520response%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26spage%3D1638%26doi%3D10.3389%2Ffimmu.2020.01638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezelj, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa Marrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polacco, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulferts, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obernier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabius, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucheray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miorin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson-Payant, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Armenta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knerr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugourd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdeolivas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HÃ¼ttenhain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cakir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muralidharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutuncuoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathy, C. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manners, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FÃ©lix, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeal, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klippsten, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wit, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortemme, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez-Rodriguez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Oever, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a-Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignuzzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogan, N. J.</span></span> <span> </span><span class="NLM_article-title">The global phosphorylation landscape of SARS-CoV-2 infection</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">685</span>â <span class="NLM_lpage">712</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.06.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cell.2020.06.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32645325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKkt7zF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2020&pages=685-712&author=M.+Bouhaddouauthor=D.+Memonauthor=B.+Meyerauthor=K.+M.+Whiteauthor=V.+V.+Rezeljauthor=M.+Correa+Marreroauthor=B.+J.+Polaccoauthor=J.+E.+Melnykauthor=S.+Ulfertsauthor=R.+M.+Kaakeauthor=J.+Batraauthor=A.+L.+Richardsauthor=E.+Stevensonauthor=D.+E.+Gordonauthor=A.+Rojcauthor=K.+Obernierauthor=J.+M.+Fabiusauthor=M.+Soucherayauthor=L.+Miorinauthor=E.+Morenoauthor=C.+Kohauthor=Q.+D.+Tranauthor=A.+Hardyauthor=R.+Robinotauthor=T.+Valletauthor=B.+E.+Nilsson-Payantauthor=C.+Hernandez-Armentaauthor=A.+Dunhamauthor=S.+Weigangauthor=J.+Knerrauthor=M.+Modakauthor=D.+Quinteroauthor=Y.+Zhouauthor=A.+Dugourdauthor=A.+Valdeolivasauthor=T.+Patilauthor=Q.+Liauthor=R.+H%C3%BCttenhainauthor=M.+Cakirauthor=M.+Muralidharanauthor=M.+Kimauthor=G.+Jangauthor=B.+Tutuncuogluauthor=J.+Hiattauthor=J.+Z.+Guoauthor=J.+Xuauthor=S.+Bouhaddouauthor=C.+J.+P.+Mathyauthor=A.+Gaultonauthor=E.+J.+Mannersauthor=E.+F%C3%A9lixauthor=Y.+Shiauthor=M.+Goffauthor=J.+K.+Limauthor=T.+McBrideauthor=M.+C.+O%E2%80%99Nealauthor=Y.+Caiauthor=J.+C.+J.+Changauthor=D.+J.+Broadhurstauthor=S.+Klippstenauthor=E.+De+Witauthor=A.+R.+Leachauthor=T.+Kortemmeauthor=B.+Shoichetauthor=M.+Ottauthor=J.+Saez-Rodriguezauthor=B.+R.+ten+Oeverauthor=R.+D.+Mullinsauthor=E.+R.+Fischerauthor=G.+Kochsauthor=R.+Grosseauthor=A.+Garc%C3%ADa-Sastreauthor=M.+Vignuzziauthor=J.+R.+Johnsonauthor=K.+M.+Shokatauthor=D.+L.+Swaneyauthor=P.+Beltraoauthor=N.+J.+Krogan&title=The+global+phosphorylation+landscape+of+SARS-CoV-2+infection&doi=10.1016%2Fj.cell.2020.06.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Global Phosphorylation Landscape of SARS-CoV-2 Infection</span></div><div class="casAuthors">Bouhaddou, Mehdi; Memon, Danish; Meyer, Bjoern; White, Kris M.; Rezelj, Veronica V.; Correa Marrero, Miguel; Polacco, Benjamin J.; Melnyk, James E.; Ulferts, Svenja; Kaake, Robyn M.; Batra, Jyoti; Richards, Alicia L.; Stevenson, Erica; Gordon, David E.; Rojc, Ajda; Obernier, Kirsten; Fabius, Jacqueline M.; Soucheray, Margaret; Miorin, Lisa; Moreno, Elena; Koh, Cassandra; Tran, Quang Dinh; Hardy, Alexandra; Robinot, Remy; Vallet, Thomas; Nilsson-Payant, Benjamin E.; Hernandez-Armenta, Claudia; Dunham, Alistair; Weigang, Sebastian; Knerr, Julian; Modak, Maya; Quintero, Diego; Zhou, Yuan; Dugourd, Aurelien; Valdeolivas, Alberto; Patil, Trupti; Li, Qiongyu; Huttenhain, Ruth; Cakir, Merve; Muralidharan, Monita; Kim, Minkyu; Jang, Gwendolyn; Tutuncuoglu, Beril; Hiatt, Joseph; Guo, Jeffrey Z.; Xu, Jiewei; Bouhaddou, Sophia; Mathy, Christopher J. P.; Gaulton, Anna; Manners, Emma J.; Felix, Eloy; Shi, Ying; Goff, Marisa; Lim, Jean K.; McBride, Timothy; O'Neal, Michael C.; Cai, Yiming; Chang, Jason C. J.; Broadhurst, David J.; Klippsten, Saker; De wit, Emmie; Leach, Andrew R.; Kortemme, Tanja; Shoichet, Brian; Ott, Melanie; Saez-Rodriguez, Julio; tenOever, Benjamin R.; Mullins, R. Dyche; Fischer, Elizabeth R.; Kochs, Georg; Grosse, Robert; Garcia-Sastre, Adolfo; Vignuzzi, Marco; Johnson, Jeffery R.; Shokat, Kevan M.; Swaney, Danielle L.; Beltrao, Pedro; Krogan, Nevan J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">685-712.e19</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The causative agent of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected millions and killed hundreds of thousands of people worldwide, highlighting an urgent need to develop antiviral therapies.  Here, we present a quant. mass spectrometry-based phosphoproteomics survey of SARS-CoV-2 infection in Vero E6 cells, revealing dramatic rewiring of phosphorylation on host and viral proteins.  SARS-CoV-2 infection promoted casein kinase II (CK2) and p38 MAPK activation, prodn. of diverse cytokines, and shutdown of mitotic kinases, resulting in cell cycle arrest.  Infection also stimulated a marked induction of CK2-contg. filopodial protrusions possessing budding viral particles.  Eighty-seven drugs and compds. were identified by mapping global phosphorylation profiles to dysregulated kinases and pathways.  We found pharmacol. inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaeZZGqGpEn7Vg90H21EOLACvtfcHk0lh0c2P2lFdrFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKkt7zF&md5=cb6e1da08aaaf061b76004416ce27355</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.06.034%26sid%3Dliteratum%253Aachs%26aulast%3DBouhaddou%26aufirst%3DM.%26aulast%3DMemon%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DB.%26aulast%3DWhite%26aufirst%3DK.%2BM.%26aulast%3DRezelj%26aufirst%3DV.%2BV.%26aulast%3DCorrea%2BMarrero%26aufirst%3DM.%26aulast%3DPolacco%26aufirst%3DB.%2BJ.%26aulast%3DMelnyk%26aufirst%3DJ.%2BE.%26aulast%3DUlferts%26aufirst%3DS.%26aulast%3DKaake%26aufirst%3DR.%2BM.%26aulast%3DBatra%26aufirst%3DJ.%26aulast%3DRichards%26aufirst%3DA.%2BL.%26aulast%3DStevenson%26aufirst%3DE.%26aulast%3DGordon%26aufirst%3DD.%2BE.%26aulast%3DRojc%26aufirst%3DA.%26aulast%3DObernier%26aufirst%3DK.%26aulast%3DFabius%26aufirst%3DJ.%2BM.%26aulast%3DSoucheray%26aufirst%3DM.%26aulast%3DMiorin%26aufirst%3DL.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DKoh%26aufirst%3DC.%26aulast%3DTran%26aufirst%3DQ.%2BD.%26aulast%3DHardy%26aufirst%3DA.%26aulast%3DRobinot%26aufirst%3DR.%26aulast%3DVallet%26aufirst%3DT.%26aulast%3DNilsson-Payant%26aufirst%3DB.%2BE.%26aulast%3DHernandez-Armenta%26aufirst%3DC.%26aulast%3DDunham%26aufirst%3DA.%26aulast%3DWeigang%26aufirst%3DS.%26aulast%3DKnerr%26aufirst%3DJ.%26aulast%3DModak%26aufirst%3DM.%26aulast%3DQuintero%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DDugourd%26aufirst%3DA.%26aulast%3DValdeolivas%26aufirst%3DA.%26aulast%3DPatil%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DH%25C3%25BCttenhain%26aufirst%3DR.%26aulast%3DCakir%26aufirst%3DM.%26aulast%3DMuralidharan%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DJang%26aufirst%3DG.%26aulast%3DTutuncuoglu%26aufirst%3DB.%26aulast%3DHiatt%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DJ.%2BZ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DBouhaddou%26aufirst%3DS.%26aulast%3DMathy%26aufirst%3DC.%2BJ.%2BP.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DManners%26aufirst%3DE.%2BJ.%26aulast%3DF%25C3%25A9lix%26aufirst%3DE.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DGoff%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DMcBride%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Neal%26aufirst%3DM.%2BC.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DBroadhurst%26aufirst%3DD.%2BJ.%26aulast%3DKlippsten%26aufirst%3DS.%26aulast%3DDe%2BWit%26aufirst%3DE.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DKortemme%26aufirst%3DT.%26aulast%3DShoichet%26aufirst%3DB.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DSaez-Rodriguez%26aufirst%3DJ.%26aulast%3Dten%2BOever%26aufirst%3DB.%2BR.%26aulast%3DMullins%26aufirst%3DR.%2BD.%26aulast%3DFischer%26aufirst%3DE.%2BR.%26aulast%3DKochs%26aufirst%3DG.%26aulast%3DGrosse%26aufirst%3DR.%26aulast%3DGarc%25C3%25ADa-Sastre%26aufirst%3DA.%26aulast%3DVignuzzi%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DSwaney%26aufirst%3DD.%2BL.%26aulast%3DBeltrao%26aufirst%3DP.%26aulast%3DKrogan%26aufirst%3DN.%2BJ.%26atitle%3DThe%2520global%2520phosphorylation%2520landscape%2520of%2520SARS-CoV-2%2520infection%26jtitle%3DCell%26date%3D2020%26volume%3D182%26spage%3D685%26epage%3D712%26doi%3D10.1016%2Fj.cell.2020.06.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorne, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, D.</span></span> <span> </span><span class="NLM_article-title">Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">21</span>â <span class="NLM_lpage">31</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01814-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01814-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20962097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlCjtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=21-31&author=P.+M.+Reevesauthor=S.+K.+Smithauthor=V.+A.+Olsonauthor=S.+H.+Thorneauthor=W.+Bornmannauthor=I.+K.+Damonauthor=D.+Kalman&title=Variola+and+monkeypox+viruses+utilize+conserved+mechanisms+of+virion+motility+and+release+that+depend+on+abl+and+SRC+family+tyrosine+kinases&doi=10.1128%2FJVI.01814-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on Abl and Src family tyrosine kinases</span></div><div class="casAuthors">Reeves, Patrick M.; Smith, Scott K.; Olson, Victoria A.; Thorne, Steve H.; Bornmann, William; Damon, Inger K.; Kalman, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-31</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Vaccinia virus (VacV) enters mammalian cells, replicates extranuclearly, and produces virions that move to the cell surface along microtubules, fuse with the plasma membrane, and move from infected cells toward apposing cells on actin-filled membranous protrusions or actin tails.  To form actin tails, cell-assocd. enveloped virions (CEV) required Abl and Src family tyrosine kinases.  Furthermore, release of CEV from the cell requires Abl but not Src family tyrosine kinases and is blocked by imatinib mesylate (STI-571; Gleevec), an Abl family kinase inhibitor used to treat chronic myelogenous leukemia in humans.  Here we demonstrate that the Poxviridae family members monkeypox virus (MPX) and variola virus (VarV) use conserved mechanisms for actin motility and extracellular enveloped virion (EEV) release.  Furthermore, we show that imatinib mesylate is effective in a mouse model of infection with VacV, whether delivered prophylactically or postinfection, and restricts spread of virions from the site of inoculation.  While inhibitors of both Src and Abl family kinases, such as dasatinib (BMS-354825; Sprycel), are effective in limiting dissemination of VacV, VarV, and MPX in vitro, members of this class of drugs appear to have immunosuppressive effects in vivo that preclude their use as anti-infectives.  Together, these data suggest a possible utility for imatinib mesylate in treating smallpox or MPX infections or complications assocd. with vaccination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp110ZF6U0WXbVg90H21EOLACvtfcHk0ligF93emb0S1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlCjtrc%253D&md5=587e7600337ba2d6169ea9c9c0ab2f5d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1128%2FJVI.01814-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01814-10%26sid%3Dliteratum%253Aachs%26aulast%3DReeves%26aufirst%3DP.%2BM.%26aulast%3DSmith%26aufirst%3DS.%2BK.%26aulast%3DOlson%26aufirst%3DV.%2BA.%26aulast%3DThorne%26aufirst%3DS.%2BH.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DDamon%26aufirst%3DI.%2BK.%26aulast%3DKalman%26aufirst%3DD.%26atitle%3DVariola%2520and%2520monkeypox%2520viruses%2520utilize%2520conserved%2520mechanisms%2520of%2520virion%2520motility%2520and%2520release%2520that%2520depend%2520on%2520abl%2520and%2520SRC%2520family%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D21%26epage%3D31%26doi%3D10.1128%2FJVI.01814-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzione, L.</span></span> <span> </span><span class="NLM_article-title">Dasatinib: A new step in molecular target therapy</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">Suppl 6</span>), <span class="NLM_elocation-id">vi42</span> <span class="refDoi">Â DOI: 10.1093/annonc/mdm223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1093%2Fannonc%2Fmdm223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17591830" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&issue=Suppl+6&author=A.+Olivieriauthor=L.+Manzione&title=Dasatinib%3A+A+new+step+in+molecular+target+therapy&doi=10.1093%2Fannonc%2Fmdm223"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdm223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdm223%26sid%3Dliteratum%253Aachs%26aulast%3DOlivieri%26aufirst%3DA.%26aulast%3DManzione%26aufirst%3DL.%26atitle%3DDasatinib%253A%2520A%2520new%2520step%2520in%2520molecular%2520target%2520therapy%26jtitle%3DAnn.%2520Oncol.%26date%3D2007%26volume%3D18%26issue%3DSuppl%25206%26doi%3D10.1093%2Fannonc%2Fmdm223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koleske, A. J.</span></span> <span> </span><span class="NLM_article-title">Regulation of cell migration and morphogenesis by Abl-family kinases: Emerging mechanisms and physiological contexts</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3441</span>â <span class="NLM_lpage">3454</span>, <span class="refDoi">Â DOI: 10.1242/jcs.039859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1242%2Fjcs.039859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=19759284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSkurnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2009&pages=3441-3454&author=W.+D.+Bradleyauthor=A.+J.+Koleske&title=Regulation+of+cell+migration+and+morphogenesis+by+Abl-family+kinases%3A+Emerging+mechanisms+and+physiological+contexts&doi=10.1242%2Fjcs.039859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts</span></div><div class="casAuthors">Bradley, William D.; Koleske, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3441-3454</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The Abl-family non-receptor tyrosine kinases are essential regulators of the cytoskeleton.  They transduce diverse extracellular cues into cytoskeletal rearrangements that have dramatic effects on cell motility and morphogenesis.  Recent biochem. and genetic studies have revealed several mechanisms that Abl-family kinases use to mediate these effects.  Abl-family kinases stimulate actin polymn. through the activation of cortactin, hematopoietic lineage cell-specific protein (HS1), WASp- and WAVE-family proteins, and Rac1.  They also attenuate cell contractility by inhibiting RhoA and altering adhesion dynamics.  These pathways impinge on several physiol. processes, including development and maintenance of the nervous and immune systems, and epithelial morphogenesis.  Elucidating how Abl-family kinases are regulated, and where and when they coordinate cytoskeletal changes, is essential for garnering a better understanding of these complex processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKfpvJfbX0xrVg90H21EOLACvtfcHk0ligF93emb0S1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSkurnM&md5=d796f40c4b2340d842be588dfa73c98c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1242%2Fjcs.039859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.039859%26sid%3Dliteratum%253Aachs%26aulast%3DBradley%26aufirst%3DW.%2BD.%26aulast%3DKoleske%26aufirst%3DA.%2BJ.%26atitle%3DRegulation%2520of%2520cell%2520migration%2520and%2520morphogenesis%2520by%2520Abl-family%2520kinases%253A%2520Emerging%2520mechanisms%2520and%2520physiological%2520contexts%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2009%26volume%3D122%26spage%3D3441%26epage%3D3454%26doi%3D10.1242%2Fjcs.039859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindrachuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ork, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span> <span> </span><span class="NLM_article-title">Antiviral potential of ERK/MAPK and PI3K/AKT/ mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1088</span>â <span class="NLM_lpage">1099</span>, <span class="refDoi">Â DOI: 10.1128/AAC.03659-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FAAC.03659-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25487801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVagsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1088-1099&author=J.+Kindrachukauthor=B.+Orkauthor=B.+J.+Hartauthor=S.+Mazurauthor=M.+R.+Holbrookauthor=M.+B.+Friemanauthor=D.+Traynorauthor=R.+F.+Johnsonauthor=J.+Dyallauthor=J.+H.+Kuhnauthor=G.+G.+Olingerauthor=L.+E.+Hensleyauthor=P.+B.+Jahrling&title=Antiviral+potential+of+ERK%2FMAPK+and+PI3K%2FAKT%2F+mTOR+signaling+modulation+for+middle+east+respiratory+syndrome+coronavirus+infection+as+identified+by+temporal+kinome+analysis&doi=10.1128%2FAAC.03659-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</span></div><div class="casAuthors">Kindrachuk, Jason; Ork, Britini; Hart, Brit J.; Mazur, Steven; Holbrook, Michael R.; Frieman, Matthew B.; Traynor, Dawn; Johnson, Reed F.; Dyall, Julie; Kuhn, Jens H.; Olinger, Gene G.; Hensley, Lisa E.; Jahrling, Peter B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1088-1099/1-1088-1099/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus, and infections with this virus can result in acute respiratory syndrome with renal failure.  Globally, MERS-CoV has been responsible for 877 lab.-confirmed infections, including 317 deaths, since Sept. 2012.  As there is a paucity of information regarding the mol. pathogenesis assocd. with this virus or the identities of novel antiviral drug targets, we performed temporal kinome anal. on human hepatocytes infected with the Erasmus isolate of MERS-CoV with peptide kinome arrays. bioinformatics anal. of our kinome data, including pathway overrepresentation anal. (ORA) and functional network anal., suggested that extracellular signalregulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphoinositol 3-kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling responses were specifically modulated in response to MERS-CoV infection in vitro throughout the course of infection.  The overrepresentation of specific intermediates within these pathways detd. by pathway and functional network anal. of our kinome data correlated with similar patterns of phosphorylation detd. through Western blot array anal.  In addn., anal. of the effects of specific kinase inhibitors on MERS-CoV infection in tissue culture models confirmed these cellular response observations.  Further, we have demonstrated that a subset of licensed kinase inhibitors targeting the ERK/MAPK and PI3K/AKT/mTOR pathways significantly inhibited MERS-CoV replication in vitro whether they were added before or after viral infection.  Taken together, our data suggest that ERK/MAPK and PI3K/AKT/mTOR signaling responses play important roles in MERS-CoV infection and may represent novel drug targets for therapeutic intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwo9H9W_zXg7Vg90H21EOLACvtfcHk0lhQXfns0xRoLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVagsbw%253D&md5=1fef3dd7bccc643cec0762fdfbee27bb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1128%2FAAC.03659-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03659-14%26sid%3Dliteratum%253Aachs%26aulast%3DKindrachuk%26aufirst%3DJ.%26aulast%3DOrk%26aufirst%3DB.%26aulast%3DHart%26aufirst%3DB.%2BJ.%26aulast%3DMazur%26aufirst%3DS.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26aulast%3DTraynor%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DR.%2BF.%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DKuhn%26aufirst%3DJ.%2BH.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26atitle%3DAntiviral%2520potential%2520of%2520ERK%252FMAPK%2520and%2520PI3K%252FAKT%252F%2520mTOR%2520signaling%2520modulation%2520for%2520middle%2520east%2520respiratory%2520syndrome%2520coronavirus%2520infection%2520as%2520identified%2520by%2520temporal%2520kinome%2520analysis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1088%26epage%3D1099%26doi%3D10.1128%2FAAC.03659-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Saracatinib inhibits Middle East respiratory syndrome-coronavirus replication in vitro</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">283</span>, <span class="refDoi">Â DOI: 10.3390/v10060283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3390%2Fv10060283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVanurzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=283&author=J.+S.+Shinauthor=E.+Jungauthor=M.+Kimauthor=R.+S.+Baricauthor=Y.+Y.+Go&title=Saracatinib+inhibits+Middle+East+respiratory+syndrome-coronavirus+replication+in+vitro&doi=10.3390%2Fv10060283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro</span></div><div class="casAuthors">Shin, Jin Soo; Jung, Eunhye; Kim, Meehyein; Baric, Ralph S.; Go, Yun Young</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">283/1-283/19</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The Middle East respiratory syndrome-coronavirus (MERS-CoV), first identified in Saudi Arabia, is an emerging zoonotic pathogen that causes severe acute respiratory illness in humans with a high fatality rate.  Since its emergence, MERS-CoV continues to spread to countries outside of the Arabian Peninsula and gives rise to sporadic human infections following the entry of infected individuals to other countries, which can ppt. outbreaks similar to the one that occurred in South Korea in 2015.  Current therapeutics against MERS-CoV infection have primarily been adapted from previous drugs used for the treatment of severe acute respiratory syndrome.  In search of new potential drug candidates, we screened a library composed of 2334 clin. approved drugs and pharmacol. active compds.  The drug saracatinib, a potent inhibitor of Src-family of tyrosine kinases (SFK), was identified as an inhibitor of MERS-CoV replication in vitro.  Our results suggest that saracatinib potently inhibits MERS-CoV at the early stages of the viral life cycle in Huh-7 cells, possibly through the suppression of SFK signaling pathways.  Furthermore, saracatinib exhibited a synergistic effect with gemcitabine, an anticancer drug with antiviral activity against several RNA viruses.  These data indicate that saracatinib alone or in combination with gemcitabine can provide a new therapeutic option for the treatment of MERS-CoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZ_gxf2E7R7Vg90H21EOLACvtfcHk0lhQXfns0xRoLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVanurzF&md5=46083e949f27772ec4ed534ea8933f27</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3390%2Fv10060283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv10060283%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DJ.%2BS.%26aulast%3DJung%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DGo%26aufirst%3DY.%2BY.%26atitle%3DSaracatinib%2520inhibits%2520Middle%2520East%2520respiratory%2520syndrome-coronavirus%2520replication%2520in%2520vitro%26jtitle%3DViruses%26date%3D2018%26volume%3D10%26spage%3D283%26doi%3D10.3390%2Fv10060283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meessen-Pinard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Coupanec, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desforges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, P. J.</span></span> <span> </span><span class="NLM_article-title">Pivotal role of receptor-interacting protein kinase 1 and mixed lineage kinase domain-like in neuronal cell death induced by the human neuroinvasive coronavirus OC43</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>, <span class="NLM_elocation-id">e01513-16</span> <span class="refDoi">Â DOI: 10.1128/JVI.01513-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01513-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27795420" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&author=M.+Meessen-Pinardauthor=A.+Le+Coupanecauthor=M.+Desforgesauthor=P.+J.+Talbot&title=Pivotal+role+of+receptor-interacting+protein+kinase+1+and+mixed+lineage+kinase+domain-like+in+neuronal+cell+death+induced+by+the+human+neuroinvasive+coronavirus+OC43&doi=10.1128%2FJVI.01513-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1128%2FJVI.01513-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01513-16%26sid%3Dliteratum%253Aachs%26aulast%3DMeessen-Pinard%26aufirst%3DM.%26aulast%3DLe%2BCoupanec%26aufirst%3DA.%26aulast%3DDesforges%26aufirst%3DM.%26aulast%3DTalbot%26aufirst%3DP.%2BJ.%26atitle%3DPivotal%2520role%2520of%2520receptor-interacting%2520protein%2520kinase%25201%2520and%2520mixed%2520lineage%2520kinase%2520domain-like%2520in%2520neuronal%2520cell%2520death%2520induced%2520by%2520the%2520human%2520neuroinvasive%2520coronavirus%2520OC43%26jtitle%3DJ.%2520Virol.%26date%3D2017%26volume%3D91%26doi%3D10.1128%2FJVI.01513-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galimberti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BaratÃ¨, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balducci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciabatti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baglietto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spezia, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggi, F.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: A possible model supporting their use in the fight against SARS-CoV-2</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1428</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2020.01428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffonc.2020.01428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33014780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FntlWmsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=1428&author=S.+Galimbertiauthor=M.+Petriniauthor=C.+Barat%C3%A8author=F.+Ricciauthor=S.+Balducciauthor=S.+Grassiauthor=F.+Guerriniauthor=E.+Ciabattiauthor=S.+Mechelliauthor=A.+Di+Paoloauthor=C.+Baldiniauthor=L.+Bagliettoauthor=L.+Maceraauthor=P.+G.+Speziaauthor=F.+Maggi&title=Tyrosine+kinase+inhibitors+play+an+antiviral+action+in+patients+affected+by+chronic+myeloid+leukemia%3A+A+possible+model+supporting+their+use+in+the+fight+against+SARS-CoV-2&doi=10.3389%2Ffonc.2020.01428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2</span></div><div class="casAuthors">Galimberti Sara; Petrini Mario; Ricci Federica; Balducci Serena; Grassi Susanna; Guerrini Francesca; Ciabatti Elena; Di Paolo Antonello; Baldini Chiara; Baglietto Laura; Barate Claudia; Mechelli Sandra; Macera Lisa; Spezia Pietro Giorgio; Maggi Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1428</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">SARS-CoV-2 is the viral agent responsible for the pandemic that in the first months of 2020 caused about 400,000 deaths.  Among compounds proposed to fight the SARS-CoV-2-related disease (COVID-19), tyrosine kinase inhibitors (TKIs), already effective in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML), have been proposed on the basis of their antiviral action already demonstrated against SARS-CoV-1.  Very few cases of COVID-19 have been reported in Ph+ ALL and in CML Italian cohorts; authors suggested that this low rate of infections might depend on the use of TKIs, but the biological causes of this phenomenon remain unknown.  In this study, the CML model was used to test if TKIs would sustain or not the viral replication and if they could damage patient immunity.  Firstly, the infection and replication rate of torquetenovirus (TTV), whose load is inversely proportional to the host immunological control, have been measured in CML patients receiving nilotinib.  A very low percentage of subjects were infected at baseline, and TTV did not replicate or at least showed a low replication rate during the follow-up, with a mean load comparable to the measured one in healthy subjects.  Then, after gene expression profiling experiments, we found that several "antiviral" genes, such as CD28 and IFN gamma, were upregulated, while genes with "proviral" action, such as ARG-1, CEACAM1, and FUT4, were less expressed during treatment with imatinib, thus demonstrating that TKIs are not detrimental from the immunological point of view.  To sum up, our data could offer some biological explanations to the low COVID-19 occurrence in Ph+ ALL and CML patients and sustain the use of TKIs in COVID-19, as already proposed by several international ongoing studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQU0RJ53r8NbgaK-_ZudimnfW6udTcc2eYgnejSi-Z4rLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FntlWmsQ%253D%253D&md5=979be41f8e43fa2089311b8f453e5f29</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2020.01428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2020.01428%26sid%3Dliteratum%253Aachs%26aulast%3DGalimberti%26aufirst%3DS.%26aulast%3DPetrini%26aufirst%3DM.%26aulast%3DBarat%25C3%25A8%26aufirst%3DC.%26aulast%3DRicci%26aufirst%3DF.%26aulast%3DBalducci%26aufirst%3DS.%26aulast%3DGrassi%26aufirst%3DS.%26aulast%3DGuerrini%26aufirst%3DF.%26aulast%3DCiabatti%26aufirst%3DE.%26aulast%3DMechelli%26aufirst%3DS.%26aulast%3DDi%2BPaolo%26aufirst%3DA.%26aulast%3DBaldini%26aufirst%3DC.%26aulast%3DBaglietto%26aufirst%3DL.%26aulast%3DMacera%26aufirst%3DL.%26aulast%3DSpezia%26aufirst%3DP.%2BG.%26aulast%3DMaggi%26aufirst%3DF.%26atitle%3DTyrosine%2520kinase%2520inhibitors%2520play%2520an%2520antiviral%2520action%2520in%2520patients%2520affected%2520by%2520chronic%2520myeloid%2520leukemia%253A%2520A%2520possible%2520model%2520supporting%2520their%2520use%2520in%2520the%2520fight%2520against%2520SARS-CoV-2%26jtitle%3DFront.%2520Oncol.%26date%3D2020%26volume%3D10%26spage%3D1428%26doi%3D10.3389%2Ffonc.2020.01428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">The p38 MAP kinase family as regulators of proinflammatory cytokine production in degenerative diseases of the CNS</span>. <i>Aging Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">199</span>â <span class="NLM_lpage">211</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=199-211&author=A.+D.+Bachstetterauthor=L.+J.+Van+Eldik&title=The+p38+MAP+kinase+family+as+regulators+of+proinflammatory+cytokine+production+in+degenerative+diseases+of+the+CNS"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DThe%2520p38%2520MAP%2520kinase%2520family%2520as%2520regulators%2520of%2520proinflammatory%2520cytokine%2520production%2520in%2520degenerative%2520diseases%2520of%2520the%2520CNS%26jtitle%3DAging%2520Dis.%26date%3D2010%26volume%3D3%26spage%3D199%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monahan, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. G.</span></span> <span> </span><span class="NLM_article-title">p38 Pathway kinases as anti-inflammatory drug targets</span>. <i>J. Dent. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">800</span>â <span class="NLM_lpage">811</span>, <span class="refDoi">Â DOI: 10.1177/154405910708600902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1177%2F154405910708600902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17720847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVOqurfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2007&pages=800-811&author=J.+F.+Schindlerauthor=J.+B.+Monahanauthor=W.+G.+Smith&title=p38+Pathway+kinases+as+anti-inflammatory+drug+targets&doi=10.1177%2F154405910708600902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">p38 pathway kinases as anti-inflammatory drug targets</span></div><div class="casAuthors">Schindler, J. F.; Monahan, J. B.; Smith, W. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dental Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">800-811</span>CODEN:
                <span class="NLM_cas:coden">JDREAF</span>;
        ISSN:<span class="NLM_cas:issn">0022-0345</span>.
    
            (<span class="NLM_cas:orgname">International Association for Dental Research</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinases (MAPK) are intracellular signaling mols. involved in cytokine synthesis.  Several classes of mammalian MAPK have been identified, including extracellular signal-regulated kinase, c-jun N-terminal kinase, and p38 MAP kinase.  P38Î± is a key MAPK involved in tumor necrosis factor Î± and other cytokine prodn., as well as enzyme induction (cyclooxygenase-2, inducible nitric oxide synthase, and matrix metalloproteinases) and adhesion mol. expression.  An understanding of the broad biol. and pathophysiol. roles of p38 MAPK family members has grown significantly over the past decade, as has the complexity of the signaling network leading to their activation.  Downstream substrates of MAPK include other kinases (e.g., mitogen-activated protein-kinase-activated protein kinase 2) and factors that regulate transcription, nuclear export, and mRNA stability and translation.  The high-resoln. crystal structure of p38Î± has led to the design of selective inhibitors that have good pharmacol. activity.  Despite the strong rationale for MAPK inhibitors in human disease, direct proof of concept in the clinic has yet to be demonstrated, with most compds. demonstrating dose-limiting adverse effects.  The role of MAPK in inflammation makes them attractive targets for new therapies, and efforts are continuing to identify newer, more selective inhibitors for inflammatory diseases.  Abbreviations used: MAPK, mitogen-activated protein kinase; ERK, extracellular signaling kinase; JNK, c-jun N-terminal kinase; COX2, cyclo-oxygenase-2; iNOS, inducible nitric oxide synthase; MMP, matrix metalloproteinase; MAPKK, mitogen-activated protein kinase kinase; MK-2, mitogen-activated protein-kinase-activated protein kinase-2; MAPKAP, mitogen-activated protein kinase-activated protein; MAPKKK, mitogen-activated protein kinase kinase kinase; RANKL, receptor activator of NF-ÎºB ligand; MNK, MAP kinase signal-integrating kinase; MSK, mitogen and stress-activated protein kinase; RSK, ribosomal S6 kinase; AP-1, activator protein-1; Tp1, tumor progression locus 2; IL, interleukin; ASK1, apoptosis signal-regulating kinase 1; TAO, thousand-and-one amino acids; MLK3, mixed-lineage kinase 3; TBK, transforming growth factor Î² activated protein kinase; TGFÎ², transforming growth factor Î²; LPS, lipopolysaccharide; TRAF6, TNF receptor-assocd. factor 6; MKK, mitogen-activated protein kinase kinase; TAK-1, TGF-beta activated protein kinase; GRK2, G-protein coupled receptor kinase-2 MKPs, MAP kinase phosphatases; PRAK, p38 regulated/ activated protein kinase; IFNÎ³, interferon gamma; AREs, AU-rich elements; AUBPs, AU-rich binding proteins; TTP, tristetraprolin; hnRNP A0, heterogeneous nuclear ribonuclear protein A0; HUR, human R antigen; PGE2, prostaglandin E2; Hsp27, small heat-shock protein-27; TNF-Î±, tumor necrosis factor alpha.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp29bqrL8B2KrVg90H21EOLACvtfcHk0lhkF47SGov8gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVOqurfN&md5=38486f3ec8603a4bf793b111441617b4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1177%2F154405910708600902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F154405910708600902%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DJ.%2BF.%26aulast%3DMonahan%26aufirst%3DJ.%2BB.%26aulast%3DSmith%26aufirst%3DW.%2BG.%26atitle%3Dp38%2520Pathway%2520kinases%2520as%2520anti-inflammatory%2520drug%2520targets%26jtitle%3DJ.%2520Dent.%2520Res.%26date%3D2007%26volume%3D86%26spage%3D800%26epage%3D811%26doi%3D10.1177%2F154405910708600902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghuvanshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, S. B.</span></span> <span> </span><span class="NLM_article-title">Recent developments in the use of kinase inhibitors for management of viral Infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c01467</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01467" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=R.+Raghuvanshiauthor=S.+B.+Bharate&title=Recent+developments+in+the+use+of+kinase+inhibitors+for+management+of+viral+Infections&doi=10.1021%2Facs.jmedchem.0c01467"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01467%26sid%3Dliteratum%253Aachs%26aulast%3DRaghuvanshi%26aufirst%3DR.%26aulast%3DBharate%26aufirst%3DS.%2BB.%26atitle%3DRecent%2520developments%2520in%2520the%2520use%2520of%2520kinase%2520inhibitors%2520for%2520management%2520of%2520viral%2520Infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26doi%3D10.1021%2Facs.jmedchem.0c01467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span> <span> </span><span class="NLM_article-title">Influenza-virusinduced signaling cascades: Targets for antiviral therapy?</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">46</span>â <span class="NLM_lpage">52</span>, <span class="refDoi">Â DOI: 10.1016/S1471-4914(02)00010-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS1471-4914%2802%2900010-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=12615037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsVWqsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=46-52&author=S.+Ludwigauthor=O.+Planzauthor=S.+Pleschkaauthor=T.+Wolff&title=Influenza-virusinduced+signaling+cascades%3A+Targets+for+antiviral+therapy%3F&doi=10.1016%2FS1471-4914%2802%2900010-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza-virus-induced signaling cascades: targets for antiviral therapy?</span></div><div class="casAuthors">Ludwig, Stephan; Planz, Oliver; Pleschka, Stephan; Wolff, Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">46-52</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Influenza viruses continue to pose a severe threat worldwide, causing thousands of deaths and an enormous economic loss every year.  The major problem in fighting influenza is the high genetic variability of the virus, resulting in the rapid formation of variants that escape the acquired immunity against previous virus strains, or have resistance to antiviral agents.  Every virus depends on its host cell and, hence, cellular functions that are essential for viral replication might be suitable targets for antiviral therapy.  As a result, intracellular signaling cascades induced by the virus, in particular mitogen-activated protein kinase pathways, have recently come into focus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqTupjREwwibVg90H21EOLACvtfcHk0lg1n7T4j5PRUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsVWqsrg%253D&md5=0824b4a81b06874f3a8e4964e4737eb8</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2FS1471-4914%2802%2900010-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4914%252802%252900010-2%26sid%3Dliteratum%253Aachs%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26atitle%3DInfluenza-virusinduced%2520signaling%2520cascades%253A%2520Targets%2520for%2520antiviral%2520therapy%253F%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D46%26epage%3D52%26doi%3D10.1016%2FS1471-4914%2802%2900010-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Development of cellular signaling pathway inhibitors as new antivirals against influenza</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">457</span>â <span class="NLM_lpage">468</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2013.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2013.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=23603495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotlGntbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=457-468&author=O.+Planz&title=Development+of+cellular+signaling+pathway+inhibitors+as+new+antivirals+against+influenza&doi=10.1016%2Fj.antiviral.2013.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Development of cellular signaling pathway inhibitors as new antivirals against influenza</span></div><div class="casAuthors">Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">457-468</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Influenza virus exploits a no. of cellular signaling pathways during the course of its replication, rendering them potential targets for new therapeutic interventions.  Several preclin. approaches are now focusing on cellular factors or pathways as a means of treating influenza.  By targeting host factors, rather than viral mechanisms, these novel therapies may be effective against multiple virus strains and subtypes, and are less likely to elicit viral drug resistance.  The most promising candidates are inhibitors of intracellular signaling cascades that are essential for virus replication.  This article reviews novel approaches and compds. that target the Raf/MEK/ERK signaling pathway, NF-ÎºB signaling, the PI3K/Akt pathway and the PKC signaling cascade.  Although these new antiviral strategies are still in an early phase of preclin. development, results to date suggest they offer a new approach to the treatment of influenza, supplementing direct-acting antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk82XeTtb077Vg90H21EOLACvtfcHk0lg1n7T4j5PRUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotlGntbk%253D&md5=51b9a73e0faa5a894c7cef307cda92cd</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2013.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2013.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DDevelopment%2520of%2520cellular%2520signaling%2520pathway%2520inhibitors%2520as%2520new%2520antivirals%2520against%2520influenza%26jtitle%3DAntiviral%2520Res.%26date%3D2013%26volume%3D98%26spage%3D457%26epage%3D468%26doi%3D10.1016%2Fj.antiviral.2013.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meineke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimmelzwaan, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elbahesh, H.</span></span> <span> </span><span class="NLM_article-title">Influenza virus infections and cellular kinases</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">171</span>, <span class="refDoi">Â DOI: 10.3390/v11020171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3390%2Fv11020171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslymtbjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=171&author=R.+Meinekeauthor=G.+F.+Rimmelzwaanauthor=H.+Elbahesh&title=Influenza+virus+infections+and+cellular+kinases&doi=10.3390%2Fv11020171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus infections and cellular kinases</span></div><div class="casAuthors">Meineke, Robert; Rimmelzwaan, Guus F.; Elbahesh, Husni</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Influenza A viruses (IAVs) are a major cause of respiratory illness and are responsible for yearly epidemics assocd. with more than 500,000 annual deaths globally.  Novel IAVs may cause pandemic outbreaks and zoonotic infections with, for example, highly pathogenic avian influenza virus (HPAIV) of the H5N1 and H7N9 subtypes, which pose a threat to public health.  Treatment options are limited and emergence of strains resistant to antiviral drugs jeopardize this even further.  Like all viruses, IAVs depend on host factors for every step of the virus replication cycle.  Host kinases link multiple signaling pathways in respond to a myriad of stimuli, including viral infections.  Their regulation of multiple response networks has justified actively targeting cellular kinases for anti-cancer therapies and immune modulators for decades.  There is a growing vol. of research highlighting the significant role of cellular kinases in regulating IAV infections.  Their functional role is illustrated by the required phosphorylation of several IAV proteins necessary for replication and/or evasion/suppression of the innate immune response.  Identified in the majority of host factor screens, functional studies further support the important role of kinases and their potential as host restriction factors.  PKC, ERK, PI3K and FAK, to name a few, are kinases that regulate viral entry and replication.  Addnl., kinases such as IKK, JNK and p38 MAPK are essential in mediating viral sensor signaling cascades that regulate expression of antiviral chemokines and cytokines.  The feasibility of targeting kinases is steadily moving from bench to clinic and already-approved cancer drugs could potentially be repurposed for treatments of severe IAV infections.  In this review, we will focus on the contribution of cellular kinases to IAV infections and their value as potential therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSc-PzlVOvnrVg90H21EOLACvtfcHk0lg1n7T4j5PRUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslymtbjI&md5=7f0bed27a7c1bf8ea5c8870c7533f087</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.3390%2Fv11020171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv11020171%26sid%3Dliteratum%253Aachs%26aulast%3DMeineke%26aufirst%3DR.%26aulast%3DRimmelzwaan%26aufirst%3DG.%2BF.%26aulast%3DElbahesh%26aufirst%3DH.%26atitle%3DInfluenza%2520virus%2520infections%2520and%2520cellular%2520kinases%26jtitle%3DViruses%26date%3D2019%26volume%3D11%26spage%3D171%26doi%3D10.3390%2Fv11020171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Repurposing of kinase inhibitors as broadspectrum antiviral drugs</span>. <i>DNA Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">63</span>â <span class="NLM_lpage">69</span>, <span class="refDoi">Â DOI: 10.1089/dna.2017.4033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1089%2Fdna.2017.4033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29148875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ylsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=63-69&author=S.+Schorauthor=S.+Einav&title=Repurposing+of+kinase+inhibitors+as+broadspectrum+antiviral+drugs&doi=10.1089%2Fdna.2017.4033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs</span></div><div class="casAuthors">Schor, Stanford; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">DNA and Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">63-69</span>CODEN:
                <span class="NLM_cas:coden">DCEBE8</span>;
        ISSN:<span class="NLM_cas:issn">1044-5498</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">The high cost of drug development and the narrow spectrum of coverage typically provided by direct-acting antivirals limit the scalability of this antiviral approach.  This review summarizes progress and challenges in the repurposing of approved kinase inhibitors as host-targeted broad-spectrum antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNoqjCQHksU7Vg90H21EOLACvtfcHk0lgX8VYt8Qo1gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ylsLg%253D&md5=4c6cad02eaecd11bf25b3d3de88f3cfe</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1089%2Fdna.2017.4033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fdna.2017.4033%26sid%3Dliteratum%253Aachs%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DRepurposing%2520of%2520kinase%2520inhibitors%2520as%2520broadspectrum%2520antiviral%2520drugs%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2018%26volume%3D37%26spage%3D63%26epage%3D69%26doi%3D10.1089%2Fdna.2017.4033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrion, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabel, G. J.</span></span> <span> </span><span class="NLM_article-title">Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">123ra24</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3003500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1126%2Fscitranslmed.3003500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22378924" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=123ra24&author=M.+Garciaauthor=A.+Cooperauthor=W.+Shiauthor=W.+Bornmannauthor=R.+Carrionauthor=D.+Kalmanauthor=G.+J.+Nabel&title=Productive+replication+of+Ebola+virus+is+regulated+by+the+c-Abl1+tyrosine+kinase&doi=10.1126%2Fscitranslmed.3003500"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003500%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DM.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DCarrion%26aufirst%3DR.%26aulast%3DKalman%26aufirst%3DD.%26aulast%3DNabel%26aufirst%3DG.%2BJ.%26atitle%3DProductive%2520replication%2520of%2520Ebola%2520virus%2520is%2520regulated%2520by%2520the%2520c-Abl1%2520tyrosine%2520kinase%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26spage%3D123ra24%26doi%3D10.1126%2Fscitranslmed.3003500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kouznetsova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Romero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKew, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Sastre, A.</span></span> <span> </span><span class="NLM_article-title">Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs</span>. <i>Emerging Microbes Infect.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">7</span>, <span class="refDoi">Â DOI: 10.1038/emi.2014.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Femi.2014.88" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=1-7&author=J.+Kouznetsovaauthor=W.+Sunauthor=C.+Martinez-Romeroauthor=G.+Tawaauthor=P.+Shinnauthor=C.+Z.+Chenauthor=A.+Schimmerauthor=P.+Sandersonauthor=J.+C.+McKewauthor=W.+Zhengauthor=A.+Garcia-Sastre&title=Identification+of+53+compounds+that+block+Ebola+virus-like+particle+entry+via+a+repurposing+screen+of+approved+drugs&doi=10.1038%2Femi.2014.88"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Femi.2014.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femi.2014.88%26sid%3Dliteratum%253Aachs%26aulast%3DKouznetsova%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DMartinez-Romero%26aufirst%3DC.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DShinn%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DC.%2BZ.%26aulast%3DSchimmer%26aufirst%3DA.%26aulast%3DSanderson%26aufirst%3DP.%26aulast%3DMcKew%26aufirst%3DJ.%2BC.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DGarcia-Sastre%26aufirst%3DA.%26atitle%3DIdentification%2520of%252053%2520compounds%2520that%2520block%2520Ebola%2520virus-like%2520particle%2520entry%2520via%2520a%2520repurposing%2520screen%2520of%2520approved%2520drugs%26jtitle%3DEmerging%2520Microbes%2520Infect.%26date%3D2014%26volume%3D3%26spage%3D1%26epage%3D7%26doi%3D10.1038%2Femi.2014.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergelson, J. M.</span></span> <span> </span><span class="NLM_article-title">Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">119</span>â <span class="NLM_lpage">131</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2005.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cell.2005.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16413486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XntVGktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2006&pages=119-131&author=C.+B.+Coyneauthor=J.+M.+Bergelson&title=Virus-induced+Abl+and+Fyn+kinase+signals+permit+coxsackievirus+entry+through+epithelial+tight+junctions&doi=10.1016%2Fj.cell.2005.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Virus-induced abl and fyn kinase signals permit coxsackievirus entry through epithelial tight junctions</span></div><div class="casAuthors">Coyne, Carolyn B.; Bergelson, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-131</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Group B coxsackieviruses (CVBs) must cross the epithelium as they initiate infection, but the mechanism by which this occurs remains uncertain.  The coxsackievirus and adenovirus receptor (CAR) is a component of the tight junction and is inaccessible to virus approaching from the apical surface.  Many CVBs also interact with the GPI-anchored protein decay-accelerating factor (DAF).  Here, we report that virus attachment to DAF on the apical cell surface activates Abl kinase, triggering Rac-dependent actin rearrangements that permit virus movement to the tight junction.  Within the junction, interaction with CAR promotes conformational changes in the virus capsid that are essential for virus entry and release of viral RNA.  Interaction with DAF also activates Fyn kinase, an event that is required for the phosphorylation of caveolin and transport of virus into the cell within caveolar vesicles.  CVBs thus exploit DAF-mediated signaling pathways to surmount the epithelial barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMExrkWO5tVLVg90H21EOLACvtfcHk0lgX8VYt8Qo1gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntVGktg%253D%253D&md5=50cd83bdbcc0356e32b163ef4dcd9f43</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DCoyne%26aufirst%3DC.%2BB.%26aulast%3DBergelson%26aufirst%3DJ.%2BM.%26atitle%3DVirus-induced%2520Abl%2520and%2520Fyn%2520kinase%2520signals%2520permit%2520coxsackievirus%2520entry%2520through%2520epithelial%2520tight%2520junctions%26jtitle%3DCell%26date%3D2006%26volume%3D124%26spage%3D119%26epage%3D131%26doi%3D10.1016%2Fj.cell.2005.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newsome, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisswange, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frischknecht, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Way, M.</span></span> <span> </span><span class="NLM_article-title">Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus</span>. <i>Cell. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">233</span>â <span class="NLM_lpage">241</span>, <span class="refDoi">Â DOI: 10.1111/j.1462-5822.2005.00613.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1111%2Fj.1462-5822.2005.00613.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16441434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFant7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=233-241&author=T.+P.+Newsomeauthor=I.+Weisswangeauthor=F.+Frischknechtauthor=M.+Way&title=Abl+collaborates+with+Src+family+kinases+to+stimulate+actin-based+motility+of+vaccinia+virus&doi=10.1111%2Fj.1462-5822.2005.00613.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus</span></div><div class="casAuthors">Newsome, Timothy P.; Weisswange, Ina; Frischknecht, Friedrich; Way, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Microbiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-241</span>CODEN:
                <span class="NLM_cas:coden">CEMIF5</span>;
        ISSN:<span class="NLM_cas:issn">1462-5814</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Local activation of Src at the plasma membrane by extracellular vaccinia virus results in a signaling cascade that acts to stimulate actin polymn. beneath the virus to enhance its cell-to-cell spread.  Initiation of this signaling cascade involves Src-mediated phosphorylation of tyrosine 112 and 132 of the viral membrane protein A36R.  Here we show that recruitment of Src is dependent on its myristoylation and an interaction with A36R upstream of tyrosine 112 and 132.  We further show that Src, Fyn and Yes have unique specificities toward these tyrosine residues.  Using cell lines deficient in Src, Fyn and Yes, we demonstrate that multiple Src family members can stimulate vaccinia-induced actin polymn. and also uncover a role for Abl family kinases.  Addnl., Abl and Arg are able to phosphorylate A36R in vitro and are recruited to vaccinia-induced actin tails.  The ability of multiple families of tyrosine kinases to directly phosphorylate A36R ensures robust cell-to-cell spread of vaccinia virus will occur under a variety of cellular conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvWPtkZkCiHLVg90H21EOLACvtfcHk0lgDKbjgnfZjvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFant7s%253D&md5=94c5c1339d85280d6f80cb7064a7f2bc</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1111%2Fj.1462-5822.2005.00613.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1462-5822.2005.00613.x%26sid%3Dliteratum%253Aachs%26aulast%3DNewsome%26aufirst%3DT.%2BP.%26aulast%3DWeisswange%26aufirst%3DI.%26aulast%3DFrischknecht%26aufirst%3DF.%26aulast%3DWay%26aufirst%3DM.%26atitle%3DAbl%2520collaborates%2520with%2520Src%2520family%2520kinases%2520to%2520stimulate%2520actin-based%2520motility%2520of%2520vaccinia%2520virus%26jtitle%3DCell.%2520Microbiol.%26date%3D2006%26volume%3D8%26spage%3D233%26epage%3D241%26doi%3D10.1111%2Fj.1462-5822.2005.00613.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindrachuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidlaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lear-Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span> <span> </span><span class="NLM_article-title">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4885</span>â <span class="NLM_lpage">4893</span>, <span class="refDoi">Â DOI: 10.1128/AAC.03036-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FAAC.03036-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24841273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1art73L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=4885-4893&author=J.+Dyallauthor=C.+M.+Colemanauthor=B.+J.+Hartauthor=T.+Venkataramanauthor=M.+R.+Holbrookauthor=J.+Kindrachukauthor=R.+F.+Johnsonauthor=G.+G.+Olingerauthor=P.+B.+Jahrlingauthor=M.+Laidlawauthor=L.+M.+Johansenauthor=C.+M.+Lear-Rooneyauthor=P.+J.+Glassauthor=L.+E.+Hensleyauthor=M.+B.+Frieman&title=Repurposing+of+clinically+developed+drugs+for+treatment+of+Middle+East+respiratory+syndrome+coronavirus+infection&doi=10.1128%2FAAC.03036-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</span></div><div class="casAuthors">Dyall, Julie; Coleman, Christopher M.; Hart, Brit J.; Venkataraman, Thiagarajan; Holbrook, Michael R.; Kindrachuk, Jason; Johnson, Reed F.; Olinger, Gene G.; Jahrling, Peter B.; Laidlaw, Monique; Johansen, Lisa M.; Lear-Rooney, Calli M.; Glass, Pamela J.; Hensley, Lisa E.; Frieman, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4885-4893, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacol. treatments in the clinic with little time available for drug testing and development.  Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options.  Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers and funding agencies.  Given the development times and manufg. requirements for new products, repurposing of existing drugs is likely the only soln. for outbreaks due to emerging viruses.  In the studies described here, a library of 290 compds. was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).  Selection of compds. for inclusion in the library was dependent on current or previous FDA approval or advanced clin. development.  Some drugs that had a well-defined cellular pathway as target were included.  In total, 27 compds. with activity against both MERS-CoV and SARS-CoV were identified.  The compds. belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics.  The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE_PH7j54pPrVg90H21EOLACvtfcHk0lgDKbjgnfZjvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1art73L&md5=4cd7f71c09de4c1965b7c6f42f3ae2ce</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1128%2FAAC.03036-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03036-14%26sid%3Dliteratum%253Aachs%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DC.%2BM.%26aulast%3DHart%26aufirst%3DB.%2BJ.%26aulast%3DVenkataraman%26aufirst%3DT.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DKindrachuk%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DR.%2BF.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26aulast%3DLaidlaw%26aufirst%3DM.%26aulast%3DJohansen%26aufirst%3DL.%2BM.%26aulast%3DLear-Rooney%26aufirst%3DC.%2BM.%26aulast%3DGlass%26aufirst%3DP.%2BJ.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26atitle%3DRepurposing%2520of%2520clinically%2520developed%2520drugs%2520for%2520treatment%2520of%2520Middle%2520East%2520respiratory%2520syndrome%2520coronavirus%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D4885%26epage%3D4893%26doi%3D10.1128%2FAAC.03036-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalmanti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saussele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauseker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietz, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanfstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proetel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabarius, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppliger-Leibundgut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegelmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfreundschuh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfirrmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hehlmann, R.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of imatinib in CML over a period of 10 years: Data from the randomized CML-study IV</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1123</span>â <span class="NLM_lpage">1132</span>, <span class="refDoi">Â DOI: 10.1038/leu.2015.36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fleu.2015.36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25676422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXks1aitbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=1123-1132&author=L.+Kalmantiauthor=S.+Sausseleauthor=M.+Lausekerauthor=M.+C.+Mullerauthor=C.+T.+Dietzauthor=L.+Heinrichauthor=B.+Hanfsteinauthor=U.+Proetelauthor=A.+Fabariusauthor=S.+W.+Krauseauthor=S.+Rinaldettiauthor=J.+Denglerauthor=C.+Falgeauthor=E.+Oppliger-Leibundgutauthor=A.+Burchertauthor=A.+Neubauerauthor=L.+Kanzauthor=F.+Stegelmannauthor=M.+Pfreundschuhauthor=K.+Spiekermannauthor=C.+Scheidauthor=M.+Pfirrmannauthor=A.+Hochhausauthor=J.+Hasfordauthor=R.+Hehlmann&title=Safety+and+efficacy+of+imatinib+in+CML+over+a+period+of+10+years%3A+Data+from+the+randomized+CML-study+IV&doi=10.1038%2Fleu.2015.36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV</span></div><div class="casAuthors">Kalmanti, L.; Saussele, S.; Lauseker, M.; Mueller, M. C.; Dietz, C. T.; Heinrich, L.; Hanfstein, B.; Proetel, U.; Fabarius, A.; Krause, S. W.; Rinaldetti, S.; Dengler, J.; Falge, C.; Oppliger-Leibundgut, E.; Burchert, A.; Neubauer, A.; Kanz, L.; Stegelmann, F.; Pfreundschuh, M.; Spiekermann, K.; Scheid, C.; Pfirrmann, M.; Hochhaus, A.; Hasford, J.; Hehlmann, R.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1123-1132</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors (TKI) have changed the natural course of chronic myeloid leukemia (CML).  With the advent of second-generation TKI safety and efficacy issues have gained interest.  The randomized CML - Study IV was used for a long-term evaluation of imatinib (IM). 1503 patients have received IM, 1379 IM monotherapy.  After a median observation of 7.1 years, 965 patients (64%) still received IM.  At 10 years, progression-free survival was 82%, overall survival 84%, 59% achieved MR5, 72% MR4.5, 81% MR4, 89% major mol. remission and 92% MR2 (mol. equiv. to complete cytogenetic remission).  All response levels were reached faster with IM800 mg except MR5.  Eight-year probabilities of adverse drug reactions (ADR) were 76%, of grades 3-4 22%, of non-hematol. 73%, and of hematol. 28%.  More ADR were obsd. with IM800 mg and IM400 mg plus interferon Î± (IFN).  Most patients had their first ADR early with decreasing frequency later on.  No new late toxicity was obsd.  ADR to IM are frequent, but mostly mild and manageable, also with IM 800 mg and IM 400 mg+IFN.  The deep mol. response rates indicate that most patients are candidates for IM discontinuation.  After 10 years, IM continues to be an excellent initial choice for most patients with CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdYjW13OccG7Vg90H21EOLACvtfcHk0lj_OYCPwZa5Nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXks1aitbw%253D&md5=83e83b1e30df4420f4944aa7d3479b02</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.36%26sid%3Dliteratum%253Aachs%26aulast%3DKalmanti%26aufirst%3DL.%26aulast%3DSaussele%26aufirst%3DS.%26aulast%3DLauseker%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DM.%2BC.%26aulast%3DDietz%26aufirst%3DC.%2BT.%26aulast%3DHeinrich%26aufirst%3DL.%26aulast%3DHanfstein%26aufirst%3DB.%26aulast%3DProetel%26aufirst%3DU.%26aulast%3DFabarius%26aufirst%3DA.%26aulast%3DKrause%26aufirst%3DS.%2BW.%26aulast%3DRinaldetti%26aufirst%3DS.%26aulast%3DDengler%26aufirst%3DJ.%26aulast%3DFalge%26aufirst%3DC.%26aulast%3DOppliger-Leibundgut%26aufirst%3DE.%26aulast%3DBurchert%26aufirst%3DA.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DKanz%26aufirst%3DL.%26aulast%3DStegelmann%26aufirst%3DF.%26aulast%3DPfreundschuh%26aufirst%3DM.%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DScheid%26aufirst%3DC.%26aulast%3DPfirrmann%26aufirst%3DM.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DHasford%26aufirst%3DJ.%26aulast%3DHehlmann%26aufirst%3DR.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520imatinib%2520in%2520CML%2520over%2520a%2520period%2520of%252010%2520years%253A%2520Data%2520from%2520the%2520randomized%2520CML-study%2520IV%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D1123%26epage%3D1132%26doi%3D10.1038%2Fleu.2015.36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâHare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffregen, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherbenou, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span> <span> </span><span class="NLM_article-title">Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">6987</span>â <span class="NLM_lpage">6993</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-05-0622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F1078-0432.CCR-05-0622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16203792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKiurvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=6987-6993&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=E.+P.+Stoffregenauthor=D.+W.+Sherbenouauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=Combined+Abl+inhibitor+therapy+for+minimizing+drug+resistance+in+chronic+myeloid+leukemia%3A+Src%2FAbl+inhibitors+are+compatible+with+imatinib&doi=10.1158%2F1078-0432.CCR-05-0622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib</span></div><div class="casAuthors">O'Hare, Thomas; Walters, Denise K.; Stoffregen, Eric P.; Sherbenou, Daniel W.; Heinrich, Michael C.; Deininger, Michael W. N.; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">19, Pt. 1</span>),
    <span class="NLM_cas:pages">6987-6993</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Chronic myeloid leukemia (CML) is effectively treated with imatinib.  However, reactivation of Bcr-Abl via kinase domain mutations that reduce sensitivity to imatinib can cause relapse.  As combination therapy is frequently used to prevent emergence of resistance, the combination of imatinib with an inhibitor of imatinib-resistant Bcr-Abl mutants (e.g., Src/Abl inhibitors AP23848 and BMS-354825) was investigated.  Exptl. Design: To test this approach, cellular proliferation and Bcr-Abl tyrosine phosphorylation assays were done on Ba/F3 cells expressing wild-type (WT) Bcr-Abl and four common imatinib-resistant mutants (Y253F, E255K, T315I, and M351T).  Colony-forming assays with primary CML cells were also done.  Results: Both Src/Abl inhibitors retained full inhibitory capacity when coadministered with imatinib at concns. above typical clin. levels.  For cells expressing WT Bcr-Abl or the marginally imatinib-resistant mutant M351T, inclusion of imatinib at therapeutic levels enhanced the effects of the Src/Abl inhibitors.  By comparison, for the highly imatinib-resistant mutants Y253F and E255K, inclusion of imatinib at clin. levels resulted in only a slight enhancement beyond the effects of the Src/Abl inhibitors.  None of the inhibitors affected Bcr-Abl T315I cells.  Colony-forming assays with primary CML cells yielded analogous results.  Conclusions: Our results indicate that Src/Abl inhibitors are compatible with imatinib and suggest that combined Abl inhibitor therapy is a feasible treatment strategy for patients with CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXeesK3Ez7wrVg90H21EOLACvtfcHk0lj_OYCPwZa5Nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKiurvF&md5=b4f21bf482289d05a9b79da55acd72f4</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0622%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DSherbenou%26aufirst%3DD.%2BW.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DCombined%2520Abl%2520inhibitor%2520therapy%2520for%2520minimizing%2520drug%2520resistance%2520in%2520chronic%2520myeloid%2520leukemia%253A%2520Src%252FAbl%2520inhibitors%2520are%2520compatible%2520with%2520imatinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D6987%26epage%3D6993%26doi%3D10.1158%2F1078-0432.CCR-05-0622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span> <span> </span><span class="NLM_article-title">Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1754</i></span>,  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">13</span>, <span class="refDoi">Â DOI: 10.1016/j.bbapap.2005.07.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.bbapap.2005.07.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16172030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlags7fI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=3-13&author=P.+Manleyauthor=S.+Cowan-Jacobauthor=J.+Mestan&title=Advances+in+the+structural+biology%2C+design+and+clinical+development+of+Bcr-Abl+kinase+inhibitors+for+the+treatment+of+chronic+myeloid+leukaemia&doi=10.1016%2Fj.bbapap.2005.07.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia</span></div><div class="casAuthors">Manley, Paul William; Cowan-Jacob, Sandra W.; Mestan, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1754</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">3-13</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The constitutively activated Abl tyrosine kinase domain of the chimeric Bcr-Abl oncoprotein is responsible for the transformation of hematopoietic stem cells and the symptoms of chronic myeloid leukemia (CML).  Imatinib targets the tyrosine kinase activity of Bcr-Abl and is a first-line therapy for this malignancy.  Although highly effective in chronic phase CML, patients who have progressed to the advanced phase of the disease frequently fail to respond to imatinib or develop resistance to therapy and relapse.  This is often due to the emergence of clones expressing mutant forms of Bcr-Abl, which exhibit a decreased sensitivity towards inhibition by imatinib.  Considerable progress has recently been made in understanding the structural biol. of Abl and the mol. basis for resistance, facilitating the discovery and development of second generation drugs designed to combat mutant forms of Bcr-Abl.  The first of these compds. to enter clin. development were BMS-354825 (BristolMyersSquibb) and AMN107 (Novartis Pharma) and, from Phase I results, both of these promise a breakthrough in the treatment of imatinib-resistant CML.  Recent advances with these and other promising classes of new CML drugs are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0fkeC4vxU_bVg90H21EOLACvtfcHk0lgf67N0f6A-RA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlags7fI&md5=b9d67d465f61804d2acd78605a4e9a75</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2005.07.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2005.07.040%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%26aulast%3DCowan-Jacob%26aufirst%3DS.%26aulast%3DMestan%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520the%2520structural%2520biology%252C%2520design%2520and%2520clinical%2520development%2520of%2520Bcr-Abl%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520myeloid%2520leukaemia%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2005%26volume%3D1754%26spage%3D3%26epage%3D13%26doi%3D10.1016%2Fj.bbapap.2005.07.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span> <span> </span><span class="NLM_article-title">Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review</span>. <i>Core Evidence</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">207</span>â <span class="NLM_lpage">213</span>, <span class="refDoi">Â DOI: 10.2147/ce.s6003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.2147%2Fce.s6003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20694077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC3cjjt1Oktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=207-213&author=E.+Jabbourauthor=J.+Cortesauthor=H.+Kantarjian&title=Nilotinib+for+the+treatment+of+chronic+myeloid+leukemia%3A+An+evidence-based+review&doi=10.2147%2Fce.s6003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review</span></div><div class="casAuthors">Jabbour Elias; Cortes Jorge; Kantarjian Hagop</div><div class="citationInfo"><span class="NLM_cas:title">Core evidence</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207-13</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm.  The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% of patients obtaining complete hematologic response, and 70%-80% of patients achieving a complete cytogenetic response.  Despite the high efficacy of imatinib, a minority of patients in chronic phase CML and more patients in advanced phases are resistant to imatinib, or develop resistance during treatment.  This is attributed, in 40% to 50% of cases, to the development of mutations in the Bcr-Abl tyrosine kinase domain that impair imatinib binding.  Attempts to circumvent resistance led to the discovery of nilotinib (Tasigna), a novel, potent and selective oral Bcr-Abl kinase inhibitor.  AIMS:  To review the evidence for the use of nilotinib in the management of CML.  EVIDENCE REVIEW:  Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has further improved the treatment of CML.  PLACE IN THERAPY:  Nilotinib is currently indicated for patients with CML in chronic and accelerated phases following imatinib failure.  Randomized studies are ongoing to assess the efficacy of nilotinib in patients with newly diagnosed CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTo9R1fEvmZGlMGsG_HTXYFfW6udTcc2eYFE2sacYDYjbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjjt1Oktg%253D%253D&md5=f4de61f0b53dc07418faae35aa8c51b4</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.2147%2Fce.s6003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fce.s6003%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DNilotinib%2520for%2520the%2520treatment%2520of%2520chronic%2520myeloid%2520leukemia%253A%2520An%2520evidence-based%2520review%26jtitle%3DCore%2520Evidence%26date%3D2010%26volume%3D4%26spage%3D207%26epage%3D213%26doi%3D10.2147%2Fce.s6003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breccia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimena, G.</span></span> <span> </span><span class="NLM_article-title">Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">129</span>â <span class="NLM_lpage">134</span>, <span class="refDoi">Â DOI: 10.1016/j.leukres.2009.08.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.leukres.2009.08.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=19783301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=129-134&author=M.+Brecciaauthor=G.+Alimena&title=Nilotinib%3A+A+second-generation+tyrosine+kinase+inhibitor+for+chronic+myeloid+leukemia&doi=10.1016%2Fj.leukres.2009.08.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia</span></div><div class="casAuthors">Breccia, Massimo; Alimena, Giuliana</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-134</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Imatinib mesylate is currently the std. of care for chronic myeloid leukemia (CML) patients in early chronic phase.  However, the emergence of resistance and intolerance has dampened the enthusiasm for this drug.  To overcome this phenomenon, different strategies have been developed, including novel targeted agents.  Nilotinib, formerly known as AMN107, is a second-generation tyrosine kinase inhibitor 30-fold more potent than imatinib, with high affinity and selectivity on BCR/ABL, and also active against a wide range of mutant clones, except T315I mutation.  Phase II trials of nilotinib showed high activity in imatinib-resistant or intolerant CML patients, whereas front-line treatment of the disease in chronic phase demonstrated rapid and stable cytogenetic responses and increasing mol. responses.  We here review the development of nilotinib and the efficacy data in phase II and front-line trials.  The aim of this review is to evaluate the pharmacol., pharmacokinetic and pharmacodynamic properties of the drug and the recent results of clin. trials performed in patients with CML and Ph+ acute lymphoblastic leukemia (ALL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHbB1d-7Xyn7Vg90H21EOLACvtfcHk0lgf67N0f6A-RA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtrc%253D&md5=182529932452e885fa2f90de7cd2b44d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2009.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2009.08.031%26sid%3Dliteratum%253Aachs%26aulast%3DBreccia%26aufirst%3DM.%26aulast%3DAlimena%26aufirst%3DG.%26atitle%3DNilotinib%253A%2520A%2520second-generation%2520tyrosine%2520kinase%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2010%26volume%3D34%26spage%3D129%26epage%3D134%26doi%3D10.1016%2Fj.leukres.2009.08.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colicelli, J.</span></span> <span> </span><span class="NLM_article-title">ABL tyrosine kinases: Evolution of function, regulation, and specificity</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">re6</span> <span class="refDoi">Â DOI: 10.1126/scisignal.3139re6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1126%2Fscisignal.3139re6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20841568" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&author=J.+Colicelli&title=ABL+tyrosine+kinases%3A+Evolution+of+function%2C+regulation%2C+and+specificity&doi=10.1126%2Fscisignal.3139re6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.3139re6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.3139re6%26sid%3Dliteratum%253Aachs%26aulast%3DColicelli%26aufirst%3DJ.%26atitle%3DABL%2520tyrosine%2520kinases%253A%2520Evolution%2520of%2520function%252C%2520regulation%252C%2520and%2520specificity%26jtitle%3DSci.%2520Signaling%26date%3D2010%26volume%3D3%26doi%3D10.1126%2Fscisignal.3139re6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newitt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittekind, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzillerri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klei, H. E.</span></span> <span> </span><span class="NLM_article-title">The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">5790</span>â <span class="NLM_lpage">5797</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-05-4187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F0008-5472.CAN-05-4187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16740718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XltFyjtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=5790-5797&author=J.+S.+Tokarskiauthor=J.+A.+Newittauthor=C.+Y.+Changauthor=J.+D.+Chengauthor=M.+Wittekindauthor=S.+E.+Kieferauthor=K.+Kishauthor=F.+Y.+Leeauthor=R.+Borzillerriauthor=L.+J.+Lombardoauthor=D.+Xieauthor=Y.+Zhangauthor=H.+E.+Klei&title=The+structure+of+Dasatinib+%28BMS-354825%29+bound+to+activated+ABL+kinase+domain+elucidates+its+inhibitory+activity+against+imatinib-resistant+ABL+mutants&doi=10.1158%2F0008-5472.CAN-05-4187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants</span></div><div class="casAuthors">Tokarski, John S.; Newitt, John A.; Chang, Chieh Ying J.; Cheng, Janet D.; Wittekind, Michael; Kiefer, Susan E.; Kish, Kevin; Lee, Francis Y. F.; Borzillerri, Robert; Lombardo, Louis J.; Xie, Dianlin; Zhang, Yaqun; Klei, Herbert E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5790-5797</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase breakpoint cluster (BCR)-ABL.  Current frontline therapy for CML is imatinib, an inhibitor of BCR-ABL.  Although imatinib has a high rate of clin. success in early phase CML, treatment resistance is problematic, particularly in later stages of the disease, and is frequently mediated by mutations in BCR-ABL.  Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets oncogenic pathways and is a more potent inhibitor than imatinib against wild-type BCR-ABL.  It has also shown preclin. activity against all but one of the imatinib-resistant BCR-ABL mutants tested to date.  Anal. of the crystal structure of dasatinib-bound ABL kinase suggests that the increased binding affinity of dasatinib over imatinib is at least partially due to its ability to recognize multiple states of BCR-ABL.  The structure also provides an explanation for the activity of dasatinib against imatinib-resistant BCR-ABL mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLZE4le_VTErVg90H21EOLACvtfcHk0ljzyLU1T4hUEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltFyjtbw%253D&md5=f48b46b8c7c38a9888a6de41f84c94fa</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-4187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-4187%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DWittekind%26aufirst%3DM.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DBorzillerri%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26atitle%3DThe%2520structure%2520of%2520Dasatinib%2520%2528BMS-354825%2529%2520bound%2520to%2520activated%2520ABL%2520kinase%2520domain%2520elucidates%2520its%2520inhibitory%2520activity%2520against%2520imatinib-resistant%2520ABL%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D5790%26epage%3D5797%26doi%3D10.1158%2F0008-5472.CAN-05-4187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendenhall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span> <span> </span><span class="NLM_article-title">Imatinib is not a potent anti-SARS-CoV-2 drug</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3085</span>â <span class="NLM_lpage">3087</span>, <span class="refDoi">Â DOI: 10.1038/s41375-020-01045-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41375-020-01045-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32999432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVSqurvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=3085-3087&author=H.+Zhaoauthor=M.+Mendenhallauthor=M.+W.+Deininger&title=Imatinib+is+not+a+potent+anti-SARS-CoV-2+drug&doi=10.1038%2Fs41375-020-01045-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib is not a potent anti-SARS-CoV-2 drug</span></div><div class="casAuthors">Zhao, Helong; Mendenhall, Michelle; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3085-3087</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Imatinib is not a potent anti-SARS-CoV-2 drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC_1Nzxr3RxrVg90H21EOLACvtfcHk0ljzyLU1T4hUEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVSqurvJ&md5=44846fa32deeaf672ba1b8bf2d066b7b</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-01045-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-01045-9%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMendenhall%26aufirst%3DM.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DImatinib%2520is%2520not%2520a%2520potent%2520anti-SARS-CoV-2%2520drug%26jtitle%3DLeukemia%26date%3D2020%26volume%3D34%26spage%3D3085%26epage%3D3087%26doi%3D10.1038%2Fs41375-020-01045-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span> <span> </span><span class="NLM_article-title">Targeting nonmalignant disorders with tyrosine kinase inhibitors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">956</span>â <span class="NLM_lpage">970</span>, <span class="refDoi">Â DOI: 10.1038/nrd3297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnrd3297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=21119733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=956-970&author=F.+Grimmingerauthor=R.+T.+Schermulyauthor=H.+A.+Ghofrani&title=Targeting+nonmalignant+disorders+with+tyrosine+kinase+inhibitors&doi=10.1038%2Fnrd3297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting non-malignant disorders with tyrosine kinase inhibitors</span></div><div class="casAuthors">Grimminger, Friedrich; Schermuly, Ralph T.; Ghofrani, Hossein A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">956-970</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor and non-receptor tyrosine kinases are involved in multiple proliferative signalling pathways.  Imatinib, one of the first tyrosine kinase inhibitors (TKIs) to be approved, revolutionized the treatment of chronic myelogenous leukemia, and other TKIs with different spectra of kinase inhibition are used to treat renal cell carcinoma, non-small-cell lung cancer and colon cancer.  Studies also support the potential use of TKIs as anti-proliferative agents in non-malignant disorders such as cardiac hypertrophy, and in benign-proliferative disorders including pulmonary hypertension, lung fibrosis, rheumatoid disorders, atherosclerosis, in-stent restenosis and glomerulonephritis.  In this Review, we provide an overview of the most recent developments - both exptl. as well as clin. - regarding the therapeutic potential of TKIs in non-malignant disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKrUsuU0d1-LVg90H21EOLACvtfcHk0lh5OxZr48zEhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfJ&md5=81869f75918ff2130e4f05d46ef7cc9c</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnrd3297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3297%26sid%3Dliteratum%253Aachs%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26atitle%3DTargeting%2520nonmalignant%2520disorders%2520with%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D956%26epage%3D970%26doi%3D10.1038%2Fnrd3297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaise, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaugler, B.</span></span> <span> </span><span class="NLM_article-title">Imatinib: The narrow line between immune tolerance and activation</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">397</span>â <span class="NLM_lpage">402</span>, <span class="refDoi">Â DOI: 10.1016/j.molmed.2005.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.molmed.2005.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16087402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvV2ltbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=397-402&author=M.+Mohtyauthor=D.+Blaiseauthor=D.+Oliveauthor=B.+Gaugler&title=Imatinib%3A+The+narrow+line+between+immune+tolerance+and+activation&doi=10.1016%2Fj.molmed.2005.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib: the narrow line between immune tolerance and activation</span></div><div class="casAuthors">Mohty, Mohamad; Blaise, Didier; Olive, Daniel; Gaugler, Beatrice</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">397-402</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite the rapid success of imatinib as a targeted cancer therapy, there seems to be some controversy about its influence on immune function.  Research relating to the immunol. effects of imatinib has aimed to gain insight into this paradoxical picture, whereby imatinib appears to be on the edge between immune tolerance and immune defense.  In addn. to the flexibility of several immune effectors, subtle but important exptl. variations might explain the seemingly conflicting data, pointing to the possible use of imatinib to modulate immune responses against tumors.  The clin. use of imatinib, and its putative immunomodulatory properties, represent challenging issues still to be resolved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSXCjWAeN4FrVg90H21EOLACvtfcHk0lh5OxZr48zEhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvV2ltbo%253D&md5=78cea06fb3c828d87fa03c4c70ccf146</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2005.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2005.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DMohty%26aufirst%3DM.%26aulast%3DBlaise%26aufirst%3DD.%26aulast%3DOlive%26aufirst%3DD.%26aulast%3DGaugler%26aufirst%3DB.%26atitle%3DImatinib%253A%2520The%2520narrow%2520line%2520between%2520immune%2520tolerance%2520and%2520activation%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D397%26epage%3D402%26doi%3D10.1016%2Fj.molmed.2005.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulgaonkar, N.</span>; <span class="NLM_string-name">Wang, H.</span>; <span class="NLM_string-name">Mallawarachchi, S.</span>; <span class="NLM_string-name">Fernando, S.</span>; <span class="NLM_string-name">Martina, B.</span>; <span class="NLM_string-name">Ruzek, D.</span></span> <span> </span><span class="NLM_article-title">Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19</span>.  <i>bioRxiv</i>, August 18, <span class="NLM_year" style="font-weight: bold;">2020</span>, ver. 1.<span class="refDoi">Â DOI: 10.1101/2020.06.18.158196</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1101%2F2020.06.18.158196" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=N.+Mulgaonkar&author=H.+Wang&author=S.+Mallawarachchi&author=S.+Fernando&author=B.+Martina&author=D.+Ruzek&title=Bcr-Abl+tyrosine+kinase+inhibitor+imatinib+as+a+potential+drug+for+COVID-19&doi=10.1101%2F2020.06.18.158196"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1101%2F2020.06.18.158196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.06.18.158196%26sid%3Dliteratum%253Aachs%26aulast%3DMulgaonkar%26aufirst%3DN.%26atitle%3DBcr-Abl%2520tyrosine%2520kinase%2520inhibitor%2520imatinib%2520as%2520a%2520potential%2520drug%2520for%2520COVID-19%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.06.18.158196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosalia, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rennekamp, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, P.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">11876</span>â <span class="NLM_lpage">11881</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0505577102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1073%2Fpnas.0505577102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16081529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFGgurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11876-11881&author=G.+Simmonsauthor=D.+N.+Gosaliaauthor=A.+J.+Rennekampauthor=J.+D.+Reevesauthor=S.+L.+Diamondauthor=P.+Bates&title=Inhibitors+of+cathepsin+L+prevent+severe+acute+respiratory+syndrome+coronavirus+entry&doi=10.1073%2Fpnas.0505577102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry</span></div><div class="casAuthors">Simmons, Graham; Gosalia, Dhaval N.; Rennekamp, Andrew J.; Reeves, Jacqueline D.; Diamond, Scott L.; Bates, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">11876-11881</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome (SARS) is caused by an emergent coronavirus (SARS-CoV), for which there is currently no effective treatment.  SARS-CoV mediates receptor binding and entry by its spike (S) glycoprotein, and infection is sensitive to lysosomotropic agents that perturb endosomal pH.  We demonstrate here that the lysosomotropic-agent-mediated block to SARS-CoV infection is overcome by protease treatment of target-cell-assocd. virus.  In addn., SARS-CoV infection was blocked by specific inhibitors of the pH-sensitive endosomal protease cathepsin L.  A cell-free membrane-fusion system demonstrates that engagement of receptor followed by proteolysis is required for SARS-CoV membrane fusion and indicates that cathepsin L is sufficient to activate membrane fusion by SARS-CoV S.  These results suggest that SARS-CoV infection results from a unique, three-step process: receptor binding and induced conformational changes in S glycoprotein followed by cathepsin L proteolysis within endosomes.  The requirement for cathepsin L proteolysis identifies a previously uncharacterized class of inhibitor for SARS-CoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol5n5BQpBDX7Vg90H21EOLACvtfcHk0lh5OxZr48zEhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFGgurw%253D&md5=99f26bc819463a5377187542db9bdfe5</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0505577102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0505577102%26sid%3Dliteratum%253Aachs%26aulast%3DSimmons%26aufirst%3DG.%26aulast%3DGosalia%26aufirst%3DD.%2BN.%26aulast%3DRennekamp%26aufirst%3DA.%2BJ.%26aulast%3DReeves%26aufirst%3DJ.%2BD.%26aulast%3DDiamond%26aufirst%3DS.%2BL.%26aulast%3DBates%26aufirst%3DP.%26atitle%3DInhibitors%2520of%2520cathepsin%2520L%2520prevent%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%2520entry%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D11876%26epage%3D11881%26doi%3D10.1073%2Fpnas.0505577102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuyama, S.</span></span> <span> </span><span class="NLM_article-title">Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">12552</span>â <span class="NLM_lpage">12561</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01890-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01890-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24027332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVygsrjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=12552-12561&author=K.+Shiratoauthor=M.+Kawaseauthor=S.+Matsuyama&title=Middle+East+respiratory+syndrome+coronavirus+infection+mediated+by+the+transmembrane+serine+protease+TMPRSS2&doi=10.1128%2FJVI.01890-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Middle east respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2</span></div><div class="casAuthors">Shirato, Kazuya; Kawase, Miyuki; Matsuyama, Shutoku</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">12552-12561</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Middle East respiratory syndrome coronavirus (MERS-CoV) utilizes host proteases for virus entry into lung cells.  In the current study, Vero cells constitutively expressing type II transmembrane serine protease (Vero-TMPRSS2 cells) showed larger syncytia at 18 h after infection with MERS-CoV than after infection with other coronaviruses.  Furthermore, the susceptibility of Vero-TMPRSS2 cells to MERS-CoV was 100-fold higher than that of non-TMPRSS2-expressing parental Vero cells.  The serine protease inhibitor camostat, which inhibits TMPRSS2 activity, completely blocked syncytium formation but only partially blocked virus entry into Vero-TMPRSS2 cells.  Importantly, the coronavirus is thought to enter cells via two distinct pathways, one mediated by TMPRSS2 at the cell surface and the other mediated by cathepsin L in the endosome.  Simultaneous treatment with inhibitors of cathepsin L and TMPRSS2 completely blocked virus entry into Vero-TMPRSS2 cells, indicating that MERS-CoV employs both the cell surface and the endosomal pathway to infect Vero-TMPRSS2 cells.  In contrast, a single camostat treatment suppressed MERS-CoV entry into human bronchial submucosal gland-derived Calu-3 cells by 10-fold and virus growth by 270-fold, although treatment with both camostat and (23,25)-trans-epoxysuccinyl-L-leucylamindo-3-methylbutane Et ester, a cathepsin inhibitor, or treatment with leupeptin, an inhibitor of cysteine, serine, and threonine peptidases, was no more efficacious than treatment with camostat alone.  Further, these inhibitors were not efficacious against MERS-CoV infection of MRC-5 and WI-38 cells, which were derived from lung, but these characters differed from those of mature pneumocytes.  These results suggest that a single treatment with camostat is sufficient to block MERS-CoV entry into a well-differentiated lung-derived cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUQYSrh_mBe7Vg90H21EOLACvtfcHk0ljSqkl4l8eAvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVygsrjM&md5=808a19ec6bbba3b9f0829f82b37bfd89</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1128%2FJVI.01890-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01890-13%26sid%3Dliteratum%253Aachs%26aulast%3DShirato%26aufirst%3DK.%26aulast%3DKawase%26aufirst%3DM.%26aulast%3DMatsuyama%26aufirst%3DS.%26atitle%3DMiddle%2520East%2520respiratory%2520syndrome%2520coronavirus%2520infection%2520mediated%2520by%2520the%2520transmembrane%2520serine%2520protease%2520TMPRSS2%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D12552%26epage%3D12561%26doi%3D10.1128%2FJVI.01890-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiore, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, R.</span></span> <span> </span><span class="NLM_article-title">Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasis</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">518</span>),  <span class="NLM_fpage">eaao0422</span>, <span class="refDoi">Â DOI: 10.1126/scisignal.aao0422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1126%2Fscisignal.aao0422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29463776" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=eaao0422&issue=518&author=R.+Tripathiauthor=L.+S.+Fioreauthor=D.+L.+Richardsauthor=Y.+Yangauthor=J.+Liuauthor=C.+Wangauthor=R.+Plattner&title=Abl+and+Arg+mediate+cysteine+cathepsin+secretion+to+facilitate+melanoma+invasion+and+metastasis&doi=10.1126%2Fscisignal.aao0422"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aao0422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aao0422%26sid%3Dliteratum%253Aachs%26aulast%3DTripathi%26aufirst%3DR.%26aulast%3DFiore%26aufirst%3DL.%2BS.%26aulast%3DRichards%26aufirst%3DD.%2BL.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DPlattner%26aufirst%3DR.%26atitle%3DAbl%2520and%2520Arg%2520mediate%2520cysteine%2520cathepsin%2520secretion%2520to%2520facilitate%2520melanoma%2520invasion%2520and%2520metastasis%26jtitle%3DSci.%2520Signaling%26date%3D2018%26volume%3D11%26issue%3D518%26spage%3Deaao0422%26doi%3D10.1126%2Fscisignal.aao0422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibaldi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunati, A. M.</span></span> <span> </span><span class="NLM_article-title">Viral proteins and Src family kinases: Mechanisms of pathogenicity from a âliaison dangereuse</span>. <i>World J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">71</span>â <span class="NLM_lpage">78</span>, <span class="refDoi">Â DOI: 10.5501/wjv.v2.i2.71</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.5501%2Fwjv.v2.i2.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24175231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC2cfltlOjsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=71-78&author=M.+A.+Paganoauthor=E.+Tibaldiauthor=G.+Paluauthor=A.+M.+Brunati&title=Viral+proteins+and+Src+family+kinases%3A+Mechanisms+of+pathogenicity+from+a+%E2%80%98liaison+dangereuse&doi=10.5501%2Fwjv.v2.i2.71"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Viral proteins and Src family kinases: Mechanisms of pathogenicity from a "liaison dangereuse"</span></div><div class="casAuthors">Pagano Mario Angelo; Tibaldi Elena; Palu Giorgio; Brunati Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">World journal of virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">71-8</span>
        ISSN:<span class="NLM_cas:issn">2220-3249</span>.
    </div><div class="casAbstract">To complete their life cycle and spread, viruses interfere with and gain control of diverse cellular processes, this most often occurring through interaction between viral proteins (VPs) and resident protein partners.  Among the latter, Src family kinases (SFKs), a class of non-receptor tyrosine kinases that contributes to the conversion of extracellular signals into intracellular signaling cascades and is involved in virtually all cellular processes, have recently emerged as critical mediators between the cell's infrastructure and the viral demands.  In this scenario, structural or ex novo synthesized VPs are able to bind to the different domains of these enzymes through specific short linear motifs present along their sequences.  Proline-rich motifs displaying the conserved minimal consensus PxxP and recognizing the SFK Src homology (SH)3 domain constitute a cardinal signature for the formation of multiprotein complexes and this interaction may promote phosphorylation of VPs by SFKs, thus creating phosphotyrosine motifs that become a docking site for the SH2 domains of SFKs or other SH2 domain-bearing signaling molecules.  Importantly, the formation of these assemblies also results in a change in the activity and/or location of SFKs, and these events are critical in perturbing key signaling pathways so that viruses can utilize the cell's machinery to their own benefit.  In the light of these observations, although VPs as such, especially those with enzyme activity, are still regarded as valuable targets for therapeutic strategies, multiprotein complexes composed of viral and host cell proteins are increasingly becoming objects of investigation with a view to deeply characterize the structural aspects that favor their formation and to develop new compounds able to contrast viral diseases in an alternative manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQl36EPxdkdnhKDYG3bNImrfW6udTcc2eZIz4somHzeGbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfltlOjsQ%253D%253D&md5=ae1a4c763cc1e225701f74d446d39598</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.5501%2Fwjv.v2.i2.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5501%252Fwjv.v2.i2.71%26sid%3Dliteratum%253Aachs%26aulast%3DPagano%26aufirst%3DM.%2BA.%26aulast%3DTibaldi%26aufirst%3DE.%26aulast%3DPalu%26aufirst%3DG.%26aulast%3DBrunati%26aufirst%3DA.%2BM.%26atitle%3DViral%2520proteins%2520and%2520Src%2520family%2520kinases%253A%2520Mechanisms%2520of%2520pathogenicity%2520from%2520a%2520%25E2%2580%2598liaison%2520dangereuse%26jtitle%3DWorld%2520J.%2520Virol.%26date%3D2013%26volume%3D2%26spage%3D71%26epage%3D78%26doi%3D10.5501%2Fwjv.v2.i2.71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">c-Src protein kinase inhibitors block assembly and maturation of dengue virus</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">3520</span>â <span class="NLM_lpage">3525</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0611681104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1073%2Fpnas.0611681104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17360676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtVWltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=3520-3525&author=J.+J.+Chuauthor=P.+L.+Yang&title=c-Src+protein+kinase+inhibitors+block+assembly+and+maturation+of+dengue+virus&doi=10.1073%2Fpnas.0611681104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src protein kinase inhibitor block assembly and maturation of dengue virus</span></div><div class="casAuthors">Chu, J. J. H.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3520-3525</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Dengue virus is a mosquito-borne flavivirus that represents an important emerging infectious disease and is an international health concern.  Currently, there is no vaccine or effective antiviral therapy to prevent or to treat dengue virus infection.  The slow progress in developing antiviral agents might be alleviated by the availability of efficient high-throughput anti-dengue virus screening assays.  In this study, we report an immunofluorescence image-based assay suitable for identification of small mol. inhibitors of dengue virus infection and replication.  Using this assay, we have discovered that inhibitors of the c-Src protein kinase exhibit a potent inhibitory effect on dengue virus (serotypes 1-4) and murine flavivirus Modoc.  Mechanism of action studies demonstrated that the c-Src protein kinase inhibitor dasatinib prevents the assembly of dengue virions within the virus-induced membranous replication complex.  These results demonstrate that this cell-based screen may provide a powerful means to identify new potential targets for anti-dengue drug development while simultaneously providing pharmacol. probes to investigate dengue virus-host cell interactions at the biochem. level.  Given the simplicity and excellent reproducibility of the assay, it should be useful in high-throughput screens of both small mol. and RNAi libraries when implemented on a robotic image-based high- throughput screen (HTS) platform.  Given the reasonable clin. safety of inhibitors such as dasatinib and AZD0530, inhibitors of c-Src protein kinase may have the potential to become a new class of anti-dengue viral therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT5wnglMCrULVg90H21EOLACvtfcHk0ljSqkl4l8eAvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtVWltbc%253D&md5=7b8dd352cb73b762b349ee386a39f649</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0611681104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0611681104%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%2BJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3Dc-Src%2520protein%2520kinase%2520inhibitors%2520block%2520assembly%2520and%2520maturation%2520of%2520dengue%2520virus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D3520%26epage%3D3525%26doi%3D10.1073%2Fpnas.0611681104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medigeshi, G. R.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of the role of c-terminal Src kinase in dengue virus replication</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">30490</span>, <span class="refDoi">Â DOI: 10.1038/srep30490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fsrep30490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27457684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12gu7%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=30490&author=R.+Kumarauthor=T.+Agrawalauthor=N.+A.+Khanauthor=Y.+Nakayamaauthor=G.+R.+Medigeshi&title=Identification+and+characterization+of+the+role+of+c-terminal+Src+kinase+in+dengue+virus+replication&doi=10.1038%2Fsrep30490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of the role of c-terminal Src kinase in dengue virus replication</span></div><div class="casAuthors">Kumar, Rinki; Agrawal, Tanvi; Khan, Naseem Ahmed; Nakayama, Yuji; Medigeshi, Guruprasad R.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30490</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We screened a siRNA library targeting human tyrosine kinases in Huh-7 cells and identified c-terminal Src kinase (Csk) as one of the kinases involved in dengue virus replication.  Knock-down of Csk expression by siRNAs or inhibition of Csk by an inhibitor reduced dengue virus RNA levels but did not affect viral entry.  Csk partially colocalized with viral replication compartments.  Dengue infection was drastically reduced in cells lacking the three ubiquitous src family kinases, Src, Fyn and Yes.  Csk knock-down in these cells failed to block dengue virus replication suggesting that the effect of Csk is via regulation of Src family kinases.  Csk was found to be hyper-phosphorylated during dengue infection and inhibition of protein kinase A led to a block in Csk phosphorylation and dengue virus replication.  Overexpression studies suggest an important role for the kinase and SH3 domains in this process.  Our results identified a novel role for Csk as a host tyrosine kinase involved in dengue virus replication and provide further insights into the role of host factors in dengue replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVlEp-nx5hb7Vg90H21EOLACvtfcHk0ljSds8avS0oZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12gu7%252FJ&md5=91a61fd24e54e8517cd5bd07bf27bb74</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fsrep30490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep30490%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DAgrawal%26aufirst%3DT.%26aulast%3DKhan%26aufirst%3DN.%2BA.%26aulast%3DNakayama%26aufirst%3DY.%26aulast%3DMedigeshi%26aufirst%3DG.%2BR.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520the%2520role%2520of%2520c-terminal%2520Src%2520kinase%2520in%2520dengue%2520virus%2520replication%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D30490%26doi%3D10.1038%2Fsrep30490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Wispelaere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCroix, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">7367</span>â <span class="NLM_lpage">7381</span>, <span class="refDoi">Â DOI: 10.1128/JVI.00632-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.00632-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=23616652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFCqsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=7367-7381&author=M.+de%0AWispelaereauthor=A.+J.+LaCroixauthor=P.+L.+Yang&title=The+small+molecules+AZD0530+and+dasatinib+inhibit+dengue+virus+RNA+replication+via+Fyn+kinase&doi=10.1128%2FJVI.00632-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase</span></div><div class="casAuthors">de Wispelaere, Melissanne; LaCroix, Amy J.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7367-7381</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In this study, we characterized the antiviral mechanism of action of AZD0530 and dasatinib, two pharmacol. inhibitors of host kinases, that also inhibit dengue virus (DV) infection.  Using Northern blot and reporter replicon assays, we demonstrated that both small mols. inhibit the DV2 infectious cycle at the step of steady-state RNA replication.  In order to identify the cellular target of AZD0530 and dasatinib mediating this anti-DV2 activity, we examd. the effects of RNA interference (RNAi)-mediated depletion of the major kinases known to be inhibited by these small mols.  We detd. that Fyn kinase, a target of both AZD0530 and dasatinib, is involved in DV2 RNA replication and is probably a major mediator of the anti-DV activity of these compds.  Furthermore, serial passaging of DV2 in the presence of dasatinib led to the identification of a mutation in the transmembrane domain 3 of the NS4B protein that overcomes the inhibition of RNA replication by AZD0530, dasatinib, and Fyn RNAi.  Although we obsd. that dasatinib also inhibits DV2 particle assembly and/or secretion, this activity does not appear to be mediated by Src-family kinases.  Together, our results suggest that AZD0530 and dasatinib inhibit DV at the step of viral RNA replication and demonstrate a crit. role for Fyn kinase in this viral process.  The antiviral activity of these compds. in vitro makes them useful pharmacol. tools to validate Fyn or other host kinases as anti-DV targets in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDobBEv8oAxrVg90H21EOLACvtfcHk0ljSds8avS0oZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFCqsbs%253D&md5=3030a3de1e36bdf7563f97d6e97b5f29</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1128%2FJVI.00632-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00632-13%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWispelaere%26aufirst%3DM.%26aulast%3DLaCroix%26aufirst%3DA.%2BJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3DThe%2520small%2520molecules%2520AZD0530%2520and%2520dasatinib%2520inhibit%2520dengue%2520virus%2520RNA%2520replication%2520via%2520Fyn%2520kinase%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D7367%26epage%3D7381%26doi%3D10.1128%2FJVI.00632-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Supekova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezacki, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlapbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span> <span> </span><span class="NLM_article-title">Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">29</span>â <span class="NLM_lpage">36</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M703988200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.M703988200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17951261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=29-36&author=L.+Supekovaauthor=F.+Supekauthor=J.+Leeauthor=S.+Chenauthor=N.+Grayauthor=J.+P.+Pezackiauthor=A.+Schlapbachauthor=P.+G.+Schultz&title=Identification+of+human+kinases+involved+in+hepatitis+C+virus+replication+by+small+interference+RNA+library+screening&doi=10.1074%2Fjbc.M703988200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human kinases involved in Hepatitis C virus replication by small interference RNA library screening</span></div><div class="casAuthors">Supekova, Lubica; Supek, Frantisek; Lee, Jongkook; Chen, Shawn; Gray, Nathanael; Pezacki, John P.; Schlapbach, Achim; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-36</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The propagation of the hepatitis C virus (HCV) is a complex process that requires both host and viral proteins.  To facilitate identification of host cell factors that are required for HCV replication, we screened a panel of small interference RNAs that preferentially target human protein kinases using an HCV replicon expressing the firefly luciferase gene as a genetic reporter.  Small interference RNAs specific for three human kinases, Csk, Jak1, and Vrk1, were identified that reproducibly reduce viral RNA and viral protein levels in HCV replicon-bearing cells.  Treatment of replicon cells with a small mol. inhibitor of Csk also resulted in a significant redn. in HCV RNA and proteins, further supporting a role for Csk in HCV replication.  The effects of siRNAs targeting eight kinases known to be neg. regulated by Csk were then examd.; knock down of one of these kinases, Fyn, resulted in up-regulation of the HCV replicon, suggesting that Csk mediates its effect on HCV replication through Fyn.  This conclusion was further corroborated by demonstration that replicon cells treated with Csk inhibitor contained lower levels of the phosphorylated form of Fyn than control cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2twHkVKI2sLVg90H21EOLACvtfcHk0ljSds8avS0oZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOksA%253D%253D&md5=a78cc4bfc82aeb94e0f3a7cdf7641200</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M703988200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M703988200%26sid%3Dliteratum%253Aachs%26aulast%3DSupekova%26aufirst%3DL.%26aulast%3DSupek%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DPezacki%26aufirst%3DJ.%2BP.%26aulast%3DSchlapbach%26aufirst%3DA.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DIdentification%2520of%2520human%2520kinases%2520involved%2520in%2520hepatitis%2520C%2520virus%2520replication%2520by%2520small%2520interference%2520RNA%2520library%2520screening%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D29%26epage%3D36%26doi%3D10.1074%2Fjbc.M703988200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medigeshi, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeFilippis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FrÃ¼h, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briese, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipkin, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. A.</span></span> <span> </span><span class="NLM_article-title">The Src family kinase c-yes is required for maturation of West Nile virus particles</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">11943</span>â <span class="NLM_lpage">11951</span>, <span class="refDoi">Â DOI: 10.1128/JVI.79.18.11943-11951.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.79.18.11943-11951.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16140770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWktL%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=11943-11951&author=A.+J.+Hirschauthor=G.+R.+Medigeshiauthor=H.+L.+Meyersauthor=V.+DeFilippisauthor=K.+Fr%C3%BChauthor=T.+Brieseauthor=W.+I.+Lipkinauthor=J.+A.+Nelson&title=The+Src+family+kinase+c-yes+is+required+for+maturation+of+West+Nile+virus+particles&doi=10.1128%2FJVI.79.18.11943-11951.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">The Src family kinase c-yes is required for maturation of West Nile virus particles</span></div><div class="casAuthors">Hirsch, Alec J.; Medigeshi, Guruprasad R.; Meyers, Heather L.; DeFilippis, Victor; Fruh, Klaus; Briese, Thomas; Lipkin, W. Ian; Nelson, Jay A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">11943-11951</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The role of cellular genes in West Nile virus (WNY) replication is not well understood.  Examn. of cellular transcripts upregulated during WNV infection revealed an increase in the expression of the src family kinase (SFK) c-Yes.  WNV-infected cell lines treated with the SFK inhibitor PP2 demonstrated a 2- to 4-log decrease in viral titers, suggesting that SFK activity is required for completion of the viral replication cycle.  RNA interference mediated knock-down of c-Yes, but not c-Src, and similarly reduced virus yield, specifically implicating c-Yes in WNV prodn.  Interestingly, PP2 treatment did not reduce intracellular levels of either viral RNA or protein, suggesting that the drug does not act on the early stages of replication.  However, endoglycosidase H (endoH) digestion of the viral envelope (E) glycoprotein revealed that the acquisition of endoH-resistant glycans by E, but not endogenous major histocompatibility complex class I, was reduced in PP2-treated cells, demonstrating that E specifically does not traffic beyond the endoplasmic reticulum in the absence of SFK activity.  Electron microscopy further revealed that PP2-treated WNV-infected cells accumulated an increased no. of virions in the ER compared to untreated cells.  Therefore, we conclude that inhibition of SFK activity did not interfere with virus assembly but prevented transit of virions through the secretory pathway.  These results identify c-Yes as a cellular protein that is involved in WNV assembly and egress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMuU3rVQ-9qLVg90H21EOLACvtfcHk0ljSds8avS0oZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWktL%252FK&md5=5826259686f57aed83606f1f44c33f38</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.18.11943-11951.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.18.11943-11951.2005%26sid%3Dliteratum%253Aachs%26aulast%3DHirsch%26aufirst%3DA.%2BJ.%26aulast%3DMedigeshi%26aufirst%3DG.%2BR.%26aulast%3DMeyers%26aufirst%3DH.%2BL.%26aulast%3DDeFilippis%26aufirst%3DV.%26aulast%3DFr%25C3%25BCh%26aufirst%3DK.%26aulast%3DBriese%26aufirst%3DT.%26aulast%3DLipkin%26aufirst%3DW.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Src%2520family%2520kinase%2520c-yes%2520is%2520required%2520for%2520maturation%2520of%2520West%2520Nile%2520virus%2520particles%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D11943%26epage%3D11951%26doi%3D10.1128%2FJVI.79.18.11943-11951.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conner, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, S. L.</span></span> <span> </span><span class="NLM_article-title">Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">921</span>â <span class="NLM_lpage">929</span>, <span class="refDoi">Â DOI: 10.1083/jcb.200108123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1083%2Fjcb.200108123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11877461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVGmtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2002&pages=921-929&author=S.+D.+Connerauthor=S.+L.+Schmid&title=Identification+of+an+adaptor-associated+kinase%2C+AAK1%2C+as+a+regulator+of+clathrin-mediated+endocytosis&doi=10.1083%2Fjcb.200108123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis</span></div><div class="casAuthors">Conner, Sean D.; Schmid, Sandra L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">921-929</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The Î¼2 subunit of the AP2 complex is known to be phosphorylated in vitro by a copurifying kinase, and it has been demonstrated recently that Î¼2 phosphorylation is required for transferrin endocytosis.  However, the identity of the endogenous kinase responsible for this phosphorylation is unknown.  Here we identify and characterize a novel member of the Prk/Ark family of serine/threonine kinases, adaptor-assocd. kinase (AAK)1.  We find that AAK1 copurifies with adaptor protein (AP)2 and that it directly binds the ear domain of Î±-adaptin in vivo and in vitro.  In neuronal cells, AAK1 is enriched at presynaptic terminals, whereas in nonneuronal cells it colocalizes with clathrin and AP2 in clathrin-coated pits and at the leading edge of migrating cells.  AAK1 specifically phosphorylates the Î¼ subunit in vitro, and stage-specific assays for endocytosis show that Î¼ phosphorylation by AAK1 results in a decrease in AP2-stimulated transferrin internalization.  Together, these results provide strong evidence that AAK1 is the endogenous Î¼2 kinase and plays a regulatory role in clathrin-mediated endocytosis.  These results also lend support to the idea that clathrin-mediated endocytosis is controlled by cycles of phosphorylation/desphosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp62q8kuSqokbVg90H21EOLACvtfcHk0lhsHdmFrXRRRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVGmtrg%253D&md5=0f9061fb428373240da331f7d25bb9bf</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200108123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200108123%26sid%3Dliteratum%253Aachs%26aulast%3DConner%26aufirst%3DS.%2BD.%26aulast%3DSchmid%26aufirst%3DS.%2BL.%26atitle%3DIdentification%2520of%2520an%2520adaptor-associated%2520kinase%252C%2520AAK1%252C%2520as%2520a%2520regulator%2520of%2520clathrin-mediated%2520endocytosis%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2002%26volume%3D156%26spage%3D921%26epage%3D929%26doi%3D10.1083%2Fjcb.200108123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Q. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S. X.</span></span> <span> </span><span class="NLM_article-title">Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence</span>. <i>Travel Med. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">101647</span>, <span class="refDoi">Â DOI: 10.1016/j.tmaid.2020.101647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.tmaid.2020.101647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32247927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB38zgvF2ktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2020&pages=101647&author=Y.+C.+Caoauthor=Q.+X.+Dengauthor=S.+X.+Dai&title=Remdesivir+for+severe+acute+respiratory+syndrome+coronavirus+2+causing+COVID-19%3A+An+evaluation+of+the+evidence&doi=10.1016%2Fj.tmaid.2020.101647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence</span></div><div class="casAuthors">Cao Yu-Chen; Deng Qi-Xin; Dai Shi-Xue</div><div class="citationInfo"><span class="NLM_cas:title">Travel medicine and infectious disease</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">101647</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The novel coronavirus infection that initially found at the end of 2019 has attracted great attention.  So far, the number of infectious cases has increased globally to more than 100 thousand and the outbreak has been defined as a pandemic situation, but there are still no "specific drug" available.  Relevant reports have pointed out the novel coronavirus has 80% homology with SARS.  In the difficulty where new synthesized drug cannot be applied immediately to patients, "conventional drug in new use" becomes a feasible solution.  The first medication experience of the recovered patients in the US has led remdesivir to be the "specific drug".  China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19).  We started from the structure, immunogenicity, and pathogenesis of coronavirus infections of the novel coronavirus.  Further, we analyzed the pharmacological actions and previous trials of remdesivir to identify the feasibility of conducting experiments on COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDTwWNXaoCBa_dlEzl_fBafW6udTcc2ebEAB7Aj91PKLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zgvF2ktg%253D%253D&md5=cdc4d26f35c81a1b931d755bc801f7be</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.tmaid.2020.101647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tmaid.2020.101647%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%2BC.%26aulast%3DDeng%26aufirst%3DQ.%2BX.%26aulast%3DDai%26aufirst%3DS.%2BX.%26atitle%3DRemdesivir%2520for%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%25202%2520causing%2520COVID-19%253A%2520An%2520evaluation%2520of%2520the%2520evidence%26jtitle%3DTravel%2520Med.%2520Infect.%2520Dis.%26date%3D2020%26volume%3D35%26spage%3D101647%26doi%3D10.1016%2Fj.tmaid.2020.101647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. E.</span></span> <span> </span><span class="NLM_article-title">Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">4311</span>â <span class="NLM_lpage">4321</span>, <span class="refDoi">Â DOI: 10.1242/jcs.02548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1242%2Fjcs.02548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16155256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCgt7fK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2005&pages=4311-4321&author=D.+W.+Leeauthor=X.+Zhaoauthor=F.+Zhangauthor=E.+Eisenbergauthor=L.+E.+Greene&title=Depletion+of+GAK%2Fauxilin+2+inhibits+receptor-mediated+endocytosis+and+recruitment+of+both+clathrin+and+clathrin+adaptors&doi=10.1242%2Fjcs.02548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors</span></div><div class="casAuthors">Lee, Dong-won; Zhao, Xiaohong; Zhang, Fang; Eisenberg, Evan; Greene, Lois E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4311-4321</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Cyclin G-assocd. kinase (GAK/auxilin 2), the ubiquitous form of the neuronal-specific protein auxilin 1, is an essential cofactor for the Hsc70-dependent uncoating of clathrin-coated vesicles.  We have now investigated the effect of knocking down GAK in HeLa cells by vector-based small hairpin RNA.  Functionally, depletion of GAK caused a marked decrease in internalization of both transferrin and epidermal growth factor and altered mannose 6-phosphate receptor trafficking, but had little effect on the recycling of transferrin receptor back to the plasma membrane.  Structurally, depletion of GAK caused a marked redn. in perinuclear clathrin assocd. with the trans-Golgi network and in the no. of clathrin-coated pits on the plasma membrane, and reduced clathrin exchange on the few clathrin-coated pits that remained.  Surprisingly, while clathrin depletion does not prevent adaptors from assembling on the membrane, depletion of GAK caused a dramatic redn. in AP2 and epsin on the plasma membrane and AP1 and GGA at the trans-Golgi network.  A similar effect was caused by expression of a dominant neg. Hsp70 mutant.  These results suggest that GAK, in conjunction with Hsc70, not only uncoats clathrin-coated vesicles and induces clathrin exchange on clathrin-coated pits, but also mediates binding of clathrin and adaptors to the plasma membrane and the trans-Golgi network.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8IvRfVSaZT7Vg90H21EOLACvtfcHk0lhsHdmFrXRRRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCgt7fK&md5=0172190491cf9b908e705e434b763d60</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1242%2Fjcs.02548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.02548%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DEisenberg%26aufirst%3DE.%26aulast%3DGreene%26aufirst%3DL.%2BE.%26atitle%3DDepletion%2520of%2520GAK%252Fauxilin%25202%2520inhibits%2520receptor-mediated%2520endocytosis%2520and%2520recruitment%2520of%2520both%2520clathrin%2520and%2520clathrin%2520adaptors%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2005%26volume%3D118%26spage%3D4311%26epage%3D4321%26doi%3D10.1242%2Fjcs.02548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e1002845</span> <span class="refDoi">Â DOI: 10.1371/journal.ppat.1002845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.ppat.1002845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22916011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&author=G.+Neveuauthor=R.+Barouch-Bentovauthor=A.+Ziv-Avauthor=D.+Gerberauthor=Y.+Jacobauthor=S.+Einav&title=Identification+and+targeting+of+an+interaction+between+a+tyrosine+motif+within+hepatitis+C+virus+core+protein+and+AP2M1+essential+for+viral+assembly&doi=10.1371%2Fjournal.ppat.1002845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span></div><div class="casAuthors">Neveu, Gregory; Barouch-Bentov, Rina; Ziv-Av, Amotz; Gerber, Doron; Jacob, Yves; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1002845</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Novel therapies are urgently needed against hepatitis C virus infection (HCV), a major global health problem.  The current model of infectious virus prodn. suggests that HCV virions are assembled on or near the surface of lipid droplets, acquire their envelope at the ER, and egress through the secretory pathway.  The mechanisms of HCV assembly and particularly the role of viral-host protein-protein interactions in mediating this process are, however, poorly understood.  We identified a conserved heretofore unrecognized YXXÎ¦ motif (Î¦ is a bulky hydrophobic residue) within the core protein.  This motif is homologous to sorting signals within host cargo proteins known to mediate binding of AP2M1, the Î¼ subunit of clathrin adaptor protein complex 2 (AP-2), and intracellular trafficking.  Using microfluidics affinity anal., protein-fragment complementation assays, and co-immunopptns. in infected cells, we show that this motif mediates core binding to AP2M1.  YXXÎ¦ mutations, silencing AP2M1 expression or overexpressing a dominant neg. AP2M1 mutant had no effect on HCV RNA replication, however, they dramatically inhibited intra- and extra-cellular infectivity, consistent with a defect in viral assembly.  Quant. confocal immunofluorescence anal. revealed that core's YXXÎ¦ motif mediates recruitment of AP2M1 to lipid droplets and that the obsd. defect in HCV assembly following disruption of core-AP2M1 binding correlates with accumulation of core on lipid droplets, reduced core colocalization with E2 and reduced core localization to trans-Golgi network (TGN), the presumed site of viral particles maturation.  Furthermore, AAK1 and GAK, serine/threonine kinases known to stimulate binding of AP2M1 to host cargo proteins, regulate core-AP2M1 binding and are essential for HCV assembly.  Last, approved anti-cancer drugs that inhibit AAK1 or GAK not only disrupt core-AP2M1 binding, but also significantly inhibit HCV assembly and infectious virus prodn.  These results validate viral-host interactions essential for HCV assembly and yield compds. for pharmaceutical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjKaGJVLP2vLVg90H21EOLACvtfcHk0ligWLm7-yy92g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF&md5=811c0818d4b2500b1b788076ac4abc5d</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002845%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DGerber%26aufirst%3DD.%26aulast%3DJacob%26aufirst%3DY.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DIdentification%2520and%2520targeting%2520of%2520an%2520interaction%2520between%2520a%2520tyrosine%2520motif%2520within%2520hepatitis%2520C%2520virus%2520core%2520protein%2520and%2520AP2M1%2520essential%2520for%2520viral%2520assembly%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26doi%3D10.1371%2Fjournal.ppat.1002845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">4387</span>â <span class="NLM_lpage">4404</span>, <span class="refDoi">Â DOI: 10.1128/JVI.02705-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.02705-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25653444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVWlurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=4387-4404&author=G.+Neveuauthor=A.+Ziv-Avauthor=R.+Barouch-Bentovauthor=E.+Berkermanauthor=J.+Mulhollandauthor=S.+Einav&title=AP-2-associated+protein+kinase+1+and+cyclin+G-associated+kinase+regulate+hepatitis+C+virus+entry+and+are+potential+drug+targets&doi=10.1128%2FJVI.02705-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets</span></div><div class="casAuthors">Neveu, Gregory; Ziv-Av, Amotz; Barouch-Bentov, Rina; Berkerman, Elena; Mulholland, Jon; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4387-4404</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) enters its target cell via clathrin-mediated endocytosis.  AP-2-assocd. protein kinase 1 (AAK1) and cyclin G-assocd. kinase (GAK) are host kinases that regulate clathrin adaptor protein (AP)-mediated trafficking in the endocytic and secretory pathways.  We previously reported that AAK1 and GAK regulate HCV assembly by stimulating binding of the Î¼ subunit of AP-2, AP2M1, to HCV core protein.  We also discovered that AAK1 and GAK inhibitors, including the approved anticancer drugs sunitinib and erlotinib, could block HCV assembly.  Here, we hypothesized that AAK1 and GAK regulate HCV entry independently of their effect on HCV assembly.  Indeed, silencing AAK1 and GAK expression inhibited entry of pseudoparticles and cell culture grown-HCV and internalization of Dil-labeled HCV particles with no effect on HCV attachment or RNA replication.  AAK1 or GAK depletion impaired epidermal growth factor (EGF)-mediated enhanced HCV entry and endocytosis of EGF receptor (EGFR), an HCV entry cofactor and erlotinib's cancer target.  Moreover, either RNA interference-mediated depletion of AP2M1 or NUMB, each a substrate of AAK1 and/or GAK, or overexpression of either an AP2M1 or NUMB phosphorylation site mutant inhibited HCV entry.  Last, in addn. to affecting assembly, sunitinib and erlotinib inhibited HCV entry at a postbinding step, their combination was synergistic, and their antiviral effect was reversed by either AAK1 or GAK overexpression.  Together, these results validate AAK1 and GAK as crit. regulators of HCV entry that function in part by activating EGFR, AP2M1, and NUMB and as the mol. targets underlying the antiviral effect of sunitinib and erlotinib (in addn. to EGFR), resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB1x5sJzyhrLVg90H21EOLACvtfcHk0ligWLm7-yy92g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVWlurg%253D&md5=cbdd3e12d29f383c73dc53c0e9954300</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1128%2FJVI.02705-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02705-14%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DBerkerman%26aufirst%3DE.%26aulast%3DMulholland%26aufirst%3DJ.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DAP-2-associated%2520protein%2520kinase%25201%2520and%2520cyclin%2520G-associated%2520kinase%2520regulate%2520hepatitis%2520C%2520virus%2520entry%2520and%2520are%2520potential%2520drug%2520targets%26jtitle%3DJ.%2520Virol.%26date%3D2015%26volume%3D89%26spage%3D4387%26epage%3D4404%26doi%3D10.1128%2FJVI.02705-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yau, S. S.</span></span> <span> </span><span class="NLM_article-title">Ebolavirus classification based on natural vectors</span>. <i>DNA Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">418</span>â <span class="NLM_lpage">428</span>, <span class="refDoi">Â DOI: 10.1089/dna.2014.2678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1089%2Fdna.2014.2678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25803489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFKqs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=418-428&author=H.+Zhengauthor=C.+Yinauthor=T.+Hoangauthor=R.+L.+Heauthor=J.+Yangauthor=S.+S.+Yau&title=Ebolavirus+classification+based+on+natural+vectors&doi=10.1089%2Fdna.2014.2678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ebolavirus Classification Based on Natural Vectors</span></div><div class="casAuthors">Zheng, Hui; Yin, Changchuan; Hoang, Tung; He, Rong Lucy; Yang, Jie; Yau, Stephen S.-T.</div><div class="citationInfo"><span class="NLM_cas:title">DNA and Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">418-428</span>CODEN:
                <span class="NLM_cas:coden">DCEBE8</span>;
        ISSN:<span class="NLM_cas:issn">1044-5498</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">According to the WHO, ebolaviruses have resulted in 8818 human deaths in West Africa as of Jan. 2015.  To better understand the evolutionary relationship of the ebolaviruses and infer virulence from the relationship, we applied the alignment-free natural vector method to classify the newest ebolaviruses.  The dataset includes three new Guinea viruses as well as 99 viruses from Sierra Leone.  For the viruses of the family of Filoviridae, both genus label classification and species label classification achieve an accuracy rate of 100%.  We represented the relationships among Filoviridae viruses by Unweighted Pair Group Method with Arithmetic Mean (UPGMA) phylogenetic trees and found that the filoviruses can be sepd. well by three genera.  We performed the phylogenetic anal. on the relationship among different species of Ebolavirus by their coding-complete genomes and seven viral protein genes (glycoprotein [GP], nucleoprotein [NP], VP24, VP30, VP35, VP40, and RNA polymerase [L]).  The topol. of the phylogenetic tree by the viral protein VP24 shows consistency with the variations of virulence of ebolaviruses.  The result suggests that VP24 be a pharmaceutical target for treating or preventing ebolaviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVq4s7RU1qiLVg90H21EOLACvtfcHk0ligWLm7-yy92g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFKqs7g%253D&md5=5c9d87e44ede9c977841ddac7b89e8c1</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1089%2Fdna.2014.2678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fdna.2014.2678%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DC.%26aulast%3DHoang%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DR.%2BL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYau%26aufirst%3DS.%2BS.%26atitle%3DEbolavirus%2520classification%2520based%2520on%2520natural%2520vectors%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2015%26volume%3D34%26spage%3D418%26epage%3D428%26doi%3D10.1089%2Fdna.2014.2678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">67</span>â <span class="NLM_lpage">75</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2018.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2018.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29753658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslaqtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=67-75&author=S.+Y.+Puauthor=F.+Xiaoauthor=S.+Schorauthor=E.+Bekermanauthor=F.+Zaniniauthor=R.+Barouch-Bentovauthor=C.+M.+Nagamineauthor=S.+Einav&title=Feasibility+and+biological+rationale+of+repurposing+sunitinib+and+erlotinib+for+dengue+treatment&doi=10.1016%2Fj.antiviral.2018.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment</span></div><div class="casAuthors">Pu, Szu-Yuan; Xiao, Fei; Schor, Stanford; Bekerman, Elena; Zanini, Fabio; Barouch-Bentov, Rina; Nagamine, Claude M.; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">67-75</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There is an urgent need for strategies to combat dengue virus (DENV) infection; a major global threat.  We reported that the cellular kinases AAK1 and GAK regulate intracellular trafficking of multiple viruses and that sunitinib and erlotinib, approved anticancer drugs with potent activity against these kinases, protect DENV-infected mice from mortality.  Nevertheless, further characterization of the therapeutic potential and underlying mechanism of this approach is required prior to clin. evaluation.  Here, we demonstrate that sunitinib/erlotinib combination achieves sustained suppression of systemic infection at approved dose in DENV-infected IFN-Î±/Î² and IFN-Î³ receptor-deficient mice.  Nevertheless, treatment with these blood-brain barrier impermeable drugs delays, yet does not prevent, late-onset paralysis; a common manifestation in this immunodeficient mouse model but not in humans.  Sunitinib and erlotinib treatment also demonstrates efficacy in human primary monocyte-derived dendritic cells.  Addnl., DENV infection induces expression of AAK1 transcripts, but not GAK, via single-cell transcriptomics, and these kinases are important mol. targets underlying the anti-DENV effect of sunitinib and erlotinib.  Lastly, sunitinib/erlotinib combination alters inflammatory cytokine responses in DENV-infected mice.  These findings support feasibility of repurposing sunitinib/erlotinib combination as a host-targeted antiviral approach and contribute to understanding its mechanism of antiviral action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2cs8UpuoykLVg90H21EOLACvtfcHk0lg5uyFuYDj5hg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslaqtbk%253D&md5=acde697b6e3c6d9f42a2011be6091e83</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DZanini%26aufirst%3DF.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DNagamine%26aufirst%3DC.%2BM.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DFeasibility%2520and%2520biological%2520rationale%2520of%2520repurposing%2520sunitinib%2520and%2520erlotinib%2520for%2520dengue%2520treatment%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D155%26spage%3D67%26epage%3D75%26doi%3D10.1016%2Fj.antiviral.2018.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oechsle, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savory, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span> <span> </span><span class="NLM_article-title">Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>, <span class="NLM_elocation-id">e30</span> <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30304-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS0140-6736%2820%2930304-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32032529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1Chtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&author=P.+Richardsonauthor=I.+Griffinauthor=C.+Tuckerauthor=D.+Smithauthor=O.+Oechsleauthor=A.+Phelanauthor=M.+Rawlingauthor=E.+Savoryauthor=J.+Stebbing&title=Baricitinib+as+potential+treatment+for+2019-nCoV+acute+respiratory+disease&doi=10.1016%2FS0140-6736%2820%2930304-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</span></div><div class="casAuthors">Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Stebbing, Justin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10223</span>),
    <span class="NLM_cas:pages">e30-e31</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced.  Results of rapid sequencing of 2019-nCoV, coupled with mol. modeling based on the genomes of related virus proteins, have suggested a few compds. that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination.  Most viruses enter cells through receptor-mediated endocytosis.  One of the known regulators of endocytosis is the AP2-assocd. protein kinase 1 (AAK1).  Disruption of AAK1 might, in turn, interrupt the passage of the virus into cells and also the intracellular assembly of virus particles.  One of six high affinity AAK1-binding drugs was the janus kinase inhibitor baricitinib, which also binds the cyclin G-assocd. kinase, another regulator of endocytosis.  Because the plasma concn. of baricitinib on therapeutic dosing (either as 2 mg or 4 mg once daily) is sufficient to inhibit AAK1, we suggest it could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT8bDm3HM7aLVg90H21EOLACvtfcHk0lg5uyFuYDj5hg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1Chtr4%253D&md5=9e884d046780c8aa5f3a0934bf4a59ed</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930304-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930304-4%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DGriffin%26aufirst%3DI.%26aulast%3DTucker%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DOechsle%26aufirst%3DO.%26aulast%3DPhelan%26aufirst%3DA.%26aulast%3DRawling%26aufirst%3DM.%26aulast%3DSavory%26aufirst%3DE.%26aulast%3DStebbing%26aufirst%3DJ.%26atitle%3DBaricitinib%2520as%2520potential%2520treatment%2520for%25202019-nCoV%2520acute%2520respiratory%2520disease%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26doi%3D10.1016%2FS0140-6736%2820%2930304-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakken, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1338</span>â <span class="NLM_lpage">1352</span>, <span class="refDoi">Â DOI: 10.1172/JCI89857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1172%2FJCI89857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28240606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC1czgvFajtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=1338-1352&author=E.+Bekermanauthor=G.+Neveuauthor=A.+Shullaauthor=J.+Brannanauthor=S.+Y.+Puauthor=S.+Wangauthor=F.+Xiaoauthor=R.+Barouch-Bentovauthor=R.+R.+Bakkenauthor=R.+Mateoauthor=J.+Goveroauthor=C.+M.+Nagamineauthor=M.+S.+Diamondauthor=S.+De+Jongheauthor=P.+Herdewijnauthor=J.+M.+Dyeauthor=G.+Randallauthor=S.+Einav&title=Anticancer+kinase+inhibitors+impair+intracellular+viral+trafficking+and+exert+broad-spectrum+antiviral+effects&doi=10.1172%2FJCI89857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</span></div><div class="casAuthors">Bekerman Elena; Neveu Gregory; Shulla Ana; Brannan Jennifer; Pu Szu-Yuan; Wang Stanley; Xiao Fei; Barouch-Bentov Rina; Bakken Russell R; Mateo Roberto; Govero Jennifer; Nagamine Claude M; Diamond Michael S; De Jonghe Steven; Herdewijn Piet; Dye John M; Randall Glenn; Einav Shirit</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1338-1352</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Global health is threatened by emerging viral infections, which largely lack effective vaccines or therapies.  Targeting host pathways that are exploited by multiple viruses could offer broad-spectrum solutions.  We previously reported that AAK1 and GAK, kinase regulators of the host adaptor proteins AP1 and AP2, are essential for hepatitis C virus (HCV) infection, but the underlying mechanism and relevance to other viruses or in vivo infections remained unknown.  Here, we have discovered that AP1 and AP2 cotraffic with HCV particles in live cells.  Moreover, we found that multiple viruses, including dengue and Ebola, exploit AAK1 and GAK during entry and infectious virus production.  In cultured cells, treatment with sunitinib and erlotinib, approved anticancer drugs that inhibit AAK1 or GAK activity, or with more selective compounds inhibited intracellular trafficking of HCV and multiple unrelated RNA viruses with a high barrier to resistance.  In murine models of dengue and Ebola infection, sunitinib/erlotinib combination protected against morbidity and mortality.  We validated sunitinib- and erlotinib-mediated inhibition of AAK1 and GAK activity as an important mechanism of antiviral action.  Additionally, we revealed potential roles for additional kinase targets.  These findings advance our understanding of virus-host interactions and establish a proof of principle for a repurposed, host-targeted approach to combat emerging viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeR1dYk1i_czQLBVDQn4bCfW6udTcc2eYNtDP9j6tterntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czgvFajtg%253D%253D&md5=2de0a5d7668651f92be3c2e79823ced4</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1172%2FJCI89857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI89857%26sid%3Dliteratum%253Aachs%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DShulla%26aufirst%3DA.%26aulast%3DBrannan%26aufirst%3DJ.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DBakken%26aufirst%3DR.%2BR.%26aulast%3DMateo%26aufirst%3DR.%26aulast%3DGovero%26aufirst%3DJ.%26aulast%3DNagamine%26aufirst%3DC.%2BM.%26aulast%3DDiamond%26aufirst%3DM.%2BS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DRandall%26aufirst%3DG.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DAnticancer%2520kinase%2520inhibitors%2520impair%2520intracellular%2520viral%2520trafficking%2520and%2520exert%2520broad-spectrum%2520antiviral%2520effects%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D1338%26epage%3D1352%26doi%3D10.1172%2FJCI89857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span> </span><span class="NLM_article-title">Coronavirus (COVID-19)
Update: FDA authorizes drug combination for treatment of COVID-19</span>; U.S. Food and Drug Administration (Press release), November 19, <span class="NLM_year">2020</span> (retrieved 2020-11-19).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Coronavirus+%28COVID-19%29%0AUpdate%3A+FDA+authorizes+drug+combination+for+treatment+of+COVID-19%3B+U.S.+Food+and+Drug+Administration+%28Press+release%29%2C+November+19%2C+2020+%28retrieved+2020-11-19%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DCoronavirus%2520%2528COVID-19%2529%250AUpdate%253A%2520FDA%2520authorizes%2520drug%2520combination%2520for%2520treatment%2520of%2520COVID-19%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casalini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirazimi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youhanna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldanti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarasini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terres, J. A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickoloff, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirula, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbellino, M.</span></span> <span> </span><span class="NLM_article-title">Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e12697</span> <span class="refDoi">Â DOI: 10.15252/emmm.202012697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.15252%2Femmm.202012697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32473600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CmurbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&author=J.+Stebbingauthor=V.+Krishnanauthor=S.+Bonoauthor=S.+Ottavianiauthor=G.+Casaliniauthor=P.+J.+Richardsonauthor=V.+Monteilauthor=V.+M.+Lauschkeauthor=A.+Mirazimiauthor=S.+Youhannaauthor=Y.-J.+Tanauthor=F.+Baldantiauthor=A.+Sarasiniauthor=J.+A.+R.+Terresauthor=B.+J.+Nickoloffauthor=R.+E.+Higgsauthor=G.+Rochaauthor=N.+L.+Byersauthor=D.+E.+Schlichtingauthor=A.+Nirulaauthor=A.+Cardosoauthor=M.+Corbellino&title=Mechanism+of+baricitinib+supports+artificial+intelligence-predicted+testing+in+COVID-19+patients&doi=10.15252%2Femmm.202012697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</span></div><div class="casAuthors">Stebbing, Justin; Krishnan, Venkatesh; de Bono, Stephanie; Ottaviani, Silvia; Casalini, Giacomo; Richardson, Peter J.; Monteil, Vanessa; Lauschke, Volker M.; Mirazimi, Ali; Youhanna, Sonia; Tan, Yee-Joo; Baldanti, Fausto; Sarasini, Antonella; Terres, Jorge A. Ross; Nickoloff, Brian J.; Higgs, Richard E.; Rocha, Guilherme; Byers, Nicole L.; Schlichting, Douglas E.; Nirula, Ajay; Cardoso, Anabela; Corbellino, Mario; the Sacco Baricitinib Study Group</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e12697</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID-19 infection via proposed anti-cytokine effects and as an inhibitor of host cell viral propagation.  We evaluated the in vitro pharmacol. of baricitinib across relevant leukocyte subpopulations coupled to its in vivo pharmacokinetics and showed it inhibited signaling of cytokines implicated in COVID-19 infection.  We validated the AI-predicted biochem. inhibitory effects of baricitinib on human numb-assocd. kinase (hNAK) members measuring nanomolar affinities for AAK1, BIKE, and GAK.  Inhibition of NAKs led to reduced viral infectivity with baricitinib using human primary liver spheroids.  These effects occurred at exposure levels seen clin.  In a case series of patients with bilateral COVID-19 pneumonia, baricitinib treatment was assocd. with clin. and radiol. recovery, a rapid decline in SARS-CoV-2 viral load, inflammatory markers, and IL-6 levels.  Collectively, these data support further evaluation of the anti-cytokine and anti-viral activity of baricitinib and support its assessment in randomized trials in hospitalized COVID-19 patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiGmXcP_Gbz7Vg90H21EOLACvtfcHk0lgw349VOOfGPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CmurbJ&md5=86d41fe8f3b03133c08acb5552266ef7</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.15252%2Femmm.202012697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.202012697%26sid%3Dliteratum%253Aachs%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DKrishnan%26aufirst%3DV.%26aulast%3DBono%26aufirst%3DS.%26aulast%3DOttaviani%26aufirst%3DS.%26aulast%3DCasalini%26aufirst%3DG.%26aulast%3DRichardson%26aufirst%3DP.%2BJ.%26aulast%3DMonteil%26aufirst%3DV.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DMirazimi%26aufirst%3DA.%26aulast%3DYouhanna%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DY.-J.%26aulast%3DBaldanti%26aufirst%3DF.%26aulast%3DSarasini%26aufirst%3DA.%26aulast%3DTerres%26aufirst%3DJ.%2BA.%2BR.%26aulast%3DNickoloff%26aufirst%3DB.%2BJ.%26aulast%3DHiggs%26aufirst%3DR.%2BE.%26aulast%3DRocha%26aufirst%3DG.%26aulast%3DByers%26aufirst%3DN.%2BL.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DNirula%26aufirst%3DA.%26aulast%3DCardoso%26aufirst%3DA.%26aulast%3DCorbellino%26aufirst%3DM.%26atitle%3DMechanism%2520of%2520baricitinib%2520supports%2520artificial%2520intelligence-predicted%2520testing%2520in%2520COVID-19%2520patients%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2020%26volume%3D12%26doi%3D10.15252%2Femmm.202012697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyslop, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddle
Camp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winthrop, K. L.</span></span> <span> </span><span class="NLM_article-title">Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">7</span>â <span class="NLM_lpage">18</span>, <span class="refDoi">Â DOI: 10.3899/jrheum.171361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3899%2Fjrheum.171361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30219772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2rtLjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2019&pages=7-18&author=J.+S.+Smolenauthor=M.+C.+Genoveseauthor=T.+Takeuchiauthor=D.+L.+Hyslopauthor=W.+L.+Maciasauthor=T.+Rooneyauthor=L.+Chenauthor=C.+L.+Dicksonauthor=J.+Riddle%0ACampauthor=T.+E.+Cardilloauthor=T.+Ishiiauthor=K.+L.+Winthrop&title=Safety+profile+of+baricitinib+in+patients+with+active+rheumatoid+arthritis+with+over+2+years+median+time+in+treatment&doi=10.3899%2Fjrheum.171361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment</span></div><div class="casAuthors">Smolen, Josef S.; Genovese, Mark C.; Takeuchi, Tsutomu; Hyslop, David L.; Macias, William L.; Rooney, Terence; Chen, Lei; Dickson, Christina L.; Camp, Jennifer Riddle; Cardillo, Tracy E.; Ishii, Taeko; Winthrop, Kevin L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-18</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">1499-2752</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA).  We evaluated baricitinib's safety profile through 288 wk (up to Sept. 1, 2016) with an integrated database [8 phase III/II/Ib trials, 1 longterm extension (LTE)].  The "all-bari-RA" group included patients who received any baricitinib dose.  Placebo comparison was based on the 6 studies with 4 mg and placebo up to Week 24 ("placebo-4 mg" dataset).  Dose response assessment was based on 4 studies with 2 mg and 4 mg including LTE data ("2 mg-4 mg - extended").  The uncommon events description used the non-controlled all-bari-RA.  There were 3492 patients who received baricitinib for 6637 total patient-years (PY) of exposure (median 2.1 yrs, max. 5.5 yrs).  No differences in rates of death, adverse events leading to drug discontinuation, malignancies, major adverse cardiovascular event (MACE), or serious infections were seen for 4 mg vs. placebo or for 4 mg vs. 2 mg.  Infections including herpes zoster were significantly more frequent for 4 mg vs. placebo.  Deep vein thrombosis/pulmonary embolism were reported with 4 mg but not placebo [all-bari-RA incidence rate (IR) 0.5/100 PY]; the IR did not differ between doses (0.5 vs 0.6/100 PY, 2 mg vs 4 mg, resp.) or compared to published RA rates.  All-bari-RA had 6 cases of lymphoma (IR 0.09/100 PY), 3 gastrointestinal perforations (0.05/100 PY), 10 cases of tuberculosis (all in endemic areas; 0.15/100 PY), and 22 all-cause deaths (0.33/100 PY).  IR for malignancies (0.8/100 PY) and MACE (0.5/100 PY) were low and did not increase with prolonged exposure.  In this integrated anal. of patients with moderate to severe active RA with exposure up to 5.5 years, baricitinib has an acceptable safety profile in the context of demonstrated efficacy.  Trial registration nos.: NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT01721044, NCT01721057, NCT01711359, and NCT01885078 at clinicaltrials.gov.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGtLt3TTbQXrVg90H21EOLACvtfcHk0lgw349VOOfGPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2rtLjL&md5=65e80ff8290c092f167e04f6505ca261</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.171361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.171361%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DHyslop%26aufirst%3DD.%2BL.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3DRooney%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDickson%26aufirst%3DC.%2BL.%26aulast%3DRiddle%2BCamp%26aufirst%3DJ.%26aulast%3DCardillo%26aufirst%3DT.%2BE.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DWinthrop%26aufirst%3DK.%2BL.%26atitle%3DSafety%2520profile%2520of%2520baricitinib%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520over%25202%2520years%2520median%2520time%2520in%2520treatment%26jtitle%3DJ.%2520Rheumatol.%26date%3D2019%26volume%3D46%26spage%3D7%26epage%3D18%26doi%3D10.3899%2Fjrheum.171361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddapati, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viox, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starke, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busman-Sahay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strongin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tharp, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirejczyk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zandi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beagle, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahar, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor-Stroud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmas, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooney, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayegh, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiskopf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filev, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waggoner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piantadosi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasturi, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakhshir, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekaly, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderford, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosinger, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paiardini, M.</span></span> <span> </span><span class="NLM_article-title">Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">460</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cell.2020.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33278358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisV2nur7F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2021&pages=460&author=T.+N.+Hoangauthor=M.+Pinoauthor=A.+K.+Boddapatiauthor=E.+G.+Vioxauthor=C.+E.+Starkeauthor=A.+A.+Upadhyayauthor=S.+Gumberauthor=K.+Busman-Sahayauthor=Z.+Stronginauthor=J.+L.+Harperauthor=G.+K.+Tharpauthor=K.+L.+Pellegriniauthor=S.+Kirejczykauthor=K.+Zandiauthor=S.+Taoauthor=T.+R.+Hortonauthor=E.+N.+Beagleauthor=E.+A.+Maharauthor=M.+Y.+Leeauthor=J.+Cohenauthor=S.+M.+Jeanauthor=J.+S.+Woodauthor=F.+Connor-Stroudauthor=R.+L.+Stammenauthor=O.+M.+Delmasauthor=S.+Wangauthor=K.+A.+Cooneyauthor=M.+N.+Sayeghauthor=L.+Wangauthor=D.+Weiskopfauthor=P.+D.+Filevauthor=J.+Waggonerauthor=A.+Piantadosiauthor=S.+P.+Kasturiauthor=H.+A.+Shakhshirauthor=S.+P.+Ribeiroauthor=R.+P.+Sekalyauthor=R.+D.+Levitauthor=J.+D.+Estesauthor=T.+H.+Vanderfordauthor=R.+F.+Schinaziauthor=S.+E.+Bosingerauthor=M.+Paiardini&title=Baricitinib+treatment+resolves+lower+airway+inflammation+and+neutrophil+recruitment+in+SARS-CoV-2-infected+rhesus+macaques&doi=10.1016%2Fj.cell.2020.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques</span></div><div class="casAuthors">Hoang, Timothy N.; Pino, Maria; Boddapati, Arun K.; Viox, Elise G.; Starke, Carly E.; Upadhyay, Amit A.; Gumber, Sanjeev; Nekorchuk, Michael; Busman-Sahay, Kathleen; Strongin, Zachary; Harper, Justin L.; Tharp, Gregory K.; Pellegrini, Kathryn L.; Kirejczyk, Shannon; Zandi, Keivan; Tao, Sijia; Horton, Tristan R.; Beagle, Elizabeth N.; Mahar, Ernestine A.; Lee, Michelle Y. H.; Cohen, Joyce; Jean, Sherrie M.; Wood, Jennifer S.; Connor-Stroud, Fawn; Stammen, Rachelle L.; Delmas, Olivia M.; Wang, Shelly; Cooney, Kimberly A.; Sayegh, Michael N.; Wang, Lanfang; Filev, Peter D.; Weiskopf, Daniela; Silvestri, Guido; Waggoner, Jesse; Piantadosi, Anne; Kasturi, Sudhir P.; Al-Shakhshir, Hilmi; Ribeiro, Susan P.; Sekaly, Rafick P.; Levit, Rebecca D.; Estes, Jacob D.; Vanderford, Thomas H.; Schinazi, Raymond F.; Bosinger, Steven E.; Paiardini, Mirko</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">460-475.e21</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">SARS-CoV-2-induced hypercytokinemia and inflammation are critically assocd. with COVID-19 severity.  Baricitinib, a clin. approved JAK1/JAK2 inhibitor, is currently being investigated in COVID-19 clin. trials.  Here, we investigated the immunol. and virol. efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection.  Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages, and tissues was not reduced with baricitinib.  Type I interferon (IFN) antiviral responses and SARS-CoV-2-specific T cell responses remained similar between the two groups.  Animals treated with baricitinib showed reduced inflammation, decreased lung infiltration of inflammatory cells, reduced NETosis activity, and more limited lung pathol.  Importantly, baricitinib-treated animals had a rapid and remarkably potent suppression of lung macrophage prodn. of cytokines and chemokines responsible for inflammation and neutrophil recruitment.  These data support a beneficial role for, and elucidate the immunol. mechanisms underlying, the use of baricitinib as a frontline treatment for inflammation induced by SARS-CoV-2 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA9Aj5Z0fOVLVg90H21EOLACvtfcHk0lgkKbok6ZI0Pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisV2nur7F&md5=3634bae4c47e11d43c0dac8637e7d6e9</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DHoang%26aufirst%3DT.%2BN.%26aulast%3DPino%26aufirst%3DM.%26aulast%3DBoddapati%26aufirst%3DA.%2BK.%26aulast%3DViox%26aufirst%3DE.%2BG.%26aulast%3DStarke%26aufirst%3DC.%2BE.%26aulast%3DUpadhyay%26aufirst%3DA.%2BA.%26aulast%3DGumber%26aufirst%3DS.%26aulast%3DBusman-Sahay%26aufirst%3DK.%26aulast%3DStrongin%26aufirst%3DZ.%26aulast%3DHarper%26aufirst%3DJ.%2BL.%26aulast%3DTharp%26aufirst%3DG.%2BK.%26aulast%3DPellegrini%26aufirst%3DK.%2BL.%26aulast%3DKirejczyk%26aufirst%3DS.%26aulast%3DZandi%26aufirst%3DK.%26aulast%3DTao%26aufirst%3DS.%26aulast%3DHorton%26aufirst%3DT.%2BR.%26aulast%3DBeagle%26aufirst%3DE.%2BN.%26aulast%3DMahar%26aufirst%3DE.%2BA.%26aulast%3DLee%26aufirst%3DM.%2BY.%26aulast%3DCohen%26aufirst%3DJ.%26aulast%3DJean%26aufirst%3DS.%2BM.%26aulast%3DWood%26aufirst%3DJ.%2BS.%26aulast%3DConnor-Stroud%26aufirst%3DF.%26aulast%3DStammen%26aufirst%3DR.%2BL.%26aulast%3DDelmas%26aufirst%3DO.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCooney%26aufirst%3DK.%2BA.%26aulast%3DSayegh%26aufirst%3DM.%2BN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWeiskopf%26aufirst%3DD.%26aulast%3DFilev%26aufirst%3DP.%2BD.%26aulast%3DWaggoner%26aufirst%3DJ.%26aulast%3DPiantadosi%26aufirst%3DA.%26aulast%3DKasturi%26aufirst%3DS.%2BP.%26aulast%3DShakhshir%26aufirst%3DH.%2BA.%26aulast%3DRibeiro%26aufirst%3DS.%2BP.%26aulast%3DSekaly%26aufirst%3DR.%2BP.%26aulast%3DLevit%26aufirst%3DR.%2BD.%26aulast%3DEstes%26aufirst%3DJ.%2BD.%26aulast%3DVanderford%26aufirst%3DT.%2BH.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DBosinger%26aufirst%3DS.%2BE.%26aulast%3DPaiardini%26aufirst%3DM.%26atitle%3DBaricitinib%2520treatment%2520resolves%2520lower%2520airway%2520inflammation%2520and%2520neutrophil%2520recruitment%2520in%2520SARS-CoV-2-infected%2520rhesus%2520macaques%26jtitle%3DCell%26date%3D2021%26volume%3D184%26spage%3D460%26doi%3D10.1016%2Fj.cell.2020.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span>FDA news
release, Coronavirus (COVID-19) update: <span> </span><span class="NLM_article-title">FDA authorizes
drug combination for treatment of COVID-19</span>, November
19, <span class="NLM_year">2020</span>. <a href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19" class="extLink">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19</a> (accessed <span class="NLM_year">2020</span>-11-26).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+news%0Arelease%2C+Coronavirus+%28COVID-19%29+update%3A+FDA+authorizes%0Adrug+combination+for+treatment+of+COVID-19%2C+November%0A19%2C+2020.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Fcoronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19+%28accessed+2020-11-26%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520authorizes%250Adrug%2520combination%2520for%2520treatment%2520of%2520COVID-19%26date%3D2020%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span> <span> </span><span class="NLM_article-title">Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19</span>. <i>Int. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">106749</span>, <span class="refDoi">Â DOI: 10.1016/j.intimp.2020.106749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.intimp.2020.106749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32645632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlent7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2020&pages=106749&author=X.+Zhangauthor=Y.+Zhangauthor=W.+Qiaoauthor=J.+Zhangauthor=Z.+Qi&title=Baricitinib%2C+a+drug+with+potential+effect+to+prevent+SARS-COV-2+from+entering+target+cells+and+control+cytokine+storm+induced+by+COVID-19&doi=10.1016%2Fj.intimp.2020.106749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19</span></div><div class="casAuthors">Zhang, Xiuhong; Zhang, Yan; Qiao, Weizhen; Zhang, Ji; Qi, Zhigang</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">106749</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In Dec. 2019, a novel coronavirus pneumonia (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly broke out in China and rapidly spread all over the world.  Recently, a cell surface protein, known as angiotensin-converting enzyme II (ACE2), has been identified to be involved in receptor-mediated endocytosis for SARS-CoV-2 entry to the cells.  Many studies have reported the clin. characteristics of COVID-19: sudden deterioration of disease around 1-2 wk after onset; much lower level of lymphocytes, esp. natural killer (NK) cells in peripheral blood; extremely high pro-inflammatory cytokines and C reactive protein (CRP).  About 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression.  Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes.  Baricitinib intracellularly inhibits the proinflammatory signal of several cytokines by suppressing Janus kinase (JAK) JAK1/JAK2.  It has been demonstrated clin. benefits for the patients with rheumatoid arthritis (RA), activew and atopic dermatitis with good efficacy and safety records.  Baricitinib is expected to interrupt the passage and intracellular assembly of SARS-CoV-2 into the target cells mediated by ACE2 receptor, and treat cytokine storm caused by COVID-19.  Several clin. trials are currently investigating the drug, and one of which has been completed with encouraging results.  In this paper, we will elaborate the role of cytokine storm mediated by JAK-STAT pathway in severe COVID-19, the possible mechanisms of baricitinib on reducing the viral entry into the target cells and cytokine storm, the key points of pharmaceutical care based on the latest research reports, clin. trials progress and drug instruction from the US FDA, so as to provide ref. for the treatment of severe COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowoPzzX14kBLVg90H21EOLACvtfcHk0lj_tVLEh-3leg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlent7vE&md5=c14838b0bae4a8b60e7eb33377245b03</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2020.106749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2020.106749%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DQiao%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DZ.%26atitle%3DBaricitinib%252C%2520a%2520drug%2520with%2520potential%2520effect%2520to%2520prevent%2520SARS-COV-2%2520from%2520entering%2520target%2520cells%2520and%2520control%2520cytokine%2520storm%2520induced%2520by%2520COVID-19%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2020%26volume%3D86%26spage%3D106749%26doi%3D10.1016%2Fj.intimp.2020.106749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâBryan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogswell, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokop, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinosa, R.,  3rd.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le
Beau, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. T.</span></span> <span> </span><span class="NLM_article-title">A transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">5016</span>â <span class="NLM_lpage">5031</span>, <span class="refDoi">Â DOI: 10.1128/MCB.11.10.5016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FMCB.11.10.5016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1656220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=5016-5031&author=J.+P.+O%E2%80%99Bryanauthor=R.+A.+Fryeauthor=P.+C.+Cogswellauthor=A.+Neubauerauthor=B.+Kitchauthor=C.+Prokopauthor=R.+Espinosaauthor=M.+M.+Le%0ABeauauthor=H.+S.+Earpauthor=E.+T.+Liu&title=A+transforming+gene+isolated+from+primary+human+myeloid+leukemia+cells%2C+encodes+a+novel+receptor+tyrosine+kinase&doi=10.1128%2FMCB.11.10.5016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">axl, A transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span></div><div class="casAuthors">O'Bryan, John P.; Frye, Roy A.; Cogswell, Patricia C.; Neubauer, Andreas; Kitch, Barry; Prokop, Carol; Espinosa, Rafael, III; Le Beau, Michelle M.; Earp, H. Shelton; Liu, Edison T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5016-31</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">A sensitive transfection-tumorigenicity assay was used to isolate a novel transforming gene from the DNA of 2 patients with chronic myelogenous leukemia.  Sequence anal. indicates that the product of this gene, axl, is a receptor tyrosine kinase.  Overexpression of axl cDNA in NIH 3T3 cells induces neoplastic transformation with the concomitant appearance of a 140-kDa axl tyrosine-phosphorylated protein.  Expression of axl cDNA in the baculovirus system results in the expression of the appropriate recombinant protein that is tyrosine kinase.  The juxtaposition of fibronectin type III and immunoglobulinlike repeats in the extracellular domain, as well as distinct amino acid sequences in the kinase domain, indicate that the axl protein represents a novel subclass of receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIaouGK3RfrVg90H21EOLACvtfcHk0lg_PdYthxjRzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D&md5=f244ff83822fdb98c22a35f918723d3a</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1128%2FMCB.11.10.5016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.11.10.5016%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Bryan%26aufirst%3DJ.%2BP.%26aulast%3DFrye%26aufirst%3DR.%2BA.%26aulast%3DCogswell%26aufirst%3DP.%2BC.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DKitch%26aufirst%3DB.%26aulast%3DProkop%26aufirst%3DC.%26aulast%3DEspinosa%26aufirst%3DR.%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26atitle%3DA%2520transforming%2520gene%2520isolated%2520from%2520primary%2520human%2520myeloid%2520leukemia%2520cells%252C%2520encodes%2520a%2520novel%2520receptor%2520tyrosine%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1991%26volume%3D11%26spage%3D5016%26epage%3D5031%26doi%3D10.1128%2FMCB.11.10.5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goruppi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruaro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C.</span></span> <span> </span><span class="NLM_article-title">Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 broblasts</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">471</span>â <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=8637702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK28XhtFCms74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1996&pages=471-480&author=S.+Goruppiauthor=E.+Ruaroauthor=C.+Schneider&title=Gas6%2C+the+ligand+of+Axl+tyrosine+kinase+receptor%2C+has+mitogenic+and+survival+activities+for+serum+starved+NIH3T3+broblasts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts</span></div><div class="casAuthors">Goruppi, Sandro; Ruaro, Elisabetta; Schneider, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">471-80</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Reversible growth arrest has been characterized for enhanced expression of a set of genes called gas (growth arrest specific).  Gas6 product (Gas6) is a secreted protein that was identified as the ligand for the tyrosine kinase receptor Axl.  Here the authors report that Gas6 is able to induce cell cycle division entry in serum starved NIH3T3 cells.  This mitogenic activity of Gas6 strictly correlates with its ability to interact with NIH3T3 endogenous Axl receptor since it can be abolished by sol. Axl extracellular domain and activates both Axl intrinsic kinase activity and the downstream MAPK pathway.  Moreover when ectopic Axl overexpression is performed by microinjection in serum starved NIH3T3 cells, addn. of a nonmitogenic level of Gas6 induces selective entry into S phase in Axl overexpressing cells.  Interestingly, Axl overexpression per se is not able to induce S phase entry.  Finally the authors present evidences indicating that Gas6 is able to protect serum starved NIH3T3 cells from cell death by apoptosis as induced by complete growth factor depletion.  The reported survival activity seems to be independent of Gas6 mitogenic activity, thus implicating a double and separable activity for Gas6 during growth arrest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmV75pwx0DQbVg90H21EOLACvtfcHk0lg_PdYthxjRzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhtFCms74%253D&md5=c9836350bb97a0f21e9e30e58da89b57</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoruppi%26aufirst%3DS.%26aulast%3DRuaro%26aufirst%3DE.%26aulast%3DSchneider%26aufirst%3DC.%26atitle%3DGas6%252C%2520the%2520ligand%2520of%2520Axl%2520tyrosine%2520kinase%2520receptor%252C%2520has%2520mitogenic%2520and%2520survival%2520activities%2520for%2520serum%2520starved%2520NIH3T3%2520broblasts%26jtitle%3DOncogene%26date%3D1996%26volume%3D12%26spage%3D471%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stitt, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radziejewski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terence, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nancy, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiStefano, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basilico, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfarb, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span> <span> </span><span class="NLM_article-title">The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">661</span>â <span class="NLM_lpage">670</span>, <span class="refDoi">Â DOI: 10.1016/0092-8674(95)90520-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2F0092-8674%2895%2990520-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=7867073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK2MXktV2it74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1995&pages=661-670&author=T.+N.+Stittauthor=G.+Connauthor=M.+Goreauthor=C.+Laiauthor=J.+Brunoauthor=C.+Radziejewskiauthor=K.+Mattssonauthor=J.+Fisherauthor=D.+R.+Giesauthor=P.+F.+Jonesauthor=M.+Piotrauthor=E.+R.+Terenceauthor=J.+T.+Nancyauthor=D.+H.+Chenauthor=P.+S.+DiStefanoauthor=G.+L.+Longauthor=C.+Basilicoauthor=M.+P.+Goldfarbauthor=G.+Lemkeauthor=D.+J.+Glassauthor=G.+D.+Yancopoulos&title=The+anticoagulation+factor+protein+S+and+its+relative%2C+Gas6%2C+are+ligands+for+the+Tyro+3%2FAxl+family+of+receptor+tyrosine+kinases&doi=10.1016%2F0092-8674%2895%2990520-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases</span></div><div class="casAuthors">Stitt, Trevor N.; Conn, Greg; Gore, Martin; Lai, Cary; Bruno, Joanne; Radziejewski, Czeslaw; Mattsson, Karen; Fisher, John; Gies, David R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">661-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The authors report the identification of ligands for Tyro 3 (alternatively called Sky, rse, brt, or tif) and Axl (alternatively, Ark or UFO), members of a previously orphan family of receptor-like tyrosine kinases.  These ligands correspond to protein S, a protease regulator that is a potent anticoagulant, and Gas6, a protein related to protein S but lacking any known function.  The results are reminiscent of recent findings that the procoagulant thrombin, a protease that drives clot formation by cleaving fibrinogen to form fibrin, also binds and activates intracellular signaling via a G protein-coupled cell surface receptor.  Proteases and protease regulators that also activate specific cell surface receptors may serve to integrate coagulation with assocd. cellular responses required for tissue repair and growth, as well as to coordinate protease cascades and assocd. cellular responses in other systems, such as those involved in growth and remodeling of the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Kc6zOMgNobVg90H21EOLACvtfcHk0ljhin13pfNYYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktV2it74%253D&md5=a12eece9ec055c4ee7927d97a9789fdb</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2895%2990520-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252895%252990520-0%26sid%3Dliteratum%253Aachs%26aulast%3DStitt%26aufirst%3DT.%2BN.%26aulast%3DConn%26aufirst%3DG.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DBruno%26aufirst%3DJ.%26aulast%3DRadziejewski%26aufirst%3DC.%26aulast%3DMattsson%26aufirst%3DK.%26aulast%3DFisher%26aufirst%3DJ.%26aulast%3DGies%26aufirst%3DD.%2BR.%26aulast%3DJones%26aufirst%3DP.%2BF.%26aulast%3DPiotr%26aufirst%3DM.%26aulast%3DTerence%26aufirst%3DE.%2BR.%26aulast%3DNancy%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DD.%2BH.%26aulast%3DDiStefano%26aufirst%3DP.%2BS.%26aulast%3DLong%26aufirst%3DG.%2BL.%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DGoldfarb%26aufirst%3DM.%2BP.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DGlass%26aufirst%3DD.%2BJ.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26atitle%3DThe%2520anticoagulation%2520factor%2520protein%2520S%2520and%2520its%2520relative%252C%2520Gas6%252C%2520are%2520ligands%2520for%2520the%2520Tyro%25203%252FAxl%2520family%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D1995%26volume%3D80%26spage%3D661%26epage%3D670%26doi%3D10.1016%2F0092-8674%2895%2990520-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toshima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, K.</span></span> <span> </span><span class="NLM_article-title">Stimulation of sky receptor tyrosine kinase by the product of growth arrestspecic gene 6</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">22681</span>â <span class="NLM_lpage">22684</span>, <span class="refDoi">Â DOI: 10.1074/jbc.270.39.22681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.270.39.22681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=7559388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK2MXosFOqtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=22681-22684&author=K.+Ohashiauthor=K.+Nagataauthor=J.+Toshimaauthor=T.+Nakanoauthor=H.+Aritaauthor=H.+Tsudaauthor=K.+Suzukiauthor=K.+Mizuno&title=Stimulation+of+sky+receptor+tyrosine+kinase+by+the+product+of+growth+arrestspecic+gene+6&doi=10.1074%2Fjbc.270.39.22681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of Sky receptor tyrosine kinase by the product of growth arrest-specific gene 6</span></div><div class="casAuthors">Ohashi, Kazumasa; Nagata, Kyoko; Toshima, Jiro; Nakano, Toru; Arita, Hitoshi; Tsuda, Hiroko; Suzuki, Koji; Mizuno, Kensaku</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">22681-4</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Sky (also called Rse, Brt, and Tyro3) is a member of a subfamily of related receptor tyrosine kinases, including Axl/Ufo/Ark and c-Eyk/Mer.  We obtained evidence that Gas6 (the product of growth arrest-specific gene 6) is a ligand of the Sky receptor tyrosine kinase.  Gas6, but not protein S (an anticoagulant protein structurally similar to Gas6), specifically bound to the sol. form of Sky (Sky-Fc), composed of the extracellular domain of Sky fused to the Fc domain of human IgG1.  The native and recombinant Gas6, but not protein S, stimulated tyrosine phosphorylation of Sky ectopically expressed in Chinese hamster ovary cells.  Stimulation of Sky in response to Gas6 was inhibited by Sky-Fc.  The half-maximal concn. of Gas6 that stimulated Sky was about 1 nM.  Thus, Gas6 as a ligand for Sky specifically binds to and stimulates Sky receptor tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGO5YQrZPEP7Vg90H21EOLACvtfcHk0ljhin13pfNYYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXosFOqtLc%253D&md5=435b45c259f3b264b78401a8d8f2e592</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.39.22681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.39.22681%26sid%3Dliteratum%253Aachs%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DNagata%26aufirst%3DK.%26aulast%3DToshima%26aufirst%3DJ.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DArita%26aufirst%3DH.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DMizuno%26aufirst%3DK.%26atitle%3DStimulation%2520of%2520sky%2520receptor%2520tyrosine%2520kinase%2520by%2520the%2520product%2520of%2520growth%2520arrestspecic%2520gene%25206%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D22681%26epage%3D22684%26doi%3D10.1074%2Fjbc.270.39.22681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, G.</span></span> <span> </span><span class="NLM_article-title">Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">306</span>â <span class="NLM_lpage">311</span>, <span class="refDoi">Â DOI: 10.1126/science.1061663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1126%2Fscience.1061663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11452127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1ymsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=306-311&author=Q.+Luauthor=G.+Lemke&title=Homeostatic+regulation+of+the+immune+system+by+receptor+tyrosine+kinases+of+the+Tyro+3+family&doi=10.1126%2Fscience.1061663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family</span></div><div class="casAuthors">Lu, Qingxian; Lemke, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">5528</span>),
    <span class="NLM_cas:pages">306-311</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases and their ligands mediate cell-cell communication and interaction in many organ systems, but have not been known to act in this capacity in the mature immune system.  The authors now provide genetic evidence that three closely related receptor tyrosine kinases, Tyro 3, Axl, and Mer, play an essential immunoregulatory role.  Mutant mice that lack these receptors develop a severe lymphoproliferative disorder accompanied by broad-spectrum autoimmunity.  These phenotypes are cell non-autonomous with respect to lymphocytes and result from the hyperactivation of antigen-presenting cells in which the three receptors are normally expressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp8p8YELw6TLVg90H21EOLACvtfcHk0ljhin13pfNYYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1ymsbY%253D&md5=7b6a3d91485e82fdb47f715331b1f310</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1126%2Fscience.1061663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1061663%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DLemke%26aufirst%3DG.%26atitle%3DHomeostatic%2520regulation%2520of%2520the%2520immune%2520system%2520by%2520receptor%2520tyrosine%2520kinases%2520of%2520the%2520Tyro%25203%2520family%26jtitle%3DScience%26date%3D2001%26volume%3D293%26spage%3D306%26epage%3D311%26doi%3D10.1126%2Fscience.1061663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linseman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaack, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnum, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandel, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidenreich, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierman, M. E.</span></span> <span> </span><span class="NLM_article-title">Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">599</span>â <span class="NLM_lpage">613</span>, <span class="refDoi">Â DOI: 10.1128/MCB.22.2.599-613.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FMCB.22.2.599-613.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11756555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvVeqtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=599-613&author=M.+P.+Allenauthor=D.+A.+Linsemanauthor=H.+Udoauthor=M.+Xuauthor=J.+B.+Schaackauthor=B.+Varnumauthor=E.+R.+Kandelauthor=K.+A.+Heidenreichauthor=M.+E.+Wierman&title=Novel+mechanism+for+gonadotropin-releasing+hormone+neuronal+migration+involving+Gas6%2FArk+signaling+to+p38+mitogen-activated+protein+kinase&doi=10.1128%2FMCB.22.2.599-613.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase</span></div><div class="casAuthors">Allen, Melissa P.; Linseman, Daniel A.; Udo, Hiroshi; Xu, Mei; Schaack, Jerome B.; Varnum, Brian; Kandel, Eric R.; Heidenreich, Kim A.; Wierman, Margaret E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">599-613</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Gonadotropin-releasing hormone (GnRH) is the central regulator of the reproductive axis.  Normal sexual maturation depends on the migration of GnRH neurons from the olfactory placode to the hypothalamus during development.  Previously, we showed restricted expression of the membrane receptor adhesion-related kinase (Ark) in immortalized cell lines derived from migratory but not postmigratory GnRH neurons.  In addn., Ark and GnRH transcripts were detected along the GnRH neuron migratory route in the E13 mouse cribriform plate.  In the present study, we examd. the role of Ark and its ligand, Gas6 (encoded by growth arrest-specific gene 6), in GnRH neuron migration.  Gas6 stimulated lamellipodial extension, membrane ruffling, and chemotaxis of immortalized NLT GnRH neuronal cells via the Ark receptor.  Gas6/Ark signaling promoted activation of the Rho family GTPase Rac, and adenoviral-mediated expression of dominant neg. N17Rac abolished Gas6/Ark-induced actin cytoskeletal reorganization and migration of GnRH neuronal cells.  In addn., p38 MAPK was activated downstream of Ark and Rac, and inhibition of p38 MAPK with either SB203580 or adenoviral dominant neg. p38Î± also blocked Gas6/Ark-mediated migration.  Finally, downstream of Rac and p38 mitogen-activated protein kinase (MAPK), Gas6/Ark signaling promoted activation of MAPK-activated protein kinase 2 and induced phosphorylation of HSP25, a known regulator of cortical actin remodeling.  The data are the first to demonstrate a migratory signaling pathway downstream of Ark/Axl family receptors and suggest a previously unidentified role for p38 MAPK in neuronal migration.  Furthermore, these studies support a potential role for Ark in the regulation of GnRH neuronal migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEtuRyVS8QebVg90H21EOLACvtfcHk0lh3geXvhYX9KA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvVeqtg%253D%253D&md5=fe1dd91600eb4efb8512719c62a9aee3</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1128%2FMCB.22.2.599-613.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.22.2.599-613.2002%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DM.%2BP.%26aulast%3DLinseman%26aufirst%3DD.%2BA.%26aulast%3DUdo%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DSchaack%26aufirst%3DJ.%2BB.%26aulast%3DVarnum%26aufirst%3DB.%26aulast%3DKandel%26aufirst%3DE.%2BR.%26aulast%3DHeidenreich%26aufirst%3DK.%2BA.%26aulast%3DWierman%26aufirst%3DM.%2BE.%26atitle%3DNovel%2520mechanism%2520for%2520gonadotropin-releasing%2520hormone%2520neuronal%2520migration%2520involving%2520Gas6%252FArk%2520signaling%2520to%2520p38%2520mitogen-activated%2520protein%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2002%26volume%3D22%26spage%3D599%26epage%3D613%26doi%3D10.1128%2FMCB.22.2.599-613.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hafizi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DahlbÃ¤ck, B.</span></span> <span> </span><span class="NLM_article-title">Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinase</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">295</span>â <span class="NLM_lpage">304</span>, <span class="refDoi">Â DOI: 10.1016/j.cytogfr.2006.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cytogfr.2006.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16737840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFSgsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=295-304&author=S.+Hafiziauthor=B.+Dahlb%C3%A4ck&title=Signalling+and+functional+diversity+within+the+Axl+subfamily+of+receptor+tyrosine+kinase&doi=10.1016%2Fj.cytogfr.2006.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases</span></div><div class="casAuthors">Hafizi, Sassan; Dahlbaeck, Bjoern</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">295-304</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The related Axl, Sky, and Mer receptor tyrosine kinases (RTKs) are increasingly being implicated in a host of discrete cellular responses including cell survival, proliferation, migration, and phagocytosis.  Furthermore, their ligands Gas6 and protein S are characteristically dependent on vitamin K for expression of their functions.  The Gas6/Axl system is implicated in several types of human cancer as well as inflammatory, autoimmune, vascular, and kidney diseases.  Each member of the Axl RTK subfamily possesses distinct expression profiles as well as discrete functions.  In this article, we review the knowledge so far on the intracellular signaling interactions and pathways concerning each of the Axl RTKs.  In this way, we hope to gain a greater understanding of the mechanisms that set each of them apart, and that relay their assocd. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdTpEe1fJt7bVg90H21EOLACvtfcHk0lh3geXvhYX9KA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFSgsbg%253D&md5=497007a195b1c20e9f4b27b7315f8f92</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2006.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2006.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DHafizi%26aufirst%3DS.%26aulast%3DDahlb%25C3%25A4ck%26aufirst%3DB.%26atitle%3DSignalling%2520and%2520functional%2520diversity%2520within%2520the%2520Axl%2520subfamily%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2006%26volume%3D17%26spage%3D295%26epage%3D304%26doi%3D10.1016%2Fj.cytogfr.2006.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span> <span> </span><span class="NLM_article-title">Giving AXL the axe: Targeting AXL in human malignancy</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">415</span>â <span class="NLM_lpage">423</span>, <span class="refDoi">Â DOI: 10.1038/bjc.2016.428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fbjc.2016.428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28072762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVSruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2017&pages=415-423&author=C.+M.+Gayauthor=K.+Balajiauthor=L.+A.+Byers&title=Giving+AXL+the+axe%3A+Targeting+AXL+in+human+malignancy&doi=10.1038%2Fbjc.2016.428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Giving AXL the axe: targeting AXL in human malignancy</span></div><div class="casAuthors">Gay, Carl M.; Balaji, Kavitha; Byers, Lauren Averett</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">415-423</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase AXL, activated by a complex interaction between its ligand growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular processes, including proliferation, survival, motility, and immunol. response.  Although not implicated as an oncogenic driver itself, AXL, a member of the TYRO3, AXL, and MERTK family of receptor tyrosine kinases, is overexpressed in several haematol. and solid malignancies, including acute myeloid leukemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers.  In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumor angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response.  As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies.  Several AXL inhibitors are currently in preclin. and clin. development.  This article reviews the structure, regulation, and function of AXL; the role of AXL in the tumor microenvironment; the development of AXL as a therapeutic target; and areas of ongoing and future investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHXM9RJ8TVsLVg90H21EOLACvtfcHk0lh9YQdS_lTlwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVSruw%253D%253D&md5=c24668744fe4b017def75b08bac2a863</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.428%26sid%3Dliteratum%253Aachs%26aulast%3DGay%26aufirst%3DC.%2BM.%26aulast%3DBalaji%26aufirst%3DK.%26aulast%3DByers%26aufirst%3DL.%2BA.%26atitle%3DGiving%2520AXL%2520the%2520axe%253A%2520Targeting%2520AXL%2520in%2520human%2520malignancy%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2017%26volume%3D116%26spage%3D415%26epage%3D423%26doi%3D10.1038%2Fbjc.2016.428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strange, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiyarom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourhabibi, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadri-Ardekani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S.</span></span> <span> </span><span class="NLM_article-title">Axl promotes zika virus entry and modulates the antiviral state of human sertoli cells</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e01372-19</span> <span class="refDoi">Â DOI: 10.1128/mBio.01372-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FmBio.01372-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31311882" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&author=D.+P.+Strangeauthor=B.+Jiyaromauthor=Z.+N.+Pourhabibiauthor=X.+Xieauthor=C.+Bakerauthor=H.+Sadri-Ardekaniauthor=P.+Y.+Shiauthor=S.+Verma&title=Axl+promotes+zika+virus+entry+and+modulates+the+antiviral+state+of+human+sertoli+cells&doi=10.1128%2FmBio.01372-19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1128%2FmBio.01372-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.01372-19%26sid%3Dliteratum%253Aachs%26aulast%3DStrange%26aufirst%3DD.%2BP.%26aulast%3DJiyarom%26aufirst%3DB.%26aulast%3DPourhabibi%26aufirst%3DZ.%2BN.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DSadri-Ardekani%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DP.%2BY.%26aulast%3DVerma%26aufirst%3DS.%26atitle%3DAxl%2520promotes%2520zika%2520virus%2520entry%2520and%2520modulates%2520the%2520antiviral%2520state%2520of%2520human%2520sertoli%2520cells%26jtitle%3DmBio%26date%3D2019%26volume%3D10%26doi%3D10.1128%2FmBio.01372-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimojima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaoka, Y.</span></span> <span> </span><span class="NLM_article-title">Tyro3 family-mediated cell entry of Ebola and Marburg viruses</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">10109</span>â <span class="NLM_lpage">10116</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01157-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01157-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17005688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVyls7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=10109-10116&author=M.+Shimojimaauthor=A.+Takadaauthor=H.+Ebiharaauthor=G.+Neumannauthor=K.+Fujiokaauthor=T.+Irimuraauthor=S.+Jonesauthor=H.+Feldmannauthor=Y.+Kawaoka&title=Tyro3+family-mediated+cell+entry+of+Ebola+and+Marburg+viruses&doi=10.1128%2FJVI.01157-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Tyro3 family-mediated cell entry of Ebola and Marburg viruses</span></div><div class="casAuthors">Shimojima, Masayuki; Takada, Ayato; Ebihara, Hideki; Neumann, Gabriele; Fujioka, Kouki; Irimura, Tatsuro; Jones, Steven; Feldmann, Heinz; Kawaoka, Yoshihiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">10109-10116</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Filoviruses, represented by the genera Ebolavirus and Marburgvirus, cause a lethal hemorrhagic fever in humans and in nonhuman primates.  Although filovirus can replicate in various tissues or cell types in these animals, the mol. mechanisms of its broad tropism remain poorly understood.  Here we show the involvement of members of the Tyro3 receptor tyrosine kinase family, Axl, Dtk, and Mer, in cell entry of filoviruses.  Ectopic expression of these family members in lymphoid cells, which otherwise are highly resistant to filovirus infection, enhanced infection by pseudotype viruses carrying filovirus glycoproteins on their envelopes.  This enhancement was reduced by antibodies to Tyro3 family members, Gas6 ligand, or sol. ectodomains of the members.  Live Ebola viruses infected both Axl- and Dtk-expressing cells more efficiently than control cells.  Antibody to Axl inhibited infection of pseudotype viruses in a no. of Axl-pos. cell lines.  These results implicate each Tyro3 family member as a cell entry factor in filovirus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqCQuIltWeVrVg90H21EOLACvtfcHk0lh9YQdS_lTlwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVyls7rP&md5=f2678cc7b5ab0c69111b960bf618876b</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1128%2FJVI.01157-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01157-06%26sid%3Dliteratum%253Aachs%26aulast%3DShimojima%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DA.%26aulast%3DEbihara%26aufirst%3DH.%26aulast%3DNeumann%26aufirst%3DG.%26aulast%3DFujioka%26aufirst%3DK.%26aulast%3DIrimura%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DFeldmann%26aufirst%3DH.%26aulast%3DKawaoka%26aufirst%3DY.%26atitle%3DTyro3%2520family-mediated%2520cell%2520entry%2520of%2520Ebola%2520and%2520Marburg%2520viruses%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D10109%26epage%3D10116%26doi%3D10.1128%2FJVI.01157-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">126</span>â <span class="NLM_lpage">140</span>, <span class="refDoi">Â DOI: 10.1038/s41422-020-00460-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41422-020-00460-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33420426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhs1Sjs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2021&pages=126-140&author=S.+Wangauthor=Z.+Qiuauthor=Y.+Houauthor=X.+Dengauthor=T.+Zhengauthor=R.+Yanauthor=P.+Wuauthor=S.+Xieauthor=Q.+Zhouauthor=J.+Huangauthor=X.+Li&title=AXL+is+a+candidate+receptor+for+SARS-CoV-2+that+promotes+infection+of+pulmonary+and+bronchial+epithelial+cells&doi=10.1038%2Fs41422-020-00460-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells</span></div><div class="casAuthors">Wang, Shuai; Qiu, Zongyang; Hou, Yingnan; Deng, Xiya; Xu, Wei; Zheng, Tingting; Wu, Peihan; Xie, Shaofang; Bian, Weixiang; Zhang, Chong; Sun, Zewei; Liu, Kunpeng; Shan, Chao; Lin, Aifu; Jiang, Shibo; Xie, Youhua; Zhou, Qiang; Lu, Lu; Huang, Jing; Li, Xu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-140</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The current coronavirus disease 2019 (COVID-19) pandemic presents a global public health challenge.  The viral pathogen responsible, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), binds to the host receptor ACE2 through its spike (S) glycoprotein, which mediates membrane fusion and viral entry.  Although the role of ACE2 as a receptor for SARS-CoV-2 is clear, studies have shown that ACE2 expression is extremely low in various human tissues, esp. in the respiratory tract.  Thus, other host receptors and/or co-receptors that promote the entry of SARS-CoV-2 into cells of the respiratory system may exist.  In this study, we found that the tyrosine-protein kinase receptor UFO (AXL) specifically interacts with the N-terminal domain of SARS-CoV-2 S.  Using both a SARS-CoV-2 virus pseudotype and authentic SARS-CoV-2, we found that overexpression of AXL in HEK293T cells promotes SARS-CoV-2 entry as efficiently as overexpression of ACE2, while knocking out AXL significantly reduces SARS-CoV-2 infection in H1299 pulmonary cells and in human primary lung epithelial cells.  Sol. human recombinant AXL blocks SARS-CoV-2 infection in cells expressing high levels of AXL.  The AXL expression level is well correlated with SARS-CoV-2 S level in bronchoalveolar lavage fluid cells from COVID-19 patients.  Taken together, our findings suggest that AXL is a novel candidate receptor for SARS-CoV-2 which may play an important role in promoting viral infection of the human respiratory system and indicate that it is a potential target for future clin. intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI1wmry9H6UrVg90H21EOLACvtfcHk0lgC8rNB6GQJZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhs1Sjs7s%253D&md5=d708204bc6dd130cdb30f0bf5fc2742b</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fs41422-020-00460-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-020-00460-y%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DT.%26aulast%3DYan%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DAXL%2520is%2520a%2520candidate%2520receptor%2520for%2520SARS-CoV-2%2520that%2520promotes%2520infection%2520of%2520pulmonary%2520and%2520bronchial%2520epithelial%2520cells%26jtitle%3DCell%2520Res.%26date%3D2021%26volume%3D31%26spage%3D126%26epage%3D140%26doi%3D10.1038%2Fs41422-020-00460-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkhowa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Preclinical studies of gilteritinib, a nextgeneration FLT3 inhibitor</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">257</span>â <span class="NLM_lpage">260</span>, <span class="refDoi">Â DOI: 10.1182/blood-2016-10-745133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1182%2Fblood-2016-10-745133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27908881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVKitL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=257-260&author=L.+Y.+Leeauthor=D.+Hernandezauthor=T.+Rajkhowaauthor=S.+C.+Smithauthor=J.+R.+Ramanauthor=B.+Nguyenauthor=D.+Smallauthor=M.+Levis&title=Preclinical+studies+of+gilteritinib%2C+a+nextgeneration+FLT3+inhibitor&doi=10.1182%2Fblood-2016-10-745133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor</span></div><div class="casAuthors">Lee, Lauren Y.; Hernandez, Daniela; Rajkhowa, Trivikram; Smith, Samuel C.; Raman, Jayant Ranganathan; Nguyen, Bao; Small, Donald; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-260</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">This article describes about the activity of gilteritinib and compared it with 4 other FLT3 TKIs in clin. development: midostaurin, sorafenib, quizartinib, and crenolanib.  In this article, inhibitory activity of gilteritinib against different forms of FLT3 in leukemia cells are studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKpTUQzYy5lrVg90H21EOLACvtfcHk0lgC8rNB6GQJZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVKitL0%253D&md5=75429ea03b906ea92d24033613f0315b</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-10-745133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-10-745133%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DL.%2BY.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DRaman%26aufirst%3DJ.%2BR.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DPreclinical%2520studies%2520of%2520gilteritinib%252C%2520a%2520nextgeneration%2520FLT3%2520inhibitor%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D257%26epage%3D260%26doi%3D10.1182%2Fblood-2016-10-745133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span> <span> </span><span class="NLM_article-title">The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">Suppl 4</span>),  <span class="NLM_fpage">S3</span>â <span class="NLM_lpage">S8</span>, <span class="refDoi">Â DOI: 10.1016/S0959-8049(01)00230-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS0959-8049%2801%2900230-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11597398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntlOku78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=S3-S8&issue=Suppl+4&author=Y.+Yarden&title=The+EGFR+family+and+its+ligands+in+human+cancer.+Signalling+mechanisms+and+therapeutic+opportunities&doi=10.1016%2FS0959-8049%2801%2900230-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities</span></div><div class="casAuthors">Yarden, Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">Suppl. 4</span>),
    <span class="NLM_cas:pages">S3-S8</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Growth factors and their transmembrane receptor tyrosine kinases play important roles in cell proliferation, survival, migration and differentiation.  One group of growth factors, comprising epidermal growth factor (EGF)-like proteins and neuregulins, stimulates cells to divide by activating members of the EGF receptor (EGFR) family, which consists of the EGFR itself and the receptors known as HER2-4.  This highly conserved signaling module plays a fundamental role in the morphogenesis of a diverse spectrum of organisms, ranging from humans to nematodes, and has also been implicated in the development and growth of many types of human tumor cells.  In humans, more than 30 ligands and the EGFR family of four receptors lie at the head of a complex, multi-layered signal-transduction network.  Different activated receptor-ligand complexes vary in both the strength and type of cellular responses that they induce.  Anal. of the multiple processes that modulate EGFR signal transduction, such as receptor heterodimerization and endocytosis, has revealed new therapeutic opportunities and elucidated mechanisms contributing to the efficacy of existing anticancer treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruCkMkD5i497Vg90H21EOLACvtfcHk0lj9NCwyUljGZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntlOku78%253D&md5=b512e9006ed63e9f01f2cdd525dc4d96</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2801%2900230-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252801%252900230-1%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DThe%2520EGFR%2520family%2520and%2520its%2520ligands%2520in%2520human%2520cancer.%2520Signalling%2520mechanisms%2520and%2520therapeutic%2520opportunities%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2001%26volume%3D37%26issue%3DSuppl%25204%26spage%3DS3%26epage%3DS8%26doi%3D10.1016%2FS0959-8049%2801%2900230-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beerli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakimovich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynoso, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaschner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, J.</span></span> <span> </span><span class="NLM_article-title">Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility</span>. <i>Nat. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">216</span>â <span class="NLM_lpage">225</span>, <span class="refDoi">Â DOI: 10.1038/s41564-018-0288-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41564-018-0288-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30420785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Sgur%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=216-225&author=C.+Beerliauthor=A.+Yakimovichauthor=S.+Kilcherauthor=G.+V.+Reynosoauthor=G.+Flaschnerauthor=D.+J.+M%C3%BCllerauthor=H.+D.+Hickmanauthor=J.+Mercer&title=Vaccinia+virus+hijacks+EGFR+signalling+to+enhance+virus+spread+through+rapid+and+directed+infected+cell+motility&doi=10.1038%2Fs41564-018-0288-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility</span></div><div class="casAuthors">Beerli, Corina; Yakimovich, Artur; Kilcher, Samuel; Reynoso, Glennys V.; Flaschner, Gotthold; Muller, Daniel J.; Hickman, Heather D.; Mercer, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Nature Microbiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">216-225</span>CODEN:
                <span class="NLM_cas:coden">NMAICH</span>;
        ISSN:<span class="NLM_cas:issn">2058-5276</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cell motility is essential for viral dissemination1.  Vaccinia virus (VACV), a close relative of smallpox virus, is thought to exploit cell motility as a means to enhance the spread of infection1.  A single viral protein, F11L, contributes to this by blocking RhoA signalling to facilitate cell retraction2.  However, F11L alone is not sufficient for VACV-induced cell motility, indicating that addnl. viral factors must be involved.  Here, we show that the VACV epidermal growth factor homolog, VGF, promotes infected cell motility and the spread of viral infection.  We found that VGF secreted from early infected cells is cleaved by ADAM10, after which it acts largely in a paracrine manner to direct cell motility at the leading edge of infection.  Real-time tracking of cells infected in the presence of EGFR, MAPK, FAK and ADAM10 inhibitors or with VGF-deleted and F11-deleted viruses revealed defects in radial velocity and directional migration efficiency, leading to impaired cell-to-cell spread of infection.  Furthermore, intravital imaging showed that virus spread and lesion formation are attenuated in the absence of VGF.  Our results demonstrate how poxviruses hijack epidermal growth factor receptor-induced cell motility to promote rapid and efficient spread of infection in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn_oMFPOjS1rVg90H21EOLACvtfcHk0lj9NCwyUljGZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Sgur%252FL&md5=6cf75250c3685c6c51097b55a33f921a</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fs41564-018-0288-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41564-018-0288-2%26sid%3Dliteratum%253Aachs%26aulast%3DBeerli%26aufirst%3DC.%26aulast%3DYakimovich%26aufirst%3DA.%26aulast%3DKilcher%26aufirst%3DS.%26aulast%3DReynoso%26aufirst%3DG.%2BV.%26aulast%3DFlaschner%26aufirst%3DG.%26aulast%3DM%25C3%25BCller%26aufirst%3DD.%2BJ.%26aulast%3DHickman%26aufirst%3DH.%2BD.%26aulast%3DMercer%26aufirst%3DJ.%26atitle%3DVaccinia%2520virus%2520hijacks%2520EGFR%2520signalling%2520to%2520enhance%2520virus%2520spread%2520through%2520rapid%2520and%2520directed%2520infected%2520cell%2520motility%26jtitle%3DNat.%2520Microbiol.%26date%3D2019%26volume%3D4%26spage%3D216%26epage%3D225%26doi%3D10.1038%2Fs41564-018-0288-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, C.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meckes, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab-Traub, N.</span></span> <span> </span><span class="NLM_article-title">Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCÎ´</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">4399</span>â <span class="NLM_lpage">4408</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01703-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01703-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=21307189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSmsLbO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=4399-4408&author=C.-P.+Kungauthor=D.+G.+Meckesauthor=N.+Raab-Traub&title=Epstein-Barr+virus+LMP1+activates+EGFR%2C+STAT3%2C+and+ERK+through+effects+on+PKC%CE%B4&doi=10.1128%2FJVI.01703-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCÎ´</span></div><div class="casAuthors">Kung, Che-Pei; Meckes, David G., Jr.; Raab-Traub, Nancy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4399-4408</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that infects more than 90% of the world's adult population and is linked to multiple malignancies, including Burkitt lymphoma, Hodgkin disease, and nasopharyngeal carcinoma (NPC).  The EBV oncoprotein LMP1 induces transcription of the epidermal growth factor receptor (EGFR), which is expressed at high levels in NPC.  EGFR transcription is induced by LMP1 through a p50 NFÎºB1-Bcl-3 complex, and Bcl-3 is induced by LMP1-mediated activation of STAT3.  This study reveals that LMP1, through its carboxyl-terminal activation domain 1 (LMP1-CTAR1), activates both STAT3 and EGFR in a serum-independent manner with constitutive serine phosphorylation of STAT3.  Upon treatment with EGF, the LMP1-CTAR1-induced EGFR was addnl. phosphorylated and STAT3 became phosphorylated on tyrosine, concomitant with upregulation of a subset of STAT3 target genes.  The kinase responsible for LMP1-CTAR1-mediated serine phosphorylation of STAT3 was identified to be PKCÎ´ using specific RNAi, a dominant neg. PKCÎ´, and the PKCÎ´ inhibitor rottlerin.  Interestingly, inhibition of PKCÎ´ also inhibited constitutive phosphorylation of EGFR and LMP1-CTAR1-induced phosphorylation of ERK.  Inhibition of PKCÎ´ blocked LMP1-CTAR1-mediated transformation of Rat-1 cells, likely through the inhibition of ERK activation.  These findings indicate that LMP1 activates multiple distinct signaling pathways and suggest that PKCÎ´ functions as a master regulator of EGFR, STAT3, and ERK activation by LMP1-CTAR1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTHHkR2eUL_rVg90H21EOLACvtfcHk0lj9NCwyUljGZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSmsLbO&md5=ab4059ceb1322fc9e283bb978502b7d7</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1128%2FJVI.01703-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01703-10%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DC.-P.%26aulast%3DMeckes%26aufirst%3DD.%2BG.%26aulast%3DRaab-Traub%26aufirst%3DN.%26atitle%3DEpstein-Barr%2520virus%2520LMP1%2520activates%2520EGFR%252C%2520STAT3%252C%2520and%2520ERK%2520through%2520effects%2520on%2520PKC%25CE%25B4%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D4399%26epage%3D4408%26doi%3D10.1128%2FJVI.01703-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Rhinovirusinduced major airway mucin production involves a novel TLR3-EGFR-dependent pathway</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">610</span>â <span class="NLM_lpage">619</span>, <span class="refDoi">Â DOI: 10.1165/rcmb.2008-0223OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1165%2Frcmb.2008-0223OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18978302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsF2itro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2009&pages=610-619&author=L.+Zhuauthor=P.+K.+Leeauthor=W.+M.+Leeauthor=Y.+Zhaoauthor=D.+Yuauthor=Y.+Chen&title=Rhinovirusinduced+major+airway+mucin+production+involves+a+novel+TLR3-EGFR-dependent+pathway&doi=10.1165%2Frcmb.2008-0223OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Rhinovirus-induced major airway mucin production involves a novel TLR3-EGFR-dependent pathway</span></div><div class="casAuthors">Zhu, Lingxiang; Lee, Pak-kei; Lee, Wai-ming; Zhao, Yuhua; Yu, Dongfang; Chen, Yin</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">610-619</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Mucociliary clearance is a crit. innate defense system responsible for clearing up invading pathogens including bacteria and virus.  Although the right amt. of mucus is good, excessive mucus causes airway obstruction and tends to ppt. disease symptoms.  Rhinovirus (RV) is a common cold virus that causes asthma and chronic obstructive pulmonary disease exacerbation.  Mucus overprodn. has been linked to the pathogenesis of RV-induced diseases and disease exacerbations.  However, the mol. mechanism is not clear.  Here, using one of the major airway mucin-MUC5AC as marker, the authors found that both major and minor groups of RV induced mucin prodn. in primary human epithelial cells and cell line.  RV1A (a minor group of RV) could induce mucous cell metaplasia in vivo.  Viral replication was needed for RV-induced mucin expression, and this induction was also dependent on TLR3, suggesting the involvement of double-stranded (ds) RNA signaling.  Indeed, dsRNA alone could also induce mucin expression.  TLR3-mediated mucin induction was neg. regulated by MyD88, and only partially dependent on TRIF, which suggests a departure from well-documented TLR3 signaling paradigm that mediates inflammatory and other innate defense gene inductions.  In addn., TLR3 signaling activated epidermal growth factor receptor (EGFR) via induction of the expression of EGFR ligands (transforming growth factor-Î± and amphiregulin), which in turn activated EGFR-ERK signaling and mucin expression through an autocrine/paracrine loop.  This novel coupling of antiviral defense machinery (i.e., TLR3) and major epithelial proliferation/repair pathway (i.e., EGFR) might play an important role in viral-induced airway remodeling and airway disease exacerbation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodfRh50tVjWLVg90H21EOLACvtfcHk0liBs3Jb4QMlXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsF2itro%253D&md5=0795eb98e37d4ad9bc7def02b77b232d</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2008-0223OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2008-0223OC%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DP.%2BK.%26aulast%3DLee%26aufirst%3DW.%2BM.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DRhinovirusinduced%2520major%2520airway%2520mucin%2520production%2520involves%2520a%2520novel%2520TLR3-EGFR-dependent%2520pathway%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2009%26volume%3D40%26spage%3D610%26epage%3D619%26doi%3D10.1165%2Frcmb.2008-0223OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eierhoff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrincius, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span> <span> </span><span class="NLM_article-title">The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e1001099</span> <span class="refDoi">Â DOI: 10.1371/journal.ppat.1001099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.ppat.1001099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20844577" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&author=T.+Eierhoffauthor=E.+R.+Hrinciusauthor=U.+Rescherauthor=S.+Ludwigauthor=C.+Ehrhardt&title=The+epidermal+growth+factor+receptor+%28EGFR%29+promotes+uptake+of+influenza+A+viruses+%28IAV%29+into+host+cells&doi=10.1371%2Fjournal.ppat.1001099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1001099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1001099%26sid%3Dliteratum%253Aachs%26aulast%3DEierhoff%26aufirst%3DT.%26aulast%3DHrincius%26aufirst%3DE.%2BR.%26aulast%3DRescher%26aufirst%3DU.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DEhrhardt%26aufirst%3DC.%26atitle%3DThe%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520promotes%2520uptake%2520of%2520influenza%2520A%2520viruses%2520%2528IAV%2529%2520into%2520host%2520cells%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26doi%3D10.1371%2Fjournal.ppat.1001099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lupberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeisel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thumann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fofana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zona, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mee, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavillette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fresquet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosset, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietschmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DoffoÃ«l, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffelsberger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeating, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, T. F.</span></span> <span> </span><span class="NLM_article-title">EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">589</span>â <span class="NLM_lpage">595</span>, <span class="refDoi">Â DOI: 10.1038/nm.2341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnm.2341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=21516087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFyqtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=589-595&author=J.+Lupbergerauthor=M.+B.+Zeiselauthor=F.+Xiaoauthor=C.+Thumannauthor=I.+Fofanaauthor=L.+Zonaauthor=C.+Davisauthor=C.+J.+Meeauthor=M.+Turekauthor=S.+Gorkeauthor=C.+Royerauthor=B.+Fischerauthor=M.+N.+Zahidauthor=D.+Lavilletteauthor=J.+Fresquetauthor=F.+L.+Cossetauthor=S.+M.+Rothenbergauthor=T.+Pietschmannauthor=A.+H.+Patelauthor=P.+Pessauxauthor=M.+Doffo%C3%ABlauthor=W.+Raffelsbergerauthor=O.+Pochauthor=J.+A.+McKeatingauthor=L.+Brinoauthor=T.+F.+Baumert&title=EGFR+and+EphA2+are+host+factors+for+hepatitis+C+virus+entry+and+possible+targets+for+antiviral+therapy&doi=10.1038%2Fnm.2341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy</span></div><div class="casAuthors">Lupberger, Joachim; Zeisel, Mirjam B.; Xiao, Fei; Thumann, Christine; Fofana, Isabel; Zona, Laetitia; Davis, Christopher; Mee, Christopher J.; Turek, Marine; Gorke, Sebastian; Royer, Cathy; Fischer, Benoit; Zahid, Muhammad N.; Lavillette, Dimitri; Fresquet, Judith; Cosset, Francois-Loic; Rothenberg, S. Michael; Pietschmann, Thomas; Patel, Arvind H.; Pessaux, Patrick; Doffoel, Michel; Raffelsberger, Wolfgang; Poch, Olivier; McKeating, Jane A.; Brino, Laurent; Baumert, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">589-595</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a major cause of liver disease, but therapeutic options are limited and there are no prevention strategies.  Viral entry is the first step of infection and requires the cooperative interaction of several host cell factors.  Using a functional RNAi kinase screen, we identified epidermal growth factor receptor and ephrin receptor A2 as host cofactors for HCV entry.  Blocking receptor kinase activity by approved inhibitors broadly impaired infection by all major HCV genotypes and viral escape variants in cell culture and in a human liver chimeric mouse model in vivo.  The identified receptor tyrosine kinases (RTKs) mediate HCV entry by regulating CD81-claudin-1 co-receptor assocns. and viral glycoprotein-dependent membrane fusion.  These results identify RTKs as previously unknown HCV entry cofactors and show that tyrosine kinase inhibitors have substantial antiviral activity.  Inhibition of RTK function may constitute a new approach for prevention and treatment of HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPNZcMOXBl57Vg90H21EOLACvtfcHk0liNzTK02s9Rsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFyqtL4%253D&md5=9a772f9cb03077335c7e7f5918a6e1ef</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1038%2Fnm.2341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2341%26sid%3Dliteratum%253Aachs%26aulast%3DLupberger%26aufirst%3DJ.%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DThumann%26aufirst%3DC.%26aulast%3DFofana%26aufirst%3DI.%26aulast%3DZona%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DC.%26aulast%3DMee%26aufirst%3DC.%2BJ.%26aulast%3DTurek%26aufirst%3DM.%26aulast%3DGorke%26aufirst%3DS.%26aulast%3DRoyer%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DZahid%26aufirst%3DM.%2BN.%26aulast%3DLavillette%26aufirst%3DD.%26aulast%3DFresquet%26aufirst%3DJ.%26aulast%3DCosset%26aufirst%3DF.%2BL.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DA.%2BH.%26aulast%3DPessaux%26aufirst%3DP.%26aulast%3DDoffo%25C3%25ABl%26aufirst%3DM.%26aulast%3DRaffelsberger%26aufirst%3DW.%26aulast%3DPoch%26aufirst%3DO.%26aulast%3DMcKeating%26aufirst%3DJ.%2BA.%26aulast%3DBrino%26aufirst%3DL.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26atitle%3DEGFR%2520and%2520EphA2%2520are%2520host%2520factors%2520for%2520hepatitis%2520C%2520virus%2520entry%2520and%2520possible%2520targets%2520for%2520antiviral%2520therapy%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D589%26epage%3D595%26doi%3D10.1038%2Fnm.2341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueki, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min-Oo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballon-Landa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanier, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koff, J. L.</span></span> <span> </span><span class="NLM_article-title">Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon l and antiviral defense in airway epithelium</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">1929</span>â <span class="NLM_lpage">1936</span>, <span class="refDoi">Â DOI: 10.1084/jem.20121401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1084%2Fjem.20121401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=23999497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFelsLvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2013&pages=1929-1936&author=I.+F.+Uekiauthor=G.+Min-Ooauthor=A.+Kalinowskiauthor=E.+Ballon-Landaauthor=L.+L.+Lanierauthor=J.+A.+Nadelauthor=J.+L.+Koff&title=Respiratory+virus-induced+EGFR+activation+suppresses+IRF1-dependent+interferon+l+and+antiviral+defense+in+airway+epithelium&doi=10.1084%2Fjem.20121401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon Î» and antiviral defense in airway epithelium</span></div><div class="casAuthors">Ueki, Iris F.; Min-Oo, Gundula; Kalinowski, April; Ballon-Landa, Eric; Lanier, Lewis L.; Nadel, Jay A.; Koff, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1929-1936</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Viruses suppress host responses to increase infection, and understanding these mechanisms has provided insights into cellular signaling and led to novel therapies.  Many viruses (e.g., influenza virus, Rhinovirus [RV], Cytomegalovirus, Epstein-Barr virus, and Hepatitis C virus) activate epithelial epidermal growth factor receptor (EGFR), a tyrosine kinase receptor, but the role of EGFR in viral pathogenesis is not clear.  Interferon (IFN) signaling is a crit. innate antiviral host response and recent expts. have implicated IFN-Î», a type III IFN, as the most significant IFN for mucosal antiviral immune responses.  Despite the importance of IFN-Î» in epithelial antiviral responses, the role and mechanisms of epithelial IFN-Î» signaling have not been fully elucidated.  We report that respiratory virus-induced EGFR activation suppresses endogenous airway epithelial antiviral signaling.  We found that Influenza virus- and RV-induced EGFR activation suppressed IFN regulatory factor (IRF) 1-induced IFN-Î» prodn. and increased viral infection.  In addn., inhibition of EGFR during viral infection augmented IRF1 and IFN-Î», which resulted in decreased viral titers in vitro and in vivo.  These findings describe a novel mechanism that viruses use to suppress endogenous antiviral defenses, and provide potential targets for future therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2xVzMrOcUv7Vg90H21EOLACvtfcHk0liNzTK02s9Rsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFelsLvM&md5=121a4a1514a53f104045e6516447e860</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1084%2Fjem.20121401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20121401%26sid%3Dliteratum%253Aachs%26aulast%3DUeki%26aufirst%3DI.%2BF.%26aulast%3DMin-Oo%26aufirst%3DG.%26aulast%3DKalinowski%26aufirst%3DA.%26aulast%3DBallon-Landa%26aufirst%3DE.%26aulast%3DLanier%26aufirst%3DL.%2BL.%26aulast%3DNadel%26aufirst%3DJ.%2BA.%26aulast%3DKoff%26aufirst%3DJ.%2BL.%26atitle%3DRespiratory%2520virus-induced%2520EGFR%2520activation%2520suppresses%2520IRF1-dependent%2520interferon%2520l%2520and%2520antiviral%2520defense%2520in%2520airway%2520epithelium%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2013%26volume%3D210%26spage%3D1929%26epage%3D1936%26doi%3D10.1084%2Fjem.20121401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorshkov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straus, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp-Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, G. R.</span></span> <span> </span><span class="NLM_article-title">Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1165</span>â <span class="NLM_lpage">1175</span>, <span class="refDoi">Â DOI: 10.1021/acsptsci.0c00112</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.0c00112" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVyku7jP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2020&pages=1165-1175&author=C.+Z.+Chenauthor=M.+Xuauthor=M.+Pradhanauthor=K.+Gorshkovauthor=J.+Petersenauthor=M.+R.+Strausauthor=W.+Zhuauthor=P.+Shinnauthor=H.+Guoauthor=M.+Shenauthor=C.+Klumpp-Thomasauthor=S.+G.+Michaelauthor=J.+Zimmerbergauthor=W.+Zhengauthor=G.+R.+Whittaker&title=Identifying+SARS-CoV-2+entry+inhibitors+through+drug+repurposing+screens+of+SARS-S+and+MERS-S+pseudotyped+particles&doi=10.1021%2Facsptsci.0c00112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles</span></div><div class="casAuthors">Chen, Catherine Z.; Xu, Miao; Pradhan, Manisha; Gorshkov, Kirill; Petersen, Jennifer D.; Straus, Marco R.; Zhu, Wei; Shinn, Paul; Guo, Hui; Shen, Min; Klumpp-Thomas, Carleen; Michael, Samuel G.; Zimmerberg, Joshua; Zheng, Wei; Whittaker, Gary R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1165-1175</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  While vaccine development will hopefully quell the global pandemic of COVID-19 caused by SARS-CoV-2, small mol. drugs that can effectively control SARS-CoV-2 infection are urgently needed.  Here, inhibitors of spike (S) mediated cell entry were identified in a high throughput screen of an approved drugs library with SARS-S and MERS-S pseudotyped particle entry assays.  We discovered six compds. (cepharanthine, abemaciclib, osimertinib, trimipramine, colforsin, and ingenol) to be broad spectrum inhibitors for spike-mediated entry.  This work could contribute to the development of effective treatments against the initial stage of viral infection, and provide mechanistic information that might aid the design of new drug combinations for clin. trials for COVID-19 patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5vCnAKlZLlLVg90H21EOLACvtfcHk0lg2P_RPiGxprQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVyku7jP&md5=86127d0e425488f7621ba547f2606c56</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.0c00112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.0c00112%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BZ.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DPradhan%26aufirst%3DM.%26aulast%3DGorshkov%26aufirst%3DK.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DStraus%26aufirst%3DM.%2BR.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DShinn%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DKlumpp-Thomas%26aufirst%3DC.%26aulast%3DMichael%26aufirst%3DS.%2BG.%26aulast%3DZimmerberg%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DWhittaker%26aufirst%3DG.%2BR.%26atitle%3DIdentifying%2520SARS-CoV-2%2520entry%2520inhibitors%2520through%2520drug%2520repurposing%2520screens%2520of%2520SARS-S%2520and%2520MERS-S%2520pseudotyped%2520particles%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2020%26volume%3D3%26spage%3D1165%26epage%3D1175%26doi%3D10.1021%2Facsptsci.0c00112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheema, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saggese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span> <span> </span><span class="NLM_article-title">Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">41</span>â <span class="NLM_lpage">50</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1913662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1056%2FNEJMoa1913662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31751012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFGgtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=41-50&author=S.+S.+Ramalingamauthor=J.+Vansteenkisteauthor=D.+Planchardauthor=B.+C.+Choauthor=J.+E.+Grayauthor=Y.+Oheauthor=C.+Zhouauthor=T.+Reungwetwattanaauthor=Y.+Chengauthor=B.+Chewaskulyongauthor=R.+Shahauthor=M.+Coboauthor=K.+H.+Leeauthor=P.+Cheemaauthor=M.+Tiseoauthor=T.+Johnauthor=M.-C.+Linauthor=F.+Imamuraauthor=T.+Kurataauthor=A.+Toddauthor=R.+Hodgeauthor=M.+Saggeseauthor=Y.+Rukazenkovauthor=J.-C.+Soria&title=Overall+survival+with+osimertinib+in+untreated%2C+EGFR-mutated+advanced+NSCLC&doi=10.1056%2FNEJMoa1913662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC</span></div><div class="casAuthors">Ramalingam, S. S.; Vansteenkiste, J.; Planchard, D.; Cho, B. C.; Gray, J. E.; Ohe, Y.; Zhou, C.; Reungwetwattana, T.; Cheng, Y.; Chewaskulyong, B.; Shah, R.; Cobo, M.; Lee, K. H.; Cheema, P.; Tiseo, M.; John, T.; Lin, M.-C.; Imamura, F.; Kurata, T.; Todd, A.; Hodge, R.; Saggese, M.; Rukazenkov, Y.; Soria, J.-C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI- sensitizing and EGFR T790M resistance mutations.  A phase 3 trial compared firstline osimertinib with other EGFR-TKIs in patients with EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  The trial showed longer progressionfree survival with osimertinib than with the comparator EGFR-TKIs (hazard ratio for disease progression or death, 0.46).  Data from the final anal. of overall survival have not been reported. methods In this trial, we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation (exon 19 deletion or L858R allele) in a 1:1 ratio to receive either osimertinib (80 mg once daily) or one of two other EGFR-TKIs (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily, with patients receiving these drugs combined in a single comparator group).  Overall survival was a secondary end point. results The median overall survival was 38.6 mo (95% confidence interval [CI], 34.5 to 41.8) in the osimertinib group and 31.8 mo (95% CI, 26.6 to 36.0) in the comparator group (hazard ratio for death, 0.80; 95.05% CI, 0.64 to 1.00; P = 0.046).  At 3 years, 79 of 279 patients (28%) in the osimertinib group and 26 of 277 (9%) in the comparator group were continuing to receive a trial regimen; the median exposure was 20.7 mo and 11.5 mo, resp.  Adverse events of grade 3 or higher were reported in 42% of the patients in the osimertinib group and in 47% of those in the comparator group. conclusions Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI.  The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq081UIt-O5nrVg90H21EOLACvtfcHk0lg2P_RPiGxprQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFGgtL4%253D&md5=2f78a87d4578be09e07e91f303b71acf</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1913662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1913662%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DCobo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DCheema%26aufirst%3DP.%26aulast%3DTiseo%26aufirst%3DM.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DM.-C.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DTodd%26aufirst%3DA.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DSaggese%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DSoria%26aufirst%3DJ.-C.%26atitle%3DOverall%2520survival%2520with%2520osimertinib%2520in%2520untreated%252C%2520EGFR-mutated%2520advanced%2520NSCLC%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D41%26epage%3D50%26doi%3D10.1056%2FNEJMoa1913662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojkova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tascher, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼nch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinatl, J.</span></span> <span> </span><span class="NLM_article-title">Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">164</span>â <span class="NLM_lpage">174</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2020.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.molcel.2020.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32877642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslCksLzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=164-174&author=K.+Klannauthor=D.+Bojkovaauthor=G.+Tascherauthor=S.+Ciesekauthor=C.+M%C3%BCnchauthor=J.+Cinatl&title=Growth+factor+receptor+signaling+inhibition+prevents+SARS-CoV-2+replication&doi=10.1016%2Fj.molcel.2020.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication</span></div><div class="casAuthors">Klann, Kevin; Bojkova, Denisa; Tascher, Georg; Ciesek, Sandra; Muench, Christian; Cinatl, Jindrich</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">164-174.e4</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">SARS-CoV-2 infections are rapidly spreading around the globe.  The rapid development of therapies is of major importance.  However, our lack of understanding of the mol. processes and host cell signaling events underlying SARS-CoV-2 infection hinders therapy development.  We use a SARS-CoV-2 infection system in permissible human cells to study signaling changes by phosphoproteomics.  We identify viral protein phosphorylation and define phosphorylation-driven host cell signaling changes upon infection.  Growth factor receptor (GFR) signaling and downstream pathways are activated.  Drug-protein network analyses revealed GFR signaling as key pathways targetable by approved drugs.  The inhibition of GFR downstream signaling by five compds. prevents SARS-CoV-2 replication in cells, assessed by cytopathic effect, viral dsRNA prodn., and viral RNA release into the supernatant.  This study describes host cell signaling events upon SARS-CoV-2 infection and reveals GFR signaling as a central pathway essential for SARS-CoV-2 replication.  It provides novel strategies for COVID-19 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2wJyMwGpdVLVg90H21EOLACvtfcHk0liQJPGaEscj2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslCksLzL&md5=feace92d14e24a5a7d59d3ac3ff94764</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2020.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2020.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DKlann%26aufirst%3DK.%26aulast%3DBojkova%26aufirst%3DD.%26aulast%3DTascher%26aufirst%3DG.%26aulast%3DCiesek%26aufirst%3DS.%26aulast%3DM%25C3%25BCnch%26aufirst%3DC.%26aulast%3DCinatl%26aufirst%3DJ.%26atitle%3DGrowth%2520factor%2520receptor%2520signaling%2520inhibition%2520prevents%2520SARS-CoV-2%2520replication%26jtitle%3DMol.%2520Cell%26date%3D2020%26volume%3D80%26spage%3D164%26epage%3D174%26doi%3D10.1016%2Fj.molcel.2020.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drosten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. A.</span></span> <span> </span><span class="NLM_article-title">Plaque assay for human coronavirus NL63 using human colon carcinoma cells</span>. <i>Virol. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">138</span>, <span class="refDoi">Â DOI: 10.1186/1743-422X-5-138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2F1743-422X-5-138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=19014487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FitFKjsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=138&author=P.+Herzogauthor=C.+Drostenauthor=M.+A.+Muller&title=Plaque+assay+for+human+coronavirus+NL63+using+human+colon+carcinoma+cells&doi=10.1186%2F1743-422X-5-138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Plaque assay for human coronavirus NL63 using human colon carcinoma cells</span></div><div class="casAuthors">Herzog Petra; Drosten Christian; Muller Marcel A</div><div class="citationInfo"><span class="NLM_cas:title">Virology journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Coronaviruses cause a broad range of diseases in animals and humans.  Human coronavirus (hCoV) NL63 is associated with up to 10% of common colds.  Viral plaque assays enable the characterization of virus infectivity and allow for purifying virus stock solutions.  They are essential for drug screening.  Hitherto used cell cultures for hCoV-NL63 show low levels of virus replication and weak and diffuse cytopathogenic effects.  It has not yet been possible to establish practicable plaque assays for this important human pathogen.  RESULTS:  12 different cell cultures were tested for susceptibility to hCoV-NL63 infection.  Human colon carcinoma cells (CaCo-2) replicated virus more than 100 fold more efficiently than commonly used African green monkey kidney cells (LLC-MK2).  CaCo-2 cells showed cytopathogenic effects 4 days post infection.  Avicel, agarose and carboxymethyl-cellulose overlays proved suitable for plaque assays.  Best results were achieved with Avicel, which produced large and clear plaques from the 4th day of infection.  The utility of plaque assays with agrose overlay was demonstrated for purifying virus, thereby increasing viral infectivity by 1 log 10 PFU/mL.  CONCLUSION:  CaCo-2 cells support hCoV-NL63 better than LLC-MK2 cells and enable cytopathogenic plaque assays.  Avicel overlay is favourable for plaque quantification, and agarose overlay is preferred for plaque purification.  HCoV-NL63 virus stock of increased infectivity will be beneficial in antiviral screening, animal modelling of disease, and other experimental tasks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtLhsJjctkv4NpW7w2tapOfW6udTcc2eZNA-Wr8NhzQLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FitFKjsg%253D%253D&md5=bdcda2504293381228c18c2fd9deb6f2</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1186%2F1743-422X-5-138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1743-422X-5-138%26sid%3Dliteratum%253Aachs%26aulast%3DHerzog%26aufirst%3DP.%26aulast%3DDrosten%26aufirst%3DC.%26aulast%3DMuller%26aufirst%3DM.%2BA.%26atitle%3DPlaque%2520assay%2520for%2520human%2520coronavirus%2520NL63%2520using%2520human%2520colon%2520carcinoma%2520cells%26jtitle%3DVirol.%2520J.%26date%3D2008%26volume%3D5%26spage%3D138%26doi%3D10.1186%2F1743-422X-5-138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glende, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Falah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwegmann-Wessels, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschernig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naim, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrler, G.</span></span> <span> </span><span class="NLM_article-title">Analysis of ACE2 in polarized epithelial cells: Surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1691</span>â <span class="NLM_lpage">1695</span>, <span class="refDoi">Â DOI: 10.1099/vir.0.81749-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1099%2Fvir.0.81749-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16690935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFCis78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2006&pages=1691-1695&author=X.+Renauthor=J.+Glendeauthor=M.+Al-Falahauthor=V.+de+Vriesauthor=C.+Schwegmann-Wesselsauthor=X.+Quauthor=L.+Tanauthor=T.+Tschernigauthor=H.+Dengauthor=H.+Y.+Naimauthor=G.+Herrler&title=Analysis+of+ACE2+in+polarized+epithelial+cells%3A+Surface+expression+and+function+as+receptor+for+severe+acute+respiratory+syndrome-associated+coronavirus&doi=10.1099%2Fvir.0.81749-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus</span></div><div class="casAuthors">Ren, Xiaofeng; Glende, Joerg; Al-Falah, Marwan; de Vries, Victor; Schwegmann-Wessels, Christel; Qu, Xiuxia; Tan, Lei; Tschernig, Thomas; Deng, Hongkui; Naim, Hassan Y.; Herrler, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1691-1695</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">The primary target of severe acute respiratory syndrome-assocd. coronavirus (SARS-CoV) is epithelial cells in the respiratory and intestinal tract.  The cellular receptor for SARS-CoV, angiotensin-converting enzyme 2 (ACE2), has been shown to be localized on the apical plasma membrane of polarized respiratory epithelial cells and to mediate infection from the apical side of these cells.  Here, these results were confirmed and extended by including a colon carcinoma cell line (Caco-2), a lung carcinoma cell line (Calu-3) and Vero E6 cells in our anal.  All three cell types expressed human ACE2 on the apical membrane domain and were infected via this route, as detd. with vesicular stomatitis virus pseudotypes contg. the S protein of SARS-CoV.  In a histol. anal. of the respiratory tract, ACE2 was detected in the trachea, main bronchus and alveoli, and occasionally also in the small bronchi.  These data will help us to understand the pathogenesis of SARS-CoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeflvctPoBUbVg90H21EOLACvtfcHk0lgcVfGIFsjnNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFCis78%253D&md5=38d7e70be96971a22d5ee2ae430d05fa</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.81749-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.81749-0%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGlende%26aufirst%3DJ.%26aulast%3DAl-Falah%26aufirst%3DM.%26aulast%3Dde%2BVries%26aufirst%3DV.%26aulast%3DSchwegmann-Wessels%26aufirst%3DC.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DTschernig%26aufirst%3DT.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DNaim%26aufirst%3DH.%2BY.%26aulast%3DHerrler%26aufirst%3DG.%26atitle%3DAnalysis%2520of%2520ACE2%2520in%2520polarized%2520epithelial%2520cells%253A%2520Surface%2520expression%2520and%2520function%2520as%2520receptor%2520for%2520severe%2520acute%2520respiratory%2520syndrome-associated%2520coronavirus%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2006%26volume%3D87%26spage%3D1691%26epage%3D1695%26doi%3D10.1099%2Fvir.0.81749-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eskens, F. A. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, M. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luyten, G. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faber, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statkevich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparreboom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanauske, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart, M.</span></span> <span> </span><span class="NLM_article-title">European organization for research and treatment of cancer early clinical studies group Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1167</span>â <span class="NLM_lpage">1175</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2001.19.4.1167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1200%2FJCO.2001.19.4.1167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11181683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhvFertrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=1167-1175&author=F.+A.+L.+M.+Eskensauthor=A.+Awadaauthor=D.+L.+Cutlerauthor=M.+J.+A.+de+Jongeauthor=G.+P.+M.+Luytenauthor=M.+N.+Faberauthor=P.+Statkevichauthor=A.+Sparreboomauthor=J.+Verweijauthor=A.+R.+Hanauskeauthor=M.+Piccart&title=European+organization+for+research+and+treatment+of+cancer+early+clinical+studies+group+Phase+I+and+pharmacokinetic+study+of+the+oral+farnesyl+transferase+inhibitor+SCH+66336+given+twice+daily+to+patients+with+advanced+solid+tumors&doi=10.1200%2FJCO.2001.19.4.1167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors</span></div><div class="casAuthors">Eskens, Ferry A. L. M.; Awada, Ahmad; Cutler, David L.; de Jonge, Maja J. A.; Luyten, Gre P. M.; Faber, Marije N.; Statkevich, Paul; Sparreboom, Alex; Verweij, Jaap; Hanauske, Axel-R.; Piccart, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1167-1175</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A single-agent dose-escalating phase I and pharmacokinetic study on the farnesyl transferase inhibitor SCH 66336 was performed to det. the safety profile, max.-tolerated dose, and recommended dose for phase II studies.  Plasma and urine pharmacokinetics were detd.  SCH 66336 was given orally bid without interruption to patients with histol. or cytol. confirmed solid tumors.  Routine antiemetics were not prescribed.  Twenty-four patients were enrolled onto the study.  Dose levels studied were 25, 50, 100, 200, 400, and 300 mg bid.  Pharmacokinetic sampling was performed on days 1 and 15.  At 400 mg bid, the dose-limiting toxicity (DLT) consisted of grade 4 vomiting, grade 4 neutropenia and thrombocytopenia, and the combination of grade 3 anorexia and diarrhea with reversible grade 3 plasma creatinine elevation.  After dose redn., at 300 mg bid, the DLTs consisted of grade 4 neutropenia, grade 3 neurocortical toxicity, and the combination of grade 3 fatigue with grade 2 nausea and diarrhea.  The recommended dose for phase II studies is 200 mg bid, which was found feasible for prolonged periods of time.  Pharmacokinetic anal. showed a greater than dose-proportional increase in drug exposure and peak plasma concns., with increased parameters at day 15 compared with day 1, indicating some accumulation on multiple dosing.  Plasma half-life ranged from 4 to 11 h and seemed to increase with increasing doses.  Steady-state plasma concns. were attained at days 7 through 14.  A large vol. of distribution at steady-state indicated extensive distribution outside the plasma compartment.  SCH 66336 can be administered safely using a continuous oral bid dosing regimen.  The recommended dose for phase II studies using this regimen is 200 mg bid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojqQZvEp_iBLVg90H21EOLACvtfcHk0lgmem_QPAizqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhvFertrg%253D&md5=3e0ff6d44b83485cac58467afe0687de</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1200%2FJCO.2001.19.4.1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2001.19.4.1167%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26aulast%3DAwada%26aufirst%3DA.%26aulast%3DCutler%26aufirst%3DD.%2BL.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BJ.%2BA.%26aulast%3DLuyten%26aufirst%3DG.%2BP.%2BM.%26aulast%3DFaber%26aufirst%3DM.%2BN.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DSparreboom%26aufirst%3DA.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DHanauske%26aufirst%3DA.%2BR.%26aulast%3DPiccart%26aufirst%3DM.%26atitle%3DEuropean%2520organization%2520for%2520research%2520and%2520treatment%2520of%2520cancer%2520early%2520clinical%2520studies%2520group%2520Phase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520the%2520oral%2520farnesyl%2520transferase%2520inhibitor%2520SCH%252066336%2520given%2520twice%2520daily%2520to%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2001%26volume%3D19%26spage%3D1167%26epage%3D1175%26doi%3D10.1200%2FJCO.2001.19.4.1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fucile, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marenco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazzica, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccoli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbiano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Gion, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stura, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savarino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattioli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picciotto, A.</span></span> <span> </span><span class="NLM_article-title">Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: Is it useful the application in clinical practice? A pilot study</span>. <i>Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">335</span>, <span class="refDoi">Â DOI: 10.1007/s12032-014-0335-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs12032-014-0335-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25429830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC2MzhtlyntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=335&author=C.+Fucileauthor=S.+Marencoauthor=M.+Bazzicaauthor=M.+L.+Zuccoliauthor=F.+Lantieriauthor=L.+Robbianoauthor=V.+Mariniauthor=P.+Di+Gionauthor=G.+Pieriauthor=P.+Sturaauthor=A.+Martelliauthor=V.+Savarinoauthor=F.+Mattioliauthor=A.+Picciotto&title=Measurement+of+sorafenib+plasma+concentration+by+high-performance+liquid+chromatography+in+patients+with+advanced+hepatocellular+carcinoma%3A+Is+it+useful+the+application+in+clinical+practice%3F+A+pilot+study&doi=10.1007%2Fs12032-014-0335-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study</span></div><div class="casAuthors">Fucile Carmen; Marenco Simona; Bazzica Marco; Zuccoli Maria Laura; Lantieri Francesca; Robbiano Luigi; Marini Valeria; Di Gion Paola; Pieri Giulia; Stura Paola; Martelli Antonietta; Savarino Vincenzo; Mattioli Francesca; Picciotto Antonino</div><div class="citationInfo"><span class="NLM_cas:title">Medical oncology (Northwood, London, England)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">335</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pharmacokinetics and dose-finding studies on sorafenib were conducted on heterogeneous groups of patients with solid tumors.  Portal hypertension, gut motility impairment and altered bile enterohepatic circulation may explain different sorafenib toxicological profile in cirrhotic patients.  This study evaluated sorafenib plasma concentration in a homogeneous group of cirrhotic patients with hepatocellular carcinoma (HCC).  Sorafenib concentrations were determined by liquid chromatography in 12 consecutive patients.  Data have been evaluated by the generalized estimating equations method (p value statistical level was set at Î± = 0.05). (1) There were not significant differences between sorafenib concentrations in patients who tolerate the full dose versus patients with reduced dose due to toxicity; (2) the average sorafenib concentrations measured 3 h after the morning dosing were lower than those measured 12 h after the evening dosing (p = 0.005); (3) sorafenib concentrations decrease overtime (p < 10(-4)); (4) it has been found an association between the development of severe adverse reactions and sorafenib concentrations (p < 10(-5)).  The relationship between dose and concentration of sorafenib in HCC patients is poor and not clinically predictable, confirming the variability both in the maximum tolerated dose and in plasma concentrations.  Several factors may influence the pharmacokinetics in patients with liver disease.  This may explain the inter-patient variability of concentrations and the lack of differences in concentration at different dosages.  It could be interesting to extend the series of HCC patients to enhance information on the kinetics of the drug; furthermore, to establish a threshold of plasma sorafenib concentrations to predict severe adverse reactions would be clinically useful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTduceYDnsZa2yYR5VtavbzfW6udTcc2eYIBcdKM2J_m7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzhtlyntA%253D%253D&md5=f7460e44778e69d7ba0ead39d70f8f30</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1007%2Fs12032-014-0335-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-014-0335-7%26sid%3Dliteratum%253Aachs%26aulast%3DFucile%26aufirst%3DC.%26aulast%3DMarenco%26aufirst%3DS.%26aulast%3DBazzica%26aufirst%3DM.%26aulast%3DZuccoli%26aufirst%3DM.%2BL.%26aulast%3DLantieri%26aufirst%3DF.%26aulast%3DRobbiano%26aufirst%3DL.%26aulast%3DMarini%26aufirst%3DV.%26aulast%3DDi%2BGion%26aufirst%3DP.%26aulast%3DPieri%26aufirst%3DG.%26aulast%3DStura%26aufirst%3DP.%26aulast%3DMartelli%26aufirst%3DA.%26aulast%3DSavarino%26aufirst%3DV.%26aulast%3DMattioli%26aufirst%3DF.%26aulast%3DPicciotto%26aufirst%3DA.%26atitle%3DMeasurement%2520of%2520sorafenib%2520plasma%2520concentration%2520by%2520high-performance%2520liquid%2520chromatography%2520in%2520patients%2520with%2520advanced%2520hepatocellular%2520carcinoma%253A%2520Is%2520it%2520useful%2520the%2520application%2520in%2520clinical%2520practice%253F%2520A%2520pilot%2520study%26jtitle%3DMed.%2520Oncol.%26date%3D2015%26volume%3D32%26spage%3D335%26doi%3D10.1007%2Fs12032-014-0335-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albanell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahleda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraeber-BodÃ©rÃ©, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guarin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessier, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shochat, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blotner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naegelen, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">First-in human, Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4806</span>â <span class="NLM_lpage">4819</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-12-0742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F1078-0432.CCR-12-0742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22761467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygsbzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4806-4819&author=M.+Martinez-Garciaauthor=U.+Banerjiauthor=J.+Albanellauthor=R.+Bahledaauthor=S.+Dollyauthor=F.+Kraeber-Bod%C3%A9r%C3%A9author=F.+Rojoauthor=E.+Routierauthor=E.+Guarinauthor=Z.+X.+Xuauthor=R.+Ruegerauthor=J.+J.+Tessierauthor=E.+Shochatauthor=S.+Blotnerauthor=V.+M.+Naegelenauthor=J.+C.+Soria&title=First-in+human%2C+Phase+I+dose-escalation+study+of+the+safety%2C+pharmacokinetics%2C+and+pharmacodynamics+of+RO5126766%2C+a+first-in-class+dual+MEK%2FRAF+inhibitor+in+patients+with+solid+tumors&doi=10.1158%2F1078-0432.CCR-12-0742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors</span></div><div class="casAuthors">Martinez-Garcia, Maria; Banerji, Udai; Albanell, Joan; Bahleda, Rastilav; Dolly, Saoirse; Kraeber-Bodere, Francoise; Rojo, Federico; Routier, Emilie; Guarin, Ernesto; Xu, Zhi-Xin; Rueger, Ruediger; Tessier, Jean J. L.; Shochat, Eliezer; Blotner, Steve; Naegelen, Valerie Meresse; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4806-4819</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This phase I study assessed the max. tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetics, pharmacodynamics, and clin. activity of the first-in-class dual MEK/RAF inhibitor, RO5126766.  Exptl. Design: Initial dose-escalation was conducted using once daily dosing over 28 consecutive days in 4-wk cycles.  Further escalation was completed using 2 intermittent dosing schedules [7 days on treatment followed by 7 days off (7on/7off); 4 days on treatment followed by 3 days off (4on/3off)].  Results: Fifty-two patients received RO5126766 at doses of 0.1 to 2.7 mg once daily, 2.7 to 4.0 mg (4 on/3 off), or 2.7 to 5.0 mg (7 on/7 off).  The most common DLTs were elevated creatine phosphokinase (CPK) and blurred vision.  The MTD for each dosing schedule was 2.25 mg once daily, 4.0 mg (4 on/3 off), and 2.7 mg (7 on/7 off).  The dose/schedule recommended for phase II (RP2D) investigation was 2.7 mg (4 on/3 off).  Frequent adverse events included rash-related disorders (94.2%), elevated CPK (55.8%), and diarrhea (51.9%).  Cmax occurred 1 to 2 h after dosing and mean terminal half-life was approx. 60 h.  Pharmacodynamic changes included reduced ERK phosphorylation, an increase in apoptosis in tumor tissue, and a redn. in fluorodeoxyglucose (FDG) uptake after 15 days of dosing.  Three partial responses were seen: two in BRAF-mutant melanoma tumors and one in an NRAS-mutant melanoma.  Conclusion: This first-in-human study shows that oral RO5126766 has manageable toxicity, a favorable pharmacokinetic/pharmacodynamic profile, and encouraging preliminary antitumor activity in this population of heavily pretreated patients, achieving tumor shrinkage in around 40% of patients across all dose levels and all tumor types.  Clin Cancer Res; 18(17); 4806-19. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0WJz0TYB2kbVg90H21EOLACvtfcHk0lgE2zwX_fz6iA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygsbzN&md5=8652ed9c0dba880907ef4125da44eb24</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0742%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Garcia%26aufirst%3DM.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DAlbanell%26aufirst%3DJ.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DDolly%26aufirst%3DS.%26aulast%3DKraeber-Bod%25C3%25A9r%25C3%25A9%26aufirst%3DF.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DRoutier%26aufirst%3DE.%26aulast%3DGuarin%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DZ.%2BX.%26aulast%3DRueger%26aufirst%3DR.%26aulast%3DTessier%26aufirst%3DJ.%2BJ.%26aulast%3DShochat%26aufirst%3DE.%26aulast%3DBlotner%26aufirst%3DS.%26aulast%3DNaegelen%26aufirst%3DV.%2BM.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DFirst-in%2520human%252C%2520Phase%2520I%2520dose-escalation%2520study%2520of%2520the%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520RO5126766%252C%2520a%2520first-in-class%2520dual%2520MEK%252FRAF%2520inhibitor%2520in%2520patients%2520with%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4806%26epage%3D4819%26doi%3D10.1158%2F1078-0432.CCR-12-0742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Noll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Specht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witteveen, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dees, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleha, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampkin, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span> <span> </span><span class="NLM_article-title">First-in-human Phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1932</span>â <span class="NLM_lpage">1939</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-15-1665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F1078-0432.CCR-15-1665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26603258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsFeqsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1932-1939&author=P.+Munsterauthor=R.+Aggarwalauthor=D.+Hongauthor=J.+H.+Schellensauthor=R.+van+der+Nollauthor=J.+Spechtauthor=P.+O.+Witteveenauthor=T.+L.+Wernerauthor=E.+C.+Deesauthor=E.+Bergslandauthor=N.+Agarwalauthor=J.+F.+Klehaauthor=M.+Duranteauthor=L.+Adamsauthor=D.+A.+Smithauthor=T.+A.+Lampkinauthor=S.+R.+Morrisauthor=R.+Kurzrock&title=First-in-human+Phase+I+study+of+GSK2126458%2C+an+oral+pan-class+I+phosphatidylinositol-3-kinase+inhibitor%2C+in+patients+with+advanced+solid+tumor+malignancies&doi=10.1158%2F1078-0432.CCR-15-1665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies</span></div><div class="casAuthors">Munster, Pamela; Aggarwal, Rahul; Hong, David; Schellens, Jan H. M.; van der Noll, Ruud; Specht, Jennifer; Witteveen, Petronella O.; Werner, Theresa L.; Dees, E. Claire; Bergsland, Emily; Agarwal, Neeraj; Kleha, Joseph F.; Durante, Michael; Adams, Laurel; Smith, Deborah A.; Lampkin, Thomas A.; Morris, Shannon R.; Kurzrock, Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1932-1939</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GSK2126458 (GSK458) is a potent inhibitor of PI3K (Î±, Î², Î³, and Î´), with preclin. studies demonstrating broad antitumor activity.  We performed a first-in-human phase I study in patients with advanced solid tumors.  Patients received oral GSK458 once or twice daily in a dose-escalation design to define the max. tolerated dose (MTD).  Expansion cohorts evaluated pharmacodynamics, pharmacokinetics, and clin. activity in histol. and molecularly defined cohorts.  One hundred and seventy patients received doses ranging from 0.1 to 3 mg once or twice daily.  Dose-limiting toxicities (grade 3 diarrhea, n = 4; fatigue and rash, n = 1) occurred in 5 patients (n = 3 at 3 mg/day).  The MTD was 2.5 mg/day (MTD with twice daily dosing undefined).  The most common grade â¥3 treatment-related adverse events included diarrhea (8%) and skin rash (5%).  Pharmacokinetic analyses demonstrated increased duration of drug exposure above target level with twice daily dosing.  Fasting insulin and glucose levels increased with dose and exposure of GSK458.  Durable objective responses (ORs) were obsd. across multiple tumor types (sarcoma, kidney, breast, endometrial, oropharyngeal, and bladder cancer).  Responses were not assocd. with PIK3CA mutations (OR rate: 5% wild-type vs. 6% mutant).  Although the MTD of GSK458 was 2.5 mg once daily, twice-daily dosing may increase duration of target inhibition.  Fasting insulin and glucose levels served as pharmacodynamic markers of drug exposure.  Select patients achieved durable responses; however, PIK3CA mutations were neither necessary nor predictive of response.  Combination treatment strategies and novel biomarkers may be needed to optimally target PI3K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5IMnYsnpPVLVg90H21EOLACvtfcHk0lgE2zwX_fz6iA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsFeqsLs%253D&md5=3306a5e6586e8865bea5ef70aadf68d6</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1665%26sid%3Dliteratum%253Aachs%26aulast%3DMunster%26aufirst%3DP.%26aulast%3DAggarwal%26aufirst%3DR.%26aulast%3DHong%26aufirst%3DD.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3Dvan%2Bder%2BNoll%26aufirst%3DR.%26aulast%3DSpecht%26aufirst%3DJ.%26aulast%3DWitteveen%26aufirst%3DP.%2BO.%26aulast%3DWerner%26aufirst%3DT.%2BL.%26aulast%3DDees%26aufirst%3DE.%2BC.%26aulast%3DBergsland%26aufirst%3DE.%26aulast%3DAgarwal%26aufirst%3DN.%26aulast%3DKleha%26aufirst%3DJ.%2BF.%26aulast%3DDurante%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DLampkin%26aufirst%3DT.%2BA.%26aulast%3DMorris%26aufirst%3DS.%2BR.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DFirst-in-human%2520Phase%2520I%2520study%2520of%2520GSK2126458%252C%2520an%2520oral%2520pan-class%2520I%2520phosphatidylinositol-3-kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumor%2520malignancies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D1932%26epage%3D1939%26doi%3D10.1158%2F1078-0432.CCR-15-1665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Riverol, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csordas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal-Llinares, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewapathirana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inuganti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenacher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uszkoreit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeuffer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yilmaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarnuczak, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ternent, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brazma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VizcaÃ­no, J. A.</span></span> <span> </span><span class="NLM_article-title">The PRIDE database and related tools and resources in 2019: Improving support for quantification data</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">D442</span>â <span class="NLM_lpage">D450</span>, <span class="refDoi">Â DOI: 10.1093/nar/gky1106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1093%2Fnar%2Fgky1106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30395289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1GqtrzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=D442-D450&author=Y.+Perez-Riverolauthor=A.+Csordasauthor=J.+Baiauthor=M.+Bernal-Llinaresauthor=S.+Hewapathiranaauthor=D.+J.+Kunduauthor=A.+Inugantiauthor=J.+Grissauthor=G.+Mayerauthor=M.+Eisenacherauthor=E.+P%C3%A9rezauthor=J.+Uszkoreitauthor=J.+Pfeufferauthor=T.+Sachsenbergauthor=S.+Yilmazauthor=S.+Tiwaryauthor=J.+Coxauthor=E.+Audainauthor=M.+Walzerauthor=A.+F.+Jarnuczakauthor=T.+Ternentauthor=A.+Brazmaauthor=J.+A.+Vizca%C3%ADno&title=The+PRIDE+database+and+related+tools+and+resources+in+2019%3A+Improving+support+for+quantification+data&doi=10.1093%2Fnar%2Fgky1106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">The PRIDE database and related tools and resources in 2019: improving support for quantification data</span></div><div class="casAuthors">Perez-Riverol, Yasset; Csordas, Attila; Bai, Jingwen; Bernal-Llinare, Manuel; Hewapathirana, Suresh; Kundu, Deepti J.; Iuganti, Avinash; Griss, Johannes; Mayer, Gerhard; Eisenacher, Martin; Perez, Enrique; Uszkoreit, Julian; Pfeuffer, Julianus; Sachsenberg, Timo; Yilmaz, Sule; Tiwary, Shivani; Cox, Jurgen; Audain, Enrique; Walzer, Mathias; Jarnuczak, Andrew F.; Ternent, Tobias; Brazma, Alvis; Vizcaino, Juan Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D442-D450</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The PRoteomics IDEntifications (PRIDE) database is the world's largest data repository of mass spectrometry-based proteomics data, and is one of the founding members of the global ProteomeXchange (PX) consortium.  In this manuscript, we summarize the developments in PRIDE resources and related tools since the previous update manuscript was published in Nucleic Acids Research in 2016.  In the last 3 years, public data sharing through PRIDE (as part of PX) has definitely become the norm in the field.  In parallel, data re-use of public proteomics data has increased enormously, with multiple applications.  We first describe the new architecture of PRIDE Archive, the archival component of PRIDE.  PRIDE Archive and the related data submission framework have been further developed to support the increase in submitted data vols. and addnl. data types.  A new scalable and fault tolerant storage backed, Application Programming Interface and web interface have been implemented, as a part of an ongoing process.  Addnl., we emphasize the improved support for quant. proteomics data through the mzTab format.  At last, we outline key statistics on the current data contents and vol. of downloads, and how PRIDE data are starting to be disseminated to added-value resources including Ensembl, UniProt and Expression Atlas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0A73vO-W9E7Vg90H21EOLACvtfcHk0lgNvRP4a6PLdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1GqtrzK&md5=4cd0f929c2df840a5cc0631d0d708d6c</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgky1106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgky1106%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Riverol%26aufirst%3DY.%26aulast%3DCsordas%26aufirst%3DA.%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DBernal-Llinares%26aufirst%3DM.%26aulast%3DHewapathirana%26aufirst%3DS.%26aulast%3DKundu%26aufirst%3DD.%2BJ.%26aulast%3DInuganti%26aufirst%3DA.%26aulast%3DGriss%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DG.%26aulast%3DEisenacher%26aufirst%3DM.%26aulast%3DP%25C3%25A9rez%26aufirst%3DE.%26aulast%3DUszkoreit%26aufirst%3DJ.%26aulast%3DPfeuffer%26aufirst%3DJ.%26aulast%3DSachsenberg%26aufirst%3DT.%26aulast%3DYilmaz%26aufirst%3DS.%26aulast%3DTiwary%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DJ.%26aulast%3DAudain%26aufirst%3DE.%26aulast%3DWalzer%26aufirst%3DM.%26aulast%3DJarnuczak%26aufirst%3DA.%2BF.%26aulast%3DTernent%26aufirst%3DT.%26aulast%3DBrazma%26aufirst%3DA.%26aulast%3DVizca%25C3%25ADno%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520PRIDE%2520database%2520and%2520related%2520tools%2520and%2520resources%2520in%25202019%253A%2520Improving%2520support%2520for%2520quantification%2520data%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2019%26volume%3D47%26spage%3DD442%26epage%3DD450%26doi%3D10.1093%2Fnar%2Fgky1106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredrickson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derynck, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span> <span> </span><span class="NLM_article-title">First-in-human Phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">77</span>â <span class="NLM_lpage">86</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-0947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F1078-0432.CCR-14-0947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25370471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis12ltw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=77-86&author=D.+Sarkerauthor=J.+E.+Angauthor=R.+Bairdauthor=R.+Kristeleitauthor=K.+Shahauthor=V.+Morenoauthor=P.+A.+Clarkeauthor=F.+I.+Raynaudauthor=G.+Levyauthor=J.+A.+Wareauthor=K.+Mazinaauthor=R.+Linauthor=J.+Wuauthor=J.+Fredricksonauthor=J.+M.+Spoerkeauthor=M.+R.+Lacknerauthor=Y.+Yanauthor=L.+S.+Friedmanauthor=S.+B.+Kayeauthor=M.+K.+Derynckauthor=P.+Workmanauthor=J.+S.+de+Bono&title=First-in-human+Phase+I+study+of+pictilisib+%28GDC-0941%29%2C+a+potent+pan-class+I+phosphatidylinositol-3-kinase+%28PI3K%29+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-14-0947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Sarker, Debashis; Ang, Joo Ern; Baird, Richard; Kristeleit, Rebecca; Shah, Krunal; Moreno, Victor; Clarke, Paul A.; Raynaud, Florence I.; Levy, Gallia; Ware, Joseph A.; Mazina, Kathryn; Lin, Ray; Wu, Jenny; Fredrickson, Jill; Spoerke, Jill M.; Lackner, Mark R.; Yan, Yibing; Friedman, Lori S.; Kaye, Stan B.; Derynck, Mika K.; Workman, Paul; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-86</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clin. activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K).  Patients and Methods: Sixty patients with solid tumors received pictilisib at 14 dose levels from 15 to 450 mg once-daily, initially on days 1 to 21 every 28 days and later, using continuous dosing for selected dose levels.  Pharmacodynamic studies incorporated 18F-FDG-PET, and assessment of phosphorylated AKT and S6 ribosomal protein in platelet-rich plasma (PRP) and tumor tissue.  Results: Pictilisib was well tolerated.  The most common toxicities were grade 1-2 nausea, rash, and fatigue, whereas the DLT was grade 3 maculopapular rash (450 mg, 2 of 3 patients; 330 mg, 1 of 7 patients).  The pharmacokinetic profile was dose-proportional and supported once-daily dosing.  Levels of phosphorylated serine-473 AKT were suppressed >90% in PRP at 3 h after dose at the MTD and in tumor at pictilisib doses assocd. with AUC >20 hÂ·Î¼mol/L.  Significant increase in plasma insulin and glucose levels, and >25% decrease in 18F-FDG uptake by PET in 7 of 32 evaluable patients confirmed target modulation.  A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, resp.  Conclusion: Pictilisib was safely administered with a dose-proportional pharmacokinetic profile, on-target pharmacodynamic activity at dose levels â¥100 mg and signs of antitumor activity.  The recommended phase II dose was continuous dosing at 330 mg once-daily.  Clin Cancer Res; 21(1); 77-86. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw-xdpJi9RV7Vg90H21EOLACvtfcHk0lgNvRP4a6PLdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis12ltw%253D%253D&md5=35d52a025e34f4f13844b2721014aca3</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0947%26sid%3Dliteratum%253Aachs%26aulast%3DSarker%26aufirst%3DD.%26aulast%3DAng%26aufirst%3DJ.%2BE.%26aulast%3DBaird%26aufirst%3DR.%26aulast%3DKristeleit%26aufirst%3DR.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DLevy%26aufirst%3DG.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DMazina%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DFredrickson%26aufirst%3DJ.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DDerynck%26aufirst%3DM.%2BK.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DFirst-in-human%2520Phase%2520I%2520study%2520of%2520pictilisib%2520%2528GDC-0941%2529%252C%2520a%2520potent%2520pan-class%2520I%2520phosphatidylinositol-3-kinase%2520%2528PI3K%2529%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D77%26epage%3D86%26doi%3D10.1158%2F1078-0432.CCR-14-0947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">301</span>â <span class="NLM_lpage">305</span>, <span class="refDoi">Â DOI: 10.1038/35060098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2F35060098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11231581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=301-305&author=S.+Pleschkaauthor=T.+Wolffauthor=C.+Ehrhardtauthor=G.+Hobomauthor=O.+Planzauthor=U.+R.+Rappauthor=S.+Ludwig&title=Influenza+virus+propagation+is+impaired+by+inhibition+of+the+Raf%2FMEK%2FERK+signalling+cascade&doi=10.1038%2F35060098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span></div><div class="casAuthors">Pleschka, Stephan; Wolff, Thorsten; Ehrhard, Christina; Hobom, Gerd; Planz, Oliver; Rapp, Ulf R.; Ludwig, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-305</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Influenza A viruses are important worldwide pathogens in humans and different animal species.  The functions of most of the ten different viral proteins of this neg.-strand RNA virus have been well elucidated.  However, little is known about the virus-induced intracellular signalling events that support viral replication.  The Raf/MEK/ERK cascade is the prototype of mitogen-activated protein (MAP) kinase cascades and has an important role in cell growth, differentiation and survival.  Investigation of the function of this pathway has been facilitated by the identification of specific inhibitors, such as U0126, which blocks the cascade at the level of MAPK/ERK kinase (MEK).  Here, the authors show that infection of cells with influenza A virus leads to biphasic activation of the Raf/MEK/ERK cascade.  Inhibition of Raf signalling results in nuclear retention of viral ribonucleoprotein complexes (RNPs), impaired function of the nuclear-export protein (NEP/NS2) and concomitant inhibition of virus prodn.  Thus, signalling through the mitogenic cascade seems to be essential for virus prodn. and RNP export from the nucleus during the viral life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx1KgfMDKJPLVg90H21EOLACvtfcHk0ljdWR0mFSxUBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D&md5=b5283932b9d29e474583d8dfa0ec5658</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2F35060098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35060098%26sid%3Dliteratum%253Aachs%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DHobom%26aufirst%3DG.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DInfluenza%2520virus%2520propagation%2520is%2520impaired%2520by%2520inhibition%2520of%2520the%2520Raf%252FMEK%252FERK%2520signalling%2520cascade%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D301%26epage%3D305%26doi%3D10.1038%2F35060098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span> <span> </span><span class="NLM_article-title">The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">142</span>â <span class="NLM_lpage">150</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2017.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2017.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28390872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXms1CgtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2017&pages=142-150&author=T.+Venkataramanauthor=M.+B.+Frieman&title=The+role+of+epidermal+growth+factor+receptor+%28EGFR%29+signaling+in+SARS+coronavirus-induced+pulmonary+fibrosis&doi=10.1016%2Fj.antiviral.2017.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis</span></div><div class="casAuthors">Venkataraman, Thiagarajan; Frieman, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">142-150</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Many survivors of the 2003 outbreak of severe acute respiratory syndrome (SARS) developed residual pulmonary fibrosis with increased severity seen in older patients.  Autopsies of patients that died from SARS also showed fibrosis to varying extents.  Pulmonary fibrosis can be occasionally seen as a consequence to several respiratory viral infections but is much more common after a SARS coronavirus (SARS-CoV) infection.  Given the threat of future outbreaks of severe coronavirus disease, including Middle East respiratory syndrome (MERS), it is important to understand the mechanisms responsible for pulmonary fibrosis, so as to support the development of therapeutic countermeasures and mitigate sequelae of infection.  In this article, we summarize pulmonary fibrotic changes obsd. after a SARS-CoV infection, discuss the extent to which other respiratory viruses induce fibrosis, describe available animal models to study the development of SARS-CoV induced fibrosis and review evidence that pulmonary fibrosis is caused by a hyperactive host response to lung injury mediated by epidermal growth factor receptor (EGFR) signaling.  We summarize work from our group and others indicating that inhibiting EGFR signaling may prevent an excessive fibrotic response to SARS-CoV and other respiratory viral infections and propose directions for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk0X-F-YtUyLVg90H21EOLACvtfcHk0ljdWR0mFSxUBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXms1CgtLs%253D&md5=35c10a0d15c558719b6a5389621984cc</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2017.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2017.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DVenkataraman%26aufirst%3DT.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26atitle%3DThe%2520role%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520signaling%2520in%2520SARS%2520coronavirus-induced%2520pulmonary%2520fibrosis%26jtitle%3DAntiviral%2520Res.%26date%3D2017%26volume%3D143%26spage%3D142%26epage%3D150%26doi%3D10.1016%2Fj.antiviral.2017.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M.</span></span> <span> </span><span class="NLM_article-title">Overactive EGFR signaling leads to increased fibrosis after SARS-CoV infection</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>, <span class="NLM_elocation-id">e00182-17</span> <span class="refDoi">Â DOI: 10.1128/JVI.00182-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.00182-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28404843" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&author=T.+Venkataramanauthor=C.+Colemanauthor=M.+Frieman&title=Overactive+EGFR+signaling+leads+to+increased+fibrosis+after+SARS-CoV+infection&doi=10.1128%2FJVI.00182-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1128%2FJVI.00182-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00182-17%26sid%3Dliteratum%253Aachs%26aulast%3DVenkataraman%26aufirst%3DT.%26aulast%3DColeman%26aufirst%3DC.%26aulast%3DFrieman%26aufirst%3DM.%26atitle%3DOveractive%2520EGFR%2520signaling%2520leads%2520to%2520increased%2520fibrosis%2520after%2520SARS-CoV%2520infection%26jtitle%3DJ.%2520Virol.%26date%3D2017%26volume%3D91%26doi%3D10.1128%2FJVI.00182-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchkovich, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alwine, J. C.</span></span> <span> </span><span class="NLM_article-title">The TORrid affairs of viruses: Effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">266</span>â <span class="NLM_lpage">275</span>, <span class="refDoi">Â DOI: 10.1038/nrmicro1855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnrmicro1855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18311165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BD1c7otVSnug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=266-275&author=N.+J.+Buchkovichauthor=Y.+Yuauthor=C.+A.+Zampieriauthor=J.+C.+Alwine&title=The+TORrid+affairs+of+viruses%3A+Effects+of+mammalian+DNA+viruses+on+the+PI3K-Akt-mTOR+signalling+pathway&doi=10.1038%2Fnrmicro1855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway</span></div><div class="casAuthors">Buchkovich Nicholas J; Yu Yongjun; Zampieri Carisa A; Alwine James C</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Microbiology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">266-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The successful replication of mammalian DNA viruses requires that they gain control of key cellular signalling pathways that affect broad aspects of cellular macromolecular synthesis, metabolism, growth and survival.  The phosphatidylinositol 3'-kinase-Akt-mammalian target of rapamycin (PI3K-Akt-mTOR) pathway is one such pathway.  Mammalian DNA viruses have evolved various mechanisms to activate this pathway to obtain the benefits of Akt activation, including the maintenance of translation through the activation of mTOR.  In addition, viruses must overcome the inhibition of this pathway that results from the activation of cellular stress responses during viral infection.  This Review will discuss the range of mechanisms that mammalian DNA viruses use to activate this pathway, as well as the multiple mechanisms these viruses have evolved to circumvent inhibitory stress signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAa934cv2xBL5oR8RchjrrfW6udTcc2eZv6pP-1Ylbn7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c7otVSnug%253D%253D&md5=475493e501e37ca759dfeb95290db1fb</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro1855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro1855%26sid%3Dliteratum%253Aachs%26aulast%3DBuchkovich%26aufirst%3DN.%2BJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZampieri%26aufirst%3DC.%2BA.%26aulast%3DAlwine%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520TORrid%2520affairs%2520of%2520viruses%253A%2520Effects%2520of%2520mammalian%2520DNA%2520viruses%2520on%2520the%2520PI3K-Akt-mTOR%2520signalling%2520pathway%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2008%26volume%3D6%26spage%3D266%26epage%3D275%26doi%3D10.1038%2Fnrmicro1855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MannovÃ¡, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beretta, L.</span></span> <span> </span><span class="NLM_article-title">Activation of the N-Ras- PI3K-Akt-mTOR pathway by hepatitis C virus: Control of cell survival and viral replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">8742</span>â <span class="NLM_lpage">8749</span>, <span class="refDoi">Â DOI: 10.1128/JVI.79.14.8742-8749.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.79.14.8742-8749.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=15994768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFOjsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=8742-8749&author=P.+Mannov%C3%A1author=L.+Beretta&title=Activation+of+the+N-Ras-+PI3K-Akt-mTOR+pathway+by+hepatitis+C+virus%3A+Control+of+cell+survival+and+viral+replication&doi=10.1128%2FJVI.79.14.8742-8749.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: Control of cell survival and viral replication</span></div><div class="casAuthors">Mannova, Petra; Beretta, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">8742-8749</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) replication complex is localized within detergent-resistant membranes or lipid rafts.  We analyzed the protein contents of detergent-resistant fractions isolated from Huh7 cells expressing a self-replicating full-length HCV-1b genome.  Using two-dimensional gel electrophoresis followed by mass spectrometry, we identified N-Ras as one of the proteins in which expression was increased in the detergent-resistant fractions from HCV genomic replicon clones compared to control cells.  N-Ras is an activator of the phosphatidylinositol-3-kinase (PI3K)-Akt pathway.  We found that the activities of PI3K and Akt, as well as the activity of their downstream target, mTOR, in the HCV-replicating cells were increased.  Both PI3K-Akt- and mTOR-dependent pathways have been shown to promote cell survival.  In agreement with this, HCV replicon cells were resistant to serum starvation-induced apoptosis.  We also characterized the role of this pathway in HCV replication.  Redn. of N-Ras expression by transfection of N-Ras small interfering RNA (siRNA) resulted in increased replication of HCV.  We obsd. a similar increase in HCV replication in cells treated with the PI3K inhibitor LY294002 and in cells transfected with mTOR siRNA.  Taken together, these data suggest that increased N-Ras levels in subcellular sites of HCV replication and stimulation of the prosurvival PI3K-Akt pathway and mTOR by HCV not only protect cells against apoptosis but also contribute to the maintenance of steady-state levels of HCV replication.  These effects may contribute to the establishment of persistent infection by HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqga8XFsHx6mrVg90H21EOLACvtfcHk0linW1c2XWcjBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFOjsrs%253D&md5=123bb247229b7f4c984fbf59fb446183</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.14.8742-8749.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.14.8742-8749.2005%26sid%3Dliteratum%253Aachs%26aulast%3DMannov%25C3%25A1%26aufirst%3DP.%26aulast%3DBeretta%26aufirst%3DL.%26atitle%3DActivation%2520of%2520the%2520N-Ras-%2520PI3K-Akt-mTOR%2520pathway%2520by%2520hepatitis%2520C%2520virus%253A%2520Control%2520of%2520cell%2520survival%2520and%2520viral%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D8742%26epage%3D8749%26doi%3D10.1128%2FJVI.79.14.8742-8749.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shives, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beatman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobson-Peters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckham, J. D.</span></span> <span> </span><span class="NLM_article-title">West Nile virus induced activation of mammalian target of rapamycin complex 1 supports viral growth and viral protein expression</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">9458</span>â <span class="NLM_lpage">9471</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01323-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01323-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24920798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1arurnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=9458-9471&author=K.+D.+Shivesauthor=E.+L.+Beatmanauthor=M.+Chamanianauthor=C.+O%E2%80%99Brienauthor=J.+Hobson-Petersauthor=J.+D.+Beckham&title=West+Nile+virus+induced+activation+of+mammalian+target+of+rapamycin+complex+1+supports+viral+growth+and+viral+protein+expression&doi=10.1128%2FJVI.01323-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">West Nile virus-induced activation of mammalian target of rapamycin complex 1 supports viral growth and viral protein expression</span></div><div class="casAuthors">Shives, Katherine D.; Beatman, Erica L.; Chamanian, Mastooreh; O'Brien, Caitlin; Hobson-Peters, Jody; Beckham, J. David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">9458-9471, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Since its introduction in New York City, NY, in 1999, West Nile virus (WNV) has spread to all 48 contiguous states of the United States and is now the leading cause of epidemic encephalitis in North America.  As a member of the family Flaviviridae, WNV is part of a group of clin. important human pathogens, including dengue virus and Japanese encephalitis virus.  The members of this family of pos.-sense, single-stranded RNA viruses have limited coding capacity and are therefore obligated to co-opt a significant amt. of cellular factors to translate their genomes effectively.  Our previous work has shown that WNV growth was independent of macroautophagy activation, but the role of the evolutionarily conserved mammalian target of rapamycin (mTOR) pathway during WNV infection was not well understood.  MTOR is a serine/threonine kinase that acts as a central cellular censor of nutrient status and exercises control of vital anabolic and catabolic cellular responses such as protein synthesis and autophagy, resp.  We now show that WNV activates mTOR and cognate downstream activators of cap-dependent protein synthesis at early time points postinfection and that pharmacol. inhibition of mTOR (KU0063794) significantly reduced WNV growth.  We used an inducible Raptor and Rictor knockout mouse embryonic fibroblast (MEF) system to further define the role of mTOR complexes 1 and 2 in WNV growth and viral protein synthesis.  Following inducible genetic knockout of the major mTOR cofactors raptor (TOR complex 1 [TORC1]) and rictor (TORC2), we now show that TORC1 supports flavivirus protein synthesis via cap-dependent protein synthesis pathways and supports subsequent WNV growth.  Importance: Since its introduction in New York City, NY, in 1999, West Nile virus (WNV) has spread to all 48 contiguous states in the United States and is now the leading cause of epidemic encephalitis in North America.  Currently, the mechanism by which flaviviruses such as WNV translate their genomes in host cells is incompletely understood.  Elucidation of the host mechanisms required to support WNV genome translation will provide broad understanding for the basic mechanisms required to translate capped viral RNAs.  We now show that WNV activates mTOR and cognate downstream activators of cap-dependent protein synthesis at early time points postinfection.  Following inducible genetic knockout of the major mTOR complex cofactors raptor (TORC1) and rictor (TORC2), we now show that TORC1 supports WNV growth and protein synthesis.  This study demonstrates the requirement for TORC1 function in support of WNV RNA translation and provides insight into the mechanisms underlying flaviviral RNA translation in mammalian cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOdvHUWOxCc7Vg90H21EOLACvtfcHk0lh3_ypDgZRhEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1arurnK&md5=48f1230ec6ba03689774e53f475c6062</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1128%2FJVI.01323-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01323-14%26sid%3Dliteratum%253Aachs%26aulast%3DShives%26aufirst%3DK.%2BD.%26aulast%3DBeatman%26aufirst%3DE.%2BL.%26aulast%3DChamanian%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DHobson-Peters%26aufirst%3DJ.%26aulast%3DBeckham%26aufirst%3DJ.%2BD.%26atitle%3DWest%2520Nile%2520virus%2520induced%2520activation%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520complex%25201%2520supports%2520viral%2520growth%2520and%2520viral%2520protein%2520expression%26jtitle%3DJ.%2520Virol.%26date%3D2014%26volume%3D88%26spage%3D9458%26epage%3D9471%26doi%3D10.1128%2FJVI.01323-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lurain, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedmak, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, A. S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide</span>. <i>Intervirology</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">412</span>â <span class="NLM_lpage">418</span>, <span class="refDoi">Â DOI: 10.1159/000053979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1159%2F000053979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVKisLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2000&pages=412-418&author=W.+J.+Waldmanauthor=D.+A.+Knightauthor=L.+Blinderauthor=J.+Shenauthor=N.+S.+Lurainauthor=D.+M.+Millerauthor=D.+D.+Sedmakauthor=J.+W.+Williamsauthor=A.+S.+Chong&title=Inhibition+of+cytomegalovirus+in+vitro+and+in+vivo+by+the+experimental+immunosuppressive+agent+leflunomide&doi=10.1159%2F000053979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide</span></div><div class="casAuthors">Waldman, W. James; Knight, Deborah A.; Blinder, Leonard; Shen, JiKun; Lurain, Nell S.; Miller, Daniel M.; Sedmak, Daniel D.; Williams, James W.; Chong, Anita S.-F.</div><div class="citationInfo"><span class="NLM_cas:title">Intervirology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">412-418</span>CODEN:
                <span class="NLM_cas:coden">IVRYAK</span>;
        ISSN:<span class="NLM_cas:issn">0300-5526</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Despite progress in antiviral chemotherapy, cytomegalovirus (CMV) remains a major cause of morbidity and mortality among pharmacol. immunosuppressed transplant recipients, frequently engaging the clinician in a struggle to balance graft preservation with control of CMV disease.  Leflunomide, an inhibitor of protein kinase activity and pyrimidine synthesis, is an exptl. immunosuppressive agent effective against acute and chronic rejection in animal models.  Herein we summarize our recent studies demonstrating that leflunomide inhibits the prodn. of multiple clin. CMV isolates (including multi-drug-resistant virus) in both human fibroblasts and endothelial cells.  In contrast to all other anti-CMV drugs currently in use, leflunomide does not inhibit viral DNA synthesis, but rather appears to interfere with virion assembly.  Finally, preliminary studies in a rat model suggest that this agent reduces viral load in vivo.  These findings imply that leflunomide, an effective immunosuppressive agent, shows potential to concurrently attenuate a major complication of immunosuppression, CMV disease, by a novel mechanism of antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolSzgyco_QqrVg90H21EOLACvtfcHk0lh3_ypDgZRhEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVKisLk%253D&md5=e2fa6f422349ef0f74d13194a944c239</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1159%2F000053979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000053979%26sid%3Dliteratum%253Aachs%26aulast%3DWaldman%26aufirst%3DW.%2BJ.%26aulast%3DKnight%26aufirst%3DD.%2BA.%26aulast%3DBlinder%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLurain%26aufirst%3DN.%2BS.%26aulast%3DMiller%26aufirst%3DD.%2BM.%26aulast%3DSedmak%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DJ.%2BW.%26aulast%3DChong%26aufirst%3DA.%2BS.%26atitle%3DInhibition%2520of%2520cytomegalovirus%2520in%2520vitro%2520and%2520in%2520vivo%2520by%2520the%2520experimental%2520immunosuppressive%2520agent%2520leflunomide%26jtitle%3DIntervirology%26date%3D2000%26volume%3D42%26spage%3D412%26epage%3D418%26doi%3D10.1159%2F000053979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Vincent, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacasse, J. J.</span></span> <span> </span><span class="NLM_article-title">Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs</span>. <i>Antivir. Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">293</span>â <span class="NLM_lpage">320</span>, <span class="refDoi">Â DOI: 10.1177/095632020601700601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1177%2F095632020601700601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17249245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1CktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=293-320&author=L.+M.+Schangauthor=M.+R.+St.+Vincentauthor=J.+J.+Lacasse&title=Five+years+of+progress+on+cyclin-dependent+kinases+and+other+cellular+proteins+as+potential+targets+for+antiviral+drugs&doi=10.1177%2F095632020601700601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs</span></div><div class="casAuthors">Schang, Luis M.; St. Vincent, Mireille R.; Lacasse, Jonathan J.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">293-320</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press, Ltd.</span>)
        </div><div class="casAbstract">A review.  In 1997-1998, the pharmacol. cyclin-dependent kinase (CDK) inhibitors (PCIs) were independently discovered to inhibit replication of human cytomegalovirus, herpes simplex virus type 1 and HIV-1.  The results from small clin. trials against cancer were then suggesting that PCIs could be safe enough to be used clin.  It was thus hypothesized that PCIs could have the potential to be developed as novel antivirals targeting cellular proteins.  Consequently, Antiviral Chem. & Chemotherapy published in 2001 the first review on the potential of CDKs, and cellular proteins in general, as potential targets for antivirals.  The viral functions inhibited by PCIs, or their cellular targets, were then just starting to be characterized.  The antiviral spectrum of PCIs and their effects on viral disease were still mostly untested.  Even their actual specificity was not yet completely characterized.  In addn., cellular proteins were not accepted as valid targets for antivirals.  Significant progress has been made in the last 5 years in understanding the antiviral activities of PCIs and the potential roles of cellular proteins in general as targets for antivirals.  The first clin. trials of the antiviral activities of PCIs and other inhibitors of cellular protein kinases have now been scheduled.  Herein, we review the progress made since the publication of the first review on PCIs as potential antiviral drugs and on CDKs, and cellular proteins in general, as potential targets for antiviral drugs.  We also highlight the major issues that still need to be addressed before PCIs or other drugs targeting cellular proteins can be developed as clin. antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrVdUG1WNgiLVg90H21EOLACvtfcHk0lh3_ypDgZRhEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1CktA%253D%253D&md5=df2f56161599faf496637f3259c7f605</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1177%2F095632020601700601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020601700601%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26aulast%3DSt.%2BVincent%26aufirst%3DM.%2BR.%26aulast%3DLacasse%26aufirst%3DJ.%2BJ.%26atitle%3DFive%2520years%2520of%2520progress%2520on%2520cyclin-dependent%2520kinases%2520and%2520other%2520cellular%2520proteins%2520as%2520potential%2520targets%2520for%2520antiviral%2520drugs%26jtitle%3DAntivir.%2520Chem.%2520Chemother.%26date%3D2006%26volume%3D17%26spage%3D293%26epage%3D320%26doi%3D10.1177%2F095632020601700601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">NÃ©meth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greff, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bencze, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SzÃ¡ntai-Kis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baska, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyuris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelemenics, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SzathmÃ¡ry, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MinÃ¡rovits, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KÃ©ri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfi, L.</span></span> <span> </span><span class="NLM_article-title">Novel, selective CDK9 inhibitors for the treatment of HIV infection</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">342</span>â <span class="NLM_lpage">358</span>, <span class="refDoi">Â DOI: 10.2174/092986711794839188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.2174%2F092986711794839188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=21143121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslahtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=342-358&author=G.+N%C3%A9methauthor=Z.+Vargaauthor=Z.+Greffauthor=G.+Benczeauthor=A.+Siposauthor=C.+Sz%C3%A1ntai-Kisauthor=F.+Baskaauthor=A.+Gyurisauthor=K.+Kelemenicsauthor=Z.+Szathm%C3%A1ryauthor=J.+Min%C3%A1rovitsauthor=G.+K%C3%A9riauthor=L.+Orfi&title=Novel%2C+selective+CDK9+inhibitors+for+the+treatment+of+HIV+infection&doi=10.2174%2F092986711794839188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, selective CDK9 inhibitors for the treatment of HIV infection</span></div><div class="casAuthors">Nemeth, G.; Varga, Z.; Greff, Z.; Bencze, G.; Sipos, A.; Szantai-Kis, C.; Baska, F.; Gyuris, A.; Kelemenics, K.; Szathmary, Z.; Minarovits, J.; Keri, G.; Orfi, L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">342-358</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclin Dependent Kinases (CDKs) are important regulators of cell cycle and gene expression.  Since an up-to-date review about the pharmacol. inhibitors of CDK family (CDK1-10) is not available; therefore in the present paper we briefly summarize the most relevant inhibitors and point out the low no. of selective inhibitors.  Among CDKs, CDK9 is a validated pathol. target in HIV infection, inflammation and cardiac hypertrophy; however selective CDK9 inhibitors are still not available.  We present a selective inhibitor family of CDK9 based on the 4-phenylamino-6-phenylpyrimidine nucleus.  We show a convenient synthetic method to prep. a useful intermediate and its derivatisation resulting in novel compds.  The CDK9 inhibitory activity of the derivs. was measured in specific kinase assay and the CDK inhibitory profile of the best ones (IC50 < 100nM) was detd.  The most selective compds. had high selectivity over CDK1, 2, 3, 5, 6, 7 and showed at least one order of magnitude higher inhibitory activity over CDK4 inhibition.  The most selective mols. were examd. in cytotoxicity assays and their ability to inhibit HIV-1 replication was detd. in cellular assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-AaopHRq0S7Vg90H21EOLACvtfcHk0li5BPIJjGEj2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslahtr4%253D&md5=2777a90d212ded68b2399beb97d48531</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.2174%2F092986711794839188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794839188%26sid%3Dliteratum%253Aachs%26aulast%3DN%25C3%25A9meth%26aufirst%3DG.%26aulast%3DVarga%26aufirst%3DZ.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DBencze%26aufirst%3DG.%26aulast%3DSipos%26aufirst%3DA.%26aulast%3DSz%25C3%25A1ntai-Kis%26aufirst%3DC.%26aulast%3DBaska%26aufirst%3DF.%26aulast%3DGyuris%26aufirst%3DA.%26aulast%3DKelemenics%26aufirst%3DK.%26aulast%3DSzathm%25C3%25A1ry%26aufirst%3DZ.%26aulast%3DMin%25C3%25A1rovits%26aufirst%3DJ.%26aulast%3DK%25C3%25A9ri%26aufirst%3DG.%26aulast%3DOrfi%26aufirst%3DL.%26atitle%3DNovel%252C%2520selective%2520CDK9%2520inhibitors%2520for%2520the%2520treatment%2520of%2520HIV%2520infection%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D342%26epage%3D358%26doi%3D10.2174%2F092986711794839188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Permanyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gubern, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-MuÃ±oz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mothe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MenÃ©ndez-Arias, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">EstÃ©, J. A.</span></span> <span> </span><span class="NLM_article-title">Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">1988</span>â <span class="NLM_lpage">1997</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1400873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.4049%2Fjimmunol.1400873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25015816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Kju7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2014&pages=1988-1997&author=E.+Paulsauthor=A.+Ruizauthor=R.+Badiaauthor=M.+Permanyerauthor=A.+Gubernauthor=E.+Riveira-Mu%C3%B1ozauthor=J.+Torres-Torronterasauthor=M.+Alvarezauthor=B.+Motheauthor=C.+Branderauthor=M.+Crespoauthor=L.+Men%C3%A9ndez-Ariasauthor=B.+Clotetauthor=O.+T.+Kepplerauthor=R.+Mart%C3%ADauthor=F.+Posasauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Cell+cycle+control+and+HIV-1+susceptibility+are+linked+by+CDK6-dependent+CDK2+phosphorylation+of+SAMHD1+in+myeloid+and+lymphoid+cells&doi=10.4049%2Fjimmunol.1400873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Cell Cycle Control and HIV-1 Susceptibility Are Linked by CDK6-Dependent CDK2 Phosphorylation of SAMHD1 in Myeloid and Lymphoid Cells</span></div><div class="casAuthors">Pauls, Eduardo; Ruiz, Alba; Badia, Roger; Permanyer, Marc; Gubern, Albert; Riveira-Munoz, Eva; Torres-Torronteras, Javier; Alvarez, Mar; Mothe, Beatriz; Brander, Christian; Crespo, Manel; Menendez-Arias, Luis; Clotet, Bonaventura; Keppler, Oliver T.; Marti, Ramon; Posas, Francesc; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1988-1997</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Proliferating cells are preferentially susceptible to infection by retroviruses.  Sterile Î± motif and HD domain-contg. protein-1 (SAMHD1) is a recently described deoxynucleotide phosphohydrolase controlling the size of the intracellular deoxynucleotide triphosphate (dNTP) pool, a limiting factor for retroviral reverse transcription in noncycling cells.  Proliferating (Ki67+) primary CD4+ T cells or macrophages express a phosphorylated form of SAMHD1 that corresponds with susceptibility to infection in cell culture.  We identified cyclin-dependent kinase (CDK) 6 as an upstream regulator of CDK2 controlling SAMHD1 phosphorylation in primary T cells and macrophages susceptible to infection by HIV-1.  In turn, CDK2 was strongly linked to cell cycle progression and coordinated SAMHD1 phosphorylation and inactivation.  CDK inhibitors specifically blocked HIV-1 infection at the reverse transcription step in a SAMHD1-dependent manner, reducing the intracellular dNTP pool.  Our findings identify a direct relationship between control of the cell cycle by CDK6 and SAMHD1 activity, which is important for replication of lentiviruses, as well as other viruses whose replication may be regulated by intracellular dNTP availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-LI-z2ggFCbVg90H21EOLACvtfcHk0li5BPIJjGEj2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Kju7%252FM&md5=5c1c895a20f64ad71e0578ea2fca74bf</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1400873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1400873%26sid%3Dliteratum%253Aachs%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DPermanyer%26aufirst%3DM.%26aulast%3DGubern%26aufirst%3DA.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3DAlvarez%26aufirst%3DM.%26aulast%3DMothe%26aufirst%3DB.%26aulast%3DBrander%26aufirst%3DC.%26aulast%3DCrespo%26aufirst%3DM.%26aulast%3DMen%25C3%25A9ndez-Arias%26aufirst%3DL.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DKeppler%26aufirst%3DO.%2BT.%26aulast%3DMart%25C3%25AD%26aufirst%3DR.%26aulast%3DPosas%26aufirst%3DF.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DCell%2520cycle%2520control%2520and%2520HIV-1%2520susceptibility%2520are%2520linked%2520by%2520CDK6-dependent%2520CDK2%2520phosphorylation%2520of%2520SAMHD1%2520in%2520myeloid%2520and%2520lymphoid%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D193%26spage%3D1988%26epage%3D1997%26doi%3D10.4049%2Fjimmunol.1400873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durand, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roizman, B.</span></span> <span> </span><span class="NLM_article-title">Role of CDK9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">10591</span>â <span class="NLM_lpage">10599</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01242-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01242-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18753202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWitbbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=10591-10599&author=L.+O.+Durandauthor=B.+Roizman&title=Role+of+CDK9+in+the+optimization+of+expression+of+the+genes+regulated+by+ICP22+of+herpes+simplex+virus+1&doi=10.1128%2FJVI.01242-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1</span></div><div class="casAuthors">Durand, Lizette Olga; Roizman, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">10591-10599</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">ICP22 is a multi-functional herpes simplex virus 1 (HSV-1) regulatory protein that regulates the accumulation of a subset of late (Î³2) proteins exemplified by UL38, UL41, and US11.  ICP22 binds the cyclin-dependent kinase 9 (cdk9) but not cdk7, and this complex in conjunction with viral protein kinases phosphorylates the carboxyl terminus of RNA polymerase II (Pol II) in vitro.  The primary function of cdk9 and its partners, the cyclin T variants, is in the elongation of RNA transcripts, although functions related to the initiation and processing of transcripts have also been reported.  We report two series of expts. designed to probe the role of cdk9 in infected cells.  In the first, infected cells were treated with 5,6-dichloro-1-Î²-D-ribofuranosylbenzimidazole (DRB), a specific inhibitor of cdk9.  In cells treated with DRB, the major effect was in the accumulation of viral RNAs and proteins regulated by ICP22.  The accumulation of Î±, Î², or Î³ proteins not regulated by ICP22 was not affected by the drug.  The results obtained with DRB were duplicated in cells transfected with small interfering RNA (siRNA) targeting cdk9 mRNAs.  Interestingly, DRB and siRNA reduced the levels of ICP22 but not those of other Î± gene products.  In addn., cdk9 and ICP22 appeared to colocalize with RNA Pol II in wild-type-virus-infected cells but not in ÎUL13-infected cells.  We conclude that cdk9 plays a crit. role in the optimization of expression of genes regulated by ICP22 and that one function of cdk9 in HSV-1-infected cells may be to bring ICP22 into the RNA Pol II transcriptional complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeXb1W_R979rVg90H21EOLACvtfcHk0li5BPIJjGEj2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWitbbF&md5=7a494e43fe778e3ad849facc21b13143</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1128%2FJVI.01242-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01242-08%26sid%3Dliteratum%253Aachs%26aulast%3DDurand%26aufirst%3DL.%2BO.%26aulast%3DRoizman%26aufirst%3DB.%26atitle%3DRole%2520of%2520CDK9%2520in%2520the%2520optimization%2520of%2520expression%2520of%2520the%2520genes%2520regulated%2520by%2520ICP22%2520of%2520herpes%2520simplex%2520virus%25201%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D10591%26epage%3D10599%26doi%3D10.1128%2FJVI.01242-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, P.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMasters, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. S.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for viral selective replication in cancer cells: Activation of CDK2 by adenovirus-induced cyclin E</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e57340</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0057340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.pone.0057340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=23437375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs12iuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=P.-H.+Chengauthor=X.-M.+Raoauthor=K.+M.+McMastersauthor=H.+S.+Zhou&title=Molecular+basis+for+viral+selective+replication+in+cancer+cells%3A+Activation+of+CDK2+by+adenovirus-induced+cyclin+E&doi=10.1371%2Fjournal.pone.0057340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for viral selective replication in cancer cells: activation of CDK2 by adenovirus-induced cyclin E</span></div><div class="casAuthors">Cheng, Pei-Hsin; Rao, Xiao-Mei; McMasters, Kelly M.; Zhou, Heshan Sam</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e57340</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Adenoviruses (Ads) with deletion of E1b55K preferentially replicate in cancer cells and have been used in cancer therapies.  We have previously shown that Ad E1B55K protein is involved in induction of cyclin E for Ad replication, but this E1B55K function is not required in cancer cells in which deregulation of cyclin E is frequently obsd.  In this study, we investigated the interaction of cyclin E and CDK2 in Ad-infected cells.  Ad infection significantly increased the large form of cyclin E (cyclin EL), promoted cyclin E/CDK2 complex formation and increased CDK2 phosphorylation at the T160 site.  Activated CDK2 caused pRb phosphorylation at the S612 site.  Repression of CDK2 activity with the chem. inhibitor roscovitine or with specific small interfering RNAs significantly decreased pRb phosphorylation, with concomitant repression of viral replication.  Our results suggest that Ad-induced cyclin E activates CDK2 that targets the transcriptional repressor pRb to generate a cellular environment for viral productive replication.  This study reveals a new mol. basis for oncolytic replication of E1b -deleted Ads and will aid in the development of new strategies for Ad oncolytic virotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL5pnNdzAc_rVg90H21EOLACvtfcHk0lgtrqaMNXW3sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjs12iuro%253D&md5=0ec9e41cac8556097e62a1b2d48a144c</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0057340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0057340%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DP.-H.%26aulast%3DRao%26aufirst%3DX.-M.%26aulast%3DMcMasters%26aufirst%3DK.%2BM.%26aulast%3DZhou%26aufirst%3DH.%2BS.%26atitle%3DMolecular%2520basis%2520for%2520viral%2520selective%2520replication%2520in%2520cancer%2520cells%253A%2520Activation%2520of%2520CDK2%2520by%2520adenovirus-induced%2520cyclin%2520E%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0057340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gearhart, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchard, M. J.</span></span> <span> </span><span class="NLM_article-title">The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">2675</span>â <span class="NLM_lpage">2686</span>, <span class="refDoi">Â DOI: 10.1128/JVI.02196-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.02196-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20053744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC3c7itVOkuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=2675-2686&author=T.+L.+Gearhartauthor=M.+J.+Bouchard&title=The+hepatitis+B+virus+X+protein+modulates+hepatocyte+proliferation+pathways+to+stimulate+viral+replication&doi=10.1128%2FJVI.02196-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication</span></div><div class="casAuthors">Gearhart Tricia L; Bouchard Michael J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2675-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Worldwide, there are over 350 million people who are chronically infected with the human hepatitis B virus (HBV); chronic HBV infections are associated with the development of hepatocellular carcinoma (HCC).  The results of various studies suggest that the HBV X protein (HBx) has a role in the development of HBV-associated HCC.  HBx can regulate numerous cellular signal transduction pathways, including those that modulate cell proliferation.  Many previous studies that analyzed the impact of HBx on cell proliferation pathways were conducted using established or immortalized cell lines, and when HBx was expressed in the absence of HBV replication, and the precise effect of HBx on these pathways has often differed depending on experimental conditions.  We have studied the effect of HBx on cell proliferation in cultured primary rat hepatocytes, a biologically relevant system.  We demonstrate that HBx, both by itself and in the context of HBV replication, affected the levels and activities of various cell cycle-regulatory proteins to induce normally quiescent hepatocytes to enter the G(1) phase of the cell cycle but not to proceed to S phase.  We linked HBx regulation of cell proliferation to cytosolic calcium signaling and HBx stimulation of HBV replication.  Cumulatively, our studies suggest that HBx induces normally quiescent hepatocytes to enter the G(1) phase of the cell cycle and that this calcium-dependent HBx activity is required for HBV replication.  These studies identify an essential function of HBx during HBV replication and a mechanism that may connect HBV infections to the development of HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxzi0KmxFNAXwOGIfWJ7-GfW6udTcc2ebFVj4-KTl2eLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7itVOkuw%253D%253D&md5=bd49db174e98c4111dc1cc4ef072bbdf</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1128%2FJVI.02196-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02196-09%26sid%3Dliteratum%253Aachs%26aulast%3DGearhart%26aufirst%3DT.%2BL.%26aulast%3DBouchard%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520hepatitis%2520B%2520virus%2520X%2520protein%2520modulates%2520hepatocyte%2520proliferation%2520pathways%2520to%2520stimulate%2520viral%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D2675%26epage%3D2686%26doi%3D10.1128%2FJVI.02196-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guendel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbottah, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human immunodeficiency virus type-1 by cdk inhibitors</span>. <i>AIDS Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7</span>, <span class="refDoi">Â DOI: 10.1186/1742-6405-7-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2F1742-6405-7-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20334651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC3c3ltFyntg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=7&author=I.+Guendelauthor=E.+T.+Agbottahauthor=K.+Kehn-Hallauthor=F.+Kashanchi&title=Inhibition+of+human+immunodeficiency+virus+type-1+by+cdk+inhibitors&doi=10.1186%2F1742-6405-7-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human immunodeficiency virus type-1 by cdk inhibitors</span></div><div class="casAuthors">Guendel Irene; Kashanchi Fatah; Guendel Irene; Kehn-Hall Kylene; Kashanchi Fatah; Agbottah Emmanuel T; Kashanchi Fatah</div><div class="citationInfo"><span class="NLM_cas:title">AIDS research and therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current therapy for human immunodeficiency virus (HIV-1) infection relies primarily on the administration of anti-retroviral nucleoside analogues, either alone or in combination with HIV-protease inhibitors.  Although these drugs have a clinical benefit, continuous therapy with the drugs leads to drug-resistant strains of the virus.  Recently, significant progress has been made towards the development of natural and synthetic agents that can directly inhibit HIV-1 replication or its essential enzymes.  We previously reported on the pharmacological cyclin-dependent kinase inhibitor (PCI) r-roscovitine as a potential inhibitor of HIV-1 replication.  PCIs are among the most promising novel antiviral agents to emerge over the past few years.  Potent activity on viral replication combined with proliferation inhibition without the emergence of resistant viruses, which are normally observed in HAART patients; make PCIs ideal candidates for HIV-1 inhibition.  To this end we evaluated twenty four cdk inhibitors for their effect on HIV-1 replication in vitro.  Screening of these compounds identified alsterpaullone as the most potent inhibitor of HIV-1 with activity at 150 nM.  We found that alsterpaullone effectively inhibits cdk2 activity in HIV-1 infected cells with a low IC50 compared to control uninfected cells.  The effects of alsterpaullone were associated with suppression of cdk2 and cyclin expression.  Combining both alsterpaullone and r-roscovitine (cyc202) in treatment exhibited even stronger inhibitory activities in HIV-1 infected PBMCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgNOPCu4WBGeb6AVA-44PTfW6udTcc2ebFVj4-KTl2eLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3ltFyntg%253D%253D&md5=1abe0f1c81cf604ffd3ac7354e5b7d95</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1186%2F1742-6405-7-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-6405-7-7%26sid%3Dliteratum%253Aachs%26aulast%3DGuendel%26aufirst%3DI.%26aulast%3DAgbottah%26aufirst%3DE.%2BT.%26aulast%3DKehn-Hall%26aufirst%3DK.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520human%2520immunodeficiency%2520virus%2520type-1%2520by%2520cdk%2520inhibitors%26jtitle%3DAIDS%2520Res.%2520Ther.%26date%3D2010%26volume%3D7%26spage%3D7%26doi%3D10.1186%2F1742-6405-7-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marion, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterlin, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. H.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol inhibits P-TEFb and blocks HIV-1 replication</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">28345</span>â <span class="NLM_lpage">28348</span>, <span class="refDoi">Â DOI: 10.1074/jbc.C000446200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.C000446200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10906320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1Crtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=28345-28348&author=S.+H.+Chaoauthor=K.+Fujinagaauthor=J.+E.+Marionauthor=R.+Taubeauthor=E.+A.+Sausvilleauthor=A.+M.+Senderowiczauthor=B.+M.+Peterlinauthor=D.+H.+Price&title=Flavopiridol+inhibits+P-TEFb+and+blocks+HIV-1+replication&doi=10.1074%2Fjbc.C000446200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol inhibits P-TEFb and blocks HIV-1 replication</span></div><div class="casAuthors">Chao, Sheng-Hao; Fujinaga, Koh; Marion, Jon E.; Taube, Ran; Sausville, Edward A.; Senderowicz, Adrian M.; Peterlin, B. Matija; Price, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">28345-28348</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor that is in clin. trials as a cancer treatment because of its antiproliferative properties.  We found that the flavonoid potently inhibited transcription by RNA polymerase II in vitro by blocking the transition into productive elongation, a step controlled by P-TEFb.  The ability of P-TEFb to phosphorylate the carboxyl-terminal domain of the large subunit of RNA polymerase II was inhibited by flavopiridol with a Ki of 3 nM.  Interestingly, the drug was not competitive with ATP.  P-TEFb composed of Cdk9 and cyclin T1 is a required cellular cofactor for the human immunodeficiency virus (HIV-1) transactivator, Tat.  Consistent with its ability to inhibit P-TEFb, flavopiridol blocked Tat transactivation of the viral promoter in vitro.  Furthermore, flavopiridol blocked HIV-1 replication in both single-round and viral spread assays with an IC50 of less than 10 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmLtfeSo62BrVg90H21EOLACvtfcHk0lgQgWo3yjtgrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1Crtbs%253D&md5=3458cf5e661acf6e5de7dd99bc8e8502</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C000446200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C000446200%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DS.%2BH.%26aulast%3DFujinaga%26aufirst%3DK.%26aulast%3DMarion%26aufirst%3DJ.%2BE.%26aulast%3DTaube%26aufirst%3DR.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DPeterlin%26aufirst%3DB.%2BM.%26aulast%3DPrice%26aufirst%3DD.%2BH.%26atitle%3DFlavopiridol%2520inhibits%2520P-TEFb%2520and%2520blocks%2520HIV-1%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D28345%26epage%3D28348%26doi%3D10.1074%2Fjbc.C000446200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perwitasari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, R. A.</span></span> <span> </span><span class="NLM_article-title">Repurposing kinase inhibitors as antiviral agents to control influenza A</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">638</span>â <span class="NLM_lpage">649</span>, <span class="refDoi">Â DOI: 10.1089/adt.2015.0003.drrr</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1089%2Fadt.2015.0003.drrr" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26192013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGiu7rF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=638-649&author=O.+Perwitasariauthor=X.+Yanauthor=J.+O%E2%80%99Donnellauthor=S.+Johnsonauthor=R.+A.+Tripp&title=Repurposing+kinase+inhibitors+as+antiviral+agents+to+control+influenza+A&doi=10.1089%2Fadt.2015.0003.drrr"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication</span></div><div class="casAuthors">Perwitasari, Olivia; Yan, Xiuzhen; O'Donnell, Jason; Johnson, Scott; Tripp, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">638-649</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Influenza A virus (IAV) infection causes seasonal epidemics of contagious respiratory illness that causes substantial morbidity and some mortality.  Regular vaccination is the principal strategy for controlling influenza virus, although vaccine efficacy is variable.  IAV antiviral drugs are available; however, substantial drug resistance has developed to two of the four currently FDA-approved antiviral drugs.  Thus, new therapeutic approaches are being sought to reduce the burden of influenza-related disease.  A high-throughput screen using a human kinase inhibitor library was performed targeting an emerging IAV strain (H7N9) in A549 cells.  The inhibitor library contained 273 structurally diverse, active cell permeable kinase inhibitors with known bioactivity and safety profiles, many of which are at advanced stages of clin. development.  The current study shows that treatment of human A549 cells with kinase inhibitors dinaciclib, flavopiridol, or PIK-75 exhibits potent antiviral activity against H7N9 IAV as well as other IAV strains.  Thus, targeting host kinases can provide a broad-spectrum therapeutic approach against IAV.  These findings provide a path forward for repurposing existing kinase inhibitors safely as potential antivirals, particularly those that can be tested in vivo and ultimately for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI0vSkwPosrrVg90H21EOLACvtfcHk0lgQgWo3yjtgrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGiu7rF&md5=cf1f193bc2e8b0278caa3e43158180d7</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1089%2Fadt.2015.0003.drrr&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2015.0003.drrr%26sid%3Dliteratum%253Aachs%26aulast%3DPerwitasari%26aufirst%3DO.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DTripp%26aufirst%3DR.%2BA.%26atitle%3DRepurposing%2520kinase%2520inhibitors%2520as%2520antiviral%2520agents%2520to%2520control%2520influenza%2520A%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2015%26volume%3D13%26spage%3D638%26epage%3D649%26doi%3D10.1089%2Fadt.2015.0003.drrr" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tcw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouznetsova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itkin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennand, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span> <span> </span><span class="NLM_article-title">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1101</span>â <span class="NLM_lpage">1107</span>, <span class="refDoi">Â DOI: 10.1038/nm.4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnm.4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27571349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWks7%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1101-1107&author=M.+Xuauthor=E.+M.+Leeauthor=Z.+Wenauthor=Y.+Chengauthor=W.+K.+Huangauthor=X.+Qianauthor=J.+Tcwauthor=J.+Kouznetsovaauthor=S.+C.+Ogdenauthor=C.+Hammackauthor=F.+Jacobauthor=H.+N.+Nguyenauthor=M.+Itkinauthor=C.+Hannaauthor=P.+Shinnauthor=C.+Allenauthor=S.+G.+Michaelauthor=A.+Simeonovauthor=W.+Huangauthor=K.+M.+Christianauthor=A.+Goateauthor=K.+J.+Brennandauthor=R.+Huangauthor=M.+Xiaauthor=G.+L.+Mingauthor=W.+Zhengauthor=H.+Songauthor=H.+Tang&title=Identification+of+small-molecule+inhibitors+of+Zika+virus+infection+and+induced+neural+cell+death+via+a+drug+repurposing+screen&doi=10.1038%2Fnm.4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</span></div><div class="casAuthors">Xu, Miao; Lee, Emily M.; Wen, Zhexing; Cheng, Yichen; Huang, Wei-Kai; Qian, Xuyu; Tcw, Julia; Kouznetsova, Jennifer; Ogden, Sarah C.; Hammack, Christy; Jacob, Fadi; Nguyen, Ha Nam; Itkin, Misha; Hanna, Catherine; Shinn, Paul; Allen, Chase; Michael, Samuel G.; Simeonov, Anton; Huang, Wenwei; Christian, Kimberly M.; Goate, Alison; Brennand, Kristen J.; Huang, Ruili; Xia, Menghang; Ming, Guo-li; Zheng, Wei; Song, Hongjun; Tang, Hengli</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1101-1107</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In response to the current global health emergency posed by the Zika virus (ZIKV) outbreak and its link to microcephaly and other neurol. conditions, we performed a drug repurposing screen of â¼6,000 compds. that included approved drugs, clin. trial drug candidates and pharmacol. active compds.; we identified compds. that either inhibit ZIKV infection or suppress infection-induced caspase-3 activity in different neural cells.  A pan-caspase inhibitor, emricasan, inhibited ZIKV-induced increases in caspase-3 activity and protected human cortical neural progenitors in both monolayer and three-dimensional organoid cultures.  Ten structurally unrelated inhibitors of cyclin-dependent kinases inhibited ZIKV replication.  Niclosamide, a category B anthelmintic drug approved by the US Food and Drug Administration, also inhibited ZIKV replication.  Finally, combination treatments using one compd. from each category (neuroprotective and antiviral) further increased protection of human neural progenitors and astrocytes from ZIKV-induced cell death.  Our results demonstrate the efficacy of this screening strategy and identify lead compds. for anti-ZIKV drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3-p_dTqQnbVg90H21EOLACvtfcHk0lgQgWo3yjtgrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWks7%252FF&md5=dd03539176ee2712f45391eca46d996f</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1038%2Fnm.4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4184%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DE.%2BM.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.%2BK.%26aulast%3DQian%26aufirst%3DX.%26aulast%3DTcw%26aufirst%3DJ.%26aulast%3DKouznetsova%26aufirst%3DJ.%26aulast%3DOgden%26aufirst%3DS.%2BC.%26aulast%3DHammack%26aufirst%3DC.%26aulast%3DJacob%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DH.%2BN.%26aulast%3DItkin%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DC.%26aulast%3DShinn%26aufirst%3DP.%26aulast%3DAllen%26aufirst%3DC.%26aulast%3DMichael%26aufirst%3DS.%2BG.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DChristian%26aufirst%3DK.%2BM.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DBrennand%26aufirst%3DK.%2BJ.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DMing%26aufirst%3DG.%2BL.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520small-molecule%2520inhibitors%2520of%2520Zika%2520virus%2520infection%2520and%2520induced%2520neural%2520cell%2520death%2520via%2520a%2520drug%2520repurposing%2520screen%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D1101%26epage%3D1107%26doi%3D10.1038%2Fnm.4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-MuÃ±oz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujantell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">EstÃ©, J. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">387</span>â <span class="NLM_lpage">394</span>, <span class="refDoi">Â DOI: 10.1093/jac/dkv363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1093%2Fjac%2Fdkv363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26542306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslWjtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2016&pages=387-394&author=R.+Badiaauthor=G.+Anguloauthor=E.+Riveira-Mu%C3%B1ozauthor=M.+Pujantellauthor=T.+Puigauthor=C.+Ramirezauthor=J.+Torres-Torronterasauthor=R.+Mart%C3%ADauthor=E.+Paulsauthor=B.+Clotetauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Inhibition+of+herpes+simplex+virus+type+1+by+the+CDK6+inhibitor+PD-0332991+%28palbociclib%29+through+the+control+of+SAMHD1&doi=10.1093%2Fjac%2Fdkv363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1</span></div><div class="casAuthors">Badia, Roger; Angulo, Guillem; Riveira-Munoz, Eva; Pujantell, Maria; Puig, Teresa; Ramirez, Cristina; Torres-Torronteras, Javier; Marti, Ramon; Pauls, Eduardo; Clotet, Bonaventura; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">387-394</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives Sterile Î± motif and histidine-aspartate domain-contg. protein 1 (SAMHD1) has been shown to restrict retroviruses and DNA viruses by decreasing the pool of intracellular deoxynucleotides.  In turn, SAMHD1 is controlled by cyclin-dependent kinases (CDK) that regulate the cell cycle and cell proliferation.  Here, we explore the effect of CDK6 inhibitors on the replication of herpes simplex virus type 1 (HSV-1) in primary monocyte-derived macrophages (MDM).  Methods MDM were treated with palbociclib, a selective CDK4/6 inhibitor, and then infected with a GFP-expressing HSV-1.  Intracellular deoxynucleotide triphosphate (dNTP) content was detd. using a polymerase-based method.  Results CDK6 inhibitor palbociclib blocked SAMHD1 phosphorylation, intracellular dNTP levels and HSV-1 replication in MDM at subtoxic concns.  Treatment of MDM with palbociclib reduced CDK2 activation, measured as the phosphorylation of the T-loop at Thr160.  The antiviral activity of palbociclib was lost when SAMHD1 was degraded by viral protein X.  Similarly, palbociclib did not block HSV-1 replication in SAMHD1-neg. Vero cells at subtoxic concns., providing further evidence for a role of SAMHD1 in mediating the antiviral effect.  Conclusions SAMHD1-mediated HSV-1 restriction is controlled by CDK and points to a preferential role for CDK6 and CDK2 as mediators of SAMHD1 activation.  Similarly, the restricting activity of SAMHD1 against DNA viruses suggests that control of dNTP availability is the major determinant of its antiviral activity.  This is the first study describing the anti-HSV-1 activity of palbociclib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-y_UxXw_iDbVg90H21EOLACvtfcHk0lgi_48rQSNhyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslWjtr4%253D&md5=b527d13ba9403fd4da637f39dd20ad5b</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv363%26sid%3Dliteratum%253Aachs%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DAngulo%26aufirst%3DG.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DPujantell%26aufirst%3DM.%26aulast%3DPuig%26aufirst%3DT.%26aulast%3DRamirez%26aufirst%3DC.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3DMart%25C3%25AD%26aufirst%3DR.%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DInhibition%2520of%2520herpes%2520simplex%2520virus%2520type%25201%2520by%2520the%2520CDK6%2520inhibitor%2520PD-0332991%2520%2528palbociclib%2529%2520through%2520the%2520control%2520of%2520SAMHD1%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2016%26volume%3D71%26spage%3D387%26epage%3D394%26doi%3D10.1093%2Fjac%2Fdkv363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dove, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicknell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiscox, J. A.</span></span> <span> </span><span class="NLM_article-title">Cell cycle perturbations induced by infection with the coronavirus infectious bronchitis virus and their effect on virus replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">4147</span>â <span class="NLM_lpage">4156</span>, <span class="refDoi">Â DOI: 10.1128/JVI.80.8.4147-4156.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.80.8.4147-4156.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16571830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs1Sqsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=4147-4156&author=B.+Doveauthor=G.+Brooksauthor=K.+Bicknellauthor=T.+Wurmauthor=J.+A.+Hiscox&title=Cell+cycle+perturbations+induced+by+infection+with+the+coronavirus+infectious+bronchitis+virus+and+their+effect+on+virus+replication&doi=10.1128%2FJVI.80.8.4147-4156.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle perturbations induced by infection with the coronavirus Infectious Bronchitis Virus and their effect on virus replication</span></div><div class="casAuthors">Dove, Brian; Brooks, Gavin; Bicknell, Katrina; Wurm, Torsten; Hiscox, Julian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4147-4156</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In eukaryotic cells, cell growth and division occur in a stepwise, orderly fashion described by a process known as the cell cycle.  The relationship between pos.-strand RNA viruses and the cell cycle and the concomitant effects on virus replication are not clearly understood.  We have shown that infection of asynchronously replicating and synchronized replicating cells with the avian coronavirus infectious bronchitis virus (IBV), a pos.-strand RNA virus, resulted in the accumulation of infected cells in the G2/M phase of the cell cycle.  Anal. of various cell cycle-regulatory proteins and cellular morphol. indicated that there was a down-regulation of cyclins D1 and D2 (G1 regulatory cyclins) and that a proportion of virus-infected cells underwent aberrant cytokinesis, in which the cells underwent nuclear, but not cytoplasmic, division.  We assessed the impact of the perturbations on the cell cycle for virus-infected cells and found that IBV-infected G2/M-phase-synchronized cells exhibited increased viral protein prodn. when released from the block when compared to cells synchronized in the G0 phase or asynchronously replicating cells.  Our data suggested that IBV induces a G2/M phase arrest in infected cells to promote favorable conditions for viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRLrM-UqXdo7Vg90H21EOLACvtfcHk0lgi_48rQSNhyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs1Sqsr8%253D&md5=47b9d4edc176e57f677ee10ca68b3369</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1128%2FJVI.80.8.4147-4156.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.80.8.4147-4156.2006%26sid%3Dliteratum%253Aachs%26aulast%3DDove%26aufirst%3DB.%26aulast%3DBrooks%26aufirst%3DG.%26aulast%3DBicknell%26aufirst%3DK.%26aulast%3DWurm%26aufirst%3DT.%26aulast%3DHiscox%26aufirst%3DJ.%2BA.%26atitle%3DCell%2520cycle%2520perturbations%2520induced%2520by%2520infection%2520with%2520the%2520coronavirus%2520infectious%2520bronchitis%2520virus%2520and%2520their%2520effect%2520on%2520virus%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D4147%26epage%3D4156%26doi%3D10.1128%2FJVI.80.8.4147-4156.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Cell cycle arrest and apoptosis induced by the coronavirus infectious bronchitis virus in the absence of p53</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">435</span>â <span class="NLM_lpage">445</span>, <span class="refDoi">Â DOI: 10.1016/j.virol.2007.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.virol.2007.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17493653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFKju7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2007&pages=435-445&author=F.+Q.+Liauthor=J.+P.+Tamauthor=D.+Liu&title=Cell+cycle+arrest+and+apoptosis+induced+by+the+coronavirus+infectious+bronchitis+virus+in+the+absence+of+p53&doi=10.1016%2Fj.virol.2007.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle arrest and apoptosis induced by the coronavirus infectious bronchitis virus in the absence of p53</span></div><div class="casAuthors">Li, Frank Q.; Tam, James P.; Liu, Ding Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">435-445</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Manipulation of the cell cycle and induction of apoptosis are two common strategies used by many viruses to regulate their infection cycles.  In cells infected with coronaviruses, cell cycle perturbation and apoptosis were obsd. in several reports.  However, little is known about how these effects are brought out, and how manipulation of the functions of host cells would influence the replication cycle of coronavirus.  In this study, we demonstrate that infection with coronavirus infectious bronchitis virus (IBV) imposed a growth-inhibitory effect on cultured cells by inducing cell cycle arrest at S and G2/M phases in both p53-null cell line H1299 and Vero cells.  This cell cycle arrest was catalyzed by the modulation of various cell cycle regulatory genes and the accumulation of hypophosphorylated RB, but was independent of p53.  Proteasome inhibitors, such as lactacystin and NLVS, could bypass the IBV-induced S-phase arrest by restoring the expression of corresponding cyclin/Cdk complexes.  Our data also showed that cell cycle arrest at both S- and G2/M-phases was manipulated by IBV for the enhancement of viral replication.  In addn., apoptosis induced by IBV at late stages of the infection cycle in cultured cells was shown to be p53-independent.  This conclusion was drawn based on the observations that apoptosis occurred in both IBV-infected H1299 and Vero cells, and that IBV infection did not affect the expression of p53 in host cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4-f-7FCWAzrVg90H21EOLACvtfcHk0lgi_48rQSNhyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFKju7c%253D&md5=fec3d4ca92d15cfd6b8a5c33beb48995</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2007.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2007.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%2BQ.%26aulast%3DTam%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DCell%2520cycle%2520arrest%2520and%2520apoptosis%2520induced%2520by%2520the%2520coronavirus%2520infectious%2520bronchitis%2520virus%2520in%2520the%2520absence%2520of%2520p53%26jtitle%3DVirology%26date%3D2007%26volume%3D365%26spage%3D435%26epage%3D445%26doi%3D10.1016%2Fj.virol.2007.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lilley, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzman, M. D.</span></span> <span> </span><span class="NLM_article-title">Using or abusing: Viruses and the cellular DNA damage response</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">119</span>â <span class="NLM_lpage">126</span>, <span class="refDoi">Â DOI: 10.1016/j.tim.2007.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.tim.2007.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17275307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisleis7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=119-126&author=C.+E.+Lilleyauthor=R.+A.+Schwartzauthor=M.+D.+Weitzman&title=Using+or+abusing%3A+Viruses+and+the+cellular+DNA+damage+response&doi=10.1016%2Fj.tim.2007.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Using or abusing: Viruses and the cellular DNA damage response</span></div><div class="casAuthors">Lilley, Caroline E.; Schwartz, Rachel A.; Weitzman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">119-126</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  During infection, viruses attempt to hijack the cell while the host responds with various defense systems.  Traditional defenses include the interferon response and apoptosis, but recent work suggests that this antiviral arsenal also includes the cellular DNA damage response machinery.  The observation of interactions between viruses and cellular DNA repair proteins has not only uncovered new complexities of the virus-host interaction but is also reinforcing the view that viruses can reveal key regulators of cellular pathways through the proteins they target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6utSPArUa4rVg90H21EOLACvtfcHk0lhG6A4s9L3eyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisleis7c%253D&md5=f0656239394aabaf27766e5c6ab93dc2</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2007.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2007.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DLilley%26aufirst%3DC.%2BE.%26aulast%3DSchwartz%26aufirst%3DR.%2BA.%26aulast%3DWeitzman%26aufirst%3DM.%2BD.%26atitle%3DUsing%2520or%2520abusing%253A%2520Viruses%2520and%2520the%2520cellular%2520DNA%2520damage%2520response%26jtitle%3DTrends%2520Microbiol.%26date%3D2007%26volume%3D15%26spage%3D119%26epage%3D126%26doi%3D10.1016%2Fj.tim.2007.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ariumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dansako, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span> <span> </span><span class="NLM_article-title">The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">9639</span>â <span class="NLM_lpage">9646</span>, <span class="refDoi">Â DOI: 10.1128/JVI.00351-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.00351-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18667510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKgsL%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=9639-9646&author=Y.+Ariumiauthor=M.+Kurokiauthor=H.+Dansakoauthor=K.+Abeauthor=M.+Ikedaauthor=T.+Wakitaauthor=N.+Kato&title=The+DNA+damage+sensors+ataxia-telangiectasia+mutated+kinase+and+checkpoint+kinase+2+are+required+for+hepatitis+C+virus+RNA+replication&doi=10.1128%2FJVI.00351-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication</span></div><div class="casAuthors">Ariumi, Yasuo; Kuroki, Misao; Dansako, Hiromichi; Abe, Ken-Ichi; Ikeda, Masanori; Wakita, Takaji; Kato, Nobuyuko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9639-9646</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Cellular responses to DNA damage are crucial for maintaining genome integrity, virus infection, and preventing the development of cancer.  Hepatitis C virus (HCV) infection and the expression of the HCV nonstructural protein NS3 and core protein have been proposed as factors involved in the induction of double-stranded DNA breaks and enhancement of the mutation frequency of cellular genes.  Since DNA damage sensors, such as the ataxia-telangiectasia mutated kinase (ATM), ATM- and Rad3-related kinase (ATR), poly(ADP-ribose) polymerase 1 (PARP-1), and checkpoint kinase 2 (Chk2), play central roles in the response to genotoxic stress, we hypothesized that these sensors might affect HCV replication.  To test this hypothesis, we examd. the level of HCV RNA in HuH-7-derived cells stably expressing short hairpin RNA targeted to ATM, ATR, PARP-1, or Chk2.  Consequently, we found that replication of both genome-length HCV RNA (HCV-O, genotype 1b) and the subgenomic replicon RNA were notably suppressed in ATM- or Chk2-knockdown cells.  In addn., the RNA replicated of HCV-JFH1 (genotype 2a) and the release of core protein into the culture supernatants were suppressed in these knockdown cells after inoculation of the cell culture-generated HCV.  Consistent with these observations, ATM kinase inhibitor could suppress the HCV RNA replication.  Furthermore, we obsd. that HCV NS3-NS4A interacted with ATM and that HCV NS5B interacted with both ATM and Chk2.  Taken together, these results suggest that the ATM signaling pathway is crit. for HCV RNA replication and may represent a novel target for the clin. treatment of patients with chronic hepatitis C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWtA81BaohzLVg90H21EOLACvtfcHk0lhG6A4s9L3eyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKgsL%252FE&md5=292d41057b357535b2b62b20387765fb</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1128%2FJVI.00351-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00351-08%26sid%3Dliteratum%253Aachs%26aulast%3DAriumi%26aufirst%3DY.%26aulast%3DKuroki%26aufirst%3DM.%26aulast%3DDansako%26aufirst%3DH.%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DM.%26aulast%3DWakita%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DN.%26atitle%3DThe%2520DNA%2520damage%2520sensors%2520ataxia-telangiectasia%2520mutated%2520kinase%2520and%2520checkpoint%2520kinase%25202%2520are%2520required%2520for%2520hepatitis%2520C%2520virus%2520RNA%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D9639%26epage%3D9646%26doi%3D10.1128%2FJVI.00351-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaurushiya, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzman, M. D.</span></span> <span> </span><span class="NLM_article-title">Viral manipulation of DNA repair and cell cycle checkpoints</span>. <i>DNA Repair</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1166</span>â <span class="NLM_lpage">1176</span>, <span class="refDoi">Â DOI: 10.1016/j.dnarep.2009.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.dnarep.2009.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=19473887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1WrsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1166-1176&author=M.+S.+Chaurushiyaauthor=M.+D.+Weitzman&title=Viral+manipulation+of+DNA+repair+and+cell+cycle+checkpoints&doi=10.1016%2Fj.dnarep.2009.04.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Viral manipulation of DNA repair and cell cycle checkpoints</span></div><div class="casAuthors">Chaurushiya, Mira S.; Weitzman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">DNA Repair</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1166-1176</span>CODEN:
                <span class="NLM_cas:coden">DRNEAR</span>;
        ISSN:<span class="NLM_cas:issn">1568-7864</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recognition and repair of DNA damage is crit. for maintaining genomic integrity and suppressing tumorigenesis.  In eukaryotic cells, the sensing and repair of DNA damage are coordinated with cell cycle progression and checkpoints, in order to prevent the propagation of damaged DNA.  The carefully maintained cellular response to DNA damage is challenged by viruses, which produce a large amt. of exogenous DNA during infection.  Viruses also express proteins that perturb cellular DNA repair and cell cycle pathways, promoting tumorigenesis in their quest for cellular domination.  This review presents an overview of strategies employed by viruses to manipulate DNA damage responses and cell cycle checkpoints as they commandeer the cell to maximize their own viral replication.  Studies of viruses have identified key cellular regulators and revealed insights into mol. mechanisms governing DNA repair, cell cycle checkpoints, and transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZN_3vCalZxrVg90H21EOLACvtfcHk0lhG6A4s9L3eyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1WrsrY%253D&md5=b49f8a14f5679514b2ecfa43f3354086</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.dnarep.2009.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dnarep.2009.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DChaurushiya%26aufirst%3DM.%2BS.%26aulast%3DWeitzman%26aufirst%3DM.%2BD.%26atitle%3DViral%2520manipulation%2520of%2520DNA%2520repair%2520and%2520cell%2520cycle%2520checkpoints%26jtitle%3DDNA%2520Repair%26date%3D2009%26volume%3D8%26spage%3D1166%26epage%3D1176%26doi%3D10.1016%2Fj.dnarep.2009.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoenen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelotti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewey, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWald, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp-Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKnight, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span> <span> </span><span class="NLM_article-title">The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0005540</span> <span class="refDoi">Â DOI: 10.1371/journal.pntd.0005540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.pntd.0005540" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28403145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWrsb3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&author=E.+A.+Nelsonauthor=J.+Dyallauthor=T.+Hoenenauthor=A.+B.+Barnesauthor=H.+Zhouauthor=J.+Y.+Liangauthor=J.+Michelottiauthor=W.+H.+Deweyauthor=L.+E.+DeWaldauthor=R.+S.+Bennettauthor=P.+J.+Morrisauthor=R.+Guhaauthor=C.+Klumpp-Thomasauthor=C.+McKnightauthor=Y.+C.+Chenauthor=X.+Xuauthor=A.+Wangauthor=E.+Hughesauthor=S.+Martinauthor=C.+Thomasauthor=P.+B.+Jahrlingauthor=L.+E.+Hensleyauthor=G.+G.+Olingerauthor=J.+M.+White&title=The+phosphatidylinositol-3-phosphate+5-kinase+inhibitor+apilimod+blocks+filoviral+entry+and+infection&doi=10.1371%2Fjournal.pntd.0005540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection</span></div><div class="casAuthors">Nelson, Elizabeth A.; Dyall, Julie; Hoenen, Thomas; Barnes, Alyson B.; Zhou, Huanying; Liang, Janie Y.; Michelotti, Julia; Dewey, William H.; DeWald, Lisa Evans; Bennett, Richard S.; Morris, Patrick J.; Guha, Rajarshi; Klumpp-Thomas, Carleen; McKnight, Crystal; Chen, Yu-Chi; Xu, Xin; Wang, Amy; Hughes, Emma; Martin, Scott; Thomas, Craig; Jahrling, Peter B.; Hensley, Lisa E.; Olinger, Gene G. Jr.; White, Judith M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0005540/1-e0005540/22</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) is a lipid kinase involved in endosome maturation that emerged from a haploid genetic screen as being required for Ebola virus (EBOV) infection.  Here we analyzed the effects of apilimod, a PIKfyve inhibitor that was reported to be well tolerated in humans in phase 2 clin. trials, for its effects on entry and infection of EBOV and Marburg virus (MARV).  We first found that apilimod blocks infections by EBOV and MARV in Huh 7, Vero E6 and primary human macrophage cells, with notable potency in the macrophages (IC50, 10 nM).  We next obsd. that similar doses of apilimod block EBOV-glycoprotein-virus like particle (VLP) entry and transcription-replication competent VLP infection, suggesting that the primary mode of action of apilimod is as an entry inhibitor, preventing release of the viral genome into the cytoplasm to initiate replication.  After providing evidence that the anti-EBOV action of apilimod is via PIKfyve, we showed that it blocks trafficking of EBOV VLPs to endolysosomes contg. Niemann-Pick C1 (NPC1), the intracellular receptor for EBOV.  Concurrently apilimod caused VLPs to accumulate in early endosome antigen 1-pos. endosomes.  We did not detect any effects of apilimod on bulk endosome acidification, on the activity of cathepsins B and L, or on cholesterol export from endolysosomes.  Hence by antagonizing PIKfyve, apilimod appears to block EBOV trafficking to its site of fusion and entry into the cytoplasm.  Given the drug's obsd. anti-filoviral activity, relatively unexplored mechanism of entry inhibition, and reported tolerability in humans, we propose that apilimod be further explored as part of a therapeutic regimen to treat filoviral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlUaAMvLkQT7Vg90H21EOLACvtfcHk0liWfxxkHMFUDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWrsb3O&md5=c2f72fa69b941bcc8c97dcacf0e210bd</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005540%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DHoenen%26aufirst%3DT.%26aulast%3DBarnes%26aufirst%3DA.%2BB.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%2BY.%26aulast%3DMichelotti%26aufirst%3DJ.%26aulast%3DDewey%26aufirst%3DW.%2BH.%26aulast%3DDeWald%26aufirst%3DL.%2BE.%26aulast%3DBennett%26aufirst%3DR.%2BS.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DKlumpp-Thomas%26aufirst%3DC.%26aulast%3DMcKnight%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DC.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520phosphatidylinositol-3-phosphate%25205-kinase%2520inhibitor%2520apilimod%2520blocks%2520filoviral%2520entry%2520and%2520infection%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26doi%3D10.1371%2Fjournal.pntd.0005540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulseberg, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FÃ©nÃ©ant, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SzymaÅska-De
Wijs, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmaljohn, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyak, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span> <span> </span><span class="NLM_article-title">Arbidol and other low-molecular-weight drugs that inhibit lassa and Ebola viruses</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>93</i></span>, <span class="NLM_elocation-id">e02185-18</span> <span class="refDoi">Â DOI: 10.1128/JVI.02185-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.02185-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30700611" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2019&author=C.+E.+Hulsebergauthor=L.+F%C3%A9n%C3%A9antauthor=K.+M.+Szyma%C5%84ska-De%0AWijsauthor=N.+P.+Kesslerauthor=E.+A.+Nelsonauthor=C.+J.+Shoemakerauthor=C.+S.+Schmaljohnauthor=S.+J.+Polyakauthor=J.+M.+White&title=Arbidol+and+other+low-molecular-weight+drugs+that+inhibit+lassa+and+Ebola+viruses&doi=10.1128%2FJVI.02185-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1128%2FJVI.02185-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02185-18%26sid%3Dliteratum%253Aachs%26aulast%3DHulseberg%26aufirst%3DC.%2BE.%26aulast%3DF%25C3%25A9n%25C3%25A9ant%26aufirst%3DL.%26aulast%3DSzyma%25C5%2584ska-De%2BWijs%26aufirst%3DK.%2BM.%26aulast%3DKessler%26aufirst%3DN.%2BP.%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DShoemaker%26aufirst%3DC.%2BJ.%26aulast%3DSchmaljohn%26aufirst%3DC.%2BS.%26aulast%3DPolyak%26aufirst%3DS.%2BJ.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26atitle%3DArbidol%2520and%2520other%2520low-molecular-weight%2520drugs%2520that%2520inhibit%2520lassa%2520and%2520Ebola%2520viruses%26jtitle%3DJ.%2520Virol.%26date%3D2019%26volume%3D93%26doi%3D10.1128%2FJVI.02185-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikonomov, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbrissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shisheva, A.</span></span> <span> </span><span class="NLM_article-title">Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">114771</span>, <span class="refDoi">Â DOI: 10.1016/j.taap.2019.114771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.taap.2019.114771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31628917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKgt7rJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2019&pages=114771&author=O.+C.+Ikonomovauthor=D.+Sbrissaauthor=A.+Shisheva&title=Small+molecule+PIKfyve+inhibitors+as+cancer+therapeutics%3A+Translational+promises+and+limitations&doi=10.1016%2Fj.taap.2019.114771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations</span></div><div class="casAuthors">Ikonomov, Ognian C.; Sbrissa, Diego; Shisheva, Assia</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114771</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Through synthesis of two rare phosphoinositides, PtdIns(3,5)P2 and PtdIns5P, the ubiquitously expressed phosphoinositide kinase PIKfyve is implicated in pleiotropic cellular functions.  Small mols. specifically inhibiting PIKfyve activity cause cytoplasmic vacuolation in all dividing cells in culture yet trigger non-apoptotic death through excessive vacuolation only in cancer cells.  Intriguingly, cancer cell toxicity appears to be inhibitor-specific suggesting that addnl. targets beyond PIKfyve are affected.  One PIKfyve inhibitor - apilimod - is already in clin. trials for treatment of B-cell malignancies.  However, apilimod is inactivated in cultured cells and exhibits unexpectedly low plasma levels in patients treated with max. oral dosage.  Thus, the potential widespread use of PIKfyve inhibitors as cancer therapeutics requires progress on multiple fronts: (i) advances in methods for isolating relevant cancer cells from individual patients; (ii) delineation of the mol. mechanisms potentiating the vacuolation induced by PIKfyve inhibitors in sensitive cancer cells; (iii) design of PIKfyve inhibitors with favorable pharmacokinetics; and (iv) development of effective drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVCqd6_1ZLsrVg90H21EOLACvtfcHk0liWfxxkHMFUDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKgt7rJ&md5=992d773408d82e75fe81132678d6c0df</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2019.114771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2019.114771%26sid%3Dliteratum%253Aachs%26aulast%3DIkonomov%26aufirst%3DO.%2BC.%26aulast%3DSbrissa%26aufirst%3DD.%26aulast%3DShisheva%26aufirst%3DA.%26atitle%3DSmall%2520molecule%2520PIKfyve%2520inhibitors%2520as%2520cancer%2520therapeutics%253A%2520Translational%2520promises%2520and%2520limitations%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2019%26volume%3D383%26spage%3D114771%26doi%3D10.1016%2Fj.taap.2019.114771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eggersmann, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhardt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gluz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuerstlein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span> <span> </span><span class="NLM_article-title">CDK4/6 inhibitors expand the therapeutic options in breast cancer: Palbociclib, Ribociclib and Abemaciclib</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">125</span>â <span class="NLM_lpage">135</span>, <span class="refDoi">Â DOI: 10.1007/s40259-019-00337-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs40259-019-00337-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30847853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyitbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=125-135&author=T.+K.+Eggersmannauthor=T.+Degenhardtauthor=O.+Gluzauthor=R.+Wuerstleinauthor=N.+Harbeck&title=CDK4%2F6+inhibitors+expand+the+therapeutic+options+in+breast+cancer%3A+Palbociclib%2C+Ribociclib+and+Abemaciclib&doi=10.1007%2Fs40259-019-00337-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib</span></div><div class="casAuthors">Eggersmann, Tanja K.; Degenhardt, Tom; Gluz, Oleg; Wuerstlein, Rachel; Harbeck, Nadia</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-135</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The majority of patients with metastatic breast cancer (MBC) have hormone receptor-pos. HER2-neg. disease.  For this subgroup, endocrine therapy is the key therapeutic option.  Recently, therapeutic options have been expanded by introduction of the inhibitors of cyclin-dependent kinases 4/6 (CDK4/6i).  Three compds., palbociclib, ribociclib, and abemaciclib, have already been approved by the FDA for use together with endocrine therapy such as aromatase inhibitors (AIs) or fulvestrant; abemaciclib is also approved as a single agent.  In the first-line setting, all three agents-together with an AI-substantially prolonged progression-free survival with a consistent hazard ratio of around 0.5 in all phase III trials.  The data for second-line settings and beyond is also quite consistent, with again a substantial prolongation of progression-free survival demonstrated for fulvestrant together with palbociclib, ribociclib, or abemaciclib.  Treatment with CDK4/6i is well tolerated and side effects are manageable.  With palbociclib and ribociclib, hematol. toxicities are most frequent.  Abemaciclib has a lower incidence of neutropenia and a much greater incidence of all grades of diarrhea compared with other CDK4/6i, making diarrhea the key toxicity for abemaciclib.  Patient quality of life is maintained under therapy and, particularly in later line settings, deterioration of quality of life is slowed down and symptoms such as pain are better controlled by CDK4/6i.  Their consistent and clin. relevant efficacy makes these drugs an important improvement in our armamentarium against MBC and, potentially, ideal candidates in early breast cancer (EBC).  This review summarizes the available clin. data for CDK4/6i and current research activities, particularly in EBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpioH0AnGSW0LVg90H21EOLACvtfcHk0ljkNazLO1nWmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyitbc%253D&md5=95c5d92b8e8a215dc3199dd4b96775c9</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1007%2Fs40259-019-00337-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-019-00337-6%26sid%3Dliteratum%253Aachs%26aulast%3DEggersmann%26aufirst%3DT.%2BK.%26aulast%3DDegenhardt%26aufirst%3DT.%26aulast%3DGluz%26aufirst%3DO.%26aulast%3DWuerstlein%26aufirst%3DR.%26aulast%3DHarbeck%26aufirst%3DN.%26atitle%3DCDK4%252F6%2520inhibitors%2520expand%2520the%2520therapeutic%2520options%2520in%2520breast%2520cancer%253A%2520Palbociclib%252C%2520Ribociclib%2520and%2520Abemaciclib%26jtitle%3DBioDrugs%26date%3D2019%26volume%3D33%26spage%3D125%26epage%3D135%26doi%3D10.1007%2Fs40259-019-00337-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poratti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzaro, G.</span></span> <span> </span><span class="NLM_article-title">Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">143</span>â <span class="NLM_lpage">153</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.03.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.ejmech.2019.03.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30978559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVSgtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2019&pages=143-153&author=M.+Porattiauthor=G.+Marzaro&title=Third-generation+CDK+inhibitors%3A+A+review+on+the+synthesis+and+binding+modes+of+Palbociclib%2C+Ribociclib+and+Abemaciclib&doi=10.1016%2Fj.ejmech.2019.03.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib</span></div><div class="casAuthors">Poratti, Melania; Marzaro, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">143-153</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The role of cyclin-dependent kinases (CDKs) in regulating the transition of cell cycle steps makes this class of enzymes a suitable target for cancer therapy.  Three different generations of CDKs inhibitors have been developed so far.  Third-generation compds. (i.e. selective CDK4/6 inhibitors) are the most promising ones, due to their limited toxicity and high in vivo activity.  To date, three compds. have entered the therapy, namely Palbociclib, Ribociclib and Abemaciclib.  Herein we review the medicinal chem. aspects of these drugs, with some refs. to very similar analogs that have been published.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXSxnZIYEUgLVg90H21EOLACvtfcHk0ljkNazLO1nWmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVSgtbk%253D&md5=4d22f955150b069a2d0418538323d71f</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.03.064%26sid%3Dliteratum%253Aachs%26aulast%3DPoratti%26aufirst%3DM.%26aulast%3DMarzaro%26aufirst%3DG.%26atitle%3DThird-generation%2520CDK%2520inhibitors%253A%2520A%2520review%2520on%2520the%2520synthesis%2520and%2520binding%2520modes%2520of%2520Palbociclib%252C%2520Ribociclib%2520and%2520Abemaciclib%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D172%26spage%3D143%26epage%3D153%26doi%3D10.1016%2Fj.ejmech.2019.03.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meggio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span> <span> </span><span class="NLM_article-title">One-thousand-and-one substrates of protein kinase CK2?</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">349</span>â <span class="NLM_lpage">368</span>, <span class="refDoi">Â DOI: 10.1096/fj.02-0473rev</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1096%2Ffj.02-0473rev" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=12631575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFeitbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=349-368&author=F.+Meggioauthor=L.+A.+Pinna&title=One-thousand-and-one+substrates+of+protein+kinase+CK2%3F&doi=10.1096%2Ffj.02-0473rev"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">One-thousand-and-one substrates of protein kinase CK2?</span></div><div class="casAuthors">Meggio, Flavio; Pinna, Lorenzo A.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-368</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review.  CK2 (formerly termed "casein kinase 2") is a ubiquitous, highly pleiotropic and constitutively active Ser/Thr protein kinase whose implication in neoplasia, cell survival, and virus infection is supported by an increasing no. of arguments.  Here an updated inventory of 307 CK2 protein substrates is presented.  More than one-third of these are implicated in gene expression and protein synthesis as being either transcriptional factors (60) or effectors of DNA/RNA structure (50) or translational elements.  Also numerous are signaling proteins and proteins of viral origin or essential to virus life cycle.  In comparison, only a minority of CK2 targets (a dozen or so) are classical metabolic enzymes.  An anal. of 308 sites phosphorylated by CK2 highlights the paramount relevance of neg. charged side chains that are (by far) predominant over any other residues at positions n+3 (the most crucial one), n+1, and n+2.  Based on this signature, it is predictable that proteins phosphorylated by CK2 are much more numerous than those identified to date, and it is possible that CK2 alone contributes to the generation of the eukaryotic phosphoproteome more so than any other individual protein kinase.  The possibility that CK2 phosphosites play some global role, e.g., by destabilizing Î± helices, counteracting caspase cleavage, and generating adhesive motifs, will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6sfPYsWeCNrVg90H21EOLACvtfcHk0ljkNazLO1nWmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFeitbk%253D&md5=0b11315ac9652e8866a1ed99a7010b68</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1096%2Ffj.02-0473rev&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.02-0473rev%26sid%3Dliteratum%253Aachs%26aulast%3DMeggio%26aufirst%3DF.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26atitle%3DOne-thousand-and-one%2520substrates%2520of%2520protein%2520kinase%2520CK2%253F%26jtitle%3DFASEB%2520J.%26date%3D2003%26volume%3D17%26spage%3D349%26epage%3D368%26doi%3D10.1096%2Ffj.02-0473rev" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keating, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striker, R.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation events during viral infections provide potential therapeutic targets</span>. <i>Rev. Med. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">166</span>â <span class="NLM_lpage">181</span>, <span class="refDoi">Â DOI: 10.1002/rmv.722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Frmv.722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22113983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVGksb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=166-181&author=J.+A.+Keatingauthor=R.+Striker&title=Phosphorylation+events+during+viral+infections+provide+potential+therapeutic+targets&doi=10.1002%2Frmv.722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation events during viral infections provide potential therapeutic targets</span></div><div class="casAuthors">Keating, Julie A.; Striker, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in Medical Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">166-181</span>CODEN:
                <span class="NLM_cas:coden">RMVIEW</span>;
        ISSN:<span class="NLM_cas:issn">1052-9276</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  SUMMARY : For many medically relevant viruses, there is now considerable evidence that both viral and cellular kinases play important roles in viral infection.  Ultimately, these kinases, and the cellular signaling pathways that they exploit, may serve as therapeutic targets for treating patients.  Currently, small mol. inhibitors of kinases are under investigation as therapy for herpes viral infections.  Addnl., a no. of cellular or host-directed tyrosine kinase inhibitors that have been previously FDA approved for cancer treatment are under study in animal models and clin. trials, as they have shown promise for the treatment of various viral infections as well.  This review will highlight the wide range of viral proteins phosphorylated by viral and cellular kinases, and the potential for variability of kinase recognition sites within viral substrates to impact phosphorylation and kinase prediction.  Research studying kinase-targeting prophylactic and therapeutic treatments for a no. of viral infections will also be discussed.  Copyright Â© 2011 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAakENW1lBobVg90H21EOLACvtfcHk0liRmLR-dixH9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVGksb4%253D&md5=101ce4dec72322383e78230028d79569</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1002%2Frmv.722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frmv.722%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DJ.%2BA.%26aulast%3DStriker%26aufirst%3DR.%26atitle%3DPhosphorylation%2520events%2520during%2520viral%2520infections%2520provide%2520potential%2520therapeutic%2520targets%26jtitle%3DRev.%2520Med.%2520Virol.%26date%3D2012%26volume%3D22%26spage%3D166%26epage%3D181%26doi%3D10.1002%2Frmv.722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarty, M. F.</span></span> <span> </span><span class="NLM_article-title">Targeting Casein kinase 2 with quercetin or enzymatically modified isoquercitrin as a strategy for boosting the type 1 interferon response to viruses and promoting cardiovascular health</span>. <i>Med. Hypotheses</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">109800</span>, <span class="refDoi">Â DOI: 10.1016/j.mehy.2020.109800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.mehy.2020.109800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32388479" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=109800&author=J.+J.+Di+Nicolantonioauthor=M.+F.+McCarty&title=Targeting+Casein+kinase+2+with+quercetin+or+enzymatically+modified+isoquercitrin+as+a+strategy+for+boosting+the+type+1+interferon+response+to+viruses+and+promoting+cardiovascular+health&doi=10.1016%2Fj.mehy.2020.109800"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.mehy.2020.109800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mehy.2020.109800%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BNicolantonio%26aufirst%3DJ.%2BJ.%26aulast%3DMcCarty%26aufirst%3DM.%2BF.%26atitle%3DTargeting%2520Casein%2520kinase%25202%2520with%2520quercetin%2520or%2520enzymatically%2520modified%2520isoquercitrin%2520as%2520a%2520strategy%2520for%2520boosting%2520the%2520type%25201%2520interferon%2520response%2520to%2520viruses%2520and%2520promoting%2520cardiovascular%2520health%26jtitle%3DMed.%2520Hypotheses%26date%3D2020%26volume%3D142%26spage%3D109800%26doi%3D10.1016%2Fj.mehy.2020.109800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agaisse, H.</span></span> <span> </span><span class="NLM_article-title">Casein kinase 2 regulates vaccinia virus actin tail formation</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">143</span>â <span class="NLM_lpage">151</span>, <span class="refDoi">Â DOI: 10.1016/j.virol.2011.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.virol.2011.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22209233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFGrtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2012&pages=143-151&author=D.+E.+Alvarezauthor=H.+Agaisse&title=Casein+kinase+2+regulates+vaccinia+virus+actin+tail+formation&doi=10.1016%2Fj.virol.2011.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Casein kinase 2 regulates vaccinia virus actin tail formation</span></div><div class="casAuthors">Alvarez, Diego E.; Agaisse, Herve</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-151</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Casein kinase 2 (CK2) is a pleiotropic serine/threonine kinase that regulates numerous cellular processes and is essential to the infectious cycle of several viruses.  Here we investigated the potential role of CK2 in vaccinia virus (VACV) infection.  We used the CK2 inhibitor TBB and found that CK2 inactivation impaired VACV dissemination and actin tail formation.  We used RNAi and confirmed that CK2 depletion impaired VACV actin tail formation.  Furthermore, we designed a recombinant virus that allowed us to specifically detect cell-assocd. enveloped viruses (CEVs) at the plasma membrane and demonstrated that CK2 inactivation does not affect CEV formation.  Finally, we showed that CK2 depletion impaired the recruitment of Src to CEVs.  We discuss the possibility that CK2 may stimulate the A36-dependent recruitment of Src through A36 phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdjQrIl5SRKrVg90H21EOLACvtfcHk0liRmLR-dixH9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFGrtw%253D%253D&md5=347c33a4c7adcfbb187411725beeef8f</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2011.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2011.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez%26aufirst%3DD.%2BE.%26aulast%3DAgaisse%26aufirst%3DH.%26atitle%3DCasein%2520kinase%25202%2520regulates%2520vaccinia%2520virus%2520actin%2520tail%2520formation%26jtitle%3DVirology%26date%3D2012%26volume%3D423%26spage%3D143%26epage%3D151%26doi%3D10.1016%2Fj.virol.2011.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baladron, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rittoles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DÃ­az, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzuela, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarÄÃ­a, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chacon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GonzÃ¡lez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RodrigueÅº, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Bloomquist, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RamÃ³n, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GuillÃ©n, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perea, S. E.</span></span> <span> </span><span class="NLM_article-title">ATENEA-Co-300 Group. Treatment with an anti-ck2 synthetic peptide improves clinical response in COVID-19 patients with pneumonia. A randomized and controlled clinical trial</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">206</span>, <span class="refDoi">Â DOI: 10.1021/acsptsci.0c00175</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.0c00175" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFeqtr7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2021&pages=206&author=L.+R.+Cruzauthor=I.+Baladronauthor=A.+Rittolesauthor=P.+A.+D%C3%ADazauthor=C.+Valenzuelaauthor=R.+Santanaauthor=M.+M.+Vazquezauthor=A.+Gar%C4%87%C3%ADaauthor=D.+Chaconauthor=D.+Thompsonauthor=G.+Pereraauthor=A.+Gonz%C3%A1lezauthor=R.+Reyesauthor=L.+Torresauthor=J.+Perezauthor=Y.+Validoauthor=R.+Rodrigue%C5%BAauthor=D.+M.+Vazquez-Bloomquistauthor=M.+Rosalesauthor=A.+C.+Ram%C3%B3nauthor=G.+V.+P%C3%A9rezauthor=G.+Guill%C3%A9nauthor=V.+Muzioauthor=Y.+Pereraauthor=S.+E.+Perea&title=ATENEA-Co-300+Group.+Treatment+with+an+anti-ck2+synthetic+peptide+improves+clinical+response+in+COVID-19+patients+with+pneumonia.+A+randomized+and+controlled+clinical+trial&doi=10.1021%2Facsptsci.0c00175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial</span></div><div class="casAuthors">Cruz, Leticia R.; Baladron, Idania; Rittoles, Aliusha; Diaz, Pablo A.; Valenzuela, Carmen; Santana, Raul; Vazquez, Maria M.; Garcia, Ariadna; Chacon, Deyli; Thompson, Delvin; Perera, Gustavo; Gonzalez, Ariel; Reyes, Rafael; Torres, Loida; Perez, Jesus; Valido, Yania; Rodriguez, Ralysmay; Vazquez-Bloomquist, Dania M.; Rosales, Mauro; Ramon, Ailyn C.; Perez, George V.; Guillen, Gerardo; Muzio, Verena; Perera, Yasser; Perea, Silvio E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">206-212</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The instrumental role of CK2 in the SARS-CoV-2 infection has pointed out this protein kinase as promising therapeutic target in COVID-19.  Anti-SARS-CoV-2 activity has been reported by CK2 inhibitors in vitro; however, no anti-CK2 clin. approach has been investigated in COVID-19.  This trial aimed to explore the safety and putative clin. benefit of CIGB-325, an anti-CK2 peptide previously assessed in cancer patients.  A monocentric, controlled, and therapeutic exploratory trial of i.v. CIGB-325 in adults hospitalized with COVID-19 was performed.  Twenty patients were randomly assigned to receive CIGB-325 (2.5 mg/kg/day during 5-consecutive days) plus std.-of-care (10 patients) or std.-of-care alone (10 patients).  Adverse events were classified by the WHO Adverse Reaction Terminol.  Parametric and nonparametric statistical analyses were performed according to the type of variable.  Considering the small sample size, differences between groups were estd. by Bayesian anal.  CIGB-325 induced transient mild and(or) moderate adverse events such as pruritus, flushing, and rash in some patients.  Both therapeutic regimens were similar with respect to SARS-CoV-2 clearance in nasopharynx swabs over time.  However, CIGB-325 significantly reduced the median no. of pulmonary lesions (9.5 to 5.5) at day 7 and the proportion of patients with such an effect was also higher according to Bayesian anal.  Also, CIGB-325 significantly reduced the CPK and LDH plasma levels at day 7.  Our preliminary findings suggest that this anti-CK2 clin. approach could be combined with std.-of-care in COVID-19 in larger studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_htv0WJqtMLVg90H21EOLACvtfcHk0lhxPecfXIO3MA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFeqtr7J&md5=3a20ffbee3ad12723ef9e54ebccfb170</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.0c00175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.0c00175%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DL.%2BR.%26aulast%3DBaladron%26aufirst%3DI.%26aulast%3DRittoles%26aufirst%3DA.%26aulast%3DD%25C3%25ADaz%26aufirst%3DP.%2BA.%26aulast%3DValenzuela%26aufirst%3DC.%26aulast%3DSantana%26aufirst%3DR.%26aulast%3DVazquez%26aufirst%3DM.%2BM.%26aulast%3DGar%25C4%2587%25C3%25ADa%26aufirst%3DA.%26aulast%3DChacon%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DD.%26aulast%3DPerera%26aufirst%3DG.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DA.%26aulast%3DReyes%26aufirst%3DR.%26aulast%3DTorres%26aufirst%3DL.%26aulast%3DPerez%26aufirst%3DJ.%26aulast%3DValido%26aufirst%3DY.%26aulast%3DRodrigue%25C5%25BA%26aufirst%3DR.%26aulast%3DVazquez-Bloomquist%26aufirst%3DD.%2BM.%26aulast%3DRosales%26aufirst%3DM.%26aulast%3DRam%25C3%25B3n%26aufirst%3DA.%2BC.%26aulast%3DP%25C3%25A9rez%26aufirst%3DG.%2BV.%26aulast%3DGuill%25C3%25A9n%26aufirst%3DG.%26aulast%3DMuzio%26aufirst%3DV.%26aulast%3DPerera%26aufirst%3DY.%26aulast%3DPerea%26aufirst%3DS.%2BE.%26atitle%3DATENEA-Co-300%2520Group.%2520Treatment%2520with%2520an%2520anti-ck2%2520synthetic%2520peptide%2520improves%2520clinical%2520response%2520in%2520COVID-19%2520patients%2520with%2520pneumonia.%2520A%2520randomized%2520and%2520controlled%2520clinical%2520trial%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2021%26volume%3D4%26spage%3D206%26doi%3D10.1021%2Facsptsci.0c00175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colunga Biancatelli, R. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catravas, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marik, P. E.</span></span> <span> </span><span class="NLM_article-title">Quercetin and vitamin C: An experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related Disease (COVID-19)</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1451</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2020.01451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffimmu.2020.01451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32636851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB38npslWmsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1451&author=R.+M.+L.+Colunga+Biancatelliauthor=M.+Berrillauthor=J.+D.+Catravasauthor=P.+E.+Marik&title=Quercetin+and+vitamin+C%3A+An+experimental%2C+synergistic+therapy+for+the+prevention+and+treatment+of+SARS-CoV-2+related+Disease+%28COVID-19%29&doi=10.3389%2Ffimmu.2020.01451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)</span></div><div class="casAuthors">Colunga Biancatelli Ruben Manuel Luciano; Catravas John D; Marik Paul E; Colunga Biancatelli Ruben Manuel Luciano; Catravas John D; Colunga Biancatelli Ruben Manuel Luciano; Berrill Max; Catravas John D</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1451</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an emergent global threat which is straining worldwide healthcare capacity.  As of May 27th, the disease caused by SARS-CoV-2 (COVID-19) has resulted in more than 340,000 deaths worldwide, with 100,000 deaths in the US alone.  It is imperative to study and develop pharmacological treatments suitable for the prevention and treatment of COVID-19.  Ascorbic acid is a crucial vitamin necessary for the correct functioning of the immune system.  It plays a role in stress response and has shown promising results when administered to the critically ill.  Quercetin is a well-known flavonoid whose antiviral properties have been investigated in numerous studies.  There is evidence that vitamin C and quercetin co-administration exerts a synergistic antiviral action due to overlapping antiviral and immunomodulatory properties and the capacity of ascorbate to recycle quercetin, increasing its efficacy.  Safe, cheap interventions which have a sound biological rationale should be prioritized for experimental use in the current context of a global health pandemic.  We present the current evidence for the use of vitamin C and quercetin both for prophylaxis in high-risk populations and for the treatment of COVID-19 patients as an adjunct to promising pharmacological agents such as Remdesivir or convalescent plasma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_Gndv-Y5NPZdYoSR9eyvsfW6udTcc2eaoZIYvIi2xvrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38npslWmsQ%253D%253D&md5=16499ce93f500885e09d016e8a4bf3c5</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.01451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.01451%26sid%3Dliteratum%253Aachs%26aulast%3DColunga%2BBiancatelli%26aufirst%3DR.%2BM.%2BL.%26aulast%3DBerrill%26aufirst%3DM.%26aulast%3DCatravas%26aufirst%3DJ.%2BD.%26aulast%3DMarik%26aufirst%3DP.%2BE.%26atitle%3DQuercetin%2520and%2520vitamin%2520C%253A%2520An%2520experimental%252C%2520synergistic%2520therapy%2520for%2520the%2520prevention%2520and%2520treatment%2520of%2520SARS-CoV-2%2520related%2520Disease%2520%2528COVID-19%2529%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26volume%3D11%26spage%3D1451%26doi%3D10.3389%2Ffimmu.2020.01451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seah, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HervÃ©, M.</span></span> <span> </span><span class="NLM_article-title">Modulation of inflammation and pathology during dengue virus infection by p38 MAPK inhibitor SB203580</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">151</span>â <span class="NLM_lpage">157</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2014.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2014.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25131378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSmsbbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2014&pages=151-157&author=Y.+Fuauthor=A.+Yipauthor=P.+G.+Seahauthor=F.+Blascoauthor=P.-Y.+Shiauthor=M.+Herv%C3%A9&title=Modulation+of+inflammation+and+pathology+during+dengue+virus+infection+by+p38+MAPK+inhibitor+SB203580&doi=10.1016%2Fj.antiviral.2014.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of inflammation and pathology during dengue virus infection by p38 MAPK inhibitor SB203580</span></div><div class="casAuthors">Fu, Yilong; Yip, Andy; Seah, Peck Gee; Blasco, Francesca; Shi, Pei-Yong; Herve, Maxime</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-157</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dengue virus (DENV) infection could lead to dengue fever (DF), dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).  The disease outcome is controlled by both viral and host factors.  Inflammation mediators from DENV-infected cells could contribute to increased vascular permeability, leading to severe DHF/DSS.  Therefore, suppression of inflammation could be a potential therapeutic approach for treatment of dengue patients.  In this context, p38 MAPK (mitogen-activated protein kinase) is a key enzyme that modulates the initiation of stress and inflammatory responses.  Here we show that SB203580, a p38 MAPK inhibitor, suppressed the over prodn. of DENV-induced pro-inflammatory mediators such as TNF-Î±, IL-8, and RANTES from human PBMCs, monocytic THP-1, and granulocyte KU812 cell lines.  Oral administration of SB203580 in DENV-infected AG129 mice prevented hematocrit rise and lymphopenia, limited the development of inflammation and pathol. (including intestine leakage), and significantly improved survival.  These results, for the first time, have provided exptl. evidence to imply that a short term inhibition of p38 MAPK may be beneficial to reduce disease symptoms in dengue patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnQAZQRmn0h7Vg90H21EOLACvtfcHk0ljBUajWGnOKmw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSmsbbF&md5=05737028353b73175d6a64146732bdd5</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DY.%26aulast%3DYip%26aufirst%3DA.%26aulast%3DSeah%26aufirst%3DP.%2BG.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DP.-Y.%26aulast%3DHerv%25C3%25A9%26aufirst%3DM.%26atitle%3DModulation%2520of%2520inflammation%2520and%2520pathology%2520during%2520dengue%2520virus%2520infection%2520by%2520p38%2520MAPK%2520inhibitor%2520SB203580%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D110%26spage%3D151%26epage%3D157%26doi%3D10.1016%2Fj.antiviral.2014.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Growcott, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galarneau, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, V. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schul, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. S.</span></span> <span> </span><span class="NLM_article-title">The effect of P38 MAP kinase inhibition in a mouse model of influenza</span>. <i>J. Med. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">452</span>â <span class="NLM_lpage">462</span>, <span class="refDoi">Â DOI: 10.1099/jmm.0.000684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1099%2Fjmm.0.000684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29458547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSmsbzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2018&pages=452-462&author=E.+J.+Growcottauthor=D.+Bambaauthor=J.+R.+Galarneauauthor=V.+H.+J.+Leonardauthor=W.+Schulauthor=D.+Steinauthor=C.+S.+Osborne&title=The+effect+of+P38+MAP+kinase+inhibition+in+a+mouse+model+of+influenza&doi=10.1099%2Fjmm.0.000684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of P38 MAP kinase inhibition in a mouse model of influenza</span></div><div class="casAuthors">Growcott, E. J.; Bamba, D.; Galarneau, J-.R.; Leonard, V. H. J.; Schul, W.; Stein, D.; Osborne, C. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">452-462</span>CODEN:
                <span class="NLM_cas:coden">JMMIAV</span>;
        ISSN:<span class="NLM_cas:issn">1473-5644</span>.
    
            (<span class="NLM_cas:orgname">Microbiology Society</span>)
        </div><div class="casAbstract">Influenza viruses are a common cause of human respiratory infections, resulting in epidemics of high morbidity and mortality.  We investigated the effect of a novel mitogen-activated protein kinase (MAPK) inhibitor in vitro and in a murine influenza model to further explore whether p38 MAPK inhibition could reduce viral replication.  Methods.In vitro, the antiviral effect of p38 MAPK inhibitor BCT194 was evaluated in differentiated human bronchial epithelial cells (HBECs); in vivo, female BALB/c mice were infected intranasally with 150 pfu of influenza H1N1 A/Puerto Rico/8/34 and treated with BCT197 (a closely related p38 MAPK inhibitor with an IC50 value of <1 Î¼M, currently in clin. testing), dexamethasone or oseltamivir (Tamiflu) starting 24 h post infection.  Body wt., bronchoalveolar lavage cells, cytokines, total protein and lactate dehydrogenase as well as serum cytokines were measured; a subset of animals was evaluated histopathol.  Results/Key findings. p38MAP kinase inhibition with BCT194 had no impact on influenza replication in HBECs.  When examg. BCT197 in vivo, and comparing to vehicle-treated animals, reduced wt. loss, improvement in survival and lack of impaired viral control was obsd. at BCT197 concns. relevant to those being used in clin. trials of acute exacerbations of chronic obstructive pulmonary disease; at higher concns. of BCT197 these effects were reduced.  Conclusions.  Compared to vehicle treatment, BCT197 (administered at a clin. relevant concn.) improved outcomes in a mouse model of influenza.  This is encouraging given that the use of innate inflammatory pathway inhibitors may raise concerns of neg. effects on infection regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp54HUMz77tu7Vg90H21EOLACvtfcHk0ljBUajWGnOKmw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSmsbzF&md5=b74cb96c7f237f3d277d67a57e0d7393</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1099%2Fjmm.0.000684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fjmm.0.000684%26sid%3Dliteratum%253Aachs%26aulast%3DGrowcott%26aufirst%3DE.%2BJ.%26aulast%3DBamba%26aufirst%3DD.%26aulast%3DGalarneau%26aufirst%3DJ.%2BR.%26aulast%3DLeonard%26aufirst%3DV.%2BH.%2BJ.%26aulast%3DSchul%26aufirst%3DW.%26aulast%3DStein%26aufirst%3DD.%26aulast%3DOsborne%26aufirst%3DC.%2BS.%26atitle%3DThe%2520effect%2520of%2520P38%2520MAP%2520kinase%2520inhibition%2520in%2520a%2520mouse%2520model%2520of%2520influenza%26jtitle%3DJ.%2520Med.%2520Microbiol.%26date%3D2018%26volume%3D67%26spage%3D452%26epage%3D462%26doi%3D10.1099%2Fjmm.0.000684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-GuardeÃ±o, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto-Torres, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeDiego, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regla-Nava, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Delgado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">CastaÃ±o-Rodriguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjuanes, L.</span></span> <span> </span><span class="NLM_article-title">The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e1004320</span> <span class="refDoi">Â DOI: 10.1371/journal.ppat.1004320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.ppat.1004320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25122212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12isrrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&author=J.+M.+Jimenez-Guarde%C3%B1oauthor=J.+L.+Nieto-Torresauthor=M.+L.+DeDiegoauthor=J.+A.+Regla-Navaauthor=R.+Fernandez-Delgadoauthor=C.+Casta%C3%B1o-Rodriguezauthor=L.+Enjuanes&title=The+PDZ-binding+motif+of+severe+acute+respiratory+syndrome+coronavirus+envelope+protein+is+a+determinant+of+viral+pathogenesis&doi=10.1371%2Fjournal.ppat.1004320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis</span></div><div class="casAuthors">Jimenez-Guardeno, Jose M.; Nieto-Torres, Jose L.; DeDiego, Marta L.; Regla-Nava, Jose A.; Fernandez-Delgado, Raul; Castano-Rodriguez, Carlos; Enjuanes, Luis</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1004320/1-e1004320/20, 20 pp.</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">A recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) lacking the envelope (E) protein is attenuated in vivo.  Here we report that E protein PDZ-binding motif (PBM), a domain involved in protein-protein interactions, is a major determinant of virulence.  Elimination of SARS-CoV E protein PBM by using reverse genetics caused a redn. in the deleterious exacerbation of the immune response triggered during infection with the parental virus and virus attenuation.  Cellular protein syntenin was identified to bind the E protein PBM during SARS-CoV infection by using three complementary strategies, yeast two-hybrid, reciprocal coimmunopptn. and confocal microscopy assays.  Syntenin redistributed from the nucleus to the cell cytoplasm during infection with viruses contg. the E protein PBM, activating p38 MAPK and leading to the overexpression of inflammatory cytokines.  Silencing of syntenin using siRNAs led to a decrease in p38 MAPK activation in SARS-CoV infected cells, further reinforcing their functional relationship.  Active p38 MAPK was reduced in lungs of mice infected with SARS-CoVs lacking E protein PBM as compared with the parental virus, leading to a decreased expression of inflammatory cytokines and to virus attenuation.  Interestingly, administration of a p38 MAPK inhibitor led to an increase in mice survival after infection with SARS-CoV, confirming the relevance of this pathway in SARS-CoV virulence.  Therefore, the E protein PBM is a virulence domain that activates immunopathol. most likely by using syntenin as a mediator of p38 MAPK induced inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoputsl14GlW7Vg90H21EOLACvtfcHk0ljwgkSNExMMYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12isrrN&md5=21aeb7c1782666ec2312cd7145130bef</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004320%26sid%3Dliteratum%253Aachs%26aulast%3DJimenez-Guarde%25C3%25B1o%26aufirst%3DJ.%2BM.%26aulast%3DNieto-Torres%26aufirst%3DJ.%2BL.%26aulast%3DDeDiego%26aufirst%3DM.%2BL.%26aulast%3DRegla-Nava%26aufirst%3DJ.%2BA.%26aulast%3DFernandez-Delgado%26aufirst%3DR.%26aulast%3DCasta%25C3%25B1o-Rodriguez%26aufirst%3DC.%26aulast%3DEnjuanes%26aufirst%3DL.%26atitle%3DThe%2520PDZ-binding%2520motif%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%2520envelope%2520protein%2520is%2520a%2520determinant%2520of%2520viral%2520pathogenesis%26jtitle%3DPLoS%2520Pathog.%26date%3D2014%26volume%3D10%26doi%3D10.1371%2Fjournal.ppat.1004320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span> <span> </span><span class="NLM_article-title">Clinical predictors of mortality due to COID-19 based on an analysis of data of 150 patients from Wuhan, China</span>. <i>Intensive Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1294</span>â <span class="NLM_lpage">1297</span>, <span class="refDoi">Â DOI: 10.1007/s00134-020-06028-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs00134-020-06028-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32253449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB38zhsFCqsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2020&pages=1294-1297&author=Q.+Ruanauthor=K.+Yangauthor=W.+Wangauthor=L.+Jiangauthor=J.+Song&title=Clinical+predictors+of+mortality+due+to+COID-19+based+on+an+analysis+of+data+of+150+patients+from+Wuhan%2C+China&doi=10.1007%2Fs00134-020-06028-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China</span></div><div class="casAuthors">Ruan Qiurong; Ruan Qiurong; Yang Kun; Wang Wenxia; Song Jianxin; Jiang Lingyu</div><div class="citationInfo"><span class="NLM_cas:title">Intensive care medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1294-1297</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfSvk7SjQ0DbGbPKh4T9eAfW6udTcc2eb8nIm5EO9kT7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zhsFCqsA%253D%253D&md5=ce3379b1871b7e841cf16e0b82a11164</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1007%2Fs00134-020-06028-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00134-020-06028-z%26sid%3Dliteratum%253Aachs%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DJ.%26atitle%3DClinical%2520predictors%2520of%2520mortality%2520due%2520to%2520COID-19%2520based%2520on%2520an%2520analysis%2520of%2520data%2520of%2520150%2520patients%2520from%2520Wuhan%252C%2520China%26jtitle%3DIntensive%2520Care%2520Med.%26date%3D2020%26volume%3D46%26spage%3D1294%26epage%3D1297%26doi%3D10.1007%2Fs00134-020-06028-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span> <span> </span><span class="NLM_article-title">Modulation of mitogen-activated protein kinase attenuates sepsis-induced acute lung injury in acute respiratory distress syndrome rats</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">9652</span>â <span class="NLM_lpage">9658</span>, <span class="refDoi">Â DOI: 10.3892/mmr.2017.7811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3892%2Fmmr.2017.7811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29039541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC1M7hsVCktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=9652-9658&author=W.+Fangauthor=S.+X.+Caiauthor=C.+L.+Wangauthor=X.+X.+Sunauthor=K.+Liauthor=X.+W.+Yanauthor=Y.+B.+Sunauthor=X.+Z.+Sunauthor=C.+K.+Guauthor=M.+Y.+Daiauthor=H.+M.+Wangauthor=Z.+Zhou&title=Modulation+of+mitogen-activated+protein+kinase+attenuates+sepsis-induced+acute+lung+injury+in+acute+respiratory+distress+syndrome+rats&doi=10.3892%2Fmmr.2017.7811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of mitogen-activated protein kinase attenuates sepsis-induced acute lung injury in acute respiratory distress syndrome rats</span></div><div class="casAuthors">Fang Wei; Cai Shi-Xia; Wang Chuan-Lei; Sun Xiao-Xia; Li Kun; Yan Xiao-Wen; Sun Yun-Bo; Sun Xiao-Zhe; Gu Chuan-Kai; Dai Ming-Ying; Wang Hui-Ming; Zhou Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular medicine reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">9652-9658</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sepsis is the most important predisposing cause inducing acute respiratory distress syndrome (ARDS); however, the mechanism of sepsis leading to the development of ARDS remains to be elucidated.  Suppression of the mitogen-activated protein kinase (MAPK) signal by blocking the phosphorylation of Jun N-terminal kinase (JNK) and p38 in lung tissues could alleviate acute lung injury induced by sepsis.  MAPK signaling may have a crucial role in development of the sepsis-induced acute lung injury.  The specific inhibitors of JNK and p38 MAPK, SP600125 and SB203580, were administrated by intragastric injection 4 h before induction of ARDS after cecal ligation and puncture (CLP).  Rats were sacrificed at 1, 6 or 24 h after CLP challenge.  The histological evaluation, lung water content, and biochemical analysis were performed.  The results revealed that the JNK and p38 MAPK inhibitor improved lung permeability, attenuated system inflammation, further alleviated the lung injury induced by sepsis.  In conclusion, JNK and p38 MAPK signaling are essential for the development of ARDS following sepsis.  Further studies are needed to illuminate the detailed mechanisms of JNK and p38 MAPK signaling in sepsis-induced ARDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkFw-oTWL33XELvajU9pjPfW6udTcc2eaI8JHIULaMmbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7hsVCktg%253D%253D&md5=a04cf910044bbb79c927defb5d0a6846</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2017.7811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2017.7811%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DS.%2BX.%26aulast%3DWang%26aufirst%3DC.%2BL.%26aulast%3DSun%26aufirst%3DX.%2BX.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DX.%2BW.%26aulast%3DSun%26aufirst%3DY.%2BB.%26aulast%3DSun%26aufirst%3DX.%2BZ.%26aulast%3DGu%26aufirst%3DC.%2BK.%26aulast%3DDai%26aufirst%3DM.%2BY.%26aulast%3DWang%26aufirst%3DH.%2BM.%26aulast%3DZhou%26aufirst%3DZ.%26atitle%3DModulation%2520of%2520mitogen-activated%2520protein%2520kinase%2520attenuates%2520sepsis-induced%2520acute%2520lung%2520injury%2520in%2520acute%2520respiratory%2520distress%2520syndrome%2520rats%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2017%26volume%3D16%26spage%3D9652%26epage%3D9658%26doi%3D10.3892%2Fmmr.2017.7811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louden, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuerstein, G. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, T. L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1685</span>â <span class="NLM_lpage">1691</span>, <span class="refDoi">Â DOI: 10.1161/01.CIR.99.13.1685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1161%2F01.CIR.99.13.1685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10190877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK1MXisFalsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1999&pages=1685-1691&author=X.+L.+Maauthor=S.+Kumarauthor=F.+Gaoauthor=C.+S.+Loudenauthor=B.+L.+Lopezauthor=T.+A.+Christopherauthor=C.+Wangauthor=J.+C.+Leeauthor=G.+Z.+Feuersteinauthor=T.+L.+Yue&title=Inhibition+of+p38+mitogen-activated+protein+kinase+decreases+cardiomyocyte+apoptosis+and+improves+cardiac+function+after+myocardial+ischemia+and+reperfusion&doi=10.1161%2F01.CIR.99.13.1685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion</span></div><div class="casAuthors">Ma, Xin L.; Kumar, Sanjay; Gao, Feng; Louden, Calvert S.; Lopez, Bernard L.; Christopher, Theodore A.; Wang, Chuanlin; Lee, John C.; Feuerstein, Giora Z.; Yue, Tian-Li</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1685-1691</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Activation of p38 mitogen-activated protein kinase (MAPK) plays an important role in apoptotic cell death.  The role of p38 MAPK in myocardial injury caused by ischemia/reperfusion, an extreme stress to the heart, is unknown.  Studies were performed with isolated, Langendorff-perfused rabbit hearts.  Ischemia alone caused a moderate but transient increase in p38 MAPK activity (3.5-fold increase).  Ischemia followed by reperfusion further activated p38 MAPK, and the maximal level of activation (6.3-fold) was reached 10 min after reperfusion.  Administration of SB 203580, a p38 MAPK inhibitor, decreased myocardial apoptosis (14.7Â±3.2% vs. 30.6Â±3.5% in vehicle) and improved postischemic cardiac function.  The cardioprotective effects of SB 203580 were closely related to its inhibition of p38 MAPK.  Administering SB 203580 before ischemia and during reperfusion completely inhibited p38 MAPK activation and exerted the most cardioprotective effects.  In contrast, administering SB 203580 10 min after reperfusion (a time point when maximal MAPK activation had already been achieved) failed to convey significant cardioprotection.  Moreover, inhibition of p38 MAPK attenuated myocardial necrosis after a prolonged reperfusion.  These results demonstrate that p38 MAPK plays a pivotal role in the signal transduction pathway mediating postischemic myocardial apoptosis and that inhibiting p38 MAPK may attenuate reperfusion injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNE1gKscK23rVg90H21EOLACvtfcHk0lhnZLyuOXyibg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXisFalsbo%253D&md5=ca83707742a145eeeffd0c3cb18568b0</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.99.13.1685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.99.13.1685%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%2BL.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DLouden%26aufirst%3DC.%2BS.%26aulast%3DLopez%26aufirst%3DB.%2BL.%26aulast%3DChristopher%26aufirst%3DT.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DFeuerstein%26aufirst%3DG.%2BZ.%26aulast%3DYue%26aufirst%3DT.%2BL.%26atitle%3DInhibition%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520decreases%2520cardiomyocyte%2520apoptosis%2520and%2520improves%2520cardiac%2520function%2520after%2520myocardial%2520ischemia%2520and%2520reperfusion%26jtitle%3DCirculation%26date%3D1999%26volume%3D99%26spage%3D1685%26epage%3D1691%26doi%3D10.1161%2F01.CIR.99.13.1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarubin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span> <span> </span><span class="NLM_article-title">Activation and signaling of the p38 MAP kinase pathway</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">11</span>â <span class="NLM_lpage">18</span>, <span class="refDoi">Â DOI: 10.1038/sj.cr.7290257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fsj.cr.7290257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=15686620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslGisb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=11-18&author=T.+Zarubinauthor=J.+Han&title=Activation+and+signaling+of+the+p38+MAP+kinase+pathway&doi=10.1038%2Fsj.cr.7290257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Activation and signaling of the p38 MAP kinase pathway</span></div><div class="casAuthors">Zarubin, Tyler; Han, Jiahuai</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-18</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Editorial Office of Cell Research</span>)
        </div><div class="casAbstract">A review.  The family members of the MAP kinases mediate a wide variety of cellular behaviors in response to extracellular stimuli.  One of the 4 main sub-groups, the p38 group of MAP kinases, serve as a nexus for signal transduction and play a vital role in numerous biol. processes.  Here, the authors highlight the known characteristics and components of the p38 pathway along with the mechanism and consequences of p38 activation.  The authors focus on the role of p38 as a signal transduction mediator and examine the evidence linking p38 to inflammation, cell cycle, cell death, development, cell differentiation, senescence, and tumorigenesis in specific cell types.  Upstream and downstream components of p38 are described and questions remaining to be answered are posed.  Finally, the authors propose several directions for future research on p38.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIDzDSa5vqULVg90H21EOLACvtfcHk0ljaFnJo4Yo5hw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslGisb4%253D&md5=c0f98c8f6db6e10b0a20357c401273d5</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1038%2Fsj.cr.7290257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cr.7290257%26sid%3Dliteratum%253Aachs%26aulast%3DZarubin%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DJ.%26atitle%3DActivation%2520and%2520signaling%2520of%2520the%2520p38%2520MAP%2520kinase%2520pathway%26jtitle%3DCell%2520Res.%26date%3D2005%26volume%3D15%26spage%3D11%26epage%3D18%26doi%3D10.1038%2Fsj.cr.7290257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gheblawi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viveiros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raizada, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudit, G. Y.</span></span> <span> </span><span class="NLM_article-title">Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1456</span>, <span class="refDoi">Â DOI: 10.1161/CIRCRESAHA.120.317015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1161%2FCIRCRESAHA.120.317015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32264791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVaksrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2020&pages=1456&author=M.+Gheblawiauthor=K.+Wangauthor=A.+Viveirosauthor=Q.+Nguyenauthor=J.+C.+Zhongauthor=A.+J.+Turnerauthor=M.+K.+Raizadaauthor=M.+B.+Grantauthor=G.+Y.+Oudit&title=Angiotensin+converting+enzyme+2%3A+SARS-CoV-2+receptor+and+regulator+of+the+renin-angiotensin+system&doi=10.1161%2FCIRCRESAHA.120.317015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2</span></div><div class="casAuthors">Gheblawi, Mahmoud; Wang, Kaiming; Viveiros, Anissa; Nguyen, Quynh; Zhong, Jiu-Chang; Turner, Anthony J.; Raizada, Mohan K.; Grant, Maria B.; Oudit, Gavin Y.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1456-1474</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  ACE2 (angiotensin-converting enzyme 2) has a multiplicity of physiol. roles that revolve around its trivalent function: a neg. regulator of the renin-angiotensin system, facilitator of amino acid transport, and the severe acute respiratory syndrome-coronavirus (SARS-CoV) and SARS-CoV-2 receptor.  ACE2 is widely expressed, including, in the lungs, cardiovascular system, gut, kidneys, central nervous system, and adipose tissue.  ACE2 has recently been identified as the SARS-CoV-2 receptor, the infective agent responsible for coronavirus disease 2019, providing a crit. link between immunity, inflammation, ACE2, and cardiovascular disease.  Although sharing a close evolutionary relationship with SARS-CoV, the receptor-binding domain of SARS-CoV-2 differs in several key amino acid residues, allowing for stronger binding affinity with the human ACE2 receptor, which may account for the greater pathogenicity of SARS-CoV-2.  The loss of ACE2 function following binding by SARS-CoV-2 is driven by endocytosis and activation of proteolytic cleavage and processing.  The ACE2 system is a crit. protective pathway against heart failure with reduced and preserved ejection fraction including, myocardial infarction and hypertension, and against lung disease and diabetes mellitus.  The control of gut dysbiosis and vascular permeability by ACE2 has emerged as an essential mechanism of pulmonary hypertension and diabetic cardiovascular complications.  Recombinant ACE2, gene-delivery of Ace2, Ang 1-7 analogs, and Mas receptor agonists enhance ACE2 action and serve as potential therapies for disease conditions assocd. with an activated renin-angiotensin system.  RhACE2 (recombinant human ACE2) has completed clin. trials and efficiently lowered or increased plasma angiotensin II and angiotensin 1-7 levels, resp.  Our review summarizes the progress over the past 20 years, highlighting the crit. role of ACE2 as the novel SARS-CoV-2 receptor and as the neg. regulator of the renin-angiotensin system, together with implications for the coronavirus disease 2019 pandemic and assocd. cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo98H70prhSX7Vg90H21EOLACvtfcHk0ljaFnJo4Yo5hw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVaksrY%253D&md5=f240902dd9bf0f970ad227a1c5d4f037</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.120.317015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.120.317015%26sid%3Dliteratum%253Aachs%26aulast%3DGheblawi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DViveiros%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DQ.%26aulast%3DZhong%26aufirst%3DJ.%2BC.%26aulast%3DTurner%26aufirst%3DA.%2BJ.%26aulast%3DRaizada%26aufirst%3DM.%2BK.%26aulast%3DGrant%26aufirst%3DM.%2BB.%26aulast%3DOudit%26aufirst%3DG.%2BY.%26atitle%3DAngiotensin%2520converting%2520enzyme%25202%253A%2520SARS-CoV-2%2520receptor%2520and%2520regulator%2520of%2520the%2520renin-angiotensin%2520system%26jtitle%3DCirc.%2520Res.%26date%3D2020%26volume%3D126%26spage%3D1456%26doi%3D10.1161%2FCIRCRESAHA.120.317015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neely, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaghubian-Malhami, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Loo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermolaeva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veldhuizen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasparakis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mech, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peiris, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slutsky, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akira, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hultqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmdahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">235</span>â <span class="NLM_lpage">249</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2008.02.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cell.2008.02.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18423196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWnu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2008&pages=235-249&author=Y.+Imaiauthor=K.+Kubaauthor=G.+G.+Neelyauthor=R.+Yaghubian-Malhamiauthor=T.+Perkmannauthor=G.+van+Looauthor=M.+Ermolaevaauthor=R.+Veldhuizenauthor=Y.+H.+Leungauthor=H.+Wangauthor=H.+Liuauthor=Y.+Sunauthor=M.+Pasparakisauthor=M.+Kopfauthor=C.+Mechauthor=S.+Bavariauthor=J.+S.+Peirisauthor=A.+S.+Slutskyauthor=S.+Akiraauthor=M.+Hultqvistauthor=R.+Holmdahlauthor=J.+Nichollsauthor=C.+Jiangauthor=C.+J.+Binderauthor=J.+M.+Penninger&title=Identification+of+oxidative+stress+and+Toll-like+receptor+4+signaling+as+a+key+pathway+of+acute+lung+injury&doi=10.1016%2Fj.cell.2008.02.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury</span></div><div class="casAuthors">Imai, Yumiko; Kuba, Keiji; Neely, G. Greg; Yaghubian-Malhami, Rubina; Perkmann, Thomas; van Loo, Geert; Ermolaeva, Maria; Veldhuizen, Ruud; Leung, Y. H. Connie; Wang, Hongliang; Liu, Haolin; Sun, Yang; Pasparakis, Manolis; Kopf, Manfred; Mech, Christin; Bavari, Sina; Peiris, J. S. Malik; Slutsky, Arthur S.; Akira, Shizuo; Hultqvist, Malin; Holmdahl, Rikard; Nicholls, John; Jiang, Chengyu; Binder, Christoph J.; Penninger, Josef M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-249</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Multiple lung pathogens such as chem. agents, H5N1 avian flu, or SARS cause high lethality due to acute respiratory distress syndrome.  Here the authors report that Toll-like receptor 4 (TLR4) mutant mice display natural resistance to acid-induced acute lung injury (ALI).  They show that TLR4-TRIF-TRAF6 signaling is a key disease pathway that controls the severity of ALI.  The oxidized phospholipid (OxPL) OxPAPC was identified to induce lung injury and cytokine prodn. by lung macrophages via TLR4-TRIF.  The authors obsd. OxPL prodn. in the lungs of humans and animals infected with SARS, Anthrax, or H5N1.  Pulmonary challenge with an inactivated H5N1 avian influenza virus rapidly induces ALI and OxPL formation in mice.  Loss of TLR4 or TRIF expression protects mice from H5N1-induced ALI.  Moreover, deletion of ncf1, which controls ROS prodn., improves the severity of H5N1-mediated ALI.  The authors' data identify oxidative stress and innate immunity as key lung injury pathways that control the severity of ALI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5xpZqE-O04rVg90H21EOLACvtfcHk0lg_28WRoH25Hw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWnu74%253D&md5=88eb341410b86cb3569841d3707a457f</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.02.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.02.043%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DY.%26aulast%3DKuba%26aufirst%3DK.%26aulast%3DNeely%26aufirst%3DG.%2BG.%26aulast%3DYaghubian-Malhami%26aufirst%3DR.%26aulast%3DPerkmann%26aufirst%3DT.%26aulast%3Dvan%2BLoo%26aufirst%3DG.%26aulast%3DErmolaeva%26aufirst%3DM.%26aulast%3DVeldhuizen%26aufirst%3DR.%26aulast%3DLeung%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DPasparakis%26aufirst%3DM.%26aulast%3DKopf%26aufirst%3DM.%26aulast%3DMech%26aufirst%3DC.%26aulast%3DBavari%26aufirst%3DS.%26aulast%3DPeiris%26aufirst%3DJ.%2BS.%26aulast%3DSlutsky%26aufirst%3DA.%2BS.%26aulast%3DAkira%26aufirst%3DS.%26aulast%3DHultqvist%26aufirst%3DM.%26aulast%3DHolmdahl%26aufirst%3DR.%26aulast%3DNicholls%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DBinder%26aufirst%3DC.%2BJ.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520oxidative%2520stress%2520and%2520Toll-like%2520receptor%25204%2520signaling%2520as%2520a%2520key%2520pathway%2520of%2520acute%2520lung%2520injury%26jtitle%3DCell%26date%3D2008%26volume%3D133%26spage%3D235%26epage%3D249%26doi%3D10.1016%2Fj.cell.2008.02.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechend, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shagdarsuren, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gapeljuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiners, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratze, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Saadi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebeler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madwed, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirdewan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luft, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, D. N.</span></span> <span> </span><span class="NLM_article-title">p38 Mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">481</span>â <span class="NLM_lpage">489</span>, <span class="refDoi">Â DOI: 10.1161/01.HYP.0000256831.33459.ea</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1161%2F01.HYP.0000256831.33459.ea" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17224470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSiu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2007&pages=481-489&author=J.+K.+Parkauthor=R.+Fischerauthor=R.+Dechendauthor=E.+Shagdarsurenauthor=A.+Gapeljukauthor=M.+Wellnerauthor=S.+Meinersauthor=P.+Gratzeauthor=N.+Al-Saadiauthor=S.+Feldtauthor=A.+Fiebelerauthor=J.+B.+Madwedauthor=A.+Schirdewanauthor=H.+Hallerauthor=F.+C.+Luftauthor=D.+N.+Muller&title=p38+Mitogen-activated+protein+kinase+inhibition+ameliorates+angiotensin+II-induced+target+organ+damage&doi=10.1161%2F01.HYP.0000256831.33459.ea"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">p38 Mitogen-Activated Protein Kinase Inhibition Ameliorates Angiotensin II-Induced Target Organ Damage</span></div><div class="casAuthors">Park, Joon-Keun; Fischer, Robert; Dechend, Ralf; Shagdarsuren, Erdenechimeg; Gapeljuk, Andrej; Wellner, Maren; Meiners, Silke; Gratze, Petra; Al-Saadi, Nidal; Feldt, Sandra; Fiebeler, Anette; Madwed, Jeffrey B.; Schirdewan, Alexander; Haller, Hermann; Luft, Friedrich C.; Muller, Dominik N.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">481-489</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We investigated whether or not p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage.  We used double transgenic rats harboring both human renin and angiotensinogen genes (dTGRs).  DTGR, with or without p38 inhibitor (BIRB796; 30 mg/kg per day in the diet), and nontransgenic Sprague-Dawley rats were studied in 2 protocols.  In protocol 1 (week 7), systolic blood pressure of untreated dTGRs was 204Â±4 mm Hg, but partially reduced after BIRB796 treatment (166Â±7 mm Hg), whereas Sprague-Dawley rats were normotensive.  The cardiac hypertrophy index was unchanged in untreated and BIRB796-treated dTGRs.  The Î²-myosin heavy chain expression of BIRB796-treated hearts was significantly lower in BIRB796 compared with dTGRs, indicating a delayed switch to the fetal isoform.  BIRB796 treatment significantly reduced cardiac fibrosis, connective tissue growth factor, tumor necrosis factor-Î±, interleukin-6, and macrophage infiltration.  Albuminuria was not reduced in BIRB796-treated dTGRs.  Tubular and glomerular damage with tumor necrosis factor-Î± expression was unaltered, although serum creatinine and cystatin C were normalized.  Renal macrophage infiltration, fibrosis, and vessel damage were reduced.  In protocol 2 (week 8), we focused on mortality and arrhythmogenic elec. remodeling.  Mortality of untreated dTGRs was 100% but was reduced to 10% in the BIRB796 group.  Cardiac magnetic field mapping showed prolongation of depolarization and repolarization in untreated dTGRs compared with Sprague-Dawley rats with a partial redn. by BIRB796.  Programmed elec. stimulation elicited ventricular tachycardias in 81% of untreated dTGRs but only in 48% of BIRB796-treated dTGRs.  In conclusion, BIRB796 improved survival, target organ damage, and arrhythmogenic potential in angiotensin II-induced target organ damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_nLfWR8l12rVg90H21EOLACvtfcHk0lh7DOptIj9Z_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSiu74%253D&md5=c8f285f1ee55b79fb6d1e39821d68199</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000256831.33459.ea&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000256831.33459.ea%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DFischer%26aufirst%3DR.%26aulast%3DDechend%26aufirst%3DR.%26aulast%3DShagdarsuren%26aufirst%3DE.%26aulast%3DGapeljuk%26aufirst%3DA.%26aulast%3DWellner%26aufirst%3DM.%26aulast%3DMeiners%26aufirst%3DS.%26aulast%3DGratze%26aufirst%3DP.%26aulast%3DAl-Saadi%26aufirst%3DN.%26aulast%3DFeldt%26aufirst%3DS.%26aulast%3DFiebeler%26aufirst%3DA.%26aulast%3DMadwed%26aufirst%3DJ.%2BB.%26aulast%3DSchirdewan%26aufirst%3DA.%26aulast%3DHaller%26aufirst%3DH.%26aulast%3DLuft%26aufirst%3DF.%2BC.%26aulast%3DMuller%26aufirst%3DD.%2BN.%26atitle%3Dp38%2520Mitogen-activated%2520protein%2520kinase%2520inhibition%2520ameliorates%2520angiotensin%2520II-induced%2520target%2520organ%2520damage%26jtitle%3DHypertension%26date%3D2007%26volume%3D49%26spage%3D481%26epage%3D489%26doi%3D10.1161%2F01.HYP.0000256831.33459.ea" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">7027</span>, <span class="refDoi">Â DOI: 10.1038/srep07027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fsrep07027" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=7027&author=P.+Yangauthor=H.+Guauthor=Z.+Zhaoauthor=W.+Wangauthor=B.+Caoauthor=C.+Laiauthor=X.+Yangauthor=L.+Zhangauthor=Y.+Duanauthor=S.+Zhangauthor=W.+Chenauthor=W.+Zhenauthor=M.+Caiauthor=J.+M.+Penningerauthor=C.+Jiangauthor=X.+Wang&title=Angiotensin-converting+enzyme+2+%28ACE2%29+mediates+influenza+H7N9+virus-induced+acute+lung+injury&doi=10.1038%2Fsrep07027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fsrep07027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep07027%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DCao%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhen%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DM.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DAngiotensin-converting%2520enzyme%25202%2520%2528ACE2%2529%2520mediates%2520influenza%2520H7N9%2520virus-induced%2520acute%2520lung%2520injury%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D4%26spage%3D7027%26doi%3D10.1038%2Fsrep07027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudemiller, N. P.</span></span> <span> </span><span class="NLM_article-title">Immunologic effects of the renin-angiotensin system</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1350</span>â <span class="NLM_lpage">1361</span>, <span class="refDoi">Â DOI: 10.1681/ASN.2016101066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1681%2FASN.2016101066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28151411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFOluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=1350-1361&author=S.+D.+Crowleyauthor=N.+P.+Rudemiller&title=Immunologic+effects+of+the+renin-angiotensin+system&doi=10.1681%2FASN.2016101066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Immunologic effects of the renin-angiotensin system</span></div><div class="casAuthors">Crowley, Steven D.; Rudemiller, Nathan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1350-1361</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">A review.  Inappropriate activation of the renin-angiotensin system (RAS) exacerbates renal and vascular injury.  Accordingly, treatment with global RAS antagonists attenuates cardiovascular risk and slows the progression of proteinuric kidney disease.  By reducing BP, RAS inhibitors limit secondary immune activation responding to hemodynamic injury in the target organ.  However, RAS activation in hematopoietic cells has immunol. effects that diverge from those of RAS stimulation in the kidney and vasculature.  In preclin. studies, activating type 1 angiotensin (AT1) receptors in T lymphocytes and myeloid cells blunts the polarization of these cells toward proinflammatory phenotypes, protecting the kidney from hypertensive injury and fibrosis.  These endogenous functions of immune AT1 receptors temper the pathogenic actions of renal and vascular AT1 receptors during hypertension.  By counteracting the effects of AT1 receptor stimulation in the target organ, exogenous administration of AT2 receptor agonists or angiotensin 1-7 analogs may similarly limit inflammatory injury to the heart and kidney.  Moreover, although angiotensin II is the classic effector mol. of the RAS, several RAS enzymes affect immune homeostasis independently of canonic angiotensin II generation.  Thus, as reviewed here, multiple components of the RAS signaling cascade influence inflammatory cell phenotype and function with unpredictable and context-specific effects on innate and adaptive immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocF-a5Lp5_QrVg90H21EOLACvtfcHk0lh7DOptIj9Z_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFOluw%253D%253D&md5=c373098083fb11ff6531e39bf3106b83</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1681%2FASN.2016101066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2016101066%26sid%3Dliteratum%253Aachs%26aulast%3DCrowley%26aufirst%3DS.%2BD.%26aulast%3DRudemiller%26aufirst%3DN.%2BP.%26atitle%3DImmunologic%2520effects%2520of%2520the%2520renin-angiotensin%2520system%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2017%26volume%3D28%26spage%3D1350%26epage%3D1361%26doi%3D10.1681%2FASN.2016101066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">SimÃµese Silva, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silveira, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, M. M.</span></span> <span> </span><span class="NLM_article-title">ACE2, angiotensin-(1â7) and Mas receptor axis in inflammation and fibrosis</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">477</span>â <span class="NLM_lpage">492</span>, <span class="refDoi">Â DOI: 10.1111/bph.12159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1111%2Fbph.12159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=23488800" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=477-492&author=A.+C.+Sim%C3%B5ese+Silvaauthor=K.+D.+Silveiraauthor=A.+J.+Ferreiraauthor=M.+M.+Teixeira&title=ACE2%2C+angiotensin-%281%E2%80%937%29+and+Mas+receptor+axis+in+inflammation+and+fibrosis&doi=10.1111%2Fbph.12159"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1111%2Fbph.12159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12159%26sid%3Dliteratum%253Aachs%26aulast%3DSim%25C3%25B5ese%2BSilva%26aufirst%3DA.%2BC.%26aulast%3DSilveira%26aufirst%3DK.%2BD.%26aulast%3DFerreira%26aufirst%3DA.%2BJ.%26aulast%3DTeixeira%26aufirst%3DM.%2BM.%26atitle%3DACE2%252C%2520angiotensin-%25281%25E2%2580%25937%2529%2520and%2520Mas%2520receptor%2520axis%2520in%2520inflammation%2520and%2520fibrosis%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D169%26spage%3D477%26epage%3D492%26doi%3D10.1111%2Fbph.12159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDea, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâCallaghan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokpesi, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handy, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takata, M.</span></span> <span> </span><span class="NLM_article-title">Reactive oxygen species and p38 mitogen-activated protein kinase mediate tumor necrosis factor Î±-converting enzyme (TACE/ADAM-17) activation in primary human monocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">35466</span>â <span class="NLM_lpage">35476</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M111.277434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.M111.277434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=21865167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yhtr3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=35466-35476&author=A.+J.+Scottauthor=K.+P.+O%E2%80%99Deaauthor=D.+O%E2%80%99Callaghanauthor=L.+Williamsauthor=J.+O.+Dokpesiauthor=L.+Tattonauthor=J.+M.+Handyauthor=P.+J.+Hoggauthor=M.+Takata&title=Reactive+oxygen+species+and+p38+mitogen-activated+protein+kinase+mediate+tumor+necrosis+factor+%CE%B1-converting+enzyme+%28TACE%2FADAM-17%29+activation+in+primary+human+monocytes&doi=10.1074%2Fjbc.M111.277434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive Oxygen Species and p38 Mitogen-activated Protein Kinase Mediate Tumor Necrosis Factor Î±-Converting Enzyme (TACE/ADAM-17) Activation in Primary Human Monocytes</span></div><div class="casAuthors">Scott, Alasdair J.; O'Dea, Kieran P.; O'Callaghan, David; Williams, Lynn; Dokpesi, Justina O.; Tatton, Louise; Handy, Jonathan M.; Hogg, Philip J.; Takata, Masao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">35466-35476</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Tumor necrosis factor Î±-converting enzyme (TACE) is responsible for the shedding of cell surface TNF.  Studies suggest that reactive oxygen species (ROS) mediate up-regulation of TACE activity by direct oxidization or modification of the protein.  However, these investigations have been largely based upon nonphysiol. stimulation of promonocytic cell lines which may respond and process TACE differently from primary cells.  Furthermore, investigators have relied upon TACE substrate shedding as a surrogate for activity quantification.  The authors addressed these concerns, employing a direct, cell-based fluorometric assay to investigate the regulation of TACE catalytic activity on freshly isolated primary human monocytes during LPS stimulation.  The authors hypothesized that ROS mediate up-regulation of TACE activity indirectly, by activation of intracellular signaling pathways.  LPS up-regulated TACE activity rapidly (within 30 min) without changing cell surface TACE expression.  Scavenging of ROS or inhibiting their prodn. by flavoprotein oxidoreductases significantly attenuated LPS-induced TACE activity up-regulation.  Exogenous ROS (H2O2) also up-regulated TACE activity with similar kinetics and magnitude as LPS.  H2O2- and LPS-induced TACE activity up-regulation were effectively abolished by a variety of selective p38 MAPK inhibitors.  Activation of p38 was redox-sensitive as H2O2 caused p38 phosphorylation, and ROS scavenging significantly reduced LPS-induced phospho-p38 expression.  Inhibition of the p38 substrate, MAPK-activated protein kinase 2, completely attenuated TACE activity up-regulation, whereas inhibition of ERK had little effect.  Lastly, inhibition of cell surface oxidoreductases prevented TACE activity up-regulation distal to p38 activation.  In conclusion, the data indicate that in primary human monocytes, ROS mediate LPS-induced up-regulation of TACE activity indirectly through activation of the p38 signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj8oHM3UMrIrVg90H21EOLACvtfcHk0lity-JbMVtJJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yhtr3F&md5=ea5da30cf2688386f84e9e631a352d1b</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.277434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.277434%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DA.%2BJ.%26aulast%3DO%25E2%2580%2599Dea%26aufirst%3DK.%2BP.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DDokpesi%26aufirst%3DJ.%2BO.%26aulast%3DTatton%26aufirst%3DL.%26aulast%3DHandy%26aufirst%3DJ.%2BM.%26aulast%3DHogg%26aufirst%3DP.%2BJ.%26aulast%3DTakata%26aufirst%3DM.%26atitle%3DReactive%2520oxygen%2520species%2520and%2520p38%2520mitogen-activated%2520protein%2520kinase%2520mediate%2520tumor%2520necrosis%2520factor%2520%25CE%25B1-converting%2520enzyme%2520%2528TACE%252FADAM-17%2529%2520activation%2520in%2520primary%2520human%2520monocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D35466%26epage%3D35476%26doi%3D10.1074%2Fjbc.M111.277434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touyz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loomba, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1671</span>â <span class="NLM_lpage">1681</span>, <span class="refDoi">Â DOI: 10.1161/CIRCRESAHA.120.317134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1161%2FCIRCRESAHA.120.317134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32302265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVylurvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2020&pages=1671-1681&author=P.+Zhangauthor=L.+Zhuauthor=J.+Caiauthor=F.+Leiauthor=J.+J.+Qinauthor=J.+Xieauthor=Y.+M.+Liuauthor=Y.+C.+Zhaoauthor=X.+Huangauthor=L.+Linauthor=M.+Xiaauthor=M.+M.+Chenauthor=X.+Chengauthor=X.+Zhangauthor=D.+Guoauthor=Y.+Pengauthor=Y.+X.+Jiauthor=J.+Chenauthor=Z.+G.+Sheauthor=Y.+Wangauthor=Q.+Xuauthor=R.+Tanauthor=H.+Wangauthor=J.+Linauthor=P.+Luoauthor=S.+Fuauthor=H.+Caiauthor=P.+Yeauthor=B.+Xiaoauthor=W.+Maoauthor=L.+Liuauthor=Y.+Yanauthor=M.+Liuauthor=M.+Chenauthor=X.+J.+Zhangauthor=X.+Wangauthor=R.+M.+Touyzauthor=J.+Xiaauthor=B.+H.+Zhangauthor=X.+Huangauthor=Y.+Yuanauthor=R.+Loombaauthor=P.+P.+Liuauthor=H.+Li&title=Association+of+inpatient+use+of+angiotensin+converting+enzyme+inhibitors+and+angiotensin+II+receptor+blockers+with+mortality+among+patients+with+hypertension+hospitalized+with+COVID-19&doi=10.1161%2FCIRCRESAHA.120.317134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19</span></div><div class="casAuthors">Zhang, Peng; Zhu, Lihua; Cai, Jingjing; Lei, Fang; Qin, Juan-Juan; Xie, Jing; Liu, Ye-Mao; Zhao, Yan-Ci; Huang, Xuewei; Lin, Lijin; Xia, Meng; Chen, Ming-Ming; Cheng, Xu; Zhang, Xiao; Guo, Deliang; Peng, Yuanyuan; Ji, Yan-Xiao; Chen, Jing; She, Zhi-Gang; Wang, Yibin; Xu, Qingbo; Tan, Renfu; Wang, Haitao; Lin, Jun; Luo, Pengcheng; Fu, Shouzhi; Cai, Hongbin; Ye, Ping; Xiao, Bing; Mao, Weiming; Liu, Liming; Yan, Youqin; Liu, Mingyu; Chen, Manhua; Zhang, Xiao-Jing; Wang, Xinghuan; Touyz, Rhian M.; Xia, Jiahong; Zhang, Bing-Hong; Huang, Xiaodong; Yuan, Yufeng; Rohit, Loomba; Liu, Peter P.; Li, Hongliang</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1671-1681</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with hypertension.  Objective: To det. the assocn. between in-hospital use of ACEI/ARB and all-cause mortality in patients with hypertension and hospitalized due to COVID-19.  Methods and results: This retrospective, multi-center study included 1128 adult patients with hypertension diagnosed with COVID-19, including 188 taking ACEI/ARB (ACEI/ARB group; median age 64 [interquartile range, 55-68] years; 53.2% men) and 940 without using ACEI/ARB (non-ACEI/ARB group; median age 64 [interquartile range 57-69]; 53.5% men), who were admitted to 9 hospitals in Hubei Province, China from Dec. 31, 2019 to Feb. 20, 2020.  In mixed-effect Cox model treating site as a random effect, after adjusting for age, gender, comorbidities, and in-hospital medications, the detected risk for all-cause mortality was lower in the ACEI/ARB group vs. the non-ACEI/ARB group (adjusted hazard ratio, 0.42 [95% CI, 0.19-0.92]; P=0.03).  In a propensity score-matched anal. followed by adjusting imbalanced variables in mixed-effect Cox model, the results consistently demonstrated lower risk of COVID-19 mortality in patients who received ACEI/ARB vs. those who did not receive ACEI/ARB (adjusted hazard ratio, 0.37 [95% CI, 0.15-0.89]; P=0.03).  Further subgroup propensity score-matched anal. indicated that, compared with use of other antihypertensive drugs, ACEI/ARB was also assocd. with decreased mortality (adjusted hazard ratio, 0.30 [95% CI, 0.12-0.70]; P=0.01) in patients with COVID-19 and coexisting hypertension.  Conclusions: Among hospitalized patients with COVID-19 and coexisting hypertension, inpatient use of ACEI/ARB was assocd. with lower risk of all-cause mortality compared with ACEI/ARB nonusers.  While study interpretation needs to consider the potential for residual confounders, it is unlikely that in-hospital use of ACEI/ARB was assocd. with an increased mortality risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1sXffk6sGnLVg90H21EOLACvtfcHk0lity-JbMVtJJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVylurvO&md5=bb6be19a3383e6f32f192a4aa1919482</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.120.317134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.120.317134%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DF.%26aulast%3DQin%26aufirst%3DJ.%2BJ.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%2BM.%26aulast%3DZhao%26aufirst%3DY.%2BC.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DM.%2BM.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DY.%2BX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DShe%26aufirst%3DZ.%2BG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DTan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DP.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DP.%26aulast%3DXiao%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%2BJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTouyz%26aufirst%3DR.%2BM.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%2BH.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DLoomba%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DP.%2BP.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DAssociation%2520of%2520inpatient%2520use%2520of%2520angiotensin%2520converting%2520enzyme%2520inhibitors%2520and%2520angiotensin%2520II%2520receptor%2520blockers%2520with%2520mortality%2520among%2520patients%2520with%2520hypertension%2520hospitalized%2520with%2520COVID-19%26jtitle%3DCirc.%2520Res.%26date%3D2020%26volume%3D126%26spage%3D1671%26epage%3D1681%26doi%3D10.1161%2FCIRCRESAHA.120.317134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span> <span> </span><span class="NLM_article-title">Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury</span>. <i>Sci. China: Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">364</span>â <span class="NLM_lpage">374</span>, <span class="refDoi">Â DOI: 10.1007/s11427-020-1643-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs11427-020-1643-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32048163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1Wgsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=364-374&author=Y.+Liuauthor=Y.+Yangauthor=C.+Zhangauthor=F.+Huangauthor=F.+Wangauthor=J.+Yuanauthor=Z.+Wangauthor=J.+Liauthor=J.+Liauthor=C.+Fengauthor=Z.+Zhangauthor=L.+Wangauthor=L.+Pengauthor=L.+Chenauthor=Y.+Qinauthor=D.+Zhaoauthor=S.+Tanauthor=L.+Yinauthor=J.+Xuauthor=C.+Zhouauthor=C.+Jiangauthor=L.+Liu&title=Clinical+and+biochemical+indexes+from+2019-nCoV+infected+patients+linked+to+viral+loads+and+lung+injury&doi=10.1007%2Fs11427-020-1643-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury</span></div><div class="casAuthors">Liu, Yingxia; Yang, Yang; Zhang, Cong; Huang, Fengming; Wang, Fuxiang; Yuan, Jing; Wang, Zhaoqin; Li, Jinxiu; Li, Jianming; Feng, Cheng; Zhang, Zheng; Wang, Lifei; Peng, Ling; Chen, Li; Qin, Yuhao; Zhao, Dandan; Tan, Shuguang; Yin, Lu; Xu, Jun; Zhou, Congzhao; Jiang, Chengyu; Liu, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Science China: Life Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">364-374</span>CODEN:
                <span class="NLM_cas:coden">SCLSCJ</span>;
        ISSN:<span class="NLM_cas:issn">1674-7305</span>.
    
            (<span class="NLM_cas:orgname">Science China Press</span>)
        </div><div class="casAbstract">The outbreak of the 2019-nCoV infection began in Dec. 2019 in Wuhan, Hubei province, and rapidly spread to many provinces in China as well as other countries.  Here we report the epidemiol., clin., lab., and radiol. characteristics, as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen, China.  All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).  The most common lab. abnormalities were hypoalbuminemia, lymphopenia, decreased percentage of lymphocytes (LYM) and neutrophils (NEU), elevated C-reactive protein (CRP), and lactate dehydrogenase (LDH), and decreased CD8 count.  The viral load of 2019-nCoV detected from patient respiratory tracts was pos. linked to lung disease severity.  ALB, LYM, LYM(%), LDH, NEU(%), and CRP were highly correlated to the acute lung injury.  Age, viral load, lung injury score, and blood biochem. indexes, albumin (ALB), CRP, LDH, LY(%), LYM, and NEU(%), may be predictors of disease severity.  Moreover, the angiotensin II level in the plasma sample from 2019-nCoV infected patients was markedly elevated and linearly assocd. to viral load and lung injury.  Our results suggest a no. of potential diagnosis biomarkers and angiotensin receptor blocker (ARB) drugs for potential repurposing treatment of 2019-nCoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF-rDj_1t-5rVg90H21EOLACvtfcHk0liQZmVrIEZ11g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1Wgsbw%253D&md5=57bf44a5f3d2b4ca7efb19ea218edc48</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1007%2Fs11427-020-1643-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11427-020-1643-8%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DL.%26atitle%3DClinical%2520and%2520biochemical%2520indexes%2520from%25202019-nCoV%2520infected%2520patients%2520linked%2520to%2520viral%2520loads%2520and%2520lung%2520injury%26jtitle%3DSci.%2520China%253A%2520Life%2520Sci.%26date%3D2020%26volume%3D63%26spage%3D364%26epage%3D374%26doi%3D10.1007%2Fs11427-020-1643-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, H.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of ginsenoside Rg3 isomers against gamma herpes virus through inhibition of p38- and JNK-associated pathways</span>. <i>J. Funct. Foods</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">219</span>â <span class="NLM_lpage">228</span>, <span class="refDoi">Â DOI: 10.1016/j.jff.2017.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jff.2017.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVeitrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2018&pages=219-228&author=S.+Kangauthor=M.+J.+Songauthor=H.+Min&title=Antiviral+activity+of+ginsenoside+Rg3+isomers+against+gamma+herpes+virus+through+inhibition+of+p38-+and+JNK-associated+pathways&doi=10.1016%2Fj.jff.2017.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of ginsenoside Rg3 isomers against gammaherpesvirus through inhibition of p38- and JNK-associated pathways</span></div><div class="casAuthors">Kang, Soowon; Song, Moon Jung; Min, Hyeyoung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Functional Foods</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JFFOAX</span>;
        ISSN:<span class="NLM_cas:issn">1756-4646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Natural compds. from functional foods targeting viruses are considered to have important role for regulating virus-related diseases.  Ginsenoside Rg3 is one of the active pharmaceutical components found in Panax ginseng C.  A. Meyer which is widely used as a functional food in East Asia.  In our present study, we have characterized the antiviral activities of the ginsenoside Rg3 isomers, 20(R)- and 20(S)-ginsenoside Rg3, against murine gammaherpesvirus 68 (MHV-68), a mouse model of human gammaherpesvirus which can cause various malignancies including cancer.  We found that both 20(R)- and 20(S)-ginsenoside Rg3 inhibited lytic replication and viral proliferation of MHV-68, although 20(S)-ginsenoside Rg3 was more effective than 20(R)-ginsenoside Rg3.  Furthermore, ginsenoside Rg3 isomers efficiently repressed chem.-induced lytic replication of human gammaherpesviruses in EBV-pos. BC-3 and KSHV-pos. Raji cell lines.  Finally, our data showed that ginsenoside Rg3 isomers suppressed the p38 and/or the JNK-assocd. MAPK signaling pathways, thereby inhibiting viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_oaZOyBy4jLVg90H21EOLACvtfcHk0ligaV6XgvlNrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVeitrrM&md5=10a34e872f4bf9805190044b8f8eec71</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.jff.2017.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jff.2017.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DM.%2BJ.%26aulast%3DMin%26aufirst%3DH.%26atitle%3DAntiviral%2520activity%2520of%2520ginsenoside%2520Rg3%2520isomers%2520against%2520gamma%2520herpes%2520virus%2520through%2520inhibition%2520of%2520p38-%2520and%2520JNK-associated%2520pathways%26jtitle%3DJ.%2520Funct.%2520Foods%26date%3D2018%26volume%3D40%26spage%3D219%26epage%3D228%26doi%3D10.1016%2Fj.jff.2017.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span> </span><span class="NLM_article-title">BerGenBioâs
bemcentinib selected to be fast-tracked as potential
treatment for covid-19 through new national UK government clinical
trial initiative</span>; Cision, <a href="https://www.prnewswire.co.uk/news-releases/bergenbio-s-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative-849232914.html" class="extLink">https://www.prnewswire.co.uk/news-releases/bergenbio-s-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative-849232914.html</a> (retrieved <span class="NLM_year">2020</span>-04-29).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BerGenBio%E2%80%99s%0Abemcentinib+selected+to+be+fast-tracked+as+potential%0Atreatment+for+covid-19+through+new+national+UK+government+clinical%0Atrial+initiative%3B+Cision%2C+https%3A%2F%2Fwww.prnewswire.co.uk%2Fnews-releases%2Fbergenbio-s-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative-849232914.html+%28retrieved+2020-04-29%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DBerGenBio%25E2%2580%2599s%250Abemcentinib%2520selected%2520to%2520be%2520fast-tracked%2520as%2520potential%250Atreatment%2520for%2520covid-19%2520through%2520new%2520national%2520UK%2520government%2520clinical%250Atrial%2520initiative%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bewley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gausdal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barclay, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Dorival, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiscox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easterbrook, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan-Pensley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funnell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vipond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haldar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span> <span> </span><span class="NLM_article-title">Antiviral screening of multiple compounds against Ebola virus</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">277</span>, <span class="refDoi">Â DOI: 10.3390/v8110277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3390%2Fv8110277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptlWmtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=277&author=S.+Dowallauthor=K.+Bewleyauthor=R.+Watsonauthor=S.+Vasanauthor=C.+Ghoshauthor=M.+Konaiauthor=G.+Gausdalauthor=J.+Lorensauthor=J.+Longauthor=W.+Barclayauthor=I.+Garcia-Dorivalauthor=J.+Hiscoxauthor=A.+Bosworthauthor=I.+Taylorauthor=L.+Easterbrookauthor=J.+Pitmanauthor=S.+Summersauthor=J.+Chan-Pensleyauthor=S.+Funnellauthor=J.+Vipondauthor=S.+Charltonauthor=J.+Haldarauthor=R.+Hewsonauthor=M.+Carroll&title=Antiviral+screening+of+multiple+compounds+against+Ebola+virus&doi=10.3390%2Fv8110277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral screening of multiple compounds against Ebola virus</span></div><div class="casAuthors">Dowall, Stuart D.; Bewley, Kevin; Watson, Robert J.; Vasan, Seshadri S.; Ghosh, Chandradhish; Konai, Mohini M.; Gausdal, Gro; Lorens, James B.; Long, Jason; Barclay, Wendy; Garcia-Dorival, Isabel; Hiscox, Julian; Bosworth, Andrew; Taylor, Irene; Easterbrook, Linda; Pitman, James; Summers, Sian; Chan-Pensley, Jenny; Funnell, Simon; Vipond, Julia; Charlton, Sue; Haldar, Jayanta; Hewson, Roger; Carroll, Miles W.</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">277/1-277/17</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In light of the recent outbreak of Ebola virus (EBOV) disease in West Africa, there have been renewed efforts to search for effective antiviral countermeasures.  A range of compds. currently available with broad antimicrobial activity have been tested for activity against EBOV.  Using live EBOV, eighteen candidate compds. were screened for antiviral activity in vitro.  The compds. were selected on a rational basis because their mechanisms of action suggested that they had the potential to disrupt EBOV entry, replication or exit from cells or because they had displayed some antiviral activity against EBOV in previous tests.  Nine compds. caused no redn. in viral replication despite cells remaining healthy, so they were excluded from further anal. (zidovudine; didanosine; stavudine; abacavir sulfate; entecavir; JB1a; Aimspro; celgosivir; and castanospermine).  A second screen of the remaining compds. and the feasibility of appropriateness for in vivo testing removed six further compds. (ouabain; omeprazole; esomeprazole; Gleevec; D-LANA-14; and Tasigna).  The three most promising compds. (17-DMAG; BGB324; and NCK-8) were further screened for in vivo activity in the guinea pig model of EBOV disease.  Two of the compds., BGB324 and NCK-8, showed some effect against lethal infection in vivo at the concns. tested, which warrants further investigation.  Further, these data add to the body of knowledge on the antiviral activities of multiple compds. against EBOV and indicate that the scientific community should invest more effort into the development of novel and specific antiviral compds. to treat Ebola virus disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWc6MB91Dl07Vg90H21EOLACvtfcHk0ligaV6XgvlNrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptlWmtg%253D%253D&md5=ed4479ad55973faa989247930cf105d8</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.3390%2Fv8110277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv8110277%26sid%3Dliteratum%253Aachs%26aulast%3DDowall%26aufirst%3DS.%26aulast%3DBewley%26aufirst%3DK.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DVasan%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DC.%26aulast%3DKonai%26aufirst%3DM.%26aulast%3DGausdal%26aufirst%3DG.%26aulast%3DLorens%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DBarclay%26aufirst%3DW.%26aulast%3DGarcia-Dorival%26aufirst%3DI.%26aulast%3DHiscox%26aufirst%3DJ.%26aulast%3DBosworth%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DEasterbrook%26aufirst%3DL.%26aulast%3DPitman%26aufirst%3DJ.%26aulast%3DSummers%26aufirst%3DS.%26aulast%3DChan-Pensley%26aufirst%3DJ.%26aulast%3DFunnell%26aufirst%3DS.%26aulast%3DVipond%26aufirst%3DJ.%26aulast%3DCharlton%26aufirst%3DS.%26aulast%3DHaldar%26aufirst%3DJ.%26aulast%3DHewson%26aufirst%3DR.%26aulast%3DCarroll%26aufirst%3DM.%26atitle%3DAntiviral%2520screening%2520of%2520multiple%2520compounds%2520against%2520Ebola%2520virus%26jtitle%3DViruses%26date%3D2016%26volume%3D8%26spage%3D277%26doi%3D10.3390%2Fv8110277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meertens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejarnac, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinigaglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet-Madin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Charpentier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafirassou, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamborlini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao-Lormeau, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulpier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MissÃ©, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouvenet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabibiazar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gressens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, A.</span></span> <span> </span><span class="NLM_article-title">Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">324</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2016.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.celrep.2016.12.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28076778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCjuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=324&author=L.+Meertensauthor=A.+Labeauauthor=O.+Dejarnacauthor=S.+Ciprianiauthor=L.+Sinigagliaauthor=L.+Bonnet-Madinauthor=T.+Le+Charpentierauthor=M.+L.+Hafirassouauthor=A.+Zamborliniauthor=V.+M.+Cao-Lormeauauthor=M.+Coulpierauthor=D.+Miss%C3%A9author=N.+Jouvenetauthor=R.+Tabibiazarauthor=P.+Gressensauthor=O.+Schwartzauthor=A.+Amara&title=Axl+mediates+ZIKA+virus+entry+in+human+glial+cells+and+modulates+innate+immune+responses&doi=10.1016%2Fj.celrep.2016.12.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses</span></div><div class="casAuthors">Meertens, Laurent; Labeau, Athena; Dejarnac, Ophelie; Cipriani, Sara; Sinigaglia, Laura; Bonnet-Madin, Lucie; Le Charpentier, Tifenn; Hafirassou, Mohamed Lamine; Zamborlini, Alessia; Cao-Lormeau, Van-Mai; Coulpier, Muriel; Misse, Dorothee; Jouvenet, Nolwenn; Tabibiazar, Ray; Gressens, Pierre; Schwartz, Olivier; Amara, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-333</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ZIKA virus (ZIKV) is an emerging pathogen responsible for neurol. disorders and congenital microcephaly.  However, the mol. basis for ZIKV neurotropism remains poorly understood.  Here, we show that Axl is expressed in human microglia and astrocytes in the developing brain and that it mediates ZIKV infection of glial cells.  Axl-mediated ZIKV entry requires the Axl ligand Gas6, which bridges ZIKV particles to glial cells.  Following binding, ZIKV is internalized through clathrin-mediated endocytosis and traffics to Rab5+ endosomes to establish productive infection.  During entry, the ZIKV/Gas6 complex activates Axl kinase activity, which downmodulates interferon signaling and facilitates infection.  ZIKV infection of human glial cells is inhibited by MYD1, an engineered Axl decoy receptor, and by the Axl kinase inhibitor R428.  Our results highlight the dual role of Axl during ZIKV infection of glial cells: promoting viral entry and modulating innate immune responses.  Therefore, inhibiting Axl function may represent a potential target for future antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDbk6ixuAbyLVg90H21EOLACvtfcHk0lhB1yEKljAveA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCjuro%253D&md5=fbc8799266529e2fef7f03e6bee1b6c6</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DMeertens%26aufirst%3DL.%26aulast%3DLabeau%26aufirst%3DA.%26aulast%3DDejarnac%26aufirst%3DO.%26aulast%3DCipriani%26aufirst%3DS.%26aulast%3DSinigaglia%26aufirst%3DL.%26aulast%3DBonnet-Madin%26aufirst%3DL.%26aulast%3DLe%2BCharpentier%26aufirst%3DT.%26aulast%3DHafirassou%26aufirst%3DM.%2BL.%26aulast%3DZamborlini%26aufirst%3DA.%26aulast%3DCao-Lormeau%26aufirst%3DV.%2BM.%26aulast%3DCoulpier%26aufirst%3DM.%26aulast%3DMiss%25C3%25A9%26aufirst%3DD.%26aulast%3DJouvenet%26aufirst%3DN.%26aulast%3DTabibiazar%26aufirst%3DR.%26aulast%3DGressens%26aufirst%3DP.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3DAmara%26aufirst%3DA.%26atitle%3DAxl%2520mediates%2520ZIKA%2520virus%2520entry%2520in%2520human%2520glial%2520cells%2520and%2520modulates%2520innate%2520immune%2520responses%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D18%26spage%3D324%26doi%3D10.1016%2Fj.celrep.2016.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlichman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lensing, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasco, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcos, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijayawardana, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stancato, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulanthaivel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulle, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrington, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, M. P.</span></span> <span> </span><span class="NLM_article-title">A first-in-human Phase I study of the oral p38 MAPK inhibitor, Ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1095</span>â <span class="NLM_lpage">1102</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-15-1718</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F1078-0432.CCR-15-1718" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26581242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVyktb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1095-1102&author=A.+Patnaikauthor=P.+Haluskaauthor=A.+W.+Tolcherauthor=C.+Erlichmanauthor=K.+P.+Papadopoulosauthor=J.+L.+Lensingauthor=M.+Beeramauthor=J.+R.+Molinaauthor=D.+W.+Rascoauthor=R.+R.+Arcosauthor=C.+S.+Kellyauthor=S.+R.+Wijayawardanaauthor=X.+Zhangauthor=L.+F.+Stancatoauthor=R.+Bellauthor=P.+Shiauthor=P.+Kulanthaivelauthor=C.+Pitouauthor=L.+B.+Mulleauthor=D.+L.+Farringtonauthor=E.+M.+Chanauthor=M.+P.+Goetz&title=A+first-in-human+Phase+I+study+of+the+oral+p38+MAPK+inhibitor%2C+Ralimetinib+%28LY2228820+Dimesylate%29%2C+in+patients+with+advanced+cancer&doi=10.1158%2F1078-0432.CCR-15-1718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer</span></div><div class="casAuthors">Patnaik, Amita; Haluska, Paul; Tolcher, Anthony W.; Erlichman, Charles; Papadopoulos, Kyriakos P.; Lensing, Janet L.; Beeram, Muralidhar; Molina, Julian R.; Rasco, Drew W.; Arcos, Rebecca R.; Kelly, Claudia S.; Wijayawardana, Sameera R.; Zhang, Xuekui; Stancato, Louis F.; Bell, Robert; Shi, Peipei; Kulanthaivel, Palaniappan; Pitou, Celine; Mulle, Lynette B.; Farrington, Daphne L.; Chan, Edward M.; Goetz, Matthew P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1095-1102</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: p38 MAPK regulates the prodn. of cytokines in the tumor microenvironment and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, and targeted therapies.  Ralimetinib (LY2228820 dimesylate) is a selective small-mol. inhibitor of p38 MAPK.  This phase I study aimed to evaluate the safety and tolerability of ralimetinib, as a single agent and in combination with tamoxifen, when administered orally to patients with advanced cancer.  Exptl. Design: The study design consisted of a dose-escalation phase performed in a 3+3 design (Part A; n = 54), two dose-confirmation phases [Part B at 420 mg (n = 18) and Part C at 300 mg (n = 8)], and a tumor-specific expansion phase in combination with tamoxifen for women with hormone receptor-pos. metastatic breast cancer refractory to aromatase inhibitors (Part D; n = 9).  Ralimetinib was administered orally every 12 h on days 1 to 14 of a 28-day cycle.  Results: Eighty-nine patients received ralimetinib at 11 dose levels (10, 20, 40, 65, 90, 120, 160, 200, 300, 420, and 560 mg).  Plasma exposure of ralimetinib (Cmax and AUC) increased in a dose-dependent manner.  After a single dose, ralimetinib inhibited p38 MAPK-induced phosphorylation of MAPKAP-K2 in peripheral blood mononuclear cells.  The most common adverse events, possibly drug-related, included rash, fatigue, nausea, constipation, pruritus, and vomiting.  The recommended phase II dose was 300 mg every 12 h as monotherapy or in combination with tamoxifen.  Although no patients achieved a complete response or partial response,19 patients (21.3%) achieved stable disease with a median duration of 3.7 mo, with 9 of these patients on study for â¥6 cycles.  Conclusions: Ralimetinib demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer.  Clin Cancer Res; 22(5); 1095-102. Â©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB5A7aYBLcy7Vg90H21EOLACvtfcHk0lhB1yEKljAveA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVyktb0%253D&md5=c24403616cc10022866e1bca8b29b5bc</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1718%26sid%3Dliteratum%253Aachs%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DHaluska%26aufirst%3DP.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DLensing%26aufirst%3DJ.%2BL.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DArcos%26aufirst%3DR.%2BR.%26aulast%3DKelly%26aufirst%3DC.%2BS.%26aulast%3DWijayawardana%26aufirst%3DS.%2BR.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DStancato%26aufirst%3DL.%2BF.%26aulast%3DBell%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DP.%26aulast%3DKulanthaivel%26aufirst%3DP.%26aulast%3DPitou%26aufirst%3DC.%26aulast%3DMulle%26aufirst%3DL.%2BB.%26aulast%3DFarrington%26aufirst%3DD.%2BL.%26aulast%3DChan%26aufirst%3DE.%2BM.%26aulast%3DGoetz%26aufirst%3DM.%2BP.%26atitle%3DA%2520first-in-human%2520Phase%2520I%2520study%2520of%2520the%2520oral%2520p38%2520MAPK%2520inhibitor%252C%2520Ralimetinib%2520%2528LY2228820%2520Dimesylate%2529%252C%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D1095%26epage%3D1102%26doi%3D10.1158%2F1078-0432.CCR-15-1718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hale, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, R. E.</span></span> <span> </span><span class="NLM_article-title">Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">14194</span>â <span class="NLM_lpage">14199</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0606109103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1073%2Fpnas.0606109103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16963558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVClsr3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=14194-14199&author=B.+G.+Haleauthor=D.+Jacksonauthor=Y.+H.+Chenauthor=R.+A.+Lambauthor=R.+E.+Randall&title=Influenza+A+virus+NS1+protein+binds+p85beta+and+activates+phosphatidylinositol-3-kinase+signaling&doi=10.1073%2Fpnas.0606109103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza A virus NS1 protein binds p85Î² and activates phosphatidylinositol-3-kinase signaling</span></div><div class="casAuthors">Hale, Benjamin G.; Jackson, David; Chen, Yun-Hsiang; Lamb, Robert A.; Randall, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">14194-14199</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Influenza A virus NS1 is a multifunctional protein, and in virus-infected cells NS1 modulates a no. of host-cell processes by interacting with cellular factors.  Here, we report that NS1 binds directly to p85Î², a regulatory subunit of phosphatidylinositol-3-kinase (PI3K), but not to the related p85Î± subunit.  Activation of P13K in influenza virus-infected cells depended on genome replication, and showed kinetics that correlated with NS1 expression.  Addnl., it was found that expression of NS1 alone was sufficient to constitutively activate P13K, causing the phosphorylation of a downstream mediator of P13K signal transduction, Akt.  Mutational anal. of a potential SH2-binding motif within NS1 indicated that the highly conserved tyrosine at residue 89 is important for both the interaction with p85Î², and the activation of P13K.  A mutant influenza virus (A/Udorn/72) expressing NS1 with the Y89F amino acid substitution exhibited a small-plaque phenotype, and grew more slowly in tissue culture than WT virus.  These data suggest that activation of P13K signaling in influenza A virus-infected cells is important for efficient virus replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdYH7ONb8077Vg90H21EOLACvtfcHk0ljVRI2XY6zhRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVClsr3L&md5=e506aedaba2ed384b6afbddf63cfe433</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0606109103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0606109103%26sid%3Dliteratum%253Aachs%26aulast%3DHale%26aufirst%3DB.%2BG.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DLamb%26aufirst%3DR.%2BA.%26aulast%3DRandall%26aufirst%3DR.%2BE.%26atitle%3DInfluenza%2520A%2520virus%2520NS1%2520protein%2520binds%2520p85beta%2520and%2520activates%2520phosphatidylinositol-3-kinase%2520signaling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D14194%26epage%3D14199%26doi%3D10.1073%2Fpnas.0606109103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky-Bromberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Sobrido, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palese, P.</span></span> <span> </span><span class="NLM_article-title">7a Protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">785</span>â <span class="NLM_lpage">793</span>, <span class="refDoi">Â DOI: 10.1128/JVI.80.2.785-793.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.80.2.785-793.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16378980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOrsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=785-793&author=S.+A.+Kopecky-Brombergauthor=L.+Martinez-Sobridoauthor=P.+Palese&title=7a+Protein+of+severe+acute+respiratory+syndrome+coronavirus+inhibits+cellular+protein+synthesis+and+activates+p38+mitogen-activated+protein+kinase&doi=10.1128%2FJVI.80.2.785-793.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase</span></div><div class="casAuthors">Kopecky-Bromberg, Sarah A.; Martinez-Sobrido, Luis; Palese, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">785-793</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">It was recently shown that the 7a protein of severe acute respiratory syndrome coronavirus induces biochem. changes assocd. with apoptosis.  In this study, the mechanism by which the 7a protein induces apoptosis was examd.  The 7a protein was tested for the ability to inhibit cellular gene expression because several proapoptotic viral proteins with this function have previously been identified.  7A protein inhibited expression of luciferase from an mRNA construct that specifically measures translation, whereas inhibitors of transcription and nucleocytoplasmic transport did not.  The inhibition of translation and other cellular processes of gene expression have been assocd. with the induction of a stress response in cells.  Western blot anal. using phosphospecific antibodies indicated that 7a protein activated p38 mitogen-activated protein kinase (MAPK), but not c-Jun N-terminal protein kinase/stress-activated protein kinase.  Taken together, these data indicate that the induction of apoptosis by the 7a protein may be related to its ability to inhibit cellular translation and activate p38 MAPK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyL8_h7kZSFrVg90H21EOLACvtfcHk0ljVRI2XY6zhRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOrsA%253D%253D&md5=91a561555a8cc07ffe0b3ab08574520b</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1128%2FJVI.80.2.785-793.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.80.2.785-793.2006%26sid%3Dliteratum%253Aachs%26aulast%3DKopecky-Bromberg%26aufirst%3DS.%2BA.%26aulast%3DMartinez-Sobrido%26aufirst%3DL.%26aulast%3DPalese%26aufirst%3DP.%26atitle%3D7a%2520Protein%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%2520inhibits%2520cellular%2520protein%2520synthesis%2520and%2520activates%2520p38%2520mitogen-activated%2520protein%2520kinase%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D785%26epage%3D793%26doi%3D10.1128%2FJVI.80.2.785-793.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¶rgeling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmolke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viemann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordhoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of p38 mitogen-activated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">13</span>â <span class="NLM_lpage">27</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M113.469239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.M113.469239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24189062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC2c7is1yntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=13-27&author=Y.+B%C3%B6rgelingauthor=M.+Schmolkeauthor=D.+Viemannauthor=C.+Nordhoffauthor=J.+Rothauthor=S.+Ludwig&title=Inhibition+of+p38+mitogen-activated+protein+kinase+impairs+influenza+virus-induced+primary+and+secondary+host+gene+responses+and+protects+mice+from+lethal+H5N1+infection&doi=10.1074%2Fjbc.M113.469239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 mitogen-activated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection</span></div><div class="casAuthors">Borgeling Yvonne; Schmolke Mirco; Viemann Dorothee; Nordhoff Carolin; Roth Johannes; Ludwig Stephan</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of biological chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Highly pathogenic avian influenza viruses (HPAIV) induce severe inflammation in poultry and men.  One characteristic of HPAIV infections is the induction of a cytokine burst that strongly contributes to viral pathogenicity.  This cell-intrinsic hypercytokinemia seems to involve hyperinduction of p38 mitogen-activated protein kinase.  Here we investigate the role of p38 MAPK signaling in the antiviral response against HPAIV in mice as well as in human endothelial cells, the latter being a primary source of cytokines during systemic infections.  Global gene expression profiling of HPAIV-infected endothelial cells in the presence of the p38-specific inhibitor SB 202190 revealed that inhibition of p38 MAPK leads to reduced expression of IFNÎ² and other cytokines after H5N1 and H7N7 infection.  More than 90% of all virus-induced genes were either partially or fully dependent on p38 signaling.  Moreover, promoter analysis confirmed a direct impact of p38 on the IFNÎ² promoter activity.  Furthermore, upon treatment with IFN or conditioned media from HPAIV-infected cells, p38 controls interferon-stimulated gene expression by coregulating STAT1 by phosphorylation at serine 727.  In vivo inhibition of p38 MAPK greatly diminishes virus-induced cytokine expression concomitant with reduced viral titers, thereby protecting mice from lethal infection.  These observations show that p38 MAPK acts on two levels of the antiviral IFN response.  Initially the kinase regulates IFN induction and, at a later stage, p38 controls IFN signaling and thereby expression of IFN-stimulated genes.  Thus, inhibition of MAP kinase p38 may be an antiviral strategy that protects mice from lethal influenza by suppressing excessive cytokine expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfTb2VzrvhIT0SWnHPWbmmfW6udTcc2eba_-6Q9NvNibntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7is1yntw%253D%253D&md5=0051eb9c971078ae13ee7ff93d1d7322</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.469239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.469239%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6rgeling%26aufirst%3DY.%26aulast%3DSchmolke%26aufirst%3DM.%26aulast%3DViemann%26aufirst%3DD.%26aulast%3DNordhoff%26aufirst%3DC.%26aulast%3DRoth%26aufirst%3DJ.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520impairs%2520influenza%2520virus-induced%2520primary%2520and%2520secondary%2520host%2520gene%2520responses%2520and%2520protects%2520mice%2520from%2520lethal%2520H5N1%2520infection%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D13%26epage%3D27%26doi%3D10.1074%2Fjbc.M113.469239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhera, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utokaparch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackett, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorscheid, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegele, R. G.</span></span> <span> </span><span class="NLM_article-title">Toll-like receptor 4-mediated activation of p38 mitogen-activated protein kinase is a determinant of respiratory virus entry and tropism</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">11359</span>â <span class="NLM_lpage">11373</span>, <span class="refDoi">Â DOI: 10.1128/JVI.00804-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.00804-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20702616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeisb%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=11359-11373&author=D.+Marchantauthor=G.+K.+Singheraauthor=S.+Utokaparchauthor=T.+L.+Hackettauthor=J.+H.+Boydauthor=Z.+Luoauthor=X.+Siauthor=D.+R.+Dorscheidauthor=B.+M.+McManusauthor=R.+G.+Hegele&title=Toll-like+receptor+4-mediated+activation+of+p38+mitogen-activated+protein+kinase+is+a+determinant+of+respiratory+virus+entry+and+tropism&doi=10.1128%2FJVI.00804-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptor 4-mediated activation of p38 mitogen-activated protein kinase is a determinant of respiratory virus entry and tropism</span></div><div class="casAuthors">Marchant, David; Singhera, Gurpreet K.; Utokaparch, Soraya; Hackett, Tillie L.; Boyd, John H.; Luo, Zongshu; Si, Xiaoning; Dorscheid, Delbert R.; McManus, Bruce M.; Hegele, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">11359-11373</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Respiratory viruses exert a heavy toll of morbidity and mortality worldwide.  Despite this burden there are few specific treatments available for respiratory virus infections.  Since many viruses utilize host cell enzymic machinery such as protein kinases for replication, we detd. whether pharmacol. inhibition of kinases could, in principle, be used as a broad antiviral strategy for common human respiratory virus infections.  A panel of green fluorescent protein (GFP)-expressing recombinant respiratory viruses, including an isolate of H1N1 influenza virus (H1N1/Weiss/43), was used to represent a broad range of virus families responsible for common respiratory infections (Adenoviridae, Paramyxoviridae, Picornaviridae, and Orthomyxoviridae).  Kinase inhibitors were screened in a high-throughput assay that detected virus infection in human airway epithelial cells (1HAEo-) using a fluorescent plate reader.  Inhibition of p38 mitogen-activated protein kinase (MAPK) signaling was able to significantly inhibit replication by all viruses tested.  Therefore, the pathways involved in virus-mediated p38 and extracellular signal-regulated kinase (ERK) MAPK activation were investigated using bronchial epithelial cells and primary fibroblasts derived from MyD88 knockout mouse lungs.  Influenza virus, which activated p38 MAPK to approx. 10-fold-greater levels than did respiratory syncytial virus (RSV) in 1HAEo- cells, was internalized about 8-fold faster and more completely than RSV.  We show for the first time that p38 MAPK is a determinant of virus infection that is dependent upon MyD88 expression and Toll-like receptor 4 (TLR4) ligation.  Imaging of virus-TLR4 interactions showed significant clustering of TLR4 at the site of virus-cell interaction, triggering phosphorylation of downstream targets of p38 MAPK, suggesting the need for a signaling receptor to activate virus internalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNBCrJg_sD_LVg90H21EOLACvtfcHk0liCW27QOe5rpA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeisb%252FF&md5=4bd7d36f4fc2e8d779d1d63136a81f1b</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1128%2FJVI.00804-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00804-10%26sid%3Dliteratum%253Aachs%26aulast%3DMarchant%26aufirst%3DD.%26aulast%3DSinghera%26aufirst%3DG.%2BK.%26aulast%3DUtokaparch%26aufirst%3DS.%26aulast%3DHackett%26aufirst%3DT.%2BL.%26aulast%3DBoyd%26aufirst%3DJ.%2BH.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DSi%26aufirst%3DX.%26aulast%3DDorscheid%26aufirst%3DD.%2BR.%26aulast%3DMcManus%26aufirst%3DB.%2BM.%26aulast%3DHegele%26aufirst%3DR.%2BG.%26atitle%3DToll-like%2520receptor%25204-mediated%2520activation%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520is%2520a%2520determinant%2520of%2520respiratory%2520virus%2520entry%2520and%2520tropism%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D11359%26epage%3D11373%26doi%3D10.1128%2FJVI.00804-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucker, I. H.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen-activated protein kinase and extracellular signal regulated kinase 1/2 signaling</span>. <i>Am. J. Physiol. Cell Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">C1073</span>â <span class="NLM_lpage">1079</span>, <span class="refDoi">Â DOI: 10.1152/ajpcell.00364.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1152%2Fajpcell.00364.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=23535237" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2013&pages=C1073-1079&author=L.+Xiaoauthor=K.+K.+Haackauthor=I.+H.+Zucker&title=Angiotensin+II+regulates+ACE+and+ACE2+in+neurons+through+p38+mitogen-activated+protein+kinase+and+extracellular+signal+regulated+kinase+1%2F2+signaling&doi=10.1152%2Fajpcell.00364.2012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.00364.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.00364.2012%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DHaack%26aufirst%3DK.%2BK.%26aulast%3DZucker%26aufirst%3DI.%2BH.%26atitle%3DAngiotensin%2520II%2520regulates%2520ACE%2520and%2520ACE2%2520in%2520neurons%2520through%2520p38%2520mitogen-activated%2520protein%2520kinase%2520and%2520extracellular%2520signal%2520regulated%2520kinase%25201%252F2%2520signaling%26jtitle%3DAm.%2520J.%2520Physiol.%2520Cell%2520Physiol.%26date%3D2013%26volume%3D304%26spage%3DC1073%26epage%3D1079%26doi%3D10.1152%2Fajpcell.00364.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshotels, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriramula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazartigues, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipeanu, C. M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-II mediates ACE2 internalization and degradation through an angiotensin-II type I receptor-dependent mechanism</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1368</span>â <span class="NLM_lpage">1375</span>, <span class="refDoi">Â DOI: 10.1161/HYPERTENSIONAHA.114.03743</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1161%2FHYPERTENSIONAHA.114.03743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25225202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2014&pages=1368-1375&author=M.+R.+Deshotelsauthor=H.+Xiaauthor=S.+Sriramulaauthor=E.+Lazartiguesauthor=C.+M.+Filipeanu&title=Angiotensin-II+mediates+ACE2+internalization+and+degradation+through+an+angiotensin-II+type+I+receptor-dependent+mechanism&doi=10.1161%2FHYPERTENSIONAHA.114.03743"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor-Dependent Mechanism</span></div><div class="casAuthors">Deshotels, Matthew R.; Xia, Huijing; Sriramula, Srinivas; Lazartigues, Eric; Filipeanu, Catalin M.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1368-1375</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Angiotensin-converting enzyme type 2 (ACE2) is a pivotal component of the renin-angiotensin system, promoting the conversion of angiotensin II (Ang-II) to Ang-(1-7).  We previously reported that decreased ACE2 expression and activity contributes to the development of Ang-II-mediated hypertension in mice.  The present study aimed to investigate the mechanisms involved in ACE2 downregulation during neurogenic hypertension.  In ACE2-transfected Neuro-2A cells, Ang-II treatment resulted in a significant attenuation of ACE2 enzymic activity.  Examn. of the subcellular localization of ACE2 revealed that Ang-II treatment leads to ACE2 internalization and degrdn. into lysosomes.  These effects were prevented by both the Ang-II type 1 receptor (AT1R) blocker losartan and the lysosomal inhibitor leupeptin.  In contrast, in HEK293T cells, which lack endogenous AT1R, Ang-II failed to promote ACE2 internalization.  Moreover, this effect could be induced after AT1R transfection.  Furthermore, coimmunopptn. expts. demonstrated that AT1R and ACE2 form complexes, and these interactions were decreased by Ang-II treatment, which also enhanced ACE2 ubiquitination.  In contrast, ACE2 activity was not changed by transfection of AT2 or Mas receptors.  In vivo, Ang-II-mediated hypertension was blunted by chronic infusion of leupeptin in wildtype C57Bl/6, but not in ACE2 knockout mice.  Overall, this is the first demonstration that elevated Ang-II levels reduce ACE2 expression and activity by stimulation of lysosomal degrdn. through an AT1R-dependent mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7T_hBPhLt1bVg90H21EOLACvtfcHk0liCW27QOe5rpA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLjI&md5=299d44058d875d0cdbcd10ef6295d0d8</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.114.03743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.114.03743%26sid%3Dliteratum%253Aachs%26aulast%3DDeshotels%26aufirst%3DM.%2BR.%26aulast%3DXia%26aufirst%3DH.%26aulast%3DSriramula%26aufirst%3DS.%26aulast%3DLazartigues%26aufirst%3DE.%26aulast%3DFilipeanu%26aufirst%3DC.%2BM.%26atitle%3DAngiotensin-II%2520mediates%2520ACE2%2520internalization%2520and%2520degradation%2520through%2520an%2520angiotensin-II%2520type%2520I%2520receptor-dependent%2520mechanism%26jtitle%3DHypertension%26date%3D2014%26volume%3D64%26spage%3D1368%26epage%3D1375%26doi%3D10.1161%2FHYPERTENSIONAHA.114.03743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, A. C.K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, H. Y.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/ p38 MAP kinase pathway</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">1174</span>â <span class="NLM_lpage">1183</span>, <span class="refDoi">Â DOI: 10.2353/ajpath.2008.070762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.2353%2Fajpath.2008.070762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=18403595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtFOntLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2008&pages=1174-1183&author=V.+Kokaauthor=X.+R.+Huangauthor=A.+C.K.+Chungauthor=W.+Wangauthor=L.+D.+Truongauthor=H.+Y.+Lan&title=Angiotensin+II+up-regulates+angiotensin+I-converting+enzyme+%28ACE%29%2C+but+down-regulates+ACE2+via+the+AT1-ERK%2F+p38+MAP+kinase+pathway&doi=10.2353%2Fajpath.2008.070762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway</span></div><div class="casAuthors">Koka, Vijay; Huang, Xiao Ru; Chung, Arthur C. K.; Wang, Wansheng; Truong, Luan D.; Lan, Hui Yao</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1174-1183</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">The recent discovery of the angiotensin II (Ang II)-breakdown enzyme, angiotensin I converting enzyme (ACE) 2, suggests the importance of Ang II degrdn. in hypertension.  The present study explored the signaling mechanism by which ACE2 is regulated under hypertensive conditions.  Real-time PCR and immunohistochem. showed that ACE2 mRNA and protein expression levels were high, whereas ACE expression levels were moderate in both normal kidney and heart.  In contrast, patients with hypertension showed marked ACE up-regulation and ACE2 down-regulation in both hypertensive cardiopathy and, particularly, hypertensive nephropathy.  The inhibition of ACE2 expression was shown to be assocd. with ACE up-regulation and activation of extracellular regulated (ERK)1/2 and p38 mitogen-activated protein (MAP) kinases.  In vitro, Ang II was able to up-regulate ACE and down-regulate ACE2 in human kidney tubular cells, which were blocked by an angiotensin II (AT)1 receptor antagonist (losartan), but not by an AT2 receptor blocker (PD123319).  Furthermore, blockade of ERK1/2 or p38 MAP kinases by either specific inhibitors or a dominant-neg. adenovirus was able to abolish Ang II-induced ACE2 down-regulation in human kidney tubular cells.  In conclusion, Ang II is able to up-regulate ACE and down-regulate ACE2 expression levels under hypertensive conditions both in vivo and in vitro.  The AT1 receptor-mediated ERK/p38 MAP kinase signaling pathway may be a key mechanism by which Ang II down-regulates ACE2 expression, implicating an ACE/ACE2 imbalance in hypertensive cardiovascular and renal damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdXJax5318hrVg90H21EOLACvtfcHk0lihVVcpv_jKXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtFOntLw%253D&md5=d176bedc3af5962d01bfa2f8e1497f47</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2008.070762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2008.070762%26sid%3Dliteratum%253Aachs%26aulast%3DKoka%26aufirst%3DV.%26aulast%3DHuang%26aufirst%3DX.%2BR.%26aulast%3DChung%26aufirst%3DA.%2BC.K.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTruong%26aufirst%3DL.%2BD.%26aulast%3DLan%26aufirst%3DH.%2BY.%26atitle%3DAngiotensin%2520II%2520up-regulates%2520angiotensin%2520I-converting%2520enzyme%2520%2528ACE%2529%252C%2520but%2520down-regulates%2520ACE2%2520via%2520the%2520AT1-ERK%252F%2520p38%2520MAP%2520kinase%2520pathway%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2008%26volume%3D172%26spage%3D1174%26epage%3D1183%26doi%3D10.2353%2Fajpath.2008.070762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span> <span> </span><span class="NLM_article-title">capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-ÎºB signaling pathway</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">104850</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2020.104850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.phrs.2020.104850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32360580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVeltLrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2020&pages=104850&author=Q.+Maauthor=W.+Panauthor=R.+Liauthor=B.+Liuauthor=C.+Liauthor=Y.+Xieauthor=Z.+Wangauthor=J.+Zhaoauthor=H.+Jiangauthor=J.+Huangauthor=Y.+Shiauthor=J.+Daiauthor=K.+Zhengauthor=X.+Liauthor=Z.+Yang&title=capsule+shows+antiviral+and+anti-inflammatory+abilities+against+novel+coronavirus+SARS-CoV-2+via+suppression+of+NF-%CE%BAB+signaling+pathway&doi=10.1016%2Fj.phrs.2020.104850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-ÎºB signaling pathway</span></div><div class="casAuthors">Ma, Qinhai; Pan, Weiqi; Li, Runfeng; Liu, Bin; Li, Chufang; Xie, Yuqi; Wang, Zhoulang; Zhao, Jin; Jiang, Haiming; Huang, Jicheng; Shi, Yongxia; Dai, Jun; Zheng, Kui; Li, Xiaobo; Yang, Zifeng</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104850</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern.  At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection.  Liu Shen capsule (LS), a traditional Chinese medicine, has been proven to have a wide spectrum of pharmacol. properties, such as anti-inflammatory, antiviral and immunomodulatory activities.  However, little is known about the antiviral effect of LS against SARS-CoV-2.  Herein, the study was designed to investigate the antiviral activity of SARS-CoV-2 and its potential effect in regulating the host's immune response.  The inhibitory effect of LS against SARS-CoV-2 replication in Vero E6 cells was evaluated by using the cytopathic effect (CPE) and plaque redn. assay.  The no. of virions of SARS-CoV-2 was obsd. under transmission electron microscope after treatment with LS.  Proinflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quant. PCR assays.  The results showed that LS could significantly inhibit SARS-CoV-2 replication in Vero E6 cells, and reduce the no. of virus particles and it could markedly reduce pro-inflammatory cytokines (TNF-Î±, IL-6, IL-1Î², IL-8, CCL-2/MCP-1 and CXCL-10/IP-10) prodn. at the mRNA levels.  Moreover, the expression of the key proteins in the NF-ÎºB/MAPK signaling pathway was detected by western blot and it was found that LS could inhibit the expression of p-NF-ÎºB p65, p-IÎºBÎ± and p-p38 MAPK, while increasing the expression of IÎºBÎ±.  These findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-ÎºB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxVNqGqzKTn7Vg90H21EOLACvtfcHk0lihVVcpv_jKXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVeltLrK&md5=2e2e69e180ef1f29b4880d5157afec5e</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2020.104850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2020.104850%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DZ.%26atitle%3Dcapsule%2520shows%2520antiviral%2520and%2520anti-inflammatory%2520abilities%2520against%2520novel%2520coronavirus%2520SARS-CoV-2%2520via%2520suppression%2520of%2520NF-%25CE%25BAB%2520signaling%2520pathway%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D158%26spage%3D104850%26doi%3D10.1016%2Fj.phrs.2020.104850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, A.</span></span> <span> </span><span class="NLM_article-title">Type I and type III interferons-induction, signaling, evasion, and application to combat COVID-19</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">870</span>â <span class="NLM_lpage">878</span>, <span class="refDoi">Â DOI: 10.1016/j.chom.2020.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.chom.2020.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32464097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVejtrvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=870-878&author=A.+Parkauthor=A.+Iwasaki&title=Type+I+and+type+III+interferons-induction%2C+signaling%2C+evasion%2C+and+application+to+combat+COVID-19&doi=10.1016%2Fj.chom.2020.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19</span></div><div class="casAuthors">Park, Annsea; Iwasaki, Akiko</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">870-878</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy.  Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host.  In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogq6K7Mhd6JbVg90H21EOLACvtfcHk0lihVVcpv_jKXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVejtrvN&md5=ab75ff6d4eea2aed7aacf15dc647471c</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2020.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2020.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DA.%26aulast%3DIwasaki%26aufirst%3DA.%26atitle%3DType%2520I%2520and%2520type%2520III%2520interferons-induction%252C%2520signaling%252C%2520evasion%252C%2520and%2520application%2520to%2520combat%2520COVID-19%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2020%26volume%3D27%26spage%3D870%26epage%3D878%26doi%3D10.1016%2Fj.chom.2020.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferdinand, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Jak/STAT signaling in immunity and disease</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">21</span>â <span class="NLM_lpage">27</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1401867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.4049%2Fjimmunol.1401867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25527793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWls7rF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2015&pages=21-27&author=A.+V.+Villarinoauthor=Y.+Kannoauthor=J.+R.+Ferdinandauthor=J.+J.+O%E2%80%99Shea&title=Mechanisms+of+Jak%2FSTAT+signaling+in+immunity+and+disease&doi=10.4049%2Fjimmunol.1401867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Jak/STAT Signaling in Immunity and Disease</span></div><div class="casAuthors">Villarino, Alejandro V.; Kanno, Yuka; Ferdinand, John R.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-27</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  More than two decades ago, expts. on the antiviral mechanisms of IFNs led to the discovery of JAKs and their downstream effectors, the STAT proteins.  This pathway has since become a paradigm for membrane-to-nucleus signaling and explains how a broad range of sol. factors, including cytokines and hormones, mediate their diverse functions.  Jak/STAT research has not only impacted basic science, particularly in the context of intercellular communication and cell-extrinsic control of gene expression, it also has become a prototype for transition from bench to bedside, culminating in the development and clin. implementation of pathway-specific therapeutics.  This brief review synthesizes our current understanding of Jak/STAT biol. while taking stock of the lessons learned and the challenges that lie ahead.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotOsFFpF-ChLVg90H21EOLACvtfcHk0liIqf_f0kushw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWls7rF&md5=777f0f64db038ca8a7f17554931e0655</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1401867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1401867%26sid%3Dliteratum%253Aachs%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DFerdinand%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DMechanisms%2520of%2520Jak%252FSTAT%2520signaling%2520in%2520immunity%2520and%2520disease%26jtitle%3DJ.%2520Immunol.%26date%3D2015%26volume%3D194%26spage%3D21%26epage%3D27%26doi%3D10.4049%2Fjimmunol.1401867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span> <span> </span><span class="NLM_article-title">Interaction of hepatitis C virus core protein with janus kinase is required for efficient production of infectious viruses</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">97</span>â <span class="NLM_lpage">106</span>, <span class="refDoi">Â DOI: 10.4062/biomolther.2013.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.4062%2Fbiomolther.2013.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt12ks7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=97-106&author=C.+Lee&title=Interaction+of+hepatitis+C+virus+core+protein+with+janus+kinase+is+required+for+efficient+production+of+infectious+viruses&doi=10.4062%2Fbiomolther.2013.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of hepatits C virus core protein with Janus kinase is required for efficient production of infectious viruses</span></div><div class="casAuthors">Lee, Choongho</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-106</span>CODEN:
                <span class="NLM_cas:coden">BTIHA3</span>;
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Applied Pharmacology</span>)
        </div><div class="casAbstract">Chronic hepatitis C virus (HCV) infection is responsible for the development of liver cirrhosis and hepatocellular carcinoma.  HCV core protein plays not only a structural role in the virion morphogenesis by encapsidating a virus RNA genome but also a nonstructural role in HCV-induced pathogenesis by blocking innate immunity.  Esp., it has been shown to regulate JAK-STAT signaling pathway through its direct interaction with Janus kinase (JAK) via its proline-rich JAK-binding motif (79PGYPWP84).  However, little is known about the physiol. significance of this HCV core-JAK assocn. in the context of the virus life cycle.  In order to gain an insight, a mutant HCV genome (J6/JFH1-79A82A) was constructed to express the mutant core with a defective JAK-binding motif (79AGYAWP84) using an HCV genotype 2a infectious clone (J6/JFH1).  When this mutant HCV genome was introduced into hepatocarcinoma cells, it was found to be severely impaired in its ability to produce infectious viruses in spite of its robust RNA genome replication.  Taken together, all these results suggest an essential requirement of HCV core-JAK protein interaction for efficient prodn. of infectious viruses and the potential of using core-JAK blockers as a new anti-HCV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB6PBOORRDBbVg90H21EOLACvtfcHk0liIqf_f0kushw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt12ks7c%253D&md5=01b53d8d5f7d333ae663f7b21e29f509</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2013.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2013.007%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26atitle%3DInteraction%2520of%2520hepatitis%2520C%2520virus%2520core%2520protein%2520with%2520janus%2520kinase%2520is%2520required%2520for%2520efficient%2520production%2520of%2520infectious%2520viruses%26jtitle%3DBiomol.%2520Ther.%26date%3D2013%26volume%3D21%26spage%3D97%26epage%3D106%26doi%3D10.4062%2Fbiomolther.2013.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubli, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinaga, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">An aberrant STAT pathway is central to COVID-19</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3209</span>â <span class="NLM_lpage">3225</span>, <span class="refDoi">Â DOI: 10.1038/s41418-020-00633-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41418-020-00633-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33037393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FpsFOisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=3209-3225&author=T.+Matsuyamaauthor=S.+P.+Kubliauthor=S.+K.+Yoshinagaauthor=K.+Pfefferauthor=T.+W.+Mak&title=An+aberrant+STAT+pathway+is+central+to+COVID-19&doi=10.1038%2Fs41418-020-00633-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">An aberrant STAT pathway is central to COVID-19</span></div><div class="casAuthors">Matsuyama Toshifumi; Kubli Shawn P; Mak Tak W; Yoshinaga Steven K; Pfeffer Klaus; Mak Tak W; Mak Tak W</div><div class="citationInfo"><span class="NLM_cas:title">Cell death and differentiation</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3209-3225</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">COVID-19 is caused by SARS-CoV-2 infection and characterized by diverse clinical symptoms.  Type I interferon (IFN-I) production is impaired and severe cases lead to ARDS and widespread coagulopathy.  We propose that COVID-19 pathophysiology is initiated by SARS-CoV-2 gene products, the NSP1 and ORF6 proteins, leading to a catastrophic cascade of failures.  These viral components induce signal transducer and activator of transcription 1 (STAT1) dysfunction and compensatory hyperactivation of STAT3.  In SARS-CoV-2-infected cells, a positive feedback loop established between STAT3 and plasminogen activator inhibitor-1 (PAI-1) may lead to an escalating cycle of activation in common with the interdependent signaling networks affected in COVID-19.  Specifically, PAI-1 upregulation leads to coagulopathy characterized by intravascular thrombi.  Overproduced PAI-1 binds to TLR4 on macrophages, inducing the secretion of proinflammatory cytokines and chemokines.  The recruitment and subsequent activation of innate immune cells within an infected lung drives the destruction of lung architecture, which leads to the infection of regional endothelial cells and produces a hypoxic environment that further stimulates PAI-1 production.  Acute lung injury also activates EGFR and leads to the phosphorylation of STAT3.  COVID-19 patients' autopsies frequently exhibit diffuse alveolar damage (DAD) and increased hyaluronan (HA) production which also leads to higher levels of PAI-1.  COVID-19 risk factors are consistent with this scenario, as PAI-1 levels are increased in hypertension, obesity, diabetes, cardiovascular diseases, and old age.  We discuss the possibility of using various approved drugs, or drugs currently in clinical development, to treat COVID-19.  This perspective suggests to enhance STAT1 activity and/or inhibit STAT3 functions for COVID-19 treatment.  This might derail the escalating STAT3/PAI-1 cycle central to COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYXP-j8pb6Qntlzo9xastyfW6udTcc2eYfUuysyaIGJrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FpsFOisg%253D%253D&md5=9c0bd0214b99bd33df55bf68d9585474</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1038%2Fs41418-020-00633-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41418-020-00633-7%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuyama%26aufirst%3DT.%26aulast%3DKubli%26aufirst%3DS.%2BP.%26aulast%3DYoshinaga%26aufirst%3DS.%2BK.%26aulast%3DPfeffer%26aufirst%3DK.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DAn%2520aberrant%2520STAT%2520pathway%2520is%2520central%2520to%2520COVID-19%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2020%26volume%3D27%26spage%3D3209%26epage%3D3225%26doi%3D10.1038%2Fs41418-020-00633-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients</span>. <i>Emerging Microbes Infect.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">761</span>â <span class="NLM_lpage">770</span>, <span class="refDoi">Â DOI: 10.1080/22221751.2020.1747363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1080%2F22221751.2020.1747363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32228226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovVWmur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=761-770&author=Y.+Xiongauthor=Y.+Liuauthor=L.+Caoauthor=D.+Wangauthor=M.+Guoauthor=A.+Jiangauthor=D.+Guoauthor=W.+Huauthor=J.+Yangauthor=Z.+Tangauthor=H.+Wuauthor=Y.+Linauthor=M.+Zhangauthor=Q.+Zhangauthor=M.+Shiauthor=Y.+Liuauthor=Y.+Zhouauthor=K.+Lanauthor=Y.+Chen&title=Transcriptomic+characteristics+of+bronchoalveolar+lavage+fluid+and+peripheral+blood+mononuclear+cells+in+COVID-19+patients&doi=10.1080%2F22221751.2020.1747363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients</span></div><div class="casAuthors">Xiong, Yong; Liu, Yuan; Cao, Liu; Wang, Dehe; Guo, Ming; Jiang, Ao; Guo, Dong; Hu, Wenjia; Yang, Jiayi; Tang, Zhidong; Wu, Honglong; Lin, Yongquan; Zhang, Meiyuan; Zhang, Qi; Shi, Mang; Liu, Yingle; Zhou, Yu; Lan, Ke; Chen, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Emerging Microbes & Infections</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">761-770</span>CODEN:
                <span class="NLM_cas:coden">EMIMC4</span>;
        ISSN:<span class="NLM_cas:issn">2222-1751</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Circulating in China and 158 other countries and areas, the ongoing COVID-19 outbreak has caused devastating mortality and posed a great threat to public health.  However, efforts to identify effectively supportive therapeutic drugs and treatments has been hampered by our limited understanding of host immune response for this fatal disease.  To characterize the transcriptional signatures of host inflammatory response to SARS-CoV-2 (HCoV-19) infection, we carried out transcriptome sequencing of the RNAs isolated from the bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cells (PBMC) specimens of COVID-19 patients.  Our results reveal distinct host inflammatory cytokine profiles to SARS-CoV-2 infection in patients, and highlight the assocn. between COVID-19 pathogenesis and excessive cytokine release such as CCL2/MCP-1, CXCL10/IP-10, CCL3/MIP-1A, and CCL4/MIP1B.  Furthermore, SARS-CoV-2 induced activation of apoptosis and P53 signalling pathway in lymphocytes may be the cause of patients' lymphopenia.  The transcriptome dataset of COVID-19 patients would be a valuable resource for clin. guidance on anti-inflammatory medication and understanding the mol. mechanisms of host response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiqUnbWEGdS7Vg90H21EOLACvtfcHk0lhkuQ6ZMsytXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovVWmur8%253D&md5=f67d028b3589eeb64fb71d8b953c1901</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1080%2F22221751.2020.1747363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F22221751.2020.1747363%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DA.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DTranscriptomic%2520characteristics%2520of%2520bronchoalveolar%2520lavage%2520fluid%2520and%2520peripheral%2520blood%2520mononuclear%2520cells%2520in%2520COVID-19%2520patients%26jtitle%3DEmerging%2520Microbes%2520Infect.%26date%3D2020%26volume%3D9%26spage%3D761%26epage%3D770%26doi%3D10.1080%2F22221751.2020.1747363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Channappanavar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, S.</span></span> <span> </span><span class="NLM_article-title">Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">529</span>â <span class="NLM_lpage">539</span>, <span class="refDoi">Â DOI: 10.1007/s00281-017-0629-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs00281-017-0629-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28466096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVGquro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2017&pages=529-539&author=R.+Channappanavarauthor=S.+Perlman&title=Pathogenic+human+coronavirus+infections%3A+Causes+and+consequences+of+cytokine+storm+and+immunopathology&doi=10.1007%2Fs00281-017-0629-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology</span></div><div class="casAuthors">Channappanavar, Rudragouda; Perlman, Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">529-539</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Human coronaviruses (hCoVs) can be divided into low pathogenic and highly pathogenic coronaviruses.  The low pathogenic CoVs infect the upper respiratory tract and cause mild, cold-like respiratory illness.  In contrast, highly pathogenic hCoVs such as severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) predominantly infect lower airways and cause fatal pneumonia.  Severe pneumonia caused by pathogenic hCoVs is often assocd. with rapid virus replication, massive inflammatory cell infiltration and elevated pro-inflammatory cytokine/chemokine responses resulting in acute lung injury (ALI), and acute respiratory distress syndrome (ARDS).  Recent studies in exptl. infected animal strongly suggest a crucial role for virus-induced immunopathol. events in causing fatal pneumonia after hCoV infections.  Here we review the current understanding of how a dysregulated immune response may cause lung immunopathol. leading to deleterious clin. manifestations after pathogenic hCoV infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrirTei_9NOcbVg90H21EOLACvtfcHk0lhkuQ6ZMsytXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVGquro%253D&md5=0a03e70c30c8d2f39db0a359f9e2e362</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1007%2Fs00281-017-0629-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-017-0629-x%26sid%3Dliteratum%253Aachs%26aulast%3DChannappanavar%26aufirst%3DR.%26aulast%3DPerlman%26aufirst%3DS.%26atitle%3DPathogenic%2520human%2520coronavirus%2520infections%253A%2520Causes%2520and%2520consequences%2520of%2520cytokine%2520storm%2520and%2520immunopathology%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2017%26volume%3D39%26spage%3D529%26epage%3D539%26doi%3D10.1007%2Fs00281-017-0629-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maini, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woody, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holgate, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussell, T.</span></span> <span> </span><span class="NLM_article-title">Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1407</span>â <span class="NLM_lpage">1409</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30858-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS0140-6736%2820%2930858-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32278362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFSlsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1407-1409&author=M.+Feldmannauthor=R.+N.+Mainiauthor=J.+N.+Woodyauthor=S.+T.+Holgateauthor=G.+Winterauthor=M.+Rowlandauthor=D.+Richardsauthor=T.+Hussell&title=Trials+of+anti-tumour+necrosis+factor+therapy+for+COVID-19+are+urgently+needed&doi=10.1016%2FS0140-6736%2820%2930858-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed</span></div><div class="casAuthors">Feldmann, Marc; Maini, Ravinder N.; Woody, James N.; Holgate, Stephen T.; Winter, Gregory; Rowland, Matthew; Richards, Duncan; Hussell, Tracy</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10234</span>),
    <span class="NLM_cas:pages">1407-1409</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A commentary on the need for more trials of anti-TNF therapy to treat COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrttyhP8InXhrVg90H21EOLACvtfcHk0lhkuQ6ZMsytXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFSlsL0%253D&md5=92f0739592011cdb3f1bcbe219cc1760</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930858-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930858-8%26sid%3Dliteratum%253Aachs%26aulast%3DFeldmann%26aufirst%3DM.%26aulast%3DMaini%26aufirst%3DR.%2BN.%26aulast%3DWoody%26aufirst%3DJ.%2BN.%26aulast%3DHolgate%26aufirst%3DS.%2BT.%26aulast%3DWinter%26aufirst%3DG.%26aulast%3DRowland%26aufirst%3DM.%26aulast%3DRichards%26aufirst%3DD.%26aulast%3DHussell%26aufirst%3DT.%26atitle%3DTrials%2520of%2520anti-tumour%2520necrosis%2520factor%2520therapy%2520for%2520COVID-19%2520are%2520urgently%2520needed%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1407%26epage%3D1409%26doi%3D10.1016%2FS0140-6736%2820%2930858-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D. W.</span></span> <span> </span><span class="NLM_article-title">Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">531</span>â <span class="NLM_lpage">543</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2020.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.tips.2020.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32580895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtF2lsLbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=531-543&author=W.+Luoauthor=Y.+X.+Liauthor=L.+J.+Jiangauthor=Q.+Chenauthor=T.+Wangauthor=D.+W.+Ye&title=Targeting+JAK-STAT+signaling+to+control+cytokine+release+syndrome+in+COVID-19&doi=10.1016%2Fj.tips.2020.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19</span></div><div class="casAuthors">Luo, Wei; Li, Yi-Xin; Jiang, Li-Jun; Chen, Qian; Wang, Tao; Ye, Da-Wei</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">531-543</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent advances in the pathophysiol. understanding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe coronavirus disease 2019 (COVID-19) might experience cytokine release syndrome (CRS), characterized by increased interleukin (IL)-6, IL-2, IL-7, IL-10, etc.  Therefore, the treatment of cytokine storm has been proposed as a crit. part of rescuing severe COVID-19.  Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs).  JAK inhibition, therefore, presents an attractive therapeutic strategy for CRS, which is a common cause of adverse clin. outcomes in COVID-19.  Below, we review the possibilities and challenges of targeting the pathway in COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8D2HH09CZ3LVg90H21EOLACvtfcHk0ljSrYA-x8lu7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtF2lsLbF&md5=4812456ab95bfb61bef7bb78f13b8229</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2020.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2020.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%2BX.%26aulast%3DJiang%26aufirst%3DL.%2BJ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DD.%2BW.%26atitle%3DTargeting%2520JAK-STAT%2520signaling%2520to%2520control%2520cytokine%2520release%2520syndrome%2520in%2520COVID-19%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2020%26volume%3D41%26spage%3D531%26epage%3D543%26doi%3D10.1016%2Fj.tips.2020.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ingraham, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotfi-Emran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thielen, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Techar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtan, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tignanelli, C. J.</span></span> <span> </span><span class="NLM_article-title">Immunomodulation in COVID-19</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">544</span>â <span class="NLM_lpage">546</span>, <span class="refDoi">Â DOI: 10.1016/S2213-2600(20)30226-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS2213-2600%2820%2930226-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32380023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXos1Wgt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=544-546&author=N.+E.+Ingrahamauthor=S.+Lotfi-Emranauthor=B.+K.+Thielenauthor=K.+Techarauthor=R.+S.+Morrisauthor=S.+G.+Holtanauthor=R.+A.+Dudleyauthor=C.+J.+Tignanelli&title=Immunomodulation+in+COVID-19&doi=10.1016%2FS2213-2600%2820%2930226-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulation in COVID-19</span></div><div class="casAuthors">Ingraham, Nicholas E.; Lotfi-Emran, Sahar; Thielen, Beth K.; Techar, Kristina; Morris, Rachel S.; Holtan, Shernan G.; Dudley, R. Adams; Tignanelli, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">544-546</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), continues to spread globally despite unprecedented social isolation and restrictions resulting in widespread economic decline.  More than 3.2 million people have been infected and more than 230,000 of them have died.  To date, no treatments have been definitively shown to be effective; however, a multipronged approach to mitigate transmission, morbidity, and mortality is ongoing.  While upstream prevention strategies such as vaccination are ideal, these strategies are unlikely to be available in time to address current clin. need.  Instead, fast-tracking of drug development and repurposing of approved drugs has facilitated and expedited clin. trials that might hasten effective therapeutics.  Many of these drugs act, at least in part, to directly limit viral replication.  By contrast, the use of interleukin-6 (IL-6) inhibition might have benefits by controlling the pathol. immune response to the virus.  Here, we expand on the theor. basis of IL-6 inhibition and propose potential benefits from other immunomodulators that could, in theory, prove more efficacious.  While IL-6 inhibition attenuates key aspects of the cytokine cascade, we posit other immune targets of inhibition to be considered and their potential to be more efficacious in the setting of COVID-19, specifically IL-1 inhibitors and Janus kinase (JAK) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5vsPO8PNStLVg90H21EOLACvtfcHk0ljSrYA-x8lu7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXos1Wgt7o%253D&md5=f46765c8f803136d15684c23ab0c73bb</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2820%2930226-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252820%252930226-5%26sid%3Dliteratum%253Aachs%26aulast%3DIngraham%26aufirst%3DN.%2BE.%26aulast%3DLotfi-Emran%26aufirst%3DS.%26aulast%3DThielen%26aufirst%3DB.%2BK.%26aulast%3DTechar%26aufirst%3DK.%26aulast%3DMorris%26aufirst%3DR.%2BS.%26aulast%3DHoltan%26aufirst%3DS.%2BG.%26aulast%3DDudley%26aufirst%3DR.%2BA.%26aulast%3DTignanelli%26aufirst%3DC.%2BJ.%26atitle%3DImmunomodulation%2520in%2520COVID-19%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2020%26volume%3D8%26spage%3D544%26epage%3D546%26doi%3D10.1016%2FS2213-2600%2820%2930226-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seif, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aazami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoshmirsafa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohsenzadegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pornour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, D.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a new treatment strategy for patients with COVID-19</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">467</span>â <span class="NLM_lpage">475</span>, <span class="refDoi">Â DOI: 10.1159/000508247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1159%2F000508247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32392562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1WjsrfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=467-475&author=F.+Seifauthor=H.+Aazamiauthor=M.+Khoshmirsafaauthor=M.+Kamaliauthor=M.+Mohsenzadeganauthor=M.+Pornourauthor=D.+Mansouri&title=JAK+inhibition+as+a+new+treatment+strategy+for+patients+with+COVID-19&doi=10.1159%2F000508247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">JAK Inhibition as a New Treatment Strategy for Patients with COVID-19</span></div><div class="casAuthors">Seif, Farhad; Aazami, Hossein; Khoshmirsafa, Majid; Kamali, Monireh; Mohsenzadegan, Monireh; Pornour, Majid; Mansouri, Davood</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">467-475</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world.  Understanding the Immunopathogenesis of COVID-19 is essential for interrupting viral infectivity and preventing aberrant immune responses before a vaccine can be developed.  In this review, we provide the latest insights into the roles of angiotensin-converting enzyme II (ACE2) and Ang II receptor-1 (AT1-R) in this disease.  Novel therapeutic strategies, including recombinant ACE2, ACE inhibitors, AT1-R blockers, and Ang 1-7 peptides, may prevent or reduce viruses-induced pulmonary, cardiac, and renal injuries.  However, more studies are needed to clarify the efficacy of these therapeutics.  Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals.  In addn. to antiviral therapy, potential ACE2- and AT1-R-inhibiting strategies, and other supportive care, we suggest other potential JAKinibs and novel anti-inflammatory combination therapies that affect the JAK-STAT pathway in patients with COVID-19.  Since the combination of MTX and baricitinib leads to outstanding clin. outcomes, the addn. of baricitinib to MTX might be a potential strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpeDIB1cKJRLVg90H21EOLACvtfcHk0ljSrYA-x8lu7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1WjsrfL&md5=dc9d52d82a5d090166752a684d100942</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1159%2F000508247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000508247%26sid%3Dliteratum%253Aachs%26aulast%3DSeif%26aufirst%3DF.%26aulast%3DAazami%26aufirst%3DH.%26aulast%3DKhoshmirsafa%26aufirst%3DM.%26aulast%3DKamali%26aufirst%3DM.%26aulast%3DMohsenzadegan%26aufirst%3DM.%26aulast%3DPornour%26aufirst%3DM.%26aulast%3DMansouri%26aufirst%3DD.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520new%2520treatment%2520strategy%2520for%2520patients%2520with%2520COVID-19%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2020%26volume%3D181%26spage%3D467%26epage%3D475%26doi%3D10.1159%2F000508247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Convertino, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdiserra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focosi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span> <span> </span><span class="NLM_article-title">Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients</span>. <i>Crit. Care</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">331</span>, <span class="refDoi">Â DOI: 10.1186/s13054-020-03020-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2Fs13054-020-03020-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32527304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB38roslykuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=331&author=I.+Convertinoauthor=M.+Tuccoriauthor=S.+Ferraroauthor=G.+Valdiserraauthor=E.+Cappelloauthor=D.+Focosiauthor=C.+Blandizzi&title=Exploring+pharmacological+approaches+for+managing+cytokine+storm+associated+with+pneumonia+and+acute+respiratory+distress+syndrome+in+COVID-19+patients&doi=10.1186%2Fs13054-020-03020-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients</span></div><div class="casAuthors">Convertino Irma; Tuccori Marco; Ferraro Sara; Valdiserra Giulia; Cappello Emiliano; Blandizzi Corrado; Tuccori Marco; Blandizzi Corrado; Focosi Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Critical care (London, England)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">331</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission.  These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality.  Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure.  Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising.  Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied.  In this article, we discuss the potential advantages of the most promising pharmacological approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrt2z806QLEuxsqfvU0ziafW6udTcc2eZiIbVvboIzTbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38roslykuw%253D%253D&md5=338f561d1c6796524ffedbcd9b6f8df3</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1186%2Fs13054-020-03020-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13054-020-03020-3%26sid%3Dliteratum%253Aachs%26aulast%3DConvertino%26aufirst%3DI.%26aulast%3DTuccori%26aufirst%3DM.%26aulast%3DFerraro%26aufirst%3DS.%26aulast%3DValdiserra%26aufirst%3DG.%26aulast%3DCappello%26aufirst%3DE.%26aulast%3DFocosi%26aufirst%3DD.%26aulast%3DBlandizzi%26aufirst%3DC.%26atitle%3DExploring%2520pharmacological%2520approaches%2520for%2520managing%2520cytokine%2520storm%2520associated%2520with%2520pneumonia%2520and%2520acute%2520respiratory%2520distress%2520syndrome%2520in%2520COVID-19%2520patients%26jtitle%3DCrit.%2520Care%26date%3D2020%26volume%3D24%26spage%3D331%26doi%3D10.1186%2Fs13054-020-03020-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib: The first FDA approved therapy for the treatment of myelofibrosis</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3008</span>â <span class="NLM_lpage">3014</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-11-3145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F1078-0432.CCR-11-3145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22474318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVOgt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3008-3014&author=J.+Mascarenhasauthor=R.+Hoffman&title=Ruxolitinib%3A+The+first+FDA+approved+therapy+for+the+treatment+of+myelofibrosis&doi=10.1158%2F1078-0432.CCR-11-3145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis</span></div><div class="casAuthors">Mascarenhas, John; Hoffman, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3008-3014</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The BCR-ABL1-neg. myeloproliferative neoplasms (e.g., essential thrombocythemia, polycythemia vera, and primary myelofibrosis) are a group of heterogeneous hematol. malignancies that involve a clonal proliferation of hematopoietic stem cells.  Thrombosis, bleeding, and transformation to acute leukemia reduce the overall survival of patients with myelofibrosis, a disease typified by progressive splenomegaly and disease-related symptoms such as fatigue, pruritus, and bony pains.  Hematopoietic stem cell transplant offers the only potential for cure in a minority of eligible patients, leaving a serious unmet need for improved therapies.  Recent advances in our understanding of the pathogenetic mechanisms underlying these diseases have led to an explosion of clin. trials evaluating novel therapies.  The discovery of an activating mutation in the Janus-activated kinase 2 (JAK2) gene provided a therapeutic target to downregulate this activated signaling pathway, which influences the phenotype of these diseases.  Ruxolitinib (Jakafi; Incyte) is a small-mol. inhibitor of JAK1/2 that has proved to be effective at reducing splenomegaly and ameliorating symptoms in myeloproliferative neoplasms.  Based on the results of 2 pivotal randomized phase III clin. trials, ruxolitinib has become the first therapeutic to be approved by the U.S.  Food and Drug Administration for treatment of patients with myelofibrosis.  Ruxolitinib offers a well-tolerated oral therapeutic option for patients with myelofibrosis with symptomatic splenomegaly and debilitating disease-related symptoms, but it does not seem to be effective at eliminating the underlying hematol. malignancy.  Clin Cancer Res; 18(11); 3008-14. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaXacNKxoFHbVg90H21EOLACvtfcHk0ljmlrps1bEOFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVOgt7g%253D&md5=ae859cee63a9ca2768164eb7d840febb</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3145%26sid%3Dliteratum%253Aachs%26aulast%3DMascarenhas%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%26atitle%3DRuxolitinib%253A%2520The%2520first%2520FDA%2520approved%2520therapy%2520for%2520the%2520treatment%2520of%2520myelofibrosis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3008%26epage%3D3014%26doi%3D10.1158%2F1078-0432.CCR-11-3145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">FDA approves Eli Lillyâs Baricitinib</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">460</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2018.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnrd.2018.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Sqtr3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=460&author=A.+Mullard&title=FDA+approves+Eli+Lilly%E2%80%99s+Baricitinib&doi=10.1038%2Fnrd.2018.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">mRNA vaccines get another booster</span></div><div class="casAuthors">Mullard, Asher</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">460</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1pR5FbMQvVLVg90H21EOLACvtfcHk0ljmlrps1bEOFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Sqtr3E&md5=025f07fb9a24835c5f349436f0372c10</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.112%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DFDA%2520approves%2520Eli%2520Lilly%25E2%2580%2599s%2520Baricitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D460%26doi%3D10.1038%2Fnrd.2018.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, K.</span></span> <span> </span><span class="NLM_article-title">FDA approves Tofacitinib for rheumatoid arthritis</span>. <i>Am. J. Health-Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2120</span>, <span class="refDoi">Â DOI: 10.2146/news120088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.2146%2Fnews120088" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=2120&author=K.+Traynor&title=FDA+approves+Tofacitinib+for+rheumatoid+arthritis&doi=10.2146%2Fnews120088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.2146%2Fnews120088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fnews120088%26sid%3Dliteratum%253Aachs%26aulast%3DTraynor%26aufirst%3DK.%26atitle%3DFDA%2520approves%2520Tofacitinib%2520for%2520rheumatoid%2520arthritis%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2012%26volume%3D69%26spage%3D2120%26doi%3D10.2146%2Fnews120088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group">American
Association for Cancer Research</span> <span> </span><span class="NLM_article-title">Fedratinib becomes new option in myelofibrosis</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1332.1</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-NB2019-102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F2159-8290.CD-NB2019-102" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1332.1&author=American%0AAssociation+for+Cancer+Research&title=Fedratinib+becomes+new+option+in+myelofibrosis&doi=10.1158%2F2159-8290.CD-NB2019-102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-NB2019-102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-NB2019-102%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFedratinib%2520becomes%2520new%2520option%2520in%2520myelofibrosis%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D1332.1%26doi%3D10.1158%2F2159-8290.CD-NB2019-102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B. A.</span></span> <span> </span><span class="NLM_article-title">JAK inhibitors in dermatology: The promise of a new drug class</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">736</span>â <span class="NLM_lpage">744</span>, <span class="refDoi">Â DOI: 10.1016/j.jaad.2016.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jaad.2016.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28139263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSmu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=736-744&author=W.+Damskyauthor=B.+A.+King&title=JAK+inhibitors+in+dermatology%3A+The+promise+of+a+new+drug+class&doi=10.1016%2Fj.jaad.2016.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibitors in dermatology: The promise of a new drug class</span></div><div class="casAuthors">Damsky, William; King, Brett A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">736-744</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">New molecularly targeted therapeutics are changing dermatol. therapy.  Janus kinase-signal transducer and activator of transcription (JAK-STAT) is an intracellular signaling pathway upon which many different proinflammatory signaling pathways converge.  Numerous inflammatory dermatoses are driven by sol. inflammatory mediators, which rely on JAK-STAT signaling, and inhibition of this pathway using JAK inhibitors might be a useful therapeutic strategy for these diseases.  Growing evidence suggests that JAK inhibitors are efficacious in atopic dermatitis, alopecia areata, psoriasis, and vitiligo.  Addnl. evidence suggests that JAK inhibition might be broadly useful in dermatol., with early reports of efficacy in several other conditions.  JAK inhibitors can be administered orally or used topically and represent a promising new class of medications.  The use of JAK inhibitors in dermatol. is reviewed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUcLA-JaUAFbVg90H21EOLACvtfcHk0ljmlrps1bEOFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSmu7g%253D&md5=6b4c7d26b0659a1d89b7f0ef8e043c0e</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2016.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2016.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DDamsky%26aufirst%3DW.%26aulast%3DKing%26aufirst%3DB.%2BA.%26atitle%3DJAK%2520inhibitors%2520in%2520dermatology%253A%2520The%2520promise%2520of%2520a%2520new%2520drug%2520class%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2017%26volume%3D76%26spage%3D736%26epage%3D744%26doi%3D10.1016%2Fj.jaad.2016.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S.</span></span> <span> </span><span class="NLM_article-title">Upadacitinib: First approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1819</span>, <span class="refDoi">Â DOI: 10.1007/s40265-019-01211-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs40265-019-01211-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31642025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3MjgvVSrtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1819&author=S.+Dugganauthor=S.+Keam&title=Upadacitinib%3A+First+approval&doi=10.1007%2Fs40265-019-01211-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Upadacitinib: First Approval</span></div><div class="casAuthors">Duggan Sean; Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1819-1828</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Upadacitinib (RinvoqÂ®), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis.  In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate.  This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfxtr5CsQWZxWfpMXQLRstfW6udTcc2eYuqNmG2JNdLbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjgvVSrtg%253D%253D&md5=3ef93907bbec16e744d0fb2b6dae65e0</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01211-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01211-z%26sid%3Dliteratum%253Aachs%26aulast%3DDuggan%26aufirst%3DS.%26aulast%3DKeam%26aufirst%3DS.%26atitle%3DUpadacitinib%253A%2520First%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1819%26doi%3D10.1007%2Fs40265-019-01211-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Z.</span>; <span class="NLM_string-name">Wang, T.</span>; <span class="NLM_string-name">Li, C.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Qin, X.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Luo, J.</span></span> <span> </span><span class="NLM_article-title">An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area</span>.  <i>MedRxiv</i>, May 7, 2020, ver. 1.<span class="refDoi">Â DOI: 10.1101/2020.04.11.20061473</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1101%2F2020.04.11.20061473" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Meng%2C+Z.%3B+Wang%2C+T.%3B+Li%2C+C.%3B+Chen%2C+X.%3B+Li%2C+L.%3B+Qin%2C+X.%3B+Li%2C+H.%3B+Luo%2C+J.+An+experimental+trial+of+recombinant+human+interferon+alpha+nasal+drops+to+prevent+coronavirus+disease+2019+in+medical+staff+in+an+epidemic+area.+MedRxiv%2C+May+7%2C+2020%2C+ver.+1.+10.1101%2F2020.04.11.20061473."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1101%2F2020.04.11.20061473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.04.11.20061473%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DZ.%26atitle%3DAn%2520experimental%2520trial%2520of%2520recombinant%2520human%2520interferon%2520alpha%2520nasal%2520drops%2520to%2520prevent%2520coronavirus%2520disease%25202019%2520in%2520medical%2520staff%2520in%2520an%2520epidemic%2520area%26jtitle%3DMedRxiv%26doi%3D10.1101%2F2020.04.11.20061473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ennis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiligada, K.</span></span> <span> </span><span class="NLM_article-title">Histamine receptors and COVID-19</span>. <i>Inflammation Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">67</span>â <span class="NLM_lpage">75</span>, <span class="refDoi">Â DOI: 10.1007/s00011-020-01422-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs00011-020-01422-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33206207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlOgsrnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2021&pages=67-75&author=M.+Ennisauthor=K.+Tiligada&title=Histamine+receptors+and+COVID-19&doi=10.1007%2Fs00011-020-01422-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine receptors and COVID-19</span></div><div class="casAuthors">Ennis, Madeleine; Tiligada, Katerina</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-75</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  Reports that the over-the-counter histamine H2 receptor antagonist famotidine could help treat the novel coronavirus disease (COVID-19) appeared from Apr. 2020.  We, therefore, examd. reports on interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and histamine receptor antagonists.  A systematic literature search was performed by 19 Sept. 2020, and updated on 28 Oct. 2020, in PubMed, Scopus, Cochrane Library and Google Scholar using (COVID-19 OR coronavirus OR SARS-CoV-2) AND (histamine antagonist OR famotidine OR cimetidine).  ClinicalTrials.gov was searched for COVID-19 and (famotidine or histamine).  Famotidine may be a useful addn. in COVID-19 treatment, but the results from prospective randomized trials are as yet awaited.  Bioinformatics/drug repurposing studies indicated that, among several medicines, H1 and H2 receptor antagonists may interact with key viral enzymes.  However, in vitro studies have to date failed to show a direct inhibition of famotidine on SARS-CoV-2 replication.  Clin. research into the potential benefits of H2 receptor antagonists in managing COVID-19 inflammation began from a simple observation and now is being tested in multi-center clin. trials.  The pos. effects of famotidine may be due to H2 receptor-mediated immunomodulatory actions on mast cell histamine-cytokine cross-talk, rather than a direct action on SARS-CoV-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY_r4jV_yKFbVg90H21EOLACvtfcHk0lhGvoZpIQbMEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlOgsrnF&md5=98ce2ef04e2487d30fd2e6a34e8dd6e5</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1007%2Fs00011-020-01422-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00011-020-01422-1%26sid%3Dliteratum%253Aachs%26aulast%3DEnnis%26aufirst%3DM.%26aulast%3DTiligada%26aufirst%3DK.%26atitle%3DHistamine%2520receptors%2520and%2520COVID-19%26jtitle%3DInflammation%2520Res.%26date%3D2021%26volume%3D70%26spage%3D67%26epage%3D75%26doi%3D10.1007%2Fs00011-020-01422-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druce, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catton, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jans, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagstaff, K. M.</span></span> <span> </span><span class="NLM_article-title">The FDA-approved drug ivermectin inhibits the replication of SARSCoV-2 in vitro</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">104787</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2020.104787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.antiviral.2020.104787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32251768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFalsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=104787&author=L.+Calyauthor=J.+D.+Druceauthor=M.+G.+Cattonauthor=D.+A.+Jansauthor=K.+M.+Wagstaff&title=The+FDA-approved+drug+ivermectin+inhibits+the+replication+of+SARSCoV-2+in+vitro&doi=10.1016%2Fj.antiviral.2020.104787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</span></div><div class="casAuthors">Caly, Leon; Druce, Julian D.; Catton, Mike G.; Jans, David A.; Wagstaff, Kylie M.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104787</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Although several clin. trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment.  We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addn. to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect â¼5000-fold redn. in viral RNA at 48 h.  Ivermectin therefore warrants further investigation for possible benefits in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHJsrOxupqz7Vg90H21EOLACvtfcHk0lhGvoZpIQbMEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFalsL8%253D&md5=d5bac8cb28292f4dc5a2feac22ce6824</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104787%26sid%3Dliteratum%253Aachs%26aulast%3DCaly%26aufirst%3DL.%26aulast%3DDruce%26aufirst%3DJ.%2BD.%26aulast%3DCatton%26aufirst%3DM.%2BG.%26aulast%3DJans%26aufirst%3DD.%2BA.%26aulast%3DWagstaff%26aufirst%3DK.%2BM.%26atitle%3DThe%2520FDA-approved%2520drug%2520ivermectin%2520inhibits%2520the%2520replication%2520of%2520SARSCoV-2%2520in%2520vitro%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D178%26spage%3D104787%26doi%3D10.1016%2Fj.antiviral.2020.104787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nice, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span> <span> </span><span class="NLM_article-title">Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">4457</span>â <span class="NLM_lpage">4469</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-15-2887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F0008-5472.CAN-15-2887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27302166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gmt7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=4457-4469&author=Q.+Douauthor=H.+N.+Chenauthor=K.+Wangauthor=K.+Yuanauthor=Y.+Leiauthor=K.+Liauthor=J.+Lanauthor=Y.+Chenauthor=Z.+Huangauthor=N.+Xieauthor=L.+Zhangauthor=R.+Xiangauthor=E.+C.+Niceauthor=Y.+Weiauthor=C.+Huang&title=Ivermectin+induces+cytostatic+autophagy+by+blocking+the+PAK1%2FAkt+axis+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-15-2887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer</span></div><div class="casAuthors">Dou, Qianhui; Chen, Hai-Ning; Wang, Kui; Yuan, Kefei; Lei, Yunlong; Li, Kai; Lan, Jiang; Chen, Yan; Huang, Zhao; Xie, Na; Zhang, Lu; Xiang, Rong; Nice, Edouard C.; Wei, Yuquan; Huang, Canhua</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4457-4469</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Breast cancer is the most common cancer among women worldwide, yet successful treatment remains a clin. challenge.  Ivermectin, a broad-spectrum antiparasitic drug, has recently been characterized as a potential anticancer agent due to obsd. antitumor effects.  However, the mol. mechanisms involved remain poorly understood.  Here, we report a role for ivermectin in breast cancer suppression by activating cytostatic autophagy both in vitro and in vivo.  Mechanistically, ivermectin-induced autophagy in breast cancer cells is assocd. with decreased P21-activated kinase 1 (PAK1) expression via the ubiquitination-mediated degrdn. pathway.  The inhibition of PAK1 decreases the phosphorylation level of Akt, resulting in the blockade of the Akt/mTOR signaling pathway.  In breast cancer xenografts, the ivermectin-induced cytostatic autophagy leads to suppression of tumor growth.  Together, our results provide a mol. basis for the use of ivermectin to inhibit the proliferation of breast cancer cells and indicate that ivermectin is a potential option for the treatment of breast cancer.  Cancer Res; 76(15); 4457-69.2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZKWcGfsuUE7Vg90H21EOLACvtfcHk0lgWKom3SHkC5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gmt7nK&md5=b1475e60805d04efee9040e91d6aaf4f</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2887%26sid%3Dliteratum%253Aachs%26aulast%3DDou%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DH.%2BN.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DK.%26aulast%3DLei%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DNice%26aufirst%3DE.%2BC.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DC.%26atitle%3DIvermectin%2520induces%2520cytostatic%2520autophagy%2520by%2520blocking%2520the%2520PAK1%252FAkt%2520axis%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D4457%26epage%3D4469%26doi%3D10.1158%2F0008-5472.CAN-15-2887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span> <span> </span><span class="NLM_article-title">Specific inhibition of STAT3 signal transduction by PIAS3</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">1803</span>â <span class="NLM_lpage">1805</span>, <span class="refDoi">Â DOI: 10.1126/science.278.5344.1803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1126%2Fscience.278.5344.1803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=9388184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK2sXnvFClt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=1997&pages=1803-1805&author=C.+D.+Chungauthor=J.+Liaoauthor=B.+Liuauthor=X.+Raoauthor=P.+Jayauthor=P.+Bertaauthor=K.+Shuai&title=Specific+inhibition+of+STAT3+signal+transduction+by+PIAS3&doi=10.1126%2Fscience.278.5344.1803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibition of Stat3 signal transduction by PIAS3</span></div><div class="casAuthors">Chung, Chan D.; Liao, Jiayu; Liu, Bin; Rao, Xiaoping; Jay, Philippe; Berta, Philippe; Shuai, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">5344</span>),
    <span class="NLM_cas:pages">1803-1805</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The signal transducer and activator of transcription-3 (Stat3) protein is activated by the interleukin 6(IL-6) family of cytokines, epidermal growth factor, and leptin.  A protein named PIAS3 (protein inhibitor of activated STAT) that binds to Stat3 was isolated and characterized.  The assocn. of PIAS3 with Stat3 in vivo was only obsd. in cells stimulated with ligands that cause the activation of Stat3.  PIAS3 blocked the DNA-binding activity of Stat3 and inhibited Stat3-mediated gene activation.  Although Stat1 is also phosphorylated in response to IL-6, PIAS3 did not interact with Stat1 or affect its DNA-binding or transcriptional activity.  The results indicate that PIAS3 is a specific inhibitor of Stat3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjxR6Y9y0qULVg90H21EOLACvtfcHk0lgWKom3SHkC5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvFClt7Y%253D&md5=781da0d380d1024071e1126bb07f6b4b</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1126%2Fscience.278.5344.1803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.278.5344.1803%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DC.%2BD.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DRao%26aufirst%3DX.%26aulast%3DJay%26aufirst%3DP.%26aulast%3DBerta%26aufirst%3DP.%26aulast%3DShuai%26aufirst%3DK.%26atitle%3DSpecific%2520inhibition%2520of%2520STAT3%2520signal%2520transduction%2520by%2520PIAS3%26jtitle%3DScience%26date%3D1997%26volume%3D278%26spage%3D1803%26epage%3D1805%26doi%3D10.1126%2Fscience.278.5344.1803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saydmohammed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, V.</span></span> <span> </span><span class="NLM_article-title">Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">447</span>â <span class="NLM_lpage">456</span>, <span class="refDoi">Â DOI: 10.1002/jcb.22558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Fjcb.22558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20235152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVSktLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2010&pages=447-456&author=M.+Saydmohammedauthor=D.+Josephauthor=V.+Syed&title=Curcumin+suppresses+constitutive+activation+of+STAT-3+by+up-regulating+protein+inhibitor+of+activated+STAT-3+%28PIAS-3%29+in+ovarian+and+endometrial+cancer+cells&doi=10.1002%2Fjcb.22558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells</span></div><div class="casAuthors">Saydmohammed, Manush; Joseph, Doina; Syed, Viqar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">447-456</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription-3 (STAT-3) is constitutively activated in ovarian and endometrial cancers and is implicated in uncontrolled cell growth.  Thus, its disruption could be an effective approach to control tumorigenesis.  Curcumin is a dihydroxyphenolic compd., with proven anti-cancer efficacy in various cancer models.  We examd. the anti-tumor mechanism of curcumin on STAT-3 and on the neg. regulators of STAT-3, including suppressors of cytokine signaling proteins (SOCS-1 and SOCS-3), protein inhibitors of activated STAT (PIAS-1 and PIAS-3), and SH2 domain-contg. phosphatases (SHP-1 and SHP-2) in ovarian and endometrial cancer cell lines.  Treatment of cancer cells with curcumin induced a dose- and time-dependent decrease of constitutive IL-6 expression and of constitutive and IL-6-induced STAT-3 phosphorylation, which is assocd. with decreased cell viability and increased cleavage of caspase-3.  The inhibition of STAT-3 activation by curcumin was reversible, and phosphorylated STAT-3 levels returned to control levels 24 h after curcumin removal.  Compared to normal cells baseline expression of SOCS-3 was high in cancer cells and a marked decrease in SOCS-3 expression was seen following curcumin treatment.  Overexpression of SOCS-3 in curcumin-treated cells increased expression of phosphorylated STAT-3 and resulted in increased cell viability.  Normal ovarian and endometrial cells exhibited high expression of PIAS-3 protein, whereas in cancer cells the expression was greatly reduced.  Curcumin increased PIAS-3 expression in cancer cells.  Of significance, siRNA-mediated knockdown of PIAS-3 overcomes the inhibitory effect of curcumin on STAT-3 phosphorylation and cell viability.  In conclusion, curcumin suppresses JAK-STAT signaling via activation of PIAS-3, thus attenuating STAT-3 phosphorylation and tumor cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH0bEhKquCdrVg90H21EOLACvtfcHk0lgWKom3SHkC5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVSktLY%253D&md5=2ec30ed38147ff6743532817f768af17</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1002%2Fjcb.22558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.22558%26sid%3Dliteratum%253Aachs%26aulast%3DSaydmohammed%26aufirst%3DM.%26aulast%3DJoseph%26aufirst%3DD.%26aulast%3DSyed%26aufirst%3DV.%26atitle%3DCurcumin%2520suppresses%2520constitutive%2520activation%2520of%2520STAT-3%2520by%2520up-regulating%2520protein%2520inhibitor%2520of%2520activated%2520STAT-3%2520%2528PIAS-3%2529%2520in%2520ovarian%2520and%2520endometrial%2520cancer%2520cells%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2010%26volume%3D110%26spage%3D447%26epage%3D456%26doi%3D10.1002%2Fjcb.22558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollenhaupt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mojcik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strengholt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazariciu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">89</span>, <span class="refDoi">Â DOI: 10.1186/s13075-019-1866-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2Fs13075-019-1866-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30953540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FitlWquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=89&author=J.+Wollenhauptauthor=E.-B.+Leeauthor=J.+R.+Curtisauthor=J.+Silverfieldauthor=K.+Terryauthor=K.+Somaauthor=C.+Mojcikauthor=R.+DeMasiauthor=S.+Strengholtauthor=K.+Kwokauthor=I.+Lazariciuauthor=L.+Wangauthor=S.+Cohen&title=Safety+and+efficacy+of+tofacitinib+for+up+to+9.5+years+in+the+treatment+of+rheumatoid+arthritis%3A+final+results+of+a+global%2C+open-label%2C+long-term+extension+study&doi=10.1186%2Fs13075-019-1866-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study</span></div><div class="casAuthors">Wollenhaupt Jurgen; Lee Eun-Bong; Curtis Jeffrey R; Silverfield Joel; Terry Ketti; Wang Lisy; Soma Koshika; Mojcik Chris; Kwok Kenneth; DeMasi Ryan; Strengholt Sander; Lazariciu Irina; Cohen Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis research & therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA).  METHODS:  Eligible patients had previously completed a phase 1, 2, or 3 qualifying index study of tofacitinib and received open-label tofacitinib 5 mg or 10 mg BID.  Stable background therapy, including csDMARDs, was continued; adjustments to tofacitinib or background therapy were permitted at investigators' discretion.  Assignment to dose groups (5 mg or 10 mg BID) was based on patients' average total daily dose.  The primary objective was to determine the long-term safety and tolerability of tofacitinib 5 mg and 10 mg BID; the key secondary objective was to evaluate the long-term persistence of efficacy.  RESULTS:  Between February 5, 2007, and November 30, 2016, 4481 patients were enrolled.  Total tofacitinib exposure was 16,291 patient-years.  Safety data are reported up to month 114 for all tofacitinib; efficacy data are reported up to month 96 for tofacitinib 5 mg BID and month 72 for 10 mg BID (with low patient numbers limiting interpretation beyond these time points).  Overall, 52% of patients discontinued (24% due to adverse events [AEs] and 4% due to insufficient clinical response); the safety profile remained consistent with that observed in prior phase 1, 2, 3, or LTE studies.  The incidence rate (IR; number of patients with events per 100 patient-years) for AEs leading to discontinuation was 6.8.  For all-cause AEs of special interest, IRs were 3.4 for herpes zoster, 2.4 for serious infections, 0.8 for malignancies excluding non-melanoma skin cancer, 0.4 for major adverse cardiovascular events, and 0.3 for all-cause mortality.  Clinically meaningful improvements in the signs and symptoms of RA and physical functioning, which were observed in the index studies, were maintained.  CONCLUSIONS:  Tofacitinib 5 mg and 10 mg BID demonstrated a consistent safety profile (as monotherapy or combination therapy) and sustained efficacy in this open-label LTE study of patients with RA.  Safety data are reported up to 9.5 years, and efficacy data up to 8 years, based on adequate patient numbers to support conclusions.  TRIAL REGISTRATION:  NCT00413699 , funded by Pfizer Inc (date of trial registration: December 20, 2006).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQry7CBP_Rh3thwrmtH4OBfW6udTcc2ea8KC2Enc1Xobntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FitlWquw%253D%253D&md5=15c33765e0ca5ffa5772fe872ede2a8a</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1186%2Fs13075-019-1866-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-019-1866-2%26sid%3Dliteratum%253Aachs%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.-B.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DSilverfield%26aufirst%3DJ.%26aulast%3DTerry%26aufirst%3DK.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DMojcik%26aufirst%3DC.%26aulast%3DDeMasi%26aufirst%3DR.%26aulast%3DStrengholt%26aufirst%3DS.%26aulast%3DKwok%26aufirst%3DK.%26aulast%3DLazariciu%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DS.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520tofacitinib%2520for%2520up%2520to%25209.5%2520years%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%253A%2520final%2520results%2520of%2520a%2520global%252C%2520open-label%252C%2520long-term%2520extension%2520study%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2019%26volume%3D21%26spage%3D89%26doi%3D10.1186%2Fs13075-019-1866-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mease, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charles-Schoeman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolcott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onofrei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanik, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauben, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span> <span> </span><span class="NLM_article-title">Incidence of venous and arterial thromboembolic events reported in the Tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1400</span>â <span class="NLM_lpage">1413</span>, <span class="refDoi">Â DOI: 10.1136/annrheumdis-2019-216761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1136%2Fannrheumdis-2019-216761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32759265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisF2nu7vN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2020&pages=1400-1413&author=P.+Measeauthor=C.+Charles-Schoemanauthor=S.+Cohenauthor=L.+Fallonauthor=J.+Woolcottauthor=H.+Yunauthor=J.+Kremerauthor=J.+Greenbergauthor=W.+Malleyauthor=A.+Onofreiauthor=K.+S.+Kanikauthor=D.+Grahamauthor=C.+Wangauthor=C.+Connellauthor=H.+Valdezauthor=M.+Haubenauthor=E.+Hungauthor=A.+Madsenauthor=T.+V.+Jonesauthor=J.+R.+Curtis&title=Incidence+of+venous+and+arterial+thromboembolic+events+reported+in+the+Tofacitinib+rheumatoid+arthritis%2C+psoriasis+and+psoriatic+arthritis+development+programmes+and+from+real-world+data&doi=10.1136%2Fannrheumdis-2019-216761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data</span></div><div class="casAuthors">Mease, Philip; Charles-Schoeman, Christina; Cohen, Stanley; Fallon, Lara; Woolcott, John; Yun, Huifeng; Kremer, Joel; Greenberg, Jeffrey; Malley, Wendi; Onofrei, Alina; Kanik, Keith S.; Graham, Daniela; Wang, Cunshan; Connell, Carol; Valdez, Hernan; Hauben, Manfred; Hung, Eric; Madsen, Ann; Jones, Thomas V.; Curtis, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1400-1413</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ</span>)
        </div><div class="casAbstract">Objectives Tofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis (PsO).  Routine pharmacovigilance of an ongoing, open-label, blinded-endpoint, tofacitinib RA trial (Study A3921133; NCT02092467) in patients aged â¥50 years and with â¥1 cardiovascular risk factor identified a higher frequency of pulmonary embolism (PE) and all-cause mortality for patients receiving tofacitinib 10 mg twice daily vs. those receiving tumor necrosis factor inhibitors and resulted in identification of a safety signal for tofacitinib.  Here, we report the incidence of deep vein thrombosis (DVT), PE, venous thromboembolism (VTE; DVT or PE) and arterial thromboembolism (ATE) from the tofacitinib RA (excluding Study A3921133), PsA and PsO development programs and observational studies.  Data from an ad hoc safety anal. of Study A3921133 are reported sep within.  Methods This post-hoc anal. used data from sep tofacitinib RA, PsO and PsA programs.  Incidence rates (IRs; patients with events per 100 patient-years exposure) were calcd. for DVT, PE, VTE and ATE, including for populations stratified by defined baseline cardiovascular or VTE risk factors.  Observational data from the US Corrona registries (including cardiovascular risk factor stratification), IBM MarketScan research database and the US FDA Adverse Event Reporting System (FAERS) database were analyzed.  Results 12 410 tofacitinib-treated patients from the development programs (RA: n = 7964; PsO: n = 3663; PsA: n = 783) were included.  IRs (95% CI) of thromboembolic events among the all tofacitinib cohorts av. tofacitinib 5 mg and 10 mg twice daily treated patients for RA, respectivley, were: DVT (0.17 (0.09-0.27) and 0.15 (0.09-0.22)); PE (0.12 (0.06-0.22) and 0.13 (0.08-0.21)); ATE (0.32 (0.22-0.46) and 0.38 (0.28-0.49)).  IRs were similar between tofacitinib doses and generally higher in patients with baseline cardiovascular or VTE risk factors.  IRs from the overall Corrona populations and in Corrona RA patients (including tofacitinib-naive/biol. disease-modifying antirheumatic drug-treated and tofacitinib-treated) with baseline cardiovascular risk factors were similar to IRs obsd. among the corresponding patients in the tofacitinib development program.  No signals of disproportionate reporting of DVT, PE or ATE with tofacitinib were identified in the FAERS database.  Conclusions DVT, PE and ATE IRs in the tofacitinib RA, PsO and PsA programs were similar across tofacitinib doses, and generally consistent with observational data and published IRs of other treatments.  As expected, IRs of thromboembolic events were elevated in patients with vs without baseline cardiovascular or VTE risk factors, and were broadly consistent with those obsd. in the Study A3921133 ad hoc safety anal. data, although the IR (95% CI) for PE was greater in patients treated with tofacitinib 10 mg twice daily in Study A3921133 (0.54 (0.32-0.87)), vs patients with baseline cardiovascular risk factors treated with tofacitinib 10 mg twice daily in the RA program (0.24 (0.13-0.41)).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXpWehht-WfbVg90H21EOLACvtfcHk0lh2yaJ3urJyEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisF2nu7vN&md5=dc3bb7d3c470a51e397502b1f5a31d28</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-216761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-216761%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DP.%26aulast%3DCharles-Schoeman%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DFallon%26aufirst%3DL.%26aulast%3DWoolcott%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DH.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DGreenberg%26aufirst%3DJ.%26aulast%3DMalley%26aufirst%3DW.%26aulast%3DOnofrei%26aufirst%3DA.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DGraham%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DConnell%26aufirst%3DC.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DHauben%26aufirst%3DM.%26aulast%3DHung%26aufirst%3DE.%26aulast%3DMadsen%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DT.%2BV.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26atitle%3DIncidence%2520of%2520venous%2520and%2520arterial%2520thromboembolic%2520events%2520reported%2520in%2520the%2520Tofacitinib%2520rheumatoid%2520arthritis%252C%2520psoriasis%2520and%2520psoriatic%2520arthritis%2520development%2520programmes%2520and%2520from%2520real-world%2520data%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2020%26volume%3D79%26spage%3D1400%26epage%3D1413%26doi%3D10.1136%2Fannrheumdis-2019-216761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark-Snustad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span> <span> </span><span class="NLM_article-title">Case report of a SARS-CoV-2 infection in a patient with ulcerative colitis on Tofacitinib</span>. <i>Inflamm. Bowel Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>, <span class="NLM_elocation-id">e64</span> <span class="refDoi">Â DOI: 10.1093/ibd/izaa093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1093%2Fibd%2Fizaa093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32342098" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&author=J.+Jacobsauthor=K.+Clark-Snustadauthor=S.+Lee&title=Case+report+of+a+SARS-CoV-2+infection+in+a+patient+with+ulcerative+colitis+on+Tofacitinib&doi=10.1093%2Fibd%2Fizaa093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1093%2Fibd%2Fizaa093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fibd%252Fizaa093%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DJ.%26aulast%3DClark-Snustad%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DS.%26atitle%3DCase%2520report%2520of%2520a%2520SARS-CoV-2%2520infection%2520in%2520a%2520patient%2520with%2520ulcerative%2520colitis%2520on%2520Tofacitinib%26jtitle%3DInflamm.%2520Bowel%2520Dis.%26date%3D2020%26volume%3D26%26doi%3D10.1093%2Fibd%2Fizaa093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. O.</span></span> <span> </span><span class="NLM_article-title">TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib</span>. <i>J. Microbiol. Immunol. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">368</span>â <span class="NLM_lpage">370</span>, <span class="refDoi">Â DOI: 10.1016/j.jmii.2020.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jmii.2020.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32205092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFalurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2020&pages=368-370&author=D.+Wuauthor=X.+O.+Yang&title=TH17+responses+in+cytokine+storm+of+COVID-19%3A+An+emerging+target+of+JAK2+inhibitor+Fedratinib&doi=10.1016%2Fj.jmii.2020.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib</span></div><div class="casAuthors">Wu, Dandan; Yang, Xuexian O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Microbiology, Immunology and Infection</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">368-370</span>CODEN:
                <span class="NLM_cas:coden">JMIIFG</span>;
        ISSN:<span class="NLM_cas:issn">1995-9133</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Taiwan LLC</span>)
        </div><div class="casAbstract">COVID-19 emerges as a pandemic disease with high mortality.  Development of effective prevention and treatment is an urgent need.  We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxQUfWxGcfQbVg90H21EOLACvtfcHk0lhuS5i8IxfUwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFalurc%253D&md5=bab4a2496a1381dd062fbaf5349baf57</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.jmii.2020.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmii.2020.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DX.%2BO.%26atitle%3DTH17%2520responses%2520in%2520cytokine%2520storm%2520of%2520COVID-19%253A%2520An%2520emerging%2520target%2520of%2520JAK2%2520inhibitor%2520Fedratinib%26jtitle%3DJ.%2520Microbiol.%2520Immunol.%2520Infect.%26date%3D2020%26volume%3D53%26spage%3D368%26epage%3D370%26doi%3D10.1016%2Fj.jmii.2020.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavegnano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detorio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planelles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1977</span>â <span class="NLM_lpage">1986</span>, <span class="refDoi">Â DOI: 10.1128/AAC.02496-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FAAC.02496-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24419350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVSltr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=1977-1986&author=C.+Gavegnanoauthor=M.+Detorioauthor=C.+Monteroauthor=A.+Bosqueauthor=V.+Planellesauthor=R.+F.+Schinazi&title=Ruxolitinib+and+tofacitinib+are+potent+and+selective+inhibitors+of+HIV-1+replication+and+virus+reactivation+in+vitro&doi=10.1128%2FAAC.02496-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro</span></div><div class="casAuthors">Gavegnano, Christina; Detorio, Mervi; Montero, Catherine; Bosque, Alberto; Planelles, Vicente; Schinazi, Raymond F.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1977-1986, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The JAK-STAT pathway is activated in both macrophages and lymphocytes upon human immunodeficiency virus type 1 (HIV-1) infection and thus represents an attractive cellular target to achieve HIV suppression and reduced inflammation, which may impact virus sanctuaries.  Ruxolitinib and tofacitinib are JAK1/2 inhibitors that are FDA approved for rheumatoid arthritis and myelofibrosis, resp., but their therapeutic application for treatment of HIV infection was unexplored.  Both drugs demonstrated submicromolar inhibition of infection with HIV-1, HIV-2, and a simian-human immunodeficiency virus, RT-SHIV, across primary human or rhesus macaque lymphocytes and macrophages, with no apparent significant cytotoxicity at 2 to 3 logs above the median effective antiviral concn.  Combination of tofacitinib and ruxolitinib increased the efficacy by 53- to 161-fold vs. that obsd. for monotherapy, resp., and each drug applied alone to primary human lymphocytes displayed similar efficacy against HIV-1 contg. various polymerase substitutions.  Both drugs inhibited virus replication in lymphocytes stimulated with phytohemagglutinin (PHA) plus interleukin-2 (IL-2), but not PHA alone, and inhibited reactivation of latent HIV-1 at low-micromolar concns. across the J-Lat T cell latency model and in primary human central memory lymphocytes.  Thus, targeted inhibition of JAK provided a selective, potent, and novel mechanism to inhibit HIV-1 replication in lymphocytes and macrophages, replication of drug-resistant HIV-1, and reactivation of latent HIV-1 and has the potential to reset the immunol. milieu in HIV-infected individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt3eFMp64h4bVg90H21EOLACvtfcHk0lhuS5i8IxfUwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVSltr8%253D&md5=85566414304fc2f381e99bca472b8691</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1128%2FAAC.02496-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02496-13%26sid%3Dliteratum%253Aachs%26aulast%3DGavegnano%26aufirst%3DC.%26aulast%3DDetorio%26aufirst%3DM.%26aulast%3DMontero%26aufirst%3DC.%26aulast%3DBosque%26aufirst%3DA.%26aulast%3DPlanelles%26aufirst%3DV.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26atitle%3DRuxolitinib%2520and%2520tofacitinib%2520are%2520potent%2520and%2520selective%2520inhibitors%2520of%2520HIV-1%2520replication%2520and%2520virus%2520reactivation%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D1977%26epage%3D1986%26doi%3D10.1128%2FAAC.02496-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavegnano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehm, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuy, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulpa, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marconi, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbagh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ©kaly, R. P.</span></span> <span> </span><span class="NLM_article-title">Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e1006740</span> <span class="refDoi">Â DOI: 10.1371/journal.ppat.1006740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1371%2Fjournal.ppat.1006740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29267399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFalsr7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&author=C.+Gavegnanoauthor=J.+H.+Brehmauthor=F.+P.+Dupuyauthor=A.+Tallaauthor=S.+P.+Ribeiroauthor=D.+A.+Kulpaauthor=C.+Cameronauthor=S.+Santosauthor=S.+J.+Hurwitzauthor=V.+C.+Marconiauthor=J.+P.+Routyauthor=L.+Sabbaghauthor=R.+F.+Schinaziauthor=R.+P.+S%C3%A9kaly&title=Novel+mechanisms+to+inhibit+HIV+reservoir+seeding+using+Jak+inhibitors&doi=10.1371%2Fjournal.ppat.1006740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors</span></div><div class="casAuthors">Gavegnano, Christina; Brehm, Jessica H.; Dupuy, Franck P.; Talla, Aarthi; Ribeiro, Susan Pereira; Kulpa, Deanna A.; Cameron, Cheryl; Santos, Stephanie; Hurwitz, Selwyn J.; Marconi, Vincent C.; Routy, Jean-Pierre; Sabbagh, Laurent; Schinazi, Raymond F.; Sekaly, Rafick Pierre</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e1006740/1-e1006740/30</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Despite advances in the treatment of HIV infection with ART, elucidating strategies to overcome HIV persistence, including blockade of viral reservoir establishment, maintenance, and expansion, remains a challenge.  T cell homeostasis is a major driver of HIV persistence.  Cytokines involved in regulating homeostasis of memory T cells, the major hub of the HIV reservoir, trigger the Jak-STAT pathway.  We evaluated the ability of tofacitinib and ruxolitinib, two FDA-approved Jak inhibitors, to block seeding and maintenance of the HIV reservoir in vitro.  We provide direct demonstration for involvement of the Jak-STAT pathway in HIV persistence in vivo, ex vivo, and in vitro; pSTAT5 strongly correlates with increased levels of integrated viral DNA in vivo, and in vitro Jak inhibitors reduce the frequency of CD4+ T cells harboring integrated HIV DNA.  We show that Jak inhibitors block viral prodn. from infected cells, inhibit Î³-C receptor cytokine (IL-15)-induced viral reactivation from latent stores thereby preventing transmission of infectious particles to bystander activated T cells.  These results show that dysregulation of the Jak-STAT pathway is assocd. with viral persistence in vivo, and that Jak inhibitors target key events downstream of Î³-C cytokine (IL-2, IL-7 and IL-15) ligation to their receptors, impacting the magnitude of the HIV reservoir in all memory CD4 T cell subsets in vitro and ex vivo.  Jak inhibitors represent a therapeutic modality to prevent key events of T cell activation that regulate HIV persistence and together, specific, potent blockade of these events may be integrated to future curative strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqUxFHplJKULVg90H21EOLACvtfcHk0lhuS5i8IxfUwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFalsr7N&md5=b311dec0f2c603fcf337df2b3b2a1e56</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1006740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1006740%26sid%3Dliteratum%253Aachs%26aulast%3DGavegnano%26aufirst%3DC.%26aulast%3DBrehm%26aufirst%3DJ.%2BH.%26aulast%3DDupuy%26aufirst%3DF.%2BP.%26aulast%3DTalla%26aufirst%3DA.%26aulast%3DRibeiro%26aufirst%3DS.%2BP.%26aulast%3DKulpa%26aufirst%3DD.%2BA.%26aulast%3DCameron%26aufirst%3DC.%26aulast%3DSantos%26aufirst%3DS.%26aulast%3DHurwitz%26aufirst%3DS.%2BJ.%26aulast%3DMarconi%26aufirst%3DV.%2BC.%26aulast%3DRouty%26aufirst%3DJ.%2BP.%26aulast%3DSabbagh%26aufirst%3DL.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DS%25C3%25A9kaly%26aufirst%3DR.%2BP.%26atitle%3DNovel%2520mechanisms%2520to%2520inhibit%2520HIV%2520reservoir%2520seeding%2520using%2520Jak%2520inhibitors%26jtitle%3DPLoS%2520Pathog.%26date%3D2017%26volume%3D13%26doi%3D10.1371%2Fjournal.ppat.1006740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manganaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, L. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potla, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiazGriffero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Sesma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, V.</span></span> <span> </span><span class="NLM_article-title">IL-15 regulates susceptibility of CD4+ T cells to HIV infection</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E9659</span>â <span class="NLM_lpage">E9667</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1806695115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1073%2Fpnas.1806695115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30257946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOntbzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E9659-E9667&author=L.+Manganaroauthor=P.+Hongauthor=M.+M.+Hernandezauthor=D.+Argyleauthor=L.+C.+F.+Mulderauthor=U.+Potlaauthor=F.+DiazGrifferoauthor=B.+Leeauthor=A.+Fernandez-Sesmaauthor=V.+Simon&title=IL-15+regulates+susceptibility+of+CD4%2B+T+cells+to+HIV+infection&doi=10.1073%2Fpnas.1806695115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">IL-15 regulates susceptibility of CD4+ T cells to HIV infection</span></div><div class="casAuthors">Manganaro, Lara; Hong, Patrick; Hernandez, Matthew M.; Argyle, Dionne; Mulder, Lubbertus C. F.; Potla, Uma; Diaz-Griffero, Felipe; Lee, Benhur; Fernandez-Sesma, Ana; Simon, Viviana</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">E9659-E9667</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">HIV integrates into the host genome to create a persistent viral reservoir.  Stimulation of CD4+ memory T lymphocytes with common Î³c-chain cytokines renders these cells more susceptible to HIV infection, making them a key component of the reservoir itself.  IL-15 is up-regulated during primary HIV infection, a time when the HIV reservoir established.  Therefore, we investigated the mol. and cellular impact of IL-15 on CD4+ T-cell infection.  We found that IL-15 stimulation induces SAM domain and HD domain-contg. protein 1 (SAMHD1) phosphorylation due to cell cycle entry, relieving an early block to infection.  Perturbation of the pathways downstream of IL-15 receptor (IL-15R) indicated that SAMHD1 phosphorylation after IL-15 stimulation is JAK dependent.  Treating CD4+ T cells with Ruxolitinib, an inhibitor of JAK1 and JAK2, effectively blocked IL-15-induced SAMHD1 phosphorylation and protected CD4+ T cells from HIV infection.  Using high-resoln. single-cell immune profiling using mass cytometry by TOF (CyTOF), we found that IL-15 stimulation altered the compn. of CD4+ T-cell memory populations by increasing proliferation of memory CD4+ T cells, including CD4+ T memory stem cells (TSCM).  IL-15-stimulated CD4+ TSCM, harboring phosphorylated SAMHD1, were preferentially infected.  We propose that IL-15 plays a pivotal role in creating a self-renewing, persistent HIV reservoir by facilitating infection of CD4+ T cells with stem cell-like properties.  Time-limited interventions with JAK1 inhibitors, such as Ruxolitinib, should prevent the inactivation of the endogenous restriction factor SAMHD1 and protect this long-lived CD4+ T-memory cell population from HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUnhS_Hhscu7Vg90H21EOLACvtfcHk0li9nKLM5Zeung"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOntbzI&md5=60940fd03686661edf95d4bae021ccf2</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1806695115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1806695115%26sid%3Dliteratum%253Aachs%26aulast%3DManganaro%26aufirst%3DL.%26aulast%3DHong%26aufirst%3DP.%26aulast%3DHernandez%26aufirst%3DM.%2BM.%26aulast%3DArgyle%26aufirst%3DD.%26aulast%3DMulder%26aufirst%3DL.%2BC.%2BF.%26aulast%3DPotla%26aufirst%3DU.%26aulast%3DDiazGriffero%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DFernandez-Sesma%26aufirst%3DA.%26aulast%3DSimon%26aufirst%3DV.%26atitle%3DIL-15%2520regulates%2520susceptibility%2520of%2520CD4%252B%2520T%2520cells%2520to%2520HIV%2520infection%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE9659%26epage%3DE9667%26doi%3D10.1073%2Fpnas.1806695115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spivak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larragoite, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, M. K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macedo, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planelles, V.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo</span>. <i>Retrovirology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">88</span>, <span class="refDoi">Â DOI: 10.1186/s12977-016-0319-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2Fs12977-016-0319-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27998278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsFGis70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=88&author=A.+M.+Spivakauthor=E.+T.+Larragoiteauthor=M.+K.+L.+Colettiauthor=A.+B.+Macedoauthor=L.+J.+Martinsauthor=A.+Bosqueauthor=V.+Planelles&title=Janus+kinase+inhibition+suppresses+PKC-induced+cytokine+release+without+affecting+HIV-1+latency+reversal+ex+vivo&doi=10.1186%2Fs12977-016-0319-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo</span></div><div class="casAuthors">Spivak, Adam M.; Larragoite, Erin T.; Coletti, McKenna L.; Macedo, Amanda B.; Martins, Laura J.; Bosque, Alberto; Planelles, Vicente</div><div class="citationInfo"><span class="NLM_cas:title">Retrovirology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">88/1-88/9</span>CODEN:
                <span class="NLM_cas:coden">RETRBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-4690</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Despite the durable viral suppression afforded by antiretroviral therapy, HIV-1 eradication will require strategies to target latently infected cells that persist in infected individuals.  Protein kinase C (PKC) activation is a promising strategy to reactivate latent proviruses and allow for subsequent recognition and clearance of infected cells by the immune system.  Ingenol derivs. are PKC agonists that induce latency reversal but also lead to T cell activation and the release of pro-inflammatory cytokines, which would be undesirable in vivo.  In this work, we sought to identify compds. that would suppress pro-inflammatory cytokine prodn. in the context of PKC activation.  Design and methods: We performed an in vitro screen to identify compds. that could dampen pro-inflammatory cytokine release assocd. with T cell activation, using IL-6 as a model cytokine.  We then tested the ability of the most promising screening hit, the FDA-approved Janus Kinase (JAK) inhibitor ruxolitinib, to diminish release of multiple cytokines and its effect on latency reversal using cells from HIV-1-pos., aviremic participants.  Results: We demonstrate that co-administration of ruxolitinib with ingenol-3,20-dibenzoate significantly reduces pro-inflammatory cytokine release without impairing latency reversal ex vivo.  Conclusions: The combination of ingenol compds. and JAK inhibition represents a novel strategy for HIV-1 eradication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV3J4XV70MabVg90H21EOLACvtfcHk0li9nKLM5Zeung"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsFGis70%253D&md5=20544d19ffe8beecb77e3670fc162bec</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1186%2Fs12977-016-0319-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12977-016-0319-0%26sid%3Dliteratum%253Aachs%26aulast%3DSpivak%26aufirst%3DA.%2BM.%26aulast%3DLarragoite%26aufirst%3DE.%2BT.%26aulast%3DColetti%26aufirst%3DM.%2BK.%2BL.%26aulast%3DMacedo%26aufirst%3DA.%2BB.%26aulast%3DMartins%26aufirst%3DL.%2BJ.%26aulast%3DBosque%26aufirst%3DA.%26aulast%3DPlanelles%26aufirst%3DV.%26atitle%3DJanus%2520kinase%2520inhibition%2520suppresses%2520PKC-induced%2520cytokine%2520release%2520without%2520affecting%2520HIV-1%2520latency%2520reversal%2520ex%2520vivo%26jtitle%3DRetrovirology%26date%3D2016%26volume%3D13%26spage%3D88%26doi%3D10.1186%2Fs12977-016-0319-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, K.</span></span> <span> </span><span class="NLM_article-title">Inflammation research association-15th international conference advances in asthma and COPD and other inflammatory diseases</span>. <i>IDrugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">863</span>â <span class="NLM_lpage">865</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=19051144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BD1cjot1Ghug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=863-865&author=K.+Walker&title=Inflammation+research+association-15th+international+conference+advances+in+asthma+and+COPD+and+other+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation Research Association--15th international conference advances in asthma and COPD and other inflammatory diseases</span></div><div class="casAuthors">Walker Karen</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs : the investigational drugs journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">863-5</span>
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgMoQJbY8mfRBrI9DTGjC0fW6udTcc2eYc0FcBerBqKbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjot1Ghug%253D%253D&md5=45aa68e772177ff24bf3fd91cfd0557b</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DK.%26atitle%3DInflammation%2520research%2520association-15th%2520international%2520conference%2520advances%2520in%2520asthma%2520and%2520COPD%2520and%2520other%2520inflammatory%2520diseases%26jtitle%3DIDrugs%26date%3D2008%26volume%3D11%26spage%3D863%26epage%3D865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussenzveig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">3538</span>, <span class="refDoi">Â DOI: 10.1182/blood.V110.11.3538.3538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1182%2Fblood.V110.11.3538.3538" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=3538&author=J.+Fridmanauthor=R.+Nussenzveigauthor=P.+Liuauthor=J.+Rodgersauthor=T.+Burnauthor=P.+Haleyauthor=P.+Scherleauthor=R.+Newtonauthor=G.+Hollisauthor=S.+Friedmanauthor=S.+Verstovsekauthor=K.+Vaddi&title=Discovery+and+preclinical+characterization+of+INCB018424%2C+a+selective+JAK2+inhibitor+for+the+treatment+of+myeloproliferative+disorders&doi=10.1182%2Fblood.V110.11.3538.3538"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1182%2Fblood.V110.11.3538.3538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V110.11.3538.3538%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%26aulast%3DNussenzveig%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DRodgers%26aufirst%3DJ.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%2520INCB018424%252C%2520a%2520selective%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520disorders%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D3538%26doi%3D10.1182%2Fblood.V110.11.3538.3538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintas-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeltz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3109</span>â <span class="NLM_lpage">3117</span>, <span class="refDoi">Â DOI: 10.1182/blood-2009-04-214957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quintas-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-04-214957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0ljWruJZNakTcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117%26doi%3D10.1182%2Fblood-2009-04-214957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Onozawa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibayama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imadome, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, A.</span></span> <span> </span><span class="NLM_article-title">STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">31077</span>â <span class="NLM_lpage">31089</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.25780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.18632%2Foncotarget.25780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30123428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ps1KrtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=31077-31089&author=E.+Onozawaauthor=H.+Shibayamaauthor=H.+Takadaauthor=K.+I.+Imadomeauthor=S.+Aokiauthor=M.+Yoshimoriauthor=N.+Shimizuauthor=S.+Fujiwaraauthor=T.+Koyamaauthor=O.+Miuraauthor=A.+Arai&title=STAT3+is+constitutively+activated+in+chronic+active+Epstein-Barr+virus+infection+and+can+be+a+therapeutic+target&doi=10.18632%2Foncotarget.25780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target</span></div><div class="casAuthors">Onozawa Erika; Shibayama Haruna; Takada Honami; Yoshimori Mayumi; Miura Osamu; Arai Ayako; Onozawa Erika; Shibayama Haruna; Takada Honami; Aoki Sho; Yoshimori Mayumi; Koyama Takatoshi; Arai Ayako; Imadome Ken-Ichi; Shimizu Norio; Fujiwara Shigeyoshi; Fujiwara Shigeyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">57</span>),
    <span class="NLM_cas:pages">31077-31089</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic active Epstein-Barr virus infection (CAEBV) is a lymphoproliferative disorder characterized by the clonal proliferation of EBV-infected T or NK cells and is related to severe systemic inflammation.  This study aims to investigate STAT3 to elucidate the mechanism underlying the CAEBV development.  We determined that STAT3 was constitutively activated in EBV-positive T- or NK-cell lines.  We also determined that STAT3 was activated in the peripheral blood mononuclear cells (PBMCs) containing EBV-infected clonally proliferating T or NK cells in six of seven patients with CAEBV.  We conducted direct sequencing of the STAT3 Src homology 2 (SH2) domain, which has previously been reported to be mutated in T- or NK-cell neoplasms.  No mutation was detected in the STAT3 SH2 domain in patients with CAEBV.  Next, we investigated the effects of ruxolitinib, an inhibitor of both JAK1 and JAK2, which phosphorylates and activates STAT3.  Ruxolitinib suppressed the phosphorylation of STAT3 in EBV-positive T- or NK-cell lines.  Ruxolitinib also decreased the viable cell number of EBV-positive T- or NK-cell lines and PBMCs from patients with CAEBV.  Furthermore, ruxolitinib suppressed the production of inflammatory cytokines in the cell lines and CAEBV patient-derived cells.  In conclusion, constitutively activated STAT3, which promotes survival and cytokine production, could be a therapeutic target for CAEBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ22Gp4PMDLXXp3bfzSLaX5fW6udTcc2eZwg46gQ0jAyrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ps1KrtQ%253D%253D&md5=cbd915fa7aadea326a75012a59d88391</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25780%26sid%3Dliteratum%253Aachs%26aulast%3DOnozawa%26aufirst%3DE.%26aulast%3DShibayama%26aufirst%3DH.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DImadome%26aufirst%3DK.%2BI.%26aulast%3DAoki%26aufirst%3DS.%26aulast%3DYoshimori%26aufirst%3DM.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DKoyama%26aufirst%3DT.%26aulast%3DMiura%26aufirst%3DO.%26aulast%3DArai%26aufirst%3DA.%26atitle%3DSTAT3%2520is%2520constitutively%2520activated%2520in%2520chronic%2520active%2520Epstein-Barr%2520virus%2520infection%2520and%2520can%2520be%2520a%2520therapeutic%2520target%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D31077%26epage%3D31089%26doi%3D10.18632%2Foncotarget.25780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">2003</span>â <span class="NLM_lpage">2004</span>, <span class="refDoi">Â DOI: 10.1007/s00277-019-03647-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1007%2Fs00277-019-03647-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30830248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgtVKiuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2019&pages=2003-2004&author=Z.+Jinauthor=Y.+Wangauthor=J.+Wangauthor=J.+Zhangauthor=L.+Wuauthor=Z.+Wang&title=Long-term+survival+benefit+of+ruxolitinib+in+a+patient+with+relapsed+refractory+chronic+active+Epstein-Barr+virus&doi=10.1007%2Fs00277-019-03647-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus</span></div><div class="casAuthors">Jin Zhili; Wang Yini; Wang Jingshi; Zhang Jia; Wu Lin; Wang Zhao</div><div class="citationInfo"><span class="NLM_cas:title">Annals of hematology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2003-2004</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRc-0Sx9gELaPh3YQQtAhNufW6udTcc2eYfwfiV-Ghh5rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgtVKiuw%253D%253D&md5=351964190ec9d8ff73772e55c697e8c0</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1007%2Fs00277-019-03647-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-019-03647-5%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DLong-term%2520survival%2520benefit%2520of%2520ruxolitinib%2520in%2520a%2520patient%2520with%2520relapsed%2520refractory%2520chronic%2520active%2520Epstein-Barr%2520virus%26jtitle%3DAnn.%2520Hematol.%26date%3D2019%26volume%3D98%26spage%3D2003%26epage%3D2004%26doi%3D10.1007%2Fs00277-019-03647-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">137</span>â <span class="NLM_lpage">146</span>, <span class="refDoi">Â DOI: 10.1016/j.jaci.2020.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jaci.2020.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32470486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlaisbnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=137-146&author=Y.+Caoauthor=J.+Weiauthor=L.+Zouauthor=T.+Jiangauthor=G.+Wangauthor=L.+Chenauthor=L.+Huangauthor=F.+Mengauthor=L.+Huangauthor=N.+Wangauthor=X.+Zhouauthor=H.+Luoauthor=Z.+Maoauthor=X.+Chenauthor=J.+Xieauthor=J.+Liuauthor=H.+Chengauthor=J.+Zhaoauthor=G.+Huangauthor=W.+Wangauthor=J.+Zhou&title=Ruxolitinib+in+treatment+of+severe+coronavirus+disease+2019+%28COVID-19%29%3A+A+multicenter%2C+single-blind%2C+randomized+controlled+trial&doi=10.1016%2Fj.jaci.2020.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial</span></div><div class="casAuthors">Cao, Yang; Wei, Jia; Zou, Liang; Jiang, Tiebin; Wang, Gaoxiang; Chen, Liting; Huang, Liang; Meng, Fankai; Huang, Lifang; Wang, Na; Zhou, Xiaoxi; Luo, Hui; Mao, Zekai; Chen, Xing; Xie, Jungang; Liu, Jing; Cheng, Hui; Zhao, Jianping; Huang, Gang; Wang, Wei; Zhou, Jianfeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-146.e3</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Accumulating evidence proposed Janus-assocd. kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation.  This study evaluated the efficacy and safety of ruxolitinib, a JAK1/2 inhibitor, for coronavirus disease 2019.  We conducted a prospective, multicenter, single-blind, randomized controlled phase II trial involving patients with severe coronavirus disease 2019.  Forty-three patients were randomly assigned (1:1) to receive ruxolitinib plus std.-of-care treatment (22 patients) or placebo based on std.-of-care treatment (21 patients).  After exclusion of 2 patients (1 ineligible, 1 consent withdrawn) from the ruxolitinib group, 20 patients in the intervention group and 21 patients in the control group were included in the study.  Treatment with ruxolitinib plus std.-of-care was not assocd. with significantly accelerated clin. improvement in severe patients with coronavirus disease 2019, although ruxolitinib recipients had a numerically faster clin. improvement.  Eighteen (90%) patients from the ruxolitinib group showed computed tomog. improvement at day 14 compared with 13 (61.9%) patients from the control group (P =.0495).  Three patients in the control group died of respiratory failure, with 14.3% overall mortality at day 28; no patients died in the ruxolitinib group.  Ruxolitinib was well tolerated with low toxicities and no new safety signals.  Levels of 7 cytokines were significantly decreased in the ruxolitinib group in comparison to the control group.  Although no statistical difference was obsd., ruxolitinib recipients had a numerically faster clin. improvement.  Significant chest computed tomog. improvement, a faster recovery from lymphopenia, and favorable side-effect profile in the ruxolitinib group were encouraging and informative to future trials to test efficacy of ruxolitinib in a larger population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsWKI4tj6YcLVg90H21EOLACvtfcHk0lgw-SRg1S0sUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlaisbnJ&md5=b758d7ebcb2a43a00d91009ad4787240</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2020.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2020.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DMao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DRuxolitinib%2520in%2520treatment%2520of%2520severe%2520coronavirus%2520disease%25202019%2520%2528COVID-19%2529%253A%2520A%2520multicenter%252C%2520single-blind%252C%2520randomized%2520controlled%2520trial%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2020%26volume%3D146%26spage%3D137%26epage%3D146%26doi%3D10.1016%2Fj.jaci.2020.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La Rosee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehrke, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birndt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellhauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Rosee, P.</span></span> <span> </span><span class="NLM_article-title">The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1805</span>â <span class="NLM_lpage">1815</span>, <span class="refDoi">Â DOI: 10.1038/s41375-020-0891-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41375-020-0891-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32518419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFelsL7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=1805-1815&author=F.+La+Roseeauthor=H.+C.+Bremerauthor=I.+Gehrkeauthor=A.+Kehrauthor=A.+Hochhausauthor=S.+Birndtauthor=M.+Fellhauerauthor=M.+Henkesauthor=B.+Kumleauthor=S.+G.+Russoauthor=P.+La+Rosee&title=The+Janus+kinase+1%2F2+inhibitor+ruxolitinib+in+COVID-19+with+severe+systemic+hyperinflammation&doi=10.1038%2Fs41375-020-0891-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation</span></div><div class="casAuthors">La Rosee, F.; Bremer, H. C.; Gehrke, I.; Kehr, A.; Hochhaus, A.; Birndt, S.; Fellhauer, M.; Henkes, M.; Kumle, B.; Russo, S. G.; La Rosee, P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1805-1815</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure.  These patients present with progressive hyperinflammation governed by proinflammatory cytokines.  An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation.  Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux).  Patients were treated with efficacy/toxicity guided step up dosing up to 14 days.  Retrospective anal. of CIS redn. and clin. outcome was performed.  Out of 105 patients treated between March 30th and Apr. 15th, 2020, 14 patients with a CIS â¥ 10 out of 16 points received Rux over a median of 9 days with a median cumulative dose of 135 mg.  A total of 12/14 patients achieved significant redn. of CIS by â¥25% on day 7 with sustained clin. improvement in 11/14 patients without short term red flag warnings of Rux-induced toxicity.  Rux treatment for COVID-19 in patients with hyperinflammation is shown to be safe with signals of efficacy in this pilot case series for CRS-intervention to prevent or overcome multiorgan failure.  A multicenter phase-II clin. trial has been initiated (NCT04338958).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnLEoRYA18u7Vg90H21EOLACvtfcHk0lgw-SRg1S0sUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFelsL7K&md5=801ce3cc74a405a334ca0d380aa53333</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-0891-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-0891-0%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRosee%26aufirst%3DF.%26aulast%3DBremer%26aufirst%3DH.%2BC.%26aulast%3DGehrke%26aufirst%3DI.%26aulast%3DKehr%26aufirst%3DA.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DBirndt%26aufirst%3DS.%26aulast%3DFellhauer%26aufirst%3DM.%26aulast%3DHenkes%26aufirst%3DM.%26aulast%3DKumle%26aufirst%3DB.%26aulast%3DRusso%26aufirst%3DS.%2BG.%26aulast%3DLa%2BRosee%26aufirst%3DP.%26atitle%3DThe%2520Janus%2520kinase%25201%252F2%2520inhibitor%2520ruxolitinib%2520in%2520COVID-19%2520with%2520severe%2520systemic%2520hyperinflammation%26jtitle%3DLeukemia%26date%3D2020%26volume%3D34%26spage%3D1805%26epage%3D1815%26doi%3D10.1038%2Fs41375-020-0891-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span> <span> </span><span class="NLM_article-title">Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1054</span>â <span class="NLM_lpage">1062</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30566-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS0140-6736%2820%2930566-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32171076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVGktL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1054-1062&author=F.+Zhouauthor=T.+Yuauthor=R.+Duauthor=G.+Fanauthor=Y.+Liuauthor=Z.+Liuauthor=J.+Xiangauthor=Y.+Wangauthor=B.+Songauthor=X.+Guauthor=L.+Guanauthor=Y.+Weiauthor=H.+Liauthor=X.+Wuauthor=J.+Xuauthor=S.+Tuauthor=Y.+Zhangauthor=H.+Chenauthor=B.+Cao&title=Clinical+course+and+risk+factors+for+mortality+of+adult+inpatients+with+COVID-19+in+Wuhan%2C+China%3A+A+retrospective+cohort+study&doi=10.1016%2FS0140-6736%2820%2930566-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</span></div><div class="casAuthors">Zhou, Fei; Yu, Ting; Du, Ronghui; Fan, Guohui; Liu, Ying; Liu, Zhibo; Xiang, Jie; Wang, Yeming; Song, Bin; Gu, Xiaoying; Guan, Lulu; Wei, Yuan; Li, Hui; Wu, Xudong; Xu, Jiuyang; Tu, Shengjin; Zhang, Yi; Chen, Hua; Cao, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10229</span>),
    <span class="NLM_cas:pages">1054-1062</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Since Dec., 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  Epidemiol. and clin. characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clin. course of illness, including viral shedding, have not been well described.  In this retrospective, multicenter cohort study, we included all adult inpatients (â¥18 yr old) with lab.-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020.  Demog., clin., treatment, and lab. data, including serial samples for viral RNA detection, were extd. from electronic medical records and compared between survivors and non-survivors.  We used univariable and multivariable logistic regression methods to explore the risk factors assocd. with in-hospital death.  One hundred ninety-one patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital.  Ninety-one (48%) patients had a comorbidity, with hypertension being the most common (58 patients), followed by diabetes (36 patients) and coronary heart disease (15 patients).  Multivariable regression showed increasing odds of in-hospital death assocd. with older age, higher Sequential Organ Failure Assessment (SOFA) score, and d-dimer >1Î¼g/L on admission.  Median duration of viral shedding was 20Â·0 days (IQR 17Â·0-24Â·0) in survivors, but SARS-CoV-2 was detectable until death in non-survivors.  The longest obsd. duration of viral shedding in survivors was 37 days.  The potential risk factors of older age, high SOFA score, and d-dimer >1Î¼g/L could help clinicians to identify patients with poor prognosis at an early stage.  Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMm2AR09dalbVg90H21EOLACvtfcHk0li7z5VMR1QeoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVGktL8%253D&md5=66ea14f4f585df80553e63820aad3f00</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930566-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930566-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DDu%26aufirst%3DR.%26aulast%3DFan%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DXiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DB.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DGuan%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DB.%26atitle%3DClinical%2520course%2520and%2520risk%2520factors%2520for%2520mortality%2520of%2520adult%2520inpatients%2520with%2520COVID-19%2520in%2520Wuhan%252C%2520China%253A%2520A%2520retrospective%2520cohort%2520study%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1054%26epage%3D1062%26doi%3D10.1016%2FS0140-6736%2820%2930566-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Decker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockinger, S.</span></span> <span> </span><span class="NLM_article-title">The yin and yang of type I interferon activity in bacterial infection</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">675</span>â <span class="NLM_lpage">687</span>, <span class="refDoi">Â DOI: 10.1038/nri1684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnri1684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16110316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslakuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=675-687&author=T.+Deckerauthor=M.+M%C3%BCllerauthor=S.+Stockinger&title=The+yin+and+yang+of+type+I+interferon+activity+in+bacterial+infection&doi=10.1038%2Fnri1684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">The Yin and Yang of type I interferon activity in bacterial infection</span></div><div class="casAuthors">Decker, Thomas; Mueller, Mathias; Stockinger, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">675-687</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Interferons (IFNs) are cytokines that are important for immune responses, particularly to intracellular pathogens.  They are divided into two structurally and functionally distinct types that interact with different cell-surface receptors.  Classically, type I IFNs are potent antiviral immunoregulators, whereas the type II IFN enhances antibacterial immunity.  However, as outlined here, type I IFNs are also produced in response to infection with other pathogens, and an increasing body of work shows that type I IFNs have an important role in the host response to bacterial infection.  Strikingly, their activity can be either favorable or detrimental, and can influence various immune effector mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY100nyqlEYLVg90H21EOLACvtfcHk0li7z5VMR1QeoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslakuro%253D&md5=6752d713459ee20fe6b78341b18546dd</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1038%2Fnri1684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1684%26sid%3Dliteratum%253Aachs%26aulast%3DDecker%26aufirst%3DT.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DStockinger%26aufirst%3DS.%26atitle%3DThe%2520yin%2520and%2520yang%2520of%2520type%2520I%2520interferon%2520activity%2520in%2520bacterial%2520infection%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2005%26volume%3D5%26spage%3D675%26epage%3D687%26doi%3D10.1038%2Fnri1684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesev, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeDesma, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploss, A.</span></span> <span> </span><span class="NLM_article-title">Decoding type I and III interferon signalling during viral infection</span>. <i>Nat. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">914</span>â <span class="NLM_lpage">924</span>, <span class="refDoi">Â DOI: 10.1038/s41564-019-0421-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41564-019-0421-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30936491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosFKjsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=914-924&author=E.+V.+Mesevauthor=R.+A.+LeDesmaauthor=A.+Ploss&title=Decoding+type+I+and+III+interferon+signalling+during+viral+infection&doi=10.1038%2Fs41564-019-0421-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Decoding type I and III interferon signalling during viral infection</span></div><div class="casAuthors">Mesev, Emily V.; LeDesma, Robert A.; Ploss, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Nature Microbiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">914-924</span>CODEN:
                <span class="NLM_cas:coden">NMAICH</span>;
        ISSN:<span class="NLM_cas:issn">2058-5276</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Interferon (IFN)-mediated antiviral responses are central to host defense against viral infection.  Despite the existence of at least 20 IFNs, there are only three known cell surface receptors.  IFN signalling and viral evasion mechanisms form an immensely complex network that differs across species.  In this Review, we begin by highlighting some of the advances that have been made towards understanding the complexity of differential IFN signalling inputs and outputs that contribute to antiviral defences.  Next, we explore some of the ways viruses can interfere with, or circumvent, these defences.  Lastly, we address the largely under-reviewed impact of IFN signalling on host tropism, and we offer perspectives on the future of research into IFN signalling complexity and viral evasion across species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6IUA6MRCEhrVg90H21EOLACvtfcHk0li7z5VMR1QeoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosFKjsrs%253D&md5=d382e535e09dd0c3e86718b29db050ce</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1038%2Fs41564-019-0421-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41564-019-0421-x%26sid%3Dliteratum%253Aachs%26aulast%3DMesev%26aufirst%3DE.%2BV.%26aulast%3DLeDesma%26aufirst%3DR.%2BA.%26aulast%3DPloss%26aufirst%3DA.%26atitle%3DDecoding%2520type%2520I%2520and%2520III%2520interferon%2520signalling%2520during%2520viral%2520infection%26jtitle%3DNat.%2520Microbiol.%26date%3D2019%26volume%3D4%26spage%3D914%26epage%3D924%26doi%3D10.1038%2Fs41564-019-0421-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span> <span> </span><span class="NLM_article-title">The host type I interferon response to viral and bacterial infections</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">407</span>â <span class="NLM_lpage">422</span>, <span class="refDoi">Â DOI: 10.1038/sj.cr.7290309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fsj.cr.7290309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=15987599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWmtrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=407-422&author=A.+K.+Perryauthor=G.+Chenauthor=D.+Zhengauthor=H.+Tangauthor=G.+Cheng&title=The+host+type+I+interferon+response+to+viral+and+bacterial+infections&doi=10.1038%2Fsj.cr.7290309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">The host type I interferon response to viral and bacterial infections</span></div><div class="casAuthors">Perry, Andrea K.; Chen, Gang; Zheng, Dahai; Tang, Hong; Cheng, Genhong</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">407-422</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Editorial Office of Cell Research</span>)
        </div><div class="casAbstract">A review.  Type I interferons (IFN) are well studied cytokines with anti-viral and immune-modulating functions.  Type I IFNs are produced following viral infections, but until recently, the mechanisms of viral recognition leading to IFN prodn. were largely unknown.  Toll like receptors (TLRs) have emerged as key transducers of type I IFN during viral infections by recognizing various viral components.  Furthermore, much progress has been made in defining the signaling pathways downstream of TLRs for type I IFN prodn.  TLR7 and TLR9 have become apparent as universally important in inducing type I IFN during infection with most viruses, particularly by plasmacytoid dendritic cells.  New intracellular viral pattern recognition receptors leading to type I IFN prodn. have been identified.  Many bacteria can also induce the up-regulation of these cytokines.  Interestingly, recent studies have found a detrimental effect on host cells if type I IFN is produced during infection with the intracellular gram-pos. bacterial pathogen, Listeria monocytogenes.  This review will discuss the recent advances made in defining the signaling pathways leading to type I IFN prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTzROOhbG9RbVg90H21EOLACvtfcHk0li2pycJHN1-uA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWmtrfJ&md5=7c23d67960bcde5cde9141e74aa5b515</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1038%2Fsj.cr.7290309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cr.7290309%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DA.%2BK.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DG.%26atitle%3DThe%2520host%2520type%2520I%2520interferon%2520response%2520to%2520viral%2520and%2520bacterial%2520infections%26jtitle%3DCell%2520Res.%26date%3D2005%26volume%3D15%26spage%3D407%26epage%3D422%26doi%3D10.1038%2Fsj.cr.7290309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lussana, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambaldi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squizzato, A.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib-associated infections: A systematic review and meta-analysis</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">339</span>â <span class="NLM_lpage">347</span>, <span class="refDoi">Â DOI: 10.1002/ajh.24976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Fajh.24976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29150886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2kur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2018&pages=339-347&author=F.+Lussanaauthor=M.+Cattaneoauthor=A.+Rambaldiauthor=A.+Squizzato&title=Ruxolitinib-associated+infections%3A+A+systematic+review+and+meta-analysis&doi=10.1002%2Fajh.24976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib-associated infections: A systematic review and meta-analysis</span></div><div class="casAuthors">Lussana, Federico; Cattaneo, Marco; Rambaldi, Alessandro; Squizzato, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-347</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Ruxolitinib exerts immunosuppressive activity that may increase the risk of infectious complications.  We performed a systematic review of the literature with the aim of estg. the risk of infections in patients treated with ruxolitinib.  Studies were identified by electronic search of MEDLINE and EMBASE database.  Differences in the incidence of infectious events between ruxolitinib and comparison groups were expressed as odds ratios (ORs) and 95% confidence intervals (95% CI).  Five phase III randomized clin. trials (RCTs) (3 phase IIIa with their extended phase and 2 phase IIIb), 6 phase IV studies and 28 case reports were included in this systematic review.  Ruxolitinib was assocd. with a statistically significant increased risk of herpes zoster infection compared to control group in 3 RCTs including patients with polycythemia vera (OR 7.39 [1.33, 41.07]) and in a pooled anal. of the extended phase IIIa RCTs (OR 5.20 [95%CI 1.27, 21.18]).  In the larger phase IV post-marketing study, the incidence of the most frequent infections was 8% for herpes zoster, 6.1% for bronchitis and 6% for urinary tract infections.  In the published case reports, the most frequent infections were tuberculosis (N = 10), hepatitis B reactivation (N = 5) and pneumocystis jeroveci infection (N = 2).  Evidence is not solid enough to accurately est. the risk of infection in ruxolitinib-treated patients.  However, published data clearly suggest that the infection risk may be clin. relevant.  Well-designed studies are warranted to evaluate the risk of ruxolitinib-assocd. infection, in order to identify the most appropriate antimicrobial prophylactic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Ugd6ZlP0dLVg90H21EOLACvtfcHk0li2pycJHN1-uA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2kur4%253D&md5=3f5fd911d19b2c0a4d561818f90fc4d0</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1002%2Fajh.24976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.24976%26sid%3Dliteratum%253Aachs%26aulast%3DLussana%26aufirst%3DF.%26aulast%3DCattaneo%26aufirst%3DM.%26aulast%3DRambaldi%26aufirst%3DA.%26aulast%3DSquizzato%26aufirst%3DA.%26atitle%3DRuxolitinib-associated%2520infections%253A%2520A%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2018%26volume%3D93%26spage%3D339%26epage%3D347%26doi%3D10.1002%2Fajh.24976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strand, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahadieh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Checchio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tensfeldt, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ³mez-Reino, J. J.</span></span> <span> </span><span class="NLM_article-title">Systematic review and meta-analysis of serious infections with Tofacitinib and biologic disease modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">362</span>, <span class="refDoi">Â DOI: 10.1186/s13075-015-0880-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1186%2Fs13075-015-0880-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26669566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1egu7jL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=362&author=V.+Strandauthor=S.+Ahadiehauthor=J.+Frenchauthor=J.+Geierauthor=S.+Krishnaswamiauthor=S.+Menonauthor=T.+Checchioauthor=T.+G.+Tensfeldtauthor=E.+Hoffmanauthor=R.+Rieseauthor=M.+Boyauthor=J.+J.+G%C3%B3mez-Reino&title=Systematic+review+and+meta-analysis+of+serious+infections+with+Tofacitinib+and+biologic+disease+modifying+antirheumatic+drug+treatment+in+rheumatoid+arthritis+clinical+trials&doi=10.1186%2Fs13075-015-0880-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials</span></div><div class="casAuthors">Strand, Vibeke; Ahadieh, Sima; French, Jonathan; Geier, Jamie; Krishnaswami, Sriram; Menon, Sujatha; Checchio, Tina; Tensfeldt, Thomas G.; Hoffman, Elaine; Riese, Richard; Boy, Mary; Gomez-Reino, Juan J.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">362/1-362/9</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).  Tofacitinib modulates the signaling of cytokines that are integral to lymphocyte activation, proliferation, and function.  Thus, tofacitinib therapy may result in suppression of multiple elements of the immune response.  Serious infections have been reported in tofacitinib RA trials.  However, limited head-to-head comparator data were available within the tofacitinib RA development program to directly compare rates of serious infections with tofacitinib relative to biol. agents, and specifically adalimumab (employed as an active control agent in two randomized controlled trials of tofacitinib).  Methods: A systematic literature search of data from interventional randomized controlled trials and long-term extension studies with biologics in RA was carried out.  Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) consensus was followed for reporting results of the review and meta-anal.  Incidence rates (unique patients with events/100 patient-years) for each therapy were estd. based on data from randomized controlled trials and long-term extension studies using a random-effects model.  Relative and abs. risk comparisons vs. placebo used Mantel-Haenszel methods.  Results: The search produced 657 hits.  In total, 66 randomized controlled trials and 22 long-term extension studies met the selection criteria.  Estd. incidence rates (95 % confidence intervals [CIs]) for abatacept, rituximab, tocilizumab, and tumor necrosis factor inhibitors were 3.04 (2.49, 3.72), 3.72 (2.99, 4.62), 5.45 (4.26, 6.96), and 4.90 (4.41, 5.44), resp.  Incidence rates (95 % CIs) for tofacitinib 5 and 10 mg twice daily (BID) in phase 3 trials were 3.02 (2.25, 4.05) and 3.00 (2.24, 4.02), resp.  Corresponding incidence rates in long-term extension studies were 2.50 (2.05, 3.04) and 3.19 (2.74, 3.72).  The risk ratios (95 % CIs) vs. placebo for tofacitinib 5 and 10 mg BID were 2.21 (0.60, 8.14) and 2.02 (0.56, 7.28), resp.  Risk differences (95 % CIs) vs. placebo for tofacitinib 5 and 10 mg BID were 0.38 % (-0.24 %, 0.99 %) and 0.40 % (-0.22 %, 1.02 %), resp.  Conclusions: In interventional studies, the risk of serious infections with tofacitinib is comparable to published rates for biol. disease-modifying antirheumatic drugs in patients with moderate to severely active RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7qaEfvstNe7Vg90H21EOLACvtfcHk0li2pycJHN1-uA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1egu7jL&md5=8421cf89c9a6b9e61c98a5886d7f37de</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1186%2Fs13075-015-0880-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-015-0880-2%26sid%3Dliteratum%253Aachs%26aulast%3DStrand%26aufirst%3DV.%26aulast%3DAhadieh%26aufirst%3DS.%26aulast%3DFrench%26aufirst%3DJ.%26aulast%3DGeier%26aufirst%3DJ.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DChecchio%26aufirst%3DT.%26aulast%3DTensfeldt%26aufirst%3DT.%2BG.%26aulast%3DHoffman%26aufirst%3DE.%26aulast%3DRiese%26aufirst%3DR.%26aulast%3DBoy%26aufirst%3DM.%26aulast%3DG%25C3%25B3mez-Reino%26aufirst%3DJ.%2BJ.%26atitle%3DSystematic%2520review%2520and%2520meta-analysis%2520of%2520serious%2520infections%2520with%2520Tofacitinib%2520and%2520biologic%2520disease%2520modifying%2520antirheumatic%2520drug%2520treatment%2520in%2520rheumatoid%2520arthritis%2520clinical%2520trials%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2015%26volume%3D17%26spage%3D362%26doi%3D10.1186%2Fs13075-015-0880-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milojkovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chacko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farquharson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span> <span> </span><span class="NLM_article-title">Response to Ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">29</span>â <span class="NLM_lpage">39</span>, <span class="refDoi">Â DOI: 10.1111/bjh.13379</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1111%2Fbjh.13379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25824940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVGmsbfP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2015&pages=29-39&author=A.+J.+Meadauthor=D.+Milojkovicauthor=S.+Knapperauthor=M.+Gargauthor=J.+Chackoauthor=M.+Farquharsonauthor=J.+Yinauthor=S.+Aliauthor=R.+E.+Clarkauthor=C.+Andrewsauthor=M.+K.+Dawsonauthor=C.+Harrison&title=Response+to+Ruxolitinib+in+patients+with+intermediate-1-%2C+intermediate-2-%2C+and+high-risk+myelofibrosis%3A+results+of+the+UK+ROBUST+Trial&doi=10.1111%2Fbjh.13379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial</span></div><div class="casAuthors">Mead, Adam J.; Milojkovic, Dragana; Knapper, Steven; Garg, Mamta; Chacko, Joseph; Farquharson, Mira; Yin, John; Ali, Sahra; Clark, Richard E.; Andrews, Chris; Dawson, Meryem Ktiouet; Harrison, Claire</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Myelofibrosis is characterized by splenomegaly and debilitating constitutional symptoms that neg. impact patients' quality of life.  ROBUST, a UK, open-label, phase II study, evaluated the safety and efficacy of ruxolitinib in patients with myelofibrosis (N = 48), including intermediate-1 risk patients.  The primary composite endpoint was the proportion of patients achieving treatment success [â¥50% redn. in palpable spleen length and/or a â¥50% decrease in Myelofibrosis Symptom Assessment Form Total Symptom Score (MF-SAF TSS)] at 48 wk.  This was the first time that efficacy of ruxolitinib in myelofibrosis has been evaluated based on these criteria and the first time the MF-SAF was used in a population of patients solely from the United Kingdom.  Overall, 50% of patients and 57% of intermediate-1 risk patients, achieved treatment success; redns. in spleen length and symptoms were obsd. in all risk groups.  The majority of patients (66Â·7%) experienced â¥50% redns. from baseline in spleen length at any time.  Improvements in MF-SAF TSS were seen in 80Â·0%, 72Â·7%, and 72Â·2% of intermediate-1, intermediate-2, and high-risk patients, resp.  Consistent with other studies of ruxolitinib, the most common haematol. adverse events were anemia and thrombocytopenia.  Results indicate that most patients with myelofibrosis, including intermediate-1 risk patients, may benefit from ruxolitinib treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUwk_Y4KOAUrVg90H21EOLACvtfcHk0livzzQJEehSRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVGmsbfP&md5=560cf8f9b5fd441f345277a18f8524ab</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1111%2Fbjh.13379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.13379%26sid%3Dliteratum%253Aachs%26aulast%3DMead%26aufirst%3DA.%2BJ.%26aulast%3DMilojkovic%26aufirst%3DD.%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DGarg%26aufirst%3DM.%26aulast%3DChacko%26aufirst%3DJ.%26aulast%3DFarquharson%26aufirst%3DM.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DR.%2BE.%26aulast%3DAndrews%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DM.%2BK.%26aulast%3DHarrison%26aufirst%3DC.%26atitle%3DResponse%2520to%2520Ruxolitinib%2520in%2520patients%2520with%2520intermediate-1-%252C%2520intermediate-2-%252C%2520and%2520high-risk%2520myelofibrosis%253A%2520results%2520of%2520the%2520UK%2520ROBUST%2520Trial%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2015%26volume%3D170%26spage%3D29%26epage%3D39%26doi%3D10.1111%2Fbjh.13379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><a href="http://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf" class="extLink">www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=www.ema.europa.eu%2Fen%2Fdocuments%2Fproduct-information%2Folumiant-epar-product-information_en.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sepriano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerschbaumer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Heijde, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougados, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vollenhoven, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bijlsma, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burmester, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falzon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LandewÃ©, R.</span></span> <span> </span><span class="NLM_article-title">Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">760</span>â <span class="NLM_lpage">770</span>, <span class="refDoi">Â DOI: 10.1136/annrheumdis-2019-216653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1136%2Fannrheumdis-2019-216653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32033941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFemtLvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2020&pages=760-770&author=A.+Seprianoauthor=A.+Kerschbaumerauthor=J.+S.+Smolenauthor=D.+van+der%0AHeijdeauthor=M.+Dougadosauthor=R.+van+Vollenhovenauthor=I.+B.+McInnesauthor=J.+W.+Bijlsmaauthor=G.+R.+Burmesterauthor=M.+de+Witauthor=L.+Falzonauthor=R.+Landew%C3%A9&title=Safety+of+synthetic+and+biological+DMARDs%3A+A+systematic+literature+review+informing+the+2019+update+of+the+EULAR+recommendations+for+the+management+of+rheumatoid+arthritis&doi=10.1136%2Fannrheumdis-2019-216653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis</span></div><div class="casAuthors">Sepriano, Alexandre; Kerschbaumer, Andreas; Smolen, Josef S.; van der Heijde, Desiree; Dougados, Maxime; van Vollenhoven, Ronald; McInnes, Iain B.; Bijlsma, Johannes W.; Burmester, Gerd R.; de Wit, Maarten; Falzon, Louise; Landewe, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">760-770</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ</span>)
        </div><div class="casAbstract">A review.  To perform a systematic literature review (SLR) concerning the safety of synthetic (s) and biol. (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis (RA).  An SLR of observational studies comparing safety outcomes of any DMARD with another intervention for the management of RA.  A comparator group was required for inclusion.  For treatments still without registry data (eg, sarilumab and the Janus kinase (JAK) inhibitors baricitinib, upadacitinib), randomised controlled trials (RCTs) and long-term extensions (LTEs) were used.  Risk of bias (RoB) was assessed according to std. procedures.  Forty-two observational studies fulfilled the inclusion criteria, addressing safety outcomes with bDMARDs and sDMARDs.  Nine studies showed no difference in the risk of serious infections across bDMARDs and two studies (high RoB) showed an increased risk with bDMARDs compared with conventional synthetic (cs) DMARDs (adjusted incidence rate ratio 3.1-3.9).  The risk of Herpes zoster infection was similar across bDMARDs, but one study showed an increased risk with tofacitinib compared with abatacept (adjusted HR (aHR) 2.0).  Five studies showed no increased risk of cancer for bDMARDs compared with csDMARDs.  An increased risk of lower intestinal perforation was found for tocilizumab compared with csDMARDs (aHR 4.5) and tumor necrosis factor inhibitor (TNFi) (aHR 2.6-4.0).  Sixty manuscripts reported safety data from RCTs/LTEs.  Overall, no unexpected safety outcomes were found, except for the possibly increased risk of venous thromboembolism (VTE) with JAK inhibitors.  Data obtained by this SLR confirm the known safety profile of bDMARDs.  The risk of VTE in RA, esp. in patients on JAK inhibitors, needs further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU7VGNx5sLKLVg90H21EOLACvtfcHk0livzzQJEehSRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFemtLvE&md5=9ccdccfff2f89cf3f2ca286321134bd2</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-216653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-216653%26sid%3Dliteratum%253Aachs%26aulast%3DSepriano%26aufirst%3DA.%26aulast%3DKerschbaumer%26aufirst%3DA.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%26aulast%3DDougados%26aufirst%3DM.%26aulast%3Dvan%2BVollenhoven%26aufirst%3DR.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DBijlsma%26aufirst%3DJ.%2BW.%26aulast%3DBurmester%26aufirst%3DG.%2BR.%26aulast%3Dde%2BWit%26aufirst%3DM.%26aulast%3DFalzon%26aufirst%3DL.%26aulast%3DLandew%25C3%25A9%26aufirst%3DR.%26atitle%3DSafety%2520of%2520synthetic%2520and%2520biological%2520DMARDs%253A%2520A%2520systematic%2520literature%2520review%2520informing%2520the%25202019%2520update%2520of%2520the%2520EULAR%2520recommendations%2520for%2520the%2520management%2520of%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2020%26volume%3D79%26spage%3D760%26epage%3D770%26doi%3D10.1136%2Fannrheumdis-2019-216653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaspari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zengarini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangeli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastroianni, A.</span></span> <span> </span><span class="NLM_article-title">Side effects of Ruxolitinib in patients with SARS-CoV-2 infection: Two case reports</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">106023</span>, <span class="refDoi">Â DOI: 10.1016/j.ijantimicag.2020.106023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.ijantimicag.2020.106023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32450201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVejtr%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=106023&author=V.+Gaspariauthor=C.+Zengariniauthor=S.+Grecoauthor=V.+Vangeliauthor=A.+Mastroianni&title=Side+effects+of+Ruxolitinib+in+patients+with+SARS-CoV-2+infection%3A+Two+case+reports&doi=10.1016%2Fj.ijantimicag.2020.106023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports</span></div><div class="casAuthors">Gaspari, Valeria; Zengarini, Corrado; Greco, Sonia; Vangeli, Valeria; Mastroianni, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">106023</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This letter to the editor looks at side effects of ruxolitinib in patients with SARS-CoV-2 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouVsdhB3krI7Vg90H21EOLACvtfcHk0lh29jthJ90z5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVejtr%252FF&md5=7e067cf2f7ee3281b15a7846c1019f92</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2020.106023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2020.106023%26sid%3Dliteratum%253Aachs%26aulast%3DGaspari%26aufirst%3DV.%26aulast%3DZengarini%26aufirst%3DC.%26aulast%3DGreco%26aufirst%3DS.%26aulast%3DVangeli%26aufirst%3DV.%26aulast%3DMastroianni%26aufirst%3DA.%26atitle%3DSide%2520effects%2520of%2520Ruxolitinib%2520in%2520patients%2520with%2520SARS-CoV-2%2520infection%253A%2520Two%2520case%2520reports%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2020%26volume%3D56%26spage%3D106023%26doi%3D10.1016%2Fj.ijantimicag.2020.106023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Channappanavar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehr, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlford-Lenane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrahante, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sompallae, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCray, P. B.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerholz, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, S.</span></span> <span> </span><span class="NLM_article-title">IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">3625</span>â <span class="NLM_lpage">3639</span>, <span class="refDoi">Â DOI: 10.1172/JCI126363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1172%2FJCI126363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=31355779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3MvitlahsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2019&pages=3625-3639&author=R.+Channappanavarauthor=A.+R.+Fehrauthor=J.+Zhengauthor=C.+Wohlford-Lenaneauthor=J.+E.+Abrahanteauthor=M.+Mackauthor=R.+Sompallaeauthor=P.+B.+McCrayauthor=D.+K.+Meyerholzauthor=S.+Perlman&title=IFN-I+response+timing+relative+to+virus+replication+determines+MERS+coronavirus+infection+outcomes&doi=10.1172%2FJCI126363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes</span></div><div class="casAuthors">Channappanavar Rudragouda; Fehr Anthony R; Zheng Jian; McCray Paul B Jr; Perlman Stanley; Channappanavar Rudragouda; Channappanavar Rudragouda; Wohlford-Lenane Christine; McCray Paul B Jr; Perlman Stanley; Abrahante Juan E; Mack Matthias; Sompallae Ramakrishna; Meyerholz David K; Perlman Stanley</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3625-3639</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type 1 IFNs (IFN-I) generally protect mammalian hosts from virus infections, but in some cases, IFN-I is pathogenic.  Because IFN-I is protective, it is commonly used to treat virus infections for which no specific approved drug or vaccine is available.  The Middle East respiratory syndrome-coronavirus (MERS-CoV) is such an infection, yet little is known about the role of IFN-I in this setting.  Here, we show that IFN-I signaling is protective during MERS-CoV infection.  Blocking IFN-I signaling resulted in delayed virus clearance, enhanced neutrophil infiltration, and impaired MERS-CoV-specific T cell responses.  Notably, IFN-I administration within 1 day after infection (before virus titers peak) protected mice from lethal infection, despite a decrease in IFN-stimulated gene (ISG) and inflammatory cytokine gene expression.  In contrast, delayed IFN-Î² treatment failed to effectively inhibit virus replication, increased infiltration and activation of monocytes, macrophages, and neutrophils in the lungs, and enhanced proinflammatory cytokine expression, resulting in fatal pneumonia in an otherwise sublethal infection.  Together, these results suggest that the relative timing of the IFN-I response and maximal virus replication is key in determining outcomes, at least in infected mice.  By extension, IFN-Î±Î² or combination therapy may need to be used cautiously to treat viral infections in clinical settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnAIHuz_P7JOR_TJajKxJDfW6udTcc2ebEzTzOGluV-Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvitlahsA%253D%253D&md5=843e52b0e3113db723d76e5a81db0e87</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1172%2FJCI126363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI126363%26sid%3Dliteratum%253Aachs%26aulast%3DChannappanavar%26aufirst%3DR.%26aulast%3DFehr%26aufirst%3DA.%2BR.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DWohlford-Lenane%26aufirst%3DC.%26aulast%3DAbrahante%26aufirst%3DJ.%2BE.%26aulast%3DMack%26aufirst%3DM.%26aulast%3DSompallae%26aufirst%3DR.%26aulast%3DMcCray%26aufirst%3DP.%2BB.%26aulast%3DMeyerholz%26aufirst%3DD.%2BK.%26aulast%3DPerlman%26aufirst%3DS.%26atitle%3DIFN-I%2520response%2520timing%2520relative%2520to%2520virus%2520replication%2520determines%2520MERS%2520coronavirus%2520infection%2520outcomes%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2019%26volume%3D129%26spage%3D3625%26epage%3D3639%26doi%3D10.1172%2FJCI126363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danesh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bermejo-Martin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poutanen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willey, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVries, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seneviratne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosinger, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greller, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somogyi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keshavjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeb, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGeer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelvin, D. J.</span></span>; <span class="NLM_contrib-group">Canadian SARS research network</span> <span> </span><span class="NLM_article-title">Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">8692</span>â <span class="NLM_lpage">8706</span>, <span class="refDoi">Â DOI: 10.1128/JVI.00527-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.00527-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17537853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslOitL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2007&pages=8692-8706&author=M.+J.+Cameronauthor=L.+Ranauthor=L.+Xuauthor=A.+Daneshauthor=J.+F.+Bermejo-Martinauthor=C.+M.+Cameronauthor=M.+P.+Mullerauthor=W.+L.+Goldauthor=S.+E.+Richardsonauthor=S.+M.+Poutanenauthor=B.+M.+Willeyauthor=M.+E.+DeVriesauthor=Y.+Fangauthor=C.+Seneviratneauthor=S.+E.+Bosingerauthor=D.+Persadauthor=P.+Wilkinsonauthor=L.+D.+Grellerauthor=R.+Somogyiauthor=A.+Humarauthor=S.+Keshavjeeauthor=M.+Louieauthor=M.+B.+Loebauthor=J.+Bruntonauthor=A.+J.+McGeerauthor=D.+J.+Kelvinauthor=Canadian+SARS+research+network&title=Interferon-mediated+immunopathological+events+are+associated+with+atypical+innate+and+adaptive+immune+responses+in+patients+with+severe+acute+respiratory+syndrome&doi=10.1128%2FJVI.00527-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome</span></div><div class="casAuthors">Cameron, Mark J.; Ran, Longsi; Xu, Luoling; Danesh, Ali; Bermejo-Martin, Jesus F.; Cameron, Cheryl M.; Muller, Matthew P.; Gold, Wayne L.; Richardson, Susan E.; Poutanen, Susan M.; Willey, Barbara M.; DeVries, Mark E.; Fang, Yuan; Seneviratne, Charit; Bosinger, Steven E.; Persad, Desmond; Wilkinson, Peter; Greller, Larry D.; Somogyi, Roland; Humar, Atul; Keshavjee, Shaf; Louie, Marie; Loeb, Mark B.; Brunton, James; McGeer, Allison J.; Kelvin, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8692-8706</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">It is not understood how immune inflammation influences the pathogenesis of severe acute respiratory syndrome (SARS).  One area of strong controversy is the role of interferon (IFN) responses in the natural history of SARS.  The fact that the majority of SARS patients recover after relatively moderate illness suggests that the prevailing notion of deficient type I IFN-mediated immunity, with hypercytokinemia driving a poor clin. course, is oversimplified.  The authors used proteomic and genomic technol. to systematically analyze host innate and adaptive immune responses of 40 clin. well-described patients with SARS during discrete phases of illness from the onset of symptoms to discharge or a fatal outcome.  A novel signature of high IFN-Î±, IFN-Î³, and IFN-stimulated chemokine levels, plus robust antiviral IFN-stimulated gene (ISG) expression, accompanied early SARS sequelae.  As acute illness progressed, SARS patients entered a crisis phase linked to oxygen satn. profiles.  The majority of SARS patients resolved IFN responses at crisis and expressed adaptive immune genes.  In contrast, patients with poor outcomes showed deviated ISG and Ig gene expression levels, persistent chemokine levels, and deficient anti-SARS spike antibody prodn.  The authors contend that unregulated IFN responses during acute-phase SARS may culminate in a malfunction of the switch from innate immunity to adaptive immunity.  The potential for the use of the gene signatures the authors describe in this study to better assess the immunopathol. and clin. management of severe viral infections, such as SARS and avian influenza (H5N1), is therefore worth careful examn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_HvMsyIdbN7Vg90H21EOLACvtfcHk0lh29jthJ90z5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslOitL4%253D&md5=25c9a316489dccdbcb4ab425f26597ab</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1128%2FJVI.00527-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00527-07%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DRan%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDanesh%26aufirst%3DA.%26aulast%3DBermejo-Martin%26aufirst%3DJ.%2BF.%26aulast%3DCameron%26aufirst%3DC.%2BM.%26aulast%3DMuller%26aufirst%3DM.%2BP.%26aulast%3DGold%26aufirst%3DW.%2BL.%26aulast%3DRichardson%26aufirst%3DS.%2BE.%26aulast%3DPoutanen%26aufirst%3DS.%2BM.%26aulast%3DWilley%26aufirst%3DB.%2BM.%26aulast%3DDeVries%26aufirst%3DM.%2BE.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DSeneviratne%26aufirst%3DC.%26aulast%3DBosinger%26aufirst%3DS.%2BE.%26aulast%3DPersad%26aufirst%3DD.%26aulast%3DWilkinson%26aufirst%3DP.%26aulast%3DGreller%26aufirst%3DL.%2BD.%26aulast%3DSomogyi%26aufirst%3DR.%26aulast%3DHumar%26aufirst%3DA.%26aulast%3DKeshavjee%26aufirst%3DS.%26aulast%3DLouie%26aufirst%3DM.%26aulast%3DLoeb%26aufirst%3DM.%2BB.%26aulast%3DBrunton%26aufirst%3DJ.%26aulast%3DMcGeer%26aufirst%3DA.%2BJ.%26aulast%3DKelvin%26aufirst%3DD.%2BJ.%26aulast%3D%26atitle%3DInterferon-mediated%2520immunopathological%2520events%2520are%2520associated%2520with%2520atypical%2520innate%2520and%2520adaptive%2520immune%2520responses%2520in%2520patients%2520with%2520severe%2520acute%2520respiratory%2520syndrome%26jtitle%3DJ.%2520Virol.%26date%3D2007%26volume%3D81%26spage%3D8692%26epage%3D8706%26doi%3D10.1128%2FJVI.00527-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanco-Melo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson-Payant, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoagland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¸ller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, T. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">tenOever, B. R.</span></span> <span> </span><span class="NLM_article-title">Imbalanced host response to SARS-CoV-2 drives development of COVID-19</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">1036</span>â <span class="NLM_lpage">1045</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.04.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cell.2020.04.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32416070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXps1yjtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=1036-1045&author=D.+Blanco-Meloauthor=B.+E.+Nilsson-Payantauthor=W.+C.+Liuauthor=S.+Uhlauthor=D.+Hoaglandauthor=R.+M%C3%B8llerauthor=T.+X.+Jordanauthor=K.+Oishiauthor=M.+Panisauthor=D.+Sachsauthor=T.+T.+Wangauthor=R.+E.+Schwartzauthor=J.+K.+Limauthor=R.+A.+Albrechtauthor=B.+R.+tenOever&title=Imbalanced+host+response+to+SARS-CoV-2+drives+development+of+COVID-19&doi=10.1016%2Fj.cell.2020.04.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19</span></div><div class="casAuthors">Blanco-Melo, Daniel; Nilsson-Payant, Benjamin E.; Liu, Wen-Chun; Uhl, Skyler; Hoagland, Daisy; Moeller, Rasmus; Jordan, Tristan X.; Oishi, Kohei; Panis, Maryline; Sachs, David; Wang, Taia T.; Schwartz, Robert E.; Lim, Jean K.; Albrecht, Randy A.; tenOever, Benjamin R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1036-1045.e9</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Viral pandemics, such as the one caused by SARS-CoV-2, pose an imminent threat to humanity.  Because of its recent emergence, there is a paucity of information regarding viral behavior and host response following SARS-CoV-2 infection.  Here we offer an in-depth anal. of the transcriptional response to SARS-CoV-2 compared with other respiratory viruses.  Cell and animal models of SARS-CoV-2 infection, in addn. to transcriptional and serum profiling of COVID-19 patients, consistently revealed a unique and inappropriate inflammatory response.  This response is defined by low levels of type I and III interferons juxtaposed to elevated chemokines and high expression of IL-6.  We propose that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine prodn. are the defining and driving features of COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMWwpoPQkdl7Vg90H21EOLACvtfcHk0lihuUge86Qh9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXps1yjtrk%253D&md5=cd1c1b429265a563ec1625972e3b07f7</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.04.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.04.026%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco-Melo%26aufirst%3DD.%26aulast%3DNilsson-Payant%26aufirst%3DB.%2BE.%26aulast%3DLiu%26aufirst%3DW.%2BC.%26aulast%3DUhl%26aufirst%3DS.%26aulast%3DHoagland%26aufirst%3DD.%26aulast%3DM%25C3%25B8ller%26aufirst%3DR.%26aulast%3DJordan%26aufirst%3DT.%2BX.%26aulast%3DOishi%26aufirst%3DK.%26aulast%3DPanis%26aufirst%3DM.%26aulast%3DSachs%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DT.%2BT.%26aulast%3DSchwartz%26aufirst%3DR.%2BE.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DAlbrecht%26aufirst%3DR.%2BA.%26aulast%3DtenOever%26aufirst%3DB.%2BR.%26atitle%3DImbalanced%2520host%2520response%2520to%2520SARS-CoV-2%2520drives%2520development%2520of%2520COVID-19%26jtitle%3DCell%26date%3D2020%26volume%3D181%26spage%3D1036%26epage%3D1045%26doi%3D10.1016%2Fj.cell.2020.04.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, C. G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyquist, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mbano, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzouanas, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousif, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bals, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, M. H.,  2nd.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatter, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taliaferro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gras, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaisant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelidis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sucre, J. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waghray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsialis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchheit, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyce, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidlaw, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonna, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkachev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gideon, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winchell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingle, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snapper, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theis, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaragosi, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiem, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortune, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finberg, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kean, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingwood, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalek, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordovas-Montanes, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is enriched in specific cell subsets across tissues</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">1016</span>â <span class="NLM_lpage">1035</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.04.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.cell.2020.04.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32413319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsVKkuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=1016-1035&author=C.+G.+K.+Zieglerauthor=S.+J.+Allonauthor=S.+K.+Nyquistauthor=I.+M.+Mbanoauthor=V.+N.+Miaoauthor=C.+N.+Tzouanasauthor=Y.+Caoauthor=A.+S.+Yousifauthor=J.+Balsauthor=B.+M.+Hauserauthor=J.+Feldmanauthor=C.+Muusauthor=M.+H.+Wadsworthauthor=S.+W.+Kazerauthor=T.+K.+Hughesauthor=B.+Doranauthor=G.+J.+Gatterauthor=M.+Vukovicauthor=F.+Taliaferroauthor=B.+E.+Meadauthor=Z.+Guoauthor=J.+P.+Wangauthor=D.+Grasauthor=M.+Plaisantauthor=M.+Ansariauthor=I.+Angelidisauthor=H.+Adlerauthor=J.+M.+S.+Sucreauthor=C.+J.+Taylorauthor=B.+Linauthor=A.+Waghrayauthor=V.+Mitsialisauthor=D.+F.+Dwyerauthor=K.+M.+Buchheitauthor=J.+A.+Boyceauthor=N.+A.+Barrettauthor=T.+M.+Laidlawauthor=S.+L.+Carrollauthor=L.+Colonnaauthor=V.+Tkachevauthor=C.+W.+Petersonauthor=A.+Yuauthor=H.+B.+Zhengauthor=H.+P.+Gideonauthor=C.+G.+Winchellauthor=P.+L.+Linauthor=C.+D.+Bingleauthor=S.+B.+Snapperauthor=J.+A.+Kropskiauthor=F.+J.+Theisauthor=H.+B.+Schillerauthor=L.+E.+Zaragosiauthor=P.+Barbryauthor=A.+Leslieauthor=H.+P.+Kiemauthor=J.+L.+Flynnauthor=S.+M.+Fortuneauthor=B.+Bergerauthor=R.+W.+Finbergauthor=L.+S.+Keanauthor=M.+Garberauthor=A.+G.+Schmidtauthor=D.+Lingwoodauthor=A.+K.+Shalekauthor=J.+Ordovas-Montanes&title=SARS-CoV-2+receptor+ACE2+is+an+interferon-stimulated+gene+in+human+airway+epithelial+cells+and+is+enriched+in+specific+cell+subsets+across+tissues&doi=10.1016%2Fj.cell.2020.04.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues</span></div><div class="casAuthors">Ziegler, Carly G. K.; Allon, Samuel J.; Nyquist, Sarah K.; Mbano, Ian M.; Miao, Vincent N.; Tzouanas, Constantine N.; Cao, Yuming; Yousif, Ashraf S.; Bals, Julia; Hauser, Blake M.; Feldman, Jared; Muus, Christoph; Wadsworth, Marc H. II; Kazer, Samuel W.; Hughes, Travis K.; Doran, Benjamin; Gatter, G. James; Vukovic, Marko; Taliaferro, Faith; Mead, Benjamin E.; Guo, Zhiru; Wang, Jennifer P.; Gras, Delphine; Plaisant, Magali; Ansari, Meshal; Angelidis, Ilias; Adler, Heiko; Sucre, Jennifer M. S.; Taylor, Chase J.; Lin, Brian; Waghray, Avinash; Mitsialis, Vanessa; Dwyer, Daniel F.; Buchheit, Kathleen M.; Boyce, Joshua A.; Barrett, Nora A.; Laidlaw, Tanya M.; Carroll, Shaina L.; Colonna, Lucrezia; Tkachev, Victor; Peterson, Christopher W.; Yu, Alison; Zheng, Hengqi Betty; Gideon, Hannah P.; Winchell, Caylin G.; Lin, Philana Ling; Bingle, Colin D.; Snapper, Scott B.; Kropski, Jonathan A.; Theis, Fabian J.; Schiller, Herbert B.; Zaragosi, Laure-Emmanuelle; Barbry, Pascal; Leslie, Alasdair; Kiem, Hans-Peter; Flynn, JoAnne L.; Fortune, Sarah M.; Berger, Bonnie; Finberg, Robert W.; Kean, Leslie S.; Garber, Manuel; Schmidt, Aaron G.; Lingwood, Daniel; Shalek, Alex K.; Ordovas-Montanes, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1016-1035.e19</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">There is pressing urgency to understand the pathogenesis of the severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2), which causes the disease COVID-19.  SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.  The cell subsets targeted by SARS-CoV-2 in host tissues and the factors that regulate ACE2 expression remain unknown.  Here, we leverage human, non-human primate, and mouse single-cell RNA-sequencing (scRNA-seq) datasets across health and disease to uncover putative targets of SARS-CoV-2 among tissue-resident cell subsets.  We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.  Strikingly, we discovered that ACE2 is a human interferon-stimulated gene (ISG) in vitro using airway epithelial cells and extend our findings to in vivo viral infections.  Our data suggest that SARS-CoV-2 could exploit species-specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmetA92lZJ7LVg90H21EOLACvtfcHk0lihuUge86Qh9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsVKkuro%253D&md5=82dbf0aa69f338ce6d3ff3b796643bb6</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.04.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.04.035%26sid%3Dliteratum%253Aachs%26aulast%3DZiegler%26aufirst%3DC.%2BG.%2BK.%26aulast%3DAllon%26aufirst%3DS.%2BJ.%26aulast%3DNyquist%26aufirst%3DS.%2BK.%26aulast%3DMbano%26aufirst%3DI.%2BM.%26aulast%3DMiao%26aufirst%3DV.%2BN.%26aulast%3DTzouanas%26aufirst%3DC.%2BN.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DYousif%26aufirst%3DA.%2BS.%26aulast%3DBals%26aufirst%3DJ.%26aulast%3DHauser%26aufirst%3DB.%2BM.%26aulast%3DFeldman%26aufirst%3DJ.%26aulast%3DMuus%26aufirst%3DC.%26aulast%3DWadsworth%26aufirst%3DM.%2BH.%26aulast%3DKazer%26aufirst%3DS.%2BW.%26aulast%3DHughes%26aufirst%3DT.%2BK.%26aulast%3DDoran%26aufirst%3DB.%26aulast%3DGatter%26aufirst%3DG.%2BJ.%26aulast%3DVukovic%26aufirst%3DM.%26aulast%3DTaliaferro%26aufirst%3DF.%26aulast%3DMead%26aufirst%3DB.%2BE.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DJ.%2BP.%26aulast%3DGras%26aufirst%3DD.%26aulast%3DPlaisant%26aufirst%3DM.%26aulast%3DAnsari%26aufirst%3DM.%26aulast%3DAngelidis%26aufirst%3DI.%26aulast%3DAdler%26aufirst%3DH.%26aulast%3DSucre%26aufirst%3DJ.%2BM.%2BS.%26aulast%3DTaylor%26aufirst%3DC.%2BJ.%26aulast%3DLin%26aufirst%3DB.%26aulast%3DWaghray%26aufirst%3DA.%26aulast%3DMitsialis%26aufirst%3DV.%26aulast%3DDwyer%26aufirst%3DD.%2BF.%26aulast%3DBuchheit%26aufirst%3DK.%2BM.%26aulast%3DBoyce%26aufirst%3DJ.%2BA.%26aulast%3DBarrett%26aufirst%3DN.%2BA.%26aulast%3DLaidlaw%26aufirst%3DT.%2BM.%26aulast%3DCarroll%26aufirst%3DS.%2BL.%26aulast%3DColonna%26aufirst%3DL.%26aulast%3DTkachev%26aufirst%3DV.%26aulast%3DPeterson%26aufirst%3DC.%2BW.%26aulast%3DYu%26aufirst%3DA.%26aulast%3DZheng%26aufirst%3DH.%2BB.%26aulast%3DGideon%26aufirst%3DH.%2BP.%26aulast%3DWinchell%26aufirst%3DC.%2BG.%26aulast%3DLin%26aufirst%3DP.%2BL.%26aulast%3DBingle%26aufirst%3DC.%2BD.%26aulast%3DSnapper%26aufirst%3DS.%2BB.%26aulast%3DKropski%26aufirst%3DJ.%2BA.%26aulast%3DTheis%26aufirst%3DF.%2BJ.%26aulast%3DSchiller%26aufirst%3DH.%2BB.%26aulast%3DZaragosi%26aufirst%3DL.%2BE.%26aulast%3DBarbry%26aufirst%3DP.%26aulast%3DLeslie%26aufirst%3DA.%26aulast%3DKiem%26aufirst%3DH.%2BP.%26aulast%3DFlynn%26aufirst%3DJ.%2BL.%26aulast%3DFortune%26aufirst%3DS.%2BM.%26aulast%3DBerger%26aufirst%3DB.%26aulast%3DFinberg%26aufirst%3DR.%2BW.%26aulast%3DKean%26aufirst%3DL.%2BS.%26aulast%3DGarber%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DA.%2BG.%26aulast%3DLingwood%26aufirst%3DD.%26aulast%3DShalek%26aufirst%3DA.%2BK.%26aulast%3DOrdovas-Montanes%26aufirst%3DJ.%26atitle%3DSARS-CoV-2%2520receptor%2520ACE2%2520is%2520an%2520interferon-stimulated%2520gene%2520in%2520human%2520airway%2520epithelial%2520cells%2520and%2520is%2520enriched%2520in%2520specific%2520cell%2520subsets%2520across%2520tissues%26jtitle%3DCell%26date%3D2020%26volume%3D181%26spage%3D1016%26epage%3D1035%26doi%3D10.1016%2Fj.cell.2020.04.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">784</span>â <span class="NLM_lpage">803</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2016.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.phrs.2016.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27473820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=784-803&author=R.+Roskoski&title=Janus+kinase+%28JAK%29+inhibitors+in+the+treatment+of+inflammatory+and+neoplastic+diseases&doi=10.1016%2Fj.phrs.2016.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">784-803</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinase (JAK) family of non-receptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (tyrosine kinase-2).  Each of these proteins contains a JAK homol. pseudokinase (JH2) domain that regulates the adjacent protein kinase domain (JH1).  JAK1/2 and TYK2 are ubiquitously expressed whereas JAK3 is found predominantly in hematopoietic cells.  The Janus kinase family is regulated by numerous cytokines including interleukins, interferons, and hormones such as erythropoietin, thrombopoietin, and growth hormone.  Ligand binding to cytokine and hormone receptors leads to the activation of assocd. Janus kinases, which then mediate the phosphorylation of the receptors.  The SH2 domain of STATs (signal transducers and activators of transcription) binds to the receptor phosphotyrosines thereby promoting STAT phosphorylation by the Janus kinases and consequent activation.  STAT dimers are translocated to the nucleus where they participate in the regulation of the expression of thousands of proteins.  JAK-STAT dysregulation results in autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, and Crohn disease.  JAK-STAT dysregulation also plays a role in the pathogenesis of myelofibrosis, polycythemia vera, and other myeloproliferative illnesses.  An activating JAK2 V617F mutation occurs in 95% of people with polycythemia vera and in a lower percentage of people with other neoplasms.  JAK1/3 signaling participates in the pathogenesis of inflammatory afflictions while JAK1/2 signaling participates in the development of several malignancies including leukemias and lymphomas as well as myeloproliferative neoplasms.  Tofacitinib is a pan-JAK inhibitor that is approved by the FDA for the treatment of rheumatoid arthritis and ruxolitinib is a JAK1/2 inhibitor that is approved for the treatment of polycythemia vera and myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov32m4UjOrv7Vg90H21EOLACvtfcHk0lhox2m9gXjUzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ&md5=a45fba1bb110eff4d5c1b31b78c1b3ac</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DJanus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520in%2520the%2520treatment%2520of%2520inflammatory%2520and%2520neoplastic%2520diseases%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D784%26epage%3D803%26doi%3D10.1016%2Fj.phrs.2016.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hermida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinesh Kumar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, N. R.</span></span> <span> </span><span class="NLM_article-title">GSK3 and its interactions with the I3K/AKT/mTOR signalling network</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">5</span>â <span class="NLM_lpage">15</span>, <span class="refDoi">Â DOI: 10.1016/j.jbior.2017.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jbior.2017.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28712664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOisr%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=5-15&author=M.+Hermidaauthor=A.+J.+Dinesh+Kumarauthor=N.+R.+Leslie&title=GSK3+and+its+interactions+with+the+I3K%2FAKT%2FmTOR+signalling+network&doi=10.1016%2Fj.jbior.2017.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 and its interactions with the PI3K/AKT/mTOR signalling network</span></div><div class="casAuthors">Hermida, Miguel A.; Dinesh Kumar, J.; Leslie, Nick R.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5-15</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Glycogen Synthase Kinase-3 (GSK3 or GSK-3) is a promiscuous protein kinase and its phosphorylation of its diverse substrates has major influences on many areas of physiol. and pathol., including cellular metab., lineage commitment and neuroscience.  GSK3 was one of the first identified substrates of the heavily studied oncogenic kinase AKT, phosphorylation by which inhibits GSK3 activity via the formation of an autoinhibitory pseudosubstrate sequence.  This has led to investigation of the role of GSK3 inhibition as a key component of the cellular responses to growth factors and insulin, which stimulate the class I PI 3-Kinases and in turn AKT activity and GSK3 phosphorylation.  GSK3 has been shown to phosphorylate several upstream and downstream components of the PI3K/AKT/mTOR signalling network, including AKT itself, RICTOR, TSC1 and 2, PTEN and IRS1 and 2, with the potential to apply feedback control within the network.  However, it has been clear for some time that functionally distinct, insulated pools of GSK3 exist which are regulated independently, so that for some GSK3 substrates such as Î² -catenin, phosphorylation by GSK3 is not controlled by input from PI3K and AKT.  Instead, as almost all GSK3 substrates require a priming phosphorylated residue to be 4 amino acids C-terminal to the Ser/Thr phosphorylated by GSK3, the predominant form of regulation of the activity of GSK3 often appears to be through control over these priming events, specific to individual substrates.  Therefore, a major role of GSK3 can be viewed as an amplifier of the electrostatic effects on protein function which are caused by these priming phosphorylation events.  Here we discuss these different aspects to GSK3 regulation and function, and the functions of GSK3 as it integrates with signalling through the PI3K-AKT-mTOR signalling axis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA5TFs3NBzFbVg90H21EOLACvtfcHk0lhox2m9gXjUzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOisr%252FE&md5=acf04cff82e167dde3e555c6e3854a16</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2017.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2017.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DHermida%26aufirst%3DM.%26aulast%3DDinesh%2BKumar%26aufirst%3DA.%2BJ.%26aulast%3DLeslie%26aufirst%3DN.%2BR.%26atitle%3DGSK3%2520and%2520its%2520interactions%2520with%2520the%2520I3K%252FAKT%252FmTOR%2520signalling%2520network%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2017%26volume%3D65%26spage%3D5%26epage%3D15%26doi%3D10.1016%2Fj.jbior.2017.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGrado, T. R.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">571</span>â <span class="NLM_lpage">593</span>, <span class="refDoi">Â DOI: 10.7150/thno.14334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.7150%2Fthno.14334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26941849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvVertbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=571-593&author=M.+K.+Pandeyauthor=T.+R.+DeGrado&title=Glycogen+synthase+kinase-3+%28GSK-3%29-targeted+therapy+and+imaging&doi=10.7150%2Fthno.14334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging</span></div><div class="casAuthors">Pandey, Mukesh K.; DeGrado, Timothy R.</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">571-593</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) is assocd. with various key biol. processes, including glucose regulation, apoptosis, protein synthesis, cell signaling, cellular transport, gene transcription, proliferation, and intracellular communication.  Accordingly, GSK-3 has been implicated in a wide variety of diseases and specifically targeted for both therapeutic and imaging applications by a large no. of academic labs. and pharmaceutical companies.  Here, we review the structure, function, expression levels, and ligand-binding properties of GSK-3 and its connection to various diseases.  A selected list of highly potent GSK-3 inhibitors, with IC50 <20 nM for ATP (ATP)-competitive inhibitors and IC50 <5 Î¼M for non-ATP-competitive inhibitors, were analyzed for structure activity relationships.  Furthermore, ubiquitous expression of GSK-3 and its possible impact on therapy and imaging are also highlighted.  Finally, a rational perspective and possible route to selective and effective GSK-3 inhibitors is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg397DfBVXrrVg90H21EOLACvtfcHk0lhox2m9gXjUzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvVertbs%253D&md5=e66feec1b1b2f460000116b722678478</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.7150%2Fthno.14334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.14334%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DM.%2BK.%26aulast%3DDeGrado%26aufirst%3DT.%2BR.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520%2528GSK-3%2529-targeted%2520therapy%2520and%2520imaging%26jtitle%3DTheranostics%26date%3D2016%26volume%3D6%26spage%3D571%26epage%3D593%26doi%3D10.7150%2Fthno.14334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eldar-Finkelman, H.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3: An emerging therapeutic target</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">126</span>â <span class="NLM_lpage">132</span>, <span class="refDoi">Â DOI: 10.1016/S1471-4914(01)02266-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2FS1471-4914%2801%2902266-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=11879773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsFahtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=126-132&author=H.+Eldar-Finkelman&title=Glycogen+synthase+kinase+3%3A+An+emerging+therapeutic+target&doi=10.1016%2FS1471-4914%2801%2902266-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3: an emerging therapeutic target</span></div><div class="casAuthors">Eldar-Finkelman, Hagit</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">126-132</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase 3 (GSK-3) is a serine/threonine protein kinase that has recently emerged as a key target in drug discovery.  It has been implicated in multiple cellular processes and linked with the pathogenesis of several diseases.  GSK-3 inhibitors might prove useful as therapeutic compds. in the treatment of conditions assocd. with elevated levels of enzyme activity, such as type 2 diabetes and Alzheimer's disease.  The pro-apoptotic feature of GSK-3 activity suggests a potential role for its inhibitors in protection against neuronal cell death, and in the treatment of traumatic head injury and stroke.  Finally, selective inhibitors of GSK-3 could mimic the action of mood stabilizers such as lithium and valproic acid and be used in the treatment of bipolar mood disorders.  Glycogen synthase kinase 3 (GSK-3) is a key therapeutic target in conditions assocd. with elevated levels of GSK-3, such as type 2 diabetes and Alzheimer's disease, as well as traumatic head injury, stroke and bipolar disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqReqQx-BihlbVg90H21EOLACvtfcHk0likQSKSKc4j3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsFahtLw%253D&md5=17c0a5efb4fc12d9f0dbf777f457ad98</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1016%2FS1471-4914%2801%2902266-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4914%252801%252902266-3%26sid%3Dliteratum%253Aachs%26aulast%3DEldar-Finkelman%26aufirst%3DH.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%253A%2520An%2520emerging%2520therapeutic%2520target%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2002%26volume%3D8%26spage%3D126%26epage%3D132%26doi%3D10.1016%2FS1471-4914%2801%2902266-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ­sniewski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ³jtowicz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ³jcicka, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaskiewicz, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drulis-Fajdasz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gizak, A.</span></span> <span> </span><span class="NLM_article-title">Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">833</span>â <span class="NLM_lpage">848</span>, <span class="refDoi">Â DOI: 10.1080/14728222.2018.1526925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1080%2F14728222.2018.1526925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30244615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKisrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=833-848&author=P.+Dudaauthor=J.+W%C3%ADsniewskiauthor=T.+W%C3%B3jtowiczauthor=O.+W%C3%B3jcickaauthor=M.+R.+Jaskiewiczauthor=D.+Drulis-Fajdaszauthor=D.+Rakusauthor=J.+A.+McCubreyauthor=A.+Gizak&title=Targeting+GSK3+signaling+as+a+potential+therapy+of+neurodegenerative+diseases+and+aging&doi=10.1080%2F14728222.2018.1526925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging</span></div><div class="casAuthors">Duda, Przemyslaw; Wisniewski, Janusz; Wojtowicz, Tomasz; Wojcicka, Olga; Jaskiewicz, Michal; Drulis-Fajdasz, Dominika; Rakus, Dariusz; McCubrey, James A.; Gizak, Agnieszka</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">833-848</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase 3 (GSK3) is at the center of cellular signaling and controls various aspects of brain functions, including development of the nervous system, neuronal plasticity and onset of neurodegenerative disorders.: In this review, recent efforts in elucidating the roles of GSK3 in neuronal plasticity and development of brain pathologies; Alzheimer's and Parkinson's disease, schizophrenia, and age-related neurodegeneration are described.  The effect of microglia and astrocytes on development of the pathol. states is also discussed.: GSK3Î² and its signaling pathway partners hold great promise as therapeutic target(s) for a multitude of neurol. disorders.  Activity of the kinase is often elevated in brain disorders.  However, due to the wide range of GSK3 cellular targets, global inhibition of the kinase leads to severe side-effects and GSK3 inhibitors rarely reach Phase-2 clin. trials.  Thus, a selective modulation of a specific cellular pool of GSK3 or specific down- or upstream partners of the kinase might provide more efficient anti-neurodegenerative therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGBAWhlK0LC7Vg90H21EOLACvtfcHk0likQSKSKc4j3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKisrfJ&md5=c209e9ce80b19ac6d489519a3a8ae461</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1080%2F14728222.2018.1526925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728222.2018.1526925%26sid%3Dliteratum%253Aachs%26aulast%3DDuda%26aufirst%3DP.%26aulast%3DW%25C3%25ADsniewski%26aufirst%3DJ.%26aulast%3DW%25C3%25B3jtowicz%26aufirst%3DT.%26aulast%3DW%25C3%25B3jcicka%26aufirst%3DO.%26aulast%3DJaskiewicz%26aufirst%3DM.%2BR.%26aulast%3DDrulis-Fajdasz%26aufirst%3DD.%26aulast%3DRakus%26aufirst%3DD.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DGizak%26aufirst%3DA.%26atitle%3DTargeting%2520GSK3%2520signaling%2520as%2520a%2520potential%2520therapy%2520of%2520neurodegenerative%2520diseases%2520and%2520aging%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2018%26volume%3D22%26spage%3D833%26epage%3D848%26doi%3D10.1080%2F14728222.2018.1526925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3Î² inhibitor reduces LPS induced acute lung injury in mice</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">6715</span>â <span class="NLM_lpage">6721</span>, <span class="refDoi">Â DOI: 10.3892/mmr.2017.7469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3892%2Fmmr.2017.7469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28901469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsFSqu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=6715-6721&author=Q.+Dingauthor=G.+Liuauthor=Y.+Zengauthor=J.+Zhuauthor=Z.+Liuauthor=J.+Jiangauthor=J.+Huang&title=Glycogen+synthase+kinase-3%CE%B2+inhibitor+reduces+LPS+induced+acute+lung+injury+in+mice&doi=10.3892%2Fmmr.2017.7469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3Î² inhibitor reduces LPS-induced acute lung injury in mice</span></div><div class="casAuthors">Ding, Qi; Liu, Gaoqin; Zeng, Yuanyuan; Zhu, Jianjie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">6715-6721</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The aim of the present study was to examine the role of Wnt signaling in lipopolysaccharide (LPS)-induced acute respiratory distress syndrome (ARDS).  ARDS was induced by LPS and compared in mice treated with either glycogen synthase kinase-3Î² inhibitor (GSKI) or PBS.  The protein expression levels of interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-Î±, IL-17, IL-18 and IL-1Î² in the bronchoalveolar lavage fluid (BALF) were examd. using murine cytokine-specific enzyme-linked immunosorbent assays.  The accumulation of neutrophils and macrophages in the BALF were detected using flow cytometry.  The extent of pathol. lesions was evaluated using an immunohistochem. assay.  The differentiation of mesenchymal stem cells (MSCs) into type II alveolar (ATII) epithelial cells was analyzed using immunofluorescence staining.  Treatment with GSKI led to maintained body wts. and survival in mice with LPS-induced ARDS.  Treatment with GSKI effectively reduced the levels of total protein, albumin, IgM and keratinocyte growth factor in the BALF.  Smith scores showed that GSKI significantly alleviated LPS-induced lung injury.  GSKI also functioned to reduce inflammatory cell accumulation and pro-inflammatory cytokine secretion.  Finally, it was found that GSKI promoted the differentiation of MSCs into ATII epithelial cells in vivo.  Taken together, the GSKI-treated mice exhibited reduced acute lung injury through inhibited intra-fluid inflammatory cell infiltration and decreased expression of pro-inflammatory cytokines, and GSKI increased the differentiation of MSCs into ATII epithelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4PO-zykxog7Vg90H21EOLACvtfcHk0ljeO1uAlZxSlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsFSqu7g%253D&md5=ed6dcc33ee211b34a1ff1de44c1b51ab</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2017.7469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2017.7469%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%26atitle%3DGlycogen%2520synthase%2520kinase-3%25CE%25B2%2520inhibitor%2520reduces%2520LPS%2520induced%2520acute%2520lung%2520injury%2520in%2520mice%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2017%26volume%3D16%26spage%3D6715%26epage%3D6721%26doi%3D10.3892%2Fmmr.2017.7469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fichtner-Feigl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesselring, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruemmele, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haimerl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geissler, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strober, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlitt, H. J.</span></span> <span> </span><span class="NLM_article-title">IL-13 orchestrates resolution of chronic intestinal inflammation via phosphorylation of glycogen synthase kinase-3Î²</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">3969</span>â <span class="NLM_lpage">3980</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1301072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.4049%2Fjimmunol.1301072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24634488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gmt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2014&pages=3969-3980&author=S.+Fichtner-Feiglauthor=R.+Kesselringauthor=M.+Martinauthor=F.+Obermeierauthor=P.+Ruemmeleauthor=A.+Kitaniauthor=S.+M.+Brunnerauthor=M.+Haimerlauthor=E.+K.+Geisslerauthor=W.+Stroberauthor=H.+J.+Schlitt&title=IL-13+orchestrates+resolution+of+chronic+intestinal+inflammation+via+phosphorylation+of+glycogen+synthase+kinase-3%CE%B2&doi=10.4049%2Fjimmunol.1301072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">IL-13 Orchestrates Resolution of Chronic Intestinal Inflammation via Phosphorylation of Glycogen Synthase Kinase-3Î²</span></div><div class="casAuthors">Fichtner-Feigl, Stefan; Kesselring, Rebecca; Martin, Maria; Obermeier, Florian; Ruemmele, Petra; Kitani, Atsushi; Brunner, Stefan M.; Haimerl, Michael; Geissler, Edward K.; Strober, Warren; Schlitt, Hans J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3969-3980</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Spontaneous amelioration of inflammation (often accompanied by fibrosis) is a well-known, but poorly understood, outcome of many chronic inflammatory processes.  We studied this phenomenon in a chronic trinitrobenzene sulfonic acid-induced colitis model, an exptl. colitis in mice that we showed to ultimately undergo spontaneous resoln., despite continued trinitrobenzene sulfonic acid stimulation.  Anal. of the mechanism of this resoln. revealed that it was critically dependent on IL-13 activation of STAT6, followed by phosphorylation (inactivation) of glycogen synthase kinase-3Î², at least in part via STAT6 induction of p38 MAPK.  Such glycogen synthase kinase-3Î² inactivation causes changes in CREB and p65 DNA-binding activity that favors decreased proinflammatory IL-17 prodn. and increased anti-inflammatory IL-10 prodn.  Thus, in this case, IL-13 acts as a mol. switch that leads to resoln. of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-2BTsj54rgLVg90H21EOLACvtfcHk0ljeO1uAlZxSlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gmt74%253D&md5=ff405b1b6f7896a44b504f162efe72df</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301072%26sid%3Dliteratum%253Aachs%26aulast%3DFichtner-Feigl%26aufirst%3DS.%26aulast%3DKesselring%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DObermeier%26aufirst%3DF.%26aulast%3DRuemmele%26aufirst%3DP.%26aulast%3DKitani%26aufirst%3DA.%26aulast%3DBrunner%26aufirst%3DS.%2BM.%26aulast%3DHaimerl%26aufirst%3DM.%26aulast%3DGeissler%26aufirst%3DE.%2BK.%26aulast%3DStrober%26aufirst%3DW.%26aulast%3DSchlitt%26aufirst%3DH.%2BJ.%26atitle%3DIL-13%2520orchestrates%2520resolution%2520of%2520chronic%2520intestinal%2520inflammation%2520via%2520phosphorylation%2520of%2520glycogen%2520synthase%2520kinase-3%25CE%25B2%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D192%26spage%3D3969%26epage%3D3980%26doi%3D10.4049%2Fjimmunol.1301072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worthen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beurel, E.</span></span> <span> </span><span class="NLM_article-title">Stressed and inflamed, can GSK3 be blamed?</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">180</span>â <span class="NLM_lpage">192</span>, <span class="refDoi">Â DOI: 10.1016/j.tibs.2016.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.tibs.2016.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27876551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVeqsrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=180-192&author=R.+S.+Jopeauthor=Y.+Chengauthor=J.+Lowellauthor=R.+Worthenauthor=Y.+H.+Sitbonauthor=E.+Beurel&title=Stressed+and+inflamed%2C+can+GSK3+be+blamed%3F&doi=10.1016%2Fj.tibs.2016.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Stressed and Inflamed, Can GSK3 Be Blamed?</span></div><div class="casAuthors">Jope, Richard S.; Cheng, Yuyan; Lowell, Jeffrey A.; Worthen, Ryan J.; Sitbon, Yoel H.; Beurel, Eleonore</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">180-192</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Psychol. stress has a pervasive influence on our lives.  In many cases adapting to stress strengthens organisms, but chronic or severe stress is usually harmful.  One surprising outcome of psychol. stress is the activation of an inflammatory response that resembles inflammation caused by infection or trauma.  Excessive psychol. stress and the consequential inflammation in the brain can increase susceptibility to psychiatric diseases, such as depression, and impair learning and memory, including in some patients with cognitive deficits.  An emerging target to control detrimental outcomes of stress and inflammation is glycogen synthase kinase-3 (GSK3).  GSK3 promotes inflammation, partly by regulating key transcription factors in the inflammation signaling pathway, and GSK3 can impair learning by promoting inflammation and by inhibiting long-term potentiation (LTP).  Drugs inhibiting GSK3 may prove beneficial for controlling mood and cognitive impairments caused by excessive stress and the assocd. neuroinflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHqIYxRhEUPrVg90H21EOLACvtfcHk0lhK-fWZI88Edw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVeqsrrM&md5=b7cda246c174af17762a8871283e518c</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2016.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2016.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DJope%26aufirst%3DR.%2BS.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DLowell%26aufirst%3DJ.%26aulast%3DWorthen%26aufirst%3DR.%26aulast%3DSitbon%26aufirst%3DY.%2BH.%26aulast%3DBeurel%26aufirst%3DE.%26atitle%3DStressed%2520and%2520inflamed%252C%2520can%2520GSK3%2520be%2520blamed%253F%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2017%26volume%3D42%26spage%3D180%26epage%3D192%26doi%3D10.1016%2Fj.tibs.2016.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganea, D.</span></span> <span> </span><span class="NLM_article-title">A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">55176</span>â <span class="NLM_lpage">55186</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M409816200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.M409816200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=15498767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFeis7zM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=55176-55186&author=H.+Jingauthor=J.+H.+Yenauthor=D.+Ganea&title=A+novel+signaling+pathway+mediates+the+inhibition+of+CCL3%2F4+expression+by+prostaglandin+E2&doi=10.1074%2Fjbc.M409816200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Signaling Pathway Mediates the Inhibition of CCL3/4 Expression by Prostaglandin E2</span></div><div class="casAuthors">Jing, Huie; Yen, Jui-Hung; Ganea, Doina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">53</span>),
    <span class="NLM_cas:pages">55176-55186</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">In response to pathogen-assocd. mol. patterns, dendritic cells initiate an innate immune response characterized by expression and release of proinflammatory cytokines and chemokines.  The extent of the inflammatory response is limited by various endogenous factors, including lipid mediators such as prostaglandin E2 (PGE2).  We described previously the inhibitory effect of PGE2 on the expression and release of the inflammatory chemokines CCL3 and CCL4 from activated dendritic cells.  In this study we describe a novel PGE2 signaling pathway that proceeds through EP-2 â cAMP â EPAC â phosphatidylinositol 3-kinase â protein kinase B â GSK-3 and results in increased DNA binding of the CCAAT displacement protein (CDP), a potent mammalian transcriptional repressor.  The direct link between CDP and CCL3/4 transcription was established in knock-down expts. using CDP small interference RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPItfa6eoQD7Vg90H21EOLACvtfcHk0lhK-fWZI88Edw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFeis7zM&md5=dba3cda10c01cf3772ae07982dffe3ea</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M409816200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M409816200%26sid%3Dliteratum%253Aachs%26aulast%3DJing%26aufirst%3DH.%26aulast%3DYen%26aufirst%3DJ.%2BH.%26aulast%3DGanea%26aufirst%3DD.%26atitle%3DA%2520novel%2520signaling%2520pathway%2520mediates%2520the%2520inhibition%2520of%2520CCL3%252F4%2520expression%2520by%2520prostaglandin%2520E2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D55176%26epage%3D55186%26doi%3D10.1074%2Fjbc.M409816200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, I.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span> <span> </span><span class="NLM_article-title">TLR3-mediated signal induces proinflammatory cytokine and chemokine gene expression in astrocytes: Differential signaling mechanisms of TLR3-induced IP-10 and IL-8 gene expression</span>. <i>Glia</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">248</span>â <span class="NLM_lpage">256</span>, <span class="refDoi">Â DOI: 10.1002/glia.20278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Fglia.20278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16265667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BD2MnotVSisQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2006&pages=248-256&author=C.+Parkauthor=S.+Leeauthor=I.-H.+Choauthor=H.+K.+Leeauthor=N.+Kimauthor=S.-Y.+Choiauthor=S.+B.+Ohauthor=K.+Parkauthor=J.+S.+Kimauthor=S.+J.+Lee&title=TLR3-mediated+signal+induces+proinflammatory+cytokine+and+chemokine+gene+expression+in+astrocytes%3A+Differential+signaling+mechanisms+of+TLR3-induced+IP-10+and+IL-8+gene+expression&doi=10.1002%2Fglia.20278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">TLR3-mediated signal induces proinflammatory cytokine and chemokine gene expression in astrocytes: differential signaling mechanisms of TLR3-induced IP-10 and IL-8 gene expression</span></div><div class="casAuthors">Park Chanhee; Lee Soojin; Cho Ik-Hyun; Lee Hyun Kyoung; Kim Donghoon; Choi Se-Young; Oh Seog Bae; Park Kyungpyo; Kim Joong Soo; Lee Sung Joong</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-56</span>
        ISSN:<span class="NLM_cas:issn">0894-1491</span>.
    </div><div class="casAbstract">Viral infection is one of the leading causes of brain encephalitis and meningitis.  Recently, it was reported that Toll-like receptor-3 (TLR3) induces a double-stranded RNA (dsRNA)-mediated inflammatory signal in the cells of the innate immune system, and studies suggested that dsRNA may induce inflammation in the central nervous system (CNS) by activating the CNS-resident glial cells.  To explore further the connection between dsRNA and inflammation in the CNS, we have studied the effects of dsRNA stimulation in astrocytes.  Our results show that the injection of polyinosinic-polycytidylic acid (poly(I:C)), a synthetic dsRNA, into the striatum of the mouse brain induces the activation of astrocytes and the expression of TNF-alpha, IFN-beta, and IP-10.  Stimulation with poly(I:C) also induces the expression of these proinflammatory genes in primary astrocytes and in CRT-MG, a human astrocyte cell line.  Furthermore, our studies on the intracellular signaling pathways reveal that poly(I:C) stimulation activates IkappaB kinase (IKK), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) in CRT-MG.  Pharmacological inhibitors of nuclear factor-kappaB (NF-kappaB), JNK, ERK, glycogen synthase kinase-3beta (GSK-3beta), and dsRNA-activated protein kinase (PKR) inhibit the expression of IL-8 and IP-10 in astrocytes, indicating that the activation of these signaling molecules is required for the TLR3-mediated chemokine gene induction.  Interestingly, the inhibition of PI3 kinase suppressed the expression of IP-10, but upregulated the expression of IL-8, suggesting differential roles for PI3 kinase, depending on the target genes.  These data suggest that the TLR3 expressed on astrocytes may initiate an inflammatory response upon viral infection in the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0VPvAkkJA_oJKJbLTgsvCfW6udTcc2ea9ZAeaP2o1bLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnotVSisQ%253D%253D&md5=dec1899574f969923d0c141ad0887dd2</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1002%2Fglia.20278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.20278%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DI.-H.%26aulast%3DLee%26aufirst%3DH.%2BK.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DChoi%26aufirst%3DS.-Y.%26aulast%3DOh%26aufirst%3DS.%2BB.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26atitle%3DTLR3-mediated%2520signal%2520induces%2520proinflammatory%2520cytokine%2520and%2520chemokine%2520gene%2520expression%2520in%2520astrocytes%253A%2520Differential%2520signaling%2520mechanisms%2520of%2520TLR3-induced%2520IP-10%2520and%2520IL-8%2520gene%2520expression%26jtitle%3DGlia%26date%3D2006%26volume%3D53%26spage%3D248%26epage%3D256%26doi%3D10.1002%2Fglia.20278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busuttil, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupiec-Weglinski, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3Î² promotes liver innate immune activation by restraining AMP-activated protein kinase activation</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">99</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1016/j.jhep.2018.01.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jhep.2018.01.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29452207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslShsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2018&pages=99-109&author=H.+Zhouauthor=H.+Wangauthor=M.+Niauthor=S.+Yueauthor=Y.+Xiaauthor=R.+W.+Busuttilauthor=J.+W.+Kupiec-Weglinskiauthor=L.+Luauthor=X.+Wangauthor=Y.+Zhai&title=Glycogen+synthase+kinase-3%CE%B2+promotes+liver+innate+immune+activation+by+restraining+AMP-activated+protein+kinase+activation&doi=10.1016%2Fj.jhep.2018.01.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3Î² promotes liver innate immune activation by restraining AMP-activated protein kinase activation</span></div><div class="casAuthors">Zhou, Haoming; Wang, Han; Ni, Ming; Yue, Shi; Xia, Yongxiang; Busuttil, Ronald W.; Kupiec-Weglinski, Jerzy W.; Lu, Ling; Wang, Xuehao; Zhai, Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-109</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3Î² (Gsk3Î² [Gsk3b]) is a ubiquitously expressed kinase with distinctive functions in different types of cells.  Although its roles in regulating innate immune activation and ischemia and reperfusion injuries (IRIs) have been well documented, the underlying mechanisms remain ambiguous, in part because of the lack of cell-specific tools in vivo.  We created a myeloid-specific Gsk3b knockout (KO) strain to study the function of Gsk3Î² in macrophages in a murine liver partial warm ischemia model.  Compared with controls, myeloid Gsk3b KO mice were protected from IRI, with diminished proinflammatory but enhanced anti-inflammatory immune responses in livers.  In bone marrow-derived macrophages, Gsk3Î² deficiency resulted in an early redn. of Tnf gene transcription but sustained increase of Il10 gene transcription on Toll-like receptor 4 stimulation in vitro.  These effects were assocd. with enhanced AMP-activated protein kinase (AMPK) activation, which led to an accelerated and higher level of induction of the novel innate immune neg. regulator small heterodimer partner (SHP [Nr0b2]).  The regulatory function of Gsk3Î² on AMPK activation and SHP induction was confirmed in wild-type bone marrow-derived macrophages with a Gsk3 inhibitor.  Furthermore, we found that this immune regulatory mechanism was independent of Gsk3Î² Ser9 phosphorylation and the phosphoinositide 3-kinase-Akt signalling pathway.  In vivo, myeloid Gsk3Î² deficiency facilitated SHP upregulation by ischemia-reperfusion in liver macrophages.  Treatment of Gsk3b KO mice with either AMPK inhibitor or SHP small interfering RNA before the onset of liver ischemia restored liver proinflammatory immune activation and IRI in these otherwise protected hosts.  Addnl., pharmacol. activation of AMPK protected wild-type mice from liver IRI, with reduced proinflammatory immune activation.  Inhibition of the AMPK-SHP pathway by liver ischemia was demonstrated in tumor resection patients.  Gsk3Î² promotes innate proinflammatory immune activation by restraining AMPK activation.  Glycogen synthase kinase 3Î² promotes macrophage inflammatory activation by inhibiting the immune regulatory signalling of AMP-activated protein kinase and the induction of small heterodimer partner.  Therefore, therapeutic targeting of glycogen synthase kinase 3Î² enhances innate immune regulation and protects liver from ischemia and reperfusion injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0qHahwWjSSrVg90H21EOLACvtfcHk0lh091hZhS6MvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslShsrw%253D&md5=f3366c5cd501a1914be3ed068533a058</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2018.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2018.01.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNi%26aufirst%3DM.%26aulast%3DYue%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DBusuttil%26aufirst%3DR.%2BW.%26aulast%3DKupiec-Weglinski%26aufirst%3DJ.%2BW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DY.%26atitle%3DGlycogen%2520synthase%2520kinase-3%25CE%25B2%2520promotes%2520liver%2520innate%2520immune%2520activation%2520by%2520restraining%2520AMP-activated%2520protein%2520kinase%2520activation%26jtitle%3DJ.%2520Hepatol.%26date%3D2018%26volume%3D69%26spage%3D99%26epage%3D109%26doi%3D10.1016%2Fj.jhep.2018.01.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DÃ´, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ClÃ©ment, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doble, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servant, M. J.</span></span> <span> </span><span class="NLM_article-title">Fine-tuning of the RIG-I-like receptor/interferon regulatory factor 3-dependent antiviral innate immune response by the glycogen synthase kinase 3/ beta-catenin pathway</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3029</span>â <span class="NLM_lpage">3043</span>, <span class="refDoi">Â DOI: 10.1128/MCB.00344-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FMCB.00344-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26100021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWksrjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=3029-3043&author=K.+A.+Khanauthor=F.+D%C3%B4author=A.+Marineauauthor=P.+Doyonauthor=J.+F.+Cl%C3%A9mentauthor=J.+R.+Woodgettauthor=B.+W.+Dobleauthor=M.+J.+Servant&title=Fine-tuning+of+the+RIG-I-like+receptor%2Finterferon+regulatory+factor+3-dependent+antiviral+innate+immune+response+by+the+glycogen+synthase+kinase+3%2F+beta-catenin+pathway&doi=10.1128%2FMCB.00344-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Fine-tuning of the RIG-I-like receptor/interferon regulatory factor 3-dependent antiviral innate immune response by the glycogen synthase kinase 3/Î²-catenin pathway</span></div><div class="casAuthors">Khan, Kashif Aziz; Do, Florence; Marineau, Alexandre; Doyon, Priscilla; Clement, Jean-Francois; Woodgett, James R.; Doble, Bradley W.; Servant, Marc J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3029-3043</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Induction of an antiviral innate immune response relies on pattern recognition receptors, including retinoic acid-inducible gene 1-like receptors (RLR), to detect invading pathogens, resulting in the activation of multiple latent transcription factors, including interferon regulatory factor 3 (IRF3).  Upon sensing of viral RNA and DNA, IRF3 is phosphorylated and recruits coactivators to induce type I interferons (IFNs) and selected sets of IRF3-regulated IFN-stimulated genes (ISGs) such as those for ISG54 (Ifit2), ISG56 (Ifit1), and viperin (Rsad2).  Here, we used wild-type, glycogen synthase kinase 3Î± knockout (GSK-3Î±_/_), GSK- 3Î²_/_, and GSK-3Î±/ Î² double-knockout (DKO) embryonic stem (ES) cells, as well as GSK-3Î²_/_ mouse embryonic fibroblast cells in which GSK-3Î± was knocked down to demonstrate that both isoforms of GSK-3, GSK-3Î± and GSK-3Î², are required for this antiviral immune response.  Moreover, the use of two selective small-mol. GSK-3 inhibitors (CHIR99021 and BIO-acetoxime) or ES cells reconstituted with the catalytically inactive versions of GSK-3 isoforms showed that GSK-3 activity is required for optimal induction of antiviral innate immunity.  Mechanistically, GSK-3 isoform activation following Sendai virus infection results in phosphorylation of Î²-catenin at S33/S37/T41, promoting IRF3 DNA binding and activation of IRF3-regulated ISGs.  This study identifies the role of a GSK-3/Î²-catenin axis in antiviral innate immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZG1M9xjxwTrVg90H21EOLACvtfcHk0lh091hZhS6MvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWksrjM&md5=f4caf844113a1aaa7d71fddf41cf8512</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1128%2FMCB.00344-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00344-15%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DK.%2BA.%26aulast%3DD%25C3%25B4%26aufirst%3DF.%26aulast%3DMarineau%26aufirst%3DA.%26aulast%3DDoyon%26aufirst%3DP.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DJ.%2BF.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DDoble%26aufirst%3DB.%2BW.%26aulast%3DServant%26aufirst%3DM.%2BJ.%26atitle%3DFine-tuning%2520of%2520the%2520RIG-I-like%2520receptor%252Finterferon%2520regulatory%2520factor%25203-dependent%2520antiviral%2520innate%2520immune%2520response%2520by%2520the%2520glycogen%2520synthase%2520kinase%25203%252F%2520beta-catenin%2520pathway%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D35%26spage%3D3029%26epage%3D3043%26doi%3D10.1128%2FMCB.00344-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alfhili, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsughayyir, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akula, S. M.</span></span> <span> </span><span class="NLM_article-title">GSK-3-associated signaling is crucial to virus infection of cells</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>1867</i></span>,  <span class="NLM_fpage">118767</span>, <span class="refDoi">Â DOI: 10.1016/j.bbamcr.2020.118767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.bbamcr.2020.118767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32522661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1altrjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1867&publication_year=2020&pages=118767&author=M.+A.+Alfhiliauthor=J.+Alsughayyirauthor=J.+A.+McCubreyauthor=S.+M.+Akula&title=GSK-3-associated+signaling+is+crucial+to+virus+infection+of+cells&doi=10.1016%2Fj.bbamcr.2020.118767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3-associated signaling is crucial to virus infection of cells</span></div><div class="casAuthors">Alfhili, Mohammad A.; Alsughayyir, Jawaher; McCubrey, James A.; Akula, Shaw M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">1867</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">118767</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Signal transduction pathways play important roles in virus infection, replication, and assocd. pathogenesis.  Some of the best understood cell signaling networks are crucial to virus infections such the mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), protein kinase C (PKC), and the WNT/Î²-catenin pathways.  Glycogen synthase kinase-3 (GSK-3) is a lesser known signaling mol. in the field of virus research.  Interestingly, GSK-3 forms the crux of multiple cell signaling pathways.  However, recent studies indicate that GSK-3 may perform key roles in the response to viral infection, replication and pathogenesis.  The effects of activated or inactivated forms of GSK-3 on virus infection are still not yet clearly understood phenomenon.  The comprehension of the mol. mechanisms underlying the regulation of GSK-3-assocd. signaling pathways in terms of different stages of virus replication could be important not only to understand the pathogenesis of virus, but also possibly leading to new therapeutic targets.  This review will focus on recent advances in understanding the roles of GSK-3 on viral replication, pathogenesis and the immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfsGRocay5ILVg90H21EOLACvtfcHk0lgS_KO_V9EhaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1altrjF&md5=5a06c524fd36161d779d1c7032d6c61a</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2020.118767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2020.118767%26sid%3Dliteratum%253Aachs%26aulast%3DAlfhili%26aufirst%3DM.%2BA.%26aulast%3DAlsughayyir%26aufirst%3DJ.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DAkula%26aufirst%3DS.%2BM.%26atitle%3DGSK-3-associated%2520signaling%2520is%2520crucial%2520to%2520virus%2520infection%2520of%2520cells%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2020%26volume%3D1867%26spage%3D118767%26doi%3D10.1016%2Fj.bbamcr.2020.118767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa-Tomikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuhara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohira, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, H.</span></span> <span> </span><span class="NLM_article-title">A novel occludin-targeting monoclonal antibody prevents hepatitis C virus infection in vitro</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">16588</span>â <span class="NLM_lpage">16598</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.24742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.18632%2Foncotarget.24742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29682171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC1MjltlOmtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=16588-16598&author=K.+Okaiauthor=N.+Ichikawa-Tomikawaauthor=A.+C.+Saitoauthor=T.+Watabeauthor=K.+Sugimotoauthor=D.+Fujitaauthor=C.+Onoauthor=T.+Fukuharaauthor=Y.+Matsuuraauthor=H.+Ohiraauthor=H.+Chiba&title=A+novel+occludin-targeting+monoclonal+antibody+prevents+hepatitis+C+virus+infection+in+vitro&doi=10.18632%2Foncotarget.24742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">A novel occludin-targeting monoclonal antibody prevents hepatitis C virus infection in vitro</span></div><div class="casAuthors">Okai Ken; Ichikawa-Tomikawa Naoki; Saito Akira C; Watabe Tetsuya; Sugimoto Kotaro; Fujita Daiki; Chiba Hideki; Okai Ken; Ohira Hiromasa; Ono Chikako; Fukuhara Takasuke; Matsuura Yoshiharu</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">16588-16598</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since hepatitis C virus (HCV) is thought to enter into host hepatocytes using the same cellular pathways regardless of the genotypes, the host factors are promising targets to prevent and treat HCV infection.  Human occludin (hOCLN) is one representative entry factor, and its second extracellular loop (EC2) contributes to the species selectivity of HCV-susceptibility.  However, the exact function of hOCLN during HCV entry remains unknown, and no hOCLN-targeting antibodies or synthetic drugs that prevent and treat HCV infection have yet been developed.  Here we generated the anti-hOCLN-EC2 monoclonal antibody (mAb) 67-2, and demonstrated that it efficiently inhibited HCV infection in the HCV-permissive human cell line Huh7.5.1.  We also showed, using three different culture systems of Huh7.5.1 cells, that this novel mAb is accessible to OCLN from the basolateral side of hepatocytes but not from the apical side.  In addition, our Western blot analyses indicated that the established 67-2 mAb reacted not only with hOCLN but also with mouse OCLN, strongly suggesting that 67-2 does not recognize the human-specific amino acids in OCLN-EC2.  Moreover, we revealed that the anti-hOCLN-EC2 mAb 67-2 showed no adverse effects on cell viability or the barrier function of tight junctions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1hytK5b3xMRwLZxei1HN8fW6udTcc2eYtSaBuiiivRLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjltlOmtw%253D%253D&md5=76b5dec2280289deb041d8f3a17b0b40</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.24742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.24742%26sid%3Dliteratum%253Aachs%26aulast%3DOkai%26aufirst%3DK.%26aulast%3DIchikawa-Tomikawa%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DA.%2BC.%26aulast%3DWatabe%26aufirst%3DT.%26aulast%3DSugimoto%26aufirst%3DK.%26aulast%3DFujita%26aufirst%3DD.%26aulast%3DOno%26aufirst%3DC.%26aulast%3DFukuhara%26aufirst%3DT.%26aulast%3DMatsuura%26aufirst%3DY.%26aulast%3DOhira%26aufirst%3DH.%26aulast%3DChiba%26aufirst%3DH.%26atitle%3DA%2520novel%2520occludin-targeting%2520monoclonal%2520antibody%2520prevents%2520hepatitis%2520C%2520virus%2520infection%2520in%2520vitro%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D16588%26epage%3D16598%26doi%3D10.18632%2Foncotarget.24742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butt, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasrullah, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idrees, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span> <span> </span><span class="NLM_article-title">Computational identification of interplay between phosphorylation and O-beta-glycosylation of human occludin as potential mechanism to impair hepatitis C virus entry</span>. <i>Infect., Genet. Evol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1235</span>â <span class="NLM_lpage">1245</span>, <span class="refDoi">Â DOI: 10.1016/j.meegid.2012.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.meegid.2012.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22516225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38XosFWjtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1235-1245&author=A.+M.+Buttauthor=D.+Fengauthor=I.+Nasrullahauthor=S.+Tahirauthor=M.+Idreesauthor=Y.+Tongauthor=J.+Lu&title=Computational+identification+of+interplay+between+phosphorylation+and+O-beta-glycosylation+of+human+occludin+as+potential+mechanism+to+impair+hepatitis+C+virus+entry&doi=10.1016%2Fj.meegid.2012.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Computational identification of interplay between phosphorylation and O-Î²-glycosylation of human occludin as potential mechanism to impair hepatitis C virus entry</span></div><div class="casAuthors">Butt, Azeem Mehmood; Feng, Dandan; Nasrullah, Izza; Tahir, Shifa; Idrees, Muhammad; Tong, Yigang; Lu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Infection, Genetics and Evolution</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1235-1245</span>CODEN:
                <span class="NLM_cas:coden">IGENCN</span>;
        ISSN:<span class="NLM_cas:issn">1567-1348</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is one of the leading causes of liver diseases.  Several host factors that facilitate the attachment and entry of HCV have been discovered, of which human occludin seems to be the most promising.  Studies have shown that activity of occludin is dependent upon its phosphorylation status, and that during HCV infection deregulation of phosphorylated occludin collectively leads to a redn. in tight junction (TJ) integrity of hepatocytes and favors HCV entry.  However, detailed information of the posttranslational modifications (PTMs) of occludin still remains largely unknown.  In addn. to phosphorylation, serine/threonine residues of several proteins are also regulated by a unique type of modification known as O-Î²-glycosylation and this crosstalk serves as a functional switch.  To identify the O-Î²-glycosylation potential and how interplay between phosphorylation and O-Î²-glycosylation can be exploited for the inhibition of HCV entry, here we report a computational anal. of PTMs of human occludin.  Several conserved phosphorylation residues and kinases that can alter the ability of occludin to regulate the integrity of TJs were identified.  In addn. to previously reported Tyr residues, two addnl. Tyr residues (Tyr29 and Tyr287) were identified as target sites of Src kinase.  To our knowledge, this is the first study to report the O-Î²-GlcNAc potential of occludin and target sites of ERK (Ser8, Ser310, and Thr345), GSK-3 (Ser8, Ser341) and Cdk5 (Thr376).  Furthermore, based on findings from this study, a potential novel interplay between phosphorylation and O-Î²-glycosylation at the two Yin Yang sites (Ser408 and Ser490) is also proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog73x49xsVVbVg90H21EOLACvtfcHk0lh17bG8zyXU7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosFWjtbw%253D&md5=dbe642ebdb0a1a96f2297e5298bf5c96</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1016%2Fj.meegid.2012.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.meegid.2012.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DButt%26aufirst%3DA.%2BM.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DNasrullah%26aufirst%3DI.%26aulast%3DTahir%26aufirst%3DS.%26aulast%3DIdrees%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DJ.%26atitle%3DComputational%2520identification%2520of%2520interplay%2520between%2520phosphorylation%2520and%2520O-beta-glycosylation%2520of%2520human%2520occludin%2520as%2520potential%2520mechanism%2520to%2520impair%2520hepatitis%2520C%2520virus%2520entry%26jtitle%3DInfect.%252C%2520Genet.%2520Evol.%26date%3D2012%26volume%3D12%26spage%3D1235%26epage%3D1245%26doi%3D10.1016%2Fj.meegid.2012.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakkola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheltsov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kainov, D. E.</span></span> <span> </span><span class="NLM_article-title">Emerging cellular targets for influenza antiviral agents</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2011.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.tips.2011.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=22196854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFamu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=89-99&author=K.+H.+M%C3%BCllerauthor=L.+Kakkolaauthor=A.+S.+Nagarajauthor=A.+V.+Cheltsovauthor=M.+Anastasinaauthor=D.+E.+Kainov&title=Emerging+cellular+targets+for+influenza+antiviral+agents&doi=10.1016%2Fj.tips.2011.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging cellular targets for influenza antiviral agents</span></div><div class="casAuthors">Mueller, Konstantin H.; Kakkola, Laura; Nagaraj, Ashwini S.; Cheltsov, Anton V.; Anastasina, Maria; Kainov, Denis E.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-99</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  At the global level, influenza A virus (IAV) is considered a major health threat because it causes significant morbidity.  Different treatment and prevention options were developed; however, these are insufficient in the face of recent IAV outbreaks.  In particular, available antiviral agents have limited effectiveness owing to IAV resistance to these virus-directed drugs.  Recent advances in understanding of IAV replication have revealed a no. of cellular drug targets that counteract viral drug resistance.  This review summarizes current knowledge on IAV replication with a focus on emerging cellular drug targets.  Interestingly, for many of these targets, compds. for which safety testing was carried out in humans are available.  It is possible that some of these compds., such as inhibitors of heat shock protein 90, proteasome, importin Î±5, or protein kinase C, will be used for treatment of IAV infections after careful evaluation in human primary cells and severely ill flu patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSsGGMfMEaD7Vg90H21EOLACvtfcHk0lh17bG8zyXU7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFamu7c%253D&md5=635a9ccff67b913aa8130c3d39b6a802</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2011.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2011.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%2BH.%26aulast%3DKakkola%26aufirst%3DL.%26aulast%3DNagaraj%26aufirst%3DA.%2BS.%26aulast%3DCheltsov%26aufirst%3DA.%2BV.%26aulast%3DAnastasina%26aufirst%3DM.%26aulast%3DKainov%26aufirst%3DD.%2BE.%26atitle%3DEmerging%2520cellular%2520targets%2520for%2520influenza%2520antiviral%2520agents%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D89%26epage%3D99%26doi%3D10.1016%2Fj.tips.2011.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suizu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda-Lennikov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Akt kinase activity suppresses entry and replication of influenza virus</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">891</span>â <span class="NLM_lpage">898</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2014.06.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.bbrc.2014.06.077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24971535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFansLbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2014&pages=891-898&author=N.+Hirataauthor=F.+Suizuauthor=M.+Matsuda-Lennikovauthor=T.+Edamuraauthor=J.+Balaauthor=M.+Noguchi&title=Inhibition+of+Akt+kinase+activity+suppresses+entry+and+replication+of+influenza+virus&doi=10.1016%2Fj.bbrc.2014.06.077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Akt kinase activity suppresses entry and replication of influenza virus</span></div><div class="casAuthors">Hirata, Noriyuki; Suizu, Futoshi; Matsuda-Lennikov, Mami; Edamura, Tatsuma; Bala, Jyoti; Noguchi, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">891-898</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The possibility of the pandemic spread of influenza viruses highlights the need for an effective cure for this life-threatening disease.  Influenza A virus, belonging to a family of orthomyxoviruses, is a neg.-strand RNA virus which encodes 11 viral proteins.  A nos. of intracellular signaling pathways in the host cells interact with influenza the viral proteins, which affect various stages of viral infection and replication.In this study, we investigated how inhibition of Akt kinase activity impacts on influenza virus infection by using "Akt-in", a peptide Akt inhibitor.  In PR8 influenza-infected A549 cells, Akt interacted with the NS1 (Non structural protein 1), and hence increased phosphorylation of Akt kinase activity and NS1.  Treatment of cells with either "TCL1- or TCL1b-based Akt-in" efficiently suppressed Akt kinase activity while decreasing the levels of phosphorylated NS1; this, in turn, inhibited viral replication in a dose- and time-dependent manner.  The inhibitory effect on viral replication appears to not be due to inhibition of the prodn. of inflammatory cytokines, including IL-6 and IL-8, in the host cells.  Inhibition of Akt kinase activity in the host cells inhibited the efficiency of viral entry, which is assocd. with decreased levels of phosphorylated glycogen synthase kinase 3, a substrate of Akt.  Thus inhibition of Akt kinase activity in host cells may have therapeutic advantages for influenza virus infection by inhibiting viral entry and replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKmcrgu_8vcLVg90H21EOLACvtfcHk0lgFYB5xKO65Cw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFansLbJ&md5=5dbdfd52b7a9b16328ca99c488a16780</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.06.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.06.077%26sid%3Dliteratum%253Aachs%26aulast%3DHirata%26aufirst%3DN.%26aulast%3DSuizu%26aufirst%3DF.%26aulast%3DMatsuda-Lennikov%26aufirst%3DM.%26aulast%3DEdamura%26aufirst%3DT.%26aulast%3DBala%26aufirst%3DJ.%26aulast%3DNoguchi%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520Akt%2520kinase%2520activity%2520suppresses%2520entry%2520and%2520replication%2520of%2520influenza%2520virus%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D450%26spage%3D891%26epage%3D898%26doi%3D10.1016%2Fj.bbrc.2014.06.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RÃ¼schenbaum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moradpour, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouttenoire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C. M.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3Î² enhances hepatitis C virus replication by supporting miR-122</span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2949</span>, <span class="refDoi">Â DOI: 10.3389/fmicb.2018.02949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffmicb.2018.02949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30542341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3cnht1yhtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2949&author=M.+Salehauthor=S.+R%C3%BCschenbaumauthor=C.+Welschauthor=S.+Zeuzemauthor=D.+Moradpourauthor=J.+Gouttenoireauthor=C.+M.+Lange&title=Glycogen+synthase+kinase-3%CE%B2+enhances+hepatitis+C+virus+replication+by+supporting+miR-122&doi=10.3389%2Ffmicb.2018.02949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen Synthase Kinase 3Î² Enhances Hepatitis C Virus Replication by Supporting miR-122</span></div><div class="casAuthors">Saleh Maged; Ruschenbaum Sabrina; Welsch Christoph; Zeuzem Stefan; Lange Christian M; Moradpour Darius; Gouttenoire Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2949</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) infection is associated with alterations in host lipid and insulin signaling cascades, which are partially explained by a dependence of the HCV life cycle on key molecules in these metabolic pathways.  Yet, little is known on the role in the HCV life cycle of glycogen synthase kinase 3 (GSK3), one of the most important kinases in cellular metabolism.  Therefore, the impact of GSK3 on the HCV life cycle was assessed in human hepatoma cell lines harboring subgenomic genotype 1b and 2a replicons or producing cell culture-derived HCV genotype 2a by exposure to synthetic GSK3 inhibitors, GSK3 gene silencing, overexpression of GSK3 constructs and immunofluorescence analyses.  In addition, the role of GSK3 in hepatitis E virus (HEV) replication was investigated to assess virus specificity of the observed findings.  We found that both inhibition of GSK3 function by synthetic inhibitors as well as silencing of GSK3Î² gene expression resulted in a decrease of HCV replication and infectious particle production, whereas silencing of the GSK3Î± isoform had no relevant effect on the HCV life cycle.  Conversely, overexpression of GSK3Î² resulted in enhanced HCV replication.  In contrast, GSK3Î² had no effect on replication of subgenomic HEV replicon.  The pro-viral effect of GSK3Î² on HCV replication was mediated by supporting expression of microRNA-122 (miR-122), a micro-RNA which is mandatory for wild-type HCV replication, as GSK3 inhibitors suppressed miR-122 levels and as inhibitors of GSK3 had no antiviral effect on a miR-122-independent HCV mutant.  In conclusion, we have identified GSK3Î² is a novel host factor supporting HCV replication by maintaining high levels of hepatic miR-122 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT47XF4UWpgq43yKPtYViAGfW6udTcc2eZAoPZ1_2kjObntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnht1yhtw%253D%253D&md5=457c0121fbe2a5b527b2ac3d0daf64af</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2018.02949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2018.02949%26sid%3Dliteratum%253Aachs%26aulast%3DSaleh%26aufirst%3DM.%26aulast%3DR%25C3%25BCschenbaum%26aufirst%3DS.%26aulast%3DWelsch%26aufirst%3DC.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DMoradpour%26aufirst%3DD.%26aulast%3DGouttenoire%26aufirst%3DJ.%26aulast%3DLange%26aufirst%3DC.%2BM.%26atitle%3DGlycogen%2520synthase%2520kinase-3%25CE%25B2%2520enhances%2520hepatitis%2520C%2520virus%2520replication%2520by%2520supporting%2520miR-122%26jtitle%3DFront.%2520Microbiol.%26date%3D2018%26volume%3D9%26spage%3D2949%26doi%3D10.3389%2Ffmicb.2018.02949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guendel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iordanskiy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Duyne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saifuddin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaworski, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampey, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepene, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Novel neuroprotective GSK-3Î² inhibitor restricts tat-mediated HIV-1 replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">1189</span>â <span class="NLM_lpage">1208</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01940-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.01940-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=24227837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOktLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=1189-1208&author=I.+Guendelauthor=S.+Iordanskiyauthor=R.+Van+Duyneauthor=K.+Kehn-Hallauthor=M.+Saifuddinauthor=R.+Dasauthor=E.+Jaworskiauthor=G.+C.+Sampeyauthor=S.+Seninaauthor=L.+Shultzauthor=A.+Narayananauthor=H.+Chenauthor=B.+Lepeneauthor=C.+Zengauthor=F.+Kashanchi&title=Novel+neuroprotective+GSK-3%CE%B2+inhibitor+restricts+tat-mediated+HIV-1+replication&doi=10.1128%2FJVI.01940-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Novel neuroprotective GSK-3Î² inhibitor restricts Tat-mediated HIV-1 replication</span></div><div class="casAuthors">Guendel, Irene; Iordanskiy, Sergey; Van Duyne, Rachel; Kehn-Hall, Kylene; Saifuddin, Mohammed; Das, Ravi; Jaworski, Elizabeth; Sampey, Gavin C.; Senina, Svetlana; Shultz, Leonard; Narayanan, Aarthi; Chen, Hao; Lepene, Benjamin; Zeng, Chen; Kashanchi, Fatah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1189-1208, 21 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The implementation of new antiretroviral therapies targeting transcription of early viral proteins in postintegrated HIV-1 can aid in overcoming current therapy limitations.  Using high-throughput screening assays, we have previously described a novel Tat-dependent HIV-1 transcriptional inhibitor named 6-bromoindirubin-3'-oxime (6BIO).  The screening of 6BIO derivs. yielded unique compds. that show potent inhibition of HIV-1 transcription.  We have identified a second-generation deriv. called 18BIOder as an inhibitor of HIV-1 Tat-dependent transcription in TZM-bl cells and a potent inhibitor of GSK-3Î² kinase in vitro.  Structurally, 18BIOder is half the mol. wt. and structure of its parental compd., 6BIO.  More importantly, we also have found a different GSK-3Î² complex present only in HIV-1-infected cells. 18BIOder preferentially inhibits this novel kinase complex from infected cells at nanomolar concns.  Finally, we obsd. that neuronal cultures treated with Tat protein are protected from Tat-mediated cytotoxicity when treated with 18BIOder.  Overall, our data suggest that HIV-1 Tat-dependent transcription is sensitive to small-mol. inhibition of GSK-3Î².</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdRWixre6PE7Vg90H21EOLACvtfcHk0liWJhlA9wd3MA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOktLg%253D&md5=5b83a53a2ef46ceea70a994ef88f7cb1</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1128%2FJVI.01940-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01940-13%26sid%3Dliteratum%253Aachs%26aulast%3DGuendel%26aufirst%3DI.%26aulast%3DIordanskiy%26aufirst%3DS.%26aulast%3DVan%2BDuyne%26aufirst%3DR.%26aulast%3DKehn-Hall%26aufirst%3DK.%26aulast%3DSaifuddin%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DR.%26aulast%3DJaworski%26aufirst%3DE.%26aulast%3DSampey%26aufirst%3DG.%2BC.%26aulast%3DSenina%26aufirst%3DS.%26aulast%3DShultz%26aufirst%3DL.%26aulast%3DNarayanan%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLepene%26aufirst%3DB.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DNovel%2520neuroprotective%2520GSK-3%25CE%25B2%2520inhibitor%2520restricts%2520tat-mediated%2520HIV-1%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2014%26volume%3D88%26spage%3D1189%26epage%3D1208%26doi%3D10.1128%2FJVI.01940-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref258"><div class="reference"><strong class="refLabel"><a href="#ref258" class="rightTabRefNumLink">258</a></strong><div class="NLM_citation" id="rightTab-cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of glycogen synthase kinase-3Î² suppresses coxsackievirus-induced cytopathic effect and apoptosis via stabilization of beta-catenin</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1097</span>â <span class="NLM_lpage">1106</span>, <span class="refDoi">Â DOI: 10.1038/sj.cdd.4401652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fsj.cdd.4401652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=15905881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVymu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=1097-1106&author=J.+Yuanauthor=J.+Zhangauthor=B.+W.+Wongauthor=X.+Siauthor=J.+Wongauthor=D.+Yangauthor=H.+Luo&title=Inhibition+of+glycogen+synthase+kinase-3%CE%B2+suppresses+coxsackievirus-induced+cytopathic+effect+and+apoptosis+via+stabilization+of+beta-catenin&doi=10.1038%2Fsj.cdd.4401652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of glycogen synthase kinase 3Î² suppresses coxsackievirus-induced cytopathic effect and apoptosis via stabilization of Î²-catenin</span></div><div class="casAuthors">Yuan, J.; Zhang, J.; Wong, B. W.; Si, X.; Wong, J.; Yang, D.; Luo, H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1097-1106</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Coxsackievirus B3 (CVB3), a common human pathogen for viral myocarditis, induces a direct cytopathic effect (CPE) and apoptosis on infected cells.  To elucidate the mechanisms that contribute to these processes, we studied the role of glycogen synthase kinase 3Î² (GSK3Î²).  GSK3Î² activity was significantly increased after CVB3 infection and addn. of tyrosine kinase inhibitors blocked CVB3-triggered GSK3Î² activation.  Inhibition of caspase activity had no inhibitory effect on CVB3-induced CPE; however, blockage of GSK3Î² activation attenuated both CVB3-induced CPE and apoptosis.  We further showed that CVB3 infection resulted in reduced Î²-catenin protein expression, and GSK3Î² inhibition led to the accumulation and nuclear translocation of Î²-catenin.  Finally, we found that CVB3-induced CPE and apoptosis were significantly reduced in cells stably overexpressing Î²-catenin.  Taken together, our results demonstrate that CVB3 infection stimulates GSK3Î² activity via a tyrosine kinase-dependent mechanism, which contributes to CVB3-induced CPE and apoptosis through dysregulation of Î²-catenin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1yBNC4k41A7Vg90H21EOLACvtfcHk0liWJhlA9wd3MA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVymu7s%253D&md5=7ca362ba0869bab75a82c52e7c335ec3</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4401652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4401652%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DB.%2BW.%26aulast%3DSi%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520glycogen%2520synthase%2520kinase-3%25CE%25B2%2520suppresses%2520coxsackievirus-induced%2520cytopathic%2520effect%2520and%2520apoptosis%2520via%2520stabilization%2520of%2520beta-catenin%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2005%26volume%3D12%26spage%3D1097%26epage%3D1106%26doi%3D10.1038%2Fsj.cdd.4401652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref259"><div class="reference"><strong class="refLabel"><a href="#ref259" class="rightTabRefNumLink">259</a></strong><div class="NLM_citation" id="rightTab-cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarhan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Hakeem, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrrell, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, M.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3Î² inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2495</span>, <span class="refDoi">Â DOI: 10.1038/s41598-017-02648-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41598-017-02648-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28566716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BC1cnjsV2rsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=2495&author=M.+A.+Sarhanauthor=M.+S.+Abdel-Hakeemauthor=A.+L.+Masonauthor=D.+L.+Tyrrellauthor=M.+Houghton&title=Glycogen+synthase+kinase-3%CE%B2+inhibitors+prevent+hepatitis+C+virus+release%2Fassembly+through+perturbation+of+lipid+metabolism&doi=10.1038%2Fs41598-017-02648-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit259R"><div class="casContent"><span class="casTitleNuber">259</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3Î² inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism</span></div><div class="casAuthors">Sarhan Mohammed A; Abdel-Hakeem Mohamed S; Mason Andrew L; Tyrrell D Lorne; Houghton Michael; Sarhan Mohammed A; Abdel-Hakeem Mohamed S; Tyrrell D Lorne; Houghton Michael; Sarhan Mohammed A; Sarhan Mohammed A; Mason Andrew L; Abdel-Hakeem Mohamed S</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2495</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Direct acting antivirals against hepatitis C virus (HCV) have markedly improved cure rates in the past few years.  However, they are expensive, with only few targeting host cell factors, and affecting virus assembly and release.  Huh7.5 cells infected with a JFH-1 clone of HCV were treated with two different glycogen synthase kinase (GSK3)-Î² inhibitors; AR-A014418 and lithium chloride.  Intra- and extracellular HCV virions and specific infectivity was determined using real-time RT-PCR and TCID50, and changes in lipid production were identified by enzyme-linked immunoassay and mass spectrometry analyses.  Similarly, effect on two HCV replicon cells were identified by the luciferase activity.  Although there was limited effect on virus replication in Huh7.5 cells and replicons, Huh7.5 cells treated with GSK3Î² inhibitors produced significantly less viral particles in comparison to untreated cells.  In addition, the treated cells synthesized significantly lower amounts of ApoB and trapped the ApoE lipoproteins in the cells.  In conclusion, our study suggests that GSK3Î² plays a pivotal role in HCV virion assembly and release mediated in part through inhibition of apolipoprotein synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRoHMUg6MLso-xsqfvU0ziafW6udTcc2eZYoL8JQUqsN7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnjsV2rsQ%253D%253D&md5=516de994e35f8c64dd72d1132c299678</span></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-02648-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-02648-6%26sid%3Dliteratum%253Aachs%26aulast%3DSarhan%26aufirst%3DM.%2BA.%26aulast%3DAbdel-Hakeem%26aufirst%3DM.%2BS.%26aulast%3DMason%26aufirst%3DA.%2BL.%26aulast%3DTyrrell%26aufirst%3DD.%2BL.%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DGlycogen%2520synthase%2520kinase-3%25CE%25B2%2520inhibitors%2520prevent%2520hepatitis%2520C%2520virus%2520release%252Fassembly%2520through%2520perturbation%2520of%2520lipid%2520metabolism%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D2495%26doi%3D10.1038%2Fs41598-017-02648-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref260"><div class="reference"><strong class="refLabel"><a href="#ref260" class="rightTabRefNumLink">260</a></strong><div class="NLM_citation" id="rightTab-cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guendel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaltsounis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Harthi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutsch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK-3Î² inhibitors</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>415</i></span>,  <span class="NLM_fpage">56</span>â <span class="NLM_lpage">68</span>, <span class="refDoi">Â DOI: 10.1016/j.virol.2011.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.virol.2011.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=21514616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsVGhsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2011&pages=56-68&author=K.+Kehn-Hallauthor=I.+Guendelauthor=L.+Carpioauthor=L.+Skaltsounisauthor=L.+Meijerauthor=L.+Al-Harthiauthor=J.+P.+Steinerauthor=A.+Nathauthor=O.+Kutschauthor=F.+Kashanchi&title=Inhibition+of+Tat-mediated+HIV-1+replication+and+neurotoxicity+by+novel+GSK-3%CE%B2+inhibitors&doi=10.1016%2Fj.virol.2011.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors</span></div><div class="casAuthors">Kehn-Hall, Kylene; Guendel, Irene; Carpio, Lawrence; Skaltsounis, Leandros; Meijer, Laurent; Al-Harthi, Lena; Steiner, Joseph P.; Nath, Avindra; Kutsch, Olaf; Kashanchi, Fatah</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">415</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-68</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The HIV-1 protein Tat is a crit. regulator of viral transcription and has also been implicated as a mediator of HIV-1 induced neurotoxicity.  Here using a high throughput screening assay, we identified the GSK-3 inhibitor 6BIO, as a Tat-dependent HIV-1 transcriptional inhibitor.  Its ability to inhibit HIV-1 transcription was confirmed in TZM-bl cells, with an IC50 of 40 nM.  Through screening 6BIO derivs., we identified 6BIOder, which has a lower IC50 of 4 nM in primary macrophages and 0.5 nM in astrocytes infected with HIV-1.  6BIOder displayed an IC50 value of 0.03 nM through in vitro GSK-3Î² kinase inhibition assays.  Finally, we demonstrated 6BIO and 6BIOder have neuroprotective effects on Tat induced cell death in rat mixed hippocampal cultures.  Therefore 6BIO and its derivs. are unique compds. which, due to their complex mechanisms of action, are able to inhibit HIV-1 transcription as well as to protect against Tat induced neurotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxBon7zHN0XbVg90H21EOLACvtfcHk0lhm6rl00F7GEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsVGhsrc%253D&md5=fc107bb83a413099573dde370407bbf9</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2011.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2011.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DKehn-Hall%26aufirst%3DK.%26aulast%3DGuendel%26aufirst%3DI.%26aulast%3DCarpio%26aufirst%3DL.%26aulast%3DSkaltsounis%26aufirst%3DL.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DAl-Harthi%26aufirst%3DL.%26aulast%3DSteiner%26aufirst%3DJ.%2BP.%26aulast%3DNath%26aufirst%3DA.%26aulast%3DKutsch%26aufirst%3DO.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520Tat-mediated%2520HIV-1%2520replication%2520and%2520neurotoxicity%2520by%2520novel%2520GSK-3%25CE%25B2%2520inhibitors%26jtitle%3DVirology%26date%3D2011%26volume%3D415%26spage%3D56%26epage%3D68%26doi%3D10.1016%2Fj.virol.2011.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref261"><div class="reference"><strong class="refLabel"><a href="#ref261" class="rightTabRefNumLink">261</a></strong><div class="NLM_citation" id="rightTab-cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruschenbaum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moradpour, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouttenoire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C. M.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3Î² enhances hepatitis C virus replication by supporting miR-122</span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2949</span>, <span class="refDoi">Â DOI: 10.3389/fmicb.2018.02949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffmicb.2018.02949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30542341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A280%3ADC%252BB3cnht1yhtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2949&author=M.+Salehauthor=S.+Ruschenbaumauthor=C.+Welschauthor=S.+Zeuzemauthor=D.+Moradpourauthor=J.+Gouttenoireauthor=C.+M.+Lange&title=Glycogen+synthase+kinase-3%CE%B2+enhances+hepatitis+C+virus+replication+by+supporting+miR-122&doi=10.3389%2Ffmicb.2018.02949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen Synthase Kinase 3Î² Enhances Hepatitis C Virus Replication by Supporting miR-122</span></div><div class="casAuthors">Saleh Maged; Ruschenbaum Sabrina; Welsch Christoph; Zeuzem Stefan; Lange Christian M; Moradpour Darius; Gouttenoire Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2949</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) infection is associated with alterations in host lipid and insulin signaling cascades, which are partially explained by a dependence of the HCV life cycle on key molecules in these metabolic pathways.  Yet, little is known on the role in the HCV life cycle of glycogen synthase kinase 3 (GSK3), one of the most important kinases in cellular metabolism.  Therefore, the impact of GSK3 on the HCV life cycle was assessed in human hepatoma cell lines harboring subgenomic genotype 1b and 2a replicons or producing cell culture-derived HCV genotype 2a by exposure to synthetic GSK3 inhibitors, GSK3 gene silencing, overexpression of GSK3 constructs and immunofluorescence analyses.  In addition, the role of GSK3 in hepatitis E virus (HEV) replication was investigated to assess virus specificity of the observed findings.  We found that both inhibition of GSK3 function by synthetic inhibitors as well as silencing of GSK3Î² gene expression resulted in a decrease of HCV replication and infectious particle production, whereas silencing of the GSK3Î± isoform had no relevant effect on the HCV life cycle.  Conversely, overexpression of GSK3Î² resulted in enhanced HCV replication.  In contrast, GSK3Î² had no effect on replication of subgenomic HEV replicon.  The pro-viral effect of GSK3Î² on HCV replication was mediated by supporting expression of microRNA-122 (miR-122), a micro-RNA which is mandatory for wild-type HCV replication, as GSK3 inhibitors suppressed miR-122 levels and as inhibitors of GSK3 had no antiviral effect on a miR-122-independent HCV mutant.  In conclusion, we have identified GSK3Î² is a novel host factor supporting HCV replication by maintaining high levels of hepatic miR-122 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT47XF4UWpgq43yKPtYViAGfW6udTcc2ebvsEKDFu8JOLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnht1yhtw%253D%253D&md5=457c0121fbe2a5b527b2ac3d0daf64af</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2018.02949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2018.02949%26sid%3Dliteratum%253Aachs%26aulast%3DSaleh%26aufirst%3DM.%26aulast%3DRuschenbaum%26aufirst%3DS.%26aulast%3DWelsch%26aufirst%3DC.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DMoradpour%26aufirst%3DD.%26aulast%3DGouttenoire%26aufirst%3DJ.%26aulast%3DLange%26aufirst%3DC.%2BM.%26atitle%3DGlycogen%2520synthase%2520kinase-3%25CE%25B2%2520enhances%2520hepatitis%2520C%2520virus%2520replication%2520by%2520supporting%2520miR-122%26jtitle%3DFront.%2520Microbiol.%26date%3D2018%26volume%3D9%26spage%3D2949%26doi%3D10.3389%2Ffmicb.2018.02949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref262"><div class="reference"><strong class="refLabel"><a href="#ref262" class="rightTabRefNumLink">262</a></strong><div class="NLM_citation" id="rightTab-cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earnest-Silveira, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeberlein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zentgraf, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowans, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torresi, J.</span></span> <span> </span><span class="NLM_article-title">Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: Factors contributing to hepatocarcinogenesis</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">325</span>â <span class="NLM_lpage">337</span>, <span class="refDoi">Â DOI: 10.1016/j.jhep.2007.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.jhep.2007.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=17512084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosF2kurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=325-337&author=R.+Chinauthor=L.+Earnest-Silveiraauthor=B.+Koeberleinauthor=S.+Franzauthor=H.+Zentgrafauthor=X.+Dongauthor=E.+Gowansauthor=C.-T.+Bockauthor=J.+Torresi&title=Modulation+of+MAPK+pathways+and+cell+cycle+by+replicating+hepatitis+B+virus%3A+Factors+contributing+to+hepatocarcinogenesis&doi=10.1016%2Fj.jhep.2007.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: Factors contributing to hepatocarcinogenesis</span></div><div class="casAuthors">Chin, Ruth; Earnest-Silveira, Linda; Koeberlein, Bernd; Franz, Susanne; Zentgraf, Hanswalter; Dong, Xuebin; Gowans, Eric; Bock, C.-Thomas; Torresi, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-337</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background/Aims: Chronic infection with the hepatitis B virus (HBV) is strongly assocd. with the development of hepatocellular carcinoma but the mechanism by which this occurs is unknown.  Numerous studies have focused on the HBV X protein showing that it activates signal transduction pathways while few have investigated these changes in HBV-replicating hepatocytes.  Methods: We utilized the recombinant adenovirus system to deliver a replication competent HBV genome into Huh7 and primary marmoset hepatocytes (PMH) to examine the effects of active viral replication on the regulation of Ras-ERK signal transduction and related pathways.  Results: Huh7 cells and PMHs replicating HBV demonstrated significant upregulation in phosphorylated ERK, Akt, c-myc together with increased p53, cyclin B1 and p21cip1 expression and cell cycle progression to G2 phase in the absence of increased cell proliferation.  Phosphorylation of the key cell survival kinase, Akt, was significantly increased, resulting in increased serine phosphorylation of the downstream target, GSK3-Î².  Conclusions: These results demonstrated simultaneous activation of the MAP Kinase and Akt pathways in HBV-replicating hepatocytes that resulted in dysregulation in the control of cell cycle progression and which help explain the early pathogenic mechanisms that underlie malignant transformation assocd. with chronic hepatitis B infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJRS5Dy5pj5bVg90H21EOLACvtfcHk0lhe8cNtXrC9gg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosF2kurs%253D&md5=0c440d213daf103e592814b15401561a</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2007.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2007.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DR.%26aulast%3DEarnest-Silveira%26aufirst%3DL.%26aulast%3DKoeberlein%26aufirst%3DB.%26aulast%3DFranz%26aufirst%3DS.%26aulast%3DZentgraf%26aufirst%3DH.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DGowans%26aufirst%3DE.%26aulast%3DBock%26aufirst%3DC.-T.%26aulast%3DTorresi%26aufirst%3DJ.%26atitle%3DModulation%2520of%2520MAPK%2520pathways%2520and%2520cell%2520cycle%2520by%2520replicating%2520hepatitis%2520B%2520virus%253A%2520Factors%2520contributing%2520to%2520hepatocarcinogenesis%26jtitle%3DJ.%2520Hepatol.%26date%3D2007%26volume%3D47%26spage%3D325%26epage%3D337%26doi%3D10.1016%2Fj.jhep.2007.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref263"><div class="reference"><strong class="refLabel"><a href="#ref263" class="rightTabRefNumLink">263</a></strong><div class="NLM_citation" id="rightTab-cit263"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piracha, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chwae, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span> <span> </span><span class="NLM_article-title">Sirtuin 2 isoform 1 enhances hepatitis B virus RNA transcription and DNA synthesis through the AKT/GSK-3beta/beta-catenin signaling pathway</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>92</i></span>, <span class="NLM_elocation-id">e00955-18</span> <span class="refDoi">Â DOI: 10.1128/JVI.00955-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.00955-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=30111572" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2018&author=Z.+Z.+Pirachaauthor=H.+Kwonauthor=U.+Saeedauthor=J.+Kimauthor=J.+Jungauthor=Y.+J.+Chwaeauthor=S.+Parkauthor=H.+J.+Shinauthor=K.+Kim&title=Sirtuin+2+isoform+1+enhances+hepatitis+B+virus+RNA+transcription+and+DNA+synthesis+through+the+AKT%2FGSK-3beta%2Fbeta-catenin+signaling+pathway&doi=10.1128%2FJVI.00955-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1128%2FJVI.00955-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00955-18%26sid%3Dliteratum%253Aachs%26aulast%3DPiracha%26aufirst%3DZ.%2BZ.%26aulast%3DKwon%26aufirst%3DH.%26aulast%3DSaeed%26aufirst%3DU.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DChwae%26aufirst%3DY.%2BJ.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DK.%26atitle%3DSirtuin%25202%2520isoform%25201%2520enhances%2520hepatitis%2520B%2520virus%2520RNA%2520transcription%2520and%2520DNA%2520synthesis%2520through%2520the%2520AKT%252FGSK-3beta%252Fbeta-catenin%2520signaling%2520pathway%26jtitle%3DJ.%2520Virol.%26date%3D2018%26volume%3D92%26doi%3D10.1128%2FJVI.00955-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref264"><div class="reference"><strong class="refLabel"><a href="#ref264" class="rightTabRefNumLink">264</a></strong><div class="NLM_citation" id="rightTab-cit264"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tatman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rixon, F. J.</span></span> <span> </span><span class="NLM_article-title">Assembly of herpes simplex virus type 1 capsids using a panel of recombinant baculoviruses</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">Pt 5</span>),  <span class="NLM_fpage">1101</span>â <span class="NLM_lpage">1113</span>, <span class="refDoi">Â DOI: 10.1099/0022-1317-75-5-1101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1099%2F0022-1317-75-5-1101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=8176371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADyaK2cXivFertLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1994&pages=1101-1113&issue=Pt+5&author=J.+D.+Tatmanauthor=V.+G.+Prestonauthor=P.+Nicholsonauthor=R.+M.+Elliottauthor=F.+J.+Rixon&title=Assembly+of+herpes+simplex+virus+type+1+capsids+using+a+panel+of+recombinant+baculoviruses&doi=10.1099%2F0022-1317-75-5-1101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit264R"><div class="casContent"><span class="casTitleNuber">264</span><div class="casTitle"><span class="NLM_cas:atitle">Assembly of herpes simplex virus type 1 capsids using a panel of recombinant baculoviruses</span></div><div class="casAuthors">Tatman, J. D.; Preston, V. G.; Nicholson, P.; Elliott, R. M.; Rixon, F. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1101-13</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    </div><div class="casAbstract">Immature or B capsids of herpes simplex virus type 1 (HSV-1) are composed of 7 proteins encoded by 6 viral genes.  The proteins encoded by UL18 (VP23), UL19 (VP5), UL35 (VP26), and UL38 (VP19C) are components of the outer capsid shell, whereas those specified by UL26 (VP21 and VP24) and UL26.5 (VP22a) are involved in scaffold formation.  A panel of recombinant baculoviruses, each expressing 1 of the capsid protein genes, was used to examine the requirements for capsid assembly.  Coexpression of the 6 genes in insect cells resulted in the formation of capsids that were indistinguishable in appearance and protein compn. from those made during HSV-1 infection of mammalian cells.  This demonstrates that the proteins encoded by the known capsid genes contain all the structural information necessary for capsid assembly and that other virus-encoded proteins are not required for this process.  Omission of single recombinant baculoviruses from this system allowed the role of individual HSV-1 proteins in capsid assembly to be detd.  Thus, capsid assembly did not take place in the absence of VP23, VP5, or VP19C, whereas lack of VP26 had no discernible effect on capsid formation.  Capsids assembled in the absence of the UL26 gene products had a large-cored phenotype resembling that previously described for the HSV-1 mutant ts1201, which has a lesion in this gene.  Some apparently intact capsid shells were also made in the absence of the major scaffolding protein, VP22a, whereas the omission of both UL26 and UL26.5 resulted in the appearance of large nos. of partial and deformed capsid shells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXsxuK92wk6LVg90H21EOLACvtfcHk0lhumVl2Og-HuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXivFertLY%253D&md5=b2f3e43d015a6ab6c3c82eb6bab3752b</span></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.1099%2F0022-1317-75-5-1101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252F0022-1317-75-5-1101%26sid%3Dliteratum%253Aachs%26aulast%3DTatman%26aufirst%3DJ.%2BD.%26aulast%3DPreston%26aufirst%3DV.%2BG.%26aulast%3DNicholson%26aufirst%3DP.%26aulast%3DElliott%26aufirst%3DR.%2BM.%26aulast%3DRixon%26aufirst%3DF.%2BJ.%26atitle%3DAssembly%2520of%2520herpes%2520simplex%2520virus%2520type%25201%2520capsids%2520using%2520a%2520panel%2520of%2520recombinant%2520baculoviruses%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D1994%26volume%3D75%26issue%3DPt%25205%26spage%3D1101%26epage%3D1113%26doi%3D10.1099%2F0022-1317-75-5-1101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref265"><div class="reference"><strong class="refLabel"><a href="#ref265" class="rightTabRefNumLink">265</a></strong><div class="NLM_citation" id="rightTab-cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casaday, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalb, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brignole, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loveland, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotter, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, W.</span></span> <span> </span><span class="NLM_article-title">Assembly protein precursor (pUL80.5 homolog) of simian cytomegalovirus is phosphorylated at a glycogen synthase kinase 3 site and its downstream âprimingâ site: Phosphorylation affects interactions of protein with itself and with major capsid protein</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">13501</span>â <span class="NLM_lpage">13511</span>, <span class="refDoi">Â DOI: 10.1128/JVI.78.24.13501-13511.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1128%2FJVI.78.24.13501-13511.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=15564461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFSis7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=13501-13511&author=R.+J.+Casadayauthor=J.+R.+Baileyauthor=S.+R.+Kalbauthor=E.+J.+Brignoleauthor=A.+N.+Lovelandauthor=R.+J.+Cotterauthor=W.+Gibson&title=Assembly+protein+precursor+%28pUL80.5+homolog%29+of+simian+cytomegalovirus+is+phosphorylated+at+a+glycogen+synthase+kinase+3+site+and+its+downstream+%E2%80%9Cpriming%E2%80%9D+site%3A+Phosphorylation+affects+interactions+of+protein+with+itself+and+with+major+capsid+protein&doi=10.1128%2FJVI.78.24.13501-13511.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">Assembly protein precursor (pUL80.5 homolog) of simian cytomegalovirus is phosphorylated at a glycogen synthase kinase 3 site and its downstream "priming" site: Phosphorylation affects interactions of protein with itself and with major capsid protein</span></div><div class="casAuthors">Casaday, Rebecca J.; Bailey, Justin R.; Kalb, Suzanne R.; Brignole, Edward J.; Loveland, Amy N.; Cotter, Robert J.; Gibson, Wade</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">13501-13511</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Capsid assembly among the herpes-group viruses is coordinated by two related scaffolding proteins.  In cytomegalovirus (CMV), the main scaffolding constituent is called the assembly protein precursor (pAP).  Like its homologs in other herpesviruses, pAP is modified by proteolytic cleavage and phosphorylation.  Cleavage is essential for capsid maturation and prodn. of infectious virus, but the role of phosphorylation is undetd.  As a first step in evaluating the significance of this modification, we have identified the specific sites of phosphorylation in the simian CMV pAP.  Two were established previously to be adjacent serines (Ser156 and Ser157) in a casein kinase II consensus sequence.  The remaining two, identified here as Thr231 and Ser235, are within consensus sequences for glycogen synthase kinase 3 (GSK-3) and mitogen-activated protein kinase, resp.  Consistent with Thr231 being a GSK-3 substrate, its phosphorylation required a downstream "priming" phosphate (i.e., Ser235) and was reduced by a GSK-3-specific inhibitor.  Phosphorylation of Ser235 converts pAP to an electrophoretically slower-mobility isoform, pAP*; subsequent phosphorylation of pAP* at Thr231 converts pAP* to a still-slower isoform, pAP**.  The mobility shift to pAP* was mimicked by substituting an acidic amino acid for either Thr231 or Ser235, but the shift to pAP** required that both positions be phosphorylated.  Glu did not substitute for pSer235 in promoting phosphorylation of Thr231.  We suggest that phosphorylation of Thr231 and Ser235 causes charge-driven conformational changes in pAP, and we demonstrate that preventing these modifications alters interactions of pAP with itself and with major capsid protein, suggesting a functional significance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFZMp5bVHghrVg90H21EOLACvtfcHk0lhumVl2Og-HuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFSis7bE&md5=69192cb01126b92e33d1efee97928dd1</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.24.13501-13511.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.24.13501-13511.2004%26sid%3Dliteratum%253Aachs%26aulast%3DCasaday%26aufirst%3DR.%2BJ.%26aulast%3DBailey%26aufirst%3DJ.%2BR.%26aulast%3DKalb%26aufirst%3DS.%2BR.%26aulast%3DBrignole%26aufirst%3DE.%2BJ.%26aulast%3DLoveland%26aufirst%3DA.%2BN.%26aulast%3DCotter%26aufirst%3DR.%2BJ.%26aulast%3DGibson%26aufirst%3DW.%26atitle%3DAssembly%2520protein%2520precursor%2520%2528pUL80.5%2520homolog%2529%2520of%2520simian%2520cytomegalovirus%2520is%2520phosphorylated%2520at%2520a%2520glycogen%2520synthase%2520kinase%25203%2520site%2520and%2520its%2520downstream%2520%25E2%2580%259Cpriming%25E2%2580%259D%2520site%253A%2520Phosphorylation%2520affects%2520interactions%2520of%2520protein%2520with%2520itself%2520and%2520with%2520major%2520capsid%2520protein%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D13501%26epage%3D13511%26doi%3D10.1128%2FJVI.78.24.13501-13511.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref266"><div class="reference"><strong class="refLabel"><a href="#ref266" class="rightTabRefNumLink">266</a></strong><div class="NLM_citation" id="rightTab-cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsay, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. J.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 regulates the phosphorylation of severe acute respiratory syndrome coronavirus nucleocapsid protein and viral replication</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">5229</span>â <span class="NLM_lpage">5239</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M805747200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1074%2Fjbc.M805747200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=19106108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVSnt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=5229-5239&author=C.+H.+Wuauthor=S.+H.+Yehauthor=Y.+G.+Tsayauthor=Y.+H.+Shiehauthor=C.+L.+Kaoauthor=Y.+S.+Chenauthor=S.+H.+Wangauthor=T.+J.+Kuoauthor=D.+S.+Chenauthor=P.+J.+Chen&title=Glycogen+synthase+kinase-3+regulates+the+phosphorylation+of+severe+acute+respiratory+syndrome+coronavirus+nucleocapsid+protein+and+viral+replication&doi=10.1074%2Fjbc.M805747200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen Synthase Kinase-3 Regulates the Phosphorylation of Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein and Viral Replication</span></div><div class="casAuthors">Wu, Chia-Hsin; Yeh, Shiou-Hwei; Tsay, Yeou-Guang; Shieh, Ya-Hsiung; Kao, Chuan-Liang; Chen, Yen-Shun; Wang, Sheng-Han; Kuo, Ti-Jung; Chen, Ding-Shinn; Chen, Pei-Jer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5229-5239</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Coronavirus (CoV) nucleocapsid (N) protein is a highly phosphorylated protein required for viral replication, but whether its phosphorylation and the related kinases are involved in the viral life cycle is unknown.  We found the severe acute respiratory syndrome CoV N protein to be an appropriate system to address this issue.  Using high resoln. PAGE anal., this protein could be sepd. into phosphorylated and unphosphorylated isoforms.  Mass spectrometric anal. and deletion mapping showed that the major phosphorylation sites were located at the central serine-arginine (SR)-rich motif that contains several glycogen synthase kinase (GSK)-3 substrate consensus sequences.  GSK-3-specific inhibitor treatment dephosphorylated the N protein, and this could be recovered by the constitutively active GSK-3 kinase.  Immunopptn. brought down both N and GSK-3 proteins in the same complex, and the N protein could be phosphorylated directly at its SR-rich motif by GSK-3 using an in vitro kinase assay.  Mutation of the two priming sites crit. for GSK-3 phosphorylation in the SR-rich motif abolished N protein phosphorylation.  Finally, GSK-3 inhibitor was found to reduce N phosphorylation in the severe acute respiratory syndrome CoV-infected VeroE6 cells and decrease the viral titer and cytopathic effects.  The effect of GSK-3 inhibitor was reproduced in another coronavirus, the neurotropic JHM strain of mouse hepatitis virus.  Our results indicate that GSK-3 is crit. for CoV N protein phosphorylation and suggest that it plays a role in regulating the viral life cycle.  This study, thus, provides new avenues to further investigate the specific role of N protein phosphorylation in CoV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtElQtVm_P7bVg90H21EOLACvtfcHk0lj2qE6r1eaiAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVSnt7s%253D&md5=b4997e0d5f5ed44449d30a9b49d8a63b</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M805747200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M805747200%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DYeh%26aufirst%3DS.%2BH.%26aulast%3DTsay%26aufirst%3DY.%2BG.%26aulast%3DShieh%26aufirst%3DY.%2BH.%26aulast%3DKao%26aufirst%3DC.%2BL.%26aulast%3DChen%26aufirst%3DY.%2BS.%26aulast%3DWang%26aufirst%3DS.%2BH.%26aulast%3DKuo%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DD.%2BS.%26aulast%3DChen%26aufirst%3DP.%2BJ.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520regulates%2520the%2520phosphorylation%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%2520nucleocapsid%2520protein%2520and%2520viral%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D5229%26epage%3D5239%26doi%3D10.1074%2Fjbc.M805747200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref267"><div class="reference"><strong class="refLabel"><a href="#ref267" class="rightTabRefNumLink">267</a></strong><div class="NLM_citation" id="rightTab-cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. H.</span></span> <span> </span><span class="NLM_article-title">Nucleocapsid phosphorylation and RNA helicase DDX1 recruitment enables coronavirus transition from discontinuous to continuous transcription</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">462</span>â <span class="NLM_lpage">472</span>, <span class="refDoi">Â DOI: 10.1016/j.chom.2014.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.chom.2014.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25299332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1GmsL%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=462-472&author=C.+H.+Wuauthor=P.+J.+Chenauthor=S.+H.+Yeh&title=Nucleocapsid+phosphorylation+and+RNA+helicase+DDX1+recruitment+enables+coronavirus+transition+from+discontinuous+to+continuous+transcription&doi=10.1016%2Fj.chom.2014.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit267R"><div class="casContent"><span class="casTitleNuber">267</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleocapsid phosphorylation and RNA helicase DDX1 recruitment enables Coronavirus transition from discontinuous to continuous transcription</span></div><div class="casAuthors">Wu, Chia-Hsin; Chen, Pei-Jer; Yeh, Shiou-Hwei</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">462-472</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Coronaviruses contain a pos.-sense single-stranded genomic (g) RNA, which encodes nonstructural proteins.  Several subgenomic mRNAs (sgmRNAs) encoding structural proteins are generated by template switching from the body transcription regulatory sequence (TRS) to the leader TRS.  The process preferentially generates shorter sgmRNA.  Appropriate readthrough of body TRSs is required to produce longer sgmRNAs and full-length gRNA.  We find that phosphorylation of the viral nucleocapsid (N) by host glycogen synthase kinase-3 (GSK-3) is required for template switching.  GSK-3 inhibition selectively reduces the generation of gRNA and longer sgmRNAs, but not shorter sgmRNAs.  N phosphorylation allows recruitment of the RNA helicase DDX1 to the phosphorylated-N-contg. complex, which facilitates template readthrough and enables longer sgmRNA synthesis.  DDX1 knockdown or loss of helicase activity markedly reduces the levels of longer sgmRNAs.  Thus, coronaviruses employ a unique strategy for the transition from discontinuous to continuous transcription to ensure balanced sgmRNAs and full-length gRNA synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvxHHI6TWiRLVg90H21EOLACvtfcHk0lj2qE6r1eaiAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1GmsL%252FN&md5=deab53b4fde6755e8a8e107861107cf9</span></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2014.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2014.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DP.%2BJ.%26aulast%3DYeh%26aufirst%3DS.%2BH.%26atitle%3DNucleocapsid%2520phosphorylation%2520and%2520RNA%2520helicase%2520DDX1%2520recruitment%2520enables%2520coronavirus%2520transition%2520from%2520discontinuous%2520to%2520continuous%2520transcription%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2014%26volume%3D16%26spage%3D462%26epage%3D472%26doi%3D10.1016%2Fj.chom.2014.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref268"><div class="reference"><strong class="refLabel"><a href="#ref268" class="rightTabRefNumLink">268</a></strong><div class="NLM_citation" id="rightTab-cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inanami, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurane, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cell proliferation by SARS-CoV infection in Vero E6 cells</span>. <i>FEMS Immunol. Med. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">236</span>â <span class="NLM_lpage">243</span>, <span class="refDoi">Â DOI: 10.1111/j.1574-695X.2005.00028.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1111%2Fj.1574-695X.2005.00028.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=16487305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFaltrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=236-243&author=T.+Mizutaniauthor=S.+Fukushiauthor=D.+Iizukaauthor=O.+Inanamiauthor=M.+Kuwabaraauthor=H.+Takashimaauthor=H.+Yanagawaauthor=M.+Saijoauthor=I.+Kuraneauthor=S.+Morikawa&title=Inhibition+of+cell+proliferation+by+SARS-CoV+infection+in+Vero+E6+cells&doi=10.1111%2Fj.1574-695X.2005.00028.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit268R"><div class="casContent"><span class="casTitleNuber">268</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cell proliferation by SARS-CoV infection in Vero E6 cells</span></div><div class="casAuthors">Mizutani, Tetsuya; Fukushi, Shuetsu; Iizuka, Daisuke; Inanami, Osamu; Kuwabara, Mikinori; Takashima, Hideaki; Yanagawa, Hiroshi; Saijo, Masayuki; Kurane, Ichiro; Morikawa, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">FEMS Immunology and Medical Microbiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">FIMIEV</span>;
        ISSN:<span class="NLM_cas:issn">0928-8244</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome (SARS) is caused by SARS-coronavirus (SARS-CoV).  Infection of Vero E6 cells with SARS-CoV inhibits cell proliferation.  Our previous study indicated that Akt, which is poorly phosphorylated in confluent cultures of Vero E6 cells, is phosphorylated and then dephosphorylated upon infection by SARS-CoV.  In the present study, we showed that a serine residue of Akt was phosphorylated in Vero E6 cells in subconfluent culture and that Akt was dephosphorylated rapidly after SARS-CoV infection without up-regulation of its phosphorylation.  Phosphorylation of glycogen synthase kinase-3Î², which is one of the downstream targets of Akt, was prevented in SARS-CoV-infected cells.  However, treatment with glycogen synthase kinase-3Î² small interfering RNA indicated that the glycogen synthase kinase-3Î² signaling pathway was not related to inhibition of cell proliferation.  Treatment of Vero E6 cells with the phosphatidylinositol 3'-kinase/Akt inhibitor, LY294002, which induces dephosphorylation of Akt, inhibited cell proliferation.  As shown in our previous studies, apoptosis occurred in virus-infected cells within 18 h postinfection.  Cellular mRNA transcription, which was reported to be up-regulated in SARS-CoV-infected Caco-2 cells, was not up-regulated in virus-infected Vero E6 cells, partially as a result of apoptosis.  These results suggested that inhibition of cell proliferation is regulated by both the phosphatidylinositol 3'-kinase/Akt signaling pathway and by apoptosis in SARS-CoV-infected Vero E6 cells.  This is the first study to analyze SARS-CoV-induced cell growth inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfktEkRYIA5bVg90H21EOLACvtfcHk0lj2qE6r1eaiAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFaltrk%253D&md5=76c0a218bb86013a3500493c395cdf10</span></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=10.1111%2Fj.1574-695X.2005.00028.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1574-695X.2005.00028.x%26sid%3Dliteratum%253Aachs%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DFukushi%26aufirst%3DS.%26aulast%3DIizuka%26aufirst%3DD.%26aulast%3DInanami%26aufirst%3DO.%26aulast%3DKuwabara%26aufirst%3DM.%26aulast%3DTakashima%26aufirst%3DH.%26aulast%3DYanagawa%26aufirst%3DH.%26aulast%3DSaijo%26aufirst%3DM.%26aulast%3DKurane%26aufirst%3DI.%26aulast%3DMorikawa%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520cell%2520proliferation%2520by%2520SARS-CoV%2520infection%2520in%2520Vero%2520E6%2520cells%26jtitle%3DFEMS%2520Immunol.%2520Med.%2520Microbiol.%26date%3D2006%26volume%3D46%26spage%3D236%26epage%3D243%26doi%3D10.1111%2Fj.1574-695X.2005.00028.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref269"><div class="reference"><strong class="refLabel"><a href="#ref269" class="rightTabRefNumLink">269</a></strong><div class="NLM_citation" id="rightTab-cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guddat, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span> <span> </span><span class="NLM_article-title">Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>582</i></span>,  <span class="NLM_fpage">289</span>â <span class="NLM_lpage">293</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2223-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fs41586-020-2223-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32272481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVyhsrrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=582&publication_year=2020&pages=289-293&author=Z.+Jinauthor=X.+Duauthor=Y.+Xuauthor=Y.+Dengauthor=M.+Liuauthor=Y.+Zhaoauthor=B.+Zhangauthor=X.+Liauthor=L.+Zhangauthor=C.+Pengauthor=Y.+Duanauthor=J.+Yuauthor=L.+Wangauthor=K.+Yangauthor=F.+Liuauthor=R.+Jiangauthor=X.+Yangauthor=T.+Youauthor=X.+Liuauthor=X.+Yangauthor=F.+Baiauthor=H.+Liuauthor=X.+Liuauthor=L.+W.+Guddatauthor=W.+Xuauthor=G.+Xiaoauthor=C.+Qinauthor=Z.+Shiauthor=H.+Jiangauthor=Z.+Raoauthor=H.+Yang&title=Structure+of+M%28pro%29+from+SARS-CoV-2+and+discovery+of+its+inhibitors&doi=10.1038%2Fs41586-020-2223-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors</span></div><div class="casAuthors">Jin, Zhenming; Du, Xiaoyu; Xu, Yechun; Deng, Yongqiang; Liu, Meiqin; Zhao, Yao; Zhang, Bing; Li, Xiaofeng; Zhang, Leike; Peng, Chao; Duan, Yinkai; Yu, Jing; Wang, Lin; Yang, Kailin; Liu, Fengjiang; Jiang, Rendi; Yang, Xinglou; You, Tian; Liu, Xiaoce; Yang, Xiuna; Bai, Fang; Liu, Hong; Liu, Xiang; Guddat, Luke W.; Xu, Wenqing; Xiao, Gengfu; Qin, Chengfeng; Shi, Zhengli; Jiang, Hualiang; Rao, Zihe; Yang, Haitao</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">582</span>
        (<span class="NLM_cas:issue">7811</span>),
    <span class="NLM_cas:pages">289-293</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the etiol. agent responsible for the 2019-2020 viral pneumonia outbreak of coronavirus disease 2019 (COVID-19).  Currently, there are no targeted therapeutic agents for the treatment of this disease, and effective treatment options remain very limited.  Here, we describe the results of a program that aimed to rapidly discover lead compds. for clin. use, by combining structure-assisted drug design, virtual drug screening and high-throughput screening.  This program focused on identifying drug leads that target main protease (Mpro) of SARS-CoV-2: Mpro is a key enzyme of coronaviruses and has a pivotal role in mediating viral replication and transcription, making it an attractive drug target for SARS-CoV-2.  We identified a mechanism-based inhibitor (N3) by computer-aided drug design, and then detd. the crystal structure of Mpro of SARS-CoV-2 in complex with this compd.  Through a combination of structure-based virtual and high-throughput screening, we assayed more than 10,000 compds.-including approved drugs, drug candidates in clin. trials and other pharmacol. active compds.-as inhibitors of Mpro.  Six of these compds. inhibited Mpro, showing half-maximal inhibitory concn. values that ranged from 0.67 to 21.4Î¼M.  One of these compds. (ebselen) also exhibited promising antiviral activity in cell-based assays.  Our results demonstrate the efficacy of our screening strategy, which can lead to the rapid discovery of drug leads with clin. potential in response to new infectious diseases for which no specific drugs or vaccines are available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFupuh6WIyW7Vg90H21EOLACvtfcHk0lhZ0puYOt9HEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVyhsrrO&md5=b84f350fe9ce1109485df6caf814ba82</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2223-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2223-y%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYou%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DGuddat%26aufirst%3DL.%2BW.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DG.%26aulast%3DQin%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DRao%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DH.%26atitle%3DStructure%2520of%2520M%2528pro%2529%2520from%2520SARS-CoV-2%2520and%2520discovery%2520of%2520its%2520inhibitors%26jtitle%3DNature%26date%3D2020%26volume%3D582%26spage%3D289%26epage%3D293%26doi%3D10.1038%2Fs41586-020-2223-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref270"><div class="reference"><strong class="refLabel"><a href="#ref270" class="rightTabRefNumLink">270</a></strong><div class="NLM_citation" id="rightTab-cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavora, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safran, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Deiry, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carneiro, B. A.</span></span> <span> </span><span class="NLM_article-title">Commentary: GSK-3 Inhibition as a therapeutic approach against SARs CoV-2: Dual benefit of inhibiting viral replication while potentiating the immune response</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">595289</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2020.595289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffimmu.2020.595289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=33193448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3MXitVCitL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=595289&author=A.+De+Souzaauthor=F.+A.+Tavoraauthor=D.+Mahalingamauthor=P.+N.+Munsterauthor=H.+P.+Safranauthor=W.+S.+El-Deiryauthor=B.+A.+Carneiro&title=Commentary%3A+GSK-3+Inhibition+as+a+therapeutic+approach+against+SARs+CoV-2%3A+Dual+benefit+of+inhibiting+viral+replication+while+potentiating+the+immune+response&doi=10.3389%2Ffimmu.2020.595289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit270R"><div class="casContent"><span class="casTitleNuber">270</span><div class="casTitle"><span class="NLM_cas:atitle">Commentary: GSK-3 inhibition as a therapeutic approach against SARs CoV2: dual benefit of inhibiting viral replication while potentiating the immune response</span></div><div class="casAuthors">De Souza, Andre; Tavora, Fabio A.; Mahalingam, Devalingam; Munster, Pamela N.; Safran, Howard P.; El-Deiry, Wafik S.; Carneiro, Benedito A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">595289</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  We read with interest the insightful manuscript by Christopher E. Rudd highlighting the potential of Glycogen Synthase Kinase-3 (GSK-3) inhibitors for the treatment of SARS-CoV2 (1).  The manuscript describes the GSK-3-mediated phosphorylation of key serine residues in SARS-CoV2 nucleocapsid proteins essential for viral replication.  These r esults coupled with preclin. evidence demonstrating the role of GSK-3 in the modulation of innate an d adaptive immune responses support the authors hypothesis that GSK-3 inhibitors could be investigated as a potential treatment for COVID-19 infection.  SK-3 small-mol. inhibitors and GSK-3 siRNA reduced PD-1expression, increased CD8+T cell function, and enhanced viral clearance in models of herpes (MHV-68) and lymphocytic choriomeningitis (LCMV-C13) viral infections .  The increased T cell function induced by GSK-3 inhibition resulted in antitumor activity comparable with the effects obsd. with anti-PD-1 monoclonal antibodies in animal models of metastatic melanoma and lymphoma.  The therapeutic relevance of GSK-3 inhibition is also suggested by studies utilizing animal models of hemorrhagic shock showing that GSK-3 Î² inhibition dampens liver and renal dysfunction by upregulation of anti-inflammatory IL-10 and down-regulation of IL-12p40 and IL-6, a cytokine implicated in the cytokine release syndrome obsd. in patients with severe SARS-CoV2 (4).  GSK-3 Î² inhibition also attenuates the systemic inflammatory response (SIR) in models of sepsis and ischemia/reperfusion injury by modulating NF-kB-induced inflammatory response (5-8).  In this review we discuss on findings which have potential implication to SIR and the frequent disseminated intravascular vascular coagulopathy obsd. during the infection with SARS-CoV2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjy3Sj1mtM8LVg90H21EOLACvtfcHk0lhZ0puYOt9HEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXitVCitL0%253D&md5=1983335c9a08a880f555c1f205156d52</span></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.595289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.595289%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSouza%26aufirst%3DA.%26aulast%3DTavora%26aufirst%3DF.%2BA.%26aulast%3DMahalingam%26aufirst%3DD.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DSafran%26aufirst%3DH.%2BP.%26aulast%3DEl-Deiry%26aufirst%3DW.%2BS.%26aulast%3DCarneiro%26aufirst%3DB.%2BA.%26atitle%3DCommentary%253A%2520GSK-3%2520Inhibition%2520as%2520a%2520therapeutic%2520approach%2520against%2520SARs%2520CoV-2%253A%2520Dual%2520benefit%2520of%2520inhibiting%2520viral%2520replication%2520while%2520potentiating%2520the%2520immune%2520response%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26volume%3D11%26spage%3D595289%26doi%3D10.3389%2Ffimmu.2020.595289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref271"><div class="reference"><strong class="refLabel"><a href="#ref271" class="rightTabRefNumLink">271</a></strong><div class="NLM_citation" id="rightTab-cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">13190</span>â <span class="NLM_lpage">13195</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1835675100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1073%2Fpnas.1835675100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=14585926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFOju7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=13190-13195&author=H.+Yangauthor=M.+Yangauthor=Y.+Dingauthor=Y.+Liuauthor=Z.+Louauthor=Z.+Zhouauthor=L.+Sunauthor=L.+Moauthor=S.+Yeauthor=H.+Pangauthor=G.+F.+Gaoauthor=K.+Anandauthor=M.+Bartlamauthor=R.+Hilgenfeldauthor=Z.+Rao&title=The+crystal+structures+of+severe+acute+respiratory+syndrome+virus+main+protease+and+its+complex+with+an+inhibitor&doi=10.1073%2Fpnas.1835675100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor</span></div><div class="casAuthors">Yang, Haitao; Yang, Maojun; Ding, Yi; Liu, Yiwei; Lou, Zhiyong; Zhou, Zhe; Sun, Lei; Mo, Lijuan; Ye, Sheng; Pang, Hai; Gao, George F.; Anand, Kanchan; Bartlam, Mark; Hilgenfeld, Rolf; Rao, Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">13190-13195</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A newly identified severe acute respiratory syndrome coronavirus (SARS-CoV), is the etiol. agent responsible for the outbreak of SARS.  The SARS-CoV main protease, which is a 33.8-kDa protease (also called the 3C-like protease), plays a pivotal role in mediating viral replication and transcription functions through extensive proteolytic processing of two replicase polyproteins, pp1a (486 kDa) and pp1ab (790 kDa).  Here, the authors report the crystal structures of the SARS-CoV main protease at different pH values and in complex with a specific inhibitor.  The protease structure has a fold that can be described as an augmented serine-protease, but with a Cys-His at the active site.  This series of crystal structures, which is the first, to the authors' knowledge, of any protein from the SARS virus, reveal substantial pH-dependent conformational changes, and an unexpected mode of inhibitor binding, providing a structural basis for rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzcMRDCS0gPbVg90H21EOLACvtfcHk0lhZ0puYOt9HEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFOju7s%253D&md5=b9eb74d9a519f31d3eeca5e26bc7d570</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1835675100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1835675100%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DMo%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DAnand%26aufirst%3DK.%26aulast%3DBartlam%26aufirst%3DM.%26aulast%3DHilgenfeld%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DThe%2520crystal%2520structures%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520virus%2520main%2520protease%2520and%2520its%2520complex%2520with%2520an%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D13190%26epage%3D13195%26doi%3D10.1073%2Fpnas.1835675100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref272"><div class="reference"><strong class="refLabel"><a href="#ref272" class="rightTabRefNumLink">272</a></strong><div class="NLM_citation" id="rightTab-cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3: A kinase for all pathways?</span>. <i>Curr. Top. Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">277</span>â <span class="NLM_lpage">302</span>, <span class="refDoi">Â DOI: 10.1016/bs.ctdb.2016.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fbs.ctdb.2016.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28236969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKjs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2017&pages=277-302&author=P.+Patelauthor=J.+R.+Woodgett&title=Glycogen+synthase+kinase+3%3A+A+kinase+for+all+pathways%3F&doi=10.1016%2Fbs.ctdb.2016.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit272R"><div class="casContent"><span class="casTitleNuber">272</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3: a kinase for all pathways?</span></div><div class="casAuthors">Patel, Prital; Woodgett, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Developmental Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">Protein Kinases in Development and Disease</span>),
    <span class="NLM_cas:pages">277-302</span>CODEN:
                <span class="NLM_cas:coden">CTDBA5</span>;
        ISSN:<span class="NLM_cas:issn">0070-2153</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) is an unusual protein-serine kinase in that it is primarily regulated by inhibition and lies downstream of multiple cell signaling pathways.  This raises a variety of questions in terms of its physiol. role(s), how signaling specificity is maintained and why so many eggs have been placed into one basket.  There are actually two baskets, as there are two isoforms, GSK-3Î± and Î², that are highly related and largely redundant.  Their many substrates range from regulators of cellular metab. to mols. that control growth and differentiation.  In this chapter, we review the characteristics of GSK-3, update progress in understanding the kinase, and try to answer some of the questions raised by its unusual properties.  Indeed, the kinase may trigger transformation in our thinking of how cellular signals are organized and controlled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolxBj01kLDaLVg90H21EOLACvtfcHk0lgP77dnZ4-pOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKjs70%253D&md5=4c219601701e017e9101b3e7a15b301c</span></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1016%2Fbs.ctdb.2016.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.ctdb.2016.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%253A%2520A%2520kinase%2520for%2520all%2520pathways%253F%26jtitle%3DCurr.%2520Top.%2520Dev.%2520Biol.%26date%3D2017%26volume%3D123%26spage%3D277%26epage%3D302%26doi%3D10.1016%2Fbs.ctdb.2016.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref273"><div class="reference"><strong class="refLabel"><a href="#ref273" class="rightTabRefNumLink">273</a></strong><div class="NLM_citation" id="rightTab-cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanthong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuniga, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">274</span>â <span class="NLM_lpage">286</span>, <span class="refDoi">Â DOI: 10.1016/j.immuni.2016.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.immuni.2016.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=26885856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVCmsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=274-286&author=A.+Taylorauthor=J.+A.+Harkerauthor=K.+Chanthongauthor=P.+G.+Stevensonauthor=E.+I.+Zunigaauthor=C.+E.+Rudd&title=Glycogen+synthase+kinase+3+inactivation+drives+T-bet-mediated+downregulation+of+co-receptor+PD-1+to+enhance+CD8%28%2B%29+cytolytic+T+cell+responses&doi=10.1016%2Fj.immuni.2016.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses</span></div><div class="casAuthors">Taylor, Alison; Harker, James A.; Chanthong, Kittiphat; Stevenson, Philip G.; Zuniga, Elina I.; Rudd, Christopher E.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-286</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Despite the importance of the co-receptor PD-1 in T cell immunity, the upstream signaling pathway that regulates PD-1 expression has not been defined.  Glycogen synthase kinase 3 (GSK-3, isoforms Î± and Î²) is a serine-threonine kinase implicated in cellular processes.  Here, we identified GSK-3 as a key upstream kinase that regulated PD-1 expression in CD8+ T cells.  GSK-3 siRNA downregulation, or inhibition by small mols., blocked PD-1 expression, resulting in increased CD8+ cytotoxic T lymphocyte (CTL) function.  Mechanistically, GSK-3 inactivation increased Tbx21 transcription, promoting enhanced T-bet expression and subsequent suppression of Pdcd1 (encodes PD-1) transcription in CD8+ CTLs.  Injection of GSK-3 inhibitors in mice increased in vivo CD8+ OT-I CTL function and the clearance of murine gamma-herpesvirus 68 and lymphocytic choriomeningitis clone 13 and reversed T cell exhaustion.  Our findings identify GSK-3 as a regulator of PD-1 expression and demonstrate the applicability of GSK-3 inhibitors in the modulation of PD-1 in immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRPdu-n1q3BrVg90H21EOLACvtfcHk0lgP77dnZ4-pOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVCmsLg%253D&md5=d9ac06a8943d7dec13d8b12ebb123f27</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2016.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2016.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DHarker%26aufirst%3DJ.%2BA.%26aulast%3DChanthong%26aufirst%3DK.%26aulast%3DStevenson%26aufirst%3DP.%2BG.%26aulast%3DZuniga%26aufirst%3DE.%2BI.%26aulast%3DRudd%26aufirst%3DC.%2BE.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520inactivation%2520drives%2520T-bet-mediated%2520downregulation%2520of%2520co-receptor%2520PD-1%2520to%2520enhance%2520CD8%2528%252B%2529%2520cytolytic%2520T%2520cell%2520responses%26jtitle%3DImmunity%26date%3D2016%26volume%3D44%26spage%3D274%26epage%3D286%26doi%3D10.1016%2Fj.immuni.2016.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref274"><div class="reference"><strong class="refLabel"><a href="#ref274" class="rightTabRefNumLink">274</a></strong><div class="NLM_citation" id="rightTab-cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohteki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakarian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, P. S.</span></span> <span> </span><span class="NLM_article-title">Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">99</span>â <span class="NLM_lpage">104</span>, <span class="refDoi">Â DOI: 10.1084/jem.192.1.99</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1084%2Fjem.192.1.99" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10880530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkslaitb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2000&pages=99-104&author=T.+Ohtekiauthor=M.+Parsonsauthor=A.+Zakarianauthor=R.+G.+Jonesauthor=L.+T.+Nguyenauthor=J.+R.+Woodgettauthor=P.+S.+Ohashi&title=Negative+regulation+of+T+cell+proliferation+and+interleukin+2+production+by+the+serine+threonine+kinase+GSK-3&doi=10.1084%2Fjem.192.1.99"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3</span></div><div class="casAuthors">Ohteki, Toshiaki; Parsons, Michael; Zakarian, Arsen; Jones, Russell G.; Nguyen, Linh T.; Woodgett, James R.; Ohashi, Pamela S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-104</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Glycogen synthase kinase (GSK)-3 is a protein serine/threonine kinase that regulates differentiation and cell fate in a variety of organisms.  This study examd. the role of GSK-3 in antigen-specific T cell responses.  Using resting T cells from P14 T cell receptor (TCR)-transgenic mice (specific for the lymphocytic choriomeningitis virus and H-2Db), the authors demonstrated that GSK-3Î² was inactivated by serine phosphorylation after viral peptide-specific stimulation in vitro.  To further investigate the role of GSK-3, the authors have generated a retroviral vector that expresses a constitutively active form of GSK-3Î² that has an alanine substitution at the regulatory amino acid, serine 9 (GSK-3Î²A9).  Retroviral transduction of P14 TCR-transgenic bone marrow stem cells, followed by reconstitution, led to the expression of GSK-3Î²A9 in bone marrow chimeric mice.  T cells from chimeric mice demonstrate a redn. in proliferation and interleukin (IL)-2 prodn.  In contrast, in vitro assays done in the presence of the GSK-3 inhibitor lithium led to dramatically prolonged T cell proliferation and increased IL-2 prodn.  Furthermore, in the presence of lithium, the authors show that nuclear factor of activated T cells (NF-AT)c remains in the nucleus after antigen-specific stimulation of T cells.  Together, these data demonstrate that GSK-3 neg. regulates the duration of T cell responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVcVS1sxU4ubVg90H21EOLACvtfcHk0li7vpkCeviOyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkslaitb8%253D&md5=6ecff0134faca0fb2c89b4ff42695b2f</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.1084%2Fjem.192.1.99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.192.1.99%26sid%3Dliteratum%253Aachs%26aulast%3DOhteki%26aufirst%3DT.%26aulast%3DParsons%26aufirst%3DM.%26aulast%3DZakarian%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DR.%2BG.%26aulast%3DNguyen%26aufirst%3DL.%2BT.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DOhashi%26aufirst%3DP.%2BS.%26atitle%3DNegative%2520regulation%2520of%2520T%2520cell%2520proliferation%2520and%2520interleukin%25202%2520production%2520by%2520the%2520serine%2520threonine%2520kinase%2520GSK-3%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D192%26spage%3D99%26epage%3D104%26doi%3D10.1084%2Fjem.192.1.99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref275"><div class="reference"><strong class="refLabel"><a href="#ref275" class="rightTabRefNumLink">275</a></strong><div class="NLM_citation" id="rightTab-cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span> <span> </span><span class="NLM_article-title">Two strings in one bow: PD-1 negatively regulates via co-receptor CD28 on T cells</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">529</span>â <span class="NLM_lpage">531</span>, <span class="refDoi">Â DOI: 10.1016/j.immuni.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.immuni.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28423334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlSku7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=529-531&author=J.+Kruegerauthor=C.+E.+Rudd&title=Two+strings+in+one+bow%3A+PD-1+negatively+regulates+via+co-receptor+CD28+on+T+cells&doi=10.1016%2Fj.immuni.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Two Strings in One Bow: PD-1 Negatively Regulates via Co-receptor CD28 on T Cells</span></div><div class="casAuthors">Krueger, Janna; Rudd, Christopher E.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-531</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The identity of PD-1 dependency on other receptors and signaling has been unclear.  In a recent issue of Science, Hui et al. (2017) and Kamphorst et al. (2017) now show that CD28 expression is a target of PD-1-assocd. phosphatases and is needed for T cell expansion in anti-PD-1 immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW47O1ASL4NbVg90H21EOLACvtfcHk0li7vpkCeviOyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlSku7w%253D&md5=c639774541610ed3efd51256cbe4a8a7</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DJ.%26aulast%3DRudd%26aufirst%3DC.%2BE.%26atitle%3DTwo%2520strings%2520in%2520one%2520bow%253A%2520PD-1%2520negatively%2520regulates%2520via%2520co-receptor%2520CD28%2520on%2520T%2520cells%26jtitle%3DImmunity%26date%3D2017%26volume%3D46%26spage%3D529%26epage%3D531%26doi%3D10.1016%2Fj.immuni.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref276"><div class="reference"><strong class="refLabel"><a href="#ref276" class="rightTabRefNumLink">276</a></strong><div class="NLM_citation" id="rightTab-cit276"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">706</span>â <span class="NLM_lpage">717</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-17-0491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F0008-5472.CAN-17-0491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29055015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWntrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=706-717&author=A.+Taylorauthor=D.+Rothsteinauthor=C.+E.+Rudd&title=Small-molecule+inhibition+of+PD-1+transcription+is+an+effective+alternative+to+antibody+blockade+in+cancer+therapy&doi=10.1158%2F0008-5472.CAN-17-0491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy</span></div><div class="casAuthors">Taylor, Alison; Rothstein, David; Rudd, Christopher E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">706-717</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The impact of PD-1 immune checkpoint therapy prompts exploration of other strategies to downregulate PD-1 for cancer therapy.  We previously showed that the serine/threonine kinase, glycogen synthase kinase, GSK-3Î±/Î², is a central regulator of PD-1 transcription in CD8+ T cells.  Here, we show that the use of small-mol. inhibitors of GSK-3Î±/Î² (GSK-3i) to reduce pcdc1 (PD-1) transcription and expression was as effective as anti-PD-1 and PD-L1-blocking antibodies in the control of B16 melanoma, or EL4 lymphoma, in primary tumor and metastatic settings.  Furthermore, the conditional genetic deletion of GSK-3Î±/Î² reduced PD-1 expression on CD8+ T cells and limited B16 pulmonary metastasis to the same degree as PD-1 gene deficiency.  In each model, GSK-3i inhibited PD-1 expression on tumor-infiltrating lymphocytes, while increasing Tbx21 (T-bet) transcription, and the expression of CD107a+ (LAMP1) and granzyme B (GZMB) on CD8+ T cells.  Finally, the adoptive transfer of T cells treated ex vivo with a GSK-3 inhibitor delayed the onset of EL4 lymphoma growth to a similar extent as anti-PD-1 pretreatment.  Overall, our findings show how GSK-3 inhibitors that downregulate PD-1 expression can enhance CD8+ T-cell function in cancer therapy to a similar degree as PD-1-blocking antibodies.  Significance: These findings show how GSK-3 inhibitors that downregulate PD-1 expression can enhance CD8+ T-cell function in cancer therapy to a similar degree as PD-1 blocking antibodies, offering a next-generation approach in the design of immunotherapeutic approaches for cancer management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxGzAyDzwXtLVg90H21EOLACvtfcHk0li7vpkCeviOyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWntrs%253D&md5=17e2c2f4dc48d76f0fa9b6c64ff010e3</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-0491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-0491%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DRothstein%26aufirst%3DD.%26aulast%3DRudd%26aufirst%3DC.%2BE.%26atitle%3DSmall-molecule%2520inhibition%2520of%2520PD-1%2520transcription%2520is%2520an%2520effective%2520alternative%2520to%2520antibody%2520blockade%2520in%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D706%26epage%3D717%26doi%3D10.1158%2F0008-5472.CAN-17-0491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref277"><div class="reference"><strong class="refLabel"><a href="#ref277" class="rightTabRefNumLink">277</a></strong><div class="NLM_citation" id="rightTab-cit277"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8(+) cytotoxic T-cells: Implications for anti-PD-1 immunotherapy</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1653</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2017.01653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.3389%2Ffimmu.2017.01653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=29312284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOgsrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1653&author=A.+Taylorauthor=C.+E.+Rudd&title=Glycogen+synthase+kinase+3+inactivation+compensates+for+the+lack+of+CD28+in+the+priming+of+CD8%28%2B%29+cytotoxic+T-cells%3A+Implications+for+anti-PD-1+immunotherapy&doi=10.3389%2Ffimmu.2017.01653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8+ cytotoxic T-cells: implications for anti-PD-1 immunotherapy</span></div><div class="casAuthors">Taylor, Alison; Rudd, Christopher E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1653/1-1653/9</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The rescue of exhausted CD8+ cytolytic T-cells (CTLs) by anti-Programmed Cell Death-1 (anti-PD-1) blockade has been found to require CD28 expression.  At the same time, we have shown that the inactivation of the serine/threonine kinase glycogen synthase kinase (GSK)-3Î±/Î² with small-interfering RNAs (siRNAs) and small mol. inhibitors (SMIs) specifically down-regulates PD-1 expression for enhanced CD8+ CTL function and clearance of tumors and viral infections.  Despite this, it has been unclear whether the GSK-3Î±/Î² pathway accounts for CD28 costimulation of CD8+ CTL function.  In this article, we show that inactivation of GSK-3Î±/Î² through siRNA or by SMIs during priming can substitute CD28 co-stimulation in the potentiation of cytotoxic CD8+ CTL function against the EL-4 lymphoma cells expressing OVA peptide.  The effect was seen using several structurally distinct GSK-3 SMIs and was accompanied by an increase in Lamp-1 and GZMB expression.  Conversely, CD28 crosslinking obviated the need for GSK-3Î±/Î² inhibition in its enhancement of CTL function.  Our findings support a model where GSK-3 is the central cosignal for CD28 priming of CD8+ CTLs in anti-PD-1 immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL4BaOmVL5gbVg90H21EOLACvtfcHk0lguM__AMhtGtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOgsrrM&md5=d9f9ec8f4dd3ba2d11f170068d77f09b</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.01653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.01653%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DRudd%26aufirst%3DC.%2BE.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520inactivation%2520compensates%2520for%2520the%2520lack%2520of%2520CD28%2520in%2520the%2520priming%2520of%2520CD8%2528%252B%2529%2520cytotoxic%2520T-cells%253A%2520Implications%2520for%2520anti-PD-1%2520immunotherapy%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D1653%26doi%3D10.3389%2Ffimmu.2017.01653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref278"><div class="reference"><strong class="refLabel"><a href="#ref278" class="rightTabRefNumLink">278</a></strong><div class="NLM_citation" id="rightTab-cit278"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanthong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibition of GSK-3 specifically inhibits the transcription of inhibitory co-receptor LAG-3 for enhanced anti-tumor I immunity</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2075</span>â <span class="NLM_lpage">2082</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2020.01.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.celrep.2020.01.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=32075731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsFyntrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=2075-2082&author=C.+E.+Ruddauthor=K.+Chanthongauthor=A.+Taylor&title=Small+molecule+inhibition+of+GSK-3+specifically+inhibits+the+transcription+of+inhibitory+co-receptor+LAG-3+for+enhanced+anti-tumor+I+immunity&doi=10.1016%2Fj.celrep.2020.01.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity</span></div><div class="casAuthors">Rudd, Christopher E.; Chanthong, Kittiphat; Taylor, Alison</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2075-2082.e4</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Immune checkpoint blockade using antibodies against neg. co-receptors such as cytolytic T cell antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) has seen much success treating cancer.  However, most patients are still not cured, underscoring the need for improved treatments and the possible development of small mol. inhibitors (SMIs) for improved immunotherapy.  We previously showed that glycogen synthase kinase (GSK)-3Î±/Î² is a central regulator of PD-1 expression, where GSK-3 inhibition down-regulates PD-1 and enhances CD8+ cytolytic T cell (CTL) function, reducing viral infections and tumor growth.  Here, we demonstrate that GSK-3 also neg. regulates Lymphocyte Activation Gene-3 (LAG-3) expression on CD4+ and CD8+ T cells.  GSK-3 SMIs are more effective than LAG-3 blockade alone in suppressing B16 melanoma growth, while their combination resulted in enhanced tumor clearance.  This was linked to increased expression of the transcription factor, Tbet, which bound the LAG-3 promoter, inhibiting its transcription, and to increased granzyme B and interferon-Î³1 expression.  Overall, we describe a small mol. approach to inhibit LAG-3, resulting in enhanced anti-tumor immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGjPkICZQtZLVg90H21EOLACvtfcHk0lguM__AMhtGtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsFyntrc%253D&md5=4290f1c9e2f45041e6d3efbdd3f5b865</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2020.01.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2020.01.076%26sid%3Dliteratum%253Aachs%26aulast%3DRudd%26aufirst%3DC.%2BE.%26aulast%3DChanthong%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DA.%26atitle%3DSmall%2520molecule%2520inhibition%2520of%2520GSK-3%2520specifically%2520inhibits%2520the%2520transcription%2520of%2520inhibitory%2520co-receptor%2520LAG-3%2520for%2520enhanced%2520anti-tumor%2520I%2520immunity%26jtitle%3DCell%2520Rep.%26date%3D2020%26volume%3D30%26spage%3D2075%26epage%3D2082%26doi%3D10.1016%2Fj.celrep.2020.01.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref279"><div class="reference"><strong class="refLabel"><a href="#ref279" class="rightTabRefNumLink">279</a></strong><div class="NLM_citation" id="rightTab-cit279"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakley, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wraith, D. C.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 controls IL-10 expression in CD4(+) effector T-cell subsets through epigenetic modification of the IL-10 promoter</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1103</span>â <span class="NLM_lpage">1115</span>, <span class="refDoi">Â DOI: 10.1002/eji.201444661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1002%2Feji.201444661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=25627813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2MXks12hu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=1103-1115&author=E.+V.+Hillauthor=T.+H.+Ngauthor=B.+R.+Burtonauthor=C.+M.+Oakleyauthor=K.+Malikauthor=D.+C.+Wraith&title=Glycogen+synthase+kinase-3+controls+IL-10+expression+in+CD4%28%2B%29+effector+T-cell+subsets+through+epigenetic+modification+of+the+IL-10+promoter&doi=10.1002%2Feji.201444661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit279R"><div class="casContent"><span class="casTitleNuber">279</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 controls IL-10 expression in CD4+ effector T-cell subsets through epigenetic modification of the IL-10 promoter</span></div><div class="casAuthors">Hill, Elaine V.; Ng, T. H. Sky; Burton, Bronwen R.; Oakley, Charly M.; Malik, Karim; Wraith, David C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1103-1115</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The serine/threonine kinase glycogen synthase kinase-3 (GSK3) plays an important role in balancing pro- and anti-inflammatory cytokines.  We have examd. the role of GSK3 in prodn. of IL-10 by subsets of CD4+ T helper cells.  Treatment of naive murine CD4+ T cells with GSK3 inhibitors did not affect their prodn. of IL-10.  However, treatment of Th1 and Th2 cells with GSK3 inhibitors dramatically increased prodn. of IL-10.  GSK3 inhibition also led to upregulation of IL-10 among Th1, Th2, and Th17 subsets isolated from human blood.  The encephalitogenic potential of GSK3 inhibitor treated murine Th1 cells was significantly reduced in adoptive transfer expts. by an IL-10-dependent mechanism.  Anal. of the murine IL-10 promoter in response to inhibition of GSK3 in Th1 cells showed modification to a transcriptionally active state indicated by changes in histone H3 acetylation and methylation.  Addnl., GSK3 inhibition increased expression of the transcription factors c-Maf, Nfil3, and GATA3, correlating with the increase in IL-10.  These findings are important in the context of autoimmune disease since they show that it is possible to reprogram disease-causing cells through GSK3 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo68yArhNbkjbVg90H21EOLACvtfcHk0lguM__AMhtGtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXks12hu78%253D&md5=5bdcb0a86817340885b740f001aff1be</span></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=10.1002%2Feji.201444661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.201444661%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DE.%2BV.%26aulast%3DNg%26aufirst%3DT.%2BH.%26aulast%3DBurton%26aufirst%3DB.%2BR.%26aulast%3DOakley%26aufirst%3DC.%2BM.%26aulast%3DMalik%26aufirst%3DK.%26aulast%3DWraith%26aufirst%3DD.%2BC.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520controls%2520IL-10%2520expression%2520in%2520CD4%2528%252B%2529%2520effector%2520T-cell%2520subsets%2520through%2520epigenetic%2520modification%2520of%2520the%2520IL-10%2520promoter%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2015%26volume%3D45%26spage%3D1103%26epage%3D1115%26doi%3D10.1002%2Feji.201444661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref280"><div class="reference"><strong class="refLabel"><a href="#ref280" class="rightTabRefNumLink">280</a></strong><div class="NLM_citation" id="rightTab-cit280"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saraiva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâGarra, A.</span></span> <span> </span><span class="NLM_article-title">The regulation of IL-10 production by immune cells</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">170</span>â <span class="NLM_lpage">181</span>, <span class="refDoi">Â DOI: 10.1038/nri2711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1038%2Fnri2711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=20154735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFGmsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=170-181&author=M.+Saraivaauthor=A.+O%E2%80%99Garra&title=The+regulation+of+IL-10+production+by+immune+cells&doi=10.1038%2Fnri2711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of IL-10 production by immune cells</span></div><div class="casAuthors">Saraiva, Margarida; O'Garra, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">170-181</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Interleukin-10 (IL-10), a cytokine with anti-inflammatory properties, has a central role in infection by limiting the immune response to pathogens and thereby preventing damage to the host.  Recently, an increasing interest in how IL10 expression is regulated in different immune cells has revealed some of the mol. mechanisms involved at the levels of signal transduction, epigenetics, transcription factor binding and gene activation.  Understanding the specific mol. events that regulate the prodn. of IL-10 will help to answer the remaining questions that are important for the design of new strategies of immune intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCxUhXRUMEvLVg90H21EOLACvtfcHk0lguM__AMhtGtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFGmsrY%253D&md5=b3a72e73c6054abd8d7ddc278083937e</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.1038%2Fnri2711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2711%26sid%3Dliteratum%253Aachs%26aulast%3DSaraiva%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Garra%26aufirst%3DA.%26atitle%3DThe%2520regulation%2520of%2520IL-10%2520production%2520by%2520immune%2520cells%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D10%26spage%3D170%26epage%3D181%26doi%3D10.1038%2Fnri2711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref281"><div class="reference"><strong class="refLabel"><a href="#ref281" class="rightTabRefNumLink">281</a></strong><div class="NLM_citation" id="rightTab-cit281"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cichocki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valamehr, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjordahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidarova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuininga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCullar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlums, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryceson, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazar, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. S.</span></span> <span> </span><span class="NLM_article-title">GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">5664</span>â <span class="NLM_lpage">5675</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-17-0799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1158%2F0008-5472.CAN-17-0799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=28790065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CqtLjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=5664-5675&author=F.+Cichockiauthor=B.+Valamehrauthor=R.+Bjordahlauthor=B.+Zhangauthor=B.+Reznerauthor=P.+Rogersauthor=S.+Gaidarovaauthor=S.+Morenoauthor=K.+Tuiningaauthor=P.+Doughertyauthor=V.+McCullarauthor=P.+Howardauthor=D.+Sarhanauthor=E.+Tarasauthor=H.+Schlumsauthor=S.+Abbotauthor=D.+Shoemakerauthor=Y.+T.+Brycesonauthor=B.+R.+Blazarauthor=S.+Wolchkoauthor=S.+Cooleyauthor=J.+S.+Miller&title=GSK3+inhibition+drives+maturation+of+NK+cells+and+enhances+their+antitumor+activity&doi=10.1158%2F0008-5472.CAN-17-0799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity</span></div><div class="casAuthors">Cichocki, Frank; Valamehr, Bahram; Bjordahl, Ryan; Zhang, Bin; Rezner, Betsy; Rogers, Paul; Gaidarova, Svetlana; Moreno, Stacey; Tuininga, Katie; Dougherty, Phillip; McCullar, Valarie; Howard, Peter; Sarhan, Dhifaf; Taras, Emily; Schlums, Heinrich; Abbot, Stewart; Shoemaker, Daniel; Bryceson, Yenan T.; Blazar, Bruce R.; Wolchko, Scott; Cooley, Sarah; Miller, Jeffrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5664-5675</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Maturation of human natural killer (NK) cells as defined by accumulation of cell-surface expression of CD57 is assocd. with increased cytotoxic character and TNF and IFNÎ³ prodn. upon target-cell recognition.  Notably, multiple studies point to a unique role for CD57+ NK cells in cancer immunosurveillance, yet there is scant information about how they mature.  In this study, we show that pharmacol. inhibition of GSK3 kinase in peripheral blood NK cells expanded ex vivo with IL15 greatly enhances CD57 upregulation and late-stage maturation.  GSK3 inhibition elevated the expression of several transcription factors assocd. with late-stage NK-cell maturation including T-BET, ZEB2, and BLIMP-1 without affecting viability or proliferation.  When exposed to human cancer cells, NK cell expanded ex vivo in the presence of a GSK3 inhibitor exhibited significantly higher prodn. of TNF and IFNÎ³, elevated natural cytotoxicity, and increased antibody-dependent cellular cytotoxicity.  In an established mouse xenograft model of ovarian cancer, adoptive transfer of NK cells conditioned in the same way also displayed more robust and durable tumor control.  Our findings show how GSK3 kinase inhibition can greatly enhance the mature character of NK cells most desired for effective cancer immunotherapy.  Cancer Res; 77(20); 5664-75. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqNbRm7jN8XLVg90H21EOLACvtfcHk0liv-N25SnIVKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CqtLjL&md5=0dfd9702064be29a2cdae6d90591a916</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-0799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-0799%26sid%3Dliteratum%253Aachs%26aulast%3DCichocki%26aufirst%3DF.%26aulast%3DValamehr%26aufirst%3DB.%26aulast%3DBjordahl%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DRezner%26aufirst%3DB.%26aulast%3DRogers%26aufirst%3DP.%26aulast%3DGaidarova%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DS.%26aulast%3DTuininga%26aufirst%3DK.%26aulast%3DDougherty%26aufirst%3DP.%26aulast%3DMcCullar%26aufirst%3DV.%26aulast%3DHoward%26aufirst%3DP.%26aulast%3DSarhan%26aufirst%3DD.%26aulast%3DTaras%26aufirst%3DE.%26aulast%3DSchlums%26aufirst%3DH.%26aulast%3DAbbot%26aufirst%3DS.%26aulast%3DShoemaker%26aufirst%3DD.%26aulast%3DBryceson%26aufirst%3DY.%2BT.%26aulast%3DBlazar%26aufirst%3DB.%2BR.%26aulast%3DWolchko%26aufirst%3DS.%26aulast%3DCooley%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DJ.%2BS.%26atitle%3DGSK3%2520inhibition%2520drives%2520maturation%2520of%2520NK%2520cells%2520and%2520enhances%2520their%2520antitumor%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D5664%26epage%3D5675%26doi%3D10.1158%2F0008-5472.CAN-17-0799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref282"><div class="reference"><strong class="refLabel"><a href="#ref282" class="rightTabRefNumLink">282</a></strong><div class="NLM_citation" id="rightTab-cit282"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lam, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanier, L. L.</span></span> <span> </span><span class="NLM_article-title">NK cells in host responses to viral infections</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">43</span>â <span class="NLM_lpage">51</span>, <span class="refDoi">Â DOI: 10.1016/j.coi.2016.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=10.1016%2Fj.coi.2016.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=27984782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSmt7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=43-51&author=V.+C.+Lamauthor=L.+L.+Lanier&title=NK+cells+in+host+responses+to+viral+infections&doi=10.1016%2Fj.coi.2016.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit282R"><div class="casContent"><span class="casTitleNuber">282</span><div class="casTitle"><span class="NLM_cas:atitle">NK cells in host responses to viral infections</span></div><div class="casAuthors">Lam, Viola C.; Lanier, Lewis L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-51</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Natural killer (NK) cells are cytotoxic innate lymphocytes that play an important role in viral clearance.  NK cell responses to viral infections were originally believed to be non-specific and lacked immune memory recall responses.  It is now appreciated that NK cell responses to viral infections can be specific and in some cases memory recall responses are established.  Increasing evidence also illuminates the complexity of NK cell interactions with both innate and adaptive immune cells.  Here, we summarize the evidence for NK cell-specific memory responses to viral infections and the intricate reciprocal interactions between NK cells and other immune cells that dictate their activation and effector functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1yNF-jweBV7Vg90H21EOLACvtfcHk0liv-N25SnIVKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSmt7jF&md5=9524466071e80c9123f7c1702de60d70</span></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2016.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2016.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DV.%2BC.%26aulast%3DLanier%26aufirst%3DL.%2BL.%26atitle%3DNK%2520cells%2520in%2520host%2520responses%2520to%2520viral%2520infections%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2017%26volume%3D44%26spage%3D43%26epage%3D51%26doi%3D10.1016%2Fj.coi.2016.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00335&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00335%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00335" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a92b4ba163bec","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
